{"docstore/data": {"8ac40fc7-e5ac-411f-8bcc-384ec7db88a0": {"__data__": {"id_": "8ac40fc7-e5ac-411f-8bcc-384ec7db88a0", "embedding": null, "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n07-May -2024  \nMcKesson Corp.   (MCK ) \nQ4 2024 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n07-May -2024  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "55848cdd-003c-4ab4-b1df-376659bdd34c", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ae78c9af3ed8825fb47ec5300f8e8196673db4929279ccf3b16ff892a04ec9fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff05beac-fb15-422d-99fe-e0eb2ab3244c", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n07-May -2024  \nMcKesson Corp.   (MCK ) \nQ4 2024 Earnings Call    ", "original_text": "(MCK ) \nQ4 2024 Earnings Call    "}, "hash": "e1b85b8ebd57dd198a8aed2f03f8380f678dec93b5126c33eadf36f8c3b2396f", "class_name": "RelatedNodeInfo"}}, "text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n07-May -2024  \nMcKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 166, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff05beac-fb15-422d-99fe-e0eb2ab3244c": {"__data__": {"id_": "ff05beac-fb15-422d-99fe-e0eb2ab3244c", "embedding": null, "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n07-May -2024  \nMcKesson Corp.   (MCK ) \nQ4 2024 Earnings Call    ", "original_text": "(MCK ) \nQ4 2024 Earnings Call    ", "page_label": "1", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "55848cdd-003c-4ab4-b1df-376659bdd34c", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ae78c9af3ed8825fb47ec5300f8e8196673db4929279ccf3b16ff892a04ec9fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ac40fc7-e5ac-411f-8bcc-384ec7db88a0", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n07-May -2024  \nMcKesson Corp.   (MCK ) \nQ4 2024 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n07-May -2024  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "850856187dd65e00e04fad65aff186f39077f1da0c9705bd6ce41b56771d1e6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e29a353b-2a1b-4319-95e4-787dccc2683f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "original_text": "McKesson Corp.  "}, "hash": "d98e5fbb0b96c23c92a3de3c93d18a7f89ac09b80eee3721bf063acf84fca096", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2024 Earnings Call    ", "start_char_idx": 166, "end_char_idx": 199, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e29a353b-2a1b-4319-95e4-787dccc2683f": {"__data__": {"id_": "e29a353b-2a1b-4319-95e4-787dccc2683f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6b5d4127-351d-4c2c-ad83-61d686441325", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ce2ac6e4ce73c917f9b54a2631f5f37a52e66740fe12681f25c92dc4d663738b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff05beac-fb15-422d-99fe-e0eb2ab3244c", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n07-May -2024  \nMcKesson Corp.   (MCK ) \nQ4 2024 Earnings Call    ", "original_text": "(MCK ) \nQ4 2024 Earnings Call    ", "page_label": "1", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "2a948111001e037fef56503c7a54e81d0e65eae5bb39f0c4349a07360243c91f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f30a7767-cc81-49a9-837d-328a55032937", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n"}, "hash": "58d4dd5b8a506cb0102340eba58af9e839737ff05b6c8d9103ed79cc9d762630", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f30a7767-cc81-49a9-837d-328a55032937": {"__data__": {"id_": "f30a7767-cc81-49a9-837d-328a55032937", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6b5d4127-351d-4c2c-ad83-61d686441325", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ce2ac6e4ce73c917f9b54a2631f5f37a52e66740fe12681f25c92dc4d663738b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e29a353b-2a1b-4319-95e4-787dccc2683f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e346b18d6fd417d428e699c0dc95bd828fe76ed22dabaed941e1474f847b2c4f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de984c38-4c8e-4d31-a34c-6b16fce63e37", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nEric Percher  \nAnalyst, Nephron Research LLC  Stephanie July Davis  \nAnalyst, Barclays PLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n", "original_text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "2cc538c6c65c6f8a3e6599b525bbd78d7fb76e8ae735dcf4b5d11657ee50f4d5", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n", "start_char_idx": 16, "end_char_idx": 283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de984c38-4c8e-4d31-a34c-6b16fce63e37": {"__data__": {"id_": "de984c38-4c8e-4d31-a34c-6b16fce63e37", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nEric Percher  \nAnalyst, Nephron Research LLC  Stephanie July Davis  \nAnalyst, Barclays PLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n", "original_text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6b5d4127-351d-4c2c-ad83-61d686441325", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ce2ac6e4ce73c917f9b54a2631f5f37a52e66740fe12681f25c92dc4d663738b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f30a7767-cc81-49a9-837d-328a55032937", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3f08aa4f955a91af4e55a83a67977e1a613c7349d3e3856b386a69ca2d9196a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee94e062-8f38-4681-b95e-291331278a0d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nEric Percher  \nAnalyst, Nephron Research LLC  Stephanie July Davis  \nAnalyst, Barclays PLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "original_text": "Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n "}, "hash": "0258ae70e3a38ef99f04085ba9218147c722f029893b6b104af02bc9ef473d75", "class_name": "RelatedNodeInfo"}}, "text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 283, "end_char_idx": 355, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee94e062-8f38-4681-b95e-291331278a0d": {"__data__": {"id_": "ee94e062-8f38-4681-b95e-291331278a0d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nEric Percher  \nAnalyst, Nephron Research LLC  Stephanie July Davis  \nAnalyst, Barclays PLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "original_text": "Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "page_label": "2", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6b5d4127-351d-4c2c-ad83-61d686441325", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ce2ac6e4ce73c917f9b54a2631f5f37a52e66740fe12681f25c92dc4d663738b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de984c38-4c8e-4d31-a34c-6b16fce63e37", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nEric Percher  \nAnalyst, Nephron Research LLC  Stephanie July Davis  \nAnalyst, Barclays PLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n", "original_text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c0bd268e08ab5b0ab7d20179629cd5988ac63430683b5f00686fe66bcbfef8cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b26c2c2e-22d2-4989-b921-ae614e541ed5", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nEric Percher  \nAnalyst, Nephron Research LLC  Stephanie July Davis  \nAnalyst, Barclays PLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  \n  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n"}, "hash": "ad477538778a9e5781b9e55e28a8cc0066f35d54600a917439e32a8ffd306151", "class_name": "RelatedNodeInfo"}}, "text": "Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "start_char_idx": 355, "end_char_idx": 445, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b26c2c2e-22d2-4989-b921-ae614e541ed5": {"__data__": {"id_": "b26c2c2e-22d2-4989-b921-ae614e541ed5", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nEric Percher  \nAnalyst, Nephron Research LLC  Stephanie July Davis  \nAnalyst, Barclays PLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  \n  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6b5d4127-351d-4c2c-ad83-61d686441325", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ce2ac6e4ce73c917f9b54a2631f5f37a52e66740fe12681f25c92dc4d663738b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee94e062-8f38-4681-b95e-291331278a0d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nEric Percher  \nAnalyst, Nephron Research LLC  Stephanie July Davis  \nAnalyst, Barclays PLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "original_text": "Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "page_label": "2", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f7b17d0be286ba26710c6a98e801b5a7b3db41672b85452aadb087bfee4409a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0087b70c-f693-4502-bd3b-1478adab45f0", "node_type": "1", "metadata": {"window": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nEric Percher  \nAnalyst, Nephron Research LLC  Stephanie July Davis  \nAnalyst, Barclays PLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  \n  ", "original_text": "Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nEric Percher  \nAnalyst, Nephron Research LLC  Stephanie July Davis  \nAnalyst, Barclays PLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n"}, "hash": "7e879e82e17022a0f14378034c5aca46f702156ffefde6e50193b0002151128d", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n", "start_char_idx": 445, "end_char_idx": 835, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0087b70c-f693-4502-bd3b-1478adab45f0": {"__data__": {"id_": "0087b70c-f693-4502-bd3b-1478adab45f0", "embedding": null, "metadata": {"window": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nEric Percher  \nAnalyst, Nephron Research LLC  Stephanie July Davis  \nAnalyst, Barclays PLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  \n  ", "original_text": "Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nEric Percher  \nAnalyst, Nephron Research LLC  Stephanie July Davis  \nAnalyst, Barclays PLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n", "page_label": "2", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6b5d4127-351d-4c2c-ad83-61d686441325", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ce2ac6e4ce73c917f9b54a2631f5f37a52e66740fe12681f25c92dc4d663738b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b26c2c2e-22d2-4989-b921-ae614e541ed5", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nEric Percher  \nAnalyst, Nephron Research LLC  Stephanie July Davis  \nAnalyst, Barclays PLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  \n  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "4e4a5ff08f9479325a660b5f122d084a9eacfef3dbbb29436052430445da9897", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1544a74c-3b5a-4abb-8665-984f7b33654e", "node_type": "1", "metadata": {"window": "Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nEric Percher  \nAnalyst, Nephron Research LLC  Stephanie July Davis  \nAnalyst, Barclays PLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  \n  ", "original_text": "Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co. "}, "hash": "593f12fc26b0d8a0fc41361aeedcfe2c3b5399ce322d8098dbdd2ac49483b20d", "class_name": "RelatedNodeInfo"}}, "text": "Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nEric Percher  \nAnalyst, Nephron Research LLC  Stephanie July Davis  \nAnalyst, Barclays PLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n", "start_char_idx": 835, "end_char_idx": 1170, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1544a74c-3b5a-4abb-8665-984f7b33654e": {"__data__": {"id_": "1544a74c-3b5a-4abb-8665-984f7b33654e", "embedding": null, "metadata": {"window": "Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nEric Percher  \nAnalyst, Nephron Research LLC  Stephanie July Davis  \nAnalyst, Barclays PLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  \n  ", "original_text": "Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "page_label": "2", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6b5d4127-351d-4c2c-ad83-61d686441325", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ce2ac6e4ce73c917f9b54a2631f5f37a52e66740fe12681f25c92dc4d663738b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0087b70c-f693-4502-bd3b-1478adab45f0", "node_type": "1", "metadata": {"window": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nEric Percher  \nAnalyst, Nephron Research LLC  Stephanie July Davis  \nAnalyst, Barclays PLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  \n  ", "original_text": "Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nEric Percher  \nAnalyst, Nephron Research LLC  Stephanie July Davis  \nAnalyst, Barclays PLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n", "page_label": "2", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "0e5127a90f6bbc386cf442e189d6ef825a2ead3ce1afba63d240f45a8679b215", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36ff605a-6c7a-4f45-94e2-09f56987a36e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nEric Percher  \nAnalyst, Nephron Research LLC  Stephanie July Davis  \nAnalyst, Barclays PLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  \n  ", "original_text": "LLC \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  \n  "}, "hash": "d403882f95fd4ef4d2f123750b4b56f9be0ccf889e1990a8df7a197ec5917895", "class_name": "RelatedNodeInfo"}}, "text": "Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "start_char_idx": 1170, "end_char_idx": 1221, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36ff605a-6c7a-4f45-94e2-09f56987a36e": {"__data__": {"id_": "36ff605a-6c7a-4f45-94e2-09f56987a36e", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nEric Percher  \nAnalyst, Nephron Research LLC  Stephanie July Davis  \nAnalyst, Barclays PLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  \n  ", "original_text": "LLC \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  \n  ", "page_label": "2", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6b5d4127-351d-4c2c-ad83-61d686441325", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ce2ac6e4ce73c917f9b54a2631f5f37a52e66740fe12681f25c92dc4d663738b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1544a74c-3b5a-4abb-8665-984f7b33654e", "node_type": "1", "metadata": {"window": "Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nEric Percher  \nAnalyst, Nephron Research LLC  Stephanie July Davis  \nAnalyst, Barclays PLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  \n  ", "original_text": "Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "page_label": "2", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "00ede2f843b0ad3e1fa806e812345792170c9dee3767303d3e7fb007e4d50fe5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1f499d1-5560-411e-87b1-7da7f6445af4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's fourth quarter fiscal 2024 earnings conference call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations. ", "original_text": "McKesson Corp.  "}, "hash": "45601c17bbf7633d18a088fd580e4d7402bf4079c2aa22c6a7d3f573af427410", "class_name": "RelatedNodeInfo"}}, "text": "LLC \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  \n  ", "start_char_idx": 1221, "end_char_idx": 1283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1f499d1-5560-411e-87b1-7da7f6445af4": {"__data__": {"id_": "f1f499d1-5560-411e-87b1-7da7f6445af4", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's fourth quarter fiscal 2024 earnings conference call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81722f07-6765-4bf6-940a-500c9ac23a6e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "37d0e14efcde6c627d24372fa0d1291cedf886ae08c85cd0828fb06bc80f84d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36ff605a-6c7a-4f45-94e2-09f56987a36e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nEric Percher  \nAnalyst, Nephron Research LLC  Stephanie July Davis  \nAnalyst, Barclays PLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  \n  ", "original_text": "LLC \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  \n  ", "page_label": "2", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "bd449311edab646a8060f531e6318c2e03c641c34d1f765bbceec320e8c02d58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e5f357d-70eb-41ef-8258-af91943248f0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's fourth quarter fiscal 2024 earnings conference call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's fourth quarter fiscal 2024 earnings conference call. "}, "hash": "e124ecfdb0c7855d66ec751679ee8c100a7dba029705549066354e6316d13f73", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e5f357d-70eb-41ef-8258-af91943248f0": {"__data__": {"id_": "8e5f357d-70eb-41ef-8258-af91943248f0", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's fourth quarter fiscal 2024 earnings conference call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's fourth quarter fiscal 2024 earnings conference call. ", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81722f07-6765-4bf6-940a-500c9ac23a6e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "37d0e14efcde6c627d24372fa0d1291cedf886ae08c85cd0828fb06bc80f84d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1f499d1-5560-411e-87b1-7da7f6445af4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's fourth quarter fiscal 2024 earnings conference call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e003a65209f5e715d9a62fb8adb6bfd04ab794255e646ad992d37b1122470856", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41e010d6-2397-4ccb-866f-ca40463df7a8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's fourth quarter fiscal 2024 earnings conference call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n", "original_text": "Please be advised that \ntoday's conference is being recorded.  \n \n"}, "hash": "656930bbda0f5933b3ec8e2ed0b61d1b050df4202edcab90199c50eb572b2d38", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's fourth quarter fiscal 2024 earnings conference call. ", "start_char_idx": 16, "end_char_idx": 303, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41e010d6-2397-4ccb-866f-ca40463df7a8": {"__data__": {"id_": "41e010d6-2397-4ccb-866f-ca40463df7a8", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's fourth quarter fiscal 2024 earnings conference call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n", "original_text": "Please be advised that \ntoday's conference is being recorded.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81722f07-6765-4bf6-940a-500c9ac23a6e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "37d0e14efcde6c627d24372fa0d1291cedf886ae08c85cd0828fb06bc80f84d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e5f357d-70eb-41ef-8258-af91943248f0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's fourth quarter fiscal 2024 earnings conference call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's fourth quarter fiscal 2024 earnings conference call. ", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "2e370cbd45830eca578900c4b707409bcceb244b75af4de0717b350e44d203dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65520944-fe11-4371-8335-73117a437ad3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's fourth quarter fiscal 2024 earnings conference call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Thank you, operator. ", "original_text": "At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations. "}, "hash": "549b0281c86bdc9bbf765624c94171741f8355706b06b7fe3eecfe612fb1fb3f", "class_name": "RelatedNodeInfo"}}, "text": "Please be advised that \ntoday's conference is being recorded.  \n \n", "start_char_idx": 303, "end_char_idx": 369, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65520944-fe11-4371-8335-73117a437ad3": {"__data__": {"id_": "65520944-fe11-4371-8335-73117a437ad3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's fourth quarter fiscal 2024 earnings conference call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Thank you, operator. ", "original_text": "At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations. ", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81722f07-6765-4bf6-940a-500c9ac23a6e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "37d0e14efcde6c627d24372fa0d1291cedf886ae08c85cd0828fb06bc80f84d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41e010d6-2397-4ccb-866f-ca40463df7a8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's fourth quarter fiscal 2024 earnings conference call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n", "original_text": "Please be advised that \ntoday's conference is being recorded.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "153c09cfb2ee4ab421f3a5964b7827d67f459067c5d68cab609d00fd4f1c3f08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "114dd88b-cc59-416e-b2c1-1522266c79dd", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's fourth quarter fiscal 2024 earnings conference call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's fourth quarter fiscal 2024 earnings \ncall. ", "original_text": "Please go ahead.  \n "}, "hash": "afa9127eadf5a45c3ef7418410b78225afdae6b0af77c546d13d35fb1bd1e7d6", "class_name": "RelatedNodeInfo"}}, "text": "At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations. ", "start_char_idx": 369, "end_char_idx": 465, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "114dd88b-cc59-416e-b2c1-1522266c79dd": {"__data__": {"id_": "114dd88b-cc59-416e-b2c1-1522266c79dd", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's fourth quarter fiscal 2024 earnings conference call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's fourth quarter fiscal 2024 earnings \ncall. ", "original_text": "Please go ahead.  \n ", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81722f07-6765-4bf6-940a-500c9ac23a6e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "37d0e14efcde6c627d24372fa0d1291cedf886ae08c85cd0828fb06bc80f84d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65520944-fe11-4371-8335-73117a437ad3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's fourth quarter fiscal 2024 earnings conference call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Thank you, operator. ", "original_text": "At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations. ", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e410a0589190b863ae1022a4335548ee0ff532c2ba621ad8203dccdb7bbe96e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "400152eb-be86-4d8f-9219-c29ee796786a", "node_type": "1", "metadata": {"window": "Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's fourth quarter fiscal 2024 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n"}, "hash": "68539ca1d146227c0428bd78de20c499c12ad3c793c98e32083ecdc2175ead02", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 465, "end_char_idx": 485, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "400152eb-be86-4d8f-9219-c29ee796786a": {"__data__": {"id_": "400152eb-be86-4d8f-9219-c29ee796786a", "embedding": null, "metadata": {"window": "Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's fourth quarter fiscal 2024 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81722f07-6765-4bf6-940a-500c9ac23a6e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "37d0e14efcde6c627d24372fa0d1291cedf886ae08c85cd0828fb06bc80f84d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "114dd88b-cc59-416e-b2c1-1522266c79dd", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's fourth quarter fiscal 2024 earnings conference call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's fourth quarter fiscal 2024 earnings \ncall. ", "original_text": "Please go ahead.  \n ", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e93dad97dda954636ecf674f2dcec23b8dbf0296df0a48dfcb25c65253d9f591", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f3ec541-6387-4e90-8561-9e06ea491b03", "node_type": "1", "metadata": {"window": "At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's fourth quarter fiscal 2024 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer sess ion. \n \n", "original_text": "Thank you, operator. "}, "hash": "5d6ff5392d617ed6aa2f2892d1fe3d109e92b18c879f8584481b4a4d56148270", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n", "start_char_idx": 485, "end_char_idx": 831, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f3ec541-6387-4e90-8561-9e06ea491b03": {"__data__": {"id_": "3f3ec541-6387-4e90-8561-9e06ea491b03", "embedding": null, "metadata": {"window": "At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's fourth quarter fiscal 2024 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer sess ion. \n \n", "original_text": "Thank you, operator. ", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81722f07-6765-4bf6-940a-500c9ac23a6e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "37d0e14efcde6c627d24372fa0d1291cedf886ae08c85cd0828fb06bc80f84d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "400152eb-be86-4d8f-9219-c29ee796786a", "node_type": "1", "metadata": {"window": "Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's fourth quarter fiscal 2024 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "1b6f568e00f747e568f905de1928ddc0a49d0650cee69938e8c69656cb076278", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff1b7a4a-3ef4-4539-ba2b-9490310efce3", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's fourth quarter fiscal 2024 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer sess ion. \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "original_text": "Good afternoon and welcome, everyone, to McKesson's fourth quarter fiscal 2024 earnings \ncall. "}, "hash": "4c42c008d4e99e676f88176365458fa0778c0d8ec5889742813373e312d82ba4", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, operator. ", "start_char_idx": 831, "end_char_idx": 852, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff1b7a4a-3ef4-4539-ba2b-9490310efce3": {"__data__": {"id_": "ff1b7a4a-3ef4-4539-ba2b-9490310efce3", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's fourth quarter fiscal 2024 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer sess ion. \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "original_text": "Good afternoon and welcome, everyone, to McKesson's fourth quarter fiscal 2024 earnings \ncall. ", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81722f07-6765-4bf6-940a-500c9ac23a6e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "37d0e14efcde6c627d24372fa0d1291cedf886ae08c85cd0828fb06bc80f84d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f3ec541-6387-4e90-8561-9e06ea491b03", "node_type": "1", "metadata": {"window": "At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's fourth quarter fiscal 2024 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer sess ion. \n \n", "original_text": "Thank you, operator. ", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f2ec0e685e21ca6f7c70d5d44892d915925e52077407cb14a1ae07e30d1153d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "847f5d51-e7e9-4e1a-8887-4e689f9921d8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's fourth quarter fiscal 2024 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer sess ion. \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable at our website at inv estor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n", "original_text": "Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n"}, "hash": "1b31b0984fd570cfc0e23f347d1fdcdf063c533bcc26befab252ed41a5cd577d", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon and welcome, everyone, to McKesson's fourth quarter fiscal 2024 earnings \ncall. ", "start_char_idx": 852, "end_char_idx": 947, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "847f5d51-e7e9-4e1a-8887-4e689f9921d8": {"__data__": {"id_": "847f5d51-e7e9-4e1a-8887-4e689f9921d8", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's fourth quarter fiscal 2024 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer sess ion. \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable at our website at inv estor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n", "original_text": "Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81722f07-6765-4bf6-940a-500c9ac23a6e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "37d0e14efcde6c627d24372fa0d1291cedf886ae08c85cd0828fb06bc80f84d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff1b7a4a-3ef4-4539-ba2b-9490310efce3", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's fourth quarter fiscal 2024 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer sess ion. \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "original_text": "Good afternoon and welcome, everyone, to McKesson's fourth quarter fiscal 2024 earnings \ncall. ", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3bfd7cf935a1fa75fd03636cfd663bac1f53163e990e47f3f80f09c25c3b99d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e560d79-dd58-4b3d-a869-70295d5c151e", "node_type": "1", "metadata": {"window": "Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's fourth quarter fiscal 2024 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer sess ion. \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable at our website at inv estor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results, can be found in today's earnings release and presentations slides. ", "original_text": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer sess ion. \n \n"}, "hash": "c35d8c03b2244068265f26f7bd6a437f55787e5ed917bb1447c3ae7d657684ec", "class_name": "RelatedNodeInfo"}}, "text": "Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n", "start_char_idx": 947, "end_char_idx": 1060, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e560d79-dd58-4b3d-a869-70295d5c151e": {"__data__": {"id_": "3e560d79-dd58-4b3d-a869-70295d5c151e", "embedding": null, "metadata": {"window": "Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's fourth quarter fiscal 2024 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer sess ion. \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable at our website at inv estor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results, can be found in today's earnings release and presentations slides. ", "original_text": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer sess ion. \n \n", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81722f07-6765-4bf6-940a-500c9ac23a6e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "37d0e14efcde6c627d24372fa0d1291cedf886ae08c85cd0828fb06bc80f84d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "847f5d51-e7e9-4e1a-8887-4e689f9921d8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's fourth quarter fiscal 2024 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer sess ion. \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable at our website at inv estor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n", "original_text": "Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5d80158aa182bfafce26e9cf205df98ec79145b1670bd13c884e4f742bb09549", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84b84bca-2089-4868-b727-6e6bac65609f", "node_type": "1", "metadata": {"window": "Good afternoon and welcome, everyone, to McKesson's fourth quarter fiscal 2024 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer sess ion. \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable at our website at inv estor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results, can be found in today's earnings release and presentations slides.  The \npresentation slides also include a s ummary of our results for the quarter and guidance assumptions.  \n \n", "original_text": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. "}, "hash": "ed31dbdd13e15efcdb0fa394f0a519ae94e78f21a39a685c46955d9db3f999c5", "class_name": "RelatedNodeInfo"}}, "text": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer sess ion. \n \n", "start_char_idx": 1060, "end_char_idx": 1161, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84b84bca-2089-4868-b727-6e6bac65609f": {"__data__": {"id_": "84b84bca-2089-4868-b727-6e6bac65609f", "embedding": null, "metadata": {"window": "Good afternoon and welcome, everyone, to McKesson's fourth quarter fiscal 2024 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer sess ion. \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable at our website at inv estor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results, can be found in today's earnings release and presentations slides.  The \npresentation slides also include a s ummary of our results for the quarter and guidance assumptions.  \n \n", "original_text": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81722f07-6765-4bf6-940a-500c9ac23a6e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "37d0e14efcde6c627d24372fa0d1291cedf886ae08c85cd0828fb06bc80f84d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e560d79-dd58-4b3d-a869-70295d5c151e", "node_type": "1", "metadata": {"window": "Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's fourth quarter fiscal 2024 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer sess ion. \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable at our website at inv estor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results, can be found in today's earnings release and presentations slides. ", "original_text": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer sess ion. \n \n", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "94612ad2518198db20542bf815d8cab775e6af18feb4152664864190a91a90a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a638280-07eb-4328-82db-a2a79b041f43", "node_type": "1", "metadata": {"window": "Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer sess ion. \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable at our website at inv estor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results, can be found in today's earnings release and presentations slides.  The \npresentation slides also include a s ummary of our results for the quarter and guidance assumptions.  \n \n With that, let me turn it over to Brian.  \n ", "original_text": "Please refer to the cautionary statements in today's earnings release and presentation slides \navailable at our website at inv estor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n"}, "hash": "1e73309997b5ca832a8ca5ec3aa3debf3a3cb2f7f66f0d01d0daa85df1c3b4a2", "class_name": "RelatedNodeInfo"}}, "text": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "start_char_idx": 1161, "end_char_idx": 1288, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a638280-07eb-4328-82db-a2a79b041f43": {"__data__": {"id_": "3a638280-07eb-4328-82db-a2a79b041f43", "embedding": null, "metadata": {"window": "Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer sess ion. \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable at our website at inv estor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results, can be found in today's earnings release and presentations slides.  The \npresentation slides also include a s ummary of our results for the quarter and guidance assumptions.  \n \n With that, let me turn it over to Brian.  \n ", "original_text": "Please refer to the cautionary statements in today's earnings release and presentation slides \navailable at our website at inv estor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81722f07-6765-4bf6-940a-500c9ac23a6e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "37d0e14efcde6c627d24372fa0d1291cedf886ae08c85cd0828fb06bc80f84d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84b84bca-2089-4868-b727-6e6bac65609f", "node_type": "1", "metadata": {"window": "Good afternoon and welcome, everyone, to McKesson's fourth quarter fiscal 2024 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer sess ion. \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable at our website at inv estor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results, can be found in today's earnings release and presentations slides.  The \npresentation slides also include a s ummary of our results for the quarter and guidance assumptions.  \n \n", "original_text": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e08c4bdbd59201a7bbba3e14b79e334059256d00338394db92aa683e5ac9cb5d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17fd159e-c8cc-4503-a560-bd88e74814d4", "node_type": "1", "metadata": {"window": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer sess ion. \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable at our website at inv estor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results, can be found in today's earnings release and presentations slides.  The \npresentation slides also include a s ummary of our results for the quarter and guidance assumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results, can be found in today's earnings release and presentations slides. "}, "hash": "3bd0393821498cfecbc389bbf665252af9f54ff584d3049eeceeef31c4d2e549", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to the cautionary statements in today's earnings release and presentation slides \navailable at our website at inv estor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n", "start_char_idx": 1288, "end_char_idx": 1678, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17fd159e-c8cc-4503-a560-bd88e74814d4": {"__data__": {"id_": "17fd159e-c8cc-4503-a560-bd88e74814d4", "embedding": null, "metadata": {"window": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer sess ion. \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable at our website at inv estor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results, can be found in today's earnings release and presentations slides.  The \npresentation slides also include a s ummary of our results for the quarter and guidance assumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results, can be found in today's earnings release and presentations slides. ", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81722f07-6765-4bf6-940a-500c9ac23a6e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "37d0e14efcde6c627d24372fa0d1291cedf886ae08c85cd0828fb06bc80f84d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a638280-07eb-4328-82db-a2a79b041f43", "node_type": "1", "metadata": {"window": "Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer sess ion. \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable at our website at inv estor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results, can be found in today's earnings release and presentations slides.  The \npresentation slides also include a s ummary of our results for the quarter and guidance assumptions.  \n \n With that, let me turn it over to Brian.  \n ", "original_text": "Please refer to the cautionary statements in today's earnings release and presentation slides \navailable at our website at inv estor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "7ed4ccb6fbe0cccd5651e59553c837191cfa743f1f78a5f1f88f11448632a1cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "358dd6ec-fecb-4ee6-a491-e829d7441b79", "node_type": "1", "metadata": {"window": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable at our website at inv estor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results, can be found in today's earnings release and presentations slides.  The \npresentation slides also include a s ummary of our results for the quarter and guidance assumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everyone. ", "original_text": "The \npresentation slides also include a s ummary of our results for the quarter and guidance assumptions.  \n \n"}, "hash": "1168ba826655deef666e4c8d08151fe6873594749726189052c66ae6034910ac", "class_name": "RelatedNodeInfo"}}, "text": "Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results, can be found in today's earnings release and presentations slides. ", "start_char_idx": 1678, "end_char_idx": 1895, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "358dd6ec-fecb-4ee6-a491-e829d7441b79": {"__data__": {"id_": "358dd6ec-fecb-4ee6-a491-e829d7441b79", "embedding": null, "metadata": {"window": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable at our website at inv estor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results, can be found in today's earnings release and presentations slides.  The \npresentation slides also include a s ummary of our results for the quarter and guidance assumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everyone. ", "original_text": "The \npresentation slides also include a s ummary of our results for the quarter and guidance assumptions.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81722f07-6765-4bf6-940a-500c9ac23a6e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "37d0e14efcde6c627d24372fa0d1291cedf886ae08c85cd0828fb06bc80f84d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17fd159e-c8cc-4503-a560-bd88e74814d4", "node_type": "1", "metadata": {"window": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer sess ion. \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable at our website at inv estor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results, can be found in today's earnings release and presentations slides.  The \npresentation slides also include a s ummary of our results for the quarter and guidance assumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results, can be found in today's earnings release and presentations slides. ", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e202b8cb62e9384b477f487ad5798bb993c697f729c7234dcc2bb741ff493c8d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4a2eb5d-ea15-471a-ae4e-644305267a1b", "node_type": "1", "metadata": {"window": "Please refer to the cautionary statements in today's earnings release and presentation slides \navailable at our website at inv estor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results, can be found in today's earnings release and presentations slides.  The \npresentation slides also include a s ummary of our results for the quarter and guidance assumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everyone.  Thanks for joining our call t his afternoon.  \n \n", "original_text": "With that, let me turn it over to Brian.  \n "}, "hash": "928882289b695f551d16366834ab477041b885cfe6860de28383ebe846b64cac", "class_name": "RelatedNodeInfo"}}, "text": "The \npresentation slides also include a s ummary of our results for the quarter and guidance assumptions.  \n \n", "start_char_idx": 1895, "end_char_idx": 2005, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4a2eb5d-ea15-471a-ae4e-644305267a1b": {"__data__": {"id_": "c4a2eb5d-ea15-471a-ae4e-644305267a1b", "embedding": null, "metadata": {"window": "Please refer to the cautionary statements in today's earnings release and presentation slides \navailable at our website at inv estor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results, can be found in today's earnings release and presentations slides.  The \npresentation slides also include a s ummary of our results for the quarter and guidance assumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everyone.  Thanks for joining our call t his afternoon.  \n \n", "original_text": "With that, let me turn it over to Brian.  \n ", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81722f07-6765-4bf6-940a-500c9ac23a6e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "37d0e14efcde6c627d24372fa0d1291cedf886ae08c85cd0828fb06bc80f84d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "358dd6ec-fecb-4ee6-a491-e829d7441b79", "node_type": "1", "metadata": {"window": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable at our website at inv estor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results, can be found in today's earnings release and presentations slides.  The \npresentation slides also include a s ummary of our results for the quarter and guidance assumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everyone. ", "original_text": "The \npresentation slides also include a s ummary of our results for the quarter and guidance assumptions.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "81d7f54ae9cd5cfedf667251c4d6177094bf0476ac4b81597cebde69530d0648", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82674211-3c89-47ee-b4dc-34c08c748ae9", "node_type": "1", "metadata": {"window": "Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results, can be found in today's earnings release and presentations slides.  The \npresentation slides also include a s ummary of our results for the quarter and guidance assumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everyone.  Thanks for joining our call t his afternoon.  \n \n Today, we reported our fiscal fourth quarter results, marking the close to a strong fiscal 2024. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n"}, "hash": "407e8be20114dd9dc44b9aab3ca2ae3f5cf538b899eb2c83db2d3d6cd827c56a", "class_name": "RelatedNodeInfo"}}, "text": "With that, let me turn it over to Brian.  \n ", "start_char_idx": 2005, "end_char_idx": 2049, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82674211-3c89-47ee-b4dc-34c08c748ae9": {"__data__": {"id_": "82674211-3c89-47ee-b4dc-34c08c748ae9", "embedding": null, "metadata": {"window": "Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results, can be found in today's earnings release and presentations slides.  The \npresentation slides also include a s ummary of our results for the quarter and guidance assumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everyone.  Thanks for joining our call t his afternoon.  \n \n Today, we reported our fiscal fourth quarter results, marking the close to a strong fiscal 2024. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81722f07-6765-4bf6-940a-500c9ac23a6e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "37d0e14efcde6c627d24372fa0d1291cedf886ae08c85cd0828fb06bc80f84d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4a2eb5d-ea15-471a-ae4e-644305267a1b", "node_type": "1", "metadata": {"window": "Please refer to the cautionary statements in today's earnings release and presentation slides \navailable at our website at inv estor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results, can be found in today's earnings release and presentations slides.  The \npresentation slides also include a s ummary of our results for the quarter and guidance assumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everyone.  Thanks for joining our call t his afternoon.  \n \n", "original_text": "With that, let me turn it over to Brian.  \n ", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "73390fb1c6dc3b47b87dc4a7145f6d72e71c8e3b750f334cc793fb8a84fc1590", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5c3283b-81a6-459b-b94c-03188fb1f5b8", "node_type": "1", "metadata": {"window": "The \npresentation slides also include a s ummary of our results for the quarter and guidance assumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everyone.  Thanks for joining our call t his afternoon.  \n \n Today, we reported our fiscal fourth quarter results, marking the close to a strong fiscal 2024.  I want to thank our \n51,000 McKesson employees for their terrific efforts over the course of this year, as together we drove the \nbusiness and ac hieved significant progress in advancing our mission and our strategies.  \n \n", "original_text": "Thank you, Rachel, and good afternoon, everyone. "}, "hash": "c00b27b4481871ff36fc53addfe9ca1ee729ae28dd3c79b5f6a874b53670b9f4", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "start_char_idx": 2049, "end_char_idx": 2394, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5c3283b-81a6-459b-b94c-03188fb1f5b8": {"__data__": {"id_": "c5c3283b-81a6-459b-b94c-03188fb1f5b8", "embedding": null, "metadata": {"window": "The \npresentation slides also include a s ummary of our results for the quarter and guidance assumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everyone.  Thanks for joining our call t his afternoon.  \n \n Today, we reported our fiscal fourth quarter results, marking the close to a strong fiscal 2024.  I want to thank our \n51,000 McKesson employees for their terrific efforts over the course of this year, as together we drove the \nbusiness and ac hieved significant progress in advancing our mission and our strategies.  \n \n", "original_text": "Thank you, Rachel, and good afternoon, everyone. ", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81722f07-6765-4bf6-940a-500c9ac23a6e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "37d0e14efcde6c627d24372fa0d1291cedf886ae08c85cd0828fb06bc80f84d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82674211-3c89-47ee-b4dc-34c08c748ae9", "node_type": "1", "metadata": {"window": "Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results, can be found in today's earnings release and presentations slides.  The \npresentation slides also include a s ummary of our results for the quarter and guidance assumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everyone.  Thanks for joining our call t his afternoon.  \n \n Today, we reported our fiscal fourth quarter results, marking the close to a strong fiscal 2024. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "03771fa1364c78e2dbf3227f1641463a5abc9ba8a74c114abe1d737747a8d013", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9f64c39-9358-486e-b2db-845a40ecdcba", "node_type": "1", "metadata": {"window": "With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everyone.  Thanks for joining our call t his afternoon.  \n \n Today, we reported our fiscal fourth quarter results, marking the close to a strong fiscal 2024.  I want to thank our \n51,000 McKesson employees for their terrific efforts over the course of this year, as together we drove the \nbusiness and ac hieved significant progress in advancing our mission and our strategies.  \n \n In fiscal 2024, consolidated revenue grew 12% to $309 billion and adjusted earnings per diluted share increased \nby 6% to $27.44, both exceeding the expectations we set out at the beg inning of the fiscal year.  \n \n", "original_text": "Thanks for joining our call t his afternoon.  \n \n"}, "hash": "acb2b51da4efe3ab10a154300ca6414678387b726e1dc974b263fa57c30adb1d", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Rachel, and good afternoon, everyone. ", "start_char_idx": 2394, "end_char_idx": 2443, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9f64c39-9358-486e-b2db-845a40ecdcba": {"__data__": {"id_": "c9f64c39-9358-486e-b2db-845a40ecdcba", "embedding": null, "metadata": {"window": "With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everyone.  Thanks for joining our call t his afternoon.  \n \n Today, we reported our fiscal fourth quarter results, marking the close to a strong fiscal 2024.  I want to thank our \n51,000 McKesson employees for their terrific efforts over the course of this year, as together we drove the \nbusiness and ac hieved significant progress in advancing our mission and our strategies.  \n \n In fiscal 2024, consolidated revenue grew 12% to $309 billion and adjusted earnings per diluted share increased \nby 6% to $27.44, both exceeding the expectations we set out at the beg inning of the fiscal year.  \n \n", "original_text": "Thanks for joining our call t his afternoon.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81722f07-6765-4bf6-940a-500c9ac23a6e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "37d0e14efcde6c627d24372fa0d1291cedf886ae08c85cd0828fb06bc80f84d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5c3283b-81a6-459b-b94c-03188fb1f5b8", "node_type": "1", "metadata": {"window": "The \npresentation slides also include a s ummary of our results for the quarter and guidance assumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everyone.  Thanks for joining our call t his afternoon.  \n \n Today, we reported our fiscal fourth quarter results, marking the close to a strong fiscal 2024.  I want to thank our \n51,000 McKesson employees for their terrific efforts over the course of this year, as together we drove the \nbusiness and ac hieved significant progress in advancing our mission and our strategies.  \n \n", "original_text": "Thank you, Rachel, and good afternoon, everyone. ", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3d1865e9cf73dce2d5d910715dfb061e2ce30597fdd086b21c80143bee2459f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ea9dbdd-9591-43fd-8025-457cca8b6b73", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everyone.  Thanks for joining our call t his afternoon.  \n \n Today, we reported our fiscal fourth quarter results, marking the close to a strong fiscal 2024.  I want to thank our \n51,000 McKesson employees for their terrific efforts over the course of this year, as together we drove the \nbusiness and ac hieved significant progress in advancing our mission and our strategies.  \n \n In fiscal 2024, consolidated revenue grew 12% to $309 billion and adjusted earnings per diluted share increased \nby 6% to $27.44, both exceeding the expectations we set out at the beg inning of the fiscal year.  \n \n We're pleased with the growth across the enterprise, supported by our differentiated portfolio of assets, our \ninnovative solutions, and our deep commitment to quality and operational excellence. ", "original_text": "Today, we reported our fiscal fourth quarter results, marking the close to a strong fiscal 2024. "}, "hash": "42b1299d590dd393671180f3ec64d85c79bd3b4a210c0799932c8f43d177b232", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for joining our call t his afternoon.  \n \n", "start_char_idx": 2443, "end_char_idx": 2492, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ea9dbdd-9591-43fd-8025-457cca8b6b73": {"__data__": {"id_": "8ea9dbdd-9591-43fd-8025-457cca8b6b73", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everyone.  Thanks for joining our call t his afternoon.  \n \n Today, we reported our fiscal fourth quarter results, marking the close to a strong fiscal 2024.  I want to thank our \n51,000 McKesson employees for their terrific efforts over the course of this year, as together we drove the \nbusiness and ac hieved significant progress in advancing our mission and our strategies.  \n \n In fiscal 2024, consolidated revenue grew 12% to $309 billion and adjusted earnings per diluted share increased \nby 6% to $27.44, both exceeding the expectations we set out at the beg inning of the fiscal year.  \n \n We're pleased with the growth across the enterprise, supported by our differentiated portfolio of assets, our \ninnovative solutions, and our deep commitment to quality and operational excellence. ", "original_text": "Today, we reported our fiscal fourth quarter results, marking the close to a strong fiscal 2024. ", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81722f07-6765-4bf6-940a-500c9ac23a6e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "37d0e14efcde6c627d24372fa0d1291cedf886ae08c85cd0828fb06bc80f84d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9f64c39-9358-486e-b2db-845a40ecdcba", "node_type": "1", "metadata": {"window": "With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everyone.  Thanks for joining our call t his afternoon.  \n \n Today, we reported our fiscal fourth quarter results, marking the close to a strong fiscal 2024.  I want to thank our \n51,000 McKesson employees for their terrific efforts over the course of this year, as together we drove the \nbusiness and ac hieved significant progress in advancing our mission and our strategies.  \n \n In fiscal 2024, consolidated revenue grew 12% to $309 billion and adjusted earnings per diluted share increased \nby 6% to $27.44, both exceeding the expectations we set out at the beg inning of the fiscal year.  \n \n", "original_text": "Thanks for joining our call t his afternoon.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c63c9cc8bddb6938637d27d38add66c04482f9e675e2a6fac90a5a0d058e8278", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "911bb5f5-525a-471a-9e29-da5714a131cb", "node_type": "1", "metadata": {"window": "Thank you, Rachel, and good afternoon, everyone.  Thanks for joining our call t his afternoon.  \n \n Today, we reported our fiscal fourth quarter results, marking the close to a strong fiscal 2024.  I want to thank our \n51,000 McKesson employees for their terrific efforts over the course of this year, as together we drove the \nbusiness and ac hieved significant progress in advancing our mission and our strategies.  \n \n In fiscal 2024, consolidated revenue grew 12% to $309 billion and adjusted earnings per diluted share increased \nby 6% to $27.44, both exceeding the expectations we set out at the beg inning of the fiscal year.  \n \n We're pleased with the growth across the enterprise, supported by our differentiated portfolio of assets, our \ninnovative solutions, and our deep commitment to quality and operational excellence.  We're particularly excited \nabout the opportunities within our strategic growth pillars of oncology and biopharma services. ", "original_text": "I want to thank our \n51,000 McKesson employees for their terrific efforts over the course of this year, as together we drove the \nbusiness and ac hieved significant progress in advancing our mission and our strategies.  \n \n"}, "hash": "0b204a66635e56c87b4a2275c599f4068a6c38349271ae73ad88977c4433fb94", "class_name": "RelatedNodeInfo"}}, "text": "Today, we reported our fiscal fourth quarter results, marking the close to a strong fiscal 2024. ", "start_char_idx": 2492, "end_char_idx": 2589, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "911bb5f5-525a-471a-9e29-da5714a131cb": {"__data__": {"id_": "911bb5f5-525a-471a-9e29-da5714a131cb", "embedding": null, "metadata": {"window": "Thank you, Rachel, and good afternoon, everyone.  Thanks for joining our call t his afternoon.  \n \n Today, we reported our fiscal fourth quarter results, marking the close to a strong fiscal 2024.  I want to thank our \n51,000 McKesson employees for their terrific efforts over the course of this year, as together we drove the \nbusiness and ac hieved significant progress in advancing our mission and our strategies.  \n \n In fiscal 2024, consolidated revenue grew 12% to $309 billion and adjusted earnings per diluted share increased \nby 6% to $27.44, both exceeding the expectations we set out at the beg inning of the fiscal year.  \n \n We're pleased with the growth across the enterprise, supported by our differentiated portfolio of assets, our \ninnovative solutions, and our deep commitment to quality and operational excellence.  We're particularly excited \nabout the opportunities within our strategic growth pillars of oncology and biopharma services. ", "original_text": "I want to thank our \n51,000 McKesson employees for their terrific efforts over the course of this year, as together we drove the \nbusiness and ac hieved significant progress in advancing our mission and our strategies.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81722f07-6765-4bf6-940a-500c9ac23a6e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "37d0e14efcde6c627d24372fa0d1291cedf886ae08c85cd0828fb06bc80f84d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ea9dbdd-9591-43fd-8025-457cca8b6b73", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everyone.  Thanks for joining our call t his afternoon.  \n \n Today, we reported our fiscal fourth quarter results, marking the close to a strong fiscal 2024.  I want to thank our \n51,000 McKesson employees for their terrific efforts over the course of this year, as together we drove the \nbusiness and ac hieved significant progress in advancing our mission and our strategies.  \n \n In fiscal 2024, consolidated revenue grew 12% to $309 billion and adjusted earnings per diluted share increased \nby 6% to $27.44, both exceeding the expectations we set out at the beg inning of the fiscal year.  \n \n We're pleased with the growth across the enterprise, supported by our differentiated portfolio of assets, our \ninnovative solutions, and our deep commitment to quality and operational excellence. ", "original_text": "Today, we reported our fiscal fourth quarter results, marking the close to a strong fiscal 2024. ", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "b3960221a59a999f45eea487ede8a40c47570345b9ae72efb357f5bdf9f2c200", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b0398bd-b3a7-409c-9c24-1356f3f9c48c", "node_type": "1", "metadata": {"window": "Thanks for joining our call t his afternoon.  \n \n Today, we reported our fiscal fourth quarter results, marking the close to a strong fiscal 2024.  I want to thank our \n51,000 McKesson employees for their terrific efforts over the course of this year, as together we drove the \nbusiness and ac hieved significant progress in advancing our mission and our strategies.  \n \n In fiscal 2024, consolidated revenue grew 12% to $309 billion and adjusted earnings per diluted share increased \nby 6% to $27.44, both exceeding the expectations we set out at the beg inning of the fiscal year.  \n \n We're pleased with the growth across the enterprise, supported by our differentiated portfolio of assets, our \ninnovative solutions, and our deep commitment to quality and operational excellence.  We're particularly excited \nabout the opportunities within our strategic growth pillars of oncology and biopharma services.  During the year, \nwe saw a record expansion in the US oncology network and strong market demand for our access, affordability, \nand adherence solutions.  \n \n", "original_text": "In fiscal 2024, consolidated revenue grew 12% to $309 billion and adjusted earnings per diluted share increased \nby 6% to $27.44, both exceeding the expectations we set out at the beg inning of the fiscal year.  \n \n"}, "hash": "d935db4f6ba483e499a13add49a86b7b28f618a3f3aa770da939ae61d8ee829b", "class_name": "RelatedNodeInfo"}}, "text": "I want to thank our \n51,000 McKesson employees for their terrific efforts over the course of this year, as together we drove the \nbusiness and ac hieved significant progress in advancing our mission and our strategies.  \n \n", "start_char_idx": 2589, "end_char_idx": 2812, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b0398bd-b3a7-409c-9c24-1356f3f9c48c": {"__data__": {"id_": "0b0398bd-b3a7-409c-9c24-1356f3f9c48c", "embedding": null, "metadata": {"window": "Thanks for joining our call t his afternoon.  \n \n Today, we reported our fiscal fourth quarter results, marking the close to a strong fiscal 2024.  I want to thank our \n51,000 McKesson employees for their terrific efforts over the course of this year, as together we drove the \nbusiness and ac hieved significant progress in advancing our mission and our strategies.  \n \n In fiscal 2024, consolidated revenue grew 12% to $309 billion and adjusted earnings per diluted share increased \nby 6% to $27.44, both exceeding the expectations we set out at the beg inning of the fiscal year.  \n \n We're pleased with the growth across the enterprise, supported by our differentiated portfolio of assets, our \ninnovative solutions, and our deep commitment to quality and operational excellence.  We're particularly excited \nabout the opportunities within our strategic growth pillars of oncology and biopharma services.  During the year, \nwe saw a record expansion in the US oncology network and strong market demand for our access, affordability, \nand adherence solutions.  \n \n", "original_text": "In fiscal 2024, consolidated revenue grew 12% to $309 billion and adjusted earnings per diluted share increased \nby 6% to $27.44, both exceeding the expectations we set out at the beg inning of the fiscal year.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81722f07-6765-4bf6-940a-500c9ac23a6e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "37d0e14efcde6c627d24372fa0d1291cedf886ae08c85cd0828fb06bc80f84d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "911bb5f5-525a-471a-9e29-da5714a131cb", "node_type": "1", "metadata": {"window": "Thank you, Rachel, and good afternoon, everyone.  Thanks for joining our call t his afternoon.  \n \n Today, we reported our fiscal fourth quarter results, marking the close to a strong fiscal 2024.  I want to thank our \n51,000 McKesson employees for their terrific efforts over the course of this year, as together we drove the \nbusiness and ac hieved significant progress in advancing our mission and our strategies.  \n \n In fiscal 2024, consolidated revenue grew 12% to $309 billion and adjusted earnings per diluted share increased \nby 6% to $27.44, both exceeding the expectations we set out at the beg inning of the fiscal year.  \n \n We're pleased with the growth across the enterprise, supported by our differentiated portfolio of assets, our \ninnovative solutions, and our deep commitment to quality and operational excellence.  We're particularly excited \nabout the opportunities within our strategic growth pillars of oncology and biopharma services. ", "original_text": "I want to thank our \n51,000 McKesson employees for their terrific efforts over the course of this year, as together we drove the \nbusiness and ac hieved significant progress in advancing our mission and our strategies.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f1ac37e7afc699fb61b7227bf8d6b22e482ba63902ea0165d86a93722eface6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f95d24c-b104-4076-8dba-f4b315cbde5a", "node_type": "1", "metadata": {"window": "Today, we reported our fiscal fourth quarter results, marking the close to a strong fiscal 2024.  I want to thank our \n51,000 McKesson employees for their terrific efforts over the course of this year, as together we drove the \nbusiness and ac hieved significant progress in advancing our mission and our strategies.  \n \n In fiscal 2024, consolidated revenue grew 12% to $309 billion and adjusted earnings per diluted share increased \nby 6% to $27.44, both exceeding the expectations we set out at the beg inning of the fiscal year.  \n \n We're pleased with the growth across the enterprise, supported by our differentiated portfolio of assets, our \ninnovative solutions, and our deep commitment to quality and operational excellence.  We're particularly excited \nabout the opportunities within our strategic growth pillars of oncology and biopharma services.  During the year, \nwe saw a record expansion in the US oncology network and strong market demand for our access, affordability, \nand adherence solutions.  \n \n I'm going to s tart my remarks today with a review of our company priorities, and then I'm going to hand it over to \nBritt, who will take us through more details on the financial performance and our outlook for fiscal 2025. ", "original_text": "We're pleased with the growth across the enterprise, supported by our differentiated portfolio of assets, our \ninnovative solutions, and our deep commitment to quality and operational excellence. "}, "hash": "ea8f6ec51c2d8f86fdbf0dd7bc0af785c76454ae5155fe6f8e8a1a77b534599e", "class_name": "RelatedNodeInfo"}}, "text": "In fiscal 2024, consolidated revenue grew 12% to $309 billion and adjusted earnings per diluted share increased \nby 6% to $27.44, both exceeding the expectations we set out at the beg inning of the fiscal year.  \n \n", "start_char_idx": 2812, "end_char_idx": 3027, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f95d24c-b104-4076-8dba-f4b315cbde5a": {"__data__": {"id_": "7f95d24c-b104-4076-8dba-f4b315cbde5a", "embedding": null, "metadata": {"window": "Today, we reported our fiscal fourth quarter results, marking the close to a strong fiscal 2024.  I want to thank our \n51,000 McKesson employees for their terrific efforts over the course of this year, as together we drove the \nbusiness and ac hieved significant progress in advancing our mission and our strategies.  \n \n In fiscal 2024, consolidated revenue grew 12% to $309 billion and adjusted earnings per diluted share increased \nby 6% to $27.44, both exceeding the expectations we set out at the beg inning of the fiscal year.  \n \n We're pleased with the growth across the enterprise, supported by our differentiated portfolio of assets, our \ninnovative solutions, and our deep commitment to quality and operational excellence.  We're particularly excited \nabout the opportunities within our strategic growth pillars of oncology and biopharma services.  During the year, \nwe saw a record expansion in the US oncology network and strong market demand for our access, affordability, \nand adherence solutions.  \n \n I'm going to s tart my remarks today with a review of our company priorities, and then I'm going to hand it over to \nBritt, who will take us through more details on the financial performance and our outlook for fiscal 2025. ", "original_text": "We're pleased with the growth across the enterprise, supported by our differentiated portfolio of assets, our \ninnovative solutions, and our deep commitment to quality and operational excellence. ", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81722f07-6765-4bf6-940a-500c9ac23a6e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "37d0e14efcde6c627d24372fa0d1291cedf886ae08c85cd0828fb06bc80f84d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b0398bd-b3a7-409c-9c24-1356f3f9c48c", "node_type": "1", "metadata": {"window": "Thanks for joining our call t his afternoon.  \n \n Today, we reported our fiscal fourth quarter results, marking the close to a strong fiscal 2024.  I want to thank our \n51,000 McKesson employees for their terrific efforts over the course of this year, as together we drove the \nbusiness and ac hieved significant progress in advancing our mission and our strategies.  \n \n In fiscal 2024, consolidated revenue grew 12% to $309 billion and adjusted earnings per diluted share increased \nby 6% to $27.44, both exceeding the expectations we set out at the beg inning of the fiscal year.  \n \n We're pleased with the growth across the enterprise, supported by our differentiated portfolio of assets, our \ninnovative solutions, and our deep commitment to quality and operational excellence.  We're particularly excited \nabout the opportunities within our strategic growth pillars of oncology and biopharma services.  During the year, \nwe saw a record expansion in the US oncology network and strong market demand for our access, affordability, \nand adherence solutions.  \n \n", "original_text": "In fiscal 2024, consolidated revenue grew 12% to $309 billion and adjusted earnings per diluted share increased \nby 6% to $27.44, both exceeding the expectations we set out at the beg inning of the fiscal year.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5e500bb3c408d32fe37bbd0b317d2f8e8fcceed2d88229d56ed8e5337ff18920", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e73320f9-7388-4d11-8cd2-f6b176def608", "node_type": "1", "metadata": {"window": "I want to thank our \n51,000 McKesson employees for their terrific efforts over the course of this year, as together we drove the \nbusiness and ac hieved significant progress in advancing our mission and our strategies.  \n \n In fiscal 2024, consolidated revenue grew 12% to $309 billion and adjusted earnings per diluted share increased \nby 6% to $27.44, both exceeding the expectations we set out at the beg inning of the fiscal year.  \n \n We're pleased with the growth across the enterprise, supported by our differentiated portfolio of assets, our \ninnovative solutions, and our deep commitment to quality and operational excellence.  We're particularly excited \nabout the opportunities within our strategic growth pillars of oncology and biopharma services.  During the year, \nwe saw a record expansion in the US oncology network and strong market demand for our access, affordability, \nand adherence solutions.  \n \n I'm going to s tart my remarks today with a review of our company priorities, and then I'm going to hand it over to \nBritt, who will take us through more details on the financial performance and our outlook for fiscal 2025.  What you ", "original_text": "We're particularly excited \nabout the opportunities within our strategic growth pillars of oncology and biopharma services. "}, "hash": "6c0f4724e6ac936ac528ce65e3b601b44f2d62dba85b8096dae7bc89c5300caf", "class_name": "RelatedNodeInfo"}}, "text": "We're pleased with the growth across the enterprise, supported by our differentiated portfolio of assets, our \ninnovative solutions, and our deep commitment to quality and operational excellence. ", "start_char_idx": 3027, "end_char_idx": 3223, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e73320f9-7388-4d11-8cd2-f6b176def608": {"__data__": {"id_": "e73320f9-7388-4d11-8cd2-f6b176def608", "embedding": null, "metadata": {"window": "I want to thank our \n51,000 McKesson employees for their terrific efforts over the course of this year, as together we drove the \nbusiness and ac hieved significant progress in advancing our mission and our strategies.  \n \n In fiscal 2024, consolidated revenue grew 12% to $309 billion and adjusted earnings per diluted share increased \nby 6% to $27.44, both exceeding the expectations we set out at the beg inning of the fiscal year.  \n \n We're pleased with the growth across the enterprise, supported by our differentiated portfolio of assets, our \ninnovative solutions, and our deep commitment to quality and operational excellence.  We're particularly excited \nabout the opportunities within our strategic growth pillars of oncology and biopharma services.  During the year, \nwe saw a record expansion in the US oncology network and strong market demand for our access, affordability, \nand adherence solutions.  \n \n I'm going to s tart my remarks today with a review of our company priorities, and then I'm going to hand it over to \nBritt, who will take us through more details on the financial performance and our outlook for fiscal 2025.  What you ", "original_text": "We're particularly excited \nabout the opportunities within our strategic growth pillars of oncology and biopharma services. ", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81722f07-6765-4bf6-940a-500c9ac23a6e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "37d0e14efcde6c627d24372fa0d1291cedf886ae08c85cd0828fb06bc80f84d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f95d24c-b104-4076-8dba-f4b315cbde5a", "node_type": "1", "metadata": {"window": "Today, we reported our fiscal fourth quarter results, marking the close to a strong fiscal 2024.  I want to thank our \n51,000 McKesson employees for their terrific efforts over the course of this year, as together we drove the \nbusiness and ac hieved significant progress in advancing our mission and our strategies.  \n \n In fiscal 2024, consolidated revenue grew 12% to $309 billion and adjusted earnings per diluted share increased \nby 6% to $27.44, both exceeding the expectations we set out at the beg inning of the fiscal year.  \n \n We're pleased with the growth across the enterprise, supported by our differentiated portfolio of assets, our \ninnovative solutions, and our deep commitment to quality and operational excellence.  We're particularly excited \nabout the opportunities within our strategic growth pillars of oncology and biopharma services.  During the year, \nwe saw a record expansion in the US oncology network and strong market demand for our access, affordability, \nand adherence solutions.  \n \n I'm going to s tart my remarks today with a review of our company priorities, and then I'm going to hand it over to \nBritt, who will take us through more details on the financial performance and our outlook for fiscal 2025. ", "original_text": "We're pleased with the growth across the enterprise, supported by our differentiated portfolio of assets, our \ninnovative solutions, and our deep commitment to quality and operational excellence. ", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f91ac134dfb5f6443541bbca07a195b9f1950b0675388931dcdee9c680528659", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb83b04a-775e-4d46-81f5-408f41092e75", "node_type": "1", "metadata": {"window": "In fiscal 2024, consolidated revenue grew 12% to $309 billion and adjusted earnings per diluted share increased \nby 6% to $27.44, both exceeding the expectations we set out at the beg inning of the fiscal year.  \n \n We're pleased with the growth across the enterprise, supported by our differentiated portfolio of assets, our \ninnovative solutions, and our deep commitment to quality and operational excellence.  We're particularly excited \nabout the opportunities within our strategic growth pillars of oncology and biopharma services.  During the year, \nwe saw a record expansion in the US oncology network and strong market demand for our access, affordability, \nand adherence solutions.  \n \n I'm going to s tart my remarks today with a review of our company priorities, and then I'm going to hand it over to \nBritt, who will take us through more details on the financial performance and our outlook for fiscal 2025.  What you ", "original_text": "During the year, \nwe saw a record expansion in the US oncology network and strong market demand for our access, affordability, \nand adherence solutions.  \n \n"}, "hash": "e2640d695652677687d37ec3b145a24a0ed508ff00c6d335643723ee49a243b9", "class_name": "RelatedNodeInfo"}}, "text": "We're particularly excited \nabout the opportunities within our strategic growth pillars of oncology and biopharma services. ", "start_char_idx": 3223, "end_char_idx": 3347, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb83b04a-775e-4d46-81f5-408f41092e75": {"__data__": {"id_": "fb83b04a-775e-4d46-81f5-408f41092e75", "embedding": null, "metadata": {"window": "In fiscal 2024, consolidated revenue grew 12% to $309 billion and adjusted earnings per diluted share increased \nby 6% to $27.44, both exceeding the expectations we set out at the beg inning of the fiscal year.  \n \n We're pleased with the growth across the enterprise, supported by our differentiated portfolio of assets, our \ninnovative solutions, and our deep commitment to quality and operational excellence.  We're particularly excited \nabout the opportunities within our strategic growth pillars of oncology and biopharma services.  During the year, \nwe saw a record expansion in the US oncology network and strong market demand for our access, affordability, \nand adherence solutions.  \n \n I'm going to s tart my remarks today with a review of our company priorities, and then I'm going to hand it over to \nBritt, who will take us through more details on the financial performance and our outlook for fiscal 2025.  What you ", "original_text": "During the year, \nwe saw a record expansion in the US oncology network and strong market demand for our access, affordability, \nand adherence solutions.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81722f07-6765-4bf6-940a-500c9ac23a6e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "37d0e14efcde6c627d24372fa0d1291cedf886ae08c85cd0828fb06bc80f84d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e73320f9-7388-4d11-8cd2-f6b176def608", "node_type": "1", "metadata": {"window": "I want to thank our \n51,000 McKesson employees for their terrific efforts over the course of this year, as together we drove the \nbusiness and ac hieved significant progress in advancing our mission and our strategies.  \n \n In fiscal 2024, consolidated revenue grew 12% to $309 billion and adjusted earnings per diluted share increased \nby 6% to $27.44, both exceeding the expectations we set out at the beg inning of the fiscal year.  \n \n We're pleased with the growth across the enterprise, supported by our differentiated portfolio of assets, our \ninnovative solutions, and our deep commitment to quality and operational excellence.  We're particularly excited \nabout the opportunities within our strategic growth pillars of oncology and biopharma services.  During the year, \nwe saw a record expansion in the US oncology network and strong market demand for our access, affordability, \nand adherence solutions.  \n \n I'm going to s tart my remarks today with a review of our company priorities, and then I'm going to hand it over to \nBritt, who will take us through more details on the financial performance and our outlook for fiscal 2025.  What you ", "original_text": "We're particularly excited \nabout the opportunities within our strategic growth pillars of oncology and biopharma services. ", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5c9a2dd168cfd70338b82664b4b3e9ae575bb7db822af776f4883e5f8be5bf63", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90b60628-780f-4a16-8ee3-c5ad9c47b691", "node_type": "1", "metadata": {"window": "We're pleased with the growth across the enterprise, supported by our differentiated portfolio of assets, our \ninnovative solutions, and our deep commitment to quality and operational excellence.  We're particularly excited \nabout the opportunities within our strategic growth pillars of oncology and biopharma services.  During the year, \nwe saw a record expansion in the US oncology network and strong market demand for our access, affordability, \nand adherence solutions.  \n \n I'm going to s tart my remarks today with a review of our company priorities, and then I'm going to hand it over to \nBritt, who will take us through more details on the financial performance and our outlook for fiscal 2025.  What you ", "original_text": "I'm going to s tart my remarks today with a review of our company priorities, and then I'm going to hand it over to \nBritt, who will take us through more details on the financial performance and our outlook for fiscal 2025. "}, "hash": "8f8fe79286b0e57821abbb6acc014cfadb9a28bbd305e9495625dde8d2bbfe50", "class_name": "RelatedNodeInfo"}}, "text": "During the year, \nwe saw a record expansion in the US oncology network and strong market demand for our access, affordability, \nand adherence solutions.  \n \n", "start_char_idx": 3347, "end_char_idx": 3504, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90b60628-780f-4a16-8ee3-c5ad9c47b691": {"__data__": {"id_": "90b60628-780f-4a16-8ee3-c5ad9c47b691", "embedding": null, "metadata": {"window": "We're pleased with the growth across the enterprise, supported by our differentiated portfolio of assets, our \ninnovative solutions, and our deep commitment to quality and operational excellence.  We're particularly excited \nabout the opportunities within our strategic growth pillars of oncology and biopharma services.  During the year, \nwe saw a record expansion in the US oncology network and strong market demand for our access, affordability, \nand adherence solutions.  \n \n I'm going to s tart my remarks today with a review of our company priorities, and then I'm going to hand it over to \nBritt, who will take us through more details on the financial performance and our outlook for fiscal 2025.  What you ", "original_text": "I'm going to s tart my remarks today with a review of our company priorities, and then I'm going to hand it over to \nBritt, who will take us through more details on the financial performance and our outlook for fiscal 2025. ", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81722f07-6765-4bf6-940a-500c9ac23a6e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "37d0e14efcde6c627d24372fa0d1291cedf886ae08c85cd0828fb06bc80f84d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb83b04a-775e-4d46-81f5-408f41092e75", "node_type": "1", "metadata": {"window": "In fiscal 2024, consolidated revenue grew 12% to $309 billion and adjusted earnings per diluted share increased \nby 6% to $27.44, both exceeding the expectations we set out at the beg inning of the fiscal year.  \n \n We're pleased with the growth across the enterprise, supported by our differentiated portfolio of assets, our \ninnovative solutions, and our deep commitment to quality and operational excellence.  We're particularly excited \nabout the opportunities within our strategic growth pillars of oncology and biopharma services.  During the year, \nwe saw a record expansion in the US oncology network and strong market demand for our access, affordability, \nand adherence solutions.  \n \n I'm going to s tart my remarks today with a review of our company priorities, and then I'm going to hand it over to \nBritt, who will take us through more details on the financial performance and our outlook for fiscal 2025.  What you ", "original_text": "During the year, \nwe saw a record expansion in the US oncology network and strong market demand for our access, affordability, \nand adherence solutions.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "31fc515d8ea34c9b19b568ac084eac9cf77cb674e0248c17b65d6797a55bf9e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b16761de-a178-4252-8846-526b974a5d34", "node_type": "1", "metadata": {"window": "We're particularly excited \nabout the opportunities within our strategic growth pillars of oncology and biopharma services.  During the year, \nwe saw a record expansion in the US oncology network and strong market demand for our access, affordability, \nand adherence solutions.  \n \n I'm going to s tart my remarks today with a review of our company priorities, and then I'm going to hand it over to \nBritt, who will take us through more details on the financial performance and our outlook for fiscal 2025.  What you ", "original_text": "What you "}, "hash": "c2a7d2ef309edeaf68b72ec462501d0a12aff13914fb40ab7b6a21c5300f6692", "class_name": "RelatedNodeInfo"}}, "text": "I'm going to s tart my remarks today with a review of our company priorities, and then I'm going to hand it over to \nBritt, who will take us through more details on the financial performance and our outlook for fiscal 2025. ", "start_char_idx": 3504, "end_char_idx": 3728, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b16761de-a178-4252-8846-526b974a5d34": {"__data__": {"id_": "b16761de-a178-4252-8846-526b974a5d34", "embedding": null, "metadata": {"window": "We're particularly excited \nabout the opportunities within our strategic growth pillars of oncology and biopharma services.  During the year, \nwe saw a record expansion in the US oncology network and strong market demand for our access, affordability, \nand adherence solutions.  \n \n I'm going to s tart my remarks today with a review of our company priorities, and then I'm going to hand it over to \nBritt, who will take us through more details on the financial performance and our outlook for fiscal 2025.  What you ", "original_text": "What you ", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81722f07-6765-4bf6-940a-500c9ac23a6e", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "37d0e14efcde6c627d24372fa0d1291cedf886ae08c85cd0828fb06bc80f84d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90b60628-780f-4a16-8ee3-c5ad9c47b691", "node_type": "1", "metadata": {"window": "We're pleased with the growth across the enterprise, supported by our differentiated portfolio of assets, our \ninnovative solutions, and our deep commitment to quality and operational excellence.  We're particularly excited \nabout the opportunities within our strategic growth pillars of oncology and biopharma services.  During the year, \nwe saw a record expansion in the US oncology network and strong market demand for our access, affordability, \nand adherence solutions.  \n \n I'm going to s tart my remarks today with a review of our company priorities, and then I'm going to hand it over to \nBritt, who will take us through more details on the financial performance and our outlook for fiscal 2025.  What you ", "original_text": "I'm going to s tart my remarks today with a review of our company priorities, and then I'm going to hand it over to \nBritt, who will take us through more details on the financial performance and our outlook for fiscal 2025. ", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "7cef4530d4be17da64ac2f3497a51ee24c5984324a7910d533406e4c4f07462c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49dd4c39-6e1e-41a1-8817-ac5fb727941e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwill take away from both of us today is  our confidence in the strength of the underlying businesses, our \ncommitment to continue carrying out the strategy, and the momentum into the next year.  \n \n The first company priority I want to touch on is our focus on people and culture.  Over the past few ye ars, we've \nmade continued progress in transforming McKesson into a diversified healthcare services company. ", "original_text": "McKesson Corp.  "}, "hash": "b189f38c6dfd01bb1973b01055809f2a42d6d71262175b0c01d8b307d8dbcde0", "class_name": "RelatedNodeInfo"}}, "text": "What you ", "start_char_idx": 3728, "end_char_idx": 3737, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49dd4c39-6e1e-41a1-8817-ac5fb727941e": {"__data__": {"id_": "49dd4c39-6e1e-41a1-8817-ac5fb727941e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwill take away from both of us today is  our confidence in the strength of the underlying businesses, our \ncommitment to continue carrying out the strategy, and the momentum into the next year.  \n \n The first company priority I want to touch on is our focus on people and culture.  Over the past few ye ars, we've \nmade continued progress in transforming McKesson into a diversified healthcare services company. ", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "503d358d-7b15-4003-8931-8eb136775d00", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "29ded6f744347902f63bba113ad0a953bccfbea02fd6e609ae1f15ad30da1955", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b16761de-a178-4252-8846-526b974a5d34", "node_type": "1", "metadata": {"window": "We're particularly excited \nabout the opportunities within our strategic growth pillars of oncology and biopharma services.  During the year, \nwe saw a record expansion in the US oncology network and strong market demand for our access, affordability, \nand adherence solutions.  \n \n I'm going to s tart my remarks today with a review of our company priorities, and then I'm going to hand it over to \nBritt, who will take us through more details on the financial performance and our outlook for fiscal 2025.  What you ", "original_text": "What you ", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "60e9cf0e7f6c5e971eed397e684b5cfcf7c0e2f50663e48c8c428bf9d0fa49de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1bb7daf-5f15-46e1-a941-d58eb7d958fc", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwill take away from both of us today is  our confidence in the strength of the underlying businesses, our \ncommitment to continue carrying out the strategy, and the momentum into the next year.  \n \n The first company priority I want to touch on is our focus on people and culture.  Over the past few ye ars, we've \nmade continued progress in transforming McKesson into a diversified healthcare services company.  That requires \nus to embrace new ideas and lead at the forefront of innovation. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwill take away from both of us today is  our confidence in the strength of the underlying businesses, our \ncommitment to continue carrying out the strategy, and the momentum into the next year.  \n \n"}, "hash": "e2ab1904cefc3df831664d74241c61052554c5409889a8b668d9d1260353c5bc", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1bb7daf-5f15-46e1-a941-d58eb7d958fc": {"__data__": {"id_": "c1bb7daf-5f15-46e1-a941-d58eb7d958fc", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwill take away from both of us today is  our confidence in the strength of the underlying businesses, our \ncommitment to continue carrying out the strategy, and the momentum into the next year.  \n \n The first company priority I want to touch on is our focus on people and culture.  Over the past few ye ars, we've \nmade continued progress in transforming McKesson into a diversified healthcare services company.  That requires \nus to embrace new ideas and lead at the forefront of innovation. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwill take away from both of us today is  our confidence in the strength of the underlying businesses, our \ncommitment to continue carrying out the strategy, and the momentum into the next year.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "503d358d-7b15-4003-8931-8eb136775d00", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "29ded6f744347902f63bba113ad0a953bccfbea02fd6e609ae1f15ad30da1955", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49dd4c39-6e1e-41a1-8817-ac5fb727941e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwill take away from both of us today is  our confidence in the strength of the underlying businesses, our \ncommitment to continue carrying out the strategy, and the momentum into the next year.  \n \n The first company priority I want to touch on is our focus on people and culture.  Over the past few ye ars, we've \nmade continued progress in transforming McKesson into a diversified healthcare services company. ", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3509b5c5b273058a44a1753f43298bd761181fc8a7ccb3f0a5dc2a201299a4cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e06340e-9eeb-422d-9fbd-80599851967d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwill take away from both of us today is  our confidence in the strength of the underlying businesses, our \ncommitment to continue carrying out the strategy, and the momentum into the next year.  \n \n The first company priority I want to touch on is our focus on people and culture.  Over the past few ye ars, we've \nmade continued progress in transforming McKesson into a diversified healthcare services company.  That requires \nus to embrace new ideas and lead at the forefront of innovation.  We're honored to be recognized as one of \nAmerica's Most Innovative Co mpanies by Fortune. ", "original_text": "The first company priority I want to touch on is our focus on people and culture. "}, "hash": "bf8216bdc6739daeb5cf530624f16b44c48eb39c83985271ff11b34b618feba8", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwill take away from both of us today is  our confidence in the strength of the underlying businesses, our \ncommitment to continue carrying out the strategy, and the momentum into the next year.  \n \n", "start_char_idx": 16, "end_char_idx": 378, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e06340e-9eeb-422d-9fbd-80599851967d": {"__data__": {"id_": "3e06340e-9eeb-422d-9fbd-80599851967d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwill take away from both of us today is  our confidence in the strength of the underlying businesses, our \ncommitment to continue carrying out the strategy, and the momentum into the next year.  \n \n The first company priority I want to touch on is our focus on people and culture.  Over the past few ye ars, we've \nmade continued progress in transforming McKesson into a diversified healthcare services company.  That requires \nus to embrace new ideas and lead at the forefront of innovation.  We're honored to be recognized as one of \nAmerica's Most Innovative Co mpanies by Fortune. ", "original_text": "The first company priority I want to touch on is our focus on people and culture. ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "503d358d-7b15-4003-8931-8eb136775d00", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "29ded6f744347902f63bba113ad0a953bccfbea02fd6e609ae1f15ad30da1955", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1bb7daf-5f15-46e1-a941-d58eb7d958fc", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwill take away from both of us today is  our confidence in the strength of the underlying businesses, our \ncommitment to continue carrying out the strategy, and the momentum into the next year.  \n \n The first company priority I want to touch on is our focus on people and culture.  Over the past few ye ars, we've \nmade continued progress in transforming McKesson into a diversified healthcare services company.  That requires \nus to embrace new ideas and lead at the forefront of innovation. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwill take away from both of us today is  our confidence in the strength of the underlying businesses, our \ncommitment to continue carrying out the strategy, and the momentum into the next year.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a8556e1baa46d80777d6c1877d26ef120c3e77af94abede61131ebf92943a10b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b9d393a-3654-4739-b091-9e9e99c314a7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwill take away from both of us today is  our confidence in the strength of the underlying businesses, our \ncommitment to continue carrying out the strategy, and the momentum into the next year.  \n \n The first company priority I want to touch on is our focus on people and culture.  Over the past few ye ars, we've \nmade continued progress in transforming McKesson into a diversified healthcare services company.  That requires \nus to embrace new ideas and lead at the forefront of innovation.  We're honored to be recognized as one of \nAmerica's Most Innovative Co mpanies by Fortune.  We'll continue to strengthen our innovative culture, which is \nessential to our growth strategy overall.  \n \n", "original_text": "Over the past few ye ars, we've \nmade continued progress in transforming McKesson into a diversified healthcare services company. "}, "hash": "21c1d35d3ee4b2c8dab1df0ae79d47c2b39818bbcb7cf708b825edc5c3dd2d47", "class_name": "RelatedNodeInfo"}}, "text": "The first company priority I want to touch on is our focus on people and culture. ", "start_char_idx": 378, "end_char_idx": 460, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b9d393a-3654-4739-b091-9e9e99c314a7": {"__data__": {"id_": "1b9d393a-3654-4739-b091-9e9e99c314a7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwill take away from both of us today is  our confidence in the strength of the underlying businesses, our \ncommitment to continue carrying out the strategy, and the momentum into the next year.  \n \n The first company priority I want to touch on is our focus on people and culture.  Over the past few ye ars, we've \nmade continued progress in transforming McKesson into a diversified healthcare services company.  That requires \nus to embrace new ideas and lead at the forefront of innovation.  We're honored to be recognized as one of \nAmerica's Most Innovative Co mpanies by Fortune.  We'll continue to strengthen our innovative culture, which is \nessential to our growth strategy overall.  \n \n", "original_text": "Over the past few ye ars, we've \nmade continued progress in transforming McKesson into a diversified healthcare services company. ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "503d358d-7b15-4003-8931-8eb136775d00", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "29ded6f744347902f63bba113ad0a953bccfbea02fd6e609ae1f15ad30da1955", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e06340e-9eeb-422d-9fbd-80599851967d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwill take away from both of us today is  our confidence in the strength of the underlying businesses, our \ncommitment to continue carrying out the strategy, and the momentum into the next year.  \n \n The first company priority I want to touch on is our focus on people and culture.  Over the past few ye ars, we've \nmade continued progress in transforming McKesson into a diversified healthcare services company.  That requires \nus to embrace new ideas and lead at the forefront of innovation.  We're honored to be recognized as one of \nAmerica's Most Innovative Co mpanies by Fortune. ", "original_text": "The first company priority I want to touch on is our focus on people and culture. ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "aa1d81abc1c92a3c9fe0d28e3475597546b15771f173f8e959b565244081175f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1184817b-9066-4074-93aa-d17f6acd4ca7", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwill take away from both of us today is  our confidence in the strength of the underlying businesses, our \ncommitment to continue carrying out the strategy, and the momentum into the next year.  \n \n The first company priority I want to touch on is our focus on people and culture.  Over the past few ye ars, we've \nmade continued progress in transforming McKesson into a diversified healthcare services company.  That requires \nus to embrace new ideas and lead at the forefront of innovation.  We're honored to be recognized as one of \nAmerica's Most Innovative Co mpanies by Fortune.  We'll continue to strengthen our innovative culture, which is \nessential to our growth strategy overall.  \n \n Recently, we were also named as one of America's Greatest Workplaces for Women by Newsweek and a Top \nWomen Employer by DiversityCom m Media. ", "original_text": "That requires \nus to embrace new ideas and lead at the forefront of innovation. "}, "hash": "5f053ce7c86047a815d87e04de4e26a545a86616f60b9f1e0fe8e3dbcbc428be", "class_name": "RelatedNodeInfo"}}, "text": "Over the past few ye ars, we've \nmade continued progress in transforming McKesson into a diversified healthcare services company. ", "start_char_idx": 460, "end_char_idx": 590, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1184817b-9066-4074-93aa-d17f6acd4ca7": {"__data__": {"id_": "1184817b-9066-4074-93aa-d17f6acd4ca7", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwill take away from both of us today is  our confidence in the strength of the underlying businesses, our \ncommitment to continue carrying out the strategy, and the momentum into the next year.  \n \n The first company priority I want to touch on is our focus on people and culture.  Over the past few ye ars, we've \nmade continued progress in transforming McKesson into a diversified healthcare services company.  That requires \nus to embrace new ideas and lead at the forefront of innovation.  We're honored to be recognized as one of \nAmerica's Most Innovative Co mpanies by Fortune.  We'll continue to strengthen our innovative culture, which is \nessential to our growth strategy overall.  \n \n Recently, we were also named as one of America's Greatest Workplaces for Women by Newsweek and a Top \nWomen Employer by DiversityCom m Media. ", "original_text": "That requires \nus to embrace new ideas and lead at the forefront of innovation. ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "503d358d-7b15-4003-8931-8eb136775d00", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "29ded6f744347902f63bba113ad0a953bccfbea02fd6e609ae1f15ad30da1955", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b9d393a-3654-4739-b091-9e9e99c314a7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwill take away from both of us today is  our confidence in the strength of the underlying businesses, our \ncommitment to continue carrying out the strategy, and the momentum into the next year.  \n \n The first company priority I want to touch on is our focus on people and culture.  Over the past few ye ars, we've \nmade continued progress in transforming McKesson into a diversified healthcare services company.  That requires \nus to embrace new ideas and lead at the forefront of innovation.  We're honored to be recognized as one of \nAmerica's Most Innovative Co mpanies by Fortune.  We'll continue to strengthen our innovative culture, which is \nessential to our growth strategy overall.  \n \n", "original_text": "Over the past few ye ars, we've \nmade continued progress in transforming McKesson into a diversified healthcare services company. ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "0671042970719529625908ce9f538701fbe90b40556b0f688403810d2e78f59f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66aaadc4-e258-4e1f-86fb-a2660cd47fec", "node_type": "1", "metadata": {"window": "The first company priority I want to touch on is our focus on people and culture.  Over the past few ye ars, we've \nmade continued progress in transforming McKesson into a diversified healthcare services company.  That requires \nus to embrace new ideas and lead at the forefront of innovation.  We're honored to be recognized as one of \nAmerica's Most Innovative Co mpanies by Fortune.  We'll continue to strengthen our innovative culture, which is \nessential to our growth strategy overall.  \n \n Recently, we were also named as one of America's Greatest Workplaces for Women by Newsweek and a Top \nWomen Employer by DiversityCom m Media.  I am pleased to see our company -wide efforts continue to be \nrecognized externally. ", "original_text": "We're honored to be recognized as one of \nAmerica's Most Innovative Co mpanies by Fortune. "}, "hash": "6ec889ce665704f2dceb70a7fe07f244d2af4660e3f5151b0b05554622b73ab6", "class_name": "RelatedNodeInfo"}}, "text": "That requires \nus to embrace new ideas and lead at the forefront of innovation. ", "start_char_idx": 590, "end_char_idx": 670, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66aaadc4-e258-4e1f-86fb-a2660cd47fec": {"__data__": {"id_": "66aaadc4-e258-4e1f-86fb-a2660cd47fec", "embedding": null, "metadata": {"window": "The first company priority I want to touch on is our focus on people and culture.  Over the past few ye ars, we've \nmade continued progress in transforming McKesson into a diversified healthcare services company.  That requires \nus to embrace new ideas and lead at the forefront of innovation.  We're honored to be recognized as one of \nAmerica's Most Innovative Co mpanies by Fortune.  We'll continue to strengthen our innovative culture, which is \nessential to our growth strategy overall.  \n \n Recently, we were also named as one of America's Greatest Workplaces for Women by Newsweek and a Top \nWomen Employer by DiversityCom m Media.  I am pleased to see our company -wide efforts continue to be \nrecognized externally. ", "original_text": "We're honored to be recognized as one of \nAmerica's Most Innovative Co mpanies by Fortune. ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "503d358d-7b15-4003-8931-8eb136775d00", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "29ded6f744347902f63bba113ad0a953bccfbea02fd6e609ae1f15ad30da1955", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1184817b-9066-4074-93aa-d17f6acd4ca7", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwill take away from both of us today is  our confidence in the strength of the underlying businesses, our \ncommitment to continue carrying out the strategy, and the momentum into the next year.  \n \n The first company priority I want to touch on is our focus on people and culture.  Over the past few ye ars, we've \nmade continued progress in transforming McKesson into a diversified healthcare services company.  That requires \nus to embrace new ideas and lead at the forefront of innovation.  We're honored to be recognized as one of \nAmerica's Most Innovative Co mpanies by Fortune.  We'll continue to strengthen our innovative culture, which is \nessential to our growth strategy overall.  \n \n Recently, we were also named as one of America's Greatest Workplaces for Women by Newsweek and a Top \nWomen Employer by DiversityCom m Media. ", "original_text": "That requires \nus to embrace new ideas and lead at the forefront of innovation. ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c02d4b981ff42ebda8a58f765a1e30191b437cf676fc93485cf20a4f6cf3fe05", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e586b312-7f70-4d10-bd1a-6246a85c7a94", "node_type": "1", "metadata": {"window": "Over the past few ye ars, we've \nmade continued progress in transforming McKesson into a diversified healthcare services company.  That requires \nus to embrace new ideas and lead at the forefront of innovation.  We're honored to be recognized as one of \nAmerica's Most Innovative Co mpanies by Fortune.  We'll continue to strengthen our innovative culture, which is \nessential to our growth strategy overall.  \n \n Recently, we were also named as one of America's Greatest Workplaces for Women by Newsweek and a Top \nWomen Employer by DiversityCom m Media.  I am pleased to see our company -wide efforts continue to be \nrecognized externally.  I'm also really quite impressed by the commitment and leadership exhibited by so many \nMcKesson employees and the initiatives they take on to support each other and to create an open and \ncollaborative culture.  \n \n", "original_text": "We'll continue to strengthen our innovative culture, which is \nessential to our growth strategy overall.  \n \n"}, "hash": "e36b51d9f41b10e24a18a2b3ce43b7548bf5788f07faca5907b9c8c4a9a09def", "class_name": "RelatedNodeInfo"}}, "text": "We're honored to be recognized as one of \nAmerica's Most Innovative Co mpanies by Fortune. ", "start_char_idx": 670, "end_char_idx": 761, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e586b312-7f70-4d10-bd1a-6246a85c7a94": {"__data__": {"id_": "e586b312-7f70-4d10-bd1a-6246a85c7a94", "embedding": null, "metadata": {"window": "Over the past few ye ars, we've \nmade continued progress in transforming McKesson into a diversified healthcare services company.  That requires \nus to embrace new ideas and lead at the forefront of innovation.  We're honored to be recognized as one of \nAmerica's Most Innovative Co mpanies by Fortune.  We'll continue to strengthen our innovative culture, which is \nessential to our growth strategy overall.  \n \n Recently, we were also named as one of America's Greatest Workplaces for Women by Newsweek and a Top \nWomen Employer by DiversityCom m Media.  I am pleased to see our company -wide efforts continue to be \nrecognized externally.  I'm also really quite impressed by the commitment and leadership exhibited by so many \nMcKesson employees and the initiatives they take on to support each other and to create an open and \ncollaborative culture.  \n \n", "original_text": "We'll continue to strengthen our innovative culture, which is \nessential to our growth strategy overall.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "503d358d-7b15-4003-8931-8eb136775d00", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "29ded6f744347902f63bba113ad0a953bccfbea02fd6e609ae1f15ad30da1955", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66aaadc4-e258-4e1f-86fb-a2660cd47fec", "node_type": "1", "metadata": {"window": "The first company priority I want to touch on is our focus on people and culture.  Over the past few ye ars, we've \nmade continued progress in transforming McKesson into a diversified healthcare services company.  That requires \nus to embrace new ideas and lead at the forefront of innovation.  We're honored to be recognized as one of \nAmerica's Most Innovative Co mpanies by Fortune.  We'll continue to strengthen our innovative culture, which is \nessential to our growth strategy overall.  \n \n Recently, we were also named as one of America's Greatest Workplaces for Women by Newsweek and a Top \nWomen Employer by DiversityCom m Media.  I am pleased to see our company -wide efforts continue to be \nrecognized externally. ", "original_text": "We're honored to be recognized as one of \nAmerica's Most Innovative Co mpanies by Fortune. ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "48e7dc6c6ce4d7d78f7bcac45e22ec15bdae86d89ba0b49401058a191bf61bd2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f160a86-0932-4ccf-a449-a096bfde2db7", "node_type": "1", "metadata": {"window": "That requires \nus to embrace new ideas and lead at the forefront of innovation.  We're honored to be recognized as one of \nAmerica's Most Innovative Co mpanies by Fortune.  We'll continue to strengthen our innovative culture, which is \nessential to our growth strategy overall.  \n \n Recently, we were also named as one of America's Greatest Workplaces for Women by Newsweek and a Top \nWomen Employer by DiversityCom m Media.  I am pleased to see our company -wide efforts continue to be \nrecognized externally.  I'm also really quite impressed by the commitment and leadership exhibited by so many \nMcKesson employees and the initiatives they take on to support each other and to create an open and \ncollaborative culture.  \n \n Moving on to our two strategic pillars of oncology and biopharma services, these are both pivotal assets that \nunlock tremendous value and bring significant benefits to our customers and stakeholders. ", "original_text": "Recently, we were also named as one of America's Greatest Workplaces for Women by Newsweek and a Top \nWomen Employer by DiversityCom m Media. "}, "hash": "dc41adc8bbf934e7fb69d0e5645a34dc10fb83bb388fb087e3fb3ac7e1e78ed2", "class_name": "RelatedNodeInfo"}}, "text": "We'll continue to strengthen our innovative culture, which is \nessential to our growth strategy overall.  \n \n", "start_char_idx": 761, "end_char_idx": 870, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f160a86-0932-4ccf-a449-a096bfde2db7": {"__data__": {"id_": "2f160a86-0932-4ccf-a449-a096bfde2db7", "embedding": null, "metadata": {"window": "That requires \nus to embrace new ideas and lead at the forefront of innovation.  We're honored to be recognized as one of \nAmerica's Most Innovative Co mpanies by Fortune.  We'll continue to strengthen our innovative culture, which is \nessential to our growth strategy overall.  \n \n Recently, we were also named as one of America's Greatest Workplaces for Women by Newsweek and a Top \nWomen Employer by DiversityCom m Media.  I am pleased to see our company -wide efforts continue to be \nrecognized externally.  I'm also really quite impressed by the commitment and leadership exhibited by so many \nMcKesson employees and the initiatives they take on to support each other and to create an open and \ncollaborative culture.  \n \n Moving on to our two strategic pillars of oncology and biopharma services, these are both pivotal assets that \nunlock tremendous value and bring significant benefits to our customers and stakeholders. ", "original_text": "Recently, we were also named as one of America's Greatest Workplaces for Women by Newsweek and a Top \nWomen Employer by DiversityCom m Media. ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "503d358d-7b15-4003-8931-8eb136775d00", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "29ded6f744347902f63bba113ad0a953bccfbea02fd6e609ae1f15ad30da1955", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e586b312-7f70-4d10-bd1a-6246a85c7a94", "node_type": "1", "metadata": {"window": "Over the past few ye ars, we've \nmade continued progress in transforming McKesson into a diversified healthcare services company.  That requires \nus to embrace new ideas and lead at the forefront of innovation.  We're honored to be recognized as one of \nAmerica's Most Innovative Co mpanies by Fortune.  We'll continue to strengthen our innovative culture, which is \nessential to our growth strategy overall.  \n \n Recently, we were also named as one of America's Greatest Workplaces for Women by Newsweek and a Top \nWomen Employer by DiversityCom m Media.  I am pleased to see our company -wide efforts continue to be \nrecognized externally.  I'm also really quite impressed by the commitment and leadership exhibited by so many \nMcKesson employees and the initiatives they take on to support each other and to create an open and \ncollaborative culture.  \n \n", "original_text": "We'll continue to strengthen our innovative culture, which is \nessential to our growth strategy overall.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "6142ef34f3a8e5614cdbfa129a6d7d779d2edb57e755642df9ab5de4956ba58d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69aae43d-dd34-481c-9b37-77831a5d3b03", "node_type": "1", "metadata": {"window": "We're honored to be recognized as one of \nAmerica's Most Innovative Co mpanies by Fortune.  We'll continue to strengthen our innovative culture, which is \nessential to our growth strategy overall.  \n \n Recently, we were also named as one of America's Greatest Workplaces for Women by Newsweek and a Top \nWomen Employer by DiversityCom m Media.  I am pleased to see our company -wide efforts continue to be \nrecognized externally.  I'm also really quite impressed by the commitment and leadership exhibited by so many \nMcKesson employees and the initiatives they take on to support each other and to create an open and \ncollaborative culture.  \n \n Moving on to our two strategic pillars of oncology and biopharma services, these are both pivotal assets that \nunlock tremendous value and bring significant benefits to our customers and stakeholders.  Over the y ears, we've \nbeen building out our portfolio of assets around oncology, spanning from the distribution of related therapies to \npractice management, to oncology data insights and other value -added services.  \n \n", "original_text": "I am pleased to see our company -wide efforts continue to be \nrecognized externally. "}, "hash": "95193696eb2304d851c8f64a8b27d07384f2513e8f40a3c708390ef2cd30bf64", "class_name": "RelatedNodeInfo"}}, "text": "Recently, we were also named as one of America's Greatest Workplaces for Women by Newsweek and a Top \nWomen Employer by DiversityCom m Media. ", "start_char_idx": 870, "end_char_idx": 1012, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69aae43d-dd34-481c-9b37-77831a5d3b03": {"__data__": {"id_": "69aae43d-dd34-481c-9b37-77831a5d3b03", "embedding": null, "metadata": {"window": "We're honored to be recognized as one of \nAmerica's Most Innovative Co mpanies by Fortune.  We'll continue to strengthen our innovative culture, which is \nessential to our growth strategy overall.  \n \n Recently, we were also named as one of America's Greatest Workplaces for Women by Newsweek and a Top \nWomen Employer by DiversityCom m Media.  I am pleased to see our company -wide efforts continue to be \nrecognized externally.  I'm also really quite impressed by the commitment and leadership exhibited by so many \nMcKesson employees and the initiatives they take on to support each other and to create an open and \ncollaborative culture.  \n \n Moving on to our two strategic pillars of oncology and biopharma services, these are both pivotal assets that \nunlock tremendous value and bring significant benefits to our customers and stakeholders.  Over the y ears, we've \nbeen building out our portfolio of assets around oncology, spanning from the distribution of related therapies to \npractice management, to oncology data insights and other value -added services.  \n \n", "original_text": "I am pleased to see our company -wide efforts continue to be \nrecognized externally. ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "503d358d-7b15-4003-8931-8eb136775d00", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "29ded6f744347902f63bba113ad0a953bccfbea02fd6e609ae1f15ad30da1955", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f160a86-0932-4ccf-a449-a096bfde2db7", "node_type": "1", "metadata": {"window": "That requires \nus to embrace new ideas and lead at the forefront of innovation.  We're honored to be recognized as one of \nAmerica's Most Innovative Co mpanies by Fortune.  We'll continue to strengthen our innovative culture, which is \nessential to our growth strategy overall.  \n \n Recently, we were also named as one of America's Greatest Workplaces for Women by Newsweek and a Top \nWomen Employer by DiversityCom m Media.  I am pleased to see our company -wide efforts continue to be \nrecognized externally.  I'm also really quite impressed by the commitment and leadership exhibited by so many \nMcKesson employees and the initiatives they take on to support each other and to create an open and \ncollaborative culture.  \n \n Moving on to our two strategic pillars of oncology and biopharma services, these are both pivotal assets that \nunlock tremendous value and bring significant benefits to our customers and stakeholders. ", "original_text": "Recently, we were also named as one of America's Greatest Workplaces for Women by Newsweek and a Top \nWomen Employer by DiversityCom m Media. ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "2bb1a18e221085f56b991054821e4842a847a9959b1e2c60908fc3f26cccefba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04ee86d4-c4ba-4a33-b27a-f72e60b834d8", "node_type": "1", "metadata": {"window": "We'll continue to strengthen our innovative culture, which is \nessential to our growth strategy overall.  \n \n Recently, we were also named as one of America's Greatest Workplaces for Women by Newsweek and a Top \nWomen Employer by DiversityCom m Media.  I am pleased to see our company -wide efforts continue to be \nrecognized externally.  I'm also really quite impressed by the commitment and leadership exhibited by so many \nMcKesson employees and the initiatives they take on to support each other and to create an open and \ncollaborative culture.  \n \n Moving on to our two strategic pillars of oncology and biopharma services, these are both pivotal assets that \nunlock tremendous value and bring significant benefits to our customers and stakeholders.  Over the y ears, we've \nbeen building out our portfolio of assets around oncology, spanning from the distribution of related therapies to \npractice management, to oncology data insights and other value -added services.  \n \n We're very pleased with the meaningful expansion i n our oncology assets, as reflected in the growth of the US \noncology network. ", "original_text": "I'm also really quite impressed by the commitment and leadership exhibited by so many \nMcKesson employees and the initiatives they take on to support each other and to create an open and \ncollaborative culture.  \n \n"}, "hash": "db44a8b29bd43320dc8fc42e42e1496083d120c76b7727d591be76bae148cae6", "class_name": "RelatedNodeInfo"}}, "text": "I am pleased to see our company -wide efforts continue to be \nrecognized externally. ", "start_char_idx": 1012, "end_char_idx": 1097, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04ee86d4-c4ba-4a33-b27a-f72e60b834d8": {"__data__": {"id_": "04ee86d4-c4ba-4a33-b27a-f72e60b834d8", "embedding": null, "metadata": {"window": "We'll continue to strengthen our innovative culture, which is \nessential to our growth strategy overall.  \n \n Recently, we were also named as one of America's Greatest Workplaces for Women by Newsweek and a Top \nWomen Employer by DiversityCom m Media.  I am pleased to see our company -wide efforts continue to be \nrecognized externally.  I'm also really quite impressed by the commitment and leadership exhibited by so many \nMcKesson employees and the initiatives they take on to support each other and to create an open and \ncollaborative culture.  \n \n Moving on to our two strategic pillars of oncology and biopharma services, these are both pivotal assets that \nunlock tremendous value and bring significant benefits to our customers and stakeholders.  Over the y ears, we've \nbeen building out our portfolio of assets around oncology, spanning from the distribution of related therapies to \npractice management, to oncology data insights and other value -added services.  \n \n We're very pleased with the meaningful expansion i n our oncology assets, as reflected in the growth of the US \noncology network. ", "original_text": "I'm also really quite impressed by the commitment and leadership exhibited by so many \nMcKesson employees and the initiatives they take on to support each other and to create an open and \ncollaborative culture.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "503d358d-7b15-4003-8931-8eb136775d00", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "29ded6f744347902f63bba113ad0a953bccfbea02fd6e609ae1f15ad30da1955", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69aae43d-dd34-481c-9b37-77831a5d3b03", "node_type": "1", "metadata": {"window": "We're honored to be recognized as one of \nAmerica's Most Innovative Co mpanies by Fortune.  We'll continue to strengthen our innovative culture, which is \nessential to our growth strategy overall.  \n \n Recently, we were also named as one of America's Greatest Workplaces for Women by Newsweek and a Top \nWomen Employer by DiversityCom m Media.  I am pleased to see our company -wide efforts continue to be \nrecognized externally.  I'm also really quite impressed by the commitment and leadership exhibited by so many \nMcKesson employees and the initiatives they take on to support each other and to create an open and \ncollaborative culture.  \n \n Moving on to our two strategic pillars of oncology and biopharma services, these are both pivotal assets that \nunlock tremendous value and bring significant benefits to our customers and stakeholders.  Over the y ears, we've \nbeen building out our portfolio of assets around oncology, spanning from the distribution of related therapies to \npractice management, to oncology data insights and other value -added services.  \n \n", "original_text": "I am pleased to see our company -wide efforts continue to be \nrecognized externally. ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "6ff80c8a6406c59d615d20c0c446082b2502dfb60014007a4c3c3198dd6752e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1b21d7c-09c9-4cb7-8e57-cc6032d5d5f5", "node_type": "1", "metadata": {"window": "Recently, we were also named as one of America's Greatest Workplaces for Women by Newsweek and a Top \nWomen Employer by DiversityCom m Media.  I am pleased to see our company -wide efforts continue to be \nrecognized externally.  I'm also really quite impressed by the commitment and leadership exhibited by so many \nMcKesson employees and the initiatives they take on to support each other and to create an open and \ncollaborative culture.  \n \n Moving on to our two strategic pillars of oncology and biopharma services, these are both pivotal assets that \nunlock tremendous value and bring significant benefits to our customers and stakeholders.  Over the y ears, we've \nbeen building out our portfolio of assets around oncology, spanning from the distribution of related therapies to \npractice management, to oncology data insights and other value -added services.  \n \n We're very pleased with the meaningful expansion i n our oncology assets, as reflected in the growth of the US \noncology network.  We welcomed four practices to the network in the fiscal year, including Regional Cancer Care \nAssociates, Cancer Center of Kansas, Nashville Oncology Associates, and SCRI Oncology  Partners. ", "original_text": "Moving on to our two strategic pillars of oncology and biopharma services, these are both pivotal assets that \nunlock tremendous value and bring significant benefits to our customers and stakeholders. "}, "hash": "6646ef1d7a329cc151645ec27193a94d05790115dbdf563697dde45b822e3757", "class_name": "RelatedNodeInfo"}}, "text": "I'm also really quite impressed by the commitment and leadership exhibited by so many \nMcKesson employees and the initiatives they take on to support each other and to create an open and \ncollaborative culture.  \n \n", "start_char_idx": 1097, "end_char_idx": 1312, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1b21d7c-09c9-4cb7-8e57-cc6032d5d5f5": {"__data__": {"id_": "f1b21d7c-09c9-4cb7-8e57-cc6032d5d5f5", "embedding": null, "metadata": {"window": "Recently, we were also named as one of America's Greatest Workplaces for Women by Newsweek and a Top \nWomen Employer by DiversityCom m Media.  I am pleased to see our company -wide efforts continue to be \nrecognized externally.  I'm also really quite impressed by the commitment and leadership exhibited by so many \nMcKesson employees and the initiatives they take on to support each other and to create an open and \ncollaborative culture.  \n \n Moving on to our two strategic pillars of oncology and biopharma services, these are both pivotal assets that \nunlock tremendous value and bring significant benefits to our customers and stakeholders.  Over the y ears, we've \nbeen building out our portfolio of assets around oncology, spanning from the distribution of related therapies to \npractice management, to oncology data insights and other value -added services.  \n \n We're very pleased with the meaningful expansion i n our oncology assets, as reflected in the growth of the US \noncology network.  We welcomed four practices to the network in the fiscal year, including Regional Cancer Care \nAssociates, Cancer Center of Kansas, Nashville Oncology Associates, and SCRI Oncology  Partners. ", "original_text": "Moving on to our two strategic pillars of oncology and biopharma services, these are both pivotal assets that \nunlock tremendous value and bring significant benefits to our customers and stakeholders. ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "503d358d-7b15-4003-8931-8eb136775d00", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "29ded6f744347902f63bba113ad0a953bccfbea02fd6e609ae1f15ad30da1955", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04ee86d4-c4ba-4a33-b27a-f72e60b834d8", "node_type": "1", "metadata": {"window": "We'll continue to strengthen our innovative culture, which is \nessential to our growth strategy overall.  \n \n Recently, we were also named as one of America's Greatest Workplaces for Women by Newsweek and a Top \nWomen Employer by DiversityCom m Media.  I am pleased to see our company -wide efforts continue to be \nrecognized externally.  I'm also really quite impressed by the commitment and leadership exhibited by so many \nMcKesson employees and the initiatives they take on to support each other and to create an open and \ncollaborative culture.  \n \n Moving on to our two strategic pillars of oncology and biopharma services, these are both pivotal assets that \nunlock tremendous value and bring significant benefits to our customers and stakeholders.  Over the y ears, we've \nbeen building out our portfolio of assets around oncology, spanning from the distribution of related therapies to \npractice management, to oncology data insights and other value -added services.  \n \n We're very pleased with the meaningful expansion i n our oncology assets, as reflected in the growth of the US \noncology network. ", "original_text": "I'm also really quite impressed by the commitment and leadership exhibited by so many \nMcKesson employees and the initiatives they take on to support each other and to create an open and \ncollaborative culture.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "6b87f806eacc7c19480969004ba5997ad440f2cf256b0d88a2f14bf6f5516822", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59608038-bc94-4f58-aac6-4e99e30048f4", "node_type": "1", "metadata": {"window": "I am pleased to see our company -wide efforts continue to be \nrecognized externally.  I'm also really quite impressed by the commitment and leadership exhibited by so many \nMcKesson employees and the initiatives they take on to support each other and to create an open and \ncollaborative culture.  \n \n Moving on to our two strategic pillars of oncology and biopharma services, these are both pivotal assets that \nunlock tremendous value and bring significant benefits to our customers and stakeholders.  Over the y ears, we've \nbeen building out our portfolio of assets around oncology, spanning from the distribution of related therapies to \npractice management, to oncology data insights and other value -added services.  \n \n We're very pleased with the meaningful expansion i n our oncology assets, as reflected in the growth of the US \noncology network.  We welcomed four practices to the network in the fiscal year, including Regional Cancer Care \nAssociates, Cancer Center of Kansas, Nashville Oncology Associates, and SCRI Oncology  Partners.  The addition \nof these new practices expands our geographic footprint and allows us to provide our services to a broader set of \nproviders and importantly to the patients they serve.  \n \n", "original_text": "Over the y ears, we've \nbeen building out our portfolio of assets around oncology, spanning from the distribution of related therapies to \npractice management, to oncology data insights and other value -added services.  \n \n"}, "hash": "f724e1473a6716c9e4df0c9b90dc40622a37322f73d68c7aacfd76cf955005e4", "class_name": "RelatedNodeInfo"}}, "text": "Moving on to our two strategic pillars of oncology and biopharma services, these are both pivotal assets that \nunlock tremendous value and bring significant benefits to our customers and stakeholders. ", "start_char_idx": 1312, "end_char_idx": 1513, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59608038-bc94-4f58-aac6-4e99e30048f4": {"__data__": {"id_": "59608038-bc94-4f58-aac6-4e99e30048f4", "embedding": null, "metadata": {"window": "I am pleased to see our company -wide efforts continue to be \nrecognized externally.  I'm also really quite impressed by the commitment and leadership exhibited by so many \nMcKesson employees and the initiatives they take on to support each other and to create an open and \ncollaborative culture.  \n \n Moving on to our two strategic pillars of oncology and biopharma services, these are both pivotal assets that \nunlock tremendous value and bring significant benefits to our customers and stakeholders.  Over the y ears, we've \nbeen building out our portfolio of assets around oncology, spanning from the distribution of related therapies to \npractice management, to oncology data insights and other value -added services.  \n \n We're very pleased with the meaningful expansion i n our oncology assets, as reflected in the growth of the US \noncology network.  We welcomed four practices to the network in the fiscal year, including Regional Cancer Care \nAssociates, Cancer Center of Kansas, Nashville Oncology Associates, and SCRI Oncology  Partners.  The addition \nof these new practices expands our geographic footprint and allows us to provide our services to a broader set of \nproviders and importantly to the patients they serve.  \n \n", "original_text": "Over the y ears, we've \nbeen building out our portfolio of assets around oncology, spanning from the distribution of related therapies to \npractice management, to oncology data insights and other value -added services.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "503d358d-7b15-4003-8931-8eb136775d00", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "29ded6f744347902f63bba113ad0a953bccfbea02fd6e609ae1f15ad30da1955", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1b21d7c-09c9-4cb7-8e57-cc6032d5d5f5", "node_type": "1", "metadata": {"window": "Recently, we were also named as one of America's Greatest Workplaces for Women by Newsweek and a Top \nWomen Employer by DiversityCom m Media.  I am pleased to see our company -wide efforts continue to be \nrecognized externally.  I'm also really quite impressed by the commitment and leadership exhibited by so many \nMcKesson employees and the initiatives they take on to support each other and to create an open and \ncollaborative culture.  \n \n Moving on to our two strategic pillars of oncology and biopharma services, these are both pivotal assets that \nunlock tremendous value and bring significant benefits to our customers and stakeholders.  Over the y ears, we've \nbeen building out our portfolio of assets around oncology, spanning from the distribution of related therapies to \npractice management, to oncology data insights and other value -added services.  \n \n We're very pleased with the meaningful expansion i n our oncology assets, as reflected in the growth of the US \noncology network.  We welcomed four practices to the network in the fiscal year, including Regional Cancer Care \nAssociates, Cancer Center of Kansas, Nashville Oncology Associates, and SCRI Oncology  Partners. ", "original_text": "Moving on to our two strategic pillars of oncology and biopharma services, these are both pivotal assets that \nunlock tremendous value and bring significant benefits to our customers and stakeholders. ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "10207345ab7e7938fbcbb7111698da8e3fbc47f8c94b6bba4294a58b4a6517ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "715a73d7-5165-4fd8-97b9-8dccfae137d6", "node_type": "1", "metadata": {"window": "I'm also really quite impressed by the commitment and leadership exhibited by so many \nMcKesson employees and the initiatives they take on to support each other and to create an open and \ncollaborative culture.  \n \n Moving on to our two strategic pillars of oncology and biopharma services, these are both pivotal assets that \nunlock tremendous value and bring significant benefits to our customers and stakeholders.  Over the y ears, we've \nbeen building out our portfolio of assets around oncology, spanning from the distribution of related therapies to \npractice management, to oncology data insights and other value -added services.  \n \n We're very pleased with the meaningful expansion i n our oncology assets, as reflected in the growth of the US \noncology network.  We welcomed four practices to the network in the fiscal year, including Regional Cancer Care \nAssociates, Cancer Center of Kansas, Nashville Oncology Associates, and SCRI Oncology  Partners.  The addition \nof these new practices expands our geographic footprint and allows us to provide our services to a broader set of \nproviders and importantly to the patients they serve.  \n \n As of April, the network has grown to approximately 2,600 provi ders at 600 sites of care across 31 states. ", "original_text": "We're very pleased with the meaningful expansion i n our oncology assets, as reflected in the growth of the US \noncology network. "}, "hash": "f712c957c59375450fe184bc712436ad9d5bc35517bc0a7fa892565b8d3f910a", "class_name": "RelatedNodeInfo"}}, "text": "Over the y ears, we've \nbeen building out our portfolio of assets around oncology, spanning from the distribution of related therapies to \npractice management, to oncology data insights and other value -added services.  \n \n", "start_char_idx": 1513, "end_char_idx": 1736, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "715a73d7-5165-4fd8-97b9-8dccfae137d6": {"__data__": {"id_": "715a73d7-5165-4fd8-97b9-8dccfae137d6", "embedding": null, "metadata": {"window": "I'm also really quite impressed by the commitment and leadership exhibited by so many \nMcKesson employees and the initiatives they take on to support each other and to create an open and \ncollaborative culture.  \n \n Moving on to our two strategic pillars of oncology and biopharma services, these are both pivotal assets that \nunlock tremendous value and bring significant benefits to our customers and stakeholders.  Over the y ears, we've \nbeen building out our portfolio of assets around oncology, spanning from the distribution of related therapies to \npractice management, to oncology data insights and other value -added services.  \n \n We're very pleased with the meaningful expansion i n our oncology assets, as reflected in the growth of the US \noncology network.  We welcomed four practices to the network in the fiscal year, including Regional Cancer Care \nAssociates, Cancer Center of Kansas, Nashville Oncology Associates, and SCRI Oncology  Partners.  The addition \nof these new practices expands our geographic footprint and allows us to provide our services to a broader set of \nproviders and importantly to the patients they serve.  \n \n As of April, the network has grown to approximately 2,600 provi ders at 600 sites of care across 31 states. ", "original_text": "We're very pleased with the meaningful expansion i n our oncology assets, as reflected in the growth of the US \noncology network. ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "503d358d-7b15-4003-8931-8eb136775d00", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "29ded6f744347902f63bba113ad0a953bccfbea02fd6e609ae1f15ad30da1955", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59608038-bc94-4f58-aac6-4e99e30048f4", "node_type": "1", "metadata": {"window": "I am pleased to see our company -wide efforts continue to be \nrecognized externally.  I'm also really quite impressed by the commitment and leadership exhibited by so many \nMcKesson employees and the initiatives they take on to support each other and to create an open and \ncollaborative culture.  \n \n Moving on to our two strategic pillars of oncology and biopharma services, these are both pivotal assets that \nunlock tremendous value and bring significant benefits to our customers and stakeholders.  Over the y ears, we've \nbeen building out our portfolio of assets around oncology, spanning from the distribution of related therapies to \npractice management, to oncology data insights and other value -added services.  \n \n We're very pleased with the meaningful expansion i n our oncology assets, as reflected in the growth of the US \noncology network.  We welcomed four practices to the network in the fiscal year, including Regional Cancer Care \nAssociates, Cancer Center of Kansas, Nashville Oncology Associates, and SCRI Oncology  Partners.  The addition \nof these new practices expands our geographic footprint and allows us to provide our services to a broader set of \nproviders and importantly to the patients they serve.  \n \n", "original_text": "Over the y ears, we've \nbeen building out our portfolio of assets around oncology, spanning from the distribution of related therapies to \npractice management, to oncology data insights and other value -added services.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "cc23158b08d3f709383d7c869210c72c0bb696ec4cc3100b411ff6901eb67a88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bce1fa01-88ce-417d-ae64-763903514008", "node_type": "1", "metadata": {"window": "Moving on to our two strategic pillars of oncology and biopharma services, these are both pivotal assets that \nunlock tremendous value and bring significant benefits to our customers and stakeholders.  Over the y ears, we've \nbeen building out our portfolio of assets around oncology, spanning from the distribution of related therapies to \npractice management, to oncology data insights and other value -added services.  \n \n We're very pleased with the meaningful expansion i n our oncology assets, as reflected in the growth of the US \noncology network.  We welcomed four practices to the network in the fiscal year, including Regional Cancer Care \nAssociates, Cancer Center of Kansas, Nashville Oncology Associates, and SCRI Oncology  Partners.  The addition \nof these new practices expands our geographic footprint and allows us to provide our services to a broader set of \nproviders and importantly to the patients they serve.  \n \n As of April, the network has grown to approximately 2,600 provi ders at 600 sites of care across 31 states.  We \ngrew the provider network through a combination of newly affiliated practices and the recruitment of new \nproviders to existing practices. ", "original_text": "We welcomed four practices to the network in the fiscal year, including Regional Cancer Care \nAssociates, Cancer Center of Kansas, Nashville Oncology Associates, and SCRI Oncology  Partners. "}, "hash": "893e66f59f1541a247eb4cc0db6a040e33b1e6756de01a9701880fa436a12c23", "class_name": "RelatedNodeInfo"}}, "text": "We're very pleased with the meaningful expansion i n our oncology assets, as reflected in the growth of the US \noncology network. ", "start_char_idx": 1736, "end_char_idx": 1866, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bce1fa01-88ce-417d-ae64-763903514008": {"__data__": {"id_": "bce1fa01-88ce-417d-ae64-763903514008", "embedding": null, "metadata": {"window": "Moving on to our two strategic pillars of oncology and biopharma services, these are both pivotal assets that \nunlock tremendous value and bring significant benefits to our customers and stakeholders.  Over the y ears, we've \nbeen building out our portfolio of assets around oncology, spanning from the distribution of related therapies to \npractice management, to oncology data insights and other value -added services.  \n \n We're very pleased with the meaningful expansion i n our oncology assets, as reflected in the growth of the US \noncology network.  We welcomed four practices to the network in the fiscal year, including Regional Cancer Care \nAssociates, Cancer Center of Kansas, Nashville Oncology Associates, and SCRI Oncology  Partners.  The addition \nof these new practices expands our geographic footprint and allows us to provide our services to a broader set of \nproviders and importantly to the patients they serve.  \n \n As of April, the network has grown to approximately 2,600 provi ders at 600 sites of care across 31 states.  We \ngrew the provider network through a combination of newly affiliated practices and the recruitment of new \nproviders to existing practices. ", "original_text": "We welcomed four practices to the network in the fiscal year, including Regional Cancer Care \nAssociates, Cancer Center of Kansas, Nashville Oncology Associates, and SCRI Oncology  Partners. ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "503d358d-7b15-4003-8931-8eb136775d00", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "29ded6f744347902f63bba113ad0a953bccfbea02fd6e609ae1f15ad30da1955", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "715a73d7-5165-4fd8-97b9-8dccfae137d6", "node_type": "1", "metadata": {"window": "I'm also really quite impressed by the commitment and leadership exhibited by so many \nMcKesson employees and the initiatives they take on to support each other and to create an open and \ncollaborative culture.  \n \n Moving on to our two strategic pillars of oncology and biopharma services, these are both pivotal assets that \nunlock tremendous value and bring significant benefits to our customers and stakeholders.  Over the y ears, we've \nbeen building out our portfolio of assets around oncology, spanning from the distribution of related therapies to \npractice management, to oncology data insights and other value -added services.  \n \n We're very pleased with the meaningful expansion i n our oncology assets, as reflected in the growth of the US \noncology network.  We welcomed four practices to the network in the fiscal year, including Regional Cancer Care \nAssociates, Cancer Center of Kansas, Nashville Oncology Associates, and SCRI Oncology  Partners.  The addition \nof these new practices expands our geographic footprint and allows us to provide our services to a broader set of \nproviders and importantly to the patients they serve.  \n \n As of April, the network has grown to approximately 2,600 provi ders at 600 sites of care across 31 states. ", "original_text": "We're very pleased with the meaningful expansion i n our oncology assets, as reflected in the growth of the US \noncology network. ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "447994def7630f758247501b0014b3a3671f252bdd7ca114b8f159db8e5f5620", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd1943b9-4636-4b58-9243-d0faa51e4b8e", "node_type": "1", "metadata": {"window": "Over the y ears, we've \nbeen building out our portfolio of assets around oncology, spanning from the distribution of related therapies to \npractice management, to oncology data insights and other value -added services.  \n \n We're very pleased with the meaningful expansion i n our oncology assets, as reflected in the growth of the US \noncology network.  We welcomed four practices to the network in the fiscal year, including Regional Cancer Care \nAssociates, Cancer Center of Kansas, Nashville Oncology Associates, and SCRI Oncology  Partners.  The addition \nof these new practices expands our geographic footprint and allows us to provide our services to a broader set of \nproviders and importantly to the patients they serve.  \n \n As of April, the network has grown to approximately 2,600 provi ders at 600 sites of care across 31 states.  We \ngrew the provider network through a combination of newly affiliated practices and the recruitment of new \nproviders to existing practices.  We saw organic growth in providers at more than 75% of the practices. ", "original_text": "The addition \nof these new practices expands our geographic footprint and allows us to provide our services to a broader set of \nproviders and importantly to the patients they serve.  \n \n"}, "hash": "f62d5ed79c92f0d926750271aca89b3d703128b995413128a140e2b48ffef0c7", "class_name": "RelatedNodeInfo"}}, "text": "We welcomed four practices to the network in the fiscal year, including Regional Cancer Care \nAssociates, Cancer Center of Kansas, Nashville Oncology Associates, and SCRI Oncology  Partners. ", "start_char_idx": 1866, "end_char_idx": 2057, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd1943b9-4636-4b58-9243-d0faa51e4b8e": {"__data__": {"id_": "cd1943b9-4636-4b58-9243-d0faa51e4b8e", "embedding": null, "metadata": {"window": "Over the y ears, we've \nbeen building out our portfolio of assets around oncology, spanning from the distribution of related therapies to \npractice management, to oncology data insights and other value -added services.  \n \n We're very pleased with the meaningful expansion i n our oncology assets, as reflected in the growth of the US \noncology network.  We welcomed four practices to the network in the fiscal year, including Regional Cancer Care \nAssociates, Cancer Center of Kansas, Nashville Oncology Associates, and SCRI Oncology  Partners.  The addition \nof these new practices expands our geographic footprint and allows us to provide our services to a broader set of \nproviders and importantly to the patients they serve.  \n \n As of April, the network has grown to approximately 2,600 provi ders at 600 sites of care across 31 states.  We \ngrew the provider network through a combination of newly affiliated practices and the recruitment of new \nproviders to existing practices.  We saw organic growth in providers at more than 75% of the practices. ", "original_text": "The addition \nof these new practices expands our geographic footprint and allows us to provide our services to a broader set of \nproviders and importantly to the patients they serve.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "503d358d-7b15-4003-8931-8eb136775d00", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "29ded6f744347902f63bba113ad0a953bccfbea02fd6e609ae1f15ad30da1955", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bce1fa01-88ce-417d-ae64-763903514008", "node_type": "1", "metadata": {"window": "Moving on to our two strategic pillars of oncology and biopharma services, these are both pivotal assets that \nunlock tremendous value and bring significant benefits to our customers and stakeholders.  Over the y ears, we've \nbeen building out our portfolio of assets around oncology, spanning from the distribution of related therapies to \npractice management, to oncology data insights and other value -added services.  \n \n We're very pleased with the meaningful expansion i n our oncology assets, as reflected in the growth of the US \noncology network.  We welcomed four practices to the network in the fiscal year, including Regional Cancer Care \nAssociates, Cancer Center of Kansas, Nashville Oncology Associates, and SCRI Oncology  Partners.  The addition \nof these new practices expands our geographic footprint and allows us to provide our services to a broader set of \nproviders and importantly to the patients they serve.  \n \n As of April, the network has grown to approximately 2,600 provi ders at 600 sites of care across 31 states.  We \ngrew the provider network through a combination of newly affiliated practices and the recruitment of new \nproviders to existing practices. ", "original_text": "We welcomed four practices to the network in the fiscal year, including Regional Cancer Care \nAssociates, Cancer Center of Kansas, Nashville Oncology Associates, and SCRI Oncology  Partners. ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "79621631cb0437ae7ea33531530d8f663c2e8861834c84990878104d3a485616", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28005547-bda4-404a-ba43-03a2b14e5ac4", "node_type": "1", "metadata": {"window": "We're very pleased with the meaningful expansion i n our oncology assets, as reflected in the growth of the US \noncology network.  We welcomed four practices to the network in the fiscal year, including Regional Cancer Care \nAssociates, Cancer Center of Kansas, Nashville Oncology Associates, and SCRI Oncology  Partners.  The addition \nof these new practices expands our geographic footprint and allows us to provide our services to a broader set of \nproviders and importantly to the patients they serve.  \n \n As of April, the network has grown to approximately 2,600 provi ders at 600 sites of care across 31 states.  We \ngrew the provider network through a combination of newly affiliated practices and the recruitment of new \nproviders to existing practices.  We saw organic growth in providers at more than 75% of the practices.  W ith this \nextensive reach within the community oncology setting, the US oncology network now treats over 1.4 million \npatients each year.  \n \n", "original_text": "As of April, the network has grown to approximately 2,600 provi ders at 600 sites of care across 31 states. "}, "hash": "6a86b1784df5b0cc91076b0e39ce84d49b6cbf4486f5f770378b7ca8bc25a2a9", "class_name": "RelatedNodeInfo"}}, "text": "The addition \nof these new practices expands our geographic footprint and allows us to provide our services to a broader set of \nproviders and importantly to the patients they serve.  \n \n", "start_char_idx": 2057, "end_char_idx": 2244, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28005547-bda4-404a-ba43-03a2b14e5ac4": {"__data__": {"id_": "28005547-bda4-404a-ba43-03a2b14e5ac4", "embedding": null, "metadata": {"window": "We're very pleased with the meaningful expansion i n our oncology assets, as reflected in the growth of the US \noncology network.  We welcomed four practices to the network in the fiscal year, including Regional Cancer Care \nAssociates, Cancer Center of Kansas, Nashville Oncology Associates, and SCRI Oncology  Partners.  The addition \nof these new practices expands our geographic footprint and allows us to provide our services to a broader set of \nproviders and importantly to the patients they serve.  \n \n As of April, the network has grown to approximately 2,600 provi ders at 600 sites of care across 31 states.  We \ngrew the provider network through a combination of newly affiliated practices and the recruitment of new \nproviders to existing practices.  We saw organic growth in providers at more than 75% of the practices.  W ith this \nextensive reach within the community oncology setting, the US oncology network now treats over 1.4 million \npatients each year.  \n \n", "original_text": "As of April, the network has grown to approximately 2,600 provi ders at 600 sites of care across 31 states. ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "503d358d-7b15-4003-8931-8eb136775d00", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "29ded6f744347902f63bba113ad0a953bccfbea02fd6e609ae1f15ad30da1955", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd1943b9-4636-4b58-9243-d0faa51e4b8e", "node_type": "1", "metadata": {"window": "Over the y ears, we've \nbeen building out our portfolio of assets around oncology, spanning from the distribution of related therapies to \npractice management, to oncology data insights and other value -added services.  \n \n We're very pleased with the meaningful expansion i n our oncology assets, as reflected in the growth of the US \noncology network.  We welcomed four practices to the network in the fiscal year, including Regional Cancer Care \nAssociates, Cancer Center of Kansas, Nashville Oncology Associates, and SCRI Oncology  Partners.  The addition \nof these new practices expands our geographic footprint and allows us to provide our services to a broader set of \nproviders and importantly to the patients they serve.  \n \n As of April, the network has grown to approximately 2,600 provi ders at 600 sites of care across 31 states.  We \ngrew the provider network through a combination of newly affiliated practices and the recruitment of new \nproviders to existing practices.  We saw organic growth in providers at more than 75% of the practices. ", "original_text": "The addition \nof these new practices expands our geographic footprint and allows us to provide our services to a broader set of \nproviders and importantly to the patients they serve.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "8c50b03dcd0b29c8742fe76e318f3a08afc7444bc737479aebf17aafeed55dc7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47f08763-68c6-4139-958b-0bb8761985da", "node_type": "1", "metadata": {"window": "We welcomed four practices to the network in the fiscal year, including Regional Cancer Care \nAssociates, Cancer Center of Kansas, Nashville Oncology Associates, and SCRI Oncology  Partners.  The addition \nof these new practices expands our geographic footprint and allows us to provide our services to a broader set of \nproviders and importantly to the patients they serve.  \n \n As of April, the network has grown to approximately 2,600 provi ders at 600 sites of care across 31 states.  We \ngrew the provider network through a combination of newly affiliated practices and the recruitment of new \nproviders to existing practices.  We saw organic growth in providers at more than 75% of the practices.  W ith this \nextensive reach within the community oncology setting, the US oncology network now treats over 1.4 million \npatients each year.  \n \n In addition to practice management, we also provide clinical trial services to these community -based practices. ", "original_text": "We \ngrew the provider network through a combination of newly affiliated practices and the recruitment of new \nproviders to existing practices. "}, "hash": "b085707ebdf937dcf35ef4792968ec4559387946d15953c70b3888fc3a6070ea", "class_name": "RelatedNodeInfo"}}, "text": "As of April, the network has grown to approximately 2,600 provi ders at 600 sites of care across 31 states. ", "start_char_idx": 2244, "end_char_idx": 2352, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47f08763-68c6-4139-958b-0bb8761985da": {"__data__": {"id_": "47f08763-68c6-4139-958b-0bb8761985da", "embedding": null, "metadata": {"window": "We welcomed four practices to the network in the fiscal year, including Regional Cancer Care \nAssociates, Cancer Center of Kansas, Nashville Oncology Associates, and SCRI Oncology  Partners.  The addition \nof these new practices expands our geographic footprint and allows us to provide our services to a broader set of \nproviders and importantly to the patients they serve.  \n \n As of April, the network has grown to approximately 2,600 provi ders at 600 sites of care across 31 states.  We \ngrew the provider network through a combination of newly affiliated practices and the recruitment of new \nproviders to existing practices.  We saw organic growth in providers at more than 75% of the practices.  W ith this \nextensive reach within the community oncology setting, the US oncology network now treats over 1.4 million \npatients each year.  \n \n In addition to practice management, we also provide clinical trial services to these community -based practices. ", "original_text": "We \ngrew the provider network through a combination of newly affiliated practices and the recruitment of new \nproviders to existing practices. ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "503d358d-7b15-4003-8931-8eb136775d00", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "29ded6f744347902f63bba113ad0a953bccfbea02fd6e609ae1f15ad30da1955", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28005547-bda4-404a-ba43-03a2b14e5ac4", "node_type": "1", "metadata": {"window": "We're very pleased with the meaningful expansion i n our oncology assets, as reflected in the growth of the US \noncology network.  We welcomed four practices to the network in the fiscal year, including Regional Cancer Care \nAssociates, Cancer Center of Kansas, Nashville Oncology Associates, and SCRI Oncology  Partners.  The addition \nof these new practices expands our geographic footprint and allows us to provide our services to a broader set of \nproviders and importantly to the patients they serve.  \n \n As of April, the network has grown to approximately 2,600 provi ders at 600 sites of care across 31 states.  We \ngrew the provider network through a combination of newly affiliated practices and the recruitment of new \nproviders to existing practices.  We saw organic growth in providers at more than 75% of the practices.  W ith this \nextensive reach within the community oncology setting, the US oncology network now treats over 1.4 million \npatients each year.  \n \n", "original_text": "As of April, the network has grown to approximately 2,600 provi ders at 600 sites of care across 31 states. ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "73e2d86cd78f5597d9019a916c8aba77dfd7c76bd7f7e822b86546a420d8ea2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb6bead6-54ad-4589-a625-4c441c3f7f22", "node_type": "1", "metadata": {"window": "The addition \nof these new practices expands our geographic footprint and allows us to provide our services to a broader set of \nproviders and importantly to the patients they serve.  \n \n As of April, the network has grown to approximately 2,600 provi ders at 600 sites of care across 31 states.  We \ngrew the provider network through a combination of newly affiliated practices and the recruitment of new \nproviders to existing practices.  We saw organic growth in providers at more than 75% of the practices.  W ith this \nextensive reach within the community oncology setting, the US oncology network now treats over 1.4 million \npatients each year.  \n \n In addition to practice management, we also provide clinical trial services to these community -based practices.  In \n2022 , we expanded our clinical trial capabilities through the formation of a joint venture that now operates under \nthe name of Sarah Cannon Research Institute, or sometimes referred to as SCRI.  \n \n", "original_text": "We saw organic growth in providers at more than 75% of the practices. "}, "hash": "fe6943e6fb696393150b3e4756f347aae631b6c29cce84e0e0a6270622d86c4e", "class_name": "RelatedNodeInfo"}}, "text": "We \ngrew the provider network through a combination of newly affiliated practices and the recruitment of new \nproviders to existing practices. ", "start_char_idx": 2352, "end_char_idx": 2495, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb6bead6-54ad-4589-a625-4c441c3f7f22": {"__data__": {"id_": "bb6bead6-54ad-4589-a625-4c441c3f7f22", "embedding": null, "metadata": {"window": "The addition \nof these new practices expands our geographic footprint and allows us to provide our services to a broader set of \nproviders and importantly to the patients they serve.  \n \n As of April, the network has grown to approximately 2,600 provi ders at 600 sites of care across 31 states.  We \ngrew the provider network through a combination of newly affiliated practices and the recruitment of new \nproviders to existing practices.  We saw organic growth in providers at more than 75% of the practices.  W ith this \nextensive reach within the community oncology setting, the US oncology network now treats over 1.4 million \npatients each year.  \n \n In addition to practice management, we also provide clinical trial services to these community -based practices.  In \n2022 , we expanded our clinical trial capabilities through the formation of a joint venture that now operates under \nthe name of Sarah Cannon Research Institute, or sometimes referred to as SCRI.  \n \n", "original_text": "We saw organic growth in providers at more than 75% of the practices. ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "503d358d-7b15-4003-8931-8eb136775d00", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "29ded6f744347902f63bba113ad0a953bccfbea02fd6e609ae1f15ad30da1955", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47f08763-68c6-4139-958b-0bb8761985da", "node_type": "1", "metadata": {"window": "We welcomed four practices to the network in the fiscal year, including Regional Cancer Care \nAssociates, Cancer Center of Kansas, Nashville Oncology Associates, and SCRI Oncology  Partners.  The addition \nof these new practices expands our geographic footprint and allows us to provide our services to a broader set of \nproviders and importantly to the patients they serve.  \n \n As of April, the network has grown to approximately 2,600 provi ders at 600 sites of care across 31 states.  We \ngrew the provider network through a combination of newly affiliated practices and the recruitment of new \nproviders to existing practices.  We saw organic growth in providers at more than 75% of the practices.  W ith this \nextensive reach within the community oncology setting, the US oncology network now treats over 1.4 million \npatients each year.  \n \n In addition to practice management, we also provide clinical trial services to these community -based practices. ", "original_text": "We \ngrew the provider network through a combination of newly affiliated practices and the recruitment of new \nproviders to existing practices. ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "015582357aac6dfaf9b68f72771dc9d6d46078e5b82634b692051528b6cffe4b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "398deb55-1fa8-4e5b-bb42-2b32e8108058", "node_type": "1", "metadata": {"window": "As of April, the network has grown to approximately 2,600 provi ders at 600 sites of care across 31 states.  We \ngrew the provider network through a combination of newly affiliated practices and the recruitment of new \nproviders to existing practices.  We saw organic growth in providers at more than 75% of the practices.  W ith this \nextensive reach within the community oncology setting, the US oncology network now treats over 1.4 million \npatients each year.  \n \n In addition to practice management, we also provide clinical trial services to these community -based practices.  In \n2022 , we expanded our clinical trial capabilities through the formation of a joint venture that now operates under \nthe name of Sarah Cannon Research Institute, or sometimes referred to as SCRI.  \n \n In the past year, practices in the US oncology network participat ed in over 200 clinical trials through SCRI, \nenrolling more than 3,100 patients in treatment studies across various disease states. ", "original_text": "W ith this \nextensive reach within the community oncology setting, the US oncology network now treats over 1.4 million \npatients each year.  \n \n"}, "hash": "59ec2a8890308af03d4558af037f0eaf980b0cf2693c38df2534ac3765045a1d", "class_name": "RelatedNodeInfo"}}, "text": "We saw organic growth in providers at more than 75% of the practices. ", "start_char_idx": 2495, "end_char_idx": 2565, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "398deb55-1fa8-4e5b-bb42-2b32e8108058": {"__data__": {"id_": "398deb55-1fa8-4e5b-bb42-2b32e8108058", "embedding": null, "metadata": {"window": "As of April, the network has grown to approximately 2,600 provi ders at 600 sites of care across 31 states.  We \ngrew the provider network through a combination of newly affiliated practices and the recruitment of new \nproviders to existing practices.  We saw organic growth in providers at more than 75% of the practices.  W ith this \nextensive reach within the community oncology setting, the US oncology network now treats over 1.4 million \npatients each year.  \n \n In addition to practice management, we also provide clinical trial services to these community -based practices.  In \n2022 , we expanded our clinical trial capabilities through the formation of a joint venture that now operates under \nthe name of Sarah Cannon Research Institute, or sometimes referred to as SCRI.  \n \n In the past year, practices in the US oncology network participat ed in over 200 clinical trials through SCRI, \nenrolling more than 3,100 patients in treatment studies across various disease states. ", "original_text": "W ith this \nextensive reach within the community oncology setting, the US oncology network now treats over 1.4 million \npatients each year.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "503d358d-7b15-4003-8931-8eb136775d00", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "29ded6f744347902f63bba113ad0a953bccfbea02fd6e609ae1f15ad30da1955", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb6bead6-54ad-4589-a625-4c441c3f7f22", "node_type": "1", "metadata": {"window": "The addition \nof these new practices expands our geographic footprint and allows us to provide our services to a broader set of \nproviders and importantly to the patients they serve.  \n \n As of April, the network has grown to approximately 2,600 provi ders at 600 sites of care across 31 states.  We \ngrew the provider network through a combination of newly affiliated practices and the recruitment of new \nproviders to existing practices.  We saw organic growth in providers at more than 75% of the practices.  W ith this \nextensive reach within the community oncology setting, the US oncology network now treats over 1.4 million \npatients each year.  \n \n In addition to practice management, we also provide clinical trial services to these community -based practices.  In \n2022 , we expanded our clinical trial capabilities through the formation of a joint venture that now operates under \nthe name of Sarah Cannon Research Institute, or sometimes referred to as SCRI.  \n \n", "original_text": "We saw organic growth in providers at more than 75% of the practices. ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "30086cc59eb2082eeb89792cb9f8faa4d04ebe850ff930f320ac12598905d804", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63737ea7-8485-4901-8546-df272bb8ff1a", "node_type": "1", "metadata": {"window": "We \ngrew the provider network through a combination of newly affiliated practices and the recruitment of new \nproviders to existing practices.  We saw organic growth in providers at more than 75% of the practices.  W ith this \nextensive reach within the community oncology setting, the US oncology network now treats over 1.4 million \npatients each year.  \n \n In addition to practice management, we also provide clinical trial services to these community -based practices.  In \n2022 , we expanded our clinical trial capabilities through the formation of a joint venture that now operates under \nthe name of Sarah Cannon Research Institute, or sometimes referred to as SCRI.  \n \n In the past year, practices in the US oncology network participat ed in over 200 clinical trials through SCRI, \nenrolling more than 3,100 patients in treatment studies across various disease states.  And in February, SCRI \nannounced a collaboration with AstraZeneca to enhance the delivery of oncology clinical trials. ", "original_text": "In addition to practice management, we also provide clinical trial services to these community -based practices. "}, "hash": "f4ca28d938ad7a6a996fc5201b37a2104193e395e96ee63829bba41d2735d98d", "class_name": "RelatedNodeInfo"}}, "text": "W ith this \nextensive reach within the community oncology setting, the US oncology network now treats over 1.4 million \npatients each year.  \n \n", "start_char_idx": 2565, "end_char_idx": 2709, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63737ea7-8485-4901-8546-df272bb8ff1a": {"__data__": {"id_": "63737ea7-8485-4901-8546-df272bb8ff1a", "embedding": null, "metadata": {"window": "We \ngrew the provider network through a combination of newly affiliated practices and the recruitment of new \nproviders to existing practices.  We saw organic growth in providers at more than 75% of the practices.  W ith this \nextensive reach within the community oncology setting, the US oncology network now treats over 1.4 million \npatients each year.  \n \n In addition to practice management, we also provide clinical trial services to these community -based practices.  In \n2022 , we expanded our clinical trial capabilities through the formation of a joint venture that now operates under \nthe name of Sarah Cannon Research Institute, or sometimes referred to as SCRI.  \n \n In the past year, practices in the US oncology network participat ed in over 200 clinical trials through SCRI, \nenrolling more than 3,100 patients in treatment studies across various disease states.  And in February, SCRI \nannounced a collaboration with AstraZeneca to enhance the delivery of oncology clinical trials. ", "original_text": "In addition to practice management, we also provide clinical trial services to these community -based practices. ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "503d358d-7b15-4003-8931-8eb136775d00", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "29ded6f744347902f63bba113ad0a953bccfbea02fd6e609ae1f15ad30da1955", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "398deb55-1fa8-4e5b-bb42-2b32e8108058", "node_type": "1", "metadata": {"window": "As of April, the network has grown to approximately 2,600 provi ders at 600 sites of care across 31 states.  We \ngrew the provider network through a combination of newly affiliated practices and the recruitment of new \nproviders to existing practices.  We saw organic growth in providers at more than 75% of the practices.  W ith this \nextensive reach within the community oncology setting, the US oncology network now treats over 1.4 million \npatients each year.  \n \n In addition to practice management, we also provide clinical trial services to these community -based practices.  In \n2022 , we expanded our clinical trial capabilities through the formation of a joint venture that now operates under \nthe name of Sarah Cannon Research Institute, or sometimes referred to as SCRI.  \n \n In the past year, practices in the US oncology network participat ed in over 200 clinical trials through SCRI, \nenrolling more than 3,100 patients in treatment studies across various disease states. ", "original_text": "W ith this \nextensive reach within the community oncology setting, the US oncology network now treats over 1.4 million \npatients each year.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "659e61cead69c2e3efa2788d4d86773f764a22123920d170697d237a82837e24", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4479e483-c95b-45db-9645-9c3f24ac4ee4", "node_type": "1", "metadata": {"window": "We saw organic growth in providers at more than 75% of the practices.  W ith this \nextensive reach within the community oncology setting, the US oncology network now treats over 1.4 million \npatients each year.  \n \n In addition to practice management, we also provide clinical trial services to these community -based practices.  In \n2022 , we expanded our clinical trial capabilities through the formation of a joint venture that now operates under \nthe name of Sarah Cannon Research Institute, or sometimes referred to as SCRI.  \n \n In the past year, practices in the US oncology network participat ed in over 200 clinical trials through SCRI, \nenrolling more than 3,100 patients in treatment studies across various disease states.  And in February, SCRI \nannounced a collaboration with AstraZeneca to enhance the delivery of oncology clinical trials.  Workin g together, \nthe two parties will implement modern solutions to accelerate clinical trial delivery timelines, reduced site burden, \nand enhance trial enrollment within our scaled provider network.  \n \n", "original_text": "In \n2022 , we expanded our clinical trial capabilities through the formation of a joint venture that now operates under \nthe name of Sarah Cannon Research Institute, or sometimes referred to as SCRI.  \n \n"}, "hash": "8ac6682426107a18030542fd8abfe1e102a0c1bd368a39278793c92a99c9df12", "class_name": "RelatedNodeInfo"}}, "text": "In addition to practice management, we also provide clinical trial services to these community -based practices. ", "start_char_idx": 2709, "end_char_idx": 2822, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4479e483-c95b-45db-9645-9c3f24ac4ee4": {"__data__": {"id_": "4479e483-c95b-45db-9645-9c3f24ac4ee4", "embedding": null, "metadata": {"window": "We saw organic growth in providers at more than 75% of the practices.  W ith this \nextensive reach within the community oncology setting, the US oncology network now treats over 1.4 million \npatients each year.  \n \n In addition to practice management, we also provide clinical trial services to these community -based practices.  In \n2022 , we expanded our clinical trial capabilities through the formation of a joint venture that now operates under \nthe name of Sarah Cannon Research Institute, or sometimes referred to as SCRI.  \n \n In the past year, practices in the US oncology network participat ed in over 200 clinical trials through SCRI, \nenrolling more than 3,100 patients in treatment studies across various disease states.  And in February, SCRI \nannounced a collaboration with AstraZeneca to enhance the delivery of oncology clinical trials.  Workin g together, \nthe two parties will implement modern solutions to accelerate clinical trial delivery timelines, reduced site burden, \nand enhance trial enrollment within our scaled provider network.  \n \n", "original_text": "In \n2022 , we expanded our clinical trial capabilities through the formation of a joint venture that now operates under \nthe name of Sarah Cannon Research Institute, or sometimes referred to as SCRI.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "503d358d-7b15-4003-8931-8eb136775d00", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "29ded6f744347902f63bba113ad0a953bccfbea02fd6e609ae1f15ad30da1955", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63737ea7-8485-4901-8546-df272bb8ff1a", "node_type": "1", "metadata": {"window": "We \ngrew the provider network through a combination of newly affiliated practices and the recruitment of new \nproviders to existing practices.  We saw organic growth in providers at more than 75% of the practices.  W ith this \nextensive reach within the community oncology setting, the US oncology network now treats over 1.4 million \npatients each year.  \n \n In addition to practice management, we also provide clinical trial services to these community -based practices.  In \n2022 , we expanded our clinical trial capabilities through the formation of a joint venture that now operates under \nthe name of Sarah Cannon Research Institute, or sometimes referred to as SCRI.  \n \n In the past year, practices in the US oncology network participat ed in over 200 clinical trials through SCRI, \nenrolling more than 3,100 patients in treatment studies across various disease states.  And in February, SCRI \nannounced a collaboration with AstraZeneca to enhance the delivery of oncology clinical trials. ", "original_text": "In addition to practice management, we also provide clinical trial services to these community -based practices. ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "b9f01bd1199d8518e5cbcfe73c03e7ed474897bc084dd2e62245ecc20cf008cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22bf9e01-60d2-4c4c-b0c5-a51fc89c0fa5", "node_type": "1", "metadata": {"window": "W ith this \nextensive reach within the community oncology setting, the US oncology network now treats over 1.4 million \npatients each year.  \n \n In addition to practice management, we also provide clinical trial services to these community -based practices.  In \n2022 , we expanded our clinical trial capabilities through the formation of a joint venture that now operates under \nthe name of Sarah Cannon Research Institute, or sometimes referred to as SCRI.  \n \n In the past year, practices in the US oncology network participat ed in over 200 clinical trials through SCRI, \nenrolling more than 3,100 patients in treatment studies across various disease states.  And in February, SCRI \nannounced a collaboration with AstraZeneca to enhance the delivery of oncology clinical trials.  Workin g together, \nthe two parties will implement modern solutions to accelerate clinical trial delivery timelines, reduced site burden, \nand enhance trial enrollment within our scaled provider network.  \n \n In addition to oncology, our other differentiated growth pri ority is our biopharma services platform. ", "original_text": "In the past year, practices in the US oncology network participat ed in over 200 clinical trials through SCRI, \nenrolling more than 3,100 patients in treatment studies across various disease states. "}, "hash": "8ccc92260f72b8bf3e0c1fc5eb0f46f47a80dd4a15850ec92f6fffad84a94e4d", "class_name": "RelatedNodeInfo"}}, "text": "In \n2022 , we expanded our clinical trial capabilities through the formation of a joint venture that now operates under \nthe name of Sarah Cannon Research Institute, or sometimes referred to as SCRI.  \n \n", "start_char_idx": 2822, "end_char_idx": 3026, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22bf9e01-60d2-4c4c-b0c5-a51fc89c0fa5": {"__data__": {"id_": "22bf9e01-60d2-4c4c-b0c5-a51fc89c0fa5", "embedding": null, "metadata": {"window": "W ith this \nextensive reach within the community oncology setting, the US oncology network now treats over 1.4 million \npatients each year.  \n \n In addition to practice management, we also provide clinical trial services to these community -based practices.  In \n2022 , we expanded our clinical trial capabilities through the formation of a joint venture that now operates under \nthe name of Sarah Cannon Research Institute, or sometimes referred to as SCRI.  \n \n In the past year, practices in the US oncology network participat ed in over 200 clinical trials through SCRI, \nenrolling more than 3,100 patients in treatment studies across various disease states.  And in February, SCRI \nannounced a collaboration with AstraZeneca to enhance the delivery of oncology clinical trials.  Workin g together, \nthe two parties will implement modern solutions to accelerate clinical trial delivery timelines, reduced site burden, \nand enhance trial enrollment within our scaled provider network.  \n \n In addition to oncology, our other differentiated growth pri ority is our biopharma services platform. ", "original_text": "In the past year, practices in the US oncology network participat ed in over 200 clinical trials through SCRI, \nenrolling more than 3,100 patients in treatment studies across various disease states. ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "503d358d-7b15-4003-8931-8eb136775d00", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "29ded6f744347902f63bba113ad0a953bccfbea02fd6e609ae1f15ad30da1955", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4479e483-c95b-45db-9645-9c3f24ac4ee4", "node_type": "1", "metadata": {"window": "We saw organic growth in providers at more than 75% of the practices.  W ith this \nextensive reach within the community oncology setting, the US oncology network now treats over 1.4 million \npatients each year.  \n \n In addition to practice management, we also provide clinical trial services to these community -based practices.  In \n2022 , we expanded our clinical trial capabilities through the formation of a joint venture that now operates under \nthe name of Sarah Cannon Research Institute, or sometimes referred to as SCRI.  \n \n In the past year, practices in the US oncology network participat ed in over 200 clinical trials through SCRI, \nenrolling more than 3,100 patients in treatment studies across various disease states.  And in February, SCRI \nannounced a collaboration with AstraZeneca to enhance the delivery of oncology clinical trials.  Workin g together, \nthe two parties will implement modern solutions to accelerate clinical trial delivery timelines, reduced site burden, \nand enhance trial enrollment within our scaled provider network.  \n \n", "original_text": "In \n2022 , we expanded our clinical trial capabilities through the formation of a joint venture that now operates under \nthe name of Sarah Cannon Research Institute, or sometimes referred to as SCRI.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d51acb04233dc42db2a169b3ffb9d75817a7d5e5803fbae4d41651672cd425d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30b9c8a0-1936-4b34-8868-7710a84f7e6c", "node_type": "1", "metadata": {"window": "In addition to practice management, we also provide clinical trial services to these community -based practices.  In \n2022 , we expanded our clinical trial capabilities through the formation of a joint venture that now operates under \nthe name of Sarah Cannon Research Institute, or sometimes referred to as SCRI.  \n \n In the past year, practices in the US oncology network participat ed in over 200 clinical trials through SCRI, \nenrolling more than 3,100 patients in treatment studies across various disease states.  And in February, SCRI \nannounced a collaboration with AstraZeneca to enhance the delivery of oncology clinical trials.  Workin g together, \nthe two parties will implement modern solutions to accelerate clinical trial delivery timelines, reduced site burden, \nand enhance trial enrollment within our scaled provider network.  \n \n In addition to oncology, our other differentiated growth pri ority is our biopharma services platform.  Our portfolio of \nconnected solutions provides unique value propositions to biopharma companies and helps them improve \nmedication access, affordability, and adherence.  \n \n", "original_text": "And in February, SCRI \nannounced a collaboration with AstraZeneca to enhance the delivery of oncology clinical trials. "}, "hash": "dd7a4f377b7a72b3a47cbc02a03a16593d27d112146e191a4ce15c2936bb0f8d", "class_name": "RelatedNodeInfo"}}, "text": "In the past year, practices in the US oncology network participat ed in over 200 clinical trials through SCRI, \nenrolling more than 3,100 patients in treatment studies across various disease states. ", "start_char_idx": 3026, "end_char_idx": 3225, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30b9c8a0-1936-4b34-8868-7710a84f7e6c": {"__data__": {"id_": "30b9c8a0-1936-4b34-8868-7710a84f7e6c", "embedding": null, "metadata": {"window": "In addition to practice management, we also provide clinical trial services to these community -based practices.  In \n2022 , we expanded our clinical trial capabilities through the formation of a joint venture that now operates under \nthe name of Sarah Cannon Research Institute, or sometimes referred to as SCRI.  \n \n In the past year, practices in the US oncology network participat ed in over 200 clinical trials through SCRI, \nenrolling more than 3,100 patients in treatment studies across various disease states.  And in February, SCRI \nannounced a collaboration with AstraZeneca to enhance the delivery of oncology clinical trials.  Workin g together, \nthe two parties will implement modern solutions to accelerate clinical trial delivery timelines, reduced site burden, \nand enhance trial enrollment within our scaled provider network.  \n \n In addition to oncology, our other differentiated growth pri ority is our biopharma services platform.  Our portfolio of \nconnected solutions provides unique value propositions to biopharma companies and helps them improve \nmedication access, affordability, and adherence.  \n \n", "original_text": "And in February, SCRI \nannounced a collaboration with AstraZeneca to enhance the delivery of oncology clinical trials. ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "503d358d-7b15-4003-8931-8eb136775d00", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "29ded6f744347902f63bba113ad0a953bccfbea02fd6e609ae1f15ad30da1955", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22bf9e01-60d2-4c4c-b0c5-a51fc89c0fa5", "node_type": "1", "metadata": {"window": "W ith this \nextensive reach within the community oncology setting, the US oncology network now treats over 1.4 million \npatients each year.  \n \n In addition to practice management, we also provide clinical trial services to these community -based practices.  In \n2022 , we expanded our clinical trial capabilities through the formation of a joint venture that now operates under \nthe name of Sarah Cannon Research Institute, or sometimes referred to as SCRI.  \n \n In the past year, practices in the US oncology network participat ed in over 200 clinical trials through SCRI, \nenrolling more than 3,100 patients in treatment studies across various disease states.  And in February, SCRI \nannounced a collaboration with AstraZeneca to enhance the delivery of oncology clinical trials.  Workin g together, \nthe two parties will implement modern solutions to accelerate clinical trial delivery timelines, reduced site burden, \nand enhance trial enrollment within our scaled provider network.  \n \n In addition to oncology, our other differentiated growth pri ority is our biopharma services platform. ", "original_text": "In the past year, practices in the US oncology network participat ed in over 200 clinical trials through SCRI, \nenrolling more than 3,100 patients in treatment studies across various disease states. ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "8176403de30807074bea3f8731b6741a4ec3162feb6fa5e398ddce2f4f8ef5d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6752e97b-3955-4822-a0c0-7b49bdf6140e", "node_type": "1", "metadata": {"window": "In \n2022 , we expanded our clinical trial capabilities through the formation of a joint venture that now operates under \nthe name of Sarah Cannon Research Institute, or sometimes referred to as SCRI.  \n \n In the past year, practices in the US oncology network participat ed in over 200 clinical trials through SCRI, \nenrolling more than 3,100 patients in treatment studies across various disease states.  And in February, SCRI \nannounced a collaboration with AstraZeneca to enhance the delivery of oncology clinical trials.  Workin g together, \nthe two parties will implement modern solutions to accelerate clinical trial delivery timelines, reduced site burden, \nand enhance trial enrollment within our scaled provider network.  \n \n In addition to oncology, our other differentiated growth pri ority is our biopharma services platform.  Our portfolio of \nconnected solutions provides unique value propositions to biopharma companies and helps them improve \nmedication access, affordability, and adherence.  \n \n In fiscal 2024, we saw strong growth in the Pr escription Technology segment, delivering 23% growth in adjusted \noperating profit. ", "original_text": "Workin g together, \nthe two parties will implement modern solutions to accelerate clinical trial delivery timelines, reduced site burden, \nand enhance trial enrollment within our scaled provider network.  \n \n"}, "hash": "d7e4a6395f6524167afbf254137ef009d230189004e519ac36c3dcac34c57e46", "class_name": "RelatedNodeInfo"}}, "text": "And in February, SCRI \nannounced a collaboration with AstraZeneca to enhance the delivery of oncology clinical trials. ", "start_char_idx": 3225, "end_char_idx": 3344, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6752e97b-3955-4822-a0c0-7b49bdf6140e": {"__data__": {"id_": "6752e97b-3955-4822-a0c0-7b49bdf6140e", "embedding": null, "metadata": {"window": "In \n2022 , we expanded our clinical trial capabilities through the formation of a joint venture that now operates under \nthe name of Sarah Cannon Research Institute, or sometimes referred to as SCRI.  \n \n In the past year, practices in the US oncology network participat ed in over 200 clinical trials through SCRI, \nenrolling more than 3,100 patients in treatment studies across various disease states.  And in February, SCRI \nannounced a collaboration with AstraZeneca to enhance the delivery of oncology clinical trials.  Workin g together, \nthe two parties will implement modern solutions to accelerate clinical trial delivery timelines, reduced site burden, \nand enhance trial enrollment within our scaled provider network.  \n \n In addition to oncology, our other differentiated growth pri ority is our biopharma services platform.  Our portfolio of \nconnected solutions provides unique value propositions to biopharma companies and helps them improve \nmedication access, affordability, and adherence.  \n \n In fiscal 2024, we saw strong growth in the Pr escription Technology segment, delivering 23% growth in adjusted \noperating profit. ", "original_text": "Workin g together, \nthe two parties will implement modern solutions to accelerate clinical trial delivery timelines, reduced site burden, \nand enhance trial enrollment within our scaled provider network.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "503d358d-7b15-4003-8931-8eb136775d00", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "29ded6f744347902f63bba113ad0a953bccfbea02fd6e609ae1f15ad30da1955", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30b9c8a0-1936-4b34-8868-7710a84f7e6c", "node_type": "1", "metadata": {"window": "In addition to practice management, we also provide clinical trial services to these community -based practices.  In \n2022 , we expanded our clinical trial capabilities through the formation of a joint venture that now operates under \nthe name of Sarah Cannon Research Institute, or sometimes referred to as SCRI.  \n \n In the past year, practices in the US oncology network participat ed in over 200 clinical trials through SCRI, \nenrolling more than 3,100 patients in treatment studies across various disease states.  And in February, SCRI \nannounced a collaboration with AstraZeneca to enhance the delivery of oncology clinical trials.  Workin g together, \nthe two parties will implement modern solutions to accelerate clinical trial delivery timelines, reduced site burden, \nand enhance trial enrollment within our scaled provider network.  \n \n In addition to oncology, our other differentiated growth pri ority is our biopharma services platform.  Our portfolio of \nconnected solutions provides unique value propositions to biopharma companies and helps them improve \nmedication access, affordability, and adherence.  \n \n", "original_text": "And in February, SCRI \nannounced a collaboration with AstraZeneca to enhance the delivery of oncology clinical trials. ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "4cf3f7da85418c0cacb67a3319bba2bc407942a45a26b1fb3cadb65ca6c94da6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16965107-e56b-4cb2-ad31-3a69904e5f13", "node_type": "1", "metadata": {"window": "In the past year, practices in the US oncology network participat ed in over 200 clinical trials through SCRI, \nenrolling more than 3,100 patients in treatment studies across various disease states.  And in February, SCRI \nannounced a collaboration with AstraZeneca to enhance the delivery of oncology clinical trials.  Workin g together, \nthe two parties will implement modern solutions to accelerate clinical trial delivery timelines, reduced site burden, \nand enhance trial enrollment within our scaled provider network.  \n \n In addition to oncology, our other differentiated growth pri ority is our biopharma services platform.  Our portfolio of \nconnected solutions provides unique value propositions to biopharma companies and helps them improve \nmedication access, affordability, and adherence.  \n \n In fiscal 2024, we saw strong growth in the Pr escription Technology segment, delivering 23% growth in adjusted \noperating profit.  More importantly, in the past year, our differentiated solutions helped patients save more than ", "original_text": "In addition to oncology, our other differentiated growth pri ority is our biopharma services platform. "}, "hash": "c6f63e3636ebeca88be891dee77c8f2ca40efcd633f1a2f7600371955ba10906", "class_name": "RelatedNodeInfo"}}, "text": "Workin g together, \nthe two parties will implement modern solutions to accelerate clinical trial delivery timelines, reduced site burden, \nand enhance trial enrollment within our scaled provider network.  \n \n", "start_char_idx": 3344, "end_char_idx": 3552, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16965107-e56b-4cb2-ad31-3a69904e5f13": {"__data__": {"id_": "16965107-e56b-4cb2-ad31-3a69904e5f13", "embedding": null, "metadata": {"window": "In the past year, practices in the US oncology network participat ed in over 200 clinical trials through SCRI, \nenrolling more than 3,100 patients in treatment studies across various disease states.  And in February, SCRI \nannounced a collaboration with AstraZeneca to enhance the delivery of oncology clinical trials.  Workin g together, \nthe two parties will implement modern solutions to accelerate clinical trial delivery timelines, reduced site burden, \nand enhance trial enrollment within our scaled provider network.  \n \n In addition to oncology, our other differentiated growth pri ority is our biopharma services platform.  Our portfolio of \nconnected solutions provides unique value propositions to biopharma companies and helps them improve \nmedication access, affordability, and adherence.  \n \n In fiscal 2024, we saw strong growth in the Pr escription Technology segment, delivering 23% growth in adjusted \noperating profit.  More importantly, in the past year, our differentiated solutions helped patients save more than ", "original_text": "In addition to oncology, our other differentiated growth pri ority is our biopharma services platform. ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "503d358d-7b15-4003-8931-8eb136775d00", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "29ded6f744347902f63bba113ad0a953bccfbea02fd6e609ae1f15ad30da1955", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6752e97b-3955-4822-a0c0-7b49bdf6140e", "node_type": "1", "metadata": {"window": "In \n2022 , we expanded our clinical trial capabilities through the formation of a joint venture that now operates under \nthe name of Sarah Cannon Research Institute, or sometimes referred to as SCRI.  \n \n In the past year, practices in the US oncology network participat ed in over 200 clinical trials through SCRI, \nenrolling more than 3,100 patients in treatment studies across various disease states.  And in February, SCRI \nannounced a collaboration with AstraZeneca to enhance the delivery of oncology clinical trials.  Workin g together, \nthe two parties will implement modern solutions to accelerate clinical trial delivery timelines, reduced site burden, \nand enhance trial enrollment within our scaled provider network.  \n \n In addition to oncology, our other differentiated growth pri ority is our biopharma services platform.  Our portfolio of \nconnected solutions provides unique value propositions to biopharma companies and helps them improve \nmedication access, affordability, and adherence.  \n \n In fiscal 2024, we saw strong growth in the Pr escription Technology segment, delivering 23% growth in adjusted \noperating profit. ", "original_text": "Workin g together, \nthe two parties will implement modern solutions to accelerate clinical trial delivery timelines, reduced site burden, \nand enhance trial enrollment within our scaled provider network.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "b5be19a07dc1072c61b31c2074dba71a7b9ea05ec001dfa8db08bef02cf5c885", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03c906eb-8e63-41fa-958c-2a8e21df420a", "node_type": "1", "metadata": {"window": "And in February, SCRI \nannounced a collaboration with AstraZeneca to enhance the delivery of oncology clinical trials.  Workin g together, \nthe two parties will implement modern solutions to accelerate clinical trial delivery timelines, reduced site burden, \nand enhance trial enrollment within our scaled provider network.  \n \n In addition to oncology, our other differentiated growth pri ority is our biopharma services platform.  Our portfolio of \nconnected solutions provides unique value propositions to biopharma companies and helps them improve \nmedication access, affordability, and adherence.  \n \n In fiscal 2024, we saw strong growth in the Pr escription Technology segment, delivering 23% growth in adjusted \noperating profit.  More importantly, in the past year, our differentiated solutions helped patients save more than ", "original_text": "Our portfolio of \nconnected solutions provides unique value propositions to biopharma companies and helps them improve \nmedication access, affordability, and adherence.  \n \n"}, "hash": "82b3bc0a0df286e87859e7d48cc9f91bbfb25341b077818e5efba26eda3aebcc", "class_name": "RelatedNodeInfo"}}, "text": "In addition to oncology, our other differentiated growth pri ority is our biopharma services platform. ", "start_char_idx": 3552, "end_char_idx": 3655, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03c906eb-8e63-41fa-958c-2a8e21df420a": {"__data__": {"id_": "03c906eb-8e63-41fa-958c-2a8e21df420a", "embedding": null, "metadata": {"window": "And in February, SCRI \nannounced a collaboration with AstraZeneca to enhance the delivery of oncology clinical trials.  Workin g together, \nthe two parties will implement modern solutions to accelerate clinical trial delivery timelines, reduced site burden, \nand enhance trial enrollment within our scaled provider network.  \n \n In addition to oncology, our other differentiated growth pri ority is our biopharma services platform.  Our portfolio of \nconnected solutions provides unique value propositions to biopharma companies and helps them improve \nmedication access, affordability, and adherence.  \n \n In fiscal 2024, we saw strong growth in the Pr escription Technology segment, delivering 23% growth in adjusted \noperating profit.  More importantly, in the past year, our differentiated solutions helped patients save more than ", "original_text": "Our portfolio of \nconnected solutions provides unique value propositions to biopharma companies and helps them improve \nmedication access, affordability, and adherence.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "503d358d-7b15-4003-8931-8eb136775d00", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "29ded6f744347902f63bba113ad0a953bccfbea02fd6e609ae1f15ad30da1955", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16965107-e56b-4cb2-ad31-3a69904e5f13", "node_type": "1", "metadata": {"window": "In the past year, practices in the US oncology network participat ed in over 200 clinical trials through SCRI, \nenrolling more than 3,100 patients in treatment studies across various disease states.  And in February, SCRI \nannounced a collaboration with AstraZeneca to enhance the delivery of oncology clinical trials.  Workin g together, \nthe two parties will implement modern solutions to accelerate clinical trial delivery timelines, reduced site burden, \nand enhance trial enrollment within our scaled provider network.  \n \n In addition to oncology, our other differentiated growth pri ority is our biopharma services platform.  Our portfolio of \nconnected solutions provides unique value propositions to biopharma companies and helps them improve \nmedication access, affordability, and adherence.  \n \n In fiscal 2024, we saw strong growth in the Pr escription Technology segment, delivering 23% growth in adjusted \noperating profit.  More importantly, in the past year, our differentiated solutions helped patients save more than ", "original_text": "In addition to oncology, our other differentiated growth pri ority is our biopharma services platform. ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "fe14b5ff9847ae6d9fff204b81ba307f0265798b5daf641995b4ffe1e10f2550", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1fe5fce4-3521-4766-84dc-ba60369c8962", "node_type": "1", "metadata": {"window": "Workin g together, \nthe two parties will implement modern solutions to accelerate clinical trial delivery timelines, reduced site burden, \nand enhance trial enrollment within our scaled provider network.  \n \n In addition to oncology, our other differentiated growth pri ority is our biopharma services platform.  Our portfolio of \nconnected solutions provides unique value propositions to biopharma companies and helps them improve \nmedication access, affordability, and adherence.  \n \n In fiscal 2024, we saw strong growth in the Pr escription Technology segment, delivering 23% growth in adjusted \noperating profit.  More importantly, in the past year, our differentiated solutions helped patients save more than ", "original_text": "In fiscal 2024, we saw strong growth in the Pr escription Technology segment, delivering 23% growth in adjusted \noperating profit. "}, "hash": "49102f88a57082a4d5e786c442c7c051d83dba53eb9e4e5ef02a5eb082fef367", "class_name": "RelatedNodeInfo"}}, "text": "Our portfolio of \nconnected solutions provides unique value propositions to biopharma companies and helps them improve \nmedication access, affordability, and adherence.  \n \n", "start_char_idx": 3655, "end_char_idx": 3828, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1fe5fce4-3521-4766-84dc-ba60369c8962": {"__data__": {"id_": "1fe5fce4-3521-4766-84dc-ba60369c8962", "embedding": null, "metadata": {"window": "Workin g together, \nthe two parties will implement modern solutions to accelerate clinical trial delivery timelines, reduced site burden, \nand enhance trial enrollment within our scaled provider network.  \n \n In addition to oncology, our other differentiated growth pri ority is our biopharma services platform.  Our portfolio of \nconnected solutions provides unique value propositions to biopharma companies and helps them improve \nmedication access, affordability, and adherence.  \n \n In fiscal 2024, we saw strong growth in the Pr escription Technology segment, delivering 23% growth in adjusted \noperating profit.  More importantly, in the past year, our differentiated solutions helped patients save more than ", "original_text": "In fiscal 2024, we saw strong growth in the Pr escription Technology segment, delivering 23% growth in adjusted \noperating profit. ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "503d358d-7b15-4003-8931-8eb136775d00", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "29ded6f744347902f63bba113ad0a953bccfbea02fd6e609ae1f15ad30da1955", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03c906eb-8e63-41fa-958c-2a8e21df420a", "node_type": "1", "metadata": {"window": "And in February, SCRI \nannounced a collaboration with AstraZeneca to enhance the delivery of oncology clinical trials.  Workin g together, \nthe two parties will implement modern solutions to accelerate clinical trial delivery timelines, reduced site burden, \nand enhance trial enrollment within our scaled provider network.  \n \n In addition to oncology, our other differentiated growth pri ority is our biopharma services platform.  Our portfolio of \nconnected solutions provides unique value propositions to biopharma companies and helps them improve \nmedication access, affordability, and adherence.  \n \n In fiscal 2024, we saw strong growth in the Pr escription Technology segment, delivering 23% growth in adjusted \noperating profit.  More importantly, in the past year, our differentiated solutions helped patients save more than ", "original_text": "Our portfolio of \nconnected solutions provides unique value propositions to biopharma companies and helps them improve \nmedication access, affordability, and adherence.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "27ca0d1027ef352084308805141e971bd791ea4e7876c8f3f1cc23a61d9aaf98", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b135ab0-7f06-475a-88b4-fb83f35d2d4f", "node_type": "1", "metadata": {"window": "In addition to oncology, our other differentiated growth pri ority is our biopharma services platform.  Our portfolio of \nconnected solutions provides unique value propositions to biopharma companies and helps them improve \nmedication access, affordability, and adherence.  \n \n In fiscal 2024, we saw strong growth in the Pr escription Technology segment, delivering 23% growth in adjusted \noperating profit.  More importantly, in the past year, our differentiated solutions helped patients save more than ", "original_text": "More importantly, in the past year, our differentiated solutions helped patients save more than "}, "hash": "56334495e9a25602126624c2dbc2a4d82d52578cbba57740188b726d88aa4f62", "class_name": "RelatedNodeInfo"}}, "text": "In fiscal 2024, we saw strong growth in the Pr escription Technology segment, delivering 23% growth in adjusted \noperating profit. ", "start_char_idx": 3828, "end_char_idx": 3959, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b135ab0-7f06-475a-88b4-fb83f35d2d4f": {"__data__": {"id_": "7b135ab0-7f06-475a-88b4-fb83f35d2d4f", "embedding": null, "metadata": {"window": "In addition to oncology, our other differentiated growth pri ority is our biopharma services platform.  Our portfolio of \nconnected solutions provides unique value propositions to biopharma companies and helps them improve \nmedication access, affordability, and adherence.  \n \n In fiscal 2024, we saw strong growth in the Pr escription Technology segment, delivering 23% growth in adjusted \noperating profit.  More importantly, in the past year, our differentiated solutions helped patients save more than ", "original_text": "More importantly, in the past year, our differentiated solutions helped patients save more than ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "503d358d-7b15-4003-8931-8eb136775d00", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "29ded6f744347902f63bba113ad0a953bccfbea02fd6e609ae1f15ad30da1955", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1fe5fce4-3521-4766-84dc-ba60369c8962", "node_type": "1", "metadata": {"window": "Workin g together, \nthe two parties will implement modern solutions to accelerate clinical trial delivery timelines, reduced site burden, \nand enhance trial enrollment within our scaled provider network.  \n \n In addition to oncology, our other differentiated growth pri ority is our biopharma services platform.  Our portfolio of \nconnected solutions provides unique value propositions to biopharma companies and helps them improve \nmedication access, affordability, and adherence.  \n \n In fiscal 2024, we saw strong growth in the Pr escription Technology segment, delivering 23% growth in adjusted \noperating profit.  More importantly, in the past year, our differentiated solutions helped patients save more than ", "original_text": "In fiscal 2024, we saw strong growth in the Pr escription Technology segment, delivering 23% growth in adjusted \noperating profit. ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c7ffe4be4f7d9d69b1a1a74b53159e120da0ec7b25fcea7c5903264da2477059", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ff67d7e-9ce5-4120-95d5-e6593656080d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n$8.8 billion on brand and specialty medications.  We helped to prevent approxi mately 10.7 million prescriptions \nfrom being abandoned due to affordability challenges, and we helped patients access their medicine more than \n94 million times.  \n \n The biopharma services platform was built through years of strategic investments. ", "original_text": "McKesson Corp.  "}, "hash": "fe52af849388033611e7f731e1af07b5fcbb746d239872db1fb174134cf41d1e", "class_name": "RelatedNodeInfo"}}, "text": "More importantly, in the past year, our differentiated solutions helped patients save more than ", "start_char_idx": 3959, "end_char_idx": 4055, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ff67d7e-9ce5-4120-95d5-e6593656080d": {"__data__": {"id_": "8ff67d7e-9ce5-4120-95d5-e6593656080d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n$8.8 billion on brand and specialty medications.  We helped to prevent approxi mately 10.7 million prescriptions \nfrom being abandoned due to affordability challenges, and we helped patients access their medicine more than \n94 million times.  \n \n The biopharma services platform was built through years of strategic investments. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "76bf9759a748d309ac2a9db3e904dc0f66f1e19acb87ea2aaa5c4a76fca9673a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b135ab0-7f06-475a-88b4-fb83f35d2d4f", "node_type": "1", "metadata": {"window": "In addition to oncology, our other differentiated growth pri ority is our biopharma services platform.  Our portfolio of \nconnected solutions provides unique value propositions to biopharma companies and helps them improve \nmedication access, affordability, and adherence.  \n \n In fiscal 2024, we saw strong growth in the Pr escription Technology segment, delivering 23% growth in adjusted \noperating profit.  More importantly, in the past year, our differentiated solutions helped patients save more than ", "original_text": "More importantly, in the past year, our differentiated solutions helped patients save more than ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "67275783f3078dbf745b17c702f59a79211c4a00e7587a816dfa1b6385b62195", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5143b55d-10db-44ab-ac47-f3a30a673bd6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n$8.8 billion on brand and specialty medications.  We helped to prevent approxi mately 10.7 million prescriptions \nfrom being abandoned due to affordability challenges, and we helped patients access their medicine more than \n94 million times.  \n \n The biopharma services platform was built through years of strategic investments.  It includes targeted \nacquisitions that accelerated our growth strategy, and internal investments that drove innovation and enhanced \ncapabilities. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n$8.8 billion on brand and specialty medications. "}, "hash": "e8b9cc37c5d422234c0f3bb096baa135c60b9038ae31c8fde73d43300851a49c", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5143b55d-10db-44ab-ac47-f3a30a673bd6": {"__data__": {"id_": "5143b55d-10db-44ab-ac47-f3a30a673bd6", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n$8.8 billion on brand and specialty medications.  We helped to prevent approxi mately 10.7 million prescriptions \nfrom being abandoned due to affordability challenges, and we helped patients access their medicine more than \n94 million times.  \n \n The biopharma services platform was built through years of strategic investments.  It includes targeted \nacquisitions that accelerated our growth strategy, and internal investments that drove innovation and enhanced \ncapabilities. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n$8.8 billion on brand and specialty medications. ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "76bf9759a748d309ac2a9db3e904dc0f66f1e19acb87ea2aaa5c4a76fca9673a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ff67d7e-9ce5-4120-95d5-e6593656080d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n$8.8 billion on brand and specialty medications.  We helped to prevent approxi mately 10.7 million prescriptions \nfrom being abandoned due to affordability challenges, and we helped patients access their medicine more than \n94 million times.  \n \n The biopharma services platform was built through years of strategic investments. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d7baeccbfcfb057d83dcc8c10c01fc69ca05a3a94a4c0c104bf6fbc8462d4cad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5339c02b-7b09-48df-9f37-e60302c5b277", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n$8.8 billion on brand and specialty medications.  We helped to prevent approxi mately 10.7 million prescriptions \nfrom being abandoned due to affordability challenges, and we helped patients access their medicine more than \n94 million times.  \n \n The biopharma services platform was built through years of strategic investments.  It includes targeted \nacquisitions that accelerated our growth strategy, and internal investments that drove innovation and enhanced \ncapabilities.  One of the first assets we acquired was RelayHealth, and it's foundational to the network and \nservices we offer today. ", "original_text": "We helped to prevent approxi mately 10.7 million prescriptions \nfrom being abandoned due to affordability challenges, and we helped patients access their medicine more than \n94 million times.  \n \n"}, "hash": "768fca45132da6f0da63225a4449cfd88f289987ca58af41850736290e3e2d25", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n$8.8 billion on brand and specialty medications. ", "start_char_idx": 16, "end_char_idx": 229, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5339c02b-7b09-48df-9f37-e60302c5b277": {"__data__": {"id_": "5339c02b-7b09-48df-9f37-e60302c5b277", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n$8.8 billion on brand and specialty medications.  We helped to prevent approxi mately 10.7 million prescriptions \nfrom being abandoned due to affordability challenges, and we helped patients access their medicine more than \n94 million times.  \n \n The biopharma services platform was built through years of strategic investments.  It includes targeted \nacquisitions that accelerated our growth strategy, and internal investments that drove innovation and enhanced \ncapabilities.  One of the first assets we acquired was RelayHealth, and it's foundational to the network and \nservices we offer today. ", "original_text": "We helped to prevent approxi mately 10.7 million prescriptions \nfrom being abandoned due to affordability challenges, and we helped patients access their medicine more than \n94 million times.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "76bf9759a748d309ac2a9db3e904dc0f66f1e19acb87ea2aaa5c4a76fca9673a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5143b55d-10db-44ab-ac47-f3a30a673bd6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n$8.8 billion on brand and specialty medications.  We helped to prevent approxi mately 10.7 million prescriptions \nfrom being abandoned due to affordability challenges, and we helped patients access their medicine more than \n94 million times.  \n \n The biopharma services platform was built through years of strategic investments.  It includes targeted \nacquisitions that accelerated our growth strategy, and internal investments that drove innovation and enhanced \ncapabilities. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n$8.8 billion on brand and specialty medications. ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "673a3b90c5bc10f418a905664092018e11fc56957687ba0ea906d1dc01a8ed8e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cff9e3a0-208b-4eb2-b117-f483be089945", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n$8.8 billion on brand and specialty medications.  We helped to prevent approxi mately 10.7 million prescriptions \nfrom being abandoned due to affordability challenges, and we helped patients access their medicine more than \n94 million times.  \n \n The biopharma services platform was built through years of strategic investments.  It includes targeted \nacquisitions that accelerated our growth strategy, and internal investments that drove innovation and enhanced \ncapabilities.  One of the first assets we acquired was RelayHealth, and it's foundational to the network and \nservices we offer today.  For  those who aren't familiar with this business, it helps adjudicate prescription claims \nand enable the efficient delivery of prescription drugs. ", "original_text": "The biopharma services platform was built through years of strategic investments. "}, "hash": "68167d83df5a2c9ede5aba5fa88b42f2ecb007442fd96c2394aebd53dc14cea3", "class_name": "RelatedNodeInfo"}}, "text": "We helped to prevent approxi mately 10.7 million prescriptions \nfrom being abandoned due to affordability challenges, and we helped patients access their medicine more than \n94 million times.  \n \n", "start_char_idx": 229, "end_char_idx": 425, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cff9e3a0-208b-4eb2-b117-f483be089945": {"__data__": {"id_": "cff9e3a0-208b-4eb2-b117-f483be089945", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n$8.8 billion on brand and specialty medications.  We helped to prevent approxi mately 10.7 million prescriptions \nfrom being abandoned due to affordability challenges, and we helped patients access their medicine more than \n94 million times.  \n \n The biopharma services platform was built through years of strategic investments.  It includes targeted \nacquisitions that accelerated our growth strategy, and internal investments that drove innovation and enhanced \ncapabilities.  One of the first assets we acquired was RelayHealth, and it's foundational to the network and \nservices we offer today.  For  those who aren't familiar with this business, it helps adjudicate prescription claims \nand enable the efficient delivery of prescription drugs. ", "original_text": "The biopharma services platform was built through years of strategic investments. ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "76bf9759a748d309ac2a9db3e904dc0f66f1e19acb87ea2aaa5c4a76fca9673a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5339c02b-7b09-48df-9f37-e60302c5b277", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n$8.8 billion on brand and specialty medications.  We helped to prevent approxi mately 10.7 million prescriptions \nfrom being abandoned due to affordability challenges, and we helped patients access their medicine more than \n94 million times.  \n \n The biopharma services platform was built through years of strategic investments.  It includes targeted \nacquisitions that accelerated our growth strategy, and internal investments that drove innovation and enhanced \ncapabilities.  One of the first assets we acquired was RelayHealth, and it's foundational to the network and \nservices we offer today. ", "original_text": "We helped to prevent approxi mately 10.7 million prescriptions \nfrom being abandoned due to affordability challenges, and we helped patients access their medicine more than \n94 million times.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "1693cd10bee900edffa7c86a517b1b6b710832ce9e761c8caa157a98cc0bf25d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbdf2d43-4daa-4b5c-8c69-f520cdd10a1d", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n$8.8 billion on brand and specialty medications.  We helped to prevent approxi mately 10.7 million prescriptions \nfrom being abandoned due to affordability challenges, and we helped patients access their medicine more than \n94 million times.  \n \n The biopharma services platform was built through years of strategic investments.  It includes targeted \nacquisitions that accelerated our growth strategy, and internal investments that drove innovation and enhanced \ncapabilities.  One of the first assets we acquired was RelayHealth, and it's foundational to the network and \nservices we offer today.  For  those who aren't familiar with this business, it helps adjudicate prescription claims \nand enable the efficient delivery of prescription drugs.  It's now connected to over 50,000 pharmacies and \nprocesses billions of transactions annually. ", "original_text": "It includes targeted \nacquisitions that accelerated our growth strategy, and internal investments that drove innovation and enhanced \ncapabilities. "}, "hash": "b509c6972d4d1ba147bec406a3c9fc10c783a908b5c116ef6036ee1b8a63df49", "class_name": "RelatedNodeInfo"}}, "text": "The biopharma services platform was built through years of strategic investments. ", "start_char_idx": 425, "end_char_idx": 507, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbdf2d43-4daa-4b5c-8c69-f520cdd10a1d": {"__data__": {"id_": "dbdf2d43-4daa-4b5c-8c69-f520cdd10a1d", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n$8.8 billion on brand and specialty medications.  We helped to prevent approxi mately 10.7 million prescriptions \nfrom being abandoned due to affordability challenges, and we helped patients access their medicine more than \n94 million times.  \n \n The biopharma services platform was built through years of strategic investments.  It includes targeted \nacquisitions that accelerated our growth strategy, and internal investments that drove innovation and enhanced \ncapabilities.  One of the first assets we acquired was RelayHealth, and it's foundational to the network and \nservices we offer today.  For  those who aren't familiar with this business, it helps adjudicate prescription claims \nand enable the efficient delivery of prescription drugs.  It's now connected to over 50,000 pharmacies and \nprocesses billions of transactions annually. ", "original_text": "It includes targeted \nacquisitions that accelerated our growth strategy, and internal investments that drove innovation and enhanced \ncapabilities. ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "76bf9759a748d309ac2a9db3e904dc0f66f1e19acb87ea2aaa5c4a76fca9673a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cff9e3a0-208b-4eb2-b117-f483be089945", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n$8.8 billion on brand and specialty medications.  We helped to prevent approxi mately 10.7 million prescriptions \nfrom being abandoned due to affordability challenges, and we helped patients access their medicine more than \n94 million times.  \n \n The biopharma services platform was built through years of strategic investments.  It includes targeted \nacquisitions that accelerated our growth strategy, and internal investments that drove innovation and enhanced \ncapabilities.  One of the first assets we acquired was RelayHealth, and it's foundational to the network and \nservices we offer today.  For  those who aren't familiar with this business, it helps adjudicate prescription claims \nand enable the efficient delivery of prescription drugs. ", "original_text": "The biopharma services platform was built through years of strategic investments. ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "9bd4d05ccd2e74177a062cfba1a0625da6877944bc7d6ed265e814b5e4c5fa0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4dc00ae4-9a6e-48e4-9970-d8062e5559fe", "node_type": "1", "metadata": {"window": "We helped to prevent approxi mately 10.7 million prescriptions \nfrom being abandoned due to affordability challenges, and we helped patients access their medicine more than \n94 million times.  \n \n The biopharma services platform was built through years of strategic investments.  It includes targeted \nacquisitions that accelerated our growth strategy, and internal investments that drove innovation and enhanced \ncapabilities.  One of the first assets we acquired was RelayHealth, and it's foundational to the network and \nservices we offer today.  For  those who aren't familiar with this business, it helps adjudicate prescription claims \nand enable the efficient delivery of prescription drugs.  It's now connected to over 50,000 pharmacies and \nprocesses billions of transactions annually.  The connectivity t o the pharmacies provides us insights into the \npatient's journey, and it helps us develop additional solutions, programs like co -pay assist programs and digital \ncoupons. ", "original_text": "One of the first assets we acquired was RelayHealth, and it's foundational to the network and \nservices we offer today. "}, "hash": "46bb1df522c2f72681f99733cdddf8a25177fdea5f5797622a425b76079e61fa", "class_name": "RelatedNodeInfo"}}, "text": "It includes targeted \nacquisitions that accelerated our growth strategy, and internal investments that drove innovation and enhanced \ncapabilities. ", "start_char_idx": 507, "end_char_idx": 655, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4dc00ae4-9a6e-48e4-9970-d8062e5559fe": {"__data__": {"id_": "4dc00ae4-9a6e-48e4-9970-d8062e5559fe", "embedding": null, "metadata": {"window": "We helped to prevent approxi mately 10.7 million prescriptions \nfrom being abandoned due to affordability challenges, and we helped patients access their medicine more than \n94 million times.  \n \n The biopharma services platform was built through years of strategic investments.  It includes targeted \nacquisitions that accelerated our growth strategy, and internal investments that drove innovation and enhanced \ncapabilities.  One of the first assets we acquired was RelayHealth, and it's foundational to the network and \nservices we offer today.  For  those who aren't familiar with this business, it helps adjudicate prescription claims \nand enable the efficient delivery of prescription drugs.  It's now connected to over 50,000 pharmacies and \nprocesses billions of transactions annually.  The connectivity t o the pharmacies provides us insights into the \npatient's journey, and it helps us develop additional solutions, programs like co -pay assist programs and digital \ncoupons. ", "original_text": "One of the first assets we acquired was RelayHealth, and it's foundational to the network and \nservices we offer today. ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "76bf9759a748d309ac2a9db3e904dc0f66f1e19acb87ea2aaa5c4a76fca9673a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbdf2d43-4daa-4b5c-8c69-f520cdd10a1d", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n$8.8 billion on brand and specialty medications.  We helped to prevent approxi mately 10.7 million prescriptions \nfrom being abandoned due to affordability challenges, and we helped patients access their medicine more than \n94 million times.  \n \n The biopharma services platform was built through years of strategic investments.  It includes targeted \nacquisitions that accelerated our growth strategy, and internal investments that drove innovation and enhanced \ncapabilities.  One of the first assets we acquired was RelayHealth, and it's foundational to the network and \nservices we offer today.  For  those who aren't familiar with this business, it helps adjudicate prescription claims \nand enable the efficient delivery of prescription drugs.  It's now connected to over 50,000 pharmacies and \nprocesses billions of transactions annually. ", "original_text": "It includes targeted \nacquisitions that accelerated our growth strategy, and internal investments that drove innovation and enhanced \ncapabilities. ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "4cb684aa77f9cee4551920fde1f761e41aa84d04a9d3f6bd3b2481b83eb0ce75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90c9dafc-38d7-444a-b4c9-a459f006f8b8", "node_type": "1", "metadata": {"window": "The biopharma services platform was built through years of strategic investments.  It includes targeted \nacquisitions that accelerated our growth strategy, and internal investments that drove innovation and enhanced \ncapabilities.  One of the first assets we acquired was RelayHealth, and it's foundational to the network and \nservices we offer today.  For  those who aren't familiar with this business, it helps adjudicate prescription claims \nand enable the efficient delivery of prescription drugs.  It's now connected to over 50,000 pharmacies and \nprocesses billions of transactions annually.  The connectivity t o the pharmacies provides us insights into the \npatient's journey, and it helps us develop additional solutions, programs like co -pay assist programs and digital \ncoupons.  We want to provide our customers not just a claims switch solution, but a robust platf orm that connects \nkey stakeholders, delivers access and affordability solutions, and ultimately improves the patient's experience and \noutcomes.  \n \n", "original_text": "For  those who aren't familiar with this business, it helps adjudicate prescription claims \nand enable the efficient delivery of prescription drugs. "}, "hash": "caf37fd4c5766be169084b8919ff2f9c205cd90395ef261378710670d8379a47", "class_name": "RelatedNodeInfo"}}, "text": "One of the first assets we acquired was RelayHealth, and it's foundational to the network and \nservices we offer today. ", "start_char_idx": 655, "end_char_idx": 775, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90c9dafc-38d7-444a-b4c9-a459f006f8b8": {"__data__": {"id_": "90c9dafc-38d7-444a-b4c9-a459f006f8b8", "embedding": null, "metadata": {"window": "The biopharma services platform was built through years of strategic investments.  It includes targeted \nacquisitions that accelerated our growth strategy, and internal investments that drove innovation and enhanced \ncapabilities.  One of the first assets we acquired was RelayHealth, and it's foundational to the network and \nservices we offer today.  For  those who aren't familiar with this business, it helps adjudicate prescription claims \nand enable the efficient delivery of prescription drugs.  It's now connected to over 50,000 pharmacies and \nprocesses billions of transactions annually.  The connectivity t o the pharmacies provides us insights into the \npatient's journey, and it helps us develop additional solutions, programs like co -pay assist programs and digital \ncoupons.  We want to provide our customers not just a claims switch solution, but a robust platf orm that connects \nkey stakeholders, delivers access and affordability solutions, and ultimately improves the patient's experience and \noutcomes.  \n \n", "original_text": "For  those who aren't familiar with this business, it helps adjudicate prescription claims \nand enable the efficient delivery of prescription drugs. ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "76bf9759a748d309ac2a9db3e904dc0f66f1e19acb87ea2aaa5c4a76fca9673a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4dc00ae4-9a6e-48e4-9970-d8062e5559fe", "node_type": "1", "metadata": {"window": "We helped to prevent approxi mately 10.7 million prescriptions \nfrom being abandoned due to affordability challenges, and we helped patients access their medicine more than \n94 million times.  \n \n The biopharma services platform was built through years of strategic investments.  It includes targeted \nacquisitions that accelerated our growth strategy, and internal investments that drove innovation and enhanced \ncapabilities.  One of the first assets we acquired was RelayHealth, and it's foundational to the network and \nservices we offer today.  For  those who aren't familiar with this business, it helps adjudicate prescription claims \nand enable the efficient delivery of prescription drugs.  It's now connected to over 50,000 pharmacies and \nprocesses billions of transactions annually.  The connectivity t o the pharmacies provides us insights into the \npatient's journey, and it helps us develop additional solutions, programs like co -pay assist programs and digital \ncoupons. ", "original_text": "One of the first assets we acquired was RelayHealth, and it's foundational to the network and \nservices we offer today. ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "9ab9f6f3fc517d6f79be47065de148d0f6f1ea402041f4e2a5f4ce3d183177c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09285cbd-d231-46c6-997a-ceece6efb841", "node_type": "1", "metadata": {"window": "It includes targeted \nacquisitions that accelerated our growth strategy, and internal investments that drove innovation and enhanced \ncapabilities.  One of the first assets we acquired was RelayHealth, and it's foundational to the network and \nservices we offer today.  For  those who aren't familiar with this business, it helps adjudicate prescription claims \nand enable the efficient delivery of prescription drugs.  It's now connected to over 50,000 pharmacies and \nprocesses billions of transactions annually.  The connectivity t o the pharmacies provides us insights into the \npatient's journey, and it helps us develop additional solutions, programs like co -pay assist programs and digital \ncoupons.  We want to provide our customers not just a claims switch solution, but a robust platf orm that connects \nkey stakeholders, delivers access and affordability solutions, and ultimately improves the patient's experience and \noutcomes.  \n \n Let's move on now to our next priority of driving sustainable core growth. ", "original_text": "It's now connected to over 50,000 pharmacies and \nprocesses billions of transactions annually. "}, "hash": "06c38dc55637e87b4c3806888a1296d2f7b16d5c0ef800b28e7c45c7fa7670c9", "class_name": "RelatedNodeInfo"}}, "text": "For  those who aren't familiar with this business, it helps adjudicate prescription claims \nand enable the efficient delivery of prescription drugs. ", "start_char_idx": 775, "end_char_idx": 924, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09285cbd-d231-46c6-997a-ceece6efb841": {"__data__": {"id_": "09285cbd-d231-46c6-997a-ceece6efb841", "embedding": null, "metadata": {"window": "It includes targeted \nacquisitions that accelerated our growth strategy, and internal investments that drove innovation and enhanced \ncapabilities.  One of the first assets we acquired was RelayHealth, and it's foundational to the network and \nservices we offer today.  For  those who aren't familiar with this business, it helps adjudicate prescription claims \nand enable the efficient delivery of prescription drugs.  It's now connected to over 50,000 pharmacies and \nprocesses billions of transactions annually.  The connectivity t o the pharmacies provides us insights into the \npatient's journey, and it helps us develop additional solutions, programs like co -pay assist programs and digital \ncoupons.  We want to provide our customers not just a claims switch solution, but a robust platf orm that connects \nkey stakeholders, delivers access and affordability solutions, and ultimately improves the patient's experience and \noutcomes.  \n \n Let's move on now to our next priority of driving sustainable core growth. ", "original_text": "It's now connected to over 50,000 pharmacies and \nprocesses billions of transactions annually. ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "76bf9759a748d309ac2a9db3e904dc0f66f1e19acb87ea2aaa5c4a76fca9673a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90c9dafc-38d7-444a-b4c9-a459f006f8b8", "node_type": "1", "metadata": {"window": "The biopharma services platform was built through years of strategic investments.  It includes targeted \nacquisitions that accelerated our growth strategy, and internal investments that drove innovation and enhanced \ncapabilities.  One of the first assets we acquired was RelayHealth, and it's foundational to the network and \nservices we offer today.  For  those who aren't familiar with this business, it helps adjudicate prescription claims \nand enable the efficient delivery of prescription drugs.  It's now connected to over 50,000 pharmacies and \nprocesses billions of transactions annually.  The connectivity t o the pharmacies provides us insights into the \npatient's journey, and it helps us develop additional solutions, programs like co -pay assist programs and digital \ncoupons.  We want to provide our customers not just a claims switch solution, but a robust platf orm that connects \nkey stakeholders, delivers access and affordability solutions, and ultimately improves the patient's experience and \noutcomes.  \n \n", "original_text": "For  those who aren't familiar with this business, it helps adjudicate prescription claims \nand enable the efficient delivery of prescription drugs. ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "786a127bab4478b581bdb99bb93abb839cfc3735e026d453280c765158518ab0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82530308-be1a-4fe7-89bb-ed44f04fce01", "node_type": "1", "metadata": {"window": "One of the first assets we acquired was RelayHealth, and it's foundational to the network and \nservices we offer today.  For  those who aren't familiar with this business, it helps adjudicate prescription claims \nand enable the efficient delivery of prescription drugs.  It's now connected to over 50,000 pharmacies and \nprocesses billions of transactions annually.  The connectivity t o the pharmacies provides us insights into the \npatient's journey, and it helps us develop additional solutions, programs like co -pay assist programs and digital \ncoupons.  We want to provide our customers not just a claims switch solution, but a robust platf orm that connects \nkey stakeholders, delivers access and affordability solutions, and ultimately improves the patient's experience and \noutcomes.  \n \n Let's move on now to our next priority of driving sustainable core growth.  We have scaled and durable assets in  \nboth pharmaceutical and medical surgical distribution, and we continue to deliver sustainable growth in these core \nbusinesses.  \n \n", "original_text": "The connectivity t o the pharmacies provides us insights into the \npatient's journey, and it helps us develop additional solutions, programs like co -pay assist programs and digital \ncoupons. "}, "hash": "b8ac4d99cc42257040f1d615335305a6408604dca36ebc97bb6a58b3cde18353", "class_name": "RelatedNodeInfo"}}, "text": "It's now connected to over 50,000 pharmacies and \nprocesses billions of transactions annually. ", "start_char_idx": 924, "end_char_idx": 1019, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82530308-be1a-4fe7-89bb-ed44f04fce01": {"__data__": {"id_": "82530308-be1a-4fe7-89bb-ed44f04fce01", "embedding": null, "metadata": {"window": "One of the first assets we acquired was RelayHealth, and it's foundational to the network and \nservices we offer today.  For  those who aren't familiar with this business, it helps adjudicate prescription claims \nand enable the efficient delivery of prescription drugs.  It's now connected to over 50,000 pharmacies and \nprocesses billions of transactions annually.  The connectivity t o the pharmacies provides us insights into the \npatient's journey, and it helps us develop additional solutions, programs like co -pay assist programs and digital \ncoupons.  We want to provide our customers not just a claims switch solution, but a robust platf orm that connects \nkey stakeholders, delivers access and affordability solutions, and ultimately improves the patient's experience and \noutcomes.  \n \n Let's move on now to our next priority of driving sustainable core growth.  We have scaled and durable assets in  \nboth pharmaceutical and medical surgical distribution, and we continue to deliver sustainable growth in these core \nbusinesses.  \n \n", "original_text": "The connectivity t o the pharmacies provides us insights into the \npatient's journey, and it helps us develop additional solutions, programs like co -pay assist programs and digital \ncoupons. ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "76bf9759a748d309ac2a9db3e904dc0f66f1e19acb87ea2aaa5c4a76fca9673a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09285cbd-d231-46c6-997a-ceece6efb841", "node_type": "1", "metadata": {"window": "It includes targeted \nacquisitions that accelerated our growth strategy, and internal investments that drove innovation and enhanced \ncapabilities.  One of the first assets we acquired was RelayHealth, and it's foundational to the network and \nservices we offer today.  For  those who aren't familiar with this business, it helps adjudicate prescription claims \nand enable the efficient delivery of prescription drugs.  It's now connected to over 50,000 pharmacies and \nprocesses billions of transactions annually.  The connectivity t o the pharmacies provides us insights into the \npatient's journey, and it helps us develop additional solutions, programs like co -pay assist programs and digital \ncoupons.  We want to provide our customers not just a claims switch solution, but a robust platf orm that connects \nkey stakeholders, delivers access and affordability solutions, and ultimately improves the patient's experience and \noutcomes.  \n \n Let's move on now to our next priority of driving sustainable core growth. ", "original_text": "It's now connected to over 50,000 pharmacies and \nprocesses billions of transactions annually. ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "fb75f7394b663e2e11ffb12fe240d754fd2084b82546b7a2c2c0f70fa243b053", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de25fd6e-fc1b-407f-acae-f17bf2140c4e", "node_type": "1", "metadata": {"window": "For  those who aren't familiar with this business, it helps adjudicate prescription claims \nand enable the efficient delivery of prescription drugs.  It's now connected to over 50,000 pharmacies and \nprocesses billions of transactions annually.  The connectivity t o the pharmacies provides us insights into the \npatient's journey, and it helps us develop additional solutions, programs like co -pay assist programs and digital \ncoupons.  We want to provide our customers not just a claims switch solution, but a robust platf orm that connects \nkey stakeholders, delivers access and affordability solutions, and ultimately improves the patient's experience and \noutcomes.  \n \n Let's move on now to our next priority of driving sustainable core growth.  We have scaled and durable assets in  \nboth pharmaceutical and medical surgical distribution, and we continue to deliver sustainable growth in these core \nbusinesses.  \n \n In fiscal 2024, US Pharmaceuticals delivered solid results with 16% increases in revenue and a 7% increase in \nadjusted operatin g profit, which I'll remind you is at the high end of our long -term target for this segment.  \n \n", "original_text": "We want to provide our customers not just a claims switch solution, but a robust platf orm that connects \nkey stakeholders, delivers access and affordability solutions, and ultimately improves the patient's experience and \noutcomes.  \n \n"}, "hash": "9378f6320819305648d022821bbdb136da543111536384e529eb4e488660cb47", "class_name": "RelatedNodeInfo"}}, "text": "The connectivity t o the pharmacies provides us insights into the \npatient's journey, and it helps us develop additional solutions, programs like co -pay assist programs and digital \ncoupons. ", "start_char_idx": 1019, "end_char_idx": 1211, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de25fd6e-fc1b-407f-acae-f17bf2140c4e": {"__data__": {"id_": "de25fd6e-fc1b-407f-acae-f17bf2140c4e", "embedding": null, "metadata": {"window": "For  those who aren't familiar with this business, it helps adjudicate prescription claims \nand enable the efficient delivery of prescription drugs.  It's now connected to over 50,000 pharmacies and \nprocesses billions of transactions annually.  The connectivity t o the pharmacies provides us insights into the \npatient's journey, and it helps us develop additional solutions, programs like co -pay assist programs and digital \ncoupons.  We want to provide our customers not just a claims switch solution, but a robust platf orm that connects \nkey stakeholders, delivers access and affordability solutions, and ultimately improves the patient's experience and \noutcomes.  \n \n Let's move on now to our next priority of driving sustainable core growth.  We have scaled and durable assets in  \nboth pharmaceutical and medical surgical distribution, and we continue to deliver sustainable growth in these core \nbusinesses.  \n \n In fiscal 2024, US Pharmaceuticals delivered solid results with 16% increases in revenue and a 7% increase in \nadjusted operatin g profit, which I'll remind you is at the high end of our long -term target for this segment.  \n \n", "original_text": "We want to provide our customers not just a claims switch solution, but a robust platf orm that connects \nkey stakeholders, delivers access and affordability solutions, and ultimately improves the patient's experience and \noutcomes.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "76bf9759a748d309ac2a9db3e904dc0f66f1e19acb87ea2aaa5c4a76fca9673a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82530308-be1a-4fe7-89bb-ed44f04fce01", "node_type": "1", "metadata": {"window": "One of the first assets we acquired was RelayHealth, and it's foundational to the network and \nservices we offer today.  For  those who aren't familiar with this business, it helps adjudicate prescription claims \nand enable the efficient delivery of prescription drugs.  It's now connected to over 50,000 pharmacies and \nprocesses billions of transactions annually.  The connectivity t o the pharmacies provides us insights into the \npatient's journey, and it helps us develop additional solutions, programs like co -pay assist programs and digital \ncoupons.  We want to provide our customers not just a claims switch solution, but a robust platf orm that connects \nkey stakeholders, delivers access and affordability solutions, and ultimately improves the patient's experience and \noutcomes.  \n \n Let's move on now to our next priority of driving sustainable core growth.  We have scaled and durable assets in  \nboth pharmaceutical and medical surgical distribution, and we continue to deliver sustainable growth in these core \nbusinesses.  \n \n", "original_text": "The connectivity t o the pharmacies provides us insights into the \npatient's journey, and it helps us develop additional solutions, programs like co -pay assist programs and digital \ncoupons. ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d5af5c463370be7331653e8a8f03b4d78b482bb45fb2a2d2235f528f4e4d2320", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbb49de7-1b3d-4360-8bd2-1d25376dd937", "node_type": "1", "metadata": {"window": "It's now connected to over 50,000 pharmacies and \nprocesses billions of transactions annually.  The connectivity t o the pharmacies provides us insights into the \npatient's journey, and it helps us develop additional solutions, programs like co -pay assist programs and digital \ncoupons.  We want to provide our customers not just a claims switch solution, but a robust platf orm that connects \nkey stakeholders, delivers access and affordability solutions, and ultimately improves the patient's experience and \noutcomes.  \n \n Let's move on now to our next priority of driving sustainable core growth.  We have scaled and durable assets in  \nboth pharmaceutical and medical surgical distribution, and we continue to deliver sustainable growth in these core \nbusinesses.  \n \n In fiscal 2024, US Pharmaceuticals delivered solid results with 16% increases in revenue and a 7% increase in \nadjusted operatin g profit, which I'll remind you is at the high end of our long -term target for this segment.  \n \n To support the business growth and the evolving needs of our customers, we continue to invest in our \ninfrastructure, ensuring that the distribution assets are technologically equipped to maximize capacity and \nefficiency. ", "original_text": "Let's move on now to our next priority of driving sustainable core growth. "}, "hash": "3c291a1d06ac90dd68c4989071275574f8f4a72d97582e0d623dde75025cf8cb", "class_name": "RelatedNodeInfo"}}, "text": "We want to provide our customers not just a claims switch solution, but a robust platf orm that connects \nkey stakeholders, delivers access and affordability solutions, and ultimately improves the patient's experience and \noutcomes.  \n \n", "start_char_idx": 1211, "end_char_idx": 1448, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbb49de7-1b3d-4360-8bd2-1d25376dd937": {"__data__": {"id_": "dbb49de7-1b3d-4360-8bd2-1d25376dd937", "embedding": null, "metadata": {"window": "It's now connected to over 50,000 pharmacies and \nprocesses billions of transactions annually.  The connectivity t o the pharmacies provides us insights into the \npatient's journey, and it helps us develop additional solutions, programs like co -pay assist programs and digital \ncoupons.  We want to provide our customers not just a claims switch solution, but a robust platf orm that connects \nkey stakeholders, delivers access and affordability solutions, and ultimately improves the patient's experience and \noutcomes.  \n \n Let's move on now to our next priority of driving sustainable core growth.  We have scaled and durable assets in  \nboth pharmaceutical and medical surgical distribution, and we continue to deliver sustainable growth in these core \nbusinesses.  \n \n In fiscal 2024, US Pharmaceuticals delivered solid results with 16% increases in revenue and a 7% increase in \nadjusted operatin g profit, which I'll remind you is at the high end of our long -term target for this segment.  \n \n To support the business growth and the evolving needs of our customers, we continue to invest in our \ninfrastructure, ensuring that the distribution assets are technologically equipped to maximize capacity and \nefficiency. ", "original_text": "Let's move on now to our next priority of driving sustainable core growth. ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "76bf9759a748d309ac2a9db3e904dc0f66f1e19acb87ea2aaa5c4a76fca9673a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de25fd6e-fc1b-407f-acae-f17bf2140c4e", "node_type": "1", "metadata": {"window": "For  those who aren't familiar with this business, it helps adjudicate prescription claims \nand enable the efficient delivery of prescription drugs.  It's now connected to over 50,000 pharmacies and \nprocesses billions of transactions annually.  The connectivity t o the pharmacies provides us insights into the \npatient's journey, and it helps us develop additional solutions, programs like co -pay assist programs and digital \ncoupons.  We want to provide our customers not just a claims switch solution, but a robust platf orm that connects \nkey stakeholders, delivers access and affordability solutions, and ultimately improves the patient's experience and \noutcomes.  \n \n Let's move on now to our next priority of driving sustainable core growth.  We have scaled and durable assets in  \nboth pharmaceutical and medical surgical distribution, and we continue to deliver sustainable growth in these core \nbusinesses.  \n \n In fiscal 2024, US Pharmaceuticals delivered solid results with 16% increases in revenue and a 7% increase in \nadjusted operatin g profit, which I'll remind you is at the high end of our long -term target for this segment.  \n \n", "original_text": "We want to provide our customers not just a claims switch solution, but a robust platf orm that connects \nkey stakeholders, delivers access and affordability solutions, and ultimately improves the patient's experience and \noutcomes.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "af37108df3bbb67ef8475070ba34416cc5f0832c0430ed3e44e79d9edce3b055", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d377790-53a1-439e-8914-85a1f707e5e0", "node_type": "1", "metadata": {"window": "The connectivity t o the pharmacies provides us insights into the \npatient's journey, and it helps us develop additional solutions, programs like co -pay assist programs and digital \ncoupons.  We want to provide our customers not just a claims switch solution, but a robust platf orm that connects \nkey stakeholders, delivers access and affordability solutions, and ultimately improves the patient's experience and \noutcomes.  \n \n Let's move on now to our next priority of driving sustainable core growth.  We have scaled and durable assets in  \nboth pharmaceutical and medical surgical distribution, and we continue to deliver sustainable growth in these core \nbusinesses.  \n \n In fiscal 2024, US Pharmaceuticals delivered solid results with 16% increases in revenue and a 7% increase in \nadjusted operatin g profit, which I'll remind you is at the high end of our long -term target for this segment.  \n \n To support the business growth and the evolving needs of our customers, we continue to invest in our \ninfrastructure, ensuring that the distribution assets are technologically equipped to maximize capacity and \nefficiency.  And while we're still in the early stages of investing in capabilities of artificial intelligence, we've already \ndeveloped tools and algorithms that apply AI in the supply chain. ", "original_text": "We have scaled and durable assets in  \nboth pharmaceutical and medical surgical distribution, and we continue to deliver sustainable growth in these core \nbusinesses.  \n \n"}, "hash": "94670c0379d15bd37ce5bdb3412640214ea1ce31cf09123cb983b42a393b0f24", "class_name": "RelatedNodeInfo"}}, "text": "Let's move on now to our next priority of driving sustainable core growth. ", "start_char_idx": 1448, "end_char_idx": 1523, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d377790-53a1-439e-8914-85a1f707e5e0": {"__data__": {"id_": "8d377790-53a1-439e-8914-85a1f707e5e0", "embedding": null, "metadata": {"window": "The connectivity t o the pharmacies provides us insights into the \npatient's journey, and it helps us develop additional solutions, programs like co -pay assist programs and digital \ncoupons.  We want to provide our customers not just a claims switch solution, but a robust platf orm that connects \nkey stakeholders, delivers access and affordability solutions, and ultimately improves the patient's experience and \noutcomes.  \n \n Let's move on now to our next priority of driving sustainable core growth.  We have scaled and durable assets in  \nboth pharmaceutical and medical surgical distribution, and we continue to deliver sustainable growth in these core \nbusinesses.  \n \n In fiscal 2024, US Pharmaceuticals delivered solid results with 16% increases in revenue and a 7% increase in \nadjusted operatin g profit, which I'll remind you is at the high end of our long -term target for this segment.  \n \n To support the business growth and the evolving needs of our customers, we continue to invest in our \ninfrastructure, ensuring that the distribution assets are technologically equipped to maximize capacity and \nefficiency.  And while we're still in the early stages of investing in capabilities of artificial intelligence, we've already \ndeveloped tools and algorithms that apply AI in the supply chain. ", "original_text": "We have scaled and durable assets in  \nboth pharmaceutical and medical surgical distribution, and we continue to deliver sustainable growth in these core \nbusinesses.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "76bf9759a748d309ac2a9db3e904dc0f66f1e19acb87ea2aaa5c4a76fca9673a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbb49de7-1b3d-4360-8bd2-1d25376dd937", "node_type": "1", "metadata": {"window": "It's now connected to over 50,000 pharmacies and \nprocesses billions of transactions annually.  The connectivity t o the pharmacies provides us insights into the \npatient's journey, and it helps us develop additional solutions, programs like co -pay assist programs and digital \ncoupons.  We want to provide our customers not just a claims switch solution, but a robust platf orm that connects \nkey stakeholders, delivers access and affordability solutions, and ultimately improves the patient's experience and \noutcomes.  \n \n Let's move on now to our next priority of driving sustainable core growth.  We have scaled and durable assets in  \nboth pharmaceutical and medical surgical distribution, and we continue to deliver sustainable growth in these core \nbusinesses.  \n \n In fiscal 2024, US Pharmaceuticals delivered solid results with 16% increases in revenue and a 7% increase in \nadjusted operatin g profit, which I'll remind you is at the high end of our long -term target for this segment.  \n \n To support the business growth and the evolving needs of our customers, we continue to invest in our \ninfrastructure, ensuring that the distribution assets are technologically equipped to maximize capacity and \nefficiency. ", "original_text": "Let's move on now to our next priority of driving sustainable core growth. ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3812f57aa5c34786025a2d3bdce5147e210373bab7ac9b39c2357f6650025d74", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "abe49091-9fdf-40c5-9a1d-4c3bee95edf7", "node_type": "1", "metadata": {"window": "We want to provide our customers not just a claims switch solution, but a robust platf orm that connects \nkey stakeholders, delivers access and affordability solutions, and ultimately improves the patient's experience and \noutcomes.  \n \n Let's move on now to our next priority of driving sustainable core growth.  We have scaled and durable assets in  \nboth pharmaceutical and medical surgical distribution, and we continue to deliver sustainable growth in these core \nbusinesses.  \n \n In fiscal 2024, US Pharmaceuticals delivered solid results with 16% increases in revenue and a 7% increase in \nadjusted operatin g profit, which I'll remind you is at the high end of our long -term target for this segment.  \n \n To support the business growth and the evolving needs of our customers, we continue to invest in our \ninfrastructure, ensuring that the distribution assets are technologically equipped to maximize capacity and \nefficiency.  And while we're still in the early stages of investing in capabilities of artificial intelligence, we've already \ndeveloped tools and algorithms that apply AI in the supply chain.  This is enablin g us to move products more \nquickly and nimbly throughout our distribution centers, generating cost savings and continuing to improve our \nservice levels. ", "original_text": "In fiscal 2024, US Pharmaceuticals delivered solid results with 16% increases in revenue and a 7% increase in \nadjusted operatin g profit, which I'll remind you is at the high end of our long -term target for this segment.  \n \n"}, "hash": "aa3a2c31ce38665372abd4f43ff30c958345372b5fe9b93bd988ca1f0ea9f05a", "class_name": "RelatedNodeInfo"}}, "text": "We have scaled and durable assets in  \nboth pharmaceutical and medical surgical distribution, and we continue to deliver sustainable growth in these core \nbusinesses.  \n \n", "start_char_idx": 1523, "end_char_idx": 1694, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "abe49091-9fdf-40c5-9a1d-4c3bee95edf7": {"__data__": {"id_": "abe49091-9fdf-40c5-9a1d-4c3bee95edf7", "embedding": null, "metadata": {"window": "We want to provide our customers not just a claims switch solution, but a robust platf orm that connects \nkey stakeholders, delivers access and affordability solutions, and ultimately improves the patient's experience and \noutcomes.  \n \n Let's move on now to our next priority of driving sustainable core growth.  We have scaled and durable assets in  \nboth pharmaceutical and medical surgical distribution, and we continue to deliver sustainable growth in these core \nbusinesses.  \n \n In fiscal 2024, US Pharmaceuticals delivered solid results with 16% increases in revenue and a 7% increase in \nadjusted operatin g profit, which I'll remind you is at the high end of our long -term target for this segment.  \n \n To support the business growth and the evolving needs of our customers, we continue to invest in our \ninfrastructure, ensuring that the distribution assets are technologically equipped to maximize capacity and \nefficiency.  And while we're still in the early stages of investing in capabilities of artificial intelligence, we've already \ndeveloped tools and algorithms that apply AI in the supply chain.  This is enablin g us to move products more \nquickly and nimbly throughout our distribution centers, generating cost savings and continuing to improve our \nservice levels. ", "original_text": "In fiscal 2024, US Pharmaceuticals delivered solid results with 16% increases in revenue and a 7% increase in \nadjusted operatin g profit, which I'll remind you is at the high end of our long -term target for this segment.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "76bf9759a748d309ac2a9db3e904dc0f66f1e19acb87ea2aaa5c4a76fca9673a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d377790-53a1-439e-8914-85a1f707e5e0", "node_type": "1", "metadata": {"window": "The connectivity t o the pharmacies provides us insights into the \npatient's journey, and it helps us develop additional solutions, programs like co -pay assist programs and digital \ncoupons.  We want to provide our customers not just a claims switch solution, but a robust platf orm that connects \nkey stakeholders, delivers access and affordability solutions, and ultimately improves the patient's experience and \noutcomes.  \n \n Let's move on now to our next priority of driving sustainable core growth.  We have scaled and durable assets in  \nboth pharmaceutical and medical surgical distribution, and we continue to deliver sustainable growth in these core \nbusinesses.  \n \n In fiscal 2024, US Pharmaceuticals delivered solid results with 16% increases in revenue and a 7% increase in \nadjusted operatin g profit, which I'll remind you is at the high end of our long -term target for this segment.  \n \n To support the business growth and the evolving needs of our customers, we continue to invest in our \ninfrastructure, ensuring that the distribution assets are technologically equipped to maximize capacity and \nefficiency.  And while we're still in the early stages of investing in capabilities of artificial intelligence, we've already \ndeveloped tools and algorithms that apply AI in the supply chain. ", "original_text": "We have scaled and durable assets in  \nboth pharmaceutical and medical surgical distribution, and we continue to deliver sustainable growth in these core \nbusinesses.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ee01ca4332c185b00b98cf7773be0bb923fa4154aef4c2156930e0708cf677dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f0cf240-0ed4-4d56-8c8d-df0e82c93a17", "node_type": "1", "metadata": {"window": "Let's move on now to our next priority of driving sustainable core growth.  We have scaled and durable assets in  \nboth pharmaceutical and medical surgical distribution, and we continue to deliver sustainable growth in these core \nbusinesses.  \n \n In fiscal 2024, US Pharmaceuticals delivered solid results with 16% increases in revenue and a 7% increase in \nadjusted operatin g profit, which I'll remind you is at the high end of our long -term target for this segment.  \n \n To support the business growth and the evolving needs of our customers, we continue to invest in our \ninfrastructure, ensuring that the distribution assets are technologically equipped to maximize capacity and \nefficiency.  And while we're still in the early stages of investing in capabilities of artificial intelligence, we've already \ndeveloped tools and algorithms that apply AI in the supply chain.  This is enablin g us to move products more \nquickly and nimbly throughout our distribution centers, generating cost savings and continuing to improve our \nservice levels.  We'll continue to make these targeted and strategic investments that support the sustainable \ngrowth of our business.  \n \n", "original_text": "To support the business growth and the evolving needs of our customers, we continue to invest in our \ninfrastructure, ensuring that the distribution assets are technologically equipped to maximize capacity and \nefficiency. "}, "hash": "eb30b4a584f03b31df94fbaa8a25c8137cc87f521d5447aaced43b6f77fbb087", "class_name": "RelatedNodeInfo"}}, "text": "In fiscal 2024, US Pharmaceuticals delivered solid results with 16% increases in revenue and a 7% increase in \nadjusted operatin g profit, which I'll remind you is at the high end of our long -term target for this segment.  \n \n", "start_char_idx": 1694, "end_char_idx": 1921, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f0cf240-0ed4-4d56-8c8d-df0e82c93a17": {"__data__": {"id_": "5f0cf240-0ed4-4d56-8c8d-df0e82c93a17", "embedding": null, "metadata": {"window": "Let's move on now to our next priority of driving sustainable core growth.  We have scaled and durable assets in  \nboth pharmaceutical and medical surgical distribution, and we continue to deliver sustainable growth in these core \nbusinesses.  \n \n In fiscal 2024, US Pharmaceuticals delivered solid results with 16% increases in revenue and a 7% increase in \nadjusted operatin g profit, which I'll remind you is at the high end of our long -term target for this segment.  \n \n To support the business growth and the evolving needs of our customers, we continue to invest in our \ninfrastructure, ensuring that the distribution assets are technologically equipped to maximize capacity and \nefficiency.  And while we're still in the early stages of investing in capabilities of artificial intelligence, we've already \ndeveloped tools and algorithms that apply AI in the supply chain.  This is enablin g us to move products more \nquickly and nimbly throughout our distribution centers, generating cost savings and continuing to improve our \nservice levels.  We'll continue to make these targeted and strategic investments that support the sustainable \ngrowth of our business.  \n \n", "original_text": "To support the business growth and the evolving needs of our customers, we continue to invest in our \ninfrastructure, ensuring that the distribution assets are technologically equipped to maximize capacity and \nefficiency. ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "76bf9759a748d309ac2a9db3e904dc0f66f1e19acb87ea2aaa5c4a76fca9673a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "abe49091-9fdf-40c5-9a1d-4c3bee95edf7", "node_type": "1", "metadata": {"window": "We want to provide our customers not just a claims switch solution, but a robust platf orm that connects \nkey stakeholders, delivers access and affordability solutions, and ultimately improves the patient's experience and \noutcomes.  \n \n Let's move on now to our next priority of driving sustainable core growth.  We have scaled and durable assets in  \nboth pharmaceutical and medical surgical distribution, and we continue to deliver sustainable growth in these core \nbusinesses.  \n \n In fiscal 2024, US Pharmaceuticals delivered solid results with 16% increases in revenue and a 7% increase in \nadjusted operatin g profit, which I'll remind you is at the high end of our long -term target for this segment.  \n \n To support the business growth and the evolving needs of our customers, we continue to invest in our \ninfrastructure, ensuring that the distribution assets are technologically equipped to maximize capacity and \nefficiency.  And while we're still in the early stages of investing in capabilities of artificial intelligence, we've already \ndeveloped tools and algorithms that apply AI in the supply chain.  This is enablin g us to move products more \nquickly and nimbly throughout our distribution centers, generating cost savings and continuing to improve our \nservice levels. ", "original_text": "In fiscal 2024, US Pharmaceuticals delivered solid results with 16% increases in revenue and a 7% increase in \nadjusted operatin g profit, which I'll remind you is at the high end of our long -term target for this segment.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3597474253b415ba586a28274e40e00046bd0c22435519c413e0a934d1ab7423", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6af05515-99d6-43bf-8697-5d5e5dbc4a41", "node_type": "1", "metadata": {"window": "We have scaled and durable assets in  \nboth pharmaceutical and medical surgical distribution, and we continue to deliver sustainable growth in these core \nbusinesses.  \n \n In fiscal 2024, US Pharmaceuticals delivered solid results with 16% increases in revenue and a 7% increase in \nadjusted operatin g profit, which I'll remind you is at the high end of our long -term target for this segment.  \n \n To support the business growth and the evolving needs of our customers, we continue to invest in our \ninfrastructure, ensuring that the distribution assets are technologically equipped to maximize capacity and \nefficiency.  And while we're still in the early stages of investing in capabilities of artificial intelligence, we've already \ndeveloped tools and algorithms that apply AI in the supply chain.  This is enablin g us to move products more \nquickly and nimbly throughout our distribution centers, generating cost savings and continuing to improve our \nservice levels.  We'll continue to make these targeted and strategic investments that support the sustainable \ngrowth of our business.  \n \n Our core distribution business is also complemented by a growing portfolio of services and solutions around \nspecialty and oncology, which adds to our differentiated market position and supports our unique value \nproposition to our customers.  \n \n", "original_text": "And while we're still in the early stages of investing in capabilities of artificial intelligence, we've already \ndeveloped tools and algorithms that apply AI in the supply chain. "}, "hash": "a1355e6414a074f6afbe3ae670e86abe91c199f5a9747a04428b2e909a31bf1c", "class_name": "RelatedNodeInfo"}}, "text": "To support the business growth and the evolving needs of our customers, we continue to invest in our \ninfrastructure, ensuring that the distribution assets are technologically equipped to maximize capacity and \nefficiency. ", "start_char_idx": 1921, "end_char_idx": 2144, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6af05515-99d6-43bf-8697-5d5e5dbc4a41": {"__data__": {"id_": "6af05515-99d6-43bf-8697-5d5e5dbc4a41", "embedding": null, "metadata": {"window": "We have scaled and durable assets in  \nboth pharmaceutical and medical surgical distribution, and we continue to deliver sustainable growth in these core \nbusinesses.  \n \n In fiscal 2024, US Pharmaceuticals delivered solid results with 16% increases in revenue and a 7% increase in \nadjusted operatin g profit, which I'll remind you is at the high end of our long -term target for this segment.  \n \n To support the business growth and the evolving needs of our customers, we continue to invest in our \ninfrastructure, ensuring that the distribution assets are technologically equipped to maximize capacity and \nefficiency.  And while we're still in the early stages of investing in capabilities of artificial intelligence, we've already \ndeveloped tools and algorithms that apply AI in the supply chain.  This is enablin g us to move products more \nquickly and nimbly throughout our distribution centers, generating cost savings and continuing to improve our \nservice levels.  We'll continue to make these targeted and strategic investments that support the sustainable \ngrowth of our business.  \n \n Our core distribution business is also complemented by a growing portfolio of services and solutions around \nspecialty and oncology, which adds to our differentiated market position and supports our unique value \nproposition to our customers.  \n \n", "original_text": "And while we're still in the early stages of investing in capabilities of artificial intelligence, we've already \ndeveloped tools and algorithms that apply AI in the supply chain. ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "76bf9759a748d309ac2a9db3e904dc0f66f1e19acb87ea2aaa5c4a76fca9673a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f0cf240-0ed4-4d56-8c8d-df0e82c93a17", "node_type": "1", "metadata": {"window": "Let's move on now to our next priority of driving sustainable core growth.  We have scaled and durable assets in  \nboth pharmaceutical and medical surgical distribution, and we continue to deliver sustainable growth in these core \nbusinesses.  \n \n In fiscal 2024, US Pharmaceuticals delivered solid results with 16% increases in revenue and a 7% increase in \nadjusted operatin g profit, which I'll remind you is at the high end of our long -term target for this segment.  \n \n To support the business growth and the evolving needs of our customers, we continue to invest in our \ninfrastructure, ensuring that the distribution assets are technologically equipped to maximize capacity and \nefficiency.  And while we're still in the early stages of investing in capabilities of artificial intelligence, we've already \ndeveloped tools and algorithms that apply AI in the supply chain.  This is enablin g us to move products more \nquickly and nimbly throughout our distribution centers, generating cost savings and continuing to improve our \nservice levels.  We'll continue to make these targeted and strategic investments that support the sustainable \ngrowth of our business.  \n \n", "original_text": "To support the business growth and the evolving needs of our customers, we continue to invest in our \ninfrastructure, ensuring that the distribution assets are technologically equipped to maximize capacity and \nefficiency. ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "392b3bb808dd6237a0c5c94ecbbd742a80347f2fe6e8efbcf492077583e9510a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c9ae138-8bd7-43b7-b0f8-310fb0977303", "node_type": "1", "metadata": {"window": "In fiscal 2024, US Pharmaceuticals delivered solid results with 16% increases in revenue and a 7% increase in \nadjusted operatin g profit, which I'll remind you is at the high end of our long -term target for this segment.  \n \n To support the business growth and the evolving needs of our customers, we continue to invest in our \ninfrastructure, ensuring that the distribution assets are technologically equipped to maximize capacity and \nefficiency.  And while we're still in the early stages of investing in capabilities of artificial intelligence, we've already \ndeveloped tools and algorithms that apply AI in the supply chain.  This is enablin g us to move products more \nquickly and nimbly throughout our distribution centers, generating cost savings and continuing to improve our \nservice levels.  We'll continue to make these targeted and strategic investments that support the sustainable \ngrowth of our business.  \n \n Our core distribution business is also complemented by a growing portfolio of services and solutions around \nspecialty and oncology, which adds to our differentiated market position and supports our unique value \nproposition to our customers.  \n \n And today, we're excited to talk about our strategic relationship with Optum. ", "original_text": "This is enablin g us to move products more \nquickly and nimbly throughout our distribution centers, generating cost savings and continuing to improve our \nservice levels. "}, "hash": "7802c97a1b4dddf53ec474e7e9a62a722ed4578fb39b296a80d0cfa2a4500879", "class_name": "RelatedNodeInfo"}}, "text": "And while we're still in the early stages of investing in capabilities of artificial intelligence, we've already \ndeveloped tools and algorithms that apply AI in the supply chain. ", "start_char_idx": 2144, "end_char_idx": 2324, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c9ae138-8bd7-43b7-b0f8-310fb0977303": {"__data__": {"id_": "9c9ae138-8bd7-43b7-b0f8-310fb0977303", "embedding": null, "metadata": {"window": "In fiscal 2024, US Pharmaceuticals delivered solid results with 16% increases in revenue and a 7% increase in \nadjusted operatin g profit, which I'll remind you is at the high end of our long -term target for this segment.  \n \n To support the business growth and the evolving needs of our customers, we continue to invest in our \ninfrastructure, ensuring that the distribution assets are technologically equipped to maximize capacity and \nefficiency.  And while we're still in the early stages of investing in capabilities of artificial intelligence, we've already \ndeveloped tools and algorithms that apply AI in the supply chain.  This is enablin g us to move products more \nquickly and nimbly throughout our distribution centers, generating cost savings and continuing to improve our \nservice levels.  We'll continue to make these targeted and strategic investments that support the sustainable \ngrowth of our business.  \n \n Our core distribution business is also complemented by a growing portfolio of services and solutions around \nspecialty and oncology, which adds to our differentiated market position and supports our unique value \nproposition to our customers.  \n \n And today, we're excited to talk about our strategic relationship with Optum. ", "original_text": "This is enablin g us to move products more \nquickly and nimbly throughout our distribution centers, generating cost savings and continuing to improve our \nservice levels. ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "76bf9759a748d309ac2a9db3e904dc0f66f1e19acb87ea2aaa5c4a76fca9673a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6af05515-99d6-43bf-8697-5d5e5dbc4a41", "node_type": "1", "metadata": {"window": "We have scaled and durable assets in  \nboth pharmaceutical and medical surgical distribution, and we continue to deliver sustainable growth in these core \nbusinesses.  \n \n In fiscal 2024, US Pharmaceuticals delivered solid results with 16% increases in revenue and a 7% increase in \nadjusted operatin g profit, which I'll remind you is at the high end of our long -term target for this segment.  \n \n To support the business growth and the evolving needs of our customers, we continue to invest in our \ninfrastructure, ensuring that the distribution assets are technologically equipped to maximize capacity and \nefficiency.  And while we're still in the early stages of investing in capabilities of artificial intelligence, we've already \ndeveloped tools and algorithms that apply AI in the supply chain.  This is enablin g us to move products more \nquickly and nimbly throughout our distribution centers, generating cost savings and continuing to improve our \nservice levels.  We'll continue to make these targeted and strategic investments that support the sustainable \ngrowth of our business.  \n \n Our core distribution business is also complemented by a growing portfolio of services and solutions around \nspecialty and oncology, which adds to our differentiated market position and supports our unique value \nproposition to our customers.  \n \n", "original_text": "And while we're still in the early stages of investing in capabilities of artificial intelligence, we've already \ndeveloped tools and algorithms that apply AI in the supply chain. ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a960d281e5c9f21f475f1c24063abe33679644487738b8dbf87ce3d274eb8389", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87029daa-966a-46ef-91b5-2aca16fc19fd", "node_type": "1", "metadata": {"window": "To support the business growth and the evolving needs of our customers, we continue to invest in our \ninfrastructure, ensuring that the distribution assets are technologically equipped to maximize capacity and \nefficiency.  And while we're still in the early stages of investing in capabilities of artificial intelligence, we've already \ndeveloped tools and algorithms that apply AI in the supply chain.  This is enablin g us to move products more \nquickly and nimbly throughout our distribution centers, generating cost savings and continuing to improve our \nservice levels.  We'll continue to make these targeted and strategic investments that support the sustainable \ngrowth of our business.  \n \n Our core distribution business is also complemented by a growing portfolio of services and solutions around \nspecialty and oncology, which adds to our differentiated market position and supports our unique value \nproposition to our customers.  \n \n And today, we're excited to talk about our strategic relationship with Optum.  We started servicing a portion of \nOptum's business last year, and we're pleased to get the opportunity to expand the scope of our services starting \nJuly of 2024. ", "original_text": "We'll continue to make these targeted and strategic investments that support the sustainable \ngrowth of our business.  \n \n"}, "hash": "f6911654a823c0a699393b7e5da853d37d27798be8987f4d5b9fe9c3a1c04263", "class_name": "RelatedNodeInfo"}}, "text": "This is enablin g us to move products more \nquickly and nimbly throughout our distribution centers, generating cost savings and continuing to improve our \nservice levels. ", "start_char_idx": 2324, "end_char_idx": 2495, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87029daa-966a-46ef-91b5-2aca16fc19fd": {"__data__": {"id_": "87029daa-966a-46ef-91b5-2aca16fc19fd", "embedding": null, "metadata": {"window": "To support the business growth and the evolving needs of our customers, we continue to invest in our \ninfrastructure, ensuring that the distribution assets are technologically equipped to maximize capacity and \nefficiency.  And while we're still in the early stages of investing in capabilities of artificial intelligence, we've already \ndeveloped tools and algorithms that apply AI in the supply chain.  This is enablin g us to move products more \nquickly and nimbly throughout our distribution centers, generating cost savings and continuing to improve our \nservice levels.  We'll continue to make these targeted and strategic investments that support the sustainable \ngrowth of our business.  \n \n Our core distribution business is also complemented by a growing portfolio of services and solutions around \nspecialty and oncology, which adds to our differentiated market position and supports our unique value \nproposition to our customers.  \n \n And today, we're excited to talk about our strategic relationship with Optum.  We started servicing a portion of \nOptum's business last year, and we're pleased to get the opportunity to expand the scope of our services starting \nJuly of 2024. ", "original_text": "We'll continue to make these targeted and strategic investments that support the sustainable \ngrowth of our business.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "76bf9759a748d309ac2a9db3e904dc0f66f1e19acb87ea2aaa5c4a76fca9673a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c9ae138-8bd7-43b7-b0f8-310fb0977303", "node_type": "1", "metadata": {"window": "In fiscal 2024, US Pharmaceuticals delivered solid results with 16% increases in revenue and a 7% increase in \nadjusted operatin g profit, which I'll remind you is at the high end of our long -term target for this segment.  \n \n To support the business growth and the evolving needs of our customers, we continue to invest in our \ninfrastructure, ensuring that the distribution assets are technologically equipped to maximize capacity and \nefficiency.  And while we're still in the early stages of investing in capabilities of artificial intelligence, we've already \ndeveloped tools and algorithms that apply AI in the supply chain.  This is enablin g us to move products more \nquickly and nimbly throughout our distribution centers, generating cost savings and continuing to improve our \nservice levels.  We'll continue to make these targeted and strategic investments that support the sustainable \ngrowth of our business.  \n \n Our core distribution business is also complemented by a growing portfolio of services and solutions around \nspecialty and oncology, which adds to our differentiated market position and supports our unique value \nproposition to our customers.  \n \n And today, we're excited to talk about our strategic relationship with Optum. ", "original_text": "This is enablin g us to move products more \nquickly and nimbly throughout our distribution centers, generating cost savings and continuing to improve our \nservice levels. ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "86d47204d7db43ba5ddb7d7e53914e1f89f926e7321afdb199814cd2e6a3de2c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "361678fa-a06c-4cdd-89b3-904b763b5e27", "node_type": "1", "metadata": {"window": "And while we're still in the early stages of investing in capabilities of artificial intelligence, we've already \ndeveloped tools and algorithms that apply AI in the supply chain.  This is enablin g us to move products more \nquickly and nimbly throughout our distribution centers, generating cost savings and continuing to improve our \nservice levels.  We'll continue to make these targeted and strategic investments that support the sustainable \ngrowth of our business.  \n \n Our core distribution business is also complemented by a growing portfolio of services and solutions around \nspecialty and oncology, which adds to our differentiated market position and supports our unique value \nproposition to our customers.  \n \n And today, we're excited to talk about our strategic relationship with Optum.  We started servicing a portion of \nOptum's business last year, and we're pleased to get the opportunity to expand the scope of our services starting \nJuly of 2024.  We believe this  relationship is a strong testament to our differentiated capabilities and services \nacross pharmaceutical distribution, sourcing, and oncology. ", "original_text": "Our core distribution business is also complemented by a growing portfolio of services and solutions around \nspecialty and oncology, which adds to our differentiated market position and supports our unique value \nproposition to our customers.  \n \n"}, "hash": "8b1c1eaf087f6175ce129a915b074c4bdf4c00a010ae2a964832f6c5232bf8aa", "class_name": "RelatedNodeInfo"}}, "text": "We'll continue to make these targeted and strategic investments that support the sustainable \ngrowth of our business.  \n \n", "start_char_idx": 2495, "end_char_idx": 2617, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "361678fa-a06c-4cdd-89b3-904b763b5e27": {"__data__": {"id_": "361678fa-a06c-4cdd-89b3-904b763b5e27", "embedding": null, "metadata": {"window": "And while we're still in the early stages of investing in capabilities of artificial intelligence, we've already \ndeveloped tools and algorithms that apply AI in the supply chain.  This is enablin g us to move products more \nquickly and nimbly throughout our distribution centers, generating cost savings and continuing to improve our \nservice levels.  We'll continue to make these targeted and strategic investments that support the sustainable \ngrowth of our business.  \n \n Our core distribution business is also complemented by a growing portfolio of services and solutions around \nspecialty and oncology, which adds to our differentiated market position and supports our unique value \nproposition to our customers.  \n \n And today, we're excited to talk about our strategic relationship with Optum.  We started servicing a portion of \nOptum's business last year, and we're pleased to get the opportunity to expand the scope of our services starting \nJuly of 2024.  We believe this  relationship is a strong testament to our differentiated capabilities and services \nacross pharmaceutical distribution, sourcing, and oncology. ", "original_text": "Our core distribution business is also complemented by a growing portfolio of services and solutions around \nspecialty and oncology, which adds to our differentiated market position and supports our unique value \nproposition to our customers.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "76bf9759a748d309ac2a9db3e904dc0f66f1e19acb87ea2aaa5c4a76fca9673a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87029daa-966a-46ef-91b5-2aca16fc19fd", "node_type": "1", "metadata": {"window": "To support the business growth and the evolving needs of our customers, we continue to invest in our \ninfrastructure, ensuring that the distribution assets are technologically equipped to maximize capacity and \nefficiency.  And while we're still in the early stages of investing in capabilities of artificial intelligence, we've already \ndeveloped tools and algorithms that apply AI in the supply chain.  This is enablin g us to move products more \nquickly and nimbly throughout our distribution centers, generating cost savings and continuing to improve our \nservice levels.  We'll continue to make these targeted and strategic investments that support the sustainable \ngrowth of our business.  \n \n Our core distribution business is also complemented by a growing portfolio of services and solutions around \nspecialty and oncology, which adds to our differentiated market position and supports our unique value \nproposition to our customers.  \n \n And today, we're excited to talk about our strategic relationship with Optum.  We started servicing a portion of \nOptum's business last year, and we're pleased to get the opportunity to expand the scope of our services starting \nJuly of 2024. ", "original_text": "We'll continue to make these targeted and strategic investments that support the sustainable \ngrowth of our business.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "20069d00e2fc6177f7e44a5b860257a3e48b534735aa27dc6f521ad5eb8ac2d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab0407de-c66d-4b19-8b63-7e801925c092", "node_type": "1", "metadata": {"window": "This is enablin g us to move products more \nquickly and nimbly throughout our distribution centers, generating cost savings and continuing to improve our \nservice levels.  We'll continue to make these targeted and strategic investments that support the sustainable \ngrowth of our business.  \n \n Our core distribution business is also complemented by a growing portfolio of services and solutions around \nspecialty and oncology, which adds to our differentiated market position and supports our unique value \nproposition to our customers.  \n \n And today, we're excited to talk about our strategic relationship with Optum.  We started servicing a portion of \nOptum's business last year, and we're pleased to get the opportunity to expand the scope of our services starting \nJuly of 2024.  We believe this  relationship is a strong testament to our differentiated capabilities and services \nacross pharmaceutical distribution, sourcing, and oncology.  We look forward to the opportunity to serve and grow \nwith all of our customers, including now Optum.  \n \n", "original_text": "And today, we're excited to talk about our strategic relationship with Optum. "}, "hash": "aa2b022280bff589e2d3d75be92d64162d53940e0eaee90d6bb249b69f082987", "class_name": "RelatedNodeInfo"}}, "text": "Our core distribution business is also complemented by a growing portfolio of services and solutions around \nspecialty and oncology, which adds to our differentiated market position and supports our unique value \nproposition to our customers.  \n \n", "start_char_idx": 2617, "end_char_idx": 2864, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab0407de-c66d-4b19-8b63-7e801925c092": {"__data__": {"id_": "ab0407de-c66d-4b19-8b63-7e801925c092", "embedding": null, "metadata": {"window": "This is enablin g us to move products more \nquickly and nimbly throughout our distribution centers, generating cost savings and continuing to improve our \nservice levels.  We'll continue to make these targeted and strategic investments that support the sustainable \ngrowth of our business.  \n \n Our core distribution business is also complemented by a growing portfolio of services and solutions around \nspecialty and oncology, which adds to our differentiated market position and supports our unique value \nproposition to our customers.  \n \n And today, we're excited to talk about our strategic relationship with Optum.  We started servicing a portion of \nOptum's business last year, and we're pleased to get the opportunity to expand the scope of our services starting \nJuly of 2024.  We believe this  relationship is a strong testament to our differentiated capabilities and services \nacross pharmaceutical distribution, sourcing, and oncology.  We look forward to the opportunity to serve and grow \nwith all of our customers, including now Optum.  \n \n", "original_text": "And today, we're excited to talk about our strategic relationship with Optum. ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "76bf9759a748d309ac2a9db3e904dc0f66f1e19acb87ea2aaa5c4a76fca9673a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "361678fa-a06c-4cdd-89b3-904b763b5e27", "node_type": "1", "metadata": {"window": "And while we're still in the early stages of investing in capabilities of artificial intelligence, we've already \ndeveloped tools and algorithms that apply AI in the supply chain.  This is enablin g us to move products more \nquickly and nimbly throughout our distribution centers, generating cost savings and continuing to improve our \nservice levels.  We'll continue to make these targeted and strategic investments that support the sustainable \ngrowth of our business.  \n \n Our core distribution business is also complemented by a growing portfolio of services and solutions around \nspecialty and oncology, which adds to our differentiated market position and supports our unique value \nproposition to our customers.  \n \n And today, we're excited to talk about our strategic relationship with Optum.  We started servicing a portion of \nOptum's business last year, and we're pleased to get the opportunity to expand the scope of our services starting \nJuly of 2024.  We believe this  relationship is a strong testament to our differentiated capabilities and services \nacross pharmaceutical distribution, sourcing, and oncology. ", "original_text": "Our core distribution business is also complemented by a growing portfolio of services and solutions around \nspecialty and oncology, which adds to our differentiated market position and supports our unique value \nproposition to our customers.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "8c7b8618a717cdb4eb6cd33279fc0bfb78ab5c9a7ef170a54ac6e35776cf974b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "595d3959-07a1-42fd-83b9-13df68bbb9d8", "node_type": "1", "metadata": {"window": "We'll continue to make these targeted and strategic investments that support the sustainable \ngrowth of our business.  \n \n Our core distribution business is also complemented by a growing portfolio of services and solutions around \nspecialty and oncology, which adds to our differentiated market position and supports our unique value \nproposition to our customers.  \n \n And today, we're excited to talk about our strategic relationship with Optum.  We started servicing a portion of \nOptum's business last year, and we're pleased to get the opportunity to expand the scope of our services starting \nJuly of 2024.  We believe this  relationship is a strong testament to our differentiated capabilities and services \nacross pharmaceutical distribution, sourcing, and oncology.  We look forward to the opportunity to serve and grow \nwith all of our customers, including now Optum.  \n \n As we asse ss investment opportunities and we allocate resources across the enterprise, we strive to ensure that \nour decisions align with our strategic priorities and with our mission of improving healthcare in every setting. ", "original_text": "We started servicing a portion of \nOptum's business last year, and we're pleased to get the opportunity to expand the scope of our services starting \nJuly of 2024. "}, "hash": "7a5ae7c298c77fe46a44b6cc91aa3eea942d7c6f4b50fd62fc9433c895c8fab4", "class_name": "RelatedNodeInfo"}}, "text": "And today, we're excited to talk about our strategic relationship with Optum. ", "start_char_idx": 2864, "end_char_idx": 2942, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "595d3959-07a1-42fd-83b9-13df68bbb9d8": {"__data__": {"id_": "595d3959-07a1-42fd-83b9-13df68bbb9d8", "embedding": null, "metadata": {"window": "We'll continue to make these targeted and strategic investments that support the sustainable \ngrowth of our business.  \n \n Our core distribution business is also complemented by a growing portfolio of services and solutions around \nspecialty and oncology, which adds to our differentiated market position and supports our unique value \nproposition to our customers.  \n \n And today, we're excited to talk about our strategic relationship with Optum.  We started servicing a portion of \nOptum's business last year, and we're pleased to get the opportunity to expand the scope of our services starting \nJuly of 2024.  We believe this  relationship is a strong testament to our differentiated capabilities and services \nacross pharmaceutical distribution, sourcing, and oncology.  We look forward to the opportunity to serve and grow \nwith all of our customers, including now Optum.  \n \n As we asse ss investment opportunities and we allocate resources across the enterprise, we strive to ensure that \nour decisions align with our strategic priorities and with our mission of improving healthcare in every setting. ", "original_text": "We started servicing a portion of \nOptum's business last year, and we're pleased to get the opportunity to expand the scope of our services starting \nJuly of 2024. ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "76bf9759a748d309ac2a9db3e904dc0f66f1e19acb87ea2aaa5c4a76fca9673a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab0407de-c66d-4b19-8b63-7e801925c092", "node_type": "1", "metadata": {"window": "This is enablin g us to move products more \nquickly and nimbly throughout our distribution centers, generating cost savings and continuing to improve our \nservice levels.  We'll continue to make these targeted and strategic investments that support the sustainable \ngrowth of our business.  \n \n Our core distribution business is also complemented by a growing portfolio of services and solutions around \nspecialty and oncology, which adds to our differentiated market position and supports our unique value \nproposition to our customers.  \n \n And today, we're excited to talk about our strategic relationship with Optum.  We started servicing a portion of \nOptum's business last year, and we're pleased to get the opportunity to expand the scope of our services starting \nJuly of 2024.  We believe this  relationship is a strong testament to our differentiated capabilities and services \nacross pharmaceutical distribution, sourcing, and oncology.  We look forward to the opportunity to serve and grow \nwith all of our customers, including now Optum.  \n \n", "original_text": "And today, we're excited to talk about our strategic relationship with Optum. ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "26c3cd223fa2b2d64bd35000e9875c20a1082ebce0549e5ca0769318ad306e0c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fcc772bb-84ec-4b50-b508-ac6f6bbec005", "node_type": "1", "metadata": {"window": "Our core distribution business is also complemented by a growing portfolio of services and solutions around \nspecialty and oncology, which adds to our differentiated market position and supports our unique value \nproposition to our customers.  \n \n And today, we're excited to talk about our strategic relationship with Optum.  We started servicing a portion of \nOptum's business last year, and we're pleased to get the opportunity to expand the scope of our services starting \nJuly of 2024.  We believe this  relationship is a strong testament to our differentiated capabilities and services \nacross pharmaceutical distribution, sourcing, and oncology.  We look forward to the opportunity to serve and grow \nwith all of our customers, including now Optum.  \n \n As we asse ss investment opportunities and we allocate resources across the enterprise, we strive to ensure that \nour decisions align with our strategic priorities and with our mission of improving healthcare in every setting.  We \nwant to become not only a diversified healthcare services company, but also a company that enables positive \nchange in our communities and drives impact.  \n \n", "original_text": "We believe this  relationship is a strong testament to our differentiated capabilities and services \nacross pharmaceutical distribution, sourcing, and oncology. "}, "hash": "2dbb57e1088415ed65b75ff79c950437c318f30ec2caf935a45d3c4ef159cb0c", "class_name": "RelatedNodeInfo"}}, "text": "We started servicing a portion of \nOptum's business last year, and we're pleased to get the opportunity to expand the scope of our services starting \nJuly of 2024. ", "start_char_idx": 2942, "end_char_idx": 3106, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fcc772bb-84ec-4b50-b508-ac6f6bbec005": {"__data__": {"id_": "fcc772bb-84ec-4b50-b508-ac6f6bbec005", "embedding": null, "metadata": {"window": "Our core distribution business is also complemented by a growing portfolio of services and solutions around \nspecialty and oncology, which adds to our differentiated market position and supports our unique value \nproposition to our customers.  \n \n And today, we're excited to talk about our strategic relationship with Optum.  We started servicing a portion of \nOptum's business last year, and we're pleased to get the opportunity to expand the scope of our services starting \nJuly of 2024.  We believe this  relationship is a strong testament to our differentiated capabilities and services \nacross pharmaceutical distribution, sourcing, and oncology.  We look forward to the opportunity to serve and grow \nwith all of our customers, including now Optum.  \n \n As we asse ss investment opportunities and we allocate resources across the enterprise, we strive to ensure that \nour decisions align with our strategic priorities and with our mission of improving healthcare in every setting.  We \nwant to become not only a diversified healthcare services company, but also a company that enables positive \nchange in our communities and drives impact.  \n \n", "original_text": "We believe this  relationship is a strong testament to our differentiated capabilities and services \nacross pharmaceutical distribution, sourcing, and oncology. ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "76bf9759a748d309ac2a9db3e904dc0f66f1e19acb87ea2aaa5c4a76fca9673a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "595d3959-07a1-42fd-83b9-13df68bbb9d8", "node_type": "1", "metadata": {"window": "We'll continue to make these targeted and strategic investments that support the sustainable \ngrowth of our business.  \n \n Our core distribution business is also complemented by a growing portfolio of services and solutions around \nspecialty and oncology, which adds to our differentiated market position and supports our unique value \nproposition to our customers.  \n \n And today, we're excited to talk about our strategic relationship with Optum.  We started servicing a portion of \nOptum's business last year, and we're pleased to get the opportunity to expand the scope of our services starting \nJuly of 2024.  We believe this  relationship is a strong testament to our differentiated capabilities and services \nacross pharmaceutical distribution, sourcing, and oncology.  We look forward to the opportunity to serve and grow \nwith all of our customers, including now Optum.  \n \n As we asse ss investment opportunities and we allocate resources across the enterprise, we strive to ensure that \nour decisions align with our strategic priorities and with our mission of improving healthcare in every setting. ", "original_text": "We started servicing a portion of \nOptum's business last year, and we're pleased to get the opportunity to expand the scope of our services starting \nJuly of 2024. ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "1fb30a87d4415fbf4dd5b86c2adb1e820c5e445a6dd8b5db8c26f85db450d27d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8a8d3c9-9b21-467d-9476-c1e4f22d8d2e", "node_type": "1", "metadata": {"window": "And today, we're excited to talk about our strategic relationship with Optum.  We started servicing a portion of \nOptum's business last year, and we're pleased to get the opportunity to expand the scope of our services starting \nJuly of 2024.  We believe this  relationship is a strong testament to our differentiated capabilities and services \nacross pharmaceutical distribution, sourcing, and oncology.  We look forward to the opportunity to serve and grow \nwith all of our customers, including now Optum.  \n \n As we asse ss investment opportunities and we allocate resources across the enterprise, we strive to ensure that \nour decisions align with our strategic priorities and with our mission of improving healthcare in every setting.  We \nwant to become not only a diversified healthcare services company, but also a company that enables positive \nchange in our communities and drives impact.  \n \n In April, we launched a new initiative aimed at advancing HealthEquity for at -risk populations in underserved \ncommunities. ", "original_text": "We look forward to the opportunity to serve and grow \nwith all of our customers, including now Optum.  \n \n"}, "hash": "46c77a159d9ceddfe5162a73fd1f7bcc935cf724f6b4ac78eab3bb8df1ced266", "class_name": "RelatedNodeInfo"}}, "text": "We believe this  relationship is a strong testament to our differentiated capabilities and services \nacross pharmaceutical distribution, sourcing, and oncology. ", "start_char_idx": 3106, "end_char_idx": 3267, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8a8d3c9-9b21-467d-9476-c1e4f22d8d2e": {"__data__": {"id_": "c8a8d3c9-9b21-467d-9476-c1e4f22d8d2e", "embedding": null, "metadata": {"window": "And today, we're excited to talk about our strategic relationship with Optum.  We started servicing a portion of \nOptum's business last year, and we're pleased to get the opportunity to expand the scope of our services starting \nJuly of 2024.  We believe this  relationship is a strong testament to our differentiated capabilities and services \nacross pharmaceutical distribution, sourcing, and oncology.  We look forward to the opportunity to serve and grow \nwith all of our customers, including now Optum.  \n \n As we asse ss investment opportunities and we allocate resources across the enterprise, we strive to ensure that \nour decisions align with our strategic priorities and with our mission of improving healthcare in every setting.  We \nwant to become not only a diversified healthcare services company, but also a company that enables positive \nchange in our communities and drives impact.  \n \n In April, we launched a new initiative aimed at advancing HealthEquity for at -risk populations in underserved \ncommunities. ", "original_text": "We look forward to the opportunity to serve and grow \nwith all of our customers, including now Optum.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "76bf9759a748d309ac2a9db3e904dc0f66f1e19acb87ea2aaa5c4a76fca9673a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fcc772bb-84ec-4b50-b508-ac6f6bbec005", "node_type": "1", "metadata": {"window": "Our core distribution business is also complemented by a growing portfolio of services and solutions around \nspecialty and oncology, which adds to our differentiated market position and supports our unique value \nproposition to our customers.  \n \n And today, we're excited to talk about our strategic relationship with Optum.  We started servicing a portion of \nOptum's business last year, and we're pleased to get the opportunity to expand the scope of our services starting \nJuly of 2024.  We believe this  relationship is a strong testament to our differentiated capabilities and services \nacross pharmaceutical distribution, sourcing, and oncology.  We look forward to the opportunity to serve and grow \nwith all of our customers, including now Optum.  \n \n As we asse ss investment opportunities and we allocate resources across the enterprise, we strive to ensure that \nour decisions align with our strategic priorities and with our mission of improving healthcare in every setting.  We \nwant to become not only a diversified healthcare services company, but also a company that enables positive \nchange in our communities and drives impact.  \n \n", "original_text": "We believe this  relationship is a strong testament to our differentiated capabilities and services \nacross pharmaceutical distribution, sourcing, and oncology. ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "0b130d9eda52ef4ede4896f28add769012e9821c2de3155618b4b6a77b84776a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b40388ad-29f9-46cf-84b7-a5a51c7168b3", "node_type": "1", "metadata": {"window": "We started servicing a portion of \nOptum's business last year, and we're pleased to get the opportunity to expand the scope of our services starting \nJuly of 2024.  We believe this  relationship is a strong testament to our differentiated capabilities and services \nacross pharmaceutical distribution, sourcing, and oncology.  We look forward to the opportunity to serve and grow \nwith all of our customers, including now Optum.  \n \n As we asse ss investment opportunities and we allocate resources across the enterprise, we strive to ensure that \nour decisions align with our strategic priorities and with our mission of improving healthcare in every setting.  We \nwant to become not only a diversified healthcare services company, but also a company that enables positive \nchange in our communities and drives impact.  \n \n In April, we launched a new initiative aimed at advancing HealthEquity for at -risk populations in underserved \ncommunities.  We have a long hi story of working with pharmacies and providers in the community setting. ", "original_text": "As we asse ss investment opportunities and we allocate resources across the enterprise, we strive to ensure that \nour decisions align with our strategic priorities and with our mission of improving healthcare in every setting. "}, "hash": "f15b26da7864dee200b298f7c322391e31dfa5e6342a54b3c28faa1041b9422e", "class_name": "RelatedNodeInfo"}}, "text": "We look forward to the opportunity to serve and grow \nwith all of our customers, including now Optum.  \n \n", "start_char_idx": 3267, "end_char_idx": 3373, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b40388ad-29f9-46cf-84b7-a5a51c7168b3": {"__data__": {"id_": "b40388ad-29f9-46cf-84b7-a5a51c7168b3", "embedding": null, "metadata": {"window": "We started servicing a portion of \nOptum's business last year, and we're pleased to get the opportunity to expand the scope of our services starting \nJuly of 2024.  We believe this  relationship is a strong testament to our differentiated capabilities and services \nacross pharmaceutical distribution, sourcing, and oncology.  We look forward to the opportunity to serve and grow \nwith all of our customers, including now Optum.  \n \n As we asse ss investment opportunities and we allocate resources across the enterprise, we strive to ensure that \nour decisions align with our strategic priorities and with our mission of improving healthcare in every setting.  We \nwant to become not only a diversified healthcare services company, but also a company that enables positive \nchange in our communities and drives impact.  \n \n In April, we launched a new initiative aimed at advancing HealthEquity for at -risk populations in underserved \ncommunities.  We have a long hi story of working with pharmacies and providers in the community setting. ", "original_text": "As we asse ss investment opportunities and we allocate resources across the enterprise, we strive to ensure that \nour decisions align with our strategic priorities and with our mission of improving healthcare in every setting. ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "76bf9759a748d309ac2a9db3e904dc0f66f1e19acb87ea2aaa5c4a76fca9673a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8a8d3c9-9b21-467d-9476-c1e4f22d8d2e", "node_type": "1", "metadata": {"window": "And today, we're excited to talk about our strategic relationship with Optum.  We started servicing a portion of \nOptum's business last year, and we're pleased to get the opportunity to expand the scope of our services starting \nJuly of 2024.  We believe this  relationship is a strong testament to our differentiated capabilities and services \nacross pharmaceutical distribution, sourcing, and oncology.  We look forward to the opportunity to serve and grow \nwith all of our customers, including now Optum.  \n \n As we asse ss investment opportunities and we allocate resources across the enterprise, we strive to ensure that \nour decisions align with our strategic priorities and with our mission of improving healthcare in every setting.  We \nwant to become not only a diversified healthcare services company, but also a company that enables positive \nchange in our communities and drives impact.  \n \n In April, we launched a new initiative aimed at advancing HealthEquity for at -risk populations in underserved \ncommunities. ", "original_text": "We look forward to the opportunity to serve and grow \nwith all of our customers, including now Optum.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "95746423e77185ee21b24ad47afce851d685c5747231c8efd3df0253cd1eaafe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36bc7910-7a82-425b-b974-4bd5bc15f7ac", "node_type": "1", "metadata": {"window": "We believe this  relationship is a strong testament to our differentiated capabilities and services \nacross pharmaceutical distribution, sourcing, and oncology.  We look forward to the opportunity to serve and grow \nwith all of our customers, including now Optum.  \n \n As we asse ss investment opportunities and we allocate resources across the enterprise, we strive to ensure that \nour decisions align with our strategic priorities and with our mission of improving healthcare in every setting.  We \nwant to become not only a diversified healthcare services company, but also a company that enables positive \nchange in our communities and drives impact.  \n \n In April, we launched a new initiative aimed at advancing HealthEquity for at -risk populations in underserved \ncommunities.  We have a long hi story of working with pharmacies and providers in the community setting.  Now, \nwe want to leverage our business resources and expertise to support their growth and enable better access to ", "original_text": "We \nwant to become not only a diversified healthcare services company, but also a company that enables positive \nchange in our communities and drives impact.  \n \n"}, "hash": "f280e753ef96c81df9923b7aec06cbbd8e6d89b9f5b0b7bf649ac384ab9ffd4b", "class_name": "RelatedNodeInfo"}}, "text": "As we asse ss investment opportunities and we allocate resources across the enterprise, we strive to ensure that \nour decisions align with our strategic priorities and with our mission of improving healthcare in every setting. ", "start_char_idx": 3373, "end_char_idx": 3600, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36bc7910-7a82-425b-b974-4bd5bc15f7ac": {"__data__": {"id_": "36bc7910-7a82-425b-b974-4bd5bc15f7ac", "embedding": null, "metadata": {"window": "We believe this  relationship is a strong testament to our differentiated capabilities and services \nacross pharmaceutical distribution, sourcing, and oncology.  We look forward to the opportunity to serve and grow \nwith all of our customers, including now Optum.  \n \n As we asse ss investment opportunities and we allocate resources across the enterprise, we strive to ensure that \nour decisions align with our strategic priorities and with our mission of improving healthcare in every setting.  We \nwant to become not only a diversified healthcare services company, but also a company that enables positive \nchange in our communities and drives impact.  \n \n In April, we launched a new initiative aimed at advancing HealthEquity for at -risk populations in underserved \ncommunities.  We have a long hi story of working with pharmacies and providers in the community setting.  Now, \nwe want to leverage our business resources and expertise to support their growth and enable better access to ", "original_text": "We \nwant to become not only a diversified healthcare services company, but also a company that enables positive \nchange in our communities and drives impact.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "76bf9759a748d309ac2a9db3e904dc0f66f1e19acb87ea2aaa5c4a76fca9673a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b40388ad-29f9-46cf-84b7-a5a51c7168b3", "node_type": "1", "metadata": {"window": "We started servicing a portion of \nOptum's business last year, and we're pleased to get the opportunity to expand the scope of our services starting \nJuly of 2024.  We believe this  relationship is a strong testament to our differentiated capabilities and services \nacross pharmaceutical distribution, sourcing, and oncology.  We look forward to the opportunity to serve and grow \nwith all of our customers, including now Optum.  \n \n As we asse ss investment opportunities and we allocate resources across the enterprise, we strive to ensure that \nour decisions align with our strategic priorities and with our mission of improving healthcare in every setting.  We \nwant to become not only a diversified healthcare services company, but also a company that enables positive \nchange in our communities and drives impact.  \n \n In April, we launched a new initiative aimed at advancing HealthEquity for at -risk populations in underserved \ncommunities.  We have a long hi story of working with pharmacies and providers in the community setting. ", "original_text": "As we asse ss investment opportunities and we allocate resources across the enterprise, we strive to ensure that \nour decisions align with our strategic priorities and with our mission of improving healthcare in every setting. ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "6fd9618ea78f113e117310ca3808ed932bc54ea3a995970a0df196f5deddfd95", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6efd9bbe-adbd-4103-bf23-479418c84465", "node_type": "1", "metadata": {"window": "We look forward to the opportunity to serve and grow \nwith all of our customers, including now Optum.  \n \n As we asse ss investment opportunities and we allocate resources across the enterprise, we strive to ensure that \nour decisions align with our strategic priorities and with our mission of improving healthcare in every setting.  We \nwant to become not only a diversified healthcare services company, but also a company that enables positive \nchange in our communities and drives impact.  \n \n In April, we launched a new initiative aimed at advancing HealthEquity for at -risk populations in underserved \ncommunities.  We have a long hi story of working with pharmacies and providers in the community setting.  Now, \nwe want to leverage our business resources and expertise to support their growth and enable better access to ", "original_text": "In April, we launched a new initiative aimed at advancing HealthEquity for at -risk populations in underserved \ncommunities. "}, "hash": "94437a9ba6b79f13c4200aa8563972d7b8fa71726369a52af096337699047d3f", "class_name": "RelatedNodeInfo"}}, "text": "We \nwant to become not only a diversified healthcare services company, but also a company that enables positive \nchange in our communities and drives impact.  \n \n", "start_char_idx": 3600, "end_char_idx": 3762, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6efd9bbe-adbd-4103-bf23-479418c84465": {"__data__": {"id_": "6efd9bbe-adbd-4103-bf23-479418c84465", "embedding": null, "metadata": {"window": "We look forward to the opportunity to serve and grow \nwith all of our customers, including now Optum.  \n \n As we asse ss investment opportunities and we allocate resources across the enterprise, we strive to ensure that \nour decisions align with our strategic priorities and with our mission of improving healthcare in every setting.  We \nwant to become not only a diversified healthcare services company, but also a company that enables positive \nchange in our communities and drives impact.  \n \n In April, we launched a new initiative aimed at advancing HealthEquity for at -risk populations in underserved \ncommunities.  We have a long hi story of working with pharmacies and providers in the community setting.  Now, \nwe want to leverage our business resources and expertise to support their growth and enable better access to ", "original_text": "In April, we launched a new initiative aimed at advancing HealthEquity for at -risk populations in underserved \ncommunities. ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "76bf9759a748d309ac2a9db3e904dc0f66f1e19acb87ea2aaa5c4a76fca9673a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36bc7910-7a82-425b-b974-4bd5bc15f7ac", "node_type": "1", "metadata": {"window": "We believe this  relationship is a strong testament to our differentiated capabilities and services \nacross pharmaceutical distribution, sourcing, and oncology.  We look forward to the opportunity to serve and grow \nwith all of our customers, including now Optum.  \n \n As we asse ss investment opportunities and we allocate resources across the enterprise, we strive to ensure that \nour decisions align with our strategic priorities and with our mission of improving healthcare in every setting.  We \nwant to become not only a diversified healthcare services company, but also a company that enables positive \nchange in our communities and drives impact.  \n \n In April, we launched a new initiative aimed at advancing HealthEquity for at -risk populations in underserved \ncommunities.  We have a long hi story of working with pharmacies and providers in the community setting.  Now, \nwe want to leverage our business resources and expertise to support their growth and enable better access to ", "original_text": "We \nwant to become not only a diversified healthcare services company, but also a company that enables positive \nchange in our communities and drives impact.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e4c4f50357bf6edc7b7e0dffed7a514bdf0b489a7250e3cfdd95966aaec3125c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "824b8022-6178-4691-9bbc-cdb975d09131", "node_type": "1", "metadata": {"window": "As we asse ss investment opportunities and we allocate resources across the enterprise, we strive to ensure that \nour decisions align with our strategic priorities and with our mission of improving healthcare in every setting.  We \nwant to become not only a diversified healthcare services company, but also a company that enables positive \nchange in our communities and drives impact.  \n \n In April, we launched a new initiative aimed at advancing HealthEquity for at -risk populations in underserved \ncommunities.  We have a long hi story of working with pharmacies and providers in the community setting.  Now, \nwe want to leverage our business resources and expertise to support their growth and enable better access to ", "original_text": "We have a long hi story of working with pharmacies and providers in the community setting. "}, "hash": "d6fbf9d2e19fd1df9fb377b141add9489607f53eb32fe79ed14ac30fee897aaa", "class_name": "RelatedNodeInfo"}}, "text": "In April, we launched a new initiative aimed at advancing HealthEquity for at -risk populations in underserved \ncommunities. ", "start_char_idx": 3762, "end_char_idx": 3887, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "824b8022-6178-4691-9bbc-cdb975d09131": {"__data__": {"id_": "824b8022-6178-4691-9bbc-cdb975d09131", "embedding": null, "metadata": {"window": "As we asse ss investment opportunities and we allocate resources across the enterprise, we strive to ensure that \nour decisions align with our strategic priorities and with our mission of improving healthcare in every setting.  We \nwant to become not only a diversified healthcare services company, but also a company that enables positive \nchange in our communities and drives impact.  \n \n In April, we launched a new initiative aimed at advancing HealthEquity for at -risk populations in underserved \ncommunities.  We have a long hi story of working with pharmacies and providers in the community setting.  Now, \nwe want to leverage our business resources and expertise to support their growth and enable better access to ", "original_text": "We have a long hi story of working with pharmacies and providers in the community setting. ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "76bf9759a748d309ac2a9db3e904dc0f66f1e19acb87ea2aaa5c4a76fca9673a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6efd9bbe-adbd-4103-bf23-479418c84465", "node_type": "1", "metadata": {"window": "We look forward to the opportunity to serve and grow \nwith all of our customers, including now Optum.  \n \n As we asse ss investment opportunities and we allocate resources across the enterprise, we strive to ensure that \nour decisions align with our strategic priorities and with our mission of improving healthcare in every setting.  We \nwant to become not only a diversified healthcare services company, but also a company that enables positive \nchange in our communities and drives impact.  \n \n In April, we launched a new initiative aimed at advancing HealthEquity for at -risk populations in underserved \ncommunities.  We have a long hi story of working with pharmacies and providers in the community setting.  Now, \nwe want to leverage our business resources and expertise to support their growth and enable better access to ", "original_text": "In April, we launched a new initiative aimed at advancing HealthEquity for at -risk populations in underserved \ncommunities. ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a73c216091c81e72c293fa320b354eddb53e379286f1e63e7ae8d3f8c077edf6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "332fff5d-26ea-4f4e-981a-b7b47b619a3b", "node_type": "1", "metadata": {"window": "We \nwant to become not only a diversified healthcare services company, but also a company that enables positive \nchange in our communities and drives impact.  \n \n In April, we launched a new initiative aimed at advancing HealthEquity for at -risk populations in underserved \ncommunities.  We have a long hi story of working with pharmacies and providers in the community setting.  Now, \nwe want to leverage our business resources and expertise to support their growth and enable better access to ", "original_text": "Now, \nwe want to leverage our business resources and expertise to support their growth and enable better access to "}, "hash": "9420d0e9a16a7fde3a8574a273808646312a51ddd40d393a38d7ed6fc7f63575", "class_name": "RelatedNodeInfo"}}, "text": "We have a long hi story of working with pharmacies and providers in the community setting. ", "start_char_idx": 3887, "end_char_idx": 3978, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "332fff5d-26ea-4f4e-981a-b7b47b619a3b": {"__data__": {"id_": "332fff5d-26ea-4f4e-981a-b7b47b619a3b", "embedding": null, "metadata": {"window": "We \nwant to become not only a diversified healthcare services company, but also a company that enables positive \nchange in our communities and drives impact.  \n \n In April, we launched a new initiative aimed at advancing HealthEquity for at -risk populations in underserved \ncommunities.  We have a long hi story of working with pharmacies and providers in the community setting.  Now, \nwe want to leverage our business resources and expertise to support their growth and enable better access to ", "original_text": "Now, \nwe want to leverage our business resources and expertise to support their growth and enable better access to ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "76bf9759a748d309ac2a9db3e904dc0f66f1e19acb87ea2aaa5c4a76fca9673a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "824b8022-6178-4691-9bbc-cdb975d09131", "node_type": "1", "metadata": {"window": "As we asse ss investment opportunities and we allocate resources across the enterprise, we strive to ensure that \nour decisions align with our strategic priorities and with our mission of improving healthcare in every setting.  We \nwant to become not only a diversified healthcare services company, but also a company that enables positive \nchange in our communities and drives impact.  \n \n In April, we launched a new initiative aimed at advancing HealthEquity for at -risk populations in underserved \ncommunities.  We have a long hi story of working with pharmacies and providers in the community setting.  Now, \nwe want to leverage our business resources and expertise to support their growth and enable better access to ", "original_text": "We have a long hi story of working with pharmacies and providers in the community setting. ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5b57395c5bcb786a6c2fc05965bdfd3e420fa3e9275b90c5de15e8454745dc9d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74ede774-3dbd-4c92-92fe-9ffe15c7aed3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nhealthcare in many of these communities.  With this project, we look t o identify and address pharmacy deserts \nwhere residents face significant challenges in accessing essential pharmacy services.  \n \n We chose Avondale, Ohio as our pilot activation site. ", "original_text": "McKesson Corp.  "}, "hash": "4626ee348364543fd23cefc57e7177f69e6439bd6d846230594337c41ddb1e5f", "class_name": "RelatedNodeInfo"}}, "text": "Now, \nwe want to leverage our business resources and expertise to support their growth and enable better access to ", "start_char_idx": 3978, "end_char_idx": 4093, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74ede774-3dbd-4c92-92fe-9ffe15c7aed3": {"__data__": {"id_": "74ede774-3dbd-4c92-92fe-9ffe15c7aed3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nhealthcare in many of these communities.  With this project, we look t o identify and address pharmacy deserts \nwhere residents face significant challenges in accessing essential pharmacy services.  \n \n We chose Avondale, Ohio as our pilot activation site. ", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "05bb6c5d181d30b8f8aa08d20902fbb57655958b638f52ad3ee99e6749958164", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "332fff5d-26ea-4f4e-981a-b7b47b619a3b", "node_type": "1", "metadata": {"window": "We \nwant to become not only a diversified healthcare services company, but also a company that enables positive \nchange in our communities and drives impact.  \n \n In April, we launched a new initiative aimed at advancing HealthEquity for at -risk populations in underserved \ncommunities.  We have a long hi story of working with pharmacies and providers in the community setting.  Now, \nwe want to leverage our business resources and expertise to support their growth and enable better access to ", "original_text": "Now, \nwe want to leverage our business resources and expertise to support their growth and enable better access to ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "214586d9f26c3d9355494bfde88c779af884106b5bd990a3c7bba012f153255b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "380bd4e2-2f70-47fd-8d9e-5e85f9a43d96", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nhealthcare in many of these communities.  With this project, we look t o identify and address pharmacy deserts \nwhere residents face significant challenges in accessing essential pharmacy services.  \n \n We chose Avondale, Ohio as our pilot activation site.  We helped facilitate an expedited path to an independent \npharmacy ownership  in the local community, and we opened the pharmacy this past December. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nhealthcare in many of these communities. "}, "hash": "bbc4688bd6de558c9f889aadb21bdc73380c24a091cc14c00b1b71d8fe3acd62", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "380bd4e2-2f70-47fd-8d9e-5e85f9a43d96": {"__data__": {"id_": "380bd4e2-2f70-47fd-8d9e-5e85f9a43d96", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nhealthcare in many of these communities.  With this project, we look t o identify and address pharmacy deserts \nwhere residents face significant challenges in accessing essential pharmacy services.  \n \n We chose Avondale, Ohio as our pilot activation site.  We helped facilitate an expedited path to an independent \npharmacy ownership  in the local community, and we opened the pharmacy this past December. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nhealthcare in many of these communities. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "05bb6c5d181d30b8f8aa08d20902fbb57655958b638f52ad3ee99e6749958164", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74ede774-3dbd-4c92-92fe-9ffe15c7aed3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nhealthcare in many of these communities.  With this project, we look t o identify and address pharmacy deserts \nwhere residents face significant challenges in accessing essential pharmacy services.  \n \n We chose Avondale, Ohio as our pilot activation site. ", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "018bbadeca2f32d4a7820f23dc653c1d069ad55731d903ecca6505c60c738ad5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "339537f8-5f06-4c07-900c-97c2efd870ca", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nhealthcare in many of these communities.  With this project, we look t o identify and address pharmacy deserts \nwhere residents face significant challenges in accessing essential pharmacy services.  \n \n We chose Avondale, Ohio as our pilot activation site.  We helped facilitate an expedited path to an independent \npharmacy ownership  in the local community, and we opened the pharmacy this past December.  I had the \nopportunity to be there personally and experience the joy of those who live in that community appreciating \nsomething that most of us take for granted, a pharmacy near our hou se. ", "original_text": "With this project, we look t o identify and address pharmacy deserts \nwhere residents face significant challenges in accessing essential pharmacy services.  \n \n"}, "hash": "1d3cab1488b5a69dc7cc36cc878817308d2e8c9104cf4feecd6858c3c1feb1ba", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nhealthcare in many of these communities. ", "start_char_idx": 16, "end_char_idx": 221, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "339537f8-5f06-4c07-900c-97c2efd870ca": {"__data__": {"id_": "339537f8-5f06-4c07-900c-97c2efd870ca", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nhealthcare in many of these communities.  With this project, we look t o identify and address pharmacy deserts \nwhere residents face significant challenges in accessing essential pharmacy services.  \n \n We chose Avondale, Ohio as our pilot activation site.  We helped facilitate an expedited path to an independent \npharmacy ownership  in the local community, and we opened the pharmacy this past December.  I had the \nopportunity to be there personally and experience the joy of those who live in that community appreciating \nsomething that most of us take for granted, a pharmacy near our hou se. ", "original_text": "With this project, we look t o identify and address pharmacy deserts \nwhere residents face significant challenges in accessing essential pharmacy services.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "05bb6c5d181d30b8f8aa08d20902fbb57655958b638f52ad3ee99e6749958164", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "380bd4e2-2f70-47fd-8d9e-5e85f9a43d96", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nhealthcare in many of these communities.  With this project, we look t o identify and address pharmacy deserts \nwhere residents face significant challenges in accessing essential pharmacy services.  \n \n We chose Avondale, Ohio as our pilot activation site.  We helped facilitate an expedited path to an independent \npharmacy ownership  in the local community, and we opened the pharmacy this past December. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nhealthcare in many of these communities. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "fcd1118f5e8fb28e2c9a7a49746e99071623fa72f7de554b6d30e988bf62cb0e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc322728-c0fb-487d-a2f4-e88b7e9b145f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nhealthcare in many of these communities.  With this project, we look t o identify and address pharmacy deserts \nwhere residents face significant challenges in accessing essential pharmacy services.  \n \n We chose Avondale, Ohio as our pilot activation site.  We helped facilitate an expedited path to an independent \npharmacy ownership  in the local community, and we opened the pharmacy this past December.  I had the \nopportunity to be there personally and experience the joy of those who live in that community appreciating \nsomething that most of us take for granted, a pharmacy near our hou se.  We look forward to making a lasting \ndifference in more communities like Avondale in the future.  \n \n", "original_text": "We chose Avondale, Ohio as our pilot activation site. "}, "hash": "d3615809bdd6a6f62c49314b553beda43c67f1c34d123c05a19f18dcb50317ee", "class_name": "RelatedNodeInfo"}}, "text": "With this project, we look t o identify and address pharmacy deserts \nwhere residents face significant challenges in accessing essential pharmacy services.  \n \n", "start_char_idx": 221, "end_char_idx": 381, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc322728-c0fb-487d-a2f4-e88b7e9b145f": {"__data__": {"id_": "cc322728-c0fb-487d-a2f4-e88b7e9b145f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nhealthcare in many of these communities.  With this project, we look t o identify and address pharmacy deserts \nwhere residents face significant challenges in accessing essential pharmacy services.  \n \n We chose Avondale, Ohio as our pilot activation site.  We helped facilitate an expedited path to an independent \npharmacy ownership  in the local community, and we opened the pharmacy this past December.  I had the \nopportunity to be there personally and experience the joy of those who live in that community appreciating \nsomething that most of us take for granted, a pharmacy near our hou se.  We look forward to making a lasting \ndifference in more communities like Avondale in the future.  \n \n", "original_text": "We chose Avondale, Ohio as our pilot activation site. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "05bb6c5d181d30b8f8aa08d20902fbb57655958b638f52ad3ee99e6749958164", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "339537f8-5f06-4c07-900c-97c2efd870ca", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nhealthcare in many of these communities.  With this project, we look t o identify and address pharmacy deserts \nwhere residents face significant challenges in accessing essential pharmacy services.  \n \n We chose Avondale, Ohio as our pilot activation site.  We helped facilitate an expedited path to an independent \npharmacy ownership  in the local community, and we opened the pharmacy this past December.  I had the \nopportunity to be there personally and experience the joy of those who live in that community appreciating \nsomething that most of us take for granted, a pharmacy near our hou se. ", "original_text": "With this project, we look t o identify and address pharmacy deserts \nwhere residents face significant challenges in accessing essential pharmacy services.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "02e4d4d4d9b5886b0363d5b4de106444c9d2863bfd1f3d3e639f818c8b7790bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb887d2c-67c4-4eb6-b56b-c17265e67a14", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nhealthcare in many of these communities.  With this project, we look t o identify and address pharmacy deserts \nwhere residents face significant challenges in accessing essential pharmacy services.  \n \n We chose Avondale, Ohio as our pilot activation site.  We helped facilitate an expedited path to an independent \npharmacy ownership  in the local community, and we opened the pharmacy this past December.  I had the \nopportunity to be there personally and experience the joy of those who live in that community appreciating \nsomething that most of us take for granted, a pharmacy near our hou se.  We look forward to making a lasting \ndifference in more communities like Avondale in the future.  \n \n We also support and fund many charitable works through the McKesson Foundation. ", "original_text": "We helped facilitate an expedited path to an independent \npharmacy ownership  in the local community, and we opened the pharmacy this past December. "}, "hash": "b4e87ba7c7c526f5d51b0d5f43a26b1b134a22b5e2fa392c3f7c0adb4ecc8201", "class_name": "RelatedNodeInfo"}}, "text": "We chose Avondale, Ohio as our pilot activation site. ", "start_char_idx": 381, "end_char_idx": 435, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb887d2c-67c4-4eb6-b56b-c17265e67a14": {"__data__": {"id_": "bb887d2c-67c4-4eb6-b56b-c17265e67a14", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nhealthcare in many of these communities.  With this project, we look t o identify and address pharmacy deserts \nwhere residents face significant challenges in accessing essential pharmacy services.  \n \n We chose Avondale, Ohio as our pilot activation site.  We helped facilitate an expedited path to an independent \npharmacy ownership  in the local community, and we opened the pharmacy this past December.  I had the \nopportunity to be there personally and experience the joy of those who live in that community appreciating \nsomething that most of us take for granted, a pharmacy near our hou se.  We look forward to making a lasting \ndifference in more communities like Avondale in the future.  \n \n We also support and fund many charitable works through the McKesson Foundation. ", "original_text": "We helped facilitate an expedited path to an independent \npharmacy ownership  in the local community, and we opened the pharmacy this past December. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "05bb6c5d181d30b8f8aa08d20902fbb57655958b638f52ad3ee99e6749958164", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc322728-c0fb-487d-a2f4-e88b7e9b145f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nhealthcare in many of these communities.  With this project, we look t o identify and address pharmacy deserts \nwhere residents face significant challenges in accessing essential pharmacy services.  \n \n We chose Avondale, Ohio as our pilot activation site.  We helped facilitate an expedited path to an independent \npharmacy ownership  in the local community, and we opened the pharmacy this past December.  I had the \nopportunity to be there personally and experience the joy of those who live in that community appreciating \nsomething that most of us take for granted, a pharmacy near our hou se.  We look forward to making a lasting \ndifference in more communities like Avondale in the future.  \n \n", "original_text": "We chose Avondale, Ohio as our pilot activation site. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "afb7cf38445bd5c1c533858467995414f301c379756d17a00cbe4d0b1d4de7d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "905b0661-4a25-4ed2-bb7c-2efd98894e46", "node_type": "1", "metadata": {"window": "With this project, we look t o identify and address pharmacy deserts \nwhere residents face significant challenges in accessing essential pharmacy services.  \n \n We chose Avondale, Ohio as our pilot activation site.  We helped facilitate an expedited path to an independent \npharmacy ownership  in the local community, and we opened the pharmacy this past December.  I had the \nopportunity to be there personally and experience the joy of those who live in that community appreciating \nsomething that most of us take for granted, a pharmacy near our hou se.  We look forward to making a lasting \ndifference in more communities like Avondale in the future.  \n \n We also support and fund many charitable works through the McKesson Foundation.  This past year marked an \nimportant milestone for the foundation as it celeb rated its 80th anniversary. ", "original_text": "I had the \nopportunity to be there personally and experience the joy of those who live in that community appreciating \nsomething that most of us take for granted, a pharmacy near our hou se. "}, "hash": "fe42ef94eb5134827f83edb6f940769b0133a95b9a6e9a2d53324ac42ebee717", "class_name": "RelatedNodeInfo"}}, "text": "We helped facilitate an expedited path to an independent \npharmacy ownership  in the local community, and we opened the pharmacy this past December. ", "start_char_idx": 435, "end_char_idx": 584, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "905b0661-4a25-4ed2-bb7c-2efd98894e46": {"__data__": {"id_": "905b0661-4a25-4ed2-bb7c-2efd98894e46", "embedding": null, "metadata": {"window": "With this project, we look t o identify and address pharmacy deserts \nwhere residents face significant challenges in accessing essential pharmacy services.  \n \n We chose Avondale, Ohio as our pilot activation site.  We helped facilitate an expedited path to an independent \npharmacy ownership  in the local community, and we opened the pharmacy this past December.  I had the \nopportunity to be there personally and experience the joy of those who live in that community appreciating \nsomething that most of us take for granted, a pharmacy near our hou se.  We look forward to making a lasting \ndifference in more communities like Avondale in the future.  \n \n We also support and fund many charitable works through the McKesson Foundation.  This past year marked an \nimportant milestone for the foundation as it celeb rated its 80th anniversary. ", "original_text": "I had the \nopportunity to be there personally and experience the joy of those who live in that community appreciating \nsomething that most of us take for granted, a pharmacy near our hou se. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "05bb6c5d181d30b8f8aa08d20902fbb57655958b638f52ad3ee99e6749958164", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb887d2c-67c4-4eb6-b56b-c17265e67a14", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nhealthcare in many of these communities.  With this project, we look t o identify and address pharmacy deserts \nwhere residents face significant challenges in accessing essential pharmacy services.  \n \n We chose Avondale, Ohio as our pilot activation site.  We helped facilitate an expedited path to an independent \npharmacy ownership  in the local community, and we opened the pharmacy this past December.  I had the \nopportunity to be there personally and experience the joy of those who live in that community appreciating \nsomething that most of us take for granted, a pharmacy near our hou se.  We look forward to making a lasting \ndifference in more communities like Avondale in the future.  \n \n We also support and fund many charitable works through the McKesson Foundation. ", "original_text": "We helped facilitate an expedited path to an independent \npharmacy ownership  in the local community, and we opened the pharmacy this past December. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a0c03131821dfa793ab7230988cd0e474cd819111942700645b59277df1abc26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8bb5cf1e-87cd-45f9-9083-68d7864a9ed0", "node_type": "1", "metadata": {"window": "We chose Avondale, Ohio as our pilot activation site.  We helped facilitate an expedited path to an independent \npharmacy ownership  in the local community, and we opened the pharmacy this past December.  I had the \nopportunity to be there personally and experience the joy of those who live in that community appreciating \nsomething that most of us take for granted, a pharmacy near our hou se.  We look forward to making a lasting \ndifference in more communities like Avondale in the future.  \n \n We also support and fund many charitable works through the McKesson Foundation.  This past year marked an \nimportant milestone for the foundation as it celeb rated its 80th anniversary.  During the last year alone, it funded \nnearly 50 organizations through its grant -making program and dispersed approximately $9 million, one -third of \nwhich supported direct patient care and assistance. ", "original_text": "We look forward to making a lasting \ndifference in more communities like Avondale in the future.  \n \n"}, "hash": "ad3cc0a8fdaced41d2e1c9c5b9072137df830befa02f4ccc976465dd66747936", "class_name": "RelatedNodeInfo"}}, "text": "I had the \nopportunity to be there personally and experience the joy of those who live in that community appreciating \nsomething that most of us take for granted, a pharmacy near our hou se. ", "start_char_idx": 584, "end_char_idx": 775, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8bb5cf1e-87cd-45f9-9083-68d7864a9ed0": {"__data__": {"id_": "8bb5cf1e-87cd-45f9-9083-68d7864a9ed0", "embedding": null, "metadata": {"window": "We chose Avondale, Ohio as our pilot activation site.  We helped facilitate an expedited path to an independent \npharmacy ownership  in the local community, and we opened the pharmacy this past December.  I had the \nopportunity to be there personally and experience the joy of those who live in that community appreciating \nsomething that most of us take for granted, a pharmacy near our hou se.  We look forward to making a lasting \ndifference in more communities like Avondale in the future.  \n \n We also support and fund many charitable works through the McKesson Foundation.  This past year marked an \nimportant milestone for the foundation as it celeb rated its 80th anniversary.  During the last year alone, it funded \nnearly 50 organizations through its grant -making program and dispersed approximately $9 million, one -third of \nwhich supported direct patient care and assistance. ", "original_text": "We look forward to making a lasting \ndifference in more communities like Avondale in the future.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "05bb6c5d181d30b8f8aa08d20902fbb57655958b638f52ad3ee99e6749958164", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "905b0661-4a25-4ed2-bb7c-2efd98894e46", "node_type": "1", "metadata": {"window": "With this project, we look t o identify and address pharmacy deserts \nwhere residents face significant challenges in accessing essential pharmacy services.  \n \n We chose Avondale, Ohio as our pilot activation site.  We helped facilitate an expedited path to an independent \npharmacy ownership  in the local community, and we opened the pharmacy this past December.  I had the \nopportunity to be there personally and experience the joy of those who live in that community appreciating \nsomething that most of us take for granted, a pharmacy near our hou se.  We look forward to making a lasting \ndifference in more communities like Avondale in the future.  \n \n We also support and fund many charitable works through the McKesson Foundation.  This past year marked an \nimportant milestone for the foundation as it celeb rated its 80th anniversary. ", "original_text": "I had the \nopportunity to be there personally and experience the joy of those who live in that community appreciating \nsomething that most of us take for granted, a pharmacy near our hou se. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "0bbb2b6a7a9114d832306b4ab2663101c13d5136293ee04add5cc68ac14313a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "974d5f55-766b-454c-8ff5-408f6796719e", "node_type": "1", "metadata": {"window": "We helped facilitate an expedited path to an independent \npharmacy ownership  in the local community, and we opened the pharmacy this past December.  I had the \nopportunity to be there personally and experience the joy of those who live in that community appreciating \nsomething that most of us take for granted, a pharmacy near our hou se.  We look forward to making a lasting \ndifference in more communities like Avondale in the future.  \n \n We also support and fund many charitable works through the McKesson Foundation.  This past year marked an \nimportant milestone for the foundation as it celeb rated its 80th anniversary.  During the last year alone, it funded \nnearly 50 organizations through its grant -making program and dispersed approximately $9 million, one -third of \nwhich supported direct patient care and assistance.  We're also pleased to see co ntinued increase in employee \nparticipation in these impactful initiatives. ", "original_text": "We also support and fund many charitable works through the McKesson Foundation. "}, "hash": "d42bf0b8d5b5af6ac2fd3c53c647576e96eb1182ab7651611e691af22ae236b0", "class_name": "RelatedNodeInfo"}}, "text": "We look forward to making a lasting \ndifference in more communities like Avondale in the future.  \n \n", "start_char_idx": 775, "end_char_idx": 876, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "974d5f55-766b-454c-8ff5-408f6796719e": {"__data__": {"id_": "974d5f55-766b-454c-8ff5-408f6796719e", "embedding": null, "metadata": {"window": "We helped facilitate an expedited path to an independent \npharmacy ownership  in the local community, and we opened the pharmacy this past December.  I had the \nopportunity to be there personally and experience the joy of those who live in that community appreciating \nsomething that most of us take for granted, a pharmacy near our hou se.  We look forward to making a lasting \ndifference in more communities like Avondale in the future.  \n \n We also support and fund many charitable works through the McKesson Foundation.  This past year marked an \nimportant milestone for the foundation as it celeb rated its 80th anniversary.  During the last year alone, it funded \nnearly 50 organizations through its grant -making program and dispersed approximately $9 million, one -third of \nwhich supported direct patient care and assistance.  We're also pleased to see co ntinued increase in employee \nparticipation in these impactful initiatives. ", "original_text": "We also support and fund many charitable works through the McKesson Foundation. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "05bb6c5d181d30b8f8aa08d20902fbb57655958b638f52ad3ee99e6749958164", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8bb5cf1e-87cd-45f9-9083-68d7864a9ed0", "node_type": "1", "metadata": {"window": "We chose Avondale, Ohio as our pilot activation site.  We helped facilitate an expedited path to an independent \npharmacy ownership  in the local community, and we opened the pharmacy this past December.  I had the \nopportunity to be there personally and experience the joy of those who live in that community appreciating \nsomething that most of us take for granted, a pharmacy near our hou se.  We look forward to making a lasting \ndifference in more communities like Avondale in the future.  \n \n We also support and fund many charitable works through the McKesson Foundation.  This past year marked an \nimportant milestone for the foundation as it celeb rated its 80th anniversary.  During the last year alone, it funded \nnearly 50 organizations through its grant -making program and dispersed approximately $9 million, one -third of \nwhich supported direct patient care and assistance. ", "original_text": "We look forward to making a lasting \ndifference in more communities like Avondale in the future.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5d1da5792d45f6ed97f375757895046257b7094ff2a98383502d048827e6bf8c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "365c27f4-81ca-4d09-9536-e2f8622d150d", "node_type": "1", "metadata": {"window": "I had the \nopportunity to be there personally and experience the joy of those who live in that community appreciating \nsomething that most of us take for granted, a pharmacy near our hou se.  We look forward to making a lasting \ndifference in more communities like Avondale in the future.  \n \n We also support and fund many charitable works through the McKesson Foundation.  This past year marked an \nimportant milestone for the foundation as it celeb rated its 80th anniversary.  During the last year alone, it funded \nnearly 50 organizations through its grant -making program and dispersed approximately $9 million, one -third of \nwhich supported direct patient care and assistance.  We're also pleased to see co ntinued increase in employee \nparticipation in these impactful initiatives.  In fiscal 2024, McKesson employees put in over 44,000 volunteer hours \nwith charities across the US and Canada. ", "original_text": "This past year marked an \nimportant milestone for the foundation as it celeb rated its 80th anniversary. "}, "hash": "4db9191cec6d0ec2ee658ae6c80345c6e6bea235960b7bb662f3551e747a1f38", "class_name": "RelatedNodeInfo"}}, "text": "We also support and fund many charitable works through the McKesson Foundation. ", "start_char_idx": 876, "end_char_idx": 956, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "365c27f4-81ca-4d09-9536-e2f8622d150d": {"__data__": {"id_": "365c27f4-81ca-4d09-9536-e2f8622d150d", "embedding": null, "metadata": {"window": "I had the \nopportunity to be there personally and experience the joy of those who live in that community appreciating \nsomething that most of us take for granted, a pharmacy near our hou se.  We look forward to making a lasting \ndifference in more communities like Avondale in the future.  \n \n We also support and fund many charitable works through the McKesson Foundation.  This past year marked an \nimportant milestone for the foundation as it celeb rated its 80th anniversary.  During the last year alone, it funded \nnearly 50 organizations through its grant -making program and dispersed approximately $9 million, one -third of \nwhich supported direct patient care and assistance.  We're also pleased to see co ntinued increase in employee \nparticipation in these impactful initiatives.  In fiscal 2024, McKesson employees put in over 44,000 volunteer hours \nwith charities across the US and Canada. ", "original_text": "This past year marked an \nimportant milestone for the foundation as it celeb rated its 80th anniversary. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "05bb6c5d181d30b8f8aa08d20902fbb57655958b638f52ad3ee99e6749958164", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "974d5f55-766b-454c-8ff5-408f6796719e", "node_type": "1", "metadata": {"window": "We helped facilitate an expedited path to an independent \npharmacy ownership  in the local community, and we opened the pharmacy this past December.  I had the \nopportunity to be there personally and experience the joy of those who live in that community appreciating \nsomething that most of us take for granted, a pharmacy near our hou se.  We look forward to making a lasting \ndifference in more communities like Avondale in the future.  \n \n We also support and fund many charitable works through the McKesson Foundation.  This past year marked an \nimportant milestone for the foundation as it celeb rated its 80th anniversary.  During the last year alone, it funded \nnearly 50 organizations through its grant -making program and dispersed approximately $9 million, one -third of \nwhich supported direct patient care and assistance.  We're also pleased to see co ntinued increase in employee \nparticipation in these impactful initiatives. ", "original_text": "We also support and fund many charitable works through the McKesson Foundation. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "0940f4a09bb31df975853e4714fccabae31592d7bca025fcc234657a0c7298d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a577b514-f183-4755-8e36-5548f8c60c8b", "node_type": "1", "metadata": {"window": "We look forward to making a lasting \ndifference in more communities like Avondale in the future.  \n \n We also support and fund many charitable works through the McKesson Foundation.  This past year marked an \nimportant milestone for the foundation as it celeb rated its 80th anniversary.  During the last year alone, it funded \nnearly 50 organizations through its grant -making program and dispersed approximately $9 million, one -third of \nwhich supported direct patient care and assistance.  We're also pleased to see co ntinued increase in employee \nparticipation in these impactful initiatives.  In fiscal 2024, McKesson employees put in over 44,000 volunteer hours \nwith charities across the US and Canada.  I'm truly proud of what we have achieved as a team to support the \ncomm unities and to live our purpose of advancing health outcomes for all.  \n \n", "original_text": "During the last year alone, it funded \nnearly 50 organizations through its grant -making program and dispersed approximately $9 million, one -third of \nwhich supported direct patient care and assistance. "}, "hash": "d62461fb2bc4b06904b9c4a016e5595e3ac6161258fed1434d566f7b2d423127", "class_name": "RelatedNodeInfo"}}, "text": "This past year marked an \nimportant milestone for the foundation as it celeb rated its 80th anniversary. ", "start_char_idx": 956, "end_char_idx": 1061, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a577b514-f183-4755-8e36-5548f8c60c8b": {"__data__": {"id_": "a577b514-f183-4755-8e36-5548f8c60c8b", "embedding": null, "metadata": {"window": "We look forward to making a lasting \ndifference in more communities like Avondale in the future.  \n \n We also support and fund many charitable works through the McKesson Foundation.  This past year marked an \nimportant milestone for the foundation as it celeb rated its 80th anniversary.  During the last year alone, it funded \nnearly 50 organizations through its grant -making program and dispersed approximately $9 million, one -third of \nwhich supported direct patient care and assistance.  We're also pleased to see co ntinued increase in employee \nparticipation in these impactful initiatives.  In fiscal 2024, McKesson employees put in over 44,000 volunteer hours \nwith charities across the US and Canada.  I'm truly proud of what we have achieved as a team to support the \ncomm unities and to live our purpose of advancing health outcomes for all.  \n \n", "original_text": "During the last year alone, it funded \nnearly 50 organizations through its grant -making program and dispersed approximately $9 million, one -third of \nwhich supported direct patient care and assistance. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "05bb6c5d181d30b8f8aa08d20902fbb57655958b638f52ad3ee99e6749958164", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "365c27f4-81ca-4d09-9536-e2f8622d150d", "node_type": "1", "metadata": {"window": "I had the \nopportunity to be there personally and experience the joy of those who live in that community appreciating \nsomething that most of us take for granted, a pharmacy near our hou se.  We look forward to making a lasting \ndifference in more communities like Avondale in the future.  \n \n We also support and fund many charitable works through the McKesson Foundation.  This past year marked an \nimportant milestone for the foundation as it celeb rated its 80th anniversary.  During the last year alone, it funded \nnearly 50 organizations through its grant -making program and dispersed approximately $9 million, one -third of \nwhich supported direct patient care and assistance.  We're also pleased to see co ntinued increase in employee \nparticipation in these impactful initiatives.  In fiscal 2024, McKesson employees put in over 44,000 volunteer hours \nwith charities across the US and Canada. ", "original_text": "This past year marked an \nimportant milestone for the foundation as it celeb rated its 80th anniversary. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "75abd24b2a2cd7c888fcd8abb95528c3c5209bec0826c693be3621bd7f39674a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e46ca8cb-af20-455d-9644-49aa158daebf", "node_type": "1", "metadata": {"window": "We also support and fund many charitable works through the McKesson Foundation.  This past year marked an \nimportant milestone for the foundation as it celeb rated its 80th anniversary.  During the last year alone, it funded \nnearly 50 organizations through its grant -making program and dispersed approximately $9 million, one -third of \nwhich supported direct patient care and assistance.  We're also pleased to see co ntinued increase in employee \nparticipation in these impactful initiatives.  In fiscal 2024, McKesson employees put in over 44,000 volunteer hours \nwith charities across the US and Canada.  I'm truly proud of what we have achieved as a team to support the \ncomm unities and to live our purpose of advancing health outcomes for all.  \n \n Now let me pull that all together. ", "original_text": "We're also pleased to see co ntinued increase in employee \nparticipation in these impactful initiatives. "}, "hash": "c3e92be5a6016fd5d3f30038640cc4590f856c7d2bc74a25263c5414dacc0055", "class_name": "RelatedNodeInfo"}}, "text": "During the last year alone, it funded \nnearly 50 organizations through its grant -making program and dispersed approximately $9 million, one -third of \nwhich supported direct patient care and assistance. ", "start_char_idx": 1061, "end_char_idx": 1265, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e46ca8cb-af20-455d-9644-49aa158daebf": {"__data__": {"id_": "e46ca8cb-af20-455d-9644-49aa158daebf", "embedding": null, "metadata": {"window": "We also support and fund many charitable works through the McKesson Foundation.  This past year marked an \nimportant milestone for the foundation as it celeb rated its 80th anniversary.  During the last year alone, it funded \nnearly 50 organizations through its grant -making program and dispersed approximately $9 million, one -third of \nwhich supported direct patient care and assistance.  We're also pleased to see co ntinued increase in employee \nparticipation in these impactful initiatives.  In fiscal 2024, McKesson employees put in over 44,000 volunteer hours \nwith charities across the US and Canada.  I'm truly proud of what we have achieved as a team to support the \ncomm unities and to live our purpose of advancing health outcomes for all.  \n \n Now let me pull that all together. ", "original_text": "We're also pleased to see co ntinued increase in employee \nparticipation in these impactful initiatives. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "05bb6c5d181d30b8f8aa08d20902fbb57655958b638f52ad3ee99e6749958164", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a577b514-f183-4755-8e36-5548f8c60c8b", "node_type": "1", "metadata": {"window": "We look forward to making a lasting \ndifference in more communities like Avondale in the future.  \n \n We also support and fund many charitable works through the McKesson Foundation.  This past year marked an \nimportant milestone for the foundation as it celeb rated its 80th anniversary.  During the last year alone, it funded \nnearly 50 organizations through its grant -making program and dispersed approximately $9 million, one -third of \nwhich supported direct patient care and assistance.  We're also pleased to see co ntinued increase in employee \nparticipation in these impactful initiatives.  In fiscal 2024, McKesson employees put in over 44,000 volunteer hours \nwith charities across the US and Canada.  I'm truly proud of what we have achieved as a team to support the \ncomm unities and to live our purpose of advancing health outcomes for all.  \n \n", "original_text": "During the last year alone, it funded \nnearly 50 organizations through its grant -making program and dispersed approximately $9 million, one -third of \nwhich supported direct patient care and assistance. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "25891221bbf18eb6935cc7808a311e1f47aab18e2692989ccb2bc264a4fd0f3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35fabb68-7891-448c-945a-c7b7ba526a83", "node_type": "1", "metadata": {"window": "This past year marked an \nimportant milestone for the foundation as it celeb rated its 80th anniversary.  During the last year alone, it funded \nnearly 50 organizations through its grant -making program and dispersed approximately $9 million, one -third of \nwhich supported direct patient care and assistance.  We're also pleased to see co ntinued increase in employee \nparticipation in these impactful initiatives.  In fiscal 2024, McKesson employees put in over 44,000 volunteer hours \nwith charities across the US and Canada.  I'm truly proud of what we have achieved as a team to support the \ncomm unities and to live our purpose of advancing health outcomes for all.  \n \n Now let me pull that all together.  McKesson delivered performance above our initial expectations in fiscal 2024, \nunderpinned by continued momentum across the businesses. ", "original_text": "In fiscal 2024, McKesson employees put in over 44,000 volunteer hours \nwith charities across the US and Canada. "}, "hash": "683da4460415dee37bdd5ceae404c63e7486f8b983fd24a7aead877bddccd9c7", "class_name": "RelatedNodeInfo"}}, "text": "We're also pleased to see co ntinued increase in employee \nparticipation in these impactful initiatives. ", "start_char_idx": 1265, "end_char_idx": 1370, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35fabb68-7891-448c-945a-c7b7ba526a83": {"__data__": {"id_": "35fabb68-7891-448c-945a-c7b7ba526a83", "embedding": null, "metadata": {"window": "This past year marked an \nimportant milestone for the foundation as it celeb rated its 80th anniversary.  During the last year alone, it funded \nnearly 50 organizations through its grant -making program and dispersed approximately $9 million, one -third of \nwhich supported direct patient care and assistance.  We're also pleased to see co ntinued increase in employee \nparticipation in these impactful initiatives.  In fiscal 2024, McKesson employees put in over 44,000 volunteer hours \nwith charities across the US and Canada.  I'm truly proud of what we have achieved as a team to support the \ncomm unities and to live our purpose of advancing health outcomes for all.  \n \n Now let me pull that all together.  McKesson delivered performance above our initial expectations in fiscal 2024, \nunderpinned by continued momentum across the businesses. ", "original_text": "In fiscal 2024, McKesson employees put in over 44,000 volunteer hours \nwith charities across the US and Canada. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "05bb6c5d181d30b8f8aa08d20902fbb57655958b638f52ad3ee99e6749958164", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e46ca8cb-af20-455d-9644-49aa158daebf", "node_type": "1", "metadata": {"window": "We also support and fund many charitable works through the McKesson Foundation.  This past year marked an \nimportant milestone for the foundation as it celeb rated its 80th anniversary.  During the last year alone, it funded \nnearly 50 organizations through its grant -making program and dispersed approximately $9 million, one -third of \nwhich supported direct patient care and assistance.  We're also pleased to see co ntinued increase in employee \nparticipation in these impactful initiatives.  In fiscal 2024, McKesson employees put in over 44,000 volunteer hours \nwith charities across the US and Canada.  I'm truly proud of what we have achieved as a team to support the \ncomm unities and to live our purpose of advancing health outcomes for all.  \n \n Now let me pull that all together. ", "original_text": "We're also pleased to see co ntinued increase in employee \nparticipation in these impactful initiatives. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c57b1dce02bcb8cecc97c13eac4c9db7cf5bf5bfdfff0967bf676f80c1101cbe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f13d2ef-f8df-4b35-bd3f-7bb58263d129", "node_type": "1", "metadata": {"window": "During the last year alone, it funded \nnearly 50 organizations through its grant -making program and dispersed approximately $9 million, one -third of \nwhich supported direct patient care and assistance.  We're also pleased to see co ntinued increase in employee \nparticipation in these impactful initiatives.  In fiscal 2024, McKesson employees put in over 44,000 volunteer hours \nwith charities across the US and Canada.  I'm truly proud of what we have achieved as a team to support the \ncomm unities and to live our purpose of advancing health outcomes for all.  \n \n Now let me pull that all together.  McKesson delivered performance above our initial expectations in fiscal 2024, \nunderpinned by continued momentum across the businesses.  We finished the  year with a growing portfolio of \noncology and biopharma services solutions and an expanded core distribution business and a stronger culture \nthat unites us all.  \n \n", "original_text": "I'm truly proud of what we have achieved as a team to support the \ncomm unities and to live our purpose of advancing health outcomes for all.  \n \n"}, "hash": "fbf60d69d627bf88cc9fcb2a9e835c6c8c46d3a698c9cfc4d6ffbd64ff4198d0", "class_name": "RelatedNodeInfo"}}, "text": "In fiscal 2024, McKesson employees put in over 44,000 volunteer hours \nwith charities across the US and Canada. ", "start_char_idx": 1370, "end_char_idx": 1482, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f13d2ef-f8df-4b35-bd3f-7bb58263d129": {"__data__": {"id_": "2f13d2ef-f8df-4b35-bd3f-7bb58263d129", "embedding": null, "metadata": {"window": "During the last year alone, it funded \nnearly 50 organizations through its grant -making program and dispersed approximately $9 million, one -third of \nwhich supported direct patient care and assistance.  We're also pleased to see co ntinued increase in employee \nparticipation in these impactful initiatives.  In fiscal 2024, McKesson employees put in over 44,000 volunteer hours \nwith charities across the US and Canada.  I'm truly proud of what we have achieved as a team to support the \ncomm unities and to live our purpose of advancing health outcomes for all.  \n \n Now let me pull that all together.  McKesson delivered performance above our initial expectations in fiscal 2024, \nunderpinned by continued momentum across the businesses.  We finished the  year with a growing portfolio of \noncology and biopharma services solutions and an expanded core distribution business and a stronger culture \nthat unites us all.  \n \n", "original_text": "I'm truly proud of what we have achieved as a team to support the \ncomm unities and to live our purpose of advancing health outcomes for all.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "05bb6c5d181d30b8f8aa08d20902fbb57655958b638f52ad3ee99e6749958164", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35fabb68-7891-448c-945a-c7b7ba526a83", "node_type": "1", "metadata": {"window": "This past year marked an \nimportant milestone for the foundation as it celeb rated its 80th anniversary.  During the last year alone, it funded \nnearly 50 organizations through its grant -making program and dispersed approximately $9 million, one -third of \nwhich supported direct patient care and assistance.  We're also pleased to see co ntinued increase in employee \nparticipation in these impactful initiatives.  In fiscal 2024, McKesson employees put in over 44,000 volunteer hours \nwith charities across the US and Canada.  I'm truly proud of what we have achieved as a team to support the \ncomm unities and to live our purpose of advancing health outcomes for all.  \n \n Now let me pull that all together.  McKesson delivered performance above our initial expectations in fiscal 2024, \nunderpinned by continued momentum across the businesses. ", "original_text": "In fiscal 2024, McKesson employees put in over 44,000 volunteer hours \nwith charities across the US and Canada. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "4afecd587f2b8ce9090f112d700587b87a68656918a1434361b6ad8eab9e0d3f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e752af75-f600-4087-ade6-e1c60c191496", "node_type": "1", "metadata": {"window": "We're also pleased to see co ntinued increase in employee \nparticipation in these impactful initiatives.  In fiscal 2024, McKesson employees put in over 44,000 volunteer hours \nwith charities across the US and Canada.  I'm truly proud of what we have achieved as a team to support the \ncomm unities and to live our purpose of advancing health outcomes for all.  \n \n Now let me pull that all together.  McKesson delivered performance above our initial expectations in fiscal 2024, \nunderpinned by continued momentum across the businesses.  We finished the  year with a growing portfolio of \noncology and biopharma services solutions and an expanded core distribution business and a stronger culture \nthat unites us all.  \n \n As we look ahead to our fiscal 2025, we're excited about the opportunities to grow our differ entiated assets and \ncapabilities. ", "original_text": "Now let me pull that all together. "}, "hash": "d1f4ec47096cffa0b801c596412faedecaa8559a53b6aaa34d34b2acc0b28355", "class_name": "RelatedNodeInfo"}}, "text": "I'm truly proud of what we have achieved as a team to support the \ncomm unities and to live our purpose of advancing health outcomes for all.  \n \n", "start_char_idx": 1482, "end_char_idx": 1628, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e752af75-f600-4087-ade6-e1c60c191496": {"__data__": {"id_": "e752af75-f600-4087-ade6-e1c60c191496", "embedding": null, "metadata": {"window": "We're also pleased to see co ntinued increase in employee \nparticipation in these impactful initiatives.  In fiscal 2024, McKesson employees put in over 44,000 volunteer hours \nwith charities across the US and Canada.  I'm truly proud of what we have achieved as a team to support the \ncomm unities and to live our purpose of advancing health outcomes for all.  \n \n Now let me pull that all together.  McKesson delivered performance above our initial expectations in fiscal 2024, \nunderpinned by continued momentum across the businesses.  We finished the  year with a growing portfolio of \noncology and biopharma services solutions and an expanded core distribution business and a stronger culture \nthat unites us all.  \n \n As we look ahead to our fiscal 2025, we're excited about the opportunities to grow our differ entiated assets and \ncapabilities. ", "original_text": "Now let me pull that all together. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "05bb6c5d181d30b8f8aa08d20902fbb57655958b638f52ad3ee99e6749958164", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f13d2ef-f8df-4b35-bd3f-7bb58263d129", "node_type": "1", "metadata": {"window": "During the last year alone, it funded \nnearly 50 organizations through its grant -making program and dispersed approximately $9 million, one -third of \nwhich supported direct patient care and assistance.  We're also pleased to see co ntinued increase in employee \nparticipation in these impactful initiatives.  In fiscal 2024, McKesson employees put in over 44,000 volunteer hours \nwith charities across the US and Canada.  I'm truly proud of what we have achieved as a team to support the \ncomm unities and to live our purpose of advancing health outcomes for all.  \n \n Now let me pull that all together.  McKesson delivered performance above our initial expectations in fiscal 2024, \nunderpinned by continued momentum across the businesses.  We finished the  year with a growing portfolio of \noncology and biopharma services solutions and an expanded core distribution business and a stronger culture \nthat unites us all.  \n \n", "original_text": "I'm truly proud of what we have achieved as a team to support the \ncomm unities and to live our purpose of advancing health outcomes for all.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e893a4f9b4ad2d6a0055902ee743bc47bd0565ff23b3f9f4c53dc91f44c6dafd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b252176-21d4-4718-adb5-e5932cb216a6", "node_type": "1", "metadata": {"window": "In fiscal 2024, McKesson employees put in over 44,000 volunteer hours \nwith charities across the US and Canada.  I'm truly proud of what we have achieved as a team to support the \ncomm unities and to live our purpose of advancing health outcomes for all.  \n \n Now let me pull that all together.  McKesson delivered performance above our initial expectations in fiscal 2024, \nunderpinned by continued momentum across the businesses.  We finished the  year with a growing portfolio of \noncology and biopharma services solutions and an expanded core distribution business and a stronger culture \nthat unites us all.  \n \n As we look ahead to our fiscal 2025, we're excited about the opportunities to grow our differ entiated assets and \ncapabilities.  We remain deeply committed to our strategies and priorities, and we're confident in our ability to drive \nsustainable business growth and generate attractive shareholder return. ", "original_text": "McKesson delivered performance above our initial expectations in fiscal 2024, \nunderpinned by continued momentum across the businesses. "}, "hash": "f897cc07d8b17cd20bc3c2634209473366bdab99ce98949ecb2096fe9750f1a4", "class_name": "RelatedNodeInfo"}}, "text": "Now let me pull that all together. ", "start_char_idx": 1628, "end_char_idx": 1663, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b252176-21d4-4718-adb5-e5932cb216a6": {"__data__": {"id_": "3b252176-21d4-4718-adb5-e5932cb216a6", "embedding": null, "metadata": {"window": "In fiscal 2024, McKesson employees put in over 44,000 volunteer hours \nwith charities across the US and Canada.  I'm truly proud of what we have achieved as a team to support the \ncomm unities and to live our purpose of advancing health outcomes for all.  \n \n Now let me pull that all together.  McKesson delivered performance above our initial expectations in fiscal 2024, \nunderpinned by continued momentum across the businesses.  We finished the  year with a growing portfolio of \noncology and biopharma services solutions and an expanded core distribution business and a stronger culture \nthat unites us all.  \n \n As we look ahead to our fiscal 2025, we're excited about the opportunities to grow our differ entiated assets and \ncapabilities.  We remain deeply committed to our strategies and priorities, and we're confident in our ability to drive \nsustainable business growth and generate attractive shareholder return. ", "original_text": "McKesson delivered performance above our initial expectations in fiscal 2024, \nunderpinned by continued momentum across the businesses. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "05bb6c5d181d30b8f8aa08d20902fbb57655958b638f52ad3ee99e6749958164", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e752af75-f600-4087-ade6-e1c60c191496", "node_type": "1", "metadata": {"window": "We're also pleased to see co ntinued increase in employee \nparticipation in these impactful initiatives.  In fiscal 2024, McKesson employees put in over 44,000 volunteer hours \nwith charities across the US and Canada.  I'm truly proud of what we have achieved as a team to support the \ncomm unities and to live our purpose of advancing health outcomes for all.  \n \n Now let me pull that all together.  McKesson delivered performance above our initial expectations in fiscal 2024, \nunderpinned by continued momentum across the businesses.  We finished the  year with a growing portfolio of \noncology and biopharma services solutions and an expanded core distribution business and a stronger culture \nthat unites us all.  \n \n As we look ahead to our fiscal 2025, we're excited about the opportunities to grow our differ entiated assets and \ncapabilities. ", "original_text": "Now let me pull that all together. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "73f88decdf841523fc163362d90301b3558f47cc83c88a783926afae7598e446", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c75275ae-3c29-4f48-a04e-3be8632301ba", "node_type": "1", "metadata": {"window": "I'm truly proud of what we have achieved as a team to support the \ncomm unities and to live our purpose of advancing health outcomes for all.  \n \n Now let me pull that all together.  McKesson delivered performance above our initial expectations in fiscal 2024, \nunderpinned by continued momentum across the businesses.  We finished the  year with a growing portfolio of \noncology and biopharma services solutions and an expanded core distribution business and a stronger culture \nthat unites us all.  \n \n As we look ahead to our fiscal 2025, we're excited about the opportunities to grow our differ entiated assets and \ncapabilities.  We remain deeply committed to our strategies and priorities, and we're confident in our ability to drive \nsustainable business growth and generate attractive shareholder return.  Team McKesson is more focused and \nmore agile as we enter this new fiscal year with strength and confidence.  \n \n", "original_text": "We finished the  year with a growing portfolio of \noncology and biopharma services solutions and an expanded core distribution business and a stronger culture \nthat unites us all.  \n \n"}, "hash": "41d59dd2000974c82103d65371e499501bf60a07c962d21e07519e709fc54e09", "class_name": "RelatedNodeInfo"}}, "text": "McKesson delivered performance above our initial expectations in fiscal 2024, \nunderpinned by continued momentum across the businesses. ", "start_char_idx": 1663, "end_char_idx": 1799, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c75275ae-3c29-4f48-a04e-3be8632301ba": {"__data__": {"id_": "c75275ae-3c29-4f48-a04e-3be8632301ba", "embedding": null, "metadata": {"window": "I'm truly proud of what we have achieved as a team to support the \ncomm unities and to live our purpose of advancing health outcomes for all.  \n \n Now let me pull that all together.  McKesson delivered performance above our initial expectations in fiscal 2024, \nunderpinned by continued momentum across the businesses.  We finished the  year with a growing portfolio of \noncology and biopharma services solutions and an expanded core distribution business and a stronger culture \nthat unites us all.  \n \n As we look ahead to our fiscal 2025, we're excited about the opportunities to grow our differ entiated assets and \ncapabilities.  We remain deeply committed to our strategies and priorities, and we're confident in our ability to drive \nsustainable business growth and generate attractive shareholder return.  Team McKesson is more focused and \nmore agile as we enter this new fiscal year with strength and confidence.  \n \n", "original_text": "We finished the  year with a growing portfolio of \noncology and biopharma services solutions and an expanded core distribution business and a stronger culture \nthat unites us all.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "05bb6c5d181d30b8f8aa08d20902fbb57655958b638f52ad3ee99e6749958164", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b252176-21d4-4718-adb5-e5932cb216a6", "node_type": "1", "metadata": {"window": "In fiscal 2024, McKesson employees put in over 44,000 volunteer hours \nwith charities across the US and Canada.  I'm truly proud of what we have achieved as a team to support the \ncomm unities and to live our purpose of advancing health outcomes for all.  \n \n Now let me pull that all together.  McKesson delivered performance above our initial expectations in fiscal 2024, \nunderpinned by continued momentum across the businesses.  We finished the  year with a growing portfolio of \noncology and biopharma services solutions and an expanded core distribution business and a stronger culture \nthat unites us all.  \n \n As we look ahead to our fiscal 2025, we're excited about the opportunities to grow our differ entiated assets and \ncapabilities.  We remain deeply committed to our strategies and priorities, and we're confident in our ability to drive \nsustainable business growth and generate attractive shareholder return. ", "original_text": "McKesson delivered performance above our initial expectations in fiscal 2024, \nunderpinned by continued momentum across the businesses. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "872dec0cd85e0bed780490557a052b7bb2f6d0821df7ffaf546574392cca6c68", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d1778ab-2d9c-44e4-a861-6318f6ff1980", "node_type": "1", "metadata": {"window": "Now let me pull that all together.  McKesson delivered performance above our initial expectations in fiscal 2024, \nunderpinned by continued momentum across the businesses.  We finished the  year with a growing portfolio of \noncology and biopharma services solutions and an expanded core distribution business and a stronger culture \nthat unites us all.  \n \n As we look ahead to our fiscal 2025, we're excited about the opportunities to grow our differ entiated assets and \ncapabilities.  We remain deeply committed to our strategies and priorities, and we're confident in our ability to drive \nsustainable business growth and generate attractive shareholder return.  Team McKesson is more focused and \nmore agile as we enter this new fiscal year with strength and confidence.  \n \n With that, Britt, I'll hand it over to you.  \n ", "original_text": "As we look ahead to our fiscal 2025, we're excited about the opportunities to grow our differ entiated assets and \ncapabilities. "}, "hash": "7e4c622c91c1903932e49610b57f64f91f7c135eb7baf0c5c05b2a2359289fac", "class_name": "RelatedNodeInfo"}}, "text": "We finished the  year with a growing portfolio of \noncology and biopharma services solutions and an expanded core distribution business and a stronger culture \nthat unites us all.  \n \n", "start_char_idx": 1799, "end_char_idx": 1983, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d1778ab-2d9c-44e4-a861-6318f6ff1980": {"__data__": {"id_": "7d1778ab-2d9c-44e4-a861-6318f6ff1980", "embedding": null, "metadata": {"window": "Now let me pull that all together.  McKesson delivered performance above our initial expectations in fiscal 2024, \nunderpinned by continued momentum across the businesses.  We finished the  year with a growing portfolio of \noncology and biopharma services solutions and an expanded core distribution business and a stronger culture \nthat unites us all.  \n \n As we look ahead to our fiscal 2025, we're excited about the opportunities to grow our differ entiated assets and \ncapabilities.  We remain deeply committed to our strategies and priorities, and we're confident in our ability to drive \nsustainable business growth and generate attractive shareholder return.  Team McKesson is more focused and \nmore agile as we enter this new fiscal year with strength and confidence.  \n \n With that, Britt, I'll hand it over to you.  \n ", "original_text": "As we look ahead to our fiscal 2025, we're excited about the opportunities to grow our differ entiated assets and \ncapabilities. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "05bb6c5d181d30b8f8aa08d20902fbb57655958b638f52ad3ee99e6749958164", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c75275ae-3c29-4f48-a04e-3be8632301ba", "node_type": "1", "metadata": {"window": "I'm truly proud of what we have achieved as a team to support the \ncomm unities and to live our purpose of advancing health outcomes for all.  \n \n Now let me pull that all together.  McKesson delivered performance above our initial expectations in fiscal 2024, \nunderpinned by continued momentum across the businesses.  We finished the  year with a growing portfolio of \noncology and biopharma services solutions and an expanded core distribution business and a stronger culture \nthat unites us all.  \n \n As we look ahead to our fiscal 2025, we're excited about the opportunities to grow our differ entiated assets and \ncapabilities.  We remain deeply committed to our strategies and priorities, and we're confident in our ability to drive \nsustainable business growth and generate attractive shareholder return.  Team McKesson is more focused and \nmore agile as we enter this new fiscal year with strength and confidence.  \n \n", "original_text": "We finished the  year with a growing portfolio of \noncology and biopharma services solutions and an expanded core distribution business and a stronger culture \nthat unites us all.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "45a63768d09e3e7eae778ec52307e7adfa2a92b100fab5f963fe3e86587004e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb1ffe2e-b91d-4dca-87b8-1a4b80a2f4c0", "node_type": "1", "metadata": {"window": "McKesson delivered performance above our initial expectations in fiscal 2024, \nunderpinned by continued momentum across the businesses.  We finished the  year with a growing portfolio of \noncology and biopharma services solutions and an expanded core distribution business and a stronger culture \nthat unites us all.  \n \n As we look ahead to our fiscal 2025, we're excited about the opportunities to grow our differ entiated assets and \ncapabilities.  We remain deeply committed to our strategies and priorities, and we're confident in our ability to drive \nsustainable business growth and generate attractive shareholder return.  Team McKesson is more focused and \nmore agile as we enter this new fiscal year with strength and confidence.  \n \n With that, Britt, I'll hand it over to you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "original_text": "We remain deeply committed to our strategies and priorities, and we're confident in our ability to drive \nsustainable business growth and generate attractive shareholder return. "}, "hash": "7b22a09c08f8ed25d9655e58340116829e77b25f0f121b4026390fd6b6038677", "class_name": "RelatedNodeInfo"}}, "text": "As we look ahead to our fiscal 2025, we're excited about the opportunities to grow our differ entiated assets and \ncapabilities. ", "start_char_idx": 1983, "end_char_idx": 2112, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb1ffe2e-b91d-4dca-87b8-1a4b80a2f4c0": {"__data__": {"id_": "bb1ffe2e-b91d-4dca-87b8-1a4b80a2f4c0", "embedding": null, "metadata": {"window": "McKesson delivered performance above our initial expectations in fiscal 2024, \nunderpinned by continued momentum across the businesses.  We finished the  year with a growing portfolio of \noncology and biopharma services solutions and an expanded core distribution business and a stronger culture \nthat unites us all.  \n \n As we look ahead to our fiscal 2025, we're excited about the opportunities to grow our differ entiated assets and \ncapabilities.  We remain deeply committed to our strategies and priorities, and we're confident in our ability to drive \nsustainable business growth and generate attractive shareholder return.  Team McKesson is more focused and \nmore agile as we enter this new fiscal year with strength and confidence.  \n \n With that, Britt, I'll hand it over to you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "original_text": "We remain deeply committed to our strategies and priorities, and we're confident in our ability to drive \nsustainable business growth and generate attractive shareholder return. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "05bb6c5d181d30b8f8aa08d20902fbb57655958b638f52ad3ee99e6749958164", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d1778ab-2d9c-44e4-a861-6318f6ff1980", "node_type": "1", "metadata": {"window": "Now let me pull that all together.  McKesson delivered performance above our initial expectations in fiscal 2024, \nunderpinned by continued momentum across the businesses.  We finished the  year with a growing portfolio of \noncology and biopharma services solutions and an expanded core distribution business and a stronger culture \nthat unites us all.  \n \n As we look ahead to our fiscal 2025, we're excited about the opportunities to grow our differ entiated assets and \ncapabilities.  We remain deeply committed to our strategies and priorities, and we're confident in our ability to drive \nsustainable business growth and generate attractive shareholder return.  Team McKesson is more focused and \nmore agile as we enter this new fiscal year with strength and confidence.  \n \n With that, Britt, I'll hand it over to you.  \n ", "original_text": "As we look ahead to our fiscal 2025, we're excited about the opportunities to grow our differ entiated assets and \ncapabilities. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "661e4dae96b3683532b0d1c6973d7cfc8d2d0e74232e85bc2242553474a315cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "344df026-a303-4f37-a2fa-88f68b706d1e", "node_type": "1", "metadata": {"window": "We finished the  year with a growing portfolio of \noncology and biopharma services solutions and an expanded core distribution business and a stronger culture \nthat unites us all.  \n \n As we look ahead to our fiscal 2025, we're excited about the opportunities to grow our differ entiated assets and \ncapabilities.  We remain deeply committed to our strategies and priorities, and we're confident in our ability to drive \nsustainable business growth and generate attractive shareholder return.  Team McKesson is more focused and \nmore agile as we enter this new fiscal year with strength and confidence.  \n \n With that, Britt, I'll hand it over to you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Great. ", "original_text": "Team McKesson is more focused and \nmore agile as we enter this new fiscal year with strength and confidence.  \n \n"}, "hash": "a9ef70c244a95e207574f3c3dc964d5dd9e279c88f7b02f016015f58296fc47b", "class_name": "RelatedNodeInfo"}}, "text": "We remain deeply committed to our strategies and priorities, and we're confident in our ability to drive \nsustainable business growth and generate attractive shareholder return. ", "start_char_idx": 2112, "end_char_idx": 2290, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "344df026-a303-4f37-a2fa-88f68b706d1e": {"__data__": {"id_": "344df026-a303-4f37-a2fa-88f68b706d1e", "embedding": null, "metadata": {"window": "We finished the  year with a growing portfolio of \noncology and biopharma services solutions and an expanded core distribution business and a stronger culture \nthat unites us all.  \n \n As we look ahead to our fiscal 2025, we're excited about the opportunities to grow our differ entiated assets and \ncapabilities.  We remain deeply committed to our strategies and priorities, and we're confident in our ability to drive \nsustainable business growth and generate attractive shareholder return.  Team McKesson is more focused and \nmore agile as we enter this new fiscal year with strength and confidence.  \n \n With that, Britt, I'll hand it over to you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Great. ", "original_text": "Team McKesson is more focused and \nmore agile as we enter this new fiscal year with strength and confidence.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "05bb6c5d181d30b8f8aa08d20902fbb57655958b638f52ad3ee99e6749958164", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb1ffe2e-b91d-4dca-87b8-1a4b80a2f4c0", "node_type": "1", "metadata": {"window": "McKesson delivered performance above our initial expectations in fiscal 2024, \nunderpinned by continued momentum across the businesses.  We finished the  year with a growing portfolio of \noncology and biopharma services solutions and an expanded core distribution business and a stronger culture \nthat unites us all.  \n \n As we look ahead to our fiscal 2025, we're excited about the opportunities to grow our differ entiated assets and \ncapabilities.  We remain deeply committed to our strategies and priorities, and we're confident in our ability to drive \nsustainable business growth and generate attractive shareholder return.  Team McKesson is more focused and \nmore agile as we enter this new fiscal year with strength and confidence.  \n \n With that, Britt, I'll hand it over to you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "original_text": "We remain deeply committed to our strategies and priorities, and we're confident in our ability to drive \nsustainable business growth and generate attractive shareholder return. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d3357dd85aa1d12063bce91f4eac8443ca4affcd3e7a7368e249749f154c0e5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c4d9547-a9d4-4b2d-96d5-e9868c9eec46", "node_type": "1", "metadata": {"window": "As we look ahead to our fiscal 2025, we're excited about the opportunities to grow our differ entiated assets and \ncapabilities.  We remain deeply committed to our strategies and priorities, and we're confident in our ability to drive \nsustainable business growth and generate attractive shareholder return.  Team McKesson is more focused and \nmore agile as we enter this new fiscal year with strength and confidence.  \n \n With that, Britt, I'll hand it over to you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Great.  Thank you, Brian, and good afternoon, everyone.  \n \n", "original_text": "With that, Britt, I'll hand it over to you.  \n "}, "hash": "f70737f39376f5bf41527232f0bee5ce354d6d546d3089eda3e27ac3e327d3b1", "class_name": "RelatedNodeInfo"}}, "text": "Team McKesson is more focused and \nmore agile as we enter this new fiscal year with strength and confidence.  \n \n", "start_char_idx": 2290, "end_char_idx": 2403, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c4d9547-a9d4-4b2d-96d5-e9868c9eec46": {"__data__": {"id_": "0c4d9547-a9d4-4b2d-96d5-e9868c9eec46", "embedding": null, "metadata": {"window": "As we look ahead to our fiscal 2025, we're excited about the opportunities to grow our differ entiated assets and \ncapabilities.  We remain deeply committed to our strategies and priorities, and we're confident in our ability to drive \nsustainable business growth and generate attractive shareholder return.  Team McKesson is more focused and \nmore agile as we enter this new fiscal year with strength and confidence.  \n \n With that, Britt, I'll hand it over to you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Great.  Thank you, Brian, and good afternoon, everyone.  \n \n", "original_text": "With that, Britt, I'll hand it over to you.  \n ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "05bb6c5d181d30b8f8aa08d20902fbb57655958b638f52ad3ee99e6749958164", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "344df026-a303-4f37-a2fa-88f68b706d1e", "node_type": "1", "metadata": {"window": "We finished the  year with a growing portfolio of \noncology and biopharma services solutions and an expanded core distribution business and a stronger culture \nthat unites us all.  \n \n As we look ahead to our fiscal 2025, we're excited about the opportunities to grow our differ entiated assets and \ncapabilities.  We remain deeply committed to our strategies and priorities, and we're confident in our ability to drive \nsustainable business growth and generate attractive shareholder return.  Team McKesson is more focused and \nmore agile as we enter this new fiscal year with strength and confidence.  \n \n With that, Britt, I'll hand it over to you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Great. ", "original_text": "Team McKesson is more focused and \nmore agile as we enter this new fiscal year with strength and confidence.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "9375def146a65f6e30abbb110b5cc660c63592b292b5b3e906977a392139aeda", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e66ad0d-3d88-44d5-b2ee-e527d723a23d", "node_type": "1", "metadata": {"window": "We remain deeply committed to our strategies and priorities, and we're confident in our ability to drive \nsustainable business growth and generate attractive shareholder return.  Team McKesson is more focused and \nmore agile as we enter this new fiscal year with strength and confidence.  \n \n With that, Britt, I'll hand it over to you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Great.  Thank you, Brian, and good afternoon, everyone.  \n \n Fiscal 2024 marks another year of strong execution and financial performance. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n"}, "hash": "162fec5e9a65f44976274dfb12614e0f6bf8abd64aa689c227920f4e98086396", "class_name": "RelatedNodeInfo"}}, "text": "With that, Britt, I'll hand it over to you.  \n ", "start_char_idx": 2403, "end_char_idx": 2450, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e66ad0d-3d88-44d5-b2ee-e527d723a23d": {"__data__": {"id_": "6e66ad0d-3d88-44d5-b2ee-e527d723a23d", "embedding": null, "metadata": {"window": "We remain deeply committed to our strategies and priorities, and we're confident in our ability to drive \nsustainable business growth and generate attractive shareholder return.  Team McKesson is more focused and \nmore agile as we enter this new fiscal year with strength and confidence.  \n \n With that, Britt, I'll hand it over to you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Great.  Thank you, Brian, and good afternoon, everyone.  \n \n Fiscal 2024 marks another year of strong execution and financial performance. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "05bb6c5d181d30b8f8aa08d20902fbb57655958b638f52ad3ee99e6749958164", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c4d9547-a9d4-4b2d-96d5-e9868c9eec46", "node_type": "1", "metadata": {"window": "As we look ahead to our fiscal 2025, we're excited about the opportunities to grow our differ entiated assets and \ncapabilities.  We remain deeply committed to our strategies and priorities, and we're confident in our ability to drive \nsustainable business growth and generate attractive shareholder return.  Team McKesson is more focused and \nmore agile as we enter this new fiscal year with strength and confidence.  \n \n With that, Britt, I'll hand it over to you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Great.  Thank you, Brian, and good afternoon, everyone.  \n \n", "original_text": "With that, Britt, I'll hand it over to you.  \n ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "2a1b791246e6988c3768fe8f9d83080c0f60983170539953104c4de3dbedbd5b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c2d1388-9671-4bf5-ac05-d951b0e0d111", "node_type": "1", "metadata": {"window": "Team McKesson is more focused and \nmore agile as we enter this new fiscal year with strength and confidence.  \n \n With that, Britt, I'll hand it over to you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Great.  Thank you, Brian, and good afternoon, everyone.  \n \n Fiscal 2024 marks another year of strong execution and financial performance.  We entered fiscal 2025 with the \nmomentum to deliver growth and create value for our customers, partners, and shareholders. ", "original_text": "Great. "}, "hash": "f5a274905bb4a7a5c2c67e362cd149dcc3b7c5541118bfc8872502521695a16e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "start_char_idx": 2450, "end_char_idx": 2811, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c2d1388-9671-4bf5-ac05-d951b0e0d111": {"__data__": {"id_": "6c2d1388-9671-4bf5-ac05-d951b0e0d111", "embedding": null, "metadata": {"window": "Team McKesson is more focused and \nmore agile as we enter this new fiscal year with strength and confidence.  \n \n With that, Britt, I'll hand it over to you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Great.  Thank you, Brian, and good afternoon, everyone.  \n \n Fiscal 2024 marks another year of strong execution and financial performance.  We entered fiscal 2025 with the \nmomentum to deliver growth and create value for our customers, partners, and shareholders. ", "original_text": "Great. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "05bb6c5d181d30b8f8aa08d20902fbb57655958b638f52ad3ee99e6749958164", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e66ad0d-3d88-44d5-b2ee-e527d723a23d", "node_type": "1", "metadata": {"window": "We remain deeply committed to our strategies and priorities, and we're confident in our ability to drive \nsustainable business growth and generate attractive shareholder return.  Team McKesson is more focused and \nmore agile as we enter this new fiscal year with strength and confidence.  \n \n With that, Britt, I'll hand it over to you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Great.  Thank you, Brian, and good afternoon, everyone.  \n \n Fiscal 2024 marks another year of strong execution and financial performance. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "57dfd1099b8a031facd1ac152108d850f7b909fcfa86de7494380d5aa712a39c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0b8d31d-449d-4f87-be4b-6eabfdf2b834", "node_type": "1", "metadata": {"window": "With that, Britt, I'll hand it over to you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Great.  Thank you, Brian, and good afternoon, everyone.  \n \n Fiscal 2024 marks another year of strong execution and financial performance.  We entered fiscal 2025 with the \nmomentum to deliver growth and create value for our customers, partners, and shareholders.  Today, I'll discuss \nour fourth quarter and full -year fi scal 2024 results. ", "original_text": "Thank you, Brian, and good afternoon, everyone.  \n \n"}, "hash": "d88fdb7566134cc48e66b1b710236414a154aa2a998eb64ad6a0e417b0fa9551", "class_name": "RelatedNodeInfo"}}, "text": "Great. ", "start_char_idx": 2811, "end_char_idx": 2818, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0b8d31d-449d-4f87-be4b-6eabfdf2b834": {"__data__": {"id_": "f0b8d31d-449d-4f87-be4b-6eabfdf2b834", "embedding": null, "metadata": {"window": "With that, Britt, I'll hand it over to you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Great.  Thank you, Brian, and good afternoon, everyone.  \n \n Fiscal 2024 marks another year of strong execution and financial performance.  We entered fiscal 2025 with the \nmomentum to deliver growth and create value for our customers, partners, and shareholders.  Today, I'll discuss \nour fourth quarter and full -year fi scal 2024 results. ", "original_text": "Thank you, Brian, and good afternoon, everyone.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "05bb6c5d181d30b8f8aa08d20902fbb57655958b638f52ad3ee99e6749958164", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c2d1388-9671-4bf5-ac05-d951b0e0d111", "node_type": "1", "metadata": {"window": "Team McKesson is more focused and \nmore agile as we enter this new fiscal year with strength and confidence.  \n \n With that, Britt, I'll hand it over to you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Great.  Thank you, Brian, and good afternoon, everyone.  \n \n Fiscal 2024 marks another year of strong execution and financial performance.  We entered fiscal 2025 with the \nmomentum to deliver growth and create value for our customers, partners, and shareholders. ", "original_text": "Great. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "69b4df9a72ab1869abac611ad90febfb548fa4e1cda5365203ce0aac2f2f2818", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60262635-2b33-452c-ba58-738437a6b69a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Great.  Thank you, Brian, and good afternoon, everyone.  \n \n Fiscal 2024 marks another year of strong execution and financial performance.  We entered fiscal 2025 with the \nmomentum to deliver growth and create value for our customers, partners, and shareholders.  Today, I'll discuss \nour fourth quarter and full -year fi scal 2024 results.  Then I'll provide an overview of our fiscal 2025 outlook. ", "original_text": "Fiscal 2024 marks another year of strong execution and financial performance. "}, "hash": "d5172428031986bff3f696b9e1e2668930cd38c8e96b23eb61bcc4d6ccb23ab0", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Brian, and good afternoon, everyone.  \n \n", "start_char_idx": 2818, "end_char_idx": 2870, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60262635-2b33-452c-ba58-738437a6b69a": {"__data__": {"id_": "60262635-2b33-452c-ba58-738437a6b69a", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Great.  Thank you, Brian, and good afternoon, everyone.  \n \n Fiscal 2024 marks another year of strong execution and financial performance.  We entered fiscal 2025 with the \nmomentum to deliver growth and create value for our customers, partners, and shareholders.  Today, I'll discuss \nour fourth quarter and full -year fi scal 2024 results.  Then I'll provide an overview of our fiscal 2025 outlook. ", "original_text": "Fiscal 2024 marks another year of strong execution and financial performance. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "05bb6c5d181d30b8f8aa08d20902fbb57655958b638f52ad3ee99e6749958164", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0b8d31d-449d-4f87-be4b-6eabfdf2b834", "node_type": "1", "metadata": {"window": "With that, Britt, I'll hand it over to you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Great.  Thank you, Brian, and good afternoon, everyone.  \n \n Fiscal 2024 marks another year of strong execution and financial performance.  We entered fiscal 2025 with the \nmomentum to deliver growth and create value for our customers, partners, and shareholders.  Today, I'll discuss \nour fourth quarter and full -year fi scal 2024 results. ", "original_text": "Thank you, Brian, and good afternoon, everyone.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "2e235cf396cca6eb11416957a987e5bcfca88b553107f86cf33657ea32c4ae51", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b8bf4ae-942d-4c4f-a4c9-522b623b8e98", "node_type": "1", "metadata": {"window": "Great.  Thank you, Brian, and good afternoon, everyone.  \n \n Fiscal 2024 marks another year of strong execution and financial performance.  We entered fiscal 2025 with the \nmomentum to deliver growth and create value for our customers, partners, and shareholders.  Today, I'll discuss \nour fourth quarter and full -year fi scal 2024 results.  Then I'll provide an overview of our fiscal 2025 outlook.  My \ncomments today will refer to our adjusted results unless I state otherwise.  \n \n", "original_text": "We entered fiscal 2025 with the \nmomentum to deliver growth and create value for our customers, partners, and shareholders. "}, "hash": "8074dca09e92e8dd048d4b6ce4aaf97bcb87a2ad759727484caea934d307d322", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal 2024 marks another year of strong execution and financial performance. ", "start_char_idx": 2870, "end_char_idx": 2948, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b8bf4ae-942d-4c4f-a4c9-522b623b8e98": {"__data__": {"id_": "9b8bf4ae-942d-4c4f-a4c9-522b623b8e98", "embedding": null, "metadata": {"window": "Great.  Thank you, Brian, and good afternoon, everyone.  \n \n Fiscal 2024 marks another year of strong execution and financial performance.  We entered fiscal 2025 with the \nmomentum to deliver growth and create value for our customers, partners, and shareholders.  Today, I'll discuss \nour fourth quarter and full -year fi scal 2024 results.  Then I'll provide an overview of our fiscal 2025 outlook.  My \ncomments today will refer to our adjusted results unless I state otherwise.  \n \n", "original_text": "We entered fiscal 2025 with the \nmomentum to deliver growth and create value for our customers, partners, and shareholders. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "05bb6c5d181d30b8f8aa08d20902fbb57655958b638f52ad3ee99e6749958164", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60262635-2b33-452c-ba58-738437a6b69a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Great.  Thank you, Brian, and good afternoon, everyone.  \n \n Fiscal 2024 marks another year of strong execution and financial performance.  We entered fiscal 2025 with the \nmomentum to deliver growth and create value for our customers, partners, and shareholders.  Today, I'll discuss \nour fourth quarter and full -year fi scal 2024 results.  Then I'll provide an overview of our fiscal 2025 outlook. ", "original_text": "Fiscal 2024 marks another year of strong execution and financial performance. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "25d5e8929c2bcd9cde7286749c474a949566c13d20d4f96ffeaba3c18c298a10", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6cd5179-011e-441b-8994-5223357d95f5", "node_type": "1", "metadata": {"window": "Thank you, Brian, and good afternoon, everyone.  \n \n Fiscal 2024 marks another year of strong execution and financial performance.  We entered fiscal 2025 with the \nmomentum to deliver growth and create value for our customers, partners, and shareholders.  Today, I'll discuss \nour fourth quarter and full -year fi scal 2024 results.  Then I'll provide an overview of our fiscal 2025 outlook.  My \ncomments today will refer to our adjusted results unless I state otherwise.  \n \n We're exiting fiscal 2024 with solid performance, delivering earnings per diluted share of $6.18 in  the fourth \nquarter and $27.44 for the full year. ", "original_text": "Today, I'll discuss \nour fourth quarter and full -year fi scal 2024 results. "}, "hash": "637e0736ba5f259c73b1aad4e3665cdee44d54f7a6e515114dbc074124cf6699", "class_name": "RelatedNodeInfo"}}, "text": "We entered fiscal 2025 with the \nmomentum to deliver growth and create value for our customers, partners, and shareholders. ", "start_char_idx": 2948, "end_char_idx": 3072, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6cd5179-011e-441b-8994-5223357d95f5": {"__data__": {"id_": "d6cd5179-011e-441b-8994-5223357d95f5", "embedding": null, "metadata": {"window": "Thank you, Brian, and good afternoon, everyone.  \n \n Fiscal 2024 marks another year of strong execution and financial performance.  We entered fiscal 2025 with the \nmomentum to deliver growth and create value for our customers, partners, and shareholders.  Today, I'll discuss \nour fourth quarter and full -year fi scal 2024 results.  Then I'll provide an overview of our fiscal 2025 outlook.  My \ncomments today will refer to our adjusted results unless I state otherwise.  \n \n We're exiting fiscal 2024 with solid performance, delivering earnings per diluted share of $6.18 in  the fourth \nquarter and $27.44 for the full year. ", "original_text": "Today, I'll discuss \nour fourth quarter and full -year fi scal 2024 results. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "05bb6c5d181d30b8f8aa08d20902fbb57655958b638f52ad3ee99e6749958164", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b8bf4ae-942d-4c4f-a4c9-522b623b8e98", "node_type": "1", "metadata": {"window": "Great.  Thank you, Brian, and good afternoon, everyone.  \n \n Fiscal 2024 marks another year of strong execution and financial performance.  We entered fiscal 2025 with the \nmomentum to deliver growth and create value for our customers, partners, and shareholders.  Today, I'll discuss \nour fourth quarter and full -year fi scal 2024 results.  Then I'll provide an overview of our fiscal 2025 outlook.  My \ncomments today will refer to our adjusted results unless I state otherwise.  \n \n", "original_text": "We entered fiscal 2025 with the \nmomentum to deliver growth and create value for our customers, partners, and shareholders. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e0f6955cd3f49cb365068e1042c960f77219065dec8fc435b0c6251d8fa8aad3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09b91605-ac46-4ff9-a534-743363b67940", "node_type": "1", "metadata": {"window": "Fiscal 2024 marks another year of strong execution and financial performance.  We entered fiscal 2025 with the \nmomentum to deliver growth and create value for our customers, partners, and shareholders.  Today, I'll discuss \nour fourth quarter and full -year fi scal 2024 results.  Then I'll provide an overview of our fiscal 2025 outlook.  My \ncomments today will refer to our adjusted results unless I state otherwise.  \n \n We're exiting fiscal 2024 with solid performance, delivering earnings per diluted share of $6.18 in  the fourth \nquarter and $27.44 for the full year.  Our fourth quarter results were in line with our expectations and with the \nearnings per diluted share guidance range that we provided on our third quarter earnings call, demonstrating our \nability to consist ently execute against company priorities and create long -term sustainable value for our \nshareholders.  \n \n", "original_text": "Then I'll provide an overview of our fiscal 2025 outlook. "}, "hash": "e345af76fafc100633380445ff14998a3a58e50a49790d205180451ed824d83c", "class_name": "RelatedNodeInfo"}}, "text": "Today, I'll discuss \nour fourth quarter and full -year fi scal 2024 results. ", "start_char_idx": 3072, "end_char_idx": 3149, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09b91605-ac46-4ff9-a534-743363b67940": {"__data__": {"id_": "09b91605-ac46-4ff9-a534-743363b67940", "embedding": null, "metadata": {"window": "Fiscal 2024 marks another year of strong execution and financial performance.  We entered fiscal 2025 with the \nmomentum to deliver growth and create value for our customers, partners, and shareholders.  Today, I'll discuss \nour fourth quarter and full -year fi scal 2024 results.  Then I'll provide an overview of our fiscal 2025 outlook.  My \ncomments today will refer to our adjusted results unless I state otherwise.  \n \n We're exiting fiscal 2024 with solid performance, delivering earnings per diluted share of $6.18 in  the fourth \nquarter and $27.44 for the full year.  Our fourth quarter results were in line with our expectations and with the \nearnings per diluted share guidance range that we provided on our third quarter earnings call, demonstrating our \nability to consist ently execute against company priorities and create long -term sustainable value for our \nshareholders.  \n \n", "original_text": "Then I'll provide an overview of our fiscal 2025 outlook. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "05bb6c5d181d30b8f8aa08d20902fbb57655958b638f52ad3ee99e6749958164", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6cd5179-011e-441b-8994-5223357d95f5", "node_type": "1", "metadata": {"window": "Thank you, Brian, and good afternoon, everyone.  \n \n Fiscal 2024 marks another year of strong execution and financial performance.  We entered fiscal 2025 with the \nmomentum to deliver growth and create value for our customers, partners, and shareholders.  Today, I'll discuss \nour fourth quarter and full -year fi scal 2024 results.  Then I'll provide an overview of our fiscal 2025 outlook.  My \ncomments today will refer to our adjusted results unless I state otherwise.  \n \n We're exiting fiscal 2024 with solid performance, delivering earnings per diluted share of $6.18 in  the fourth \nquarter and $27.44 for the full year. ", "original_text": "Today, I'll discuss \nour fourth quarter and full -year fi scal 2024 results. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "cef7fcc358e14be0035811225fe1ad791e5b896deaca223ef6e64012aa41d288", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1d8d47e-728a-4728-99ab-385abaedcf7c", "node_type": "1", "metadata": {"window": "We entered fiscal 2025 with the \nmomentum to deliver growth and create value for our customers, partners, and shareholders.  Today, I'll discuss \nour fourth quarter and full -year fi scal 2024 results.  Then I'll provide an overview of our fiscal 2025 outlook.  My \ncomments today will refer to our adjusted results unless I state otherwise.  \n \n We're exiting fiscal 2024 with solid performance, delivering earnings per diluted share of $6.18 in  the fourth \nquarter and $27.44 for the full year.  Our fourth quarter results were in line with our expectations and with the \nearnings per diluted share guidance range that we provided on our third quarter earnings call, demonstrating our \nability to consist ently execute against company priorities and create long -term sustainable value for our \nshareholders.  \n \n For the full year, when excluding fiscal 2023 contributions from COVID -related programs and McKesson \nVentures, adjusted operating profit grew 9% and adju sted EPS increased 17%. ", "original_text": "My \ncomments today will refer to our adjusted results unless I state otherwise.  \n \n"}, "hash": "df2e69269d994996f2576dcc4796b7171e4bea28c9b7fbdc1d4800423668ce5f", "class_name": "RelatedNodeInfo"}}, "text": "Then I'll provide an overview of our fiscal 2025 outlook. ", "start_char_idx": 3149, "end_char_idx": 3207, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1d8d47e-728a-4728-99ab-385abaedcf7c": {"__data__": {"id_": "e1d8d47e-728a-4728-99ab-385abaedcf7c", "embedding": null, "metadata": {"window": "We entered fiscal 2025 with the \nmomentum to deliver growth and create value for our customers, partners, and shareholders.  Today, I'll discuss \nour fourth quarter and full -year fi scal 2024 results.  Then I'll provide an overview of our fiscal 2025 outlook.  My \ncomments today will refer to our adjusted results unless I state otherwise.  \n \n We're exiting fiscal 2024 with solid performance, delivering earnings per diluted share of $6.18 in  the fourth \nquarter and $27.44 for the full year.  Our fourth quarter results were in line with our expectations and with the \nearnings per diluted share guidance range that we provided on our third quarter earnings call, demonstrating our \nability to consist ently execute against company priorities and create long -term sustainable value for our \nshareholders.  \n \n For the full year, when excluding fiscal 2023 contributions from COVID -related programs and McKesson \nVentures, adjusted operating profit grew 9% and adju sted EPS increased 17%. ", "original_text": "My \ncomments today will refer to our adjusted results unless I state otherwise.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "05bb6c5d181d30b8f8aa08d20902fbb57655958b638f52ad3ee99e6749958164", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09b91605-ac46-4ff9-a534-743363b67940", "node_type": "1", "metadata": {"window": "Fiscal 2024 marks another year of strong execution and financial performance.  We entered fiscal 2025 with the \nmomentum to deliver growth and create value for our customers, partners, and shareholders.  Today, I'll discuss \nour fourth quarter and full -year fi scal 2024 results.  Then I'll provide an overview of our fiscal 2025 outlook.  My \ncomments today will refer to our adjusted results unless I state otherwise.  \n \n We're exiting fiscal 2024 with solid performance, delivering earnings per diluted share of $6.18 in  the fourth \nquarter and $27.44 for the full year.  Our fourth quarter results were in line with our expectations and with the \nearnings per diluted share guidance range that we provided on our third quarter earnings call, demonstrating our \nability to consist ently execute against company priorities and create long -term sustainable value for our \nshareholders.  \n \n", "original_text": "Then I'll provide an overview of our fiscal 2025 outlook. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "793db92867fe249514f4f3e3c1cfb2f23ceeff21c879776745e3bad60dae6dd3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb6beb49-5567-4fa8-a3ec-ea61b4d7fdd4", "node_type": "1", "metadata": {"window": "Today, I'll discuss \nour fourth quarter and full -year fi scal 2024 results.  Then I'll provide an overview of our fiscal 2025 outlook.  My \ncomments today will refer to our adjusted results unless I state otherwise.  \n \n We're exiting fiscal 2024 with solid performance, delivering earnings per diluted share of $6.18 in  the fourth \nquarter and $27.44 for the full year.  Our fourth quarter results were in line with our expectations and with the \nearnings per diluted share guidance range that we provided on our third quarter earnings call, demonstrating our \nability to consist ently execute against company priorities and create long -term sustainable value for our \nshareholders.  \n \n For the full year, when excluding fiscal 2023 contributions from COVID -related programs and McKesson \nVentures, adjusted operating profit grew 9% and adju sted EPS increased 17%.  These results are above our long -\nrange targets and reflect the strength of our products, services, and operating execution.  \n ", "original_text": "We're exiting fiscal 2024 with solid performance, delivering earnings per diluted share of $6.18 in  the fourth \nquarter and $27.44 for the full year. "}, "hash": "3323738beaa176c58c42457c0b64d8fdc46b56d0915ccf6147ed32ab6fe67e37", "class_name": "RelatedNodeInfo"}}, "text": "My \ncomments today will refer to our adjusted results unless I state otherwise.  \n \n", "start_char_idx": 3207, "end_char_idx": 3291, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb6beb49-5567-4fa8-a3ec-ea61b4d7fdd4": {"__data__": {"id_": "eb6beb49-5567-4fa8-a3ec-ea61b4d7fdd4", "embedding": null, "metadata": {"window": "Today, I'll discuss \nour fourth quarter and full -year fi scal 2024 results.  Then I'll provide an overview of our fiscal 2025 outlook.  My \ncomments today will refer to our adjusted results unless I state otherwise.  \n \n We're exiting fiscal 2024 with solid performance, delivering earnings per diluted share of $6.18 in  the fourth \nquarter and $27.44 for the full year.  Our fourth quarter results were in line with our expectations and with the \nearnings per diluted share guidance range that we provided on our third quarter earnings call, demonstrating our \nability to consist ently execute against company priorities and create long -term sustainable value for our \nshareholders.  \n \n For the full year, when excluding fiscal 2023 contributions from COVID -related programs and McKesson \nVentures, adjusted operating profit grew 9% and adju sted EPS increased 17%.  These results are above our long -\nrange targets and reflect the strength of our products, services, and operating execution.  \n ", "original_text": "We're exiting fiscal 2024 with solid performance, delivering earnings per diluted share of $6.18 in  the fourth \nquarter and $27.44 for the full year. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "05bb6c5d181d30b8f8aa08d20902fbb57655958b638f52ad3ee99e6749958164", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1d8d47e-728a-4728-99ab-385abaedcf7c", "node_type": "1", "metadata": {"window": "We entered fiscal 2025 with the \nmomentum to deliver growth and create value for our customers, partners, and shareholders.  Today, I'll discuss \nour fourth quarter and full -year fi scal 2024 results.  Then I'll provide an overview of our fiscal 2025 outlook.  My \ncomments today will refer to our adjusted results unless I state otherwise.  \n \n We're exiting fiscal 2024 with solid performance, delivering earnings per diluted share of $6.18 in  the fourth \nquarter and $27.44 for the full year.  Our fourth quarter results were in line with our expectations and with the \nearnings per diluted share guidance range that we provided on our third quarter earnings call, demonstrating our \nability to consist ently execute against company priorities and create long -term sustainable value for our \nshareholders.  \n \n For the full year, when excluding fiscal 2023 contributions from COVID -related programs and McKesson \nVentures, adjusted operating profit grew 9% and adju sted EPS increased 17%. ", "original_text": "My \ncomments today will refer to our adjusted results unless I state otherwise.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "7d489b1b83108c9394ccc27c8ee357b046bfe473e4b4ce06cdbb1530cf5b8bda", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "421a3275-fed2-4637-8985-5f91dc93c4a8", "node_type": "1", "metadata": {"window": "Then I'll provide an overview of our fiscal 2025 outlook.  My \ncomments today will refer to our adjusted results unless I state otherwise.  \n \n We're exiting fiscal 2024 with solid performance, delivering earnings per diluted share of $6.18 in  the fourth \nquarter and $27.44 for the full year.  Our fourth quarter results were in line with our expectations and with the \nearnings per diluted share guidance range that we provided on our third quarter earnings call, demonstrating our \nability to consist ently execute against company priorities and create long -term sustainable value for our \nshareholders.  \n \n For the full year, when excluding fiscal 2023 contributions from COVID -related programs and McKesson \nVentures, adjusted operating profit grew 9% and adju sted EPS increased 17%.  These results are above our long -\nrange targets and reflect the strength of our products, services, and operating execution.  \n ", "original_text": "Our fourth quarter results were in line with our expectations and with the \nearnings per diluted share guidance range that we provided on our third quarter earnings call, demonstrating our \nability to consist ently execute against company priorities and create long -term sustainable value for our \nshareholders.  \n \n"}, "hash": "a6c7d50899b9377d57f58d8f9d4eb11fc1bf7c0f1bf0ad49b6fdeeeda3035c4f", "class_name": "RelatedNodeInfo"}}, "text": "We're exiting fiscal 2024 with solid performance, delivering earnings per diluted share of $6.18 in  the fourth \nquarter and $27.44 for the full year. ", "start_char_idx": 3291, "end_char_idx": 3442, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "421a3275-fed2-4637-8985-5f91dc93c4a8": {"__data__": {"id_": "421a3275-fed2-4637-8985-5f91dc93c4a8", "embedding": null, "metadata": {"window": "Then I'll provide an overview of our fiscal 2025 outlook.  My \ncomments today will refer to our adjusted results unless I state otherwise.  \n \n We're exiting fiscal 2024 with solid performance, delivering earnings per diluted share of $6.18 in  the fourth \nquarter and $27.44 for the full year.  Our fourth quarter results were in line with our expectations and with the \nearnings per diluted share guidance range that we provided on our third quarter earnings call, demonstrating our \nability to consist ently execute against company priorities and create long -term sustainable value for our \nshareholders.  \n \n For the full year, when excluding fiscal 2023 contributions from COVID -related programs and McKesson \nVentures, adjusted operating profit grew 9% and adju sted EPS increased 17%.  These results are above our long -\nrange targets and reflect the strength of our products, services, and operating execution.  \n ", "original_text": "Our fourth quarter results were in line with our expectations and with the \nearnings per diluted share guidance range that we provided on our third quarter earnings call, demonstrating our \nability to consist ently execute against company priorities and create long -term sustainable value for our \nshareholders.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "05bb6c5d181d30b8f8aa08d20902fbb57655958b638f52ad3ee99e6749958164", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb6beb49-5567-4fa8-a3ec-ea61b4d7fdd4", "node_type": "1", "metadata": {"window": "Today, I'll discuss \nour fourth quarter and full -year fi scal 2024 results.  Then I'll provide an overview of our fiscal 2025 outlook.  My \ncomments today will refer to our adjusted results unless I state otherwise.  \n \n We're exiting fiscal 2024 with solid performance, delivering earnings per diluted share of $6.18 in  the fourth \nquarter and $27.44 for the full year.  Our fourth quarter results were in line with our expectations and with the \nearnings per diluted share guidance range that we provided on our third quarter earnings call, demonstrating our \nability to consist ently execute against company priorities and create long -term sustainable value for our \nshareholders.  \n \n For the full year, when excluding fiscal 2023 contributions from COVID -related programs and McKesson \nVentures, adjusted operating profit grew 9% and adju sted EPS increased 17%.  These results are above our long -\nrange targets and reflect the strength of our products, services, and operating execution.  \n ", "original_text": "We're exiting fiscal 2024 with solid performance, delivering earnings per diluted share of $6.18 in  the fourth \nquarter and $27.44 for the full year. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "05b9b2679244f08000a10455d2ddd9a1f4b44d8625be5415dff315417c5fd1aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c87be482-b8e0-4df1-b59b-84c7c7fee107", "node_type": "1", "metadata": {"window": "My \ncomments today will refer to our adjusted results unless I state otherwise.  \n \n We're exiting fiscal 2024 with solid performance, delivering earnings per diluted share of $6.18 in  the fourth \nquarter and $27.44 for the full year.  Our fourth quarter results were in line with our expectations and with the \nearnings per diluted share guidance range that we provided on our third quarter earnings call, demonstrating our \nability to consist ently execute against company priorities and create long -term sustainable value for our \nshareholders.  \n \n For the full year, when excluding fiscal 2023 contributions from COVID -related programs and McKesson \nVentures, adjusted operating profit grew 9% and adju sted EPS increased 17%.  These results are above our long -\nrange targets and reflect the strength of our products, services, and operating execution.  \n ", "original_text": "For the full year, when excluding fiscal 2023 contributions from COVID -related programs and McKesson \nVentures, adjusted operating profit grew 9% and adju sted EPS increased 17%. "}, "hash": "cf08f129794f72fb0ad4f4b8100efa6e9a30554b5cc2a878490d934079fb17da", "class_name": "RelatedNodeInfo"}}, "text": "Our fourth quarter results were in line with our expectations and with the \nearnings per diluted share guidance range that we provided on our third quarter earnings call, demonstrating our \nability to consist ently execute against company priorities and create long -term sustainable value for our \nshareholders.  \n \n", "start_char_idx": 3442, "end_char_idx": 3759, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c87be482-b8e0-4df1-b59b-84c7c7fee107": {"__data__": {"id_": "c87be482-b8e0-4df1-b59b-84c7c7fee107", "embedding": null, "metadata": {"window": "My \ncomments today will refer to our adjusted results unless I state otherwise.  \n \n We're exiting fiscal 2024 with solid performance, delivering earnings per diluted share of $6.18 in  the fourth \nquarter and $27.44 for the full year.  Our fourth quarter results were in line with our expectations and with the \nearnings per diluted share guidance range that we provided on our third quarter earnings call, demonstrating our \nability to consist ently execute against company priorities and create long -term sustainable value for our \nshareholders.  \n \n For the full year, when excluding fiscal 2023 contributions from COVID -related programs and McKesson \nVentures, adjusted operating profit grew 9% and adju sted EPS increased 17%.  These results are above our long -\nrange targets and reflect the strength of our products, services, and operating execution.  \n ", "original_text": "For the full year, when excluding fiscal 2023 contributions from COVID -related programs and McKesson \nVentures, adjusted operating profit grew 9% and adju sted EPS increased 17%. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "05bb6c5d181d30b8f8aa08d20902fbb57655958b638f52ad3ee99e6749958164", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "421a3275-fed2-4637-8985-5f91dc93c4a8", "node_type": "1", "metadata": {"window": "Then I'll provide an overview of our fiscal 2025 outlook.  My \ncomments today will refer to our adjusted results unless I state otherwise.  \n \n We're exiting fiscal 2024 with solid performance, delivering earnings per diluted share of $6.18 in  the fourth \nquarter and $27.44 for the full year.  Our fourth quarter results were in line with our expectations and with the \nearnings per diluted share guidance range that we provided on our third quarter earnings call, demonstrating our \nability to consist ently execute against company priorities and create long -term sustainable value for our \nshareholders.  \n \n For the full year, when excluding fiscal 2023 contributions from COVID -related programs and McKesson \nVentures, adjusted operating profit grew 9% and adju sted EPS increased 17%.  These results are above our long -\nrange targets and reflect the strength of our products, services, and operating execution.  \n ", "original_text": "Our fourth quarter results were in line with our expectations and with the \nearnings per diluted share guidance range that we provided on our third quarter earnings call, demonstrating our \nability to consist ently execute against company priorities and create long -term sustainable value for our \nshareholders.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "41224fb8660db350fc8150bd97908c77dbb6218059ba0f4c798bbfbfa02c9fd9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be2e2175-c71c-404c-9e5f-d9377877646d", "node_type": "1", "metadata": {"window": "We're exiting fiscal 2024 with solid performance, delivering earnings per diluted share of $6.18 in  the fourth \nquarter and $27.44 for the full year.  Our fourth quarter results were in line with our expectations and with the \nearnings per diluted share guidance range that we provided on our third quarter earnings call, demonstrating our \nability to consist ently execute against company priorities and create long -term sustainable value for our \nshareholders.  \n \n For the full year, when excluding fiscal 2023 contributions from COVID -related programs and McKesson \nVentures, adjusted operating profit grew 9% and adju sted EPS increased 17%.  These results are above our long -\nrange targets and reflect the strength of our products, services, and operating execution.  \n ", "original_text": "These results are above our long -\nrange targets and reflect the strength of our products, services, and operating execution.  \n "}, "hash": "8ec0ccb564c2e16f72a000ce74ad4cb48b76d4ed7a7afaf9a93ce24301c70dd7", "class_name": "RelatedNodeInfo"}}, "text": "For the full year, when excluding fiscal 2023 contributions from COVID -related programs and McKesson \nVentures, adjusted operating profit grew 9% and adju sted EPS increased 17%. ", "start_char_idx": 3759, "end_char_idx": 3939, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be2e2175-c71c-404c-9e5f-d9377877646d": {"__data__": {"id_": "be2e2175-c71c-404c-9e5f-d9377877646d", "embedding": null, "metadata": {"window": "We're exiting fiscal 2024 with solid performance, delivering earnings per diluted share of $6.18 in  the fourth \nquarter and $27.44 for the full year.  Our fourth quarter results were in line with our expectations and with the \nearnings per diluted share guidance range that we provided on our third quarter earnings call, demonstrating our \nability to consist ently execute against company priorities and create long -term sustainable value for our \nshareholders.  \n \n For the full year, when excluding fiscal 2023 contributions from COVID -related programs and McKesson \nVentures, adjusted operating profit grew 9% and adju sted EPS increased 17%.  These results are above our long -\nrange targets and reflect the strength of our products, services, and operating execution.  \n ", "original_text": "These results are above our long -\nrange targets and reflect the strength of our products, services, and operating execution.  \n ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "05bb6c5d181d30b8f8aa08d20902fbb57655958b638f52ad3ee99e6749958164", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c87be482-b8e0-4df1-b59b-84c7c7fee107", "node_type": "1", "metadata": {"window": "My \ncomments today will refer to our adjusted results unless I state otherwise.  \n \n We're exiting fiscal 2024 with solid performance, delivering earnings per diluted share of $6.18 in  the fourth \nquarter and $27.44 for the full year.  Our fourth quarter results were in line with our expectations and with the \nearnings per diluted share guidance range that we provided on our third quarter earnings call, demonstrating our \nability to consist ently execute against company priorities and create long -term sustainable value for our \nshareholders.  \n \n For the full year, when excluding fiscal 2023 contributions from COVID -related programs and McKesson \nVentures, adjusted operating profit grew 9% and adju sted EPS increased 17%.  These results are above our long -\nrange targets and reflect the strength of our products, services, and operating execution.  \n ", "original_text": "For the full year, when excluding fiscal 2023 contributions from COVID -related programs and McKesson \nVentures, adjusted operating profit grew 9% and adju sted EPS increased 17%. ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "6f85beeb00b44907bf99041840ee0d18ae037a19eb88d80ae8fed05f553a09f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b43a3cfa-4587-40ad-89e6-6e27c7b4e777", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me start with a review of the fiscal fourth quarter.  Revenues increased 11% to $76.4 billion, led by gr owth in \nthe US Pharmaceutical segment, resulting from increased prescription volumes, including higher volumes from \nspecialty products, retail national account customers, and GLP -1 medications.  Gross profit was $3.3 billion, an \nincrease of 7%, primarily a result of specialty distribution growth within the US Pharmaceutical segment, including \nour leading plasma and biologics business.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "214dfd3673fe39bd611a95f75141b299d82b163093916567aa8c568bb02f08b2", "class_name": "RelatedNodeInfo"}}, "text": "These results are above our long -\nrange targets and reflect the strength of our products, services, and operating execution.  \n ", "start_char_idx": 3939, "end_char_idx": 4068, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b43a3cfa-4587-40ad-89e6-6e27c7b4e777": {"__data__": {"id_": "b43a3cfa-4587-40ad-89e6-6e27c7b4e777", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me start with a review of the fiscal fourth quarter.  Revenues increased 11% to $76.4 billion, led by gr owth in \nthe US Pharmaceutical segment, resulting from increased prescription volumes, including higher volumes from \nspecialty products, retail national account customers, and GLP -1 medications.  Gross profit was $3.3 billion, an \nincrease of 7%, primarily a result of specialty distribution growth within the US Pharmaceutical segment, including \nour leading plasma and biologics business.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e6912a644a9226dda45bfb3ebccc370b9d1a990f8f13bd1bffcf77b67a1c4894", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be2e2175-c71c-404c-9e5f-d9377877646d", "node_type": "1", "metadata": {"window": "We're exiting fiscal 2024 with solid performance, delivering earnings per diluted share of $6.18 in  the fourth \nquarter and $27.44 for the full year.  Our fourth quarter results were in line with our expectations and with the \nearnings per diluted share guidance range that we provided on our third quarter earnings call, demonstrating our \nability to consist ently execute against company priorities and create long -term sustainable value for our \nshareholders.  \n \n For the full year, when excluding fiscal 2023 contributions from COVID -related programs and McKesson \nVentures, adjusted operating profit grew 9% and adju sted EPS increased 17%.  These results are above our long -\nrange targets and reflect the strength of our products, services, and operating execution.  \n ", "original_text": "These results are above our long -\nrange targets and reflect the strength of our products, services, and operating execution.  \n ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "730c3e4379d1fbd16f8c69a27b355a0448924b012679e1b2b899a3986cf4b159", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a6019e2-a159-4f4f-8ec2-53736662c676", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me start with a review of the fiscal fourth quarter.  Revenues increased 11% to $76.4 billion, led by gr owth in \nthe US Pharmaceutical segment, resulting from increased prescription volumes, including higher volumes from \nspecialty products, retail national account customers, and GLP -1 medications.  Gross profit was $3.3 billion, an \nincrease of 7%, primarily a result of specialty distribution growth within the US Pharmaceutical segment, including \nour leading plasma and biologics business.  \n \n Operating expenses increased 11% to $2.1 billion, driven by higher costs to support growth across the \nbusinesses. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me start with a review of the fiscal fourth quarter. "}, "hash": "ce2e18cf5d7c518089032cbc909ea27b9e08357616715c117adebdbb84ae8423", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a6019e2-a159-4f4f-8ec2-53736662c676": {"__data__": {"id_": "5a6019e2-a159-4f4f-8ec2-53736662c676", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me start with a review of the fiscal fourth quarter.  Revenues increased 11% to $76.4 billion, led by gr owth in \nthe US Pharmaceutical segment, resulting from increased prescription volumes, including higher volumes from \nspecialty products, retail national account customers, and GLP -1 medications.  Gross profit was $3.3 billion, an \nincrease of 7%, primarily a result of specialty distribution growth within the US Pharmaceutical segment, including \nour leading plasma and biologics business.  \n \n Operating expenses increased 11% to $2.1 billion, driven by higher costs to support growth across the \nbusinesses. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me start with a review of the fiscal fourth quarter. ", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e6912a644a9226dda45bfb3ebccc370b9d1a990f8f13bd1bffcf77b67a1c4894", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b43a3cfa-4587-40ad-89e6-6e27c7b4e777", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me start with a review of the fiscal fourth quarter.  Revenues increased 11% to $76.4 billion, led by gr owth in \nthe US Pharmaceutical segment, resulting from increased prescription volumes, including higher volumes from \nspecialty products, retail national account customers, and GLP -1 medications.  Gross profit was $3.3 billion, an \nincrease of 7%, primarily a result of specialty distribution growth within the US Pharmaceutical segment, including \nour leading plasma and biologics business.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5592001e8d936a6501e859f34daa0f288ad1cd57d43484f978c6fae05d56b51e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6e1c877-d22f-4eb3-9238-892d3c428be3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me start with a review of the fiscal fourth quarter.  Revenues increased 11% to $76.4 billion, led by gr owth in \nthe US Pharmaceutical segment, resulting from increased prescription volumes, including higher volumes from \nspecialty products, retail national account customers, and GLP -1 medications.  Gross profit was $3.3 billion, an \nincrease of 7%, primarily a result of specialty distribution growth within the US Pharmaceutical segment, including \nour leading plasma and biologics business.  \n \n Operating expenses increased 11% to $2.1 billion, driven by higher costs to support growth across the \nbusinesses.  During the  quarter, we recorded a reserve for environmental matters of $0.09 per share for increased \nremediation costs related to McKesson's former chemical business, which we disposed of several years ago. ", "original_text": "Revenues increased 11% to $76.4 billion, led by gr owth in \nthe US Pharmaceutical segment, resulting from increased prescription volumes, including higher volumes from \nspecialty products, retail national account customers, and GLP -1 medications. "}, "hash": "8578840eab54e600533357c388419776713aacf715b030638b6ec1f4020dffc5", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me start with a review of the fiscal fourth quarter. ", "start_char_idx": 16, "end_char_idx": 237, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6e1c877-d22f-4eb3-9238-892d3c428be3": {"__data__": {"id_": "f6e1c877-d22f-4eb3-9238-892d3c428be3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me start with a review of the fiscal fourth quarter.  Revenues increased 11% to $76.4 billion, led by gr owth in \nthe US Pharmaceutical segment, resulting from increased prescription volumes, including higher volumes from \nspecialty products, retail national account customers, and GLP -1 medications.  Gross profit was $3.3 billion, an \nincrease of 7%, primarily a result of specialty distribution growth within the US Pharmaceutical segment, including \nour leading plasma and biologics business.  \n \n Operating expenses increased 11% to $2.1 billion, driven by higher costs to support growth across the \nbusinesses.  During the  quarter, we recorded a reserve for environmental matters of $0.09 per share for increased \nremediation costs related to McKesson's former chemical business, which we disposed of several years ago. ", "original_text": "Revenues increased 11% to $76.4 billion, led by gr owth in \nthe US Pharmaceutical segment, resulting from increased prescription volumes, including higher volumes from \nspecialty products, retail national account customers, and GLP -1 medications. ", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e6912a644a9226dda45bfb3ebccc370b9d1a990f8f13bd1bffcf77b67a1c4894", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a6019e2-a159-4f4f-8ec2-53736662c676", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me start with a review of the fiscal fourth quarter.  Revenues increased 11% to $76.4 billion, led by gr owth in \nthe US Pharmaceutical segment, resulting from increased prescription volumes, including higher volumes from \nspecialty products, retail national account customers, and GLP -1 medications.  Gross profit was $3.3 billion, an \nincrease of 7%, primarily a result of specialty distribution growth within the US Pharmaceutical segment, including \nour leading plasma and biologics business.  \n \n Operating expenses increased 11% to $2.1 billion, driven by higher costs to support growth across the \nbusinesses. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me start with a review of the fiscal fourth quarter. ", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ac090409539ebc91a5d5d38785b4906e16638f5644ab4b2609b2303293538c4f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0beddf3-650b-4b62-8ec2-1895f2e8c4aa", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me start with a review of the fiscal fourth quarter.  Revenues increased 11% to $76.4 billion, led by gr owth in \nthe US Pharmaceutical segment, resulting from increased prescription volumes, including higher volumes from \nspecialty products, retail national account customers, and GLP -1 medications.  Gross profit was $3.3 billion, an \nincrease of 7%, primarily a result of specialty distribution growth within the US Pharmaceutical segment, including \nour leading plasma and biologics business.  \n \n Operating expenses increased 11% to $2.1 billion, driven by higher costs to support growth across the \nbusinesses.  During the  quarter, we recorded a reserve for environmental matters of $0.09 per share for increased \nremediation costs related to McKesson's former chemical business, which we disposed of several years ago.  The \nenvironmental reserve was recorded in our corporate seg ment.  \n \n", "original_text": "Gross profit was $3.3 billion, an \nincrease of 7%, primarily a result of specialty distribution growth within the US Pharmaceutical segment, including \nour leading plasma and biologics business.  \n \n"}, "hash": "03e548a8e83273862c28925f2061a493ea17a77d04c6773c5aa87432f5261f08", "class_name": "RelatedNodeInfo"}}, "text": "Revenues increased 11% to $76.4 billion, led by gr owth in \nthe US Pharmaceutical segment, resulting from increased prescription volumes, including higher volumes from \nspecialty products, retail national account customers, and GLP -1 medications. ", "start_char_idx": 237, "end_char_idx": 485, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0beddf3-650b-4b62-8ec2-1895f2e8c4aa": {"__data__": {"id_": "d0beddf3-650b-4b62-8ec2-1895f2e8c4aa", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me start with a review of the fiscal fourth quarter.  Revenues increased 11% to $76.4 billion, led by gr owth in \nthe US Pharmaceutical segment, resulting from increased prescription volumes, including higher volumes from \nspecialty products, retail national account customers, and GLP -1 medications.  Gross profit was $3.3 billion, an \nincrease of 7%, primarily a result of specialty distribution growth within the US Pharmaceutical segment, including \nour leading plasma and biologics business.  \n \n Operating expenses increased 11% to $2.1 billion, driven by higher costs to support growth across the \nbusinesses.  During the  quarter, we recorded a reserve for environmental matters of $0.09 per share for increased \nremediation costs related to McKesson's former chemical business, which we disposed of several years ago.  The \nenvironmental reserve was recorded in our corporate seg ment.  \n \n", "original_text": "Gross profit was $3.3 billion, an \nincrease of 7%, primarily a result of specialty distribution growth within the US Pharmaceutical segment, including \nour leading plasma and biologics business.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e6912a644a9226dda45bfb3ebccc370b9d1a990f8f13bd1bffcf77b67a1c4894", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6e1c877-d22f-4eb3-9238-892d3c428be3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me start with a review of the fiscal fourth quarter.  Revenues increased 11% to $76.4 billion, led by gr owth in \nthe US Pharmaceutical segment, resulting from increased prescription volumes, including higher volumes from \nspecialty products, retail national account customers, and GLP -1 medications.  Gross profit was $3.3 billion, an \nincrease of 7%, primarily a result of specialty distribution growth within the US Pharmaceutical segment, including \nour leading plasma and biologics business.  \n \n Operating expenses increased 11% to $2.1 billion, driven by higher costs to support growth across the \nbusinesses.  During the  quarter, we recorded a reserve for environmental matters of $0.09 per share for increased \nremediation costs related to McKesson's former chemical business, which we disposed of several years ago. ", "original_text": "Revenues increased 11% to $76.4 billion, led by gr owth in \nthe US Pharmaceutical segment, resulting from increased prescription volumes, including higher volumes from \nspecialty products, retail national account customers, and GLP -1 medications. ", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "34136e6707ddb947e1006b9f55fb84145ae137ae1a50209c88fa3fe871a1393e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "143207ad-1c0a-4709-a6b2-5ecfcaed702e", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me start with a review of the fiscal fourth quarter.  Revenues increased 11% to $76.4 billion, led by gr owth in \nthe US Pharmaceutical segment, resulting from increased prescription volumes, including higher volumes from \nspecialty products, retail national account customers, and GLP -1 medications.  Gross profit was $3.3 billion, an \nincrease of 7%, primarily a result of specialty distribution growth within the US Pharmaceutical segment, including \nour leading plasma and biologics business.  \n \n Operating expenses increased 11% to $2.1 billion, driven by higher costs to support growth across the \nbusinesses.  During the  quarter, we recorded a reserve for environmental matters of $0.09 per share for increased \nremediation costs related to McKesson's former chemical business, which we disposed of several years ago.  The \nenvironmental reserve was recorded in our corporate seg ment.  \n \n Operating profit was $1.3 billion, which was flat to the prior year, driven by growth in the US Pharmaceutical \nsegment, offset by increased corporate expenses, which included the previously outlined environmental reserve. \n", "original_text": "Operating expenses increased 11% to $2.1 billion, driven by higher costs to support growth across the \nbusinesses. "}, "hash": "4badeda032d945d3b9376856e8c163a0ab385067a8c3ddb902040a5b06824352", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit was $3.3 billion, an \nincrease of 7%, primarily a result of specialty distribution growth within the US Pharmaceutical segment, including \nour leading plasma and biologics business.  \n \n", "start_char_idx": 485, "end_char_idx": 684, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "143207ad-1c0a-4709-a6b2-5ecfcaed702e": {"__data__": {"id_": "143207ad-1c0a-4709-a6b2-5ecfcaed702e", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me start with a review of the fiscal fourth quarter.  Revenues increased 11% to $76.4 billion, led by gr owth in \nthe US Pharmaceutical segment, resulting from increased prescription volumes, including higher volumes from \nspecialty products, retail national account customers, and GLP -1 medications.  Gross profit was $3.3 billion, an \nincrease of 7%, primarily a result of specialty distribution growth within the US Pharmaceutical segment, including \nour leading plasma and biologics business.  \n \n Operating expenses increased 11% to $2.1 billion, driven by higher costs to support growth across the \nbusinesses.  During the  quarter, we recorded a reserve for environmental matters of $0.09 per share for increased \nremediation costs related to McKesson's former chemical business, which we disposed of several years ago.  The \nenvironmental reserve was recorded in our corporate seg ment.  \n \n Operating profit was $1.3 billion, which was flat to the prior year, driven by growth in the US Pharmaceutical \nsegment, offset by increased corporate expenses, which included the previously outlined environmental reserve. \n", "original_text": "Operating expenses increased 11% to $2.1 billion, driven by higher costs to support growth across the \nbusinesses. ", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e6912a644a9226dda45bfb3ebccc370b9d1a990f8f13bd1bffcf77b67a1c4894", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0beddf3-650b-4b62-8ec2-1895f2e8c4aa", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me start with a review of the fiscal fourth quarter.  Revenues increased 11% to $76.4 billion, led by gr owth in \nthe US Pharmaceutical segment, resulting from increased prescription volumes, including higher volumes from \nspecialty products, retail national account customers, and GLP -1 medications.  Gross profit was $3.3 billion, an \nincrease of 7%, primarily a result of specialty distribution growth within the US Pharmaceutical segment, including \nour leading plasma and biologics business.  \n \n Operating expenses increased 11% to $2.1 billion, driven by higher costs to support growth across the \nbusinesses.  During the  quarter, we recorded a reserve for environmental matters of $0.09 per share for increased \nremediation costs related to McKesson's former chemical business, which we disposed of several years ago.  The \nenvironmental reserve was recorded in our corporate seg ment.  \n \n", "original_text": "Gross profit was $3.3 billion, an \nincrease of 7%, primarily a result of specialty distribution growth within the US Pharmaceutical segment, including \nour leading plasma and biologics business.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "eac9fa31a26d4acda08d1844a297ec7631dabade2edbe9ac42471b89954444e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49fc402e-1b88-4b02-a411-39322df34800", "node_type": "1", "metadata": {"window": "Revenues increased 11% to $76.4 billion, led by gr owth in \nthe US Pharmaceutical segment, resulting from increased prescription volumes, including higher volumes from \nspecialty products, retail national account customers, and GLP -1 medications.  Gross profit was $3.3 billion, an \nincrease of 7%, primarily a result of specialty distribution growth within the US Pharmaceutical segment, including \nour leading plasma and biologics business.  \n \n Operating expenses increased 11% to $2.1 billion, driven by higher costs to support growth across the \nbusinesses.  During the  quarter, we recorded a reserve for environmental matters of $0.09 per share for increased \nremediation costs related to McKesson's former chemical business, which we disposed of several years ago.  The \nenvironmental reserve was recorded in our corporate seg ment.  \n \n Operating profit was $1.3 billion, which was flat to the prior year, driven by growth in the US Pharmaceutical \nsegment, offset by increased corporate expenses, which included the previously outlined environmental reserve. \n Year -over-year results were  also impacted by anticipated lower contributions from US government COVID -19 \nprograms in both the US Pharmaceutical and Medical Surgical Solutions segments when compared to the prior \nyear. ", "original_text": "During the  quarter, we recorded a reserve for environmental matters of $0.09 per share for increased \nremediation costs related to McKesson's former chemical business, which we disposed of several years ago. "}, "hash": "ea9b1782b76f6b6cde5165bb627f33aefff111e3422e3406ba4722251b316b16", "class_name": "RelatedNodeInfo"}}, "text": "Operating expenses increased 11% to $2.1 billion, driven by higher costs to support growth across the \nbusinesses. ", "start_char_idx": 684, "end_char_idx": 799, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49fc402e-1b88-4b02-a411-39322df34800": {"__data__": {"id_": "49fc402e-1b88-4b02-a411-39322df34800", "embedding": null, "metadata": {"window": "Revenues increased 11% to $76.4 billion, led by gr owth in \nthe US Pharmaceutical segment, resulting from increased prescription volumes, including higher volumes from \nspecialty products, retail national account customers, and GLP -1 medications.  Gross profit was $3.3 billion, an \nincrease of 7%, primarily a result of specialty distribution growth within the US Pharmaceutical segment, including \nour leading plasma and biologics business.  \n \n Operating expenses increased 11% to $2.1 billion, driven by higher costs to support growth across the \nbusinesses.  During the  quarter, we recorded a reserve for environmental matters of $0.09 per share for increased \nremediation costs related to McKesson's former chemical business, which we disposed of several years ago.  The \nenvironmental reserve was recorded in our corporate seg ment.  \n \n Operating profit was $1.3 billion, which was flat to the prior year, driven by growth in the US Pharmaceutical \nsegment, offset by increased corporate expenses, which included the previously outlined environmental reserve. \n Year -over-year results were  also impacted by anticipated lower contributions from US government COVID -19 \nprograms in both the US Pharmaceutical and Medical Surgical Solutions segments when compared to the prior \nyear. ", "original_text": "During the  quarter, we recorded a reserve for environmental matters of $0.09 per share for increased \nremediation costs related to McKesson's former chemical business, which we disposed of several years ago. ", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e6912a644a9226dda45bfb3ebccc370b9d1a990f8f13bd1bffcf77b67a1c4894", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "143207ad-1c0a-4709-a6b2-5ecfcaed702e", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me start with a review of the fiscal fourth quarter.  Revenues increased 11% to $76.4 billion, led by gr owth in \nthe US Pharmaceutical segment, resulting from increased prescription volumes, including higher volumes from \nspecialty products, retail national account customers, and GLP -1 medications.  Gross profit was $3.3 billion, an \nincrease of 7%, primarily a result of specialty distribution growth within the US Pharmaceutical segment, including \nour leading plasma and biologics business.  \n \n Operating expenses increased 11% to $2.1 billion, driven by higher costs to support growth across the \nbusinesses.  During the  quarter, we recorded a reserve for environmental matters of $0.09 per share for increased \nremediation costs related to McKesson's former chemical business, which we disposed of several years ago.  The \nenvironmental reserve was recorded in our corporate seg ment.  \n \n Operating profit was $1.3 billion, which was flat to the prior year, driven by growth in the US Pharmaceutical \nsegment, offset by increased corporate expenses, which included the previously outlined environmental reserve. \n", "original_text": "Operating expenses increased 11% to $2.1 billion, driven by higher costs to support growth across the \nbusinesses. ", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "9ca50f956e0a331b494a6bdeca9827b81be9e6e9a8f0c8821a81a5dcc8e844b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08751485-bd05-47ea-9e71-bf5dfa8d2591", "node_type": "1", "metadata": {"window": "Gross profit was $3.3 billion, an \nincrease of 7%, primarily a result of specialty distribution growth within the US Pharmaceutical segment, including \nour leading plasma and biologics business.  \n \n Operating expenses increased 11% to $2.1 billion, driven by higher costs to support growth across the \nbusinesses.  During the  quarter, we recorded a reserve for environmental matters of $0.09 per share for increased \nremediation costs related to McKesson's former chemical business, which we disposed of several years ago.  The \nenvironmental reserve was recorded in our corporate seg ment.  \n \n Operating profit was $1.3 billion, which was flat to the prior year, driven by growth in the US Pharmaceutical \nsegment, offset by increased corporate expenses, which included the previously outlined environmental reserve. \n Year -over-year results were  also impacted by anticipated lower contributions from US government COVID -19 \nprograms in both the US Pharmaceutical and Medical Surgical Solutions segments when compared to the prior \nyear.  When adjusting for the COVID -19 programs and a modest McKesson Ven tures loss in fiscal 2023, adjusted \noperating profit increased 4% in the quarter.  \n \n", "original_text": "The \nenvironmental reserve was recorded in our corporate seg ment.  \n \n"}, "hash": "7cf2fc67536b6e1a80dde07d0ab450a416b2a1bf0b9a776af95b698e00e02e20", "class_name": "RelatedNodeInfo"}}, "text": "During the  quarter, we recorded a reserve for environmental matters of $0.09 per share for increased \nremediation costs related to McKesson's former chemical business, which we disposed of several years ago. ", "start_char_idx": 799, "end_char_idx": 1008, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08751485-bd05-47ea-9e71-bf5dfa8d2591": {"__data__": {"id_": "08751485-bd05-47ea-9e71-bf5dfa8d2591", "embedding": null, "metadata": {"window": "Gross profit was $3.3 billion, an \nincrease of 7%, primarily a result of specialty distribution growth within the US Pharmaceutical segment, including \nour leading plasma and biologics business.  \n \n Operating expenses increased 11% to $2.1 billion, driven by higher costs to support growth across the \nbusinesses.  During the  quarter, we recorded a reserve for environmental matters of $0.09 per share for increased \nremediation costs related to McKesson's former chemical business, which we disposed of several years ago.  The \nenvironmental reserve was recorded in our corporate seg ment.  \n \n Operating profit was $1.3 billion, which was flat to the prior year, driven by growth in the US Pharmaceutical \nsegment, offset by increased corporate expenses, which included the previously outlined environmental reserve. \n Year -over-year results were  also impacted by anticipated lower contributions from US government COVID -19 \nprograms in both the US Pharmaceutical and Medical Surgical Solutions segments when compared to the prior \nyear.  When adjusting for the COVID -19 programs and a modest McKesson Ven tures loss in fiscal 2023, adjusted \noperating profit increased 4% in the quarter.  \n \n", "original_text": "The \nenvironmental reserve was recorded in our corporate seg ment.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e6912a644a9226dda45bfb3ebccc370b9d1a990f8f13bd1bffcf77b67a1c4894", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49fc402e-1b88-4b02-a411-39322df34800", "node_type": "1", "metadata": {"window": "Revenues increased 11% to $76.4 billion, led by gr owth in \nthe US Pharmaceutical segment, resulting from increased prescription volumes, including higher volumes from \nspecialty products, retail national account customers, and GLP -1 medications.  Gross profit was $3.3 billion, an \nincrease of 7%, primarily a result of specialty distribution growth within the US Pharmaceutical segment, including \nour leading plasma and biologics business.  \n \n Operating expenses increased 11% to $2.1 billion, driven by higher costs to support growth across the \nbusinesses.  During the  quarter, we recorded a reserve for environmental matters of $0.09 per share for increased \nremediation costs related to McKesson's former chemical business, which we disposed of several years ago.  The \nenvironmental reserve was recorded in our corporate seg ment.  \n \n Operating profit was $1.3 billion, which was flat to the prior year, driven by growth in the US Pharmaceutical \nsegment, offset by increased corporate expenses, which included the previously outlined environmental reserve. \n Year -over-year results were  also impacted by anticipated lower contributions from US government COVID -19 \nprograms in both the US Pharmaceutical and Medical Surgical Solutions segments when compared to the prior \nyear. ", "original_text": "During the  quarter, we recorded a reserve for environmental matters of $0.09 per share for increased \nremediation costs related to McKesson's former chemical business, which we disposed of several years ago. ", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "8cd7973b42f9f1c6c2ed87921949451ec5026fb2288696e667ef019b5bc9e590", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4b9d2e9-eb58-4dbb-b59e-e9fec18c1b22", "node_type": "1", "metadata": {"window": "Operating expenses increased 11% to $2.1 billion, driven by higher costs to support growth across the \nbusinesses.  During the  quarter, we recorded a reserve for environmental matters of $0.09 per share for increased \nremediation costs related to McKesson's former chemical business, which we disposed of several years ago.  The \nenvironmental reserve was recorded in our corporate seg ment.  \n \n Operating profit was $1.3 billion, which was flat to the prior year, driven by growth in the US Pharmaceutical \nsegment, offset by increased corporate expenses, which included the previously outlined environmental reserve. \n Year -over-year results were  also impacted by anticipated lower contributions from US government COVID -19 \nprograms in both the US Pharmaceutical and Medical Surgical Solutions segments when compared to the prior \nyear.  When adjusting for the COVID -19 programs and a modest McKesson Ven tures loss in fiscal 2023, adjusted \noperating profit increased 4% in the quarter.  \n \n Moving below the line, interest expense was $75 million, an increase of 7%, driven by higher short -term \nborrowings of commercial paper compared to the prior year. ", "original_text": "Operating profit was $1.3 billion, which was flat to the prior year, driven by growth in the US Pharmaceutical \nsegment, offset by increased corporate expenses, which included the previously outlined environmental reserve. \n"}, "hash": "7471d3c6f1736a6e20a2d62cf54353848bdf597912a48c98d18e8f65f67748eb", "class_name": "RelatedNodeInfo"}}, "text": "The \nenvironmental reserve was recorded in our corporate seg ment.  \n \n", "start_char_idx": 1008, "end_char_idx": 1079, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4b9d2e9-eb58-4dbb-b59e-e9fec18c1b22": {"__data__": {"id_": "a4b9d2e9-eb58-4dbb-b59e-e9fec18c1b22", "embedding": null, "metadata": {"window": "Operating expenses increased 11% to $2.1 billion, driven by higher costs to support growth across the \nbusinesses.  During the  quarter, we recorded a reserve for environmental matters of $0.09 per share for increased \nremediation costs related to McKesson's former chemical business, which we disposed of several years ago.  The \nenvironmental reserve was recorded in our corporate seg ment.  \n \n Operating profit was $1.3 billion, which was flat to the prior year, driven by growth in the US Pharmaceutical \nsegment, offset by increased corporate expenses, which included the previously outlined environmental reserve. \n Year -over-year results were  also impacted by anticipated lower contributions from US government COVID -19 \nprograms in both the US Pharmaceutical and Medical Surgical Solutions segments when compared to the prior \nyear.  When adjusting for the COVID -19 programs and a modest McKesson Ven tures loss in fiscal 2023, adjusted \noperating profit increased 4% in the quarter.  \n \n Moving below the line, interest expense was $75 million, an increase of 7%, driven by higher short -term \nborrowings of commercial paper compared to the prior year. ", "original_text": "Operating profit was $1.3 billion, which was flat to the prior year, driven by growth in the US Pharmaceutical \nsegment, offset by increased corporate expenses, which included the previously outlined environmental reserve. \n", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e6912a644a9226dda45bfb3ebccc370b9d1a990f8f13bd1bffcf77b67a1c4894", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08751485-bd05-47ea-9e71-bf5dfa8d2591", "node_type": "1", "metadata": {"window": "Gross profit was $3.3 billion, an \nincrease of 7%, primarily a result of specialty distribution growth within the US Pharmaceutical segment, including \nour leading plasma and biologics business.  \n \n Operating expenses increased 11% to $2.1 billion, driven by higher costs to support growth across the \nbusinesses.  During the  quarter, we recorded a reserve for environmental matters of $0.09 per share for increased \nremediation costs related to McKesson's former chemical business, which we disposed of several years ago.  The \nenvironmental reserve was recorded in our corporate seg ment.  \n \n Operating profit was $1.3 billion, which was flat to the prior year, driven by growth in the US Pharmaceutical \nsegment, offset by increased corporate expenses, which included the previously outlined environmental reserve. \n Year -over-year results were  also impacted by anticipated lower contributions from US government COVID -19 \nprograms in both the US Pharmaceutical and Medical Surgical Solutions segments when compared to the prior \nyear.  When adjusting for the COVID -19 programs and a modest McKesson Ven tures loss in fiscal 2023, adjusted \noperating profit increased 4% in the quarter.  \n \n", "original_text": "The \nenvironmental reserve was recorded in our corporate seg ment.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d720e38a1aa0a103a34b0d7e3bfd7b8620ab9d7468d59ea2106d2a66e9a44346", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69a19da3-7319-4658-9057-0887341b178a", "node_type": "1", "metadata": {"window": "During the  quarter, we recorded a reserve for environmental matters of $0.09 per share for increased \nremediation costs related to McKesson's former chemical business, which we disposed of several years ago.  The \nenvironmental reserve was recorded in our corporate seg ment.  \n \n Operating profit was $1.3 billion, which was flat to the prior year, driven by growth in the US Pharmaceutical \nsegment, offset by increased corporate expenses, which included the previously outlined environmental reserve. \n Year -over-year results were  also impacted by anticipated lower contributions from US government COVID -19 \nprograms in both the US Pharmaceutical and Medical Surgical Solutions segments when compared to the prior \nyear.  When adjusting for the COVID -19 programs and a modest McKesson Ven tures loss in fiscal 2023, adjusted \noperating profit increased 4% in the quarter.  \n \n Moving below the line, interest expense was $75 million, an increase of 7%, driven by higher short -term \nborrowings of commercial paper compared to the prior year.  The higher  short -term borrowings resulted from lower \naverage cash balances, in part due to the impact from the Change Healthcare outage.  \n \n", "original_text": "Year -over-year results were  also impacted by anticipated lower contributions from US government COVID -19 \nprograms in both the US Pharmaceutical and Medical Surgical Solutions segments when compared to the prior \nyear. "}, "hash": "1699229a3bc50b59796cd669297c173c02dd81a83d99dd8685c938980e4386cc", "class_name": "RelatedNodeInfo"}}, "text": "Operating profit was $1.3 billion, which was flat to the prior year, driven by growth in the US Pharmaceutical \nsegment, offset by increased corporate expenses, which included the previously outlined environmental reserve. \n", "start_char_idx": 1079, "end_char_idx": 1303, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69a19da3-7319-4658-9057-0887341b178a": {"__data__": {"id_": "69a19da3-7319-4658-9057-0887341b178a", "embedding": null, "metadata": {"window": "During the  quarter, we recorded a reserve for environmental matters of $0.09 per share for increased \nremediation costs related to McKesson's former chemical business, which we disposed of several years ago.  The \nenvironmental reserve was recorded in our corporate seg ment.  \n \n Operating profit was $1.3 billion, which was flat to the prior year, driven by growth in the US Pharmaceutical \nsegment, offset by increased corporate expenses, which included the previously outlined environmental reserve. \n Year -over-year results were  also impacted by anticipated lower contributions from US government COVID -19 \nprograms in both the US Pharmaceutical and Medical Surgical Solutions segments when compared to the prior \nyear.  When adjusting for the COVID -19 programs and a modest McKesson Ven tures loss in fiscal 2023, adjusted \noperating profit increased 4% in the quarter.  \n \n Moving below the line, interest expense was $75 million, an increase of 7%, driven by higher short -term \nborrowings of commercial paper compared to the prior year.  The higher  short -term borrowings resulted from lower \naverage cash balances, in part due to the impact from the Change Healthcare outage.  \n \n", "original_text": "Year -over-year results were  also impacted by anticipated lower contributions from US government COVID -19 \nprograms in both the US Pharmaceutical and Medical Surgical Solutions segments when compared to the prior \nyear. ", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e6912a644a9226dda45bfb3ebccc370b9d1a990f8f13bd1bffcf77b67a1c4894", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4b9d2e9-eb58-4dbb-b59e-e9fec18c1b22", "node_type": "1", "metadata": {"window": "Operating expenses increased 11% to $2.1 billion, driven by higher costs to support growth across the \nbusinesses.  During the  quarter, we recorded a reserve for environmental matters of $0.09 per share for increased \nremediation costs related to McKesson's former chemical business, which we disposed of several years ago.  The \nenvironmental reserve was recorded in our corporate seg ment.  \n \n Operating profit was $1.3 billion, which was flat to the prior year, driven by growth in the US Pharmaceutical \nsegment, offset by increased corporate expenses, which included the previously outlined environmental reserve. \n Year -over-year results were  also impacted by anticipated lower contributions from US government COVID -19 \nprograms in both the US Pharmaceutical and Medical Surgical Solutions segments when compared to the prior \nyear.  When adjusting for the COVID -19 programs and a modest McKesson Ven tures loss in fiscal 2023, adjusted \noperating profit increased 4% in the quarter.  \n \n Moving below the line, interest expense was $75 million, an increase of 7%, driven by higher short -term \nborrowings of commercial paper compared to the prior year. ", "original_text": "Operating profit was $1.3 billion, which was flat to the prior year, driven by growth in the US Pharmaceutical \nsegment, offset by increased corporate expenses, which included the previously outlined environmental reserve. \n", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "8b4ef561f3f51b91cd1abef8078cc135cb0138ca5e90db37eacd988e3664fa68", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "afc07965-63a2-474d-9ed8-469a36b01856", "node_type": "1", "metadata": {"window": "The \nenvironmental reserve was recorded in our corporate seg ment.  \n \n Operating profit was $1.3 billion, which was flat to the prior year, driven by growth in the US Pharmaceutical \nsegment, offset by increased corporate expenses, which included the previously outlined environmental reserve. \n Year -over-year results were  also impacted by anticipated lower contributions from US government COVID -19 \nprograms in both the US Pharmaceutical and Medical Surgical Solutions segments when compared to the prior \nyear.  When adjusting for the COVID -19 programs and a modest McKesson Ven tures loss in fiscal 2023, adjusted \noperating profit increased 4% in the quarter.  \n \n Moving below the line, interest expense was $75 million, an increase of 7%, driven by higher short -term \nborrowings of commercial paper compared to the prior year.  The higher  short -term borrowings resulted from lower \naverage cash balances, in part due to the impact from the Change Healthcare outage.  \n \n The effective tax rate for the quarter was 28.1%, which is in line with our previous guidance and driven by a \ndiscrete tax item.  ", "original_text": "When adjusting for the COVID -19 programs and a modest McKesson Ven tures loss in fiscal 2023, adjusted \noperating profit increased 4% in the quarter.  \n \n"}, "hash": "15523fb86ebc16ecb13f27717c37ef7f276a458b0cba5e266cad3536f1c2dcc3", "class_name": "RelatedNodeInfo"}}, "text": "Year -over-year results were  also impacted by anticipated lower contributions from US government COVID -19 \nprograms in both the US Pharmaceutical and Medical Surgical Solutions segments when compared to the prior \nyear. ", "start_char_idx": 1303, "end_char_idx": 1525, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "afc07965-63a2-474d-9ed8-469a36b01856": {"__data__": {"id_": "afc07965-63a2-474d-9ed8-469a36b01856", "embedding": null, "metadata": {"window": "The \nenvironmental reserve was recorded in our corporate seg ment.  \n \n Operating profit was $1.3 billion, which was flat to the prior year, driven by growth in the US Pharmaceutical \nsegment, offset by increased corporate expenses, which included the previously outlined environmental reserve. \n Year -over-year results were  also impacted by anticipated lower contributions from US government COVID -19 \nprograms in both the US Pharmaceutical and Medical Surgical Solutions segments when compared to the prior \nyear.  When adjusting for the COVID -19 programs and a modest McKesson Ven tures loss in fiscal 2023, adjusted \noperating profit increased 4% in the quarter.  \n \n Moving below the line, interest expense was $75 million, an increase of 7%, driven by higher short -term \nborrowings of commercial paper compared to the prior year.  The higher  short -term borrowings resulted from lower \naverage cash balances, in part due to the impact from the Change Healthcare outage.  \n \n The effective tax rate for the quarter was 28.1%, which is in line with our previous guidance and driven by a \ndiscrete tax item.  ", "original_text": "When adjusting for the COVID -19 programs and a modest McKesson Ven tures loss in fiscal 2023, adjusted \noperating profit increased 4% in the quarter.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e6912a644a9226dda45bfb3ebccc370b9d1a990f8f13bd1bffcf77b67a1c4894", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69a19da3-7319-4658-9057-0887341b178a", "node_type": "1", "metadata": {"window": "During the  quarter, we recorded a reserve for environmental matters of $0.09 per share for increased \nremediation costs related to McKesson's former chemical business, which we disposed of several years ago.  The \nenvironmental reserve was recorded in our corporate seg ment.  \n \n Operating profit was $1.3 billion, which was flat to the prior year, driven by growth in the US Pharmaceutical \nsegment, offset by increased corporate expenses, which included the previously outlined environmental reserve. \n Year -over-year results were  also impacted by anticipated lower contributions from US government COVID -19 \nprograms in both the US Pharmaceutical and Medical Surgical Solutions segments when compared to the prior \nyear.  When adjusting for the COVID -19 programs and a modest McKesson Ven tures loss in fiscal 2023, adjusted \noperating profit increased 4% in the quarter.  \n \n Moving below the line, interest expense was $75 million, an increase of 7%, driven by higher short -term \nborrowings of commercial paper compared to the prior year.  The higher  short -term borrowings resulted from lower \naverage cash balances, in part due to the impact from the Change Healthcare outage.  \n \n", "original_text": "Year -over-year results were  also impacted by anticipated lower contributions from US government COVID -19 \nprograms in both the US Pharmaceutical and Medical Surgical Solutions segments when compared to the prior \nyear. ", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a49c79da5a82c2c8a18da12e6fe49f2a586cc37882770e9454aaab50dc66c270", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de33f76c-e38e-47ce-bafa-0d28b8c12f3f", "node_type": "1", "metadata": {"window": "Operating profit was $1.3 billion, which was flat to the prior year, driven by growth in the US Pharmaceutical \nsegment, offset by increased corporate expenses, which included the previously outlined environmental reserve. \n Year -over-year results were  also impacted by anticipated lower contributions from US government COVID -19 \nprograms in both the US Pharmaceutical and Medical Surgical Solutions segments when compared to the prior \nyear.  When adjusting for the COVID -19 programs and a modest McKesson Ven tures loss in fiscal 2023, adjusted \noperating profit increased 4% in the quarter.  \n \n Moving below the line, interest expense was $75 million, an increase of 7%, driven by higher short -term \nborrowings of commercial paper compared to the prior year.  The higher  short -term borrowings resulted from lower \naverage cash balances, in part due to the impact from the Change Healthcare outage.  \n \n The effective tax rate for the quarter was 28.1%, which is in line with our previous guidance and driven by a \ndiscrete tax item.   Fourth quarter diluted weighted average shares outstanding was 131.6 million, a decrease of \n5% year over year.  \n \n", "original_text": "Moving below the line, interest expense was $75 million, an increase of 7%, driven by higher short -term \nborrowings of commercial paper compared to the prior year. "}, "hash": "063c9bade2d89e877bbd317b3265b76aee3329fb76d8434d631a94d88959b9fc", "class_name": "RelatedNodeInfo"}}, "text": "When adjusting for the COVID -19 programs and a modest McKesson Ven tures loss in fiscal 2023, adjusted \noperating profit increased 4% in the quarter.  \n \n", "start_char_idx": 1525, "end_char_idx": 1680, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de33f76c-e38e-47ce-bafa-0d28b8c12f3f": {"__data__": {"id_": "de33f76c-e38e-47ce-bafa-0d28b8c12f3f", "embedding": null, "metadata": {"window": "Operating profit was $1.3 billion, which was flat to the prior year, driven by growth in the US Pharmaceutical \nsegment, offset by increased corporate expenses, which included the previously outlined environmental reserve. \n Year -over-year results were  also impacted by anticipated lower contributions from US government COVID -19 \nprograms in both the US Pharmaceutical and Medical Surgical Solutions segments when compared to the prior \nyear.  When adjusting for the COVID -19 programs and a modest McKesson Ven tures loss in fiscal 2023, adjusted \noperating profit increased 4% in the quarter.  \n \n Moving below the line, interest expense was $75 million, an increase of 7%, driven by higher short -term \nborrowings of commercial paper compared to the prior year.  The higher  short -term borrowings resulted from lower \naverage cash balances, in part due to the impact from the Change Healthcare outage.  \n \n The effective tax rate for the quarter was 28.1%, which is in line with our previous guidance and driven by a \ndiscrete tax item.   Fourth quarter diluted weighted average shares outstanding was 131.6 million, a decrease of \n5% year over year.  \n \n", "original_text": "Moving below the line, interest expense was $75 million, an increase of 7%, driven by higher short -term \nborrowings of commercial paper compared to the prior year. ", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e6912a644a9226dda45bfb3ebccc370b9d1a990f8f13bd1bffcf77b67a1c4894", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "afc07965-63a2-474d-9ed8-469a36b01856", "node_type": "1", "metadata": {"window": "The \nenvironmental reserve was recorded in our corporate seg ment.  \n \n Operating profit was $1.3 billion, which was flat to the prior year, driven by growth in the US Pharmaceutical \nsegment, offset by increased corporate expenses, which included the previously outlined environmental reserve. \n Year -over-year results were  also impacted by anticipated lower contributions from US government COVID -19 \nprograms in both the US Pharmaceutical and Medical Surgical Solutions segments when compared to the prior \nyear.  When adjusting for the COVID -19 programs and a modest McKesson Ven tures loss in fiscal 2023, adjusted \noperating profit increased 4% in the quarter.  \n \n Moving below the line, interest expense was $75 million, an increase of 7%, driven by higher short -term \nborrowings of commercial paper compared to the prior year.  The higher  short -term borrowings resulted from lower \naverage cash balances, in part due to the impact from the Change Healthcare outage.  \n \n The effective tax rate for the quarter was 28.1%, which is in line with our previous guidance and driven by a \ndiscrete tax item.  ", "original_text": "When adjusting for the COVID -19 programs and a modest McKesson Ven tures loss in fiscal 2023, adjusted \noperating profit increased 4% in the quarter.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "8be15023e8bf70e0040491c6219d66f3f1cb4a721ba60c30ec938685bf73d04e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28379bbe-1016-4646-8269-88589887374a", "node_type": "1", "metadata": {"window": "Year -over-year results were  also impacted by anticipated lower contributions from US government COVID -19 \nprograms in both the US Pharmaceutical and Medical Surgical Solutions segments when compared to the prior \nyear.  When adjusting for the COVID -19 programs and a modest McKesson Ven tures loss in fiscal 2023, adjusted \noperating profit increased 4% in the quarter.  \n \n Moving below the line, interest expense was $75 million, an increase of 7%, driven by higher short -term \nborrowings of commercial paper compared to the prior year.  The higher  short -term borrowings resulted from lower \naverage cash balances, in part due to the impact from the Change Healthcare outage.  \n \n The effective tax rate for the quarter was 28.1%, which is in line with our previous guidance and driven by a \ndiscrete tax item.   Fourth quarter diluted weighted average shares outstanding was 131.6 million, a decrease of \n5% year over year.  \n \n Wrapping up our consolidated results, earnings per diluted share was $6.18, again, in line with the implied \nearnings per diluted share that we provided on our third quarter earnings call. ", "original_text": "The higher  short -term borrowings resulted from lower \naverage cash balances, in part due to the impact from the Change Healthcare outage.  \n \n"}, "hash": "1170d4ddca37bf9abb4d2c4f9e6c4c372b174660692544e7d3cac6f9fe914e06", "class_name": "RelatedNodeInfo"}}, "text": "Moving below the line, interest expense was $75 million, an increase of 7%, driven by higher short -term \nborrowings of commercial paper compared to the prior year. ", "start_char_idx": 1680, "end_char_idx": 1845, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28379bbe-1016-4646-8269-88589887374a": {"__data__": {"id_": "28379bbe-1016-4646-8269-88589887374a", "embedding": null, "metadata": {"window": "Year -over-year results were  also impacted by anticipated lower contributions from US government COVID -19 \nprograms in both the US Pharmaceutical and Medical Surgical Solutions segments when compared to the prior \nyear.  When adjusting for the COVID -19 programs and a modest McKesson Ven tures loss in fiscal 2023, adjusted \noperating profit increased 4% in the quarter.  \n \n Moving below the line, interest expense was $75 million, an increase of 7%, driven by higher short -term \nborrowings of commercial paper compared to the prior year.  The higher  short -term borrowings resulted from lower \naverage cash balances, in part due to the impact from the Change Healthcare outage.  \n \n The effective tax rate for the quarter was 28.1%, which is in line with our previous guidance and driven by a \ndiscrete tax item.   Fourth quarter diluted weighted average shares outstanding was 131.6 million, a decrease of \n5% year over year.  \n \n Wrapping up our consolidated results, earnings per diluted share was $6.18, again, in line with the implied \nearnings per diluted share that we provided on our third quarter earnings call. ", "original_text": "The higher  short -term borrowings resulted from lower \naverage cash balances, in part due to the impact from the Change Healthcare outage.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e6912a644a9226dda45bfb3ebccc370b9d1a990f8f13bd1bffcf77b67a1c4894", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de33f76c-e38e-47ce-bafa-0d28b8c12f3f", "node_type": "1", "metadata": {"window": "Operating profit was $1.3 billion, which was flat to the prior year, driven by growth in the US Pharmaceutical \nsegment, offset by increased corporate expenses, which included the previously outlined environmental reserve. \n Year -over-year results were  also impacted by anticipated lower contributions from US government COVID -19 \nprograms in both the US Pharmaceutical and Medical Surgical Solutions segments when compared to the prior \nyear.  When adjusting for the COVID -19 programs and a modest McKesson Ven tures loss in fiscal 2023, adjusted \noperating profit increased 4% in the quarter.  \n \n Moving below the line, interest expense was $75 million, an increase of 7%, driven by higher short -term \nborrowings of commercial paper compared to the prior year.  The higher  short -term borrowings resulted from lower \naverage cash balances, in part due to the impact from the Change Healthcare outage.  \n \n The effective tax rate for the quarter was 28.1%, which is in line with our previous guidance and driven by a \ndiscrete tax item.   Fourth quarter diluted weighted average shares outstanding was 131.6 million, a decrease of \n5% year over year.  \n \n", "original_text": "Moving below the line, interest expense was $75 million, an increase of 7%, driven by higher short -term \nborrowings of commercial paper compared to the prior year. ", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c9e40f49ac9b41cff427d8e37924722247e36e979faf45c32dde57c94c7cfdf5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf615f13-7b72-4cd5-b5e2-d8225d8e8718", "node_type": "1", "metadata": {"window": "When adjusting for the COVID -19 programs and a modest McKesson Ven tures loss in fiscal 2023, adjusted \noperating profit increased 4% in the quarter.  \n \n Moving below the line, interest expense was $75 million, an increase of 7%, driven by higher short -term \nborrowings of commercial paper compared to the prior year.  The higher  short -term borrowings resulted from lower \naverage cash balances, in part due to the impact from the Change Healthcare outage.  \n \n The effective tax rate for the quarter was 28.1%, which is in line with our previous guidance and driven by a \ndiscrete tax item.   Fourth quarter diluted weighted average shares outstanding was 131.6 million, a decrease of \n5% year over year.  \n \n Wrapping up our consolidated results, earnings per diluted share was $6.18, again, in line with the implied \nearnings per diluted share that we provided on our third quarter earnings call.  While this represents a decrease of \n14% compared to the prior year, fourth quarter results were principally driven by a higher tax rate and lower \nCOVID -19 program contributions in fiscal 2024, partially offset b y a lower share count and growth in the US \nPharmaceutical segment.  \n \n", "original_text": "The effective tax rate for the quarter was 28.1%, which is in line with our previous guidance and driven by a \ndiscrete tax item.  "}, "hash": "92b6f750bc21604bf2c4575ab4d07b09e0de15dea468bfb7d23ed7dd7040d3dd", "class_name": "RelatedNodeInfo"}}, "text": "The higher  short -term borrowings resulted from lower \naverage cash balances, in part due to the impact from the Change Healthcare outage.  \n \n", "start_char_idx": 1845, "end_char_idx": 1989, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf615f13-7b72-4cd5-b5e2-d8225d8e8718": {"__data__": {"id_": "bf615f13-7b72-4cd5-b5e2-d8225d8e8718", "embedding": null, "metadata": {"window": "When adjusting for the COVID -19 programs and a modest McKesson Ven tures loss in fiscal 2023, adjusted \noperating profit increased 4% in the quarter.  \n \n Moving below the line, interest expense was $75 million, an increase of 7%, driven by higher short -term \nborrowings of commercial paper compared to the prior year.  The higher  short -term borrowings resulted from lower \naverage cash balances, in part due to the impact from the Change Healthcare outage.  \n \n The effective tax rate for the quarter was 28.1%, which is in line with our previous guidance and driven by a \ndiscrete tax item.   Fourth quarter diluted weighted average shares outstanding was 131.6 million, a decrease of \n5% year over year.  \n \n Wrapping up our consolidated results, earnings per diluted share was $6.18, again, in line with the implied \nearnings per diluted share that we provided on our third quarter earnings call.  While this represents a decrease of \n14% compared to the prior year, fourth quarter results were principally driven by a higher tax rate and lower \nCOVID -19 program contributions in fiscal 2024, partially offset b y a lower share count and growth in the US \nPharmaceutical segment.  \n \n", "original_text": "The effective tax rate for the quarter was 28.1%, which is in line with our previous guidance and driven by a \ndiscrete tax item.  ", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e6912a644a9226dda45bfb3ebccc370b9d1a990f8f13bd1bffcf77b67a1c4894", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28379bbe-1016-4646-8269-88589887374a", "node_type": "1", "metadata": {"window": "Year -over-year results were  also impacted by anticipated lower contributions from US government COVID -19 \nprograms in both the US Pharmaceutical and Medical Surgical Solutions segments when compared to the prior \nyear.  When adjusting for the COVID -19 programs and a modest McKesson Ven tures loss in fiscal 2023, adjusted \noperating profit increased 4% in the quarter.  \n \n Moving below the line, interest expense was $75 million, an increase of 7%, driven by higher short -term \nborrowings of commercial paper compared to the prior year.  The higher  short -term borrowings resulted from lower \naverage cash balances, in part due to the impact from the Change Healthcare outage.  \n \n The effective tax rate for the quarter was 28.1%, which is in line with our previous guidance and driven by a \ndiscrete tax item.   Fourth quarter diluted weighted average shares outstanding was 131.6 million, a decrease of \n5% year over year.  \n \n Wrapping up our consolidated results, earnings per diluted share was $6.18, again, in line with the implied \nearnings per diluted share that we provided on our third quarter earnings call. ", "original_text": "The higher  short -term borrowings resulted from lower \naverage cash balances, in part due to the impact from the Change Healthcare outage.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "b192e9a0f5b48ff83bc6d89e57c84b7ca87415be7412a8624d4e350fc2aae497", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab685eb2-112b-4216-bf84-cfa2783b9b6c", "node_type": "1", "metadata": {"window": "Moving below the line, interest expense was $75 million, an increase of 7%, driven by higher short -term \nborrowings of commercial paper compared to the prior year.  The higher  short -term borrowings resulted from lower \naverage cash balances, in part due to the impact from the Change Healthcare outage.  \n \n The effective tax rate for the quarter was 28.1%, which is in line with our previous guidance and driven by a \ndiscrete tax item.   Fourth quarter diluted weighted average shares outstanding was 131.6 million, a decrease of \n5% year over year.  \n \n Wrapping up our consolidated results, earnings per diluted share was $6.18, again, in line with the implied \nearnings per diluted share that we provided on our third quarter earnings call.  While this represents a decrease of \n14% compared to the prior year, fourth quarter results were principally driven by a higher tax rate and lower \nCOVID -19 program contributions in fiscal 2024, partially offset b y a lower share count and growth in the US \nPharmaceutical segment.  \n \n Turning now to our fourth quarter segment results, which can be found on slides 7 through 11 and starting with \nUS Pharmaceutical. ", "original_text": "Fourth quarter diluted weighted average shares outstanding was 131.6 million, a decrease of \n5% year over year.  \n \n"}, "hash": "f5ffb2671b9aa75aae2113b196ff9f41a7a04489a73ae5926a74f8482cda3141", "class_name": "RelatedNodeInfo"}}, "text": "The effective tax rate for the quarter was 28.1%, which is in line with our previous guidance and driven by a \ndiscrete tax item.  ", "start_char_idx": 1989, "end_char_idx": 2120, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab685eb2-112b-4216-bf84-cfa2783b9b6c": {"__data__": {"id_": "ab685eb2-112b-4216-bf84-cfa2783b9b6c", "embedding": null, "metadata": {"window": "Moving below the line, interest expense was $75 million, an increase of 7%, driven by higher short -term \nborrowings of commercial paper compared to the prior year.  The higher  short -term borrowings resulted from lower \naverage cash balances, in part due to the impact from the Change Healthcare outage.  \n \n The effective tax rate for the quarter was 28.1%, which is in line with our previous guidance and driven by a \ndiscrete tax item.   Fourth quarter diluted weighted average shares outstanding was 131.6 million, a decrease of \n5% year over year.  \n \n Wrapping up our consolidated results, earnings per diluted share was $6.18, again, in line with the implied \nearnings per diluted share that we provided on our third quarter earnings call.  While this represents a decrease of \n14% compared to the prior year, fourth quarter results were principally driven by a higher tax rate and lower \nCOVID -19 program contributions in fiscal 2024, partially offset b y a lower share count and growth in the US \nPharmaceutical segment.  \n \n Turning now to our fourth quarter segment results, which can be found on slides 7 through 11 and starting with \nUS Pharmaceutical. ", "original_text": "Fourth quarter diluted weighted average shares outstanding was 131.6 million, a decrease of \n5% year over year.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e6912a644a9226dda45bfb3ebccc370b9d1a990f8f13bd1bffcf77b67a1c4894", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf615f13-7b72-4cd5-b5e2-d8225d8e8718", "node_type": "1", "metadata": {"window": "When adjusting for the COVID -19 programs and a modest McKesson Ven tures loss in fiscal 2023, adjusted \noperating profit increased 4% in the quarter.  \n \n Moving below the line, interest expense was $75 million, an increase of 7%, driven by higher short -term \nborrowings of commercial paper compared to the prior year.  The higher  short -term borrowings resulted from lower \naverage cash balances, in part due to the impact from the Change Healthcare outage.  \n \n The effective tax rate for the quarter was 28.1%, which is in line with our previous guidance and driven by a \ndiscrete tax item.   Fourth quarter diluted weighted average shares outstanding was 131.6 million, a decrease of \n5% year over year.  \n \n Wrapping up our consolidated results, earnings per diluted share was $6.18, again, in line with the implied \nearnings per diluted share that we provided on our third quarter earnings call.  While this represents a decrease of \n14% compared to the prior year, fourth quarter results were principally driven by a higher tax rate and lower \nCOVID -19 program contributions in fiscal 2024, partially offset b y a lower share count and growth in the US \nPharmaceutical segment.  \n \n", "original_text": "The effective tax rate for the quarter was 28.1%, which is in line with our previous guidance and driven by a \ndiscrete tax item.  ", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f2a8a6e30de1f925a86cbddd1865b71521036564aee1a662057d28db6084975f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e1aa21d-b7e9-4a6e-8a14-0daf93818fce", "node_type": "1", "metadata": {"window": "The higher  short -term borrowings resulted from lower \naverage cash balances, in part due to the impact from the Change Healthcare outage.  \n \n The effective tax rate for the quarter was 28.1%, which is in line with our previous guidance and driven by a \ndiscrete tax item.   Fourth quarter diluted weighted average shares outstanding was 131.6 million, a decrease of \n5% year over year.  \n \n Wrapping up our consolidated results, earnings per diluted share was $6.18, again, in line with the implied \nearnings per diluted share that we provided on our third quarter earnings call.  While this represents a decrease of \n14% compared to the prior year, fourth quarter results were principally driven by a higher tax rate and lower \nCOVID -19 program contributions in fiscal 2024, partially offset b y a lower share count and growth in the US \nPharmaceutical segment.  \n \n Turning now to our fourth quarter segment results, which can be found on slides 7 through 11 and starting with \nUS Pharmaceutical.  Revenues were $68.8 billion, an increase of 12%, driven by  increased prescription volumes, \nincluding higher volumes from specialty products, retail national account customers, and GLP -1 medications.  \n \n", "original_text": "Wrapping up our consolidated results, earnings per diluted share was $6.18, again, in line with the implied \nearnings per diluted share that we provided on our third quarter earnings call. "}, "hash": "9c789f61da1e7230151ef80bfba804d15aec7e9a09c028779e49b980a6931aa3", "class_name": "RelatedNodeInfo"}}, "text": "Fourth quarter diluted weighted average shares outstanding was 131.6 million, a decrease of \n5% year over year.  \n \n", "start_char_idx": 2120, "end_char_idx": 2236, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e1aa21d-b7e9-4a6e-8a14-0daf93818fce": {"__data__": {"id_": "1e1aa21d-b7e9-4a6e-8a14-0daf93818fce", "embedding": null, "metadata": {"window": "The higher  short -term borrowings resulted from lower \naverage cash balances, in part due to the impact from the Change Healthcare outage.  \n \n The effective tax rate for the quarter was 28.1%, which is in line with our previous guidance and driven by a \ndiscrete tax item.   Fourth quarter diluted weighted average shares outstanding was 131.6 million, a decrease of \n5% year over year.  \n \n Wrapping up our consolidated results, earnings per diluted share was $6.18, again, in line with the implied \nearnings per diluted share that we provided on our third quarter earnings call.  While this represents a decrease of \n14% compared to the prior year, fourth quarter results were principally driven by a higher tax rate and lower \nCOVID -19 program contributions in fiscal 2024, partially offset b y a lower share count and growth in the US \nPharmaceutical segment.  \n \n Turning now to our fourth quarter segment results, which can be found on slides 7 through 11 and starting with \nUS Pharmaceutical.  Revenues were $68.8 billion, an increase of 12%, driven by  increased prescription volumes, \nincluding higher volumes from specialty products, retail national account customers, and GLP -1 medications.  \n \n", "original_text": "Wrapping up our consolidated results, earnings per diluted share was $6.18, again, in line with the implied \nearnings per diluted share that we provided on our third quarter earnings call. ", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e6912a644a9226dda45bfb3ebccc370b9d1a990f8f13bd1bffcf77b67a1c4894", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab685eb2-112b-4216-bf84-cfa2783b9b6c", "node_type": "1", "metadata": {"window": "Moving below the line, interest expense was $75 million, an increase of 7%, driven by higher short -term \nborrowings of commercial paper compared to the prior year.  The higher  short -term borrowings resulted from lower \naverage cash balances, in part due to the impact from the Change Healthcare outage.  \n \n The effective tax rate for the quarter was 28.1%, which is in line with our previous guidance and driven by a \ndiscrete tax item.   Fourth quarter diluted weighted average shares outstanding was 131.6 million, a decrease of \n5% year over year.  \n \n Wrapping up our consolidated results, earnings per diluted share was $6.18, again, in line with the implied \nearnings per diluted share that we provided on our third quarter earnings call.  While this represents a decrease of \n14% compared to the prior year, fourth quarter results were principally driven by a higher tax rate and lower \nCOVID -19 program contributions in fiscal 2024, partially offset b y a lower share count and growth in the US \nPharmaceutical segment.  \n \n Turning now to our fourth quarter segment results, which can be found on slides 7 through 11 and starting with \nUS Pharmaceutical. ", "original_text": "Fourth quarter diluted weighted average shares outstanding was 131.6 million, a decrease of \n5% year over year.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f801e32ab7562f32028df2ebaa7abc8557a2b3fcdfc0ab9339733556d86df352", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a06cb467-ef04-4c0f-88da-7ca4f4426cab", "node_type": "1", "metadata": {"window": "The effective tax rate for the quarter was 28.1%, which is in line with our previous guidance and driven by a \ndiscrete tax item.   Fourth quarter diluted weighted average shares outstanding was 131.6 million, a decrease of \n5% year over year.  \n \n Wrapping up our consolidated results, earnings per diluted share was $6.18, again, in line with the implied \nearnings per diluted share that we provided on our third quarter earnings call.  While this represents a decrease of \n14% compared to the prior year, fourth quarter results were principally driven by a higher tax rate and lower \nCOVID -19 program contributions in fiscal 2024, partially offset b y a lower share count and growth in the US \nPharmaceutical segment.  \n \n Turning now to our fourth quarter segment results, which can be found on slides 7 through 11 and starting with \nUS Pharmaceutical.  Revenues were $68.8 billion, an increase of 12%, driven by  increased prescription volumes, \nincluding higher volumes from specialty products, retail national account customers, and GLP -1 medications.  \n \n As we have previously guided, GLP -1 medications continued to show growth year over year. ", "original_text": "While this represents a decrease of \n14% compared to the prior year, fourth quarter results were principally driven by a higher tax rate and lower \nCOVID -19 program contributions in fiscal 2024, partially offset b y a lower share count and growth in the US \nPharmaceutical segment.  \n \n"}, "hash": "1c7ec7ef145edbf47587f49296ce1eabbfb896e5170718d811987772c23faa82", "class_name": "RelatedNodeInfo"}}, "text": "Wrapping up our consolidated results, earnings per diluted share was $6.18, again, in line with the implied \nearnings per diluted share that we provided on our third quarter earnings call. ", "start_char_idx": 2236, "end_char_idx": 2425, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a06cb467-ef04-4c0f-88da-7ca4f4426cab": {"__data__": {"id_": "a06cb467-ef04-4c0f-88da-7ca4f4426cab", "embedding": null, "metadata": {"window": "The effective tax rate for the quarter was 28.1%, which is in line with our previous guidance and driven by a \ndiscrete tax item.   Fourth quarter diluted weighted average shares outstanding was 131.6 million, a decrease of \n5% year over year.  \n \n Wrapping up our consolidated results, earnings per diluted share was $6.18, again, in line with the implied \nearnings per diluted share that we provided on our third quarter earnings call.  While this represents a decrease of \n14% compared to the prior year, fourth quarter results were principally driven by a higher tax rate and lower \nCOVID -19 program contributions in fiscal 2024, partially offset b y a lower share count and growth in the US \nPharmaceutical segment.  \n \n Turning now to our fourth quarter segment results, which can be found on slides 7 through 11 and starting with \nUS Pharmaceutical.  Revenues were $68.8 billion, an increase of 12%, driven by  increased prescription volumes, \nincluding higher volumes from specialty products, retail national account customers, and GLP -1 medications.  \n \n As we have previously guided, GLP -1 medications continued to show growth year over year. ", "original_text": "While this represents a decrease of \n14% compared to the prior year, fourth quarter results were principally driven by a higher tax rate and lower \nCOVID -19 program contributions in fiscal 2024, partially offset b y a lower share count and growth in the US \nPharmaceutical segment.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e6912a644a9226dda45bfb3ebccc370b9d1a990f8f13bd1bffcf77b67a1c4894", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e1aa21d-b7e9-4a6e-8a14-0daf93818fce", "node_type": "1", "metadata": {"window": "The higher  short -term borrowings resulted from lower \naverage cash balances, in part due to the impact from the Change Healthcare outage.  \n \n The effective tax rate for the quarter was 28.1%, which is in line with our previous guidance and driven by a \ndiscrete tax item.   Fourth quarter diluted weighted average shares outstanding was 131.6 million, a decrease of \n5% year over year.  \n \n Wrapping up our consolidated results, earnings per diluted share was $6.18, again, in line with the implied \nearnings per diluted share that we provided on our third quarter earnings call.  While this represents a decrease of \n14% compared to the prior year, fourth quarter results were principally driven by a higher tax rate and lower \nCOVID -19 program contributions in fiscal 2024, partially offset b y a lower share count and growth in the US \nPharmaceutical segment.  \n \n Turning now to our fourth quarter segment results, which can be found on slides 7 through 11 and starting with \nUS Pharmaceutical.  Revenues were $68.8 billion, an increase of 12%, driven by  increased prescription volumes, \nincluding higher volumes from specialty products, retail national account customers, and GLP -1 medications.  \n \n", "original_text": "Wrapping up our consolidated results, earnings per diluted share was $6.18, again, in line with the implied \nearnings per diluted share that we provided on our third quarter earnings call. ", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "9c15dd580067371ab459bf23f2f62397927f5d1e72f4757ebc594ce14fec55e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b13e28a-8c2f-4b0b-ba42-3d3fec236d85", "node_type": "1", "metadata": {"window": "Fourth quarter diluted weighted average shares outstanding was 131.6 million, a decrease of \n5% year over year.  \n \n Wrapping up our consolidated results, earnings per diluted share was $6.18, again, in line with the implied \nearnings per diluted share that we provided on our third quarter earnings call.  While this represents a decrease of \n14% compared to the prior year, fourth quarter results were principally driven by a higher tax rate and lower \nCOVID -19 program contributions in fiscal 2024, partially offset b y a lower share count and growth in the US \nPharmaceutical segment.  \n \n Turning now to our fourth quarter segment results, which can be found on slides 7 through 11 and starting with \nUS Pharmaceutical.  Revenues were $68.8 billion, an increase of 12%, driven by  increased prescription volumes, \nincluding higher volumes from specialty products, retail national account customers, and GLP -1 medications.  \n \n As we have previously guided, GLP -1 medications continued to show growth year over year.  But despite this \nincrease, the rate of growth continues to moderate. ", "original_text": "Turning now to our fourth quarter segment results, which can be found on slides 7 through 11 and starting with \nUS Pharmaceutical. "}, "hash": "d709fbf31734511a2b66009d7d32fda6dea26edd79de66cc115f44419b25ab50", "class_name": "RelatedNodeInfo"}}, "text": "While this represents a decrease of \n14% compared to the prior year, fourth quarter results were principally driven by a higher tax rate and lower \nCOVID -19 program contributions in fiscal 2024, partially offset b y a lower share count and growth in the US \nPharmaceutical segment.  \n \n", "start_char_idx": 2425, "end_char_idx": 2712, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b13e28a-8c2f-4b0b-ba42-3d3fec236d85": {"__data__": {"id_": "6b13e28a-8c2f-4b0b-ba42-3d3fec236d85", "embedding": null, "metadata": {"window": "Fourth quarter diluted weighted average shares outstanding was 131.6 million, a decrease of \n5% year over year.  \n \n Wrapping up our consolidated results, earnings per diluted share was $6.18, again, in line with the implied \nearnings per diluted share that we provided on our third quarter earnings call.  While this represents a decrease of \n14% compared to the prior year, fourth quarter results were principally driven by a higher tax rate and lower \nCOVID -19 program contributions in fiscal 2024, partially offset b y a lower share count and growth in the US \nPharmaceutical segment.  \n \n Turning now to our fourth quarter segment results, which can be found on slides 7 through 11 and starting with \nUS Pharmaceutical.  Revenues were $68.8 billion, an increase of 12%, driven by  increased prescription volumes, \nincluding higher volumes from specialty products, retail national account customers, and GLP -1 medications.  \n \n As we have previously guided, GLP -1 medications continued to show growth year over year.  But despite this \nincrease, the rate of growth continues to moderate. ", "original_text": "Turning now to our fourth quarter segment results, which can be found on slides 7 through 11 and starting with \nUS Pharmaceutical. ", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e6912a644a9226dda45bfb3ebccc370b9d1a990f8f13bd1bffcf77b67a1c4894", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a06cb467-ef04-4c0f-88da-7ca4f4426cab", "node_type": "1", "metadata": {"window": "The effective tax rate for the quarter was 28.1%, which is in line with our previous guidance and driven by a \ndiscrete tax item.   Fourth quarter diluted weighted average shares outstanding was 131.6 million, a decrease of \n5% year over year.  \n \n Wrapping up our consolidated results, earnings per diluted share was $6.18, again, in line with the implied \nearnings per diluted share that we provided on our third quarter earnings call.  While this represents a decrease of \n14% compared to the prior year, fourth quarter results were principally driven by a higher tax rate and lower \nCOVID -19 program contributions in fiscal 2024, partially offset b y a lower share count and growth in the US \nPharmaceutical segment.  \n \n Turning now to our fourth quarter segment results, which can be found on slides 7 through 11 and starting with \nUS Pharmaceutical.  Revenues were $68.8 billion, an increase of 12%, driven by  increased prescription volumes, \nincluding higher volumes from specialty products, retail national account customers, and GLP -1 medications.  \n \n As we have previously guided, GLP -1 medications continued to show growth year over year. ", "original_text": "While this represents a decrease of \n14% compared to the prior year, fourth quarter results were principally driven by a higher tax rate and lower \nCOVID -19 program contributions in fiscal 2024, partially offset b y a lower share count and growth in the US \nPharmaceutical segment.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f8e9e4dfa20bb7197602599b0d76cff03741bda9b1dd4798cc4191a91794789c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7782c9e-5af3-4fd3-ac45-311c046c4f68", "node_type": "1", "metadata": {"window": "Wrapping up our consolidated results, earnings per diluted share was $6.18, again, in line with the implied \nearnings per diluted share that we provided on our third quarter earnings call.  While this represents a decrease of \n14% compared to the prior year, fourth quarter results were principally driven by a higher tax rate and lower \nCOVID -19 program contributions in fiscal 2024, partially offset b y a lower share count and growth in the US \nPharmaceutical segment.  \n \n Turning now to our fourth quarter segment results, which can be found on slides 7 through 11 and starting with \nUS Pharmaceutical.  Revenues were $68.8 billion, an increase of 12%, driven by  increased prescription volumes, \nincluding higher volumes from specialty products, retail national account customers, and GLP -1 medications.  \n \n As we have previously guided, GLP -1 medications continued to show growth year over year.  But despite this \nincrease, the rate of growth continues to moderate.  In the quarter, GLP -1 revenues were $7.5 billion, an increase \nof approximately $1.5 billion or 24% compared to fiscal 2023. ", "original_text": "Revenues were $68.8 billion, an increase of 12%, driven by  increased prescription volumes, \nincluding higher volumes from specialty products, retail national account customers, and GLP -1 medications.  \n \n"}, "hash": "858c14b5e0bcc0c475584ec19f9db874e6a8fe8fc4887e16dff181a50f74e609", "class_name": "RelatedNodeInfo"}}, "text": "Turning now to our fourth quarter segment results, which can be found on slides 7 through 11 and starting with \nUS Pharmaceutical. ", "start_char_idx": 2712, "end_char_idx": 2843, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7782c9e-5af3-4fd3-ac45-311c046c4f68": {"__data__": {"id_": "b7782c9e-5af3-4fd3-ac45-311c046c4f68", "embedding": null, "metadata": {"window": "Wrapping up our consolidated results, earnings per diluted share was $6.18, again, in line with the implied \nearnings per diluted share that we provided on our third quarter earnings call.  While this represents a decrease of \n14% compared to the prior year, fourth quarter results were principally driven by a higher tax rate and lower \nCOVID -19 program contributions in fiscal 2024, partially offset b y a lower share count and growth in the US \nPharmaceutical segment.  \n \n Turning now to our fourth quarter segment results, which can be found on slides 7 through 11 and starting with \nUS Pharmaceutical.  Revenues were $68.8 billion, an increase of 12%, driven by  increased prescription volumes, \nincluding higher volumes from specialty products, retail national account customers, and GLP -1 medications.  \n \n As we have previously guided, GLP -1 medications continued to show growth year over year.  But despite this \nincrease, the rate of growth continues to moderate.  In the quarter, GLP -1 revenues were $7.5 billion, an increase \nof approximately $1.5 billion or 24% compared to fiscal 2023. ", "original_text": "Revenues were $68.8 billion, an increase of 12%, driven by  increased prescription volumes, \nincluding higher volumes from specialty products, retail national account customers, and GLP -1 medications.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e6912a644a9226dda45bfb3ebccc370b9d1a990f8f13bd1bffcf77b67a1c4894", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b13e28a-8c2f-4b0b-ba42-3d3fec236d85", "node_type": "1", "metadata": {"window": "Fourth quarter diluted weighted average shares outstanding was 131.6 million, a decrease of \n5% year over year.  \n \n Wrapping up our consolidated results, earnings per diluted share was $6.18, again, in line with the implied \nearnings per diluted share that we provided on our third quarter earnings call.  While this represents a decrease of \n14% compared to the prior year, fourth quarter results were principally driven by a higher tax rate and lower \nCOVID -19 program contributions in fiscal 2024, partially offset b y a lower share count and growth in the US \nPharmaceutical segment.  \n \n Turning now to our fourth quarter segment results, which can be found on slides 7 through 11 and starting with \nUS Pharmaceutical.  Revenues were $68.8 billion, an increase of 12%, driven by  increased prescription volumes, \nincluding higher volumes from specialty products, retail national account customers, and GLP -1 medications.  \n \n As we have previously guided, GLP -1 medications continued to show growth year over year.  But despite this \nincrease, the rate of growth continues to moderate. ", "original_text": "Turning now to our fourth quarter segment results, which can be found on slides 7 through 11 and starting with \nUS Pharmaceutical. ", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "bd56500f971a9f8e98ee9f1ee5f7f714abec16650f1db89b22976117db1a660f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0842ba64-f75e-4112-a5e2-0b56ac0b2261", "node_type": "1", "metadata": {"window": "While this represents a decrease of \n14% compared to the prior year, fourth quarter results were principally driven by a higher tax rate and lower \nCOVID -19 program contributions in fiscal 2024, partially offset b y a lower share count and growth in the US \nPharmaceutical segment.  \n \n Turning now to our fourth quarter segment results, which can be found on slides 7 through 11 and starting with \nUS Pharmaceutical.  Revenues were $68.8 billion, an increase of 12%, driven by  increased prescription volumes, \nincluding higher volumes from specialty products, retail national account customers, and GLP -1 medications.  \n \n As we have previously guided, GLP -1 medications continued to show growth year over year.  But despite this \nincrease, the rate of growth continues to moderate.  In the quarter, GLP -1 revenues were $7.5 billion, an increase \nof approximately $1.5 billion or 24% compared to fiscal 2023.  However, GLP -1 revenues were flat on a sequential \nbasis.  \n \n", "original_text": "As we have previously guided, GLP -1 medications continued to show growth year over year. "}, "hash": "80bdf274f8cf4668895db44d80e1b3b635171b24148a236481801039ffeb22a2", "class_name": "RelatedNodeInfo"}}, "text": "Revenues were $68.8 billion, an increase of 12%, driven by  increased prescription volumes, \nincluding higher volumes from specialty products, retail national account customers, and GLP -1 medications.  \n \n", "start_char_idx": 2843, "end_char_idx": 3049, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0842ba64-f75e-4112-a5e2-0b56ac0b2261": {"__data__": {"id_": "0842ba64-f75e-4112-a5e2-0b56ac0b2261", "embedding": null, "metadata": {"window": "While this represents a decrease of \n14% compared to the prior year, fourth quarter results were principally driven by a higher tax rate and lower \nCOVID -19 program contributions in fiscal 2024, partially offset b y a lower share count and growth in the US \nPharmaceutical segment.  \n \n Turning now to our fourth quarter segment results, which can be found on slides 7 through 11 and starting with \nUS Pharmaceutical.  Revenues were $68.8 billion, an increase of 12%, driven by  increased prescription volumes, \nincluding higher volumes from specialty products, retail national account customers, and GLP -1 medications.  \n \n As we have previously guided, GLP -1 medications continued to show growth year over year.  But despite this \nincrease, the rate of growth continues to moderate.  In the quarter, GLP -1 revenues were $7.5 billion, an increase \nof approximately $1.5 billion or 24% compared to fiscal 2023.  However, GLP -1 revenues were flat on a sequential \nbasis.  \n \n", "original_text": "As we have previously guided, GLP -1 medications continued to show growth year over year. ", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e6912a644a9226dda45bfb3ebccc370b9d1a990f8f13bd1bffcf77b67a1c4894", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7782c9e-5af3-4fd3-ac45-311c046c4f68", "node_type": "1", "metadata": {"window": "Wrapping up our consolidated results, earnings per diluted share was $6.18, again, in line with the implied \nearnings per diluted share that we provided on our third quarter earnings call.  While this represents a decrease of \n14% compared to the prior year, fourth quarter results were principally driven by a higher tax rate and lower \nCOVID -19 program contributions in fiscal 2024, partially offset b y a lower share count and growth in the US \nPharmaceutical segment.  \n \n Turning now to our fourth quarter segment results, which can be found on slides 7 through 11 and starting with \nUS Pharmaceutical.  Revenues were $68.8 billion, an increase of 12%, driven by  increased prescription volumes, \nincluding higher volumes from specialty products, retail national account customers, and GLP -1 medications.  \n \n As we have previously guided, GLP -1 medications continued to show growth year over year.  But despite this \nincrease, the rate of growth continues to moderate.  In the quarter, GLP -1 revenues were $7.5 billion, an increase \nof approximately $1.5 billion or 24% compared to fiscal 2023. ", "original_text": "Revenues were $68.8 billion, an increase of 12%, driven by  increased prescription volumes, \nincluding higher volumes from specialty products, retail national account customers, and GLP -1 medications.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c2fccddf9086ad7596d7fceb0066901276698fe4e2959ab6034a06a9aab09a51", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f47e8d8b-d2b7-4951-98e9-9e785b20aff5", "node_type": "1", "metadata": {"window": "Turning now to our fourth quarter segment results, which can be found on slides 7 through 11 and starting with \nUS Pharmaceutical.  Revenues were $68.8 billion, an increase of 12%, driven by  increased prescription volumes, \nincluding higher volumes from specialty products, retail national account customers, and GLP -1 medications.  \n \n As we have previously guided, GLP -1 medications continued to show growth year over year.  But despite this \nincrease, the rate of growth continues to moderate.  In the quarter, GLP -1 revenues were $7.5 billion, an increase \nof approximately $1.5 billion or 24% compared to fiscal 2023.  However, GLP -1 revenues were flat on a sequential \nbasis.  \n \n For the quarter, opera ting profit increased 5% to $901 million, driven by growth in the distribution of specialty \nproducts to providers and health systems and increased contributions from our generics program. ", "original_text": "But despite this \nincrease, the rate of growth continues to moderate. "}, "hash": "455f0a9881ef8d97bd2fc9fe5f3544224da3c2711b8e7db39befb160d576544e", "class_name": "RelatedNodeInfo"}}, "text": "As we have previously guided, GLP -1 medications continued to show growth year over year. ", "start_char_idx": 3049, "end_char_idx": 3139, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f47e8d8b-d2b7-4951-98e9-9e785b20aff5": {"__data__": {"id_": "f47e8d8b-d2b7-4951-98e9-9e785b20aff5", "embedding": null, "metadata": {"window": "Turning now to our fourth quarter segment results, which can be found on slides 7 through 11 and starting with \nUS Pharmaceutical.  Revenues were $68.8 billion, an increase of 12%, driven by  increased prescription volumes, \nincluding higher volumes from specialty products, retail national account customers, and GLP -1 medications.  \n \n As we have previously guided, GLP -1 medications continued to show growth year over year.  But despite this \nincrease, the rate of growth continues to moderate.  In the quarter, GLP -1 revenues were $7.5 billion, an increase \nof approximately $1.5 billion or 24% compared to fiscal 2023.  However, GLP -1 revenues were flat on a sequential \nbasis.  \n \n For the quarter, opera ting profit increased 5% to $901 million, driven by growth in the distribution of specialty \nproducts to providers and health systems and increased contributions from our generics program. ", "original_text": "But despite this \nincrease, the rate of growth continues to moderate. ", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e6912a644a9226dda45bfb3ebccc370b9d1a990f8f13bd1bffcf77b67a1c4894", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0842ba64-f75e-4112-a5e2-0b56ac0b2261", "node_type": "1", "metadata": {"window": "While this represents a decrease of \n14% compared to the prior year, fourth quarter results were principally driven by a higher tax rate and lower \nCOVID -19 program contributions in fiscal 2024, partially offset b y a lower share count and growth in the US \nPharmaceutical segment.  \n \n Turning now to our fourth quarter segment results, which can be found on slides 7 through 11 and starting with \nUS Pharmaceutical.  Revenues were $68.8 billion, an increase of 12%, driven by  increased prescription volumes, \nincluding higher volumes from specialty products, retail national account customers, and GLP -1 medications.  \n \n As we have previously guided, GLP -1 medications continued to show growth year over year.  But despite this \nincrease, the rate of growth continues to moderate.  In the quarter, GLP -1 revenues were $7.5 billion, an increase \nof approximately $1.5 billion or 24% compared to fiscal 2023.  However, GLP -1 revenues were flat on a sequential \nbasis.  \n \n", "original_text": "As we have previously guided, GLP -1 medications continued to show growth year over year. ", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "31ca3c29a840e58c4839b6c4c8b81270ed144c032b2a9f876ceb8676406dfb4b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "896f0cc5-23e9-466b-80c4-d14900911c43", "node_type": "1", "metadata": {"window": "Revenues were $68.8 billion, an increase of 12%, driven by  increased prescription volumes, \nincluding higher volumes from specialty products, retail national account customers, and GLP -1 medications.  \n \n As we have previously guided, GLP -1 medications continued to show growth year over year.  But despite this \nincrease, the rate of growth continues to moderate.  In the quarter, GLP -1 revenues were $7.5 billion, an increase \nof approximately $1.5 billion or 24% compared to fiscal 2023.  However, GLP -1 revenues were flat on a sequential \nbasis.  \n \n For the quarter, opera ting profit increased 5% to $901 million, driven by growth in the distribution of specialty \nproducts to providers and health systems and increased contributions from our generics program.  The breadth of \ncapabilities and assets continued to deliver robust v alue to our stakeholders.  \n \n", "original_text": "In the quarter, GLP -1 revenues were $7.5 billion, an increase \nof approximately $1.5 billion or 24% compared to fiscal 2023. "}, "hash": "09c1e64c54bdc13dabc2a58f0e157cd7120499dc7e53159f0463b782a12aa63c", "class_name": "RelatedNodeInfo"}}, "text": "But despite this \nincrease, the rate of growth continues to moderate. ", "start_char_idx": 3139, "end_char_idx": 3209, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "896f0cc5-23e9-466b-80c4-d14900911c43": {"__data__": {"id_": "896f0cc5-23e9-466b-80c4-d14900911c43", "embedding": null, "metadata": {"window": "Revenues were $68.8 billion, an increase of 12%, driven by  increased prescription volumes, \nincluding higher volumes from specialty products, retail national account customers, and GLP -1 medications.  \n \n As we have previously guided, GLP -1 medications continued to show growth year over year.  But despite this \nincrease, the rate of growth continues to moderate.  In the quarter, GLP -1 revenues were $7.5 billion, an increase \nof approximately $1.5 billion or 24% compared to fiscal 2023.  However, GLP -1 revenues were flat on a sequential \nbasis.  \n \n For the quarter, opera ting profit increased 5% to $901 million, driven by growth in the distribution of specialty \nproducts to providers and health systems and increased contributions from our generics program.  The breadth of \ncapabilities and assets continued to deliver robust v alue to our stakeholders.  \n \n", "original_text": "In the quarter, GLP -1 revenues were $7.5 billion, an increase \nof approximately $1.5 billion or 24% compared to fiscal 2023. ", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e6912a644a9226dda45bfb3ebccc370b9d1a990f8f13bd1bffcf77b67a1c4894", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f47e8d8b-d2b7-4951-98e9-9e785b20aff5", "node_type": "1", "metadata": {"window": "Turning now to our fourth quarter segment results, which can be found on slides 7 through 11 and starting with \nUS Pharmaceutical.  Revenues were $68.8 billion, an increase of 12%, driven by  increased prescription volumes, \nincluding higher volumes from specialty products, retail national account customers, and GLP -1 medications.  \n \n As we have previously guided, GLP -1 medications continued to show growth year over year.  But despite this \nincrease, the rate of growth continues to moderate.  In the quarter, GLP -1 revenues were $7.5 billion, an increase \nof approximately $1.5 billion or 24% compared to fiscal 2023.  However, GLP -1 revenues were flat on a sequential \nbasis.  \n \n For the quarter, opera ting profit increased 5% to $901 million, driven by growth in the distribution of specialty \nproducts to providers and health systems and increased contributions from our generics program. ", "original_text": "But despite this \nincrease, the rate of growth continues to moderate. ", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "b603c08024a33dfd19f1a6d0a81a0923bd79670253ae60c478fa97480ef40e8d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f3a7c40-62cb-42c3-bfe1-6d37a51c5b47", "node_type": "1", "metadata": {"window": "As we have previously guided, GLP -1 medications continued to show growth year over year.  But despite this \nincrease, the rate of growth continues to moderate.  In the quarter, GLP -1 revenues were $7.5 billion, an increase \nof approximately $1.5 billion or 24% compared to fiscal 2023.  However, GLP -1 revenues were flat on a sequential \nbasis.  \n \n For the quarter, opera ting profit increased 5% to $901 million, driven by growth in the distribution of specialty \nproducts to providers and health systems and increased contributions from our generics program.  The breadth of \ncapabilities and assets continued to deliver robust v alue to our stakeholders.  \n \n In our Prescription Technology Solutions segment, revenues were $1.2 billion, which were flat to the prior year. \n", "original_text": "However, GLP -1 revenues were flat on a sequential \nbasis.  \n \n"}, "hash": "b3f11d697a8300f0e4681a786b12972db047e1fd5add9a75933f956526fe31fd", "class_name": "RelatedNodeInfo"}}, "text": "In the quarter, GLP -1 revenues were $7.5 billion, an increase \nof approximately $1.5 billion or 24% compared to fiscal 2023. ", "start_char_idx": 3209, "end_char_idx": 3335, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f3a7c40-62cb-42c3-bfe1-6d37a51c5b47": {"__data__": {"id_": "4f3a7c40-62cb-42c3-bfe1-6d37a51c5b47", "embedding": null, "metadata": {"window": "As we have previously guided, GLP -1 medications continued to show growth year over year.  But despite this \nincrease, the rate of growth continues to moderate.  In the quarter, GLP -1 revenues were $7.5 billion, an increase \nof approximately $1.5 billion or 24% compared to fiscal 2023.  However, GLP -1 revenues were flat on a sequential \nbasis.  \n \n For the quarter, opera ting profit increased 5% to $901 million, driven by growth in the distribution of specialty \nproducts to providers and health systems and increased contributions from our generics program.  The breadth of \ncapabilities and assets continued to deliver robust v alue to our stakeholders.  \n \n In our Prescription Technology Solutions segment, revenues were $1.2 billion, which were flat to the prior year. \n", "original_text": "However, GLP -1 revenues were flat on a sequential \nbasis.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e6912a644a9226dda45bfb3ebccc370b9d1a990f8f13bd1bffcf77b67a1c4894", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "896f0cc5-23e9-466b-80c4-d14900911c43", "node_type": "1", "metadata": {"window": "Revenues were $68.8 billion, an increase of 12%, driven by  increased prescription volumes, \nincluding higher volumes from specialty products, retail national account customers, and GLP -1 medications.  \n \n As we have previously guided, GLP -1 medications continued to show growth year over year.  But despite this \nincrease, the rate of growth continues to moderate.  In the quarter, GLP -1 revenues were $7.5 billion, an increase \nof approximately $1.5 billion or 24% compared to fiscal 2023.  However, GLP -1 revenues were flat on a sequential \nbasis.  \n \n For the quarter, opera ting profit increased 5% to $901 million, driven by growth in the distribution of specialty \nproducts to providers and health systems and increased contributions from our generics program.  The breadth of \ncapabilities and assets continued to deliver robust v alue to our stakeholders.  \n \n", "original_text": "In the quarter, GLP -1 revenues were $7.5 billion, an increase \nof approximately $1.5 billion or 24% compared to fiscal 2023. ", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "482af49dd591e09b92d69e0f7f4a174492ba3700b1f24c6fc2da442bb9996c9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e6939a9-ad83-4987-a232-0437c58d146e", "node_type": "1", "metadata": {"window": "But despite this \nincrease, the rate of growth continues to moderate.  In the quarter, GLP -1 revenues were $7.5 billion, an increase \nof approximately $1.5 billion or 24% compared to fiscal 2023.  However, GLP -1 revenues were flat on a sequential \nbasis.  \n \n For the quarter, opera ting profit increased 5% to $901 million, driven by growth in the distribution of specialty \nproducts to providers and health systems and increased contributions from our generics program.  The breadth of \ncapabilities and assets continued to deliver robust v alue to our stakeholders.  \n \n In our Prescription Technology Solutions segment, revenues were $1.2 billion, which were flat to the prior year. \n Lower contributions from the third -party logistics business were offset by growth across our technology services \nproducts and primarily our access solutions.  ", "original_text": "For the quarter, opera ting profit increased 5% to $901 million, driven by growth in the distribution of specialty \nproducts to providers and health systems and increased contributions from our generics program. "}, "hash": "0ad5122c9b766a91bc3085ef68ed8d27c35b877d18586dc05b91441248844ebc", "class_name": "RelatedNodeInfo"}}, "text": "However, GLP -1 revenues were flat on a sequential \nbasis.  \n \n", "start_char_idx": 3335, "end_char_idx": 3398, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e6939a9-ad83-4987-a232-0437c58d146e": {"__data__": {"id_": "7e6939a9-ad83-4987-a232-0437c58d146e", "embedding": null, "metadata": {"window": "But despite this \nincrease, the rate of growth continues to moderate.  In the quarter, GLP -1 revenues were $7.5 billion, an increase \nof approximately $1.5 billion or 24% compared to fiscal 2023.  However, GLP -1 revenues were flat on a sequential \nbasis.  \n \n For the quarter, opera ting profit increased 5% to $901 million, driven by growth in the distribution of specialty \nproducts to providers and health systems and increased contributions from our generics program.  The breadth of \ncapabilities and assets continued to deliver robust v alue to our stakeholders.  \n \n In our Prescription Technology Solutions segment, revenues were $1.2 billion, which were flat to the prior year. \n Lower contributions from the third -party logistics business were offset by growth across our technology services \nproducts and primarily our access solutions.  ", "original_text": "For the quarter, opera ting profit increased 5% to $901 million, driven by growth in the distribution of specialty \nproducts to providers and health systems and increased contributions from our generics program. ", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e6912a644a9226dda45bfb3ebccc370b9d1a990f8f13bd1bffcf77b67a1c4894", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f3a7c40-62cb-42c3-bfe1-6d37a51c5b47", "node_type": "1", "metadata": {"window": "As we have previously guided, GLP -1 medications continued to show growth year over year.  But despite this \nincrease, the rate of growth continues to moderate.  In the quarter, GLP -1 revenues were $7.5 billion, an increase \nof approximately $1.5 billion or 24% compared to fiscal 2023.  However, GLP -1 revenues were flat on a sequential \nbasis.  \n \n For the quarter, opera ting profit increased 5% to $901 million, driven by growth in the distribution of specialty \nproducts to providers and health systems and increased contributions from our generics program.  The breadth of \ncapabilities and assets continued to deliver robust v alue to our stakeholders.  \n \n In our Prescription Technology Solutions segment, revenues were $1.2 billion, which were flat to the prior year. \n", "original_text": "However, GLP -1 revenues were flat on a sequential \nbasis.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "0c001b81dc3897fb39c072d59404cf564b5e45c5522d023a394df8bee01b46f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6614de2f-e6ef-4b89-9fa1-985b64d3c424", "node_type": "1", "metadata": {"window": "In the quarter, GLP -1 revenues were $7.5 billion, an increase \nof approximately $1.5 billion or 24% compared to fiscal 2023.  However, GLP -1 revenues were flat on a sequential \nbasis.  \n \n For the quarter, opera ting profit increased 5% to $901 million, driven by growth in the distribution of specialty \nproducts to providers and health systems and increased contributions from our generics program.  The breadth of \ncapabilities and assets continued to deliver robust v alue to our stakeholders.  \n \n In our Prescription Technology Solutions segment, revenues were $1.2 billion, which were flat to the prior year. \n Lower contributions from the third -party logistics business were offset by growth across our technology services \nproducts and primarily our access solutions.  ", "original_text": "The breadth of \ncapabilities and assets continued to deliver robust v alue to our stakeholders.  \n \n"}, "hash": "01114272416435d66488891b4bd421aae76b016f6e08405e0d5aa4ca8076a1f0", "class_name": "RelatedNodeInfo"}}, "text": "For the quarter, opera ting profit increased 5% to $901 million, driven by growth in the distribution of specialty \nproducts to providers and health systems and increased contributions from our generics program. ", "start_char_idx": 3398, "end_char_idx": 3610, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6614de2f-e6ef-4b89-9fa1-985b64d3c424": {"__data__": {"id_": "6614de2f-e6ef-4b89-9fa1-985b64d3c424", "embedding": null, "metadata": {"window": "In the quarter, GLP -1 revenues were $7.5 billion, an increase \nof approximately $1.5 billion or 24% compared to fiscal 2023.  However, GLP -1 revenues were flat on a sequential \nbasis.  \n \n For the quarter, opera ting profit increased 5% to $901 million, driven by growth in the distribution of specialty \nproducts to providers and health systems and increased contributions from our generics program.  The breadth of \ncapabilities and assets continued to deliver robust v alue to our stakeholders.  \n \n In our Prescription Technology Solutions segment, revenues were $1.2 billion, which were flat to the prior year. \n Lower contributions from the third -party logistics business were offset by growth across our technology services \nproducts and primarily our access solutions.  ", "original_text": "The breadth of \ncapabilities and assets continued to deliver robust v alue to our stakeholders.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e6912a644a9226dda45bfb3ebccc370b9d1a990f8f13bd1bffcf77b67a1c4894", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e6939a9-ad83-4987-a232-0437c58d146e", "node_type": "1", "metadata": {"window": "But despite this \nincrease, the rate of growth continues to moderate.  In the quarter, GLP -1 revenues were $7.5 billion, an increase \nof approximately $1.5 billion or 24% compared to fiscal 2023.  However, GLP -1 revenues were flat on a sequential \nbasis.  \n \n For the quarter, opera ting profit increased 5% to $901 million, driven by growth in the distribution of specialty \nproducts to providers and health systems and increased contributions from our generics program.  The breadth of \ncapabilities and assets continued to deliver robust v alue to our stakeholders.  \n \n In our Prescription Technology Solutions segment, revenues were $1.2 billion, which were flat to the prior year. \n Lower contributions from the third -party logistics business were offset by growth across our technology services \nproducts and primarily our access solutions.  ", "original_text": "For the quarter, opera ting profit increased 5% to $901 million, driven by growth in the distribution of specialty \nproducts to providers and health systems and increased contributions from our generics program. ", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "7adc813fd41fa7e7bb653940558cbbdc527cca8af33109eac5832bd8308a2eef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9ae0397-0f32-43ef-9ad9-b4abf334528e", "node_type": "1", "metadata": {"window": "However, GLP -1 revenues were flat on a sequential \nbasis.  \n \n For the quarter, opera ting profit increased 5% to $901 million, driven by growth in the distribution of specialty \nproducts to providers and health systems and increased contributions from our generics program.  The breadth of \ncapabilities and assets continued to deliver robust v alue to our stakeholders.  \n \n In our Prescription Technology Solutions segment, revenues were $1.2 billion, which were flat to the prior year. \n Lower contributions from the third -party logistics business were offset by growth across our technology services \nproducts and primarily our access solutions.  ", "original_text": "In our Prescription Technology Solutions segment, revenues were $1.2 billion, which were flat to the prior year. \n"}, "hash": "fb8b378358452b52b9ea00d5704a169b64fe5fc34e9bef1075006778803c9b03", "class_name": "RelatedNodeInfo"}}, "text": "The breadth of \ncapabilities and assets continued to deliver robust v alue to our stakeholders.  \n \n", "start_char_idx": 3610, "end_char_idx": 3710, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9ae0397-0f32-43ef-9ad9-b4abf334528e": {"__data__": {"id_": "b9ae0397-0f32-43ef-9ad9-b4abf334528e", "embedding": null, "metadata": {"window": "However, GLP -1 revenues were flat on a sequential \nbasis.  \n \n For the quarter, opera ting profit increased 5% to $901 million, driven by growth in the distribution of specialty \nproducts to providers and health systems and increased contributions from our generics program.  The breadth of \ncapabilities and assets continued to deliver robust v alue to our stakeholders.  \n \n In our Prescription Technology Solutions segment, revenues were $1.2 billion, which were flat to the prior year. \n Lower contributions from the third -party logistics business were offset by growth across our technology services \nproducts and primarily our access solutions.  ", "original_text": "In our Prescription Technology Solutions segment, revenues were $1.2 billion, which were flat to the prior year. \n", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e6912a644a9226dda45bfb3ebccc370b9d1a990f8f13bd1bffcf77b67a1c4894", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6614de2f-e6ef-4b89-9fa1-985b64d3c424", "node_type": "1", "metadata": {"window": "In the quarter, GLP -1 revenues were $7.5 billion, an increase \nof approximately $1.5 billion or 24% compared to fiscal 2023.  However, GLP -1 revenues were flat on a sequential \nbasis.  \n \n For the quarter, opera ting profit increased 5% to $901 million, driven by growth in the distribution of specialty \nproducts to providers and health systems and increased contributions from our generics program.  The breadth of \ncapabilities and assets continued to deliver robust v alue to our stakeholders.  \n \n In our Prescription Technology Solutions segment, revenues were $1.2 billion, which were flat to the prior year. \n Lower contributions from the third -party logistics business were offset by growth across our technology services \nproducts and primarily our access solutions.  ", "original_text": "The breadth of \ncapabilities and assets continued to deliver robust v alue to our stakeholders.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d776acf574489397db74898aa4f9e1c3032e3e72b74cc5561f18e82bbff64272", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "485f756e-de49-4a78-add2-bf1cbcf9a3e5", "node_type": "1", "metadata": {"window": "For the quarter, opera ting profit increased 5% to $901 million, driven by growth in the distribution of specialty \nproducts to providers and health systems and increased contributions from our generics program.  The breadth of \ncapabilities and assets continued to deliver robust v alue to our stakeholders.  \n \n In our Prescription Technology Solutions segment, revenues were $1.2 billion, which were flat to the prior year. \n Lower contributions from the third -party logistics business were offset by growth across our technology services \nproducts and primarily our access solutions.  ", "original_text": "Lower contributions from the third -party logistics business were offset by growth across our technology services \nproducts and primarily our access solutions.  "}, "hash": "1f15fed1e3a63f1e1856bed9629db29cb1c36ac600817d9f64a83fafed4339f6", "class_name": "RelatedNodeInfo"}}, "text": "In our Prescription Technology Solutions segment, revenues were $1.2 billion, which were flat to the prior year. \n", "start_char_idx": 3710, "end_char_idx": 3824, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "485f756e-de49-4a78-add2-bf1cbcf9a3e5": {"__data__": {"id_": "485f756e-de49-4a78-add2-bf1cbcf9a3e5", "embedding": null, "metadata": {"window": "For the quarter, opera ting profit increased 5% to $901 million, driven by growth in the distribution of specialty \nproducts to providers and health systems and increased contributions from our generics program.  The breadth of \ncapabilities and assets continued to deliver robust v alue to our stakeholders.  \n \n In our Prescription Technology Solutions segment, revenues were $1.2 billion, which were flat to the prior year. \n Lower contributions from the third -party logistics business were offset by growth across our technology services \nproducts and primarily our access solutions.  ", "original_text": "Lower contributions from the third -party logistics business were offset by growth across our technology services \nproducts and primarily our access solutions.  ", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e6912a644a9226dda45bfb3ebccc370b9d1a990f8f13bd1bffcf77b67a1c4894", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9ae0397-0f32-43ef-9ad9-b4abf334528e", "node_type": "1", "metadata": {"window": "However, GLP -1 revenues were flat on a sequential \nbasis.  \n \n For the quarter, opera ting profit increased 5% to $901 million, driven by growth in the distribution of specialty \nproducts to providers and health systems and increased contributions from our generics program.  The breadth of \ncapabilities and assets continued to deliver robust v alue to our stakeholders.  \n \n In our Prescription Technology Solutions segment, revenues were $1.2 billion, which were flat to the prior year. \n Lower contributions from the third -party logistics business were offset by growth across our technology services \nproducts and primarily our access solutions.  ", "original_text": "In our Prescription Technology Solutions segment, revenues were $1.2 billion, which were flat to the prior year. \n", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "b5e78a0ff1da226f64e8afa9352f99b18437e3cf46d1ffba5189d8e53d795ba6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c44a06c-8ee9-48f3-a4a6-9d41e51c5c1e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nWithin this segment, CoverMyMeds continues to deliver value for our partners by increasing connectivity between \npharmacies, providers, payers, and biopharma manufacturers through next -generation access, affordabil ity, and \nadherence solutions that are automated and integrated into provider workflows.  \n \n Results in the fourth quarter reflect organic growth across our access solutions, including prior authorization \nservices, as we extended existing partnerships with bio pharma manufacturers.  In addition to the strength of our \naccess solutions, year -over-year performance was also supported by higher volumes across our affordability \nsolutions.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "03ecb0b62da4cff55b03e944cc1120e40fde0ff6df3c376f7366c38b1f177e24", "class_name": "RelatedNodeInfo"}}, "text": "Lower contributions from the third -party logistics business were offset by growth across our technology services \nproducts and primarily our access solutions.  ", "start_char_idx": 3824, "end_char_idx": 3985, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c44a06c-8ee9-48f3-a4a6-9d41e51c5c1e": {"__data__": {"id_": "4c44a06c-8ee9-48f3-a4a6-9d41e51c5c1e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nWithin this segment, CoverMyMeds continues to deliver value for our partners by increasing connectivity between \npharmacies, providers, payers, and biopharma manufacturers through next -generation access, affordabil ity, and \nadherence solutions that are automated and integrated into provider workflows.  \n \n Results in the fourth quarter reflect organic growth across our access solutions, including prior authorization \nservices, as we extended existing partnerships with bio pharma manufacturers.  In addition to the strength of our \naccess solutions, year -over-year performance was also supported by higher volumes across our affordability \nsolutions.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3868fd7f528170285cbc98e0690577279603138755dc4b5f3c172ad24104f9b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "485f756e-de49-4a78-add2-bf1cbcf9a3e5", "node_type": "1", "metadata": {"window": "For the quarter, opera ting profit increased 5% to $901 million, driven by growth in the distribution of specialty \nproducts to providers and health systems and increased contributions from our generics program.  The breadth of \ncapabilities and assets continued to deliver robust v alue to our stakeholders.  \n \n In our Prescription Technology Solutions segment, revenues were $1.2 billion, which were flat to the prior year. \n Lower contributions from the third -party logistics business were offset by growth across our technology services \nproducts and primarily our access solutions.  ", "original_text": "Lower contributions from the third -party logistics business were offset by growth across our technology services \nproducts and primarily our access solutions.  ", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "2a747832389141df8c674458ed232a830151e1a95403070f4df7fb47d4da41af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b0829ee-212d-4106-9a36-ec850f0c07b4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nWithin this segment, CoverMyMeds continues to deliver value for our partners by increasing connectivity between \npharmacies, providers, payers, and biopharma manufacturers through next -generation access, affordabil ity, and \nadherence solutions that are automated and integrated into provider workflows.  \n \n Results in the fourth quarter reflect organic growth across our access solutions, including prior authorization \nservices, as we extended existing partnerships with bio pharma manufacturers.  In addition to the strength of our \naccess solutions, year -over-year performance was also supported by higher volumes across our affordability \nsolutions.  \n \n Operating profit decreased 3% to $212 million, driven by higher costs and invest ments to sustain the momentum \nand growth across the biopharma services platform. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nWithin this segment, CoverMyMeds continues to deliver value for our partners by increasing connectivity between \npharmacies, providers, payers, and biopharma manufacturers through next -generation access, affordabil ity, and \nadherence solutions that are automated and integrated into provider workflows.  \n \n"}, "hash": "1eb9ca81a81b6a010e79f825a0dab491ea23dd2431aef9eb69b8a7e936472036", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b0829ee-212d-4106-9a36-ec850f0c07b4": {"__data__": {"id_": "7b0829ee-212d-4106-9a36-ec850f0c07b4", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nWithin this segment, CoverMyMeds continues to deliver value for our partners by increasing connectivity between \npharmacies, providers, payers, and biopharma manufacturers through next -generation access, affordabil ity, and \nadherence solutions that are automated and integrated into provider workflows.  \n \n Results in the fourth quarter reflect organic growth across our access solutions, including prior authorization \nservices, as we extended existing partnerships with bio pharma manufacturers.  In addition to the strength of our \naccess solutions, year -over-year performance was also supported by higher volumes across our affordability \nsolutions.  \n \n Operating profit decreased 3% to $212 million, driven by higher costs and invest ments to sustain the momentum \nand growth across the biopharma services platform. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nWithin this segment, CoverMyMeds continues to deliver value for our partners by increasing connectivity between \npharmacies, providers, payers, and biopharma manufacturers through next -generation access, affordabil ity, and \nadherence solutions that are automated and integrated into provider workflows.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3868fd7f528170285cbc98e0690577279603138755dc4b5f3c172ad24104f9b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c44a06c-8ee9-48f3-a4a6-9d41e51c5c1e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nWithin this segment, CoverMyMeds continues to deliver value for our partners by increasing connectivity between \npharmacies, providers, payers, and biopharma manufacturers through next -generation access, affordabil ity, and \nadherence solutions that are automated and integrated into provider workflows.  \n \n Results in the fourth quarter reflect organic growth across our access solutions, including prior authorization \nservices, as we extended existing partnerships with bio pharma manufacturers.  In addition to the strength of our \naccess solutions, year -over-year performance was also supported by higher volumes across our affordability \nsolutions.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d5c4bde25ba6a3a6a2f2fd58b3bc0f59118da0f46f0c419e885c55f9e84dc847", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e88e08a7-f3e4-4683-86ff-9c5b37640e87", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nWithin this segment, CoverMyMeds continues to deliver value for our partners by increasing connectivity between \npharmacies, providers, payers, and biopharma manufacturers through next -generation access, affordabil ity, and \nadherence solutions that are automated and integrated into provider workflows.  \n \n Results in the fourth quarter reflect organic growth across our access solutions, including prior authorization \nservices, as we extended existing partnerships with bio pharma manufacturers.  In addition to the strength of our \naccess solutions, year -over-year performance was also supported by higher volumes across our affordability \nsolutions.  \n \n Operating profit decreased 3% to $212 million, driven by higher costs and invest ments to sustain the momentum \nand growth across the biopharma services platform.  This included incremental infrastructure investments and \ncosts to deliver increasing levels of ROI for our customers. ", "original_text": "Results in the fourth quarter reflect organic growth across our access solutions, including prior authorization \nservices, as we extended existing partnerships with bio pharma manufacturers. "}, "hash": "32e3d5a5ac7ccdc645df736816c74ad656b1932a9e325e133dd2396dd1d47663", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nWithin this segment, CoverMyMeds continues to deliver value for our partners by increasing connectivity between \npharmacies, providers, payers, and biopharma manufacturers through next -generation access, affordabil ity, and \nadherence solutions that are automated and integrated into provider workflows.  \n \n", "start_char_idx": 16, "end_char_idx": 491, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e88e08a7-f3e4-4683-86ff-9c5b37640e87": {"__data__": {"id_": "e88e08a7-f3e4-4683-86ff-9c5b37640e87", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nWithin this segment, CoverMyMeds continues to deliver value for our partners by increasing connectivity between \npharmacies, providers, payers, and biopharma manufacturers through next -generation access, affordabil ity, and \nadherence solutions that are automated and integrated into provider workflows.  \n \n Results in the fourth quarter reflect organic growth across our access solutions, including prior authorization \nservices, as we extended existing partnerships with bio pharma manufacturers.  In addition to the strength of our \naccess solutions, year -over-year performance was also supported by higher volumes across our affordability \nsolutions.  \n \n Operating profit decreased 3% to $212 million, driven by higher costs and invest ments to sustain the momentum \nand growth across the biopharma services platform.  This included incremental infrastructure investments and \ncosts to deliver increasing levels of ROI for our customers. ", "original_text": "Results in the fourth quarter reflect organic growth across our access solutions, including prior authorization \nservices, as we extended existing partnerships with bio pharma manufacturers. ", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3868fd7f528170285cbc98e0690577279603138755dc4b5f3c172ad24104f9b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b0829ee-212d-4106-9a36-ec850f0c07b4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nWithin this segment, CoverMyMeds continues to deliver value for our partners by increasing connectivity between \npharmacies, providers, payers, and biopharma manufacturers through next -generation access, affordabil ity, and \nadherence solutions that are automated and integrated into provider workflows.  \n \n Results in the fourth quarter reflect organic growth across our access solutions, including prior authorization \nservices, as we extended existing partnerships with bio pharma manufacturers.  In addition to the strength of our \naccess solutions, year -over-year performance was also supported by higher volumes across our affordability \nsolutions.  \n \n Operating profit decreased 3% to $212 million, driven by higher costs and invest ments to sustain the momentum \nand growth across the biopharma services platform. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nWithin this segment, CoverMyMeds continues to deliver value for our partners by increasing connectivity between \npharmacies, providers, payers, and biopharma manufacturers through next -generation access, affordabil ity, and \nadherence solutions that are automated and integrated into provider workflows.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "892b3d3b6b4d1f9e08701176393e83a03c54277462e537e367f787bcc03b39de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b858aeba-1b89-4c13-ba7c-dd5ec51a4600", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nWithin this segment, CoverMyMeds continues to deliver value for our partners by increasing connectivity between \npharmacies, providers, payers, and biopharma manufacturers through next -generation access, affordabil ity, and \nadherence solutions that are automated and integrated into provider workflows.  \n \n Results in the fourth quarter reflect organic growth across our access solutions, including prior authorization \nservices, as we extended existing partnerships with bio pharma manufacturers.  In addition to the strength of our \naccess solutions, year -over-year performance was also supported by higher volumes across our affordability \nsolutions.  \n \n Operating profit decreased 3% to $212 million, driven by higher costs and invest ments to sustain the momentum \nand growth across the biopharma services platform.  This included incremental infrastructure investments and \ncosts to deliver increasing levels of ROI for our customers.  Operating profit was also impacted by lower third -party \nlogistics performance in the quarter as compared to the prior year.  \n \n", "original_text": "In addition to the strength of our \naccess solutions, year -over-year performance was also supported by higher volumes across our affordability \nsolutions.  \n \n"}, "hash": "f7dbf4ddd7de0d7be6111e033577b0a0c616e1478465155f34f2e400b197e3de", "class_name": "RelatedNodeInfo"}}, "text": "Results in the fourth quarter reflect organic growth across our access solutions, including prior authorization \nservices, as we extended existing partnerships with bio pharma manufacturers. ", "start_char_idx": 491, "end_char_idx": 682, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b858aeba-1b89-4c13-ba7c-dd5ec51a4600": {"__data__": {"id_": "b858aeba-1b89-4c13-ba7c-dd5ec51a4600", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nWithin this segment, CoverMyMeds continues to deliver value for our partners by increasing connectivity between \npharmacies, providers, payers, and biopharma manufacturers through next -generation access, affordabil ity, and \nadherence solutions that are automated and integrated into provider workflows.  \n \n Results in the fourth quarter reflect organic growth across our access solutions, including prior authorization \nservices, as we extended existing partnerships with bio pharma manufacturers.  In addition to the strength of our \naccess solutions, year -over-year performance was also supported by higher volumes across our affordability \nsolutions.  \n \n Operating profit decreased 3% to $212 million, driven by higher costs and invest ments to sustain the momentum \nand growth across the biopharma services platform.  This included incremental infrastructure investments and \ncosts to deliver increasing levels of ROI for our customers.  Operating profit was also impacted by lower third -party \nlogistics performance in the quarter as compared to the prior year.  \n \n", "original_text": "In addition to the strength of our \naccess solutions, year -over-year performance was also supported by higher volumes across our affordability \nsolutions.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3868fd7f528170285cbc98e0690577279603138755dc4b5f3c172ad24104f9b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e88e08a7-f3e4-4683-86ff-9c5b37640e87", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nWithin this segment, CoverMyMeds continues to deliver value for our partners by increasing connectivity between \npharmacies, providers, payers, and biopharma manufacturers through next -generation access, affordabil ity, and \nadherence solutions that are automated and integrated into provider workflows.  \n \n Results in the fourth quarter reflect organic growth across our access solutions, including prior authorization \nservices, as we extended existing partnerships with bio pharma manufacturers.  In addition to the strength of our \naccess solutions, year -over-year performance was also supported by higher volumes across our affordability \nsolutions.  \n \n Operating profit decreased 3% to $212 million, driven by higher costs and invest ments to sustain the momentum \nand growth across the biopharma services platform.  This included incremental infrastructure investments and \ncosts to deliver increasing levels of ROI for our customers. ", "original_text": "Results in the fourth quarter reflect organic growth across our access solutions, including prior authorization \nservices, as we extended existing partnerships with bio pharma manufacturers. ", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a8a41c50aefd6e1e58c469984fb3066e6b8d2f87dc3a319230d7dd20a2c49c34", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1cf367d-ef1c-4eac-b95d-46bd1ea3e834", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nWithin this segment, CoverMyMeds continues to deliver value for our partners by increasing connectivity between \npharmacies, providers, payers, and biopharma manufacturers through next -generation access, affordabil ity, and \nadherence solutions that are automated and integrated into provider workflows.  \n \n Results in the fourth quarter reflect organic growth across our access solutions, including prior authorization \nservices, as we extended existing partnerships with bio pharma manufacturers.  In addition to the strength of our \naccess solutions, year -over-year performance was also supported by higher volumes across our affordability \nsolutions.  \n \n Operating profit decreased 3% to $212 million, driven by higher costs and invest ments to sustain the momentum \nand growth across the biopharma services platform.  This included incremental infrastructure investments and \ncosts to deliver increasing levels of ROI for our customers.  Operating profit was also impacted by lower third -party \nlogistics performance in the quarter as compared to the prior year.  \n \n Turning to Medical Surgical Solutions, revenues were $2.8 billion, an increase of 6%. ", "original_text": "Operating profit decreased 3% to $212 million, driven by higher costs and invest ments to sustain the momentum \nand growth across the biopharma services platform. "}, "hash": "73e6505d3c101c37cc54c3bfcab3ea6c2ab9f367228fec65a749417e69834c9e", "class_name": "RelatedNodeInfo"}}, "text": "In addition to the strength of our \naccess solutions, year -over-year performance was also supported by higher volumes across our affordability \nsolutions.  \n \n", "start_char_idx": 682, "end_char_idx": 842, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1cf367d-ef1c-4eac-b95d-46bd1ea3e834": {"__data__": {"id_": "b1cf367d-ef1c-4eac-b95d-46bd1ea3e834", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nWithin this segment, CoverMyMeds continues to deliver value for our partners by increasing connectivity between \npharmacies, providers, payers, and biopharma manufacturers through next -generation access, affordabil ity, and \nadherence solutions that are automated and integrated into provider workflows.  \n \n Results in the fourth quarter reflect organic growth across our access solutions, including prior authorization \nservices, as we extended existing partnerships with bio pharma manufacturers.  In addition to the strength of our \naccess solutions, year -over-year performance was also supported by higher volumes across our affordability \nsolutions.  \n \n Operating profit decreased 3% to $212 million, driven by higher costs and invest ments to sustain the momentum \nand growth across the biopharma services platform.  This included incremental infrastructure investments and \ncosts to deliver increasing levels of ROI for our customers.  Operating profit was also impacted by lower third -party \nlogistics performance in the quarter as compared to the prior year.  \n \n Turning to Medical Surgical Solutions, revenues were $2.8 billion, an increase of 6%. ", "original_text": "Operating profit decreased 3% to $212 million, driven by higher costs and invest ments to sustain the momentum \nand growth across the biopharma services platform. ", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3868fd7f528170285cbc98e0690577279603138755dc4b5f3c172ad24104f9b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b858aeba-1b89-4c13-ba7c-dd5ec51a4600", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nWithin this segment, CoverMyMeds continues to deliver value for our partners by increasing connectivity between \npharmacies, providers, payers, and biopharma manufacturers through next -generation access, affordabil ity, and \nadherence solutions that are automated and integrated into provider workflows.  \n \n Results in the fourth quarter reflect organic growth across our access solutions, including prior authorization \nservices, as we extended existing partnerships with bio pharma manufacturers.  In addition to the strength of our \naccess solutions, year -over-year performance was also supported by higher volumes across our affordability \nsolutions.  \n \n Operating profit decreased 3% to $212 million, driven by higher costs and invest ments to sustain the momentum \nand growth across the biopharma services platform.  This included incremental infrastructure investments and \ncosts to deliver increasing levels of ROI for our customers.  Operating profit was also impacted by lower third -party \nlogistics performance in the quarter as compared to the prior year.  \n \n", "original_text": "In addition to the strength of our \naccess solutions, year -over-year performance was also supported by higher volumes across our affordability \nsolutions.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "521557ba4183b52127d7005dad1a8f4d645a261d8502d1999bead66e52ef17d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1d5490c-a5eb-460f-a8c2-eaaf4b6700a4", "node_type": "1", "metadata": {"window": "Results in the fourth quarter reflect organic growth across our access solutions, including prior authorization \nservices, as we extended existing partnerships with bio pharma manufacturers.  In addition to the strength of our \naccess solutions, year -over-year performance was also supported by higher volumes across our affordability \nsolutions.  \n \n Operating profit decreased 3% to $212 million, driven by higher costs and invest ments to sustain the momentum \nand growth across the biopharma services platform.  This included incremental infrastructure investments and \ncosts to deliver increasing levels of ROI for our customers.  Operating profit was also impacted by lower third -party \nlogistics performance in the quarter as compared to the prior year.  \n \n Turning to Medical Surgical Solutions, revenues were $2.8 billion, an increase of 6%.  And operating profit was \n$248 million, which was flat versus the prior year. ", "original_text": "This included incremental infrastructure investments and \ncosts to deliver increasing levels of ROI for our customers. "}, "hash": "dd8d2e841cd98e25b0551f867044f3dc2ac6644ffa272b0e3b81e2c40215dfb9", "class_name": "RelatedNodeInfo"}}, "text": "Operating profit decreased 3% to $212 million, driven by higher costs and invest ments to sustain the momentum \nand growth across the biopharma services platform. ", "start_char_idx": 842, "end_char_idx": 1005, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1d5490c-a5eb-460f-a8c2-eaaf4b6700a4": {"__data__": {"id_": "e1d5490c-a5eb-460f-a8c2-eaaf4b6700a4", "embedding": null, "metadata": {"window": "Results in the fourth quarter reflect organic growth across our access solutions, including prior authorization \nservices, as we extended existing partnerships with bio pharma manufacturers.  In addition to the strength of our \naccess solutions, year -over-year performance was also supported by higher volumes across our affordability \nsolutions.  \n \n Operating profit decreased 3% to $212 million, driven by higher costs and invest ments to sustain the momentum \nand growth across the biopharma services platform.  This included incremental infrastructure investments and \ncosts to deliver increasing levels of ROI for our customers.  Operating profit was also impacted by lower third -party \nlogistics performance in the quarter as compared to the prior year.  \n \n Turning to Medical Surgical Solutions, revenues were $2.8 billion, an increase of 6%.  And operating profit was \n$248 million, which was flat versus the prior year. ", "original_text": "This included incremental infrastructure investments and \ncosts to deliver increasing levels of ROI for our customers. ", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3868fd7f528170285cbc98e0690577279603138755dc4b5f3c172ad24104f9b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1cf367d-ef1c-4eac-b95d-46bd1ea3e834", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nWithin this segment, CoverMyMeds continues to deliver value for our partners by increasing connectivity between \npharmacies, providers, payers, and biopharma manufacturers through next -generation access, affordabil ity, and \nadherence solutions that are automated and integrated into provider workflows.  \n \n Results in the fourth quarter reflect organic growth across our access solutions, including prior authorization \nservices, as we extended existing partnerships with bio pharma manufacturers.  In addition to the strength of our \naccess solutions, year -over-year performance was also supported by higher volumes across our affordability \nsolutions.  \n \n Operating profit decreased 3% to $212 million, driven by higher costs and invest ments to sustain the momentum \nand growth across the biopharma services platform.  This included incremental infrastructure investments and \ncosts to deliver increasing levels of ROI for our customers.  Operating profit was also impacted by lower third -party \nlogistics performance in the quarter as compared to the prior year.  \n \n Turning to Medical Surgical Solutions, revenues were $2.8 billion, an increase of 6%. ", "original_text": "Operating profit decreased 3% to $212 million, driven by higher costs and invest ments to sustain the momentum \nand growth across the biopharma services platform. ", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "0c42160ce3db45525527ccf66c461c1cc3e9e171f5cda0005929081889a5003d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17585a7f-75c6-4ae7-844a-ec10eeca85dd", "node_type": "1", "metadata": {"window": "In addition to the strength of our \naccess solutions, year -over-year performance was also supported by higher volumes across our affordability \nsolutions.  \n \n Operating profit decreased 3% to $212 million, driven by higher costs and invest ments to sustain the momentum \nand growth across the biopharma services platform.  This included incremental infrastructure investments and \ncosts to deliver increasing levels of ROI for our customers.  Operating profit was also impacted by lower third -party \nlogistics performance in the quarter as compared to the prior year.  \n \n Turning to Medical Surgical Solutions, revenues were $2.8 billion, an increase of 6%.  And operating profit was \n$248 million, which was flat versus the prior year.  Fourth quarter results re flect growth in the primary care and \nextended care businesses, including higher volumes of illness season testing, partially offset by lower \ncontributions from the kitting storage and distribution of ancillary supplies for the US government's COVID -19 \nprogram compared to the prior year. ", "original_text": "Operating profit was also impacted by lower third -party \nlogistics performance in the quarter as compared to the prior year.  \n \n"}, "hash": "a3baac60f6e9e57df0bab6e43be3418dac8839446152d1e68a8d999ee8716402", "class_name": "RelatedNodeInfo"}}, "text": "This included incremental infrastructure investments and \ncosts to deliver increasing levels of ROI for our customers. ", "start_char_idx": 1005, "end_char_idx": 1124, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17585a7f-75c6-4ae7-844a-ec10eeca85dd": {"__data__": {"id_": "17585a7f-75c6-4ae7-844a-ec10eeca85dd", "embedding": null, "metadata": {"window": "In addition to the strength of our \naccess solutions, year -over-year performance was also supported by higher volumes across our affordability \nsolutions.  \n \n Operating profit decreased 3% to $212 million, driven by higher costs and invest ments to sustain the momentum \nand growth across the biopharma services platform.  This included incremental infrastructure investments and \ncosts to deliver increasing levels of ROI for our customers.  Operating profit was also impacted by lower third -party \nlogistics performance in the quarter as compared to the prior year.  \n \n Turning to Medical Surgical Solutions, revenues were $2.8 billion, an increase of 6%.  And operating profit was \n$248 million, which was flat versus the prior year.  Fourth quarter results re flect growth in the primary care and \nextended care businesses, including higher volumes of illness season testing, partially offset by lower \ncontributions from the kitting storage and distribution of ancillary supplies for the US government's COVID -19 \nprogram compared to the prior year. ", "original_text": "Operating profit was also impacted by lower third -party \nlogistics performance in the quarter as compared to the prior year.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3868fd7f528170285cbc98e0690577279603138755dc4b5f3c172ad24104f9b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1d5490c-a5eb-460f-a8c2-eaaf4b6700a4", "node_type": "1", "metadata": {"window": "Results in the fourth quarter reflect organic growth across our access solutions, including prior authorization \nservices, as we extended existing partnerships with bio pharma manufacturers.  In addition to the strength of our \naccess solutions, year -over-year performance was also supported by higher volumes across our affordability \nsolutions.  \n \n Operating profit decreased 3% to $212 million, driven by higher costs and invest ments to sustain the momentum \nand growth across the biopharma services platform.  This included incremental infrastructure investments and \ncosts to deliver increasing levels of ROI for our customers.  Operating profit was also impacted by lower third -party \nlogistics performance in the quarter as compared to the prior year.  \n \n Turning to Medical Surgical Solutions, revenues were $2.8 billion, an increase of 6%.  And operating profit was \n$248 million, which was flat versus the prior year. ", "original_text": "This included incremental infrastructure investments and \ncosts to deliver increasing levels of ROI for our customers. ", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "023c7a81cfbcd3870eda577dd8694bce24fa47eea10afdd63fd61a03d75aa190", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "857f6cc1-d0f0-43c8-87f7-2318785ea4eb", "node_type": "1", "metadata": {"window": "Operating profit decreased 3% to $212 million, driven by higher costs and invest ments to sustain the momentum \nand growth across the biopharma services platform.  This included incremental infrastructure investments and \ncosts to deliver increasing levels of ROI for our customers.  Operating profit was also impacted by lower third -party \nlogistics performance in the quarter as compared to the prior year.  \n \n Turning to Medical Surgical Solutions, revenues were $2.8 billion, an increase of 6%.  And operating profit was \n$248 million, which was flat versus the prior year.  Fourth quarter results re flect growth in the primary care and \nextended care businesses, including higher volumes of illness season testing, partially offset by lower \ncontributions from the kitting storage and distribution of ancillary supplies for the US government's COVID -19 \nprogram compared to the prior year.  As a reminder, each illness season is unique depending on the onset and \nseverity of various respiratory illnesses during that particular year.  \n \n", "original_text": "Turning to Medical Surgical Solutions, revenues were $2.8 billion, an increase of 6%. "}, "hash": "332fddc5aaf01c80a64011d1fdeabae9b5c5b0c31fa15a7b8e15ba80a27bffbf", "class_name": "RelatedNodeInfo"}}, "text": "Operating profit was also impacted by lower third -party \nlogistics performance in the quarter as compared to the prior year.  \n \n", "start_char_idx": 1124, "end_char_idx": 1254, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "857f6cc1-d0f0-43c8-87f7-2318785ea4eb": {"__data__": {"id_": "857f6cc1-d0f0-43c8-87f7-2318785ea4eb", "embedding": null, "metadata": {"window": "Operating profit decreased 3% to $212 million, driven by higher costs and invest ments to sustain the momentum \nand growth across the biopharma services platform.  This included incremental infrastructure investments and \ncosts to deliver increasing levels of ROI for our customers.  Operating profit was also impacted by lower third -party \nlogistics performance in the quarter as compared to the prior year.  \n \n Turning to Medical Surgical Solutions, revenues were $2.8 billion, an increase of 6%.  And operating profit was \n$248 million, which was flat versus the prior year.  Fourth quarter results re flect growth in the primary care and \nextended care businesses, including higher volumes of illness season testing, partially offset by lower \ncontributions from the kitting storage and distribution of ancillary supplies for the US government's COVID -19 \nprogram compared to the prior year.  As a reminder, each illness season is unique depending on the onset and \nseverity of various respiratory illnesses during that particular year.  \n \n", "original_text": "Turning to Medical Surgical Solutions, revenues were $2.8 billion, an increase of 6%. ", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3868fd7f528170285cbc98e0690577279603138755dc4b5f3c172ad24104f9b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17585a7f-75c6-4ae7-844a-ec10eeca85dd", "node_type": "1", "metadata": {"window": "In addition to the strength of our \naccess solutions, year -over-year performance was also supported by higher volumes across our affordability \nsolutions.  \n \n Operating profit decreased 3% to $212 million, driven by higher costs and invest ments to sustain the momentum \nand growth across the biopharma services platform.  This included incremental infrastructure investments and \ncosts to deliver increasing levels of ROI for our customers.  Operating profit was also impacted by lower third -party \nlogistics performance in the quarter as compared to the prior year.  \n \n Turning to Medical Surgical Solutions, revenues were $2.8 billion, an increase of 6%.  And operating profit was \n$248 million, which was flat versus the prior year.  Fourth quarter results re flect growth in the primary care and \nextended care businesses, including higher volumes of illness season testing, partially offset by lower \ncontributions from the kitting storage and distribution of ancillary supplies for the US government's COVID -19 \nprogram compared to the prior year. ", "original_text": "Operating profit was also impacted by lower third -party \nlogistics performance in the quarter as compared to the prior year.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "63f3fd5b0fdcec1cdc01c56c54de15885b8bd4cee978d094764b5ed33a8fadb7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbcef71c-8f56-453d-8ff0-73d1641ac3de", "node_type": "1", "metadata": {"window": "This included incremental infrastructure investments and \ncosts to deliver increasing levels of ROI for our customers.  Operating profit was also impacted by lower third -party \nlogistics performance in the quarter as compared to the prior year.  \n \n Turning to Medical Surgical Solutions, revenues were $2.8 billion, an increase of 6%.  And operating profit was \n$248 million, which was flat versus the prior year.  Fourth quarter results re flect growth in the primary care and \nextended care businesses, including higher volumes of illness season testing, partially offset by lower \ncontributions from the kitting storage and distribution of ancillary supplies for the US government's COVID -19 \nprogram compared to the prior year.  As a reminder, each illness season is unique depending on the onset and \nseverity of various respiratory illnesses during that particular year.  \n \n Next, let me address our international results. ", "original_text": "And operating profit was \n$248 million, which was flat versus the prior year. "}, "hash": "952844fe1f3a11040efef30f7b1ac60ad745385c6a0e06a7b10548e1ec5cd260", "class_name": "RelatedNodeInfo"}}, "text": "Turning to Medical Surgical Solutions, revenues were $2.8 billion, an increase of 6%. ", "start_char_idx": 1254, "end_char_idx": 1340, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbcef71c-8f56-453d-8ff0-73d1641ac3de": {"__data__": {"id_": "bbcef71c-8f56-453d-8ff0-73d1641ac3de", "embedding": null, "metadata": {"window": "This included incremental infrastructure investments and \ncosts to deliver increasing levels of ROI for our customers.  Operating profit was also impacted by lower third -party \nlogistics performance in the quarter as compared to the prior year.  \n \n Turning to Medical Surgical Solutions, revenues were $2.8 billion, an increase of 6%.  And operating profit was \n$248 million, which was flat versus the prior year.  Fourth quarter results re flect growth in the primary care and \nextended care businesses, including higher volumes of illness season testing, partially offset by lower \ncontributions from the kitting storage and distribution of ancillary supplies for the US government's COVID -19 \nprogram compared to the prior year.  As a reminder, each illness season is unique depending on the onset and \nseverity of various respiratory illnesses during that particular year.  \n \n Next, let me address our international results. ", "original_text": "And operating profit was \n$248 million, which was flat versus the prior year. ", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3868fd7f528170285cbc98e0690577279603138755dc4b5f3c172ad24104f9b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "857f6cc1-d0f0-43c8-87f7-2318785ea4eb", "node_type": "1", "metadata": {"window": "Operating profit decreased 3% to $212 million, driven by higher costs and invest ments to sustain the momentum \nand growth across the biopharma services platform.  This included incremental infrastructure investments and \ncosts to deliver increasing levels of ROI for our customers.  Operating profit was also impacted by lower third -party \nlogistics performance in the quarter as compared to the prior year.  \n \n Turning to Medical Surgical Solutions, revenues were $2.8 billion, an increase of 6%.  And operating profit was \n$248 million, which was flat versus the prior year.  Fourth quarter results re flect growth in the primary care and \nextended care businesses, including higher volumes of illness season testing, partially offset by lower \ncontributions from the kitting storage and distribution of ancillary supplies for the US government's COVID -19 \nprogram compared to the prior year.  As a reminder, each illness season is unique depending on the onset and \nseverity of various respiratory illnesses during that particular year.  \n \n", "original_text": "Turning to Medical Surgical Solutions, revenues were $2.8 billion, an increase of 6%. ", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ff5ecc216456ff77876c9f6ad0d58f9bbe34a06ff3827c1306ddb51515670820", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6cc1b1fc-0f90-4c31-b421-f4a7148e3e23", "node_type": "1", "metadata": {"window": "Operating profit was also impacted by lower third -party \nlogistics performance in the quarter as compared to the prior year.  \n \n Turning to Medical Surgical Solutions, revenues were $2.8 billion, an increase of 6%.  And operating profit was \n$248 million, which was flat versus the prior year.  Fourth quarter results re flect growth in the primary care and \nextended care businesses, including higher volumes of illness season testing, partially offset by lower \ncontributions from the kitting storage and distribution of ancillary supplies for the US government's COVID -19 \nprogram compared to the prior year.  As a reminder, each illness season is unique depending on the onset and \nseverity of various respiratory illnesses during that particular year.  \n \n Next, let me address our international results.  Revenues were $3.5 billion, an i ncrease of 6%. ", "original_text": "Fourth quarter results re flect growth in the primary care and \nextended care businesses, including higher volumes of illness season testing, partially offset by lower \ncontributions from the kitting storage and distribution of ancillary supplies for the US government's COVID -19 \nprogram compared to the prior year. "}, "hash": "2090eba629ba965ce5f267e92f7a35666afc1dadb7595fa4128d0cf902813706", "class_name": "RelatedNodeInfo"}}, "text": "And operating profit was \n$248 million, which was flat versus the prior year. ", "start_char_idx": 1340, "end_char_idx": 1418, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6cc1b1fc-0f90-4c31-b421-f4a7148e3e23": {"__data__": {"id_": "6cc1b1fc-0f90-4c31-b421-f4a7148e3e23", "embedding": null, "metadata": {"window": "Operating profit was also impacted by lower third -party \nlogistics performance in the quarter as compared to the prior year.  \n \n Turning to Medical Surgical Solutions, revenues were $2.8 billion, an increase of 6%.  And operating profit was \n$248 million, which was flat versus the prior year.  Fourth quarter results re flect growth in the primary care and \nextended care businesses, including higher volumes of illness season testing, partially offset by lower \ncontributions from the kitting storage and distribution of ancillary supplies for the US government's COVID -19 \nprogram compared to the prior year.  As a reminder, each illness season is unique depending on the onset and \nseverity of various respiratory illnesses during that particular year.  \n \n Next, let me address our international results.  Revenues were $3.5 billion, an i ncrease of 6%. ", "original_text": "Fourth quarter results re flect growth in the primary care and \nextended care businesses, including higher volumes of illness season testing, partially offset by lower \ncontributions from the kitting storage and distribution of ancillary supplies for the US government's COVID -19 \nprogram compared to the prior year. ", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3868fd7f528170285cbc98e0690577279603138755dc4b5f3c172ad24104f9b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbcef71c-8f56-453d-8ff0-73d1641ac3de", "node_type": "1", "metadata": {"window": "This included incremental infrastructure investments and \ncosts to deliver increasing levels of ROI for our customers.  Operating profit was also impacted by lower third -party \nlogistics performance in the quarter as compared to the prior year.  \n \n Turning to Medical Surgical Solutions, revenues were $2.8 billion, an increase of 6%.  And operating profit was \n$248 million, which was flat versus the prior year.  Fourth quarter results re flect growth in the primary care and \nextended care businesses, including higher volumes of illness season testing, partially offset by lower \ncontributions from the kitting storage and distribution of ancillary supplies for the US government's COVID -19 \nprogram compared to the prior year.  As a reminder, each illness season is unique depending on the onset and \nseverity of various respiratory illnesses during that particular year.  \n \n Next, let me address our international results. ", "original_text": "And operating profit was \n$248 million, which was flat versus the prior year. ", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "39aad9b4ee1f49a06d18e16823fad190069f48bbdbe2a2d8fd77b175cb5e8c21", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d89ee0b9-8e9d-4877-a6a2-feb6b1631af6", "node_type": "1", "metadata": {"window": "Turning to Medical Surgical Solutions, revenues were $2.8 billion, an increase of 6%.  And operating profit was \n$248 million, which was flat versus the prior year.  Fourth quarter results re flect growth in the primary care and \nextended care businesses, including higher volumes of illness season testing, partially offset by lower \ncontributions from the kitting storage and distribution of ancillary supplies for the US government's COVID -19 \nprogram compared to the prior year.  As a reminder, each illness season is unique depending on the onset and \nseverity of various respiratory illnesses during that particular year.  \n \n Next, let me address our international results.  Revenues were $3.5 billion, an i ncrease of 6%.  And operating profit \nwas $94 million, an increase of 18%. ", "original_text": "As a reminder, each illness season is unique depending on the onset and \nseverity of various respiratory illnesses during that particular year.  \n \n"}, "hash": "8b5a553f9d2ccff6c4c2a1c5e980647c0b5d3c7ceb3bf9eeef30f73d287c6ba6", "class_name": "RelatedNodeInfo"}}, "text": "Fourth quarter results re flect growth in the primary care and \nextended care businesses, including higher volumes of illness season testing, partially offset by lower \ncontributions from the kitting storage and distribution of ancillary supplies for the US government's COVID -19 \nprogram compared to the prior year. ", "start_char_idx": 1418, "end_char_idx": 1736, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d89ee0b9-8e9d-4877-a6a2-feb6b1631af6": {"__data__": {"id_": "d89ee0b9-8e9d-4877-a6a2-feb6b1631af6", "embedding": null, "metadata": {"window": "Turning to Medical Surgical Solutions, revenues were $2.8 billion, an increase of 6%.  And operating profit was \n$248 million, which was flat versus the prior year.  Fourth quarter results re flect growth in the primary care and \nextended care businesses, including higher volumes of illness season testing, partially offset by lower \ncontributions from the kitting storage and distribution of ancillary supplies for the US government's COVID -19 \nprogram compared to the prior year.  As a reminder, each illness season is unique depending on the onset and \nseverity of various respiratory illnesses during that particular year.  \n \n Next, let me address our international results.  Revenues were $3.5 billion, an i ncrease of 6%.  And operating profit \nwas $94 million, an increase of 18%. ", "original_text": "As a reminder, each illness season is unique depending on the onset and \nseverity of various respiratory illnesses during that particular year.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3868fd7f528170285cbc98e0690577279603138755dc4b5f3c172ad24104f9b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6cc1b1fc-0f90-4c31-b421-f4a7148e3e23", "node_type": "1", "metadata": {"window": "Operating profit was also impacted by lower third -party \nlogistics performance in the quarter as compared to the prior year.  \n \n Turning to Medical Surgical Solutions, revenues were $2.8 billion, an increase of 6%.  And operating profit was \n$248 million, which was flat versus the prior year.  Fourth quarter results re flect growth in the primary care and \nextended care businesses, including higher volumes of illness season testing, partially offset by lower \ncontributions from the kitting storage and distribution of ancillary supplies for the US government's COVID -19 \nprogram compared to the prior year.  As a reminder, each illness season is unique depending on the onset and \nseverity of various respiratory illnesses during that particular year.  \n \n Next, let me address our international results.  Revenues were $3.5 billion, an i ncrease of 6%. ", "original_text": "Fourth quarter results re flect growth in the primary care and \nextended care businesses, including higher volumes of illness season testing, partially offset by lower \ncontributions from the kitting storage and distribution of ancillary supplies for the US government's COVID -19 \nprogram compared to the prior year. ", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e5e86de07b726df03fdb16941281297f4f984b44a7014bbc918e16d01e4157aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "895b8ae8-2abe-4699-b487-a8f063c8b4b2", "node_type": "1", "metadata": {"window": "And operating profit was \n$248 million, which was flat versus the prior year.  Fourth quarter results re flect growth in the primary care and \nextended care businesses, including higher volumes of illness season testing, partially offset by lower \ncontributions from the kitting storage and distribution of ancillary supplies for the US government's COVID -19 \nprogram compared to the prior year.  As a reminder, each illness season is unique depending on the onset and \nseverity of various respiratory illnesses during that particular year.  \n \n Next, let me address our international results.  Revenues were $3.5 billion, an i ncrease of 6%.  And operating profit \nwas $94 million, an increase of 18%.  These strong results were driven by higher pharmaceutical distribution \nvolumes in the Canadian business compared to the prior year.  \n \n", "original_text": "Next, let me address our international results. "}, "hash": "8a357dd0c5fa13c75b2c91bbd3aa0baac467905da0866cdbecd26042695b36b0", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, each illness season is unique depending on the onset and \nseverity of various respiratory illnesses during that particular year.  \n \n", "start_char_idx": 1736, "end_char_idx": 1884, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "895b8ae8-2abe-4699-b487-a8f063c8b4b2": {"__data__": {"id_": "895b8ae8-2abe-4699-b487-a8f063c8b4b2", "embedding": null, "metadata": {"window": "And operating profit was \n$248 million, which was flat versus the prior year.  Fourth quarter results re flect growth in the primary care and \nextended care businesses, including higher volumes of illness season testing, partially offset by lower \ncontributions from the kitting storage and distribution of ancillary supplies for the US government's COVID -19 \nprogram compared to the prior year.  As a reminder, each illness season is unique depending on the onset and \nseverity of various respiratory illnesses during that particular year.  \n \n Next, let me address our international results.  Revenues were $3.5 billion, an i ncrease of 6%.  And operating profit \nwas $94 million, an increase of 18%.  These strong results were driven by higher pharmaceutical distribution \nvolumes in the Canadian business compared to the prior year.  \n \n", "original_text": "Next, let me address our international results. ", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3868fd7f528170285cbc98e0690577279603138755dc4b5f3c172ad24104f9b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d89ee0b9-8e9d-4877-a6a2-feb6b1631af6", "node_type": "1", "metadata": {"window": "Turning to Medical Surgical Solutions, revenues were $2.8 billion, an increase of 6%.  And operating profit was \n$248 million, which was flat versus the prior year.  Fourth quarter results re flect growth in the primary care and \nextended care businesses, including higher volumes of illness season testing, partially offset by lower \ncontributions from the kitting storage and distribution of ancillary supplies for the US government's COVID -19 \nprogram compared to the prior year.  As a reminder, each illness season is unique depending on the onset and \nseverity of various respiratory illnesses during that particular year.  \n \n Next, let me address our international results.  Revenues were $3.5 billion, an i ncrease of 6%.  And operating profit \nwas $94 million, an increase of 18%. ", "original_text": "As a reminder, each illness season is unique depending on the onset and \nseverity of various respiratory illnesses during that particular year.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "46f2fe3c723ca7221e4583375c52b267996ef59b9a10192d5e401e820d740f05", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d3e953c-149a-4a06-b62a-3d86acf171ea", "node_type": "1", "metadata": {"window": "Fourth quarter results re flect growth in the primary care and \nextended care businesses, including higher volumes of illness season testing, partially offset by lower \ncontributions from the kitting storage and distribution of ancillary supplies for the US government's COVID -19 \nprogram compared to the prior year.  As a reminder, each illness season is unique depending on the onset and \nseverity of various respiratory illnesses during that particular year.  \n \n Next, let me address our international results.  Revenues were $3.5 billion, an i ncrease of 6%.  And operating profit \nwas $94 million, an increase of 18%.  These strong results were driven by higher pharmaceutical distribution \nvolumes in the Canadian business compared to the prior year.  \n \n Wrapping up our segment review, corporate expenses  were $193 million in the quarter, an increase of 30%, \ndriven by the previously discussed environmental reserve and higher technology infrastructure and compliance \nspend.  \n \n", "original_text": "Revenues were $3.5 billion, an i ncrease of 6%. "}, "hash": "6a40f3a9a44cef31ba10c7bff71615ac55e051e9a910a895b369fa9dad205d3e", "class_name": "RelatedNodeInfo"}}, "text": "Next, let me address our international results. ", "start_char_idx": 1884, "end_char_idx": 1932, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d3e953c-149a-4a06-b62a-3d86acf171ea": {"__data__": {"id_": "6d3e953c-149a-4a06-b62a-3d86acf171ea", "embedding": null, "metadata": {"window": "Fourth quarter results re flect growth in the primary care and \nextended care businesses, including higher volumes of illness season testing, partially offset by lower \ncontributions from the kitting storage and distribution of ancillary supplies for the US government's COVID -19 \nprogram compared to the prior year.  As a reminder, each illness season is unique depending on the onset and \nseverity of various respiratory illnesses during that particular year.  \n \n Next, let me address our international results.  Revenues were $3.5 billion, an i ncrease of 6%.  And operating profit \nwas $94 million, an increase of 18%.  These strong results were driven by higher pharmaceutical distribution \nvolumes in the Canadian business compared to the prior year.  \n \n Wrapping up our segment review, corporate expenses  were $193 million in the quarter, an increase of 30%, \ndriven by the previously discussed environmental reserve and higher technology infrastructure and compliance \nspend.  \n \n", "original_text": "Revenues were $3.5 billion, an i ncrease of 6%. ", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3868fd7f528170285cbc98e0690577279603138755dc4b5f3c172ad24104f9b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "895b8ae8-2abe-4699-b487-a8f063c8b4b2", "node_type": "1", "metadata": {"window": "And operating profit was \n$248 million, which was flat versus the prior year.  Fourth quarter results re flect growth in the primary care and \nextended care businesses, including higher volumes of illness season testing, partially offset by lower \ncontributions from the kitting storage and distribution of ancillary supplies for the US government's COVID -19 \nprogram compared to the prior year.  As a reminder, each illness season is unique depending on the onset and \nseverity of various respiratory illnesses during that particular year.  \n \n Next, let me address our international results.  Revenues were $3.5 billion, an i ncrease of 6%.  And operating profit \nwas $94 million, an increase of 18%.  These strong results were driven by higher pharmaceutical distribution \nvolumes in the Canadian business compared to the prior year.  \n \n", "original_text": "Next, let me address our international results. ", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e579354313299702ba45d5badcf0081ef1642b18bed0948d5ed48ceb1ebf3255", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "352868c6-5d36-4875-ba9f-843a8c66a993", "node_type": "1", "metadata": {"window": "As a reminder, each illness season is unique depending on the onset and \nseverity of various respiratory illnesses during that particular year.  \n \n Next, let me address our international results.  Revenues were $3.5 billion, an i ncrease of 6%.  And operating profit \nwas $94 million, an increase of 18%.  These strong results were driven by higher pharmaceutical distribution \nvolumes in the Canadian business compared to the prior year.  \n \n Wrapping up our segment review, corporate expenses  were $193 million in the quarter, an increase of 30%, \ndriven by the previously discussed environmental reserve and higher technology infrastructure and compliance \nspend.  \n \n Let me now turn to cash and capital deployment, which can be found on slide 12. ", "original_text": "And operating profit \nwas $94 million, an increase of 18%. "}, "hash": "8eb19e763365b799b6d70b5a99ba31d3487d70f696ff90ba218f32539c18d6d2", "class_name": "RelatedNodeInfo"}}, "text": "Revenues were $3.5 billion, an i ncrease of 6%. ", "start_char_idx": 1932, "end_char_idx": 1980, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "352868c6-5d36-4875-ba9f-843a8c66a993": {"__data__": {"id_": "352868c6-5d36-4875-ba9f-843a8c66a993", "embedding": null, "metadata": {"window": "As a reminder, each illness season is unique depending on the onset and \nseverity of various respiratory illnesses during that particular year.  \n \n Next, let me address our international results.  Revenues were $3.5 billion, an i ncrease of 6%.  And operating profit \nwas $94 million, an increase of 18%.  These strong results were driven by higher pharmaceutical distribution \nvolumes in the Canadian business compared to the prior year.  \n \n Wrapping up our segment review, corporate expenses  were $193 million in the quarter, an increase of 30%, \ndriven by the previously discussed environmental reserve and higher technology infrastructure and compliance \nspend.  \n \n Let me now turn to cash and capital deployment, which can be found on slide 12. ", "original_text": "And operating profit \nwas $94 million, an increase of 18%. ", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3868fd7f528170285cbc98e0690577279603138755dc4b5f3c172ad24104f9b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d3e953c-149a-4a06-b62a-3d86acf171ea", "node_type": "1", "metadata": {"window": "Fourth quarter results re flect growth in the primary care and \nextended care businesses, including higher volumes of illness season testing, partially offset by lower \ncontributions from the kitting storage and distribution of ancillary supplies for the US government's COVID -19 \nprogram compared to the prior year.  As a reminder, each illness season is unique depending on the onset and \nseverity of various respiratory illnesses during that particular year.  \n \n Next, let me address our international results.  Revenues were $3.5 billion, an i ncrease of 6%.  And operating profit \nwas $94 million, an increase of 18%.  These strong results were driven by higher pharmaceutical distribution \nvolumes in the Canadian business compared to the prior year.  \n \n Wrapping up our segment review, corporate expenses  were $193 million in the quarter, an increase of 30%, \ndriven by the previously discussed environmental reserve and higher technology infrastructure and compliance \nspend.  \n \n", "original_text": "Revenues were $3.5 billion, an i ncrease of 6%. ", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "6cbaa7d6900e3bfaccc72dd6d822fc15da6685dc874416c5bb6127299968f6b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db65b094-fe05-4670-bf1a-a1ef2840e779", "node_type": "1", "metadata": {"window": "Next, let me address our international results.  Revenues were $3.5 billion, an i ncrease of 6%.  And operating profit \nwas $94 million, an increase of 18%.  These strong results were driven by higher pharmaceutical distribution \nvolumes in the Canadian business compared to the prior year.  \n \n Wrapping up our segment review, corporate expenses  were $193 million in the quarter, an increase of 30%, \ndriven by the previously discussed environmental reserve and higher technology infrastructure and compliance \nspend.  \n \n Let me now turn to cash and capital deployment, which can be found on slide 12.  We e nded the quarter with $4.6 \nbillion in cash and cash equivalents. ", "original_text": "These strong results were driven by higher pharmaceutical distribution \nvolumes in the Canadian business compared to the prior year.  \n \n"}, "hash": "c4fd798e0abbef419682cb3db506aad10b399f7d476c3ad08852882ff820df65", "class_name": "RelatedNodeInfo"}}, "text": "And operating profit \nwas $94 million, an increase of 18%. ", "start_char_idx": 1980, "end_char_idx": 2039, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db65b094-fe05-4670-bf1a-a1ef2840e779": {"__data__": {"id_": "db65b094-fe05-4670-bf1a-a1ef2840e779", "embedding": null, "metadata": {"window": "Next, let me address our international results.  Revenues were $3.5 billion, an i ncrease of 6%.  And operating profit \nwas $94 million, an increase of 18%.  These strong results were driven by higher pharmaceutical distribution \nvolumes in the Canadian business compared to the prior year.  \n \n Wrapping up our segment review, corporate expenses  were $193 million in the quarter, an increase of 30%, \ndriven by the previously discussed environmental reserve and higher technology infrastructure and compliance \nspend.  \n \n Let me now turn to cash and capital deployment, which can be found on slide 12.  We e nded the quarter with $4.6 \nbillion in cash and cash equivalents. ", "original_text": "These strong results were driven by higher pharmaceutical distribution \nvolumes in the Canadian business compared to the prior year.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3868fd7f528170285cbc98e0690577279603138755dc4b5f3c172ad24104f9b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "352868c6-5d36-4875-ba9f-843a8c66a993", "node_type": "1", "metadata": {"window": "As a reminder, each illness season is unique depending on the onset and \nseverity of various respiratory illnesses during that particular year.  \n \n Next, let me address our international results.  Revenues were $3.5 billion, an i ncrease of 6%.  And operating profit \nwas $94 million, an increase of 18%.  These strong results were driven by higher pharmaceutical distribution \nvolumes in the Canadian business compared to the prior year.  \n \n Wrapping up our segment review, corporate expenses  were $193 million in the quarter, an increase of 30%, \ndriven by the previously discussed environmental reserve and higher technology infrastructure and compliance \nspend.  \n \n Let me now turn to cash and capital deployment, which can be found on slide 12. ", "original_text": "And operating profit \nwas $94 million, an increase of 18%. ", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "55a4876195ed6743966f63beae5117942b9e2b690a340b7fba6b4ce6fb73821c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f16bc65-6d77-4525-9f9e-6fb795d4ec3c", "node_type": "1", "metadata": {"window": "Revenues were $3.5 billion, an i ncrease of 6%.  And operating profit \nwas $94 million, an increase of 18%.  These strong results were driven by higher pharmaceutical distribution \nvolumes in the Canadian business compared to the prior year.  \n \n Wrapping up our segment review, corporate expenses  were $193 million in the quarter, an increase of 30%, \ndriven by the previously discussed environmental reserve and higher technology infrastructure and compliance \nspend.  \n \n Let me now turn to cash and capital deployment, which can be found on slide 12.  We e nded the quarter with $4.6 \nbillion in cash and cash equivalents.  For the fiscal year, we generated $3.6 billion in free cash flow, including $687 \nmillion of capital expenditures, which included new and existing distribution centers as well as investments i n \ntechnology, data, and analytics to support our growth priorities.  \n \n", "original_text": "Wrapping up our segment review, corporate expenses  were $193 million in the quarter, an increase of 30%, \ndriven by the previously discussed environmental reserve and higher technology infrastructure and compliance \nspend.  \n \n"}, "hash": "a7d8ce7a0242438448099969a3886738d5952674b5572b6549b689832231251f", "class_name": "RelatedNodeInfo"}}, "text": "These strong results were driven by higher pharmaceutical distribution \nvolumes in the Canadian business compared to the prior year.  \n \n", "start_char_idx": 2039, "end_char_idx": 2176, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f16bc65-6d77-4525-9f9e-6fb795d4ec3c": {"__data__": {"id_": "9f16bc65-6d77-4525-9f9e-6fb795d4ec3c", "embedding": null, "metadata": {"window": "Revenues were $3.5 billion, an i ncrease of 6%.  And operating profit \nwas $94 million, an increase of 18%.  These strong results were driven by higher pharmaceutical distribution \nvolumes in the Canadian business compared to the prior year.  \n \n Wrapping up our segment review, corporate expenses  were $193 million in the quarter, an increase of 30%, \ndriven by the previously discussed environmental reserve and higher technology infrastructure and compliance \nspend.  \n \n Let me now turn to cash and capital deployment, which can be found on slide 12.  We e nded the quarter with $4.6 \nbillion in cash and cash equivalents.  For the fiscal year, we generated $3.6 billion in free cash flow, including $687 \nmillion of capital expenditures, which included new and existing distribution centers as well as investments i n \ntechnology, data, and analytics to support our growth priorities.  \n \n", "original_text": "Wrapping up our segment review, corporate expenses  were $193 million in the quarter, an increase of 30%, \ndriven by the previously discussed environmental reserve and higher technology infrastructure and compliance \nspend.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3868fd7f528170285cbc98e0690577279603138755dc4b5f3c172ad24104f9b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db65b094-fe05-4670-bf1a-a1ef2840e779", "node_type": "1", "metadata": {"window": "Next, let me address our international results.  Revenues were $3.5 billion, an i ncrease of 6%.  And operating profit \nwas $94 million, an increase of 18%.  These strong results were driven by higher pharmaceutical distribution \nvolumes in the Canadian business compared to the prior year.  \n \n Wrapping up our segment review, corporate expenses  were $193 million in the quarter, an increase of 30%, \ndriven by the previously discussed environmental reserve and higher technology infrastructure and compliance \nspend.  \n \n Let me now turn to cash and capital deployment, which can be found on slide 12.  We e nded the quarter with $4.6 \nbillion in cash and cash equivalents. ", "original_text": "These strong results were driven by higher pharmaceutical distribution \nvolumes in the Canadian business compared to the prior year.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "cc7d8433449366ce2e22879674781892e037282fc14b6016c69ccce4c6f76adb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2a0c458-2532-4872-821b-9d5648c44201", "node_type": "1", "metadata": {"window": "And operating profit \nwas $94 million, an increase of 18%.  These strong results were driven by higher pharmaceutical distribution \nvolumes in the Canadian business compared to the prior year.  \n \n Wrapping up our segment review, corporate expenses  were $193 million in the quarter, an increase of 30%, \ndriven by the previously discussed environmental reserve and higher technology infrastructure and compliance \nspend.  \n \n Let me now turn to cash and capital deployment, which can be found on slide 12.  We e nded the quarter with $4.6 \nbillion in cash and cash equivalents.  For the fiscal year, we generated $3.6 billion in free cash flow, including $687 \nmillion of capital expenditures, which included new and existing distribution centers as well as investments i n \ntechnology, data, and analytics to support our growth priorities.  \n \n During the quarter, several of our customers were impacted by the Change Healthcare outage, delaying billing \nfunctions and claims payments. ", "original_text": "Let me now turn to cash and capital deployment, which can be found on slide 12. "}, "hash": "5da4787f512c454c4a98a05c463638e3cf9525dda3993f22920e5a32340cf8b5", "class_name": "RelatedNodeInfo"}}, "text": "Wrapping up our segment review, corporate expenses  were $193 million in the quarter, an increase of 30%, \ndriven by the previously discussed environmental reserve and higher technology infrastructure and compliance \nspend.  \n \n", "start_char_idx": 2176, "end_char_idx": 2404, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2a0c458-2532-4872-821b-9d5648c44201": {"__data__": {"id_": "f2a0c458-2532-4872-821b-9d5648c44201", "embedding": null, "metadata": {"window": "And operating profit \nwas $94 million, an increase of 18%.  These strong results were driven by higher pharmaceutical distribution \nvolumes in the Canadian business compared to the prior year.  \n \n Wrapping up our segment review, corporate expenses  were $193 million in the quarter, an increase of 30%, \ndriven by the previously discussed environmental reserve and higher technology infrastructure and compliance \nspend.  \n \n Let me now turn to cash and capital deployment, which can be found on slide 12.  We e nded the quarter with $4.6 \nbillion in cash and cash equivalents.  For the fiscal year, we generated $3.6 billion in free cash flow, including $687 \nmillion of capital expenditures, which included new and existing distribution centers as well as investments i n \ntechnology, data, and analytics to support our growth priorities.  \n \n During the quarter, several of our customers were impacted by the Change Healthcare outage, delaying billing \nfunctions and claims payments. ", "original_text": "Let me now turn to cash and capital deployment, which can be found on slide 12. ", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3868fd7f528170285cbc98e0690577279603138755dc4b5f3c172ad24104f9b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f16bc65-6d77-4525-9f9e-6fb795d4ec3c", "node_type": "1", "metadata": {"window": "Revenues were $3.5 billion, an i ncrease of 6%.  And operating profit \nwas $94 million, an increase of 18%.  These strong results were driven by higher pharmaceutical distribution \nvolumes in the Canadian business compared to the prior year.  \n \n Wrapping up our segment review, corporate expenses  were $193 million in the quarter, an increase of 30%, \ndriven by the previously discussed environmental reserve and higher technology infrastructure and compliance \nspend.  \n \n Let me now turn to cash and capital deployment, which can be found on slide 12.  We e nded the quarter with $4.6 \nbillion in cash and cash equivalents.  For the fiscal year, we generated $3.6 billion in free cash flow, including $687 \nmillion of capital expenditures, which included new and existing distribution centers as well as investments i n \ntechnology, data, and analytics to support our growth priorities.  \n \n", "original_text": "Wrapping up our segment review, corporate expenses  were $193 million in the quarter, an increase of 30%, \ndriven by the previously discussed environmental reserve and higher technology infrastructure and compliance \nspend.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "98f7bebb626db1be70b7f02b2034e20772401c988d4f48130969c2a7f52ece55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82194558-082c-49b6-98d6-5d7e8a1ce63e", "node_type": "1", "metadata": {"window": "These strong results were driven by higher pharmaceutical distribution \nvolumes in the Canadian business compared to the prior year.  \n \n Wrapping up our segment review, corporate expenses  were $193 million in the quarter, an increase of 30%, \ndriven by the previously discussed environmental reserve and higher technology infrastructure and compliance \nspend.  \n \n Let me now turn to cash and capital deployment, which can be found on slide 12.  We e nded the quarter with $4.6 \nbillion in cash and cash equivalents.  For the fiscal year, we generated $3.6 billion in free cash flow, including $687 \nmillion of capital expenditures, which included new and existing distribution centers as well as investments i n \ntechnology, data, and analytics to support our growth priorities.  \n \n During the quarter, several of our customers were impacted by the Change Healthcare outage, delaying billing \nfunctions and claims payments.  This outage created a timing impact on McKesson 's cash flows. ", "original_text": "We e nded the quarter with $4.6 \nbillion in cash and cash equivalents. "}, "hash": "f38f83ae0df8843e43d27f632a48e7b2264e12d9c32d4851468806af558d29ac", "class_name": "RelatedNodeInfo"}}, "text": "Let me now turn to cash and capital deployment, which can be found on slide 12. ", "start_char_idx": 2404, "end_char_idx": 2484, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82194558-082c-49b6-98d6-5d7e8a1ce63e": {"__data__": {"id_": "82194558-082c-49b6-98d6-5d7e8a1ce63e", "embedding": null, "metadata": {"window": "These strong results were driven by higher pharmaceutical distribution \nvolumes in the Canadian business compared to the prior year.  \n \n Wrapping up our segment review, corporate expenses  were $193 million in the quarter, an increase of 30%, \ndriven by the previously discussed environmental reserve and higher technology infrastructure and compliance \nspend.  \n \n Let me now turn to cash and capital deployment, which can be found on slide 12.  We e nded the quarter with $4.6 \nbillion in cash and cash equivalents.  For the fiscal year, we generated $3.6 billion in free cash flow, including $687 \nmillion of capital expenditures, which included new and existing distribution centers as well as investments i n \ntechnology, data, and analytics to support our growth priorities.  \n \n During the quarter, several of our customers were impacted by the Change Healthcare outage, delaying billing \nfunctions and claims payments.  This outage created a timing impact on McKesson 's cash flows. ", "original_text": "We e nded the quarter with $4.6 \nbillion in cash and cash equivalents. ", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3868fd7f528170285cbc98e0690577279603138755dc4b5f3c172ad24104f9b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2a0c458-2532-4872-821b-9d5648c44201", "node_type": "1", "metadata": {"window": "And operating profit \nwas $94 million, an increase of 18%.  These strong results were driven by higher pharmaceutical distribution \nvolumes in the Canadian business compared to the prior year.  \n \n Wrapping up our segment review, corporate expenses  were $193 million in the quarter, an increase of 30%, \ndriven by the previously discussed environmental reserve and higher technology infrastructure and compliance \nspend.  \n \n Let me now turn to cash and capital deployment, which can be found on slide 12.  We e nded the quarter with $4.6 \nbillion in cash and cash equivalents.  For the fiscal year, we generated $3.6 billion in free cash flow, including $687 \nmillion of capital expenditures, which included new and existing distribution centers as well as investments i n \ntechnology, data, and analytics to support our growth priorities.  \n \n During the quarter, several of our customers were impacted by the Change Healthcare outage, delaying billing \nfunctions and claims payments. ", "original_text": "Let me now turn to cash and capital deployment, which can be found on slide 12. ", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a5858cb84d6a2eaa6977a1804b0e9bde6eb9dcc677ec884900e108e5953cb31e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "703f7ca5-e788-4f94-9455-416b5bd7cdfa", "node_type": "1", "metadata": {"window": "Wrapping up our segment review, corporate expenses  were $193 million in the quarter, an increase of 30%, \ndriven by the previously discussed environmental reserve and higher technology infrastructure and compliance \nspend.  \n \n Let me now turn to cash and capital deployment, which can be found on slide 12.  We e nded the quarter with $4.6 \nbillion in cash and cash equivalents.  For the fiscal year, we generated $3.6 billion in free cash flow, including $687 \nmillion of capital expenditures, which included new and existing distribution centers as well as investments i n \ntechnology, data, and analytics to support our growth priorities.  \n \n During the quarter, several of our customers were impacted by the Change Healthcare outage, delaying billing \nfunctions and claims payments.  This outage created a timing impact on McKesson 's cash flows.  However, the \nimpact was less severe than we had previously indicated.  \n \n", "original_text": "For the fiscal year, we generated $3.6 billion in free cash flow, including $687 \nmillion of capital expenditures, which included new and existing distribution centers as well as investments i n \ntechnology, data, and analytics to support our growth priorities.  \n \n"}, "hash": "4eb66e7751ad1587463894ae9e07abbb4f5e5740d0d301b33ac3c4d54b32aa43", "class_name": "RelatedNodeInfo"}}, "text": "We e nded the quarter with $4.6 \nbillion in cash and cash equivalents. ", "start_char_idx": 2484, "end_char_idx": 2555, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "703f7ca5-e788-4f94-9455-416b5bd7cdfa": {"__data__": {"id_": "703f7ca5-e788-4f94-9455-416b5bd7cdfa", "embedding": null, "metadata": {"window": "Wrapping up our segment review, corporate expenses  were $193 million in the quarter, an increase of 30%, \ndriven by the previously discussed environmental reserve and higher technology infrastructure and compliance \nspend.  \n \n Let me now turn to cash and capital deployment, which can be found on slide 12.  We e nded the quarter with $4.6 \nbillion in cash and cash equivalents.  For the fiscal year, we generated $3.6 billion in free cash flow, including $687 \nmillion of capital expenditures, which included new and existing distribution centers as well as investments i n \ntechnology, data, and analytics to support our growth priorities.  \n \n During the quarter, several of our customers were impacted by the Change Healthcare outage, delaying billing \nfunctions and claims payments.  This outage created a timing impact on McKesson 's cash flows.  However, the \nimpact was less severe than we had previously indicated.  \n \n", "original_text": "For the fiscal year, we generated $3.6 billion in free cash flow, including $687 \nmillion of capital expenditures, which included new and existing distribution centers as well as investments i n \ntechnology, data, and analytics to support our growth priorities.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3868fd7f528170285cbc98e0690577279603138755dc4b5f3c172ad24104f9b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82194558-082c-49b6-98d6-5d7e8a1ce63e", "node_type": "1", "metadata": {"window": "These strong results were driven by higher pharmaceutical distribution \nvolumes in the Canadian business compared to the prior year.  \n \n Wrapping up our segment review, corporate expenses  were $193 million in the quarter, an increase of 30%, \ndriven by the previously discussed environmental reserve and higher technology infrastructure and compliance \nspend.  \n \n Let me now turn to cash and capital deployment, which can be found on slide 12.  We e nded the quarter with $4.6 \nbillion in cash and cash equivalents.  For the fiscal year, we generated $3.6 billion in free cash flow, including $687 \nmillion of capital expenditures, which included new and existing distribution centers as well as investments i n \ntechnology, data, and analytics to support our growth priorities.  \n \n During the quarter, several of our customers were impacted by the Change Healthcare outage, delaying billing \nfunctions and claims payments.  This outage created a timing impact on McKesson 's cash flows. ", "original_text": "We e nded the quarter with $4.6 \nbillion in cash and cash equivalents. ", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "735eaeddedf76c43414d35aa36d960a9ec61bfceec6d790cac8d24f4371b72b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e08df7c5-fad0-48b0-b005-b8829fd29a5f", "node_type": "1", "metadata": {"window": "Let me now turn to cash and capital deployment, which can be found on slide 12.  We e nded the quarter with $4.6 \nbillion in cash and cash equivalents.  For the fiscal year, we generated $3.6 billion in free cash flow, including $687 \nmillion of capital expenditures, which included new and existing distribution centers as well as investments i n \ntechnology, data, and analytics to support our growth priorities.  \n \n During the quarter, several of our customers were impacted by the Change Healthcare outage, delaying billing \nfunctions and claims payments.  This outage created a timing impact on McKesson 's cash flows.  However, the \nimpact was less severe than we had previously indicated.  \n \n We continue to focus on capital deployment to drive value for our stakeholders. ", "original_text": "During the quarter, several of our customers were impacted by the Change Healthcare outage, delaying billing \nfunctions and claims payments. "}, "hash": "2324d40111ba1223c261968cadd248615b54a9e02499899df61ef7bfaa0b577b", "class_name": "RelatedNodeInfo"}}, "text": "For the fiscal year, we generated $3.6 billion in free cash flow, including $687 \nmillion of capital expenditures, which included new and existing distribution centers as well as investments i n \ntechnology, data, and analytics to support our growth priorities.  \n \n", "start_char_idx": 2555, "end_char_idx": 2821, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e08df7c5-fad0-48b0-b005-b8829fd29a5f": {"__data__": {"id_": "e08df7c5-fad0-48b0-b005-b8829fd29a5f", "embedding": null, "metadata": {"window": "Let me now turn to cash and capital deployment, which can be found on slide 12.  We e nded the quarter with $4.6 \nbillion in cash and cash equivalents.  For the fiscal year, we generated $3.6 billion in free cash flow, including $687 \nmillion of capital expenditures, which included new and existing distribution centers as well as investments i n \ntechnology, data, and analytics to support our growth priorities.  \n \n During the quarter, several of our customers were impacted by the Change Healthcare outage, delaying billing \nfunctions and claims payments.  This outage created a timing impact on McKesson 's cash flows.  However, the \nimpact was less severe than we had previously indicated.  \n \n We continue to focus on capital deployment to drive value for our stakeholders. ", "original_text": "During the quarter, several of our customers were impacted by the Change Healthcare outage, delaying billing \nfunctions and claims payments. ", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3868fd7f528170285cbc98e0690577279603138755dc4b5f3c172ad24104f9b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "703f7ca5-e788-4f94-9455-416b5bd7cdfa", "node_type": "1", "metadata": {"window": "Wrapping up our segment review, corporate expenses  were $193 million in the quarter, an increase of 30%, \ndriven by the previously discussed environmental reserve and higher technology infrastructure and compliance \nspend.  \n \n Let me now turn to cash and capital deployment, which can be found on slide 12.  We e nded the quarter with $4.6 \nbillion in cash and cash equivalents.  For the fiscal year, we generated $3.6 billion in free cash flow, including $687 \nmillion of capital expenditures, which included new and existing distribution centers as well as investments i n \ntechnology, data, and analytics to support our growth priorities.  \n \n During the quarter, several of our customers were impacted by the Change Healthcare outage, delaying billing \nfunctions and claims payments.  This outage created a timing impact on McKesson 's cash flows.  However, the \nimpact was less severe than we had previously indicated.  \n \n", "original_text": "For the fiscal year, we generated $3.6 billion in free cash flow, including $687 \nmillion of capital expenditures, which included new and existing distribution centers as well as investments i n \ntechnology, data, and analytics to support our growth priorities.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "9094638f4b5a8ebc77a3ef546b3b8b8e56642353312d8574e362a2ee94721714", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14b9fe16-c167-4a85-a755-db6980133991", "node_type": "1", "metadata": {"window": "We e nded the quarter with $4.6 \nbillion in cash and cash equivalents.  For the fiscal year, we generated $3.6 billion in free cash flow, including $687 \nmillion of capital expenditures, which included new and existing distribution centers as well as investments i n \ntechnology, data, and analytics to support our growth priorities.  \n \n During the quarter, several of our customers were impacted by the Change Healthcare outage, delaying billing \nfunctions and claims payments.  This outage created a timing impact on McKesson 's cash flows.  However, the \nimpact was less severe than we had previously indicated.  \n \n We continue to focus on capital deployment to drive value for our stakeholders.  In fiscal 2024, we returned $3.3 \nbillion of cash to shareholders. ", "original_text": "This outage created a timing impact on McKesson 's cash flows. "}, "hash": "8858059110075db6d634e4a15d67deee491e442dc9021db4e5cdb811dcf51615", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter, several of our customers were impacted by the Change Healthcare outage, delaying billing \nfunctions and claims payments. ", "start_char_idx": 2821, "end_char_idx": 2962, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14b9fe16-c167-4a85-a755-db6980133991": {"__data__": {"id_": "14b9fe16-c167-4a85-a755-db6980133991", "embedding": null, "metadata": {"window": "We e nded the quarter with $4.6 \nbillion in cash and cash equivalents.  For the fiscal year, we generated $3.6 billion in free cash flow, including $687 \nmillion of capital expenditures, which included new and existing distribution centers as well as investments i n \ntechnology, data, and analytics to support our growth priorities.  \n \n During the quarter, several of our customers were impacted by the Change Healthcare outage, delaying billing \nfunctions and claims payments.  This outage created a timing impact on McKesson 's cash flows.  However, the \nimpact was less severe than we had previously indicated.  \n \n We continue to focus on capital deployment to drive value for our stakeholders.  In fiscal 2024, we returned $3.3 \nbillion of cash to shareholders. ", "original_text": "This outage created a timing impact on McKesson 's cash flows. ", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3868fd7f528170285cbc98e0690577279603138755dc4b5f3c172ad24104f9b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e08df7c5-fad0-48b0-b005-b8829fd29a5f", "node_type": "1", "metadata": {"window": "Let me now turn to cash and capital deployment, which can be found on slide 12.  We e nded the quarter with $4.6 \nbillion in cash and cash equivalents.  For the fiscal year, we generated $3.6 billion in free cash flow, including $687 \nmillion of capital expenditures, which included new and existing distribution centers as well as investments i n \ntechnology, data, and analytics to support our growth priorities.  \n \n During the quarter, several of our customers were impacted by the Change Healthcare outage, delaying billing \nfunctions and claims payments.  This outage created a timing impact on McKesson 's cash flows.  However, the \nimpact was less severe than we had previously indicated.  \n \n We continue to focus on capital deployment to drive value for our stakeholders. ", "original_text": "During the quarter, several of our customers were impacted by the Change Healthcare outage, delaying billing \nfunctions and claims payments. ", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "963f1fbe6bd3138ab3073268d46ce4ce17a99d5980f42ee7e5145a39d96d1f0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f181601-711c-4e2c-8f12-024f78c29635", "node_type": "1", "metadata": {"window": "For the fiscal year, we generated $3.6 billion in free cash flow, including $687 \nmillion of capital expenditures, which included new and existing distribution centers as well as investments i n \ntechnology, data, and analytics to support our growth priorities.  \n \n During the quarter, several of our customers were impacted by the Change Healthcare outage, delaying billing \nfunctions and claims payments.  This outage created a timing impact on McKesson 's cash flows.  However, the \nimpact was less severe than we had previously indicated.  \n \n We continue to focus on capital deployment to drive value for our stakeholders.  In fiscal 2024, we returned $3.3 \nbillion of cash to shareholders.  We returned $3 billion t hrough share repurchases at an average price per share of \napproximately $436, including $678 million of share repurchases in the fiscal fourth quarter.  \n \n", "original_text": "However, the \nimpact was less severe than we had previously indicated.  \n \n"}, "hash": "74f1e75a57bfa4e67239a8f956738256b59ffa941f254a404de10f074f684e9d", "class_name": "RelatedNodeInfo"}}, "text": "This outage created a timing impact on McKesson 's cash flows. ", "start_char_idx": 2962, "end_char_idx": 3025, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f181601-711c-4e2c-8f12-024f78c29635": {"__data__": {"id_": "4f181601-711c-4e2c-8f12-024f78c29635", "embedding": null, "metadata": {"window": "For the fiscal year, we generated $3.6 billion in free cash flow, including $687 \nmillion of capital expenditures, which included new and existing distribution centers as well as investments i n \ntechnology, data, and analytics to support our growth priorities.  \n \n During the quarter, several of our customers were impacted by the Change Healthcare outage, delaying billing \nfunctions and claims payments.  This outage created a timing impact on McKesson 's cash flows.  However, the \nimpact was less severe than we had previously indicated.  \n \n We continue to focus on capital deployment to drive value for our stakeholders.  In fiscal 2024, we returned $3.3 \nbillion of cash to shareholders.  We returned $3 billion t hrough share repurchases at an average price per share of \napproximately $436, including $678 million of share repurchases in the fiscal fourth quarter.  \n \n", "original_text": "However, the \nimpact was less severe than we had previously indicated.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3868fd7f528170285cbc98e0690577279603138755dc4b5f3c172ad24104f9b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14b9fe16-c167-4a85-a755-db6980133991", "node_type": "1", "metadata": {"window": "We e nded the quarter with $4.6 \nbillion in cash and cash equivalents.  For the fiscal year, we generated $3.6 billion in free cash flow, including $687 \nmillion of capital expenditures, which included new and existing distribution centers as well as investments i n \ntechnology, data, and analytics to support our growth priorities.  \n \n During the quarter, several of our customers were impacted by the Change Healthcare outage, delaying billing \nfunctions and claims payments.  This outage created a timing impact on McKesson 's cash flows.  However, the \nimpact was less severe than we had previously indicated.  \n \n We continue to focus on capital deployment to drive value for our stakeholders.  In fiscal 2024, we returned $3.3 \nbillion of cash to shareholders. ", "original_text": "This outage created a timing impact on McKesson 's cash flows. ", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "bec38fef7452c3b1fd812f1c44fc1b3d3eea942ee5bd24f0e0e6dad7727578ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f09a82d5-eec1-4538-a576-47f5d39790b7", "node_type": "1", "metadata": {"window": "During the quarter, several of our customers were impacted by the Change Healthcare outage, delaying billing \nfunctions and claims payments.  This outage created a timing impact on McKesson 's cash flows.  However, the \nimpact was less severe than we had previously indicated.  \n \n We continue to focus on capital deployment to drive value for our stakeholders.  In fiscal 2024, we returned $3.3 \nbillion of cash to shareholders.  We returned $3 billion t hrough share repurchases at an average price per share of \napproximately $436, including $678 million of share repurchases in the fiscal fourth quarter.  \n \n Additionally, we paid dividends of $314 million for the full year. ", "original_text": "We continue to focus on capital deployment to drive value for our stakeholders. "}, "hash": "700c8e096707ae33743dcb0b3b47ef21a6b557f2310d63e37bc51e7deb66b374", "class_name": "RelatedNodeInfo"}}, "text": "However, the \nimpact was less severe than we had previously indicated.  \n \n", "start_char_idx": 3025, "end_char_idx": 3100, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f09a82d5-eec1-4538-a576-47f5d39790b7": {"__data__": {"id_": "f09a82d5-eec1-4538-a576-47f5d39790b7", "embedding": null, "metadata": {"window": "During the quarter, several of our customers were impacted by the Change Healthcare outage, delaying billing \nfunctions and claims payments.  This outage created a timing impact on McKesson 's cash flows.  However, the \nimpact was less severe than we had previously indicated.  \n \n We continue to focus on capital deployment to drive value for our stakeholders.  In fiscal 2024, we returned $3.3 \nbillion of cash to shareholders.  We returned $3 billion t hrough share repurchases at an average price per share of \napproximately $436, including $678 million of share repurchases in the fiscal fourth quarter.  \n \n Additionally, we paid dividends of $314 million for the full year. ", "original_text": "We continue to focus on capital deployment to drive value for our stakeholders. ", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3868fd7f528170285cbc98e0690577279603138755dc4b5f3c172ad24104f9b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f181601-711c-4e2c-8f12-024f78c29635", "node_type": "1", "metadata": {"window": "For the fiscal year, we generated $3.6 billion in free cash flow, including $687 \nmillion of capital expenditures, which included new and existing distribution centers as well as investments i n \ntechnology, data, and analytics to support our growth priorities.  \n \n During the quarter, several of our customers were impacted by the Change Healthcare outage, delaying billing \nfunctions and claims payments.  This outage created a timing impact on McKesson 's cash flows.  However, the \nimpact was less severe than we had previously indicated.  \n \n We continue to focus on capital deployment to drive value for our stakeholders.  In fiscal 2024, we returned $3.3 \nbillion of cash to shareholders.  We returned $3 billion t hrough share repurchases at an average price per share of \napproximately $436, including $678 million of share repurchases in the fiscal fourth quarter.  \n \n", "original_text": "However, the \nimpact was less severe than we had previously indicated.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d2e87479e69be76083b0bd17822085f5e5e54ea355a1a2581c29c56bfbe6f522", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e92a396-0532-4271-9d35-d881805e2691", "node_type": "1", "metadata": {"window": "This outage created a timing impact on McKesson 's cash flows.  However, the \nimpact was less severe than we had previously indicated.  \n \n We continue to focus on capital deployment to drive value for our stakeholders.  In fiscal 2024, we returned $3.3 \nbillion of cash to shareholders.  We returned $3 billion t hrough share repurchases at an average price per share of \napproximately $436, including $678 million of share repurchases in the fiscal fourth quarter.  \n \n Additionally, we paid dividends of $314 million for the full year.  When combining share repurchases wit h dividends \npaid, we returned approximately 92% of free cash flow to shareholders in fiscal 2024.  \n ", "original_text": "In fiscal 2024, we returned $3.3 \nbillion of cash to shareholders. "}, "hash": "97b1bfb1591aeec36b246719c59044b38d1b270aed393975d574c2f325eb0c6f", "class_name": "RelatedNodeInfo"}}, "text": "We continue to focus on capital deployment to drive value for our stakeholders. ", "start_char_idx": 3100, "end_char_idx": 3180, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e92a396-0532-4271-9d35-d881805e2691": {"__data__": {"id_": "6e92a396-0532-4271-9d35-d881805e2691", "embedding": null, "metadata": {"window": "This outage created a timing impact on McKesson 's cash flows.  However, the \nimpact was less severe than we had previously indicated.  \n \n We continue to focus on capital deployment to drive value for our stakeholders.  In fiscal 2024, we returned $3.3 \nbillion of cash to shareholders.  We returned $3 billion t hrough share repurchases at an average price per share of \napproximately $436, including $678 million of share repurchases in the fiscal fourth quarter.  \n \n Additionally, we paid dividends of $314 million for the full year.  When combining share repurchases wit h dividends \npaid, we returned approximately 92% of free cash flow to shareholders in fiscal 2024.  \n ", "original_text": "In fiscal 2024, we returned $3.3 \nbillion of cash to shareholders. ", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3868fd7f528170285cbc98e0690577279603138755dc4b5f3c172ad24104f9b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f09a82d5-eec1-4538-a576-47f5d39790b7", "node_type": "1", "metadata": {"window": "During the quarter, several of our customers were impacted by the Change Healthcare outage, delaying billing \nfunctions and claims payments.  This outage created a timing impact on McKesson 's cash flows.  However, the \nimpact was less severe than we had previously indicated.  \n \n We continue to focus on capital deployment to drive value for our stakeholders.  In fiscal 2024, we returned $3.3 \nbillion of cash to shareholders.  We returned $3 billion t hrough share repurchases at an average price per share of \napproximately $436, including $678 million of share repurchases in the fiscal fourth quarter.  \n \n Additionally, we paid dividends of $314 million for the full year. ", "original_text": "We continue to focus on capital deployment to drive value for our stakeholders. ", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "7f2c55b011b4f88216cf258805e4355ec9e82befb55961e73c75dbc16b61352a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94e7c04a-b5ee-4daa-8a95-ef6d9ac4fb79", "node_type": "1", "metadata": {"window": "However, the \nimpact was less severe than we had previously indicated.  \n \n We continue to focus on capital deployment to drive value for our stakeholders.  In fiscal 2024, we returned $3.3 \nbillion of cash to shareholders.  We returned $3 billion t hrough share repurchases at an average price per share of \napproximately $436, including $678 million of share repurchases in the fiscal fourth quarter.  \n \n Additionally, we paid dividends of $314 million for the full year.  When combining share repurchases wit h dividends \npaid, we returned approximately 92% of free cash flow to shareholders in fiscal 2024.  \n ", "original_text": "We returned $3 billion t hrough share repurchases at an average price per share of \napproximately $436, including $678 million of share repurchases in the fiscal fourth quarter.  \n \n"}, "hash": "7ebbbd6599005f495d2c15b5e5414f1bb6de0f111b1f4148f1f716009dd5ea86", "class_name": "RelatedNodeInfo"}}, "text": "In fiscal 2024, we returned $3.3 \nbillion of cash to shareholders. ", "start_char_idx": 3180, "end_char_idx": 3247, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94e7c04a-b5ee-4daa-8a95-ef6d9ac4fb79": {"__data__": {"id_": "94e7c04a-b5ee-4daa-8a95-ef6d9ac4fb79", "embedding": null, "metadata": {"window": "However, the \nimpact was less severe than we had previously indicated.  \n \n We continue to focus on capital deployment to drive value for our stakeholders.  In fiscal 2024, we returned $3.3 \nbillion of cash to shareholders.  We returned $3 billion t hrough share repurchases at an average price per share of \napproximately $436, including $678 million of share repurchases in the fiscal fourth quarter.  \n \n Additionally, we paid dividends of $314 million for the full year.  When combining share repurchases wit h dividends \npaid, we returned approximately 92% of free cash flow to shareholders in fiscal 2024.  \n ", "original_text": "We returned $3 billion t hrough share repurchases at an average price per share of \napproximately $436, including $678 million of share repurchases in the fiscal fourth quarter.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3868fd7f528170285cbc98e0690577279603138755dc4b5f3c172ad24104f9b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e92a396-0532-4271-9d35-d881805e2691", "node_type": "1", "metadata": {"window": "This outage created a timing impact on McKesson 's cash flows.  However, the \nimpact was less severe than we had previously indicated.  \n \n We continue to focus on capital deployment to drive value for our stakeholders.  In fiscal 2024, we returned $3.3 \nbillion of cash to shareholders.  We returned $3 billion t hrough share repurchases at an average price per share of \napproximately $436, including $678 million of share repurchases in the fiscal fourth quarter.  \n \n Additionally, we paid dividends of $314 million for the full year.  When combining share repurchases wit h dividends \npaid, we returned approximately 92% of free cash flow to shareholders in fiscal 2024.  \n ", "original_text": "In fiscal 2024, we returned $3.3 \nbillion of cash to shareholders. ", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "2ec35a7d5201b6ebb4f1c77e9e24129bf7c93227a5240ad72c99ecb19c58d75a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "710b52ee-572b-4752-81ab-69455b2cb0f5", "node_type": "1", "metadata": {"window": "We continue to focus on capital deployment to drive value for our stakeholders.  In fiscal 2024, we returned $3.3 \nbillion of cash to shareholders.  We returned $3 billion t hrough share repurchases at an average price per share of \napproximately $436, including $678 million of share repurchases in the fiscal fourth quarter.  \n \n Additionally, we paid dividends of $314 million for the full year.  When combining share repurchases wit h dividends \npaid, we returned approximately 92% of free cash flow to shareholders in fiscal 2024.  \n ", "original_text": "Additionally, we paid dividends of $314 million for the full year. "}, "hash": "99c381580d657872480996cdf5ca27714c900a0b9c4277e35df592de68b5425a", "class_name": "RelatedNodeInfo"}}, "text": "We returned $3 billion t hrough share repurchases at an average price per share of \napproximately $436, including $678 million of share repurchases in the fiscal fourth quarter.  \n \n", "start_char_idx": 3247, "end_char_idx": 3429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "710b52ee-572b-4752-81ab-69455b2cb0f5": {"__data__": {"id_": "710b52ee-572b-4752-81ab-69455b2cb0f5", "embedding": null, "metadata": {"window": "We continue to focus on capital deployment to drive value for our stakeholders.  In fiscal 2024, we returned $3.3 \nbillion of cash to shareholders.  We returned $3 billion t hrough share repurchases at an average price per share of \napproximately $436, including $678 million of share repurchases in the fiscal fourth quarter.  \n \n Additionally, we paid dividends of $314 million for the full year.  When combining share repurchases wit h dividends \npaid, we returned approximately 92% of free cash flow to shareholders in fiscal 2024.  \n ", "original_text": "Additionally, we paid dividends of $314 million for the full year. ", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3868fd7f528170285cbc98e0690577279603138755dc4b5f3c172ad24104f9b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94e7c04a-b5ee-4daa-8a95-ef6d9ac4fb79", "node_type": "1", "metadata": {"window": "However, the \nimpact was less severe than we had previously indicated.  \n \n We continue to focus on capital deployment to drive value for our stakeholders.  In fiscal 2024, we returned $3.3 \nbillion of cash to shareholders.  We returned $3 billion t hrough share repurchases at an average price per share of \napproximately $436, including $678 million of share repurchases in the fiscal fourth quarter.  \n \n Additionally, we paid dividends of $314 million for the full year.  When combining share repurchases wit h dividends \npaid, we returned approximately 92% of free cash flow to shareholders in fiscal 2024.  \n ", "original_text": "We returned $3 billion t hrough share repurchases at an average price per share of \napproximately $436, including $678 million of share repurchases in the fiscal fourth quarter.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f4faab6e2b36df224984007db49bf1ecc67e655b925e5ec69d0a8167bca5e02c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27ad667c-f83f-4383-bc69-e8e4d06a9c54", "node_type": "1", "metadata": {"window": "In fiscal 2024, we returned $3.3 \nbillion of cash to shareholders.  We returned $3 billion t hrough share repurchases at an average price per share of \napproximately $436, including $678 million of share repurchases in the fiscal fourth quarter.  \n \n Additionally, we paid dividends of $314 million for the full year.  When combining share repurchases wit h dividends \npaid, we returned approximately 92% of free cash flow to shareholders in fiscal 2024.  \n ", "original_text": "When combining share repurchases wit h dividends \npaid, we returned approximately 92% of free cash flow to shareholders in fiscal 2024.  \n "}, "hash": "2dafd72997553e8368b30cbb53edf459f541a9bc4266356922a36a40dda9e004", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, we paid dividends of $314 million for the full year. ", "start_char_idx": 3429, "end_char_idx": 3496, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27ad667c-f83f-4383-bc69-e8e4d06a9c54": {"__data__": {"id_": "27ad667c-f83f-4383-bc69-e8e4d06a9c54", "embedding": null, "metadata": {"window": "In fiscal 2024, we returned $3.3 \nbillion of cash to shareholders.  We returned $3 billion t hrough share repurchases at an average price per share of \napproximately $436, including $678 million of share repurchases in the fiscal fourth quarter.  \n \n Additionally, we paid dividends of $314 million for the full year.  When combining share repurchases wit h dividends \npaid, we returned approximately 92% of free cash flow to shareholders in fiscal 2024.  \n ", "original_text": "When combining share repurchases wit h dividends \npaid, we returned approximately 92% of free cash flow to shareholders in fiscal 2024.  \n ", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3868fd7f528170285cbc98e0690577279603138755dc4b5f3c172ad24104f9b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "710b52ee-572b-4752-81ab-69455b2cb0f5", "node_type": "1", "metadata": {"window": "We continue to focus on capital deployment to drive value for our stakeholders.  In fiscal 2024, we returned $3.3 \nbillion of cash to shareholders.  We returned $3 billion t hrough share repurchases at an average price per share of \napproximately $436, including $678 million of share repurchases in the fiscal fourth quarter.  \n \n Additionally, we paid dividends of $314 million for the full year.  When combining share repurchases wit h dividends \npaid, we returned approximately 92% of free cash flow to shareholders in fiscal 2024.  \n ", "original_text": "Additionally, we paid dividends of $314 million for the full year. ", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "fe0e1bbee8336126e61042b6823d4b51c454fb0ec96c77fba90a0b5cd5985be3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2486b7d7-8c18-470f-a9e7-b12111c60908", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nSince the beginning of fiscal 2019, we have returned $16.2 billion of cash to shareholders through share \nrepurchases and dividends.  Of this amount, approxima tely $14.5 billion has been returned through share \nrepurchases, reducing our total average shares outstanding by nearly 36%.  \n \n The strength of our balance sheet and strong credit metrics, supported by our strong operating performance and \ndisciplined and balanced financial policy, was recognized in the quarter by the recent Moody's credit rating \nupgrade to A3 from Baa1. ", "original_text": "McKesson Corp.  "}, "hash": "ca573a61e1c307b1ef58ec3285b93f25df51d4ab649d938d5fd0a987ed585f2e", "class_name": "RelatedNodeInfo"}}, "text": "When combining share repurchases wit h dividends \npaid, we returned approximately 92% of free cash flow to shareholders in fiscal 2024.  \n ", "start_char_idx": 3496, "end_char_idx": 3635, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2486b7d7-8c18-470f-a9e7-b12111c60908": {"__data__": {"id_": "2486b7d7-8c18-470f-a9e7-b12111c60908", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nSince the beginning of fiscal 2019, we have returned $16.2 billion of cash to shareholders through share \nrepurchases and dividends.  Of this amount, approxima tely $14.5 billion has been returned through share \nrepurchases, reducing our total average shares outstanding by nearly 36%.  \n \n The strength of our balance sheet and strong credit metrics, supported by our strong operating performance and \ndisciplined and balanced financial policy, was recognized in the quarter by the recent Moody's credit rating \nupgrade to A3 from Baa1. ", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "11afdf5f84178d874ec9d4cd01a502ca741a123c1d5790d22c38f57eb334b75d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27ad667c-f83f-4383-bc69-e8e4d06a9c54", "node_type": "1", "metadata": {"window": "In fiscal 2024, we returned $3.3 \nbillion of cash to shareholders.  We returned $3 billion t hrough share repurchases at an average price per share of \napproximately $436, including $678 million of share repurchases in the fiscal fourth quarter.  \n \n Additionally, we paid dividends of $314 million for the full year.  When combining share repurchases wit h dividends \npaid, we returned approximately 92% of free cash flow to shareholders in fiscal 2024.  \n ", "original_text": "When combining share repurchases wit h dividends \npaid, we returned approximately 92% of free cash flow to shareholders in fiscal 2024.  \n ", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "1658d6bfd71875f00488000e7ef19416382dda4549d6deef7b588823bfc0a967", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b64dded-0068-4e47-90b9-47ef5b0016f1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nSince the beginning of fiscal 2019, we have returned $16.2 billion of cash to shareholders through share \nrepurchases and dividends.  Of this amount, approxima tely $14.5 billion has been returned through share \nrepurchases, reducing our total average shares outstanding by nearly 36%.  \n \n The strength of our balance sheet and strong credit metrics, supported by our strong operating performance and \ndisciplined and balanced financial policy, was recognized in the quarter by the recent Moody's credit rating \nupgrade to A3 from Baa1.  We are now A -rated by two of the three major credit rating agencies.  \n \n", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nSince the beginning of fiscal 2019, we have returned $16.2 billion of cash to shareholders through share \nrepurchases and dividends. "}, "hash": "6a248a210dab84c00f648ccc106ef9bbec759227d53c7a6eccf134613478f070", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b64dded-0068-4e47-90b9-47ef5b0016f1": {"__data__": {"id_": "4b64dded-0068-4e47-90b9-47ef5b0016f1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nSince the beginning of fiscal 2019, we have returned $16.2 billion of cash to shareholders through share \nrepurchases and dividends.  Of this amount, approxima tely $14.5 billion has been returned through share \nrepurchases, reducing our total average shares outstanding by nearly 36%.  \n \n The strength of our balance sheet and strong credit metrics, supported by our strong operating performance and \ndisciplined and balanced financial policy, was recognized in the quarter by the recent Moody's credit rating \nupgrade to A3 from Baa1.  We are now A -rated by two of the three major credit rating agencies.  \n \n", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nSince the beginning of fiscal 2019, we have returned $16.2 billion of cash to shareholders through share \nrepurchases and dividends. ", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "11afdf5f84178d874ec9d4cd01a502ca741a123c1d5790d22c38f57eb334b75d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2486b7d7-8c18-470f-a9e7-b12111c60908", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nSince the beginning of fiscal 2019, we have returned $16.2 billion of cash to shareholders through share \nrepurchases and dividends.  Of this amount, approxima tely $14.5 billion has been returned through share \nrepurchases, reducing our total average shares outstanding by nearly 36%.  \n \n The strength of our balance sheet and strong credit metrics, supported by our strong operating performance and \ndisciplined and balanced financial policy, was recognized in the quarter by the recent Moody's credit rating \nupgrade to A3 from Baa1. ", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e1e0932907a4874902daf2c086b761a6af222c0c7fd1785d2f40ae1cb8a1ae4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3411858-78ce-4726-9f7d-6e0043965945", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nSince the beginning of fiscal 2019, we have returned $16.2 billion of cash to shareholders through share \nrepurchases and dividends.  Of this amount, approxima tely $14.5 billion has been returned through share \nrepurchases, reducing our total average shares outstanding by nearly 36%.  \n \n The strength of our balance sheet and strong credit metrics, supported by our strong operating performance and \ndisciplined and balanced financial policy, was recognized in the quarter by the recent Moody's credit rating \nupgrade to A3 from Baa1.  We are now A -rated by two of the three major credit rating agencies.  \n \n Our strong balance sheet and consistently robust cash flow generatio n, along with disciplined capital allocation, \ncontinues to provide us with the financial flexibility to invest in our growth initiatives, pursue strategic \nopportunities, and return capital to shareholders, all while maintaining a durable capital structure.  \n \n", "original_text": "Of this amount, approxima tely $14.5 billion has been returned through share \nrepurchases, reducing our total average shares outstanding by nearly 36%.  \n \n"}, "hash": "a51a2a4a25a85a415d0e514af8cf2f1d380ac1c5622d68faf1de629dc1a43f55", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nSince the beginning of fiscal 2019, we have returned $16.2 billion of cash to shareholders through share \nrepurchases and dividends. ", "start_char_idx": 16, "end_char_idx": 313, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3411858-78ce-4726-9f7d-6e0043965945": {"__data__": {"id_": "a3411858-78ce-4726-9f7d-6e0043965945", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nSince the beginning of fiscal 2019, we have returned $16.2 billion of cash to shareholders through share \nrepurchases and dividends.  Of this amount, approxima tely $14.5 billion has been returned through share \nrepurchases, reducing our total average shares outstanding by nearly 36%.  \n \n The strength of our balance sheet and strong credit metrics, supported by our strong operating performance and \ndisciplined and balanced financial policy, was recognized in the quarter by the recent Moody's credit rating \nupgrade to A3 from Baa1.  We are now A -rated by two of the three major credit rating agencies.  \n \n Our strong balance sheet and consistently robust cash flow generatio n, along with disciplined capital allocation, \ncontinues to provide us with the financial flexibility to invest in our growth initiatives, pursue strategic \nopportunities, and return capital to shareholders, all while maintaining a durable capital structure.  \n \n", "original_text": "Of this amount, approxima tely $14.5 billion has been returned through share \nrepurchases, reducing our total average shares outstanding by nearly 36%.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "11afdf5f84178d874ec9d4cd01a502ca741a123c1d5790d22c38f57eb334b75d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b64dded-0068-4e47-90b9-47ef5b0016f1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nSince the beginning of fiscal 2019, we have returned $16.2 billion of cash to shareholders through share \nrepurchases and dividends.  Of this amount, approxima tely $14.5 billion has been returned through share \nrepurchases, reducing our total average shares outstanding by nearly 36%.  \n \n The strength of our balance sheet and strong credit metrics, supported by our strong operating performance and \ndisciplined and balanced financial policy, was recognized in the quarter by the recent Moody's credit rating \nupgrade to A3 from Baa1.  We are now A -rated by two of the three major credit rating agencies.  \n \n", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nSince the beginning of fiscal 2019, we have returned $16.2 billion of cash to shareholders through share \nrepurchases and dividends. ", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "cbcf485c5643c6b7009d16aed55fa4418a373136d6e4a3171186b6411447eac9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42d0222c-80bf-4af0-a259-ed68ec56ae54", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nSince the beginning of fiscal 2019, we have returned $16.2 billion of cash to shareholders through share \nrepurchases and dividends.  Of this amount, approxima tely $14.5 billion has been returned through share \nrepurchases, reducing our total average shares outstanding by nearly 36%.  \n \n The strength of our balance sheet and strong credit metrics, supported by our strong operating performance and \ndisciplined and balanced financial policy, was recognized in the quarter by the recent Moody's credit rating \nupgrade to A3 from Baa1.  We are now A -rated by two of the three major credit rating agencies.  \n \n Our strong balance sheet and consistently robust cash flow generatio n, along with disciplined capital allocation, \ncontinues to provide us with the financial flexibility to invest in our growth initiatives, pursue strategic \nopportunities, and return capital to shareholders, all while maintaining a durable capital structure.  \n \n Now let me discuss our fiscal 2025 outlook. ", "original_text": "The strength of our balance sheet and strong credit metrics, supported by our strong operating performance and \ndisciplined and balanced financial policy, was recognized in the quarter by the recent Moody's credit rating \nupgrade to A3 from Baa1. "}, "hash": "77fc9c3c03413076a63550e9672b358deadd6208daa74e11e2c59fa10a390259", "class_name": "RelatedNodeInfo"}}, "text": "Of this amount, approxima tely $14.5 billion has been returned through share \nrepurchases, reducing our total average shares outstanding by nearly 36%.  \n \n", "start_char_idx": 313, "end_char_idx": 469, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42d0222c-80bf-4af0-a259-ed68ec56ae54": {"__data__": {"id_": "42d0222c-80bf-4af0-a259-ed68ec56ae54", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nSince the beginning of fiscal 2019, we have returned $16.2 billion of cash to shareholders through share \nrepurchases and dividends.  Of this amount, approxima tely $14.5 billion has been returned through share \nrepurchases, reducing our total average shares outstanding by nearly 36%.  \n \n The strength of our balance sheet and strong credit metrics, supported by our strong operating performance and \ndisciplined and balanced financial policy, was recognized in the quarter by the recent Moody's credit rating \nupgrade to A3 from Baa1.  We are now A -rated by two of the three major credit rating agencies.  \n \n Our strong balance sheet and consistently robust cash flow generatio n, along with disciplined capital allocation, \ncontinues to provide us with the financial flexibility to invest in our growth initiatives, pursue strategic \nopportunities, and return capital to shareholders, all while maintaining a durable capital structure.  \n \n Now let me discuss our fiscal 2025 outlook. ", "original_text": "The strength of our balance sheet and strong credit metrics, supported by our strong operating performance and \ndisciplined and balanced financial policy, was recognized in the quarter by the recent Moody's credit rating \nupgrade to A3 from Baa1. ", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "11afdf5f84178d874ec9d4cd01a502ca741a123c1d5790d22c38f57eb334b75d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3411858-78ce-4726-9f7d-6e0043965945", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nSince the beginning of fiscal 2019, we have returned $16.2 billion of cash to shareholders through share \nrepurchases and dividends.  Of this amount, approxima tely $14.5 billion has been returned through share \nrepurchases, reducing our total average shares outstanding by nearly 36%.  \n \n The strength of our balance sheet and strong credit metrics, supported by our strong operating performance and \ndisciplined and balanced financial policy, was recognized in the quarter by the recent Moody's credit rating \nupgrade to A3 from Baa1.  We are now A -rated by two of the three major credit rating agencies.  \n \n Our strong balance sheet and consistently robust cash flow generatio n, along with disciplined capital allocation, \ncontinues to provide us with the financial flexibility to invest in our growth initiatives, pursue strategic \nopportunities, and return capital to shareholders, all while maintaining a durable capital structure.  \n \n", "original_text": "Of this amount, approxima tely $14.5 billion has been returned through share \nrepurchases, reducing our total average shares outstanding by nearly 36%.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "4e1532e4460c0685a3c041189a98eaa0ef4f5cd74ac746dfd426c9e0fd63eef0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43947561-9b21-417b-8fad-7862167acf99", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nSince the beginning of fiscal 2019, we have returned $16.2 billion of cash to shareholders through share \nrepurchases and dividends.  Of this amount, approxima tely $14.5 billion has been returned through share \nrepurchases, reducing our total average shares outstanding by nearly 36%.  \n \n The strength of our balance sheet and strong credit metrics, supported by our strong operating performance and \ndisciplined and balanced financial policy, was recognized in the quarter by the recent Moody's credit rating \nupgrade to A3 from Baa1.  We are now A -rated by two of the three major credit rating agencies.  \n \n Our strong balance sheet and consistently robust cash flow generatio n, along with disciplined capital allocation, \ncontinues to provide us with the financial flexibility to invest in our growth initiatives, pursue strategic \nopportunities, and return capital to shareholders, all while maintaining a durable capital structure.  \n \n Now let me discuss our fiscal 2025 outlook.  The breadth of our capabilities and leading portfolio of assets across \noncology and biopharma services have led to value creation for our customers, partners, and shareholders over \nthe last five years. ", "original_text": "We are now A -rated by two of the three major credit rating agencies.  \n \n"}, "hash": "56027c1952a887086d2b8620b0298257a9dc2a5517276119a8f5851690161310", "class_name": "RelatedNodeInfo"}}, "text": "The strength of our balance sheet and strong credit metrics, supported by our strong operating performance and \ndisciplined and balanced financial policy, was recognized in the quarter by the recent Moody's credit rating \nupgrade to A3 from Baa1. ", "start_char_idx": 469, "end_char_idx": 716, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43947561-9b21-417b-8fad-7862167acf99": {"__data__": {"id_": "43947561-9b21-417b-8fad-7862167acf99", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nSince the beginning of fiscal 2019, we have returned $16.2 billion of cash to shareholders through share \nrepurchases and dividends.  Of this amount, approxima tely $14.5 billion has been returned through share \nrepurchases, reducing our total average shares outstanding by nearly 36%.  \n \n The strength of our balance sheet and strong credit metrics, supported by our strong operating performance and \ndisciplined and balanced financial policy, was recognized in the quarter by the recent Moody's credit rating \nupgrade to A3 from Baa1.  We are now A -rated by two of the three major credit rating agencies.  \n \n Our strong balance sheet and consistently robust cash flow generatio n, along with disciplined capital allocation, \ncontinues to provide us with the financial flexibility to invest in our growth initiatives, pursue strategic \nopportunities, and return capital to shareholders, all while maintaining a durable capital structure.  \n \n Now let me discuss our fiscal 2025 outlook.  The breadth of our capabilities and leading portfolio of assets across \noncology and biopharma services have led to value creation for our customers, partners, and shareholders over \nthe last five years. ", "original_text": "We are now A -rated by two of the three major credit rating agencies.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "11afdf5f84178d874ec9d4cd01a502ca741a123c1d5790d22c38f57eb334b75d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42d0222c-80bf-4af0-a259-ed68ec56ae54", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nSince the beginning of fiscal 2019, we have returned $16.2 billion of cash to shareholders through share \nrepurchases and dividends.  Of this amount, approxima tely $14.5 billion has been returned through share \nrepurchases, reducing our total average shares outstanding by nearly 36%.  \n \n The strength of our balance sheet and strong credit metrics, supported by our strong operating performance and \ndisciplined and balanced financial policy, was recognized in the quarter by the recent Moody's credit rating \nupgrade to A3 from Baa1.  We are now A -rated by two of the three major credit rating agencies.  \n \n Our strong balance sheet and consistently robust cash flow generatio n, along with disciplined capital allocation, \ncontinues to provide us with the financial flexibility to invest in our growth initiatives, pursue strategic \nopportunities, and return capital to shareholders, all while maintaining a durable capital structure.  \n \n Now let me discuss our fiscal 2025 outlook. ", "original_text": "The strength of our balance sheet and strong credit metrics, supported by our strong operating performance and \ndisciplined and balanced financial policy, was recognized in the quarter by the recent Moody's credit rating \nupgrade to A3 from Baa1. ", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d88201e0b9e3af0fc91b456d6fc20b5d12e613561caf041cb5ef62429991f898", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4526a51-c4b0-422e-a410-08f551995553", "node_type": "1", "metadata": {"window": "Of this amount, approxima tely $14.5 billion has been returned through share \nrepurchases, reducing our total average shares outstanding by nearly 36%.  \n \n The strength of our balance sheet and strong credit metrics, supported by our strong operating performance and \ndisciplined and balanced financial policy, was recognized in the quarter by the recent Moody's credit rating \nupgrade to A3 from Baa1.  We are now A -rated by two of the three major credit rating agencies.  \n \n Our strong balance sheet and consistently robust cash flow generatio n, along with disciplined capital allocation, \ncontinues to provide us with the financial flexibility to invest in our growth initiatives, pursue strategic \nopportunities, and return capital to shareholders, all while maintaining a durable capital structure.  \n \n Now let me discuss our fiscal 2025 outlook.  The breadth of our capabilities and leading portfolio of assets across \noncology and biopharma services have led to value creation for our customers, partners, and shareholders over \nthe last five years.  Our fisc al 2025 outlook is a continuation of this momentum.  \n \n", "original_text": "Our strong balance sheet and consistently robust cash flow generatio n, along with disciplined capital allocation, \ncontinues to provide us with the financial flexibility to invest in our growth initiatives, pursue strategic \nopportunities, and return capital to shareholders, all while maintaining a durable capital structure.  \n \n"}, "hash": "8e8c02ae9defecbbde8d826d372eb480eb2b5daf3cc8b5ac1b606252ce555a70", "class_name": "RelatedNodeInfo"}}, "text": "We are now A -rated by two of the three major credit rating agencies.  \n \n", "start_char_idx": 716, "end_char_idx": 790, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4526a51-c4b0-422e-a410-08f551995553": {"__data__": {"id_": "b4526a51-c4b0-422e-a410-08f551995553", "embedding": null, "metadata": {"window": "Of this amount, approxima tely $14.5 billion has been returned through share \nrepurchases, reducing our total average shares outstanding by nearly 36%.  \n \n The strength of our balance sheet and strong credit metrics, supported by our strong operating performance and \ndisciplined and balanced financial policy, was recognized in the quarter by the recent Moody's credit rating \nupgrade to A3 from Baa1.  We are now A -rated by two of the three major credit rating agencies.  \n \n Our strong balance sheet and consistently robust cash flow generatio n, along with disciplined capital allocation, \ncontinues to provide us with the financial flexibility to invest in our growth initiatives, pursue strategic \nopportunities, and return capital to shareholders, all while maintaining a durable capital structure.  \n \n Now let me discuss our fiscal 2025 outlook.  The breadth of our capabilities and leading portfolio of assets across \noncology and biopharma services have led to value creation for our customers, partners, and shareholders over \nthe last five years.  Our fisc al 2025 outlook is a continuation of this momentum.  \n \n", "original_text": "Our strong balance sheet and consistently robust cash flow generatio n, along with disciplined capital allocation, \ncontinues to provide us with the financial flexibility to invest in our growth initiatives, pursue strategic \nopportunities, and return capital to shareholders, all while maintaining a durable capital structure.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "11afdf5f84178d874ec9d4cd01a502ca741a123c1d5790d22c38f57eb334b75d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43947561-9b21-417b-8fad-7862167acf99", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nSince the beginning of fiscal 2019, we have returned $16.2 billion of cash to shareholders through share \nrepurchases and dividends.  Of this amount, approxima tely $14.5 billion has been returned through share \nrepurchases, reducing our total average shares outstanding by nearly 36%.  \n \n The strength of our balance sheet and strong credit metrics, supported by our strong operating performance and \ndisciplined and balanced financial policy, was recognized in the quarter by the recent Moody's credit rating \nupgrade to A3 from Baa1.  We are now A -rated by two of the three major credit rating agencies.  \n \n Our strong balance sheet and consistently robust cash flow generatio n, along with disciplined capital allocation, \ncontinues to provide us with the financial flexibility to invest in our growth initiatives, pursue strategic \nopportunities, and return capital to shareholders, all while maintaining a durable capital structure.  \n \n Now let me discuss our fiscal 2025 outlook.  The breadth of our capabilities and leading portfolio of assets across \noncology and biopharma services have led to value creation for our customers, partners, and shareholders over \nthe last five years. ", "original_text": "We are now A -rated by two of the three major credit rating agencies.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "76c4e4c02a0a207426c9029bcf7dae3ba4377f99904c445316a85f2f5d32c965", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fae03bb5-1ac7-4d8a-a1d3-43d18f722da2", "node_type": "1", "metadata": {"window": "The strength of our balance sheet and strong credit metrics, supported by our strong operating performance and \ndisciplined and balanced financial policy, was recognized in the quarter by the recent Moody's credit rating \nupgrade to A3 from Baa1.  We are now A -rated by two of the three major credit rating agencies.  \n \n Our strong balance sheet and consistently robust cash flow generatio n, along with disciplined capital allocation, \ncontinues to provide us with the financial flexibility to invest in our growth initiatives, pursue strategic \nopportunities, and return capital to shareholders, all while maintaining a durable capital structure.  \n \n Now let me discuss our fiscal 2025 outlook.  The breadth of our capabilities and leading portfolio of assets across \noncology and biopharma services have led to value creation for our customers, partners, and shareholders over \nthe last five years.  Our fisc al 2025 outlook is a continuation of this momentum.  \n \n Let me start with our segments. ", "original_text": "Now let me discuss our fiscal 2025 outlook. "}, "hash": "58bbd419a544b37317bef21f8d6cf5c9f9c17e9b71801f92405d013d72e88ac7", "class_name": "RelatedNodeInfo"}}, "text": "Our strong balance sheet and consistently robust cash flow generatio n, along with disciplined capital allocation, \ncontinues to provide us with the financial flexibility to invest in our growth initiatives, pursue strategic \nopportunities, and return capital to shareholders, all while maintaining a durable capital structure.  \n \n", "start_char_idx": 790, "end_char_idx": 1122, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fae03bb5-1ac7-4d8a-a1d3-43d18f722da2": {"__data__": {"id_": "fae03bb5-1ac7-4d8a-a1d3-43d18f722da2", "embedding": null, "metadata": {"window": "The strength of our balance sheet and strong credit metrics, supported by our strong operating performance and \ndisciplined and balanced financial policy, was recognized in the quarter by the recent Moody's credit rating \nupgrade to A3 from Baa1.  We are now A -rated by two of the three major credit rating agencies.  \n \n Our strong balance sheet and consistently robust cash flow generatio n, along with disciplined capital allocation, \ncontinues to provide us with the financial flexibility to invest in our growth initiatives, pursue strategic \nopportunities, and return capital to shareholders, all while maintaining a durable capital structure.  \n \n Now let me discuss our fiscal 2025 outlook.  The breadth of our capabilities and leading portfolio of assets across \noncology and biopharma services have led to value creation for our customers, partners, and shareholders over \nthe last five years.  Our fisc al 2025 outlook is a continuation of this momentum.  \n \n Let me start with our segments. ", "original_text": "Now let me discuss our fiscal 2025 outlook. ", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "11afdf5f84178d874ec9d4cd01a502ca741a123c1d5790d22c38f57eb334b75d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4526a51-c4b0-422e-a410-08f551995553", "node_type": "1", "metadata": {"window": "Of this amount, approxima tely $14.5 billion has been returned through share \nrepurchases, reducing our total average shares outstanding by nearly 36%.  \n \n The strength of our balance sheet and strong credit metrics, supported by our strong operating performance and \ndisciplined and balanced financial policy, was recognized in the quarter by the recent Moody's credit rating \nupgrade to A3 from Baa1.  We are now A -rated by two of the three major credit rating agencies.  \n \n Our strong balance sheet and consistently robust cash flow generatio n, along with disciplined capital allocation, \ncontinues to provide us with the financial flexibility to invest in our growth initiatives, pursue strategic \nopportunities, and return capital to shareholders, all while maintaining a durable capital structure.  \n \n Now let me discuss our fiscal 2025 outlook.  The breadth of our capabilities and leading portfolio of assets across \noncology and biopharma services have led to value creation for our customers, partners, and shareholders over \nthe last five years.  Our fisc al 2025 outlook is a continuation of this momentum.  \n \n", "original_text": "Our strong balance sheet and consistently robust cash flow generatio n, along with disciplined capital allocation, \ncontinues to provide us with the financial flexibility to invest in our growth initiatives, pursue strategic \nopportunities, and return capital to shareholders, all while maintaining a durable capital structure.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "771b05b474b893b537976994b6f39870e878cd9625dde142a37a0ed74ff4b043", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82aa04a4-76f1-47da-a4fc-c472816598b6", "node_type": "1", "metadata": {"window": "We are now A -rated by two of the three major credit rating agencies.  \n \n Our strong balance sheet and consistently robust cash flow generatio n, along with disciplined capital allocation, \ncontinues to provide us with the financial flexibility to invest in our growth initiatives, pursue strategic \nopportunities, and return capital to shareholders, all while maintaining a durable capital structure.  \n \n Now let me discuss our fiscal 2025 outlook.  The breadth of our capabilities and leading portfolio of assets across \noncology and biopharma services have led to value creation for our customers, partners, and shareholders over \nthe last five years.  Our fisc al 2025 outlook is a continuation of this momentum.  \n \n Let me start with our segments.  We anticipate US Pharmaceutical revenues to increase 16% to 19% and \noperating profit to increase 8% to 10%, propelled by sustainable momentum in the core distribution busi ness and \ngrowth across our oncology platform. ", "original_text": "The breadth of our capabilities and leading portfolio of assets across \noncology and biopharma services have led to value creation for our customers, partners, and shareholders over \nthe last five years. "}, "hash": "f4e8046dccb357d4c20dc52f905ccbf152a197cf059cf7cd53a6517bdb2f9c1c", "class_name": "RelatedNodeInfo"}}, "text": "Now let me discuss our fiscal 2025 outlook. ", "start_char_idx": 1122, "end_char_idx": 1166, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82aa04a4-76f1-47da-a4fc-c472816598b6": {"__data__": {"id_": "82aa04a4-76f1-47da-a4fc-c472816598b6", "embedding": null, "metadata": {"window": "We are now A -rated by two of the three major credit rating agencies.  \n \n Our strong balance sheet and consistently robust cash flow generatio n, along with disciplined capital allocation, \ncontinues to provide us with the financial flexibility to invest in our growth initiatives, pursue strategic \nopportunities, and return capital to shareholders, all while maintaining a durable capital structure.  \n \n Now let me discuss our fiscal 2025 outlook.  The breadth of our capabilities and leading portfolio of assets across \noncology and biopharma services have led to value creation for our customers, partners, and shareholders over \nthe last five years.  Our fisc al 2025 outlook is a continuation of this momentum.  \n \n Let me start with our segments.  We anticipate US Pharmaceutical revenues to increase 16% to 19% and \noperating profit to increase 8% to 10%, propelled by sustainable momentum in the core distribution busi ness and \ngrowth across our oncology platform. ", "original_text": "The breadth of our capabilities and leading portfolio of assets across \noncology and biopharma services have led to value creation for our customers, partners, and shareholders over \nthe last five years. ", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "11afdf5f84178d874ec9d4cd01a502ca741a123c1d5790d22c38f57eb334b75d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fae03bb5-1ac7-4d8a-a1d3-43d18f722da2", "node_type": "1", "metadata": {"window": "The strength of our balance sheet and strong credit metrics, supported by our strong operating performance and \ndisciplined and balanced financial policy, was recognized in the quarter by the recent Moody's credit rating \nupgrade to A3 from Baa1.  We are now A -rated by two of the three major credit rating agencies.  \n \n Our strong balance sheet and consistently robust cash flow generatio n, along with disciplined capital allocation, \ncontinues to provide us with the financial flexibility to invest in our growth initiatives, pursue strategic \nopportunities, and return capital to shareholders, all while maintaining a durable capital structure.  \n \n Now let me discuss our fiscal 2025 outlook.  The breadth of our capabilities and leading portfolio of assets across \noncology and biopharma services have led to value creation for our customers, partners, and shareholders over \nthe last five years.  Our fisc al 2025 outlook is a continuation of this momentum.  \n \n Let me start with our segments. ", "original_text": "Now let me discuss our fiscal 2025 outlook. ", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e4392a9ffe984d1c12d9ecdcdaecdf90ce665532a0539a3f89a5d0275b1324fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13b718db-6114-4638-aded-5b1a632401cf", "node_type": "1", "metadata": {"window": "Our strong balance sheet and consistently robust cash flow generatio n, along with disciplined capital allocation, \ncontinues to provide us with the financial flexibility to invest in our growth initiatives, pursue strategic \nopportunities, and return capital to shareholders, all while maintaining a durable capital structure.  \n \n Now let me discuss our fiscal 2025 outlook.  The breadth of our capabilities and leading portfolio of assets across \noncology and biopharma services have led to value creation for our customers, partners, and shareholders over \nthe last five years.  Our fisc al 2025 outlook is a continuation of this momentum.  \n \n Let me start with our segments.  We anticipate US Pharmaceutical revenues to increase 16% to 19% and \noperating profit to increase 8% to 10%, propelled by sustainable momentum in the core distribution busi ness and \ngrowth across our oncology platform.  We continue to make investments in the core distribution network to deliver \nmore efficiency and value for our stakeholders.  \n \n", "original_text": "Our fisc al 2025 outlook is a continuation of this momentum.  \n \n"}, "hash": "c5a7e464380ce72024c33ee718f6b1ca5d6b46bb13140542001130167de9a27f", "class_name": "RelatedNodeInfo"}}, "text": "The breadth of our capabilities and leading portfolio of assets across \noncology and biopharma services have led to value creation for our customers, partners, and shareholders over \nthe last five years. ", "start_char_idx": 1166, "end_char_idx": 1370, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13b718db-6114-4638-aded-5b1a632401cf": {"__data__": {"id_": "13b718db-6114-4638-aded-5b1a632401cf", "embedding": null, "metadata": {"window": "Our strong balance sheet and consistently robust cash flow generatio n, along with disciplined capital allocation, \ncontinues to provide us with the financial flexibility to invest in our growth initiatives, pursue strategic \nopportunities, and return capital to shareholders, all while maintaining a durable capital structure.  \n \n Now let me discuss our fiscal 2025 outlook.  The breadth of our capabilities and leading portfolio of assets across \noncology and biopharma services have led to value creation for our customers, partners, and shareholders over \nthe last five years.  Our fisc al 2025 outlook is a continuation of this momentum.  \n \n Let me start with our segments.  We anticipate US Pharmaceutical revenues to increase 16% to 19% and \noperating profit to increase 8% to 10%, propelled by sustainable momentum in the core distribution busi ness and \ngrowth across our oncology platform.  We continue to make investments in the core distribution network to deliver \nmore efficiency and value for our stakeholders.  \n \n", "original_text": "Our fisc al 2025 outlook is a continuation of this momentum.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "11afdf5f84178d874ec9d4cd01a502ca741a123c1d5790d22c38f57eb334b75d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82aa04a4-76f1-47da-a4fc-c472816598b6", "node_type": "1", "metadata": {"window": "We are now A -rated by two of the three major credit rating agencies.  \n \n Our strong balance sheet and consistently robust cash flow generatio n, along with disciplined capital allocation, \ncontinues to provide us with the financial flexibility to invest in our growth initiatives, pursue strategic \nopportunities, and return capital to shareholders, all while maintaining a durable capital structure.  \n \n Now let me discuss our fiscal 2025 outlook.  The breadth of our capabilities and leading portfolio of assets across \noncology and biopharma services have led to value creation for our customers, partners, and shareholders over \nthe last five years.  Our fisc al 2025 outlook is a continuation of this momentum.  \n \n Let me start with our segments.  We anticipate US Pharmaceutical revenues to increase 16% to 19% and \noperating profit to increase 8% to 10%, propelled by sustainable momentum in the core distribution busi ness and \ngrowth across our oncology platform. ", "original_text": "The breadth of our capabilities and leading portfolio of assets across \noncology and biopharma services have led to value creation for our customers, partners, and shareholders over \nthe last five years. ", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3cdab9d6691ca5226ef270ab66c90b951346b434c01c111b642e96fbb9b9663f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce90eec4-e7d6-4dd1-92d6-b7ff81446a51", "node_type": "1", "metadata": {"window": "Now let me discuss our fiscal 2025 outlook.  The breadth of our capabilities and leading portfolio of assets across \noncology and biopharma services have led to value creation for our customers, partners, and shareholders over \nthe last five years.  Our fisc al 2025 outlook is a continuation of this momentum.  \n \n Let me start with our segments.  We anticipate US Pharmaceutical revenues to increase 16% to 19% and \noperating profit to increase 8% to 10%, propelled by sustainable momentum in the core distribution busi ness and \ngrowth across our oncology platform.  We continue to make investments in the core distribution network to deliver \nmore efficiency and value for our stakeholders.  \n \n The strength of our value proposition was highlighted by the recent agreement to buil d on our existing \npharmaceutical distribution partnership with Optum. ", "original_text": "Let me start with our segments. "}, "hash": "abc26e94d821dfce655ad7ea90a2a03a3cce477ab3a6c42158eb4d64463adc08", "class_name": "RelatedNodeInfo"}}, "text": "Our fisc al 2025 outlook is a continuation of this momentum.  \n \n", "start_char_idx": 1370, "end_char_idx": 1435, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce90eec4-e7d6-4dd1-92d6-b7ff81446a51": {"__data__": {"id_": "ce90eec4-e7d6-4dd1-92d6-b7ff81446a51", "embedding": null, "metadata": {"window": "Now let me discuss our fiscal 2025 outlook.  The breadth of our capabilities and leading portfolio of assets across \noncology and biopharma services have led to value creation for our customers, partners, and shareholders over \nthe last five years.  Our fisc al 2025 outlook is a continuation of this momentum.  \n \n Let me start with our segments.  We anticipate US Pharmaceutical revenues to increase 16% to 19% and \noperating profit to increase 8% to 10%, propelled by sustainable momentum in the core distribution busi ness and \ngrowth across our oncology platform.  We continue to make investments in the core distribution network to deliver \nmore efficiency and value for our stakeholders.  \n \n The strength of our value proposition was highlighted by the recent agreement to buil d on our existing \npharmaceutical distribution partnership with Optum. ", "original_text": "Let me start with our segments. ", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "11afdf5f84178d874ec9d4cd01a502ca741a123c1d5790d22c38f57eb334b75d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13b718db-6114-4638-aded-5b1a632401cf", "node_type": "1", "metadata": {"window": "Our strong balance sheet and consistently robust cash flow generatio n, along with disciplined capital allocation, \ncontinues to provide us with the financial flexibility to invest in our growth initiatives, pursue strategic \nopportunities, and return capital to shareholders, all while maintaining a durable capital structure.  \n \n Now let me discuss our fiscal 2025 outlook.  The breadth of our capabilities and leading portfolio of assets across \noncology and biopharma services have led to value creation for our customers, partners, and shareholders over \nthe last five years.  Our fisc al 2025 outlook is a continuation of this momentum.  \n \n Let me start with our segments.  We anticipate US Pharmaceutical revenues to increase 16% to 19% and \noperating profit to increase 8% to 10%, propelled by sustainable momentum in the core distribution busi ness and \ngrowth across our oncology platform.  We continue to make investments in the core distribution network to deliver \nmore efficiency and value for our stakeholders.  \n \n", "original_text": "Our fisc al 2025 outlook is a continuation of this momentum.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "225acac3a4ed070714e86c2c6fa0379852f7f97f4dd2b0b17f637f5bfb0037d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "467c9dea-820b-41d0-8ccc-fbb1190191cf", "node_type": "1", "metadata": {"window": "The breadth of our capabilities and leading portfolio of assets across \noncology and biopharma services have led to value creation for our customers, partners, and shareholders over \nthe last five years.  Our fisc al 2025 outlook is a continuation of this momentum.  \n \n Let me start with our segments.  We anticipate US Pharmaceutical revenues to increase 16% to 19% and \noperating profit to increase 8% to 10%, propelled by sustainable momentum in the core distribution busi ness and \ngrowth across our oncology platform.  We continue to make investments in the core distribution network to deliver \nmore efficiency and value for our stakeholders.  \n \n The strength of our value proposition was highlighted by the recent agreement to buil d on our existing \npharmaceutical distribution partnership with Optum.  This five -year contract begins on July 1, 2024. ", "original_text": "We anticipate US Pharmaceutical revenues to increase 16% to 19% and \noperating profit to increase 8% to 10%, propelled by sustainable momentum in the core distribution busi ness and \ngrowth across our oncology platform. "}, "hash": "5316c700a4456f17916d812e7e35ccfe24416992c8396836439fdd2dc90764f4", "class_name": "RelatedNodeInfo"}}, "text": "Let me start with our segments. ", "start_char_idx": 1435, "end_char_idx": 1467, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "467c9dea-820b-41d0-8ccc-fbb1190191cf": {"__data__": {"id_": "467c9dea-820b-41d0-8ccc-fbb1190191cf", "embedding": null, "metadata": {"window": "The breadth of our capabilities and leading portfolio of assets across \noncology and biopharma services have led to value creation for our customers, partners, and shareholders over \nthe last five years.  Our fisc al 2025 outlook is a continuation of this momentum.  \n \n Let me start with our segments.  We anticipate US Pharmaceutical revenues to increase 16% to 19% and \noperating profit to increase 8% to 10%, propelled by sustainable momentum in the core distribution busi ness and \ngrowth across our oncology platform.  We continue to make investments in the core distribution network to deliver \nmore efficiency and value for our stakeholders.  \n \n The strength of our value proposition was highlighted by the recent agreement to buil d on our existing \npharmaceutical distribution partnership with Optum.  This five -year contract begins on July 1, 2024. ", "original_text": "We anticipate US Pharmaceutical revenues to increase 16% to 19% and \noperating profit to increase 8% to 10%, propelled by sustainable momentum in the core distribution busi ness and \ngrowth across our oncology platform. ", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "11afdf5f84178d874ec9d4cd01a502ca741a123c1d5790d22c38f57eb334b75d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce90eec4-e7d6-4dd1-92d6-b7ff81446a51", "node_type": "1", "metadata": {"window": "Now let me discuss our fiscal 2025 outlook.  The breadth of our capabilities and leading portfolio of assets across \noncology and biopharma services have led to value creation for our customers, partners, and shareholders over \nthe last five years.  Our fisc al 2025 outlook is a continuation of this momentum.  \n \n Let me start with our segments.  We anticipate US Pharmaceutical revenues to increase 16% to 19% and \noperating profit to increase 8% to 10%, propelled by sustainable momentum in the core distribution busi ness and \ngrowth across our oncology platform.  We continue to make investments in the core distribution network to deliver \nmore efficiency and value for our stakeholders.  \n \n The strength of our value proposition was highlighted by the recent agreement to buil d on our existing \npharmaceutical distribution partnership with Optum. ", "original_text": "Let me start with our segments. ", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "18ca51993ddd7dbdc65f548d398f253ff2f77e41dfcd086c18c1a3b732523e2c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e631ffd2-93fd-46cc-95b9-0ead9241bb07", "node_type": "1", "metadata": {"window": "Our fisc al 2025 outlook is a continuation of this momentum.  \n \n Let me start with our segments.  We anticipate US Pharmaceutical revenues to increase 16% to 19% and \noperating profit to increase 8% to 10%, propelled by sustainable momentum in the core distribution busi ness and \ngrowth across our oncology platform.  We continue to make investments in the core distribution network to deliver \nmore efficiency and value for our stakeholders.  \n \n The strength of our value proposition was highlighted by the recent agreement to buil d on our existing \npharmaceutical distribution partnership with Optum.  This five -year contract begins on July 1, 2024.  The fiscal \n2025 segment outlook incorporates stable, growing prescription utilization trends, bolstered by further growth in \nour generic s ourcing programs and specialty distribution, including our leading plasma and biologics business.  \n \n", "original_text": "We continue to make investments in the core distribution network to deliver \nmore efficiency and value for our stakeholders.  \n \n"}, "hash": "eea60f6e46cb78588a265cd0e9d15d3bf017437e4e6bbe21c82a5f99575f7cce", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate US Pharmaceutical revenues to increase 16% to 19% and \noperating profit to increase 8% to 10%, propelled by sustainable momentum in the core distribution busi ness and \ngrowth across our oncology platform. ", "start_char_idx": 1467, "end_char_idx": 1687, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e631ffd2-93fd-46cc-95b9-0ead9241bb07": {"__data__": {"id_": "e631ffd2-93fd-46cc-95b9-0ead9241bb07", "embedding": null, "metadata": {"window": "Our fisc al 2025 outlook is a continuation of this momentum.  \n \n Let me start with our segments.  We anticipate US Pharmaceutical revenues to increase 16% to 19% and \noperating profit to increase 8% to 10%, propelled by sustainable momentum in the core distribution busi ness and \ngrowth across our oncology platform.  We continue to make investments in the core distribution network to deliver \nmore efficiency and value for our stakeholders.  \n \n The strength of our value proposition was highlighted by the recent agreement to buil d on our existing \npharmaceutical distribution partnership with Optum.  This five -year contract begins on July 1, 2024.  The fiscal \n2025 segment outlook incorporates stable, growing prescription utilization trends, bolstered by further growth in \nour generic s ourcing programs and specialty distribution, including our leading plasma and biologics business.  \n \n", "original_text": "We continue to make investments in the core distribution network to deliver \nmore efficiency and value for our stakeholders.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "11afdf5f84178d874ec9d4cd01a502ca741a123c1d5790d22c38f57eb334b75d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "467c9dea-820b-41d0-8ccc-fbb1190191cf", "node_type": "1", "metadata": {"window": "The breadth of our capabilities and leading portfolio of assets across \noncology and biopharma services have led to value creation for our customers, partners, and shareholders over \nthe last five years.  Our fisc al 2025 outlook is a continuation of this momentum.  \n \n Let me start with our segments.  We anticipate US Pharmaceutical revenues to increase 16% to 19% and \noperating profit to increase 8% to 10%, propelled by sustainable momentum in the core distribution busi ness and \ngrowth across our oncology platform.  We continue to make investments in the core distribution network to deliver \nmore efficiency and value for our stakeholders.  \n \n The strength of our value proposition was highlighted by the recent agreement to buil d on our existing \npharmaceutical distribution partnership with Optum.  This five -year contract begins on July 1, 2024. ", "original_text": "We anticipate US Pharmaceutical revenues to increase 16% to 19% and \noperating profit to increase 8% to 10%, propelled by sustainable momentum in the core distribution busi ness and \ngrowth across our oncology platform. ", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c5c2b998593c546794cd514ac93cadf524d59817bbe0f65d5256c2f5a0b56173", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f2846a6-80f0-4fdf-bb02-9d4e2132f879", "node_type": "1", "metadata": {"window": "Let me start with our segments.  We anticipate US Pharmaceutical revenues to increase 16% to 19% and \noperating profit to increase 8% to 10%, propelled by sustainable momentum in the core distribution busi ness and \ngrowth across our oncology platform.  We continue to make investments in the core distribution network to deliver \nmore efficiency and value for our stakeholders.  \n \n The strength of our value proposition was highlighted by the recent agreement to buil d on our existing \npharmaceutical distribution partnership with Optum.  This five -year contract begins on July 1, 2024.  The fiscal \n2025 segment outlook incorporates stable, growing prescription utilization trends, bolstered by further growth in \nour generic s ourcing programs and specialty distribution, including our leading plasma and biologics business.  \n \n We anticipate further growth from our differentiated oncology platform through the breadth of our assets, US \noncology network, Ontada, and the Sarah Cannon R esearch Institute joint venture. ", "original_text": "The strength of our value proposition was highlighted by the recent agreement to buil d on our existing \npharmaceutical distribution partnership with Optum. "}, "hash": "1f8404a3efadd143f7b522e4008855a6b6a648ac73d871ff21b0da3c5bc72dba", "class_name": "RelatedNodeInfo"}}, "text": "We continue to make investments in the core distribution network to deliver \nmore efficiency and value for our stakeholders.  \n \n", "start_char_idx": 1687, "end_char_idx": 1816, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f2846a6-80f0-4fdf-bb02-9d4e2132f879": {"__data__": {"id_": "8f2846a6-80f0-4fdf-bb02-9d4e2132f879", "embedding": null, "metadata": {"window": "Let me start with our segments.  We anticipate US Pharmaceutical revenues to increase 16% to 19% and \noperating profit to increase 8% to 10%, propelled by sustainable momentum in the core distribution busi ness and \ngrowth across our oncology platform.  We continue to make investments in the core distribution network to deliver \nmore efficiency and value for our stakeholders.  \n \n The strength of our value proposition was highlighted by the recent agreement to buil d on our existing \npharmaceutical distribution partnership with Optum.  This five -year contract begins on July 1, 2024.  The fiscal \n2025 segment outlook incorporates stable, growing prescription utilization trends, bolstered by further growth in \nour generic s ourcing programs and specialty distribution, including our leading plasma and biologics business.  \n \n We anticipate further growth from our differentiated oncology platform through the breadth of our assets, US \noncology network, Ontada, and the Sarah Cannon R esearch Institute joint venture. ", "original_text": "The strength of our value proposition was highlighted by the recent agreement to buil d on our existing \npharmaceutical distribution partnership with Optum. ", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "11afdf5f84178d874ec9d4cd01a502ca741a123c1d5790d22c38f57eb334b75d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e631ffd2-93fd-46cc-95b9-0ead9241bb07", "node_type": "1", "metadata": {"window": "Our fisc al 2025 outlook is a continuation of this momentum.  \n \n Let me start with our segments.  We anticipate US Pharmaceutical revenues to increase 16% to 19% and \noperating profit to increase 8% to 10%, propelled by sustainable momentum in the core distribution busi ness and \ngrowth across our oncology platform.  We continue to make investments in the core distribution network to deliver \nmore efficiency and value for our stakeholders.  \n \n The strength of our value proposition was highlighted by the recent agreement to buil d on our existing \npharmaceutical distribution partnership with Optum.  This five -year contract begins on July 1, 2024.  The fiscal \n2025 segment outlook incorporates stable, growing prescription utilization trends, bolstered by further growth in \nour generic s ourcing programs and specialty distribution, including our leading plasma and biologics business.  \n \n", "original_text": "We continue to make investments in the core distribution network to deliver \nmore efficiency and value for our stakeholders.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "9d2652c80752a591e57f9e5e9d991839be0c2e39c36ef3521adb17f5978f7204", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9ac5b92-6be7-49b3-a381-d2cb73e6d5ac", "node_type": "1", "metadata": {"window": "We anticipate US Pharmaceutical revenues to increase 16% to 19% and \noperating profit to increase 8% to 10%, propelled by sustainable momentum in the core distribution busi ness and \ngrowth across our oncology platform.  We continue to make investments in the core distribution network to deliver \nmore efficiency and value for our stakeholders.  \n \n The strength of our value proposition was highlighted by the recent agreement to buil d on our existing \npharmaceutical distribution partnership with Optum.  This five -year contract begins on July 1, 2024.  The fiscal \n2025 segment outlook incorporates stable, growing prescription utilization trends, bolstered by further growth in \nour generic s ourcing programs and specialty distribution, including our leading plasma and biologics business.  \n \n We anticipate further growth from our differentiated oncology platform through the breadth of our assets, US \noncology network, Ontada, and the Sarah Cannon R esearch Institute joint venture.  As Brian mentioned, as of \nApril 2024, the US oncology network has grown to approximately 2,600 providers in 31 states, and we're pleased \nwith the advancements we've made with Ontada and Sarah Cannon Research Institute suppo rting our mission to \nadvance cancer care. ", "original_text": "This five -year contract begins on July 1, 2024. "}, "hash": "15616c49f33b3d04cb778ce6b10cb69feffec7070642e4c35e65fb9214010125", "class_name": "RelatedNodeInfo"}}, "text": "The strength of our value proposition was highlighted by the recent agreement to buil d on our existing \npharmaceutical distribution partnership with Optum. ", "start_char_idx": 1816, "end_char_idx": 1973, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9ac5b92-6be7-49b3-a381-d2cb73e6d5ac": {"__data__": {"id_": "f9ac5b92-6be7-49b3-a381-d2cb73e6d5ac", "embedding": null, "metadata": {"window": "We anticipate US Pharmaceutical revenues to increase 16% to 19% and \noperating profit to increase 8% to 10%, propelled by sustainable momentum in the core distribution busi ness and \ngrowth across our oncology platform.  We continue to make investments in the core distribution network to deliver \nmore efficiency and value for our stakeholders.  \n \n The strength of our value proposition was highlighted by the recent agreement to buil d on our existing \npharmaceutical distribution partnership with Optum.  This five -year contract begins on July 1, 2024.  The fiscal \n2025 segment outlook incorporates stable, growing prescription utilization trends, bolstered by further growth in \nour generic s ourcing programs and specialty distribution, including our leading plasma and biologics business.  \n \n We anticipate further growth from our differentiated oncology platform through the breadth of our assets, US \noncology network, Ontada, and the Sarah Cannon R esearch Institute joint venture.  As Brian mentioned, as of \nApril 2024, the US oncology network has grown to approximately 2,600 providers in 31 states, and we're pleased \nwith the advancements we've made with Ontada and Sarah Cannon Research Institute suppo rting our mission to \nadvance cancer care. ", "original_text": "This five -year contract begins on July 1, 2024. ", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "11afdf5f84178d874ec9d4cd01a502ca741a123c1d5790d22c38f57eb334b75d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f2846a6-80f0-4fdf-bb02-9d4e2132f879", "node_type": "1", "metadata": {"window": "Let me start with our segments.  We anticipate US Pharmaceutical revenues to increase 16% to 19% and \noperating profit to increase 8% to 10%, propelled by sustainable momentum in the core distribution busi ness and \ngrowth across our oncology platform.  We continue to make investments in the core distribution network to deliver \nmore efficiency and value for our stakeholders.  \n \n The strength of our value proposition was highlighted by the recent agreement to buil d on our existing \npharmaceutical distribution partnership with Optum.  This five -year contract begins on July 1, 2024.  The fiscal \n2025 segment outlook incorporates stable, growing prescription utilization trends, bolstered by further growth in \nour generic s ourcing programs and specialty distribution, including our leading plasma and biologics business.  \n \n We anticipate further growth from our differentiated oncology platform through the breadth of our assets, US \noncology network, Ontada, and the Sarah Cannon R esearch Institute joint venture. ", "original_text": "The strength of our value proposition was highlighted by the recent agreement to buil d on our existing \npharmaceutical distribution partnership with Optum. ", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "cbcd0c922bd8de76f4d2b50d263e11d09174b84232cbf25597907a453b81f2dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "078c99b7-9a83-4be9-acbd-be31c9860397", "node_type": "1", "metadata": {"window": "We continue to make investments in the core distribution network to deliver \nmore efficiency and value for our stakeholders.  \n \n The strength of our value proposition was highlighted by the recent agreement to buil d on our existing \npharmaceutical distribution partnership with Optum.  This five -year contract begins on July 1, 2024.  The fiscal \n2025 segment outlook incorporates stable, growing prescription utilization trends, bolstered by further growth in \nour generic s ourcing programs and specialty distribution, including our leading plasma and biologics business.  \n \n We anticipate further growth from our differentiated oncology platform through the breadth of our assets, US \noncology network, Ontada, and the Sarah Cannon R esearch Institute joint venture.  As Brian mentioned, as of \nApril 2024, the US oncology network has grown to approximately 2,600 providers in 31 states, and we're pleased \nwith the advancements we've made with Ontada and Sarah Cannon Research Institute suppo rting our mission to \nadvance cancer care.  We are pleased with the growth we're seeing in the US Pharmaceutical segment as our \nassets and capabilities and core distribution and the oncology platform continue to accelerate growth.  \n \n", "original_text": "The fiscal \n2025 segment outlook incorporates stable, growing prescription utilization trends, bolstered by further growth in \nour generic s ourcing programs and specialty distribution, including our leading plasma and biologics business.  \n \n"}, "hash": "28b5fe86d696dc96a50c67820f320769c8bb270c0ea672d3bca32fc1a47c59c9", "class_name": "RelatedNodeInfo"}}, "text": "This five -year contract begins on July 1, 2024. ", "start_char_idx": 1973, "end_char_idx": 2022, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "078c99b7-9a83-4be9-acbd-be31c9860397": {"__data__": {"id_": "078c99b7-9a83-4be9-acbd-be31c9860397", "embedding": null, "metadata": {"window": "We continue to make investments in the core distribution network to deliver \nmore efficiency and value for our stakeholders.  \n \n The strength of our value proposition was highlighted by the recent agreement to buil d on our existing \npharmaceutical distribution partnership with Optum.  This five -year contract begins on July 1, 2024.  The fiscal \n2025 segment outlook incorporates stable, growing prescription utilization trends, bolstered by further growth in \nour generic s ourcing programs and specialty distribution, including our leading plasma and biologics business.  \n \n We anticipate further growth from our differentiated oncology platform through the breadth of our assets, US \noncology network, Ontada, and the Sarah Cannon R esearch Institute joint venture.  As Brian mentioned, as of \nApril 2024, the US oncology network has grown to approximately 2,600 providers in 31 states, and we're pleased \nwith the advancements we've made with Ontada and Sarah Cannon Research Institute suppo rting our mission to \nadvance cancer care.  We are pleased with the growth we're seeing in the US Pharmaceutical segment as our \nassets and capabilities and core distribution and the oncology platform continue to accelerate growth.  \n \n", "original_text": "The fiscal \n2025 segment outlook incorporates stable, growing prescription utilization trends, bolstered by further growth in \nour generic s ourcing programs and specialty distribution, including our leading plasma and biologics business.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "11afdf5f84178d874ec9d4cd01a502ca741a123c1d5790d22c38f57eb334b75d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9ac5b92-6be7-49b3-a381-d2cb73e6d5ac", "node_type": "1", "metadata": {"window": "We anticipate US Pharmaceutical revenues to increase 16% to 19% and \noperating profit to increase 8% to 10%, propelled by sustainable momentum in the core distribution busi ness and \ngrowth across our oncology platform.  We continue to make investments in the core distribution network to deliver \nmore efficiency and value for our stakeholders.  \n \n The strength of our value proposition was highlighted by the recent agreement to buil d on our existing \npharmaceutical distribution partnership with Optum.  This five -year contract begins on July 1, 2024.  The fiscal \n2025 segment outlook incorporates stable, growing prescription utilization trends, bolstered by further growth in \nour generic s ourcing programs and specialty distribution, including our leading plasma and biologics business.  \n \n We anticipate further growth from our differentiated oncology platform through the breadth of our assets, US \noncology network, Ontada, and the Sarah Cannon R esearch Institute joint venture.  As Brian mentioned, as of \nApril 2024, the US oncology network has grown to approximately 2,600 providers in 31 states, and we're pleased \nwith the advancements we've made with Ontada and Sarah Cannon Research Institute suppo rting our mission to \nadvance cancer care. ", "original_text": "This five -year contract begins on July 1, 2024. ", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "188f31c7deab4ce42130358e7bdbc9e603a90eac341543d2d27dbf078e845f5d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71ac2222-3677-4d07-af67-0e90a82a61bc", "node_type": "1", "metadata": {"window": "The strength of our value proposition was highlighted by the recent agreement to buil d on our existing \npharmaceutical distribution partnership with Optum.  This five -year contract begins on July 1, 2024.  The fiscal \n2025 segment outlook incorporates stable, growing prescription utilization trends, bolstered by further growth in \nour generic s ourcing programs and specialty distribution, including our leading plasma and biologics business.  \n \n We anticipate further growth from our differentiated oncology platform through the breadth of our assets, US \noncology network, Ontada, and the Sarah Cannon R esearch Institute joint venture.  As Brian mentioned, as of \nApril 2024, the US oncology network has grown to approximately 2,600 providers in 31 states, and we're pleased \nwith the advancements we've made with Ontada and Sarah Cannon Research Institute suppo rting our mission to \nadvance cancer care.  We are pleased with the growth we're seeing in the US Pharmaceutical segment as our \nassets and capabilities and core distribution and the oncology platform continue to accelerate growth.  \n \n In the Prescription Techno logy Solutions segment, we anticipate revenues to increase 18% to 22% and operating \nprofit to increase 12% to 16%. ", "original_text": "We anticipate further growth from our differentiated oncology platform through the breadth of our assets, US \noncology network, Ontada, and the Sarah Cannon R esearch Institute joint venture. "}, "hash": "9c00a2c1408976a71f4436159448326906b1bbbb0ce3dd326c8601f176adc069", "class_name": "RelatedNodeInfo"}}, "text": "The fiscal \n2025 segment outlook incorporates stable, growing prescription utilization trends, bolstered by further growth in \nour generic s ourcing programs and specialty distribution, including our leading plasma and biologics business.  \n \n", "start_char_idx": 2022, "end_char_idx": 2265, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71ac2222-3677-4d07-af67-0e90a82a61bc": {"__data__": {"id_": "71ac2222-3677-4d07-af67-0e90a82a61bc", "embedding": null, "metadata": {"window": "The strength of our value proposition was highlighted by the recent agreement to buil d on our existing \npharmaceutical distribution partnership with Optum.  This five -year contract begins on July 1, 2024.  The fiscal \n2025 segment outlook incorporates stable, growing prescription utilization trends, bolstered by further growth in \nour generic s ourcing programs and specialty distribution, including our leading plasma and biologics business.  \n \n We anticipate further growth from our differentiated oncology platform through the breadth of our assets, US \noncology network, Ontada, and the Sarah Cannon R esearch Institute joint venture.  As Brian mentioned, as of \nApril 2024, the US oncology network has grown to approximately 2,600 providers in 31 states, and we're pleased \nwith the advancements we've made with Ontada and Sarah Cannon Research Institute suppo rting our mission to \nadvance cancer care.  We are pleased with the growth we're seeing in the US Pharmaceutical segment as our \nassets and capabilities and core distribution and the oncology platform continue to accelerate growth.  \n \n In the Prescription Techno logy Solutions segment, we anticipate revenues to increase 18% to 22% and operating \nprofit to increase 12% to 16%. ", "original_text": "We anticipate further growth from our differentiated oncology platform through the breadth of our assets, US \noncology network, Ontada, and the Sarah Cannon R esearch Institute joint venture. ", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "11afdf5f84178d874ec9d4cd01a502ca741a123c1d5790d22c38f57eb334b75d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "078c99b7-9a83-4be9-acbd-be31c9860397", "node_type": "1", "metadata": {"window": "We continue to make investments in the core distribution network to deliver \nmore efficiency and value for our stakeholders.  \n \n The strength of our value proposition was highlighted by the recent agreement to buil d on our existing \npharmaceutical distribution partnership with Optum.  This five -year contract begins on July 1, 2024.  The fiscal \n2025 segment outlook incorporates stable, growing prescription utilization trends, bolstered by further growth in \nour generic s ourcing programs and specialty distribution, including our leading plasma and biologics business.  \n \n We anticipate further growth from our differentiated oncology platform through the breadth of our assets, US \noncology network, Ontada, and the Sarah Cannon R esearch Institute joint venture.  As Brian mentioned, as of \nApril 2024, the US oncology network has grown to approximately 2,600 providers in 31 states, and we're pleased \nwith the advancements we've made with Ontada and Sarah Cannon Research Institute suppo rting our mission to \nadvance cancer care.  We are pleased with the growth we're seeing in the US Pharmaceutical segment as our \nassets and capabilities and core distribution and the oncology platform continue to accelerate growth.  \n \n", "original_text": "The fiscal \n2025 segment outlook incorporates stable, growing prescription utilization trends, bolstered by further growth in \nour generic s ourcing programs and specialty distribution, including our leading plasma and biologics business.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "8b5cc058ada29c7d669f34fd232eff8af1ba337242c3494d4ced1666e82f4e8d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09443bee-e8c3-453f-9b3d-81334763cb17", "node_type": "1", "metadata": {"window": "This five -year contract begins on July 1, 2024.  The fiscal \n2025 segment outlook incorporates stable, growing prescription utilization trends, bolstered by further growth in \nour generic s ourcing programs and specialty distribution, including our leading plasma and biologics business.  \n \n We anticipate further growth from our differentiated oncology platform through the breadth of our assets, US \noncology network, Ontada, and the Sarah Cannon R esearch Institute joint venture.  As Brian mentioned, as of \nApril 2024, the US oncology network has grown to approximately 2,600 providers in 31 states, and we're pleased \nwith the advancements we've made with Ontada and Sarah Cannon Research Institute suppo rting our mission to \nadvance cancer care.  We are pleased with the growth we're seeing in the US Pharmaceutical segment as our \nassets and capabilities and core distribution and the oncology platform continue to accelerate growth.  \n \n In the Prescription Techno logy Solutions segment, we anticipate revenues to increase 18% to 22% and operating \nprofit to increase 12% to 16%.  This outlook reflects organic growth across our solutions and services as we \nexpand and extend partnerships with biopharma manufacturers and increase the number of brands utilizing our \naccess, affordability, and adherence programs. ", "original_text": "As Brian mentioned, as of \nApril 2024, the US oncology network has grown to approximately 2,600 providers in 31 states, and we're pleased \nwith the advancements we've made with Ontada and Sarah Cannon Research Institute suppo rting our mission to \nadvance cancer care. "}, "hash": "a9fc10a1c9900541ffed88200aa98bc657666ae4fc33954219006f020d5d1a90", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate further growth from our differentiated oncology platform through the breadth of our assets, US \noncology network, Ontada, and the Sarah Cannon R esearch Institute joint venture. ", "start_char_idx": 2265, "end_char_idx": 2457, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09443bee-e8c3-453f-9b3d-81334763cb17": {"__data__": {"id_": "09443bee-e8c3-453f-9b3d-81334763cb17", "embedding": null, "metadata": {"window": "This five -year contract begins on July 1, 2024.  The fiscal \n2025 segment outlook incorporates stable, growing prescription utilization trends, bolstered by further growth in \nour generic s ourcing programs and specialty distribution, including our leading plasma and biologics business.  \n \n We anticipate further growth from our differentiated oncology platform through the breadth of our assets, US \noncology network, Ontada, and the Sarah Cannon R esearch Institute joint venture.  As Brian mentioned, as of \nApril 2024, the US oncology network has grown to approximately 2,600 providers in 31 states, and we're pleased \nwith the advancements we've made with Ontada and Sarah Cannon Research Institute suppo rting our mission to \nadvance cancer care.  We are pleased with the growth we're seeing in the US Pharmaceutical segment as our \nassets and capabilities and core distribution and the oncology platform continue to accelerate growth.  \n \n In the Prescription Techno logy Solutions segment, we anticipate revenues to increase 18% to 22% and operating \nprofit to increase 12% to 16%.  This outlook reflects organic growth across our solutions and services as we \nexpand and extend partnerships with biopharma manufacturers and increase the number of brands utilizing our \naccess, affordability, and adherence programs. ", "original_text": "As Brian mentioned, as of \nApril 2024, the US oncology network has grown to approximately 2,600 providers in 31 states, and we're pleased \nwith the advancements we've made with Ontada and Sarah Cannon Research Institute suppo rting our mission to \nadvance cancer care. ", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "11afdf5f84178d874ec9d4cd01a502ca741a123c1d5790d22c38f57eb334b75d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71ac2222-3677-4d07-af67-0e90a82a61bc", "node_type": "1", "metadata": {"window": "The strength of our value proposition was highlighted by the recent agreement to buil d on our existing \npharmaceutical distribution partnership with Optum.  This five -year contract begins on July 1, 2024.  The fiscal \n2025 segment outlook incorporates stable, growing prescription utilization trends, bolstered by further growth in \nour generic s ourcing programs and specialty distribution, including our leading plasma and biologics business.  \n \n We anticipate further growth from our differentiated oncology platform through the breadth of our assets, US \noncology network, Ontada, and the Sarah Cannon R esearch Institute joint venture.  As Brian mentioned, as of \nApril 2024, the US oncology network has grown to approximately 2,600 providers in 31 states, and we're pleased \nwith the advancements we've made with Ontada and Sarah Cannon Research Institute suppo rting our mission to \nadvance cancer care.  We are pleased with the growth we're seeing in the US Pharmaceutical segment as our \nassets and capabilities and core distribution and the oncology platform continue to accelerate growth.  \n \n In the Prescription Techno logy Solutions segment, we anticipate revenues to increase 18% to 22% and operating \nprofit to increase 12% to 16%. ", "original_text": "We anticipate further growth from our differentiated oncology platform through the breadth of our assets, US \noncology network, Ontada, and the Sarah Cannon R esearch Institute joint venture. ", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e358f8d7303a685e8b4d06a096865f4c9315c0281ae516a89a4f8be26167f67e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d71ecd9-d023-441d-9623-bf81fcc4b1b1", "node_type": "1", "metadata": {"window": "The fiscal \n2025 segment outlook incorporates stable, growing prescription utilization trends, bolstered by further growth in \nour generic s ourcing programs and specialty distribution, including our leading plasma and biologics business.  \n \n We anticipate further growth from our differentiated oncology platform through the breadth of our assets, US \noncology network, Ontada, and the Sarah Cannon R esearch Institute joint venture.  As Brian mentioned, as of \nApril 2024, the US oncology network has grown to approximately 2,600 providers in 31 states, and we're pleased \nwith the advancements we've made with Ontada and Sarah Cannon Research Institute suppo rting our mission to \nadvance cancer care.  We are pleased with the growth we're seeing in the US Pharmaceutical segment as our \nassets and capabilities and core distribution and the oncology platform continue to accelerate growth.  \n \n In the Prescription Techno logy Solutions segment, we anticipate revenues to increase 18% to 22% and operating \nprofit to increase 12% to 16%.  This outlook reflects organic growth across our solutions and services as we \nexpand and extend partnerships with biopharma manufacturers and increase the number of brands utilizing our \naccess, affordability, and adherence programs.  Throughout fiscal 2024, we continued to see increased demand \nfor our access and affordability solutions, particularly those related to GLP -1 medications. ", "original_text": "We are pleased with the growth we're seeing in the US Pharmaceutical segment as our \nassets and capabilities and core distribution and the oncology platform continue to accelerate growth.  \n \n"}, "hash": "57ed9ff8271ff5a142204452fc55b2354884d93e988282631a2d41cc041a1814", "class_name": "RelatedNodeInfo"}}, "text": "As Brian mentioned, as of \nApril 2024, the US oncology network has grown to approximately 2,600 providers in 31 states, and we're pleased \nwith the advancements we've made with Ontada and Sarah Cannon Research Institute suppo rting our mission to \nadvance cancer care. ", "start_char_idx": 2457, "end_char_idx": 2726, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d71ecd9-d023-441d-9623-bf81fcc4b1b1": {"__data__": {"id_": "8d71ecd9-d023-441d-9623-bf81fcc4b1b1", "embedding": null, "metadata": {"window": "The fiscal \n2025 segment outlook incorporates stable, growing prescription utilization trends, bolstered by further growth in \nour generic s ourcing programs and specialty distribution, including our leading plasma and biologics business.  \n \n We anticipate further growth from our differentiated oncology platform through the breadth of our assets, US \noncology network, Ontada, and the Sarah Cannon R esearch Institute joint venture.  As Brian mentioned, as of \nApril 2024, the US oncology network has grown to approximately 2,600 providers in 31 states, and we're pleased \nwith the advancements we've made with Ontada and Sarah Cannon Research Institute suppo rting our mission to \nadvance cancer care.  We are pleased with the growth we're seeing in the US Pharmaceutical segment as our \nassets and capabilities and core distribution and the oncology platform continue to accelerate growth.  \n \n In the Prescription Techno logy Solutions segment, we anticipate revenues to increase 18% to 22% and operating \nprofit to increase 12% to 16%.  This outlook reflects organic growth across our solutions and services as we \nexpand and extend partnerships with biopharma manufacturers and increase the number of brands utilizing our \naccess, affordability, and adherence programs.  Throughout fiscal 2024, we continued to see increased demand \nfor our access and affordability solutions, particularly those related to GLP -1 medications. ", "original_text": "We are pleased with the growth we're seeing in the US Pharmaceutical segment as our \nassets and capabilities and core distribution and the oncology platform continue to accelerate growth.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "11afdf5f84178d874ec9d4cd01a502ca741a123c1d5790d22c38f57eb334b75d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09443bee-e8c3-453f-9b3d-81334763cb17", "node_type": "1", "metadata": {"window": "This five -year contract begins on July 1, 2024.  The fiscal \n2025 segment outlook incorporates stable, growing prescription utilization trends, bolstered by further growth in \nour generic s ourcing programs and specialty distribution, including our leading plasma and biologics business.  \n \n We anticipate further growth from our differentiated oncology platform through the breadth of our assets, US \noncology network, Ontada, and the Sarah Cannon R esearch Institute joint venture.  As Brian mentioned, as of \nApril 2024, the US oncology network has grown to approximately 2,600 providers in 31 states, and we're pleased \nwith the advancements we've made with Ontada and Sarah Cannon Research Institute suppo rting our mission to \nadvance cancer care.  We are pleased with the growth we're seeing in the US Pharmaceutical segment as our \nassets and capabilities and core distribution and the oncology platform continue to accelerate growth.  \n \n In the Prescription Techno logy Solutions segment, we anticipate revenues to increase 18% to 22% and operating \nprofit to increase 12% to 16%.  This outlook reflects organic growth across our solutions and services as we \nexpand and extend partnerships with biopharma manufacturers and increase the number of brands utilizing our \naccess, affordability, and adherence programs. ", "original_text": "As Brian mentioned, as of \nApril 2024, the US oncology network has grown to approximately 2,600 providers in 31 states, and we're pleased \nwith the advancements we've made with Ontada and Sarah Cannon Research Institute suppo rting our mission to \nadvance cancer care. ", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "8901a8e4ceb7416a34309198b3e379f1f9d8c76727a2ab81ae0f78ef188e97b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a44973ce-ecf3-4ccf-a631-49bb4b3ae240", "node_type": "1", "metadata": {"window": "We anticipate further growth from our differentiated oncology platform through the breadth of our assets, US \noncology network, Ontada, and the Sarah Cannon R esearch Institute joint venture.  As Brian mentioned, as of \nApril 2024, the US oncology network has grown to approximately 2,600 providers in 31 states, and we're pleased \nwith the advancements we've made with Ontada and Sarah Cannon Research Institute suppo rting our mission to \nadvance cancer care.  We are pleased with the growth we're seeing in the US Pharmaceutical segment as our \nassets and capabilities and core distribution and the oncology platform continue to accelerate growth.  \n \n In the Prescription Techno logy Solutions segment, we anticipate revenues to increase 18% to 22% and operating \nprofit to increase 12% to 16%.  This outlook reflects organic growth across our solutions and services as we \nexpand and extend partnerships with biopharma manufacturers and increase the number of brands utilizing our \naccess, affordability, and adherence programs.  Throughout fiscal 2024, we continued to see increased demand \nfor our access and affordability solutions, particularly those related to GLP -1 medications.  As a remind er, \nMcKesson's prior authorization products serve the majority of the brands through GLP -1 medications. ", "original_text": "In the Prescription Techno logy Solutions segment, we anticipate revenues to increase 18% to 22% and operating \nprofit to increase 12% to 16%. "}, "hash": "bd04d63103ab1f7db487e0923fe4e5ea962be88b30bcbd46b6717c23249a57f6", "class_name": "RelatedNodeInfo"}}, "text": "We are pleased with the growth we're seeing in the US Pharmaceutical segment as our \nassets and capabilities and core distribution and the oncology platform continue to accelerate growth.  \n \n", "start_char_idx": 2726, "end_char_idx": 2918, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a44973ce-ecf3-4ccf-a631-49bb4b3ae240": {"__data__": {"id_": "a44973ce-ecf3-4ccf-a631-49bb4b3ae240", "embedding": null, "metadata": {"window": "We anticipate further growth from our differentiated oncology platform through the breadth of our assets, US \noncology network, Ontada, and the Sarah Cannon R esearch Institute joint venture.  As Brian mentioned, as of \nApril 2024, the US oncology network has grown to approximately 2,600 providers in 31 states, and we're pleased \nwith the advancements we've made with Ontada and Sarah Cannon Research Institute suppo rting our mission to \nadvance cancer care.  We are pleased with the growth we're seeing in the US Pharmaceutical segment as our \nassets and capabilities and core distribution and the oncology platform continue to accelerate growth.  \n \n In the Prescription Techno logy Solutions segment, we anticipate revenues to increase 18% to 22% and operating \nprofit to increase 12% to 16%.  This outlook reflects organic growth across our solutions and services as we \nexpand and extend partnerships with biopharma manufacturers and increase the number of brands utilizing our \naccess, affordability, and adherence programs.  Throughout fiscal 2024, we continued to see increased demand \nfor our access and affordability solutions, particularly those related to GLP -1 medications.  As a remind er, \nMcKesson's prior authorization products serve the majority of the brands through GLP -1 medications. ", "original_text": "In the Prescription Techno logy Solutions segment, we anticipate revenues to increase 18% to 22% and operating \nprofit to increase 12% to 16%. ", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "11afdf5f84178d874ec9d4cd01a502ca741a123c1d5790d22c38f57eb334b75d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d71ecd9-d023-441d-9623-bf81fcc4b1b1", "node_type": "1", "metadata": {"window": "The fiscal \n2025 segment outlook incorporates stable, growing prescription utilization trends, bolstered by further growth in \nour generic s ourcing programs and specialty distribution, including our leading plasma and biologics business.  \n \n We anticipate further growth from our differentiated oncology platform through the breadth of our assets, US \noncology network, Ontada, and the Sarah Cannon R esearch Institute joint venture.  As Brian mentioned, as of \nApril 2024, the US oncology network has grown to approximately 2,600 providers in 31 states, and we're pleased \nwith the advancements we've made with Ontada and Sarah Cannon Research Institute suppo rting our mission to \nadvance cancer care.  We are pleased with the growth we're seeing in the US Pharmaceutical segment as our \nassets and capabilities and core distribution and the oncology platform continue to accelerate growth.  \n \n In the Prescription Techno logy Solutions segment, we anticipate revenues to increase 18% to 22% and operating \nprofit to increase 12% to 16%.  This outlook reflects organic growth across our solutions and services as we \nexpand and extend partnerships with biopharma manufacturers and increase the number of brands utilizing our \naccess, affordability, and adherence programs.  Throughout fiscal 2024, we continued to see increased demand \nfor our access and affordability solutions, particularly those related to GLP -1 medications. ", "original_text": "We are pleased with the growth we're seeing in the US Pharmaceutical segment as our \nassets and capabilities and core distribution and the oncology platform continue to accelerate growth.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3f13e1084aa6d6260be45ac634e8caa4dad6ab796b0416c3cab8ecf0a49cd23e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0abd5464-9b4c-4ad9-bf36-10bafc28e2a7", "node_type": "1", "metadata": {"window": "As Brian mentioned, as of \nApril 2024, the US oncology network has grown to approximately 2,600 providers in 31 states, and we're pleased \nwith the advancements we've made with Ontada and Sarah Cannon Research Institute suppo rting our mission to \nadvance cancer care.  We are pleased with the growth we're seeing in the US Pharmaceutical segment as our \nassets and capabilities and core distribution and the oncology platform continue to accelerate growth.  \n \n In the Prescription Techno logy Solutions segment, we anticipate revenues to increase 18% to 22% and operating \nprofit to increase 12% to 16%.  This outlook reflects organic growth across our solutions and services as we \nexpand and extend partnerships with biopharma manufacturers and increase the number of brands utilizing our \naccess, affordability, and adherence programs.  Throughout fiscal 2024, we continued to see increased demand \nfor our access and affordability solutions, particularly those related to GLP -1 medications.  As a remind er, \nMcKesson's prior authorization products serve the majority of the brands through GLP -1 medications.  Our \nproducts continue to generate value for our partners. ", "original_text": "This outlook reflects organic growth across our solutions and services as we \nexpand and extend partnerships with biopharma manufacturers and increase the number of brands utilizing our \naccess, affordability, and adherence programs. "}, "hash": "d0637956a12988f70640835a3f71eb6e7c153b5f71396a4fa26242f20de3b9a3", "class_name": "RelatedNodeInfo"}}, "text": "In the Prescription Techno logy Solutions segment, we anticipate revenues to increase 18% to 22% and operating \nprofit to increase 12% to 16%. ", "start_char_idx": 2918, "end_char_idx": 3061, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0abd5464-9b4c-4ad9-bf36-10bafc28e2a7": {"__data__": {"id_": "0abd5464-9b4c-4ad9-bf36-10bafc28e2a7", "embedding": null, "metadata": {"window": "As Brian mentioned, as of \nApril 2024, the US oncology network has grown to approximately 2,600 providers in 31 states, and we're pleased \nwith the advancements we've made with Ontada and Sarah Cannon Research Institute suppo rting our mission to \nadvance cancer care.  We are pleased with the growth we're seeing in the US Pharmaceutical segment as our \nassets and capabilities and core distribution and the oncology platform continue to accelerate growth.  \n \n In the Prescription Techno logy Solutions segment, we anticipate revenues to increase 18% to 22% and operating \nprofit to increase 12% to 16%.  This outlook reflects organic growth across our solutions and services as we \nexpand and extend partnerships with biopharma manufacturers and increase the number of brands utilizing our \naccess, affordability, and adherence programs.  Throughout fiscal 2024, we continued to see increased demand \nfor our access and affordability solutions, particularly those related to GLP -1 medications.  As a remind er, \nMcKesson's prior authorization products serve the majority of the brands through GLP -1 medications.  Our \nproducts continue to generate value for our partners. ", "original_text": "This outlook reflects organic growth across our solutions and services as we \nexpand and extend partnerships with biopharma manufacturers and increase the number of brands utilizing our \naccess, affordability, and adherence programs. ", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "11afdf5f84178d874ec9d4cd01a502ca741a123c1d5790d22c38f57eb334b75d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a44973ce-ecf3-4ccf-a631-49bb4b3ae240", "node_type": "1", "metadata": {"window": "We anticipate further growth from our differentiated oncology platform through the breadth of our assets, US \noncology network, Ontada, and the Sarah Cannon R esearch Institute joint venture.  As Brian mentioned, as of \nApril 2024, the US oncology network has grown to approximately 2,600 providers in 31 states, and we're pleased \nwith the advancements we've made with Ontada and Sarah Cannon Research Institute suppo rting our mission to \nadvance cancer care.  We are pleased with the growth we're seeing in the US Pharmaceutical segment as our \nassets and capabilities and core distribution and the oncology platform continue to accelerate growth.  \n \n In the Prescription Techno logy Solutions segment, we anticipate revenues to increase 18% to 22% and operating \nprofit to increase 12% to 16%.  This outlook reflects organic growth across our solutions and services as we \nexpand and extend partnerships with biopharma manufacturers and increase the number of brands utilizing our \naccess, affordability, and adherence programs.  Throughout fiscal 2024, we continued to see increased demand \nfor our access and affordability solutions, particularly those related to GLP -1 medications.  As a remind er, \nMcKesson's prior authorization products serve the majority of the brands through GLP -1 medications. ", "original_text": "In the Prescription Techno logy Solutions segment, we anticipate revenues to increase 18% to 22% and operating \nprofit to increase 12% to 16%. ", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "9ff927d63d25772d5ea6825e97ff0b5e80b642763c3965b7256a09d9a7dd0c21", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f566e053-56b9-417c-bc4a-aa1bfcc5c689", "node_type": "1", "metadata": {"window": "We are pleased with the growth we're seeing in the US Pharmaceutical segment as our \nassets and capabilities and core distribution and the oncology platform continue to accelerate growth.  \n \n In the Prescription Techno logy Solutions segment, we anticipate revenues to increase 18% to 22% and operating \nprofit to increase 12% to 16%.  This outlook reflects organic growth across our solutions and services as we \nexpand and extend partnerships with biopharma manufacturers and increase the number of brands utilizing our \naccess, affordability, and adherence programs.  Throughout fiscal 2024, we continued to see increased demand \nfor our access and affordability solutions, particularly those related to GLP -1 medications.  As a remind er, \nMcKesson's prior authorization products serve the majority of the brands through GLP -1 medications.  Our \nproducts continue to generate value for our partners.  Looking ahead to fiscal 2025, we anticipate that this demand \nwill remain elevated, yet lessen as the rate of increase will be slower than prior years for GLP -1 medications.  \n \n", "original_text": "Throughout fiscal 2024, we continued to see increased demand \nfor our access and affordability solutions, particularly those related to GLP -1 medications. "}, "hash": "df49010422be4451e89a64f5d3af6320bd83b98b768cad95362fb614745f132c", "class_name": "RelatedNodeInfo"}}, "text": "This outlook reflects organic growth across our solutions and services as we \nexpand and extend partnerships with biopharma manufacturers and increase the number of brands utilizing our \naccess, affordability, and adherence programs. ", "start_char_idx": 3061, "end_char_idx": 3295, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f566e053-56b9-417c-bc4a-aa1bfcc5c689": {"__data__": {"id_": "f566e053-56b9-417c-bc4a-aa1bfcc5c689", "embedding": null, "metadata": {"window": "We are pleased with the growth we're seeing in the US Pharmaceutical segment as our \nassets and capabilities and core distribution and the oncology platform continue to accelerate growth.  \n \n In the Prescription Techno logy Solutions segment, we anticipate revenues to increase 18% to 22% and operating \nprofit to increase 12% to 16%.  This outlook reflects organic growth across our solutions and services as we \nexpand and extend partnerships with biopharma manufacturers and increase the number of brands utilizing our \naccess, affordability, and adherence programs.  Throughout fiscal 2024, we continued to see increased demand \nfor our access and affordability solutions, particularly those related to GLP -1 medications.  As a remind er, \nMcKesson's prior authorization products serve the majority of the brands through GLP -1 medications.  Our \nproducts continue to generate value for our partners.  Looking ahead to fiscal 2025, we anticipate that this demand \nwill remain elevated, yet lessen as the rate of increase will be slower than prior years for GLP -1 medications.  \n \n", "original_text": "Throughout fiscal 2024, we continued to see increased demand \nfor our access and affordability solutions, particularly those related to GLP -1 medications. ", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "11afdf5f84178d874ec9d4cd01a502ca741a123c1d5790d22c38f57eb334b75d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0abd5464-9b4c-4ad9-bf36-10bafc28e2a7", "node_type": "1", "metadata": {"window": "As Brian mentioned, as of \nApril 2024, the US oncology network has grown to approximately 2,600 providers in 31 states, and we're pleased \nwith the advancements we've made with Ontada and Sarah Cannon Research Institute suppo rting our mission to \nadvance cancer care.  We are pleased with the growth we're seeing in the US Pharmaceutical segment as our \nassets and capabilities and core distribution and the oncology platform continue to accelerate growth.  \n \n In the Prescription Techno logy Solutions segment, we anticipate revenues to increase 18% to 22% and operating \nprofit to increase 12% to 16%.  This outlook reflects organic growth across our solutions and services as we \nexpand and extend partnerships with biopharma manufacturers and increase the number of brands utilizing our \naccess, affordability, and adherence programs.  Throughout fiscal 2024, we continued to see increased demand \nfor our access and affordability solutions, particularly those related to GLP -1 medications.  As a remind er, \nMcKesson's prior authorization products serve the majority of the brands through GLP -1 medications.  Our \nproducts continue to generate value for our partners. ", "original_text": "This outlook reflects organic growth across our solutions and services as we \nexpand and extend partnerships with biopharma manufacturers and increase the number of brands utilizing our \naccess, affordability, and adherence programs. ", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "25e6fe296f86c89a28d78819ab11807ce56420453498ff546a8d263717a5b01e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "454195e0-9e7e-4c0e-987d-69a03361eff9", "node_type": "1", "metadata": {"window": "In the Prescription Techno logy Solutions segment, we anticipate revenues to increase 18% to 22% and operating \nprofit to increase 12% to 16%.  This outlook reflects organic growth across our solutions and services as we \nexpand and extend partnerships with biopharma manufacturers and increase the number of brands utilizing our \naccess, affordability, and adherence programs.  Throughout fiscal 2024, we continued to see increased demand \nfor our access and affordability solutions, particularly those related to GLP -1 medications.  As a remind er, \nMcKesson's prior authorization products serve the majority of the brands through GLP -1 medications.  Our \nproducts continue to generate value for our partners.  Looking ahead to fiscal 2025, we anticipate that this demand \nwill remain elevated, yet lessen as the rate of increase will be slower than prior years for GLP -1 medications.  \n \n The Medical Surgical business remains well positioned to leverage the breadth and depth of its services and \nassets across all alternate sites of care, including growth in the p rimary care business and our comprehensive \nprivate label portfolio. ", "original_text": "As a remind er, \nMcKesson's prior authorization products serve the majority of the brands through GLP -1 medications. "}, "hash": "7ad0caa5334c8e850a29f85deba7665f8f23612ced312e51443ae268037172c1", "class_name": "RelatedNodeInfo"}}, "text": "Throughout fiscal 2024, we continued to see increased demand \nfor our access and affordability solutions, particularly those related to GLP -1 medications. ", "start_char_idx": 3295, "end_char_idx": 3451, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "454195e0-9e7e-4c0e-987d-69a03361eff9": {"__data__": {"id_": "454195e0-9e7e-4c0e-987d-69a03361eff9", "embedding": null, "metadata": {"window": "In the Prescription Techno logy Solutions segment, we anticipate revenues to increase 18% to 22% and operating \nprofit to increase 12% to 16%.  This outlook reflects organic growth across our solutions and services as we \nexpand and extend partnerships with biopharma manufacturers and increase the number of brands utilizing our \naccess, affordability, and adherence programs.  Throughout fiscal 2024, we continued to see increased demand \nfor our access and affordability solutions, particularly those related to GLP -1 medications.  As a remind er, \nMcKesson's prior authorization products serve the majority of the brands through GLP -1 medications.  Our \nproducts continue to generate value for our partners.  Looking ahead to fiscal 2025, we anticipate that this demand \nwill remain elevated, yet lessen as the rate of increase will be slower than prior years for GLP -1 medications.  \n \n The Medical Surgical business remains well positioned to leverage the breadth and depth of its services and \nassets across all alternate sites of care, including growth in the p rimary care business and our comprehensive \nprivate label portfolio. ", "original_text": "As a remind er, \nMcKesson's prior authorization products serve the majority of the brands through GLP -1 medications. ", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "11afdf5f84178d874ec9d4cd01a502ca741a123c1d5790d22c38f57eb334b75d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f566e053-56b9-417c-bc4a-aa1bfcc5c689", "node_type": "1", "metadata": {"window": "We are pleased with the growth we're seeing in the US Pharmaceutical segment as our \nassets and capabilities and core distribution and the oncology platform continue to accelerate growth.  \n \n In the Prescription Techno logy Solutions segment, we anticipate revenues to increase 18% to 22% and operating \nprofit to increase 12% to 16%.  This outlook reflects organic growth across our solutions and services as we \nexpand and extend partnerships with biopharma manufacturers and increase the number of brands utilizing our \naccess, affordability, and adherence programs.  Throughout fiscal 2024, we continued to see increased demand \nfor our access and affordability solutions, particularly those related to GLP -1 medications.  As a remind er, \nMcKesson's prior authorization products serve the majority of the brands through GLP -1 medications.  Our \nproducts continue to generate value for our partners.  Looking ahead to fiscal 2025, we anticipate that this demand \nwill remain elevated, yet lessen as the rate of increase will be slower than prior years for GLP -1 medications.  \n \n", "original_text": "Throughout fiscal 2024, we continued to see increased demand \nfor our access and affordability solutions, particularly those related to GLP -1 medications. ", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "34c216ec8126f5cf391a8e2efc75e60bbd3c813673ed6eac97bed1eb1e8fe556", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13cd2a0a-93e6-4955-8a9d-a16927c86c22", "node_type": "1", "metadata": {"window": "This outlook reflects organic growth across our solutions and services as we \nexpand and extend partnerships with biopharma manufacturers and increase the number of brands utilizing our \naccess, affordability, and adherence programs.  Throughout fiscal 2024, we continued to see increased demand \nfor our access and affordability solutions, particularly those related to GLP -1 medications.  As a remind er, \nMcKesson's prior authorization products serve the majority of the brands through GLP -1 medications.  Our \nproducts continue to generate value for our partners.  Looking ahead to fiscal 2025, we anticipate that this demand \nwill remain elevated, yet lessen as the rate of increase will be slower than prior years for GLP -1 medications.  \n \n The Medical Surgical business remains well positioned to leverage the breadth and depth of its services and \nassets across all alternate sites of care, including growth in the p rimary care business and our comprehensive \nprivate label portfolio.  We anticipate Medical Surgical Solutions revenues to increase 4% to 8% and operating \nprofit to increase 6% to 8%.  \n ", "original_text": "Our \nproducts continue to generate value for our partners. "}, "hash": "66db1e40cf6c69d958c6480110f8f9fbedc730f915a354597736095557bba941", "class_name": "RelatedNodeInfo"}}, "text": "As a remind er, \nMcKesson's prior authorization products serve the majority of the brands through GLP -1 medications. ", "start_char_idx": 3451, "end_char_idx": 3569, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13cd2a0a-93e6-4955-8a9d-a16927c86c22": {"__data__": {"id_": "13cd2a0a-93e6-4955-8a9d-a16927c86c22", "embedding": null, "metadata": {"window": "This outlook reflects organic growth across our solutions and services as we \nexpand and extend partnerships with biopharma manufacturers and increase the number of brands utilizing our \naccess, affordability, and adherence programs.  Throughout fiscal 2024, we continued to see increased demand \nfor our access and affordability solutions, particularly those related to GLP -1 medications.  As a remind er, \nMcKesson's prior authorization products serve the majority of the brands through GLP -1 medications.  Our \nproducts continue to generate value for our partners.  Looking ahead to fiscal 2025, we anticipate that this demand \nwill remain elevated, yet lessen as the rate of increase will be slower than prior years for GLP -1 medications.  \n \n The Medical Surgical business remains well positioned to leverage the breadth and depth of its services and \nassets across all alternate sites of care, including growth in the p rimary care business and our comprehensive \nprivate label portfolio.  We anticipate Medical Surgical Solutions revenues to increase 4% to 8% and operating \nprofit to increase 6% to 8%.  \n ", "original_text": "Our \nproducts continue to generate value for our partners. ", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "11afdf5f84178d874ec9d4cd01a502ca741a123c1d5790d22c38f57eb334b75d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "454195e0-9e7e-4c0e-987d-69a03361eff9", "node_type": "1", "metadata": {"window": "In the Prescription Techno logy Solutions segment, we anticipate revenues to increase 18% to 22% and operating \nprofit to increase 12% to 16%.  This outlook reflects organic growth across our solutions and services as we \nexpand and extend partnerships with biopharma manufacturers and increase the number of brands utilizing our \naccess, affordability, and adherence programs.  Throughout fiscal 2024, we continued to see increased demand \nfor our access and affordability solutions, particularly those related to GLP -1 medications.  As a remind er, \nMcKesson's prior authorization products serve the majority of the brands through GLP -1 medications.  Our \nproducts continue to generate value for our partners.  Looking ahead to fiscal 2025, we anticipate that this demand \nwill remain elevated, yet lessen as the rate of increase will be slower than prior years for GLP -1 medications.  \n \n The Medical Surgical business remains well positioned to leverage the breadth and depth of its services and \nassets across all alternate sites of care, including growth in the p rimary care business and our comprehensive \nprivate label portfolio. ", "original_text": "As a remind er, \nMcKesson's prior authorization products serve the majority of the brands through GLP -1 medications. ", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "fb91f633687b1a91521a6b712ce87ce08acfb03fd356fd08870542dbec1f81c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6de37fbe-b35c-441d-be75-505eec1716a5", "node_type": "1", "metadata": {"window": "Throughout fiscal 2024, we continued to see increased demand \nfor our access and affordability solutions, particularly those related to GLP -1 medications.  As a remind er, \nMcKesson's prior authorization products serve the majority of the brands through GLP -1 medications.  Our \nproducts continue to generate value for our partners.  Looking ahead to fiscal 2025, we anticipate that this demand \nwill remain elevated, yet lessen as the rate of increase will be slower than prior years for GLP -1 medications.  \n \n The Medical Surgical business remains well positioned to leverage the breadth and depth of its services and \nassets across all alternate sites of care, including growth in the p rimary care business and our comprehensive \nprivate label portfolio.  We anticipate Medical Surgical Solutions revenues to increase 4% to 8% and operating \nprofit to increase 6% to 8%.  \n ", "original_text": "Looking ahead to fiscal 2025, we anticipate that this demand \nwill remain elevated, yet lessen as the rate of increase will be slower than prior years for GLP -1 medications.  \n \n"}, "hash": "7f189634bd3fa3fc41c462a0edc17e445aea5d5fd20686b1b02292820b73dc67", "class_name": "RelatedNodeInfo"}}, "text": "Our \nproducts continue to generate value for our partners. ", "start_char_idx": 3569, "end_char_idx": 3628, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6de37fbe-b35c-441d-be75-505eec1716a5": {"__data__": {"id_": "6de37fbe-b35c-441d-be75-505eec1716a5", "embedding": null, "metadata": {"window": "Throughout fiscal 2024, we continued to see increased demand \nfor our access and affordability solutions, particularly those related to GLP -1 medications.  As a remind er, \nMcKesson's prior authorization products serve the majority of the brands through GLP -1 medications.  Our \nproducts continue to generate value for our partners.  Looking ahead to fiscal 2025, we anticipate that this demand \nwill remain elevated, yet lessen as the rate of increase will be slower than prior years for GLP -1 medications.  \n \n The Medical Surgical business remains well positioned to leverage the breadth and depth of its services and \nassets across all alternate sites of care, including growth in the p rimary care business and our comprehensive \nprivate label portfolio.  We anticipate Medical Surgical Solutions revenues to increase 4% to 8% and operating \nprofit to increase 6% to 8%.  \n ", "original_text": "Looking ahead to fiscal 2025, we anticipate that this demand \nwill remain elevated, yet lessen as the rate of increase will be slower than prior years for GLP -1 medications.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "11afdf5f84178d874ec9d4cd01a502ca741a123c1d5790d22c38f57eb334b75d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13cd2a0a-93e6-4955-8a9d-a16927c86c22", "node_type": "1", "metadata": {"window": "This outlook reflects organic growth across our solutions and services as we \nexpand and extend partnerships with biopharma manufacturers and increase the number of brands utilizing our \naccess, affordability, and adherence programs.  Throughout fiscal 2024, we continued to see increased demand \nfor our access and affordability solutions, particularly those related to GLP -1 medications.  As a remind er, \nMcKesson's prior authorization products serve the majority of the brands through GLP -1 medications.  Our \nproducts continue to generate value for our partners.  Looking ahead to fiscal 2025, we anticipate that this demand \nwill remain elevated, yet lessen as the rate of increase will be slower than prior years for GLP -1 medications.  \n \n The Medical Surgical business remains well positioned to leverage the breadth and depth of its services and \nassets across all alternate sites of care, including growth in the p rimary care business and our comprehensive \nprivate label portfolio.  We anticipate Medical Surgical Solutions revenues to increase 4% to 8% and operating \nprofit to increase 6% to 8%.  \n ", "original_text": "Our \nproducts continue to generate value for our partners. ", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "bde15d860f189fd5dea85143622632bf31cf1c57f90cb4b6b6746d10273f47e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8400fec-4032-4c3e-8b9b-2f8933e525ee", "node_type": "1", "metadata": {"window": "As a remind er, \nMcKesson's prior authorization products serve the majority of the brands through GLP -1 medications.  Our \nproducts continue to generate value for our partners.  Looking ahead to fiscal 2025, we anticipate that this demand \nwill remain elevated, yet lessen as the rate of increase will be slower than prior years for GLP -1 medications.  \n \n The Medical Surgical business remains well positioned to leverage the breadth and depth of its services and \nassets across all alternate sites of care, including growth in the p rimary care business and our comprehensive \nprivate label portfolio.  We anticipate Medical Surgical Solutions revenues to increase 4% to 8% and operating \nprofit to increase 6% to 8%.  \n ", "original_text": "The Medical Surgical business remains well positioned to leverage the breadth and depth of its services and \nassets across all alternate sites of care, including growth in the p rimary care business and our comprehensive \nprivate label portfolio. "}, "hash": "ea27b7661b0a7ae8cb860732e9822337560fc894a62d29c17d97285586abc5b2", "class_name": "RelatedNodeInfo"}}, "text": "Looking ahead to fiscal 2025, we anticipate that this demand \nwill remain elevated, yet lessen as the rate of increase will be slower than prior years for GLP -1 medications.  \n \n", "start_char_idx": 3628, "end_char_idx": 3807, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8400fec-4032-4c3e-8b9b-2f8933e525ee": {"__data__": {"id_": "a8400fec-4032-4c3e-8b9b-2f8933e525ee", "embedding": null, "metadata": {"window": "As a remind er, \nMcKesson's prior authorization products serve the majority of the brands through GLP -1 medications.  Our \nproducts continue to generate value for our partners.  Looking ahead to fiscal 2025, we anticipate that this demand \nwill remain elevated, yet lessen as the rate of increase will be slower than prior years for GLP -1 medications.  \n \n The Medical Surgical business remains well positioned to leverage the breadth and depth of its services and \nassets across all alternate sites of care, including growth in the p rimary care business and our comprehensive \nprivate label portfolio.  We anticipate Medical Surgical Solutions revenues to increase 4% to 8% and operating \nprofit to increase 6% to 8%.  \n ", "original_text": "The Medical Surgical business remains well positioned to leverage the breadth and depth of its services and \nassets across all alternate sites of care, including growth in the p rimary care business and our comprehensive \nprivate label portfolio. ", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "11afdf5f84178d874ec9d4cd01a502ca741a123c1d5790d22c38f57eb334b75d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6de37fbe-b35c-441d-be75-505eec1716a5", "node_type": "1", "metadata": {"window": "Throughout fiscal 2024, we continued to see increased demand \nfor our access and affordability solutions, particularly those related to GLP -1 medications.  As a remind er, \nMcKesson's prior authorization products serve the majority of the brands through GLP -1 medications.  Our \nproducts continue to generate value for our partners.  Looking ahead to fiscal 2025, we anticipate that this demand \nwill remain elevated, yet lessen as the rate of increase will be slower than prior years for GLP -1 medications.  \n \n The Medical Surgical business remains well positioned to leverage the breadth and depth of its services and \nassets across all alternate sites of care, including growth in the p rimary care business and our comprehensive \nprivate label portfolio.  We anticipate Medical Surgical Solutions revenues to increase 4% to 8% and operating \nprofit to increase 6% to 8%.  \n ", "original_text": "Looking ahead to fiscal 2025, we anticipate that this demand \nwill remain elevated, yet lessen as the rate of increase will be slower than prior years for GLP -1 medications.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "29e08a87e7de16e0c425393026197f419407c6f27bed42c6722a5fa2c832d2e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6e886e4-567d-4fc2-b593-7a4aebae0355", "node_type": "1", "metadata": {"window": "Our \nproducts continue to generate value for our partners.  Looking ahead to fiscal 2025, we anticipate that this demand \nwill remain elevated, yet lessen as the rate of increase will be slower than prior years for GLP -1 medications.  \n \n The Medical Surgical business remains well positioned to leverage the breadth and depth of its services and \nassets across all alternate sites of care, including growth in the p rimary care business and our comprehensive \nprivate label portfolio.  We anticipate Medical Surgical Solutions revenues to increase 4% to 8% and operating \nprofit to increase 6% to 8%.  \n ", "original_text": "We anticipate Medical Surgical Solutions revenues to increase 4% to 8% and operating \nprofit to increase 6% to 8%.  \n "}, "hash": "c0342b23320ce1e2d182cdfc077895623c8f1fe79b0e4b01e1167350c8ee66bd", "class_name": "RelatedNodeInfo"}}, "text": "The Medical Surgical business remains well positioned to leverage the breadth and depth of its services and \nassets across all alternate sites of care, including growth in the p rimary care business and our comprehensive \nprivate label portfolio. ", "start_char_idx": 3807, "end_char_idx": 4054, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6e886e4-567d-4fc2-b593-7a4aebae0355": {"__data__": {"id_": "b6e886e4-567d-4fc2-b593-7a4aebae0355", "embedding": null, "metadata": {"window": "Our \nproducts continue to generate value for our partners.  Looking ahead to fiscal 2025, we anticipate that this demand \nwill remain elevated, yet lessen as the rate of increase will be slower than prior years for GLP -1 medications.  \n \n The Medical Surgical business remains well positioned to leverage the breadth and depth of its services and \nassets across all alternate sites of care, including growth in the p rimary care business and our comprehensive \nprivate label portfolio.  We anticipate Medical Surgical Solutions revenues to increase 4% to 8% and operating \nprofit to increase 6% to 8%.  \n ", "original_text": "We anticipate Medical Surgical Solutions revenues to increase 4% to 8% and operating \nprofit to increase 6% to 8%.  \n ", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "11afdf5f84178d874ec9d4cd01a502ca741a123c1d5790d22c38f57eb334b75d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8400fec-4032-4c3e-8b9b-2f8933e525ee", "node_type": "1", "metadata": {"window": "As a remind er, \nMcKesson's prior authorization products serve the majority of the brands through GLP -1 medications.  Our \nproducts continue to generate value for our partners.  Looking ahead to fiscal 2025, we anticipate that this demand \nwill remain elevated, yet lessen as the rate of increase will be slower than prior years for GLP -1 medications.  \n \n The Medical Surgical business remains well positioned to leverage the breadth and depth of its services and \nassets across all alternate sites of care, including growth in the p rimary care business and our comprehensive \nprivate label portfolio.  We anticipate Medical Surgical Solutions revenues to increase 4% to 8% and operating \nprofit to increase 6% to 8%.  \n ", "original_text": "The Medical Surgical business remains well positioned to leverage the breadth and depth of its services and \nassets across all alternate sites of care, including growth in the p rimary care business and our comprehensive \nprivate label portfolio. ", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "fd1045e14aa9a6ab84b7cde38e56d69aa3b0111933f68ca06efb7357ca821bb6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d440c117-e651-4bb9-b8da-1997cfc03768", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWithin the primary care market, we anticipate continued growth in Lab Sol utions and Specialty Pharmaceuticals. \n Our scale, sourcing, and distribution footprint has propelled expansion and growth of our private label portfolio, \nproviding superior value for our customers while maintaining sound economics for McKesson.  \n \n In fiscal 2 025, we're making investments in this segment to support the recent acquisition of Compile, a \nhealthcare data platform that captures and aggregates data to provide insights and analytics for biopharma. ", "original_text": "McKesson Corp.  "}, "hash": "c9d8d02fadb2310ad6be3c7328abc13ac7d17d38536bfedbb1bfa10bc633a7a0", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate Medical Surgical Solutions revenues to increase 4% to 8% and operating \nprofit to increase 6% to 8%.  \n ", "start_char_idx": 4054, "end_char_idx": 4172, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d440c117-e651-4bb9-b8da-1997cfc03768": {"__data__": {"id_": "d440c117-e651-4bb9-b8da-1997cfc03768", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWithin the primary care market, we anticipate continued growth in Lab Sol utions and Specialty Pharmaceuticals. \n Our scale, sourcing, and distribution footprint has propelled expansion and growth of our private label portfolio, \nproviding superior value for our customers while maintaining sound economics for McKesson.  \n \n In fiscal 2 025, we're making investments in this segment to support the recent acquisition of Compile, a \nhealthcare data platform that captures and aggregates data to provide insights and analytics for biopharma. ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b4739fd-a210-4020-aa76-6a4d4c165542", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ff6c7d3dda3fc8ff6cb6e78127986ed7d66e4815b2d8cee05bf07a64fa4d9d62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6e886e4-567d-4fc2-b593-7a4aebae0355", "node_type": "1", "metadata": {"window": "Our \nproducts continue to generate value for our partners.  Looking ahead to fiscal 2025, we anticipate that this demand \nwill remain elevated, yet lessen as the rate of increase will be slower than prior years for GLP -1 medications.  \n \n The Medical Surgical business remains well positioned to leverage the breadth and depth of its services and \nassets across all alternate sites of care, including growth in the p rimary care business and our comprehensive \nprivate label portfolio.  We anticipate Medical Surgical Solutions revenues to increase 4% to 8% and operating \nprofit to increase 6% to 8%.  \n ", "original_text": "We anticipate Medical Surgical Solutions revenues to increase 4% to 8% and operating \nprofit to increase 6% to 8%.  \n ", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5e653c07dcbed4e03a6c382e26b9d8d39378d4d3539c0aa04caf6d0d3f976529", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d94be135-37cf-4d75-83cf-c3a278d83644", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWithin the primary care market, we anticipate continued growth in Lab Sol utions and Specialty Pharmaceuticals. \n Our scale, sourcing, and distribution footprint has propelled expansion and growth of our private label portfolio, \nproviding superior value for our customers while maintaining sound economics for McKesson.  \n \n In fiscal 2 025, we're making investments in this segment to support the recent acquisition of Compile, a \nhealthcare data platform that captures and aggregates data to provide insights and analytics for biopharma.  We \nbelieve there's an initial use case across the brea dth of the Medical Surgical Solutions segment. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWithin the primary care market, we anticipate continued growth in Lab Sol utions and Specialty Pharmaceuticals. \n"}, "hash": "acb769b0ce43412e227342d319046dfda2724b4ba7886fd02a1cba0ce502f383", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d94be135-37cf-4d75-83cf-c3a278d83644": {"__data__": {"id_": "d94be135-37cf-4d75-83cf-c3a278d83644", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWithin the primary care market, we anticipate continued growth in Lab Sol utions and Specialty Pharmaceuticals. \n Our scale, sourcing, and distribution footprint has propelled expansion and growth of our private label portfolio, \nproviding superior value for our customers while maintaining sound economics for McKesson.  \n \n In fiscal 2 025, we're making investments in this segment to support the recent acquisition of Compile, a \nhealthcare data platform that captures and aggregates data to provide insights and analytics for biopharma.  We \nbelieve there's an initial use case across the brea dth of the Medical Surgical Solutions segment. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWithin the primary care market, we anticipate continued growth in Lab Sol utions and Specialty Pharmaceuticals. \n", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b4739fd-a210-4020-aa76-6a4d4c165542", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ff6c7d3dda3fc8ff6cb6e78127986ed7d66e4815b2d8cee05bf07a64fa4d9d62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d440c117-e651-4bb9-b8da-1997cfc03768", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWithin the primary care market, we anticipate continued growth in Lab Sol utions and Specialty Pharmaceuticals. \n Our scale, sourcing, and distribution footprint has propelled expansion and growth of our private label portfolio, \nproviding superior value for our customers while maintaining sound economics for McKesson.  \n \n In fiscal 2 025, we're making investments in this segment to support the recent acquisition of Compile, a \nhealthcare data platform that captures and aggregates data to provide insights and analytics for biopharma. ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "202f2b74c5007c7099c24207b522c2fe2aa3956e6ce4981a931336e5368688b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cac09502-6524-4c8c-b0b2-2730ea674f2a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWithin the primary care market, we anticipate continued growth in Lab Sol utions and Specialty Pharmaceuticals. \n Our scale, sourcing, and distribution footprint has propelled expansion and growth of our private label portfolio, \nproviding superior value for our customers while maintaining sound economics for McKesson.  \n \n In fiscal 2 025, we're making investments in this segment to support the recent acquisition of Compile, a \nhealthcare data platform that captures and aggregates data to provide insights and analytics for biopharma.  We \nbelieve there's an initial use case across the brea dth of the Medical Surgical Solutions segment.  The Medical \nSurgical Solutions segment has broad relationships with providers and extensive data sets, leading to \nopportunities to develop incremental value creation opportunities.  \n \n", "original_text": "Our scale, sourcing, and distribution footprint has propelled expansion and growth of our private label portfolio, \nproviding superior value for our customers while maintaining sound economics for McKesson.  \n \n"}, "hash": "fd1121c9434e785baba4606c0e424c5d4cbf53a31e522772cfee16ceabba0787", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWithin the primary care market, we anticipate continued growth in Lab Sol utions and Specialty Pharmaceuticals. \n", "start_char_idx": 16, "end_char_idx": 294, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cac09502-6524-4c8c-b0b2-2730ea674f2a": {"__data__": {"id_": "cac09502-6524-4c8c-b0b2-2730ea674f2a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWithin the primary care market, we anticipate continued growth in Lab Sol utions and Specialty Pharmaceuticals. \n Our scale, sourcing, and distribution footprint has propelled expansion and growth of our private label portfolio, \nproviding superior value for our customers while maintaining sound economics for McKesson.  \n \n In fiscal 2 025, we're making investments in this segment to support the recent acquisition of Compile, a \nhealthcare data platform that captures and aggregates data to provide insights and analytics for biopharma.  We \nbelieve there's an initial use case across the brea dth of the Medical Surgical Solutions segment.  The Medical \nSurgical Solutions segment has broad relationships with providers and extensive data sets, leading to \nopportunities to develop incremental value creation opportunities.  \n \n", "original_text": "Our scale, sourcing, and distribution footprint has propelled expansion and growth of our private label portfolio, \nproviding superior value for our customers while maintaining sound economics for McKesson.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b4739fd-a210-4020-aa76-6a4d4c165542", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ff6c7d3dda3fc8ff6cb6e78127986ed7d66e4815b2d8cee05bf07a64fa4d9d62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d94be135-37cf-4d75-83cf-c3a278d83644", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWithin the primary care market, we anticipate continued growth in Lab Sol utions and Specialty Pharmaceuticals. \n Our scale, sourcing, and distribution footprint has propelled expansion and growth of our private label portfolio, \nproviding superior value for our customers while maintaining sound economics for McKesson.  \n \n In fiscal 2 025, we're making investments in this segment to support the recent acquisition of Compile, a \nhealthcare data platform that captures and aggregates data to provide insights and analytics for biopharma.  We \nbelieve there's an initial use case across the brea dth of the Medical Surgical Solutions segment. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWithin the primary care market, we anticipate continued growth in Lab Sol utions and Specialty Pharmaceuticals. \n", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "61df6e2e02c6f0b5c5b52aa50d29347ed9f8563c6cd90d071135aa9f27bb7682", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09160517-6042-47b0-b639-2cddb956a2c3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWithin the primary care market, we anticipate continued growth in Lab Sol utions and Specialty Pharmaceuticals. \n Our scale, sourcing, and distribution footprint has propelled expansion and growth of our private label portfolio, \nproviding superior value for our customers while maintaining sound economics for McKesson.  \n \n In fiscal 2 025, we're making investments in this segment to support the recent acquisition of Compile, a \nhealthcare data platform that captures and aggregates data to provide insights and analytics for biopharma.  We \nbelieve there's an initial use case across the brea dth of the Medical Surgical Solutions segment.  The Medical \nSurgical Solutions segment has broad relationships with providers and extensive data sets, leading to \nopportunities to develop incremental value creation opportunities.  \n \n Longer term, there are incr eased opportunities to integrate the capabilities and commercial applications across \nour oncology and biopharma services platforms. ", "original_text": "In fiscal 2 025, we're making investments in this segment to support the recent acquisition of Compile, a \nhealthcare data platform that captures and aggregates data to provide insights and analytics for biopharma. "}, "hash": "50d4eb1714218c294fc82d8844c81d65af1da1665cce6db2fc9e7c6d1b76a979", "class_name": "RelatedNodeInfo"}}, "text": "Our scale, sourcing, and distribution footprint has propelled expansion and growth of our private label portfolio, \nproviding superior value for our customers while maintaining sound economics for McKesson.  \n \n", "start_char_idx": 294, "end_char_idx": 505, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09160517-6042-47b0-b639-2cddb956a2c3": {"__data__": {"id_": "09160517-6042-47b0-b639-2cddb956a2c3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWithin the primary care market, we anticipate continued growth in Lab Sol utions and Specialty Pharmaceuticals. \n Our scale, sourcing, and distribution footprint has propelled expansion and growth of our private label portfolio, \nproviding superior value for our customers while maintaining sound economics for McKesson.  \n \n In fiscal 2 025, we're making investments in this segment to support the recent acquisition of Compile, a \nhealthcare data platform that captures and aggregates data to provide insights and analytics for biopharma.  We \nbelieve there's an initial use case across the brea dth of the Medical Surgical Solutions segment.  The Medical \nSurgical Solutions segment has broad relationships with providers and extensive data sets, leading to \nopportunities to develop incremental value creation opportunities.  \n \n Longer term, there are incr eased opportunities to integrate the capabilities and commercial applications across \nour oncology and biopharma services platforms. ", "original_text": "In fiscal 2 025, we're making investments in this segment to support the recent acquisition of Compile, a \nhealthcare data platform that captures and aggregates data to provide insights and analytics for biopharma. ", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b4739fd-a210-4020-aa76-6a4d4c165542", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ff6c7d3dda3fc8ff6cb6e78127986ed7d66e4815b2d8cee05bf07a64fa4d9d62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cac09502-6524-4c8c-b0b2-2730ea674f2a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWithin the primary care market, we anticipate continued growth in Lab Sol utions and Specialty Pharmaceuticals. \n Our scale, sourcing, and distribution footprint has propelled expansion and growth of our private label portfolio, \nproviding superior value for our customers while maintaining sound economics for McKesson.  \n \n In fiscal 2 025, we're making investments in this segment to support the recent acquisition of Compile, a \nhealthcare data platform that captures and aggregates data to provide insights and analytics for biopharma.  We \nbelieve there's an initial use case across the brea dth of the Medical Surgical Solutions segment.  The Medical \nSurgical Solutions segment has broad relationships with providers and extensive data sets, leading to \nopportunities to develop incremental value creation opportunities.  \n \n", "original_text": "Our scale, sourcing, and distribution footprint has propelled expansion and growth of our private label portfolio, \nproviding superior value for our customers while maintaining sound economics for McKesson.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "755f3ccfb328781520bf42539da13a8f9e44b1813dacfb99e3f487deb0cbd082", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b28ff09e-9953-483e-b900-a576d011c081", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWithin the primary care market, we anticipate continued growth in Lab Sol utions and Specialty Pharmaceuticals. \n Our scale, sourcing, and distribution footprint has propelled expansion and growth of our private label portfolio, \nproviding superior value for our customers while maintaining sound economics for McKesson.  \n \n In fiscal 2 025, we're making investments in this segment to support the recent acquisition of Compile, a \nhealthcare data platform that captures and aggregates data to provide insights and analytics for biopharma.  We \nbelieve there's an initial use case across the brea dth of the Medical Surgical Solutions segment.  The Medical \nSurgical Solutions segment has broad relationships with providers and extensive data sets, leading to \nopportunities to develop incremental value creation opportunities.  \n \n Longer term, there are incr eased opportunities to integrate the capabilities and commercial applications across \nour oncology and biopharma services platforms.  These investments will deliver meaningful returns to the segment \nand to the enterprise.  \n \n", "original_text": "We \nbelieve there's an initial use case across the brea dth of the Medical Surgical Solutions segment. "}, "hash": "5f2307eee091554324c0251f0d57e400112a8d1e7eaa304d6e9c1f28678c9d6e", "class_name": "RelatedNodeInfo"}}, "text": "In fiscal 2 025, we're making investments in this segment to support the recent acquisition of Compile, a \nhealthcare data platform that captures and aggregates data to provide insights and analytics for biopharma. ", "start_char_idx": 505, "end_char_idx": 720, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b28ff09e-9953-483e-b900-a576d011c081": {"__data__": {"id_": "b28ff09e-9953-483e-b900-a576d011c081", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWithin the primary care market, we anticipate continued growth in Lab Sol utions and Specialty Pharmaceuticals. \n Our scale, sourcing, and distribution footprint has propelled expansion and growth of our private label portfolio, \nproviding superior value for our customers while maintaining sound economics for McKesson.  \n \n In fiscal 2 025, we're making investments in this segment to support the recent acquisition of Compile, a \nhealthcare data platform that captures and aggregates data to provide insights and analytics for biopharma.  We \nbelieve there's an initial use case across the brea dth of the Medical Surgical Solutions segment.  The Medical \nSurgical Solutions segment has broad relationships with providers and extensive data sets, leading to \nopportunities to develop incremental value creation opportunities.  \n \n Longer term, there are incr eased opportunities to integrate the capabilities and commercial applications across \nour oncology and biopharma services platforms.  These investments will deliver meaningful returns to the segment \nand to the enterprise.  \n \n", "original_text": "We \nbelieve there's an initial use case across the brea dth of the Medical Surgical Solutions segment. ", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b4739fd-a210-4020-aa76-6a4d4c165542", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ff6c7d3dda3fc8ff6cb6e78127986ed7d66e4815b2d8cee05bf07a64fa4d9d62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09160517-6042-47b0-b639-2cddb956a2c3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWithin the primary care market, we anticipate continued growth in Lab Sol utions and Specialty Pharmaceuticals. \n Our scale, sourcing, and distribution footprint has propelled expansion and growth of our private label portfolio, \nproviding superior value for our customers while maintaining sound economics for McKesson.  \n \n In fiscal 2 025, we're making investments in this segment to support the recent acquisition of Compile, a \nhealthcare data platform that captures and aggregates data to provide insights and analytics for biopharma.  We \nbelieve there's an initial use case across the brea dth of the Medical Surgical Solutions segment.  The Medical \nSurgical Solutions segment has broad relationships with providers and extensive data sets, leading to \nopportunities to develop incremental value creation opportunities.  \n \n Longer term, there are incr eased opportunities to integrate the capabilities and commercial applications across \nour oncology and biopharma services platforms. ", "original_text": "In fiscal 2 025, we're making investments in this segment to support the recent acquisition of Compile, a \nhealthcare data platform that captures and aggregates data to provide insights and analytics for biopharma. ", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ba35616fdb3de6e02a7debc3e6976913718cd5d54b98070e376bb4b460d7fc9d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5be6ff53-d4cb-4116-8d00-b57356d2e800", "node_type": "1", "metadata": {"window": "Our scale, sourcing, and distribution footprint has propelled expansion and growth of our private label portfolio, \nproviding superior value for our customers while maintaining sound economics for McKesson.  \n \n In fiscal 2 025, we're making investments in this segment to support the recent acquisition of Compile, a \nhealthcare data platform that captures and aggregates data to provide insights and analytics for biopharma.  We \nbelieve there's an initial use case across the brea dth of the Medical Surgical Solutions segment.  The Medical \nSurgical Solutions segment has broad relationships with providers and extensive data sets, leading to \nopportunities to develop incremental value creation opportunities.  \n \n Longer term, there are incr eased opportunities to integrate the capabilities and commercial applications across \nour oncology and biopharma services platforms.  These investments will deliver meaningful returns to the segment \nand to the enterprise.  \n \n In fiscal 2025, we anticipate that these investments will account for an approximate 2% operating profit headwind \nin the Medical segment as compared to the prior year.  \n \n", "original_text": "The Medical \nSurgical Solutions segment has broad relationships with providers and extensive data sets, leading to \nopportunities to develop incremental value creation opportunities.  \n \n"}, "hash": "2580789e9964c06c14029ce1a9804ef91d4710ee6941139f64810c93bb6c9789", "class_name": "RelatedNodeInfo"}}, "text": "We \nbelieve there's an initial use case across the brea dth of the Medical Surgical Solutions segment. ", "start_char_idx": 720, "end_char_idx": 823, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5be6ff53-d4cb-4116-8d00-b57356d2e800": {"__data__": {"id_": "5be6ff53-d4cb-4116-8d00-b57356d2e800", "embedding": null, "metadata": {"window": "Our scale, sourcing, and distribution footprint has propelled expansion and growth of our private label portfolio, \nproviding superior value for our customers while maintaining sound economics for McKesson.  \n \n In fiscal 2 025, we're making investments in this segment to support the recent acquisition of Compile, a \nhealthcare data platform that captures and aggregates data to provide insights and analytics for biopharma.  We \nbelieve there's an initial use case across the brea dth of the Medical Surgical Solutions segment.  The Medical \nSurgical Solutions segment has broad relationships with providers and extensive data sets, leading to \nopportunities to develop incremental value creation opportunities.  \n \n Longer term, there are incr eased opportunities to integrate the capabilities and commercial applications across \nour oncology and biopharma services platforms.  These investments will deliver meaningful returns to the segment \nand to the enterprise.  \n \n In fiscal 2025, we anticipate that these investments will account for an approximate 2% operating profit headwind \nin the Medical segment as compared to the prior year.  \n \n", "original_text": "The Medical \nSurgical Solutions segment has broad relationships with providers and extensive data sets, leading to \nopportunities to develop incremental value creation opportunities.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b4739fd-a210-4020-aa76-6a4d4c165542", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ff6c7d3dda3fc8ff6cb6e78127986ed7d66e4815b2d8cee05bf07a64fa4d9d62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b28ff09e-9953-483e-b900-a576d011c081", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWithin the primary care market, we anticipate continued growth in Lab Sol utions and Specialty Pharmaceuticals. \n Our scale, sourcing, and distribution footprint has propelled expansion and growth of our private label portfolio, \nproviding superior value for our customers while maintaining sound economics for McKesson.  \n \n In fiscal 2 025, we're making investments in this segment to support the recent acquisition of Compile, a \nhealthcare data platform that captures and aggregates data to provide insights and analytics for biopharma.  We \nbelieve there's an initial use case across the brea dth of the Medical Surgical Solutions segment.  The Medical \nSurgical Solutions segment has broad relationships with providers and extensive data sets, leading to \nopportunities to develop incremental value creation opportunities.  \n \n Longer term, there are incr eased opportunities to integrate the capabilities and commercial applications across \nour oncology and biopharma services platforms.  These investments will deliver meaningful returns to the segment \nand to the enterprise.  \n \n", "original_text": "We \nbelieve there's an initial use case across the brea dth of the Medical Surgical Solutions segment. ", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "2fb546bc496635011c95392b1fb6143e0535d23a35de74afecd85cbc082fbc2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "578b3af0-3642-4a8e-b8a6-b8347f4dc39e", "node_type": "1", "metadata": {"window": "In fiscal 2 025, we're making investments in this segment to support the recent acquisition of Compile, a \nhealthcare data platform that captures and aggregates data to provide insights and analytics for biopharma.  We \nbelieve there's an initial use case across the brea dth of the Medical Surgical Solutions segment.  The Medical \nSurgical Solutions segment has broad relationships with providers and extensive data sets, leading to \nopportunities to develop incremental value creation opportunities.  \n \n Longer term, there are incr eased opportunities to integrate the capabilities and commercial applications across \nour oncology and biopharma services platforms.  These investments will deliver meaningful returns to the segment \nand to the enterprise.  \n \n In fiscal 2025, we anticipate that these investments will account for an approximate 2% operating profit headwind \nin the Medical segment as compared to the prior year.  \n \n Finally, the International segment, we anticipate revenues to increase 4% to 8% and operating profit increase 6% \nto 10% ye ar over year. ", "original_text": "Longer term, there are incr eased opportunities to integrate the capabilities and commercial applications across \nour oncology and biopharma services platforms. "}, "hash": "36b9d250da36d40a904bbaa6dfd012ae9bc7d39332ae993790e66e2ec0664989", "class_name": "RelatedNodeInfo"}}, "text": "The Medical \nSurgical Solutions segment has broad relationships with providers and extensive data sets, leading to \nopportunities to develop incremental value creation opportunities.  \n \n", "start_char_idx": 823, "end_char_idx": 1010, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "578b3af0-3642-4a8e-b8a6-b8347f4dc39e": {"__data__": {"id_": "578b3af0-3642-4a8e-b8a6-b8347f4dc39e", "embedding": null, "metadata": {"window": "In fiscal 2 025, we're making investments in this segment to support the recent acquisition of Compile, a \nhealthcare data platform that captures and aggregates data to provide insights and analytics for biopharma.  We \nbelieve there's an initial use case across the brea dth of the Medical Surgical Solutions segment.  The Medical \nSurgical Solutions segment has broad relationships with providers and extensive data sets, leading to \nopportunities to develop incremental value creation opportunities.  \n \n Longer term, there are incr eased opportunities to integrate the capabilities and commercial applications across \nour oncology and biopharma services platforms.  These investments will deliver meaningful returns to the segment \nand to the enterprise.  \n \n In fiscal 2025, we anticipate that these investments will account for an approximate 2% operating profit headwind \nin the Medical segment as compared to the prior year.  \n \n Finally, the International segment, we anticipate revenues to increase 4% to 8% and operating profit increase 6% \nto 10% ye ar over year. ", "original_text": "Longer term, there are incr eased opportunities to integrate the capabilities and commercial applications across \nour oncology and biopharma services platforms. ", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b4739fd-a210-4020-aa76-6a4d4c165542", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ff6c7d3dda3fc8ff6cb6e78127986ed7d66e4815b2d8cee05bf07a64fa4d9d62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5be6ff53-d4cb-4116-8d00-b57356d2e800", "node_type": "1", "metadata": {"window": "Our scale, sourcing, and distribution footprint has propelled expansion and growth of our private label portfolio, \nproviding superior value for our customers while maintaining sound economics for McKesson.  \n \n In fiscal 2 025, we're making investments in this segment to support the recent acquisition of Compile, a \nhealthcare data platform that captures and aggregates data to provide insights and analytics for biopharma.  We \nbelieve there's an initial use case across the brea dth of the Medical Surgical Solutions segment.  The Medical \nSurgical Solutions segment has broad relationships with providers and extensive data sets, leading to \nopportunities to develop incremental value creation opportunities.  \n \n Longer term, there are incr eased opportunities to integrate the capabilities and commercial applications across \nour oncology and biopharma services platforms.  These investments will deliver meaningful returns to the segment \nand to the enterprise.  \n \n In fiscal 2025, we anticipate that these investments will account for an approximate 2% operating profit headwind \nin the Medical segment as compared to the prior year.  \n \n", "original_text": "The Medical \nSurgical Solutions segment has broad relationships with providers and extensive data sets, leading to \nopportunities to develop incremental value creation opportunities.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d9d8a39ca7f47c92a505fe9d6c1aa6a63fc7103d119618394db6dc85f25fc364", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "490468b6-7405-4fb5-ade5-8a2e568c6652", "node_type": "1", "metadata": {"window": "We \nbelieve there's an initial use case across the brea dth of the Medical Surgical Solutions segment.  The Medical \nSurgical Solutions segment has broad relationships with providers and extensive data sets, leading to \nopportunities to develop incremental value creation opportunities.  \n \n Longer term, there are incr eased opportunities to integrate the capabilities and commercial applications across \nour oncology and biopharma services platforms.  These investments will deliver meaningful returns to the segment \nand to the enterprise.  \n \n In fiscal 2025, we anticipate that these investments will account for an approximate 2% operating profit headwind \nin the Medical segment as compared to the prior year.  \n \n Finally, the International segment, we anticipate revenues to increase 4% to 8% and operating profit increase 6% \nto 10% ye ar over year.  Our diversified set of assets within our Canadian business, including the scaled \ndistribution business, continues to support growth in the international segment. ", "original_text": "These investments will deliver meaningful returns to the segment \nand to the enterprise.  \n \n"}, "hash": "24bd6470458356671379edc6c5615f14b6044302292f4c67d31ddf4482239886", "class_name": "RelatedNodeInfo"}}, "text": "Longer term, there are incr eased opportunities to integrate the capabilities and commercial applications across \nour oncology and biopharma services platforms. ", "start_char_idx": 1010, "end_char_idx": 1171, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "490468b6-7405-4fb5-ade5-8a2e568c6652": {"__data__": {"id_": "490468b6-7405-4fb5-ade5-8a2e568c6652", "embedding": null, "metadata": {"window": "We \nbelieve there's an initial use case across the brea dth of the Medical Surgical Solutions segment.  The Medical \nSurgical Solutions segment has broad relationships with providers and extensive data sets, leading to \nopportunities to develop incremental value creation opportunities.  \n \n Longer term, there are incr eased opportunities to integrate the capabilities and commercial applications across \nour oncology and biopharma services platforms.  These investments will deliver meaningful returns to the segment \nand to the enterprise.  \n \n In fiscal 2025, we anticipate that these investments will account for an approximate 2% operating profit headwind \nin the Medical segment as compared to the prior year.  \n \n Finally, the International segment, we anticipate revenues to increase 4% to 8% and operating profit increase 6% \nto 10% ye ar over year.  Our diversified set of assets within our Canadian business, including the scaled \ndistribution business, continues to support growth in the international segment. ", "original_text": "These investments will deliver meaningful returns to the segment \nand to the enterprise.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b4739fd-a210-4020-aa76-6a4d4c165542", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ff6c7d3dda3fc8ff6cb6e78127986ed7d66e4815b2d8cee05bf07a64fa4d9d62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "578b3af0-3642-4a8e-b8a6-b8347f4dc39e", "node_type": "1", "metadata": {"window": "In fiscal 2 025, we're making investments in this segment to support the recent acquisition of Compile, a \nhealthcare data platform that captures and aggregates data to provide insights and analytics for biopharma.  We \nbelieve there's an initial use case across the brea dth of the Medical Surgical Solutions segment.  The Medical \nSurgical Solutions segment has broad relationships with providers and extensive data sets, leading to \nopportunities to develop incremental value creation opportunities.  \n \n Longer term, there are incr eased opportunities to integrate the capabilities and commercial applications across \nour oncology and biopharma services platforms.  These investments will deliver meaningful returns to the segment \nand to the enterprise.  \n \n In fiscal 2025, we anticipate that these investments will account for an approximate 2% operating profit headwind \nin the Medical segment as compared to the prior year.  \n \n Finally, the International segment, we anticipate revenues to increase 4% to 8% and operating profit increase 6% \nto 10% ye ar over year. ", "original_text": "Longer term, there are incr eased opportunities to integrate the capabilities and commercial applications across \nour oncology and biopharma services platforms. ", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ca663e7f6392aac83381eef751ddad9dbfd88e0f0e39cc2e57832a2abe2e6824", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1bb80b24-e18c-4e5e-aefc-7c22901a888b", "node_type": "1", "metadata": {"window": "The Medical \nSurgical Solutions segment has broad relationships with providers and extensive data sets, leading to \nopportunities to develop incremental value creation opportunities.  \n \n Longer term, there are incr eased opportunities to integrate the capabilities and commercial applications across \nour oncology and biopharma services platforms.  These investments will deliver meaningful returns to the segment \nand to the enterprise.  \n \n In fiscal 2025, we anticipate that these investments will account for an approximate 2% operating profit headwind \nin the Medical segment as compared to the prior year.  \n \n Finally, the International segment, we anticipate revenues to increase 4% to 8% and operating profit increase 6% \nto 10% ye ar over year.  Our diversified set of assets within our Canadian business, including the scaled \ndistribution business, continues to support growth in the international segment.  We continue to make investments \nin our Canadian technology footprint to create a  more custom and integrated supply chain for specialty drugs.  \n \n", "original_text": "In fiscal 2025, we anticipate that these investments will account for an approximate 2% operating profit headwind \nin the Medical segment as compared to the prior year.  \n \n"}, "hash": "93602e96acc4eaa83742790d42ebc860116be8b392630d29cd49407330446fa2", "class_name": "RelatedNodeInfo"}}, "text": "These investments will deliver meaningful returns to the segment \nand to the enterprise.  \n \n", "start_char_idx": 1171, "end_char_idx": 1264, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1bb80b24-e18c-4e5e-aefc-7c22901a888b": {"__data__": {"id_": "1bb80b24-e18c-4e5e-aefc-7c22901a888b", "embedding": null, "metadata": {"window": "The Medical \nSurgical Solutions segment has broad relationships with providers and extensive data sets, leading to \nopportunities to develop incremental value creation opportunities.  \n \n Longer term, there are incr eased opportunities to integrate the capabilities and commercial applications across \nour oncology and biopharma services platforms.  These investments will deliver meaningful returns to the segment \nand to the enterprise.  \n \n In fiscal 2025, we anticipate that these investments will account for an approximate 2% operating profit headwind \nin the Medical segment as compared to the prior year.  \n \n Finally, the International segment, we anticipate revenues to increase 4% to 8% and operating profit increase 6% \nto 10% ye ar over year.  Our diversified set of assets within our Canadian business, including the scaled \ndistribution business, continues to support growth in the international segment.  We continue to make investments \nin our Canadian technology footprint to create a  more custom and integrated supply chain for specialty drugs.  \n \n", "original_text": "In fiscal 2025, we anticipate that these investments will account for an approximate 2% operating profit headwind \nin the Medical segment as compared to the prior year.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b4739fd-a210-4020-aa76-6a4d4c165542", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ff6c7d3dda3fc8ff6cb6e78127986ed7d66e4815b2d8cee05bf07a64fa4d9d62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "490468b6-7405-4fb5-ade5-8a2e568c6652", "node_type": "1", "metadata": {"window": "We \nbelieve there's an initial use case across the brea dth of the Medical Surgical Solutions segment.  The Medical \nSurgical Solutions segment has broad relationships with providers and extensive data sets, leading to \nopportunities to develop incremental value creation opportunities.  \n \n Longer term, there are incr eased opportunities to integrate the capabilities and commercial applications across \nour oncology and biopharma services platforms.  These investments will deliver meaningful returns to the segment \nand to the enterprise.  \n \n In fiscal 2025, we anticipate that these investments will account for an approximate 2% operating profit headwind \nin the Medical segment as compared to the prior year.  \n \n Finally, the International segment, we anticipate revenues to increase 4% to 8% and operating profit increase 6% \nto 10% ye ar over year.  Our diversified set of assets within our Canadian business, including the scaled \ndistribution business, continues to support growth in the international segment. ", "original_text": "These investments will deliver meaningful returns to the segment \nand to the enterprise.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "21e4f93bd7aae49a5cd935babcd62e197a14619237e0f3cbc1f6eec94b44860a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb17da20-897a-46e8-9c2a-5e70e2df4f0e", "node_type": "1", "metadata": {"window": "Longer term, there are incr eased opportunities to integrate the capabilities and commercial applications across \nour oncology and biopharma services platforms.  These investments will deliver meaningful returns to the segment \nand to the enterprise.  \n \n In fiscal 2025, we anticipate that these investments will account for an approximate 2% operating profit headwind \nin the Medical segment as compared to the prior year.  \n \n Finally, the International segment, we anticipate revenues to increase 4% to 8% and operating profit increase 6% \nto 10% ye ar over year.  Our diversified set of assets within our Canadian business, including the scaled \ndistribution business, continues to support growth in the international segment.  We continue to make investments \nin our Canadian technology footprint to create a  more custom and integrated supply chain for specialty drugs.  \n \n As a reminder, Norway remains the only operating country in Europe that we have not entered into an agreement \nto sell, and contributions related to operations in Norway are included in the fisc al 2025 outlook for the segment. \n", "original_text": "Finally, the International segment, we anticipate revenues to increase 4% to 8% and operating profit increase 6% \nto 10% ye ar over year. "}, "hash": "1cd96befc0540ba922713ddc316044983144978f55207d9ef7dc97bb2cd2dc77", "class_name": "RelatedNodeInfo"}}, "text": "In fiscal 2025, we anticipate that these investments will account for an approximate 2% operating profit headwind \nin the Medical segment as compared to the prior year.  \n \n", "start_char_idx": 1264, "end_char_idx": 1437, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb17da20-897a-46e8-9c2a-5e70e2df4f0e": {"__data__": {"id_": "fb17da20-897a-46e8-9c2a-5e70e2df4f0e", "embedding": null, "metadata": {"window": "Longer term, there are incr eased opportunities to integrate the capabilities and commercial applications across \nour oncology and biopharma services platforms.  These investments will deliver meaningful returns to the segment \nand to the enterprise.  \n \n In fiscal 2025, we anticipate that these investments will account for an approximate 2% operating profit headwind \nin the Medical segment as compared to the prior year.  \n \n Finally, the International segment, we anticipate revenues to increase 4% to 8% and operating profit increase 6% \nto 10% ye ar over year.  Our diversified set of assets within our Canadian business, including the scaled \ndistribution business, continues to support growth in the international segment.  We continue to make investments \nin our Canadian technology footprint to create a  more custom and integrated supply chain for specialty drugs.  \n \n As a reminder, Norway remains the only operating country in Europe that we have not entered into an agreement \nto sell, and contributions related to operations in Norway are included in the fisc al 2025 outlook for the segment. \n", "original_text": "Finally, the International segment, we anticipate revenues to increase 4% to 8% and operating profit increase 6% \nto 10% ye ar over year. ", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b4739fd-a210-4020-aa76-6a4d4c165542", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ff6c7d3dda3fc8ff6cb6e78127986ed7d66e4815b2d8cee05bf07a64fa4d9d62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1bb80b24-e18c-4e5e-aefc-7c22901a888b", "node_type": "1", "metadata": {"window": "The Medical \nSurgical Solutions segment has broad relationships with providers and extensive data sets, leading to \nopportunities to develop incremental value creation opportunities.  \n \n Longer term, there are incr eased opportunities to integrate the capabilities and commercial applications across \nour oncology and biopharma services platforms.  These investments will deliver meaningful returns to the segment \nand to the enterprise.  \n \n In fiscal 2025, we anticipate that these investments will account for an approximate 2% operating profit headwind \nin the Medical segment as compared to the prior year.  \n \n Finally, the International segment, we anticipate revenues to increase 4% to 8% and operating profit increase 6% \nto 10% ye ar over year.  Our diversified set of assets within our Canadian business, including the scaled \ndistribution business, continues to support growth in the international segment.  We continue to make investments \nin our Canadian technology footprint to create a  more custom and integrated supply chain for specialty drugs.  \n \n", "original_text": "In fiscal 2025, we anticipate that these investments will account for an approximate 2% operating profit headwind \nin the Medical segment as compared to the prior year.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "261a704f6a771f76b25ea563c7c50b29cc252ea6e53d2b64ed87343feadfc7be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c067191-e598-47a8-b656-ff26c1febee3", "node_type": "1", "metadata": {"window": "These investments will deliver meaningful returns to the segment \nand to the enterprise.  \n \n In fiscal 2025, we anticipate that these investments will account for an approximate 2% operating profit headwind \nin the Medical segment as compared to the prior year.  \n \n Finally, the International segment, we anticipate revenues to increase 4% to 8% and operating profit increase 6% \nto 10% ye ar over year.  Our diversified set of assets within our Canadian business, including the scaled \ndistribution business, continues to support growth in the international segment.  We continue to make investments \nin our Canadian technology footprint to create a  more custom and integrated supply chain for specialty drugs.  \n \n As a reminder, Norway remains the only operating country in Europe that we have not entered into an agreement \nto sell, and contributions related to operations in Norway are included in the fisc al 2025 outlook for the segment. \n We intend to exit Norway as part of the completion of our European exit.  \n \n", "original_text": "Our diversified set of assets within our Canadian business, including the scaled \ndistribution business, continues to support growth in the international segment. "}, "hash": "cbfc4bca920c985ccf61ccda056bf1fb42a0a3a469a346e7bb956610c146046d", "class_name": "RelatedNodeInfo"}}, "text": "Finally, the International segment, we anticipate revenues to increase 4% to 8% and operating profit increase 6% \nto 10% ye ar over year. ", "start_char_idx": 1437, "end_char_idx": 1575, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c067191-e598-47a8-b656-ff26c1febee3": {"__data__": {"id_": "1c067191-e598-47a8-b656-ff26c1febee3", "embedding": null, "metadata": {"window": "These investments will deliver meaningful returns to the segment \nand to the enterprise.  \n \n In fiscal 2025, we anticipate that these investments will account for an approximate 2% operating profit headwind \nin the Medical segment as compared to the prior year.  \n \n Finally, the International segment, we anticipate revenues to increase 4% to 8% and operating profit increase 6% \nto 10% ye ar over year.  Our diversified set of assets within our Canadian business, including the scaled \ndistribution business, continues to support growth in the international segment.  We continue to make investments \nin our Canadian technology footprint to create a  more custom and integrated supply chain for specialty drugs.  \n \n As a reminder, Norway remains the only operating country in Europe that we have not entered into an agreement \nto sell, and contributions related to operations in Norway are included in the fisc al 2025 outlook for the segment. \n We intend to exit Norway as part of the completion of our European exit.  \n \n", "original_text": "Our diversified set of assets within our Canadian business, including the scaled \ndistribution business, continues to support growth in the international segment. ", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b4739fd-a210-4020-aa76-6a4d4c165542", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ff6c7d3dda3fc8ff6cb6e78127986ed7d66e4815b2d8cee05bf07a64fa4d9d62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb17da20-897a-46e8-9c2a-5e70e2df4f0e", "node_type": "1", "metadata": {"window": "Longer term, there are incr eased opportunities to integrate the capabilities and commercial applications across \nour oncology and biopharma services platforms.  These investments will deliver meaningful returns to the segment \nand to the enterprise.  \n \n In fiscal 2025, we anticipate that these investments will account for an approximate 2% operating profit headwind \nin the Medical segment as compared to the prior year.  \n \n Finally, the International segment, we anticipate revenues to increase 4% to 8% and operating profit increase 6% \nto 10% ye ar over year.  Our diversified set of assets within our Canadian business, including the scaled \ndistribution business, continues to support growth in the international segment.  We continue to make investments \nin our Canadian technology footprint to create a  more custom and integrated supply chain for specialty drugs.  \n \n As a reminder, Norway remains the only operating country in Europe that we have not entered into an agreement \nto sell, and contributions related to operations in Norway are included in the fisc al 2025 outlook for the segment. \n", "original_text": "Finally, the International segment, we anticipate revenues to increase 4% to 8% and operating profit increase 6% \nto 10% ye ar over year. ", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "8dce91c8a3ea827cfbb3aa56f3542420816a8d145facc09d6c262d16e4f0729a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c28fc01a-a6b7-41ac-88af-e7a6bdf75d2b", "node_type": "1", "metadata": {"window": "In fiscal 2025, we anticipate that these investments will account for an approximate 2% operating profit headwind \nin the Medical segment as compared to the prior year.  \n \n Finally, the International segment, we anticipate revenues to increase 4% to 8% and operating profit increase 6% \nto 10% ye ar over year.  Our diversified set of assets within our Canadian business, including the scaled \ndistribution business, continues to support growth in the international segment.  We continue to make investments \nin our Canadian technology footprint to create a  more custom and integrated supply chain for specialty drugs.  \n \n As a reminder, Norway remains the only operating country in Europe that we have not entered into an agreement \nto sell, and contributions related to operations in Norway are included in the fisc al 2025 outlook for the segment. \n We intend to exit Norway as part of the completion of our European exit.  \n \n In the Corporate segment, we anticipate expenses to be in the range of $580 million to $640 million, which \nincludes increased technology spend to support the growth of our businesses and infrastructure and compliance \ninvestments. ", "original_text": "We continue to make investments \nin our Canadian technology footprint to create a  more custom and integrated supply chain for specialty drugs.  \n \n"}, "hash": "2bf45f3912718d84d0c48d948b407159f10b955048a84d6541dec5687297a5f9", "class_name": "RelatedNodeInfo"}}, "text": "Our diversified set of assets within our Canadian business, including the scaled \ndistribution business, continues to support growth in the international segment. ", "start_char_idx": 1575, "end_char_idx": 1738, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c28fc01a-a6b7-41ac-88af-e7a6bdf75d2b": {"__data__": {"id_": "c28fc01a-a6b7-41ac-88af-e7a6bdf75d2b", "embedding": null, "metadata": {"window": "In fiscal 2025, we anticipate that these investments will account for an approximate 2% operating profit headwind \nin the Medical segment as compared to the prior year.  \n \n Finally, the International segment, we anticipate revenues to increase 4% to 8% and operating profit increase 6% \nto 10% ye ar over year.  Our diversified set of assets within our Canadian business, including the scaled \ndistribution business, continues to support growth in the international segment.  We continue to make investments \nin our Canadian technology footprint to create a  more custom and integrated supply chain for specialty drugs.  \n \n As a reminder, Norway remains the only operating country in Europe that we have not entered into an agreement \nto sell, and contributions related to operations in Norway are included in the fisc al 2025 outlook for the segment. \n We intend to exit Norway as part of the completion of our European exit.  \n \n In the Corporate segment, we anticipate expenses to be in the range of $580 million to $640 million, which \nincludes increased technology spend to support the growth of our businesses and infrastructure and compliance \ninvestments. ", "original_text": "We continue to make investments \nin our Canadian technology footprint to create a  more custom and integrated supply chain for specialty drugs.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b4739fd-a210-4020-aa76-6a4d4c165542", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ff6c7d3dda3fc8ff6cb6e78127986ed7d66e4815b2d8cee05bf07a64fa4d9d62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c067191-e598-47a8-b656-ff26c1febee3", "node_type": "1", "metadata": {"window": "These investments will deliver meaningful returns to the segment \nand to the enterprise.  \n \n In fiscal 2025, we anticipate that these investments will account for an approximate 2% operating profit headwind \nin the Medical segment as compared to the prior year.  \n \n Finally, the International segment, we anticipate revenues to increase 4% to 8% and operating profit increase 6% \nto 10% ye ar over year.  Our diversified set of assets within our Canadian business, including the scaled \ndistribution business, continues to support growth in the international segment.  We continue to make investments \nin our Canadian technology footprint to create a  more custom and integrated supply chain for specialty drugs.  \n \n As a reminder, Norway remains the only operating country in Europe that we have not entered into an agreement \nto sell, and contributions related to operations in Norway are included in the fisc al 2025 outlook for the segment. \n We intend to exit Norway as part of the completion of our European exit.  \n \n", "original_text": "Our diversified set of assets within our Canadian business, including the scaled \ndistribution business, continues to support growth in the international segment. ", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a5c439f047d646e5f5e5f326868751ec83152f885967d590e8290d4cc3971636", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ffa44fd8-68da-4afc-8905-ee84eb175bc7", "node_type": "1", "metadata": {"window": "Finally, the International segment, we anticipate revenues to increase 4% to 8% and operating profit increase 6% \nto 10% ye ar over year.  Our diversified set of assets within our Canadian business, including the scaled \ndistribution business, continues to support growth in the international segment.  We continue to make investments \nin our Canadian technology footprint to create a  more custom and integrated supply chain for specialty drugs.  \n \n As a reminder, Norway remains the only operating country in Europe that we have not entered into an agreement \nto sell, and contributions related to operations in Norway are included in the fisc al 2025 outlook for the segment. \n We intend to exit Norway as part of the completion of our European exit.  \n \n In the Corporate segment, we anticipate expenses to be in the range of $580 million to $640 million, which \nincludes increased technology spend to support the growth of our businesses and infrastructure and compliance \ninvestments.  We will also continue to invest in data and analytics, including the acceleration of several \ninvestments in artificial intelligence. ", "original_text": "As a reminder, Norway remains the only operating country in Europe that we have not entered into an agreement \nto sell, and contributions related to operations in Norway are included in the fisc al 2025 outlook for the segment. \n"}, "hash": "2106b1cfd03443b947d0673ce8908e448b0f777cd63b0d38dceb70f7c90c4653", "class_name": "RelatedNodeInfo"}}, "text": "We continue to make investments \nin our Canadian technology footprint to create a  more custom and integrated supply chain for specialty drugs.  \n \n", "start_char_idx": 1738, "end_char_idx": 1886, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ffa44fd8-68da-4afc-8905-ee84eb175bc7": {"__data__": {"id_": "ffa44fd8-68da-4afc-8905-ee84eb175bc7", "embedding": null, "metadata": {"window": "Finally, the International segment, we anticipate revenues to increase 4% to 8% and operating profit increase 6% \nto 10% ye ar over year.  Our diversified set of assets within our Canadian business, including the scaled \ndistribution business, continues to support growth in the international segment.  We continue to make investments \nin our Canadian technology footprint to create a  more custom and integrated supply chain for specialty drugs.  \n \n As a reminder, Norway remains the only operating country in Europe that we have not entered into an agreement \nto sell, and contributions related to operations in Norway are included in the fisc al 2025 outlook for the segment. \n We intend to exit Norway as part of the completion of our European exit.  \n \n In the Corporate segment, we anticipate expenses to be in the range of $580 million to $640 million, which \nincludes increased technology spend to support the growth of our businesses and infrastructure and compliance \ninvestments.  We will also continue to invest in data and analytics, including the acceleration of several \ninvestments in artificial intelligence. ", "original_text": "As a reminder, Norway remains the only operating country in Europe that we have not entered into an agreement \nto sell, and contributions related to operations in Norway are included in the fisc al 2025 outlook for the segment. \n", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b4739fd-a210-4020-aa76-6a4d4c165542", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ff6c7d3dda3fc8ff6cb6e78127986ed7d66e4815b2d8cee05bf07a64fa4d9d62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c28fc01a-a6b7-41ac-88af-e7a6bdf75d2b", "node_type": "1", "metadata": {"window": "In fiscal 2025, we anticipate that these investments will account for an approximate 2% operating profit headwind \nin the Medical segment as compared to the prior year.  \n \n Finally, the International segment, we anticipate revenues to increase 4% to 8% and operating profit increase 6% \nto 10% ye ar over year.  Our diversified set of assets within our Canadian business, including the scaled \ndistribution business, continues to support growth in the international segment.  We continue to make investments \nin our Canadian technology footprint to create a  more custom and integrated supply chain for specialty drugs.  \n \n As a reminder, Norway remains the only operating country in Europe that we have not entered into an agreement \nto sell, and contributions related to operations in Norway are included in the fisc al 2025 outlook for the segment. \n We intend to exit Norway as part of the completion of our European exit.  \n \n In the Corporate segment, we anticipate expenses to be in the range of $580 million to $640 million, which \nincludes increased technology spend to support the growth of our businesses and infrastructure and compliance \ninvestments. ", "original_text": "We continue to make investments \nin our Canadian technology footprint to create a  more custom and integrated supply chain for specialty drugs.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e189b0ef08839911af95e00743671c5ca7c7cb14240086e5f07aa0b2129a598e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a1d8b1c-89a3-4da3-be8e-fa18ad34e1f7", "node_type": "1", "metadata": {"window": "Our diversified set of assets within our Canadian business, including the scaled \ndistribution business, continues to support growth in the international segment.  We continue to make investments \nin our Canadian technology footprint to create a  more custom and integrated supply chain for specialty drugs.  \n \n As a reminder, Norway remains the only operating country in Europe that we have not entered into an agreement \nto sell, and contributions related to operations in Norway are included in the fisc al 2025 outlook for the segment. \n We intend to exit Norway as part of the completion of our European exit.  \n \n In the Corporate segment, we anticipate expenses to be in the range of $580 million to $640 million, which \nincludes increased technology spend to support the growth of our businesses and infrastructure and compliance \ninvestments.  We will also continue to invest in data and analytics, including the acceleration of several \ninvestments in artificial intelligence.  We are leveraging AI to increase the ef ficiency across our operations and \nincrease automation and productivity for our customers.  \n \n", "original_text": "We intend to exit Norway as part of the completion of our European exit.  \n \n"}, "hash": "8e0f4da6d8f5ebafe5f025adcdeccd625952846469926302757271b5090c2b35", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, Norway remains the only operating country in Europe that we have not entered into an agreement \nto sell, and contributions related to operations in Norway are included in the fisc al 2025 outlook for the segment. \n", "start_char_idx": 1886, "end_char_idx": 2115, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a1d8b1c-89a3-4da3-be8e-fa18ad34e1f7": {"__data__": {"id_": "2a1d8b1c-89a3-4da3-be8e-fa18ad34e1f7", "embedding": null, "metadata": {"window": "Our diversified set of assets within our Canadian business, including the scaled \ndistribution business, continues to support growth in the international segment.  We continue to make investments \nin our Canadian technology footprint to create a  more custom and integrated supply chain for specialty drugs.  \n \n As a reminder, Norway remains the only operating country in Europe that we have not entered into an agreement \nto sell, and contributions related to operations in Norway are included in the fisc al 2025 outlook for the segment. \n We intend to exit Norway as part of the completion of our European exit.  \n \n In the Corporate segment, we anticipate expenses to be in the range of $580 million to $640 million, which \nincludes increased technology spend to support the growth of our businesses and infrastructure and compliance \ninvestments.  We will also continue to invest in data and analytics, including the acceleration of several \ninvestments in artificial intelligence.  We are leveraging AI to increase the ef ficiency across our operations and \nincrease automation and productivity for our customers.  \n \n", "original_text": "We intend to exit Norway as part of the completion of our European exit.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b4739fd-a210-4020-aa76-6a4d4c165542", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ff6c7d3dda3fc8ff6cb6e78127986ed7d66e4815b2d8cee05bf07a64fa4d9d62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ffa44fd8-68da-4afc-8905-ee84eb175bc7", "node_type": "1", "metadata": {"window": "Finally, the International segment, we anticipate revenues to increase 4% to 8% and operating profit increase 6% \nto 10% ye ar over year.  Our diversified set of assets within our Canadian business, including the scaled \ndistribution business, continues to support growth in the international segment.  We continue to make investments \nin our Canadian technology footprint to create a  more custom and integrated supply chain for specialty drugs.  \n \n As a reminder, Norway remains the only operating country in Europe that we have not entered into an agreement \nto sell, and contributions related to operations in Norway are included in the fisc al 2025 outlook for the segment. \n We intend to exit Norway as part of the completion of our European exit.  \n \n In the Corporate segment, we anticipate expenses to be in the range of $580 million to $640 million, which \nincludes increased technology spend to support the growth of our businesses and infrastructure and compliance \ninvestments.  We will also continue to invest in data and analytics, including the acceleration of several \ninvestments in artificial intelligence. ", "original_text": "As a reminder, Norway remains the only operating country in Europe that we have not entered into an agreement \nto sell, and contributions related to operations in Norway are included in the fisc al 2025 outlook for the segment. \n", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c94d4e70d93b0a24f7c6919560f999a0c81831e5797da8cbe0615e45d447bff5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dea283fd-d725-401e-9b6b-4a4473add89e", "node_type": "1", "metadata": {"window": "We continue to make investments \nin our Canadian technology footprint to create a  more custom and integrated supply chain for specialty drugs.  \n \n As a reminder, Norway remains the only operating country in Europe that we have not entered into an agreement \nto sell, and contributions related to operations in Norway are included in the fisc al 2025 outlook for the segment. \n We intend to exit Norway as part of the completion of our European exit.  \n \n In the Corporate segment, we anticipate expenses to be in the range of $580 million to $640 million, which \nincludes increased technology spend to support the growth of our businesses and infrastructure and compliance \ninvestments.  We will also continue to invest in data and analytics, including the acceleration of several \ninvestments in artificial intelligence.  We are leveraging AI to increase the ef ficiency across our operations and \nincrease automation and productivity for our customers.  \n \n Our investments in AI and other advanced technologies play an important role in improving customer service and \nprovider productivity. ", "original_text": "In the Corporate segment, we anticipate expenses to be in the range of $580 million to $640 million, which \nincludes increased technology spend to support the growth of our businesses and infrastructure and compliance \ninvestments. "}, "hash": "2082ee300856d82ffd96d4882e66575d18d06cc8876e6f23a43cd386c6663b2d", "class_name": "RelatedNodeInfo"}}, "text": "We intend to exit Norway as part of the completion of our European exit.  \n \n", "start_char_idx": 2115, "end_char_idx": 2192, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dea283fd-d725-401e-9b6b-4a4473add89e": {"__data__": {"id_": "dea283fd-d725-401e-9b6b-4a4473add89e", "embedding": null, "metadata": {"window": "We continue to make investments \nin our Canadian technology footprint to create a  more custom and integrated supply chain for specialty drugs.  \n \n As a reminder, Norway remains the only operating country in Europe that we have not entered into an agreement \nto sell, and contributions related to operations in Norway are included in the fisc al 2025 outlook for the segment. \n We intend to exit Norway as part of the completion of our European exit.  \n \n In the Corporate segment, we anticipate expenses to be in the range of $580 million to $640 million, which \nincludes increased technology spend to support the growth of our businesses and infrastructure and compliance \ninvestments.  We will also continue to invest in data and analytics, including the acceleration of several \ninvestments in artificial intelligence.  We are leveraging AI to increase the ef ficiency across our operations and \nincrease automation and productivity for our customers.  \n \n Our investments in AI and other advanced technologies play an important role in improving customer service and \nprovider productivity. ", "original_text": "In the Corporate segment, we anticipate expenses to be in the range of $580 million to $640 million, which \nincludes increased technology spend to support the growth of our businesses and infrastructure and compliance \ninvestments. ", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b4739fd-a210-4020-aa76-6a4d4c165542", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ff6c7d3dda3fc8ff6cb6e78127986ed7d66e4815b2d8cee05bf07a64fa4d9d62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a1d8b1c-89a3-4da3-be8e-fa18ad34e1f7", "node_type": "1", "metadata": {"window": "Our diversified set of assets within our Canadian business, including the scaled \ndistribution business, continues to support growth in the international segment.  We continue to make investments \nin our Canadian technology footprint to create a  more custom and integrated supply chain for specialty drugs.  \n \n As a reminder, Norway remains the only operating country in Europe that we have not entered into an agreement \nto sell, and contributions related to operations in Norway are included in the fisc al 2025 outlook for the segment. \n We intend to exit Norway as part of the completion of our European exit.  \n \n In the Corporate segment, we anticipate expenses to be in the range of $580 million to $640 million, which \nincludes increased technology spend to support the growth of our businesses and infrastructure and compliance \ninvestments.  We will also continue to invest in data and analytics, including the acceleration of several \ninvestments in artificial intelligence.  We are leveraging AI to increase the ef ficiency across our operations and \nincrease automation and productivity for our customers.  \n \n", "original_text": "We intend to exit Norway as part of the completion of our European exit.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3a7230085a6f4588a26e10ebf1d6f41636a1eb92c5afe5181435aa74f9673107", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bae7a823-d919-4fff-af03-bbaa85b55eea", "node_type": "1", "metadata": {"window": "As a reminder, Norway remains the only operating country in Europe that we have not entered into an agreement \nto sell, and contributions related to operations in Norway are included in the fisc al 2025 outlook for the segment. \n We intend to exit Norway as part of the completion of our European exit.  \n \n In the Corporate segment, we anticipate expenses to be in the range of $580 million to $640 million, which \nincludes increased technology spend to support the growth of our businesses and infrastructure and compliance \ninvestments.  We will also continue to invest in data and analytics, including the acceleration of several \ninvestments in artificial intelligence.  We are leveraging AI to increase the ef ficiency across our operations and \nincrease automation and productivity for our customers.  \n \n Our investments in AI and other advanced technologies play an important role in improving customer service and \nprovider productivity.  We continue to build these too ls across the value chain to increase speed and success \nrates.  \n \n", "original_text": "We will also continue to invest in data and analytics, including the acceleration of several \ninvestments in artificial intelligence. "}, "hash": "79f3ff35cc298b256ddf4a45ea139efbda9df34a0672dae65ea31d633623b8bf", "class_name": "RelatedNodeInfo"}}, "text": "In the Corporate segment, we anticipate expenses to be in the range of $580 million to $640 million, which \nincludes increased technology spend to support the growth of our businesses and infrastructure and compliance \ninvestments. ", "start_char_idx": 2192, "end_char_idx": 2424, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bae7a823-d919-4fff-af03-bbaa85b55eea": {"__data__": {"id_": "bae7a823-d919-4fff-af03-bbaa85b55eea", "embedding": null, "metadata": {"window": "As a reminder, Norway remains the only operating country in Europe that we have not entered into an agreement \nto sell, and contributions related to operations in Norway are included in the fisc al 2025 outlook for the segment. \n We intend to exit Norway as part of the completion of our European exit.  \n \n In the Corporate segment, we anticipate expenses to be in the range of $580 million to $640 million, which \nincludes increased technology spend to support the growth of our businesses and infrastructure and compliance \ninvestments.  We will also continue to invest in data and analytics, including the acceleration of several \ninvestments in artificial intelligence.  We are leveraging AI to increase the ef ficiency across our operations and \nincrease automation and productivity for our customers.  \n \n Our investments in AI and other advanced technologies play an important role in improving customer service and \nprovider productivity.  We continue to build these too ls across the value chain to increase speed and success \nrates.  \n \n", "original_text": "We will also continue to invest in data and analytics, including the acceleration of several \ninvestments in artificial intelligence. ", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b4739fd-a210-4020-aa76-6a4d4c165542", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ff6c7d3dda3fc8ff6cb6e78127986ed7d66e4815b2d8cee05bf07a64fa4d9d62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dea283fd-d725-401e-9b6b-4a4473add89e", "node_type": "1", "metadata": {"window": "We continue to make investments \nin our Canadian technology footprint to create a  more custom and integrated supply chain for specialty drugs.  \n \n As a reminder, Norway remains the only operating country in Europe that we have not entered into an agreement \nto sell, and contributions related to operations in Norway are included in the fisc al 2025 outlook for the segment. \n We intend to exit Norway as part of the completion of our European exit.  \n \n In the Corporate segment, we anticipate expenses to be in the range of $580 million to $640 million, which \nincludes increased technology spend to support the growth of our businesses and infrastructure and compliance \ninvestments.  We will also continue to invest in data and analytics, including the acceleration of several \ninvestments in artificial intelligence.  We are leveraging AI to increase the ef ficiency across our operations and \nincrease automation and productivity for our customers.  \n \n Our investments in AI and other advanced technologies play an important role in improving customer service and \nprovider productivity. ", "original_text": "In the Corporate segment, we anticipate expenses to be in the range of $580 million to $640 million, which \nincludes increased technology spend to support the growth of our businesses and infrastructure and compliance \ninvestments. ", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "8b5d1e74d28b46e46d132a0e28dbccec2e4a075824f45e91f649cebf2cc9d581", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03c30d01-39b6-499d-9877-a02af067d8a0", "node_type": "1", "metadata": {"window": "We intend to exit Norway as part of the completion of our European exit.  \n \n In the Corporate segment, we anticipate expenses to be in the range of $580 million to $640 million, which \nincludes increased technology spend to support the growth of our businesses and infrastructure and compliance \ninvestments.  We will also continue to invest in data and analytics, including the acceleration of several \ninvestments in artificial intelligence.  We are leveraging AI to increase the ef ficiency across our operations and \nincrease automation and productivity for our customers.  \n \n Our investments in AI and other advanced technologies play an important role in improving customer service and \nprovider productivity.  We continue to build these too ls across the value chain to increase speed and success \nrates.  \n \n One example where we're implementing AI is in our oncology platform. ", "original_text": "We are leveraging AI to increase the ef ficiency across our operations and \nincrease automation and productivity for our customers.  \n \n"}, "hash": "8259d5f13a9931d44d884a08744b7942d1c5b1ef9b9adf36f5825f567ae0e167", "class_name": "RelatedNodeInfo"}}, "text": "We will also continue to invest in data and analytics, including the acceleration of several \ninvestments in artificial intelligence. ", "start_char_idx": 2424, "end_char_idx": 2558, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03c30d01-39b6-499d-9877-a02af067d8a0": {"__data__": {"id_": "03c30d01-39b6-499d-9877-a02af067d8a0", "embedding": null, "metadata": {"window": "We intend to exit Norway as part of the completion of our European exit.  \n \n In the Corporate segment, we anticipate expenses to be in the range of $580 million to $640 million, which \nincludes increased technology spend to support the growth of our businesses and infrastructure and compliance \ninvestments.  We will also continue to invest in data and analytics, including the acceleration of several \ninvestments in artificial intelligence.  We are leveraging AI to increase the ef ficiency across our operations and \nincrease automation and productivity for our customers.  \n \n Our investments in AI and other advanced technologies play an important role in improving customer service and \nprovider productivity.  We continue to build these too ls across the value chain to increase speed and success \nrates.  \n \n One example where we're implementing AI is in our oncology platform. ", "original_text": "We are leveraging AI to increase the ef ficiency across our operations and \nincrease automation and productivity for our customers.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b4739fd-a210-4020-aa76-6a4d4c165542", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ff6c7d3dda3fc8ff6cb6e78127986ed7d66e4815b2d8cee05bf07a64fa4d9d62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bae7a823-d919-4fff-af03-bbaa85b55eea", "node_type": "1", "metadata": {"window": "As a reminder, Norway remains the only operating country in Europe that we have not entered into an agreement \nto sell, and contributions related to operations in Norway are included in the fisc al 2025 outlook for the segment. \n We intend to exit Norway as part of the completion of our European exit.  \n \n In the Corporate segment, we anticipate expenses to be in the range of $580 million to $640 million, which \nincludes increased technology spend to support the growth of our businesses and infrastructure and compliance \ninvestments.  We will also continue to invest in data and analytics, including the acceleration of several \ninvestments in artificial intelligence.  We are leveraging AI to increase the ef ficiency across our operations and \nincrease automation and productivity for our customers.  \n \n Our investments in AI and other advanced technologies play an important role in improving customer service and \nprovider productivity.  We continue to build these too ls across the value chain to increase speed and success \nrates.  \n \n", "original_text": "We will also continue to invest in data and analytics, including the acceleration of several \ninvestments in artificial intelligence. ", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "fdb945ca191c4eee5739771e84d6bd03150f93f0c66bb4c8ed3b146682f31963", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad45e2f2-ce2f-484b-92af-2cc7dc381961", "node_type": "1", "metadata": {"window": "In the Corporate segment, we anticipate expenses to be in the range of $580 million to $640 million, which \nincludes increased technology spend to support the growth of our businesses and infrastructure and compliance \ninvestments.  We will also continue to invest in data and analytics, including the acceleration of several \ninvestments in artificial intelligence.  We are leveraging AI to increase the ef ficiency across our operations and \nincrease automation and productivity for our customers.  \n \n Our investments in AI and other advanced technologies play an important role in improving customer service and \nprovider productivity.  We continue to build these too ls across the value chain to increase speed and success \nrates.  \n \n One example where we're implementing AI is in our oncology platform.  The iKnowMed EHR contains structured \ndata that can often be sparsely entered for patients' longitudinal records. ", "original_text": "Our investments in AI and other advanced technologies play an important role in improving customer service and \nprovider productivity. "}, "hash": "a2d9d75b7be5ca54e2ed9ee81bc0788a822fe4babe504537a2a466b07d0a92f2", "class_name": "RelatedNodeInfo"}}, "text": "We are leveraging AI to increase the ef ficiency across our operations and \nincrease automation and productivity for our customers.  \n \n", "start_char_idx": 2558, "end_char_idx": 2694, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad45e2f2-ce2f-484b-92af-2cc7dc381961": {"__data__": {"id_": "ad45e2f2-ce2f-484b-92af-2cc7dc381961", "embedding": null, "metadata": {"window": "In the Corporate segment, we anticipate expenses to be in the range of $580 million to $640 million, which \nincludes increased technology spend to support the growth of our businesses and infrastructure and compliance \ninvestments.  We will also continue to invest in data and analytics, including the acceleration of several \ninvestments in artificial intelligence.  We are leveraging AI to increase the ef ficiency across our operations and \nincrease automation and productivity for our customers.  \n \n Our investments in AI and other advanced technologies play an important role in improving customer service and \nprovider productivity.  We continue to build these too ls across the value chain to increase speed and success \nrates.  \n \n One example where we're implementing AI is in our oncology platform.  The iKnowMed EHR contains structured \ndata that can often be sparsely entered for patients' longitudinal records. ", "original_text": "Our investments in AI and other advanced technologies play an important role in improving customer service and \nprovider productivity. ", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b4739fd-a210-4020-aa76-6a4d4c165542", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ff6c7d3dda3fc8ff6cb6e78127986ed7d66e4815b2d8cee05bf07a64fa4d9d62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03c30d01-39b6-499d-9877-a02af067d8a0", "node_type": "1", "metadata": {"window": "We intend to exit Norway as part of the completion of our European exit.  \n \n In the Corporate segment, we anticipate expenses to be in the range of $580 million to $640 million, which \nincludes increased technology spend to support the growth of our businesses and infrastructure and compliance \ninvestments.  We will also continue to invest in data and analytics, including the acceleration of several \ninvestments in artificial intelligence.  We are leveraging AI to increase the ef ficiency across our operations and \nincrease automation and productivity for our customers.  \n \n Our investments in AI and other advanced technologies play an important role in improving customer service and \nprovider productivity.  We continue to build these too ls across the value chain to increase speed and success \nrates.  \n \n One example where we're implementing AI is in our oncology platform. ", "original_text": "We are leveraging AI to increase the ef ficiency across our operations and \nincrease automation and productivity for our customers.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f57a4a64eba3154963b5c16f9c0010d0fb402ea703e64a2e081c05bb125b9b7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc18613b-55a1-4d73-88d7-37c1faae23d7", "node_type": "1", "metadata": {"window": "We will also continue to invest in data and analytics, including the acceleration of several \ninvestments in artificial intelligence.  We are leveraging AI to increase the ef ficiency across our operations and \nincrease automation and productivity for our customers.  \n \n Our investments in AI and other advanced technologies play an important role in improving customer service and \nprovider productivity.  We continue to build these too ls across the value chain to increase speed and success \nrates.  \n \n One example where we're implementing AI is in our oncology platform.  The iKnowMed EHR contains structured \ndata that can often be sparsely entered for patients' longitudinal records.  Instead, u nstructured data, such as \nuploaded documents and provider -authored notes, are used to capture details on patients' disease condition and \nresponse to treatment as well as many core clinical factors.  \n \n", "original_text": "We continue to build these too ls across the value chain to increase speed and success \nrates.  \n \n"}, "hash": "1cec2f27f5c6e16377e68b2eed0ceb6aea402bbd1b7e230dffc0de996ba71b20", "class_name": "RelatedNodeInfo"}}, "text": "Our investments in AI and other advanced technologies play an important role in improving customer service and \nprovider productivity. ", "start_char_idx": 2694, "end_char_idx": 2829, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc18613b-55a1-4d73-88d7-37c1faae23d7": {"__data__": {"id_": "bc18613b-55a1-4d73-88d7-37c1faae23d7", "embedding": null, "metadata": {"window": "We will also continue to invest in data and analytics, including the acceleration of several \ninvestments in artificial intelligence.  We are leveraging AI to increase the ef ficiency across our operations and \nincrease automation and productivity for our customers.  \n \n Our investments in AI and other advanced technologies play an important role in improving customer service and \nprovider productivity.  We continue to build these too ls across the value chain to increase speed and success \nrates.  \n \n One example where we're implementing AI is in our oncology platform.  The iKnowMed EHR contains structured \ndata that can often be sparsely entered for patients' longitudinal records.  Instead, u nstructured data, such as \nuploaded documents and provider -authored notes, are used to capture details on patients' disease condition and \nresponse to treatment as well as many core clinical factors.  \n \n", "original_text": "We continue to build these too ls across the value chain to increase speed and success \nrates.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b4739fd-a210-4020-aa76-6a4d4c165542", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ff6c7d3dda3fc8ff6cb6e78127986ed7d66e4815b2d8cee05bf07a64fa4d9d62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad45e2f2-ce2f-484b-92af-2cc7dc381961", "node_type": "1", "metadata": {"window": "In the Corporate segment, we anticipate expenses to be in the range of $580 million to $640 million, which \nincludes increased technology spend to support the growth of our businesses and infrastructure and compliance \ninvestments.  We will also continue to invest in data and analytics, including the acceleration of several \ninvestments in artificial intelligence.  We are leveraging AI to increase the ef ficiency across our operations and \nincrease automation and productivity for our customers.  \n \n Our investments in AI and other advanced technologies play an important role in improving customer service and \nprovider productivity.  We continue to build these too ls across the value chain to increase speed and success \nrates.  \n \n One example where we're implementing AI is in our oncology platform.  The iKnowMed EHR contains structured \ndata that can often be sparsely entered for patients' longitudinal records. ", "original_text": "Our investments in AI and other advanced technologies play an important role in improving customer service and \nprovider productivity. ", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "11664ae33fe87c74b53d020aa0345cde0043667fa64eb7925535da5f851f555c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17277776-8340-42a5-93a1-e3c8d303e8ff", "node_type": "1", "metadata": {"window": "We are leveraging AI to increase the ef ficiency across our operations and \nincrease automation and productivity for our customers.  \n \n Our investments in AI and other advanced technologies play an important role in improving customer service and \nprovider productivity.  We continue to build these too ls across the value chain to increase speed and success \nrates.  \n \n One example where we're implementing AI is in our oncology platform.  The iKnowMed EHR contains structured \ndata that can often be sparsely entered for patients' longitudinal records.  Instead, u nstructured data, such as \nuploaded documents and provider -authored notes, are used to capture details on patients' disease condition and \nresponse to treatment as well as many core clinical factors.  \n \n To have complete longitudinal patient records for real -world research, core variables are required to be extracted \nfrom the unstructured data into a well -organized database. ", "original_text": "One example where we're implementing AI is in our oncology platform. "}, "hash": "6bf5acf3a83cef5cccfe8bbc8ff0a65bc635e79908ca0a692ff18c217bf220df", "class_name": "RelatedNodeInfo"}}, "text": "We continue to build these too ls across the value chain to increase speed and success \nrates.  \n \n", "start_char_idx": 2829, "end_char_idx": 2928, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17277776-8340-42a5-93a1-e3c8d303e8ff": {"__data__": {"id_": "17277776-8340-42a5-93a1-e3c8d303e8ff", "embedding": null, "metadata": {"window": "We are leveraging AI to increase the ef ficiency across our operations and \nincrease automation and productivity for our customers.  \n \n Our investments in AI and other advanced technologies play an important role in improving customer service and \nprovider productivity.  We continue to build these too ls across the value chain to increase speed and success \nrates.  \n \n One example where we're implementing AI is in our oncology platform.  The iKnowMed EHR contains structured \ndata that can often be sparsely entered for patients' longitudinal records.  Instead, u nstructured data, such as \nuploaded documents and provider -authored notes, are used to capture details on patients' disease condition and \nresponse to treatment as well as many core clinical factors.  \n \n To have complete longitudinal patient records for real -world research, core variables are required to be extracted \nfrom the unstructured data into a well -organized database. ", "original_text": "One example where we're implementing AI is in our oncology platform. ", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b4739fd-a210-4020-aa76-6a4d4c165542", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ff6c7d3dda3fc8ff6cb6e78127986ed7d66e4815b2d8cee05bf07a64fa4d9d62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc18613b-55a1-4d73-88d7-37c1faae23d7", "node_type": "1", "metadata": {"window": "We will also continue to invest in data and analytics, including the acceleration of several \ninvestments in artificial intelligence.  We are leveraging AI to increase the ef ficiency across our operations and \nincrease automation and productivity for our customers.  \n \n Our investments in AI and other advanced technologies play an important role in improving customer service and \nprovider productivity.  We continue to build these too ls across the value chain to increase speed and success \nrates.  \n \n One example where we're implementing AI is in our oncology platform.  The iKnowMed EHR contains structured \ndata that can often be sparsely entered for patients' longitudinal records.  Instead, u nstructured data, such as \nuploaded documents and provider -authored notes, are used to capture details on patients' disease condition and \nresponse to treatment as well as many core clinical factors.  \n \n", "original_text": "We continue to build these too ls across the value chain to increase speed and success \nrates.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "1b4b1a4b602c3dd0fa554e59014cb766f6b64d58f6d95150cf9c259e748db57c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df378f16-01c5-46a1-8100-e6f100f4a2a9", "node_type": "1", "metadata": {"window": "Our investments in AI and other advanced technologies play an important role in improving customer service and \nprovider productivity.  We continue to build these too ls across the value chain to increase speed and success \nrates.  \n \n One example where we're implementing AI is in our oncology platform.  The iKnowMed EHR contains structured \ndata that can often be sparsely entered for patients' longitudinal records.  Instead, u nstructured data, such as \nuploaded documents and provider -authored notes, are used to capture details on patients' disease condition and \nresponse to treatment as well as many core clinical factors.  \n \n To have complete longitudinal patient records for real -world research, core variables are required to be extracted \nfrom the unstructured data into a well -organized database.  Natural language process is the only scalable solution \nto achieve more than 100 million documents in iKnowMed today and growing at the rate  of 1 million documents \nper week.  \n \n", "original_text": "The iKnowMed EHR contains structured \ndata that can often be sparsely entered for patients' longitudinal records. "}, "hash": "b9706d50e62c0fe8cc366f6a776849f28214268515a14f2a48209801ac8eadf0", "class_name": "RelatedNodeInfo"}}, "text": "One example where we're implementing AI is in our oncology platform. ", "start_char_idx": 2928, "end_char_idx": 2997, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df378f16-01c5-46a1-8100-e6f100f4a2a9": {"__data__": {"id_": "df378f16-01c5-46a1-8100-e6f100f4a2a9", "embedding": null, "metadata": {"window": "Our investments in AI and other advanced technologies play an important role in improving customer service and \nprovider productivity.  We continue to build these too ls across the value chain to increase speed and success \nrates.  \n \n One example where we're implementing AI is in our oncology platform.  The iKnowMed EHR contains structured \ndata that can often be sparsely entered for patients' longitudinal records.  Instead, u nstructured data, such as \nuploaded documents and provider -authored notes, are used to capture details on patients' disease condition and \nresponse to treatment as well as many core clinical factors.  \n \n To have complete longitudinal patient records for real -world research, core variables are required to be extracted \nfrom the unstructured data into a well -organized database.  Natural language process is the only scalable solution \nto achieve more than 100 million documents in iKnowMed today and growing at the rate  of 1 million documents \nper week.  \n \n", "original_text": "The iKnowMed EHR contains structured \ndata that can often be sparsely entered for patients' longitudinal records. ", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b4739fd-a210-4020-aa76-6a4d4c165542", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ff6c7d3dda3fc8ff6cb6e78127986ed7d66e4815b2d8cee05bf07a64fa4d9d62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17277776-8340-42a5-93a1-e3c8d303e8ff", "node_type": "1", "metadata": {"window": "We are leveraging AI to increase the ef ficiency across our operations and \nincrease automation and productivity for our customers.  \n \n Our investments in AI and other advanced technologies play an important role in improving customer service and \nprovider productivity.  We continue to build these too ls across the value chain to increase speed and success \nrates.  \n \n One example where we're implementing AI is in our oncology platform.  The iKnowMed EHR contains structured \ndata that can often be sparsely entered for patients' longitudinal records.  Instead, u nstructured data, such as \nuploaded documents and provider -authored notes, are used to capture details on patients' disease condition and \nresponse to treatment as well as many core clinical factors.  \n \n To have complete longitudinal patient records for real -world research, core variables are required to be extracted \nfrom the unstructured data into a well -organized database. ", "original_text": "One example where we're implementing AI is in our oncology platform. ", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "be9508a62fda24304f9739c7773216f4968c2fd147852790cbe4191d0532cacd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35f6c835-e1de-495e-b08e-70f0b0f0fb9f", "node_type": "1", "metadata": {"window": "We continue to build these too ls across the value chain to increase speed and success \nrates.  \n \n One example where we're implementing AI is in our oncology platform.  The iKnowMed EHR contains structured \ndata that can often be sparsely entered for patients' longitudinal records.  Instead, u nstructured data, such as \nuploaded documents and provider -authored notes, are used to capture details on patients' disease condition and \nresponse to treatment as well as many core clinical factors.  \n \n To have complete longitudinal patient records for real -world research, core variables are required to be extracted \nfrom the unstructured data into a well -organized database.  Natural language process is the only scalable solution \nto achieve more than 100 million documents in iKnowMed today and growing at the rate  of 1 million documents \nper week.  \n \n The application of AI reduces clinicians' exhaustive burden in finding related documents for care and \nreimbursement workflows, ultimately leading to practice efficiencies and better patient care. ", "original_text": "Instead, u nstructured data, such as \nuploaded documents and provider -authored notes, are used to capture details on patients' disease condition and \nresponse to treatment as well as many core clinical factors.  \n \n"}, "hash": "1680a2f952e8cdf08cc78b27af140af96f23e191e00b570d3b28a3ea102426a7", "class_name": "RelatedNodeInfo"}}, "text": "The iKnowMed EHR contains structured \ndata that can often be sparsely entered for patients' longitudinal records. ", "start_char_idx": 2997, "end_char_idx": 3111, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35f6c835-e1de-495e-b08e-70f0b0f0fb9f": {"__data__": {"id_": "35f6c835-e1de-495e-b08e-70f0b0f0fb9f", "embedding": null, "metadata": {"window": "We continue to build these too ls across the value chain to increase speed and success \nrates.  \n \n One example where we're implementing AI is in our oncology platform.  The iKnowMed EHR contains structured \ndata that can often be sparsely entered for patients' longitudinal records.  Instead, u nstructured data, such as \nuploaded documents and provider -authored notes, are used to capture details on patients' disease condition and \nresponse to treatment as well as many core clinical factors.  \n \n To have complete longitudinal patient records for real -world research, core variables are required to be extracted \nfrom the unstructured data into a well -organized database.  Natural language process is the only scalable solution \nto achieve more than 100 million documents in iKnowMed today and growing at the rate  of 1 million documents \nper week.  \n \n The application of AI reduces clinicians' exhaustive burden in finding related documents for care and \nreimbursement workflows, ultimately leading to practice efficiencies and better patient care. ", "original_text": "Instead, u nstructured data, such as \nuploaded documents and provider -authored notes, are used to capture details on patients' disease condition and \nresponse to treatment as well as many core clinical factors.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b4739fd-a210-4020-aa76-6a4d4c165542", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ff6c7d3dda3fc8ff6cb6e78127986ed7d66e4815b2d8cee05bf07a64fa4d9d62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df378f16-01c5-46a1-8100-e6f100f4a2a9", "node_type": "1", "metadata": {"window": "Our investments in AI and other advanced technologies play an important role in improving customer service and \nprovider productivity.  We continue to build these too ls across the value chain to increase speed and success \nrates.  \n \n One example where we're implementing AI is in our oncology platform.  The iKnowMed EHR contains structured \ndata that can often be sparsely entered for patients' longitudinal records.  Instead, u nstructured data, such as \nuploaded documents and provider -authored notes, are used to capture details on patients' disease condition and \nresponse to treatment as well as many core clinical factors.  \n \n To have complete longitudinal patient records for real -world research, core variables are required to be extracted \nfrom the unstructured data into a well -organized database.  Natural language process is the only scalable solution \nto achieve more than 100 million documents in iKnowMed today and growing at the rate  of 1 million documents \nper week.  \n \n", "original_text": "The iKnowMed EHR contains structured \ndata that can often be sparsely entered for patients' longitudinal records. ", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "4d7980cc4dbf6d5f3f01790c4c96a296a80711b1f14345ade038997dd28b3c06", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "252b97b9-d573-46c8-889a-4d2abaa1f822", "node_type": "1", "metadata": {"window": "One example where we're implementing AI is in our oncology platform.  The iKnowMed EHR contains structured \ndata that can often be sparsely entered for patients' longitudinal records.  Instead, u nstructured data, such as \nuploaded documents and provider -authored notes, are used to capture details on patients' disease condition and \nresponse to treatment as well as many core clinical factors.  \n \n To have complete longitudinal patient records for real -world research, core variables are required to be extracted \nfrom the unstructured data into a well -organized database.  Natural language process is the only scalable solution \nto achieve more than 100 million documents in iKnowMed today and growing at the rate  of 1 million documents \nper week.  \n \n The application of AI reduces clinicians' exhaustive burden in finding related documents for care and \nreimbursement workflows, ultimately leading to practice efficiencies and better patient care.  This is just one ", "original_text": "To have complete longitudinal patient records for real -world research, core variables are required to be extracted \nfrom the unstructured data into a well -organized database. "}, "hash": "97a0e16ad117c494b7cc62679dff91ca76ece8043211dc9b2cd86ce73f006aa7", "class_name": "RelatedNodeInfo"}}, "text": "Instead, u nstructured data, such as \nuploaded documents and provider -authored notes, are used to capture details on patients' disease condition and \nresponse to treatment as well as many core clinical factors.  \n \n", "start_char_idx": 3111, "end_char_idx": 3327, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "252b97b9-d573-46c8-889a-4d2abaa1f822": {"__data__": {"id_": "252b97b9-d573-46c8-889a-4d2abaa1f822", "embedding": null, "metadata": {"window": "One example where we're implementing AI is in our oncology platform.  The iKnowMed EHR contains structured \ndata that can often be sparsely entered for patients' longitudinal records.  Instead, u nstructured data, such as \nuploaded documents and provider -authored notes, are used to capture details on patients' disease condition and \nresponse to treatment as well as many core clinical factors.  \n \n To have complete longitudinal patient records for real -world research, core variables are required to be extracted \nfrom the unstructured data into a well -organized database.  Natural language process is the only scalable solution \nto achieve more than 100 million documents in iKnowMed today and growing at the rate  of 1 million documents \nper week.  \n \n The application of AI reduces clinicians' exhaustive burden in finding related documents for care and \nreimbursement workflows, ultimately leading to practice efficiencies and better patient care.  This is just one ", "original_text": "To have complete longitudinal patient records for real -world research, core variables are required to be extracted \nfrom the unstructured data into a well -organized database. ", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b4739fd-a210-4020-aa76-6a4d4c165542", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ff6c7d3dda3fc8ff6cb6e78127986ed7d66e4815b2d8cee05bf07a64fa4d9d62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35f6c835-e1de-495e-b08e-70f0b0f0fb9f", "node_type": "1", "metadata": {"window": "We continue to build these too ls across the value chain to increase speed and success \nrates.  \n \n One example where we're implementing AI is in our oncology platform.  The iKnowMed EHR contains structured \ndata that can often be sparsely entered for patients' longitudinal records.  Instead, u nstructured data, such as \nuploaded documents and provider -authored notes, are used to capture details on patients' disease condition and \nresponse to treatment as well as many core clinical factors.  \n \n To have complete longitudinal patient records for real -world research, core variables are required to be extracted \nfrom the unstructured data into a well -organized database.  Natural language process is the only scalable solution \nto achieve more than 100 million documents in iKnowMed today and growing at the rate  of 1 million documents \nper week.  \n \n The application of AI reduces clinicians' exhaustive burden in finding related documents for care and \nreimbursement workflows, ultimately leading to practice efficiencies and better patient care. ", "original_text": "Instead, u nstructured data, such as \nuploaded documents and provider -authored notes, are used to capture details on patients' disease condition and \nresponse to treatment as well as many core clinical factors.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d01c8a2de033727a215e31189d034009c2592f982dbf36cf14a7bba0cfb90392", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4af490a-fe7f-448c-aae1-06f482452e05", "node_type": "1", "metadata": {"window": "The iKnowMed EHR contains structured \ndata that can often be sparsely entered for patients' longitudinal records.  Instead, u nstructured data, such as \nuploaded documents and provider -authored notes, are used to capture details on patients' disease condition and \nresponse to treatment as well as many core clinical factors.  \n \n To have complete longitudinal patient records for real -world research, core variables are required to be extracted \nfrom the unstructured data into a well -organized database.  Natural language process is the only scalable solution \nto achieve more than 100 million documents in iKnowMed today and growing at the rate  of 1 million documents \nper week.  \n \n The application of AI reduces clinicians' exhaustive burden in finding related documents for care and \nreimbursement workflows, ultimately leading to practice efficiencies and better patient care.  This is just one ", "original_text": "Natural language process is the only scalable solution \nto achieve more than 100 million documents in iKnowMed today and growing at the rate  of 1 million documents \nper week.  \n \n"}, "hash": "ee1e068e6ba7d0c94e7543f52f29875f568d90eb55b9d89c8b0f06a18edb26fd", "class_name": "RelatedNodeInfo"}}, "text": "To have complete longitudinal patient records for real -world research, core variables are required to be extracted \nfrom the unstructured data into a well -organized database. ", "start_char_idx": 3327, "end_char_idx": 3504, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4af490a-fe7f-448c-aae1-06f482452e05": {"__data__": {"id_": "d4af490a-fe7f-448c-aae1-06f482452e05", "embedding": null, "metadata": {"window": "The iKnowMed EHR contains structured \ndata that can often be sparsely entered for patients' longitudinal records.  Instead, u nstructured data, such as \nuploaded documents and provider -authored notes, are used to capture details on patients' disease condition and \nresponse to treatment as well as many core clinical factors.  \n \n To have complete longitudinal patient records for real -world research, core variables are required to be extracted \nfrom the unstructured data into a well -organized database.  Natural language process is the only scalable solution \nto achieve more than 100 million documents in iKnowMed today and growing at the rate  of 1 million documents \nper week.  \n \n The application of AI reduces clinicians' exhaustive burden in finding related documents for care and \nreimbursement workflows, ultimately leading to practice efficiencies and better patient care.  This is just one ", "original_text": "Natural language process is the only scalable solution \nto achieve more than 100 million documents in iKnowMed today and growing at the rate  of 1 million documents \nper week.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b4739fd-a210-4020-aa76-6a4d4c165542", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ff6c7d3dda3fc8ff6cb6e78127986ed7d66e4815b2d8cee05bf07a64fa4d9d62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "252b97b9-d573-46c8-889a-4d2abaa1f822", "node_type": "1", "metadata": {"window": "One example where we're implementing AI is in our oncology platform.  The iKnowMed EHR contains structured \ndata that can often be sparsely entered for patients' longitudinal records.  Instead, u nstructured data, such as \nuploaded documents and provider -authored notes, are used to capture details on patients' disease condition and \nresponse to treatment as well as many core clinical factors.  \n \n To have complete longitudinal patient records for real -world research, core variables are required to be extracted \nfrom the unstructured data into a well -organized database.  Natural language process is the only scalable solution \nto achieve more than 100 million documents in iKnowMed today and growing at the rate  of 1 million documents \nper week.  \n \n The application of AI reduces clinicians' exhaustive burden in finding related documents for care and \nreimbursement workflows, ultimately leading to practice efficiencies and better patient care.  This is just one ", "original_text": "To have complete longitudinal patient records for real -world research, core variables are required to be extracted \nfrom the unstructured data into a well -organized database. ", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d671387bf283dced8105ebfb279f60a1c50b3cb9eef048d89b084cf6baae3c96", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59331b4f-93ab-4a88-a594-ba5080e05e77", "node_type": "1", "metadata": {"window": "Instead, u nstructured data, such as \nuploaded documents and provider -authored notes, are used to capture details on patients' disease condition and \nresponse to treatment as well as many core clinical factors.  \n \n To have complete longitudinal patient records for real -world research, core variables are required to be extracted \nfrom the unstructured data into a well -organized database.  Natural language process is the only scalable solution \nto achieve more than 100 million documents in iKnowMed today and growing at the rate  of 1 million documents \nper week.  \n \n The application of AI reduces clinicians' exhaustive burden in finding related documents for care and \nreimbursement workflows, ultimately leading to practice efficiencies and better patient care.  This is just one ", "original_text": "The application of AI reduces clinicians' exhaustive burden in finding related documents for care and \nreimbursement workflows, ultimately leading to practice efficiencies and better patient care. "}, "hash": "b50ed8323ce5119602f2f85c54e5025cd975a36d38b7b4651fcc272eeeddb975", "class_name": "RelatedNodeInfo"}}, "text": "Natural language process is the only scalable solution \nto achieve more than 100 million documents in iKnowMed today and growing at the rate  of 1 million documents \nper week.  \n \n", "start_char_idx": 3504, "end_char_idx": 3684, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59331b4f-93ab-4a88-a594-ba5080e05e77": {"__data__": {"id_": "59331b4f-93ab-4a88-a594-ba5080e05e77", "embedding": null, "metadata": {"window": "Instead, u nstructured data, such as \nuploaded documents and provider -authored notes, are used to capture details on patients' disease condition and \nresponse to treatment as well as many core clinical factors.  \n \n To have complete longitudinal patient records for real -world research, core variables are required to be extracted \nfrom the unstructured data into a well -organized database.  Natural language process is the only scalable solution \nto achieve more than 100 million documents in iKnowMed today and growing at the rate  of 1 million documents \nper week.  \n \n The application of AI reduces clinicians' exhaustive burden in finding related documents for care and \nreimbursement workflows, ultimately leading to practice efficiencies and better patient care.  This is just one ", "original_text": "The application of AI reduces clinicians' exhaustive burden in finding related documents for care and \nreimbursement workflows, ultimately leading to practice efficiencies and better patient care. ", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b4739fd-a210-4020-aa76-6a4d4c165542", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ff6c7d3dda3fc8ff6cb6e78127986ed7d66e4815b2d8cee05bf07a64fa4d9d62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4af490a-fe7f-448c-aae1-06f482452e05", "node_type": "1", "metadata": {"window": "The iKnowMed EHR contains structured \ndata that can often be sparsely entered for patients' longitudinal records.  Instead, u nstructured data, such as \nuploaded documents and provider -authored notes, are used to capture details on patients' disease condition and \nresponse to treatment as well as many core clinical factors.  \n \n To have complete longitudinal patient records for real -world research, core variables are required to be extracted \nfrom the unstructured data into a well -organized database.  Natural language process is the only scalable solution \nto achieve more than 100 million documents in iKnowMed today and growing at the rate  of 1 million documents \nper week.  \n \n The application of AI reduces clinicians' exhaustive burden in finding related documents for care and \nreimbursement workflows, ultimately leading to practice efficiencies and better patient care.  This is just one ", "original_text": "Natural language process is the only scalable solution \nto achieve more than 100 million documents in iKnowMed today and growing at the rate  of 1 million documents \nper week.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f29ec8cf42a98d78c465da9efd91ec9663a44fdef68191152cdf2cd165ce838c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca9d6e59-6d9f-47cc-ba35-442130f2d4db", "node_type": "1", "metadata": {"window": "To have complete longitudinal patient records for real -world research, core variables are required to be extracted \nfrom the unstructured data into a well -organized database.  Natural language process is the only scalable solution \nto achieve more than 100 million documents in iKnowMed today and growing at the rate  of 1 million documents \nper week.  \n \n The application of AI reduces clinicians' exhaustive burden in finding related documents for care and \nreimbursement workflows, ultimately leading to practice efficiencies and better patient care.  This is just one ", "original_text": "This is just one "}, "hash": "d2380872be5f5ec485356ae7d3bcc0192c4fa7ad579e1175f0f95b26a97dc3ad", "class_name": "RelatedNodeInfo"}}, "text": "The application of AI reduces clinicians' exhaustive burden in finding related documents for care and \nreimbursement workflows, ultimately leading to practice efficiencies and better patient care. ", "start_char_idx": 3684, "end_char_idx": 3881, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca9d6e59-6d9f-47cc-ba35-442130f2d4db": {"__data__": {"id_": "ca9d6e59-6d9f-47cc-ba35-442130f2d4db", "embedding": null, "metadata": {"window": "To have complete longitudinal patient records for real -world research, core variables are required to be extracted \nfrom the unstructured data into a well -organized database.  Natural language process is the only scalable solution \nto achieve more than 100 million documents in iKnowMed today and growing at the rate  of 1 million documents \nper week.  \n \n The application of AI reduces clinicians' exhaustive burden in finding related documents for care and \nreimbursement workflows, ultimately leading to practice efficiencies and better patient care.  This is just one ", "original_text": "This is just one ", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b4739fd-a210-4020-aa76-6a4d4c165542", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ff6c7d3dda3fc8ff6cb6e78127986ed7d66e4815b2d8cee05bf07a64fa4d9d62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59331b4f-93ab-4a88-a594-ba5080e05e77", "node_type": "1", "metadata": {"window": "Instead, u nstructured data, such as \nuploaded documents and provider -authored notes, are used to capture details on patients' disease condition and \nresponse to treatment as well as many core clinical factors.  \n \n To have complete longitudinal patient records for real -world research, core variables are required to be extracted \nfrom the unstructured data into a well -organized database.  Natural language process is the only scalable solution \nto achieve more than 100 million documents in iKnowMed today and growing at the rate  of 1 million documents \nper week.  \n \n The application of AI reduces clinicians' exhaustive burden in finding related documents for care and \nreimbursement workflows, ultimately leading to practice efficiencies and better patient care.  This is just one ", "original_text": "The application of AI reduces clinicians' exhaustive burden in finding related documents for care and \nreimbursement workflows, ultimately leading to practice efficiencies and better patient care. ", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "55ab812eae9cf48223e3855fb55c1fffbc8147bc92a948b41445f4ddb9d23685", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42de0b0f-cf97-4afc-8b99-d4eb4948704b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nexample of many where we're using AI to power insights and deliver clinical and financial value to our \nstakeholders.  \n \n We've been pleased with our progress to date as we work to develop and implement various AI technologies, and \nwe remain committed to increased inv estment to further extend our leadership positions and deliver value to our \npartners and stakeholders.  \n \n Now moving below the line, we anticipate interest expense to be approximately $220 million to $240 million, and \nincome attributable to non -controlling i nterests to be in the range of $140 million to $160 million. ", "original_text": "McKesson Corp.  "}, "hash": "4f107c9e5adf2c586d68f13aa3171d00ac3137cb475c3dd371a2653c0829d2c1", "class_name": "RelatedNodeInfo"}}, "text": "This is just one ", "start_char_idx": 3881, "end_char_idx": 3898, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42de0b0f-cf97-4afc-8b99-d4eb4948704b": {"__data__": {"id_": "42de0b0f-cf97-4afc-8b99-d4eb4948704b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nexample of many where we're using AI to power insights and deliver clinical and financial value to our \nstakeholders.  \n \n We've been pleased with our progress to date as we work to develop and implement various AI technologies, and \nwe remain committed to increased inv estment to further extend our leadership positions and deliver value to our \npartners and stakeholders.  \n \n Now moving below the line, we anticipate interest expense to be approximately $220 million to $240 million, and \nincome attributable to non -controlling i nterests to be in the range of $140 million to $160 million. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd6eacc3-18ee-4daa-936d-290440082d8d", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "135d466d7ec9bb0716b764cabd296029bbfd0d1c9794ed763ec9c520e0d552ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca9d6e59-6d9f-47cc-ba35-442130f2d4db", "node_type": "1", "metadata": {"window": "To have complete longitudinal patient records for real -world research, core variables are required to be extracted \nfrom the unstructured data into a well -organized database.  Natural language process is the only scalable solution \nto achieve more than 100 million documents in iKnowMed today and growing at the rate  of 1 million documents \nper week.  \n \n The application of AI reduces clinicians' exhaustive burden in finding related documents for care and \nreimbursement workflows, ultimately leading to practice efficiencies and better patient care.  This is just one ", "original_text": "This is just one ", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "aff669773a1e42f817a6557c759cc708e750f10533afcd5cc0282ccbf7b1153e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f52ffaee-7b46-477d-a1a3-0883c78fe76b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nexample of many where we're using AI to power insights and deliver clinical and financial value to our \nstakeholders.  \n \n We've been pleased with our progress to date as we work to develop and implement various AI technologies, and \nwe remain committed to increased inv estment to further extend our leadership positions and deliver value to our \npartners and stakeholders.  \n \n Now moving below the line, we anticipate interest expense to be approximately $220 million to $240 million, and \nincome attributable to non -controlling i nterests to be in the range of $140 million to $160 million.  We anticipate the \nfull-year effective tax rate will be in the range of approximately 18% to 20%. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nexample of many where we're using AI to power insights and deliver clinical and financial value to our \nstakeholders.  \n \n"}, "hash": "6e7a6272c7803dde579ba9f11b7286871a7f135f5df50107a8b3ec1cfe6f1925", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f52ffaee-7b46-477d-a1a3-0883c78fe76b": {"__data__": {"id_": "f52ffaee-7b46-477d-a1a3-0883c78fe76b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nexample of many where we're using AI to power insights and deliver clinical and financial value to our \nstakeholders.  \n \n We've been pleased with our progress to date as we work to develop and implement various AI technologies, and \nwe remain committed to increased inv estment to further extend our leadership positions and deliver value to our \npartners and stakeholders.  \n \n Now moving below the line, we anticipate interest expense to be approximately $220 million to $240 million, and \nincome attributable to non -controlling i nterests to be in the range of $140 million to $160 million.  We anticipate the \nfull-year effective tax rate will be in the range of approximately 18% to 20%. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nexample of many where we're using AI to power insights and deliver clinical and financial value to our \nstakeholders.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd6eacc3-18ee-4daa-936d-290440082d8d", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "135d466d7ec9bb0716b764cabd296029bbfd0d1c9794ed763ec9c520e0d552ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42de0b0f-cf97-4afc-8b99-d4eb4948704b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nexample of many where we're using AI to power insights and deliver clinical and financial value to our \nstakeholders.  \n \n We've been pleased with our progress to date as we work to develop and implement various AI technologies, and \nwe remain committed to increased inv estment to further extend our leadership positions and deliver value to our \npartners and stakeholders.  \n \n Now moving below the line, we anticipate interest expense to be approximately $220 million to $240 million, and \nincome attributable to non -controlling i nterests to be in the range of $140 million to $160 million. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a6ae989af258d2254271f630798fa4057f417b8769850b2e32592a2564f6984d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41e30d40-fc09-4f75-81d7-f8f5f9824ff3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nexample of many where we're using AI to power insights and deliver clinical and financial value to our \nstakeholders.  \n \n We've been pleased with our progress to date as we work to develop and implement various AI technologies, and \nwe remain committed to increased inv estment to further extend our leadership positions and deliver value to our \npartners and stakeholders.  \n \n Now moving below the line, we anticipate interest expense to be approximately $220 million to $240 million, and \nincome attributable to non -controlling i nterests to be in the range of $140 million to $160 million.  We anticipate the \nfull-year effective tax rate will be in the range of approximately 18% to 20%.  And as a reminder, the timing and \namount of discrete tax items are difficult to predict, and there fore, we do not provide quarterly effective tax rate \nguidance.  \n \n", "original_text": "We've been pleased with our progress to date as we work to develop and implement various AI technologies, and \nwe remain committed to increased inv estment to further extend our leadership positions and deliver value to our \npartners and stakeholders.  \n \n"}, "hash": "07f7807ec8479d50802adf26e92be8cf44931c3b268b5fd46ab6db355ff30c15", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nexample of many where we're using AI to power insights and deliver clinical and financial value to our \nstakeholders.  \n \n", "start_char_idx": 16, "end_char_idx": 303, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41e30d40-fc09-4f75-81d7-f8f5f9824ff3": {"__data__": {"id_": "41e30d40-fc09-4f75-81d7-f8f5f9824ff3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nexample of many where we're using AI to power insights and deliver clinical and financial value to our \nstakeholders.  \n \n We've been pleased with our progress to date as we work to develop and implement various AI technologies, and \nwe remain committed to increased inv estment to further extend our leadership positions and deliver value to our \npartners and stakeholders.  \n \n Now moving below the line, we anticipate interest expense to be approximately $220 million to $240 million, and \nincome attributable to non -controlling i nterests to be in the range of $140 million to $160 million.  We anticipate the \nfull-year effective tax rate will be in the range of approximately 18% to 20%.  And as a reminder, the timing and \namount of discrete tax items are difficult to predict, and there fore, we do not provide quarterly effective tax rate \nguidance.  \n \n", "original_text": "We've been pleased with our progress to date as we work to develop and implement various AI technologies, and \nwe remain committed to increased inv estment to further extend our leadership positions and deliver value to our \npartners and stakeholders.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd6eacc3-18ee-4daa-936d-290440082d8d", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "135d466d7ec9bb0716b764cabd296029bbfd0d1c9794ed763ec9c520e0d552ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f52ffaee-7b46-477d-a1a3-0883c78fe76b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nexample of many where we're using AI to power insights and deliver clinical and financial value to our \nstakeholders.  \n \n We've been pleased with our progress to date as we work to develop and implement various AI technologies, and \nwe remain committed to increased inv estment to further extend our leadership positions and deliver value to our \npartners and stakeholders.  \n \n Now moving below the line, we anticipate interest expense to be approximately $220 million to $240 million, and \nincome attributable to non -controlling i nterests to be in the range of $140 million to $160 million.  We anticipate the \nfull-year effective tax rate will be in the range of approximately 18% to 20%. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nexample of many where we're using AI to power insights and deliver clinical and financial value to our \nstakeholders.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "0dfc3975923f3dcb2e16cedfdffb43621ceeaff8e32134820f3a53d90a0f81d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93f70569-5c39-440b-88e5-01fa382a56e2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nexample of many where we're using AI to power insights and deliver clinical and financial value to our \nstakeholders.  \n \n We've been pleased with our progress to date as we work to develop and implement various AI technologies, and \nwe remain committed to increased inv estment to further extend our leadership positions and deliver value to our \npartners and stakeholders.  \n \n Now moving below the line, we anticipate interest expense to be approximately $220 million to $240 million, and \nincome attributable to non -controlling i nterests to be in the range of $140 million to $160 million.  We anticipate the \nfull-year effective tax rate will be in the range of approximately 18% to 20%.  And as a reminder, the timing and \namount of discrete tax items are difficult to predict, and there fore, we do not provide quarterly effective tax rate \nguidance.  \n \n Turning now to cash flow and capital deployment, we anticipate free cash flow of approximately $4.8 billion to \n$5.2 billion. ", "original_text": "Now moving below the line, we anticipate interest expense to be approximately $220 million to $240 million, and \nincome attributable to non -controlling i nterests to be in the range of $140 million to $160 million. "}, "hash": "51305a59cdebbfe62a40c6a3786bd29573276116b21cab8c18bc9a3aa6bed91f", "class_name": "RelatedNodeInfo"}}, "text": "We've been pleased with our progress to date as we work to develop and implement various AI technologies, and \nwe remain committed to increased inv estment to further extend our leadership positions and deliver value to our \npartners and stakeholders.  \n \n", "start_char_idx": 303, "end_char_idx": 559, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93f70569-5c39-440b-88e5-01fa382a56e2": {"__data__": {"id_": "93f70569-5c39-440b-88e5-01fa382a56e2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nexample of many where we're using AI to power insights and deliver clinical and financial value to our \nstakeholders.  \n \n We've been pleased with our progress to date as we work to develop and implement various AI technologies, and \nwe remain committed to increased inv estment to further extend our leadership positions and deliver value to our \npartners and stakeholders.  \n \n Now moving below the line, we anticipate interest expense to be approximately $220 million to $240 million, and \nincome attributable to non -controlling i nterests to be in the range of $140 million to $160 million.  We anticipate the \nfull-year effective tax rate will be in the range of approximately 18% to 20%.  And as a reminder, the timing and \namount of discrete tax items are difficult to predict, and there fore, we do not provide quarterly effective tax rate \nguidance.  \n \n Turning now to cash flow and capital deployment, we anticipate free cash flow of approximately $4.8 billion to \n$5.2 billion. ", "original_text": "Now moving below the line, we anticipate interest expense to be approximately $220 million to $240 million, and \nincome attributable to non -controlling i nterests to be in the range of $140 million to $160 million. ", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd6eacc3-18ee-4daa-936d-290440082d8d", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "135d466d7ec9bb0716b764cabd296029bbfd0d1c9794ed763ec9c520e0d552ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41e30d40-fc09-4f75-81d7-f8f5f9824ff3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nexample of many where we're using AI to power insights and deliver clinical and financial value to our \nstakeholders.  \n \n We've been pleased with our progress to date as we work to develop and implement various AI technologies, and \nwe remain committed to increased inv estment to further extend our leadership positions and deliver value to our \npartners and stakeholders.  \n \n Now moving below the line, we anticipate interest expense to be approximately $220 million to $240 million, and \nincome attributable to non -controlling i nterests to be in the range of $140 million to $160 million.  We anticipate the \nfull-year effective tax rate will be in the range of approximately 18% to 20%.  And as a reminder, the timing and \namount of discrete tax items are difficult to predict, and there fore, we do not provide quarterly effective tax rate \nguidance.  \n \n", "original_text": "We've been pleased with our progress to date as we work to develop and implement various AI technologies, and \nwe remain committed to increased inv estment to further extend our leadership positions and deliver value to our \npartners and stakeholders.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "22b78c4f9885f319f0e4e0755c873580c58de1bb23817bd11d21b7bd9b033ea7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9409955-f515-423e-b4d6-f8c7802ec090", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nexample of many where we're using AI to power insights and deliver clinical and financial value to our \nstakeholders.  \n \n We've been pleased with our progress to date as we work to develop and implement various AI technologies, and \nwe remain committed to increased inv estment to further extend our leadership positions and deliver value to our \npartners and stakeholders.  \n \n Now moving below the line, we anticipate interest expense to be approximately $220 million to $240 million, and \nincome attributable to non -controlling i nterests to be in the range of $140 million to $160 million.  We anticipate the \nfull-year effective tax rate will be in the range of approximately 18% to 20%.  And as a reminder, the timing and \namount of discrete tax items are difficult to predict, and there fore, we do not provide quarterly effective tax rate \nguidance.  \n \n Turning now to cash flow and capital deployment, we anticipate free cash flow of approximately $4.8 billion to \n$5.2 billion.  Our working capital metrics and resultant free cash flow will vary from quarter to quarter and are \nimpacted by timing, including the day of the week that marks the close of a quarter.  \n \n", "original_text": "We anticipate the \nfull-year effective tax rate will be in the range of approximately 18% to 20%. "}, "hash": "92b82fba892d1bf3e0f4b984584535b4cf7090e48c1da91a444e1117860aca08", "class_name": "RelatedNodeInfo"}}, "text": "Now moving below the line, we anticipate interest expense to be approximately $220 million to $240 million, and \nincome attributable to non -controlling i nterests to be in the range of $140 million to $160 million. ", "start_char_idx": 559, "end_char_idx": 775, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9409955-f515-423e-b4d6-f8c7802ec090": {"__data__": {"id_": "e9409955-f515-423e-b4d6-f8c7802ec090", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nexample of many where we're using AI to power insights and deliver clinical and financial value to our \nstakeholders.  \n \n We've been pleased with our progress to date as we work to develop and implement various AI technologies, and \nwe remain committed to increased inv estment to further extend our leadership positions and deliver value to our \npartners and stakeholders.  \n \n Now moving below the line, we anticipate interest expense to be approximately $220 million to $240 million, and \nincome attributable to non -controlling i nterests to be in the range of $140 million to $160 million.  We anticipate the \nfull-year effective tax rate will be in the range of approximately 18% to 20%.  And as a reminder, the timing and \namount of discrete tax items are difficult to predict, and there fore, we do not provide quarterly effective tax rate \nguidance.  \n \n Turning now to cash flow and capital deployment, we anticipate free cash flow of approximately $4.8 billion to \n$5.2 billion.  Our working capital metrics and resultant free cash flow will vary from quarter to quarter and are \nimpacted by timing, including the day of the week that marks the close of a quarter.  \n \n", "original_text": "We anticipate the \nfull-year effective tax rate will be in the range of approximately 18% to 20%. ", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd6eacc3-18ee-4daa-936d-290440082d8d", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "135d466d7ec9bb0716b764cabd296029bbfd0d1c9794ed763ec9c520e0d552ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93f70569-5c39-440b-88e5-01fa382a56e2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nexample of many where we're using AI to power insights and deliver clinical and financial value to our \nstakeholders.  \n \n We've been pleased with our progress to date as we work to develop and implement various AI technologies, and \nwe remain committed to increased inv estment to further extend our leadership positions and deliver value to our \npartners and stakeholders.  \n \n Now moving below the line, we anticipate interest expense to be approximately $220 million to $240 million, and \nincome attributable to non -controlling i nterests to be in the range of $140 million to $160 million.  We anticipate the \nfull-year effective tax rate will be in the range of approximately 18% to 20%.  And as a reminder, the timing and \namount of discrete tax items are difficult to predict, and there fore, we do not provide quarterly effective tax rate \nguidance.  \n \n Turning now to cash flow and capital deployment, we anticipate free cash flow of approximately $4.8 billion to \n$5.2 billion. ", "original_text": "Now moving below the line, we anticipate interest expense to be approximately $220 million to $240 million, and \nincome attributable to non -controlling i nterests to be in the range of $140 million to $160 million. ", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "268dde941d47a1a32f558dd182e8e3d569d10a2f5f9da87cd45b616361cbad89", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fbd36146-593d-4b56-af1f-e3b788b0da1f", "node_type": "1", "metadata": {"window": "We've been pleased with our progress to date as we work to develop and implement various AI technologies, and \nwe remain committed to increased inv estment to further extend our leadership positions and deliver value to our \npartners and stakeholders.  \n \n Now moving below the line, we anticipate interest expense to be approximately $220 million to $240 million, and \nincome attributable to non -controlling i nterests to be in the range of $140 million to $160 million.  We anticipate the \nfull-year effective tax rate will be in the range of approximately 18% to 20%.  And as a reminder, the timing and \namount of discrete tax items are difficult to predict, and there fore, we do not provide quarterly effective tax rate \nguidance.  \n \n Turning now to cash flow and capital deployment, we anticipate free cash flow of approximately $4.8 billion to \n$5.2 billion.  Our working capital metrics and resultant free cash flow will vary from quarter to quarter and are \nimpacted by timing, including the day of the week that marks the close of a quarter.  \n \n Our guidance reflects plans to repurchase approximately $2.8 billion of shares in fiscal 2025. ", "original_text": "And as a reminder, the timing and \namount of discrete tax items are difficult to predict, and there fore, we do not provide quarterly effective tax rate \nguidance.  \n \n"}, "hash": "0f5fa993d5df2526ea70648edf442959c8f94f9c24039d7b83a086c0ce07c182", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate the \nfull-year effective tax rate will be in the range of approximately 18% to 20%. ", "start_char_idx": 775, "end_char_idx": 873, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fbd36146-593d-4b56-af1f-e3b788b0da1f": {"__data__": {"id_": "fbd36146-593d-4b56-af1f-e3b788b0da1f", "embedding": null, "metadata": {"window": "We've been pleased with our progress to date as we work to develop and implement various AI technologies, and \nwe remain committed to increased inv estment to further extend our leadership positions and deliver value to our \npartners and stakeholders.  \n \n Now moving below the line, we anticipate interest expense to be approximately $220 million to $240 million, and \nincome attributable to non -controlling i nterests to be in the range of $140 million to $160 million.  We anticipate the \nfull-year effective tax rate will be in the range of approximately 18% to 20%.  And as a reminder, the timing and \namount of discrete tax items are difficult to predict, and there fore, we do not provide quarterly effective tax rate \nguidance.  \n \n Turning now to cash flow and capital deployment, we anticipate free cash flow of approximately $4.8 billion to \n$5.2 billion.  Our working capital metrics and resultant free cash flow will vary from quarter to quarter and are \nimpacted by timing, including the day of the week that marks the close of a quarter.  \n \n Our guidance reflects plans to repurchase approximately $2.8 billion of shares in fiscal 2025. ", "original_text": "And as a reminder, the timing and \namount of discrete tax items are difficult to predict, and there fore, we do not provide quarterly effective tax rate \nguidance.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd6eacc3-18ee-4daa-936d-290440082d8d", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "135d466d7ec9bb0716b764cabd296029bbfd0d1c9794ed763ec9c520e0d552ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9409955-f515-423e-b4d6-f8c7802ec090", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nexample of many where we're using AI to power insights and deliver clinical and financial value to our \nstakeholders.  \n \n We've been pleased with our progress to date as we work to develop and implement various AI technologies, and \nwe remain committed to increased inv estment to further extend our leadership positions and deliver value to our \npartners and stakeholders.  \n \n Now moving below the line, we anticipate interest expense to be approximately $220 million to $240 million, and \nincome attributable to non -controlling i nterests to be in the range of $140 million to $160 million.  We anticipate the \nfull-year effective tax rate will be in the range of approximately 18% to 20%.  And as a reminder, the timing and \namount of discrete tax items are difficult to predict, and there fore, we do not provide quarterly effective tax rate \nguidance.  \n \n Turning now to cash flow and capital deployment, we anticipate free cash flow of approximately $4.8 billion to \n$5.2 billion.  Our working capital metrics and resultant free cash flow will vary from quarter to quarter and are \nimpacted by timing, including the day of the week that marks the close of a quarter.  \n \n", "original_text": "We anticipate the \nfull-year effective tax rate will be in the range of approximately 18% to 20%. ", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "97b60f080cb2c71568bcccc02f5055b99afae55578e5e07e471228e76c16b5b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d8be690-28e0-40bc-a2c5-826e545d2674", "node_type": "1", "metadata": {"window": "Now moving below the line, we anticipate interest expense to be approximately $220 million to $240 million, and \nincome attributable to non -controlling i nterests to be in the range of $140 million to $160 million.  We anticipate the \nfull-year effective tax rate will be in the range of approximately 18% to 20%.  And as a reminder, the timing and \namount of discrete tax items are difficult to predict, and there fore, we do not provide quarterly effective tax rate \nguidance.  \n \n Turning now to cash flow and capital deployment, we anticipate free cash flow of approximately $4.8 billion to \n$5.2 billion.  Our working capital metrics and resultant free cash flow will vary from quarter to quarter and are \nimpacted by timing, including the day of the week that marks the close of a quarter.  \n \n Our guidance reflects plans to repurchase approximately $2.8 billion of shares in fiscal 2025.  As a result of this \nshare repurchase activi ty, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 128 million to 130 million. ", "original_text": "Turning now to cash flow and capital deployment, we anticipate free cash flow of approximately $4.8 billion to \n$5.2 billion. "}, "hash": "3a1f2e38e6e398c66fbb0ca828a10aeb75223f64c94e3cac65185dff3ed84868", "class_name": "RelatedNodeInfo"}}, "text": "And as a reminder, the timing and \namount of discrete tax items are difficult to predict, and there fore, we do not provide quarterly effective tax rate \nguidance.  \n \n", "start_char_idx": 873, "end_char_idx": 1041, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d8be690-28e0-40bc-a2c5-826e545d2674": {"__data__": {"id_": "4d8be690-28e0-40bc-a2c5-826e545d2674", "embedding": null, "metadata": {"window": "Now moving below the line, we anticipate interest expense to be approximately $220 million to $240 million, and \nincome attributable to non -controlling i nterests to be in the range of $140 million to $160 million.  We anticipate the \nfull-year effective tax rate will be in the range of approximately 18% to 20%.  And as a reminder, the timing and \namount of discrete tax items are difficult to predict, and there fore, we do not provide quarterly effective tax rate \nguidance.  \n \n Turning now to cash flow and capital deployment, we anticipate free cash flow of approximately $4.8 billion to \n$5.2 billion.  Our working capital metrics and resultant free cash flow will vary from quarter to quarter and are \nimpacted by timing, including the day of the week that marks the close of a quarter.  \n \n Our guidance reflects plans to repurchase approximately $2.8 billion of shares in fiscal 2025.  As a result of this \nshare repurchase activi ty, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 128 million to 130 million. ", "original_text": "Turning now to cash flow and capital deployment, we anticipate free cash flow of approximately $4.8 billion to \n$5.2 billion. ", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd6eacc3-18ee-4daa-936d-290440082d8d", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "135d466d7ec9bb0716b764cabd296029bbfd0d1c9794ed763ec9c520e0d552ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fbd36146-593d-4b56-af1f-e3b788b0da1f", "node_type": "1", "metadata": {"window": "We've been pleased with our progress to date as we work to develop and implement various AI technologies, and \nwe remain committed to increased inv estment to further extend our leadership positions and deliver value to our \npartners and stakeholders.  \n \n Now moving below the line, we anticipate interest expense to be approximately $220 million to $240 million, and \nincome attributable to non -controlling i nterests to be in the range of $140 million to $160 million.  We anticipate the \nfull-year effective tax rate will be in the range of approximately 18% to 20%.  And as a reminder, the timing and \namount of discrete tax items are difficult to predict, and there fore, we do not provide quarterly effective tax rate \nguidance.  \n \n Turning now to cash flow and capital deployment, we anticipate free cash flow of approximately $4.8 billion to \n$5.2 billion.  Our working capital metrics and resultant free cash flow will vary from quarter to quarter and are \nimpacted by timing, including the day of the week that marks the close of a quarter.  \n \n Our guidance reflects plans to repurchase approximately $2.8 billion of shares in fiscal 2025. ", "original_text": "And as a reminder, the timing and \namount of discrete tax items are difficult to predict, and there fore, we do not provide quarterly effective tax rate \nguidance.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "090348e8445d2c57f50f430580f9e7e90a8dfd99643ba8205c0d8d2e7463601e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c4ee0ba-92b9-41dd-bf1c-b1d733f81381", "node_type": "1", "metadata": {"window": "We anticipate the \nfull-year effective tax rate will be in the range of approximately 18% to 20%.  And as a reminder, the timing and \namount of discrete tax items are difficult to predict, and there fore, we do not provide quarterly effective tax rate \nguidance.  \n \n Turning now to cash flow and capital deployment, we anticipate free cash flow of approximately $4.8 billion to \n$5.2 billion.  Our working capital metrics and resultant free cash flow will vary from quarter to quarter and are \nimpacted by timing, including the day of the week that marks the close of a quarter.  \n \n Our guidance reflects plans to repurchase approximately $2.8 billion of shares in fiscal 2025.  As a result of this \nshare repurchase activi ty, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 128 million to 130 million.  The strength of our balance sheet and operating cash flows provides the \nfinancial flexibility to incrementally invest both organical ly and inorganically for growth as well as return capital to \nour shareholders.  \n \n", "original_text": "Our working capital metrics and resultant free cash flow will vary from quarter to quarter and are \nimpacted by timing, including the day of the week that marks the close of a quarter.  \n \n"}, "hash": "d95876cc1b2320949a470edab4c3cd36d1089458c3e231d06c5949391b7b15c8", "class_name": "RelatedNodeInfo"}}, "text": "Turning now to cash flow and capital deployment, we anticipate free cash flow of approximately $4.8 billion to \n$5.2 billion. ", "start_char_idx": 1041, "end_char_idx": 1167, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c4ee0ba-92b9-41dd-bf1c-b1d733f81381": {"__data__": {"id_": "6c4ee0ba-92b9-41dd-bf1c-b1d733f81381", "embedding": null, "metadata": {"window": "We anticipate the \nfull-year effective tax rate will be in the range of approximately 18% to 20%.  And as a reminder, the timing and \namount of discrete tax items are difficult to predict, and there fore, we do not provide quarterly effective tax rate \nguidance.  \n \n Turning now to cash flow and capital deployment, we anticipate free cash flow of approximately $4.8 billion to \n$5.2 billion.  Our working capital metrics and resultant free cash flow will vary from quarter to quarter and are \nimpacted by timing, including the day of the week that marks the close of a quarter.  \n \n Our guidance reflects plans to repurchase approximately $2.8 billion of shares in fiscal 2025.  As a result of this \nshare repurchase activi ty, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 128 million to 130 million.  The strength of our balance sheet and operating cash flows provides the \nfinancial flexibility to incrementally invest both organical ly and inorganically for growth as well as return capital to \nour shareholders.  \n \n", "original_text": "Our working capital metrics and resultant free cash flow will vary from quarter to quarter and are \nimpacted by timing, including the day of the week that marks the close of a quarter.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd6eacc3-18ee-4daa-936d-290440082d8d", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "135d466d7ec9bb0716b764cabd296029bbfd0d1c9794ed763ec9c520e0d552ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d8be690-28e0-40bc-a2c5-826e545d2674", "node_type": "1", "metadata": {"window": "Now moving below the line, we anticipate interest expense to be approximately $220 million to $240 million, and \nincome attributable to non -controlling i nterests to be in the range of $140 million to $160 million.  We anticipate the \nfull-year effective tax rate will be in the range of approximately 18% to 20%.  And as a reminder, the timing and \namount of discrete tax items are difficult to predict, and there fore, we do not provide quarterly effective tax rate \nguidance.  \n \n Turning now to cash flow and capital deployment, we anticipate free cash flow of approximately $4.8 billion to \n$5.2 billion.  Our working capital metrics and resultant free cash flow will vary from quarter to quarter and are \nimpacted by timing, including the day of the week that marks the close of a quarter.  \n \n Our guidance reflects plans to repurchase approximately $2.8 billion of shares in fiscal 2025.  As a result of this \nshare repurchase activi ty, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 128 million to 130 million. ", "original_text": "Turning now to cash flow and capital deployment, we anticipate free cash flow of approximately $4.8 billion to \n$5.2 billion. ", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "375d1885cbba6a6d350f26d5c3ad5335f78825e6b3e65991c9312de3bbce2994", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89f02fa5-8f79-4ed0-b147-1cffed7f34f8", "node_type": "1", "metadata": {"window": "And as a reminder, the timing and \namount of discrete tax items are difficult to predict, and there fore, we do not provide quarterly effective tax rate \nguidance.  \n \n Turning now to cash flow and capital deployment, we anticipate free cash flow of approximately $4.8 billion to \n$5.2 billion.  Our working capital metrics and resultant free cash flow will vary from quarter to quarter and are \nimpacted by timing, including the day of the week that marks the close of a quarter.  \n \n Our guidance reflects plans to repurchase approximately $2.8 billion of shares in fiscal 2025.  As a result of this \nshare repurchase activi ty, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 128 million to 130 million.  The strength of our balance sheet and operating cash flows provides the \nfinancial flexibility to incrementally invest both organical ly and inorganically for growth as well as return capital to \nour shareholders.  \n \n Wrapping up fiscal 2025 guidance, we anticipate revenue growth of 15% to 17% and operating profit growth of \n9% to 14% as compared to the prior year. ", "original_text": "Our guidance reflects plans to repurchase approximately $2.8 billion of shares in fiscal 2025. "}, "hash": "54acc47749ff20be940f64b6687f8d67e14cd5dd18bf75960da068229e8179fe", "class_name": "RelatedNodeInfo"}}, "text": "Our working capital metrics and resultant free cash flow will vary from quarter to quarter and are \nimpacted by timing, including the day of the week that marks the close of a quarter.  \n \n", "start_char_idx": 1167, "end_char_idx": 1356, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89f02fa5-8f79-4ed0-b147-1cffed7f34f8": {"__data__": {"id_": "89f02fa5-8f79-4ed0-b147-1cffed7f34f8", "embedding": null, "metadata": {"window": "And as a reminder, the timing and \namount of discrete tax items are difficult to predict, and there fore, we do not provide quarterly effective tax rate \nguidance.  \n \n Turning now to cash flow and capital deployment, we anticipate free cash flow of approximately $4.8 billion to \n$5.2 billion.  Our working capital metrics and resultant free cash flow will vary from quarter to quarter and are \nimpacted by timing, including the day of the week that marks the close of a quarter.  \n \n Our guidance reflects plans to repurchase approximately $2.8 billion of shares in fiscal 2025.  As a result of this \nshare repurchase activi ty, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 128 million to 130 million.  The strength of our balance sheet and operating cash flows provides the \nfinancial flexibility to incrementally invest both organical ly and inorganically for growth as well as return capital to \nour shareholders.  \n \n Wrapping up fiscal 2025 guidance, we anticipate revenue growth of 15% to 17% and operating profit growth of \n9% to 14% as compared to the prior year. ", "original_text": "Our guidance reflects plans to repurchase approximately $2.8 billion of shares in fiscal 2025. ", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd6eacc3-18ee-4daa-936d-290440082d8d", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "135d466d7ec9bb0716b764cabd296029bbfd0d1c9794ed763ec9c520e0d552ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c4ee0ba-92b9-41dd-bf1c-b1d733f81381", "node_type": "1", "metadata": {"window": "We anticipate the \nfull-year effective tax rate will be in the range of approximately 18% to 20%.  And as a reminder, the timing and \namount of discrete tax items are difficult to predict, and there fore, we do not provide quarterly effective tax rate \nguidance.  \n \n Turning now to cash flow and capital deployment, we anticipate free cash flow of approximately $4.8 billion to \n$5.2 billion.  Our working capital metrics and resultant free cash flow will vary from quarter to quarter and are \nimpacted by timing, including the day of the week that marks the close of a quarter.  \n \n Our guidance reflects plans to repurchase approximately $2.8 billion of shares in fiscal 2025.  As a result of this \nshare repurchase activi ty, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 128 million to 130 million.  The strength of our balance sheet and operating cash flows provides the \nfinancial flexibility to incrementally invest both organical ly and inorganically for growth as well as return capital to \nour shareholders.  \n \n", "original_text": "Our working capital metrics and resultant free cash flow will vary from quarter to quarter and are \nimpacted by timing, including the day of the week that marks the close of a quarter.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "4a70d6e03af2a93739d6e9999232afe1ced8dfdeae95097f6caaaddd2d86ce4a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f81f85e0-103e-4364-9c38-f2507c42fea9", "node_type": "1", "metadata": {"window": "Turning now to cash flow and capital deployment, we anticipate free cash flow of approximately $4.8 billion to \n$5.2 billion.  Our working capital metrics and resultant free cash flow will vary from quarter to quarter and are \nimpacted by timing, including the day of the week that marks the close of a quarter.  \n \n Our guidance reflects plans to repurchase approximately $2.8 billion of shares in fiscal 2025.  As a result of this \nshare repurchase activi ty, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 128 million to 130 million.  The strength of our balance sheet and operating cash flows provides the \nfinancial flexibility to incrementally invest both organical ly and inorganically for growth as well as return capital to \nour shareholders.  \n \n Wrapping up fiscal 2025 guidance, we anticipate revenue growth of 15% to 17% and operating profit growth of \n9% to 14% as compared to the prior year.  For fiscal 2025, we anticip ate earnings per diluted share of $31.25 to \n$32.05, which represents growth of 14% to 17% as compared to fiscal 2024. ", "original_text": "As a result of this \nshare repurchase activi ty, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 128 million to 130 million. "}, "hash": "894ed366983f523ea47eebcca7b9d71a07ccf2972aae8f18ff788f0eb58660b9", "class_name": "RelatedNodeInfo"}}, "text": "Our guidance reflects plans to repurchase approximately $2.8 billion of shares in fiscal 2025. ", "start_char_idx": 1356, "end_char_idx": 1451, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f81f85e0-103e-4364-9c38-f2507c42fea9": {"__data__": {"id_": "f81f85e0-103e-4364-9c38-f2507c42fea9", "embedding": null, "metadata": {"window": "Turning now to cash flow and capital deployment, we anticipate free cash flow of approximately $4.8 billion to \n$5.2 billion.  Our working capital metrics and resultant free cash flow will vary from quarter to quarter and are \nimpacted by timing, including the day of the week that marks the close of a quarter.  \n \n Our guidance reflects plans to repurchase approximately $2.8 billion of shares in fiscal 2025.  As a result of this \nshare repurchase activi ty, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 128 million to 130 million.  The strength of our balance sheet and operating cash flows provides the \nfinancial flexibility to incrementally invest both organical ly and inorganically for growth as well as return capital to \nour shareholders.  \n \n Wrapping up fiscal 2025 guidance, we anticipate revenue growth of 15% to 17% and operating profit growth of \n9% to 14% as compared to the prior year.  For fiscal 2025, we anticip ate earnings per diluted share of $31.25 to \n$32.05, which represents growth of 14% to 17% as compared to fiscal 2024. ", "original_text": "As a result of this \nshare repurchase activi ty, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 128 million to 130 million. ", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd6eacc3-18ee-4daa-936d-290440082d8d", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "135d466d7ec9bb0716b764cabd296029bbfd0d1c9794ed763ec9c520e0d552ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89f02fa5-8f79-4ed0-b147-1cffed7f34f8", "node_type": "1", "metadata": {"window": "And as a reminder, the timing and \namount of discrete tax items are difficult to predict, and there fore, we do not provide quarterly effective tax rate \nguidance.  \n \n Turning now to cash flow and capital deployment, we anticipate free cash flow of approximately $4.8 billion to \n$5.2 billion.  Our working capital metrics and resultant free cash flow will vary from quarter to quarter and are \nimpacted by timing, including the day of the week that marks the close of a quarter.  \n \n Our guidance reflects plans to repurchase approximately $2.8 billion of shares in fiscal 2025.  As a result of this \nshare repurchase activi ty, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 128 million to 130 million.  The strength of our balance sheet and operating cash flows provides the \nfinancial flexibility to incrementally invest both organical ly and inorganically for growth as well as return capital to \nour shareholders.  \n \n Wrapping up fiscal 2025 guidance, we anticipate revenue growth of 15% to 17% and operating profit growth of \n9% to 14% as compared to the prior year. ", "original_text": "Our guidance reflects plans to repurchase approximately $2.8 billion of shares in fiscal 2025. ", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "9d530913ec991b1f2484160583b369a3ebfbaa847e7b50a83019fc2d5dd92470", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75970add-9264-4031-8c95-ed60aa8ae899", "node_type": "1", "metadata": {"window": "Our working capital metrics and resultant free cash flow will vary from quarter to quarter and are \nimpacted by timing, including the day of the week that marks the close of a quarter.  \n \n Our guidance reflects plans to repurchase approximately $2.8 billion of shares in fiscal 2025.  As a result of this \nshare repurchase activi ty, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 128 million to 130 million.  The strength of our balance sheet and operating cash flows provides the \nfinancial flexibility to incrementally invest both organical ly and inorganically for growth as well as return capital to \nour shareholders.  \n \n Wrapping up fiscal 2025 guidance, we anticipate revenue growth of 15% to 17% and operating profit growth of \n9% to 14% as compared to the prior year.  For fiscal 2025, we anticip ate earnings per diluted share of $31.25 to \n$32.05, which represents growth of 14% to 17% as compared to fiscal 2024.  We expect earnings per share will \nbe more heavily weighted towards the second half of the fiscal year. ", "original_text": "The strength of our balance sheet and operating cash flows provides the \nfinancial flexibility to incrementally invest both organical ly and inorganically for growth as well as return capital to \nour shareholders.  \n \n"}, "hash": "c69839e63c3224f5abf235a68778afdd55321392ecc957b548fd12e4b12ea1ed", "class_name": "RelatedNodeInfo"}}, "text": "As a result of this \nshare repurchase activi ty, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 128 million to 130 million. ", "start_char_idx": 1451, "end_char_idx": 1621, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75970add-9264-4031-8c95-ed60aa8ae899": {"__data__": {"id_": "75970add-9264-4031-8c95-ed60aa8ae899", "embedding": null, "metadata": {"window": "Our working capital metrics and resultant free cash flow will vary from quarter to quarter and are \nimpacted by timing, including the day of the week that marks the close of a quarter.  \n \n Our guidance reflects plans to repurchase approximately $2.8 billion of shares in fiscal 2025.  As a result of this \nshare repurchase activi ty, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 128 million to 130 million.  The strength of our balance sheet and operating cash flows provides the \nfinancial flexibility to incrementally invest both organical ly and inorganically for growth as well as return capital to \nour shareholders.  \n \n Wrapping up fiscal 2025 guidance, we anticipate revenue growth of 15% to 17% and operating profit growth of \n9% to 14% as compared to the prior year.  For fiscal 2025, we anticip ate earnings per diluted share of $31.25 to \n$32.05, which represents growth of 14% to 17% as compared to fiscal 2024.  We expect earnings per share will \nbe more heavily weighted towards the second half of the fiscal year. ", "original_text": "The strength of our balance sheet and operating cash flows provides the \nfinancial flexibility to incrementally invest both organical ly and inorganically for growth as well as return capital to \nour shareholders.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd6eacc3-18ee-4daa-936d-290440082d8d", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "135d466d7ec9bb0716b764cabd296029bbfd0d1c9794ed763ec9c520e0d552ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f81f85e0-103e-4364-9c38-f2507c42fea9", "node_type": "1", "metadata": {"window": "Turning now to cash flow and capital deployment, we anticipate free cash flow of approximately $4.8 billion to \n$5.2 billion.  Our working capital metrics and resultant free cash flow will vary from quarter to quarter and are \nimpacted by timing, including the day of the week that marks the close of a quarter.  \n \n Our guidance reflects plans to repurchase approximately $2.8 billion of shares in fiscal 2025.  As a result of this \nshare repurchase activi ty, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 128 million to 130 million.  The strength of our balance sheet and operating cash flows provides the \nfinancial flexibility to incrementally invest both organical ly and inorganically for growth as well as return capital to \nour shareholders.  \n \n Wrapping up fiscal 2025 guidance, we anticipate revenue growth of 15% to 17% and operating profit growth of \n9% to 14% as compared to the prior year.  For fiscal 2025, we anticip ate earnings per diluted share of $31.25 to \n$32.05, which represents growth of 14% to 17% as compared to fiscal 2024. ", "original_text": "As a result of this \nshare repurchase activi ty, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 128 million to 130 million. ", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a4c1f5548c13b2281b85f254dd6240b47c1759c5ee88e86a7b5a0e4b0a6e48c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57ba9e51-0e4f-4872-9a0a-c5de3a66676f", "node_type": "1", "metadata": {"window": "Our guidance reflects plans to repurchase approximately $2.8 billion of shares in fiscal 2025.  As a result of this \nshare repurchase activi ty, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 128 million to 130 million.  The strength of our balance sheet and operating cash flows provides the \nfinancial flexibility to incrementally invest both organical ly and inorganically for growth as well as return capital to \nour shareholders.  \n \n Wrapping up fiscal 2025 guidance, we anticipate revenue growth of 15% to 17% and operating profit growth of \n9% to 14% as compared to the prior year.  For fiscal 2025, we anticip ate earnings per diluted share of $31.25 to \n$32.05, which represents growth of 14% to 17% as compared to fiscal 2024.  We expect earnings per share will \nbe more heavily weighted towards the second half of the fiscal year.  We also anticipate the first quarte r to have \nthe lowest contribution. ", "original_text": "Wrapping up fiscal 2025 guidance, we anticipate revenue growth of 15% to 17% and operating profit growth of \n9% to 14% as compared to the prior year. "}, "hash": "a1b3bcb5ddf1fe75c8e3a7cef16ad9c13784b560c4dd826e42c02ad18b2f6cea", "class_name": "RelatedNodeInfo"}}, "text": "The strength of our balance sheet and operating cash flows provides the \nfinancial flexibility to incrementally invest both organical ly and inorganically for growth as well as return capital to \nour shareholders.  \n \n", "start_char_idx": 1621, "end_char_idx": 1839, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57ba9e51-0e4f-4872-9a0a-c5de3a66676f": {"__data__": {"id_": "57ba9e51-0e4f-4872-9a0a-c5de3a66676f", "embedding": null, "metadata": {"window": "Our guidance reflects plans to repurchase approximately $2.8 billion of shares in fiscal 2025.  As a result of this \nshare repurchase activi ty, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 128 million to 130 million.  The strength of our balance sheet and operating cash flows provides the \nfinancial flexibility to incrementally invest both organical ly and inorganically for growth as well as return capital to \nour shareholders.  \n \n Wrapping up fiscal 2025 guidance, we anticipate revenue growth of 15% to 17% and operating profit growth of \n9% to 14% as compared to the prior year.  For fiscal 2025, we anticip ate earnings per diluted share of $31.25 to \n$32.05, which represents growth of 14% to 17% as compared to fiscal 2024.  We expect earnings per share will \nbe more heavily weighted towards the second half of the fiscal year.  We also anticipate the first quarte r to have \nthe lowest contribution. ", "original_text": "Wrapping up fiscal 2025 guidance, we anticipate revenue growth of 15% to 17% and operating profit growth of \n9% to 14% as compared to the prior year. ", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd6eacc3-18ee-4daa-936d-290440082d8d", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "135d466d7ec9bb0716b764cabd296029bbfd0d1c9794ed763ec9c520e0d552ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75970add-9264-4031-8c95-ed60aa8ae899", "node_type": "1", "metadata": {"window": "Our working capital metrics and resultant free cash flow will vary from quarter to quarter and are \nimpacted by timing, including the day of the week that marks the close of a quarter.  \n \n Our guidance reflects plans to repurchase approximately $2.8 billion of shares in fiscal 2025.  As a result of this \nshare repurchase activi ty, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 128 million to 130 million.  The strength of our balance sheet and operating cash flows provides the \nfinancial flexibility to incrementally invest both organical ly and inorganically for growth as well as return capital to \nour shareholders.  \n \n Wrapping up fiscal 2025 guidance, we anticipate revenue growth of 15% to 17% and operating profit growth of \n9% to 14% as compared to the prior year.  For fiscal 2025, we anticip ate earnings per diluted share of $31.25 to \n$32.05, which represents growth of 14% to 17% as compared to fiscal 2024.  We expect earnings per share will \nbe more heavily weighted towards the second half of the fiscal year. ", "original_text": "The strength of our balance sheet and operating cash flows provides the \nfinancial flexibility to incrementally invest both organical ly and inorganically for growth as well as return capital to \nour shareholders.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "11ad682335e5947b7431f0babf663ae362f1ffd457de7062fd416b34a6588c07", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94cc51a9-ba7e-440d-90a0-eb43a51b5bcb", "node_type": "1", "metadata": {"window": "As a result of this \nshare repurchase activi ty, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 128 million to 130 million.  The strength of our balance sheet and operating cash flows provides the \nfinancial flexibility to incrementally invest both organical ly and inorganically for growth as well as return capital to \nour shareholders.  \n \n Wrapping up fiscal 2025 guidance, we anticipate revenue growth of 15% to 17% and operating profit growth of \n9% to 14% as compared to the prior year.  For fiscal 2025, we anticip ate earnings per diluted share of $31.25 to \n$32.05, which represents growth of 14% to 17% as compared to fiscal 2024.  We expect earnings per share will \nbe more heavily weighted towards the second half of the fiscal year.  We also anticipate the first quarte r to have \nthe lowest contribution.  As a reminder, we had a lower effective tax rate in the first quarter of fiscal 2024 due to a \ndiscrete tax item.  \n \n", "original_text": "For fiscal 2025, we anticip ate earnings per diluted share of $31.25 to \n$32.05, which represents growth of 14% to 17% as compared to fiscal 2024. "}, "hash": "e8b0f64cde2d1561d932dc54097ccabcf8d0bfa6dfee9d4ed9564f5b74370d7a", "class_name": "RelatedNodeInfo"}}, "text": "Wrapping up fiscal 2025 guidance, we anticipate revenue growth of 15% to 17% and operating profit growth of \n9% to 14% as compared to the prior year. ", "start_char_idx": 1839, "end_char_idx": 1989, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94cc51a9-ba7e-440d-90a0-eb43a51b5bcb": {"__data__": {"id_": "94cc51a9-ba7e-440d-90a0-eb43a51b5bcb", "embedding": null, "metadata": {"window": "As a result of this \nshare repurchase activi ty, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 128 million to 130 million.  The strength of our balance sheet and operating cash flows provides the \nfinancial flexibility to incrementally invest both organical ly and inorganically for growth as well as return capital to \nour shareholders.  \n \n Wrapping up fiscal 2025 guidance, we anticipate revenue growth of 15% to 17% and operating profit growth of \n9% to 14% as compared to the prior year.  For fiscal 2025, we anticip ate earnings per diluted share of $31.25 to \n$32.05, which represents growth of 14% to 17% as compared to fiscal 2024.  We expect earnings per share will \nbe more heavily weighted towards the second half of the fiscal year.  We also anticipate the first quarte r to have \nthe lowest contribution.  As a reminder, we had a lower effective tax rate in the first quarter of fiscal 2024 due to a \ndiscrete tax item.  \n \n", "original_text": "For fiscal 2025, we anticip ate earnings per diluted share of $31.25 to \n$32.05, which represents growth of 14% to 17% as compared to fiscal 2024. ", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd6eacc3-18ee-4daa-936d-290440082d8d", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "135d466d7ec9bb0716b764cabd296029bbfd0d1c9794ed763ec9c520e0d552ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57ba9e51-0e4f-4872-9a0a-c5de3a66676f", "node_type": "1", "metadata": {"window": "Our guidance reflects plans to repurchase approximately $2.8 billion of shares in fiscal 2025.  As a result of this \nshare repurchase activi ty, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 128 million to 130 million.  The strength of our balance sheet and operating cash flows provides the \nfinancial flexibility to incrementally invest both organical ly and inorganically for growth as well as return capital to \nour shareholders.  \n \n Wrapping up fiscal 2025 guidance, we anticipate revenue growth of 15% to 17% and operating profit growth of \n9% to 14% as compared to the prior year.  For fiscal 2025, we anticip ate earnings per diluted share of $31.25 to \n$32.05, which represents growth of 14% to 17% as compared to fiscal 2024.  We expect earnings per share will \nbe more heavily weighted towards the second half of the fiscal year.  We also anticipate the first quarte r to have \nthe lowest contribution. ", "original_text": "Wrapping up fiscal 2025 guidance, we anticipate revenue growth of 15% to 17% and operating profit growth of \n9% to 14% as compared to the prior year. ", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "baee538674e4f05fc8191ff493c47c35db201547b04d0737da481f9236be0567", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e52838c-c35e-48c5-8ce1-12d39a751bc4", "node_type": "1", "metadata": {"window": "The strength of our balance sheet and operating cash flows provides the \nfinancial flexibility to incrementally invest both organical ly and inorganically for growth as well as return capital to \nour shareholders.  \n \n Wrapping up fiscal 2025 guidance, we anticipate revenue growth of 15% to 17% and operating profit growth of \n9% to 14% as compared to the prior year.  For fiscal 2025, we anticip ate earnings per diluted share of $31.25 to \n$32.05, which represents growth of 14% to 17% as compared to fiscal 2024.  We expect earnings per share will \nbe more heavily weighted towards the second half of the fiscal year.  We also anticipate the first quarte r to have \nthe lowest contribution.  As a reminder, we had a lower effective tax rate in the first quarter of fiscal 2024 due to a \ndiscrete tax item.  \n \n In summary, we see strength and stability in the underlying fundamentals across our businesses. ", "original_text": "We expect earnings per share will \nbe more heavily weighted towards the second half of the fiscal year. "}, "hash": "e66777f2dd637f4114e527580868a606faa88a08cf456a83c9507f968d68f8ea", "class_name": "RelatedNodeInfo"}}, "text": "For fiscal 2025, we anticip ate earnings per diluted share of $31.25 to \n$32.05, which represents growth of 14% to 17% as compared to fiscal 2024. ", "start_char_idx": 1989, "end_char_idx": 2136, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e52838c-c35e-48c5-8ce1-12d39a751bc4": {"__data__": {"id_": "6e52838c-c35e-48c5-8ce1-12d39a751bc4", "embedding": null, "metadata": {"window": "The strength of our balance sheet and operating cash flows provides the \nfinancial flexibility to incrementally invest both organical ly and inorganically for growth as well as return capital to \nour shareholders.  \n \n Wrapping up fiscal 2025 guidance, we anticipate revenue growth of 15% to 17% and operating profit growth of \n9% to 14% as compared to the prior year.  For fiscal 2025, we anticip ate earnings per diluted share of $31.25 to \n$32.05, which represents growth of 14% to 17% as compared to fiscal 2024.  We expect earnings per share will \nbe more heavily weighted towards the second half of the fiscal year.  We also anticipate the first quarte r to have \nthe lowest contribution.  As a reminder, we had a lower effective tax rate in the first quarter of fiscal 2024 due to a \ndiscrete tax item.  \n \n In summary, we see strength and stability in the underlying fundamentals across our businesses. ", "original_text": "We expect earnings per share will \nbe more heavily weighted towards the second half of the fiscal year. ", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd6eacc3-18ee-4daa-936d-290440082d8d", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "135d466d7ec9bb0716b764cabd296029bbfd0d1c9794ed763ec9c520e0d552ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94cc51a9-ba7e-440d-90a0-eb43a51b5bcb", "node_type": "1", "metadata": {"window": "As a result of this \nshare repurchase activi ty, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 128 million to 130 million.  The strength of our balance sheet and operating cash flows provides the \nfinancial flexibility to incrementally invest both organical ly and inorganically for growth as well as return capital to \nour shareholders.  \n \n Wrapping up fiscal 2025 guidance, we anticipate revenue growth of 15% to 17% and operating profit growth of \n9% to 14% as compared to the prior year.  For fiscal 2025, we anticip ate earnings per diluted share of $31.25 to \n$32.05, which represents growth of 14% to 17% as compared to fiscal 2024.  We expect earnings per share will \nbe more heavily weighted towards the second half of the fiscal year.  We also anticipate the first quarte r to have \nthe lowest contribution.  As a reminder, we had a lower effective tax rate in the first quarter of fiscal 2024 due to a \ndiscrete tax item.  \n \n", "original_text": "For fiscal 2025, we anticip ate earnings per diluted share of $31.25 to \n$32.05, which represents growth of 14% to 17% as compared to fiscal 2024. ", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "325f082dd81c3cae7882eda24aa23cb333b459551ba498652b6a14b31d32684f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18886824-e815-40cc-8067-8de1cadca36a", "node_type": "1", "metadata": {"window": "Wrapping up fiscal 2025 guidance, we anticipate revenue growth of 15% to 17% and operating profit growth of \n9% to 14% as compared to the prior year.  For fiscal 2025, we anticip ate earnings per diluted share of $31.25 to \n$32.05, which represents growth of 14% to 17% as compared to fiscal 2024.  We expect earnings per share will \nbe more heavily weighted towards the second half of the fiscal year.  We also anticipate the first quarte r to have \nthe lowest contribution.  As a reminder, we had a lower effective tax rate in the first quarter of fiscal 2024 due to a \ndiscrete tax item.  \n \n In summary, we see strength and stability in the underlying fundamentals across our businesses.  Our sustain ed \nfinancial performance over the past several years has been bolstered by the strength of our financial position and \nthe consistent operating execution, leading to compelling value creation for our customers, partners, and \nshareholders. ", "original_text": "We also anticipate the first quarte r to have \nthe lowest contribution. "}, "hash": "7af0d20ce3671747d2624858dbfe1a1982b759b697296f3813c7769c99bd801c", "class_name": "RelatedNodeInfo"}}, "text": "We expect earnings per share will \nbe more heavily weighted towards the second half of the fiscal year. ", "start_char_idx": 2136, "end_char_idx": 2240, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18886824-e815-40cc-8067-8de1cadca36a": {"__data__": {"id_": "18886824-e815-40cc-8067-8de1cadca36a", "embedding": null, "metadata": {"window": "Wrapping up fiscal 2025 guidance, we anticipate revenue growth of 15% to 17% and operating profit growth of \n9% to 14% as compared to the prior year.  For fiscal 2025, we anticip ate earnings per diluted share of $31.25 to \n$32.05, which represents growth of 14% to 17% as compared to fiscal 2024.  We expect earnings per share will \nbe more heavily weighted towards the second half of the fiscal year.  We also anticipate the first quarte r to have \nthe lowest contribution.  As a reminder, we had a lower effective tax rate in the first quarter of fiscal 2024 due to a \ndiscrete tax item.  \n \n In summary, we see strength and stability in the underlying fundamentals across our businesses.  Our sustain ed \nfinancial performance over the past several years has been bolstered by the strength of our financial position and \nthe consistent operating execution, leading to compelling value creation for our customers, partners, and \nshareholders. ", "original_text": "We also anticipate the first quarte r to have \nthe lowest contribution. ", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd6eacc3-18ee-4daa-936d-290440082d8d", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "135d466d7ec9bb0716b764cabd296029bbfd0d1c9794ed763ec9c520e0d552ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e52838c-c35e-48c5-8ce1-12d39a751bc4", "node_type": "1", "metadata": {"window": "The strength of our balance sheet and operating cash flows provides the \nfinancial flexibility to incrementally invest both organical ly and inorganically for growth as well as return capital to \nour shareholders.  \n \n Wrapping up fiscal 2025 guidance, we anticipate revenue growth of 15% to 17% and operating profit growth of \n9% to 14% as compared to the prior year.  For fiscal 2025, we anticip ate earnings per diluted share of $31.25 to \n$32.05, which represents growth of 14% to 17% as compared to fiscal 2024.  We expect earnings per share will \nbe more heavily weighted towards the second half of the fiscal year.  We also anticipate the first quarte r to have \nthe lowest contribution.  As a reminder, we had a lower effective tax rate in the first quarter of fiscal 2024 due to a \ndiscrete tax item.  \n \n In summary, we see strength and stability in the underlying fundamentals across our businesses. ", "original_text": "We expect earnings per share will \nbe more heavily weighted towards the second half of the fiscal year. ", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f820e9e7198fafd39cc596e54e8cdfbc8fbc3dcdb7b2a7a88efe3364ce144f07", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "efca4bd1-bbff-40bc-a75b-b26d46ec023b", "node_type": "1", "metadata": {"window": "For fiscal 2025, we anticip ate earnings per diluted share of $31.25 to \n$32.05, which represents growth of 14% to 17% as compared to fiscal 2024.  We expect earnings per share will \nbe more heavily weighted towards the second half of the fiscal year.  We also anticipate the first quarte r to have \nthe lowest contribution.  As a reminder, we had a lower effective tax rate in the first quarter of fiscal 2024 due to a \ndiscrete tax item.  \n \n In summary, we see strength and stability in the underlying fundamentals across our businesses.  Our sustain ed \nfinancial performance over the past several years has been bolstered by the strength of our financial position and \nthe consistent operating execution, leading to compelling value creation for our customers, partners, and \nshareholders.  We're pleased with  the strong fiscal 2024 performance. ", "original_text": "As a reminder, we had a lower effective tax rate in the first quarter of fiscal 2024 due to a \ndiscrete tax item.  \n \n"}, "hash": "1ca315d490fad47cb8ca91ec213314ce2877369fbf761bc917bd66ab5215882b", "class_name": "RelatedNodeInfo"}}, "text": "We also anticipate the first quarte r to have \nthe lowest contribution. ", "start_char_idx": 2240, "end_char_idx": 2312, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "efca4bd1-bbff-40bc-a75b-b26d46ec023b": {"__data__": {"id_": "efca4bd1-bbff-40bc-a75b-b26d46ec023b", "embedding": null, "metadata": {"window": "For fiscal 2025, we anticip ate earnings per diluted share of $31.25 to \n$32.05, which represents growth of 14% to 17% as compared to fiscal 2024.  We expect earnings per share will \nbe more heavily weighted towards the second half of the fiscal year.  We also anticipate the first quarte r to have \nthe lowest contribution.  As a reminder, we had a lower effective tax rate in the first quarter of fiscal 2024 due to a \ndiscrete tax item.  \n \n In summary, we see strength and stability in the underlying fundamentals across our businesses.  Our sustain ed \nfinancial performance over the past several years has been bolstered by the strength of our financial position and \nthe consistent operating execution, leading to compelling value creation for our customers, partners, and \nshareholders.  We're pleased with  the strong fiscal 2024 performance. ", "original_text": "As a reminder, we had a lower effective tax rate in the first quarter of fiscal 2024 due to a \ndiscrete tax item.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd6eacc3-18ee-4daa-936d-290440082d8d", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "135d466d7ec9bb0716b764cabd296029bbfd0d1c9794ed763ec9c520e0d552ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18886824-e815-40cc-8067-8de1cadca36a", "node_type": "1", "metadata": {"window": "Wrapping up fiscal 2025 guidance, we anticipate revenue growth of 15% to 17% and operating profit growth of \n9% to 14% as compared to the prior year.  For fiscal 2025, we anticip ate earnings per diluted share of $31.25 to \n$32.05, which represents growth of 14% to 17% as compared to fiscal 2024.  We expect earnings per share will \nbe more heavily weighted towards the second half of the fiscal year.  We also anticipate the first quarte r to have \nthe lowest contribution.  As a reminder, we had a lower effective tax rate in the first quarter of fiscal 2024 due to a \ndiscrete tax item.  \n \n In summary, we see strength and stability in the underlying fundamentals across our businesses.  Our sustain ed \nfinancial performance over the past several years has been bolstered by the strength of our financial position and \nthe consistent operating execution, leading to compelling value creation for our customers, partners, and \nshareholders. ", "original_text": "We also anticipate the first quarte r to have \nthe lowest contribution. ", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a727230de99eb503d2e72467bb927137b670c167f6a672f48b271541988bd335", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "866c13e6-cff3-4b79-875d-b9e3c5b50a6b", "node_type": "1", "metadata": {"window": "We expect earnings per share will \nbe more heavily weighted towards the second half of the fiscal year.  We also anticipate the first quarte r to have \nthe lowest contribution.  As a reminder, we had a lower effective tax rate in the first quarter of fiscal 2024 due to a \ndiscrete tax item.  \n \n In summary, we see strength and stability in the underlying fundamentals across our businesses.  Our sustain ed \nfinancial performance over the past several years has been bolstered by the strength of our financial position and \nthe consistent operating execution, leading to compelling value creation for our customers, partners, and \nshareholders.  We're pleased with  the strong fiscal 2024 performance.  And the fiscal 2025 outlook reflects our \ncontinued confidence in the operating profit growth momentum across all segments of the business, \nsupplemented by the strength of our balance sheet and strong financial position.  ", "original_text": "In summary, we see strength and stability in the underlying fundamentals across our businesses. "}, "hash": "17e6e09f928cdda2dcaa880b069d4e524891a5cd16905b640188b4395ca866d4", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, we had a lower effective tax rate in the first quarter of fiscal 2024 due to a \ndiscrete tax item.  \n \n", "start_char_idx": 2312, "end_char_idx": 2430, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "866c13e6-cff3-4b79-875d-b9e3c5b50a6b": {"__data__": {"id_": "866c13e6-cff3-4b79-875d-b9e3c5b50a6b", "embedding": null, "metadata": {"window": "We expect earnings per share will \nbe more heavily weighted towards the second half of the fiscal year.  We also anticipate the first quarte r to have \nthe lowest contribution.  As a reminder, we had a lower effective tax rate in the first quarter of fiscal 2024 due to a \ndiscrete tax item.  \n \n In summary, we see strength and stability in the underlying fundamentals across our businesses.  Our sustain ed \nfinancial performance over the past several years has been bolstered by the strength of our financial position and \nthe consistent operating execution, leading to compelling value creation for our customers, partners, and \nshareholders.  We're pleased with  the strong fiscal 2024 performance.  And the fiscal 2025 outlook reflects our \ncontinued confidence in the operating profit growth momentum across all segments of the business, \nsupplemented by the strength of our balance sheet and strong financial position.  ", "original_text": "In summary, we see strength and stability in the underlying fundamentals across our businesses. ", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd6eacc3-18ee-4daa-936d-290440082d8d", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "135d466d7ec9bb0716b764cabd296029bbfd0d1c9794ed763ec9c520e0d552ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "efca4bd1-bbff-40bc-a75b-b26d46ec023b", "node_type": "1", "metadata": {"window": "For fiscal 2025, we anticip ate earnings per diluted share of $31.25 to \n$32.05, which represents growth of 14% to 17% as compared to fiscal 2024.  We expect earnings per share will \nbe more heavily weighted towards the second half of the fiscal year.  We also anticipate the first quarte r to have \nthe lowest contribution.  As a reminder, we had a lower effective tax rate in the first quarter of fiscal 2024 due to a \ndiscrete tax item.  \n \n In summary, we see strength and stability in the underlying fundamentals across our businesses.  Our sustain ed \nfinancial performance over the past several years has been bolstered by the strength of our financial position and \nthe consistent operating execution, leading to compelling value creation for our customers, partners, and \nshareholders.  We're pleased with  the strong fiscal 2024 performance. ", "original_text": "As a reminder, we had a lower effective tax rate in the first quarter of fiscal 2024 due to a \ndiscrete tax item.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "311daa8e98130b8a77d5c3e25da5b8534a66a64709eb7db4f30658d8430c17c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18a1cb3b-8011-464b-a98c-256ee2927578", "node_type": "1", "metadata": {"window": "We also anticipate the first quarte r to have \nthe lowest contribution.  As a reminder, we had a lower effective tax rate in the first quarter of fiscal 2024 due to a \ndiscrete tax item.  \n \n In summary, we see strength and stability in the underlying fundamentals across our businesses.  Our sustain ed \nfinancial performance over the past several years has been bolstered by the strength of our financial position and \nthe consistent operating execution, leading to compelling value creation for our customers, partners, and \nshareholders.  We're pleased with  the strong fiscal 2024 performance.  And the fiscal 2025 outlook reflects our \ncontinued confidence in the operating profit growth momentum across all segments of the business, \nsupplemented by the strength of our balance sheet and strong financial position.   McKesson is well positioned to \ndeliver strong results as we successfully execute against our strategic and financial framework to drive long -term \nsustainable growth for all stakeholders.  \n \n", "original_text": "Our sustain ed \nfinancial performance over the past several years has been bolstered by the strength of our financial position and \nthe consistent operating execution, leading to compelling value creation for our customers, partners, and \nshareholders. "}, "hash": "5c456461d142ffa26d0dfd1bffca451d45a2cdec36ce9f6cf3bd061714158522", "class_name": "RelatedNodeInfo"}}, "text": "In summary, we see strength and stability in the underlying fundamentals across our businesses. ", "start_char_idx": 2430, "end_char_idx": 2526, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18a1cb3b-8011-464b-a98c-256ee2927578": {"__data__": {"id_": "18a1cb3b-8011-464b-a98c-256ee2927578", "embedding": null, "metadata": {"window": "We also anticipate the first quarte r to have \nthe lowest contribution.  As a reminder, we had a lower effective tax rate in the first quarter of fiscal 2024 due to a \ndiscrete tax item.  \n \n In summary, we see strength and stability in the underlying fundamentals across our businesses.  Our sustain ed \nfinancial performance over the past several years has been bolstered by the strength of our financial position and \nthe consistent operating execution, leading to compelling value creation for our customers, partners, and \nshareholders.  We're pleased with  the strong fiscal 2024 performance.  And the fiscal 2025 outlook reflects our \ncontinued confidence in the operating profit growth momentum across all segments of the business, \nsupplemented by the strength of our balance sheet and strong financial position.   McKesson is well positioned to \ndeliver strong results as we successfully execute against our strategic and financial framework to drive long -term \nsustainable growth for all stakeholders.  \n \n", "original_text": "Our sustain ed \nfinancial performance over the past several years has been bolstered by the strength of our financial position and \nthe consistent operating execution, leading to compelling value creation for our customers, partners, and \nshareholders. ", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd6eacc3-18ee-4daa-936d-290440082d8d", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "135d466d7ec9bb0716b764cabd296029bbfd0d1c9794ed763ec9c520e0d552ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "866c13e6-cff3-4b79-875d-b9e3c5b50a6b", "node_type": "1", "metadata": {"window": "We expect earnings per share will \nbe more heavily weighted towards the second half of the fiscal year.  We also anticipate the first quarte r to have \nthe lowest contribution.  As a reminder, we had a lower effective tax rate in the first quarter of fiscal 2024 due to a \ndiscrete tax item.  \n \n In summary, we see strength and stability in the underlying fundamentals across our businesses.  Our sustain ed \nfinancial performance over the past several years has been bolstered by the strength of our financial position and \nthe consistent operating execution, leading to compelling value creation for our customers, partners, and \nshareholders.  We're pleased with  the strong fiscal 2024 performance.  And the fiscal 2025 outlook reflects our \ncontinued confidence in the operating profit growth momentum across all segments of the business, \nsupplemented by the strength of our balance sheet and strong financial position.  ", "original_text": "In summary, we see strength and stability in the underlying fundamentals across our businesses. ", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f459bdd77ede79779a829f6ca72cdb4e77493e08faaaf869c37b05d509be2caa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2e65a66-db25-428b-ac66-2cb8b0f938d1", "node_type": "1", "metadata": {"window": "As a reminder, we had a lower effective tax rate in the first quarter of fiscal 2024 due to a \ndiscrete tax item.  \n \n In summary, we see strength and stability in the underlying fundamentals across our businesses.  Our sustain ed \nfinancial performance over the past several years has been bolstered by the strength of our financial position and \nthe consistent operating execution, leading to compelling value creation for our customers, partners, and \nshareholders.  We're pleased with  the strong fiscal 2024 performance.  And the fiscal 2025 outlook reflects our \ncontinued confidence in the operating profit growth momentum across all segments of the business, \nsupplemented by the strength of our balance sheet and strong financial position.   McKesson is well positioned to \ndeliver strong results as we successfully execute against our strategic and financial framework to drive long -term \nsustainable growth for all stakeholders.  \n \n With that, we can move to Q&A  \n  ", "original_text": "We're pleased with  the strong fiscal 2024 performance. "}, "hash": "8d648f7481e639e117447d263ce537191eaff52d7bdaaa4a0b50564045604575", "class_name": "RelatedNodeInfo"}}, "text": "Our sustain ed \nfinancial performance over the past several years has been bolstered by the strength of our financial position and \nthe consistent operating execution, leading to compelling value creation for our customers, partners, and \nshareholders. ", "start_char_idx": 2526, "end_char_idx": 2779, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2e65a66-db25-428b-ac66-2cb8b0f938d1": {"__data__": {"id_": "e2e65a66-db25-428b-ac66-2cb8b0f938d1", "embedding": null, "metadata": {"window": "As a reminder, we had a lower effective tax rate in the first quarter of fiscal 2024 due to a \ndiscrete tax item.  \n \n In summary, we see strength and stability in the underlying fundamentals across our businesses.  Our sustain ed \nfinancial performance over the past several years has been bolstered by the strength of our financial position and \nthe consistent operating execution, leading to compelling value creation for our customers, partners, and \nshareholders.  We're pleased with  the strong fiscal 2024 performance.  And the fiscal 2025 outlook reflects our \ncontinued confidence in the operating profit growth momentum across all segments of the business, \nsupplemented by the strength of our balance sheet and strong financial position.   McKesson is well positioned to \ndeliver strong results as we successfully execute against our strategic and financial framework to drive long -term \nsustainable growth for all stakeholders.  \n \n With that, we can move to Q&A  \n  ", "original_text": "We're pleased with  the strong fiscal 2024 performance. ", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd6eacc3-18ee-4daa-936d-290440082d8d", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "135d466d7ec9bb0716b764cabd296029bbfd0d1c9794ed763ec9c520e0d552ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18a1cb3b-8011-464b-a98c-256ee2927578", "node_type": "1", "metadata": {"window": "We also anticipate the first quarte r to have \nthe lowest contribution.  As a reminder, we had a lower effective tax rate in the first quarter of fiscal 2024 due to a \ndiscrete tax item.  \n \n In summary, we see strength and stability in the underlying fundamentals across our businesses.  Our sustain ed \nfinancial performance over the past several years has been bolstered by the strength of our financial position and \nthe consistent operating execution, leading to compelling value creation for our customers, partners, and \nshareholders.  We're pleased with  the strong fiscal 2024 performance.  And the fiscal 2025 outlook reflects our \ncontinued confidence in the operating profit growth momentum across all segments of the business, \nsupplemented by the strength of our balance sheet and strong financial position.   McKesson is well positioned to \ndeliver strong results as we successfully execute against our strategic and financial framework to drive long -term \nsustainable growth for all stakeholders.  \n \n", "original_text": "Our sustain ed \nfinancial performance over the past several years has been bolstered by the strength of our financial position and \nthe consistent operating execution, leading to compelling value creation for our customers, partners, and \nshareholders. ", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c037e03a4abfa89a08fc0447b7a8b4953478d45a8196ea5ca0ef394a04d8e3cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69353733-eb16-438e-8302-7535f4a4ea16", "node_type": "1", "metadata": {"window": "In summary, we see strength and stability in the underlying fundamentals across our businesses.  Our sustain ed \nfinancial performance over the past several years has been bolstered by the strength of our financial position and \nthe consistent operating execution, leading to compelling value creation for our customers, partners, and \nshareholders.  We're pleased with  the strong fiscal 2024 performance.  And the fiscal 2025 outlook reflects our \ncontinued confidence in the operating profit growth momentum across all segments of the business, \nsupplemented by the strength of our balance sheet and strong financial position.   McKesson is well positioned to \ndeliver strong results as we successfully execute against our strategic and financial framework to drive long -term \nsustainable growth for all stakeholders.  \n \n With that, we can move to Q&A  \n  ", "original_text": "And the fiscal 2025 outlook reflects our \ncontinued confidence in the operating profit growth momentum across all segments of the business, \nsupplemented by the strength of our balance sheet and strong financial position.  "}, "hash": "048955bfa78cf011d7cafa95fd381d1e3a466d00ba5efa89fca0713a5d3cb401", "class_name": "RelatedNodeInfo"}}, "text": "We're pleased with  the strong fiscal 2024 performance. ", "start_char_idx": 2779, "end_char_idx": 2835, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69353733-eb16-438e-8302-7535f4a4ea16": {"__data__": {"id_": "69353733-eb16-438e-8302-7535f4a4ea16", "embedding": null, "metadata": {"window": "In summary, we see strength and stability in the underlying fundamentals across our businesses.  Our sustain ed \nfinancial performance over the past several years has been bolstered by the strength of our financial position and \nthe consistent operating execution, leading to compelling value creation for our customers, partners, and \nshareholders.  We're pleased with  the strong fiscal 2024 performance.  And the fiscal 2025 outlook reflects our \ncontinued confidence in the operating profit growth momentum across all segments of the business, \nsupplemented by the strength of our balance sheet and strong financial position.   McKesson is well positioned to \ndeliver strong results as we successfully execute against our strategic and financial framework to drive long -term \nsustainable growth for all stakeholders.  \n \n With that, we can move to Q&A  \n  ", "original_text": "And the fiscal 2025 outlook reflects our \ncontinued confidence in the operating profit growth momentum across all segments of the business, \nsupplemented by the strength of our balance sheet and strong financial position.  ", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd6eacc3-18ee-4daa-936d-290440082d8d", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "135d466d7ec9bb0716b764cabd296029bbfd0d1c9794ed763ec9c520e0d552ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2e65a66-db25-428b-ac66-2cb8b0f938d1", "node_type": "1", "metadata": {"window": "As a reminder, we had a lower effective tax rate in the first quarter of fiscal 2024 due to a \ndiscrete tax item.  \n \n In summary, we see strength and stability in the underlying fundamentals across our businesses.  Our sustain ed \nfinancial performance over the past several years has been bolstered by the strength of our financial position and \nthe consistent operating execution, leading to compelling value creation for our customers, partners, and \nshareholders.  We're pleased with  the strong fiscal 2024 performance.  And the fiscal 2025 outlook reflects our \ncontinued confidence in the operating profit growth momentum across all segments of the business, \nsupplemented by the strength of our balance sheet and strong financial position.   McKesson is well positioned to \ndeliver strong results as we successfully execute against our strategic and financial framework to drive long -term \nsustainable growth for all stakeholders.  \n \n With that, we can move to Q&A  \n  ", "original_text": "We're pleased with  the strong fiscal 2024 performance. ", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e75aecc2dc49379a8f7fbbe8eb9d7d1d890d0b10949710fe91d89720ef92bca9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c59410e-8ac3-4b97-91b8-c3a0c6c5af0c", "node_type": "1", "metadata": {"window": "Our sustain ed \nfinancial performance over the past several years has been bolstered by the strength of our financial position and \nthe consistent operating execution, leading to compelling value creation for our customers, partners, and \nshareholders.  We're pleased with  the strong fiscal 2024 performance.  And the fiscal 2025 outlook reflects our \ncontinued confidence in the operating profit growth momentum across all segments of the business, \nsupplemented by the strength of our balance sheet and strong financial position.   McKesson is well positioned to \ndeliver strong results as we successfully execute against our strategic and financial framework to drive long -term \nsustainable growth for all stakeholders.  \n \n With that, we can move to Q&A  \n  ", "original_text": "McKesson is well positioned to \ndeliver strong results as we successfully execute against our strategic and financial framework to drive long -term \nsustainable growth for all stakeholders.  \n \n"}, "hash": "ca7f7c4da7453fe918c7962201ec3156cb77fdf9d89caa228ac1f98d4dc07d46", "class_name": "RelatedNodeInfo"}}, "text": "And the fiscal 2025 outlook reflects our \ncontinued confidence in the operating profit growth momentum across all segments of the business, \nsupplemented by the strength of our balance sheet and strong financial position.  ", "start_char_idx": 2835, "end_char_idx": 3058, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c59410e-8ac3-4b97-91b8-c3a0c6c5af0c": {"__data__": {"id_": "2c59410e-8ac3-4b97-91b8-c3a0c6c5af0c", "embedding": null, "metadata": {"window": "Our sustain ed \nfinancial performance over the past several years has been bolstered by the strength of our financial position and \nthe consistent operating execution, leading to compelling value creation for our customers, partners, and \nshareholders.  We're pleased with  the strong fiscal 2024 performance.  And the fiscal 2025 outlook reflects our \ncontinued confidence in the operating profit growth momentum across all segments of the business, \nsupplemented by the strength of our balance sheet and strong financial position.   McKesson is well positioned to \ndeliver strong results as we successfully execute against our strategic and financial framework to drive long -term \nsustainable growth for all stakeholders.  \n \n With that, we can move to Q&A  \n  ", "original_text": "McKesson is well positioned to \ndeliver strong results as we successfully execute against our strategic and financial framework to drive long -term \nsustainable growth for all stakeholders.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd6eacc3-18ee-4daa-936d-290440082d8d", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "135d466d7ec9bb0716b764cabd296029bbfd0d1c9794ed763ec9c520e0d552ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69353733-eb16-438e-8302-7535f4a4ea16", "node_type": "1", "metadata": {"window": "In summary, we see strength and stability in the underlying fundamentals across our businesses.  Our sustain ed \nfinancial performance over the past several years has been bolstered by the strength of our financial position and \nthe consistent operating execution, leading to compelling value creation for our customers, partners, and \nshareholders.  We're pleased with  the strong fiscal 2024 performance.  And the fiscal 2025 outlook reflects our \ncontinued confidence in the operating profit growth momentum across all segments of the business, \nsupplemented by the strength of our balance sheet and strong financial position.   McKesson is well positioned to \ndeliver strong results as we successfully execute against our strategic and financial framework to drive long -term \nsustainable growth for all stakeholders.  \n \n With that, we can move to Q&A  \n  ", "original_text": "And the fiscal 2025 outlook reflects our \ncontinued confidence in the operating profit growth momentum across all segments of the business, \nsupplemented by the strength of our balance sheet and strong financial position.  ", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "7ebe82266a35fb7b5bfa024106cccc44bb3902906b352b3042e91dceb13f4627", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c01ffc8-294c-4c6d-b7e4-b5532d61381b", "node_type": "1", "metadata": {"window": "We're pleased with  the strong fiscal 2024 performance.  And the fiscal 2025 outlook reflects our \ncontinued confidence in the operating profit growth momentum across all segments of the business, \nsupplemented by the strength of our balance sheet and strong financial position.   McKesson is well positioned to \ndeliver strong results as we successfully execute against our strategic and financial framework to drive long -term \nsustainable growth for all stakeholders.  \n \n With that, we can move to Q&A  \n  ", "original_text": "With that, we can move to Q&A  \n  "}, "hash": "1950e5e61eecf363d4d31766183857af7b5f07692bda563159f08cf9c8f36769", "class_name": "RelatedNodeInfo"}}, "text": "McKesson is well positioned to \ndeliver strong results as we successfully execute against our strategic and financial framework to drive long -term \nsustainable growth for all stakeholders.  \n \n", "start_char_idx": 3058, "end_char_idx": 3252, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c01ffc8-294c-4c6d-b7e4-b5532d61381b": {"__data__": {"id_": "7c01ffc8-294c-4c6d-b7e4-b5532d61381b", "embedding": null, "metadata": {"window": "We're pleased with  the strong fiscal 2024 performance.  And the fiscal 2025 outlook reflects our \ncontinued confidence in the operating profit growth momentum across all segments of the business, \nsupplemented by the strength of our balance sheet and strong financial position.   McKesson is well positioned to \ndeliver strong results as we successfully execute against our strategic and financial framework to drive long -term \nsustainable growth for all stakeholders.  \n \n With that, we can move to Q&A  \n  ", "original_text": "With that, we can move to Q&A  \n  ", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd6eacc3-18ee-4daa-936d-290440082d8d", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "135d466d7ec9bb0716b764cabd296029bbfd0d1c9794ed763ec9c520e0d552ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c59410e-8ac3-4b97-91b8-c3a0c6c5af0c", "node_type": "1", "metadata": {"window": "Our sustain ed \nfinancial performance over the past several years has been bolstered by the strength of our financial position and \nthe consistent operating execution, leading to compelling value creation for our customers, partners, and \nshareholders.  We're pleased with  the strong fiscal 2024 performance.  And the fiscal 2025 outlook reflects our \ncontinued confidence in the operating profit growth momentum across all segments of the business, \nsupplemented by the strength of our balance sheet and strong financial position.   McKesson is well positioned to \ndeliver strong results as we successfully execute against our strategic and financial framework to drive long -term \nsustainable growth for all stakeholders.  \n \n With that, we can move to Q&A  \n  ", "original_text": "McKesson is well positioned to \ndeliver strong results as we successfully execute against our strategic and financial framework to drive long -term \nsustainable growth for all stakeholders.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "47d0777ab7f117fc7d648eab94d670edde44e97b65bc19a4081324fac3e3d7fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d0cba2c-a85f-482e-8e66-91c8f2aa06f3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Kevin Caliendo with UBS. \n Please go ahead.  \n ", "original_text": "McKesson Corp.  "}, "hash": "0b6259607dadaf677380fbf3657102787700e977edcce2469e25624631462e69", "class_name": "RelatedNodeInfo"}}, "text": "With that, we can move to Q&A  \n  ", "start_char_idx": 3252, "end_char_idx": 3286, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d0cba2c-a85f-482e-8e66-91c8f2aa06f3": {"__data__": {"id_": "7d0cba2c-a85f-482e-8e66-91c8f2aa06f3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Kevin Caliendo with UBS. \n Please go ahead.  \n ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c01ffc8-294c-4c6d-b7e4-b5532d61381b", "node_type": "1", "metadata": {"window": "We're pleased with  the strong fiscal 2024 performance.  And the fiscal 2025 outlook reflects our \ncontinued confidence in the operating profit growth momentum across all segments of the business, \nsupplemented by the strength of our balance sheet and strong financial position.   McKesson is well positioned to \ndeliver strong results as we successfully execute against our strategic and financial framework to drive long -term \nsustainable growth for all stakeholders.  \n \n With that, we can move to Q&A  \n  ", "original_text": "With that, we can move to Q&A  \n  ", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "b7e22d845d4378587a4f15b1b562eda8d963bb6c566de1cb0597dfe5d3dfc52b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a3de324-84b0-4de3-8116-fcd551574684", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Kevin Caliendo with UBS. \n Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat, thanks for taking my question. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. "}, "hash": "bc1e3e2773663f1127794824947b9cec50d0b98aae68bd50eecb061bd05113e3", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a3de324-84b0-4de3-8116-fcd551574684": {"__data__": {"id_": "0a3de324-84b0-4de3-8116-fcd551574684", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Kevin Caliendo with UBS. \n Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat, thanks for taking my question. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d0cba2c-a85f-482e-8e66-91c8f2aa06f3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Kevin Caliendo with UBS. \n Please go ahead.  \n ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "21561f54331ad45b52c4b902a1d5511f2e27254329a646bfa7d347cc7172a414", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0d93f61-4f23-466f-aa1e-497b404f6afb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Kevin Caliendo with UBS. \n Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat, thanks for taking my question.  I appreciate all the color on the guidance. ", "original_text": "[Operator Instructions] And our first question will come from Kevin Caliendo with UBS. \n"}, "hash": "e4381a87332fbeea51dffcecf02b45ed61195bd7f983020ae6e1dbb55a873e93", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "start_char_idx": 16, "end_char_idx": 238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0d93f61-4f23-466f-aa1e-497b404f6afb": {"__data__": {"id_": "c0d93f61-4f23-466f-aa1e-497b404f6afb", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Kevin Caliendo with UBS. \n Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat, thanks for taking my question.  I appreciate all the color on the guidance. ", "original_text": "[Operator Instructions] And our first question will come from Kevin Caliendo with UBS. \n", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a3de324-84b0-4de3-8116-fcd551574684", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Kevin Caliendo with UBS. \n Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat, thanks for taking my question. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "77f920f4e2f92d57a620eeb6e4dd9f3e984e2d19c173bb236e9d486373b6cc86", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08e8d609-ba88-4e88-90a8-c3f9455fbe1c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Kevin Caliendo with UBS. \n Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat, thanks for taking my question.  I appreciate all the color on the guidance.  I  just want to delve into a little bit \nof the pharma growth increase. ", "original_text": "Please go ahead.  \n "}, "hash": "1c5fea4f6fb01cf93b1d4e255a3a650a73b84bfdac55174289221719e9ea94a1", "class_name": "RelatedNodeInfo"}}, "text": "[Operator Instructions] And our first question will come from Kevin Caliendo with UBS. \n", "start_char_idx": 238, "end_char_idx": 326, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08e8d609-ba88-4e88-90a8-c3f9455fbe1c": {"__data__": {"id_": "08e8d609-ba88-4e88-90a8-c3f9455fbe1c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Kevin Caliendo with UBS. \n Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat, thanks for taking my question.  I appreciate all the color on the guidance.  I  just want to delve into a little bit \nof the pharma growth increase. ", "original_text": "Please go ahead.  \n ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0d93f61-4f23-466f-aa1e-497b404f6afb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Kevin Caliendo with UBS. \n Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat, thanks for taking my question.  I appreciate all the color on the guidance. ", "original_text": "[Operator Instructions] And our first question will come from Kevin Caliendo with UBS. \n", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "602214dab6077ea8a82720dfbfae6c6b1c7fefcff5c1564873c3c91ae3251547", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d3ca547-754d-4941-870e-ddf9e91f6d47", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Kevin Caliendo with UBS. \n Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat, thanks for taking my question.  I appreciate all the color on the guidance.  I  just want to delve into a little bit \nof the pharma growth increase.  How much of that is related to Optum? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat, thanks for taking my question. "}, "hash": "f9597349b2257c581f6d3685011a820fe081e09589f476e38aff88a5572a3c0b", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 326, "end_char_idx": 346, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d3ca547-754d-4941-870e-ddf9e91f6d47": {"__data__": {"id_": "8d3ca547-754d-4941-870e-ddf9e91f6d47", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Kevin Caliendo with UBS. \n Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat, thanks for taking my question.  I appreciate all the color on the guidance.  I  just want to delve into a little bit \nof the pharma growth increase.  How much of that is related to Optum? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat, thanks for taking my question. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08e8d609-ba88-4e88-90a8-c3f9455fbe1c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Kevin Caliendo with UBS. \n Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat, thanks for taking my question.  I appreciate all the color on the guidance.  I  just want to delve into a little bit \nof the pharma growth increase. ", "original_text": "Please go ahead.  \n ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "4d3e4927a6baa2e5e910d9ab4dcec533d9218b12b9ff22b54fbf51851c5069f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb18493a-0d58-4189-8d9a-5c635a719b9f", "node_type": "1", "metadata": {"window": "[Operator Instructions] And our first question will come from Kevin Caliendo with UBS. \n Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat, thanks for taking my question.  I appreciate all the color on the guidance.  I  just want to delve into a little bit \nof the pharma growth increase.  How much of that is related to Optum?  And were there any costs \u2013 onboarding \ncosts associated with bringing a contract like that on board, meaning did it dilute the impact this year?  \n \n", "original_text": "I appreciate all the color on the guidance. "}, "hash": "1236f6a0be1e13fddf5007f1571c774c42987e870c1141396f41aee54b04c323", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat, thanks for taking my question. ", "start_char_idx": 346, "end_char_idx": 705, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb18493a-0d58-4189-8d9a-5c635a719b9f": {"__data__": {"id_": "cb18493a-0d58-4189-8d9a-5c635a719b9f", "embedding": null, "metadata": {"window": "[Operator Instructions] And our first question will come from Kevin Caliendo with UBS. \n Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat, thanks for taking my question.  I appreciate all the color on the guidance.  I  just want to delve into a little bit \nof the pharma growth increase.  How much of that is related to Optum?  And were there any costs \u2013 onboarding \ncosts associated with bringing a contract like that on board, meaning did it dilute the impact this year?  \n \n", "original_text": "I appreciate all the color on the guidance. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d3ca547-754d-4941-870e-ddf9e91f6d47", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Kevin Caliendo with UBS. \n Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat, thanks for taking my question.  I appreciate all the color on the guidance.  I  just want to delve into a little bit \nof the pharma growth increase.  How much of that is related to Optum? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat, thanks for taking my question. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "eb9d2e50e022e7cdf640f071ff53081208df5f7375eb78e6ae5bb37262884f66", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e993a1c7-1f1b-4e42-ad2b-acbeff25c359", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat, thanks for taking my question.  I appreciate all the color on the guidance.  I  just want to delve into a little bit \nof the pharma growth increase.  How much of that is related to Optum?  And were there any costs \u2013 onboarding \ncosts associated with bringing a contract like that on board, meaning did it dilute the impact this year?  \n \n And then as a quick follow -up, I noticed you didn't mention Optum as being part of the MedSurg guidance. ", "original_text": "I  just want to delve into a little bit \nof the pharma growth increase. "}, "hash": "22f00af0ae142b17f0b2e75be409104d44354160b3e44cb4dc33eddc24749c59", "class_name": "RelatedNodeInfo"}}, "text": "I appreciate all the color on the guidance. ", "start_char_idx": 705, "end_char_idx": 749, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e993a1c7-1f1b-4e42-ad2b-acbeff25c359": {"__data__": {"id_": "e993a1c7-1f1b-4e42-ad2b-acbeff25c359", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat, thanks for taking my question.  I appreciate all the color on the guidance.  I  just want to delve into a little bit \nof the pharma growth increase.  How much of that is related to Optum?  And were there any costs \u2013 onboarding \ncosts associated with bringing a contract like that on board, meaning did it dilute the impact this year?  \n \n And then as a quick follow -up, I noticed you didn't mention Optum as being part of the MedSurg guidance. ", "original_text": "I  just want to delve into a little bit \nof the pharma growth increase. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb18493a-0d58-4189-8d9a-5c635a719b9f", "node_type": "1", "metadata": {"window": "[Operator Instructions] And our first question will come from Kevin Caliendo with UBS. \n Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat, thanks for taking my question.  I appreciate all the color on the guidance.  I  just want to delve into a little bit \nof the pharma growth increase.  How much of that is related to Optum?  And were there any costs \u2013 onboarding \ncosts associated with bringing a contract like that on board, meaning did it dilute the impact this year?  \n \n", "original_text": "I appreciate all the color on the guidance. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f00eaa66682bde9f74d1e23355bf1d73c9afa0ea1714e8d4d977e453c3d68fa1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9b2ed59-1aa8-4ee0-8d45-0dd107d8717d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat, thanks for taking my question.  I appreciate all the color on the guidance.  I  just want to delve into a little bit \nof the pharma growth increase.  How much of that is related to Optum?  And were there any costs \u2013 onboarding \ncosts associated with bringing a contract like that on board, meaning did it dilute the impact this year?  \n \n And then as a quick follow -up, I noticed you didn't mention Optum as being part of the MedSurg guidance.  There \nis some belief that that was also a potential contract win for you or an incremental contract win for you there. ", "original_text": "How much of that is related to Optum? "}, "hash": "8b037334fb2416a578182fd45020a4634bdb557b3a1bafc0facc04672973d317", "class_name": "RelatedNodeInfo"}}, "text": "I  just want to delve into a little bit \nof the pharma growth increase. ", "start_char_idx": 749, "end_char_idx": 821, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9b2ed59-1aa8-4ee0-8d45-0dd107d8717d": {"__data__": {"id_": "d9b2ed59-1aa8-4ee0-8d45-0dd107d8717d", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat, thanks for taking my question.  I appreciate all the color on the guidance.  I  just want to delve into a little bit \nof the pharma growth increase.  How much of that is related to Optum?  And were there any costs \u2013 onboarding \ncosts associated with bringing a contract like that on board, meaning did it dilute the impact this year?  \n \n And then as a quick follow -up, I noticed you didn't mention Optum as being part of the MedSurg guidance.  There \nis some belief that that was also a potential contract win for you or an incremental contract win for you there. ", "original_text": "How much of that is related to Optum? ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e993a1c7-1f1b-4e42-ad2b-acbeff25c359", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat, thanks for taking my question.  I appreciate all the color on the guidance.  I  just want to delve into a little bit \nof the pharma growth increase.  How much of that is related to Optum?  And were there any costs \u2013 onboarding \ncosts associated with bringing a contract like that on board, meaning did it dilute the impact this year?  \n \n And then as a quick follow -up, I noticed you didn't mention Optum as being part of the MedSurg guidance. ", "original_text": "I  just want to delve into a little bit \nof the pharma growth increase. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "587dd88712fc379e347a928f76527015402f0e3f3e06521ccf391f32c17acf81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "294cdb5b-a4a8-4a2f-9e7f-dbd689c450e2", "node_type": "1", "metadata": {"window": "I appreciate all the color on the guidance.  I  just want to delve into a little bit \nof the pharma growth increase.  How much of that is related to Optum?  And were there any costs \u2013 onboarding \ncosts associated with bringing a contract like that on board, meaning did it dilute the impact this year?  \n \n And then as a quick follow -up, I noticed you didn't mention Optum as being part of the MedSurg guidance.  There \nis some belief that that was also a potential contract win for you or an incremental contract win for you there.  Is \nthat not true, or is there just n o impact this year?  \n ", "original_text": "And were there any costs \u2013 onboarding \ncosts associated with bringing a contract like that on board, meaning did it dilute the impact this year?  \n \n"}, "hash": "e507e27ef2c2574fcaa426b91f1a612650ac80f5a522879d5a7cd938df0de49a", "class_name": "RelatedNodeInfo"}}, "text": "How much of that is related to Optum? ", "start_char_idx": 821, "end_char_idx": 859, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "294cdb5b-a4a8-4a2f-9e7f-dbd689c450e2": {"__data__": {"id_": "294cdb5b-a4a8-4a2f-9e7f-dbd689c450e2", "embedding": null, "metadata": {"window": "I appreciate all the color on the guidance.  I  just want to delve into a little bit \nof the pharma growth increase.  How much of that is related to Optum?  And were there any costs \u2013 onboarding \ncosts associated with bringing a contract like that on board, meaning did it dilute the impact this year?  \n \n And then as a quick follow -up, I noticed you didn't mention Optum as being part of the MedSurg guidance.  There \nis some belief that that was also a potential contract win for you or an incremental contract win for you there.  Is \nthat not true, or is there just n o impact this year?  \n ", "original_text": "And were there any costs \u2013 onboarding \ncosts associated with bringing a contract like that on board, meaning did it dilute the impact this year?  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9b2ed59-1aa8-4ee0-8d45-0dd107d8717d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat, thanks for taking my question.  I appreciate all the color on the guidance.  I  just want to delve into a little bit \nof the pharma growth increase.  How much of that is related to Optum?  And were there any costs \u2013 onboarding \ncosts associated with bringing a contract like that on board, meaning did it dilute the impact this year?  \n \n And then as a quick follow -up, I noticed you didn't mention Optum as being part of the MedSurg guidance.  There \nis some belief that that was also a potential contract win for you or an incremental contract win for you there. ", "original_text": "How much of that is related to Optum? ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "8c42553e1689247e60850b3d1db22303d306a788e74418fbf8fb0295798db000", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51abc90c-0dd4-4192-a258-5e5b37009c6d", "node_type": "1", "metadata": {"window": "I  just want to delve into a little bit \nof the pharma growth increase.  How much of that is related to Optum?  And were there any costs \u2013 onboarding \ncosts associated with bringing a contract like that on board, meaning did it dilute the impact this year?  \n \n And then as a quick follow -up, I noticed you didn't mention Optum as being part of the MedSurg guidance.  There \nis some belief that that was also a potential contract win for you or an incremental contract win for you there.  Is \nthat not true, or is there just n o impact this year?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "And then as a quick follow -up, I noticed you didn't mention Optum as being part of the MedSurg guidance. "}, "hash": "22c552651868fb935207d5564915124ab0e6df68ffa895a4016c9136946140ad", "class_name": "RelatedNodeInfo"}}, "text": "And were there any costs \u2013 onboarding \ncosts associated with bringing a contract like that on board, meaning did it dilute the impact this year?  \n \n", "start_char_idx": 859, "end_char_idx": 1008, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51abc90c-0dd4-4192-a258-5e5b37009c6d": {"__data__": {"id_": "51abc90c-0dd4-4192-a258-5e5b37009c6d", "embedding": null, "metadata": {"window": "I  just want to delve into a little bit \nof the pharma growth increase.  How much of that is related to Optum?  And were there any costs \u2013 onboarding \ncosts associated with bringing a contract like that on board, meaning did it dilute the impact this year?  \n \n And then as a quick follow -up, I noticed you didn't mention Optum as being part of the MedSurg guidance.  There \nis some belief that that was also a potential contract win for you or an incremental contract win for you there.  Is \nthat not true, or is there just n o impact this year?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "And then as a quick follow -up, I noticed you didn't mention Optum as being part of the MedSurg guidance. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "294cdb5b-a4a8-4a2f-9e7f-dbd689c450e2", "node_type": "1", "metadata": {"window": "I appreciate all the color on the guidance.  I  just want to delve into a little bit \nof the pharma growth increase.  How much of that is related to Optum?  And were there any costs \u2013 onboarding \ncosts associated with bringing a contract like that on board, meaning did it dilute the impact this year?  \n \n And then as a quick follow -up, I noticed you didn't mention Optum as being part of the MedSurg guidance.  There \nis some belief that that was also a potential contract win for you or an incremental contract win for you there.  Is \nthat not true, or is there just n o impact this year?  \n ", "original_text": "And were there any costs \u2013 onboarding \ncosts associated with bringing a contract like that on board, meaning did it dilute the impact this year?  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "64d6d69b380ec7a8adc44f3c57273a6855d2d515eb1647d76c2e6262256bacb6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6222e6a-42e6-4981-b3ec-b097d7cfa9ff", "node_type": "1", "metadata": {"window": "How much of that is related to Optum?  And were there any costs \u2013 onboarding \ncosts associated with bringing a contract like that on board, meaning did it dilute the impact this year?  \n \n And then as a quick follow -up, I noticed you didn't mention Optum as being part of the MedSurg guidance.  There \nis some belief that that was also a potential contract win for you or an incremental contract win for you there.  Is \nthat not true, or is there just n o impact this year?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Kevin. ", "original_text": "There \nis some belief that that was also a potential contract win for you or an incremental contract win for you there. "}, "hash": "3a16f5f2d75e003be6a85273c54f98142be0577dc7aece47e10b0ae699e450c2", "class_name": "RelatedNodeInfo"}}, "text": "And then as a quick follow -up, I noticed you didn't mention Optum as being part of the MedSurg guidance. ", "start_char_idx": 1008, "end_char_idx": 1114, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6222e6a-42e6-4981-b3ec-b097d7cfa9ff": {"__data__": {"id_": "f6222e6a-42e6-4981-b3ec-b097d7cfa9ff", "embedding": null, "metadata": {"window": "How much of that is related to Optum?  And were there any costs \u2013 onboarding \ncosts associated with bringing a contract like that on board, meaning did it dilute the impact this year?  \n \n And then as a quick follow -up, I noticed you didn't mention Optum as being part of the MedSurg guidance.  There \nis some belief that that was also a potential contract win for you or an incremental contract win for you there.  Is \nthat not true, or is there just n o impact this year?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Kevin. ", "original_text": "There \nis some belief that that was also a potential contract win for you or an incremental contract win for you there. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51abc90c-0dd4-4192-a258-5e5b37009c6d", "node_type": "1", "metadata": {"window": "I  just want to delve into a little bit \nof the pharma growth increase.  How much of that is related to Optum?  And were there any costs \u2013 onboarding \ncosts associated with bringing a contract like that on board, meaning did it dilute the impact this year?  \n \n And then as a quick follow -up, I noticed you didn't mention Optum as being part of the MedSurg guidance.  There \nis some belief that that was also a potential contract win for you or an incremental contract win for you there.  Is \nthat not true, or is there just n o impact this year?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "And then as a quick follow -up, I noticed you didn't mention Optum as being part of the MedSurg guidance. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "6a0cf614a68b0a3458d7d968687abe7aac98bf623ae35dcccc1630a24559750d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1234c52e-5a57-48ce-a9e5-5640bff9f9e9", "node_type": "1", "metadata": {"window": "And were there any costs \u2013 onboarding \ncosts associated with bringing a contract like that on board, meaning did it dilute the impact this year?  \n \n And then as a quick follow -up, I noticed you didn't mention Optum as being part of the MedSurg guidance.  There \nis some belief that that was also a potential contract win for you or an incremental contract win for you there.  Is \nthat not true, or is there just n o impact this year?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Kevin.  I'll start. ", "original_text": "Is \nthat not true, or is there just n o impact this year?  \n "}, "hash": "081fd2119d2a95aceb45070934a11dc295aea55bc7c22940fa7e04ad4c9b3a53", "class_name": "RelatedNodeInfo"}}, "text": "There \nis some belief that that was also a potential contract win for you or an incremental contract win for you there. ", "start_char_idx": 1114, "end_char_idx": 1234, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1234c52e-5a57-48ce-a9e5-5640bff9f9e9": {"__data__": {"id_": "1234c52e-5a57-48ce-a9e5-5640bff9f9e9", "embedding": null, "metadata": {"window": "And were there any costs \u2013 onboarding \ncosts associated with bringing a contract like that on board, meaning did it dilute the impact this year?  \n \n And then as a quick follow -up, I noticed you didn't mention Optum as being part of the MedSurg guidance.  There \nis some belief that that was also a potential contract win for you or an incremental contract win for you there.  Is \nthat not true, or is there just n o impact this year?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Kevin.  I'll start. ", "original_text": "Is \nthat not true, or is there just n o impact this year?  \n ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6222e6a-42e6-4981-b3ec-b097d7cfa9ff", "node_type": "1", "metadata": {"window": "How much of that is related to Optum?  And were there any costs \u2013 onboarding \ncosts associated with bringing a contract like that on board, meaning did it dilute the impact this year?  \n \n And then as a quick follow -up, I noticed you didn't mention Optum as being part of the MedSurg guidance.  There \nis some belief that that was also a potential contract win for you or an incremental contract win for you there.  Is \nthat not true, or is there just n o impact this year?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Kevin. ", "original_text": "There \nis some belief that that was also a potential contract win for you or an incremental contract win for you there. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "7f7b8d411c3e744cfbb218acf10e8f8d7b55c74d45eb3bcccbd5e73f7b38e26f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c0e0a0c-13dd-4304-b1ff-0d3e335f0ed4", "node_type": "1", "metadata": {"window": "And then as a quick follow -up, I noticed you didn't mention Optum as being part of the MedSurg guidance.  There \nis some belief that that was also a potential contract win for you or an incremental contract win for you there.  Is \nthat not true, or is there just n o impact this year?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Kevin.  I'll start.  Maybe I'll go in reverse order. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "b6638c8c30875ddd2874e3d6a6448db992e5735fd23ffa1632cb47037125c9db", "class_name": "RelatedNodeInfo"}}, "text": "Is \nthat not true, or is there just n o impact this year?  \n ", "start_char_idx": 1234, "end_char_idx": 1295, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c0e0a0c-13dd-4304-b1ff-0d3e335f0ed4": {"__data__": {"id_": "3c0e0a0c-13dd-4304-b1ff-0d3e335f0ed4", "embedding": null, "metadata": {"window": "And then as a quick follow -up, I noticed you didn't mention Optum as being part of the MedSurg guidance.  There \nis some belief that that was also a potential contract win for you or an incremental contract win for you there.  Is \nthat not true, or is there just n o impact this year?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Kevin.  I'll start.  Maybe I'll go in reverse order. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1234c52e-5a57-48ce-a9e5-5640bff9f9e9", "node_type": "1", "metadata": {"window": "And were there any costs \u2013 onboarding \ncosts associated with bringing a contract like that on board, meaning did it dilute the impact this year?  \n \n And then as a quick follow -up, I noticed you didn't mention Optum as being part of the MedSurg guidance.  There \nis some belief that that was also a potential contract win for you or an incremental contract win for you there.  Is \nthat not true, or is there just n o impact this year?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Kevin.  I'll start. ", "original_text": "Is \nthat not true, or is there just n o impact this year?  \n ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "869cb8e38cd66a00f5d2c373ce1db23ad5cdfdebb04df03698cf6d86449d3e77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "250b8ed7-74ae-4cb9-bd01-6133ae1494d8", "node_type": "1", "metadata": {"window": "There \nis some belief that that was also a potential contract win for you or an incremental contract win for you there.  Is \nthat not true, or is there just n o impact this year?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Kevin.  I'll start.  Maybe I'll go in reverse order.  Our win of the Optum contract, and we're \ncertainly pleased to extend a nd expand our partnership, as Brian mentioned, is pharmaceutical -related only. ", "original_text": "A \nThanks for the question, Kevin. "}, "hash": "b77a219151bd359887f4feaca38c62775dc4c765ee2d55c168fc29b01c2f5b80", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 1295, "end_char_idx": 1655, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "250b8ed7-74ae-4cb9-bd01-6133ae1494d8": {"__data__": {"id_": "250b8ed7-74ae-4cb9-bd01-6133ae1494d8", "embedding": null, "metadata": {"window": "There \nis some belief that that was also a potential contract win for you or an incremental contract win for you there.  Is \nthat not true, or is there just n o impact this year?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Kevin.  I'll start.  Maybe I'll go in reverse order.  Our win of the Optum contract, and we're \ncertainly pleased to extend a nd expand our partnership, as Brian mentioned, is pharmaceutical -related only. ", "original_text": "A \nThanks for the question, Kevin. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c0e0a0c-13dd-4304-b1ff-0d3e335f0ed4", "node_type": "1", "metadata": {"window": "And then as a quick follow -up, I noticed you didn't mention Optum as being part of the MedSurg guidance.  There \nis some belief that that was also a potential contract win for you or an incremental contract win for you there.  Is \nthat not true, or is there just n o impact this year?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Kevin.  I'll start.  Maybe I'll go in reverse order. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f43b41e3d4f0e2691b22a90d8450672a8537b6014caebedf7c5234623ce3395b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca26a64e-19bf-4bb4-9b24-921604de3de3", "node_type": "1", "metadata": {"window": "Is \nthat not true, or is there just n o impact this year?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Kevin.  I'll start.  Maybe I'll go in reverse order.  Our win of the Optum contract, and we're \ncertainly pleased to extend a nd expand our partnership, as Brian mentioned, is pharmaceutical -related only.  As \nwe think about next year, Optum is included in our guide. ", "original_text": "I'll start. "}, "hash": "6060d24f6c1a66afd92602ff07c01c01e010a1e7518a06d58963110ff20fbb8c", "class_name": "RelatedNodeInfo"}}, "text": "A \nThanks for the question, Kevin. ", "start_char_idx": 1655, "end_char_idx": 1690, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca26a64e-19bf-4bb4-9b24-921604de3de3": {"__data__": {"id_": "ca26a64e-19bf-4bb4-9b24-921604de3de3", "embedding": null, "metadata": {"window": "Is \nthat not true, or is there just n o impact this year?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Kevin.  I'll start.  Maybe I'll go in reverse order.  Our win of the Optum contract, and we're \ncertainly pleased to extend a nd expand our partnership, as Brian mentioned, is pharmaceutical -related only.  As \nwe think about next year, Optum is included in our guide. ", "original_text": "I'll start. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "250b8ed7-74ae-4cb9-bd01-6133ae1494d8", "node_type": "1", "metadata": {"window": "There \nis some belief that that was also a potential contract win for you or an incremental contract win for you there.  Is \nthat not true, or is there just n o impact this year?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Kevin.  I'll start.  Maybe I'll go in reverse order.  Our win of the Optum contract, and we're \ncertainly pleased to extend a nd expand our partnership, as Brian mentioned, is pharmaceutical -related only. ", "original_text": "A \nThanks for the question, Kevin. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "042294fc15d6810f5b8bb840ad36305f855f39dda231cc4c43388068be650a83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c98109cc-d651-4c5f-bb2d-d648731d3d70", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Kevin.  I'll start.  Maybe I'll go in reverse order.  Our win of the Optum contract, and we're \ncertainly pleased to extend a nd expand our partnership, as Brian mentioned, is pharmaceutical -related only.  As \nwe think about next year, Optum is included in our guide.  As you know, we do not specifically talk about customer \ncontract details, and so we have not provided specific contr ibutions for Optum, and we don't intend to do that \ngoing forward. ", "original_text": "Maybe I'll go in reverse order. "}, "hash": "7957d47a17c9cea539928f6d1d1838d4884548cb328d31c73ed75af4f0d28fce", "class_name": "RelatedNodeInfo"}}, "text": "I'll start. ", "start_char_idx": 1690, "end_char_idx": 1702, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c98109cc-d651-4c5f-bb2d-d648731d3d70": {"__data__": {"id_": "c98109cc-d651-4c5f-bb2d-d648731d3d70", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Kevin.  I'll start.  Maybe I'll go in reverse order.  Our win of the Optum contract, and we're \ncertainly pleased to extend a nd expand our partnership, as Brian mentioned, is pharmaceutical -related only.  As \nwe think about next year, Optum is included in our guide.  As you know, we do not specifically talk about customer \ncontract details, and so we have not provided specific contr ibutions for Optum, and we don't intend to do that \ngoing forward. ", "original_text": "Maybe I'll go in reverse order. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca26a64e-19bf-4bb4-9b24-921604de3de3", "node_type": "1", "metadata": {"window": "Is \nthat not true, or is there just n o impact this year?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Kevin.  I'll start.  Maybe I'll go in reverse order.  Our win of the Optum contract, and we're \ncertainly pleased to extend a nd expand our partnership, as Brian mentioned, is pharmaceutical -related only.  As \nwe think about next year, Optum is included in our guide. ", "original_text": "I'll start. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "167d9fefe06eed5b949d70ef85544be389037782d5b31c2765c161f7433589e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bec0e24f-87a8-4394-aec1-bd24f3bfedf2", "node_type": "1", "metadata": {"window": "A \nThanks for the question, Kevin.  I'll start.  Maybe I'll go in reverse order.  Our win of the Optum contract, and we're \ncertainly pleased to extend a nd expand our partnership, as Brian mentioned, is pharmaceutical -related only.  As \nwe think about next year, Optum is included in our guide.  As you know, we do not specifically talk about customer \ncontract details, and so we have not provided specific contr ibutions for Optum, and we don't intend to do that \ngoing forward.  This is a recent contract win. ", "original_text": "Our win of the Optum contract, and we're \ncertainly pleased to extend a nd expand our partnership, as Brian mentioned, is pharmaceutical -related only. "}, "hash": "2c3c243ff5190f385fb6b838faf0623e607375972ffd698358024c1ac5855e74", "class_name": "RelatedNodeInfo"}}, "text": "Maybe I'll go in reverse order. ", "start_char_idx": 1702, "end_char_idx": 1734, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bec0e24f-87a8-4394-aec1-bd24f3bfedf2": {"__data__": {"id_": "bec0e24f-87a8-4394-aec1-bd24f3bfedf2", "embedding": null, "metadata": {"window": "A \nThanks for the question, Kevin.  I'll start.  Maybe I'll go in reverse order.  Our win of the Optum contract, and we're \ncertainly pleased to extend a nd expand our partnership, as Brian mentioned, is pharmaceutical -related only.  As \nwe think about next year, Optum is included in our guide.  As you know, we do not specifically talk about customer \ncontract details, and so we have not provided specific contr ibutions for Optum, and we don't intend to do that \ngoing forward.  This is a recent contract win. ", "original_text": "Our win of the Optum contract, and we're \ncertainly pleased to extend a nd expand our partnership, as Brian mentioned, is pharmaceutical -related only. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c98109cc-d651-4c5f-bb2d-d648731d3d70", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Kevin.  I'll start.  Maybe I'll go in reverse order.  Our win of the Optum contract, and we're \ncertainly pleased to extend a nd expand our partnership, as Brian mentioned, is pharmaceutical -related only.  As \nwe think about next year, Optum is included in our guide.  As you know, we do not specifically talk about customer \ncontract details, and so we have not provided specific contr ibutions for Optum, and we don't intend to do that \ngoing forward. ", "original_text": "Maybe I'll go in reverse order. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ca6c5349e5dc72cf3fef71459bf43ba8209a362ee56cbd9fdbd4b4d0648745d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "076520a3-3725-49af-814c-6bd2fcee8d4d", "node_type": "1", "metadata": {"window": "I'll start.  Maybe I'll go in reverse order.  Our win of the Optum contract, and we're \ncertainly pleased to extend a nd expand our partnership, as Brian mentioned, is pharmaceutical -related only.  As \nwe think about next year, Optum is included in our guide.  As you know, we do not specifically talk about customer \ncontract details, and so we have not provided specific contr ibutions for Optum, and we don't intend to do that \ngoing forward.  This is a recent contract win.  We have not incurred any costs yet related to that transition. ", "original_text": "As \nwe think about next year, Optum is included in our guide. "}, "hash": "fd473262931f8cd16f9f0bdc09cad828d527b7b3681b16f2dbd98e44fb4d6e14", "class_name": "RelatedNodeInfo"}}, "text": "Our win of the Optum contract, and we're \ncertainly pleased to extend a nd expand our partnership, as Brian mentioned, is pharmaceutical -related only. ", "start_char_idx": 1734, "end_char_idx": 1886, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "076520a3-3725-49af-814c-6bd2fcee8d4d": {"__data__": {"id_": "076520a3-3725-49af-814c-6bd2fcee8d4d", "embedding": null, "metadata": {"window": "I'll start.  Maybe I'll go in reverse order.  Our win of the Optum contract, and we're \ncertainly pleased to extend a nd expand our partnership, as Brian mentioned, is pharmaceutical -related only.  As \nwe think about next year, Optum is included in our guide.  As you know, we do not specifically talk about customer \ncontract details, and so we have not provided specific contr ibutions for Optum, and we don't intend to do that \ngoing forward.  This is a recent contract win.  We have not incurred any costs yet related to that transition. ", "original_text": "As \nwe think about next year, Optum is included in our guide. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bec0e24f-87a8-4394-aec1-bd24f3bfedf2", "node_type": "1", "metadata": {"window": "A \nThanks for the question, Kevin.  I'll start.  Maybe I'll go in reverse order.  Our win of the Optum contract, and we're \ncertainly pleased to extend a nd expand our partnership, as Brian mentioned, is pharmaceutical -related only.  As \nwe think about next year, Optum is included in our guide.  As you know, we do not specifically talk about customer \ncontract details, and so we have not provided specific contr ibutions for Optum, and we don't intend to do that \ngoing forward.  This is a recent contract win. ", "original_text": "Our win of the Optum contract, and we're \ncertainly pleased to extend a nd expand our partnership, as Brian mentioned, is pharmaceutical -related only. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "8f6a0291903e75ade9b811855a9c9a3490d95c5f813799ba115cadfe0187c9c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb98ff75-8bbe-4cf1-ab75-b270b39415fb", "node_type": "1", "metadata": {"window": "Maybe I'll go in reverse order.  Our win of the Optum contract, and we're \ncertainly pleased to extend a nd expand our partnership, as Brian mentioned, is pharmaceutical -related only.  As \nwe think about next year, Optum is included in our guide.  As you know, we do not specifically talk about customer \ncontract details, and so we have not provided specific contr ibutions for Optum, and we don't intend to do that \ngoing forward.  This is a recent contract win.  We have not incurred any costs yet related to that transition.  We do \nexpect that there will be some costs in the transition, but not material and certainly inc luded in our guidance.  \n ", "original_text": "As you know, we do not specifically talk about customer \ncontract details, and so we have not provided specific contr ibutions for Optum, and we don't intend to do that \ngoing forward. "}, "hash": "415dc3affc7313383942e60fef78aaa88cc4660884b1f2ca9144ba73da5bb4b5", "class_name": "RelatedNodeInfo"}}, "text": "As \nwe think about next year, Optum is included in our guide. ", "start_char_idx": 1886, "end_char_idx": 1948, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb98ff75-8bbe-4cf1-ab75-b270b39415fb": {"__data__": {"id_": "eb98ff75-8bbe-4cf1-ab75-b270b39415fb", "embedding": null, "metadata": {"window": "Maybe I'll go in reverse order.  Our win of the Optum contract, and we're \ncertainly pleased to extend a nd expand our partnership, as Brian mentioned, is pharmaceutical -related only.  As \nwe think about next year, Optum is included in our guide.  As you know, we do not specifically talk about customer \ncontract details, and so we have not provided specific contr ibutions for Optum, and we don't intend to do that \ngoing forward.  This is a recent contract win.  We have not incurred any costs yet related to that transition.  We do \nexpect that there will be some costs in the transition, but not material and certainly inc luded in our guidance.  \n ", "original_text": "As you know, we do not specifically talk about customer \ncontract details, and so we have not provided specific contr ibutions for Optum, and we don't intend to do that \ngoing forward. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "076520a3-3725-49af-814c-6bd2fcee8d4d", "node_type": "1", "metadata": {"window": "I'll start.  Maybe I'll go in reverse order.  Our win of the Optum contract, and we're \ncertainly pleased to extend a nd expand our partnership, as Brian mentioned, is pharmaceutical -related only.  As \nwe think about next year, Optum is included in our guide.  As you know, we do not specifically talk about customer \ncontract details, and so we have not provided specific contr ibutions for Optum, and we don't intend to do that \ngoing forward.  This is a recent contract win.  We have not incurred any costs yet related to that transition. ", "original_text": "As \nwe think about next year, Optum is included in our guide. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "80fd7e1fb67275cba76918ca3fc665014b502dced49d88d2eb3537c88d8abdc2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ffad55a-c889-4952-9bc4-d777df738b7a", "node_type": "1", "metadata": {"window": "Our win of the Optum contract, and we're \ncertainly pleased to extend a nd expand our partnership, as Brian mentioned, is pharmaceutical -related only.  As \nwe think about next year, Optum is included in our guide.  As you know, we do not specifically talk about customer \ncontract details, and so we have not provided specific contr ibutions for Optum, and we don't intend to do that \ngoing forward.  This is a recent contract win.  We have not incurred any costs yet related to that transition.  We do \nexpect that there will be some costs in the transition, but not material and certainly inc luded in our guidance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "This is a recent contract win. "}, "hash": "201a2479d1684819ad44fe729a60fe852b6aec33075fdf2b6654830b94688936", "class_name": "RelatedNodeInfo"}}, "text": "As you know, we do not specifically talk about customer \ncontract details, and so we have not provided specific contr ibutions for Optum, and we don't intend to do that \ngoing forward. ", "start_char_idx": 1948, "end_char_idx": 2133, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ffad55a-c889-4952-9bc4-d777df738b7a": {"__data__": {"id_": "3ffad55a-c889-4952-9bc4-d777df738b7a", "embedding": null, "metadata": {"window": "Our win of the Optum contract, and we're \ncertainly pleased to extend a nd expand our partnership, as Brian mentioned, is pharmaceutical -related only.  As \nwe think about next year, Optum is included in our guide.  As you know, we do not specifically talk about customer \ncontract details, and so we have not provided specific contr ibutions for Optum, and we don't intend to do that \ngoing forward.  This is a recent contract win.  We have not incurred any costs yet related to that transition.  We do \nexpect that there will be some costs in the transition, but not material and certainly inc luded in our guidance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "This is a recent contract win. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb98ff75-8bbe-4cf1-ab75-b270b39415fb", "node_type": "1", "metadata": {"window": "Maybe I'll go in reverse order.  Our win of the Optum contract, and we're \ncertainly pleased to extend a nd expand our partnership, as Brian mentioned, is pharmaceutical -related only.  As \nwe think about next year, Optum is included in our guide.  As you know, we do not specifically talk about customer \ncontract details, and so we have not provided specific contr ibutions for Optum, and we don't intend to do that \ngoing forward.  This is a recent contract win.  We have not incurred any costs yet related to that transition.  We do \nexpect that there will be some costs in the transition, but not material and certainly inc luded in our guidance.  \n ", "original_text": "As you know, we do not specifically talk about customer \ncontract details, and so we have not provided specific contr ibutions for Optum, and we don't intend to do that \ngoing forward. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a74d5b0875d63a1300a37bfdd014db30a4dddaa009319cde5eec95e2906ca8ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb10868f-579d-422b-b549-33e3dfbc575a", "node_type": "1", "metadata": {"window": "As \nwe think about next year, Optum is included in our guide.  As you know, we do not specifically talk about customer \ncontract details, and so we have not provided specific contr ibutions for Optum, and we don't intend to do that \ngoing forward.  This is a recent contract win.  We have not incurred any costs yet related to that transition.  We do \nexpect that there will be some costs in the transition, but not material and certainly inc luded in our guidance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "We have not incurred any costs yet related to that transition. "}, "hash": "95c7ceb7ae161204533469378d50db653b560d9968beb0a103a647a339c0c6a4", "class_name": "RelatedNodeInfo"}}, "text": "This is a recent contract win. ", "start_char_idx": 2133, "end_char_idx": 2164, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb10868f-579d-422b-b549-33e3dfbc575a": {"__data__": {"id_": "fb10868f-579d-422b-b549-33e3dfbc575a", "embedding": null, "metadata": {"window": "As \nwe think about next year, Optum is included in our guide.  As you know, we do not specifically talk about customer \ncontract details, and so we have not provided specific contr ibutions for Optum, and we don't intend to do that \ngoing forward.  This is a recent contract win.  We have not incurred any costs yet related to that transition.  We do \nexpect that there will be some costs in the transition, but not material and certainly inc luded in our guidance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "We have not incurred any costs yet related to that transition. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ffad55a-c889-4952-9bc4-d777df738b7a", "node_type": "1", "metadata": {"window": "Our win of the Optum contract, and we're \ncertainly pleased to extend a nd expand our partnership, as Brian mentioned, is pharmaceutical -related only.  As \nwe think about next year, Optum is included in our guide.  As you know, we do not specifically talk about customer \ncontract details, and so we have not provided specific contr ibutions for Optum, and we don't intend to do that \ngoing forward.  This is a recent contract win.  We have not incurred any costs yet related to that transition.  We do \nexpect that there will be some costs in the transition, but not material and certainly inc luded in our guidance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "This is a recent contract win. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "9170d13ebb000ad1feed90cb6c600a16606fa9be1dcc935a5b0baed9db396626", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "583a7b99-ed16-4acc-a252-aa5af3aadaa1", "node_type": "1", "metadata": {"window": "As you know, we do not specifically talk about customer \ncontract details, and so we have not provided specific contr ibutions for Optum, and we don't intend to do that \ngoing forward.  This is a recent contract win.  We have not incurred any costs yet related to that transition.  We do \nexpect that there will be some costs in the transition, but not material and certainly inc luded in our guidance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America. ", "original_text": "We do \nexpect that there will be some costs in the transition, but not material and certainly inc luded in our guidance.  \n "}, "hash": "53896b7c98281fcc82588a2c5526279e23142969194271280716f8475132d9a1", "class_name": "RelatedNodeInfo"}}, "text": "We have not incurred any costs yet related to that transition. ", "start_char_idx": 2164, "end_char_idx": 2227, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "583a7b99-ed16-4acc-a252-aa5af3aadaa1": {"__data__": {"id_": "583a7b99-ed16-4acc-a252-aa5af3aadaa1", "embedding": null, "metadata": {"window": "As you know, we do not specifically talk about customer \ncontract details, and so we have not provided specific contr ibutions for Optum, and we don't intend to do that \ngoing forward.  This is a recent contract win.  We have not incurred any costs yet related to that transition.  We do \nexpect that there will be some costs in the transition, but not material and certainly inc luded in our guidance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America. ", "original_text": "We do \nexpect that there will be some costs in the transition, but not material and certainly inc luded in our guidance.  \n ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb10868f-579d-422b-b549-33e3dfbc575a", "node_type": "1", "metadata": {"window": "As \nwe think about next year, Optum is included in our guide.  As you know, we do not specifically talk about customer \ncontract details, and so we have not provided specific contr ibutions for Optum, and we don't intend to do that \ngoing forward.  This is a recent contract win.  We have not incurred any costs yet related to that transition.  We do \nexpect that there will be some costs in the transition, but not material and certainly inc luded in our guidance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "We have not incurred any costs yet related to that transition. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a16a29b6882b0e7d62212ae3a208097787fa80125b7eab7b349988c7072345fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27df0b27-aacc-480b-8c25-0f763e954650", "node_type": "1", "metadata": {"window": "This is a recent contract win.  We have not incurred any costs yet related to that transition.  We do \nexpect that there will be some costs in the transition, but not material and certainly inc luded in our guidance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  "}, "hash": "a84984d126a97b7bc12553fe1dc79efed820d5ec58664ace304dcaa7fa298f95", "class_name": "RelatedNodeInfo"}}, "text": "We do \nexpect that there will be some costs in the transition, but not material and certainly inc luded in our guidance.  \n ", "start_char_idx": 2227, "end_char_idx": 2351, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27df0b27-aacc-480b-8c25-0f763e954650": {"__data__": {"id_": "27df0b27-aacc-480b-8c25-0f763e954650", "embedding": null, "metadata": {"window": "This is a recent contract win.  We have not incurred any costs yet related to that transition.  We do \nexpect that there will be some costs in the transition, but not material and certainly inc luded in our guidance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "583a7b99-ed16-4acc-a252-aa5af3aadaa1", "node_type": "1", "metadata": {"window": "As you know, we do not specifically talk about customer \ncontract details, and so we have not provided specific contr ibutions for Optum, and we don't intend to do that \ngoing forward.  This is a recent contract win.  We have not incurred any costs yet related to that transition.  We do \nexpect that there will be some costs in the transition, but not material and certainly inc luded in our guidance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America. ", "original_text": "We do \nexpect that there will be some costs in the transition, but not material and certainly inc luded in our guidance.  \n ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "040babaddbc6d7172fbdbee18a0a7badcbb76361715be1c628aca2fc9f4a73e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23d871fe-c1de-4d00-bca8-6564815ff92a", "node_type": "1", "metadata": {"window": "We have not incurred any costs yet related to that transition.  We do \nexpect that there will be some costs in the transition, but not material and certainly inc luded in our guidance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  ", "original_text": "A \nNext question, please.  \n "}, "hash": "4f03a76afd230ceea7fc8ca266745d683cc22ff45a2347dc112786d8806746fa", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "start_char_idx": 2351, "end_char_idx": 2696, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23d871fe-c1de-4d00-bca8-6564815ff92a": {"__data__": {"id_": "23d871fe-c1de-4d00-bca8-6564815ff92a", "embedding": null, "metadata": {"window": "We have not incurred any costs yet related to that transition.  We do \nexpect that there will be some costs in the transition, but not material and certainly inc luded in our guidance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  ", "original_text": "A \nNext question, please.  \n ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27df0b27-aacc-480b-8c25-0f763e954650", "node_type": "1", "metadata": {"window": "This is a recent contract win.  We have not incurred any costs yet related to that transition.  We do \nexpect that there will be some costs in the transition, but not material and certainly inc luded in our guidance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "dc49f0e56813ff19f02e31fcdc860c5e94f31e872bb29ecaede63c0f6f62d051", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd753cc4-6c9f-4980-b74c-eae6a2f696cc", "node_type": "1", "metadata": {"window": "We do \nexpect that there will be some costs in the transition, but not material and certainly inc luded in our guidance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon and thanks for taking the questions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America. "}, "hash": "d10e3304c9f68105692258fb7041c1b43f4a3cd30bfa1f5a9e0724c8d5798ffb", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please.  \n ", "start_char_idx": 2696, "end_char_idx": 2725, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd753cc4-6c9f-4980-b74c-eae6a2f696cc": {"__data__": {"id_": "cd753cc4-6c9f-4980-b74c-eae6a2f696cc", "embedding": null, "metadata": {"window": "We do \nexpect that there will be some costs in the transition, but not material and certainly inc luded in our guidance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon and thanks for taking the questions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23d871fe-c1de-4d00-bca8-6564815ff92a", "node_type": "1", "metadata": {"window": "We have not incurred any costs yet related to that transition.  We do \nexpect that there will be some costs in the transition, but not material and certainly inc luded in our guidance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  ", "original_text": "A \nNext question, please.  \n ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "cc3051327b464f33c5aca4750cee82b4699d16a1311ded4a4f10ed5b85eb1d92", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "800d2f17-b9bd-45d2-a66f-6ffaa2ab7e0e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon and thanks for taking the questions.  One for Britt, I want to ask about the prior authorization \nbusiness and RxTS. ", "original_text": "Please go ahead.  \n "}, "hash": "b8f815193d477e684778e5f7a3fea6e7db4cd58a4e50d1fa9524938ef2bc5ffc", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America. ", "start_char_idx": 2725, "end_char_idx": 3060, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "800d2f17-b9bd-45d2-a66f-6ffaa2ab7e0e": {"__data__": {"id_": "800d2f17-b9bd-45d2-a66f-6ffaa2ab7e0e", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon and thanks for taking the questions.  One for Britt, I want to ask about the prior authorization \nbusiness and RxTS. ", "original_text": "Please go ahead.  \n ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd753cc4-6c9f-4980-b74c-eae6a2f696cc", "node_type": "1", "metadata": {"window": "We do \nexpect that there will be some costs in the transition, but not material and certainly inc luded in our guidance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon and thanks for taking the questions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a0073ec01cd16294174d82d37fb2e71aa4b40a963b353304443d589d67baca6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "262260fd-adb5-46f0-a15e-54f5072c7667", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon and thanks for taking the questions.  One for Britt, I want to ask about the prior authorization \nbusiness and RxTS.  We've heard that employer coverage for GLP -1s doubled year over year, so the amount of \nemployees that have coverage of GLP -1s is no w twice as high as it was in 2023. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  "}, "hash": "70f582938931c99e57a54c64ca584223967172b00bbb7dc429f66abf4551d1d8", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 326, "end_char_idx": 346, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "262260fd-adb5-46f0-a15e-54f5072c7667": {"__data__": {"id_": "262260fd-adb5-46f0-a15e-54f5072c7667", "embedding": null, "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon and thanks for taking the questions.  One for Britt, I want to ask about the prior authorization \nbusiness and RxTS.  We've heard that employer coverage for GLP -1s doubled year over year, so the amount of \nemployees that have coverage of GLP -1s is no w twice as high as it was in 2023. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "800d2f17-b9bd-45d2-a66f-6ffaa2ab7e0e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon and thanks for taking the questions.  One for Britt, I want to ask about the prior authorization \nbusiness and RxTS. ", "original_text": "Please go ahead.  \n ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "6986c7d4110b84946a95b3428f945991f71a2f8d93866e4b9fe7d3d887e58b9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d85c177-4077-4af6-9da7-58d9a8301e0e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon and thanks for taking the questions.  One for Britt, I want to ask about the prior authorization \nbusiness and RxTS.  We've heard that employer coverage for GLP -1s doubled year over year, so the amount of \nemployees that have coverage of GLP -1s is no w twice as high as it was in 2023.  So even though the amount of \nGLP-1s that you're dispensing is lower, we would have still expected that prior authorization activity in that \nbusiness would have benefited pretty significantly in calendar 1Q. ", "original_text": "Q \nGood afternoon and thanks for taking the questions. "}, "hash": "05d0bc71728b66cabffe13d017e354fde768ee530f9f5778ceb94cbed9212193", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  ", "start_char_idx": 3080, "end_char_idx": 3397, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d85c177-4077-4af6-9da7-58d9a8301e0e": {"__data__": {"id_": "6d85c177-4077-4af6-9da7-58d9a8301e0e", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon and thanks for taking the questions.  One for Britt, I want to ask about the prior authorization \nbusiness and RxTS.  We've heard that employer coverage for GLP -1s doubled year over year, so the amount of \nemployees that have coverage of GLP -1s is no w twice as high as it was in 2023.  So even though the amount of \nGLP-1s that you're dispensing is lower, we would have still expected that prior authorization activity in that \nbusiness would have benefited pretty significantly in calendar 1Q. ", "original_text": "Q \nGood afternoon and thanks for taking the questions. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "262260fd-adb5-46f0-a15e-54f5072c7667", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon and thanks for taking the questions.  One for Britt, I want to ask about the prior authorization \nbusiness and RxTS.  We've heard that employer coverage for GLP -1s doubled year over year, so the amount of \nemployees that have coverage of GLP -1s is no w twice as high as it was in 2023. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "0b475604ee60c51cf092dcd1eccbf4c1b81703ca53e62e458cc6127ca3eb1412", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45c45a1e-0f06-4a0f-9382-91ef808dbc04", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon and thanks for taking the questions.  One for Britt, I want to ask about the prior authorization \nbusiness and RxTS.  We've heard that employer coverage for GLP -1s doubled year over year, so the amount of \nemployees that have coverage of GLP -1s is no w twice as high as it was in 2023.  So even though the amount of \nGLP-1s that you're dispensing is lower, we would have still expected that prior authorization activity in that \nbusiness would have benefited pretty significantly in calendar 1Q.  Did any of the  GLP-1 related prior \nauthorizations get pushed out of calendar 1Q? ", "original_text": "One for Britt, I want to ask about the prior authorization \nbusiness and RxTS. "}, "hash": "8924230facd2e3a73383a534f28123fef90c47c921ee12437d1ccb6cb3753aae", "class_name": "RelatedNodeInfo"}}, "text": "Q \nGood afternoon and thanks for taking the questions. ", "start_char_idx": 3397, "end_char_idx": 3452, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45c45a1e-0f06-4a0f-9382-91ef808dbc04": {"__data__": {"id_": "45c45a1e-0f06-4a0f-9382-91ef808dbc04", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon and thanks for taking the questions.  One for Britt, I want to ask about the prior authorization \nbusiness and RxTS.  We've heard that employer coverage for GLP -1s doubled year over year, so the amount of \nemployees that have coverage of GLP -1s is no w twice as high as it was in 2023.  So even though the amount of \nGLP-1s that you're dispensing is lower, we would have still expected that prior authorization activity in that \nbusiness would have benefited pretty significantly in calendar 1Q.  Did any of the  GLP-1 related prior \nauthorizations get pushed out of calendar 1Q? ", "original_text": "One for Britt, I want to ask about the prior authorization \nbusiness and RxTS. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d85c177-4077-4af6-9da7-58d9a8301e0e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon and thanks for taking the questions.  One for Britt, I want to ask about the prior authorization \nbusiness and RxTS.  We've heard that employer coverage for GLP -1s doubled year over year, so the amount of \nemployees that have coverage of GLP -1s is no w twice as high as it was in 2023.  So even though the amount of \nGLP-1s that you're dispensing is lower, we would have still expected that prior authorization activity in that \nbusiness would have benefited pretty significantly in calendar 1Q. ", "original_text": "Q \nGood afternoon and thanks for taking the questions. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "7bff669d407919e2c14ae6d324248ed4fabe8863e13a0fa79f5d01f53ab7d710", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b1e1e46-93f2-4a4d-873a-a65aeee58c19", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon and thanks for taking the questions.  One for Britt, I want to ask about the prior authorization \nbusiness and RxTS.  We've heard that employer coverage for GLP -1s doubled year over year, so the amount of \nemployees that have coverage of GLP -1s is no w twice as high as it was in 2023.  So even though the amount of \nGLP-1s that you're dispensing is lower, we would have still expected that prior authorization activity in that \nbusiness would have benefited pretty significantly in calendar 1Q.  Did any of the  GLP-1 related prior \nauthorizations get pushed out of calendar 1Q?  Was there any impact from change? ", "original_text": "We've heard that employer coverage for GLP -1s doubled year over year, so the amount of \nemployees that have coverage of GLP -1s is no w twice as high as it was in 2023. "}, "hash": "a69e67c30800334f737726186d1cbe1af9756e49506d254bd8fd7f8a7f4dc846", "class_name": "RelatedNodeInfo"}}, "text": "One for Britt, I want to ask about the prior authorization \nbusiness and RxTS. ", "start_char_idx": 3452, "end_char_idx": 3531, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b1e1e46-93f2-4a4d-873a-a65aeee58c19": {"__data__": {"id_": "7b1e1e46-93f2-4a4d-873a-a65aeee58c19", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon and thanks for taking the questions.  One for Britt, I want to ask about the prior authorization \nbusiness and RxTS.  We've heard that employer coverage for GLP -1s doubled year over year, so the amount of \nemployees that have coverage of GLP -1s is no w twice as high as it was in 2023.  So even though the amount of \nGLP-1s that you're dispensing is lower, we would have still expected that prior authorization activity in that \nbusiness would have benefited pretty significantly in calendar 1Q.  Did any of the  GLP-1 related prior \nauthorizations get pushed out of calendar 1Q?  Was there any impact from change? ", "original_text": "We've heard that employer coverage for GLP -1s doubled year over year, so the amount of \nemployees that have coverage of GLP -1s is no w twice as high as it was in 2023. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45c45a1e-0f06-4a0f-9382-91ef808dbc04", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon and thanks for taking the questions.  One for Britt, I want to ask about the prior authorization \nbusiness and RxTS.  We've heard that employer coverage for GLP -1s doubled year over year, so the amount of \nemployees that have coverage of GLP -1s is no w twice as high as it was in 2023.  So even though the amount of \nGLP-1s that you're dispensing is lower, we would have still expected that prior authorization activity in that \nbusiness would have benefited pretty significantly in calendar 1Q.  Did any of the  GLP-1 related prior \nauthorizations get pushed out of calendar 1Q? ", "original_text": "One for Britt, I want to ask about the prior authorization \nbusiness and RxTS. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "fc9da1fbc72c9c5fa63a3cd1acc84c5129e44fcb20b7face47db0a32c8851950", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98897dcc-eb46-42b3-9264-b8c90087f0fe", "node_type": "1", "metadata": {"window": "Q \nGood afternoon and thanks for taking the questions.  One for Britt, I want to ask about the prior authorization \nbusiness and RxTS.  We've heard that employer coverage for GLP -1s doubled year over year, so the amount of \nemployees that have coverage of GLP -1s is no w twice as high as it was in 2023.  So even though the amount of \nGLP-1s that you're dispensing is lower, we would have still expected that prior authorization activity in that \nbusiness would have benefited pretty significantly in calendar 1Q.  Did any of the  GLP-1 related prior \nauthorizations get pushed out of calendar 1Q?  Was there any impact from change?  And can you just speak to the \ngrowth rate of that business more broadly? ", "original_text": "So even though the amount of \nGLP-1s that you're dispensing is lower, we would have still expected that prior authorization activity in that \nbusiness would have benefited pretty significantly in calendar 1Q. "}, "hash": "f7fb118f4098abb4552b773b8072e4feba249d5d50c971ea2578497ae431aed2", "class_name": "RelatedNodeInfo"}}, "text": "We've heard that employer coverage for GLP -1s doubled year over year, so the amount of \nemployees that have coverage of GLP -1s is no w twice as high as it was in 2023. ", "start_char_idx": 3531, "end_char_idx": 3701, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98897dcc-eb46-42b3-9264-b8c90087f0fe": {"__data__": {"id_": "98897dcc-eb46-42b3-9264-b8c90087f0fe", "embedding": null, "metadata": {"window": "Q \nGood afternoon and thanks for taking the questions.  One for Britt, I want to ask about the prior authorization \nbusiness and RxTS.  We've heard that employer coverage for GLP -1s doubled year over year, so the amount of \nemployees that have coverage of GLP -1s is no w twice as high as it was in 2023.  So even though the amount of \nGLP-1s that you're dispensing is lower, we would have still expected that prior authorization activity in that \nbusiness would have benefited pretty significantly in calendar 1Q.  Did any of the  GLP-1 related prior \nauthorizations get pushed out of calendar 1Q?  Was there any impact from change?  And can you just speak to the \ngrowth rate of that business more broadly? ", "original_text": "So even though the amount of \nGLP-1s that you're dispensing is lower, we would have still expected that prior authorization activity in that \nbusiness would have benefited pretty significantly in calendar 1Q. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b1e1e46-93f2-4a4d-873a-a65aeee58c19", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon and thanks for taking the questions.  One for Britt, I want to ask about the prior authorization \nbusiness and RxTS.  We've heard that employer coverage for GLP -1s doubled year over year, so the amount of \nemployees that have coverage of GLP -1s is no w twice as high as it was in 2023.  So even though the amount of \nGLP-1s that you're dispensing is lower, we would have still expected that prior authorization activity in that \nbusiness would have benefited pretty significantly in calendar 1Q.  Did any of the  GLP-1 related prior \nauthorizations get pushed out of calendar 1Q?  Was there any impact from change? ", "original_text": "We've heard that employer coverage for GLP -1s doubled year over year, so the amount of \nemployees that have coverage of GLP -1s is no w twice as high as it was in 2023. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e9bdea7497953f433b551d98c2d628ea3e867d7e2aaa29bc5e09ef3be9326f63", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3fd04acf-7a95-4976-b999-a6deb07ff29b", "node_type": "1", "metadata": {"window": "One for Britt, I want to ask about the prior authorization \nbusiness and RxTS.  We've heard that employer coverage for GLP -1s doubled year over year, so the amount of \nemployees that have coverage of GLP -1s is no w twice as high as it was in 2023.  So even though the amount of \nGLP-1s that you're dispensing is lower, we would have still expected that prior authorization activity in that \nbusiness would have benefited pretty significantly in calendar 1Q.  Did any of the  GLP-1 related prior \nauthorizations get pushed out of calendar 1Q?  Was there any impact from change?  And can you just speak to the \ngrowth rate of that business more broadly?  Thanks.  \n ", "original_text": "Did any of the  GLP-1 related prior \nauthorizations get pushed out of calendar 1Q? "}, "hash": "fdceaf04324bef4704fd9c37c9f847b301722eb8745deb14a3a0d0d02e4a99bc", "class_name": "RelatedNodeInfo"}}, "text": "So even though the amount of \nGLP-1s that you're dispensing is lower, we would have still expected that prior authorization activity in that \nbusiness would have benefited pretty significantly in calendar 1Q. ", "start_char_idx": 3701, "end_char_idx": 3910, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3fd04acf-7a95-4976-b999-a6deb07ff29b": {"__data__": {"id_": "3fd04acf-7a95-4976-b999-a6deb07ff29b", "embedding": null, "metadata": {"window": "One for Britt, I want to ask about the prior authorization \nbusiness and RxTS.  We've heard that employer coverage for GLP -1s doubled year over year, so the amount of \nemployees that have coverage of GLP -1s is no w twice as high as it was in 2023.  So even though the amount of \nGLP-1s that you're dispensing is lower, we would have still expected that prior authorization activity in that \nbusiness would have benefited pretty significantly in calendar 1Q.  Did any of the  GLP-1 related prior \nauthorizations get pushed out of calendar 1Q?  Was there any impact from change?  And can you just speak to the \ngrowth rate of that business more broadly?  Thanks.  \n ", "original_text": "Did any of the  GLP-1 related prior \nauthorizations get pushed out of calendar 1Q? ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98897dcc-eb46-42b3-9264-b8c90087f0fe", "node_type": "1", "metadata": {"window": "Q \nGood afternoon and thanks for taking the questions.  One for Britt, I want to ask about the prior authorization \nbusiness and RxTS.  We've heard that employer coverage for GLP -1s doubled year over year, so the amount of \nemployees that have coverage of GLP -1s is no w twice as high as it was in 2023.  So even though the amount of \nGLP-1s that you're dispensing is lower, we would have still expected that prior authorization activity in that \nbusiness would have benefited pretty significantly in calendar 1Q.  Did any of the  GLP-1 related prior \nauthorizations get pushed out of calendar 1Q?  Was there any impact from change?  And can you just speak to the \ngrowth rate of that business more broadly? ", "original_text": "So even though the amount of \nGLP-1s that you're dispensing is lower, we would have still expected that prior authorization activity in that \nbusiness would have benefited pretty significantly in calendar 1Q. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "2e5572247d4c369a72ae82371ffb721c3ca5451f11bba9fc99405797bfbd804f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4bd6292e-da66-40b2-bffd-0e7e8031325f", "node_type": "1", "metadata": {"window": "We've heard that employer coverage for GLP -1s doubled year over year, so the amount of \nemployees that have coverage of GLP -1s is no w twice as high as it was in 2023.  So even though the amount of \nGLP-1s that you're dispensing is lower, we would have still expected that prior authorization activity in that \nbusiness would have benefited pretty significantly in calendar 1Q.  Did any of the  GLP-1 related prior \nauthorizations get pushed out of calendar 1Q?  Was there any impact from change?  And can you just speak to the \ngrowth rate of that business more broadly?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, Mc Kesson Corp.  ", "original_text": "Was there any impact from change? "}, "hash": "8dc7535555e5d9d295c7e7f0ac228d4d62c70f7441f4c9a1cecf2a6f12bcafda", "class_name": "RelatedNodeInfo"}}, "text": "Did any of the  GLP-1 related prior \nauthorizations get pushed out of calendar 1Q? ", "start_char_idx": 3910, "end_char_idx": 3993, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4bd6292e-da66-40b2-bffd-0e7e8031325f": {"__data__": {"id_": "4bd6292e-da66-40b2-bffd-0e7e8031325f", "embedding": null, "metadata": {"window": "We've heard that employer coverage for GLP -1s doubled year over year, so the amount of \nemployees that have coverage of GLP -1s is no w twice as high as it was in 2023.  So even though the amount of \nGLP-1s that you're dispensing is lower, we would have still expected that prior authorization activity in that \nbusiness would have benefited pretty significantly in calendar 1Q.  Did any of the  GLP-1 related prior \nauthorizations get pushed out of calendar 1Q?  Was there any impact from change?  And can you just speak to the \ngrowth rate of that business more broadly?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, Mc Kesson Corp.  ", "original_text": "Was there any impact from change? ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3fd04acf-7a95-4976-b999-a6deb07ff29b", "node_type": "1", "metadata": {"window": "One for Britt, I want to ask about the prior authorization \nbusiness and RxTS.  We've heard that employer coverage for GLP -1s doubled year over year, so the amount of \nemployees that have coverage of GLP -1s is no w twice as high as it was in 2023.  So even though the amount of \nGLP-1s that you're dispensing is lower, we would have still expected that prior authorization activity in that \nbusiness would have benefited pretty significantly in calendar 1Q.  Did any of the  GLP-1 related prior \nauthorizations get pushed out of calendar 1Q?  Was there any impact from change?  And can you just speak to the \ngrowth rate of that business more broadly?  Thanks.  \n ", "original_text": "Did any of the  GLP-1 related prior \nauthorizations get pushed out of calendar 1Q? ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a9d0c894e47b62a534a3b7d5c27c13bc89357cb6c73e736f4df19d871d04ddaa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "399a0073-b49e-44c8-88e0-6ea141907c51", "node_type": "1", "metadata": {"window": "So even though the amount of \nGLP-1s that you're dispensing is lower, we would have still expected that prior authorization activity in that \nbusiness would have benefited pretty significantly in calendar 1Q.  Did any of the  GLP-1 related prior \nauthorizations get pushed out of calendar 1Q?  Was there any impact from change?  And can you just speak to the \ngrowth rate of that business more broadly?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, Mc Kesson Corp.   A \nYeah, thanks for the question. ", "original_text": "And can you just speak to the \ngrowth rate of that business more broadly? "}, "hash": "209048ac8ced22bf772eadcddfd3084a3242192eace6f7ea56de29e123dea0d9", "class_name": "RelatedNodeInfo"}}, "text": "Was there any impact from change? ", "start_char_idx": 3993, "end_char_idx": 4027, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "399a0073-b49e-44c8-88e0-6ea141907c51": {"__data__": {"id_": "399a0073-b49e-44c8-88e0-6ea141907c51", "embedding": null, "metadata": {"window": "So even though the amount of \nGLP-1s that you're dispensing is lower, we would have still expected that prior authorization activity in that \nbusiness would have benefited pretty significantly in calendar 1Q.  Did any of the  GLP-1 related prior \nauthorizations get pushed out of calendar 1Q?  Was there any impact from change?  And can you just speak to the \ngrowth rate of that business more broadly?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, Mc Kesson Corp.   A \nYeah, thanks for the question. ", "original_text": "And can you just speak to the \ngrowth rate of that business more broadly? ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4bd6292e-da66-40b2-bffd-0e7e8031325f", "node_type": "1", "metadata": {"window": "We've heard that employer coverage for GLP -1s doubled year over year, so the amount of \nemployees that have coverage of GLP -1s is no w twice as high as it was in 2023.  So even though the amount of \nGLP-1s that you're dispensing is lower, we would have still expected that prior authorization activity in that \nbusiness would have benefited pretty significantly in calendar 1Q.  Did any of the  GLP-1 related prior \nauthorizations get pushed out of calendar 1Q?  Was there any impact from change?  And can you just speak to the \ngrowth rate of that business more broadly?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, Mc Kesson Corp.  ", "original_text": "Was there any impact from change? ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "2cd5acb28f313dbb99fd67e52531eba7e8bdddb2b3f8bc27870cccf5eeb726fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "156755df-165e-4907-a125-0ad230d5ee01", "node_type": "1", "metadata": {"window": "Did any of the  GLP-1 related prior \nauthorizations get pushed out of calendar 1Q?  Was there any impact from change?  And can you just speak to the \ngrowth rate of that business more broadly?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, Mc Kesson Corp.   A \nYeah, thanks for the question.  I'll start, and certainly Brian could add to this. ", "original_text": "Thanks.  \n "}, "hash": "edde0118e7c88da03604ca9c4ae6f66d34e19a59297a445e1fd3c36afee9102a", "class_name": "RelatedNodeInfo"}}, "text": "And can you just speak to the \ngrowth rate of that business more broadly? ", "start_char_idx": 4027, "end_char_idx": 4101, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "156755df-165e-4907-a125-0ad230d5ee01": {"__data__": {"id_": "156755df-165e-4907-a125-0ad230d5ee01", "embedding": null, "metadata": {"window": "Did any of the  GLP-1 related prior \nauthorizations get pushed out of calendar 1Q?  Was there any impact from change?  And can you just speak to the \ngrowth rate of that business more broadly?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, Mc Kesson Corp.   A \nYeah, thanks for the question.  I'll start, and certainly Brian could add to this. ", "original_text": "Thanks.  \n ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "399a0073-b49e-44c8-88e0-6ea141907c51", "node_type": "1", "metadata": {"window": "So even though the amount of \nGLP-1s that you're dispensing is lower, we would have still expected that prior authorization activity in that \nbusiness would have benefited pretty significantly in calendar 1Q.  Did any of the  GLP-1 related prior \nauthorizations get pushed out of calendar 1Q?  Was there any impact from change?  And can you just speak to the \ngrowth rate of that business more broadly?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, Mc Kesson Corp.   A \nYeah, thanks for the question. ", "original_text": "And can you just speak to the \ngrowth rate of that business more broadly? ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "6fbd8364b1354fe50e77ef6e6490fb0ab30b6568611c4187ef2af3ed0842b707", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72c7b5a3-2c99-421a-ac6e-40d7227724f7", "node_type": "1", "metadata": {"window": "Was there any impact from change?  And can you just speak to the \ngrowth rate of that business more broadly?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, Mc Kesson Corp.   A \nYeah, thanks for the question.  I'll start, and certainly Brian could add to this.  I think when we've talked about this \nsegment in the past, there are many different things that go through this segment, one of those being our 3PL ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, Mc Kesson Corp.  "}, "hash": "24472c45b3a58209ffc0a1b603f1dd32b2657e01f8bf9dc3b548a2d8b5135442", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 4101, "end_char_idx": 4112, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72c7b5a3-2c99-421a-ac6e-40d7227724f7": {"__data__": {"id_": "72c7b5a3-2c99-421a-ac6e-40d7227724f7", "embedding": null, "metadata": {"window": "Was there any impact from change?  And can you just speak to the \ngrowth rate of that business more broadly?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, Mc Kesson Corp.   A \nYeah, thanks for the question.  I'll start, and certainly Brian could add to this.  I think when we've talked about this \nsegment in the past, there are many different things that go through this segment, one of those being our 3PL ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, Mc Kesson Corp.  ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "156755df-165e-4907-a125-0ad230d5ee01", "node_type": "1", "metadata": {"window": "Did any of the  GLP-1 related prior \nauthorizations get pushed out of calendar 1Q?  Was there any impact from change?  And can you just speak to the \ngrowth rate of that business more broadly?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, Mc Kesson Corp.   A \nYeah, thanks for the question.  I'll start, and certainly Brian could add to this. ", "original_text": "Thanks.  \n ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "cd4029d5fa7c0e2c47ffad8e44d56ace6460c96fe8a27fb10beb5994ac6c4434", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d651ef9a-9cd9-457d-95c6-fa16086344a9", "node_type": "1", "metadata": {"window": "And can you just speak to the \ngrowth rate of that business more broadly?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, Mc Kesson Corp.   A \nYeah, thanks for the question.  I'll start, and certainly Brian could add to this.  I think when we've talked about this \nsegment in the past, there are many different things that go through this segment, one of those being our 3PL ", "original_text": "A \nYeah, thanks for the question. "}, "hash": "c897dc3cf922cc3a6d2d7a9499f4cdef7c153670a44cfec575cbb1845e184585", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, Mc Kesson Corp.  ", "start_char_idx": 4112, "end_char_idx": 4473, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d651ef9a-9cd9-457d-95c6-fa16086344a9": {"__data__": {"id_": "d651ef9a-9cd9-457d-95c6-fa16086344a9", "embedding": null, "metadata": {"window": "And can you just speak to the \ngrowth rate of that business more broadly?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, Mc Kesson Corp.   A \nYeah, thanks for the question.  I'll start, and certainly Brian could add to this.  I think when we've talked about this \nsegment in the past, there are many different things that go through this segment, one of those being our 3PL ", "original_text": "A \nYeah, thanks for the question. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72c7b5a3-2c99-421a-ac6e-40d7227724f7", "node_type": "1", "metadata": {"window": "Was there any impact from change?  And can you just speak to the \ngrowth rate of that business more broadly?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, Mc Kesson Corp.   A \nYeah, thanks for the question.  I'll start, and certainly Brian could add to this.  I think when we've talked about this \nsegment in the past, there are many different things that go through this segment, one of those being our 3PL ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, Mc Kesson Corp.  ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "cf079cf7890a04daedca0dee38958a0fa90af024fa71ee690325313f1ddaf1e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d96892a1-e59b-4d74-bb05-90f921c095eb", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, Mc Kesson Corp.   A \nYeah, thanks for the question.  I'll start, and certainly Brian could add to this.  I think when we've talked about this \nsegment in the past, there are many different things that go through this segment, one of those being our 3PL ", "original_text": "I'll start, and certainly Brian could add to this. "}, "hash": "da68b10ba5846971b19672400cf33dc5bc5504e0f2d0b1f0a63addc879fafeff", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah, thanks for the question. ", "start_char_idx": 4473, "end_char_idx": 4507, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d96892a1-e59b-4d74-bb05-90f921c095eb": {"__data__": {"id_": "d96892a1-e59b-4d74-bb05-90f921c095eb", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, Mc Kesson Corp.   A \nYeah, thanks for the question.  I'll start, and certainly Brian could add to this.  I think when we've talked about this \nsegment in the past, there are many different things that go through this segment, one of those being our 3PL ", "original_text": "I'll start, and certainly Brian could add to this. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d651ef9a-9cd9-457d-95c6-fa16086344a9", "node_type": "1", "metadata": {"window": "And can you just speak to the \ngrowth rate of that business more broadly?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, Mc Kesson Corp.   A \nYeah, thanks for the question.  I'll start, and certainly Brian could add to this.  I think when we've talked about this \nsegment in the past, there are many different things that go through this segment, one of those being our 3PL ", "original_text": "A \nYeah, thanks for the question. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "54da1555707f87cd73ad7004ea517d57a36b661f6a017ce7fb7e834a68b5dd62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2a64860-36c3-474f-b8ad-ed8d2939105b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, Mc Kesson Corp.   A \nYeah, thanks for the question.  I'll start, and certainly Brian could add to this.  I think when we've talked about this \nsegment in the past, there are many different things that go through this segment, one of those being our 3PL ", "original_text": "I think when we've talked about this \nsegment in the past, there are many different things that go through this segment, one of those being our 3PL "}, "hash": "01120b0a69bea3e0ddd6a8093b19141c45f77d5928e0b8fda078b1dee34e86c5", "class_name": "RelatedNodeInfo"}}, "text": "I'll start, and certainly Brian could add to this. ", "start_char_idx": 4507, "end_char_idx": 4558, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2a64860-36c3-474f-b8ad-ed8d2939105b": {"__data__": {"id_": "e2a64860-36c3-474f-b8ad-ed8d2939105b", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, Mc Kesson Corp.   A \nYeah, thanks for the question.  I'll start, and certainly Brian could add to this.  I think when we've talked about this \nsegment in the past, there are many different things that go through this segment, one of those being our 3PL ", "original_text": "I think when we've talked about this \nsegment in the past, there are many different things that go through this segment, one of those being our 3PL ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "698a5806cb5cdf2168e31f3fff67a39a9ce51ad87050274ec897eb38c334ab7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d96892a1-e59b-4d74-bb05-90f921c095eb", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, Mc Kesson Corp.   A \nYeah, thanks for the question.  I'll start, and certainly Brian could add to this.  I think when we've talked about this \nsegment in the past, there are many different things that go through this segment, one of those being our 3PL ", "original_text": "I'll start, and certainly Brian could add to this. ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "17ad05d39b72568a8cf8a8f8e821fd694220df50a99ab121ba8481904b89a522", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a95a5ac-540a-4f92-9059-6cecb4796aa7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nbusiness.  Our 3PL business, as we talked about in the past, is slightly more than half of the revenue.  And as I \nmentioned in my comments, the 3PL performance was lower than the prior year for various customer and contract \nconsiderations.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "8be3231ce2016d76370156dc9eb753064e29a134719148f96eea435feb55f3f8", "class_name": "RelatedNodeInfo"}}, "text": "I think when we've talked about this \nsegment in the past, there are many different things that go through this segment, one of those being our 3PL ", "start_char_idx": 4558, "end_char_idx": 4706, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a95a5ac-540a-4f92-9059-6cecb4796aa7": {"__data__": {"id_": "8a95a5ac-540a-4f92-9059-6cecb4796aa7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nbusiness.  Our 3PL business, as we talked about in the past, is slightly more than half of the revenue.  And as I \nmentioned in my comments, the 3PL performance was lower than the prior year for various customer and contract \nconsiderations.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c70fbf6f5051ce27733916749a7319ff4226fa528aec42ed218b7fefb39f7978", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2a64860-36c3-474f-b8ad-ed8d2939105b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, Mc Kesson Corp.   A \nYeah, thanks for the question.  I'll start, and certainly Brian could add to this.  I think when we've talked about this \nsegment in the past, there are many different things that go through this segment, one of those being our 3PL ", "original_text": "I think when we've talked about this \nsegment in the past, there are many different things that go through this segment, one of those being our 3PL ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3a3bf2d7f4e042089be85092adfcd517a7d798880470923bd32090a849bca3c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b4c5952-4155-4365-9def-21fbe067eee8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nbusiness.  Our 3PL business, as we talked about in the past, is slightly more than half of the revenue.  And as I \nmentioned in my comments, the 3PL performance was lower than the prior year for various customer and contract \nconsiderations.  \n \n We're certainly pleased wit h what we're seeing in our prior authorization business. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nbusiness. "}, "hash": "77e497aef06ff1567f3f97c384b92896bc7ab3d38182e11b3668a66d6eb8a38e", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b4c5952-4155-4365-9def-21fbe067eee8": {"__data__": {"id_": "1b4c5952-4155-4365-9def-21fbe067eee8", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nbusiness.  Our 3PL business, as we talked about in the past, is slightly more than half of the revenue.  And as I \nmentioned in my comments, the 3PL performance was lower than the prior year for various customer and contract \nconsiderations.  \n \n We're certainly pleased wit h what we're seeing in our prior authorization business. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nbusiness. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c70fbf6f5051ce27733916749a7319ff4226fa528aec42ed218b7fefb39f7978", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a95a5ac-540a-4f92-9059-6cecb4796aa7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nbusiness.  Our 3PL business, as we talked about in the past, is slightly more than half of the revenue.  And as I \nmentioned in my comments, the 3PL performance was lower than the prior year for various customer and contract \nconsiderations.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "0ebf633413c8296c8598efa880dc82de74b13abdd256a445b865df1d51ca732a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d982ddfa-cd29-4863-bee2-bc3cbd2b8ef1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nbusiness.  Our 3PL business, as we talked about in the past, is slightly more than half of the revenue.  And as I \nmentioned in my comments, the 3PL performance was lower than the prior year for various customer and contract \nconsiderations.  \n \n We're certainly pleased wit h what we're seeing in our prior authorization business.  We continue to see growth in \nthat business. ", "original_text": "Our 3PL business, as we talked about in the past, is slightly more than half of the revenue. "}, "hash": "56b8b1b8754e2da712433be916e1ae0b90998b8a12645b90146f61a0fa0bbf14", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nbusiness. ", "start_char_idx": 16, "end_char_idx": 191, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d982ddfa-cd29-4863-bee2-bc3cbd2b8ef1": {"__data__": {"id_": "d982ddfa-cd29-4863-bee2-bc3cbd2b8ef1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nbusiness.  Our 3PL business, as we talked about in the past, is slightly more than half of the revenue.  And as I \nmentioned in my comments, the 3PL performance was lower than the prior year for various customer and contract \nconsiderations.  \n \n We're certainly pleased wit h what we're seeing in our prior authorization business.  We continue to see growth in \nthat business. ", "original_text": "Our 3PL business, as we talked about in the past, is slightly more than half of the revenue. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c70fbf6f5051ce27733916749a7319ff4226fa528aec42ed218b7fefb39f7978", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b4c5952-4155-4365-9def-21fbe067eee8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nbusiness.  Our 3PL business, as we talked about in the past, is slightly more than half of the revenue.  And as I \nmentioned in my comments, the 3PL performance was lower than the prior year for various customer and contract \nconsiderations.  \n \n We're certainly pleased wit h what we're seeing in our prior authorization business. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nbusiness. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "cd846b3114831ee615c16c3418a4cd9e76063d9586f3ea20b996698f4b0573dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7bc891e7-56ea-452d-b256-047978d3c099", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nbusiness.  Our 3PL business, as we talked about in the past, is slightly more than half of the revenue.  And as I \nmentioned in my comments, the 3PL performance was lower than the prior year for various customer and contract \nconsiderations.  \n \n We're certainly pleased wit h what we're seeing in our prior authorization business.  We continue to see growth in \nthat business.  We continue to see growth in our fiscal fourth quarter as well. ", "original_text": "And as I \nmentioned in my comments, the 3PL performance was lower than the prior year for various customer and contract \nconsiderations.  \n \n"}, "hash": "f7aef055fb3003e037dc0c47fc5a738e704d457cd5b2e312d6f14d664aaff9b9", "class_name": "RelatedNodeInfo"}}, "text": "Our 3PL business, as we talked about in the past, is slightly more than half of the revenue. ", "start_char_idx": 191, "end_char_idx": 284, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7bc891e7-56ea-452d-b256-047978d3c099": {"__data__": {"id_": "7bc891e7-56ea-452d-b256-047978d3c099", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nbusiness.  Our 3PL business, as we talked about in the past, is slightly more than half of the revenue.  And as I \nmentioned in my comments, the 3PL performance was lower than the prior year for various customer and contract \nconsiderations.  \n \n We're certainly pleased wit h what we're seeing in our prior authorization business.  We continue to see growth in \nthat business.  We continue to see growth in our fiscal fourth quarter as well. ", "original_text": "And as I \nmentioned in my comments, the 3PL performance was lower than the prior year for various customer and contract \nconsiderations.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c70fbf6f5051ce27733916749a7319ff4226fa528aec42ed218b7fefb39f7978", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d982ddfa-cd29-4863-bee2-bc3cbd2b8ef1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nbusiness.  Our 3PL business, as we talked about in the past, is slightly more than half of the revenue.  And as I \nmentioned in my comments, the 3PL performance was lower than the prior year for various customer and contract \nconsiderations.  \n \n We're certainly pleased wit h what we're seeing in our prior authorization business.  We continue to see growth in \nthat business. ", "original_text": "Our 3PL business, as we talked about in the past, is slightly more than half of the revenue. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "b52b7bdec67b21b0b5b220c1b3c088cec618678076df7470b6612226d87372bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1860fd08-e980-41a9-ad08-2a9f7c33c68f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nbusiness.  Our 3PL business, as we talked about in the past, is slightly more than half of the revenue.  And as I \nmentioned in my comments, the 3PL performance was lower than the prior year for various customer and contract \nconsiderations.  \n \n We're certainly pleased wit h what we're seeing in our prior authorization business.  We continue to see growth in \nthat business.  We continue to see growth in our fiscal fourth quarter as well.  We did make a number of \ninvestments, as I talked about, and we also made some investments f or future years to continue our growth and \ncontinue the value that we're providing to our customers.  \n \n", "original_text": "We're certainly pleased wit h what we're seeing in our prior authorization business. "}, "hash": "fe0ecd3331e0326767aca9f470425ff12e8889e94934482b1b1700c68972ce82", "class_name": "RelatedNodeInfo"}}, "text": "And as I \nmentioned in my comments, the 3PL performance was lower than the prior year for various customer and contract \nconsiderations.  \n \n", "start_char_idx": 284, "end_char_idx": 425, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1860fd08-e980-41a9-ad08-2a9f7c33c68f": {"__data__": {"id_": "1860fd08-e980-41a9-ad08-2a9f7c33c68f", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nbusiness.  Our 3PL business, as we talked about in the past, is slightly more than half of the revenue.  And as I \nmentioned in my comments, the 3PL performance was lower than the prior year for various customer and contract \nconsiderations.  \n \n We're certainly pleased wit h what we're seeing in our prior authorization business.  We continue to see growth in \nthat business.  We continue to see growth in our fiscal fourth quarter as well.  We did make a number of \ninvestments, as I talked about, and we also made some investments f or future years to continue our growth and \ncontinue the value that we're providing to our customers.  \n \n", "original_text": "We're certainly pleased wit h what we're seeing in our prior authorization business. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c70fbf6f5051ce27733916749a7319ff4226fa528aec42ed218b7fefb39f7978", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7bc891e7-56ea-452d-b256-047978d3c099", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nbusiness.  Our 3PL business, as we talked about in the past, is slightly more than half of the revenue.  And as I \nmentioned in my comments, the 3PL performance was lower than the prior year for various customer and contract \nconsiderations.  \n \n We're certainly pleased wit h what we're seeing in our prior authorization business.  We continue to see growth in \nthat business.  We continue to see growth in our fiscal fourth quarter as well. ", "original_text": "And as I \nmentioned in my comments, the 3PL performance was lower than the prior year for various customer and contract \nconsiderations.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "442b34686100b46eb0a60ad1b208aae8f296fe0f7a59b28c3f8f7181345aaa9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54d581e7-e554-45c1-9c7c-998716e4ae5e", "node_type": "1", "metadata": {"window": "Our 3PL business, as we talked about in the past, is slightly more than half of the revenue.  And as I \nmentioned in my comments, the 3PL performance was lower than the prior year for various customer and contract \nconsiderations.  \n \n We're certainly pleased wit h what we're seeing in our prior authorization business.  We continue to see growth in \nthat business.  We continue to see growth in our fiscal fourth quarter as well.  We did make a number of \ninvestments, as I talked about, and we also made some investments f or future years to continue our growth and \ncontinue the value that we're providing to our customers.  \n \n So underlying all of that, we had a very strong year. ", "original_text": "We continue to see growth in \nthat business. "}, "hash": "a1bd158176e2db5286f79a1a44fdc48112b877b16a915c5d4f9d87cc8f6afb12", "class_name": "RelatedNodeInfo"}}, "text": "We're certainly pleased wit h what we're seeing in our prior authorization business. ", "start_char_idx": 425, "end_char_idx": 510, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54d581e7-e554-45c1-9c7c-998716e4ae5e": {"__data__": {"id_": "54d581e7-e554-45c1-9c7c-998716e4ae5e", "embedding": null, "metadata": {"window": "Our 3PL business, as we talked about in the past, is slightly more than half of the revenue.  And as I \nmentioned in my comments, the 3PL performance was lower than the prior year for various customer and contract \nconsiderations.  \n \n We're certainly pleased wit h what we're seeing in our prior authorization business.  We continue to see growth in \nthat business.  We continue to see growth in our fiscal fourth quarter as well.  We did make a number of \ninvestments, as I talked about, and we also made some investments f or future years to continue our growth and \ncontinue the value that we're providing to our customers.  \n \n So underlying all of that, we had a very strong year. ", "original_text": "We continue to see growth in \nthat business. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c70fbf6f5051ce27733916749a7319ff4226fa528aec42ed218b7fefb39f7978", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1860fd08-e980-41a9-ad08-2a9f7c33c68f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nbusiness.  Our 3PL business, as we talked about in the past, is slightly more than half of the revenue.  And as I \nmentioned in my comments, the 3PL performance was lower than the prior year for various customer and contract \nconsiderations.  \n \n We're certainly pleased wit h what we're seeing in our prior authorization business.  We continue to see growth in \nthat business.  We continue to see growth in our fiscal fourth quarter as well.  We did make a number of \ninvestments, as I talked about, and we also made some investments f or future years to continue our growth and \ncontinue the value that we're providing to our customers.  \n \n", "original_text": "We're certainly pleased wit h what we're seeing in our prior authorization business. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e691c78ad3735e2d8bf23dd158336f71f8d91344c38116a19b257cf4219f1bc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5e58d7b-d435-4093-9e03-262157e76e7c", "node_type": "1", "metadata": {"window": "And as I \nmentioned in my comments, the 3PL performance was lower than the prior year for various customer and contract \nconsiderations.  \n \n We're certainly pleased wit h what we're seeing in our prior authorization business.  We continue to see growth in \nthat business.  We continue to see growth in our fiscal fourth quarter as well.  We did make a number of \ninvestments, as I talked about, and we also made some investments f or future years to continue our growth and \ncontinue the value that we're providing to our customers.  \n \n So underlying all of that, we had a very strong year.  The business grew on the bottom line 23% year over year, so \nthere's great momentum there. ", "original_text": "We continue to see growth in our fiscal fourth quarter as well. "}, "hash": "55f93142fb776f836a0539b1f6cd761b1e172e25de039cf4cd324d27ef22f26b", "class_name": "RelatedNodeInfo"}}, "text": "We continue to see growth in \nthat business. ", "start_char_idx": 510, "end_char_idx": 555, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5e58d7b-d435-4093-9e03-262157e76e7c": {"__data__": {"id_": "d5e58d7b-d435-4093-9e03-262157e76e7c", "embedding": null, "metadata": {"window": "And as I \nmentioned in my comments, the 3PL performance was lower than the prior year for various customer and contract \nconsiderations.  \n \n We're certainly pleased wit h what we're seeing in our prior authorization business.  We continue to see growth in \nthat business.  We continue to see growth in our fiscal fourth quarter as well.  We did make a number of \ninvestments, as I talked about, and we also made some investments f or future years to continue our growth and \ncontinue the value that we're providing to our customers.  \n \n So underlying all of that, we had a very strong year.  The business grew on the bottom line 23% year over year, so \nthere's great momentum there. ", "original_text": "We continue to see growth in our fiscal fourth quarter as well. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c70fbf6f5051ce27733916749a7319ff4226fa528aec42ed218b7fefb39f7978", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54d581e7-e554-45c1-9c7c-998716e4ae5e", "node_type": "1", "metadata": {"window": "Our 3PL business, as we talked about in the past, is slightly more than half of the revenue.  And as I \nmentioned in my comments, the 3PL performance was lower than the prior year for various customer and contract \nconsiderations.  \n \n We're certainly pleased wit h what we're seeing in our prior authorization business.  We continue to see growth in \nthat business.  We continue to see growth in our fiscal fourth quarter as well.  We did make a number of \ninvestments, as I talked about, and we also made some investments f or future years to continue our growth and \ncontinue the value that we're providing to our customers.  \n \n So underlying all of that, we had a very strong year. ", "original_text": "We continue to see growth in \nthat business. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "838eff89411c6448a8ea5cc67c6425f74edea29d50e2dcc48c35b4ba8e678bea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2561468-4c4b-4a8b-b781-ebd35c734bb5", "node_type": "1", "metadata": {"window": "We're certainly pleased wit h what we're seeing in our prior authorization business.  We continue to see growth in \nthat business.  We continue to see growth in our fiscal fourth quarter as well.  We did make a number of \ninvestments, as I talked about, and we also made some investments f or future years to continue our growth and \ncontinue the value that we're providing to our customers.  \n \n So underlying all of that, we had a very strong year.  The business grew on the bottom line 23% year over year, so \nthere's great momentum there.  Prior auth orization business as part of our access solutions did have growth in the \nfirst quarter. ", "original_text": "We did make a number of \ninvestments, as I talked about, and we also made some investments f or future years to continue our growth and \ncontinue the value that we're providing to our customers.  \n \n"}, "hash": "d7628ae6655223f8b71602f096bdc8d88d901247d6e3d819f534a98c16eefbf7", "class_name": "RelatedNodeInfo"}}, "text": "We continue to see growth in our fiscal fourth quarter as well. ", "start_char_idx": 555, "end_char_idx": 619, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2561468-4c4b-4a8b-b781-ebd35c734bb5": {"__data__": {"id_": "e2561468-4c4b-4a8b-b781-ebd35c734bb5", "embedding": null, "metadata": {"window": "We're certainly pleased wit h what we're seeing in our prior authorization business.  We continue to see growth in \nthat business.  We continue to see growth in our fiscal fourth quarter as well.  We did make a number of \ninvestments, as I talked about, and we also made some investments f or future years to continue our growth and \ncontinue the value that we're providing to our customers.  \n \n So underlying all of that, we had a very strong year.  The business grew on the bottom line 23% year over year, so \nthere's great momentum there.  Prior auth orization business as part of our access solutions did have growth in the \nfirst quarter. ", "original_text": "We did make a number of \ninvestments, as I talked about, and we also made some investments f or future years to continue our growth and \ncontinue the value that we're providing to our customers.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c70fbf6f5051ce27733916749a7319ff4226fa528aec42ed218b7fefb39f7978", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5e58d7b-d435-4093-9e03-262157e76e7c", "node_type": "1", "metadata": {"window": "And as I \nmentioned in my comments, the 3PL performance was lower than the prior year for various customer and contract \nconsiderations.  \n \n We're certainly pleased wit h what we're seeing in our prior authorization business.  We continue to see growth in \nthat business.  We continue to see growth in our fiscal fourth quarter as well.  We did make a number of \ninvestments, as I talked about, and we also made some investments f or future years to continue our growth and \ncontinue the value that we're providing to our customers.  \n \n So underlying all of that, we had a very strong year.  The business grew on the bottom line 23% year over year, so \nthere's great momentum there. ", "original_text": "We continue to see growth in our fiscal fourth quarter as well. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "6a0c88d2c527b7b50e71827ea774a4639d61f1491a404fc9307d6480ed071864", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61c0cb39-4565-4341-aecf-e34694726350", "node_type": "1", "metadata": {"window": "We continue to see growth in \nthat business.  We continue to see growth in our fiscal fourth quarter as well.  We did make a number of \ninvestments, as I talked about, and we also made some investments f or future years to continue our growth and \ncontinue the value that we're providing to our customers.  \n \n So underlying all of that, we had a very strong year.  The business grew on the bottom line 23% year over year, so \nthere's great momentum there.  Prior auth orization business as part of our access solutions did have growth in the \nfirst quarter.  But as I mentioned, we had slower 3PL performance and we continue to make some investments \ninto the business for future growth.  \n ", "original_text": "So underlying all of that, we had a very strong year. "}, "hash": "3e968a8d8e310db5564f713a07d8f89436326de9e11c4ea2628b8c36e986d6d5", "class_name": "RelatedNodeInfo"}}, "text": "We did make a number of \ninvestments, as I talked about, and we also made some investments f or future years to continue our growth and \ncontinue the value that we're providing to our customers.  \n \n", "start_char_idx": 619, "end_char_idx": 818, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61c0cb39-4565-4341-aecf-e34694726350": {"__data__": {"id_": "61c0cb39-4565-4341-aecf-e34694726350", "embedding": null, "metadata": {"window": "We continue to see growth in \nthat business.  We continue to see growth in our fiscal fourth quarter as well.  We did make a number of \ninvestments, as I talked about, and we also made some investments f or future years to continue our growth and \ncontinue the value that we're providing to our customers.  \n \n So underlying all of that, we had a very strong year.  The business grew on the bottom line 23% year over year, so \nthere's great momentum there.  Prior auth orization business as part of our access solutions did have growth in the \nfirst quarter.  But as I mentioned, we had slower 3PL performance and we continue to make some investments \ninto the business for future growth.  \n ", "original_text": "So underlying all of that, we had a very strong year. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c70fbf6f5051ce27733916749a7319ff4226fa528aec42ed218b7fefb39f7978", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2561468-4c4b-4a8b-b781-ebd35c734bb5", "node_type": "1", "metadata": {"window": "We're certainly pleased wit h what we're seeing in our prior authorization business.  We continue to see growth in \nthat business.  We continue to see growth in our fiscal fourth quarter as well.  We did make a number of \ninvestments, as I talked about, and we also made some investments f or future years to continue our growth and \ncontinue the value that we're providing to our customers.  \n \n So underlying all of that, we had a very strong year.  The business grew on the bottom line 23% year over year, so \nthere's great momentum there.  Prior auth orization business as part of our access solutions did have growth in the \nfirst quarter. ", "original_text": "We did make a number of \ninvestments, as I talked about, and we also made some investments f or future years to continue our growth and \ncontinue the value that we're providing to our customers.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5ef40ee5bc660de6c7bd9794de48ae6334fed30172d2c0808967bbc2f3bcd39d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29508c18-fc28-424a-b39b-286f8e483938", "node_type": "1", "metadata": {"window": "We continue to see growth in our fiscal fourth quarter as well.  We did make a number of \ninvestments, as I talked about, and we also made some investments f or future years to continue our growth and \ncontinue the value that we're providing to our customers.  \n \n So underlying all of that, we had a very strong year.  The business grew on the bottom line 23% year over year, so \nthere's great momentum there.  Prior auth orization business as part of our access solutions did have growth in the \nfirst quarter.  But as I mentioned, we had slower 3PL performance and we continue to make some investments \ninto the business for future growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Off icer & Director, McKesson Corp.  ", "original_text": "The business grew on the bottom line 23% year over year, so \nthere's great momentum there. "}, "hash": "5ab946f2ecf64858f028ccea75cd4fbbf14a5c6c19d4c14b9d7f8ab5ab30643a", "class_name": "RelatedNodeInfo"}}, "text": "So underlying all of that, we had a very strong year. ", "start_char_idx": 818, "end_char_idx": 872, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29508c18-fc28-424a-b39b-286f8e483938": {"__data__": {"id_": "29508c18-fc28-424a-b39b-286f8e483938", "embedding": null, "metadata": {"window": "We continue to see growth in our fiscal fourth quarter as well.  We did make a number of \ninvestments, as I talked about, and we also made some investments f or future years to continue our growth and \ncontinue the value that we're providing to our customers.  \n \n So underlying all of that, we had a very strong year.  The business grew on the bottom line 23% year over year, so \nthere's great momentum there.  Prior auth orization business as part of our access solutions did have growth in the \nfirst quarter.  But as I mentioned, we had slower 3PL performance and we continue to make some investments \ninto the business for future growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Off icer & Director, McKesson Corp.  ", "original_text": "The business grew on the bottom line 23% year over year, so \nthere's great momentum there. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c70fbf6f5051ce27733916749a7319ff4226fa528aec42ed218b7fefb39f7978", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61c0cb39-4565-4341-aecf-e34694726350", "node_type": "1", "metadata": {"window": "We continue to see growth in \nthat business.  We continue to see growth in our fiscal fourth quarter as well.  We did make a number of \ninvestments, as I talked about, and we also made some investments f or future years to continue our growth and \ncontinue the value that we're providing to our customers.  \n \n So underlying all of that, we had a very strong year.  The business grew on the bottom line 23% year over year, so \nthere's great momentum there.  Prior auth orization business as part of our access solutions did have growth in the \nfirst quarter.  But as I mentioned, we had slower 3PL performance and we continue to make some investments \ninto the business for future growth.  \n ", "original_text": "So underlying all of that, we had a very strong year. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3d6a606e8b612c4723982e95b3f2722eb517c0291f42e04268b7d2607ab2c1b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b75cd9f5-b2f1-45aa-8232-a7f62f357ba9", "node_type": "1", "metadata": {"window": "We did make a number of \ninvestments, as I talked about, and we also made some investments f or future years to continue our growth and \ncontinue the value that we're providing to our customers.  \n \n So underlying all of that, we had a very strong year.  The business grew on the bottom line 23% year over year, so \nthere's great momentum there.  Prior auth orization business as part of our access solutions did have growth in the \nfirst quarter.  But as I mentioned, we had slower 3PL performance and we continue to make some investments \ninto the business for future growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Off icer & Director, McKesson Corp.   A \nAs it relates to payer and frankly employer behavior as it relates to the coverage of these drugs, I think you've got \nto probably bifurcate it into diabetes, which is a more mature indication, weight loss, which is kind o f emerging \ntracking follow -on conditions that it may or may not be applicable to. ", "original_text": "Prior auth orization business as part of our access solutions did have growth in the \nfirst quarter. "}, "hash": "1927063f2eed32c92a65dd7c0ef917f71ded5705fb39e7522b6020ed908882fd", "class_name": "RelatedNodeInfo"}}, "text": "The business grew on the bottom line 23% year over year, so \nthere's great momentum there. ", "start_char_idx": 872, "end_char_idx": 963, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b75cd9f5-b2f1-45aa-8232-a7f62f357ba9": {"__data__": {"id_": "b75cd9f5-b2f1-45aa-8232-a7f62f357ba9", "embedding": null, "metadata": {"window": "We did make a number of \ninvestments, as I talked about, and we also made some investments f or future years to continue our growth and \ncontinue the value that we're providing to our customers.  \n \n So underlying all of that, we had a very strong year.  The business grew on the bottom line 23% year over year, so \nthere's great momentum there.  Prior auth orization business as part of our access solutions did have growth in the \nfirst quarter.  But as I mentioned, we had slower 3PL performance and we continue to make some investments \ninto the business for future growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Off icer & Director, McKesson Corp.   A \nAs it relates to payer and frankly employer behavior as it relates to the coverage of these drugs, I think you've got \nto probably bifurcate it into diabetes, which is a more mature indication, weight loss, which is kind o f emerging \ntracking follow -on conditions that it may or may not be applicable to. ", "original_text": "Prior auth orization business as part of our access solutions did have growth in the \nfirst quarter. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c70fbf6f5051ce27733916749a7319ff4226fa528aec42ed218b7fefb39f7978", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29508c18-fc28-424a-b39b-286f8e483938", "node_type": "1", "metadata": {"window": "We continue to see growth in our fiscal fourth quarter as well.  We did make a number of \ninvestments, as I talked about, and we also made some investments f or future years to continue our growth and \ncontinue the value that we're providing to our customers.  \n \n So underlying all of that, we had a very strong year.  The business grew on the bottom line 23% year over year, so \nthere's great momentum there.  Prior auth orization business as part of our access solutions did have growth in the \nfirst quarter.  But as I mentioned, we had slower 3PL performance and we continue to make some investments \ninto the business for future growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Off icer & Director, McKesson Corp.  ", "original_text": "The business grew on the bottom line 23% year over year, so \nthere's great momentum there. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "257aae61361e99386d77c7fec427ec7968c026ea3c78591ca687f112aba5a0fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fae67ec7-0924-4510-91c5-f4108fc2e5b3", "node_type": "1", "metadata": {"window": "So underlying all of that, we had a very strong year.  The business grew on the bottom line 23% year over year, so \nthere's great momentum there.  Prior auth orization business as part of our access solutions did have growth in the \nfirst quarter.  But as I mentioned, we had slower 3PL performance and we continue to make some investments \ninto the business for future growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Off icer & Director, McKesson Corp.   A \nAs it relates to payer and frankly employer behavior as it relates to the coverage of these drugs, I think you've got \nto probably bifurcate it into diabetes, which is a more mature indication, weight loss, which is kind o f emerging \ntracking follow -on conditions that it may or may not be applicable to.  So I think it's in the early days of employers \nand payers figuring out how to handle this, and across that spectrum, it can be quite different.  \n ", "original_text": "But as I mentioned, we had slower 3PL performance and we continue to make some investments \ninto the business for future growth.  \n "}, "hash": "6b577a46f3ba6494d714e367d85805459f2ee8c1407b01a9ddca301918e3b1be", "class_name": "RelatedNodeInfo"}}, "text": "Prior auth orization business as part of our access solutions did have growth in the \nfirst quarter. ", "start_char_idx": 963, "end_char_idx": 1064, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fae67ec7-0924-4510-91c5-f4108fc2e5b3": {"__data__": {"id_": "fae67ec7-0924-4510-91c5-f4108fc2e5b3", "embedding": null, "metadata": {"window": "So underlying all of that, we had a very strong year.  The business grew on the bottom line 23% year over year, so \nthere's great momentum there.  Prior auth orization business as part of our access solutions did have growth in the \nfirst quarter.  But as I mentioned, we had slower 3PL performance and we continue to make some investments \ninto the business for future growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Off icer & Director, McKesson Corp.   A \nAs it relates to payer and frankly employer behavior as it relates to the coverage of these drugs, I think you've got \nto probably bifurcate it into diabetes, which is a more mature indication, weight loss, which is kind o f emerging \ntracking follow -on conditions that it may or may not be applicable to.  So I think it's in the early days of employers \nand payers figuring out how to handle this, and across that spectrum, it can be quite different.  \n ", "original_text": "But as I mentioned, we had slower 3PL performance and we continue to make some investments \ninto the business for future growth.  \n ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c70fbf6f5051ce27733916749a7319ff4226fa528aec42ed218b7fefb39f7978", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b75cd9f5-b2f1-45aa-8232-a7f62f357ba9", "node_type": "1", "metadata": {"window": "We did make a number of \ninvestments, as I talked about, and we also made some investments f or future years to continue our growth and \ncontinue the value that we're providing to our customers.  \n \n So underlying all of that, we had a very strong year.  The business grew on the bottom line 23% year over year, so \nthere's great momentum there.  Prior auth orization business as part of our access solutions did have growth in the \nfirst quarter.  But as I mentioned, we had slower 3PL performance and we continue to make some investments \ninto the business for future growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Off icer & Director, McKesson Corp.   A \nAs it relates to payer and frankly employer behavior as it relates to the coverage of these drugs, I think you've got \nto probably bifurcate it into diabetes, which is a more mature indication, weight loss, which is kind o f emerging \ntracking follow -on conditions that it may or may not be applicable to. ", "original_text": "Prior auth orization business as part of our access solutions did have growth in the \nfirst quarter. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "1bb428d100120c46f19e523f391254b3b4a635763464e18297072eb5fdae3dad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34e978c5-8b27-4d0d-ad5a-dcb2e7922a61", "node_type": "1", "metadata": {"window": "The business grew on the bottom line 23% year over year, so \nthere's great momentum there.  Prior auth orization business as part of our access solutions did have growth in the \nfirst quarter.  But as I mentioned, we had slower 3PL performance and we continue to make some investments \ninto the business for future growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Off icer & Director, McKesson Corp.   A \nAs it relates to payer and frankly employer behavior as it relates to the coverage of these drugs, I think you've got \nto probably bifurcate it into diabetes, which is a more mature indication, weight loss, which is kind o f emerging \ntracking follow -on conditions that it may or may not be applicable to.  So I think it's in the early days of employers \nand payers figuring out how to handle this, and across that spectrum, it can be quite different.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presid ent of Investor Relations, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Off icer & Director, McKesson Corp.  "}, "hash": "a83e0b09ff8cfd736facb642efd0dc72f6df10d473d69245e50c51c3d68997cb", "class_name": "RelatedNodeInfo"}}, "text": "But as I mentioned, we had slower 3PL performance and we continue to make some investments \ninto the business for future growth.  \n ", "start_char_idx": 1064, "end_char_idx": 1196, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34e978c5-8b27-4d0d-ad5a-dcb2e7922a61": {"__data__": {"id_": "34e978c5-8b27-4d0d-ad5a-dcb2e7922a61", "embedding": null, "metadata": {"window": "The business grew on the bottom line 23% year over year, so \nthere's great momentum there.  Prior auth orization business as part of our access solutions did have growth in the \nfirst quarter.  But as I mentioned, we had slower 3PL performance and we continue to make some investments \ninto the business for future growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Off icer & Director, McKesson Corp.   A \nAs it relates to payer and frankly employer behavior as it relates to the coverage of these drugs, I think you've got \nto probably bifurcate it into diabetes, which is a more mature indication, weight loss, which is kind o f emerging \ntracking follow -on conditions that it may or may not be applicable to.  So I think it's in the early days of employers \nand payers figuring out how to handle this, and across that spectrum, it can be quite different.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presid ent of Investor Relations, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Off icer & Director, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c70fbf6f5051ce27733916749a7319ff4226fa528aec42ed218b7fefb39f7978", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fae67ec7-0924-4510-91c5-f4108fc2e5b3", "node_type": "1", "metadata": {"window": "So underlying all of that, we had a very strong year.  The business grew on the bottom line 23% year over year, so \nthere's great momentum there.  Prior auth orization business as part of our access solutions did have growth in the \nfirst quarter.  But as I mentioned, we had slower 3PL performance and we continue to make some investments \ninto the business for future growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Off icer & Director, McKesson Corp.   A \nAs it relates to payer and frankly employer behavior as it relates to the coverage of these drugs, I think you've got \nto probably bifurcate it into diabetes, which is a more mature indication, weight loss, which is kind o f emerging \ntracking follow -on conditions that it may or may not be applicable to.  So I think it's in the early days of employers \nand payers figuring out how to handle this, and across that spectrum, it can be quite different.  \n ", "original_text": "But as I mentioned, we had slower 3PL performance and we continue to make some investments \ninto the business for future growth.  \n ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "932be1e0e17149cabfab2fe5db350f09cf7f74e6d8d47a6b6ffecdb7a9b13764", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a686d9e4-a369-4c7d-96ea-9f7e71c492e1", "node_type": "1", "metadata": {"window": "Prior auth orization business as part of our access solutions did have growth in the \nfirst quarter.  But as I mentioned, we had slower 3PL performance and we continue to make some investments \ninto the business for future growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Off icer & Director, McKesson Corp.   A \nAs it relates to payer and frankly employer behavior as it relates to the coverage of these drugs, I think you've got \nto probably bifurcate it into diabetes, which is a more mature indication, weight loss, which is kind o f emerging \ntracking follow -on conditions that it may or may not be applicable to.  So I think it's in the early days of employers \nand payers figuring out how to handle this, and across that spectrum, it can be quite different.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presid ent of Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "A \nAs it relates to payer and frankly employer behavior as it relates to the coverage of these drugs, I think you've got \nto probably bifurcate it into diabetes, which is a more mature indication, weight loss, which is kind o f emerging \ntracking follow -on conditions that it may or may not be applicable to. "}, "hash": "e7bb0e342a17ee77aa1dcc12e27f0783ead5b1bfb1523d8c834122e3c44f4896", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Off icer & Director, McKesson Corp.  ", "start_char_idx": 1196, "end_char_idx": 1541, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a686d9e4-a369-4c7d-96ea-9f7e71c492e1": {"__data__": {"id_": "a686d9e4-a369-4c7d-96ea-9f7e71c492e1", "embedding": null, "metadata": {"window": "Prior auth orization business as part of our access solutions did have growth in the \nfirst quarter.  But as I mentioned, we had slower 3PL performance and we continue to make some investments \ninto the business for future growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Off icer & Director, McKesson Corp.   A \nAs it relates to payer and frankly employer behavior as it relates to the coverage of these drugs, I think you've got \nto probably bifurcate it into diabetes, which is a more mature indication, weight loss, which is kind o f emerging \ntracking follow -on conditions that it may or may not be applicable to.  So I think it's in the early days of employers \nand payers figuring out how to handle this, and across that spectrum, it can be quite different.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presid ent of Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "A \nAs it relates to payer and frankly employer behavior as it relates to the coverage of these drugs, I think you've got \nto probably bifurcate it into diabetes, which is a more mature indication, weight loss, which is kind o f emerging \ntracking follow -on conditions that it may or may not be applicable to. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c70fbf6f5051ce27733916749a7319ff4226fa528aec42ed218b7fefb39f7978", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34e978c5-8b27-4d0d-ad5a-dcb2e7922a61", "node_type": "1", "metadata": {"window": "The business grew on the bottom line 23% year over year, so \nthere's great momentum there.  Prior auth orization business as part of our access solutions did have growth in the \nfirst quarter.  But as I mentioned, we had slower 3PL performance and we continue to make some investments \ninto the business for future growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Off icer & Director, McKesson Corp.   A \nAs it relates to payer and frankly employer behavior as it relates to the coverage of these drugs, I think you've got \nto probably bifurcate it into diabetes, which is a more mature indication, weight loss, which is kind o f emerging \ntracking follow -on conditions that it may or may not be applicable to.  So I think it's in the early days of employers \nand payers figuring out how to handle this, and across that spectrum, it can be quite different.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presid ent of Investor Relations, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Off icer & Director, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "861d77c8d19d8f3cc313714c74ef5ef49cc24e19b6f56aa887bd6b6ce0b1f75d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5bbd12d1-7e6b-400f-a3d0-17b3214e7699", "node_type": "1", "metadata": {"window": "But as I mentioned, we had slower 3PL performance and we continue to make some investments \ninto the business for future growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Off icer & Director, McKesson Corp.   A \nAs it relates to payer and frankly employer behavior as it relates to the coverage of these drugs, I think you've got \nto probably bifurcate it into diabetes, which is a more mature indication, weight loss, which is kind o f emerging \ntracking follow -on conditions that it may or may not be applicable to.  So I think it's in the early days of employers \nand payers figuring out how to handle this, and across that spectrum, it can be quite different.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presid ent of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan. ", "original_text": "So I think it's in the early days of employers \nand payers figuring out how to handle this, and across that spectrum, it can be quite different.  \n "}, "hash": "ebdf8c86ee423ca17e29bcb84d8e2b28293d7022c36fcab0fd17924129ef6ba1", "class_name": "RelatedNodeInfo"}}, "text": "A \nAs it relates to payer and frankly employer behavior as it relates to the coverage of these drugs, I think you've got \nto probably bifurcate it into diabetes, which is a more mature indication, weight loss, which is kind o f emerging \ntracking follow -on conditions that it may or may not be applicable to. ", "start_char_idx": 1541, "end_char_idx": 1851, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5bbd12d1-7e6b-400f-a3d0-17b3214e7699": {"__data__": {"id_": "5bbd12d1-7e6b-400f-a3d0-17b3214e7699", "embedding": null, "metadata": {"window": "But as I mentioned, we had slower 3PL performance and we continue to make some investments \ninto the business for future growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Off icer & Director, McKesson Corp.   A \nAs it relates to payer and frankly employer behavior as it relates to the coverage of these drugs, I think you've got \nto probably bifurcate it into diabetes, which is a more mature indication, weight loss, which is kind o f emerging \ntracking follow -on conditions that it may or may not be applicable to.  So I think it's in the early days of employers \nand payers figuring out how to handle this, and across that spectrum, it can be quite different.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presid ent of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan. ", "original_text": "So I think it's in the early days of employers \nand payers figuring out how to handle this, and across that spectrum, it can be quite different.  \n ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c70fbf6f5051ce27733916749a7319ff4226fa528aec42ed218b7fefb39f7978", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a686d9e4-a369-4c7d-96ea-9f7e71c492e1", "node_type": "1", "metadata": {"window": "Prior auth orization business as part of our access solutions did have growth in the \nfirst quarter.  But as I mentioned, we had slower 3PL performance and we continue to make some investments \ninto the business for future growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Off icer & Director, McKesson Corp.   A \nAs it relates to payer and frankly employer behavior as it relates to the coverage of these drugs, I think you've got \nto probably bifurcate it into diabetes, which is a more mature indication, weight loss, which is kind o f emerging \ntracking follow -on conditions that it may or may not be applicable to.  So I think it's in the early days of employers \nand payers figuring out how to handle this, and across that spectrum, it can be quite different.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presid ent of Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "A \nAs it relates to payer and frankly employer behavior as it relates to the coverage of these drugs, I think you've got \nto probably bifurcate it into diabetes, which is a more mature indication, weight loss, which is kind o f emerging \ntracking follow -on conditions that it may or may not be applicable to. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "25b847f04000a6cecb10f4897aa08bd1383ab7ec131f4c06bb85e82891c88761", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db3731f1-fd57-4720-81b8-e405cdfbf6d4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Off icer & Director, McKesson Corp.   A \nAs it relates to payer and frankly employer behavior as it relates to the coverage of these drugs, I think you've got \nto probably bifurcate it into diabetes, which is a more mature indication, weight loss, which is kind o f emerging \ntracking follow -on conditions that it may or may not be applicable to.  So I think it's in the early days of employers \nand payers figuring out how to handle this, and across that spectrum, it can be quite different.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presid ent of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presid ent of Investor Relations, McKesson Corp.  "}, "hash": "6ffd18e5c00ddcf0191385a8fc10f3043f3247f58ecf06839c4e0e32b71a5b4e", "class_name": "RelatedNodeInfo"}}, "text": "So I think it's in the early days of employers \nand payers figuring out how to handle this, and across that spectrum, it can be quite different.  \n ", "start_char_idx": 1851, "end_char_idx": 1999, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db3731f1-fd57-4720-81b8-e405cdfbf6d4": {"__data__": {"id_": "db3731f1-fd57-4720-81b8-e405cdfbf6d4", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Off icer & Director, McKesson Corp.   A \nAs it relates to payer and frankly employer behavior as it relates to the coverage of these drugs, I think you've got \nto probably bifurcate it into diabetes, which is a more mature indication, weight loss, which is kind o f emerging \ntracking follow -on conditions that it may or may not be applicable to.  So I think it's in the early days of employers \nand payers figuring out how to handle this, and across that spectrum, it can be quite different.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presid ent of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presid ent of Investor Relations, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c70fbf6f5051ce27733916749a7319ff4226fa528aec42ed218b7fefb39f7978", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5bbd12d1-7e6b-400f-a3d0-17b3214e7699", "node_type": "1", "metadata": {"window": "But as I mentioned, we had slower 3PL performance and we continue to make some investments \ninto the business for future growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Off icer & Director, McKesson Corp.   A \nAs it relates to payer and frankly employer behavior as it relates to the coverage of these drugs, I think you've got \nto probably bifurcate it into diabetes, which is a more mature indication, weight loss, which is kind o f emerging \ntracking follow -on conditions that it may or may not be applicable to.  So I think it's in the early days of employers \nand payers figuring out how to handle this, and across that spectrum, it can be quite different.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presid ent of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan. ", "original_text": "So I think it's in the early days of employers \nand payers figuring out how to handle this, and across that spectrum, it can be quite different.  \n ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f9484eaca03fae2f78e2f87785efa5ae4e448d34a59ac28094bc06e65d23430a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5717f748-6c63-407d-8980-3e33fe971360", "node_type": "1", "metadata": {"window": "A \nAs it relates to payer and frankly employer behavior as it relates to the coverage of these drugs, I think you've got \nto probably bifurcate it into diabetes, which is a more mature indication, weight loss, which is kind o f emerging \ntracking follow -on conditions that it may or may not be applicable to.  So I think it's in the early days of employers \nand payers figuring out how to handle this, and across that spectrum, it can be quite different.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presid ent of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "original_text": "A \nNext question, please.  \n "}, "hash": "8de556f2c0bfb29773c87e8a7d2584a893100f4f9441c129306de037e071c527", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presid ent of Investor Relations, McKesson Corp.  ", "start_char_idx": 1999, "end_char_idx": 2345, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5717f748-6c63-407d-8980-3e33fe971360": {"__data__": {"id_": "5717f748-6c63-407d-8980-3e33fe971360", "embedding": null, "metadata": {"window": "A \nAs it relates to payer and frankly employer behavior as it relates to the coverage of these drugs, I think you've got \nto probably bifurcate it into diabetes, which is a more mature indication, weight loss, which is kind o f emerging \ntracking follow -on conditions that it may or may not be applicable to.  So I think it's in the early days of employers \nand payers figuring out how to handle this, and across that spectrum, it can be quite different.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presid ent of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "original_text": "A \nNext question, please.  \n ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c70fbf6f5051ce27733916749a7319ff4226fa528aec42ed218b7fefb39f7978", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db3731f1-fd57-4720-81b8-e405cdfbf6d4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Off icer & Director, McKesson Corp.   A \nAs it relates to payer and frankly employer behavior as it relates to the coverage of these drugs, I think you've got \nto probably bifurcate it into diabetes, which is a more mature indication, weight loss, which is kind o f emerging \ntracking follow -on conditions that it may or may not be applicable to.  So I think it's in the early days of employers \nand payers figuring out how to handle this, and across that spectrum, it can be quite different.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presid ent of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presid ent of Investor Relations, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "fcf67770f675ac25a697c420f5830b9e785527bceb7c627b75bbdeccb798d44b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7fc313df-3e32-45af-98a2-776583b1ad4d", "node_type": "1", "metadata": {"window": "So I think it's in the early days of employers \nand payers figuring out how to handle this, and across that spectrum, it can be quite different.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presid ent of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  I just want to go back to the Pharmaceutical operating profit for 2025. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan. "}, "hash": "591feb4900bc4fb55eaf03ee20cdad13c20b579c8e8766d6472966b68936a276", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please.  \n ", "start_char_idx": 2345, "end_char_idx": 2374, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7fc313df-3e32-45af-98a2-776583b1ad4d": {"__data__": {"id_": "7fc313df-3e32-45af-98a2-776583b1ad4d", "embedding": null, "metadata": {"window": "So I think it's in the early days of employers \nand payers figuring out how to handle this, and across that spectrum, it can be quite different.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presid ent of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  I just want to go back to the Pharmaceutical operating profit for 2025. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c70fbf6f5051ce27733916749a7319ff4226fa528aec42ed218b7fefb39f7978", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5717f748-6c63-407d-8980-3e33fe971360", "node_type": "1", "metadata": {"window": "A \nAs it relates to payer and frankly employer behavior as it relates to the coverage of these drugs, I think you've got \nto probably bifurcate it into diabetes, which is a more mature indication, weight loss, which is kind o f emerging \ntracking follow -on conditions that it may or may not be applicable to.  So I think it's in the early days of employers \nand payers figuring out how to handle this, and across that spectrum, it can be quite different.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presid ent of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "original_text": "A \nNext question, please.  \n ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ae894182294bccc86e0f370641dfd6bb50da99d066fc2ccb66af999dce61d9db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ad03831-a761-49ee-a46c-0d95853c64f8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presid ent of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  I just want to go back to the Pharmaceutical operating profit for 2025.  If I go back and I look at \nkind of your long term out, like you talked about 5% to 7% growth. ", "original_text": "Please go ahead.  \n "}, "hash": "15b38e7aa14abf8c21f335e37b9056a45ce8377396cfc9576ce046214ea5a61f", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan. ", "start_char_idx": 2374, "end_char_idx": 2701, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ad03831-a761-49ee-a46c-0d95853c64f8": {"__data__": {"id_": "1ad03831-a761-49ee-a46c-0d95853c64f8", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presid ent of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  I just want to go back to the Pharmaceutical operating profit for 2025.  If I go back and I look at \nkind of your long term out, like you talked about 5% to 7% growth. ", "original_text": "Please go ahead.  \n ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c70fbf6f5051ce27733916749a7319ff4226fa528aec42ed218b7fefb39f7978", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7fc313df-3e32-45af-98a2-776583b1ad4d", "node_type": "1", "metadata": {"window": "So I think it's in the early days of employers \nand payers figuring out how to handle this, and across that spectrum, it can be quite different.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presid ent of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  I just want to go back to the Pharmaceutical operating profit for 2025. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ffd446b58e7b6900f9eb44d9f99d020c26b4c14fa2cd8d3060603a970853c53e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb518ca1-279b-42ca-ac21-6b81e9449762", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  I just want to go back to the Pharmaceutical operating profit for 2025.  If I go back and I look at \nkind of your long term out, like you talked about 5% to 7% growth.  You're now talking about 8% to 10%. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. "}, "hash": "8c6ac2c8d1b50bdcb1bcd6c7002e26816d38d590d9ada3da79516889b9a459c2", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 2701, "end_char_idx": 2721, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb518ca1-279b-42ca-ac21-6b81e9449762": {"__data__": {"id_": "eb518ca1-279b-42ca-ac21-6b81e9449762", "embedding": null, "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  I just want to go back to the Pharmaceutical operating profit for 2025.  If I go back and I look at \nkind of your long term out, like you talked about 5% to 7% growth.  You're now talking about 8% to 10%. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c70fbf6f5051ce27733916749a7319ff4226fa528aec42ed218b7fefb39f7978", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ad03831-a761-49ee-a46c-0d95853c64f8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presid ent of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  I just want to go back to the Pharmaceutical operating profit for 2025.  If I go back and I look at \nkind of your long term out, like you talked about 5% to 7% growth. ", "original_text": "Please go ahead.  \n ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c33fdb2f227f9dcf73e5042dac8cf8bea00feba3a4ad8022366e282fbd904ba2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b16b8379-ef02-4fe5-b884-5c96b9499773", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  I just want to go back to the Pharmaceutical operating profit for 2025.  If I go back and I look at \nkind of your long term out, like you talked about 5% to 7% growth.  You're now talking about 8% to 10%.  One, I \nknow you don't want to talk about specific customers, but is this tied to the new customer w in, or is there \nsomething else that's propelling that?  \n \n", "original_text": "I just want to go back to the Pharmaceutical operating profit for 2025. "}, "hash": "092bd4821aeac2652bde29f69bce2fd89875e2ee7682ad9eb44f8fa5e933d081", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "start_char_idx": 2721, "end_char_idx": 3063, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b16b8379-ef02-4fe5-b884-5c96b9499773": {"__data__": {"id_": "b16b8379-ef02-4fe5-b884-5c96b9499773", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  I just want to go back to the Pharmaceutical operating profit for 2025.  If I go back and I look at \nkind of your long term out, like you talked about 5% to 7% growth.  You're now talking about 8% to 10%.  One, I \nknow you don't want to talk about specific customers, but is this tied to the new customer w in, or is there \nsomething else that's propelling that?  \n \n", "original_text": "I just want to go back to the Pharmaceutical operating profit for 2025. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c70fbf6f5051ce27733916749a7319ff4226fa528aec42ed218b7fefb39f7978", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb518ca1-279b-42ca-ac21-6b81e9449762", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  I just want to go back to the Pharmaceutical operating profit for 2025.  If I go back and I look at \nkind of your long term out, like you talked about 5% to 7% growth.  You're now talking about 8% to 10%. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c3ddbd3c7fa890fdb73db035817ee458d5b23794eb7df91a30f87e762543de19", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c49d8c7-cd6f-488a-b02e-800e41c6bbf0", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  I just want to go back to the Pharmaceutical operating profit for 2025.  If I go back and I look at \nkind of your long term out, like you talked about 5% to 7% growth.  You're now talking about 8% to 10%.  One, I \nknow you don't want to talk about specific customers, but is this tied to the new customer w in, or is there \nsomething else that's propelling that?  \n \n And then as I think about Optum, your comments were that you started a relationship last year. ", "original_text": "If I go back and I look at \nkind of your long term out, like you talked about 5% to 7% growth. "}, "hash": "98d7120ffc2b4a538e749b97d7b00459dbbac64839dd28fcb8601bd4cb0f1df4", "class_name": "RelatedNodeInfo"}}, "text": "I just want to go back to the Pharmaceutical operating profit for 2025. ", "start_char_idx": 3063, "end_char_idx": 3135, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c49d8c7-cd6f-488a-b02e-800e41c6bbf0": {"__data__": {"id_": "7c49d8c7-cd6f-488a-b02e-800e41c6bbf0", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  I just want to go back to the Pharmaceutical operating profit for 2025.  If I go back and I look at \nkind of your long term out, like you talked about 5% to 7% growth.  You're now talking about 8% to 10%.  One, I \nknow you don't want to talk about specific customers, but is this tied to the new customer w in, or is there \nsomething else that's propelling that?  \n \n And then as I think about Optum, your comments were that you started a relationship last year. ", "original_text": "If I go back and I look at \nkind of your long term out, like you talked about 5% to 7% growth. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c70fbf6f5051ce27733916749a7319ff4226fa528aec42ed218b7fefb39f7978", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b16b8379-ef02-4fe5-b884-5c96b9499773", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  I just want to go back to the Pharmaceutical operating profit for 2025.  If I go back and I look at \nkind of your long term out, like you talked about 5% to 7% growth.  You're now talking about 8% to 10%.  One, I \nknow you don't want to talk about specific customers, but is this tied to the new customer w in, or is there \nsomething else that's propelling that?  \n \n", "original_text": "I just want to go back to the Pharmaceutical operating profit for 2025. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f10132f9b6db8d33b3b47028ca6a93956786a285c102a42602aa9172df900b13", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c080594-1cfa-4397-a842-73e96476bd0c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  I just want to go back to the Pharmaceutical operating profit for 2025.  If I go back and I look at \nkind of your long term out, like you talked about 5% to 7% growth.  You're now talking about 8% to 10%.  One, I \nknow you don't want to talk about specific customers, but is this tied to the new customer w in, or is there \nsomething else that's propelling that?  \n \n And then as I think about Optum, your comments were that you started a relationship last year.  You've increased \nthe scope of services. ", "original_text": "You're now talking about 8% to 10%. "}, "hash": "ba3ca136a19b0cb38027a9fbe39bd493fe52ab7f2fc2c3e84a63547bd80fc652", "class_name": "RelatedNodeInfo"}}, "text": "If I go back and I look at \nkind of your long term out, like you talked about 5% to 7% growth. ", "start_char_idx": 3135, "end_char_idx": 3230, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c080594-1cfa-4397-a842-73e96476bd0c": {"__data__": {"id_": "8c080594-1cfa-4397-a842-73e96476bd0c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  I just want to go back to the Pharmaceutical operating profit for 2025.  If I go back and I look at \nkind of your long term out, like you talked about 5% to 7% growth.  You're now talking about 8% to 10%.  One, I \nknow you don't want to talk about specific customers, but is this tied to the new customer w in, or is there \nsomething else that's propelling that?  \n \n And then as I think about Optum, your comments were that you started a relationship last year.  You've increased \nthe scope of services. ", "original_text": "You're now talking about 8% to 10%. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c70fbf6f5051ce27733916749a7319ff4226fa528aec42ed218b7fefb39f7978", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c49d8c7-cd6f-488a-b02e-800e41c6bbf0", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  I just want to go back to the Pharmaceutical operating profit for 2025.  If I go back and I look at \nkind of your long term out, like you talked about 5% to 7% growth.  You're now talking about 8% to 10%.  One, I \nknow you don't want to talk about specific customers, but is this tied to the new customer w in, or is there \nsomething else that's propelling that?  \n \n And then as I think about Optum, your comments were that you started a relationship last year. ", "original_text": "If I go back and I look at \nkind of your long term out, like you talked about 5% to 7% growth. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ac35a804c1b3d3997828e60668cbda5595b90e5da37d531eebd3d52cec30cc28", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a64fa916-2585-411f-b2a3-7c28e0d9a24b", "node_type": "1", "metadata": {"window": "I just want to go back to the Pharmaceutical operating profit for 2025.  If I go back and I look at \nkind of your long term out, like you talked about 5% to 7% growth.  You're now talking about 8% to 10%.  One, I \nknow you don't want to talk about specific customers, but is this tied to the new customer w in, or is there \nsomething else that's propelling that?  \n \n And then as I think about Optum, your comments were that you started a relationship last year.  You've increased \nthe scope of services.  You're now doing sourcing, distribution, oncology. ", "original_text": "One, I \nknow you don't want to talk about specific customers, but is this tied to the new customer w in, or is there \nsomething else that's propelling that?  \n \n"}, "hash": "dd2b3423dd939be4733a2d8598d7ebcdda0fa9cbaad5c8d471596b2b05484faa", "class_name": "RelatedNodeInfo"}}, "text": "You're now talking about 8% to 10%. ", "start_char_idx": 3230, "end_char_idx": 3266, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a64fa916-2585-411f-b2a3-7c28e0d9a24b": {"__data__": {"id_": "a64fa916-2585-411f-b2a3-7c28e0d9a24b", "embedding": null, "metadata": {"window": "I just want to go back to the Pharmaceutical operating profit for 2025.  If I go back and I look at \nkind of your long term out, like you talked about 5% to 7% growth.  You're now talking about 8% to 10%.  One, I \nknow you don't want to talk about specific customers, but is this tied to the new customer w in, or is there \nsomething else that's propelling that?  \n \n And then as I think about Optum, your comments were that you started a relationship last year.  You've increased \nthe scope of services.  You're now doing sourcing, distribution, oncology. ", "original_text": "One, I \nknow you don't want to talk about specific customers, but is this tied to the new customer w in, or is there \nsomething else that's propelling that?  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c70fbf6f5051ce27733916749a7319ff4226fa528aec42ed218b7fefb39f7978", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c080594-1cfa-4397-a842-73e96476bd0c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  I just want to go back to the Pharmaceutical operating profit for 2025.  If I go back and I look at \nkind of your long term out, like you talked about 5% to 7% growth.  You're now talking about 8% to 10%.  One, I \nknow you don't want to talk about specific customers, but is this tied to the new customer w in, or is there \nsomething else that's propelling that?  \n \n And then as I think about Optum, your comments were that you started a relationship last year.  You've increased \nthe scope of services. ", "original_text": "You're now talking about 8% to 10%. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "b2a9d5f173103fd82b2b4656b53c7f681d664bb15aeaea7149b0a3b81ec3eecd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88b84626-4943-4a37-bbcc-072575c60934", "node_type": "1", "metadata": {"window": "If I go back and I look at \nkind of your long term out, like you talked about 5% to 7% growth.  You're now talking about 8% to 10%.  One, I \nknow you don't want to talk about specific customers, but is this tied to the new customer w in, or is there \nsomething else that's propelling that?  \n \n And then as I think about Optum, your comments were that you started a relationship last year.  You've increased \nthe scope of services.  You're now doing sourcing, distribution, oncology.  Can you maybe just help us understand, \none, in winning that business; and secondly, how we look at Optum versus maybe some of your other clients and \nany incremental opportunities you see with Optum going forward?  \n ", "original_text": "And then as I think about Optum, your comments were that you started a relationship last year. "}, "hash": "3f3f6fc49773a5f00a2b41f8cf34007e4e444ba066cbe8f39d17c3bd8b37dc9c", "class_name": "RelatedNodeInfo"}}, "text": "One, I \nknow you don't want to talk about specific customers, but is this tied to the new customer w in, or is there \nsomething else that's propelling that?  \n \n", "start_char_idx": 3266, "end_char_idx": 3427, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88b84626-4943-4a37-bbcc-072575c60934": {"__data__": {"id_": "88b84626-4943-4a37-bbcc-072575c60934", "embedding": null, "metadata": {"window": "If I go back and I look at \nkind of your long term out, like you talked about 5% to 7% growth.  You're now talking about 8% to 10%.  One, I \nknow you don't want to talk about specific customers, but is this tied to the new customer w in, or is there \nsomething else that's propelling that?  \n \n And then as I think about Optum, your comments were that you started a relationship last year.  You've increased \nthe scope of services.  You're now doing sourcing, distribution, oncology.  Can you maybe just help us understand, \none, in winning that business; and secondly, how we look at Optum versus maybe some of your other clients and \nany incremental opportunities you see with Optum going forward?  \n ", "original_text": "And then as I think about Optum, your comments were that you started a relationship last year. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c70fbf6f5051ce27733916749a7319ff4226fa528aec42ed218b7fefb39f7978", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a64fa916-2585-411f-b2a3-7c28e0d9a24b", "node_type": "1", "metadata": {"window": "I just want to go back to the Pharmaceutical operating profit for 2025.  If I go back and I look at \nkind of your long term out, like you talked about 5% to 7% growth.  You're now talking about 8% to 10%.  One, I \nknow you don't want to talk about specific customers, but is this tied to the new customer w in, or is there \nsomething else that's propelling that?  \n \n And then as I think about Optum, your comments were that you started a relationship last year.  You've increased \nthe scope of services.  You're now doing sourcing, distribution, oncology. ", "original_text": "One, I \nknow you don't want to talk about specific customers, but is this tied to the new customer w in, or is there \nsomething else that's propelling that?  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "9976cd29155ce7b92e8f8e0173a7e089cbda5635a08c142cb9e1e5710b2d32fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f82035a4-6c8b-4624-ac5b-6e8ec8f9db16", "node_type": "1", "metadata": {"window": "You're now talking about 8% to 10%.  One, I \nknow you don't want to talk about specific customers, but is this tied to the new customer w in, or is there \nsomething else that's propelling that?  \n \n And then as I think about Optum, your comments were that you started a relationship last year.  You've increased \nthe scope of services.  You're now doing sourcing, distribution, oncology.  Can you maybe just help us understand, \none, in winning that business; and secondly, how we look at Optum versus maybe some of your other clients and \nany incremental opportunities you see with Optum going forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.  ", "original_text": "You've increased \nthe scope of services. "}, "hash": "018c986b63b6afa35f9bc59e46328943554d6fb7c8103bc6c24ac13a350db32e", "class_name": "RelatedNodeInfo"}}, "text": "And then as I think about Optum, your comments were that you started a relationship last year. ", "start_char_idx": 3427, "end_char_idx": 3522, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f82035a4-6c8b-4624-ac5b-6e8ec8f9db16": {"__data__": {"id_": "f82035a4-6c8b-4624-ac5b-6e8ec8f9db16", "embedding": null, "metadata": {"window": "You're now talking about 8% to 10%.  One, I \nknow you don't want to talk about specific customers, but is this tied to the new customer w in, or is there \nsomething else that's propelling that?  \n \n And then as I think about Optum, your comments were that you started a relationship last year.  You've increased \nthe scope of services.  You're now doing sourcing, distribution, oncology.  Can you maybe just help us understand, \none, in winning that business; and secondly, how we look at Optum versus maybe some of your other clients and \nany incremental opportunities you see with Optum going forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.  ", "original_text": "You've increased \nthe scope of services. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c70fbf6f5051ce27733916749a7319ff4226fa528aec42ed218b7fefb39f7978", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88b84626-4943-4a37-bbcc-072575c60934", "node_type": "1", "metadata": {"window": "If I go back and I look at \nkind of your long term out, like you talked about 5% to 7% growth.  You're now talking about 8% to 10%.  One, I \nknow you don't want to talk about specific customers, but is this tied to the new customer w in, or is there \nsomething else that's propelling that?  \n \n And then as I think about Optum, your comments were that you started a relationship last year.  You've increased \nthe scope of services.  You're now doing sourcing, distribution, oncology.  Can you maybe just help us understand, \none, in winning that business; and secondly, how we look at Optum versus maybe some of your other clients and \nany incremental opportunities you see with Optum going forward?  \n ", "original_text": "And then as I think about Optum, your comments were that you started a relationship last year. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "b92a83481d2e550a231692f78b224c50f1f1015caa68da005978e8ec39daead2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce48bb2f-fe86-4525-94d4-7c210c572930", "node_type": "1", "metadata": {"window": "One, I \nknow you don't want to talk about specific customers, but is this tied to the new customer w in, or is there \nsomething else that's propelling that?  \n \n And then as I think about Optum, your comments were that you started a relationship last year.  You've increased \nthe scope of services.  You're now doing sourcing, distribution, oncology.  Can you maybe just help us understand, \none, in winning that business; and secondly, how we look at Optum versus maybe some of your other clients and \nany incremental opportunities you see with Optum going forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nThank you, Lisa. ", "original_text": "You're now doing sourcing, distribution, oncology. "}, "hash": "9adb98794c1c3a311f03d905085d7d1927e85874328798bc23c9f4780e47692b", "class_name": "RelatedNodeInfo"}}, "text": "You've increased \nthe scope of services. ", "start_char_idx": 3522, "end_char_idx": 3563, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce48bb2f-fe86-4525-94d4-7c210c572930": {"__data__": {"id_": "ce48bb2f-fe86-4525-94d4-7c210c572930", "embedding": null, "metadata": {"window": "One, I \nknow you don't want to talk about specific customers, but is this tied to the new customer w in, or is there \nsomething else that's propelling that?  \n \n And then as I think about Optum, your comments were that you started a relationship last year.  You've increased \nthe scope of services.  You're now doing sourcing, distribution, oncology.  Can you maybe just help us understand, \none, in winning that business; and secondly, how we look at Optum versus maybe some of your other clients and \nany incremental opportunities you see with Optum going forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nThank you, Lisa. ", "original_text": "You're now doing sourcing, distribution, oncology. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c70fbf6f5051ce27733916749a7319ff4226fa528aec42ed218b7fefb39f7978", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f82035a4-6c8b-4624-ac5b-6e8ec8f9db16", "node_type": "1", "metadata": {"window": "You're now talking about 8% to 10%.  One, I \nknow you don't want to talk about specific customers, but is this tied to the new customer w in, or is there \nsomething else that's propelling that?  \n \n And then as I think about Optum, your comments were that you started a relationship last year.  You've increased \nthe scope of services.  You're now doing sourcing, distribution, oncology.  Can you maybe just help us understand, \none, in winning that business; and secondly, how we look at Optum versus maybe some of your other clients and \nany incremental opportunities you see with Optum going forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.  ", "original_text": "You've increased \nthe scope of services. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f397b0dcd64a50379e7b6d70473df01f345701aa908db07c54eb0fae5ca71065", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9452c8e-12c9-49b7-90a6-8bae8bd37fee", "node_type": "1", "metadata": {"window": "And then as I think about Optum, your comments were that you started a relationship last year.  You've increased \nthe scope of services.  You're now doing sourcing, distribution, oncology.  Can you maybe just help us understand, \none, in winning that business; and secondly, how we look at Optum versus maybe some of your other clients and \nany incremental opportunities you see with Optum going forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nThank you, Lisa.  I appreciate the question. ", "original_text": "Can you maybe just help us understand, \none, in winning that business; and secondly, how we look at Optum versus maybe some of your other clients and \nany incremental opportunities you see with Optum going forward?  \n "}, "hash": "eb0ab95750723f455fda86783fd5c999ff2b949cda0264344ced79414c91ba17", "class_name": "RelatedNodeInfo"}}, "text": "You're now doing sourcing, distribution, oncology. ", "start_char_idx": 3563, "end_char_idx": 3614, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9452c8e-12c9-49b7-90a6-8bae8bd37fee": {"__data__": {"id_": "b9452c8e-12c9-49b7-90a6-8bae8bd37fee", "embedding": null, "metadata": {"window": "And then as I think about Optum, your comments were that you started a relationship last year.  You've increased \nthe scope of services.  You're now doing sourcing, distribution, oncology.  Can you maybe just help us understand, \none, in winning that business; and secondly, how we look at Optum versus maybe some of your other clients and \nany incremental opportunities you see with Optum going forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nThank you, Lisa.  I appreciate the question. ", "original_text": "Can you maybe just help us understand, \none, in winning that business; and secondly, how we look at Optum versus maybe some of your other clients and \nany incremental opportunities you see with Optum going forward?  \n ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c70fbf6f5051ce27733916749a7319ff4226fa528aec42ed218b7fefb39f7978", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce48bb2f-fe86-4525-94d4-7c210c572930", "node_type": "1", "metadata": {"window": "One, I \nknow you don't want to talk about specific customers, but is this tied to the new customer w in, or is there \nsomething else that's propelling that?  \n \n And then as I think about Optum, your comments were that you started a relationship last year.  You've increased \nthe scope of services.  You're now doing sourcing, distribution, oncology.  Can you maybe just help us understand, \none, in winning that business; and secondly, how we look at Optum versus maybe some of your other clients and \nany incremental opportunities you see with Optum going forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nThank you, Lisa. ", "original_text": "You're now doing sourcing, distribution, oncology. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5b7823ae17e43370bb18e012e42ebd27c40d85fc61473aef70ab073ae60225ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44f14888-86b2-45b9-9946-cd46ab275f6e", "node_type": "1", "metadata": {"window": "You've increased \nthe scope of services.  You're now doing sourcing, distribution, oncology.  Can you maybe just help us understand, \none, in winning that business; and secondly, how we look at Optum versus maybe some of your other clients and \nany incremental opportunities you see with Optum going forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nThank you, Lisa.  I appreciate the question.  Look, we're obviously really excited to get the privilege and the \nopportunity to expand our relationship with Optum. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.  "}, "hash": "fdfeca587db22784066c9a94fadd2759621f0b728ff1c1820a70790bb54755f4", "class_name": "RelatedNodeInfo"}}, "text": "Can you maybe just help us understand, \none, in winning that business; and secondly, how we look at Optum versus maybe some of your other clients and \nany incremental opportunities you see with Optum going forward?  \n ", "start_char_idx": 3614, "end_char_idx": 3832, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44f14888-86b2-45b9-9946-cd46ab275f6e": {"__data__": {"id_": "44f14888-86b2-45b9-9946-cd46ab275f6e", "embedding": null, "metadata": {"window": "You've increased \nthe scope of services.  You're now doing sourcing, distribution, oncology.  Can you maybe just help us understand, \none, in winning that business; and secondly, how we look at Optum versus maybe some of your other clients and \nany incremental opportunities you see with Optum going forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nThank you, Lisa.  I appreciate the question.  Look, we're obviously really excited to get the privilege and the \nopportunity to expand our relationship with Optum. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c70fbf6f5051ce27733916749a7319ff4226fa528aec42ed218b7fefb39f7978", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9452c8e-12c9-49b7-90a6-8bae8bd37fee", "node_type": "1", "metadata": {"window": "And then as I think about Optum, your comments were that you started a relationship last year.  You've increased \nthe scope of services.  You're now doing sourcing, distribution, oncology.  Can you maybe just help us understand, \none, in winning that business; and secondly, how we look at Optum versus maybe some of your other clients and \nany incremental opportunities you see with Optum going forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nThank you, Lisa.  I appreciate the question. ", "original_text": "Can you maybe just help us understand, \none, in winning that business; and secondly, how we look at Optum versus maybe some of your other clients and \nany incremental opportunities you see with Optum going forward?  \n ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "46c549e616af3c5709a9ea431a9d131f577909bedd9f360a941cc3d0fb1606a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a6e5fdf-a827-42cb-a804-29901157840f", "node_type": "1", "metadata": {"window": "You're now doing sourcing, distribution, oncology.  Can you maybe just help us understand, \none, in winning that business; and secondly, how we look at Optum versus maybe some of your other clients and \nany incremental opportunities you see with Optum going forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nThank you, Lisa.  I appreciate the question.  Look, we're obviously really excited to get the privilege and the \nopportunity to expand our relationship with Optum.  And I think it's a testament to the differentiated services and \nsolutions, the  breadth of our diversified healthcare service offerings. ", "original_text": "A \nThank you, Lisa. "}, "hash": "cf4341cb33cd33e9ac9bbc542bf8fb7e9e6b4e352c8350350bec7126401dd8d7", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.  ", "start_char_idx": 3832, "end_char_idx": 4177, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a6e5fdf-a827-42cb-a804-29901157840f": {"__data__": {"id_": "8a6e5fdf-a827-42cb-a804-29901157840f", "embedding": null, "metadata": {"window": "You're now doing sourcing, distribution, oncology.  Can you maybe just help us understand, \none, in winning that business; and secondly, how we look at Optum versus maybe some of your other clients and \nany incremental opportunities you see with Optum going forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nThank you, Lisa.  I appreciate the question.  Look, we're obviously really excited to get the privilege and the \nopportunity to expand our relationship with Optum.  And I think it's a testament to the differentiated services and \nsolutions, the  breadth of our diversified healthcare service offerings. ", "original_text": "A \nThank you, Lisa. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c70fbf6f5051ce27733916749a7319ff4226fa528aec42ed218b7fefb39f7978", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44f14888-86b2-45b9-9946-cd46ab275f6e", "node_type": "1", "metadata": {"window": "You've increased \nthe scope of services.  You're now doing sourcing, distribution, oncology.  Can you maybe just help us understand, \none, in winning that business; and secondly, how we look at Optum versus maybe some of your other clients and \nany incremental opportunities you see with Optum going forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nThank you, Lisa.  I appreciate the question.  Look, we're obviously really excited to get the privilege and the \nopportunity to expand our relationship with Optum. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "4685e986f88b85e74fa7315f9f965ddd02e57a141f1d6674d623ad43fcc901ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41c63d24-4842-4fe2-b9ee-d20cd70c4a86", "node_type": "1", "metadata": {"window": "Can you maybe just help us understand, \none, in winning that business; and secondly, how we look at Optum versus maybe some of your other clients and \nany incremental opportunities you see with Optum going forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nThank you, Lisa.  I appreciate the question.  Look, we're obviously really excited to get the privilege and the \nopportunity to expand our relationship with Optum.  And I think it's a testament to the differentiated services and \nsolutions, the  breadth of our diversified healthcare service offerings.  Optum itself is a big complicated entity with \nlots of services and lots of solutions, so we're really happy to have the opportunity.  \n ", "original_text": "I appreciate the question. "}, "hash": "cd037427987ab91e19159c5e7a430d58e23ba1e8ecbf94ea4499f2cea7190f76", "class_name": "RelatedNodeInfo"}}, "text": "A \nThank you, Lisa. ", "start_char_idx": 4177, "end_char_idx": 4197, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41c63d24-4842-4fe2-b9ee-d20cd70c4a86": {"__data__": {"id_": "41c63d24-4842-4fe2-b9ee-d20cd70c4a86", "embedding": null, "metadata": {"window": "Can you maybe just help us understand, \none, in winning that business; and secondly, how we look at Optum versus maybe some of your other clients and \nany incremental opportunities you see with Optum going forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nThank you, Lisa.  I appreciate the question.  Look, we're obviously really excited to get the privilege and the \nopportunity to expand our relationship with Optum.  And I think it's a testament to the differentiated services and \nsolutions, the  breadth of our diversified healthcare service offerings.  Optum itself is a big complicated entity with \nlots of services and lots of solutions, so we're really happy to have the opportunity.  \n ", "original_text": "I appreciate the question. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c70fbf6f5051ce27733916749a7319ff4226fa528aec42ed218b7fefb39f7978", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a6e5fdf-a827-42cb-a804-29901157840f", "node_type": "1", "metadata": {"window": "You're now doing sourcing, distribution, oncology.  Can you maybe just help us understand, \none, in winning that business; and secondly, how we look at Optum versus maybe some of your other clients and \nany incremental opportunities you see with Optum going forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nThank you, Lisa.  I appreciate the question.  Look, we're obviously really excited to get the privilege and the \nopportunity to expand our relationship with Optum.  And I think it's a testament to the differentiated services and \nsolutions, the  breadth of our diversified healthcare service offerings. ", "original_text": "A \nThank you, Lisa. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "abddc74e1169de256b74f6ffc7764760b41cb1c28ecc81c55ba3e1830ba2a51c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2df21050-6f9c-4ceb-8a07-d19dc6cc3931", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nThank you, Lisa.  I appreciate the question.  Look, we're obviously really excited to get the privilege and the \nopportunity to expand our relationship with Optum.  And I think it's a testament to the differentiated services and \nsolutions, the  breadth of our diversified healthcare service offerings.  Optum itself is a big complicated entity with \nlots of services and lots of solutions, so we're really happy to have the opportunity.  \n ", "original_text": "Look, we're obviously really excited to get the privilege and the \nopportunity to expand our relationship with Optum. "}, "hash": "ce23250696cf5668e5aaa6f44744dedfe71b73f21f873ab6b788cc941b055aff", "class_name": "RelatedNodeInfo"}}, "text": "I appreciate the question. ", "start_char_idx": 4197, "end_char_idx": 4224, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2df21050-6f9c-4ceb-8a07-d19dc6cc3931": {"__data__": {"id_": "2df21050-6f9c-4ceb-8a07-d19dc6cc3931", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nThank you, Lisa.  I appreciate the question.  Look, we're obviously really excited to get the privilege and the \nopportunity to expand our relationship with Optum.  And I think it's a testament to the differentiated services and \nsolutions, the  breadth of our diversified healthcare service offerings.  Optum itself is a big complicated entity with \nlots of services and lots of solutions, so we're really happy to have the opportunity.  \n ", "original_text": "Look, we're obviously really excited to get the privilege and the \nopportunity to expand our relationship with Optum. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c70fbf6f5051ce27733916749a7319ff4226fa528aec42ed218b7fefb39f7978", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41c63d24-4842-4fe2-b9ee-d20cd70c4a86", "node_type": "1", "metadata": {"window": "Can you maybe just help us understand, \none, in winning that business; and secondly, how we look at Optum versus maybe some of your other clients and \nany incremental opportunities you see with Optum going forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nThank you, Lisa.  I appreciate the question.  Look, we're obviously really excited to get the privilege and the \nopportunity to expand our relationship with Optum.  And I think it's a testament to the differentiated services and \nsolutions, the  breadth of our diversified healthcare service offerings.  Optum itself is a big complicated entity with \nlots of services and lots of solutions, so we're really happy to have the opportunity.  \n ", "original_text": "I appreciate the question. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "cc20f443c7fe23cf41dcd0f75e04bf3a3829cff07a6c155e6ea62b99a0043981", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53afae79-7be3-4299-9eac-f8869771a81f", "node_type": "1", "metadata": {"window": "A \nThank you, Lisa.  I appreciate the question.  Look, we're obviously really excited to get the privilege and the \nopportunity to expand our relationship with Optum.  And I think it's a testament to the differentiated services and \nsolutions, the  breadth of our diversified healthcare service offerings.  Optum itself is a big complicated entity with \nlots of services and lots of solutions, so we're really happy to have the opportunity.  \n ", "original_text": "And I think it's a testament to the differentiated services and \nsolutions, the  breadth of our diversified healthcare service offerings. "}, "hash": "b8170e3942de5c0923a978e411d9008e598293c831c9bc9f9db48ef89fce8716", "class_name": "RelatedNodeInfo"}}, "text": "Look, we're obviously really excited to get the privilege and the \nopportunity to expand our relationship with Optum. ", "start_char_idx": 4224, "end_char_idx": 4342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53afae79-7be3-4299-9eac-f8869771a81f": {"__data__": {"id_": "53afae79-7be3-4299-9eac-f8869771a81f", "embedding": null, "metadata": {"window": "A \nThank you, Lisa.  I appreciate the question.  Look, we're obviously really excited to get the privilege and the \nopportunity to expand our relationship with Optum.  And I think it's a testament to the differentiated services and \nsolutions, the  breadth of our diversified healthcare service offerings.  Optum itself is a big complicated entity with \nlots of services and lots of solutions, so we're really happy to have the opportunity.  \n ", "original_text": "And I think it's a testament to the differentiated services and \nsolutions, the  breadth of our diversified healthcare service offerings. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c70fbf6f5051ce27733916749a7319ff4226fa528aec42ed218b7fefb39f7978", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2df21050-6f9c-4ceb-8a07-d19dc6cc3931", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nThank you, Lisa.  I appreciate the question.  Look, we're obviously really excited to get the privilege and the \nopportunity to expand our relationship with Optum.  And I think it's a testament to the differentiated services and \nsolutions, the  breadth of our diversified healthcare service offerings.  Optum itself is a big complicated entity with \nlots of services and lots of solutions, so we're really happy to have the opportunity.  \n ", "original_text": "Look, we're obviously really excited to get the privilege and the \nopportunity to expand our relationship with Optum. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5fbee5d81089551a1ff99966bcf633d76b4519c523976138acd6266a3594e544", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ddc448ba-7e6f-4478-b6c6-476a13941e57", "node_type": "1", "metadata": {"window": "I appreciate the question.  Look, we're obviously really excited to get the privilege and the \nopportunity to expand our relationship with Optum.  And I think it's a testament to the differentiated services and \nsolutions, the  breadth of our diversified healthcare service offerings.  Optum itself is a big complicated entity with \nlots of services and lots of solutions, so we're really happy to have the opportunity.  \n ", "original_text": "Optum itself is a big complicated entity with \nlots of services and lots of solutions, so we're really happy to have the opportunity.  \n "}, "hash": "566ed30eebffd49b4118b664d90eb553c91c3fcbec1a26866b15ae23fc650ced", "class_name": "RelatedNodeInfo"}}, "text": "And I think it's a testament to the differentiated services and \nsolutions, the  breadth of our diversified healthcare service offerings. ", "start_char_idx": 4342, "end_char_idx": 4480, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ddc448ba-7e6f-4478-b6c6-476a13941e57": {"__data__": {"id_": "ddc448ba-7e6f-4478-b6c6-476a13941e57", "embedding": null, "metadata": {"window": "I appreciate the question.  Look, we're obviously really excited to get the privilege and the \nopportunity to expand our relationship with Optum.  And I think it's a testament to the differentiated services and \nsolutions, the  breadth of our diversified healthcare service offerings.  Optum itself is a big complicated entity with \nlots of services and lots of solutions, so we're really happy to have the opportunity.  \n ", "original_text": "Optum itself is a big complicated entity with \nlots of services and lots of solutions, so we're really happy to have the opportunity.  \n ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c70fbf6f5051ce27733916749a7319ff4226fa528aec42ed218b7fefb39f7978", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53afae79-7be3-4299-9eac-f8869771a81f", "node_type": "1", "metadata": {"window": "A \nThank you, Lisa.  I appreciate the question.  Look, we're obviously really excited to get the privilege and the \nopportunity to expand our relationship with Optum.  And I think it's a testament to the differentiated services and \nsolutions, the  breadth of our diversified healthcare service offerings.  Optum itself is a big complicated entity with \nlots of services and lots of solutions, so we're really happy to have the opportunity.  \n ", "original_text": "And I think it's a testament to the differentiated services and \nsolutions, the  breadth of our diversified healthcare service offerings. ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "80f38aa43e1f6f6e6780ad18ce144d38d2460993656d7fc76c3472cd60db6e0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14823974-546b-465d-893b-39cee0308cd5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nI do think it's a reflection on the investments that we've made over the past several years and the efficiency of our \ncore operations, our commitment to continuing to make those investments, not just in efficiency, but in innovations \nand thinking about how we use our tools to solve different problems.  This is very much  today a distribution \nagreement.  We'll be servicing Optum home delivery to Optum infusion, OptumCare, the specialty pharmacy. ", "original_text": "McKesson Corp.  "}, "hash": "d6662840b3a48c90fd23cc97e0317a1853fc1964000595107382d305dc12c539", "class_name": "RelatedNodeInfo"}}, "text": "Optum itself is a big complicated entity with \nlots of services and lots of solutions, so we're really happy to have the opportunity.  \n ", "start_char_idx": 4480, "end_char_idx": 4617, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14823974-546b-465d-893b-39cee0308cd5": {"__data__": {"id_": "14823974-546b-465d-893b-39cee0308cd5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nI do think it's a reflection on the investments that we've made over the past several years and the efficiency of our \ncore operations, our commitment to continuing to make those investments, not just in efficiency, but in innovations \nand thinking about how we use our tools to solve different problems.  This is very much  today a distribution \nagreement.  We'll be servicing Optum home delivery to Optum infusion, OptumCare, the specialty pharmacy. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05741e79-c295-4ca9-8e03-5359351afb04", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ba6b5674b271661980e6c8adcec2aa40c1d08cd954dce16f564e47c300ff320f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ddc448ba-7e6f-4478-b6c6-476a13941e57", "node_type": "1", "metadata": {"window": "I appreciate the question.  Look, we're obviously really excited to get the privilege and the \nopportunity to expand our relationship with Optum.  And I think it's a testament to the differentiated services and \nsolutions, the  breadth of our diversified healthcare service offerings.  Optum itself is a big complicated entity with \nlots of services and lots of solutions, so we're really happy to have the opportunity.  \n ", "original_text": "Optum itself is a big complicated entity with \nlots of services and lots of solutions, so we're really happy to have the opportunity.  \n ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "1d40d743e5f13c4a4bfeff8d47af890c478b80ed6130e1d9ceb7a3b20f0b0ab5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b130c306-1fee-4efb-a71a-8d27b6ced077", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nI do think it's a reflection on the investments that we've made over the past several years and the efficiency of our \ncore operations, our commitment to continuing to make those investments, not just in efficiency, but in innovations \nand thinking about how we use our tools to solve different problems.  This is very much  today a distribution \nagreement.  We'll be servicing Optum home delivery to Optum infusion, OptumCare, the specialty pharmacy.  So \nit's very broad in that regard. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nI do think it's a reflection on the investments that we've made over the past several years and the efficiency of our \ncore operations, our commitment to continuing to make those investments, not just in efficiency, but in innovations \nand thinking about how we use our tools to solve different problems. "}, "hash": "7495b083713978badfa41ec9b1ee303094de4d4eba6efc1022b269ff82b7c5f4", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b130c306-1fee-4efb-a71a-8d27b6ced077": {"__data__": {"id_": "b130c306-1fee-4efb-a71a-8d27b6ced077", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nI do think it's a reflection on the investments that we've made over the past several years and the efficiency of our \ncore operations, our commitment to continuing to make those investments, not just in efficiency, but in innovations \nand thinking about how we use our tools to solve different problems.  This is very much  today a distribution \nagreement.  We'll be servicing Optum home delivery to Optum infusion, OptumCare, the specialty pharmacy.  So \nit's very broad in that regard. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nI do think it's a reflection on the investments that we've made over the past several years and the efficiency of our \ncore operations, our commitment to continuing to make those investments, not just in efficiency, but in innovations \nand thinking about how we use our tools to solve different problems. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05741e79-c295-4ca9-8e03-5359351afb04", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ba6b5674b271661980e6c8adcec2aa40c1d08cd954dce16f564e47c300ff320f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14823974-546b-465d-893b-39cee0308cd5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nI do think it's a reflection on the investments that we've made over the past several years and the efficiency of our \ncore operations, our commitment to continuing to make those investments, not just in efficiency, but in innovations \nand thinking about how we use our tools to solve different problems.  This is very much  today a distribution \nagreement.  We'll be servicing Optum home delivery to Optum infusion, OptumCare, the specialty pharmacy. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "0c175dfe0e049b890cceed999c5c3705af7369b551be68ed52f99d110fca3f69", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8910f53-7681-4a1e-b7d2-d17d84e191f2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nI do think it's a reflection on the investments that we've made over the past several years and the efficiency of our \ncore operations, our commitment to continuing to make those investments, not just in efficiency, but in innovations \nand thinking about how we use our tools to solve different problems.  This is very much  today a distribution \nagreement.  We'll be servicing Optum home delivery to Optum infusion, OptumCare, the specialty pharmacy.  So \nit's very broad in that regard.  But I do think it's a reflection of past investments that we've made, not just in \ndistribution,  but in the portfolio of capabilities that we offer.  \n ", "original_text": "This is very much  today a distribution \nagreement. "}, "hash": "754ddddf31d32fa2324805c55de5154ae0f20e8f5d8ece9f7983506a9f38627e", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nI do think it's a reflection on the investments that we've made over the past several years and the efficiency of our \ncore operations, our commitment to continuing to make those investments, not just in efficiency, but in innovations \nand thinking about how we use our tools to solve different problems. ", "start_char_idx": 16, "end_char_idx": 486, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8910f53-7681-4a1e-b7d2-d17d84e191f2": {"__data__": {"id_": "b8910f53-7681-4a1e-b7d2-d17d84e191f2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nI do think it's a reflection on the investments that we've made over the past several years and the efficiency of our \ncore operations, our commitment to continuing to make those investments, not just in efficiency, but in innovations \nand thinking about how we use our tools to solve different problems.  This is very much  today a distribution \nagreement.  We'll be servicing Optum home delivery to Optum infusion, OptumCare, the specialty pharmacy.  So \nit's very broad in that regard.  But I do think it's a reflection of past investments that we've made, not just in \ndistribution,  but in the portfolio of capabilities that we offer.  \n ", "original_text": "This is very much  today a distribution \nagreement. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05741e79-c295-4ca9-8e03-5359351afb04", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ba6b5674b271661980e6c8adcec2aa40c1d08cd954dce16f564e47c300ff320f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b130c306-1fee-4efb-a71a-8d27b6ced077", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nI do think it's a reflection on the investments that we've made over the past several years and the efficiency of our \ncore operations, our commitment to continuing to make those investments, not just in efficiency, but in innovations \nand thinking about how we use our tools to solve different problems.  This is very much  today a distribution \nagreement.  We'll be servicing Optum home delivery to Optum infusion, OptumCare, the specialty pharmacy.  So \nit's very broad in that regard. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nI do think it's a reflection on the investments that we've made over the past several years and the efficiency of our \ncore operations, our commitment to continuing to make those investments, not just in efficiency, but in innovations \nand thinking about how we use our tools to solve different problems. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "eb0eea34d445f997476585ad5499ebeeb11128d321167f25d2df0ba1908bdb4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14294311-682e-4b3a-9a9f-9a4aea6f6f23", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nI do think it's a reflection on the investments that we've made over the past several years and the efficiency of our \ncore operations, our commitment to continuing to make those investments, not just in efficiency, but in innovations \nand thinking about how we use our tools to solve different problems.  This is very much  today a distribution \nagreement.  We'll be servicing Optum home delivery to Optum infusion, OptumCare, the specialty pharmacy.  So \nit's very broad in that regard.  But I do think it's a reflection of past investments that we've made, not just in \ndistribution,  but in the portfolio of capabilities that we offer.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "We'll be servicing Optum home delivery to Optum infusion, OptumCare, the specialty pharmacy. "}, "hash": "3dc5d8acdd64149ed5b77b7ed3980014b382ebad172a95b092cb972ea2f44f33", "class_name": "RelatedNodeInfo"}}, "text": "This is very much  today a distribution \nagreement. ", "start_char_idx": 486, "end_char_idx": 538, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14294311-682e-4b3a-9a9f-9a4aea6f6f23": {"__data__": {"id_": "14294311-682e-4b3a-9a9f-9a4aea6f6f23", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nI do think it's a reflection on the investments that we've made over the past several years and the efficiency of our \ncore operations, our commitment to continuing to make those investments, not just in efficiency, but in innovations \nand thinking about how we use our tools to solve different problems.  This is very much  today a distribution \nagreement.  We'll be servicing Optum home delivery to Optum infusion, OptumCare, the specialty pharmacy.  So \nit's very broad in that regard.  But I do think it's a reflection of past investments that we've made, not just in \ndistribution,  but in the portfolio of capabilities that we offer.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "We'll be servicing Optum home delivery to Optum infusion, OptumCare, the specialty pharmacy. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05741e79-c295-4ca9-8e03-5359351afb04", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ba6b5674b271661980e6c8adcec2aa40c1d08cd954dce16f564e47c300ff320f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8910f53-7681-4a1e-b7d2-d17d84e191f2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nI do think it's a reflection on the investments that we've made over the past several years and the efficiency of our \ncore operations, our commitment to continuing to make those investments, not just in efficiency, but in innovations \nand thinking about how we use our tools to solve different problems.  This is very much  today a distribution \nagreement.  We'll be servicing Optum home delivery to Optum infusion, OptumCare, the specialty pharmacy.  So \nit's very broad in that regard.  But I do think it's a reflection of past investments that we've made, not just in \ndistribution,  but in the portfolio of capabilities that we offer.  \n ", "original_text": "This is very much  today a distribution \nagreement. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "1e87313a316825c320fdc64ddbfcb912512c9bf8b416f7d005259fe4a35bb055", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "809485e5-d879-4fe0-8c13-f0049bcec8fa", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nI do think it's a reflection on the investments that we've made over the past several years and the efficiency of our \ncore operations, our commitment to continuing to make those investments, not just in efficiency, but in innovations \nand thinking about how we use our tools to solve different problems.  This is very much  today a distribution \nagreement.  We'll be servicing Optum home delivery to Optum infusion, OptumCare, the specialty pharmacy.  So \nit's very broad in that regard.  But I do think it's a reflection of past investments that we've made, not just in \ndistribution,  but in the portfolio of capabilities that we offer.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLisa, maybe I'll answer your question. ", "original_text": "So \nit's very broad in that regard. "}, "hash": "07b0383b1ceb63f5f498eced85ab49d86f83dd6cfea8020f6187460e4be2df4f", "class_name": "RelatedNodeInfo"}}, "text": "We'll be servicing Optum home delivery to Optum infusion, OptumCare, the specialty pharmacy. ", "start_char_idx": 538, "end_char_idx": 631, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "809485e5-d879-4fe0-8c13-f0049bcec8fa": {"__data__": {"id_": "809485e5-d879-4fe0-8c13-f0049bcec8fa", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nI do think it's a reflection on the investments that we've made over the past several years and the efficiency of our \ncore operations, our commitment to continuing to make those investments, not just in efficiency, but in innovations \nand thinking about how we use our tools to solve different problems.  This is very much  today a distribution \nagreement.  We'll be servicing Optum home delivery to Optum infusion, OptumCare, the specialty pharmacy.  So \nit's very broad in that regard.  But I do think it's a reflection of past investments that we've made, not just in \ndistribution,  but in the portfolio of capabilities that we offer.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLisa, maybe I'll answer your question. ", "original_text": "So \nit's very broad in that regard. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05741e79-c295-4ca9-8e03-5359351afb04", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ba6b5674b271661980e6c8adcec2aa40c1d08cd954dce16f564e47c300ff320f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14294311-682e-4b3a-9a9f-9a4aea6f6f23", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nI do think it's a reflection on the investments that we've made over the past several years and the efficiency of our \ncore operations, our commitment to continuing to make those investments, not just in efficiency, but in innovations \nand thinking about how we use our tools to solve different problems.  This is very much  today a distribution \nagreement.  We'll be servicing Optum home delivery to Optum infusion, OptumCare, the specialty pharmacy.  So \nit's very broad in that regard.  But I do think it's a reflection of past investments that we've made, not just in \ndistribution,  but in the portfolio of capabilities that we offer.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "We'll be servicing Optum home delivery to Optum infusion, OptumCare, the specialty pharmacy. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c8dff30ea930feb0bcbc9da89358d6a06ec3426544e256df8f4fad5aaa64aaa0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0021cb65-01a2-4abb-a5f5-fb469b20d1a9", "node_type": "1", "metadata": {"window": "This is very much  today a distribution \nagreement.  We'll be servicing Optum home delivery to Optum infusion, OptumCare, the specialty pharmacy.  So \nit's very broad in that regard.  But I do think it's a reflection of past investments that we've made, not just in \ndistribution,  but in the portfolio of capabilities that we offer.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLisa, maybe I'll answer your question.  Maybe I would just start with just a little bit of a foundation building h ere. ", "original_text": "But I do think it's a reflection of past investments that we've made, not just in \ndistribution,  but in the portfolio of capabilities that we offer.  \n "}, "hash": "3413b1722a8f4b704aa07cda4349af449a6a088ba5caaf4cb80707d8bcad98ff", "class_name": "RelatedNodeInfo"}}, "text": "So \nit's very broad in that regard. ", "start_char_idx": 631, "end_char_idx": 667, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0021cb65-01a2-4abb-a5f5-fb469b20d1a9": {"__data__": {"id_": "0021cb65-01a2-4abb-a5f5-fb469b20d1a9", "embedding": null, "metadata": {"window": "This is very much  today a distribution \nagreement.  We'll be servicing Optum home delivery to Optum infusion, OptumCare, the specialty pharmacy.  So \nit's very broad in that regard.  But I do think it's a reflection of past investments that we've made, not just in \ndistribution,  but in the portfolio of capabilities that we offer.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLisa, maybe I'll answer your question.  Maybe I would just start with just a little bit of a foundation building h ere. ", "original_text": "But I do think it's a reflection of past investments that we've made, not just in \ndistribution,  but in the portfolio of capabilities that we offer.  \n ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05741e79-c295-4ca9-8e03-5359351afb04", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ba6b5674b271661980e6c8adcec2aa40c1d08cd954dce16f564e47c300ff320f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "809485e5-d879-4fe0-8c13-f0049bcec8fa", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nI do think it's a reflection on the investments that we've made over the past several years and the efficiency of our \ncore operations, our commitment to continuing to make those investments, not just in efficiency, but in innovations \nand thinking about how we use our tools to solve different problems.  This is very much  today a distribution \nagreement.  We'll be servicing Optum home delivery to Optum infusion, OptumCare, the specialty pharmacy.  So \nit's very broad in that regard.  But I do think it's a reflection of past investments that we've made, not just in \ndistribution,  but in the portfolio of capabilities that we offer.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLisa, maybe I'll answer your question. ", "original_text": "So \nit's very broad in that regard. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c28e3b5d3aea610e806d8aedfbb78604ca04645ebd1890b48a5a69865b8267de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ee064aa-c3ed-4ad0-94da-5b19b7cef415", "node_type": "1", "metadata": {"window": "We'll be servicing Optum home delivery to Optum infusion, OptumCare, the specialty pharmacy.  So \nit's very broad in that regard.  But I do think it's a reflection of past investments that we've made, not just in \ndistribution,  but in the portfolio of capabilities that we offer.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLisa, maybe I'll answer your question.  Maybe I would just start with just a little bit of a foundation building h ere.  If \nyou think about the US Pharma segment over the last four years, the adjusted operating profit has grown at a \ncompound annual growth rate of about 6%, so really right in the middle of the long -term targets that we provided. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "96cada63e06ba5c15c1cf7f755b0ead4fa0c121b2167ec8cc2d725826759222a", "class_name": "RelatedNodeInfo"}}, "text": "But I do think it's a reflection of past investments that we've made, not just in \ndistribution,  but in the portfolio of capabilities that we offer.  \n ", "start_char_idx": 667, "end_char_idx": 820, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ee064aa-c3ed-4ad0-94da-5b19b7cef415": {"__data__": {"id_": "2ee064aa-c3ed-4ad0-94da-5b19b7cef415", "embedding": null, "metadata": {"window": "We'll be servicing Optum home delivery to Optum infusion, OptumCare, the specialty pharmacy.  So \nit's very broad in that regard.  But I do think it's a reflection of past investments that we've made, not just in \ndistribution,  but in the portfolio of capabilities that we offer.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLisa, maybe I'll answer your question.  Maybe I would just start with just a little bit of a foundation building h ere.  If \nyou think about the US Pharma segment over the last four years, the adjusted operating profit has grown at a \ncompound annual growth rate of about 6%, so really right in the middle of the long -term targets that we provided. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05741e79-c295-4ca9-8e03-5359351afb04", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ba6b5674b271661980e6c8adcec2aa40c1d08cd954dce16f564e47c300ff320f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0021cb65-01a2-4abb-a5f5-fb469b20d1a9", "node_type": "1", "metadata": {"window": "This is very much  today a distribution \nagreement.  We'll be servicing Optum home delivery to Optum infusion, OptumCare, the specialty pharmacy.  So \nit's very broad in that regard.  But I do think it's a reflection of past investments that we've made, not just in \ndistribution,  but in the portfolio of capabilities that we offer.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLisa, maybe I'll answer your question.  Maybe I would just start with just a little bit of a foundation building h ere. ", "original_text": "But I do think it's a reflection of past investments that we've made, not just in \ndistribution,  but in the portfolio of capabilities that we offer.  \n ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "160275401a6f47443f679721b8a63dee304f398146ce75f29f4b8b1c2256fba8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6aaedec-4e4c-4429-af85-24294b915901", "node_type": "1", "metadata": {"window": "So \nit's very broad in that regard.  But I do think it's a reflection of past investments that we've made, not just in \ndistribution,  but in the portfolio of capabilities that we offer.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLisa, maybe I'll answer your question.  Maybe I would just start with just a little bit of a foundation building h ere.  If \nyou think about the US Pharma segment over the last four years, the adjusted operating profit has grown at a \ncompound annual growth rate of about 6%, so really right in the middle of the long -term targets that we provided. \n They're long -term targets  for a reason. ", "original_text": "A \nLisa, maybe I'll answer your question. "}, "hash": "c524ac977fbd191f5fb2a1dc604367ead3c2afc7862c6b308bf669acd707b35a", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 820, "end_char_idx": 1180, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6aaedec-4e4c-4429-af85-24294b915901": {"__data__": {"id_": "a6aaedec-4e4c-4429-af85-24294b915901", "embedding": null, "metadata": {"window": "So \nit's very broad in that regard.  But I do think it's a reflection of past investments that we've made, not just in \ndistribution,  but in the portfolio of capabilities that we offer.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLisa, maybe I'll answer your question.  Maybe I would just start with just a little bit of a foundation building h ere.  If \nyou think about the US Pharma segment over the last four years, the adjusted operating profit has grown at a \ncompound annual growth rate of about 6%, so really right in the middle of the long -term targets that we provided. \n They're long -term targets  for a reason. ", "original_text": "A \nLisa, maybe I'll answer your question. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05741e79-c295-4ca9-8e03-5359351afb04", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ba6b5674b271661980e6c8adcec2aa40c1d08cd954dce16f564e47c300ff320f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ee064aa-c3ed-4ad0-94da-5b19b7cef415", "node_type": "1", "metadata": {"window": "We'll be servicing Optum home delivery to Optum infusion, OptumCare, the specialty pharmacy.  So \nit's very broad in that regard.  But I do think it's a reflection of past investments that we've made, not just in \ndistribution,  but in the portfolio of capabilities that we offer.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLisa, maybe I'll answer your question.  Maybe I would just start with just a little bit of a foundation building h ere.  If \nyou think about the US Pharma segment over the last four years, the adjusted operating profit has grown at a \ncompound annual growth rate of about 6%, so really right in the middle of the long -term targets that we provided. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "48671e67e05934a6c5ca220696baec8d7771125d4aa390aae1d8592d2c1eedec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "782bd23d-99f9-4d64-a441-4e2e547bf1ec", "node_type": "1", "metadata": {"window": "But I do think it's a reflection of past investments that we've made, not just in \ndistribution,  but in the portfolio of capabilities that we offer.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLisa, maybe I'll answer your question.  Maybe I would just start with just a little bit of a foundation building h ere.  If \nyou think about the US Pharma segment over the last four years, the adjusted operating profit has grown at a \ncompound annual growth rate of about 6%, so really right in the middle of the long -term targets that we provided. \n They're long -term targets  for a reason.  It's what we expect as a sustainable growth rate for the segment. ", "original_text": "Maybe I would just start with just a little bit of a foundation building h ere. "}, "hash": "a3d39668bcd21817dd4db5a096b90e6613a575dacc9b09c06175cb58accb8bbe", "class_name": "RelatedNodeInfo"}}, "text": "A \nLisa, maybe I'll answer your question. ", "start_char_idx": 1180, "end_char_idx": 1222, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "782bd23d-99f9-4d64-a441-4e2e547bf1ec": {"__data__": {"id_": "782bd23d-99f9-4d64-a441-4e2e547bf1ec", "embedding": null, "metadata": {"window": "But I do think it's a reflection of past investments that we've made, not just in \ndistribution,  but in the portfolio of capabilities that we offer.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLisa, maybe I'll answer your question.  Maybe I would just start with just a little bit of a foundation building h ere.  If \nyou think about the US Pharma segment over the last four years, the adjusted operating profit has grown at a \ncompound annual growth rate of about 6%, so really right in the middle of the long -term targets that we provided. \n They're long -term targets  for a reason.  It's what we expect as a sustainable growth rate for the segment. ", "original_text": "Maybe I would just start with just a little bit of a foundation building h ere. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05741e79-c295-4ca9-8e03-5359351afb04", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ba6b5674b271661980e6c8adcec2aa40c1d08cd954dce16f564e47c300ff320f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6aaedec-4e4c-4429-af85-24294b915901", "node_type": "1", "metadata": {"window": "So \nit's very broad in that regard.  But I do think it's a reflection of past investments that we've made, not just in \ndistribution,  but in the portfolio of capabilities that we offer.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLisa, maybe I'll answer your question.  Maybe I would just start with just a little bit of a foundation building h ere.  If \nyou think about the US Pharma segment over the last four years, the adjusted operating profit has grown at a \ncompound annual growth rate of about 6%, so really right in the middle of the long -term targets that we provided. \n They're long -term targets  for a reason. ", "original_text": "A \nLisa, maybe I'll answer your question. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "834ddd96c055c54a3c89360cb0141233c8efc0f4610eee191f19b0caacea031f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9fa34d35-bf99-490a-aa0a-08ab6a718f6d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLisa, maybe I'll answer your question.  Maybe I would just start with just a little bit of a foundation building h ere.  If \nyou think about the US Pharma segment over the last four years, the adjusted operating profit has grown at a \ncompound annual growth rate of about 6%, so really right in the middle of the long -term targets that we provided. \n They're long -term targets  for a reason.  It's what we expect as a sustainable growth rate for the segment.  We're \ncertainly pleased with the growth that we saw in FY 2024. ", "original_text": "If \nyou think about the US Pharma segment over the last four years, the adjusted operating profit has grown at a \ncompound annual growth rate of about 6%, so really right in the middle of the long -term targets that we provided. \n"}, "hash": "74a2b1e257576f2dd4cb623caeff6c2b48e1e6eb33e59e441a009b4c56e7961f", "class_name": "RelatedNodeInfo"}}, "text": "Maybe I would just start with just a little bit of a foundation building h ere. ", "start_char_idx": 1222, "end_char_idx": 1302, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9fa34d35-bf99-490a-aa0a-08ab6a718f6d": {"__data__": {"id_": "9fa34d35-bf99-490a-aa0a-08ab6a718f6d", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLisa, maybe I'll answer your question.  Maybe I would just start with just a little bit of a foundation building h ere.  If \nyou think about the US Pharma segment over the last four years, the adjusted operating profit has grown at a \ncompound annual growth rate of about 6%, so really right in the middle of the long -term targets that we provided. \n They're long -term targets  for a reason.  It's what we expect as a sustainable growth rate for the segment.  We're \ncertainly pleased with the growth that we saw in FY 2024. ", "original_text": "If \nyou think about the US Pharma segment over the last four years, the adjusted operating profit has grown at a \ncompound annual growth rate of about 6%, so really right in the middle of the long -term targets that we provided. \n", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05741e79-c295-4ca9-8e03-5359351afb04", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ba6b5674b271661980e6c8adcec2aa40c1d08cd954dce16f564e47c300ff320f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "782bd23d-99f9-4d64-a441-4e2e547bf1ec", "node_type": "1", "metadata": {"window": "But I do think it's a reflection of past investments that we've made, not just in \ndistribution,  but in the portfolio of capabilities that we offer.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLisa, maybe I'll answer your question.  Maybe I would just start with just a little bit of a foundation building h ere.  If \nyou think about the US Pharma segment over the last four years, the adjusted operating profit has grown at a \ncompound annual growth rate of about 6%, so really right in the middle of the long -term targets that we provided. \n They're long -term targets  for a reason.  It's what we expect as a sustainable growth rate for the segment. ", "original_text": "Maybe I would just start with just a little bit of a foundation building h ere. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d4b6f3d9806ea482bd98d21717a2adaae3655974ff9a1a0f94e613ad4e3b1a29", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aead0c3b-07f0-496f-bc54-176dd707240f", "node_type": "1", "metadata": {"window": "A \nLisa, maybe I'll answer your question.  Maybe I would just start with just a little bit of a foundation building h ere.  If \nyou think about the US Pharma segment over the last four years, the adjusted operating profit has grown at a \ncompound annual growth rate of about 6%, so really right in the middle of the long -term targets that we provided. \n They're long -term targets  for a reason.  It's what we expect as a sustainable growth rate for the segment.  We're \ncertainly pleased with the growth that we saw in FY 2024.  If you exclude the impact of COVID -related programs in \nFY 2023, the segment grew 12%. ", "original_text": "They're long -term targets  for a reason. "}, "hash": "32738069c3e1e6fbf151fa7660871670d086ac113fc7fac5028738c32543b8ea", "class_name": "RelatedNodeInfo"}}, "text": "If \nyou think about the US Pharma segment over the last four years, the adjusted operating profit has grown at a \ncompound annual growth rate of about 6%, so really right in the middle of the long -term targets that we provided. \n", "start_char_idx": 1302, "end_char_idx": 1532, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aead0c3b-07f0-496f-bc54-176dd707240f": {"__data__": {"id_": "aead0c3b-07f0-496f-bc54-176dd707240f", "embedding": null, "metadata": {"window": "A \nLisa, maybe I'll answer your question.  Maybe I would just start with just a little bit of a foundation building h ere.  If \nyou think about the US Pharma segment over the last four years, the adjusted operating profit has grown at a \ncompound annual growth rate of about 6%, so really right in the middle of the long -term targets that we provided. \n They're long -term targets  for a reason.  It's what we expect as a sustainable growth rate for the segment.  We're \ncertainly pleased with the growth that we saw in FY 2024.  If you exclude the impact of COVID -related programs in \nFY 2023, the segment grew 12%. ", "original_text": "They're long -term targets  for a reason. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05741e79-c295-4ca9-8e03-5359351afb04", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ba6b5674b271661980e6c8adcec2aa40c1d08cd954dce16f564e47c300ff320f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9fa34d35-bf99-490a-aa0a-08ab6a718f6d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLisa, maybe I'll answer your question.  Maybe I would just start with just a little bit of a foundation building h ere.  If \nyou think about the US Pharma segment over the last four years, the adjusted operating profit has grown at a \ncompound annual growth rate of about 6%, so really right in the middle of the long -term targets that we provided. \n They're long -term targets  for a reason.  It's what we expect as a sustainable growth rate for the segment.  We're \ncertainly pleased with the growth that we saw in FY 2024. ", "original_text": "If \nyou think about the US Pharma segment over the last four years, the adjusted operating profit has grown at a \ncompound annual growth rate of about 6%, so really right in the middle of the long -term targets that we provided. \n", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "8ae6793b72f7c5a62819cb7a8d518c9136062954908a62194a130db095f97ff2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a0d84f8-f7bc-40b4-bdd9-aeecb1bc270d", "node_type": "1", "metadata": {"window": "Maybe I would just start with just a little bit of a foundation building h ere.  If \nyou think about the US Pharma segment over the last four years, the adjusted operating profit has grown at a \ncompound annual growth rate of about 6%, so really right in the middle of the long -term targets that we provided. \n They're long -term targets  for a reason.  It's what we expect as a sustainable growth rate for the segment.  We're \ncertainly pleased with the growth that we saw in FY 2024.  If you exclude the impact of COVID -related programs in \nFY 2023, the segment grew 12%.  So we certainly have a lo t of momentum in that business as we enter into FY \n2025. ", "original_text": "It's what we expect as a sustainable growth rate for the segment. "}, "hash": "54221e46c44ef5a29e931b353397448065f9a16de0e92a60f7b0766736f10fd7", "class_name": "RelatedNodeInfo"}}, "text": "They're long -term targets  for a reason. ", "start_char_idx": 1532, "end_char_idx": 1574, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a0d84f8-f7bc-40b4-bdd9-aeecb1bc270d": {"__data__": {"id_": "1a0d84f8-f7bc-40b4-bdd9-aeecb1bc270d", "embedding": null, "metadata": {"window": "Maybe I would just start with just a little bit of a foundation building h ere.  If \nyou think about the US Pharma segment over the last four years, the adjusted operating profit has grown at a \ncompound annual growth rate of about 6%, so really right in the middle of the long -term targets that we provided. \n They're long -term targets  for a reason.  It's what we expect as a sustainable growth rate for the segment.  We're \ncertainly pleased with the growth that we saw in FY 2024.  If you exclude the impact of COVID -related programs in \nFY 2023, the segment grew 12%.  So we certainly have a lo t of momentum in that business as we enter into FY \n2025. ", "original_text": "It's what we expect as a sustainable growth rate for the segment. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05741e79-c295-4ca9-8e03-5359351afb04", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ba6b5674b271661980e6c8adcec2aa40c1d08cd954dce16f564e47c300ff320f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aead0c3b-07f0-496f-bc54-176dd707240f", "node_type": "1", "metadata": {"window": "A \nLisa, maybe I'll answer your question.  Maybe I would just start with just a little bit of a foundation building h ere.  If \nyou think about the US Pharma segment over the last four years, the adjusted operating profit has grown at a \ncompound annual growth rate of about 6%, so really right in the middle of the long -term targets that we provided. \n They're long -term targets  for a reason.  It's what we expect as a sustainable growth rate for the segment.  We're \ncertainly pleased with the growth that we saw in FY 2024.  If you exclude the impact of COVID -related programs in \nFY 2023, the segment grew 12%. ", "original_text": "They're long -term targets  for a reason. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "948a58dd170ef9eb8931812b6c7655e2e00466cf7e7fcff176a540c458f0f185", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d9a8cf6-ba1f-45f4-9758-5a68858c6a90", "node_type": "1", "metadata": {"window": "If \nyou think about the US Pharma segment over the last four years, the adjusted operating profit has grown at a \ncompound annual growth rate of about 6%, so really right in the middle of the long -term targets that we provided. \n They're long -term targets  for a reason.  It's what we expect as a sustainable growth rate for the segment.  We're \ncertainly pleased with the growth that we saw in FY 2024.  If you exclude the impact of COVID -related programs in \nFY 2023, the segment grew 12%.  So we certainly have a lo t of momentum in that business as we enter into FY \n2025.  As Brian mentioned, we're certainly pleased with the opportunity to serve Optum as well.  \n \n", "original_text": "We're \ncertainly pleased with the growth that we saw in FY 2024. "}, "hash": "e57a159e9183549d2cc0c80ecc86ca7f7ef752927725cc498712498d7328d438", "class_name": "RelatedNodeInfo"}}, "text": "It's what we expect as a sustainable growth rate for the segment. ", "start_char_idx": 1574, "end_char_idx": 1640, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d9a8cf6-ba1f-45f4-9758-5a68858c6a90": {"__data__": {"id_": "7d9a8cf6-ba1f-45f4-9758-5a68858c6a90", "embedding": null, "metadata": {"window": "If \nyou think about the US Pharma segment over the last four years, the adjusted operating profit has grown at a \ncompound annual growth rate of about 6%, so really right in the middle of the long -term targets that we provided. \n They're long -term targets  for a reason.  It's what we expect as a sustainable growth rate for the segment.  We're \ncertainly pleased with the growth that we saw in FY 2024.  If you exclude the impact of COVID -related programs in \nFY 2023, the segment grew 12%.  So we certainly have a lo t of momentum in that business as we enter into FY \n2025.  As Brian mentioned, we're certainly pleased with the opportunity to serve Optum as well.  \n \n", "original_text": "We're \ncertainly pleased with the growth that we saw in FY 2024. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05741e79-c295-4ca9-8e03-5359351afb04", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ba6b5674b271661980e6c8adcec2aa40c1d08cd954dce16f564e47c300ff320f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a0d84f8-f7bc-40b4-bdd9-aeecb1bc270d", "node_type": "1", "metadata": {"window": "Maybe I would just start with just a little bit of a foundation building h ere.  If \nyou think about the US Pharma segment over the last four years, the adjusted operating profit has grown at a \ncompound annual growth rate of about 6%, so really right in the middle of the long -term targets that we provided. \n They're long -term targets  for a reason.  It's what we expect as a sustainable growth rate for the segment.  We're \ncertainly pleased with the growth that we saw in FY 2024.  If you exclude the impact of COVID -related programs in \nFY 2023, the segment grew 12%.  So we certainly have a lo t of momentum in that business as we enter into FY \n2025. ", "original_text": "It's what we expect as a sustainable growth rate for the segment. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f3dad85b70faf4879c07b16dbb1d38c2100e45a358ab298e9e54419a5b0a403b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2f528c9-b8da-4746-b5a9-c458efe30db5", "node_type": "1", "metadata": {"window": "They're long -term targets  for a reason.  It's what we expect as a sustainable growth rate for the segment.  We're \ncertainly pleased with the growth that we saw in FY 2024.  If you exclude the impact of COVID -related programs in \nFY 2023, the segment grew 12%.  So we certainly have a lo t of momentum in that business as we enter into FY \n2025.  As Brian mentioned, we're certainly pleased with the opportunity to serve Optum as well.  \n \n So this is a business that we've been making a lot of investments in. ", "original_text": "If you exclude the impact of COVID -related programs in \nFY 2023, the segment grew 12%. "}, "hash": "9d083bc1b46f2a121bb3d04953a8745cadcb5f9b8d90a3a4c76ebc3b8db14b39", "class_name": "RelatedNodeInfo"}}, "text": "We're \ncertainly pleased with the growth that we saw in FY 2024. ", "start_char_idx": 1640, "end_char_idx": 1705, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2f528c9-b8da-4746-b5a9-c458efe30db5": {"__data__": {"id_": "c2f528c9-b8da-4746-b5a9-c458efe30db5", "embedding": null, "metadata": {"window": "They're long -term targets  for a reason.  It's what we expect as a sustainable growth rate for the segment.  We're \ncertainly pleased with the growth that we saw in FY 2024.  If you exclude the impact of COVID -related programs in \nFY 2023, the segment grew 12%.  So we certainly have a lo t of momentum in that business as we enter into FY \n2025.  As Brian mentioned, we're certainly pleased with the opportunity to serve Optum as well.  \n \n So this is a business that we've been making a lot of investments in. ", "original_text": "If you exclude the impact of COVID -related programs in \nFY 2023, the segment grew 12%. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05741e79-c295-4ca9-8e03-5359351afb04", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ba6b5674b271661980e6c8adcec2aa40c1d08cd954dce16f564e47c300ff320f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d9a8cf6-ba1f-45f4-9758-5a68858c6a90", "node_type": "1", "metadata": {"window": "If \nyou think about the US Pharma segment over the last four years, the adjusted operating profit has grown at a \ncompound annual growth rate of about 6%, so really right in the middle of the long -term targets that we provided. \n They're long -term targets  for a reason.  It's what we expect as a sustainable growth rate for the segment.  We're \ncertainly pleased with the growth that we saw in FY 2024.  If you exclude the impact of COVID -related programs in \nFY 2023, the segment grew 12%.  So we certainly have a lo t of momentum in that business as we enter into FY \n2025.  As Brian mentioned, we're certainly pleased with the opportunity to serve Optum as well.  \n \n", "original_text": "We're \ncertainly pleased with the growth that we saw in FY 2024. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "11170aeba5ff8c9a1b1119634eb75a2ea7f115705a40109c3f97810aa99ae7a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f5610d1-16f6-4269-a272-cc20c6dc772b", "node_type": "1", "metadata": {"window": "It's what we expect as a sustainable growth rate for the segment.  We're \ncertainly pleased with the growth that we saw in FY 2024.  If you exclude the impact of COVID -related programs in \nFY 2023, the segment grew 12%.  So we certainly have a lo t of momentum in that business as we enter into FY \n2025.  As Brian mentioned, we're certainly pleased with the opportunity to serve Optum as well.  \n \n So this is a business that we've been making a lot of investments in.  It's a business that we have some exper tise \nthat we're continuing to add to in terms of our sourcing capabilities, providing value back to our customers. ", "original_text": "So we certainly have a lo t of momentum in that business as we enter into FY \n2025. "}, "hash": "3cf506d9b190e23eaa8e3f8be5650d5476488ce62e5e63916278b17d62e3a5a4", "class_name": "RelatedNodeInfo"}}, "text": "If you exclude the impact of COVID -related programs in \nFY 2023, the segment grew 12%. ", "start_char_idx": 1705, "end_char_idx": 1793, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f5610d1-16f6-4269-a272-cc20c6dc772b": {"__data__": {"id_": "2f5610d1-16f6-4269-a272-cc20c6dc772b", "embedding": null, "metadata": {"window": "It's what we expect as a sustainable growth rate for the segment.  We're \ncertainly pleased with the growth that we saw in FY 2024.  If you exclude the impact of COVID -related programs in \nFY 2023, the segment grew 12%.  So we certainly have a lo t of momentum in that business as we enter into FY \n2025.  As Brian mentioned, we're certainly pleased with the opportunity to serve Optum as well.  \n \n So this is a business that we've been making a lot of investments in.  It's a business that we have some exper tise \nthat we're continuing to add to in terms of our sourcing capabilities, providing value back to our customers. ", "original_text": "So we certainly have a lo t of momentum in that business as we enter into FY \n2025. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05741e79-c295-4ca9-8e03-5359351afb04", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ba6b5674b271661980e6c8adcec2aa40c1d08cd954dce16f564e47c300ff320f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2f528c9-b8da-4746-b5a9-c458efe30db5", "node_type": "1", "metadata": {"window": "They're long -term targets  for a reason.  It's what we expect as a sustainable growth rate for the segment.  We're \ncertainly pleased with the growth that we saw in FY 2024.  If you exclude the impact of COVID -related programs in \nFY 2023, the segment grew 12%.  So we certainly have a lo t of momentum in that business as we enter into FY \n2025.  As Brian mentioned, we're certainly pleased with the opportunity to serve Optum as well.  \n \n So this is a business that we've been making a lot of investments in. ", "original_text": "If you exclude the impact of COVID -related programs in \nFY 2023, the segment grew 12%. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a98c276d37d12f5901299b136394514f64dbce731596cd225dad28492b1ddf2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6523ab68-79d3-441b-a378-483b6d822222", "node_type": "1", "metadata": {"window": "We're \ncertainly pleased with the growth that we saw in FY 2024.  If you exclude the impact of COVID -related programs in \nFY 2023, the segment grew 12%.  So we certainly have a lo t of momentum in that business as we enter into FY \n2025.  As Brian mentioned, we're certainly pleased with the opportunity to serve Optum as well.  \n \n So this is a business that we've been making a lot of investments in.  It's a business that we have some exper tise \nthat we're continuing to add to in terms of our sourcing capabilities, providing value back to our customers.  And \nwe have a lot of momentum in this segment. ", "original_text": "As Brian mentioned, we're certainly pleased with the opportunity to serve Optum as well.  \n \n"}, "hash": "9a9d45760cf461a0f81934887e2727974a8462247755803a53663188a04c7166", "class_name": "RelatedNodeInfo"}}, "text": "So we certainly have a lo t of momentum in that business as we enter into FY \n2025. ", "start_char_idx": 1793, "end_char_idx": 1877, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6523ab68-79d3-441b-a378-483b6d822222": {"__data__": {"id_": "6523ab68-79d3-441b-a378-483b6d822222", "embedding": null, "metadata": {"window": "We're \ncertainly pleased with the growth that we saw in FY 2024.  If you exclude the impact of COVID -related programs in \nFY 2023, the segment grew 12%.  So we certainly have a lo t of momentum in that business as we enter into FY \n2025.  As Brian mentioned, we're certainly pleased with the opportunity to serve Optum as well.  \n \n So this is a business that we've been making a lot of investments in.  It's a business that we have some exper tise \nthat we're continuing to add to in terms of our sourcing capabilities, providing value back to our customers.  And \nwe have a lot of momentum in this segment. ", "original_text": "As Brian mentioned, we're certainly pleased with the opportunity to serve Optum as well.  \n \n", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05741e79-c295-4ca9-8e03-5359351afb04", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ba6b5674b271661980e6c8adcec2aa40c1d08cd954dce16f564e47c300ff320f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f5610d1-16f6-4269-a272-cc20c6dc772b", "node_type": "1", "metadata": {"window": "It's what we expect as a sustainable growth rate for the segment.  We're \ncertainly pleased with the growth that we saw in FY 2024.  If you exclude the impact of COVID -related programs in \nFY 2023, the segment grew 12%.  So we certainly have a lo t of momentum in that business as we enter into FY \n2025.  As Brian mentioned, we're certainly pleased with the opportunity to serve Optum as well.  \n \n So this is a business that we've been making a lot of investments in.  It's a business that we have some exper tise \nthat we're continuing to add to in terms of our sourcing capabilities, providing value back to our customers. ", "original_text": "So we certainly have a lo t of momentum in that business as we enter into FY \n2025. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "1a330c142154b81567ed997ae54a9d9fe8808177a4bdad3f8b7608781905a544", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf22e1e4-5564-4745-a679-5bbb9fbd6ace", "node_type": "1", "metadata": {"window": "If you exclude the impact of COVID -related programs in \nFY 2023, the segment grew 12%.  So we certainly have a lo t of momentum in that business as we enter into FY \n2025.  As Brian mentioned, we're certainly pleased with the opportunity to serve Optum as well.  \n \n So this is a business that we've been making a lot of investments in.  It's a business that we have some exper tise \nthat we're continuing to add to in terms of our sourcing capabilities, providing value back to our customers.  And \nwe have a lot of momentum in this segment.  And so I think the growth rate that we've outlined here for 2025 is a \ncontinuation of the mome ntum that we've seen now over the last several years.  \n ", "original_text": "So this is a business that we've been making a lot of investments in. "}, "hash": "64a02a13de07bfb59ff855a4038ff73a2f656492961248c780634908a9a31f5f", "class_name": "RelatedNodeInfo"}}, "text": "As Brian mentioned, we're certainly pleased with the opportunity to serve Optum as well.  \n \n", "start_char_idx": 1877, "end_char_idx": 1970, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf22e1e4-5564-4745-a679-5bbb9fbd6ace": {"__data__": {"id_": "bf22e1e4-5564-4745-a679-5bbb9fbd6ace", "embedding": null, "metadata": {"window": "If you exclude the impact of COVID -related programs in \nFY 2023, the segment grew 12%.  So we certainly have a lo t of momentum in that business as we enter into FY \n2025.  As Brian mentioned, we're certainly pleased with the opportunity to serve Optum as well.  \n \n So this is a business that we've been making a lot of investments in.  It's a business that we have some exper tise \nthat we're continuing to add to in terms of our sourcing capabilities, providing value back to our customers.  And \nwe have a lot of momentum in this segment.  And so I think the growth rate that we've outlined here for 2025 is a \ncontinuation of the mome ntum that we've seen now over the last several years.  \n ", "original_text": "So this is a business that we've been making a lot of investments in. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05741e79-c295-4ca9-8e03-5359351afb04", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ba6b5674b271661980e6c8adcec2aa40c1d08cd954dce16f564e47c300ff320f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6523ab68-79d3-441b-a378-483b6d822222", "node_type": "1", "metadata": {"window": "We're \ncertainly pleased with the growth that we saw in FY 2024.  If you exclude the impact of COVID -related programs in \nFY 2023, the segment grew 12%.  So we certainly have a lo t of momentum in that business as we enter into FY \n2025.  As Brian mentioned, we're certainly pleased with the opportunity to serve Optum as well.  \n \n So this is a business that we've been making a lot of investments in.  It's a business that we have some exper tise \nthat we're continuing to add to in terms of our sourcing capabilities, providing value back to our customers.  And \nwe have a lot of momentum in this segment. ", "original_text": "As Brian mentioned, we're certainly pleased with the opportunity to serve Optum as well.  \n \n", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "663ee47e48d57aa24018cd16494105254a66e7b166ec3fbabcfa8dbd254d4abd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "647f33a3-3b52-4cb3-979d-a19e3bd71ed8", "node_type": "1", "metadata": {"window": "So we certainly have a lo t of momentum in that business as we enter into FY \n2025.  As Brian mentioned, we're certainly pleased with the opportunity to serve Optum as well.  \n \n So this is a business that we've been making a lot of investments in.  It's a business that we have some exper tise \nthat we're continuing to add to in terms of our sourcing capabilities, providing value back to our customers.  And \nwe have a lot of momentum in this segment.  And so I think the growth rate that we've outlined here for 2025 is a \ncontinuation of the mome ntum that we've seen now over the last several years.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "It's a business that we have some exper tise \nthat we're continuing to add to in terms of our sourcing capabilities, providing value back to our customers. "}, "hash": "6ab13ad03d107b196ed2934e597d8d398c7961b1e21b44d5feaa12eef0c76363", "class_name": "RelatedNodeInfo"}}, "text": "So this is a business that we've been making a lot of investments in. ", "start_char_idx": 1970, "end_char_idx": 2040, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "647f33a3-3b52-4cb3-979d-a19e3bd71ed8": {"__data__": {"id_": "647f33a3-3b52-4cb3-979d-a19e3bd71ed8", "embedding": null, "metadata": {"window": "So we certainly have a lo t of momentum in that business as we enter into FY \n2025.  As Brian mentioned, we're certainly pleased with the opportunity to serve Optum as well.  \n \n So this is a business that we've been making a lot of investments in.  It's a business that we have some exper tise \nthat we're continuing to add to in terms of our sourcing capabilities, providing value back to our customers.  And \nwe have a lot of momentum in this segment.  And so I think the growth rate that we've outlined here for 2025 is a \ncontinuation of the mome ntum that we've seen now over the last several years.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "It's a business that we have some exper tise \nthat we're continuing to add to in terms of our sourcing capabilities, providing value back to our customers. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05741e79-c295-4ca9-8e03-5359351afb04", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ba6b5674b271661980e6c8adcec2aa40c1d08cd954dce16f564e47c300ff320f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf22e1e4-5564-4745-a679-5bbb9fbd6ace", "node_type": "1", "metadata": {"window": "If you exclude the impact of COVID -related programs in \nFY 2023, the segment grew 12%.  So we certainly have a lo t of momentum in that business as we enter into FY \n2025.  As Brian mentioned, we're certainly pleased with the opportunity to serve Optum as well.  \n \n So this is a business that we've been making a lot of investments in.  It's a business that we have some exper tise \nthat we're continuing to add to in terms of our sourcing capabilities, providing value back to our customers.  And \nwe have a lot of momentum in this segment.  And so I think the growth rate that we've outlined here for 2025 is a \ncontinuation of the mome ntum that we've seen now over the last several years.  \n ", "original_text": "So this is a business that we've been making a lot of investments in. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "725687c55b3cf123d44c9b562580b004522b1e700d3e78ac73f94d95ee6d92ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0141545c-e756-4c1c-aafc-61b46a10029e", "node_type": "1", "metadata": {"window": "As Brian mentioned, we're certainly pleased with the opportunity to serve Optum as well.  \n \n So this is a business that we've been making a lot of investments in.  It's a business that we have some exper tise \nthat we're continuing to add to in terms of our sourcing capabilities, providing value back to our customers.  And \nwe have a lot of momentum in this segment.  And so I think the growth rate that we've outlined here for 2025 is a \ncontinuation of the mome ntum that we've seen now over the last several years.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "And \nwe have a lot of momentum in this segment. "}, "hash": "74dbe3cc24774ee97ede79d797b7bbfcdb50b45490c33239b8772b5ea8c9ddf1", "class_name": "RelatedNodeInfo"}}, "text": "It's a business that we have some exper tise \nthat we're continuing to add to in terms of our sourcing capabilities, providing value back to our customers. ", "start_char_idx": 2040, "end_char_idx": 2196, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0141545c-e756-4c1c-aafc-61b46a10029e": {"__data__": {"id_": "0141545c-e756-4c1c-aafc-61b46a10029e", "embedding": null, "metadata": {"window": "As Brian mentioned, we're certainly pleased with the opportunity to serve Optum as well.  \n \n So this is a business that we've been making a lot of investments in.  It's a business that we have some exper tise \nthat we're continuing to add to in terms of our sourcing capabilities, providing value back to our customers.  And \nwe have a lot of momentum in this segment.  And so I think the growth rate that we've outlined here for 2025 is a \ncontinuation of the mome ntum that we've seen now over the last several years.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "And \nwe have a lot of momentum in this segment. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05741e79-c295-4ca9-8e03-5359351afb04", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ba6b5674b271661980e6c8adcec2aa40c1d08cd954dce16f564e47c300ff320f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "647f33a3-3b52-4cb3-979d-a19e3bd71ed8", "node_type": "1", "metadata": {"window": "So we certainly have a lo t of momentum in that business as we enter into FY \n2025.  As Brian mentioned, we're certainly pleased with the opportunity to serve Optum as well.  \n \n So this is a business that we've been making a lot of investments in.  It's a business that we have some exper tise \nthat we're continuing to add to in terms of our sourcing capabilities, providing value back to our customers.  And \nwe have a lot of momentum in this segment.  And so I think the growth rate that we've outlined here for 2025 is a \ncontinuation of the mome ntum that we've seen now over the last several years.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "It's a business that we have some exper tise \nthat we're continuing to add to in terms of our sourcing capabilities, providing value back to our customers. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "8ac3cee1455b1e499ce4ec04bfe425032c1a4eccb4ac5bf5534307b2199361a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea21a2bc-d08c-45fc-861e-d0eb8dea3c1b", "node_type": "1", "metadata": {"window": "So this is a business that we've been making a lot of investments in.  It's a business that we have some exper tise \nthat we're continuing to add to in terms of our sourcing capabilities, providing value back to our customers.  And \nwe have a lot of momentum in this segment.  And so I think the growth rate that we've outlined here for 2025 is a \ncontinuation of the mome ntum that we've seen now over the last several years.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Leerink Partners. ", "original_text": "And so I think the growth rate that we've outlined here for 2025 is a \ncontinuation of the mome ntum that we've seen now over the last several years.  \n "}, "hash": "f8887d6147e8d2cd7409f85cefb2b745e04608ffae2fec80a746c84c228840b0", "class_name": "RelatedNodeInfo"}}, "text": "And \nwe have a lot of momentum in this segment. ", "start_char_idx": 2196, "end_char_idx": 2244, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea21a2bc-d08c-45fc-861e-d0eb8dea3c1b": {"__data__": {"id_": "ea21a2bc-d08c-45fc-861e-d0eb8dea3c1b", "embedding": null, "metadata": {"window": "So this is a business that we've been making a lot of investments in.  It's a business that we have some exper tise \nthat we're continuing to add to in terms of our sourcing capabilities, providing value back to our customers.  And \nwe have a lot of momentum in this segment.  And so I think the growth rate that we've outlined here for 2025 is a \ncontinuation of the mome ntum that we've seen now over the last several years.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Leerink Partners. ", "original_text": "And so I think the growth rate that we've outlined here for 2025 is a \ncontinuation of the mome ntum that we've seen now over the last several years.  \n ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05741e79-c295-4ca9-8e03-5359351afb04", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ba6b5674b271661980e6c8adcec2aa40c1d08cd954dce16f564e47c300ff320f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0141545c-e756-4c1c-aafc-61b46a10029e", "node_type": "1", "metadata": {"window": "As Brian mentioned, we're certainly pleased with the opportunity to serve Optum as well.  \n \n So this is a business that we've been making a lot of investments in.  It's a business that we have some exper tise \nthat we're continuing to add to in terms of our sourcing capabilities, providing value back to our customers.  And \nwe have a lot of momentum in this segment.  And so I think the growth rate that we've outlined here for 2025 is a \ncontinuation of the mome ntum that we've seen now over the last several years.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "And \nwe have a lot of momentum in this segment. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "94207fddacd01796efbba5a0faa78b5df6bcc89b078a43626996e7be51dbab0d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0c4b3ff-29d4-4525-879d-6818847ba48e", "node_type": "1", "metadata": {"window": "It's a business that we have some exper tise \nthat we're continuing to add to in terms of our sourcing capabilities, providing value back to our customers.  And \nwe have a lot of momentum in this segment.  And so I think the growth rate that we've outlined here for 2025 is a \ncontinuation of the mome ntum that we've seen now over the last several years.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Leerink Partners.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  "}, "hash": "fe8545fb65b824c2200043c1da0198b12e0491633d954b8488ea203e3f58ab35", "class_name": "RelatedNodeInfo"}}, "text": "And so I think the growth rate that we've outlined here for 2025 is a \ncontinuation of the mome ntum that we've seen now over the last several years.  \n ", "start_char_idx": 2244, "end_char_idx": 2397, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0c4b3ff-29d4-4525-879d-6818847ba48e": {"__data__": {"id_": "f0c4b3ff-29d4-4525-879d-6818847ba48e", "embedding": null, "metadata": {"window": "It's a business that we have some exper tise \nthat we're continuing to add to in terms of our sourcing capabilities, providing value back to our customers.  And \nwe have a lot of momentum in this segment.  And so I think the growth rate that we've outlined here for 2025 is a \ncontinuation of the mome ntum that we've seen now over the last several years.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Leerink Partners.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05741e79-c295-4ca9-8e03-5359351afb04", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ba6b5674b271661980e6c8adcec2aa40c1d08cd954dce16f564e47c300ff320f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea21a2bc-d08c-45fc-861e-d0eb8dea3c1b", "node_type": "1", "metadata": {"window": "So this is a business that we've been making a lot of investments in.  It's a business that we have some exper tise \nthat we're continuing to add to in terms of our sourcing capabilities, providing value back to our customers.  And \nwe have a lot of momentum in this segment.  And so I think the growth rate that we've outlined here for 2025 is a \ncontinuation of the mome ntum that we've seen now over the last several years.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Leerink Partners. ", "original_text": "And so I think the growth rate that we've outlined here for 2025 is a \ncontinuation of the mome ntum that we've seen now over the last several years.  \n ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d503d8b41e01b996a87e258e1e93e8fb9501c7ec812e1a75bb34ad85d8d70df4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35d4d5ab-629f-4b7e-8c34-cf53c0eb51c2", "node_type": "1", "metadata": {"window": "And \nwe have a lot of momentum in this segment.  And so I think the growth rate that we've outlined here for 2025 is a \ncontinuation of the mome ntum that we've seen now over the last several years.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Leerink Partners.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  Q \nGood afternoon. ", "original_text": "A \nNext question, please.  \n "}, "hash": "129a2ffe5b6ef0ccb3436ed77ade96abe7d30d94bad2113c1981f7e90093bcde", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "start_char_idx": 2397, "end_char_idx": 2742, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35d4d5ab-629f-4b7e-8c34-cf53c0eb51c2": {"__data__": {"id_": "35d4d5ab-629f-4b7e-8c34-cf53c0eb51c2", "embedding": null, "metadata": {"window": "And \nwe have a lot of momentum in this segment.  And so I think the growth rate that we've outlined here for 2025 is a \ncontinuation of the mome ntum that we've seen now over the last several years.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Leerink Partners.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  Q \nGood afternoon. ", "original_text": "A \nNext question, please.  \n ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05741e79-c295-4ca9-8e03-5359351afb04", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ba6b5674b271661980e6c8adcec2aa40c1d08cd954dce16f564e47c300ff320f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0c4b3ff-29d4-4525-879d-6818847ba48e", "node_type": "1", "metadata": {"window": "It's a business that we have some exper tise \nthat we're continuing to add to in terms of our sourcing capabilities, providing value back to our customers.  And \nwe have a lot of momentum in this segment.  And so I think the growth rate that we've outlined here for 2025 is a \ncontinuation of the mome ntum that we've seen now over the last several years.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Leerink Partners.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f977f1d22d1440d4b3ff9632c3efdadea30859c6e5bec58f6cae44dcf0c1e207", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48f031c8-2359-40b9-9c53-bf57cc994cdd", "node_type": "1", "metadata": {"window": "And so I think the growth rate that we've outlined here for 2025 is a \ncontinuation of the mome ntum that we've seen now over the last several years.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Leerink Partners.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  Q \nGood afternoon.  Thanks for taking the question and congratulations on a really nice guide. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Leerink Partners. "}, "hash": "ec054ebe431e14ea086e76385220661c10fecc56a28ef87d2d9d9598b1c9d5f1", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please.  \n ", "start_char_idx": 2742, "end_char_idx": 2771, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48f031c8-2359-40b9-9c53-bf57cc994cdd": {"__data__": {"id_": "48f031c8-2359-40b9-9c53-bf57cc994cdd", "embedding": null, "metadata": {"window": "And so I think the growth rate that we've outlined here for 2025 is a \ncontinuation of the mome ntum that we've seen now over the last several years.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Leerink Partners.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  Q \nGood afternoon.  Thanks for taking the question and congratulations on a really nice guide. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Leerink Partners. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05741e79-c295-4ca9-8e03-5359351afb04", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ba6b5674b271661980e6c8adcec2aa40c1d08cd954dce16f564e47c300ff320f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35d4d5ab-629f-4b7e-8c34-cf53c0eb51c2", "node_type": "1", "metadata": {"window": "And \nwe have a lot of momentum in this segment.  And so I think the growth rate that we've outlined here for 2025 is a \ncontinuation of the mome ntum that we've seen now over the last several years.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Leerink Partners.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  Q \nGood afternoon. ", "original_text": "A \nNext question, please.  \n ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e1471006d7cfefe10dd8d37676234b0e2500c544837037c572ba583db96615d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c6b9043-a55d-404f-bc8d-581c7ef2ff6a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Leerink Partners.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  Q \nGood afternoon.  Thanks for taking the question and congratulations on a really nice guide.  As we think forward, \nboth for 2025 and beyond, I want to ask a little bit about the oncology side of your assets and maybe wrap it i nto \nthe secondary question, but you continue to scale stuff like USO and Ontada alongside, obviously, everything \ninside the Pharma Services segment. ", "original_text": "Please go ahead.  \n "}, "hash": "fd0376f33b2db968007eff438f275b4554408000898c4c878baff18f8a70eec1", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Leerink Partners. ", "start_char_idx": 2771, "end_char_idx": 3111, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c6b9043-a55d-404f-bc8d-581c7ef2ff6a": {"__data__": {"id_": "5c6b9043-a55d-404f-bc8d-581c7ef2ff6a", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Leerink Partners.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  Q \nGood afternoon.  Thanks for taking the question and congratulations on a really nice guide.  As we think forward, \nboth for 2025 and beyond, I want to ask a little bit about the oncology side of your assets and maybe wrap it i nto \nthe secondary question, but you continue to scale stuff like USO and Ontada alongside, obviously, everything \ninside the Pharma Services segment. ", "original_text": "Please go ahead.  \n ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05741e79-c295-4ca9-8e03-5359351afb04", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ba6b5674b271661980e6c8adcec2aa40c1d08cd954dce16f564e47c300ff320f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48f031c8-2359-40b9-9c53-bf57cc994cdd", "node_type": "1", "metadata": {"window": "And so I think the growth rate that we've outlined here for 2025 is a \ncontinuation of the mome ntum that we've seen now over the last several years.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Leerink Partners.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  Q \nGood afternoon.  Thanks for taking the question and congratulations on a really nice guide. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Leerink Partners. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a2d6b4f8977c420dc77003c191b26f03dbc2b83dd4e98ad436d78bbba63347cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0ecf790-ec74-4a77-915c-7c92fa8ce40a", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Leerink Partners.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  Q \nGood afternoon.  Thanks for taking the question and congratulations on a really nice guide.  As we think forward, \nboth for 2025 and beyond, I want to ask a little bit about the oncology side of your assets and maybe wrap it i nto \nthe secondary question, but you continue to scale stuff like USO and Ontada alongside, obviously, everything \ninside the Pharma Services segment.  As you think about the totality of the assets and the ability to build off of that \nplatform, how does that dovetail with your ability also to utilize your ever -growing free cash flow to continue to \ndrive inorganic growth on top of organic? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  Q \nGood afternoon. "}, "hash": "5a0b8328852a30def98dc440056cefd0943a9dd7e264ee9243cdef72b61d3bda", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 3111, "end_char_idx": 3131, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0ecf790-ec74-4a77-915c-7c92fa8ce40a": {"__data__": {"id_": "d0ecf790-ec74-4a77-915c-7c92fa8ce40a", "embedding": null, "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Leerink Partners.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  Q \nGood afternoon.  Thanks for taking the question and congratulations on a really nice guide.  As we think forward, \nboth for 2025 and beyond, I want to ask a little bit about the oncology side of your assets and maybe wrap it i nto \nthe secondary question, but you continue to scale stuff like USO and Ontada alongside, obviously, everything \ninside the Pharma Services segment.  As you think about the totality of the assets and the ability to build off of that \nplatform, how does that dovetail with your ability also to utilize your ever -growing free cash flow to continue to \ndrive inorganic growth on top of organic? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  Q \nGood afternoon. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05741e79-c295-4ca9-8e03-5359351afb04", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ba6b5674b271661980e6c8adcec2aa40c1d08cd954dce16f564e47c300ff320f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c6b9043-a55d-404f-bc8d-581c7ef2ff6a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Leerink Partners.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  Q \nGood afternoon.  Thanks for taking the question and congratulations on a really nice guide.  As we think forward, \nboth for 2025 and beyond, I want to ask a little bit about the oncology side of your assets and maybe wrap it i nto \nthe secondary question, but you continue to scale stuff like USO and Ontada alongside, obviously, everything \ninside the Pharma Services segment. ", "original_text": "Please go ahead.  \n ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "dd562aec61aa8287477bb80b50a7b38576c873eda7f4d849c8d0f03b57b149b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28fd606d-5cc3-4ea7-8ea7-ccfeab28d896", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Leerink Partners.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  Q \nGood afternoon.  Thanks for taking the question and congratulations on a really nice guide.  As we think forward, \nboth for 2025 and beyond, I want to ask a little bit about the oncology side of your assets and maybe wrap it i nto \nthe secondary question, but you continue to scale stuff like USO and Ontada alongside, obviously, everything \ninside the Pharma Services segment.  As you think about the totality of the assets and the ability to build off of that \nplatform, how does that dovetail with your ability also to utilize your ever -growing free cash flow to continue to \ndrive inorganic growth on top of organic?  And within that portfolio of, again, broad -based oncology assets, what \nare the best areas you have to continue to expand be yond where you already are?  \n ", "original_text": "Thanks for taking the question and congratulations on a really nice guide. "}, "hash": "390e42c94b3dd4002d9cb89d3495e6b44afd36ede1957399e50cf73d0e320796", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  Q \nGood afternoon. ", "start_char_idx": 3131, "end_char_idx": 3470, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28fd606d-5cc3-4ea7-8ea7-ccfeab28d896": {"__data__": {"id_": "28fd606d-5cc3-4ea7-8ea7-ccfeab28d896", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Leerink Partners.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  Q \nGood afternoon.  Thanks for taking the question and congratulations on a really nice guide.  As we think forward, \nboth for 2025 and beyond, I want to ask a little bit about the oncology side of your assets and maybe wrap it i nto \nthe secondary question, but you continue to scale stuff like USO and Ontada alongside, obviously, everything \ninside the Pharma Services segment.  As you think about the totality of the assets and the ability to build off of that \nplatform, how does that dovetail with your ability also to utilize your ever -growing free cash flow to continue to \ndrive inorganic growth on top of organic?  And within that portfolio of, again, broad -based oncology assets, what \nare the best areas you have to continue to expand be yond where you already are?  \n ", "original_text": "Thanks for taking the question and congratulations on a really nice guide. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05741e79-c295-4ca9-8e03-5359351afb04", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ba6b5674b271661980e6c8adcec2aa40c1d08cd954dce16f564e47c300ff320f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0ecf790-ec74-4a77-915c-7c92fa8ce40a", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Leerink Partners.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  Q \nGood afternoon.  Thanks for taking the question and congratulations on a really nice guide.  As we think forward, \nboth for 2025 and beyond, I want to ask a little bit about the oncology side of your assets and maybe wrap it i nto \nthe secondary question, but you continue to scale stuff like USO and Ontada alongside, obviously, everything \ninside the Pharma Services segment.  As you think about the totality of the assets and the ability to build off of that \nplatform, how does that dovetail with your ability also to utilize your ever -growing free cash flow to continue to \ndrive inorganic growth on top of organic? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  Q \nGood afternoon. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "bbcd679d790ce9f7dad7b39f85738b44222f46b8adb8aec8809c0bbf73401f48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4a75192-81d2-49de-bc80-5ae83be20556", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  Q \nGood afternoon.  Thanks for taking the question and congratulations on a really nice guide.  As we think forward, \nboth for 2025 and beyond, I want to ask a little bit about the oncology side of your assets and maybe wrap it i nto \nthe secondary question, but you continue to scale stuff like USO and Ontada alongside, obviously, everything \ninside the Pharma Services segment.  As you think about the totality of the assets and the ability to build off of that \nplatform, how does that dovetail with your ability also to utilize your ever -growing free cash flow to continue to \ndrive inorganic growth on top of organic?  And within that portfolio of, again, broad -based oncology assets, what \nare the best areas you have to continue to expand be yond where you already are?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "As we think forward, \nboth for 2025 and beyond, I want to ask a little bit about the oncology side of your assets and maybe wrap it i nto \nthe secondary question, but you continue to scale stuff like USO and Ontada alongside, obviously, everything \ninside the Pharma Services segment. "}, "hash": "dcb932a5507fc59fe53e371bdaaa6a3b63a21e7f68672aaf500c0b6c80ad9966", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking the question and congratulations on a really nice guide. ", "start_char_idx": 3470, "end_char_idx": 3545, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4a75192-81d2-49de-bc80-5ae83be20556": {"__data__": {"id_": "e4a75192-81d2-49de-bc80-5ae83be20556", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  Q \nGood afternoon.  Thanks for taking the question and congratulations on a really nice guide.  As we think forward, \nboth for 2025 and beyond, I want to ask a little bit about the oncology side of your assets and maybe wrap it i nto \nthe secondary question, but you continue to scale stuff like USO and Ontada alongside, obviously, everything \ninside the Pharma Services segment.  As you think about the totality of the assets and the ability to build off of that \nplatform, how does that dovetail with your ability also to utilize your ever -growing free cash flow to continue to \ndrive inorganic growth on top of organic?  And within that portfolio of, again, broad -based oncology assets, what \nare the best areas you have to continue to expand be yond where you already are?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "As we think forward, \nboth for 2025 and beyond, I want to ask a little bit about the oncology side of your assets and maybe wrap it i nto \nthe secondary question, but you continue to scale stuff like USO and Ontada alongside, obviously, everything \ninside the Pharma Services segment. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05741e79-c295-4ca9-8e03-5359351afb04", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ba6b5674b271661980e6c8adcec2aa40c1d08cd954dce16f564e47c300ff320f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28fd606d-5cc3-4ea7-8ea7-ccfeab28d896", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Leerink Partners.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  Q \nGood afternoon.  Thanks for taking the question and congratulations on a really nice guide.  As we think forward, \nboth for 2025 and beyond, I want to ask a little bit about the oncology side of your assets and maybe wrap it i nto \nthe secondary question, but you continue to scale stuff like USO and Ontada alongside, obviously, everything \ninside the Pharma Services segment.  As you think about the totality of the assets and the ability to build off of that \nplatform, how does that dovetail with your ability also to utilize your ever -growing free cash flow to continue to \ndrive inorganic growth on top of organic?  And within that portfolio of, again, broad -based oncology assets, what \nare the best areas you have to continue to expand be yond where you already are?  \n ", "original_text": "Thanks for taking the question and congratulations on a really nice guide. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e30d79f1610facfaa5ef1cbf8a3f95d7dd695a3d62aefa5b758d8e753a0b481e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c54ebc60-9f18-483e-9006-cd6cc07f51a1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  Q \nGood afternoon.  Thanks for taking the question and congratulations on a really nice guide.  As we think forward, \nboth for 2025 and beyond, I want to ask a little bit about the oncology side of your assets and maybe wrap it i nto \nthe secondary question, but you continue to scale stuff like USO and Ontada alongside, obviously, everything \ninside the Pharma Services segment.  As you think about the totality of the assets and the ability to build off of that \nplatform, how does that dovetail with your ability also to utilize your ever -growing free cash flow to continue to \ndrive inorganic growth on top of organic?  And within that portfolio of, again, broad -based oncology assets, what \nare the best areas you have to continue to expand be yond where you already are?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you. ", "original_text": "As you think about the totality of the assets and the ability to build off of that \nplatform, how does that dovetail with your ability also to utilize your ever -growing free cash flow to continue to \ndrive inorganic growth on top of organic? "}, "hash": "7b3d80bff3d0d4d9ae67007f5c4b807bb0baea72e8526c06c433e5029b8f5461", "class_name": "RelatedNodeInfo"}}, "text": "As we think forward, \nboth for 2025 and beyond, I want to ask a little bit about the oncology side of your assets and maybe wrap it i nto \nthe secondary question, but you continue to scale stuff like USO and Ontada alongside, obviously, everything \ninside the Pharma Services segment. ", "start_char_idx": 3545, "end_char_idx": 3830, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c54ebc60-9f18-483e-9006-cd6cc07f51a1": {"__data__": {"id_": "c54ebc60-9f18-483e-9006-cd6cc07f51a1", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  Q \nGood afternoon.  Thanks for taking the question and congratulations on a really nice guide.  As we think forward, \nboth for 2025 and beyond, I want to ask a little bit about the oncology side of your assets and maybe wrap it i nto \nthe secondary question, but you continue to scale stuff like USO and Ontada alongside, obviously, everything \ninside the Pharma Services segment.  As you think about the totality of the assets and the ability to build off of that \nplatform, how does that dovetail with your ability also to utilize your ever -growing free cash flow to continue to \ndrive inorganic growth on top of organic?  And within that portfolio of, again, broad -based oncology assets, what \nare the best areas you have to continue to expand be yond where you already are?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you. ", "original_text": "As you think about the totality of the assets and the ability to build off of that \nplatform, how does that dovetail with your ability also to utilize your ever -growing free cash flow to continue to \ndrive inorganic growth on top of organic? ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05741e79-c295-4ca9-8e03-5359351afb04", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ba6b5674b271661980e6c8adcec2aa40c1d08cd954dce16f564e47c300ff320f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4a75192-81d2-49de-bc80-5ae83be20556", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  Q \nGood afternoon.  Thanks for taking the question and congratulations on a really nice guide.  As we think forward, \nboth for 2025 and beyond, I want to ask a little bit about the oncology side of your assets and maybe wrap it i nto \nthe secondary question, but you continue to scale stuff like USO and Ontada alongside, obviously, everything \ninside the Pharma Services segment.  As you think about the totality of the assets and the ability to build off of that \nplatform, how does that dovetail with your ability also to utilize your ever -growing free cash flow to continue to \ndrive inorganic growth on top of organic?  And within that portfolio of, again, broad -based oncology assets, what \nare the best areas you have to continue to expand be yond where you already are?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "As we think forward, \nboth for 2025 and beyond, I want to ask a little bit about the oncology side of your assets and maybe wrap it i nto \nthe secondary question, but you continue to scale stuff like USO and Ontada alongside, obviously, everything \ninside the Pharma Services segment. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "25b6b424bf1c13c8de3bf71d0745acf419c04a07565489be4fcd863c8a7d5739", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ffa91fb-fd7c-46f0-8aa5-132bd2153ae6", "node_type": "1", "metadata": {"window": "Thanks for taking the question and congratulations on a really nice guide.  As we think forward, \nboth for 2025 and beyond, I want to ask a little bit about the oncology side of your assets and maybe wrap it i nto \nthe secondary question, but you continue to scale stuff like USO and Ontada alongside, obviously, everything \ninside the Pharma Services segment.  As you think about the totality of the assets and the ability to build off of that \nplatform, how does that dovetail with your ability also to utilize your ever -growing free cash flow to continue to \ndrive inorganic growth on top of organic?  And within that portfolio of, again, broad -based oncology assets, what \nare the best areas you have to continue to expand be yond where you already are?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you.  Michael, I appreciate that. ", "original_text": "And within that portfolio of, again, broad -based oncology assets, what \nare the best areas you have to continue to expand be yond where you already are?  \n "}, "hash": "16742058fdf01decb0899049463f4d192cf41a9bf6f634d4bf48ac58647c9d6e", "class_name": "RelatedNodeInfo"}}, "text": "As you think about the totality of the assets and the ability to build off of that \nplatform, how does that dovetail with your ability also to utilize your ever -growing free cash flow to continue to \ndrive inorganic growth on top of organic? ", "start_char_idx": 3830, "end_char_idx": 4073, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ffa91fb-fd7c-46f0-8aa5-132bd2153ae6": {"__data__": {"id_": "6ffa91fb-fd7c-46f0-8aa5-132bd2153ae6", "embedding": null, "metadata": {"window": "Thanks for taking the question and congratulations on a really nice guide.  As we think forward, \nboth for 2025 and beyond, I want to ask a little bit about the oncology side of your assets and maybe wrap it i nto \nthe secondary question, but you continue to scale stuff like USO and Ontada alongside, obviously, everything \ninside the Pharma Services segment.  As you think about the totality of the assets and the ability to build off of that \nplatform, how does that dovetail with your ability also to utilize your ever -growing free cash flow to continue to \ndrive inorganic growth on top of organic?  And within that portfolio of, again, broad -based oncology assets, what \nare the best areas you have to continue to expand be yond where you already are?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you.  Michael, I appreciate that. ", "original_text": "And within that portfolio of, again, broad -based oncology assets, what \nare the best areas you have to continue to expand be yond where you already are?  \n ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05741e79-c295-4ca9-8e03-5359351afb04", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ba6b5674b271661980e6c8adcec2aa40c1d08cd954dce16f564e47c300ff320f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c54ebc60-9f18-483e-9006-cd6cc07f51a1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Leerink Partners LLC  Q \nGood afternoon.  Thanks for taking the question and congratulations on a really nice guide.  As we think forward, \nboth for 2025 and beyond, I want to ask a little bit about the oncology side of your assets and maybe wrap it i nto \nthe secondary question, but you continue to scale stuff like USO and Ontada alongside, obviously, everything \ninside the Pharma Services segment.  As you think about the totality of the assets and the ability to build off of that \nplatform, how does that dovetail with your ability also to utilize your ever -growing free cash flow to continue to \ndrive inorganic growth on top of organic?  And within that portfolio of, again, broad -based oncology assets, what \nare the best areas you have to continue to expand be yond where you already are?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you. ", "original_text": "As you think about the totality of the assets and the ability to build off of that \nplatform, how does that dovetail with your ability also to utilize your ever -growing free cash flow to continue to \ndrive inorganic growth on top of organic? ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c474127f1f1a74e83cf1ee47c5135c016c8e684ab95b82f32d05e57bdc02dd95", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "842531df-9ff8-48c1-98e5-5693d772c333", "node_type": "1", "metadata": {"window": "As we think forward, \nboth for 2025 and beyond, I want to ask a little bit about the oncology side of your assets and maybe wrap it i nto \nthe secondary question, but you continue to scale stuff like USO and Ontada alongside, obviously, everything \ninside the Pharma Services segment.  As you think about the totality of the assets and the ability to build off of that \nplatform, how does that dovetail with your ability also to utilize your ever -growing free cash flow to continue to \ndrive inorganic growth on top of organic?  And within that portfolio of, again, broad -based oncology assets, what \nare the best areas you have to continue to expand be yond where you already are?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you.  Michael, I appreciate that.  We talked about many times our capital allocation strategy, and our first \npriority in that strategy is to invest to  grow the business either through internal development and investments in \ninnovation or inorganic opportunities.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "87a3924d67a8aaec14646daf47b5ba32c71078d40706750eb26f42696627d52c", "class_name": "RelatedNodeInfo"}}, "text": "And within that portfolio of, again, broad -based oncology assets, what \nare the best areas you have to continue to expand be yond where you already are?  \n ", "start_char_idx": 4073, "end_char_idx": 4230, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "842531df-9ff8-48c1-98e5-5693d772c333": {"__data__": {"id_": "842531df-9ff8-48c1-98e5-5693d772c333", "embedding": null, "metadata": {"window": "As we think forward, \nboth for 2025 and beyond, I want to ask a little bit about the oncology side of your assets and maybe wrap it i nto \nthe secondary question, but you continue to scale stuff like USO and Ontada alongside, obviously, everything \ninside the Pharma Services segment.  As you think about the totality of the assets and the ability to build off of that \nplatform, how does that dovetail with your ability also to utilize your ever -growing free cash flow to continue to \ndrive inorganic growth on top of organic?  And within that portfolio of, again, broad -based oncology assets, what \nare the best areas you have to continue to expand be yond where you already are?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you.  Michael, I appreciate that.  We talked about many times our capital allocation strategy, and our first \npriority in that strategy is to invest to  grow the business either through internal development and investments in \ninnovation or inorganic opportunities.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05741e79-c295-4ca9-8e03-5359351afb04", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ba6b5674b271661980e6c8adcec2aa40c1d08cd954dce16f564e47c300ff320f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ffa91fb-fd7c-46f0-8aa5-132bd2153ae6", "node_type": "1", "metadata": {"window": "Thanks for taking the question and congratulations on a really nice guide.  As we think forward, \nboth for 2025 and beyond, I want to ask a little bit about the oncology side of your assets and maybe wrap it i nto \nthe secondary question, but you continue to scale stuff like USO and Ontada alongside, obviously, everything \ninside the Pharma Services segment.  As you think about the totality of the assets and the ability to build off of that \nplatform, how does that dovetail with your ability also to utilize your ever -growing free cash flow to continue to \ndrive inorganic growth on top of organic?  And within that portfolio of, again, broad -based oncology assets, what \nare the best areas you have to continue to expand be yond where you already are?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you.  Michael, I appreciate that. ", "original_text": "And within that portfolio of, again, broad -based oncology assets, what \nare the best areas you have to continue to expand be yond where you already are?  \n ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "897f23262509597dc617572e376a69369041d5d07c3f777ee9b4eb0ea649633a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1bdee844-68d0-454f-93b2-1d8003f9c525", "node_type": "1", "metadata": {"window": "As you think about the totality of the assets and the ability to build off of that \nplatform, how does that dovetail with your ability also to utilize your ever -growing free cash flow to continue to \ndrive inorganic growth on top of organic?  And within that portfolio of, again, broad -based oncology assets, what \nare the best areas you have to continue to expand be yond where you already are?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you.  Michael, I appreciate that.  We talked about many times our capital allocation strategy, and our first \npriority in that strategy is to invest to  grow the business either through internal development and investments in \ninnovation or inorganic opportunities.  \n \n Certainly, when we look at inorganic opportunities or M&A, we like that to be very, very tightly aligned to our \narticulated strategy with the associated proper financial returns, of course. ", "original_text": "A \nThank you. "}, "hash": "1bd1e8d2294f1d015c13c675f1d3667da638d83ced903ee1159b4f6774cd3854", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 4230, "end_char_idx": 4574, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1bdee844-68d0-454f-93b2-1d8003f9c525": {"__data__": {"id_": "1bdee844-68d0-454f-93b2-1d8003f9c525", "embedding": null, "metadata": {"window": "As you think about the totality of the assets and the ability to build off of that \nplatform, how does that dovetail with your ability also to utilize your ever -growing free cash flow to continue to \ndrive inorganic growth on top of organic?  And within that portfolio of, again, broad -based oncology assets, what \nare the best areas you have to continue to expand be yond where you already are?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you.  Michael, I appreciate that.  We talked about many times our capital allocation strategy, and our first \npriority in that strategy is to invest to  grow the business either through internal development and investments in \ninnovation or inorganic opportunities.  \n \n Certainly, when we look at inorganic opportunities or M&A, we like that to be very, very tightly aligned to our \narticulated strategy with the associated proper financial returns, of course. ", "original_text": "A \nThank you. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05741e79-c295-4ca9-8e03-5359351afb04", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ba6b5674b271661980e6c8adcec2aa40c1d08cd954dce16f564e47c300ff320f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "842531df-9ff8-48c1-98e5-5693d772c333", "node_type": "1", "metadata": {"window": "As we think forward, \nboth for 2025 and beyond, I want to ask a little bit about the oncology side of your assets and maybe wrap it i nto \nthe secondary question, but you continue to scale stuff like USO and Ontada alongside, obviously, everything \ninside the Pharma Services segment.  As you think about the totality of the assets and the ability to build off of that \nplatform, how does that dovetail with your ability also to utilize your ever -growing free cash flow to continue to \ndrive inorganic growth on top of organic?  And within that portfolio of, again, broad -based oncology assets, what \nare the best areas you have to continue to expand be yond where you already are?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you.  Michael, I appreciate that.  We talked about many times our capital allocation strategy, and our first \npriority in that strategy is to invest to  grow the business either through internal development and investments in \ninnovation or inorganic opportunities.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "2f368a3565eda53f0a506cc6aac1e5003c95505e80dfc981303d8621c2ec07ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0311cb09-d9c9-41b8-b9f1-ed7bb158eabe", "node_type": "1", "metadata": {"window": "And within that portfolio of, again, broad -based oncology assets, what \nare the best areas you have to continue to expand be yond where you already are?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you.  Michael, I appreciate that.  We talked about many times our capital allocation strategy, and our first \npriority in that strategy is to invest to  grow the business either through internal development and investments in \ninnovation or inorganic opportunities.  \n \n Certainly, when we look at inorganic opportunities or M&A, we like that to be very, very tightly aligned to our \narticulated strategy with the associated proper financial returns, of course.  And so oncology is one of those \ngrowth areas and one of those growth priorities. ", "original_text": "Michael, I appreciate that. "}, "hash": "bacc3f0f0fc51dee87164cebd482b15b48ed35770c6bfd92ba2be1c61014a2b7", "class_name": "RelatedNodeInfo"}}, "text": "A \nThank you. ", "start_char_idx": 4574, "end_char_idx": 4588, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0311cb09-d9c9-41b8-b9f1-ed7bb158eabe": {"__data__": {"id_": "0311cb09-d9c9-41b8-b9f1-ed7bb158eabe", "embedding": null, "metadata": {"window": "And within that portfolio of, again, broad -based oncology assets, what \nare the best areas you have to continue to expand be yond where you already are?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you.  Michael, I appreciate that.  We talked about many times our capital allocation strategy, and our first \npriority in that strategy is to invest to  grow the business either through internal development and investments in \ninnovation or inorganic opportunities.  \n \n Certainly, when we look at inorganic opportunities or M&A, we like that to be very, very tightly aligned to our \narticulated strategy with the associated proper financial returns, of course.  And so oncology is one of those \ngrowth areas and one of those growth priorities. ", "original_text": "Michael, I appreciate that. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05741e79-c295-4ca9-8e03-5359351afb04", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ba6b5674b271661980e6c8adcec2aa40c1d08cd954dce16f564e47c300ff320f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1bdee844-68d0-454f-93b2-1d8003f9c525", "node_type": "1", "metadata": {"window": "As you think about the totality of the assets and the ability to build off of that \nplatform, how does that dovetail with your ability also to utilize your ever -growing free cash flow to continue to \ndrive inorganic growth on top of organic?  And within that portfolio of, again, broad -based oncology assets, what \nare the best areas you have to continue to expand be yond where you already are?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you.  Michael, I appreciate that.  We talked about many times our capital allocation strategy, and our first \npriority in that strategy is to invest to  grow the business either through internal development and investments in \ninnovation or inorganic opportunities.  \n \n Certainly, when we look at inorganic opportunities or M&A, we like that to be very, very tightly aligned to our \narticulated strategy with the associated proper financial returns, of course. ", "original_text": "A \nThank you. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "13f9e38f12c36f10a318ed3bc3bda6a4e5b6c093cfed6381c35f1b2ef19a295d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd12198b-eec0-44a5-8b4a-e89ce348451d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you.  Michael, I appreciate that.  We talked about many times our capital allocation strategy, and our first \npriority in that strategy is to invest to  grow the business either through internal development and investments in \ninnovation or inorganic opportunities.  \n \n Certainly, when we look at inorganic opportunities or M&A, we like that to be very, very tightly aligned to our \narticulated strategy with the associated proper financial returns, of course.  And so oncology is one of those \ngrowth areas and one of those growth priorities.  And being a pretty significant player in the oncology space in ", "original_text": "We talked about many times our capital allocation strategy, and our first \npriority in that strategy is to invest to  grow the business either through internal development and investments in \ninnovation or inorganic opportunities.  \n \n"}, "hash": "74137101bf0255f1d56f7194ee6f232d5e4548ec263af41753837dbf4d9bfa68", "class_name": "RelatedNodeInfo"}}, "text": "Michael, I appreciate that. ", "start_char_idx": 4588, "end_char_idx": 4616, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd12198b-eec0-44a5-8b4a-e89ce348451d": {"__data__": {"id_": "dd12198b-eec0-44a5-8b4a-e89ce348451d", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you.  Michael, I appreciate that.  We talked about many times our capital allocation strategy, and our first \npriority in that strategy is to invest to  grow the business either through internal development and investments in \ninnovation or inorganic opportunities.  \n \n Certainly, when we look at inorganic opportunities or M&A, we like that to be very, very tightly aligned to our \narticulated strategy with the associated proper financial returns, of course.  And so oncology is one of those \ngrowth areas and one of those growth priorities.  And being a pretty significant player in the oncology space in ", "original_text": "We talked about many times our capital allocation strategy, and our first \npriority in that strategy is to invest to  grow the business either through internal development and investments in \ninnovation or inorganic opportunities.  \n \n", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05741e79-c295-4ca9-8e03-5359351afb04", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ba6b5674b271661980e6c8adcec2aa40c1d08cd954dce16f564e47c300ff320f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0311cb09-d9c9-41b8-b9f1-ed7bb158eabe", "node_type": "1", "metadata": {"window": "And within that portfolio of, again, broad -based oncology assets, what \nare the best areas you have to continue to expand be yond where you already are?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you.  Michael, I appreciate that.  We talked about many times our capital allocation strategy, and our first \npriority in that strategy is to invest to  grow the business either through internal development and investments in \ninnovation or inorganic opportunities.  \n \n Certainly, when we look at inorganic opportunities or M&A, we like that to be very, very tightly aligned to our \narticulated strategy with the associated proper financial returns, of course.  And so oncology is one of those \ngrowth areas and one of those growth priorities. ", "original_text": "Michael, I appreciate that. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "55208a77b644f833978dffbd79b7fd676b0d8b85e69b6f89c6b79b18a6c4643b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d662d5f-152d-4808-952e-507da404da9b", "node_type": "1", "metadata": {"window": "A \nThank you.  Michael, I appreciate that.  We talked about many times our capital allocation strategy, and our first \npriority in that strategy is to invest to  grow the business either through internal development and investments in \ninnovation or inorganic opportunities.  \n \n Certainly, when we look at inorganic opportunities or M&A, we like that to be very, very tightly aligned to our \narticulated strategy with the associated proper financial returns, of course.  And so oncology is one of those \ngrowth areas and one of those growth priorities.  And being a pretty significant player in the oncology space in ", "original_text": "Certainly, when we look at inorganic opportunities or M&A, we like that to be very, very tightly aligned to our \narticulated strategy with the associated proper financial returns, of course. "}, "hash": "0755ba769463533681cbcf0b479c60129464d9d469dbacc7ba6420b8f4690bd8", "class_name": "RelatedNodeInfo"}}, "text": "We talked about many times our capital allocation strategy, and our first \npriority in that strategy is to invest to  grow the business either through internal development and investments in \ninnovation or inorganic opportunities.  \n \n", "start_char_idx": 4616, "end_char_idx": 4851, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d662d5f-152d-4808-952e-507da404da9b": {"__data__": {"id_": "8d662d5f-152d-4808-952e-507da404da9b", "embedding": null, "metadata": {"window": "A \nThank you.  Michael, I appreciate that.  We talked about many times our capital allocation strategy, and our first \npriority in that strategy is to invest to  grow the business either through internal development and investments in \ninnovation or inorganic opportunities.  \n \n Certainly, when we look at inorganic opportunities or M&A, we like that to be very, very tightly aligned to our \narticulated strategy with the associated proper financial returns, of course.  And so oncology is one of those \ngrowth areas and one of those growth priorities.  And being a pretty significant player in the oncology space in ", "original_text": "Certainly, when we look at inorganic opportunities or M&A, we like that to be very, very tightly aligned to our \narticulated strategy with the associated proper financial returns, of course. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05741e79-c295-4ca9-8e03-5359351afb04", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ba6b5674b271661980e6c8adcec2aa40c1d08cd954dce16f564e47c300ff320f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd12198b-eec0-44a5-8b4a-e89ce348451d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you.  Michael, I appreciate that.  We talked about many times our capital allocation strategy, and our first \npriority in that strategy is to invest to  grow the business either through internal development and investments in \ninnovation or inorganic opportunities.  \n \n Certainly, when we look at inorganic opportunities or M&A, we like that to be very, very tightly aligned to our \narticulated strategy with the associated proper financial returns, of course.  And so oncology is one of those \ngrowth areas and one of those growth priorities.  And being a pretty significant player in the oncology space in ", "original_text": "We talked about many times our capital allocation strategy, and our first \npriority in that strategy is to invest to  grow the business either through internal development and investments in \ninnovation or inorganic opportunities.  \n \n", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "562dbc88fe2a2640849ae3aa389ea15e98c2c72569aec77c327aa4b8d51ed6b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54b47dde-58d5-4cea-a851-b091c3143772", "node_type": "1", "metadata": {"window": "Michael, I appreciate that.  We talked about many times our capital allocation strategy, and our first \npriority in that strategy is to invest to  grow the business either through internal development and investments in \ninnovation or inorganic opportunities.  \n \n Certainly, when we look at inorganic opportunities or M&A, we like that to be very, very tightly aligned to our \narticulated strategy with the associated proper financial returns, of course.  And so oncology is one of those \ngrowth areas and one of those growth priorities.  And being a pretty significant player in the oncology space in ", "original_text": "And so oncology is one of those \ngrowth areas and one of those growth priorities. "}, "hash": "b6acab9657225cb428193ab888adcc3de850e2148552891a2d816334cd62b9d3", "class_name": "RelatedNodeInfo"}}, "text": "Certainly, when we look at inorganic opportunities or M&A, we like that to be very, very tightly aligned to our \narticulated strategy with the associated proper financial returns, of course. ", "start_char_idx": 4851, "end_char_idx": 5042, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54b47dde-58d5-4cea-a851-b091c3143772": {"__data__": {"id_": "54b47dde-58d5-4cea-a851-b091c3143772", "embedding": null, "metadata": {"window": "Michael, I appreciate that.  We talked about many times our capital allocation strategy, and our first \npriority in that strategy is to invest to  grow the business either through internal development and investments in \ninnovation or inorganic opportunities.  \n \n Certainly, when we look at inorganic opportunities or M&A, we like that to be very, very tightly aligned to our \narticulated strategy with the associated proper financial returns, of course.  And so oncology is one of those \ngrowth areas and one of those growth priorities.  And being a pretty significant player in the oncology space in ", "original_text": "And so oncology is one of those \ngrowth areas and one of those growth priorities. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05741e79-c295-4ca9-8e03-5359351afb04", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ba6b5674b271661980e6c8adcec2aa40c1d08cd954dce16f564e47c300ff320f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d662d5f-152d-4808-952e-507da404da9b", "node_type": "1", "metadata": {"window": "A \nThank you.  Michael, I appreciate that.  We talked about many times our capital allocation strategy, and our first \npriority in that strategy is to invest to  grow the business either through internal development and investments in \ninnovation or inorganic opportunities.  \n \n Certainly, when we look at inorganic opportunities or M&A, we like that to be very, very tightly aligned to our \narticulated strategy with the associated proper financial returns, of course.  And so oncology is one of those \ngrowth areas and one of those growth priorities.  And being a pretty significant player in the oncology space in ", "original_text": "Certainly, when we look at inorganic opportunities or M&A, we like that to be very, very tightly aligned to our \narticulated strategy with the associated proper financial returns, of course. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e7c68501dd327cf5db3ee3720235aa16ad6316071381b324b991eb04944ac6ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "edd5a3b3-e9e3-42e1-86aa-dabf0421ae20", "node_type": "1", "metadata": {"window": "We talked about many times our capital allocation strategy, and our first \npriority in that strategy is to invest to  grow the business either through internal development and investments in \ninnovation or inorganic opportunities.  \n \n Certainly, when we look at inorganic opportunities or M&A, we like that to be very, very tightly aligned to our \narticulated strategy with the associated proper financial returns, of course.  And so oncology is one of those \ngrowth areas and one of those growth priorities.  And being a pretty significant player in the oncology space in ", "original_text": "And being a pretty significant player in the oncology space in "}, "hash": "e719f359bfa048771b00e5c0cf170c6ecbb8f5c687e6e2fd97757ca9658243d3", "class_name": "RelatedNodeInfo"}}, "text": "And so oncology is one of those \ngrowth areas and one of those growth priorities. ", "start_char_idx": 5042, "end_char_idx": 5124, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "edd5a3b3-e9e3-42e1-86aa-dabf0421ae20": {"__data__": {"id_": "edd5a3b3-e9e3-42e1-86aa-dabf0421ae20", "embedding": null, "metadata": {"window": "We talked about many times our capital allocation strategy, and our first \npriority in that strategy is to invest to  grow the business either through internal development and investments in \ninnovation or inorganic opportunities.  \n \n Certainly, when we look at inorganic opportunities or M&A, we like that to be very, very tightly aligned to our \narticulated strategy with the associated proper financial returns, of course.  And so oncology is one of those \ngrowth areas and one of those growth priorities.  And being a pretty significant player in the oncology space in ", "original_text": "And being a pretty significant player in the oncology space in ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05741e79-c295-4ca9-8e03-5359351afb04", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ba6b5674b271661980e6c8adcec2aa40c1d08cd954dce16f564e47c300ff320f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54b47dde-58d5-4cea-a851-b091c3143772", "node_type": "1", "metadata": {"window": "Michael, I appreciate that.  We talked about many times our capital allocation strategy, and our first \npriority in that strategy is to invest to  grow the business either through internal development and investments in \ninnovation or inorganic opportunities.  \n \n Certainly, when we look at inorganic opportunities or M&A, we like that to be very, very tightly aligned to our \narticulated strategy with the associated proper financial returns, of course.  And so oncology is one of those \ngrowth areas and one of those growth priorities.  And being a pretty significant player in the oncology space in ", "original_text": "And so oncology is one of those \ngrowth areas and one of those growth priorities. ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ec5b6fd2293fd6aa5d5d6afba650f4886bbd28ee38a35ee854ea8c0d5a3b1521", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea0a92b2-cd45-4c25-bb66-6ab6c4ba517b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ngeneral and the leading player in the community oncology space, we're very familiar with a lot of, I would call, \nemerging tools, technologies, and companies out there.  And anywhere that we can find an asset that's aligned to \nour strategy in community oncology that we think is additive to either the footprint that we ha ve in US oncology or \nour leading EMR or our adds capability to our data insight business or accelerates clinical trials would be very \nmuch a sweet spot for us.  \n \n Britt actually referenced in his comments some internal stuff we're doing around AI. ", "original_text": "McKesson Corp.  "}, "hash": "e39e4bffd8530e695b08a8166cd90815cdf5880d5e7f14acb45a4f2dc3c03947", "class_name": "RelatedNodeInfo"}}, "text": "And being a pretty significant player in the oncology space in ", "start_char_idx": 5124, "end_char_idx": 5187, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea0a92b2-cd45-4c25-bb66-6ab6c4ba517b": {"__data__": {"id_": "ea0a92b2-cd45-4c25-bb66-6ab6c4ba517b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ngeneral and the leading player in the community oncology space, we're very familiar with a lot of, I would call, \nemerging tools, technologies, and companies out there.  And anywhere that we can find an asset that's aligned to \nour strategy in community oncology that we think is additive to either the footprint that we ha ve in US oncology or \nour leading EMR or our adds capability to our data insight business or accelerates clinical trials would be very \nmuch a sweet spot for us.  \n \n Britt actually referenced in his comments some internal stuff we're doing around AI. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "98047684-7eaf-431b-abdc-d76ed6294538", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "32ee64f29bbc3dd35b99b5fe8ce8f3d18f6702098e8d1a38dc6d4dedc2636637", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "edd5a3b3-e9e3-42e1-86aa-dabf0421ae20", "node_type": "1", "metadata": {"window": "We talked about many times our capital allocation strategy, and our first \npriority in that strategy is to invest to  grow the business either through internal development and investments in \ninnovation or inorganic opportunities.  \n \n Certainly, when we look at inorganic opportunities or M&A, we like that to be very, very tightly aligned to our \narticulated strategy with the associated proper financial returns, of course.  And so oncology is one of those \ngrowth areas and one of those growth priorities.  And being a pretty significant player in the oncology space in ", "original_text": "And being a pretty significant player in the oncology space in ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "791319d8c6176d93a1c75d43d5e91fd38d71ad4ceac3fbfdad90abcd9d295a3c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c93743f-e700-45d0-bbf9-5f76e9ee4c77", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ngeneral and the leading player in the community oncology space, we're very familiar with a lot of, I would call, \nemerging tools, technologies, and companies out there.  And anywhere that we can find an asset that's aligned to \nour strategy in community oncology that we think is additive to either the footprint that we ha ve in US oncology or \nour leading EMR or our adds capability to our data insight business or accelerates clinical trials would be very \nmuch a sweet spot for us.  \n \n Britt actually referenced in his comments some internal stuff we're doing around AI.  And we hav e made some \nsmall acquisitions in the past that bring us capabilities in this area that are helping us improve our interface with \npatients, our efficiency in serving those patients, and improving the practice quality or the lifestyle basically of our \noncol ogists, the practices part of US Oncology. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ngeneral and the leading player in the community oncology space, we're very familiar with a lot of, I would call, \nemerging tools, technologies, and companies out there. "}, "hash": "be41eff1f16bab2583846ff5b204a776dc4bcceccbc50cd3e3a022e4520b1faa", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c93743f-e700-45d0-bbf9-5f76e9ee4c77": {"__data__": {"id_": "5c93743f-e700-45d0-bbf9-5f76e9ee4c77", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ngeneral and the leading player in the community oncology space, we're very familiar with a lot of, I would call, \nemerging tools, technologies, and companies out there.  And anywhere that we can find an asset that's aligned to \nour strategy in community oncology that we think is additive to either the footprint that we ha ve in US oncology or \nour leading EMR or our adds capability to our data insight business or accelerates clinical trials would be very \nmuch a sweet spot for us.  \n \n Britt actually referenced in his comments some internal stuff we're doing around AI.  And we hav e made some \nsmall acquisitions in the past that bring us capabilities in this area that are helping us improve our interface with \npatients, our efficiency in serving those patients, and improving the practice quality or the lifestyle basically of our \noncol ogists, the practices part of US Oncology. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ngeneral and the leading player in the community oncology space, we're very familiar with a lot of, I would call, \nemerging tools, technologies, and companies out there. ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "98047684-7eaf-431b-abdc-d76ed6294538", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "32ee64f29bbc3dd35b99b5fe8ce8f3d18f6702098e8d1a38dc6d4dedc2636637", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea0a92b2-cd45-4c25-bb66-6ab6c4ba517b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ngeneral and the leading player in the community oncology space, we're very familiar with a lot of, I would call, \nemerging tools, technologies, and companies out there.  And anywhere that we can find an asset that's aligned to \nour strategy in community oncology that we think is additive to either the footprint that we ha ve in US oncology or \nour leading EMR or our adds capability to our data insight business or accelerates clinical trials would be very \nmuch a sweet spot for us.  \n \n Britt actually referenced in his comments some internal stuff we're doing around AI. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "1941e9a165a538c16c0c0d967ad290fda195a0ae13827beca2cc606124471640", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ae4e56b-c7df-4227-b02f-5d1dcf31c018", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ngeneral and the leading player in the community oncology space, we're very familiar with a lot of, I would call, \nemerging tools, technologies, and companies out there.  And anywhere that we can find an asset that's aligned to \nour strategy in community oncology that we think is additive to either the footprint that we ha ve in US oncology or \nour leading EMR or our adds capability to our data insight business or accelerates clinical trials would be very \nmuch a sweet spot for us.  \n \n Britt actually referenced in his comments some internal stuff we're doing around AI.  And we hav e made some \nsmall acquisitions in the past that bring us capabilities in this area that are helping us improve our interface with \npatients, our efficiency in serving those patients, and improving the practice quality or the lifestyle basically of our \noncol ogists, the practices part of US Oncology.  And we think that's part of the overall formula that's been really \nsupporting and enabling, quite frankly, the record growth that we had last year.  \n ", "original_text": "And anywhere that we can find an asset that's aligned to \nour strategy in community oncology that we think is additive to either the footprint that we ha ve in US oncology or \nour leading EMR or our adds capability to our data insight business or accelerates clinical trials would be very \nmuch a sweet spot for us.  \n \n"}, "hash": "f23d6e10c8155293995ec779ac5f97144220a960f1882a27ef2459028a782626", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ngeneral and the leading player in the community oncology space, we're very familiar with a lot of, I would call, \nemerging tools, technologies, and companies out there. ", "start_char_idx": 16, "end_char_idx": 350, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ae4e56b-c7df-4227-b02f-5d1dcf31c018": {"__data__": {"id_": "0ae4e56b-c7df-4227-b02f-5d1dcf31c018", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ngeneral and the leading player in the community oncology space, we're very familiar with a lot of, I would call, \nemerging tools, technologies, and companies out there.  And anywhere that we can find an asset that's aligned to \nour strategy in community oncology that we think is additive to either the footprint that we ha ve in US oncology or \nour leading EMR or our adds capability to our data insight business or accelerates clinical trials would be very \nmuch a sweet spot for us.  \n \n Britt actually referenced in his comments some internal stuff we're doing around AI.  And we hav e made some \nsmall acquisitions in the past that bring us capabilities in this area that are helping us improve our interface with \npatients, our efficiency in serving those patients, and improving the practice quality or the lifestyle basically of our \noncol ogists, the practices part of US Oncology.  And we think that's part of the overall formula that's been really \nsupporting and enabling, quite frankly, the record growth that we had last year.  \n ", "original_text": "And anywhere that we can find an asset that's aligned to \nour strategy in community oncology that we think is additive to either the footprint that we ha ve in US oncology or \nour leading EMR or our adds capability to our data insight business or accelerates clinical trials would be very \nmuch a sweet spot for us.  \n \n", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "98047684-7eaf-431b-abdc-d76ed6294538", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "32ee64f29bbc3dd35b99b5fe8ce8f3d18f6702098e8d1a38dc6d4dedc2636637", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c93743f-e700-45d0-bbf9-5f76e9ee4c77", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ngeneral and the leading player in the community oncology space, we're very familiar with a lot of, I would call, \nemerging tools, technologies, and companies out there.  And anywhere that we can find an asset that's aligned to \nour strategy in community oncology that we think is additive to either the footprint that we ha ve in US oncology or \nour leading EMR or our adds capability to our data insight business or accelerates clinical trials would be very \nmuch a sweet spot for us.  \n \n Britt actually referenced in his comments some internal stuff we're doing around AI.  And we hav e made some \nsmall acquisitions in the past that bring us capabilities in this area that are helping us improve our interface with \npatients, our efficiency in serving those patients, and improving the practice quality or the lifestyle basically of our \noncol ogists, the practices part of US Oncology. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ngeneral and the leading player in the community oncology space, we're very familiar with a lot of, I would call, \nemerging tools, technologies, and companies out there. ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c9bc17fd5376791ce864cc71331f5a2acf634c8e50bc3f442d4ccff1040a1d2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07867a1c-7e21-4924-b332-b4477a577b95", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ngeneral and the leading player in the community oncology space, we're very familiar with a lot of, I would call, \nemerging tools, technologies, and companies out there.  And anywhere that we can find an asset that's aligned to \nour strategy in community oncology that we think is additive to either the footprint that we ha ve in US oncology or \nour leading EMR or our adds capability to our data insight business or accelerates clinical trials would be very \nmuch a sweet spot for us.  \n \n Britt actually referenced in his comments some internal stuff we're doing around AI.  And we hav e made some \nsmall acquisitions in the past that bring us capabilities in this area that are helping us improve our interface with \npatients, our efficiency in serving those patients, and improving the practice quality or the lifestyle basically of our \noncol ogists, the practices part of US Oncology.  And we think that's part of the overall formula that's been really \nsupporting and enabling, quite frankly, the record growth that we had last year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson  Corp.  ", "original_text": "Britt actually referenced in his comments some internal stuff we're doing around AI. "}, "hash": "a447c223867ea4de29174f9a67f7f09f2e5ba7f4004defb824ddefc3caf7504f", "class_name": "RelatedNodeInfo"}}, "text": "And anywhere that we can find an asset that's aligned to \nour strategy in community oncology that we think is additive to either the footprint that we ha ve in US oncology or \nour leading EMR or our adds capability to our data insight business or accelerates clinical trials would be very \nmuch a sweet spot for us.  \n \n", "start_char_idx": 350, "end_char_idx": 670, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07867a1c-7e21-4924-b332-b4477a577b95": {"__data__": {"id_": "07867a1c-7e21-4924-b332-b4477a577b95", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ngeneral and the leading player in the community oncology space, we're very familiar with a lot of, I would call, \nemerging tools, technologies, and companies out there.  And anywhere that we can find an asset that's aligned to \nour strategy in community oncology that we think is additive to either the footprint that we ha ve in US oncology or \nour leading EMR or our adds capability to our data insight business or accelerates clinical trials would be very \nmuch a sweet spot for us.  \n \n Britt actually referenced in his comments some internal stuff we're doing around AI.  And we hav e made some \nsmall acquisitions in the past that bring us capabilities in this area that are helping us improve our interface with \npatients, our efficiency in serving those patients, and improving the practice quality or the lifestyle basically of our \noncol ogists, the practices part of US Oncology.  And we think that's part of the overall formula that's been really \nsupporting and enabling, quite frankly, the record growth that we had last year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson  Corp.  ", "original_text": "Britt actually referenced in his comments some internal stuff we're doing around AI. ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "98047684-7eaf-431b-abdc-d76ed6294538", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "32ee64f29bbc3dd35b99b5fe8ce8f3d18f6702098e8d1a38dc6d4dedc2636637", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ae4e56b-c7df-4227-b02f-5d1dcf31c018", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ngeneral and the leading player in the community oncology space, we're very familiar with a lot of, I would call, \nemerging tools, technologies, and companies out there.  And anywhere that we can find an asset that's aligned to \nour strategy in community oncology that we think is additive to either the footprint that we ha ve in US oncology or \nour leading EMR or our adds capability to our data insight business or accelerates clinical trials would be very \nmuch a sweet spot for us.  \n \n Britt actually referenced in his comments some internal stuff we're doing around AI.  And we hav e made some \nsmall acquisitions in the past that bring us capabilities in this area that are helping us improve our interface with \npatients, our efficiency in serving those patients, and improving the practice quality or the lifestyle basically of our \noncol ogists, the practices part of US Oncology.  And we think that's part of the overall formula that's been really \nsupporting and enabling, quite frankly, the record growth that we had last year.  \n ", "original_text": "And anywhere that we can find an asset that's aligned to \nour strategy in community oncology that we think is additive to either the footprint that we ha ve in US oncology or \nour leading EMR or our adds capability to our data insight business or accelerates clinical trials would be very \nmuch a sweet spot for us.  \n \n", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "eff559e00157b5d18527ddb78ec7c7d298c1ddaec4fdefeb86a5ad90b197c5b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ee4048e-9f98-457e-93bf-b5bfa12a1352", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ngeneral and the leading player in the community oncology space, we're very familiar with a lot of, I would call, \nemerging tools, technologies, and companies out there.  And anywhere that we can find an asset that's aligned to \nour strategy in community oncology that we think is additive to either the footprint that we ha ve in US oncology or \nour leading EMR or our adds capability to our data insight business or accelerates clinical trials would be very \nmuch a sweet spot for us.  \n \n Britt actually referenced in his comments some internal stuff we're doing around AI.  And we hav e made some \nsmall acquisitions in the past that bring us capabilities in this area that are helping us improve our interface with \npatients, our efficiency in serving those patients, and improving the practice quality or the lifestyle basically of our \noncol ogists, the practices part of US Oncology.  And we think that's part of the overall formula that's been really \nsupporting and enabling, quite frankly, the record growth that we had last year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson  Corp.   A \nNext question, please.  \n ", "original_text": "And we hav e made some \nsmall acquisitions in the past that bring us capabilities in this area that are helping us improve our interface with \npatients, our efficiency in serving those patients, and improving the practice quality or the lifestyle basically of our \noncol ogists, the practices part of US Oncology. "}, "hash": "9c4311f39888011305538909d80766c368322911c4e527bb562b74cd5363f924", "class_name": "RelatedNodeInfo"}}, "text": "Britt actually referenced in his comments some internal stuff we're doing around AI. ", "start_char_idx": 670, "end_char_idx": 755, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ee4048e-9f98-457e-93bf-b5bfa12a1352": {"__data__": {"id_": "1ee4048e-9f98-457e-93bf-b5bfa12a1352", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ngeneral and the leading player in the community oncology space, we're very familiar with a lot of, I would call, \nemerging tools, technologies, and companies out there.  And anywhere that we can find an asset that's aligned to \nour strategy in community oncology that we think is additive to either the footprint that we ha ve in US oncology or \nour leading EMR or our adds capability to our data insight business or accelerates clinical trials would be very \nmuch a sweet spot for us.  \n \n Britt actually referenced in his comments some internal stuff we're doing around AI.  And we hav e made some \nsmall acquisitions in the past that bring us capabilities in this area that are helping us improve our interface with \npatients, our efficiency in serving those patients, and improving the practice quality or the lifestyle basically of our \noncol ogists, the practices part of US Oncology.  And we think that's part of the overall formula that's been really \nsupporting and enabling, quite frankly, the record growth that we had last year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson  Corp.   A \nNext question, please.  \n ", "original_text": "And we hav e made some \nsmall acquisitions in the past that bring us capabilities in this area that are helping us improve our interface with \npatients, our efficiency in serving those patients, and improving the practice quality or the lifestyle basically of our \noncol ogists, the practices part of US Oncology. ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "98047684-7eaf-431b-abdc-d76ed6294538", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "32ee64f29bbc3dd35b99b5fe8ce8f3d18f6702098e8d1a38dc6d4dedc2636637", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07867a1c-7e21-4924-b332-b4477a577b95", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ngeneral and the leading player in the community oncology space, we're very familiar with a lot of, I would call, \nemerging tools, technologies, and companies out there.  And anywhere that we can find an asset that's aligned to \nour strategy in community oncology that we think is additive to either the footprint that we ha ve in US oncology or \nour leading EMR or our adds capability to our data insight business or accelerates clinical trials would be very \nmuch a sweet spot for us.  \n \n Britt actually referenced in his comments some internal stuff we're doing around AI.  And we hav e made some \nsmall acquisitions in the past that bring us capabilities in this area that are helping us improve our interface with \npatients, our efficiency in serving those patients, and improving the practice quality or the lifestyle basically of our \noncol ogists, the practices part of US Oncology.  And we think that's part of the overall formula that's been really \nsupporting and enabling, quite frankly, the record growth that we had last year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson  Corp.  ", "original_text": "Britt actually referenced in his comments some internal stuff we're doing around AI. ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "20ee7d6fb62c5d6d638f19c933bfb6563f9b93000570813e7b9a565ce50fa1d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7da0328-088f-4837-a632-5d81205a6d6d", "node_type": "1", "metadata": {"window": "And anywhere that we can find an asset that's aligned to \nour strategy in community oncology that we think is additive to either the footprint that we ha ve in US oncology or \nour leading EMR or our adds capability to our data insight business or accelerates clinical trials would be very \nmuch a sweet spot for us.  \n \n Britt actually referenced in his comments some internal stuff we're doing around AI.  And we hav e made some \nsmall acquisitions in the past that bring us capabilities in this area that are helping us improve our interface with \npatients, our efficiency in serving those patients, and improving the practice quality or the lifestyle basically of our \noncol ogists, the practices part of US Oncology.  And we think that's part of the overall formula that's been really \nsupporting and enabling, quite frankly, the record growth that we had last year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson  Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen. ", "original_text": "And we think that's part of the overall formula that's been really \nsupporting and enabling, quite frankly, the record growth that we had last year.  \n "}, "hash": "a350d4f20c2248ec7738d8809bed26905685d9e46bffde85ddc16f7d590bcf00", "class_name": "RelatedNodeInfo"}}, "text": "And we hav e made some \nsmall acquisitions in the past that bring us capabilities in this area that are helping us improve our interface with \npatients, our efficiency in serving those patients, and improving the practice quality or the lifestyle basically of our \noncol ogists, the practices part of US Oncology. ", "start_char_idx": 755, "end_char_idx": 1069, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7da0328-088f-4837-a632-5d81205a6d6d": {"__data__": {"id_": "f7da0328-088f-4837-a632-5d81205a6d6d", "embedding": null, "metadata": {"window": "And anywhere that we can find an asset that's aligned to \nour strategy in community oncology that we think is additive to either the footprint that we ha ve in US oncology or \nour leading EMR or our adds capability to our data insight business or accelerates clinical trials would be very \nmuch a sweet spot for us.  \n \n Britt actually referenced in his comments some internal stuff we're doing around AI.  And we hav e made some \nsmall acquisitions in the past that bring us capabilities in this area that are helping us improve our interface with \npatients, our efficiency in serving those patients, and improving the practice quality or the lifestyle basically of our \noncol ogists, the practices part of US Oncology.  And we think that's part of the overall formula that's been really \nsupporting and enabling, quite frankly, the record growth that we had last year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson  Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen. ", "original_text": "And we think that's part of the overall formula that's been really \nsupporting and enabling, quite frankly, the record growth that we had last year.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "98047684-7eaf-431b-abdc-d76ed6294538", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "32ee64f29bbc3dd35b99b5fe8ce8f3d18f6702098e8d1a38dc6d4dedc2636637", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ee4048e-9f98-457e-93bf-b5bfa12a1352", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ngeneral and the leading player in the community oncology space, we're very familiar with a lot of, I would call, \nemerging tools, technologies, and companies out there.  And anywhere that we can find an asset that's aligned to \nour strategy in community oncology that we think is additive to either the footprint that we ha ve in US oncology or \nour leading EMR or our adds capability to our data insight business or accelerates clinical trials would be very \nmuch a sweet spot for us.  \n \n Britt actually referenced in his comments some internal stuff we're doing around AI.  And we hav e made some \nsmall acquisitions in the past that bring us capabilities in this area that are helping us improve our interface with \npatients, our efficiency in serving those patients, and improving the practice quality or the lifestyle basically of our \noncol ogists, the practices part of US Oncology.  And we think that's part of the overall formula that's been really \nsupporting and enabling, quite frankly, the record growth that we had last year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson  Corp.   A \nNext question, please.  \n ", "original_text": "And we hav e made some \nsmall acquisitions in the past that bring us capabilities in this area that are helping us improve our interface with \npatients, our efficiency in serving those patients, and improving the practice quality or the lifestyle basically of our \noncol ogists, the practices part of US Oncology. ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "30447b44a5739b639edea9aa1c3f1300c89ddee7fe24bbf639b99647f4d9da0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59344675-7454-457d-a7ad-9af4f73608f2", "node_type": "1", "metadata": {"window": "Britt actually referenced in his comments some internal stuff we're doing around AI.  And we hav e made some \nsmall acquisitions in the past that bring us capabilities in this area that are helping us improve our interface with \npatients, our efficiency in serving those patients, and improving the practice quality or the lifestyle basically of our \noncol ogists, the practices part of US Oncology.  And we think that's part of the overall formula that's been really \nsupporting and enabling, quite frankly, the record growth that we had last year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson  Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson  Corp.  "}, "hash": "9bdd8bcc7aa2965ee9ed3e607adfc0aed2ad90a6e7fba9999f2c1ff8979854c4", "class_name": "RelatedNodeInfo"}}, "text": "And we think that's part of the overall formula that's been really \nsupporting and enabling, quite frankly, the record growth that we had last year.  \n ", "start_char_idx": 1069, "end_char_idx": 1221, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59344675-7454-457d-a7ad-9af4f73608f2": {"__data__": {"id_": "59344675-7454-457d-a7ad-9af4f73608f2", "embedding": null, "metadata": {"window": "Britt actually referenced in his comments some internal stuff we're doing around AI.  And we hav e made some \nsmall acquisitions in the past that bring us capabilities in this area that are helping us improve our interface with \npatients, our efficiency in serving those patients, and improving the practice quality or the lifestyle basically of our \noncol ogists, the practices part of US Oncology.  And we think that's part of the overall formula that's been really \nsupporting and enabling, quite frankly, the record growth that we had last year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson  Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson  Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "98047684-7eaf-431b-abdc-d76ed6294538", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "32ee64f29bbc3dd35b99b5fe8ce8f3d18f6702098e8d1a38dc6d4dedc2636637", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7da0328-088f-4837-a632-5d81205a6d6d", "node_type": "1", "metadata": {"window": "And anywhere that we can find an asset that's aligned to \nour strategy in community oncology that we think is additive to either the footprint that we ha ve in US oncology or \nour leading EMR or our adds capability to our data insight business or accelerates clinical trials would be very \nmuch a sweet spot for us.  \n \n Britt actually referenced in his comments some internal stuff we're doing around AI.  And we hav e made some \nsmall acquisitions in the past that bring us capabilities in this area that are helping us improve our interface with \npatients, our efficiency in serving those patients, and improving the practice quality or the lifestyle basically of our \noncol ogists, the practices part of US Oncology.  And we think that's part of the overall formula that's been really \nsupporting and enabling, quite frankly, the record growth that we had last year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson  Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen. ", "original_text": "And we think that's part of the overall formula that's been really \nsupporting and enabling, quite frankly, the record growth that we had last year.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "49584b97963a7d2cb3b729918d00a017c17af44b8ca01d740846e4c1b834e122", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6633efc3-52fc-46c0-9255-aeebde3efdec", "node_type": "1", "metadata": {"window": "And we hav e made some \nsmall acquisitions in the past that bring us capabilities in this area that are helping us improve our interface with \npatients, our efficiency in serving those patients, and improving the practice quality or the lifestyle basically of our \noncol ogists, the practices part of US Oncology.  And we think that's part of the overall formula that's been really \nsupporting and enabling, quite frankly, the record growth that we had last year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson  Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nThanks for taking the question. ", "original_text": "A \nNext question, please.  \n "}, "hash": "11210233acaab66d95100612f7db7d36d677285152c8d101cb7ea53158cf8202", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson  Corp.  ", "start_char_idx": 1221, "end_char_idx": 1567, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6633efc3-52fc-46c0-9255-aeebde3efdec": {"__data__": {"id_": "6633efc3-52fc-46c0-9255-aeebde3efdec", "embedding": null, "metadata": {"window": "And we hav e made some \nsmall acquisitions in the past that bring us capabilities in this area that are helping us improve our interface with \npatients, our efficiency in serving those patients, and improving the practice quality or the lifestyle basically of our \noncol ogists, the practices part of US Oncology.  And we think that's part of the overall formula that's been really \nsupporting and enabling, quite frankly, the record growth that we had last year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson  Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nThanks for taking the question. ", "original_text": "A \nNext question, please.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "98047684-7eaf-431b-abdc-d76ed6294538", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "32ee64f29bbc3dd35b99b5fe8ce8f3d18f6702098e8d1a38dc6d4dedc2636637", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59344675-7454-457d-a7ad-9af4f73608f2", "node_type": "1", "metadata": {"window": "Britt actually referenced in his comments some internal stuff we're doing around AI.  And we hav e made some \nsmall acquisitions in the past that bring us capabilities in this area that are helping us improve our interface with \npatients, our efficiency in serving those patients, and improving the practice quality or the lifestyle basically of our \noncol ogists, the practices part of US Oncology.  And we think that's part of the overall formula that's been really \nsupporting and enabling, quite frankly, the record growth that we had last year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson  Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson  Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c28eae12c923c8c9b5742286d20c0b89957c54a43ba8120a500488d04270b1dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6031ce14-4f84-4e56-b3ff-ed58e447abf9", "node_type": "1", "metadata": {"window": "And we think that's part of the overall formula that's been really \nsupporting and enabling, quite frankly, the record growth that we had last year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson  Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nThanks for taking the question.  I wanted to circle back to RxTS, obviously, looking at a really positive outlook. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen. "}, "hash": "1f11905fe27b978474ec65ac136672c4fdd41596376dc12a8a2a65e87e556003", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please.  \n ", "start_char_idx": 1567, "end_char_idx": 1596, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6031ce14-4f84-4e56-b3ff-ed58e447abf9": {"__data__": {"id_": "6031ce14-4f84-4e56-b3ff-ed58e447abf9", "embedding": null, "metadata": {"window": "And we think that's part of the overall formula that's been really \nsupporting and enabling, quite frankly, the record growth that we had last year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson  Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nThanks for taking the question.  I wanted to circle back to RxTS, obviously, looking at a really positive outlook. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen. ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "98047684-7eaf-431b-abdc-d76ed6294538", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "32ee64f29bbc3dd35b99b5fe8ce8f3d18f6702098e8d1a38dc6d4dedc2636637", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6633efc3-52fc-46c0-9255-aeebde3efdec", "node_type": "1", "metadata": {"window": "And we hav e made some \nsmall acquisitions in the past that bring us capabilities in this area that are helping us improve our interface with \npatients, our efficiency in serving those patients, and improving the practice quality or the lifestyle basically of our \noncol ogists, the practices part of US Oncology.  And we think that's part of the overall formula that's been really \nsupporting and enabling, quite frankly, the record growth that we had last year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson  Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nThanks for taking the question. ", "original_text": "A \nNext question, please.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "bf536f55d26424945fbcf32beef2f23a2de08693a386b40e47c4dc6ad17dfd45", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bca3e4b4-649f-4389-9f83-7f45e0991803", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson  Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nThanks for taking the question.  I wanted to circle back to RxTS, obviously, looking at a really positive outlook.  But \nthinking about the preliminary fiscal 2025 guide you kind of gave for this segment last quarter, the final guide \nactually is a little bit better here. ", "original_text": "Please go ahead.  \n "}, "hash": "be14afb5ccf222b26e5eaba757b18bd1b5cd33451c743b0983a715519a64f940", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen. ", "start_char_idx": 1596, "end_char_idx": 1927, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bca3e4b4-649f-4389-9f83-7f45e0991803": {"__data__": {"id_": "bca3e4b4-649f-4389-9f83-7f45e0991803", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson  Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nThanks for taking the question.  I wanted to circle back to RxTS, obviously, looking at a really positive outlook.  But \nthinking about the preliminary fiscal 2025 guide you kind of gave for this segment last quarter, the final guide \nactually is a little bit better here. ", "original_text": "Please go ahead.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "98047684-7eaf-431b-abdc-d76ed6294538", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "32ee64f29bbc3dd35b99b5fe8ce8f3d18f6702098e8d1a38dc6d4dedc2636637", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6031ce14-4f84-4e56-b3ff-ed58e447abf9", "node_type": "1", "metadata": {"window": "And we think that's part of the overall formula that's been really \nsupporting and enabling, quite frankly, the record growth that we had last year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson  Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nThanks for taking the question.  I wanted to circle back to RxTS, obviously, looking at a really positive outlook. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen. ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d950f9e4b675c767ebf7c9f4774e94c2c6469de8fc3979fb794714f330cb7296", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74e3a48d-51cd-4f80-9668-c7bd2b189dd5", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nThanks for taking the question.  I wanted to circle back to RxTS, obviously, looking at a really positive outlook.  But \nthinking about the preliminary fiscal 2025 guide you kind of gave for this segment last quarter, the final guide \nactually is a little bit better here.  Any sort of comments on what is driving sort of the increased optimism here? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nThanks for taking the question. "}, "hash": "5665ec88e71c4ff14fce7c8d28691fabcebdd59ca8b2f9d1ab0135295a910810", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 1927, "end_char_idx": 1947, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74e3a48d-51cd-4f80-9668-c7bd2b189dd5": {"__data__": {"id_": "74e3a48d-51cd-4f80-9668-c7bd2b189dd5", "embedding": null, "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nThanks for taking the question.  I wanted to circle back to RxTS, obviously, looking at a really positive outlook.  But \nthinking about the preliminary fiscal 2025 guide you kind of gave for this segment last quarter, the final guide \nactually is a little bit better here.  Any sort of comments on what is driving sort of the increased optimism here? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nThanks for taking the question. ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "98047684-7eaf-431b-abdc-d76ed6294538", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "32ee64f29bbc3dd35b99b5fe8ce8f3d18f6702098e8d1a38dc6d4dedc2636637", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bca3e4b4-649f-4389-9f83-7f45e0991803", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson  Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nThanks for taking the question.  I wanted to circle back to RxTS, obviously, looking at a really positive outlook.  But \nthinking about the preliminary fiscal 2025 guide you kind of gave for this segment last quarter, the final guide \nactually is a little bit better here. ", "original_text": "Please go ahead.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "79d3c715fd032dffc157c922e5a51ea2d29e95612edf8644a70b44cda1fab63a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a68360c-9cf6-44ae-9b6e-1cdad2f93d5f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nThanks for taking the question.  I wanted to circle back to RxTS, obviously, looking at a really positive outlook.  But \nthinking about the preliminary fiscal 2025 guide you kind of gave for this segment last quarter, the final guide \nactually is a little bit better here.  Any sort of comments on what is driving sort of the increased optimism here?  Is it \nsolely ju st as we're thinking about maybe GLP -1s? ", "original_text": "I wanted to circle back to RxTS, obviously, looking at a really positive outlook. "}, "hash": "bc43024312961fffb5e89ff3bdc702117ab2e0345f8dc1bb6742ce29168eafea", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nThanks for taking the question. ", "start_char_idx": 1947, "end_char_idx": 2289, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a68360c-9cf6-44ae-9b6e-1cdad2f93d5f": {"__data__": {"id_": "5a68360c-9cf6-44ae-9b6e-1cdad2f93d5f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nThanks for taking the question.  I wanted to circle back to RxTS, obviously, looking at a really positive outlook.  But \nthinking about the preliminary fiscal 2025 guide you kind of gave for this segment last quarter, the final guide \nactually is a little bit better here.  Any sort of comments on what is driving sort of the increased optimism here?  Is it \nsolely ju st as we're thinking about maybe GLP -1s? ", "original_text": "I wanted to circle back to RxTS, obviously, looking at a really positive outlook. ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "98047684-7eaf-431b-abdc-d76ed6294538", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "32ee64f29bbc3dd35b99b5fe8ce8f3d18f6702098e8d1a38dc6d4dedc2636637", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74e3a48d-51cd-4f80-9668-c7bd2b189dd5", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nThanks for taking the question.  I wanted to circle back to RxTS, obviously, looking at a really positive outlook.  But \nthinking about the preliminary fiscal 2025 guide you kind of gave for this segment last quarter, the final guide \nactually is a little bit better here.  Any sort of comments on what is driving sort of the increased optimism here? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nThanks for taking the question. ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "b6f242555f73323f007b9f4b1c9cfef3d0186c1b2fdb381ea80209d415ed01dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a30d2ca5-2f1a-4931-a96a-f6d8f063ebe2", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nThanks for taking the question.  I wanted to circle back to RxTS, obviously, looking at a really positive outlook.  But \nthinking about the preliminary fiscal 2025 guide you kind of gave for this segment last quarter, the final guide \nactually is a little bit better here.  Any sort of comments on what is driving sort of the increased optimism here?  Is it \nsolely ju st as we're thinking about maybe GLP -1s?  Or maybe can you talk about sort of any kind of gains at \nRelayHealth as it relates to the Change Healthcare outage? ", "original_text": "But \nthinking about the preliminary fiscal 2025 guide you kind of gave for this segment last quarter, the final guide \nactually is a little bit better here. "}, "hash": "4dca57d2f384a4a4a94d432ecce9612451d54da62d53510adcd0ee993a724e9d", "class_name": "RelatedNodeInfo"}}, "text": "I wanted to circle back to RxTS, obviously, looking at a really positive outlook. ", "start_char_idx": 2289, "end_char_idx": 2371, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a30d2ca5-2f1a-4931-a96a-f6d8f063ebe2": {"__data__": {"id_": "a30d2ca5-2f1a-4931-a96a-f6d8f063ebe2", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nThanks for taking the question.  I wanted to circle back to RxTS, obviously, looking at a really positive outlook.  But \nthinking about the preliminary fiscal 2025 guide you kind of gave for this segment last quarter, the final guide \nactually is a little bit better here.  Any sort of comments on what is driving sort of the increased optimism here?  Is it \nsolely ju st as we're thinking about maybe GLP -1s?  Or maybe can you talk about sort of any kind of gains at \nRelayHealth as it relates to the Change Healthcare outage? ", "original_text": "But \nthinking about the preliminary fiscal 2025 guide you kind of gave for this segment last quarter, the final guide \nactually is a little bit better here. ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "98047684-7eaf-431b-abdc-d76ed6294538", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "32ee64f29bbc3dd35b99b5fe8ce8f3d18f6702098e8d1a38dc6d4dedc2636637", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a68360c-9cf6-44ae-9b6e-1cdad2f93d5f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nThanks for taking the question.  I wanted to circle back to RxTS, obviously, looking at a really positive outlook.  But \nthinking about the preliminary fiscal 2025 guide you kind of gave for this segment last quarter, the final guide \nactually is a little bit better here.  Any sort of comments on what is driving sort of the increased optimism here?  Is it \nsolely ju st as we're thinking about maybe GLP -1s? ", "original_text": "I wanted to circle back to RxTS, obviously, looking at a really positive outlook. ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "edd5537f02e79e14454a4c55ed3bef4e9c5865119738bea79d077761bac05f85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1224e2c-c3de-4888-858e-ac6f7848b242", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nThanks for taking the question.  I wanted to circle back to RxTS, obviously, looking at a really positive outlook.  But \nthinking about the preliminary fiscal 2025 guide you kind of gave for this segment last quarter, the final guide \nactually is a little bit better here.  Any sort of comments on what is driving sort of the increased optimism here?  Is it \nsolely ju st as we're thinking about maybe GLP -1s?  Or maybe can you talk about sort of any kind of gains at \nRelayHealth as it relates to the Change Healthcare outage?  Any comments there would be helpful. ", "original_text": "Any sort of comments on what is driving sort of the increased optimism here? "}, "hash": "d377c13e9b4978e3e37b5ab0746df16ac94fc7945a133f4509e90cd5c08b364d", "class_name": "RelatedNodeInfo"}}, "text": "But \nthinking about the preliminary fiscal 2025 guide you kind of gave for this segment last quarter, the final guide \nactually is a little bit better here. ", "start_char_idx": 2371, "end_char_idx": 2528, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1224e2c-c3de-4888-858e-ac6f7848b242": {"__data__": {"id_": "e1224e2c-c3de-4888-858e-ac6f7848b242", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nThanks for taking the question.  I wanted to circle back to RxTS, obviously, looking at a really positive outlook.  But \nthinking about the preliminary fiscal 2025 guide you kind of gave for this segment last quarter, the final guide \nactually is a little bit better here.  Any sort of comments on what is driving sort of the increased optimism here?  Is it \nsolely ju st as we're thinking about maybe GLP -1s?  Or maybe can you talk about sort of any kind of gains at \nRelayHealth as it relates to the Change Healthcare outage?  Any comments there would be helpful. ", "original_text": "Any sort of comments on what is driving sort of the increased optimism here? ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "98047684-7eaf-431b-abdc-d76ed6294538", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "32ee64f29bbc3dd35b99b5fe8ce8f3d18f6702098e8d1a38dc6d4dedc2636637", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a30d2ca5-2f1a-4931-a96a-f6d8f063ebe2", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nThanks for taking the question.  I wanted to circle back to RxTS, obviously, looking at a really positive outlook.  But \nthinking about the preliminary fiscal 2025 guide you kind of gave for this segment last quarter, the final guide \nactually is a little bit better here.  Any sort of comments on what is driving sort of the increased optimism here?  Is it \nsolely ju st as we're thinking about maybe GLP -1s?  Or maybe can you talk about sort of any kind of gains at \nRelayHealth as it relates to the Change Healthcare outage? ", "original_text": "But \nthinking about the preliminary fiscal 2025 guide you kind of gave for this segment last quarter, the final guide \nactually is a little bit better here. ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f78145dd446b91c735f576e984ba688ce3157286c22f56ab7aefd5e101055ae4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5bf65d9-e9bc-4917-aaac-50dac40f7af5", "node_type": "1", "metadata": {"window": "I wanted to circle back to RxTS, obviously, looking at a really positive outlook.  But \nthinking about the preliminary fiscal 2025 guide you kind of gave for this segment last quarter, the final guide \nactually is a little bit better here.  Any sort of comments on what is driving sort of the increased optimism here?  Is it \nsolely ju st as we're thinking about maybe GLP -1s?  Or maybe can you talk about sort of any kind of gains at \nRelayHealth as it relates to the Change Healthcare outage?  Any comments there would be helpful.  Thanks.  \n ", "original_text": "Is it \nsolely ju st as we're thinking about maybe GLP -1s? "}, "hash": "e44e3a3dd2a236ea0997e5152bf7c58910b2c50de83c45562334784af0b913fd", "class_name": "RelatedNodeInfo"}}, "text": "Any sort of comments on what is driving sort of the increased optimism here? ", "start_char_idx": 2528, "end_char_idx": 2605, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5bf65d9-e9bc-4917-aaac-50dac40f7af5": {"__data__": {"id_": "a5bf65d9-e9bc-4917-aaac-50dac40f7af5", "embedding": null, "metadata": {"window": "I wanted to circle back to RxTS, obviously, looking at a really positive outlook.  But \nthinking about the preliminary fiscal 2025 guide you kind of gave for this segment last quarter, the final guide \nactually is a little bit better here.  Any sort of comments on what is driving sort of the increased optimism here?  Is it \nsolely ju st as we're thinking about maybe GLP -1s?  Or maybe can you talk about sort of any kind of gains at \nRelayHealth as it relates to the Change Healthcare outage?  Any comments there would be helpful.  Thanks.  \n ", "original_text": "Is it \nsolely ju st as we're thinking about maybe GLP -1s? ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "98047684-7eaf-431b-abdc-d76ed6294538", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "32ee64f29bbc3dd35b99b5fe8ce8f3d18f6702098e8d1a38dc6d4dedc2636637", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1224e2c-c3de-4888-858e-ac6f7848b242", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nThanks for taking the question.  I wanted to circle back to RxTS, obviously, looking at a really positive outlook.  But \nthinking about the preliminary fiscal 2025 guide you kind of gave for this segment last quarter, the final guide \nactually is a little bit better here.  Any sort of comments on what is driving sort of the increased optimism here?  Is it \nsolely ju st as we're thinking about maybe GLP -1s?  Or maybe can you talk about sort of any kind of gains at \nRelayHealth as it relates to the Change Healthcare outage?  Any comments there would be helpful. ", "original_text": "Any sort of comments on what is driving sort of the increased optimism here? ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "729e2daae11bfd482c52c8e1c0c27675e11ba9100e78743d448f1e7d3dd660b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9efd44d8-d25e-4e7d-b895-b28b7275fd81", "node_type": "1", "metadata": {"window": "But \nthinking about the preliminary fiscal 2025 guide you kind of gave for this segment last quarter, the final guide \nactually is a little bit better here.  Any sort of comments on what is driving sort of the increased optimism here?  Is it \nsolely ju st as we're thinking about maybe GLP -1s?  Or maybe can you talk about sort of any kind of gains at \nRelayHealth as it relates to the Change Healthcare outage?  Any comments there would be helpful.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executiv e Vice President, McKesson Corp.  ", "original_text": "Or maybe can you talk about sort of any kind of gains at \nRelayHealth as it relates to the Change Healthcare outage? "}, "hash": "b0cafac1738283a645ef168b07c836c94a653bb37a6155a6838270b3ae1ccbf0", "class_name": "RelatedNodeInfo"}}, "text": "Is it \nsolely ju st as we're thinking about maybe GLP -1s? ", "start_char_idx": 2605, "end_char_idx": 2664, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9efd44d8-d25e-4e7d-b895-b28b7275fd81": {"__data__": {"id_": "9efd44d8-d25e-4e7d-b895-b28b7275fd81", "embedding": null, "metadata": {"window": "But \nthinking about the preliminary fiscal 2025 guide you kind of gave for this segment last quarter, the final guide \nactually is a little bit better here.  Any sort of comments on what is driving sort of the increased optimism here?  Is it \nsolely ju st as we're thinking about maybe GLP -1s?  Or maybe can you talk about sort of any kind of gains at \nRelayHealth as it relates to the Change Healthcare outage?  Any comments there would be helpful.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executiv e Vice President, McKesson Corp.  ", "original_text": "Or maybe can you talk about sort of any kind of gains at \nRelayHealth as it relates to the Change Healthcare outage? ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "98047684-7eaf-431b-abdc-d76ed6294538", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "32ee64f29bbc3dd35b99b5fe8ce8f3d18f6702098e8d1a38dc6d4dedc2636637", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5bf65d9-e9bc-4917-aaac-50dac40f7af5", "node_type": "1", "metadata": {"window": "I wanted to circle back to RxTS, obviously, looking at a really positive outlook.  But \nthinking about the preliminary fiscal 2025 guide you kind of gave for this segment last quarter, the final guide \nactually is a little bit better here.  Any sort of comments on what is driving sort of the increased optimism here?  Is it \nsolely ju st as we're thinking about maybe GLP -1s?  Or maybe can you talk about sort of any kind of gains at \nRelayHealth as it relates to the Change Healthcare outage?  Any comments there would be helpful.  Thanks.  \n ", "original_text": "Is it \nsolely ju st as we're thinking about maybe GLP -1s? ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "198c520fac4ec4b6f18c52de09b01395348d2161a0fc89cba4de79a37f90e1e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b50205b-447f-4882-8899-c69ab5e4df78", "node_type": "1", "metadata": {"window": "Any sort of comments on what is driving sort of the increased optimism here?  Is it \nsolely ju st as we're thinking about maybe GLP -1s?  Or maybe can you talk about sort of any kind of gains at \nRelayHealth as it relates to the Change Healthcare outage?  Any comments there would be helpful.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executiv e Vice President, McKesson Corp.   A \nThanks for the question. ", "original_text": "Any comments there would be helpful. "}, "hash": "7f01aa7d853e0871d163ccfa03b24369d6eefcd7b2ae93befad8cd27dd0e615a", "class_name": "RelatedNodeInfo"}}, "text": "Or maybe can you talk about sort of any kind of gains at \nRelayHealth as it relates to the Change Healthcare outage? ", "start_char_idx": 2664, "end_char_idx": 2781, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b50205b-447f-4882-8899-c69ab5e4df78": {"__data__": {"id_": "0b50205b-447f-4882-8899-c69ab5e4df78", "embedding": null, "metadata": {"window": "Any sort of comments on what is driving sort of the increased optimism here?  Is it \nsolely ju st as we're thinking about maybe GLP -1s?  Or maybe can you talk about sort of any kind of gains at \nRelayHealth as it relates to the Change Healthcare outage?  Any comments there would be helpful.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executiv e Vice President, McKesson Corp.   A \nThanks for the question. ", "original_text": "Any comments there would be helpful. ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "98047684-7eaf-431b-abdc-d76ed6294538", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "32ee64f29bbc3dd35b99b5fe8ce8f3d18f6702098e8d1a38dc6d4dedc2636637", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9efd44d8-d25e-4e7d-b895-b28b7275fd81", "node_type": "1", "metadata": {"window": "But \nthinking about the preliminary fiscal 2025 guide you kind of gave for this segment last quarter, the final guide \nactually is a little bit better here.  Any sort of comments on what is driving sort of the increased optimism here?  Is it \nsolely ju st as we're thinking about maybe GLP -1s?  Or maybe can you talk about sort of any kind of gains at \nRelayHealth as it relates to the Change Healthcare outage?  Any comments there would be helpful.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executiv e Vice President, McKesson Corp.  ", "original_text": "Or maybe can you talk about sort of any kind of gains at \nRelayHealth as it relates to the Change Healthcare outage? ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "959d7df4fd0a657bb286e1ae8060bc89c946d1d264350b87015e360886138b41", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3fb9816b-ac1b-4f78-894a-9dd9dd35b07c", "node_type": "1", "metadata": {"window": "Is it \nsolely ju st as we're thinking about maybe GLP -1s?  Or maybe can you talk about sort of any kind of gains at \nRelayHealth as it relates to the Change Healthcare outage?  Any comments there would be helpful.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executiv e Vice President, McKesson Corp.   A \nThanks for the question.  I'll start. ", "original_text": "Thanks.  \n "}, "hash": "49946a4428aeccf79f3f29b234a5b2d0e41b944c9999b9499af152a2d19083fd", "class_name": "RelatedNodeInfo"}}, "text": "Any comments there would be helpful. ", "start_char_idx": 2781, "end_char_idx": 2818, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3fb9816b-ac1b-4f78-894a-9dd9dd35b07c": {"__data__": {"id_": "3fb9816b-ac1b-4f78-894a-9dd9dd35b07c", "embedding": null, "metadata": {"window": "Is it \nsolely ju st as we're thinking about maybe GLP -1s?  Or maybe can you talk about sort of any kind of gains at \nRelayHealth as it relates to the Change Healthcare outage?  Any comments there would be helpful.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executiv e Vice President, McKesson Corp.   A \nThanks for the question.  I'll start. ", "original_text": "Thanks.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "98047684-7eaf-431b-abdc-d76ed6294538", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "32ee64f29bbc3dd35b99b5fe8ce8f3d18f6702098e8d1a38dc6d4dedc2636637", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b50205b-447f-4882-8899-c69ab5e4df78", "node_type": "1", "metadata": {"window": "Any sort of comments on what is driving sort of the increased optimism here?  Is it \nsolely ju st as we're thinking about maybe GLP -1s?  Or maybe can you talk about sort of any kind of gains at \nRelayHealth as it relates to the Change Healthcare outage?  Any comments there would be helpful.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executiv e Vice President, McKesson Corp.   A \nThanks for the question. ", "original_text": "Any comments there would be helpful. ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "96ab4a05e790d517089a4fad02e9b6d4e19d27a88ec69b42346aff26953ec582", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3189d73e-fb7c-48f3-a2bd-2d5ea43100c3", "node_type": "1", "metadata": {"window": "Or maybe can you talk about sort of any kind of gains at \nRelayHealth as it relates to the Change Healthcare outage?  Any comments there would be helpful.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executiv e Vice President, McKesson Corp.   A \nThanks for the question.  I'll start.  So the AOP growth guide that we provided you for FY 2025 is really right in the \nrange of what we've seen for growth over the last four years, maybe just slightly below. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executiv e Vice President, McKesson Corp.  "}, "hash": "61183942a2e3c8dfbd966ea75a7821e5d071abf58a5f3689ea316206675ec618", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 2818, "end_char_idx": 2829, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3189d73e-fb7c-48f3-a2bd-2d5ea43100c3": {"__data__": {"id_": "3189d73e-fb7c-48f3-a2bd-2d5ea43100c3", "embedding": null, "metadata": {"window": "Or maybe can you talk about sort of any kind of gains at \nRelayHealth as it relates to the Change Healthcare outage?  Any comments there would be helpful.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executiv e Vice President, McKesson Corp.   A \nThanks for the question.  I'll start.  So the AOP growth guide that we provided you for FY 2025 is really right in the \nrange of what we've seen for growth over the last four years, maybe just slightly below. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executiv e Vice President, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "98047684-7eaf-431b-abdc-d76ed6294538", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "32ee64f29bbc3dd35b99b5fe8ce8f3d18f6702098e8d1a38dc6d4dedc2636637", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3fb9816b-ac1b-4f78-894a-9dd9dd35b07c", "node_type": "1", "metadata": {"window": "Is it \nsolely ju st as we're thinking about maybe GLP -1s?  Or maybe can you talk about sort of any kind of gains at \nRelayHealth as it relates to the Change Healthcare outage?  Any comments there would be helpful.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executiv e Vice President, McKesson Corp.   A \nThanks for the question.  I'll start. ", "original_text": "Thanks.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a9db0d3d2254b0477a4eb206fbcc3781e23658c7f9bdb3946c784033a2163051", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11e6535f-9c7d-4bd7-b6e1-b2fe42b237a3", "node_type": "1", "metadata": {"window": "Any comments there would be helpful.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executiv e Vice President, McKesson Corp.   A \nThanks for the question.  I'll start.  So the AOP growth guide that we provided you for FY 2025 is really right in the \nrange of what we've seen for growth over the last four years, maybe just slightly below.  We had 16% com pound \nannual growth rate in this business on operating profit since FY 2020. ", "original_text": "A \nThanks for the question. "}, "hash": "ce30a9af5aeafbb4c44be971c0838014676e9d1e22be1ff8fcfaf6670c3da2d8", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executiv e Vice President, McKesson Corp.  ", "start_char_idx": 2829, "end_char_idx": 3190, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11e6535f-9c7d-4bd7-b6e1-b2fe42b237a3": {"__data__": {"id_": "11e6535f-9c7d-4bd7-b6e1-b2fe42b237a3", "embedding": null, "metadata": {"window": "Any comments there would be helpful.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executiv e Vice President, McKesson Corp.   A \nThanks for the question.  I'll start.  So the AOP growth guide that we provided you for FY 2025 is really right in the \nrange of what we've seen for growth over the last four years, maybe just slightly below.  We had 16% com pound \nannual growth rate in this business on operating profit since FY 2020. ", "original_text": "A \nThanks for the question. ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "98047684-7eaf-431b-abdc-d76ed6294538", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "32ee64f29bbc3dd35b99b5fe8ce8f3d18f6702098e8d1a38dc6d4dedc2636637", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3189d73e-fb7c-48f3-a2bd-2d5ea43100c3", "node_type": "1", "metadata": {"window": "Or maybe can you talk about sort of any kind of gains at \nRelayHealth as it relates to the Change Healthcare outage?  Any comments there would be helpful.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executiv e Vice President, McKesson Corp.   A \nThanks for the question.  I'll start.  So the AOP growth guide that we provided you for FY 2025 is really right in the \nrange of what we've seen for growth over the last four years, maybe just slightly below. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executiv e Vice President, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "fde50bdb690809ec350a4683537dae38adb80035d81e1cd5686003c3e90e3dd1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3fd468c5-c500-433c-a7e8-f14e083e8bad", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executiv e Vice President, McKesson Corp.   A \nThanks for the question.  I'll start.  So the AOP growth guide that we provided you for FY 2025 is really right in the \nrange of what we've seen for growth over the last four years, maybe just slightly below.  We had 16% com pound \nannual growth rate in this business on operating profit since FY 2020.  And so the growth rate that we've provided \nyou this year is really kind of right in line with that. ", "original_text": "I'll start. "}, "hash": "833192ac531f74c0bdfb944a0898715a6323e7d3d42714b28a39229a24f89e4b", "class_name": "RelatedNodeInfo"}}, "text": "A \nThanks for the question. ", "start_char_idx": 3190, "end_char_idx": 3218, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3fd468c5-c500-433c-a7e8-f14e083e8bad": {"__data__": {"id_": "3fd468c5-c500-433c-a7e8-f14e083e8bad", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executiv e Vice President, McKesson Corp.   A \nThanks for the question.  I'll start.  So the AOP growth guide that we provided you for FY 2025 is really right in the \nrange of what we've seen for growth over the last four years, maybe just slightly below.  We had 16% com pound \nannual growth rate in this business on operating profit since FY 2020.  And so the growth rate that we've provided \nyou this year is really kind of right in line with that. ", "original_text": "I'll start. ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "98047684-7eaf-431b-abdc-d76ed6294538", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "32ee64f29bbc3dd35b99b5fe8ce8f3d18f6702098e8d1a38dc6d4dedc2636637", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11e6535f-9c7d-4bd7-b6e1-b2fe42b237a3", "node_type": "1", "metadata": {"window": "Any comments there would be helpful.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executiv e Vice President, McKesson Corp.   A \nThanks for the question.  I'll start.  So the AOP growth guide that we provided you for FY 2025 is really right in the \nrange of what we've seen for growth over the last four years, maybe just slightly below.  We had 16% com pound \nannual growth rate in this business on operating profit since FY 2020. ", "original_text": "A \nThanks for the question. ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "dbb0657588cdc4f26027af011a24ee62825523c48c928d622f326424b23613be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ed0612e-5c0f-4df6-a817-8242dbc881a7", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executiv e Vice President, McKesson Corp.   A \nThanks for the question.  I'll start.  So the AOP growth guide that we provided you for FY 2025 is really right in the \nrange of what we've seen for growth over the last four years, maybe just slightly below.  We had 16% com pound \nannual growth rate in this business on operating profit since FY 2020.  And so the growth rate that we've provided \nyou this year is really kind of right in line with that.  And we intend to continue to make investments in this business \nas we go forward  to develop additional solutions and capabilities for our customers.  \n \n", "original_text": "So the AOP growth guide that we provided you for FY 2025 is really right in the \nrange of what we've seen for growth over the last four years, maybe just slightly below. "}, "hash": "c2a47be04537118e849ce85ae0aeabfbb46f68489e24b3ccbd7daaca55497a99", "class_name": "RelatedNodeInfo"}}, "text": "I'll start. ", "start_char_idx": 3218, "end_char_idx": 3230, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ed0612e-5c0f-4df6-a817-8242dbc881a7": {"__data__": {"id_": "3ed0612e-5c0f-4df6-a817-8242dbc881a7", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executiv e Vice President, McKesson Corp.   A \nThanks for the question.  I'll start.  So the AOP growth guide that we provided you for FY 2025 is really right in the \nrange of what we've seen for growth over the last four years, maybe just slightly below.  We had 16% com pound \nannual growth rate in this business on operating profit since FY 2020.  And so the growth rate that we've provided \nyou this year is really kind of right in line with that.  And we intend to continue to make investments in this business \nas we go forward  to develop additional solutions and capabilities for our customers.  \n \n", "original_text": "So the AOP growth guide that we provided you for FY 2025 is really right in the \nrange of what we've seen for growth over the last four years, maybe just slightly below. ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "98047684-7eaf-431b-abdc-d76ed6294538", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "32ee64f29bbc3dd35b99b5fe8ce8f3d18f6702098e8d1a38dc6d4dedc2636637", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3fd468c5-c500-433c-a7e8-f14e083e8bad", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executiv e Vice President, McKesson Corp.   A \nThanks for the question.  I'll start.  So the AOP growth guide that we provided you for FY 2025 is really right in the \nrange of what we've seen for growth over the last four years, maybe just slightly below.  We had 16% com pound \nannual growth rate in this business on operating profit since FY 2020.  And so the growth rate that we've provided \nyou this year is really kind of right in line with that. ", "original_text": "I'll start. ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "730f8f365f5867cf947340a285d6636cd8bbf2c2aca48bea258892145e01cd68", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1049d467-2585-4876-b6b7-c4e8fe1d6858", "node_type": "1", "metadata": {"window": "A \nThanks for the question.  I'll start.  So the AOP growth guide that we provided you for FY 2025 is really right in the \nrange of what we've seen for growth over the last four years, maybe just slightly below.  We had 16% com pound \nannual growth rate in this business on operating profit since FY 2020.  And so the growth rate that we've provided \nyou this year is really kind of right in line with that.  And we intend to continue to make investments in this business \nas we go forward  to develop additional solutions and capabilities for our customers.  \n \n So we expect that our technology solutions and services will continue to grow as they have over the last few \nyears. ", "original_text": "We had 16% com pound \nannual growth rate in this business on operating profit since FY 2020. "}, "hash": "f5c22b1a20490f4b28c3816659e7518fa6685ae8e2f0f1b6739e3bf9b5987a67", "class_name": "RelatedNodeInfo"}}, "text": "So the AOP growth guide that we provided you for FY 2025 is really right in the \nrange of what we've seen for growth over the last four years, maybe just slightly below. ", "start_char_idx": 3230, "end_char_idx": 3400, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1049d467-2585-4876-b6b7-c4e8fe1d6858": {"__data__": {"id_": "1049d467-2585-4876-b6b7-c4e8fe1d6858", "embedding": null, "metadata": {"window": "A \nThanks for the question.  I'll start.  So the AOP growth guide that we provided you for FY 2025 is really right in the \nrange of what we've seen for growth over the last four years, maybe just slightly below.  We had 16% com pound \nannual growth rate in this business on operating profit since FY 2020.  And so the growth rate that we've provided \nyou this year is really kind of right in line with that.  And we intend to continue to make investments in this business \nas we go forward  to develop additional solutions and capabilities for our customers.  \n \n So we expect that our technology solutions and services will continue to grow as they have over the last few \nyears. ", "original_text": "We had 16% com pound \nannual growth rate in this business on operating profit since FY 2020. ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "98047684-7eaf-431b-abdc-d76ed6294538", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "32ee64f29bbc3dd35b99b5fe8ce8f3d18f6702098e8d1a38dc6d4dedc2636637", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ed0612e-5c0f-4df6-a817-8242dbc881a7", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executiv e Vice President, McKesson Corp.   A \nThanks for the question.  I'll start.  So the AOP growth guide that we provided you for FY 2025 is really right in the \nrange of what we've seen for growth over the last four years, maybe just slightly below.  We had 16% com pound \nannual growth rate in this business on operating profit since FY 2020.  And so the growth rate that we've provided \nyou this year is really kind of right in line with that.  And we intend to continue to make investments in this business \nas we go forward  to develop additional solutions and capabilities for our customers.  \n \n", "original_text": "So the AOP growth guide that we provided you for FY 2025 is really right in the \nrange of what we've seen for growth over the last four years, maybe just slightly below. ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "0139282c5bf3f60712f55609e523d6e8931e79f22adc54600c979d2d04aa33eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c449142b-e8a4-4ec8-96c8-5693e9dd7aeb", "node_type": "1", "metadata": {"window": "I'll start.  So the AOP growth guide that we provided you for FY 2025 is really right in the \nrange of what we've seen for growth over the last four years, maybe just slightly below.  We had 16% com pound \nannual growth rate in this business on operating profit since FY 2020.  And so the growth rate that we've provided \nyou this year is really kind of right in line with that.  And we intend to continue to make investments in this business \nas we go forward  to develop additional solutions and capabilities for our customers.  \n \n So we expect that our technology solutions and services will continue to grow as they have over the last few \nyears.  The value that we're providing for our partners is continuing to reson ate, and we see stable prescription \ngrowth. ", "original_text": "And so the growth rate that we've provided \nyou this year is really kind of right in line with that. "}, "hash": "24dca28942358cc98bfd9d495197554b9f6f453e8ee4b51e57c7ff3f80d7728a", "class_name": "RelatedNodeInfo"}}, "text": "We had 16% com pound \nannual growth rate in this business on operating profit since FY 2020. ", "start_char_idx": 3400, "end_char_idx": 3493, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c449142b-e8a4-4ec8-96c8-5693e9dd7aeb": {"__data__": {"id_": "c449142b-e8a4-4ec8-96c8-5693e9dd7aeb", "embedding": null, "metadata": {"window": "I'll start.  So the AOP growth guide that we provided you for FY 2025 is really right in the \nrange of what we've seen for growth over the last four years, maybe just slightly below.  We had 16% com pound \nannual growth rate in this business on operating profit since FY 2020.  And so the growth rate that we've provided \nyou this year is really kind of right in line with that.  And we intend to continue to make investments in this business \nas we go forward  to develop additional solutions and capabilities for our customers.  \n \n So we expect that our technology solutions and services will continue to grow as they have over the last few \nyears.  The value that we're providing for our partners is continuing to reson ate, and we see stable prescription \ngrowth. ", "original_text": "And so the growth rate that we've provided \nyou this year is really kind of right in line with that. ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "98047684-7eaf-431b-abdc-d76ed6294538", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "32ee64f29bbc3dd35b99b5fe8ce8f3d18f6702098e8d1a38dc6d4dedc2636637", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1049d467-2585-4876-b6b7-c4e8fe1d6858", "node_type": "1", "metadata": {"window": "A \nThanks for the question.  I'll start.  So the AOP growth guide that we provided you for FY 2025 is really right in the \nrange of what we've seen for growth over the last four years, maybe just slightly below.  We had 16% com pound \nannual growth rate in this business on operating profit since FY 2020.  And so the growth rate that we've provided \nyou this year is really kind of right in line with that.  And we intend to continue to make investments in this business \nas we go forward  to develop additional solutions and capabilities for our customers.  \n \n So we expect that our technology solutions and services will continue to grow as they have over the last few \nyears. ", "original_text": "We had 16% com pound \nannual growth rate in this business on operating profit since FY 2020. ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "2a6cc24fde661c074a787f413aca009a31981c93bd52555b107919a3b8773919", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f086e2a9-2a55-431d-b39c-3fbb687e5e10", "node_type": "1", "metadata": {"window": "So the AOP growth guide that we provided you for FY 2025 is really right in the \nrange of what we've seen for growth over the last four years, maybe just slightly below.  We had 16% com pound \nannual growth rate in this business on operating profit since FY 2020.  And so the growth rate that we've provided \nyou this year is really kind of right in line with that.  And we intend to continue to make investments in this business \nas we go forward  to develop additional solutions and capabilities for our customers.  \n \n So we expect that our technology solutions and services will continue to grow as they have over the last few \nyears.  The value that we're providing for our partners is continuing to reson ate, and we see stable prescription \ngrowth.  It's really underpinning a lot of the programs and solutions that we have. ", "original_text": "And we intend to continue to make investments in this business \nas we go forward  to develop additional solutions and capabilities for our customers.  \n \n"}, "hash": "d3679c099e0167a2668adfe6ef41624c5de3bc67ae64dcb54df68b28e5604da3", "class_name": "RelatedNodeInfo"}}, "text": "And so the growth rate that we've provided \nyou this year is really kind of right in line with that. ", "start_char_idx": 3493, "end_char_idx": 3594, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f086e2a9-2a55-431d-b39c-3fbb687e5e10": {"__data__": {"id_": "f086e2a9-2a55-431d-b39c-3fbb687e5e10", "embedding": null, "metadata": {"window": "So the AOP growth guide that we provided you for FY 2025 is really right in the \nrange of what we've seen for growth over the last four years, maybe just slightly below.  We had 16% com pound \nannual growth rate in this business on operating profit since FY 2020.  And so the growth rate that we've provided \nyou this year is really kind of right in line with that.  And we intend to continue to make investments in this business \nas we go forward  to develop additional solutions and capabilities for our customers.  \n \n So we expect that our technology solutions and services will continue to grow as they have over the last few \nyears.  The value that we're providing for our partners is continuing to reson ate, and we see stable prescription \ngrowth.  It's really underpinning a lot of the programs and solutions that we have. ", "original_text": "And we intend to continue to make investments in this business \nas we go forward  to develop additional solutions and capabilities for our customers.  \n \n", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "98047684-7eaf-431b-abdc-d76ed6294538", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "32ee64f29bbc3dd35b99b5fe8ce8f3d18f6702098e8d1a38dc6d4dedc2636637", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c449142b-e8a4-4ec8-96c8-5693e9dd7aeb", "node_type": "1", "metadata": {"window": "I'll start.  So the AOP growth guide that we provided you for FY 2025 is really right in the \nrange of what we've seen for growth over the last four years, maybe just slightly below.  We had 16% com pound \nannual growth rate in this business on operating profit since FY 2020.  And so the growth rate that we've provided \nyou this year is really kind of right in line with that.  And we intend to continue to make investments in this business \nas we go forward  to develop additional solutions and capabilities for our customers.  \n \n So we expect that our technology solutions and services will continue to grow as they have over the last few \nyears.  The value that we're providing for our partners is continuing to reson ate, and we see stable prescription \ngrowth. ", "original_text": "And so the growth rate that we've provided \nyou this year is really kind of right in line with that. ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c675a16aff42e2b13df4be8669a1878bbfd09ede8a9ff16e7fc7585742c688cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "291424e6-0cac-4618-a5df-bff01e25ef86", "node_type": "1", "metadata": {"window": "We had 16% com pound \nannual growth rate in this business on operating profit since FY 2020.  And so the growth rate that we've provided \nyou this year is really kind of right in line with that.  And we intend to continue to make investments in this business \nas we go forward  to develop additional solutions and capabilities for our customers.  \n \n So we expect that our technology solutions and services will continue to grow as they have over the last few \nyears.  The value that we're providing for our partners is continuing to reson ate, and we see stable prescription \ngrowth.  It's really underpinning a lot of the programs and solutions that we have.  And the growth rate that we \nexpect for next year is really in line with what we've been able to deliver over the last several. ", "original_text": "So we expect that our technology solutions and services will continue to grow as they have over the last few \nyears. "}, "hash": "db0dbe74739b5db3ace0fb1893d7acf5c5f967c18ce0ec3b2350a7873c8ac063", "class_name": "RelatedNodeInfo"}}, "text": "And we intend to continue to make investments in this business \nas we go forward  to develop additional solutions and capabilities for our customers.  \n \n", "start_char_idx": 3594, "end_char_idx": 3748, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "291424e6-0cac-4618-a5df-bff01e25ef86": {"__data__": {"id_": "291424e6-0cac-4618-a5df-bff01e25ef86", "embedding": null, "metadata": {"window": "We had 16% com pound \nannual growth rate in this business on operating profit since FY 2020.  And so the growth rate that we've provided \nyou this year is really kind of right in line with that.  And we intend to continue to make investments in this business \nas we go forward  to develop additional solutions and capabilities for our customers.  \n \n So we expect that our technology solutions and services will continue to grow as they have over the last few \nyears.  The value that we're providing for our partners is continuing to reson ate, and we see stable prescription \ngrowth.  It's really underpinning a lot of the programs and solutions that we have.  And the growth rate that we \nexpect for next year is really in line with what we've been able to deliver over the last several. ", "original_text": "So we expect that our technology solutions and services will continue to grow as they have over the last few \nyears. ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "98047684-7eaf-431b-abdc-d76ed6294538", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "32ee64f29bbc3dd35b99b5fe8ce8f3d18f6702098e8d1a38dc6d4dedc2636637", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f086e2a9-2a55-431d-b39c-3fbb687e5e10", "node_type": "1", "metadata": {"window": "So the AOP growth guide that we provided you for FY 2025 is really right in the \nrange of what we've seen for growth over the last four years, maybe just slightly below.  We had 16% com pound \nannual growth rate in this business on operating profit since FY 2020.  And so the growth rate that we've provided \nyou this year is really kind of right in line with that.  And we intend to continue to make investments in this business \nas we go forward  to develop additional solutions and capabilities for our customers.  \n \n So we expect that our technology solutions and services will continue to grow as they have over the last few \nyears.  The value that we're providing for our partners is continuing to reson ate, and we see stable prescription \ngrowth.  It's really underpinning a lot of the programs and solutions that we have. ", "original_text": "And we intend to continue to make investments in this business \nas we go forward  to develop additional solutions and capabilities for our customers.  \n \n", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "dc69e187a2ea660d96fc848a4d9ce80846bb0cc35dbb1a81ebf084b6d48cc50e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79a77e6e-4f4d-4a22-a8a6-e30f0092bf14", "node_type": "1", "metadata": {"window": "And so the growth rate that we've provided \nyou this year is really kind of right in line with that.  And we intend to continue to make investments in this business \nas we go forward  to develop additional solutions and capabilities for our customers.  \n \n So we expect that our technology solutions and services will continue to grow as they have over the last few \nyears.  The value that we're providing for our partners is continuing to reson ate, and we see stable prescription \ngrowth.  It's really underpinning a lot of the programs and solutions that we have.  And the growth rate that we \nexpect for next year is really in line with what we've been able to deliver over the last several.  And we'll continue \nto, as Brian talked about, we'll use our free cash flow to invest in our growth opportunities as we go forward.  \n ", "original_text": "The value that we're providing for our partners is continuing to reson ate, and we see stable prescription \ngrowth. "}, "hash": "a7c0cb41f4f936f131f144d4608594487b23681509eadf79895fc1bb8e0309fd", "class_name": "RelatedNodeInfo"}}, "text": "So we expect that our technology solutions and services will continue to grow as they have over the last few \nyears. ", "start_char_idx": 3748, "end_char_idx": 3865, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79a77e6e-4f4d-4a22-a8a6-e30f0092bf14": {"__data__": {"id_": "79a77e6e-4f4d-4a22-a8a6-e30f0092bf14", "embedding": null, "metadata": {"window": "And so the growth rate that we've provided \nyou this year is really kind of right in line with that.  And we intend to continue to make investments in this business \nas we go forward  to develop additional solutions and capabilities for our customers.  \n \n So we expect that our technology solutions and services will continue to grow as they have over the last few \nyears.  The value that we're providing for our partners is continuing to reson ate, and we see stable prescription \ngrowth.  It's really underpinning a lot of the programs and solutions that we have.  And the growth rate that we \nexpect for next year is really in line with what we've been able to deliver over the last several.  And we'll continue \nto, as Brian talked about, we'll use our free cash flow to invest in our growth opportunities as we go forward.  \n ", "original_text": "The value that we're providing for our partners is continuing to reson ate, and we see stable prescription \ngrowth. ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "98047684-7eaf-431b-abdc-d76ed6294538", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "32ee64f29bbc3dd35b99b5fe8ce8f3d18f6702098e8d1a38dc6d4dedc2636637", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "291424e6-0cac-4618-a5df-bff01e25ef86", "node_type": "1", "metadata": {"window": "We had 16% com pound \nannual growth rate in this business on operating profit since FY 2020.  And so the growth rate that we've provided \nyou this year is really kind of right in line with that.  And we intend to continue to make investments in this business \nas we go forward  to develop additional solutions and capabilities for our customers.  \n \n So we expect that our technology solutions and services will continue to grow as they have over the last few \nyears.  The value that we're providing for our partners is continuing to reson ate, and we see stable prescription \ngrowth.  It's really underpinning a lot of the programs and solutions that we have.  And the growth rate that we \nexpect for next year is really in line with what we've been able to deliver over the last several. ", "original_text": "So we expect that our technology solutions and services will continue to grow as they have over the last few \nyears. ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d821e11d71142e358ab60f91a2f0c06b311fb8b7902b92c9e43007b128f4dc3f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3dea05e-8db8-4c1d-8022-d74f856e8604", "node_type": "1", "metadata": {"window": "And we intend to continue to make investments in this business \nas we go forward  to develop additional solutions and capabilities for our customers.  \n \n So we expect that our technology solutions and services will continue to grow as they have over the last few \nyears.  The value that we're providing for our partners is continuing to reson ate, and we see stable prescription \ngrowth.  It's really underpinning a lot of the programs and solutions that we have.  And the growth rate that we \nexpect for next year is really in line with what we've been able to deliver over the last several.  And we'll continue \nto, as Brian talked about, we'll use our free cash flow to invest in our growth opportunities as we go forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "It's really underpinning a lot of the programs and solutions that we have. "}, "hash": "cd4becc5f6a57dba104639f485a550fde7253ca0f718bd4930238765fbc66982", "class_name": "RelatedNodeInfo"}}, "text": "The value that we're providing for our partners is continuing to reson ate, and we see stable prescription \ngrowth. ", "start_char_idx": 3865, "end_char_idx": 3981, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3dea05e-8db8-4c1d-8022-d74f856e8604": {"__data__": {"id_": "a3dea05e-8db8-4c1d-8022-d74f856e8604", "embedding": null, "metadata": {"window": "And we intend to continue to make investments in this business \nas we go forward  to develop additional solutions and capabilities for our customers.  \n \n So we expect that our technology solutions and services will continue to grow as they have over the last few \nyears.  The value that we're providing for our partners is continuing to reson ate, and we see stable prescription \ngrowth.  It's really underpinning a lot of the programs and solutions that we have.  And the growth rate that we \nexpect for next year is really in line with what we've been able to deliver over the last several.  And we'll continue \nto, as Brian talked about, we'll use our free cash flow to invest in our growth opportunities as we go forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "It's really underpinning a lot of the programs and solutions that we have. ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "98047684-7eaf-431b-abdc-d76ed6294538", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "32ee64f29bbc3dd35b99b5fe8ce8f3d18f6702098e8d1a38dc6d4dedc2636637", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79a77e6e-4f4d-4a22-a8a6-e30f0092bf14", "node_type": "1", "metadata": {"window": "And so the growth rate that we've provided \nyou this year is really kind of right in line with that.  And we intend to continue to make investments in this business \nas we go forward  to develop additional solutions and capabilities for our customers.  \n \n So we expect that our technology solutions and services will continue to grow as they have over the last few \nyears.  The value that we're providing for our partners is continuing to reson ate, and we see stable prescription \ngrowth.  It's really underpinning a lot of the programs and solutions that we have.  And the growth rate that we \nexpect for next year is really in line with what we've been able to deliver over the last several.  And we'll continue \nto, as Brian talked about, we'll use our free cash flow to invest in our growth opportunities as we go forward.  \n ", "original_text": "The value that we're providing for our partners is continuing to reson ate, and we see stable prescription \ngrowth. ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "20811a62c1a890246fbe75119a73282041a0b03da584cd778d2d72e14a0d4b81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e78c846-8e3d-490c-85fe-1265fac09a4f", "node_type": "1", "metadata": {"window": "So we expect that our technology solutions and services will continue to grow as they have over the last few \nyears.  The value that we're providing for our partners is continuing to reson ate, and we see stable prescription \ngrowth.  It's really underpinning a lot of the programs and solutions that we have.  And the growth rate that we \nexpect for next year is really in line with what we've been able to deliver over the last several.  And we'll continue \nto, as Brian talked about, we'll use our free cash flow to invest in our growth opportunities as we go forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "And the growth rate that we \nexpect for next year is really in line with what we've been able to deliver over the last several. "}, "hash": "97050080b3969153b4bd3571aedf1701c9d53745ee4bb326e9ffdb1b9534e8b8", "class_name": "RelatedNodeInfo"}}, "text": "It's really underpinning a lot of the programs and solutions that we have. ", "start_char_idx": 3981, "end_char_idx": 4056, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e78c846-8e3d-490c-85fe-1265fac09a4f": {"__data__": {"id_": "0e78c846-8e3d-490c-85fe-1265fac09a4f", "embedding": null, "metadata": {"window": "So we expect that our technology solutions and services will continue to grow as they have over the last few \nyears.  The value that we're providing for our partners is continuing to reson ate, and we see stable prescription \ngrowth.  It's really underpinning a lot of the programs and solutions that we have.  And the growth rate that we \nexpect for next year is really in line with what we've been able to deliver over the last several.  And we'll continue \nto, as Brian talked about, we'll use our free cash flow to invest in our growth opportunities as we go forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "And the growth rate that we \nexpect for next year is really in line with what we've been able to deliver over the last several. ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "98047684-7eaf-431b-abdc-d76ed6294538", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "32ee64f29bbc3dd35b99b5fe8ce8f3d18f6702098e8d1a38dc6d4dedc2636637", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3dea05e-8db8-4c1d-8022-d74f856e8604", "node_type": "1", "metadata": {"window": "And we intend to continue to make investments in this business \nas we go forward  to develop additional solutions and capabilities for our customers.  \n \n So we expect that our technology solutions and services will continue to grow as they have over the last few \nyears.  The value that we're providing for our partners is continuing to reson ate, and we see stable prescription \ngrowth.  It's really underpinning a lot of the programs and solutions that we have.  And the growth rate that we \nexpect for next year is really in line with what we've been able to deliver over the last several.  And we'll continue \nto, as Brian talked about, we'll use our free cash flow to invest in our growth opportunities as we go forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "It's really underpinning a lot of the programs and solutions that we have. ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5bd3a58d9280608b6c46332b04cc3b51c61674fcdc739e8caa5f510da0113b83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d874a44a-8c0f-4cd6-aba1-886a05a7ca00", "node_type": "1", "metadata": {"window": "The value that we're providing for our partners is continuing to reson ate, and we see stable prescription \ngrowth.  It's really underpinning a lot of the programs and solutions that we have.  And the growth rate that we \nexpect for next year is really in line with what we've been able to deliver over the last several.  And we'll continue \nto, as Brian talked about, we'll use our free cash flow to invest in our growth opportunities as we go forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research. ", "original_text": "And we'll continue \nto, as Brian talked about, we'll use our free cash flow to invest in our growth opportunities as we go forward.  \n "}, "hash": "93155e2ffa14839c50211172b58331d344fa484c4d9efab6c4759e177c67a237", "class_name": "RelatedNodeInfo"}}, "text": "And the growth rate that we \nexpect for next year is really in line with what we've been able to deliver over the last several. ", "start_char_idx": 4056, "end_char_idx": 4184, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d874a44a-8c0f-4cd6-aba1-886a05a7ca00": {"__data__": {"id_": "d874a44a-8c0f-4cd6-aba1-886a05a7ca00", "embedding": null, "metadata": {"window": "The value that we're providing for our partners is continuing to reson ate, and we see stable prescription \ngrowth.  It's really underpinning a lot of the programs and solutions that we have.  And the growth rate that we \nexpect for next year is really in line with what we've been able to deliver over the last several.  And we'll continue \nto, as Brian talked about, we'll use our free cash flow to invest in our growth opportunities as we go forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research. ", "original_text": "And we'll continue \nto, as Brian talked about, we'll use our free cash flow to invest in our growth opportunities as we go forward.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "98047684-7eaf-431b-abdc-d76ed6294538", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "32ee64f29bbc3dd35b99b5fe8ce8f3d18f6702098e8d1a38dc6d4dedc2636637", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e78c846-8e3d-490c-85fe-1265fac09a4f", "node_type": "1", "metadata": {"window": "So we expect that our technology solutions and services will continue to grow as they have over the last few \nyears.  The value that we're providing for our partners is continuing to reson ate, and we see stable prescription \ngrowth.  It's really underpinning a lot of the programs and solutions that we have.  And the growth rate that we \nexpect for next year is really in line with what we've been able to deliver over the last several.  And we'll continue \nto, as Brian talked about, we'll use our free cash flow to invest in our growth opportunities as we go forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "And the growth rate that we \nexpect for next year is really in line with what we've been able to deliver over the last several. ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "4e8d3a27ccb1af58633a43c4d747a44af1a427a67fa3e59b2f440d75f8700b6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b31fa255-8aad-45a2-b60e-b97b0f34f85b", "node_type": "1", "metadata": {"window": "It's really underpinning a lot of the programs and solutions that we have.  And the growth rate that we \nexpect for next year is really in line with what we've been able to deliver over the last several.  And we'll continue \nto, as Brian talked about, we'll use our free cash flow to invest in our growth opportunities as we go forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  "}, "hash": "9ddaa248b03c164afd77d709f96cb87889f2c98e3b65755eb63098213a51393f", "class_name": "RelatedNodeInfo"}}, "text": "And we'll continue \nto, as Brian talked about, we'll use our free cash flow to invest in our growth opportunities as we go forward.  \n ", "start_char_idx": 4184, "end_char_idx": 4319, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b31fa255-8aad-45a2-b60e-b97b0f34f85b": {"__data__": {"id_": "b31fa255-8aad-45a2-b60e-b97b0f34f85b", "embedding": null, "metadata": {"window": "It's really underpinning a lot of the programs and solutions that we have.  And the growth rate that we \nexpect for next year is really in line with what we've been able to deliver over the last several.  And we'll continue \nto, as Brian talked about, we'll use our free cash flow to invest in our growth opportunities as we go forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "98047684-7eaf-431b-abdc-d76ed6294538", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "32ee64f29bbc3dd35b99b5fe8ce8f3d18f6702098e8d1a38dc6d4dedc2636637", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d874a44a-8c0f-4cd6-aba1-886a05a7ca00", "node_type": "1", "metadata": {"window": "The value that we're providing for our partners is continuing to reson ate, and we see stable prescription \ngrowth.  It's really underpinning a lot of the programs and solutions that we have.  And the growth rate that we \nexpect for next year is really in line with what we've been able to deliver over the last several.  And we'll continue \nto, as Brian talked about, we'll use our free cash flow to invest in our growth opportunities as we go forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research. ", "original_text": "And we'll continue \nto, as Brian talked about, we'll use our free cash flow to invest in our growth opportunities as we go forward.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "4ecbce11133f495f4a19529a3bbcb0292ebb21426d3edd4f0cc01e8610d89d02", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5930a1be-db59-4b83-a67d-04099ebc6032", "node_type": "1", "metadata": {"window": "And the growth rate that we \nexpect for next year is really in line with what we've been able to deliver over the last several.  And we'll continue \nto, as Brian talked about, we'll use our free cash flow to invest in our growth opportunities as we go forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "A \nNext question, please.  \n "}, "hash": "e545f8622beb7e225b463f11996a7f3602182596587b66efd434a8a55e10a8f3", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "start_char_idx": 4319, "end_char_idx": 4664, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5930a1be-db59-4b83-a67d-04099ebc6032": {"__data__": {"id_": "5930a1be-db59-4b83-a67d-04099ebc6032", "embedding": null, "metadata": {"window": "And the growth rate that we \nexpect for next year is really in line with what we've been able to deliver over the last several.  And we'll continue \nto, as Brian talked about, we'll use our free cash flow to invest in our growth opportunities as we go forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "A \nNext question, please.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "98047684-7eaf-431b-abdc-d76ed6294538", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "32ee64f29bbc3dd35b99b5fe8ce8f3d18f6702098e8d1a38dc6d4dedc2636637", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b31fa255-8aad-45a2-b60e-b97b0f34f85b", "node_type": "1", "metadata": {"window": "It's really underpinning a lot of the programs and solutions that we have.  And the growth rate that we \nexpect for next year is really in line with what we've been able to deliver over the last several.  And we'll continue \nto, as Brian talked about, we'll use our free cash flow to invest in our growth opportunities as we go forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "0f96d15d8cc4de1ea497c7975cc5eba32f5633e04038515c300aeddd284acbd9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e7a0f7d-7c9f-4763-8c78-ecc792e369a1", "node_type": "1", "metadata": {"window": "And we'll continue \nto, as Brian talked about, we'll use our free cash flow to invest in our growth opportunities as we go forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research. "}, "hash": "4cca884bc81425cb23af38e52edf9ba4768581ed831c86aa61d4df522feec8eb", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please.  \n ", "start_char_idx": 1567, "end_char_idx": 1596, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e7a0f7d-7c9f-4763-8c78-ecc792e369a1": {"__data__": {"id_": "7e7a0f7d-7c9f-4763-8c78-ecc792e369a1", "embedding": null, "metadata": {"window": "And we'll continue \nto, as Brian talked about, we'll use our free cash flow to invest in our growth opportunities as we go forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research. ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "98047684-7eaf-431b-abdc-d76ed6294538", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "32ee64f29bbc3dd35b99b5fe8ce8f3d18f6702098e8d1a38dc6d4dedc2636637", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5930a1be-db59-4b83-a67d-04099ebc6032", "node_type": "1", "metadata": {"window": "And the growth rate that we \nexpect for next year is really in line with what we've been able to deliver over the last several.  And we'll continue \nto, as Brian talked about, we'll use our free cash flow to invest in our growth opportunities as we go forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "A \nNext question, please.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "0251ad83a2feab83fd8ac7d1604d1c30d42962e8e3bea5b037f1bf71eb970d86", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a729acfa-e2ae-42b3-a6b7-200d118ff5e1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Please go ahead.  \n "}, "hash": "c1497789e7210fe1b88d21acaa30ee0bebe4b58fa217c2f4825c6fd8346e3704", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research. ", "start_char_idx": 4693, "end_char_idx": 5031, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a729acfa-e2ae-42b3-a6b7-200d118ff5e1": {"__data__": {"id_": "a729acfa-e2ae-42b3-a6b7-200d118ff5e1", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Please go ahead.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "98047684-7eaf-431b-abdc-d76ed6294538", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "32ee64f29bbc3dd35b99b5fe8ce8f3d18f6702098e8d1a38dc6d4dedc2636637", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e7a0f7d-7c9f-4763-8c78-ecc792e369a1", "node_type": "1", "metadata": {"window": "And we'll continue \nto, as Brian talked about, we'll use our free cash flow to invest in our growth opportunities as we go forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research. ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d1d1896198cec78a90af3d952f1a5e28580e98ec2dce8c53c40609a2b2962d48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "995a0bfb-dea4-4148-a06c-6109c5973123", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  "}, "hash": "e28de3f553200f0b480487ad84e61e129693d18588b8bfff3866518f0a714c0d", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 1927, "end_char_idx": 1947, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "995a0bfb-dea4-4148-a06c-6109c5973123": {"__data__": {"id_": "995a0bfb-dea4-4148-a06c-6109c5973123", "embedding": null, "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "98047684-7eaf-431b-abdc-d76ed6294538", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "32ee64f29bbc3dd35b99b5fe8ce8f3d18f6702098e8d1a38dc6d4dedc2636637", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a729acfa-e2ae-42b3-a6b7-200d118ff5e1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Please go ahead.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "837cb48c3ab59e550ec481e254f491d8b14293c4bf5fb068ec506dd67b509bef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be4d602b-c449-4e6d-9fd8-0e34161270d9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, a question related to competitive intensity, and specifically contract movement we've seen.  I think with \nOptum, there was a real concern that the con tract could even be outsourced or element of specialty could be \noutsourced.  And yet here it comes to you, and we've also seen CVS outsourcing scale to you.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "3720fec239d3a85f1dfd062d4f75f828a803284aa9b659e9a77641794e9887a3", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "start_char_idx": 1221, "end_char_idx": 1492, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be4d602b-c449-4e6d-9fd8-0e34161270d9": {"__data__": {"id_": "be4d602b-c449-4e6d-9fd8-0e34161270d9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, a question related to competitive intensity, and specifically contract movement we've seen.  I think with \nOptum, there was a real concern that the con tract could even be outsourced or element of specialty could be \noutsourced.  And yet here it comes to you, and we've also seen CVS outsourcing scale to you.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c43cfbd4-7d3d-4708-b910-e363c305368e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "09cddd3a5c708d99d040448e9f7a46c73095b6b88cba89635a8ecbdc5785eae4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "995a0bfb-dea4-4148-a06c-6109c5973123", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "8966330d2264a5d6b8b5fc98ce46f44ef0ef3a022a0d0329692eba9f4d56615c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "196fddef-c9f2-4745-baff-9c02ba34a61f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, a question related to competitive intensity, and specifically contract movement we've seen.  I think with \nOptum, there was a real concern that the con tract could even be outsourced or element of specialty could be \noutsourced.  And yet here it comes to you, and we've also seen CVS outsourcing scale to you.  \n \n So my question would be, do you believe that you've developed a scale advantage and mail on special ty that is \nunique relative to other distributors, and/or how important is the specialty footprint in driving the value that has led \nto these significant gains?  \n ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, a question related to competitive intensity, and specifically contract movement we've seen. "}, "hash": "ff202ef453366a9b5c43e5e8b6bc0e79f91f5599ca0ea95b36c58ac9d8fa7d0e", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "196fddef-c9f2-4745-baff-9c02ba34a61f": {"__data__": {"id_": "196fddef-c9f2-4745-baff-9c02ba34a61f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, a question related to competitive intensity, and specifically contract movement we've seen.  I think with \nOptum, there was a real concern that the con tract could even be outsourced or element of specialty could be \noutsourced.  And yet here it comes to you, and we've also seen CVS outsourcing scale to you.  \n \n So my question would be, do you believe that you've developed a scale advantage and mail on special ty that is \nunique relative to other distributors, and/or how important is the specialty footprint in driving the value that has led \nto these significant gains?  \n ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, a question related to competitive intensity, and specifically contract movement we've seen. ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c43cfbd4-7d3d-4708-b910-e363c305368e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "09cddd3a5c708d99d040448e9f7a46c73095b6b88cba89635a8ecbdc5785eae4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be4d602b-c449-4e6d-9fd8-0e34161270d9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, a question related to competitive intensity, and specifically contract movement we've seen.  I think with \nOptum, there was a real concern that the con tract could even be outsourced or element of specialty could be \noutsourced.  And yet here it comes to you, and we've also seen CVS outsourcing scale to you.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "dcafafb58a4f8b4f3f1767073779baffd52e6c437beb9167fd3bef87455020ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1cebcfde-aaad-4204-bc65-ffa989c104e5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, a question related to competitive intensity, and specifically contract movement we've seen.  I think with \nOptum, there was a real concern that the con tract could even be outsourced or element of specialty could be \noutsourced.  And yet here it comes to you, and we've also seen CVS outsourcing scale to you.  \n \n So my question would be, do you believe that you've developed a scale advantage and mail on special ty that is \nunique relative to other distributors, and/or how important is the specialty footprint in driving the value that has led \nto these significant gains?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I think with \nOptum, there was a real concern that the con tract could even be outsourced or element of specialty could be \noutsourced. "}, "hash": "796b4c268a96122ccc7567610e649ece2de6338758b18d4d6e7df3c1dc65501c", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, a question related to competitive intensity, and specifically contract movement we've seen. ", "start_char_idx": 16, "end_char_idx": 333, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1cebcfde-aaad-4204-bc65-ffa989c104e5": {"__data__": {"id_": "1cebcfde-aaad-4204-bc65-ffa989c104e5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, a question related to competitive intensity, and specifically contract movement we've seen.  I think with \nOptum, there was a real concern that the con tract could even be outsourced or element of specialty could be \noutsourced.  And yet here it comes to you, and we've also seen CVS outsourcing scale to you.  \n \n So my question would be, do you believe that you've developed a scale advantage and mail on special ty that is \nunique relative to other distributors, and/or how important is the specialty footprint in driving the value that has led \nto these significant gains?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I think with \nOptum, there was a real concern that the con tract could even be outsourced or element of specialty could be \noutsourced. ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c43cfbd4-7d3d-4708-b910-e363c305368e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "09cddd3a5c708d99d040448e9f7a46c73095b6b88cba89635a8ecbdc5785eae4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "196fddef-c9f2-4745-baff-9c02ba34a61f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, a question related to competitive intensity, and specifically contract movement we've seen.  I think with \nOptum, there was a real concern that the con tract could even be outsourced or element of specialty could be \noutsourced.  And yet here it comes to you, and we've also seen CVS outsourcing scale to you.  \n \n So my question would be, do you believe that you've developed a scale advantage and mail on special ty that is \nunique relative to other distributors, and/or how important is the specialty footprint in driving the value that has led \nto these significant gains?  \n ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, a question related to competitive intensity, and specifically contract movement we've seen. ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "36b0cce1cc4e671b1ee52e058d96194cdfd35e93003778c91d68e72d8d136708", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59e48306-3c22-420e-85c1-64f8977c99d8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, a question related to competitive intensity, and specifically contract movement we've seen.  I think with \nOptum, there was a real concern that the con tract could even be outsourced or element of specialty could be \noutsourced.  And yet here it comes to you, and we've also seen CVS outsourcing scale to you.  \n \n So my question would be, do you believe that you've developed a scale advantage and mail on special ty that is \nunique relative to other distributors, and/or how important is the specialty footprint in driving the value that has led \nto these significant gains?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Eric. ", "original_text": "And yet here it comes to you, and we've also seen CVS outsourcing scale to you.  \n \n"}, "hash": "d9f88195f24f3c47762f3bb56acedeed9d5bcbf195a6ffdd67f9ddabf743f69a", "class_name": "RelatedNodeInfo"}}, "text": "I think with \nOptum, there was a real concern that the con tract could even be outsourced or element of specialty could be \noutsourced. ", "start_char_idx": 333, "end_char_idx": 469, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59e48306-3c22-420e-85c1-64f8977c99d8": {"__data__": {"id_": "59e48306-3c22-420e-85c1-64f8977c99d8", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, a question related to competitive intensity, and specifically contract movement we've seen.  I think with \nOptum, there was a real concern that the con tract could even be outsourced or element of specialty could be \noutsourced.  And yet here it comes to you, and we've also seen CVS outsourcing scale to you.  \n \n So my question would be, do you believe that you've developed a scale advantage and mail on special ty that is \nunique relative to other distributors, and/or how important is the specialty footprint in driving the value that has led \nto these significant gains?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Eric. ", "original_text": "And yet here it comes to you, and we've also seen CVS outsourcing scale to you.  \n \n", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c43cfbd4-7d3d-4708-b910-e363c305368e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "09cddd3a5c708d99d040448e9f7a46c73095b6b88cba89635a8ecbdc5785eae4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1cebcfde-aaad-4204-bc65-ffa989c104e5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, a question related to competitive intensity, and specifically contract movement we've seen.  I think with \nOptum, there was a real concern that the con tract could even be outsourced or element of specialty could be \noutsourced.  And yet here it comes to you, and we've also seen CVS outsourcing scale to you.  \n \n So my question would be, do you believe that you've developed a scale advantage and mail on special ty that is \nunique relative to other distributors, and/or how important is the specialty footprint in driving the value that has led \nto these significant gains?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I think with \nOptum, there was a real concern that the con tract could even be outsourced or element of specialty could be \noutsourced. ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "6d3f7e1b8049c982bade929a3f39e3a8895e5117cc8fc6d898ccac6340eb5ca8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e762317-a3dd-4964-b0f3-6e74ba73ef5a", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, a question related to competitive intensity, and specifically contract movement we've seen.  I think with \nOptum, there was a real concern that the con tract could even be outsourced or element of specialty could be \noutsourced.  And yet here it comes to you, and we've also seen CVS outsourcing scale to you.  \n \n So my question would be, do you believe that you've developed a scale advantage and mail on special ty that is \nunique relative to other distributors, and/or how important is the specialty footprint in driving the value that has led \nto these significant gains?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Eric.  Look, I' m not going to comment much on the competitive set. ", "original_text": "So my question would be, do you believe that you've developed a scale advantage and mail on special ty that is \nunique relative to other distributors, and/or how important is the specialty footprint in driving the value that has led \nto these significant gains?  \n "}, "hash": "b44f5421cbcbec6edde0c349d7bf24cd3661c31cba8cba86339dac179765f8c3", "class_name": "RelatedNodeInfo"}}, "text": "And yet here it comes to you, and we've also seen CVS outsourcing scale to you.  \n \n", "start_char_idx": 469, "end_char_idx": 553, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e762317-a3dd-4964-b0f3-6e74ba73ef5a": {"__data__": {"id_": "5e762317-a3dd-4964-b0f3-6e74ba73ef5a", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, a question related to competitive intensity, and specifically contract movement we've seen.  I think with \nOptum, there was a real concern that the con tract could even be outsourced or element of specialty could be \noutsourced.  And yet here it comes to you, and we've also seen CVS outsourcing scale to you.  \n \n So my question would be, do you believe that you've developed a scale advantage and mail on special ty that is \nunique relative to other distributors, and/or how important is the specialty footprint in driving the value that has led \nto these significant gains?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Eric.  Look, I' m not going to comment much on the competitive set. ", "original_text": "So my question would be, do you believe that you've developed a scale advantage and mail on special ty that is \nunique relative to other distributors, and/or how important is the specialty footprint in driving the value that has led \nto these significant gains?  \n ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c43cfbd4-7d3d-4708-b910-e363c305368e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "09cddd3a5c708d99d040448e9f7a46c73095b6b88cba89635a8ecbdc5785eae4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59e48306-3c22-420e-85c1-64f8977c99d8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, a question related to competitive intensity, and specifically contract movement we've seen.  I think with \nOptum, there was a real concern that the con tract could even be outsourced or element of specialty could be \noutsourced.  And yet here it comes to you, and we've also seen CVS outsourcing scale to you.  \n \n So my question would be, do you believe that you've developed a scale advantage and mail on special ty that is \nunique relative to other distributors, and/or how important is the specialty footprint in driving the value that has led \nto these significant gains?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Eric. ", "original_text": "And yet here it comes to you, and we've also seen CVS outsourcing scale to you.  \n \n", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "2c12d14a6b49693c03ae2d1000c54ebec13a45f8ae5b76fc1baaf106316eb8d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c17526c-e866-4019-9bb3-3ef9af9b0081", "node_type": "1", "metadata": {"window": "I think with \nOptum, there was a real concern that the con tract could even be outsourced or element of specialty could be \noutsourced.  And yet here it comes to you, and we've also seen CVS outsourcing scale to you.  \n \n So my question would be, do you believe that you've developed a scale advantage and mail on special ty that is \nunique relative to other distributors, and/or how important is the specialty footprint in driving the value that has led \nto these significant gains?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Eric.  Look, I' m not going to comment much on the competitive set.  But I can say we have made some \npretty significant investments in the business to modernize our distribution infrastructure. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "07f3d3ede2507efbbf2f13f2f6b36ffa4c0a5ddc3fe0682d097e4bf600a24648", "class_name": "RelatedNodeInfo"}}, "text": "So my question would be, do you believe that you've developed a scale advantage and mail on special ty that is \nunique relative to other distributors, and/or how important is the specialty footprint in driving the value that has led \nto these significant gains?  \n ", "start_char_idx": 553, "end_char_idx": 818, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c17526c-e866-4019-9bb3-3ef9af9b0081": {"__data__": {"id_": "2c17526c-e866-4019-9bb3-3ef9af9b0081", "embedding": null, "metadata": {"window": "I think with \nOptum, there was a real concern that the con tract could even be outsourced or element of specialty could be \noutsourced.  And yet here it comes to you, and we've also seen CVS outsourcing scale to you.  \n \n So my question would be, do you believe that you've developed a scale advantage and mail on special ty that is \nunique relative to other distributors, and/or how important is the specialty footprint in driving the value that has led \nto these significant gains?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Eric.  Look, I' m not going to comment much on the competitive set.  But I can say we have made some \npretty significant investments in the business to modernize our distribution infrastructure. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c43cfbd4-7d3d-4708-b910-e363c305368e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "09cddd3a5c708d99d040448e9f7a46c73095b6b88cba89635a8ecbdc5785eae4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e762317-a3dd-4964-b0f3-6e74ba73ef5a", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, a question related to competitive intensity, and specifically contract movement we've seen.  I think with \nOptum, there was a real concern that the con tract could even be outsourced or element of specialty could be \noutsourced.  And yet here it comes to you, and we've also seen CVS outsourcing scale to you.  \n \n So my question would be, do you believe that you've developed a scale advantage and mail on special ty that is \nunique relative to other distributors, and/or how important is the specialty footprint in driving the value that has led \nto these significant gains?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Eric.  Look, I' m not going to comment much on the competitive set. ", "original_text": "So my question would be, do you believe that you've developed a scale advantage and mail on special ty that is \nunique relative to other distributors, and/or how important is the specialty footprint in driving the value that has led \nto these significant gains?  \n ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f7d913befe69dab1ff4ee51fb6ca8d848ddfc9b95146411cc03a726a8cc7e193", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c940a4b6-c4d9-4082-bd19-a4ba21685329", "node_type": "1", "metadata": {"window": "And yet here it comes to you, and we've also seen CVS outsourcing scale to you.  \n \n So my question would be, do you believe that you've developed a scale advantage and mail on special ty that is \nunique relative to other distributors, and/or how important is the specialty footprint in driving the value that has led \nto these significant gains?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Eric.  Look, I' m not going to comment much on the competitive set.  But I can say we have made some \npretty significant investments in the business to modernize our distribution infrastructure.  Think about cold chain, \nhow you handle cold chain efficiently, have a highly co mpliant distribution network. ", "original_text": "A \nThanks, Eric. "}, "hash": "e6b5cdc9d9187f71c2254bcf300cfa4eb29f97ca96d3ec99fc4ae93fcac19cc7", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 818, "end_char_idx": 1162, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c940a4b6-c4d9-4082-bd19-a4ba21685329": {"__data__": {"id_": "c940a4b6-c4d9-4082-bd19-a4ba21685329", "embedding": null, "metadata": {"window": "And yet here it comes to you, and we've also seen CVS outsourcing scale to you.  \n \n So my question would be, do you believe that you've developed a scale advantage and mail on special ty that is \nunique relative to other distributors, and/or how important is the specialty footprint in driving the value that has led \nto these significant gains?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Eric.  Look, I' m not going to comment much on the competitive set.  But I can say we have made some \npretty significant investments in the business to modernize our distribution infrastructure.  Think about cold chain, \nhow you handle cold chain efficiently, have a highly co mpliant distribution network. ", "original_text": "A \nThanks, Eric. ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c43cfbd4-7d3d-4708-b910-e363c305368e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "09cddd3a5c708d99d040448e9f7a46c73095b6b88cba89635a8ecbdc5785eae4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c17526c-e866-4019-9bb3-3ef9af9b0081", "node_type": "1", "metadata": {"window": "I think with \nOptum, there was a real concern that the con tract could even be outsourced or element of specialty could be \noutsourced.  And yet here it comes to you, and we've also seen CVS outsourcing scale to you.  \n \n So my question would be, do you believe that you've developed a scale advantage and mail on special ty that is \nunique relative to other distributors, and/or how important is the specialty footprint in driving the value that has led \nto these significant gains?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Eric.  Look, I' m not going to comment much on the competitive set.  But I can say we have made some \npretty significant investments in the business to modernize our distribution infrastructure. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "12b6cca7e3a81e5b198043f519e274b36a96a24a961d0c3d3bd2418fbfe7e698", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ba52f94-68c3-4062-8193-4e037cd02b4d", "node_type": "1", "metadata": {"window": "So my question would be, do you believe that you've developed a scale advantage and mail on special ty that is \nunique relative to other distributors, and/or how important is the specialty footprint in driving the value that has led \nto these significant gains?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Eric.  Look, I' m not going to comment much on the competitive set.  But I can say we have made some \npretty significant investments in the business to modernize our distribution infrastructure.  Think about cold chain, \nhow you handle cold chain efficiently, have a highly co mpliant distribution network.  We certainly have scale.  \n \n", "original_text": "Look, I' m not going to comment much on the competitive set. "}, "hash": "dc20d948383bfe6c83e9032d871a517524cea2a4a9a4cd13a39b61630490e2e7", "class_name": "RelatedNodeInfo"}}, "text": "A \nThanks, Eric. ", "start_char_idx": 1162, "end_char_idx": 1179, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ba52f94-68c3-4062-8193-4e037cd02b4d": {"__data__": {"id_": "2ba52f94-68c3-4062-8193-4e037cd02b4d", "embedding": null, "metadata": {"window": "So my question would be, do you believe that you've developed a scale advantage and mail on special ty that is \nunique relative to other distributors, and/or how important is the specialty footprint in driving the value that has led \nto these significant gains?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Eric.  Look, I' m not going to comment much on the competitive set.  But I can say we have made some \npretty significant investments in the business to modernize our distribution infrastructure.  Think about cold chain, \nhow you handle cold chain efficiently, have a highly co mpliant distribution network.  We certainly have scale.  \n \n", "original_text": "Look, I' m not going to comment much on the competitive set. ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c43cfbd4-7d3d-4708-b910-e363c305368e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "09cddd3a5c708d99d040448e9f7a46c73095b6b88cba89635a8ecbdc5785eae4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c940a4b6-c4d9-4082-bd19-a4ba21685329", "node_type": "1", "metadata": {"window": "And yet here it comes to you, and we've also seen CVS outsourcing scale to you.  \n \n So my question would be, do you believe that you've developed a scale advantage and mail on special ty that is \nunique relative to other distributors, and/or how important is the specialty footprint in driving the value that has led \nto these significant gains?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Eric.  Look, I' m not going to comment much on the competitive set.  But I can say we have made some \npretty significant investments in the business to modernize our distribution infrastructure.  Think about cold chain, \nhow you handle cold chain efficiently, have a highly co mpliant distribution network. ", "original_text": "A \nThanks, Eric. ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "6dbd3e8ababde6071e476988bee562c107c5bc1ed1f4985070bc13aa661f0383", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e16c010-b99d-4168-b497-2647a106bf49", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Eric.  Look, I' m not going to comment much on the competitive set.  But I can say we have made some \npretty significant investments in the business to modernize our distribution infrastructure.  Think about cold chain, \nhow you handle cold chain efficiently, have a highly co mpliant distribution network.  We certainly have scale.  \n \n And in this business, I've been in this business 28 years, and scale does tend to help. ", "original_text": "But I can say we have made some \npretty significant investments in the business to modernize our distribution infrastructure. "}, "hash": "1f748bc7ef51c630c5614e4c5516260f9684e7d5ce836e89a08e18ea159405c2", "class_name": "RelatedNodeInfo"}}, "text": "Look, I' m not going to comment much on the competitive set. ", "start_char_idx": 1179, "end_char_idx": 1240, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e16c010-b99d-4168-b497-2647a106bf49": {"__data__": {"id_": "5e16c010-b99d-4168-b497-2647a106bf49", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Eric.  Look, I' m not going to comment much on the competitive set.  But I can say we have made some \npretty significant investments in the business to modernize our distribution infrastructure.  Think about cold chain, \nhow you handle cold chain efficiently, have a highly co mpliant distribution network.  We certainly have scale.  \n \n And in this business, I've been in this business 28 years, and scale does tend to help. ", "original_text": "But I can say we have made some \npretty significant investments in the business to modernize our distribution infrastructure. ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c43cfbd4-7d3d-4708-b910-e363c305368e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "09cddd3a5c708d99d040448e9f7a46c73095b6b88cba89635a8ecbdc5785eae4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ba52f94-68c3-4062-8193-4e037cd02b4d", "node_type": "1", "metadata": {"window": "So my question would be, do you believe that you've developed a scale advantage and mail on special ty that is \nunique relative to other distributors, and/or how important is the specialty footprint in driving the value that has led \nto these significant gains?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Eric.  Look, I' m not going to comment much on the competitive set.  But I can say we have made some \npretty significant investments in the business to modernize our distribution infrastructure.  Think about cold chain, \nhow you handle cold chain efficiently, have a highly co mpliant distribution network.  We certainly have scale.  \n \n", "original_text": "Look, I' m not going to comment much on the competitive set. ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "9f9b458fd8cfdd5823d532a301f9052d1bbcc33b8f9dfd6055b26a75a7b71a97", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ef8c035-5d03-4dc7-9ebf-b9c012e1bec6", "node_type": "1", "metadata": {"window": "A \nThanks, Eric.  Look, I' m not going to comment much on the competitive set.  But I can say we have made some \npretty significant investments in the business to modernize our distribution infrastructure.  Think about cold chain, \nhow you handle cold chain efficiently, have a highly co mpliant distribution network.  We certainly have scale.  \n \n And in this business, I've been in this business 28 years, and scale does tend to help.  But I really come back to \nthe fact that we've made the investments in core distribution excellence. ", "original_text": "Think about cold chain, \nhow you handle cold chain efficiently, have a highly co mpliant distribution network. "}, "hash": "ae8b1131445966a9bdc26fe24740ef26345045781515f43315aed76c82cd9325", "class_name": "RelatedNodeInfo"}}, "text": "But I can say we have made some \npretty significant investments in the business to modernize our distribution infrastructure. ", "start_char_idx": 1240, "end_char_idx": 1366, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ef8c035-5d03-4dc7-9ebf-b9c012e1bec6": {"__data__": {"id_": "2ef8c035-5d03-4dc7-9ebf-b9c012e1bec6", "embedding": null, "metadata": {"window": "A \nThanks, Eric.  Look, I' m not going to comment much on the competitive set.  But I can say we have made some \npretty significant investments in the business to modernize our distribution infrastructure.  Think about cold chain, \nhow you handle cold chain efficiently, have a highly co mpliant distribution network.  We certainly have scale.  \n \n And in this business, I've been in this business 28 years, and scale does tend to help.  But I really come back to \nthe fact that we've made the investments in core distribution excellence. ", "original_text": "Think about cold chain, \nhow you handle cold chain efficiently, have a highly co mpliant distribution network. ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c43cfbd4-7d3d-4708-b910-e363c305368e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "09cddd3a5c708d99d040448e9f7a46c73095b6b88cba89635a8ecbdc5785eae4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e16c010-b99d-4168-b497-2647a106bf49", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Eric.  Look, I' m not going to comment much on the competitive set.  But I can say we have made some \npretty significant investments in the business to modernize our distribution infrastructure.  Think about cold chain, \nhow you handle cold chain efficiently, have a highly co mpliant distribution network.  We certainly have scale.  \n \n And in this business, I've been in this business 28 years, and scale does tend to help. ", "original_text": "But I can say we have made some \npretty significant investments in the business to modernize our distribution infrastructure. ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f9954aa284bed3768778b2dff327751d30d1158839ba7cc105603daf9ff37a56", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64ebce46-02eb-47ab-84b3-14a6f249128c", "node_type": "1", "metadata": {"window": "Look, I' m not going to comment much on the competitive set.  But I can say we have made some \npretty significant investments in the business to modernize our distribution infrastructure.  Think about cold chain, \nhow you handle cold chain efficiently, have a highly co mpliant distribution network.  We certainly have scale.  \n \n And in this business, I've been in this business 28 years, and scale does tend to help.  But I really come back to \nthe fact that we've made the investments in core distribution excellence.  We clearly u nderstand this piece of the \nmarket quite well. ", "original_text": "We certainly have scale.  \n \n"}, "hash": "aefc49a36ece2acb91a7bd363f75bba67b210b2fcc634cb1a6fed671dd26c69b", "class_name": "RelatedNodeInfo"}}, "text": "Think about cold chain, \nhow you handle cold chain efficiently, have a highly co mpliant distribution network. ", "start_char_idx": 1366, "end_char_idx": 1477, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64ebce46-02eb-47ab-84b3-14a6f249128c": {"__data__": {"id_": "64ebce46-02eb-47ab-84b3-14a6f249128c", "embedding": null, "metadata": {"window": "Look, I' m not going to comment much on the competitive set.  But I can say we have made some \npretty significant investments in the business to modernize our distribution infrastructure.  Think about cold chain, \nhow you handle cold chain efficiently, have a highly co mpliant distribution network.  We certainly have scale.  \n \n And in this business, I've been in this business 28 years, and scale does tend to help.  But I really come back to \nthe fact that we've made the investments in core distribution excellence.  We clearly u nderstand this piece of the \nmarket quite well. ", "original_text": "We certainly have scale.  \n \n", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c43cfbd4-7d3d-4708-b910-e363c305368e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "09cddd3a5c708d99d040448e9f7a46c73095b6b88cba89635a8ecbdc5785eae4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ef8c035-5d03-4dc7-9ebf-b9c012e1bec6", "node_type": "1", "metadata": {"window": "A \nThanks, Eric.  Look, I' m not going to comment much on the competitive set.  But I can say we have made some \npretty significant investments in the business to modernize our distribution infrastructure.  Think about cold chain, \nhow you handle cold chain efficiently, have a highly co mpliant distribution network.  We certainly have scale.  \n \n And in this business, I've been in this business 28 years, and scale does tend to help.  But I really come back to \nthe fact that we've made the investments in core distribution excellence. ", "original_text": "Think about cold chain, \nhow you handle cold chain efficiently, have a highly co mpliant distribution network. ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "7d9e5239b0c84388a0f19c79dbfce7932c7fc01ef15a2c9f21efcd9c77aeffe0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf6d0c8c-be48-401e-9a96-110889d8e6af", "node_type": "1", "metadata": {"window": "But I can say we have made some \npretty significant investments in the business to modernize our distribution infrastructure.  Think about cold chain, \nhow you handle cold chain efficiently, have a highly co mpliant distribution network.  We certainly have scale.  \n \n And in this business, I've been in this business 28 years, and scale does tend to help.  But I really come back to \nthe fact that we've made the investments in core distribution excellence.  We clearly u nderstand this piece of the \nmarket quite well.  and that we think of ourselves as a solution -oriented value -added kind of partner and try to \npaint a broad picture of not just what we could do if we had a relationship but how we could grow that relationship \nthrough time using an array of the capabilities represented within McKesson.  \n ", "original_text": "And in this business, I've been in this business 28 years, and scale does tend to help. "}, "hash": "4c0104db646725f8893f37b9c6ce9b4749a24a978e68f0d8ecac7c828746d50e", "class_name": "RelatedNodeInfo"}}, "text": "We certainly have scale.  \n \n", "start_char_idx": 1477, "end_char_idx": 1506, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf6d0c8c-be48-401e-9a96-110889d8e6af": {"__data__": {"id_": "cf6d0c8c-be48-401e-9a96-110889d8e6af", "embedding": null, "metadata": {"window": "But I can say we have made some \npretty significant investments in the business to modernize our distribution infrastructure.  Think about cold chain, \nhow you handle cold chain efficiently, have a highly co mpliant distribution network.  We certainly have scale.  \n \n And in this business, I've been in this business 28 years, and scale does tend to help.  But I really come back to \nthe fact that we've made the investments in core distribution excellence.  We clearly u nderstand this piece of the \nmarket quite well.  and that we think of ourselves as a solution -oriented value -added kind of partner and try to \npaint a broad picture of not just what we could do if we had a relationship but how we could grow that relationship \nthrough time using an array of the capabilities represented within McKesson.  \n ", "original_text": "And in this business, I've been in this business 28 years, and scale does tend to help. ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c43cfbd4-7d3d-4708-b910-e363c305368e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "09cddd3a5c708d99d040448e9f7a46c73095b6b88cba89635a8ecbdc5785eae4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64ebce46-02eb-47ab-84b3-14a6f249128c", "node_type": "1", "metadata": {"window": "Look, I' m not going to comment much on the competitive set.  But I can say we have made some \npretty significant investments in the business to modernize our distribution infrastructure.  Think about cold chain, \nhow you handle cold chain efficiently, have a highly co mpliant distribution network.  We certainly have scale.  \n \n And in this business, I've been in this business 28 years, and scale does tend to help.  But I really come back to \nthe fact that we've made the investments in core distribution excellence.  We clearly u nderstand this piece of the \nmarket quite well. ", "original_text": "We certainly have scale.  \n \n", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a98b0592275a9cd232b46a29ef5f7079de933aa047f266f51928e8e93f714cd0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25d3136a-ee0b-4376-9aac-3abfed9c79c5", "node_type": "1", "metadata": {"window": "Think about cold chain, \nhow you handle cold chain efficiently, have a highly co mpliant distribution network.  We certainly have scale.  \n \n And in this business, I've been in this business 28 years, and scale does tend to help.  But I really come back to \nthe fact that we've made the investments in core distribution excellence.  We clearly u nderstand this piece of the \nmarket quite well.  and that we think of ourselves as a solution -oriented value -added kind of partner and try to \npaint a broad picture of not just what we could do if we had a relationship but how we could grow that relationship \nthrough time using an array of the capabilities represented within McKesson.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "But I really come back to \nthe fact that we've made the investments in core distribution excellence. "}, "hash": "2cb581956558a2d6963e03eb1fc78ad43ab7e8ae6fe65b1bec62b42fc435440a", "class_name": "RelatedNodeInfo"}}, "text": "And in this business, I've been in this business 28 years, and scale does tend to help. ", "start_char_idx": 1506, "end_char_idx": 1594, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25d3136a-ee0b-4376-9aac-3abfed9c79c5": {"__data__": {"id_": "25d3136a-ee0b-4376-9aac-3abfed9c79c5", "embedding": null, "metadata": {"window": "Think about cold chain, \nhow you handle cold chain efficiently, have a highly co mpliant distribution network.  We certainly have scale.  \n \n And in this business, I've been in this business 28 years, and scale does tend to help.  But I really come back to \nthe fact that we've made the investments in core distribution excellence.  We clearly u nderstand this piece of the \nmarket quite well.  and that we think of ourselves as a solution -oriented value -added kind of partner and try to \npaint a broad picture of not just what we could do if we had a relationship but how we could grow that relationship \nthrough time using an array of the capabilities represented within McKesson.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "But I really come back to \nthe fact that we've made the investments in core distribution excellence. ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c43cfbd4-7d3d-4708-b910-e363c305368e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "09cddd3a5c708d99d040448e9f7a46c73095b6b88cba89635a8ecbdc5785eae4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf6d0c8c-be48-401e-9a96-110889d8e6af", "node_type": "1", "metadata": {"window": "But I can say we have made some \npretty significant investments in the business to modernize our distribution infrastructure.  Think about cold chain, \nhow you handle cold chain efficiently, have a highly co mpliant distribution network.  We certainly have scale.  \n \n And in this business, I've been in this business 28 years, and scale does tend to help.  But I really come back to \nthe fact that we've made the investments in core distribution excellence.  We clearly u nderstand this piece of the \nmarket quite well.  and that we think of ourselves as a solution -oriented value -added kind of partner and try to \npaint a broad picture of not just what we could do if we had a relationship but how we could grow that relationship \nthrough time using an array of the capabilities represented within McKesson.  \n ", "original_text": "And in this business, I've been in this business 28 years, and scale does tend to help. ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "7d1ce5926086b28214e8320ca413beee2bddb94225fc05d0bcb4e5625feb9107", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ebfd5c6-0946-456b-ad7c-f24e16790b2c", "node_type": "1", "metadata": {"window": "We certainly have scale.  \n \n And in this business, I've been in this business 28 years, and scale does tend to help.  But I really come back to \nthe fact that we've made the investments in core distribution excellence.  We clearly u nderstand this piece of the \nmarket quite well.  and that we think of ourselves as a solution -oriented value -added kind of partner and try to \npaint a broad picture of not just what we could do if we had a relationship but how we could grow that relationship \nthrough time using an array of the capabilities represented within McKesson.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nEric, I would just add to that. ", "original_text": "We clearly u nderstand this piece of the \nmarket quite well. "}, "hash": "0977d227d54c76edae165df6b3c95309ec87eb69d4ea6082d549540aad20e0ad", "class_name": "RelatedNodeInfo"}}, "text": "But I really come back to \nthe fact that we've made the investments in core distribution excellence. ", "start_char_idx": 1594, "end_char_idx": 1695, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ebfd5c6-0946-456b-ad7c-f24e16790b2c": {"__data__": {"id_": "5ebfd5c6-0946-456b-ad7c-f24e16790b2c", "embedding": null, "metadata": {"window": "We certainly have scale.  \n \n And in this business, I've been in this business 28 years, and scale does tend to help.  But I really come back to \nthe fact that we've made the investments in core distribution excellence.  We clearly u nderstand this piece of the \nmarket quite well.  and that we think of ourselves as a solution -oriented value -added kind of partner and try to \npaint a broad picture of not just what we could do if we had a relationship but how we could grow that relationship \nthrough time using an array of the capabilities represented within McKesson.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nEric, I would just add to that. ", "original_text": "We clearly u nderstand this piece of the \nmarket quite well. ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c43cfbd4-7d3d-4708-b910-e363c305368e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "09cddd3a5c708d99d040448e9f7a46c73095b6b88cba89635a8ecbdc5785eae4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25d3136a-ee0b-4376-9aac-3abfed9c79c5", "node_type": "1", "metadata": {"window": "Think about cold chain, \nhow you handle cold chain efficiently, have a highly co mpliant distribution network.  We certainly have scale.  \n \n And in this business, I've been in this business 28 years, and scale does tend to help.  But I really come back to \nthe fact that we've made the investments in core distribution excellence.  We clearly u nderstand this piece of the \nmarket quite well.  and that we think of ourselves as a solution -oriented value -added kind of partner and try to \npaint a broad picture of not just what we could do if we had a relationship but how we could grow that relationship \nthrough time using an array of the capabilities represented within McKesson.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "But I really come back to \nthe fact that we've made the investments in core distribution excellence. ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "fd6602b4d53f21a14f68f91c911a3d5ebb428e38ab799317fecf51b952f1e463", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac6a3550-1ad8-40c5-93b1-7c048f6bc73e", "node_type": "1", "metadata": {"window": "And in this business, I've been in this business 28 years, and scale does tend to help.  But I really come back to \nthe fact that we've made the investments in core distribution excellence.  We clearly u nderstand this piece of the \nmarket quite well.  and that we think of ourselves as a solution -oriented value -added kind of partner and try to \npaint a broad picture of not just what we could do if we had a relationship but how we could grow that relationship \nthrough time using an array of the capabilities represented within McKesson.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nEric, I would just add to that.  If you think about the strategy that we've executed on over the last several years, \nwe've been very disciplined and focused and really growing our capabilities in oncology and pharma services, \nincluding the investments that Brian spoke of in terms of our distribution network.  \n \n", "original_text": "and that we think of ourselves as a solution -oriented value -added kind of partner and try to \npaint a broad picture of not just what we could do if we had a relationship but how we could grow that relationship \nthrough time using an array of the capabilities represented within McKesson.  \n "}, "hash": "03bb0ff2a82e48a11350b5b923430ed0c4040b9268c56e83e11e4735fef723d5", "class_name": "RelatedNodeInfo"}}, "text": "We clearly u nderstand this piece of the \nmarket quite well. ", "start_char_idx": 1695, "end_char_idx": 1756, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac6a3550-1ad8-40c5-93b1-7c048f6bc73e": {"__data__": {"id_": "ac6a3550-1ad8-40c5-93b1-7c048f6bc73e", "embedding": null, "metadata": {"window": "And in this business, I've been in this business 28 years, and scale does tend to help.  But I really come back to \nthe fact that we've made the investments in core distribution excellence.  We clearly u nderstand this piece of the \nmarket quite well.  and that we think of ourselves as a solution -oriented value -added kind of partner and try to \npaint a broad picture of not just what we could do if we had a relationship but how we could grow that relationship \nthrough time using an array of the capabilities represented within McKesson.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nEric, I would just add to that.  If you think about the strategy that we've executed on over the last several years, \nwe've been very disciplined and focused and really growing our capabilities in oncology and pharma services, \nincluding the investments that Brian spoke of in terms of our distribution network.  \n \n", "original_text": "and that we think of ourselves as a solution -oriented value -added kind of partner and try to \npaint a broad picture of not just what we could do if we had a relationship but how we could grow that relationship \nthrough time using an array of the capabilities represented within McKesson.  \n ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c43cfbd4-7d3d-4708-b910-e363c305368e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "09cddd3a5c708d99d040448e9f7a46c73095b6b88cba89635a8ecbdc5785eae4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ebfd5c6-0946-456b-ad7c-f24e16790b2c", "node_type": "1", "metadata": {"window": "We certainly have scale.  \n \n And in this business, I've been in this business 28 years, and scale does tend to help.  But I really come back to \nthe fact that we've made the investments in core distribution excellence.  We clearly u nderstand this piece of the \nmarket quite well.  and that we think of ourselves as a solution -oriented value -added kind of partner and try to \npaint a broad picture of not just what we could do if we had a relationship but how we could grow that relationship \nthrough time using an array of the capabilities represented within McKesson.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nEric, I would just add to that. ", "original_text": "We clearly u nderstand this piece of the \nmarket quite well. ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d912709b9cfb33703f75bf8347230d18e0cd6abd9063f0f133709934b65102ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "232f9546-3b37-4090-beae-65177e256295", "node_type": "1", "metadata": {"window": "But I really come back to \nthe fact that we've made the investments in core distribution excellence.  We clearly u nderstand this piece of the \nmarket quite well.  and that we think of ourselves as a solution -oriented value -added kind of partner and try to \npaint a broad picture of not just what we could do if we had a relationship but how we could grow that relationship \nthrough time using an array of the capabilities represented within McKesson.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nEric, I would just add to that.  If you think about the strategy that we've executed on over the last several years, \nwe've been very disciplined and focused and really growing our capabilities in oncology and pharma services, \nincluding the investments that Brian spoke of in terms of our distribution network.  \n \n So the breadth of capabilities th at we have today is more significant than it was a few years ago. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "3e805d56f743e64f9bb152a3d0144de2f57838b8eace705ce7c3a4bfca743cc9", "class_name": "RelatedNodeInfo"}}, "text": "and that we think of ourselves as a solution -oriented value -added kind of partner and try to \npaint a broad picture of not just what we could do if we had a relationship but how we could grow that relationship \nthrough time using an array of the capabilities represented within McKesson.  \n ", "start_char_idx": 1756, "end_char_idx": 2049, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "232f9546-3b37-4090-beae-65177e256295": {"__data__": {"id_": "232f9546-3b37-4090-beae-65177e256295", "embedding": null, "metadata": {"window": "But I really come back to \nthe fact that we've made the investments in core distribution excellence.  We clearly u nderstand this piece of the \nmarket quite well.  and that we think of ourselves as a solution -oriented value -added kind of partner and try to \npaint a broad picture of not just what we could do if we had a relationship but how we could grow that relationship \nthrough time using an array of the capabilities represented within McKesson.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nEric, I would just add to that.  If you think about the strategy that we've executed on over the last several years, \nwe've been very disciplined and focused and really growing our capabilities in oncology and pharma services, \nincluding the investments that Brian spoke of in terms of our distribution network.  \n \n So the breadth of capabilities th at we have today is more significant than it was a few years ago. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c43cfbd4-7d3d-4708-b910-e363c305368e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "09cddd3a5c708d99d040448e9f7a46c73095b6b88cba89635a8ecbdc5785eae4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac6a3550-1ad8-40c5-93b1-7c048f6bc73e", "node_type": "1", "metadata": {"window": "And in this business, I've been in this business 28 years, and scale does tend to help.  But I really come back to \nthe fact that we've made the investments in core distribution excellence.  We clearly u nderstand this piece of the \nmarket quite well.  and that we think of ourselves as a solution -oriented value -added kind of partner and try to \npaint a broad picture of not just what we could do if we had a relationship but how we could grow that relationship \nthrough time using an array of the capabilities represented within McKesson.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nEric, I would just add to that.  If you think about the strategy that we've executed on over the last several years, \nwe've been very disciplined and focused and really growing our capabilities in oncology and pharma services, \nincluding the investments that Brian spoke of in terms of our distribution network.  \n \n", "original_text": "and that we think of ourselves as a solution -oriented value -added kind of partner and try to \npaint a broad picture of not just what we could do if we had a relationship but how we could grow that relationship \nthrough time using an array of the capabilities represented within McKesson.  \n ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "1e5052493091b76beb00f9f05b1d4febbfd2563aa51d0b2c8df35a6344155c4b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "481d7454-285a-4c45-9cfc-7dc20809f40d", "node_type": "1", "metadata": {"window": "We clearly u nderstand this piece of the \nmarket quite well.  and that we think of ourselves as a solution -oriented value -added kind of partner and try to \npaint a broad picture of not just what we could do if we had a relationship but how we could grow that relationship \nthrough time using an array of the capabilities represented within McKesson.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nEric, I would just add to that.  If you think about the strategy that we've executed on over the last several years, \nwe've been very disciplined and focused and really growing our capabilities in oncology and pharma services, \nincluding the investments that Brian spoke of in terms of our distribution network.  \n \n So the breadth of capabilities th at we have today is more significant than it was a few years ago.  And the value \nthat we're able to provide now through the investments that we've made through some of the other acquisitions \nthat we've made in like oncology as an example, we believe that th at value is what is attractive and the breadth of \ncapabilities that we have as well.  \n ", "original_text": "A \nEric, I would just add to that. "}, "hash": "1f0223b1d8472cba6e714f90dd54ab9674851514aa560da19161a7e828ac3ec1", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 2049, "end_char_idx": 2409, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "481d7454-285a-4c45-9cfc-7dc20809f40d": {"__data__": {"id_": "481d7454-285a-4c45-9cfc-7dc20809f40d", "embedding": null, "metadata": {"window": "We clearly u nderstand this piece of the \nmarket quite well.  and that we think of ourselves as a solution -oriented value -added kind of partner and try to \npaint a broad picture of not just what we could do if we had a relationship but how we could grow that relationship \nthrough time using an array of the capabilities represented within McKesson.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nEric, I would just add to that.  If you think about the strategy that we've executed on over the last several years, \nwe've been very disciplined and focused and really growing our capabilities in oncology and pharma services, \nincluding the investments that Brian spoke of in terms of our distribution network.  \n \n So the breadth of capabilities th at we have today is more significant than it was a few years ago.  And the value \nthat we're able to provide now through the investments that we've made through some of the other acquisitions \nthat we've made in like oncology as an example, we believe that th at value is what is attractive and the breadth of \ncapabilities that we have as well.  \n ", "original_text": "A \nEric, I would just add to that. ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c43cfbd4-7d3d-4708-b910-e363c305368e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "09cddd3a5c708d99d040448e9f7a46c73095b6b88cba89635a8ecbdc5785eae4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "232f9546-3b37-4090-beae-65177e256295", "node_type": "1", "metadata": {"window": "But I really come back to \nthe fact that we've made the investments in core distribution excellence.  We clearly u nderstand this piece of the \nmarket quite well.  and that we think of ourselves as a solution -oriented value -added kind of partner and try to \npaint a broad picture of not just what we could do if we had a relationship but how we could grow that relationship \nthrough time using an array of the capabilities represented within McKesson.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nEric, I would just add to that.  If you think about the strategy that we've executed on over the last several years, \nwe've been very disciplined and focused and really growing our capabilities in oncology and pharma services, \nincluding the investments that Brian spoke of in terms of our distribution network.  \n \n So the breadth of capabilities th at we have today is more significant than it was a few years ago. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c2351870817798610df1d319bdfd6238190f30d2e757369ccc3dc3429aeec933", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02e5cb42-1bba-4ec0-871c-b3f2be726426", "node_type": "1", "metadata": {"window": "and that we think of ourselves as a solution -oriented value -added kind of partner and try to \npaint a broad picture of not just what we could do if we had a relationship but how we could grow that relationship \nthrough time using an array of the capabilities represented within McKesson.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nEric, I would just add to that.  If you think about the strategy that we've executed on over the last several years, \nwe've been very disciplined and focused and really growing our capabilities in oncology and pharma services, \nincluding the investments that Brian spoke of in terms of our distribution network.  \n \n So the breadth of capabilities th at we have today is more significant than it was a few years ago.  And the value \nthat we're able to provide now through the investments that we've made through some of the other acquisitions \nthat we've made in like oncology as an example, we believe that th at value is what is attractive and the breadth of \ncapabilities that we have as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "If you think about the strategy that we've executed on over the last several years, \nwe've been very disciplined and focused and really growing our capabilities in oncology and pharma services, \nincluding the investments that Brian spoke of in terms of our distribution network.  \n \n"}, "hash": "7334615ef2790f96d91f8363ad0772af6512176268df8a2853170ed550ac582d", "class_name": "RelatedNodeInfo"}}, "text": "A \nEric, I would just add to that. ", "start_char_idx": 2409, "end_char_idx": 2444, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02e5cb42-1bba-4ec0-871c-b3f2be726426": {"__data__": {"id_": "02e5cb42-1bba-4ec0-871c-b3f2be726426", "embedding": null, "metadata": {"window": "and that we think of ourselves as a solution -oriented value -added kind of partner and try to \npaint a broad picture of not just what we could do if we had a relationship but how we could grow that relationship \nthrough time using an array of the capabilities represented within McKesson.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nEric, I would just add to that.  If you think about the strategy that we've executed on over the last several years, \nwe've been very disciplined and focused and really growing our capabilities in oncology and pharma services, \nincluding the investments that Brian spoke of in terms of our distribution network.  \n \n So the breadth of capabilities th at we have today is more significant than it was a few years ago.  And the value \nthat we're able to provide now through the investments that we've made through some of the other acquisitions \nthat we've made in like oncology as an example, we believe that th at value is what is attractive and the breadth of \ncapabilities that we have as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "If you think about the strategy that we've executed on over the last several years, \nwe've been very disciplined and focused and really growing our capabilities in oncology and pharma services, \nincluding the investments that Brian spoke of in terms of our distribution network.  \n \n", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c43cfbd4-7d3d-4708-b910-e363c305368e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "09cddd3a5c708d99d040448e9f7a46c73095b6b88cba89635a8ecbdc5785eae4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "481d7454-285a-4c45-9cfc-7dc20809f40d", "node_type": "1", "metadata": {"window": "We clearly u nderstand this piece of the \nmarket quite well.  and that we think of ourselves as a solution -oriented value -added kind of partner and try to \npaint a broad picture of not just what we could do if we had a relationship but how we could grow that relationship \nthrough time using an array of the capabilities represented within McKesson.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nEric, I would just add to that.  If you think about the strategy that we've executed on over the last several years, \nwe've been very disciplined and focused and really growing our capabilities in oncology and pharma services, \nincluding the investments that Brian spoke of in terms of our distribution network.  \n \n So the breadth of capabilities th at we have today is more significant than it was a few years ago.  And the value \nthat we're able to provide now through the investments that we've made through some of the other acquisitions \nthat we've made in like oncology as an example, we believe that th at value is what is attractive and the breadth of \ncapabilities that we have as well.  \n ", "original_text": "A \nEric, I would just add to that. ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c759c544ec3db35128171b7536d7956ed468149fe303e06ef4966f813780be84", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d642ae8-54d0-4125-bfe6-060179aefe50", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nEric, I would just add to that.  If you think about the strategy that we've executed on over the last several years, \nwe've been very disciplined and focused and really growing our capabilities in oncology and pharma services, \nincluding the investments that Brian spoke of in terms of our distribution network.  \n \n So the breadth of capabilities th at we have today is more significant than it was a few years ago.  And the value \nthat we're able to provide now through the investments that we've made through some of the other acquisitions \nthat we've made in like oncology as an example, we believe that th at value is what is attractive and the breadth of \ncapabilities that we have as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "So the breadth of capabilities th at we have today is more significant than it was a few years ago. "}, "hash": "36203c984d0cefc4501708b46c3844f5f848040000fd0468741bd6b07de60efb", "class_name": "RelatedNodeInfo"}}, "text": "If you think about the strategy that we've executed on over the last several years, \nwe've been very disciplined and focused and really growing our capabilities in oncology and pharma services, \nincluding the investments that Brian spoke of in terms of our distribution network.  \n \n", "start_char_idx": 2444, "end_char_idx": 2727, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d642ae8-54d0-4125-bfe6-060179aefe50": {"__data__": {"id_": "3d642ae8-54d0-4125-bfe6-060179aefe50", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nEric, I would just add to that.  If you think about the strategy that we've executed on over the last several years, \nwe've been very disciplined and focused and really growing our capabilities in oncology and pharma services, \nincluding the investments that Brian spoke of in terms of our distribution network.  \n \n So the breadth of capabilities th at we have today is more significant than it was a few years ago.  And the value \nthat we're able to provide now through the investments that we've made through some of the other acquisitions \nthat we've made in like oncology as an example, we believe that th at value is what is attractive and the breadth of \ncapabilities that we have as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "So the breadth of capabilities th at we have today is more significant than it was a few years ago. ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c43cfbd4-7d3d-4708-b910-e363c305368e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "09cddd3a5c708d99d040448e9f7a46c73095b6b88cba89635a8ecbdc5785eae4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02e5cb42-1bba-4ec0-871c-b3f2be726426", "node_type": "1", "metadata": {"window": "and that we think of ourselves as a solution -oriented value -added kind of partner and try to \npaint a broad picture of not just what we could do if we had a relationship but how we could grow that relationship \nthrough time using an array of the capabilities represented within McKesson.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nEric, I would just add to that.  If you think about the strategy that we've executed on over the last several years, \nwe've been very disciplined and focused and really growing our capabilities in oncology and pharma services, \nincluding the investments that Brian spoke of in terms of our distribution network.  \n \n So the breadth of capabilities th at we have today is more significant than it was a few years ago.  And the value \nthat we're able to provide now through the investments that we've made through some of the other acquisitions \nthat we've made in like oncology as an example, we believe that th at value is what is attractive and the breadth of \ncapabilities that we have as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "If you think about the strategy that we've executed on over the last several years, \nwe've been very disciplined and focused and really growing our capabilities in oncology and pharma services, \nincluding the investments that Brian spoke of in terms of our distribution network.  \n \n", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c913e0b89d394196448e5aa16331082286d4e462fe1ee434e85c5cdfc3df17ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e99a060-1bd9-44cc-b967-5e9d68861c86", "node_type": "1", "metadata": {"window": "A \nEric, I would just add to that.  If you think about the strategy that we've executed on over the last several years, \nwe've been very disciplined and focused and really growing our capabilities in oncology and pharma services, \nincluding the investments that Brian spoke of in terms of our distribution network.  \n \n So the breadth of capabilities th at we have today is more significant than it was a few years ago.  And the value \nthat we're able to provide now through the investments that we've made through some of the other acquisitions \nthat we've made in like oncology as an example, we believe that th at value is what is attractive and the breadth of \ncapabilities that we have as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays. ", "original_text": "And the value \nthat we're able to provide now through the investments that we've made through some of the other acquisitions \nthat we've made in like oncology as an example, we believe that th at value is what is attractive and the breadth of \ncapabilities that we have as well.  \n "}, "hash": "ae62dd6c146396b6bd17c6cc3c1b92967124d6c91b49359241a6a9be5690bdd6", "class_name": "RelatedNodeInfo"}}, "text": "So the breadth of capabilities th at we have today is more significant than it was a few years ago. ", "start_char_idx": 2727, "end_char_idx": 2827, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e99a060-1bd9-44cc-b967-5e9d68861c86": {"__data__": {"id_": "8e99a060-1bd9-44cc-b967-5e9d68861c86", "embedding": null, "metadata": {"window": "A \nEric, I would just add to that.  If you think about the strategy that we've executed on over the last several years, \nwe've been very disciplined and focused and really growing our capabilities in oncology and pharma services, \nincluding the investments that Brian spoke of in terms of our distribution network.  \n \n So the breadth of capabilities th at we have today is more significant than it was a few years ago.  And the value \nthat we're able to provide now through the investments that we've made through some of the other acquisitions \nthat we've made in like oncology as an example, we believe that th at value is what is attractive and the breadth of \ncapabilities that we have as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays. ", "original_text": "And the value \nthat we're able to provide now through the investments that we've made through some of the other acquisitions \nthat we've made in like oncology as an example, we believe that th at value is what is attractive and the breadth of \ncapabilities that we have as well.  \n ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c43cfbd4-7d3d-4708-b910-e363c305368e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "09cddd3a5c708d99d040448e9f7a46c73095b6b88cba89635a8ecbdc5785eae4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d642ae8-54d0-4125-bfe6-060179aefe50", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nEric, I would just add to that.  If you think about the strategy that we've executed on over the last several years, \nwe've been very disciplined and focused and really growing our capabilities in oncology and pharma services, \nincluding the investments that Brian spoke of in terms of our distribution network.  \n \n So the breadth of capabilities th at we have today is more significant than it was a few years ago.  And the value \nthat we're able to provide now through the investments that we've made through some of the other acquisitions \nthat we've made in like oncology as an example, we believe that th at value is what is attractive and the breadth of \ncapabilities that we have as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "So the breadth of capabilities th at we have today is more significant than it was a few years ago. ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f3993f5cb926b1a497def856ebea8adc8277f3c7576e48d5df1c33b5ce3299ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14597d71-cdd3-4755-a5c4-e11628aba269", "node_type": "1", "metadata": {"window": "If you think about the strategy that we've executed on over the last several years, \nwe've been very disciplined and focused and really growing our capabilities in oncology and pharma services, \nincluding the investments that Brian spoke of in terms of our distribution network.  \n \n So the breadth of capabilities th at we have today is more significant than it was a few years ago.  And the value \nthat we're able to provide now through the investments that we've made through some of the other acquisitions \nthat we've made in like oncology as an example, we believe that th at value is what is attractive and the breadth of \ncapabilities that we have as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays.  Please go ah ead. \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  "}, "hash": "1438a188a193e8554fa3b442a68a7b23e6c7f5ff5a55318419eb68396a3e2930", "class_name": "RelatedNodeInfo"}}, "text": "And the value \nthat we're able to provide now through the investments that we've made through some of the other acquisitions \nthat we've made in like oncology as an example, we believe that th at value is what is attractive and the breadth of \ncapabilities that we have as well.  \n ", "start_char_idx": 2827, "end_char_idx": 3109, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14597d71-cdd3-4755-a5c4-e11628aba269": {"__data__": {"id_": "14597d71-cdd3-4755-a5c4-e11628aba269", "embedding": null, "metadata": {"window": "If you think about the strategy that we've executed on over the last several years, \nwe've been very disciplined and focused and really growing our capabilities in oncology and pharma services, \nincluding the investments that Brian spoke of in terms of our distribution network.  \n \n So the breadth of capabilities th at we have today is more significant than it was a few years ago.  And the value \nthat we're able to provide now through the investments that we've made through some of the other acquisitions \nthat we've made in like oncology as an example, we believe that th at value is what is attractive and the breadth of \ncapabilities that we have as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays.  Please go ah ead. \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c43cfbd4-7d3d-4708-b910-e363c305368e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "09cddd3a5c708d99d040448e9f7a46c73095b6b88cba89635a8ecbdc5785eae4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e99a060-1bd9-44cc-b967-5e9d68861c86", "node_type": "1", "metadata": {"window": "A \nEric, I would just add to that.  If you think about the strategy that we've executed on over the last several years, \nwe've been very disciplined and focused and really growing our capabilities in oncology and pharma services, \nincluding the investments that Brian spoke of in terms of our distribution network.  \n \n So the breadth of capabilities th at we have today is more significant than it was a few years ago.  And the value \nthat we're able to provide now through the investments that we've made through some of the other acquisitions \nthat we've made in like oncology as an example, we believe that th at value is what is attractive and the breadth of \ncapabilities that we have as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays. ", "original_text": "And the value \nthat we're able to provide now through the investments that we've made through some of the other acquisitions \nthat we've made in like oncology as an example, we believe that th at value is what is attractive and the breadth of \ncapabilities that we have as well.  \n ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "51a1fce5c8f8b7f558807547efe670ad177480a5064cbadd03585811fc4077fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "142b2123-f432-477a-b824-f41243a836d6", "node_type": "1", "metadata": {"window": "So the breadth of capabilities th at we have today is more significant than it was a few years ago.  And the value \nthat we're able to provide now through the investments that we've made through some of the other acquisitions \nthat we've made in like oncology as an example, we believe that th at value is what is attractive and the breadth of \ncapabilities that we have as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays.  Please go ah ead. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHey, guys, thank you for taking my questions and congrats on the guidance. ", "original_text": "A \nNext question, please.  \n "}, "hash": "bf9be97e4eea3793b788ce69db897658be64af21cb7517232919b4f594b49dd0", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "start_char_idx": 3109, "end_char_idx": 3454, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "142b2123-f432-477a-b824-f41243a836d6": {"__data__": {"id_": "142b2123-f432-477a-b824-f41243a836d6", "embedding": null, "metadata": {"window": "So the breadth of capabilities th at we have today is more significant than it was a few years ago.  And the value \nthat we're able to provide now through the investments that we've made through some of the other acquisitions \nthat we've made in like oncology as an example, we believe that th at value is what is attractive and the breadth of \ncapabilities that we have as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays.  Please go ah ead. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHey, guys, thank you for taking my questions and congrats on the guidance. ", "original_text": "A \nNext question, please.  \n ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c43cfbd4-7d3d-4708-b910-e363c305368e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "09cddd3a5c708d99d040448e9f7a46c73095b6b88cba89635a8ecbdc5785eae4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14597d71-cdd3-4755-a5c4-e11628aba269", "node_type": "1", "metadata": {"window": "If you think about the strategy that we've executed on over the last several years, \nwe've been very disciplined and focused and really growing our capabilities in oncology and pharma services, \nincluding the investments that Brian spoke of in terms of our distribution network.  \n \n So the breadth of capabilities th at we have today is more significant than it was a few years ago.  And the value \nthat we're able to provide now through the investments that we've made through some of the other acquisitions \nthat we've made in like oncology as an example, we believe that th at value is what is attractive and the breadth of \ncapabilities that we have as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays.  Please go ah ead. \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "dd4609402fd9d28cf6b486ca799a3808bf2c4166088ef96a0f473ae0cca620d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5ce631a-9fb9-4772-a0ba-b72b15ac87d3", "node_type": "1", "metadata": {"window": "And the value \nthat we're able to provide now through the investments that we've made through some of the other acquisitions \nthat we've made in like oncology as an example, we believe that th at value is what is attractive and the breadth of \ncapabilities that we have as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays.  Please go ah ead. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHey, guys, thank you for taking my questions and congrats on the guidance.  I was hoping to get a little bit more \ncolor about the nature of the biopharma investments you're making in the prescription transaction business. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays. "}, "hash": "9e0130f94a5992cae1f73b38b7491a762eea8b4679aa14700bcabfad3f5b59d9", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please.  \n ", "start_char_idx": 3454, "end_char_idx": 3483, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5ce631a-9fb9-4772-a0ba-b72b15ac87d3": {"__data__": {"id_": "d5ce631a-9fb9-4772-a0ba-b72b15ac87d3", "embedding": null, "metadata": {"window": "And the value \nthat we're able to provide now through the investments that we've made through some of the other acquisitions \nthat we've made in like oncology as an example, we believe that th at value is what is attractive and the breadth of \ncapabilities that we have as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays.  Please go ah ead. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHey, guys, thank you for taking my questions and congrats on the guidance.  I was hoping to get a little bit more \ncolor about the nature of the biopharma investments you're making in the prescription transaction business. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays. ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c43cfbd4-7d3d-4708-b910-e363c305368e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "09cddd3a5c708d99d040448e9f7a46c73095b6b88cba89635a8ecbdc5785eae4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "142b2123-f432-477a-b824-f41243a836d6", "node_type": "1", "metadata": {"window": "So the breadth of capabilities th at we have today is more significant than it was a few years ago.  And the value \nthat we're able to provide now through the investments that we've made through some of the other acquisitions \nthat we've made in like oncology as an example, we believe that th at value is what is attractive and the breadth of \ncapabilities that we have as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays.  Please go ah ead. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHey, guys, thank you for taking my questions and congrats on the guidance. ", "original_text": "A \nNext question, please.  \n ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "9833d0851b643b7ef86ee16653c537e020da4e261af4a9188a3bad529286aa5f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90ef63a4-b34a-4a30-9251-51d658f3e11b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays.  Please go ah ead. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHey, guys, thank you for taking my questions and congrats on the guidance.  I was hoping to get a little bit more \ncolor about the nature of the biopharma investments you're making in the prescription transaction business.  Just \nkind of nature of it, whether they're more of a recurring expense, like head count compared to more near -term \npockets of them like platform development, and anything you can give us on that?  \n ", "original_text": "Please go ah ead. \n "}, "hash": "1e7a7cf709a9755120029dd3b69c9fe86462f4247c938e5f264ad84303fc8926", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays. ", "start_char_idx": 3483, "end_char_idx": 3816, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90ef63a4-b34a-4a30-9251-51d658f3e11b": {"__data__": {"id_": "90ef63a4-b34a-4a30-9251-51d658f3e11b", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays.  Please go ah ead. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHey, guys, thank you for taking my questions and congrats on the guidance.  I was hoping to get a little bit more \ncolor about the nature of the biopharma investments you're making in the prescription transaction business.  Just \nkind of nature of it, whether they're more of a recurring expense, like head count compared to more near -term \npockets of them like platform development, and anything you can give us on that?  \n ", "original_text": "Please go ah ead. \n ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c43cfbd4-7d3d-4708-b910-e363c305368e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "09cddd3a5c708d99d040448e9f7a46c73095b6b88cba89635a8ecbdc5785eae4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5ce631a-9fb9-4772-a0ba-b72b15ac87d3", "node_type": "1", "metadata": {"window": "And the value \nthat we're able to provide now through the investments that we've made through some of the other acquisitions \nthat we've made in like oncology as an example, we believe that th at value is what is attractive and the breadth of \ncapabilities that we have as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays.  Please go ah ead. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHey, guys, thank you for taking my questions and congrats on the guidance.  I was hoping to get a little bit more \ncolor about the nature of the biopharma investments you're making in the prescription transaction business. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays. ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a37972f9613a864f50222b5cf35df02cd1f4292c460c2c36bba25c696e8a98d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05487628-7938-4a9a-9110-7bcfe40d2bf8", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays.  Please go ah ead. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHey, guys, thank you for taking my questions and congrats on the guidance.  I was hoping to get a little bit more \ncolor about the nature of the biopharma investments you're making in the prescription transaction business.  Just \nkind of nature of it, whether they're more of a recurring expense, like head count compared to more near -term \npockets of them like platform development, and anything you can give us on that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHey, guys, thank you for taking my questions and congrats on the guidance. "}, "hash": "7b798b34a6a817c268f59289286a4495b1e29dee455d82d31670827519fc85b0", "class_name": "RelatedNodeInfo"}}, "text": "Please go ah ead. \n ", "start_char_idx": 3816, "end_char_idx": 3836, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05487628-7938-4a9a-9110-7bcfe40d2bf8": {"__data__": {"id_": "05487628-7938-4a9a-9110-7bcfe40d2bf8", "embedding": null, "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays.  Please go ah ead. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHey, guys, thank you for taking my questions and congrats on the guidance.  I was hoping to get a little bit more \ncolor about the nature of the biopharma investments you're making in the prescription transaction business.  Just \nkind of nature of it, whether they're more of a recurring expense, like head count compared to more near -term \npockets of them like platform development, and anything you can give us on that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHey, guys, thank you for taking my questions and congrats on the guidance. ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c43cfbd4-7d3d-4708-b910-e363c305368e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "09cddd3a5c708d99d040448e9f7a46c73095b6b88cba89635a8ecbdc5785eae4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90ef63a4-b34a-4a30-9251-51d658f3e11b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays.  Please go ah ead. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHey, guys, thank you for taking my questions and congrats on the guidance.  I was hoping to get a little bit more \ncolor about the nature of the biopharma investments you're making in the prescription transaction business.  Just \nkind of nature of it, whether they're more of a recurring expense, like head count compared to more near -term \npockets of them like platform development, and anything you can give us on that?  \n ", "original_text": "Please go ah ead. \n ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "357c19d69dda019039dd114f70078398ae0916835899477d2e663320b83307af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ddea0275-67cd-4e35-88e2-a4e573475e4f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays.  Please go ah ead. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHey, guys, thank you for taking my questions and congrats on the guidance.  I was hoping to get a little bit more \ncolor about the nature of the biopharma investments you're making in the prescription transaction business.  Just \nkind of nature of it, whether they're more of a recurring expense, like head count compared to more near -term \npockets of them like platform development, and anything you can give us on that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "I was hoping to get a little bit more \ncolor about the nature of the biopharma investments you're making in the prescription transaction business. "}, "hash": "99bc559d744825e708ad9aaa9047c67b0eea3ef5ed3e5a5386b6b4a46863039f", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHey, guys, thank you for taking my questions and congrats on the guidance. ", "start_char_idx": 3836, "end_char_idx": 4232, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ddea0275-67cd-4e35-88e2-a4e573475e4f": {"__data__": {"id_": "ddea0275-67cd-4e35-88e2-a4e573475e4f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays.  Please go ah ead. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHey, guys, thank you for taking my questions and congrats on the guidance.  I was hoping to get a little bit more \ncolor about the nature of the biopharma investments you're making in the prescription transaction business.  Just \nkind of nature of it, whether they're more of a recurring expense, like head count compared to more near -term \npockets of them like platform development, and anything you can give us on that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "I was hoping to get a little bit more \ncolor about the nature of the biopharma investments you're making in the prescription transaction business. ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c43cfbd4-7d3d-4708-b910-e363c305368e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "09cddd3a5c708d99d040448e9f7a46c73095b6b88cba89635a8ecbdc5785eae4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05487628-7938-4a9a-9110-7bcfe40d2bf8", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays.  Please go ah ead. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHey, guys, thank you for taking my questions and congrats on the guidance.  I was hoping to get a little bit more \ncolor about the nature of the biopharma investments you're making in the prescription transaction business.  Just \nkind of nature of it, whether they're more of a recurring expense, like head count compared to more near -term \npockets of them like platform development, and anything you can give us on that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHey, guys, thank you for taking my questions and congrats on the guidance. ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "9a89392a7f2e0e7a26a961806442e7bb30a5d1db847a285789e2bec12f076d01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8cea02c8-85e8-417a-b058-229f774e5525", "node_type": "1", "metadata": {"window": "Please go ah ead. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHey, guys, thank you for taking my questions and congrats on the guidance.  I was hoping to get a little bit more \ncolor about the nature of the biopharma investments you're making in the prescription transaction business.  Just \nkind of nature of it, whether they're more of a recurring expense, like head count compared to more near -term \npockets of them like platform development, and anything you can give us on that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Just \nkind of nature of it, whether they're more of a recurring expense, like head count compared to more near -term \npockets of them like platform development, and anything you can give us on that?  \n "}, "hash": "44b65927e89d8452849b4a62c562028b9cb92a8036440f303b63bb614779be56", "class_name": "RelatedNodeInfo"}}, "text": "I was hoping to get a little bit more \ncolor about the nature of the biopharma investments you're making in the prescription transaction business. ", "start_char_idx": 4232, "end_char_idx": 4379, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8cea02c8-85e8-417a-b058-229f774e5525": {"__data__": {"id_": "8cea02c8-85e8-417a-b058-229f774e5525", "embedding": null, "metadata": {"window": "Please go ah ead. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHey, guys, thank you for taking my questions and congrats on the guidance.  I was hoping to get a little bit more \ncolor about the nature of the biopharma investments you're making in the prescription transaction business.  Just \nkind of nature of it, whether they're more of a recurring expense, like head count compared to more near -term \npockets of them like platform development, and anything you can give us on that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Just \nkind of nature of it, whether they're more of a recurring expense, like head count compared to more near -term \npockets of them like platform development, and anything you can give us on that?  \n ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c43cfbd4-7d3d-4708-b910-e363c305368e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "09cddd3a5c708d99d040448e9f7a46c73095b6b88cba89635a8ecbdc5785eae4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ddea0275-67cd-4e35-88e2-a4e573475e4f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays.  Please go ah ead. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHey, guys, thank you for taking my questions and congrats on the guidance.  I was hoping to get a little bit more \ncolor about the nature of the biopharma investments you're making in the prescription transaction business.  Just \nkind of nature of it, whether they're more of a recurring expense, like head count compared to more near -term \npockets of them like platform development, and anything you can give us on that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "I was hoping to get a little bit more \ncolor about the nature of the biopharma investments you're making in the prescription transaction business. ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "2c8341e41b4fc63b4fadc391844a186e1c1ebc93f8d40b6af4869b6f023cbcd3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68340171-4f6b-4cb4-9767-fe695bbfe8cb", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHey, guys, thank you for taking my questions and congrats on the guidance.  I was hoping to get a little bit more \ncolor about the nature of the biopharma investments you're making in the prescription transaction business.  Just \nkind of nature of it, whether they're more of a recurring expense, like head count compared to more near -term \npockets of them like platform development, and anything you can give us on that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  "}, "hash": "f8890e8d0464b39f21e4a2cdcb3af905588a99e1e8a0f0b4081de6a0d6e57508", "class_name": "RelatedNodeInfo"}}, "text": "Just \nkind of nature of it, whether they're more of a recurring expense, like head count compared to more near -term \npockets of them like platform development, and anything you can give us on that?  \n ", "start_char_idx": 4379, "end_char_idx": 4581, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68340171-4f6b-4cb4-9767-fe695bbfe8cb": {"__data__": {"id_": "68340171-4f6b-4cb4-9767-fe695bbfe8cb", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHey, guys, thank you for taking my questions and congrats on the guidance.  I was hoping to get a little bit more \ncolor about the nature of the biopharma investments you're making in the prescription transaction business.  Just \nkind of nature of it, whether they're more of a recurring expense, like head count compared to more near -term \npockets of them like platform development, and anything you can give us on that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c43cfbd4-7d3d-4708-b910-e363c305368e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "09cddd3a5c708d99d040448e9f7a46c73095b6b88cba89635a8ecbdc5785eae4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8cea02c8-85e8-417a-b058-229f774e5525", "node_type": "1", "metadata": {"window": "Please go ah ead. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHey, guys, thank you for taking my questions and congrats on the guidance.  I was hoping to get a little bit more \ncolor about the nature of the biopharma investments you're making in the prescription transaction business.  Just \nkind of nature of it, whether they're more of a recurring expense, like head count compared to more near -term \npockets of them like platform development, and anything you can give us on that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Just \nkind of nature of it, whether they're more of a recurring expense, like head count compared to more near -term \npockets of them like platform development, and anything you can give us on that?  \n ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a1f294a626eec89177e4fc86154a17f37ec99fb40c465357e6a859436e6f896a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dfa8fc22-de74-45ae-95c4-971a627d9379", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Of ficer & Director, McKesson Corp.   A \nYes.  So I'll start, and if Britt wants to add anything he can. ", "original_text": "McKesson Corp.  "}, "hash": "94eff5e452ce403613a37e55e0ed756b0cf04da3728f35c8456f7875828a76ab", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "start_char_idx": 818, "end_char_idx": 1089, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dfa8fc22-de74-45ae-95c4-971a627d9379": {"__data__": {"id_": "dfa8fc22-de74-45ae-95c4-971a627d9379", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Of ficer & Director, McKesson Corp.   A \nYes.  So I'll start, and if Britt wants to add anything he can. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d649effd72c4876779238658a2dc6b4313355ea2addc149abc8e442ec679c54f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68340171-4f6b-4cb4-9767-fe695bbfe8cb", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHey, guys, thank you for taking my questions and congrats on the guidance.  I was hoping to get a little bit more \ncolor about the nature of the biopharma investments you're making in the prescription transaction business.  Just \nkind of nature of it, whether they're more of a recurring expense, like head count compared to more near -term \npockets of them like platform development, and anything you can give us on that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "16e50ccf3d5901a94c3e77c0b9bbe430acfca09d2cd8ea234754121fcd78e47b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60ad3e2e-ea2e-49ae-a457-d059404225b1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Of ficer & Director, McKesson Corp.   A \nYes.  So I'll start, and if Britt wants to add anything he can.  I mean we have a pretty differentiated set of assets in \nthis business, scaled \u2013 multiple scaled networks is what we call them, which includes connectivity in to provider \nworkflow, and we very much fundamentally think part of our job is to continue to innovate off of those to both \nenhance the value and the return our products provide to biopharma and to continue to solve new problems for \nthem.  \n \n", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Of ficer & Director, McKesson Corp.  "}, "hash": "28e4433a445fd025b0bf5b97efb6a6511bc7e79e27be047645b7d0eb693277be", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60ad3e2e-ea2e-49ae-a457-d059404225b1": {"__data__": {"id_": "60ad3e2e-ea2e-49ae-a457-d059404225b1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Of ficer & Director, McKesson Corp.   A \nYes.  So I'll start, and if Britt wants to add anything he can.  I mean we have a pretty differentiated set of assets in \nthis business, scaled \u2013 multiple scaled networks is what we call them, which includes connectivity in to provider \nworkflow, and we very much fundamentally think part of our job is to continue to innovate off of those to both \nenhance the value and the return our products provide to biopharma and to continue to solve new problems for \nthem.  \n \n", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Of ficer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d649effd72c4876779238658a2dc6b4313355ea2addc149abc8e442ec679c54f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dfa8fc22-de74-45ae-95c4-971a627d9379", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Of ficer & Director, McKesson Corp.   A \nYes.  So I'll start, and if Britt wants to add anything he can. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e141dd1e64d02bcae926aa1284b3f7963f880218ee476a8f13a3eabbde35c1b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4cb61342-3415-4048-91ef-21794a2cf8f3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Of ficer & Director, McKesson Corp.   A \nYes.  So I'll start, and if Britt wants to add anything he can.  I mean we have a pretty differentiated set of assets in \nthis business, scaled \u2013 multiple scaled networks is what we call them, which includes connectivity in to provider \nworkflow, and we very much fundamentally think part of our job is to continue to innovate off of those to both \nenhance the value and the return our products provide to biopharma and to continue to solve new problems for \nthem.  \n \n So we have histor ically always invested in this business. ", "original_text": "A \nYes. "}, "hash": "be48f62058aea606b3b84e8c55954bcedd79a8aa732cd09164b45791ee2d1ad7", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Of ficer & Director, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 254, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4cb61342-3415-4048-91ef-21794a2cf8f3": {"__data__": {"id_": "4cb61342-3415-4048-91ef-21794a2cf8f3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Of ficer & Director, McKesson Corp.   A \nYes.  So I'll start, and if Britt wants to add anything he can.  I mean we have a pretty differentiated set of assets in \nthis business, scaled \u2013 multiple scaled networks is what we call them, which includes connectivity in to provider \nworkflow, and we very much fundamentally think part of our job is to continue to innovate off of those to both \nenhance the value and the return our products provide to biopharma and to continue to solve new problems for \nthem.  \n \n So we have histor ically always invested in this business. ", "original_text": "A \nYes. ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d649effd72c4876779238658a2dc6b4313355ea2addc149abc8e442ec679c54f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60ad3e2e-ea2e-49ae-a457-d059404225b1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Of ficer & Director, McKesson Corp.   A \nYes.  So I'll start, and if Britt wants to add anything he can.  I mean we have a pretty differentiated set of assets in \nthis business, scaled \u2013 multiple scaled networks is what we call them, which includes connectivity in to provider \nworkflow, and we very much fundamentally think part of our job is to continue to innovate off of those to both \nenhance the value and the return our products provide to biopharma and to continue to solve new problems for \nthem.  \n \n", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Of ficer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d60d9ddd3dd14689298bf9ca25b460fecf1df499e303a04b0d5f0ae7f1d943f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e21bb1bc-0138-4b73-992c-658fcc0ab533", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Of ficer & Director, McKesson Corp.   A \nYes.  So I'll start, and if Britt wants to add anything he can.  I mean we have a pretty differentiated set of assets in \nthis business, scaled \u2013 multiple scaled networks is what we call them, which includes connectivity in to provider \nworkflow, and we very much fundamentally think part of our job is to continue to innovate off of those to both \nenhance the value and the return our products provide to biopharma and to continue to solve new problems for \nthem.  \n \n So we have histor ically always invested in this business.  And when we see an opportunity ahead of us, we are \nnot afraid to increase that investment to run at that because we think these differentiated assets allow us to solve \nproblems in unique ways. ", "original_text": "So I'll start, and if Britt wants to add anything he can. "}, "hash": "3a4d652c1d9cf366de83775cb4e7736688e1840e0399226daa7c27de6799c1b3", "class_name": "RelatedNodeInfo"}}, "text": "A \nYes. ", "start_char_idx": 254, "end_char_idx": 262, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e21bb1bc-0138-4b73-992c-658fcc0ab533": {"__data__": {"id_": "e21bb1bc-0138-4b73-992c-658fcc0ab533", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Of ficer & Director, McKesson Corp.   A \nYes.  So I'll start, and if Britt wants to add anything he can.  I mean we have a pretty differentiated set of assets in \nthis business, scaled \u2013 multiple scaled networks is what we call them, which includes connectivity in to provider \nworkflow, and we very much fundamentally think part of our job is to continue to innovate off of those to both \nenhance the value and the return our products provide to biopharma and to continue to solve new problems for \nthem.  \n \n So we have histor ically always invested in this business.  And when we see an opportunity ahead of us, we are \nnot afraid to increase that investment to run at that because we think these differentiated assets allow us to solve \nproblems in unique ways. ", "original_text": "So I'll start, and if Britt wants to add anything he can. ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d649effd72c4876779238658a2dc6b4313355ea2addc149abc8e442ec679c54f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4cb61342-3415-4048-91ef-21794a2cf8f3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Of ficer & Director, McKesson Corp.   A \nYes.  So I'll start, and if Britt wants to add anything he can.  I mean we have a pretty differentiated set of assets in \nthis business, scaled \u2013 multiple scaled networks is what we call them, which includes connectivity in to provider \nworkflow, and we very much fundamentally think part of our job is to continue to innovate off of those to both \nenhance the value and the return our products provide to biopharma and to continue to solve new problems for \nthem.  \n \n So we have histor ically always invested in this business. ", "original_text": "A \nYes. ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "20707f5edc90a98ed577171fb213633702ce138496b71fe245dee68aca169042", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7d99f01-e9a1-49a5-a938-934293b38e61", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Of ficer & Director, McKesson Corp.   A \nYes.  So I'll start, and if Britt wants to add anything he can.  I mean we have a pretty differentiated set of assets in \nthis business, scaled \u2013 multiple scaled networks is what we call them, which includes connectivity in to provider \nworkflow, and we very much fundamentally think part of our job is to continue to innovate off of those to both \nenhance the value and the return our products provide to biopharma and to continue to solve new problems for \nthem.  \n \n So we have histor ically always invested in this business.  And when we see an opportunity ahead of us, we are \nnot afraid to increase that investment to run at that because we think these differentiated assets allow us to solve \nproblems in unique ways.  Most of this investmen t has been in technology, and that's probably about all I would \nsay. \n ", "original_text": "I mean we have a pretty differentiated set of assets in \nthis business, scaled \u2013 multiple scaled networks is what we call them, which includes connectivity in to provider \nworkflow, and we very much fundamentally think part of our job is to continue to innovate off of those to both \nenhance the value and the return our products provide to biopharma and to continue to solve new problems for \nthem.  \n \n"}, "hash": "19076345e4ce427b645f34e5bc1867af7ca5ad0593aee42d61d0a5ac10016bdb", "class_name": "RelatedNodeInfo"}}, "text": "So I'll start, and if Britt wants to add anything he can. ", "start_char_idx": 262, "end_char_idx": 320, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7d99f01-e9a1-49a5-a938-934293b38e61": {"__data__": {"id_": "d7d99f01-e9a1-49a5-a938-934293b38e61", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Of ficer & Director, McKesson Corp.   A \nYes.  So I'll start, and if Britt wants to add anything he can.  I mean we have a pretty differentiated set of assets in \nthis business, scaled \u2013 multiple scaled networks is what we call them, which includes connectivity in to provider \nworkflow, and we very much fundamentally think part of our job is to continue to innovate off of those to both \nenhance the value and the return our products provide to biopharma and to continue to solve new problems for \nthem.  \n \n So we have histor ically always invested in this business.  And when we see an opportunity ahead of us, we are \nnot afraid to increase that investment to run at that because we think these differentiated assets allow us to solve \nproblems in unique ways.  Most of this investmen t has been in technology, and that's probably about all I would \nsay. \n ", "original_text": "I mean we have a pretty differentiated set of assets in \nthis business, scaled \u2013 multiple scaled networks is what we call them, which includes connectivity in to provider \nworkflow, and we very much fundamentally think part of our job is to continue to innovate off of those to both \nenhance the value and the return our products provide to biopharma and to continue to solve new problems for \nthem.  \n \n", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d649effd72c4876779238658a2dc6b4313355ea2addc149abc8e442ec679c54f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e21bb1bc-0138-4b73-992c-658fcc0ab533", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Of ficer & Director, McKesson Corp.   A \nYes.  So I'll start, and if Britt wants to add anything he can.  I mean we have a pretty differentiated set of assets in \nthis business, scaled \u2013 multiple scaled networks is what we call them, which includes connectivity in to provider \nworkflow, and we very much fundamentally think part of our job is to continue to innovate off of those to both \nenhance the value and the return our products provide to biopharma and to continue to solve new problems for \nthem.  \n \n So we have histor ically always invested in this business.  And when we see an opportunity ahead of us, we are \nnot afraid to increase that investment to run at that because we think these differentiated assets allow us to solve \nproblems in unique ways. ", "original_text": "So I'll start, and if Britt wants to add anything he can. ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "df25e5e0fffab4593c63fed138bd3b0d7e57acf7efe288dd21198862b73016c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f72314f-f9f3-42c3-9a06-bdcfaa77f007", "node_type": "1", "metadata": {"window": "A \nYes.  So I'll start, and if Britt wants to add anything he can.  I mean we have a pretty differentiated set of assets in \nthis business, scaled \u2013 multiple scaled networks is what we call them, which includes connectivity in to provider \nworkflow, and we very much fundamentally think part of our job is to continue to innovate off of those to both \nenhance the value and the return our products provide to biopharma and to continue to solve new problems for \nthem.  \n \n So we have histor ically always invested in this business.  And when we see an opportunity ahead of us, we are \nnot afraid to increase that investment to run at that because we think these differentiated assets allow us to solve \nproblems in unique ways.  Most of this investmen t has been in technology, and that's probably about all I would \nsay. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "So we have histor ically always invested in this business. "}, "hash": "0d42d6a045b6bd72b59bb51f3c0ca0091e56ccb949359d60d09e01648fdec118", "class_name": "RelatedNodeInfo"}}, "text": "I mean we have a pretty differentiated set of assets in \nthis business, scaled \u2013 multiple scaled networks is what we call them, which includes connectivity in to provider \nworkflow, and we very much fundamentally think part of our job is to continue to innovate off of those to both \nenhance the value and the return our products provide to biopharma and to continue to solve new problems for \nthem.  \n \n", "start_char_idx": 320, "end_char_idx": 724, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f72314f-f9f3-42c3-9a06-bdcfaa77f007": {"__data__": {"id_": "2f72314f-f9f3-42c3-9a06-bdcfaa77f007", "embedding": null, "metadata": {"window": "A \nYes.  So I'll start, and if Britt wants to add anything he can.  I mean we have a pretty differentiated set of assets in \nthis business, scaled \u2013 multiple scaled networks is what we call them, which includes connectivity in to provider \nworkflow, and we very much fundamentally think part of our job is to continue to innovate off of those to both \nenhance the value and the return our products provide to biopharma and to continue to solve new problems for \nthem.  \n \n So we have histor ically always invested in this business.  And when we see an opportunity ahead of us, we are \nnot afraid to increase that investment to run at that because we think these differentiated assets allow us to solve \nproblems in unique ways.  Most of this investmen t has been in technology, and that's probably about all I would \nsay. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "So we have histor ically always invested in this business. ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d649effd72c4876779238658a2dc6b4313355ea2addc149abc8e442ec679c54f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7d99f01-e9a1-49a5-a938-934293b38e61", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Of ficer & Director, McKesson Corp.   A \nYes.  So I'll start, and if Britt wants to add anything he can.  I mean we have a pretty differentiated set of assets in \nthis business, scaled \u2013 multiple scaled networks is what we call them, which includes connectivity in to provider \nworkflow, and we very much fundamentally think part of our job is to continue to innovate off of those to both \nenhance the value and the return our products provide to biopharma and to continue to solve new problems for \nthem.  \n \n So we have histor ically always invested in this business.  And when we see an opportunity ahead of us, we are \nnot afraid to increase that investment to run at that because we think these differentiated assets allow us to solve \nproblems in unique ways.  Most of this investmen t has been in technology, and that's probably about all I would \nsay. \n ", "original_text": "I mean we have a pretty differentiated set of assets in \nthis business, scaled \u2013 multiple scaled networks is what we call them, which includes connectivity in to provider \nworkflow, and we very much fundamentally think part of our job is to continue to innovate off of those to both \nenhance the value and the return our products provide to biopharma and to continue to solve new problems for \nthem.  \n \n", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c24f0cd1ec597cad67dbbc4bb0f5031fa19bedfe41a97022c2da8f08730e99a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ea13848-c32c-4a65-a332-e97d3f699b6a", "node_type": "1", "metadata": {"window": "So I'll start, and if Britt wants to add anything he can.  I mean we have a pretty differentiated set of assets in \nthis business, scaled \u2013 multiple scaled networks is what we call them, which includes connectivity in to provider \nworkflow, and we very much fundamentally think part of our job is to continue to innovate off of those to both \nenhance the value and the return our products provide to biopharma and to continue to solve new problems for \nthem.  \n \n So we have histor ically always invested in this business.  And when we see an opportunity ahead of us, we are \nnot afraid to increase that investment to run at that because we think these differentiated assets allow us to solve \nproblems in unique ways.  Most of this investmen t has been in technology, and that's probably about all I would \nsay. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "And when we see an opportunity ahead of us, we are \nnot afraid to increase that investment to run at that because we think these differentiated assets allow us to solve \nproblems in unique ways. "}, "hash": "6365e2c099976748cdbc86f4c53d49870354f3e6d87006cf610dc2490db3645c", "class_name": "RelatedNodeInfo"}}, "text": "So we have histor ically always invested in this business. ", "start_char_idx": 724, "end_char_idx": 783, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ea13848-c32c-4a65-a332-e97d3f699b6a": {"__data__": {"id_": "8ea13848-c32c-4a65-a332-e97d3f699b6a", "embedding": null, "metadata": {"window": "So I'll start, and if Britt wants to add anything he can.  I mean we have a pretty differentiated set of assets in \nthis business, scaled \u2013 multiple scaled networks is what we call them, which includes connectivity in to provider \nworkflow, and we very much fundamentally think part of our job is to continue to innovate off of those to both \nenhance the value and the return our products provide to biopharma and to continue to solve new problems for \nthem.  \n \n So we have histor ically always invested in this business.  And when we see an opportunity ahead of us, we are \nnot afraid to increase that investment to run at that because we think these differentiated assets allow us to solve \nproblems in unique ways.  Most of this investmen t has been in technology, and that's probably about all I would \nsay. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "And when we see an opportunity ahead of us, we are \nnot afraid to increase that investment to run at that because we think these differentiated assets allow us to solve \nproblems in unique ways. ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d649effd72c4876779238658a2dc6b4313355ea2addc149abc8e442ec679c54f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f72314f-f9f3-42c3-9a06-bdcfaa77f007", "node_type": "1", "metadata": {"window": "A \nYes.  So I'll start, and if Britt wants to add anything he can.  I mean we have a pretty differentiated set of assets in \nthis business, scaled \u2013 multiple scaled networks is what we call them, which includes connectivity in to provider \nworkflow, and we very much fundamentally think part of our job is to continue to innovate off of those to both \nenhance the value and the return our products provide to biopharma and to continue to solve new problems for \nthem.  \n \n So we have histor ically always invested in this business.  And when we see an opportunity ahead of us, we are \nnot afraid to increase that investment to run at that because we think these differentiated assets allow us to solve \nproblems in unique ways.  Most of this investmen t has been in technology, and that's probably about all I would \nsay. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "So we have histor ically always invested in this business. ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "4007b149a0709debc9f793260ced1bd4c607aa25ee079d4c4ce82a8a92050c9a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37307ed3-4a12-420b-911a-3eb6161ced48", "node_type": "1", "metadata": {"window": "I mean we have a pretty differentiated set of assets in \nthis business, scaled \u2013 multiple scaled networks is what we call them, which includes connectivity in to provider \nworkflow, and we very much fundamentally think part of our job is to continue to innovate off of those to both \nenhance the value and the return our products provide to biopharma and to continue to solve new problems for \nthem.  \n \n So we have histor ically always invested in this business.  And when we see an opportunity ahead of us, we are \nnot afraid to increase that investment to run at that because we think these differentiated assets allow us to solve \nproblems in unique ways.  Most of this investmen t has been in technology, and that's probably about all I would \nsay. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Elizabeth Anderson with Evercore ISI. ", "original_text": "Most of this investmen t has been in technology, and that's probably about all I would \nsay. \n "}, "hash": "957585ff3c3f740e49c9c4bd9f94630d803bd460cdee562ea0b051acc6105855", "class_name": "RelatedNodeInfo"}}, "text": "And when we see an opportunity ahead of us, we are \nnot afraid to increase that investment to run at that because we think these differentiated assets allow us to solve \nproblems in unique ways. ", "start_char_idx": 783, "end_char_idx": 978, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37307ed3-4a12-420b-911a-3eb6161ced48": {"__data__": {"id_": "37307ed3-4a12-420b-911a-3eb6161ced48", "embedding": null, "metadata": {"window": "I mean we have a pretty differentiated set of assets in \nthis business, scaled \u2013 multiple scaled networks is what we call them, which includes connectivity in to provider \nworkflow, and we very much fundamentally think part of our job is to continue to innovate off of those to both \nenhance the value and the return our products provide to biopharma and to continue to solve new problems for \nthem.  \n \n So we have histor ically always invested in this business.  And when we see an opportunity ahead of us, we are \nnot afraid to increase that investment to run at that because we think these differentiated assets allow us to solve \nproblems in unique ways.  Most of this investmen t has been in technology, and that's probably about all I would \nsay. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Elizabeth Anderson with Evercore ISI. ", "original_text": "Most of this investmen t has been in technology, and that's probably about all I would \nsay. \n ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d649effd72c4876779238658a2dc6b4313355ea2addc149abc8e442ec679c54f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ea13848-c32c-4a65-a332-e97d3f699b6a", "node_type": "1", "metadata": {"window": "So I'll start, and if Britt wants to add anything he can.  I mean we have a pretty differentiated set of assets in \nthis business, scaled \u2013 multiple scaled networks is what we call them, which includes connectivity in to provider \nworkflow, and we very much fundamentally think part of our job is to continue to innovate off of those to both \nenhance the value and the return our products provide to biopharma and to continue to solve new problems for \nthem.  \n \n So we have histor ically always invested in this business.  And when we see an opportunity ahead of us, we are \nnot afraid to increase that investment to run at that because we think these differentiated assets allow us to solve \nproblems in unique ways.  Most of this investmen t has been in technology, and that's probably about all I would \nsay. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "And when we see an opportunity ahead of us, we are \nnot afraid to increase that investment to run at that because we think these differentiated assets allow us to solve \nproblems in unique ways. ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "4d7d05d174d10994d9fc8c2b852dc663facd2baad33a416f2c44087aebe9eadd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4008944-10ef-48ed-8a8d-0ffbd527ed7e", "node_type": "1", "metadata": {"window": "So we have histor ically always invested in this business.  And when we see an opportunity ahead of us, we are \nnot afraid to increase that investment to run at that because we think these differentiated assets allow us to solve \nproblems in unique ways.  Most of this investmen t has been in technology, and that's probably about all I would \nsay. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  "}, "hash": "99d2c33c9d36326745e3449a69c5fca34b2d44b619512582651d9bdf9082e56c", "class_name": "RelatedNodeInfo"}}, "text": "Most of this investmen t has been in technology, and that's probably about all I would \nsay. \n ", "start_char_idx": 978, "end_char_idx": 1073, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4008944-10ef-48ed-8a8d-0ffbd527ed7e": {"__data__": {"id_": "d4008944-10ef-48ed-8a8d-0ffbd527ed7e", "embedding": null, "metadata": {"window": "So we have histor ically always invested in this business.  And when we see an opportunity ahead of us, we are \nnot afraid to increase that investment to run at that because we think these differentiated assets allow us to solve \nproblems in unique ways.  Most of this investmen t has been in technology, and that's probably about all I would \nsay. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d649effd72c4876779238658a2dc6b4313355ea2addc149abc8e442ec679c54f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37307ed3-4a12-420b-911a-3eb6161ced48", "node_type": "1", "metadata": {"window": "I mean we have a pretty differentiated set of assets in \nthis business, scaled \u2013 multiple scaled networks is what we call them, which includes connectivity in to provider \nworkflow, and we very much fundamentally think part of our job is to continue to innovate off of those to both \nenhance the value and the return our products provide to biopharma and to continue to solve new problems for \nthem.  \n \n So we have histor ically always invested in this business.  And when we see an opportunity ahead of us, we are \nnot afraid to increase that investment to run at that because we think these differentiated assets allow us to solve \nproblems in unique ways.  Most of this investmen t has been in technology, and that's probably about all I would \nsay. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Elizabeth Anderson with Evercore ISI. ", "original_text": "Most of this investmen t has been in technology, and that's probably about all I would \nsay. \n ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "637c506ef5ad988e1e3a38aecd8a77d93b941644335bda322423910ad22cd3eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20a08aaf-48b1-4728-993e-8c4c2452f006", "node_type": "1", "metadata": {"window": "And when we see an opportunity ahead of us, we are \nnot afraid to increase that investment to run at that because we think these differentiated assets allow us to solve \nproblems in unique ways.  Most of this investmen t has been in technology, and that's probably about all I would \nsay. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys. ", "original_text": "A \nNext question, please.  \n "}, "hash": "2bd7316fbd2075ca05d59933201a73300fc4a3142199cdf3a1cec6b4f029ee9e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "start_char_idx": 1073, "end_char_idx": 1418, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20a08aaf-48b1-4728-993e-8c4c2452f006": {"__data__": {"id_": "20a08aaf-48b1-4728-993e-8c4c2452f006", "embedding": null, "metadata": {"window": "And when we see an opportunity ahead of us, we are \nnot afraid to increase that investment to run at that because we think these differentiated assets allow us to solve \nproblems in unique ways.  Most of this investmen t has been in technology, and that's probably about all I would \nsay. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys. ", "original_text": "A \nNext question, please.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d649effd72c4876779238658a2dc6b4313355ea2addc149abc8e442ec679c54f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4008944-10ef-48ed-8a8d-0ffbd527ed7e", "node_type": "1", "metadata": {"window": "So we have histor ically always invested in this business.  And when we see an opportunity ahead of us, we are \nnot afraid to increase that investment to run at that because we think these differentiated assets allow us to solve \nproblems in unique ways.  Most of this investmen t has been in technology, and that's probably about all I would \nsay. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "2292d344f0ab8414380537f86ac9e92cb875249d6304cea771d8496db44d80e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bee94bd7-c020-4380-aede-6cc895169753", "node_type": "1", "metadata": {"window": "Most of this investmen t has been in technology, and that's probably about all I would \nsay. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question and congrats on a nice guide. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Elizabeth Anderson with Evercore ISI. "}, "hash": "79998134ebeaff9ce7c505689e4ac60a25f4cb35bd0862dfb51d21dba2c8e529", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please.  \n ", "start_char_idx": 1418, "end_char_idx": 1447, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bee94bd7-c020-4380-aede-6cc895169753": {"__data__": {"id_": "bee94bd7-c020-4380-aede-6cc895169753", "embedding": null, "metadata": {"window": "Most of this investmen t has been in technology, and that's probably about all I would \nsay. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question and congrats on a nice guide. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Elizabeth Anderson with Evercore ISI. ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d649effd72c4876779238658a2dc6b4313355ea2addc149abc8e442ec679c54f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20a08aaf-48b1-4728-993e-8c4c2452f006", "node_type": "1", "metadata": {"window": "And when we see an opportunity ahead of us, we are \nnot afraid to increase that investment to run at that because we think these differentiated assets allow us to solve \nproblems in unique ways.  Most of this investmen t has been in technology, and that's probably about all I would \nsay. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys. ", "original_text": "A \nNext question, please.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "03ad7ad41195304dc43b12cc9eb25b8bbce4d6c22f5a61d4db958ace9b6c9c8d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "727dce1b-ca5d-40cc-a293-847d683a992c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question and congrats on a nice guide.  I was intrigued by your comments about \nthe MedSurg segment and sort of how you're thinking about data and the use of assets with the new acq uisition \nyou just made. ", "original_text": "Please go ahead.  \n "}, "hash": "aa0802916a152188aaffec1292d020ffbc1d78fe3a05004f22272f70cd3d3c4d", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Elizabeth Anderson with Evercore ISI. ", "start_char_idx": 1447, "end_char_idx": 1787, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "727dce1b-ca5d-40cc-a293-847d683a992c": {"__data__": {"id_": "727dce1b-ca5d-40cc-a293-847d683a992c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question and congrats on a nice guide.  I was intrigued by your comments about \nthe MedSurg segment and sort of how you're thinking about data and the use of assets with the new acq uisition \nyou just made. ", "original_text": "Please go ahead.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d649effd72c4876779238658a2dc6b4313355ea2addc149abc8e442ec679c54f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bee94bd7-c020-4380-aede-6cc895169753", "node_type": "1", "metadata": {"window": "Most of this investmen t has been in technology, and that's probably about all I would \nsay. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question and congrats on a nice guide. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Elizabeth Anderson with Evercore ISI. ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "9ec23db8b77719457601d06907f86d7a72030deda172c58edba9e268d100b00a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a47b62f5-6248-4e0d-a7ec-11064462b3a1", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question and congrats on a nice guide.  I was intrigued by your comments about \nthe MedSurg segment and sort of how you're thinking about data and the use of assets with the new acq uisition \nyou just made.  It seems like a little bit of a shift into more sort of additional value -added services in that segment. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys. "}, "hash": "063e19566ab0938d55aefc4ffb72a7fb03ffee6d08e8b25392dd5277914e36a9", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 1787, "end_char_idx": 1807, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a47b62f5-6248-4e0d-a7ec-11064462b3a1": {"__data__": {"id_": "a47b62f5-6248-4e0d-a7ec-11064462b3a1", "embedding": null, "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question and congrats on a nice guide.  I was intrigued by your comments about \nthe MedSurg segment and sort of how you're thinking about data and the use of assets with the new acq uisition \nyou just made.  It seems like a little bit of a shift into more sort of additional value -added services in that segment. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys. ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d649effd72c4876779238658a2dc6b4313355ea2addc149abc8e442ec679c54f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "727dce1b-ca5d-40cc-a293-847d683a992c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question and congrats on a nice guide.  I was intrigued by your comments about \nthe MedSurg segment and sort of how you're thinking about data and the use of assets with the new acq uisition \nyou just made. ", "original_text": "Please go ahead.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "79db8bb2065057f21336f0df713d1093372b30c3154c885c20552c18e46ce4ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "865dfbb0-93ec-44e6-8b15-4fdd3e720e4d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question and congrats on a nice guide.  I was intrigued by your comments about \nthe MedSurg segment and sort of how you're thinking about data and the use of assets with the new acq uisition \nyou just made.  It seems like a little bit of a shift into more sort of additional value -added services in that segment. \n Could you give a little bit more color on that and sort of how you see that evolving over the next couple of years?  \n ", "original_text": "Thanks so much for the question and congrats on a nice guide. "}, "hash": "1c18ef91e983ce3af07c74d8de43270525dc0bc55fe44b870de10c35734144b8", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys. ", "start_char_idx": 1807, "end_char_idx": 2136, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "865dfbb0-93ec-44e6-8b15-4fdd3e720e4d": {"__data__": {"id_": "865dfbb0-93ec-44e6-8b15-4fdd3e720e4d", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question and congrats on a nice guide.  I was intrigued by your comments about \nthe MedSurg segment and sort of how you're thinking about data and the use of assets with the new acq uisition \nyou just made.  It seems like a little bit of a shift into more sort of additional value -added services in that segment. \n Could you give a little bit more color on that and sort of how you see that evolving over the next couple of years?  \n ", "original_text": "Thanks so much for the question and congrats on a nice guide. ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d649effd72c4876779238658a2dc6b4313355ea2addc149abc8e442ec679c54f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a47b62f5-6248-4e0d-a7ec-11064462b3a1", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question and congrats on a nice guide.  I was intrigued by your comments about \nthe MedSurg segment and sort of how you're thinking about data and the use of assets with the new acq uisition \nyou just made.  It seems like a little bit of a shift into more sort of additional value -added services in that segment. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys. ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5cba586e4d3ec510d38641b31bb136710bd633302d91465eb2af2ce49600f124", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c22d2d2-db5c-4c3d-9abf-18cb7f125201", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question and congrats on a nice guide.  I was intrigued by your comments about \nthe MedSurg segment and sort of how you're thinking about data and the use of assets with the new acq uisition \nyou just made.  It seems like a little bit of a shift into more sort of additional value -added services in that segment. \n Could you give a little bit more color on that and sort of how you see that evolving over the next couple of years?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I was intrigued by your comments about \nthe MedSurg segment and sort of how you're thinking about data and the use of assets with the new acq uisition \nyou just made. "}, "hash": "eef82ef3ef69c021f8bce886f0f29eb4d33fbfc2b19c0b4d6c30efde919a6052", "class_name": "RelatedNodeInfo"}}, "text": "Thanks so much for the question and congrats on a nice guide. ", "start_char_idx": 2136, "end_char_idx": 2198, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c22d2d2-db5c-4c3d-9abf-18cb7f125201": {"__data__": {"id_": "8c22d2d2-db5c-4c3d-9abf-18cb7f125201", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question and congrats on a nice guide.  I was intrigued by your comments about \nthe MedSurg segment and sort of how you're thinking about data and the use of assets with the new acq uisition \nyou just made.  It seems like a little bit of a shift into more sort of additional value -added services in that segment. \n Could you give a little bit more color on that and sort of how you see that evolving over the next couple of years?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I was intrigued by your comments about \nthe MedSurg segment and sort of how you're thinking about data and the use of assets with the new acq uisition \nyou just made. ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d649effd72c4876779238658a2dc6b4313355ea2addc149abc8e442ec679c54f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "865dfbb0-93ec-44e6-8b15-4fdd3e720e4d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : The next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question and congrats on a nice guide.  I was intrigued by your comments about \nthe MedSurg segment and sort of how you're thinking about data and the use of assets with the new acq uisition \nyou just made.  It seems like a little bit of a shift into more sort of additional value -added services in that segment. \n Could you give a little bit more color on that and sort of how you see that evolving over the next couple of years?  \n ", "original_text": "Thanks so much for the question and congrats on a nice guide. ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "887b36cb392d883198f836d0dc19cd684e3f7c54d0666f42161b16c58d5aa7b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27c2cedc-eda7-4627-a3cb-c476a748eee1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question and congrats on a nice guide.  I was intrigued by your comments about \nthe MedSurg segment and sort of how you're thinking about data and the use of assets with the new acq uisition \nyou just made.  It seems like a little bit of a shift into more sort of additional value -added services in that segment. \n Could you give a little bit more color on that and sort of how you see that evolving over the next couple of years?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure. ", "original_text": "It seems like a little bit of a shift into more sort of additional value -added services in that segment. \n"}, "hash": "6c4efb5583bdebed7f143028431617a9e445416572a18ef6c1017cfb3aff5392", "class_name": "RelatedNodeInfo"}}, "text": "I was intrigued by your comments about \nthe MedSurg segment and sort of how you're thinking about data and the use of assets with the new acq uisition \nyou just made. ", "start_char_idx": 2198, "end_char_idx": 2365, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27c2cedc-eda7-4627-a3cb-c476a748eee1": {"__data__": {"id_": "27c2cedc-eda7-4627-a3cb-c476a748eee1", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question and congrats on a nice guide.  I was intrigued by your comments about \nthe MedSurg segment and sort of how you're thinking about data and the use of assets with the new acq uisition \nyou just made.  It seems like a little bit of a shift into more sort of additional value -added services in that segment. \n Could you give a little bit more color on that and sort of how you see that evolving over the next couple of years?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure. ", "original_text": "It seems like a little bit of a shift into more sort of additional value -added services in that segment. \n", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d649effd72c4876779238658a2dc6b4313355ea2addc149abc8e442ec679c54f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c22d2d2-db5c-4c3d-9abf-18cb7f125201", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question and congrats on a nice guide.  I was intrigued by your comments about \nthe MedSurg segment and sort of how you're thinking about data and the use of assets with the new acq uisition \nyou just made.  It seems like a little bit of a shift into more sort of additional value -added services in that segment. \n Could you give a little bit more color on that and sort of how you see that evolving over the next couple of years?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I was intrigued by your comments about \nthe MedSurg segment and sort of how you're thinking about data and the use of assets with the new acq uisition \nyou just made. ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "b309146f4fa5884e7076cc5819895a45acbccfc6542549900bac8de121a34b24", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e30f53f4-6bef-4128-84b0-6296b3132047", "node_type": "1", "metadata": {"window": "Thanks so much for the question and congrats on a nice guide.  I was intrigued by your comments about \nthe MedSurg segment and sort of how you're thinking about data and the use of assets with the new acq uisition \nyou just made.  It seems like a little bit of a shift into more sort of additional value -added services in that segment. \n Could you give a little bit more color on that and sort of how you see that evolving over the next couple of years?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  I mean in many ways, we thought of Compile as a foundational data investment for us. ", "original_text": "Could you give a little bit more color on that and sort of how you see that evolving over the next couple of years?  \n "}, "hash": "4ab58ee9a581224af7b97c28963f7a1c171bc4571f44de7bd5c02cdb0db6d5f8", "class_name": "RelatedNodeInfo"}}, "text": "It seems like a little bit of a shift into more sort of additional value -added services in that segment. \n", "start_char_idx": 2365, "end_char_idx": 2472, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e30f53f4-6bef-4128-84b0-6296b3132047": {"__data__": {"id_": "e30f53f4-6bef-4128-84b0-6296b3132047", "embedding": null, "metadata": {"window": "Thanks so much for the question and congrats on a nice guide.  I was intrigued by your comments about \nthe MedSurg segment and sort of how you're thinking about data and the use of assets with the new acq uisition \nyou just made.  It seems like a little bit of a shift into more sort of additional value -added services in that segment. \n Could you give a little bit more color on that and sort of how you see that evolving over the next couple of years?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  I mean in many ways, we thought of Compile as a foundational data investment for us. ", "original_text": "Could you give a little bit more color on that and sort of how you see that evolving over the next couple of years?  \n ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d649effd72c4876779238658a2dc6b4313355ea2addc149abc8e442ec679c54f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27c2cedc-eda7-4627-a3cb-c476a748eee1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question and congrats on a nice guide.  I was intrigued by your comments about \nthe MedSurg segment and sort of how you're thinking about data and the use of assets with the new acq uisition \nyou just made.  It seems like a little bit of a shift into more sort of additional value -added services in that segment. \n Could you give a little bit more color on that and sort of how you see that evolving over the next couple of years?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure. ", "original_text": "It seems like a little bit of a shift into more sort of additional value -added services in that segment. \n", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "cfbe24d8f0b175efa329a226890ccb1a9a9a241af93cc627e2568d01f2807dd8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66f7e7c1-54a4-4bf7-9a76-ecc26ba9ee63", "node_type": "1", "metadata": {"window": "I was intrigued by your comments about \nthe MedSurg segment and sort of how you're thinking about data and the use of assets with the new acq uisition \nyou just made.  It seems like a little bit of a shift into more sort of additional value -added services in that segment. \n Could you give a little bit more color on that and sort of how you see that evolving over the next couple of years?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  I mean in many ways, we thought of Compile as a foundational data investment for us.  And we like the \nbusiness by itself, but we also thought, given some of the other data sets, transaction sets that reside in the \ncompany, we could augment and add and accelerate that.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "06d20af40a8ef9a2242e53a48d27d6833261b3ceb597fa45366c9897707195bd", "class_name": "RelatedNodeInfo"}}, "text": "Could you give a little bit more color on that and sort of how you see that evolving over the next couple of years?  \n ", "start_char_idx": 2472, "end_char_idx": 2591, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66f7e7c1-54a4-4bf7-9a76-ecc26ba9ee63": {"__data__": {"id_": "66f7e7c1-54a4-4bf7-9a76-ecc26ba9ee63", "embedding": null, "metadata": {"window": "I was intrigued by your comments about \nthe MedSurg segment and sort of how you're thinking about data and the use of assets with the new acq uisition \nyou just made.  It seems like a little bit of a shift into more sort of additional value -added services in that segment. \n Could you give a little bit more color on that and sort of how you see that evolving over the next couple of years?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  I mean in many ways, we thought of Compile as a foundational data investment for us.  And we like the \nbusiness by itself, but we also thought, given some of the other data sets, transaction sets that reside in the \ncompany, we could augment and add and accelerate that.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d649effd72c4876779238658a2dc6b4313355ea2addc149abc8e442ec679c54f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e30f53f4-6bef-4128-84b0-6296b3132047", "node_type": "1", "metadata": {"window": "Thanks so much for the question and congrats on a nice guide.  I was intrigued by your comments about \nthe MedSurg segment and sort of how you're thinking about data and the use of assets with the new acq uisition \nyou just made.  It seems like a little bit of a shift into more sort of additional value -added services in that segment. \n Could you give a little bit more color on that and sort of how you see that evolving over the next couple of years?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  I mean in many ways, we thought of Compile as a foundational data investment for us. ", "original_text": "Could you give a little bit more color on that and sort of how you see that evolving over the next couple of years?  \n ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "4568874ba6484b4cb5f30809cc834cad1f7f831887926255c3fe00ac6120eb23", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2020b708-72f9-471a-845d-7df7dceed5c3", "node_type": "1", "metadata": {"window": "It seems like a little bit of a shift into more sort of additional value -added services in that segment. \n Could you give a little bit more color on that and sort of how you see that evolving over the next couple of years?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  I mean in many ways, we thought of Compile as a foundational data investment for us.  And we like the \nbusiness by itself, but we also thought, given some of the other data sets, transaction sets that reside in the \ncompany, we could augment and add and accelerate that.  \n \n We chose the first use case in the medical business, where we have extensive, hundreds of thousands of \nrelationships with providers and data that complement their a lready strong provider data service offering. ", "original_text": "A \nSure. "}, "hash": "c6d54e86b511767bbee3755b6bf48c2df92706b4f365e81c23c851b323ce1b0a", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 2591, "end_char_idx": 2936, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2020b708-72f9-471a-845d-7df7dceed5c3": {"__data__": {"id_": "2020b708-72f9-471a-845d-7df7dceed5c3", "embedding": null, "metadata": {"window": "It seems like a little bit of a shift into more sort of additional value -added services in that segment. \n Could you give a little bit more color on that and sort of how you see that evolving over the next couple of years?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  I mean in many ways, we thought of Compile as a foundational data investment for us.  And we like the \nbusiness by itself, but we also thought, given some of the other data sets, transaction sets that reside in the \ncompany, we could augment and add and accelerate that.  \n \n We chose the first use case in the medical business, where we have extensive, hundreds of thousands of \nrelationships with providers and data that complement their a lready strong provider data service offering. ", "original_text": "A \nSure. ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d649effd72c4876779238658a2dc6b4313355ea2addc149abc8e442ec679c54f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66f7e7c1-54a4-4bf7-9a76-ecc26ba9ee63", "node_type": "1", "metadata": {"window": "I was intrigued by your comments about \nthe MedSurg segment and sort of how you're thinking about data and the use of assets with the new acq uisition \nyou just made.  It seems like a little bit of a shift into more sort of additional value -added services in that segment. \n Could you give a little bit more color on that and sort of how you see that evolving over the next couple of years?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  I mean in many ways, we thought of Compile as a foundational data investment for us.  And we like the \nbusiness by itself, but we also thought, given some of the other data sets, transaction sets that reside in the \ncompany, we could augment and add and accelerate that.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "45202dd7e2ddee29ceb72b26b51629b55b2905e33da025e32bad1f5f4806081f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "667431cf-fcde-471f-9b77-009b1d3479f4", "node_type": "1", "metadata": {"window": "Could you give a little bit more color on that and sort of how you see that evolving over the next couple of years?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  I mean in many ways, we thought of Compile as a foundational data investment for us.  And we like the \nbusiness by itself, but we also thought, given some of the other data sets, transaction sets that reside in the \ncompany, we could augment and add and accelerate that.  \n \n We chose the first use case in the medical business, where we have extensive, hundreds of thousands of \nrelationships with providers and data that complement their a lready strong provider data service offering.  So we \nthink we can both augment that and unlock unique value because of the footprint and reach in MedSurg. ", "original_text": "I mean in many ways, we thought of Compile as a foundational data investment for us. "}, "hash": "321de9b06bc285ae102ddf338de01c5ce3507e83e4b3233a69735635b72ca7aa", "class_name": "RelatedNodeInfo"}}, "text": "A \nSure. ", "start_char_idx": 2936, "end_char_idx": 2945, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "667431cf-fcde-471f-9b77-009b1d3479f4": {"__data__": {"id_": "667431cf-fcde-471f-9b77-009b1d3479f4", "embedding": null, "metadata": {"window": "Could you give a little bit more color on that and sort of how you see that evolving over the next couple of years?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  I mean in many ways, we thought of Compile as a foundational data investment for us.  And we like the \nbusiness by itself, but we also thought, given some of the other data sets, transaction sets that reside in the \ncompany, we could augment and add and accelerate that.  \n \n We chose the first use case in the medical business, where we have extensive, hundreds of thousands of \nrelationships with providers and data that complement their a lready strong provider data service offering.  So we \nthink we can both augment that and unlock unique value because of the footprint and reach in MedSurg. ", "original_text": "I mean in many ways, we thought of Compile as a foundational data investment for us. ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d649effd72c4876779238658a2dc6b4313355ea2addc149abc8e442ec679c54f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2020b708-72f9-471a-845d-7df7dceed5c3", "node_type": "1", "metadata": {"window": "It seems like a little bit of a shift into more sort of additional value -added services in that segment. \n Could you give a little bit more color on that and sort of how you see that evolving over the next couple of years?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  I mean in many ways, we thought of Compile as a foundational data investment for us.  And we like the \nbusiness by itself, but we also thought, given some of the other data sets, transaction sets that reside in the \ncompany, we could augment and add and accelerate that.  \n \n We chose the first use case in the medical business, where we have extensive, hundreds of thousands of \nrelationships with providers and data that complement their a lready strong provider data service offering. ", "original_text": "A \nSure. ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "2659d0c67c72b9b23c83db5a3a7e0f63fc2bd4ec5476f0027ac3fb2ed1e36446", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0010a6d9-b9de-4042-9f4a-dbc03f36ff9c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  I mean in many ways, we thought of Compile as a foundational data investment for us.  And we like the \nbusiness by itself, but we also thought, given some of the other data sets, transaction sets that reside in the \ncompany, we could augment and add and accelerate that.  \n \n We chose the first use case in the medical business, where we have extensive, hundreds of thousands of \nrelationships with providers and data that complement their a lready strong provider data service offering.  So we \nthink we can both augment that and unlock unique value because of the footprint and reach in MedSurg.  And so \nwe're making an investment into that thesis.  \n ", "original_text": "And we like the \nbusiness by itself, but we also thought, given some of the other data sets, transaction sets that reside in the \ncompany, we could augment and add and accelerate that.  \n \n"}, "hash": "3129ec9615d1bd641f5113571b4d6cf4d4db76c309a175cc84a8f0a213c99535", "class_name": "RelatedNodeInfo"}}, "text": "I mean in many ways, we thought of Compile as a foundational data investment for us. ", "start_char_idx": 2945, "end_char_idx": 3030, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0010a6d9-b9de-4042-9f4a-dbc03f36ff9c": {"__data__": {"id_": "0010a6d9-b9de-4042-9f4a-dbc03f36ff9c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  I mean in many ways, we thought of Compile as a foundational data investment for us.  And we like the \nbusiness by itself, but we also thought, given some of the other data sets, transaction sets that reside in the \ncompany, we could augment and add and accelerate that.  \n \n We chose the first use case in the medical business, where we have extensive, hundreds of thousands of \nrelationships with providers and data that complement their a lready strong provider data service offering.  So we \nthink we can both augment that and unlock unique value because of the footprint and reach in MedSurg.  And so \nwe're making an investment into that thesis.  \n ", "original_text": "And we like the \nbusiness by itself, but we also thought, given some of the other data sets, transaction sets that reside in the \ncompany, we could augment and add and accelerate that.  \n \n", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d649effd72c4876779238658a2dc6b4313355ea2addc149abc8e442ec679c54f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "667431cf-fcde-471f-9b77-009b1d3479f4", "node_type": "1", "metadata": {"window": "Could you give a little bit more color on that and sort of how you see that evolving over the next couple of years?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  I mean in many ways, we thought of Compile as a foundational data investment for us.  And we like the \nbusiness by itself, but we also thought, given some of the other data sets, transaction sets that reside in the \ncompany, we could augment and add and accelerate that.  \n \n We chose the first use case in the medical business, where we have extensive, hundreds of thousands of \nrelationships with providers and data that complement their a lready strong provider data service offering.  So we \nthink we can both augment that and unlock unique value because of the footprint and reach in MedSurg. ", "original_text": "I mean in many ways, we thought of Compile as a foundational data investment for us. ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "1eb0e9d1c5f5d1b32ba0f2263abe909e1e85c1fd79f3468d99fbf8b09a73683e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "828b9072-4682-49cf-b9f5-de40661705e2", "node_type": "1", "metadata": {"window": "A \nSure.  I mean in many ways, we thought of Compile as a foundational data investment for us.  And we like the \nbusiness by itself, but we also thought, given some of the other data sets, transaction sets that reside in the \ncompany, we could augment and add and accelerate that.  \n \n We chose the first use case in the medical business, where we have extensive, hundreds of thousands of \nrelationships with providers and data that complement their a lready strong provider data service offering.  So we \nthink we can both augment that and unlock unique value because of the footprint and reach in MedSurg.  And so \nwe're making an investment into that thesis.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Rela tions, McKesson Corp.  ", "original_text": "We chose the first use case in the medical business, where we have extensive, hundreds of thousands of \nrelationships with providers and data that complement their a lready strong provider data service offering. "}, "hash": "86fb6665290cc51a207b6856fbca1252869bb335c3efcd8cfe27e6b991f91ff5", "class_name": "RelatedNodeInfo"}}, "text": "And we like the \nbusiness by itself, but we also thought, given some of the other data sets, transaction sets that reside in the \ncompany, we could augment and add and accelerate that.  \n \n", "start_char_idx": 3030, "end_char_idx": 3219, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "828b9072-4682-49cf-b9f5-de40661705e2": {"__data__": {"id_": "828b9072-4682-49cf-b9f5-de40661705e2", "embedding": null, "metadata": {"window": "A \nSure.  I mean in many ways, we thought of Compile as a foundational data investment for us.  And we like the \nbusiness by itself, but we also thought, given some of the other data sets, transaction sets that reside in the \ncompany, we could augment and add and accelerate that.  \n \n We chose the first use case in the medical business, where we have extensive, hundreds of thousands of \nrelationships with providers and data that complement their a lready strong provider data service offering.  So we \nthink we can both augment that and unlock unique value because of the footprint and reach in MedSurg.  And so \nwe're making an investment into that thesis.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Rela tions, McKesson Corp.  ", "original_text": "We chose the first use case in the medical business, where we have extensive, hundreds of thousands of \nrelationships with providers and data that complement their a lready strong provider data service offering. ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d649effd72c4876779238658a2dc6b4313355ea2addc149abc8e442ec679c54f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0010a6d9-b9de-4042-9f4a-dbc03f36ff9c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  I mean in many ways, we thought of Compile as a foundational data investment for us.  And we like the \nbusiness by itself, but we also thought, given some of the other data sets, transaction sets that reside in the \ncompany, we could augment and add and accelerate that.  \n \n We chose the first use case in the medical business, where we have extensive, hundreds of thousands of \nrelationships with providers and data that complement their a lready strong provider data service offering.  So we \nthink we can both augment that and unlock unique value because of the footprint and reach in MedSurg.  And so \nwe're making an investment into that thesis.  \n ", "original_text": "And we like the \nbusiness by itself, but we also thought, given some of the other data sets, transaction sets that reside in the \ncompany, we could augment and add and accelerate that.  \n \n", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d1feb8900d3cf0fcf7ffe67c559dff04a4c510332921bd043276fc00e7fb76c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c51a94da-67cb-4999-a40b-50e769dcebe8", "node_type": "1", "metadata": {"window": "I mean in many ways, we thought of Compile as a foundational data investment for us.  And we like the \nbusiness by itself, but we also thought, given some of the other data sets, transaction sets that reside in the \ncompany, we could augment and add and accelerate that.  \n \n We chose the first use case in the medical business, where we have extensive, hundreds of thousands of \nrelationships with providers and data that complement their a lready strong provider data service offering.  So we \nthink we can both augment that and unlock unique value because of the footprint and reach in MedSurg.  And so \nwe're making an investment into that thesis.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Rela tions, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "So we \nthink we can both augment that and unlock unique value because of the footprint and reach in MedSurg. "}, "hash": "060d053fc5d4f3fce0c098e9365c3ab1f3c3a0eb16b33ab959877c460d1d4b4b", "class_name": "RelatedNodeInfo"}}, "text": "We chose the first use case in the medical business, where we have extensive, hundreds of thousands of \nrelationships with providers and data that complement their a lready strong provider data service offering. ", "start_char_idx": 3219, "end_char_idx": 3431, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c51a94da-67cb-4999-a40b-50e769dcebe8": {"__data__": {"id_": "c51a94da-67cb-4999-a40b-50e769dcebe8", "embedding": null, "metadata": {"window": "I mean in many ways, we thought of Compile as a foundational data investment for us.  And we like the \nbusiness by itself, but we also thought, given some of the other data sets, transaction sets that reside in the \ncompany, we could augment and add and accelerate that.  \n \n We chose the first use case in the medical business, where we have extensive, hundreds of thousands of \nrelationships with providers and data that complement their a lready strong provider data service offering.  So we \nthink we can both augment that and unlock unique value because of the footprint and reach in MedSurg.  And so \nwe're making an investment into that thesis.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Rela tions, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "So we \nthink we can both augment that and unlock unique value because of the footprint and reach in MedSurg. ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d649effd72c4876779238658a2dc6b4313355ea2addc149abc8e442ec679c54f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "828b9072-4682-49cf-b9f5-de40661705e2", "node_type": "1", "metadata": {"window": "A \nSure.  I mean in many ways, we thought of Compile as a foundational data investment for us.  And we like the \nbusiness by itself, but we also thought, given some of the other data sets, transaction sets that reside in the \ncompany, we could augment and add and accelerate that.  \n \n We chose the first use case in the medical business, where we have extensive, hundreds of thousands of \nrelationships with providers and data that complement their a lready strong provider data service offering.  So we \nthink we can both augment that and unlock unique value because of the footprint and reach in MedSurg.  And so \nwe're making an investment into that thesis.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Rela tions, McKesson Corp.  ", "original_text": "We chose the first use case in the medical business, where we have extensive, hundreds of thousands of \nrelationships with providers and data that complement their a lready strong provider data service offering. ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5fadc04f193b3e0cd6c530a5662313cd9ef39ec73552e8d38c8405dcd28b59e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4212dde1-58ad-4a3b-8ba6-956dba97efab", "node_type": "1", "metadata": {"window": "And we like the \nbusiness by itself, but we also thought, given some of the other data sets, transaction sets that reside in the \ncompany, we could augment and add and accelerate that.  \n \n We chose the first use case in the medical business, where we have extensive, hundreds of thousands of \nrelationships with providers and data that complement their a lready strong provider data service offering.  So we \nthink we can both augment that and unlock unique value because of the footprint and reach in MedSurg.  And so \nwe're making an investment into that thesis.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Rela tions, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi. ", "original_text": "And so \nwe're making an investment into that thesis.  \n "}, "hash": "8c1fb72a3ba5bb28603af0aac42885e816ee514f49e00490e4f88b7009eabb2e", "class_name": "RelatedNodeInfo"}}, "text": "So we \nthink we can both augment that and unlock unique value because of the footprint and reach in MedSurg. ", "start_char_idx": 3431, "end_char_idx": 3540, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4212dde1-58ad-4a3b-8ba6-956dba97efab": {"__data__": {"id_": "4212dde1-58ad-4a3b-8ba6-956dba97efab", "embedding": null, "metadata": {"window": "And we like the \nbusiness by itself, but we also thought, given some of the other data sets, transaction sets that reside in the \ncompany, we could augment and add and accelerate that.  \n \n We chose the first use case in the medical business, where we have extensive, hundreds of thousands of \nrelationships with providers and data that complement their a lready strong provider data service offering.  So we \nthink we can both augment that and unlock unique value because of the footprint and reach in MedSurg.  And so \nwe're making an investment into that thesis.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Rela tions, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi. ", "original_text": "And so \nwe're making an investment into that thesis.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d649effd72c4876779238658a2dc6b4313355ea2addc149abc8e442ec679c54f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c51a94da-67cb-4999-a40b-50e769dcebe8", "node_type": "1", "metadata": {"window": "I mean in many ways, we thought of Compile as a foundational data investment for us.  And we like the \nbusiness by itself, but we also thought, given some of the other data sets, transaction sets that reside in the \ncompany, we could augment and add and accelerate that.  \n \n We chose the first use case in the medical business, where we have extensive, hundreds of thousands of \nrelationships with providers and data that complement their a lready strong provider data service offering.  So we \nthink we can both augment that and unlock unique value because of the footprint and reach in MedSurg.  And so \nwe're making an investment into that thesis.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Rela tions, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "So we \nthink we can both augment that and unlock unique value because of the footprint and reach in MedSurg. ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a12f3df1bbe4a9b2e15d529be3db01fc442c66e7c98a8a96de1cf3e43d827136", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14248ca7-04b2-46cb-bf0e-b7a2de5918dd", "node_type": "1", "metadata": {"window": "We chose the first use case in the medical business, where we have extensive, hundreds of thousands of \nrelationships with providers and data that complement their a lready strong provider data service offering.  So we \nthink we can both augment that and unlock unique value because of the footprint and reach in MedSurg.  And so \nwe're making an investment into that thesis.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Rela tions, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Rela tions, McKesson Corp.  "}, "hash": "bf91a482d227acad24a9f15ec09e945bf0fe20ccbb008886686473146bbadadc", "class_name": "RelatedNodeInfo"}}, "text": "And so \nwe're making an investment into that thesis.  \n ", "start_char_idx": 3540, "end_char_idx": 3596, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14248ca7-04b2-46cb-bf0e-b7a2de5918dd": {"__data__": {"id_": "14248ca7-04b2-46cb-bf0e-b7a2de5918dd", "embedding": null, "metadata": {"window": "We chose the first use case in the medical business, where we have extensive, hundreds of thousands of \nrelationships with providers and data that complement their a lready strong provider data service offering.  So we \nthink we can both augment that and unlock unique value because of the footprint and reach in MedSurg.  And so \nwe're making an investment into that thesis.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Rela tions, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Rela tions, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d649effd72c4876779238658a2dc6b4313355ea2addc149abc8e442ec679c54f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4212dde1-58ad-4a3b-8ba6-956dba97efab", "node_type": "1", "metadata": {"window": "And we like the \nbusiness by itself, but we also thought, given some of the other data sets, transaction sets that reside in the \ncompany, we could augment and add and accelerate that.  \n \n We chose the first use case in the medical business, where we have extensive, hundreds of thousands of \nrelationships with providers and data that complement their a lready strong provider data service offering.  So we \nthink we can both augment that and unlock unique value because of the footprint and reach in MedSurg.  And so \nwe're making an investment into that thesis.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Rela tions, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi. ", "original_text": "And so \nwe're making an investment into that thesis.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "95e63b8f6e04dd55417f7f151422694ea157941a579a7304818ed877e3052b71", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a199ca5f-aa55-45cb-bc02-823c56724aab", "node_type": "1", "metadata": {"window": "So we \nthink we can both augment that and unlock unique value because of the footprint and reach in MedSurg.  And so \nwe're making an investment into that thesis.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Rela tions, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  ", "original_text": "A \nNext question, please.  \n "}, "hash": "ac0c34db5b46adacc2ab58e3526961d599d8b546dc39f2cc5216ffb91e266156", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Rela tions, McKesson Corp.  ", "start_char_idx": 3596, "end_char_idx": 3942, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a199ca5f-aa55-45cb-bc02-823c56724aab": {"__data__": {"id_": "a199ca5f-aa55-45cb-bc02-823c56724aab", "embedding": null, "metadata": {"window": "So we \nthink we can both augment that and unlock unique value because of the footprint and reach in MedSurg.  And so \nwe're making an investment into that thesis.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Rela tions, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  ", "original_text": "A \nNext question, please.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d649effd72c4876779238658a2dc6b4313355ea2addc149abc8e442ec679c54f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14248ca7-04b2-46cb-bf0e-b7a2de5918dd", "node_type": "1", "metadata": {"window": "We chose the first use case in the medical business, where we have extensive, hundreds of thousands of \nrelationships with providers and data that complement their a lready strong provider data service offering.  So we \nthink we can both augment that and unlock unique value because of the footprint and reach in MedSurg.  And so \nwe're making an investment into that thesis.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Rela tions, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Rela tions, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "71ea7974a204fcdb88e4c2e23058654a730fe67746dbcccd5d8b81a4e4c17421", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "790d479a-aecf-4342-a23b-481624024b29", "node_type": "1", "metadata": {"window": "And so \nwe're making an investment into that thesis.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Rela tions, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi. "}, "hash": "c69460f85cbdf8d2e986378682b1869bf891cbd3e9b722e1f8be1a51aac56500", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please.  \n ", "start_char_idx": 1418, "end_char_idx": 1447, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "790d479a-aecf-4342-a23b-481624024b29": {"__data__": {"id_": "790d479a-aecf-4342-a23b-481624024b29", "embedding": null, "metadata": {"window": "And so \nwe're making an investment into that thesis.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Rela tions, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi. ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d649effd72c4876779238658a2dc6b4313355ea2addc149abc8e442ec679c54f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a199ca5f-aa55-45cb-bc02-823c56724aab", "node_type": "1", "metadata": {"window": "So we \nthink we can both augment that and unlock unique value because of the footprint and reach in MedSurg.  And so \nwe're making an investment into that thesis.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Rela tions, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  ", "original_text": "A \nNext question, please.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "35cc172d56bd3e48b5b6782d68f1471c673e3c42f01f0327559782e568cc20e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "572cfe70-78cc-4632-80fc-208c6f911530", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Rela tions, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q ", "original_text": "Please go ahead.  \n "}, "hash": "99ffa3a596e61a59ba6eca15d5bb8248c81e1089401fa7a711562edd5320d016", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi. ", "start_char_idx": 3971, "end_char_idx": 4302, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "572cfe70-78cc-4632-80fc-208c6f911530": {"__data__": {"id_": "572cfe70-78cc-4632-80fc-208c6f911530", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Rela tions, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q ", "original_text": "Please go ahead.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d649effd72c4876779238658a2dc6b4313355ea2addc149abc8e442ec679c54f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "790d479a-aecf-4342-a23b-481624024b29", "node_type": "1", "metadata": {"window": "And so \nwe're making an investment into that thesis.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Rela tions, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi. ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f2f5cf7482d79177434a3494c1915aa4e149bde7b3914688a6694b029d63afce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c1c8df6-94bf-4334-ae09-40069f20d656", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  "}, "hash": "b6666cb52dc2b25f3e5bcc486694639582035ec2817e9abeeee3f3fa32e9ffda", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 1787, "end_char_idx": 1807, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c1c8df6-94bf-4334-ae09-40069f20d656": {"__data__": {"id_": "1c1c8df6-94bf-4334-ae09-40069f20d656", "embedding": null, "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d649effd72c4876779238658a2dc6b4313355ea2addc149abc8e442ec679c54f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "572cfe70-78cc-4632-80fc-208c6f911530", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Rela tions, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q ", "original_text": "Please go ahead.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "097136386903284bf974db68440ed86f97ca05148ea305e1ac5162e33e370d79", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad22aaea-306a-4ad4-ab03-4dffdac571ea", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q ", "original_text": "Q "}, "hash": "f7f784aee797d4a1e1081ed6eb427245b1cbc486a7d984786a003287b4cdd904", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  ", "start_char_idx": 4322, "end_char_idx": 4655, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad22aaea-306a-4ad4-ab03-4dffdac571ea": {"__data__": {"id_": "ad22aaea-306a-4ad4-ab03-4dffdac571ea", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q ", "original_text": "Q ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "d649effd72c4876779238658a2dc6b4313355ea2addc149abc8e442ec679c54f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c1c8df6-94bf-4334-ae09-40069f20d656", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5c7d11323cc23cd52f858250461422d8742879d48bfe18e32f26962670601923", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24cfb745-772d-4936-8891-107c83def0ce", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nHey, guys.  Thanks for taking my question.  I want to go back to the question that Charles asked on RxTS. ", "original_text": "McKesson Corp.  "}, "hash": "57dac8788ee3361bdaf86b09ad25c565356dff7d7c89b3762eed6d90e72e0fe8", "class_name": "RelatedNodeInfo"}}, "text": "Q ", "start_char_idx": 2123, "end_char_idx": 2125, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24cfb745-772d-4936-8891-107c83def0ce": {"__data__": {"id_": "24cfb745-772d-4936-8891-107c83def0ce", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nHey, guys.  Thanks for taking my question.  I want to go back to the question that Charles asked on RxTS. ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5fb8371ab6f895d394ff4bcbdaea2e37603103828615feac885bfb2e5bd10f0a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad22aaea-306a-4ad4-ab03-4dffdac571ea", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q ", "original_text": "Q ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "16bbb0783ef78312ecb2d0c7c27b1fefbea214ef3c5afa4b9bcd38bf1d23cb7d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da5c07c8-b49c-4fe9-be3a-877e539d76c8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nHey, guys.  Thanks for taking my question.  I want to go back to the question that Charles asked on RxTS.  But \nreally on the top line, you're seeing a material acceleration in growth next year while, as you mentioned, the \nadjusted operating income is kind of in line with where you've been historically. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nHey, guys. "}, "hash": "d59598776d0d74f90ab03ab8de06e87557d77edac18c5726d662ee2d6e6797f9", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da5c07c8-b49c-4fe9-be3a-877e539d76c8": {"__data__": {"id_": "da5c07c8-b49c-4fe9-be3a-877e539d76c8", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nHey, guys.  Thanks for taking my question.  I want to go back to the question that Charles asked on RxTS.  But \nreally on the top line, you're seeing a material acceleration in growth next year while, as you mentioned, the \nadjusted operating income is kind of in line with where you've been historically. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nHey, guys. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5fb8371ab6f895d394ff4bcbdaea2e37603103828615feac885bfb2e5bd10f0a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24cfb745-772d-4936-8891-107c83def0ce", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nHey, guys.  Thanks for taking my question.  I want to go back to the question that Charles asked on RxTS. ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c32b6f73cfdf1862d88f59fc5b76a85f090253af5ccfcb0492bfc3cc0d4711ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3db19a3c-bb30-462b-bca8-f5559373c375", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nHey, guys.  Thanks for taking my question.  I want to go back to the question that Charles asked on RxTS.  But \nreally on the top line, you're seeing a material acceleration in growth next year while, as you mentioned, the \nadjusted operating income is kind of in line with where you've been historically.  So that does imply a b it of a \ndegradation in margin. ", "original_text": "Thanks for taking my question. "}, "hash": "d63a24c4eacea419e153a5d83ce86e65e34505949969606bea837c5a7abffdf3", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nHey, guys. ", "start_char_idx": 16, "end_char_idx": 192, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3db19a3c-bb30-462b-bca8-f5559373c375": {"__data__": {"id_": "3db19a3c-bb30-462b-bca8-f5559373c375", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nHey, guys.  Thanks for taking my question.  I want to go back to the question that Charles asked on RxTS.  But \nreally on the top line, you're seeing a material acceleration in growth next year while, as you mentioned, the \nadjusted operating income is kind of in line with where you've been historically.  So that does imply a b it of a \ndegradation in margin. ", "original_text": "Thanks for taking my question. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5fb8371ab6f895d394ff4bcbdaea2e37603103828615feac885bfb2e5bd10f0a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da5c07c8-b49c-4fe9-be3a-877e539d76c8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nHey, guys.  Thanks for taking my question.  I want to go back to the question that Charles asked on RxTS.  But \nreally on the top line, you're seeing a material acceleration in growth next year while, as you mentioned, the \nadjusted operating income is kind of in line with where you've been historically. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nHey, guys. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "57934f49e0a37858fcef403c8c22b666043905fe5845e8628a61add9bba33248", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93c6db2b-ce4d-45dd-af32-7323b96540eb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nHey, guys.  Thanks for taking my question.  I want to go back to the question that Charles asked on RxTS.  But \nreally on the top line, you're seeing a material acceleration in growth next year while, as you mentioned, the \nadjusted operating income is kind of in line with where you've been historically.  So that does imply a b it of a \ndegradation in margin.  So I was hoping you could put a finer point on the growth acceleration on the top line and \nmargin compression you're seeing. ", "original_text": "I want to go back to the question that Charles asked on RxTS. "}, "hash": "73a4b5e2b4af28ca1a49ec0e6d666c247b39bb8b62665c1ae33be5e7f2188575", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking my question. ", "start_char_idx": 192, "end_char_idx": 223, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93c6db2b-ce4d-45dd-af32-7323b96540eb": {"__data__": {"id_": "93c6db2b-ce4d-45dd-af32-7323b96540eb", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nHey, guys.  Thanks for taking my question.  I want to go back to the question that Charles asked on RxTS.  But \nreally on the top line, you're seeing a material acceleration in growth next year while, as you mentioned, the \nadjusted operating income is kind of in line with where you've been historically.  So that does imply a b it of a \ndegradation in margin.  So I was hoping you could put a finer point on the growth acceleration on the top line and \nmargin compression you're seeing. ", "original_text": "I want to go back to the question that Charles asked on RxTS. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5fb8371ab6f895d394ff4bcbdaea2e37603103828615feac885bfb2e5bd10f0a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3db19a3c-bb30-462b-bca8-f5559373c375", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nHey, guys.  Thanks for taking my question.  I want to go back to the question that Charles asked on RxTS.  But \nreally on the top line, you're seeing a material acceleration in growth next year while, as you mentioned, the \nadjusted operating income is kind of in line with where you've been historically.  So that does imply a b it of a \ndegradation in margin. ", "original_text": "Thanks for taking my question. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "b095f70b840a1180e641febf5616669f0a85e2789117e63f97217dbf34a77b23", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "522dffa0-d330-4982-9283-aa8a0af7dbeb", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nHey, guys.  Thanks for taking my question.  I want to go back to the question that Charles asked on RxTS.  But \nreally on the top line, you're seeing a material acceleration in growth next year while, as you mentioned, the \nadjusted operating income is kind of in line with where you've been historically.  So that does imply a b it of a \ndegradation in margin.  So I was hoping you could put a finer point on the growth acceleration on the top line and \nmargin compression you're seeing.  Is that mix shift to lower margin businesses? ", "original_text": "But \nreally on the top line, you're seeing a material acceleration in growth next year while, as you mentioned, the \nadjusted operating income is kind of in line with where you've been historically. "}, "hash": "1f6a760f930f8f9a2f007373b94afce85c6e0153a3dd0bc06c0d6d271a0b1479", "class_name": "RelatedNodeInfo"}}, "text": "I want to go back to the question that Charles asked on RxTS. ", "start_char_idx": 223, "end_char_idx": 285, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "522dffa0-d330-4982-9283-aa8a0af7dbeb": {"__data__": {"id_": "522dffa0-d330-4982-9283-aa8a0af7dbeb", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nHey, guys.  Thanks for taking my question.  I want to go back to the question that Charles asked on RxTS.  But \nreally on the top line, you're seeing a material acceleration in growth next year while, as you mentioned, the \nadjusted operating income is kind of in line with where you've been historically.  So that does imply a b it of a \ndegradation in margin.  So I was hoping you could put a finer point on the growth acceleration on the top line and \nmargin compression you're seeing.  Is that mix shift to lower margin businesses? ", "original_text": "But \nreally on the top line, you're seeing a material acceleration in growth next year while, as you mentioned, the \nadjusted operating income is kind of in line with where you've been historically. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5fb8371ab6f895d394ff4bcbdaea2e37603103828615feac885bfb2e5bd10f0a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93c6db2b-ce4d-45dd-af32-7323b96540eb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nHey, guys.  Thanks for taking my question.  I want to go back to the question that Charles asked on RxTS.  But \nreally on the top line, you're seeing a material acceleration in growth next year while, as you mentioned, the \nadjusted operating income is kind of in line with where you've been historically.  So that does imply a b it of a \ndegradation in margin.  So I was hoping you could put a finer point on the growth acceleration on the top line and \nmargin compression you're seeing. ", "original_text": "I want to go back to the question that Charles asked on RxTS. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e67057666bc58f1837cab6fc756725de8f05a6e83ea55e919dd3a79ba13936d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59864f47-4310-4c90-a9fe-ecb8b64737d5", "node_type": "1", "metadata": {"window": "Thanks for taking my question.  I want to go back to the question that Charles asked on RxTS.  But \nreally on the top line, you're seeing a material acceleration in growth next year while, as you mentioned, the \nadjusted operating income is kind of in line with where you've been historically.  So that does imply a b it of a \ndegradation in margin.  So I was hoping you could put a finer point on the growth acceleration on the top line and \nmargin compression you're seeing.  Is that mix shift to lower margin businesses?  Is that the increased investments \nyou're making? ", "original_text": "So that does imply a b it of a \ndegradation in margin. "}, "hash": "8f6952a3f79625e41fb9a6ab779e0c7d92de705a04333c8fe19007dd741bf9b0", "class_name": "RelatedNodeInfo"}}, "text": "But \nreally on the top line, you're seeing a material acceleration in growth next year while, as you mentioned, the \nadjusted operating income is kind of in line with where you've been historically. ", "start_char_idx": 285, "end_char_idx": 484, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59864f47-4310-4c90-a9fe-ecb8b64737d5": {"__data__": {"id_": "59864f47-4310-4c90-a9fe-ecb8b64737d5", "embedding": null, "metadata": {"window": "Thanks for taking my question.  I want to go back to the question that Charles asked on RxTS.  But \nreally on the top line, you're seeing a material acceleration in growth next year while, as you mentioned, the \nadjusted operating income is kind of in line with where you've been historically.  So that does imply a b it of a \ndegradation in margin.  So I was hoping you could put a finer point on the growth acceleration on the top line and \nmargin compression you're seeing.  Is that mix shift to lower margin businesses?  Is that the increased investments \nyou're making? ", "original_text": "So that does imply a b it of a \ndegradation in margin. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5fb8371ab6f895d394ff4bcbdaea2e37603103828615feac885bfb2e5bd10f0a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "522dffa0-d330-4982-9283-aa8a0af7dbeb", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nHey, guys.  Thanks for taking my question.  I want to go back to the question that Charles asked on RxTS.  But \nreally on the top line, you're seeing a material acceleration in growth next year while, as you mentioned, the \nadjusted operating income is kind of in line with where you've been historically.  So that does imply a b it of a \ndegradation in margin.  So I was hoping you could put a finer point on the growth acceleration on the top line and \nmargin compression you're seeing.  Is that mix shift to lower margin businesses? ", "original_text": "But \nreally on the top line, you're seeing a material acceleration in growth next year while, as you mentioned, the \nadjusted operating income is kind of in line with where you've been historically. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5e999708c9347577c9106634a5348786429443ae3373f2d290cec3eb797c5f88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f30ac62-9943-431d-902b-609e8004a33d", "node_type": "1", "metadata": {"window": "I want to go back to the question that Charles asked on RxTS.  But \nreally on the top line, you're seeing a material acceleration in growth next year while, as you mentioned, the \nadjusted operating income is kind of in line with where you've been historically.  So that does imply a b it of a \ndegradation in margin.  So I was hoping you could put a finer point on the growth acceleration on the top line and \nmargin compression you're seeing.  Is that mix shift to lower margin businesses?  Is that the increased investments \nyou're making?  Any c olor there would be great. ", "original_text": "So I was hoping you could put a finer point on the growth acceleration on the top line and \nmargin compression you're seeing. "}, "hash": "ce3247afc99e6edc1414b7cee60fc6fe6c1c90b180dff338c9435205ac86430a", "class_name": "RelatedNodeInfo"}}, "text": "So that does imply a b it of a \ndegradation in margin. ", "start_char_idx": 484, "end_char_idx": 539, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f30ac62-9943-431d-902b-609e8004a33d": {"__data__": {"id_": "8f30ac62-9943-431d-902b-609e8004a33d", "embedding": null, "metadata": {"window": "I want to go back to the question that Charles asked on RxTS.  But \nreally on the top line, you're seeing a material acceleration in growth next year while, as you mentioned, the \nadjusted operating income is kind of in line with where you've been historically.  So that does imply a b it of a \ndegradation in margin.  So I was hoping you could put a finer point on the growth acceleration on the top line and \nmargin compression you're seeing.  Is that mix shift to lower margin businesses?  Is that the increased investments \nyou're making?  Any c olor there would be great. ", "original_text": "So I was hoping you could put a finer point on the growth acceleration on the top line and \nmargin compression you're seeing. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5fb8371ab6f895d394ff4bcbdaea2e37603103828615feac885bfb2e5bd10f0a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59864f47-4310-4c90-a9fe-ecb8b64737d5", "node_type": "1", "metadata": {"window": "Thanks for taking my question.  I want to go back to the question that Charles asked on RxTS.  But \nreally on the top line, you're seeing a material acceleration in growth next year while, as you mentioned, the \nadjusted operating income is kind of in line with where you've been historically.  So that does imply a b it of a \ndegradation in margin.  So I was hoping you could put a finer point on the growth acceleration on the top line and \nmargin compression you're seeing.  Is that mix shift to lower margin businesses?  Is that the increased investments \nyou're making? ", "original_text": "So that does imply a b it of a \ndegradation in margin. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "6f7bc977514ff9b7322f4582c6ea3e444850c07850ea5dc17cb7d9af224c9188", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9e9cb97-8f1c-4d56-bf26-73d4994ae4ed", "node_type": "1", "metadata": {"window": "But \nreally on the top line, you're seeing a material acceleration in growth next year while, as you mentioned, the \nadjusted operating income is kind of in line with where you've been historically.  So that does imply a b it of a \ndegradation in margin.  So I was hoping you could put a finer point on the growth acceleration on the top line and \nmargin compression you're seeing.  Is that mix shift to lower margin businesses?  Is that the increased investments \nyou're making?  Any c olor there would be great.  Thanks.  \n ", "original_text": "Is that mix shift to lower margin businesses? "}, "hash": "ea269c1d2a9417911ad4b2279cab21c84804d25188d7ca6af403317eb8d81a5e", "class_name": "RelatedNodeInfo"}}, "text": "So I was hoping you could put a finer point on the growth acceleration on the top line and \nmargin compression you're seeing. ", "start_char_idx": 539, "end_char_idx": 665, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9e9cb97-8f1c-4d56-bf26-73d4994ae4ed": {"__data__": {"id_": "a9e9cb97-8f1c-4d56-bf26-73d4994ae4ed", "embedding": null, "metadata": {"window": "But \nreally on the top line, you're seeing a material acceleration in growth next year while, as you mentioned, the \nadjusted operating income is kind of in line with where you've been historically.  So that does imply a b it of a \ndegradation in margin.  So I was hoping you could put a finer point on the growth acceleration on the top line and \nmargin compression you're seeing.  Is that mix shift to lower margin businesses?  Is that the increased investments \nyou're making?  Any c olor there would be great.  Thanks.  \n ", "original_text": "Is that mix shift to lower margin businesses? ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5fb8371ab6f895d394ff4bcbdaea2e37603103828615feac885bfb2e5bd10f0a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f30ac62-9943-431d-902b-609e8004a33d", "node_type": "1", "metadata": {"window": "I want to go back to the question that Charles asked on RxTS.  But \nreally on the top line, you're seeing a material acceleration in growth next year while, as you mentioned, the \nadjusted operating income is kind of in line with where you've been historically.  So that does imply a b it of a \ndegradation in margin.  So I was hoping you could put a finer point on the growth acceleration on the top line and \nmargin compression you're seeing.  Is that mix shift to lower margin businesses?  Is that the increased investments \nyou're making?  Any c olor there would be great. ", "original_text": "So I was hoping you could put a finer point on the growth acceleration on the top line and \nmargin compression you're seeing. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "903172eec38b0315efcc9aafd5cfb93a3b05a6a6c02d2673212e9801b6404bdc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5dc3c628-a538-4152-9e48-4d654878fc99", "node_type": "1", "metadata": {"window": "So that does imply a b it of a \ndegradation in margin.  So I was hoping you could put a finer point on the growth acceleration on the top line and \nmargin compression you're seeing.  Is that mix shift to lower margin businesses?  Is that the increased investments \nyou're making?  Any c olor there would be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Is that the increased investments \nyou're making? "}, "hash": "26757e8bc79c07103b46055c2539235e99bea73848c9ed3b0ea6e980da4b4e8c", "class_name": "RelatedNodeInfo"}}, "text": "Is that mix shift to lower margin businesses? ", "start_char_idx": 665, "end_char_idx": 711, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5dc3c628-a538-4152-9e48-4d654878fc99": {"__data__": {"id_": "5dc3c628-a538-4152-9e48-4d654878fc99", "embedding": null, "metadata": {"window": "So that does imply a b it of a \ndegradation in margin.  So I was hoping you could put a finer point on the growth acceleration on the top line and \nmargin compression you're seeing.  Is that mix shift to lower margin businesses?  Is that the increased investments \nyou're making?  Any c olor there would be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Is that the increased investments \nyou're making? ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5fb8371ab6f895d394ff4bcbdaea2e37603103828615feac885bfb2e5bd10f0a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9e9cb97-8f1c-4d56-bf26-73d4994ae4ed", "node_type": "1", "metadata": {"window": "But \nreally on the top line, you're seeing a material acceleration in growth next year while, as you mentioned, the \nadjusted operating income is kind of in line with where you've been historically.  So that does imply a b it of a \ndegradation in margin.  So I was hoping you could put a finer point on the growth acceleration on the top line and \nmargin compression you're seeing.  Is that mix shift to lower margin businesses?  Is that the increased investments \nyou're making?  Any c olor there would be great.  Thanks.  \n ", "original_text": "Is that mix shift to lower margin businesses? ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "dae489800ff764ddc11ed2e18a5650be96df7ece46ac9949cafea03380e81c7b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5cf0d87-8087-4917-81f3-a9082a39076a", "node_type": "1", "metadata": {"window": "So I was hoping you could put a finer point on the growth acceleration on the top line and \nmargin compression you're seeing.  Is that mix shift to lower margin businesses?  Is that the increased investments \nyou're making?  Any c olor there would be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for that question. ", "original_text": "Any c olor there would be great. "}, "hash": "54e70aaf4eca76e8e2c8abc0c4e9a98ac2da7b529040e6bea21b9c722c069656", "class_name": "RelatedNodeInfo"}}, "text": "Is that the increased investments \nyou're making? ", "start_char_idx": 711, "end_char_idx": 761, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5cf0d87-8087-4917-81f3-a9082a39076a": {"__data__": {"id_": "e5cf0d87-8087-4917-81f3-a9082a39076a", "embedding": null, "metadata": {"window": "So I was hoping you could put a finer point on the growth acceleration on the top line and \nmargin compression you're seeing.  Is that mix shift to lower margin businesses?  Is that the increased investments \nyou're making?  Any c olor there would be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for that question. ", "original_text": "Any c olor there would be great. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5fb8371ab6f895d394ff4bcbdaea2e37603103828615feac885bfb2e5bd10f0a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5dc3c628-a538-4152-9e48-4d654878fc99", "node_type": "1", "metadata": {"window": "So that does imply a b it of a \ndegradation in margin.  So I was hoping you could put a finer point on the growth acceleration on the top line and \nmargin compression you're seeing.  Is that mix shift to lower margin businesses?  Is that the increased investments \nyou're making?  Any c olor there would be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Is that the increased investments \nyou're making? ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "2fcf95bea0951dec40b75791cd93a1b3eaaab7a68cd28d8784bad7d78ac27950", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0492be5b-b309-4e40-b373-0736cd36a0a3", "node_type": "1", "metadata": {"window": "Is that mix shift to lower margin businesses?  Is that the increased investments \nyou're making?  Any c olor there would be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for that question.  I can answer that. ", "original_text": "Thanks.  \n "}, "hash": "0c86e3b7af6d6a13a9678716ab367c003b2a68599f9755cdfedf11943dfb30a4", "class_name": "RelatedNodeInfo"}}, "text": "Any c olor there would be great. ", "start_char_idx": 761, "end_char_idx": 794, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0492be5b-b309-4e40-b373-0736cd36a0a3": {"__data__": {"id_": "0492be5b-b309-4e40-b373-0736cd36a0a3", "embedding": null, "metadata": {"window": "Is that mix shift to lower margin businesses?  Is that the increased investments \nyou're making?  Any c olor there would be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for that question.  I can answer that. ", "original_text": "Thanks.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5fb8371ab6f895d394ff4bcbdaea2e37603103828615feac885bfb2e5bd10f0a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5cf0d87-8087-4917-81f3-a9082a39076a", "node_type": "1", "metadata": {"window": "So I was hoping you could put a finer point on the growth acceleration on the top line and \nmargin compression you're seeing.  Is that mix shift to lower margin businesses?  Is that the increased investments \nyou're making?  Any c olor there would be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for that question. ", "original_text": "Any c olor there would be great. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "e7ea1eeb63c875114de4f0a85e020eb6969d6901fa939a86bff47eb7264eb471", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d69a87ce-2373-44bb-a58e-d32f1f900774", "node_type": "1", "metadata": {"window": "Is that the increased investments \nyou're making?  Any c olor there would be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for that question.  I can answer that.  The growth that we're seeing next year on the top line is more \naccelerated growth in o ur 3PL business. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "c244efb0b27931b69277300217d90729586e5da4b5e09909d58bad4e3865d97b", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 794, "end_char_idx": 805, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d69a87ce-2373-44bb-a58e-d32f1f900774": {"__data__": {"id_": "d69a87ce-2373-44bb-a58e-d32f1f900774", "embedding": null, "metadata": {"window": "Is that the increased investments \nyou're making?  Any c olor there would be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for that question.  I can answer that.  The growth that we're seeing next year on the top line is more \naccelerated growth in o ur 3PL business. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5fb8371ab6f895d394ff4bcbdaea2e37603103828615feac885bfb2e5bd10f0a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0492be5b-b309-4e40-b373-0736cd36a0a3", "node_type": "1", "metadata": {"window": "Is that mix shift to lower margin businesses?  Is that the increased investments \nyou're making?  Any c olor there would be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for that question.  I can answer that. ", "original_text": "Thanks.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "2b0610869eeb61e28881432dd023b8dbfb5968838bc8d37c13875bab9ed1b8a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f418f31f-f6f4-4d7b-9ffc-7b1c4265017f", "node_type": "1", "metadata": {"window": "Any c olor there would be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for that question.  I can answer that.  The growth that we're seeing next year on the top line is more \naccelerated growth in o ur 3PL business.  As we've talked about before, the 3PL business generally represents a \nlittle more than half of the revenue in the segment, but less than 10% of the adjusted operating profit. ", "original_text": "A \nThanks for that question. "}, "hash": "d025bd9bad8693daf5591a887df3c6c2da47c69f0a7b66b90a8ae9cfd5071757", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 805, "end_char_idx": 1165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f418f31f-f6f4-4d7b-9ffc-7b1c4265017f": {"__data__": {"id_": "f418f31f-f6f4-4d7b-9ffc-7b1c4265017f", "embedding": null, "metadata": {"window": "Any c olor there would be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for that question.  I can answer that.  The growth that we're seeing next year on the top line is more \naccelerated growth in o ur 3PL business.  As we've talked about before, the 3PL business generally represents a \nlittle more than half of the revenue in the segment, but less than 10% of the adjusted operating profit. ", "original_text": "A \nThanks for that question. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5fb8371ab6f895d394ff4bcbdaea2e37603103828615feac885bfb2e5bd10f0a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d69a87ce-2373-44bb-a58e-d32f1f900774", "node_type": "1", "metadata": {"window": "Is that the increased investments \nyou're making?  Any c olor there would be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for that question.  I can answer that.  The growth that we're seeing next year on the top line is more \naccelerated growth in o ur 3PL business. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "660372ce08082e3dbb72e34524d9a3fde3015fc8fadf18b264a54a24e9652464", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d419631-835e-4ad5-abf4-8f3f9a244380", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for that question.  I can answer that.  The growth that we're seeing next year on the top line is more \naccelerated growth in o ur 3PL business.  As we've talked about before, the 3PL business generally represents a \nlittle more than half of the revenue in the segment, but less than 10% of the adjusted operating profit.  And so as \nwe expect to win some additional business next year an d see some of our customers continue to grow, that \nrevenue will be faster rate than we've seen in prior years.  \n \n", "original_text": "I can answer that. "}, "hash": "a6a0de8ea4b2e5b1fd092f5ccfe4323bf81c153366504968c007fe783e688180", "class_name": "RelatedNodeInfo"}}, "text": "A \nThanks for that question. ", "start_char_idx": 1165, "end_char_idx": 1194, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d419631-835e-4ad5-abf4-8f3f9a244380": {"__data__": {"id_": "6d419631-835e-4ad5-abf4-8f3f9a244380", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for that question.  I can answer that.  The growth that we're seeing next year on the top line is more \naccelerated growth in o ur 3PL business.  As we've talked about before, the 3PL business generally represents a \nlittle more than half of the revenue in the segment, but less than 10% of the adjusted operating profit.  And so as \nwe expect to win some additional business next year an d see some of our customers continue to grow, that \nrevenue will be faster rate than we've seen in prior years.  \n \n", "original_text": "I can answer that. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5fb8371ab6f895d394ff4bcbdaea2e37603103828615feac885bfb2e5bd10f0a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f418f31f-f6f4-4d7b-9ffc-7b1c4265017f", "node_type": "1", "metadata": {"window": "Any c olor there would be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for that question.  I can answer that.  The growth that we're seeing next year on the top line is more \naccelerated growth in o ur 3PL business.  As we've talked about before, the 3PL business generally represents a \nlittle more than half of the revenue in the segment, but less than 10% of the adjusted operating profit. ", "original_text": "A \nThanks for that question. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "eb9d060aefc8b9759b2960177e8bd301e1a4e43ff5b9f4685252a949d16473ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff54db1d-4027-4187-a82a-b09776d1b602", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for that question.  I can answer that.  The growth that we're seeing next year on the top line is more \naccelerated growth in o ur 3PL business.  As we've talked about before, the 3PL business generally represents a \nlittle more than half of the revenue in the segment, but less than 10% of the adjusted operating profit.  And so as \nwe expect to win some additional business next year an d see some of our customers continue to grow, that \nrevenue will be faster rate than we've seen in prior years.  \n \n And given the mix that that represents in the segments driving faster top line again, at a lower margin rate on the \nbottom line from that partic ular business, 3PL business. ", "original_text": "The growth that we're seeing next year on the top line is more \naccelerated growth in o ur 3PL business. "}, "hash": "b7fec92a92007809664c1b955d3d9a7e7133f265d6b782c9def89c714aa516b7", "class_name": "RelatedNodeInfo"}}, "text": "I can answer that. ", "start_char_idx": 1194, "end_char_idx": 1213, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff54db1d-4027-4187-a82a-b09776d1b602": {"__data__": {"id_": "ff54db1d-4027-4187-a82a-b09776d1b602", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for that question.  I can answer that.  The growth that we're seeing next year on the top line is more \naccelerated growth in o ur 3PL business.  As we've talked about before, the 3PL business generally represents a \nlittle more than half of the revenue in the segment, but less than 10% of the adjusted operating profit.  And so as \nwe expect to win some additional business next year an d see some of our customers continue to grow, that \nrevenue will be faster rate than we've seen in prior years.  \n \n And given the mix that that represents in the segments driving faster top line again, at a lower margin rate on the \nbottom line from that partic ular business, 3PL business. ", "original_text": "The growth that we're seeing next year on the top line is more \naccelerated growth in o ur 3PL business. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5fb8371ab6f895d394ff4bcbdaea2e37603103828615feac885bfb2e5bd10f0a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d419631-835e-4ad5-abf4-8f3f9a244380", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for that question.  I can answer that.  The growth that we're seeing next year on the top line is more \naccelerated growth in o ur 3PL business.  As we've talked about before, the 3PL business generally represents a \nlittle more than half of the revenue in the segment, but less than 10% of the adjusted operating profit.  And so as \nwe expect to win some additional business next year an d see some of our customers continue to grow, that \nrevenue will be faster rate than we've seen in prior years.  \n \n", "original_text": "I can answer that. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "55c94582f9d98203c49f3535b74fc9fc1a425ea1d5df26c4b90febed175be290", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2bd4993c-715a-4bab-a8dc-d810ddb5af6e", "node_type": "1", "metadata": {"window": "A \nThanks for that question.  I can answer that.  The growth that we're seeing next year on the top line is more \naccelerated growth in o ur 3PL business.  As we've talked about before, the 3PL business generally represents a \nlittle more than half of the revenue in the segment, but less than 10% of the adjusted operating profit.  And so as \nwe expect to win some additional business next year an d see some of our customers continue to grow, that \nrevenue will be faster rate than we've seen in prior years.  \n \n And given the mix that that represents in the segments driving faster top line again, at a lower margin rate on the \nbottom line from that partic ular business, 3PL business.  So the underlying technology businesses are continuing \nto grow in a consistent manner, and we're really pleased with the growth that we're seeing there. ", "original_text": "As we've talked about before, the 3PL business generally represents a \nlittle more than half of the revenue in the segment, but less than 10% of the adjusted operating profit. "}, "hash": "5480a3e1ca5bc909de5447b29e0cbf03006a92f9fca7d148e296d660450ba42a", "class_name": "RelatedNodeInfo"}}, "text": "The growth that we're seeing next year on the top line is more \naccelerated growth in o ur 3PL business. ", "start_char_idx": 1213, "end_char_idx": 1318, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2bd4993c-715a-4bab-a8dc-d810ddb5af6e": {"__data__": {"id_": "2bd4993c-715a-4bab-a8dc-d810ddb5af6e", "embedding": null, "metadata": {"window": "A \nThanks for that question.  I can answer that.  The growth that we're seeing next year on the top line is more \naccelerated growth in o ur 3PL business.  As we've talked about before, the 3PL business generally represents a \nlittle more than half of the revenue in the segment, but less than 10% of the adjusted operating profit.  And so as \nwe expect to win some additional business next year an d see some of our customers continue to grow, that \nrevenue will be faster rate than we've seen in prior years.  \n \n And given the mix that that represents in the segments driving faster top line again, at a lower margin rate on the \nbottom line from that partic ular business, 3PL business.  So the underlying technology businesses are continuing \nto grow in a consistent manner, and we're really pleased with the growth that we're seeing there. ", "original_text": "As we've talked about before, the 3PL business generally represents a \nlittle more than half of the revenue in the segment, but less than 10% of the adjusted operating profit. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5fb8371ab6f895d394ff4bcbdaea2e37603103828615feac885bfb2e5bd10f0a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff54db1d-4027-4187-a82a-b09776d1b602", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for that question.  I can answer that.  The growth that we're seeing next year on the top line is more \naccelerated growth in o ur 3PL business.  As we've talked about before, the 3PL business generally represents a \nlittle more than half of the revenue in the segment, but less than 10% of the adjusted operating profit.  And so as \nwe expect to win some additional business next year an d see some of our customers continue to grow, that \nrevenue will be faster rate than we've seen in prior years.  \n \n And given the mix that that represents in the segments driving faster top line again, at a lower margin rate on the \nbottom line from that partic ular business, 3PL business. ", "original_text": "The growth that we're seeing next year on the top line is more \naccelerated growth in o ur 3PL business. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "9004727fdd8398da07fc20bdb5bc0639aeec1f4f9dd61b7bad70b949c615a0bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa515cc8-7177-424a-99f0-9cd6fc471f7c", "node_type": "1", "metadata": {"window": "I can answer that.  The growth that we're seeing next year on the top line is more \naccelerated growth in o ur 3PL business.  As we've talked about before, the 3PL business generally represents a \nlittle more than half of the revenue in the segment, but less than 10% of the adjusted operating profit.  And so as \nwe expect to win some additional business next year an d see some of our customers continue to grow, that \nrevenue will be faster rate than we've seen in prior years.  \n \n And given the mix that that represents in the segments driving faster top line again, at a lower margin rate on the \nbottom line from that partic ular business, 3PL business.  So the underlying technology businesses are continuing \nto grow in a consistent manner, and we're really pleased with the growth that we're seeing there.  But what you're \nseeing is a mix impact in FY 2025 from the 3PL business.  \n ", "original_text": "And so as \nwe expect to win some additional business next year an d see some of our customers continue to grow, that \nrevenue will be faster rate than we've seen in prior years.  \n \n"}, "hash": "22c926b4236fe78950812d3dfc748b1cdaa1bee65db3d321b7f3e880295b5c92", "class_name": "RelatedNodeInfo"}}, "text": "As we've talked about before, the 3PL business generally represents a \nlittle more than half of the revenue in the segment, but less than 10% of the adjusted operating profit. ", "start_char_idx": 1318, "end_char_idx": 1494, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa515cc8-7177-424a-99f0-9cd6fc471f7c": {"__data__": {"id_": "fa515cc8-7177-424a-99f0-9cd6fc471f7c", "embedding": null, "metadata": {"window": "I can answer that.  The growth that we're seeing next year on the top line is more \naccelerated growth in o ur 3PL business.  As we've talked about before, the 3PL business generally represents a \nlittle more than half of the revenue in the segment, but less than 10% of the adjusted operating profit.  And so as \nwe expect to win some additional business next year an d see some of our customers continue to grow, that \nrevenue will be faster rate than we've seen in prior years.  \n \n And given the mix that that represents in the segments driving faster top line again, at a lower margin rate on the \nbottom line from that partic ular business, 3PL business.  So the underlying technology businesses are continuing \nto grow in a consistent manner, and we're really pleased with the growth that we're seeing there.  But what you're \nseeing is a mix impact in FY 2025 from the 3PL business.  \n ", "original_text": "And so as \nwe expect to win some additional business next year an d see some of our customers continue to grow, that \nrevenue will be faster rate than we've seen in prior years.  \n \n", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5fb8371ab6f895d394ff4bcbdaea2e37603103828615feac885bfb2e5bd10f0a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2bd4993c-715a-4bab-a8dc-d810ddb5af6e", "node_type": "1", "metadata": {"window": "A \nThanks for that question.  I can answer that.  The growth that we're seeing next year on the top line is more \naccelerated growth in o ur 3PL business.  As we've talked about before, the 3PL business generally represents a \nlittle more than half of the revenue in the segment, but less than 10% of the adjusted operating profit.  And so as \nwe expect to win some additional business next year an d see some of our customers continue to grow, that \nrevenue will be faster rate than we've seen in prior years.  \n \n And given the mix that that represents in the segments driving faster top line again, at a lower margin rate on the \nbottom line from that partic ular business, 3PL business.  So the underlying technology businesses are continuing \nto grow in a consistent manner, and we're really pleased with the growth that we're seeing there. ", "original_text": "As we've talked about before, the 3PL business generally represents a \nlittle more than half of the revenue in the segment, but less than 10% of the adjusted operating profit. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "afca8c530bd4ab19bb98d3d29cb3f05526e48fac7198b03007721bb6f737ea77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0075170-f557-4759-b796-7f96bcadf986", "node_type": "1", "metadata": {"window": "The growth that we're seeing next year on the top line is more \naccelerated growth in o ur 3PL business.  As we've talked about before, the 3PL business generally represents a \nlittle more than half of the revenue in the segment, but less than 10% of the adjusted operating profit.  And so as \nwe expect to win some additional business next year an d see some of our customers continue to grow, that \nrevenue will be faster rate than we've seen in prior years.  \n \n And given the mix that that represents in the segments driving faster top line again, at a lower margin rate on the \nbottom line from that partic ular business, 3PL business.  So the underlying technology businesses are continuing \nto grow in a consistent manner, and we're really pleased with the growth that we're seeing there.  But what you're \nseeing is a mix impact in FY 2025 from the 3PL business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "And given the mix that that represents in the segments driving faster top line again, at a lower margin rate on the \nbottom line from that partic ular business, 3PL business. "}, "hash": "75514f3327159027a25a574f3b051409a08cad126a47e846d386c814f529b629", "class_name": "RelatedNodeInfo"}}, "text": "And so as \nwe expect to win some additional business next year an d see some of our customers continue to grow, that \nrevenue will be faster rate than we've seen in prior years.  \n \n", "start_char_idx": 1494, "end_char_idx": 1676, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0075170-f557-4759-b796-7f96bcadf986": {"__data__": {"id_": "e0075170-f557-4759-b796-7f96bcadf986", "embedding": null, "metadata": {"window": "The growth that we're seeing next year on the top line is more \naccelerated growth in o ur 3PL business.  As we've talked about before, the 3PL business generally represents a \nlittle more than half of the revenue in the segment, but less than 10% of the adjusted operating profit.  And so as \nwe expect to win some additional business next year an d see some of our customers continue to grow, that \nrevenue will be faster rate than we've seen in prior years.  \n \n And given the mix that that represents in the segments driving faster top line again, at a lower margin rate on the \nbottom line from that partic ular business, 3PL business.  So the underlying technology businesses are continuing \nto grow in a consistent manner, and we're really pleased with the growth that we're seeing there.  But what you're \nseeing is a mix impact in FY 2025 from the 3PL business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "And given the mix that that represents in the segments driving faster top line again, at a lower margin rate on the \nbottom line from that partic ular business, 3PL business. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5fb8371ab6f895d394ff4bcbdaea2e37603103828615feac885bfb2e5bd10f0a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa515cc8-7177-424a-99f0-9cd6fc471f7c", "node_type": "1", "metadata": {"window": "I can answer that.  The growth that we're seeing next year on the top line is more \naccelerated growth in o ur 3PL business.  As we've talked about before, the 3PL business generally represents a \nlittle more than half of the revenue in the segment, but less than 10% of the adjusted operating profit.  And so as \nwe expect to win some additional business next year an d see some of our customers continue to grow, that \nrevenue will be faster rate than we've seen in prior years.  \n \n And given the mix that that represents in the segments driving faster top line again, at a lower margin rate on the \nbottom line from that partic ular business, 3PL business.  So the underlying technology businesses are continuing \nto grow in a consistent manner, and we're really pleased with the growth that we're seeing there.  But what you're \nseeing is a mix impact in FY 2025 from the 3PL business.  \n ", "original_text": "And so as \nwe expect to win some additional business next year an d see some of our customers continue to grow, that \nrevenue will be faster rate than we've seen in prior years.  \n \n", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "aae88f9c446e68de832b873e8204c3aa37def4cfb53da2472aacbc3d890deeb0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7e22737-4279-4215-b456-928a12f43139", "node_type": "1", "metadata": {"window": "As we've talked about before, the 3PL business generally represents a \nlittle more than half of the revenue in the segment, but less than 10% of the adjusted operating profit.  And so as \nwe expect to win some additional business next year an d see some of our customers continue to grow, that \nrevenue will be faster rate than we've seen in prior years.  \n \n And given the mix that that represents in the segments driving faster top line again, at a lower margin rate on the \nbottom line from that partic ular business, 3PL business.  So the underlying technology businesses are continuing \nto grow in a consistent manner, and we're really pleased with the growth that we're seeing there.  But what you're \nseeing is a mix impact in FY 2025 from the 3PL business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "So the underlying technology businesses are continuing \nto grow in a consistent manner, and we're really pleased with the growth that we're seeing there. "}, "hash": "9d87bee78eae98f06d165e76347dda945f6211646e61612413b54719067abcac", "class_name": "RelatedNodeInfo"}}, "text": "And given the mix that that represents in the segments driving faster top line again, at a lower margin rate on the \nbottom line from that partic ular business, 3PL business. ", "start_char_idx": 1676, "end_char_idx": 1851, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7e22737-4279-4215-b456-928a12f43139": {"__data__": {"id_": "c7e22737-4279-4215-b456-928a12f43139", "embedding": null, "metadata": {"window": "As we've talked about before, the 3PL business generally represents a \nlittle more than half of the revenue in the segment, but less than 10% of the adjusted operating profit.  And so as \nwe expect to win some additional business next year an d see some of our customers continue to grow, that \nrevenue will be faster rate than we've seen in prior years.  \n \n And given the mix that that represents in the segments driving faster top line again, at a lower margin rate on the \nbottom line from that partic ular business, 3PL business.  So the underlying technology businesses are continuing \nto grow in a consistent manner, and we're really pleased with the growth that we're seeing there.  But what you're \nseeing is a mix impact in FY 2025 from the 3PL business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "So the underlying technology businesses are continuing \nto grow in a consistent manner, and we're really pleased with the growth that we're seeing there. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5fb8371ab6f895d394ff4bcbdaea2e37603103828615feac885bfb2e5bd10f0a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0075170-f557-4759-b796-7f96bcadf986", "node_type": "1", "metadata": {"window": "The growth that we're seeing next year on the top line is more \naccelerated growth in o ur 3PL business.  As we've talked about before, the 3PL business generally represents a \nlittle more than half of the revenue in the segment, but less than 10% of the adjusted operating profit.  And so as \nwe expect to win some additional business next year an d see some of our customers continue to grow, that \nrevenue will be faster rate than we've seen in prior years.  \n \n And given the mix that that represents in the segments driving faster top line again, at a lower margin rate on the \nbottom line from that partic ular business, 3PL business.  So the underlying technology businesses are continuing \nto grow in a consistent manner, and we're really pleased with the growth that we're seeing there.  But what you're \nseeing is a mix impact in FY 2025 from the 3PL business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "And given the mix that that represents in the segments driving faster top line again, at a lower margin rate on the \nbottom line from that partic ular business, 3PL business. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "054ea69d76cdb3a9c185c74e6a457a443afd067cfc30b6064df25470cda5141a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af9726ed-fd53-4543-97d5-d4d837ce1427", "node_type": "1", "metadata": {"window": "And so as \nwe expect to win some additional business next year an d see some of our customers continue to grow, that \nrevenue will be faster rate than we've seen in prior years.  \n \n And given the mix that that represents in the segments driving faster top line again, at a lower margin rate on the \nbottom line from that partic ular business, 3PL business.  So the underlying technology businesses are continuing \nto grow in a consistent manner, and we're really pleased with the growth that we're seeing there.  But what you're \nseeing is a mix impact in FY 2025 from the 3PL business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley. ", "original_text": "But what you're \nseeing is a mix impact in FY 2025 from the 3PL business.  \n "}, "hash": "11a17adb0c6ebd644ef33173c03605e03dee097bafbe0c955cb9b11227ad1d09", "class_name": "RelatedNodeInfo"}}, "text": "So the underlying technology businesses are continuing \nto grow in a consistent manner, and we're really pleased with the growth that we're seeing there. ", "start_char_idx": 1851, "end_char_idx": 2005, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af9726ed-fd53-4543-97d5-d4d837ce1427": {"__data__": {"id_": "af9726ed-fd53-4543-97d5-d4d837ce1427", "embedding": null, "metadata": {"window": "And so as \nwe expect to win some additional business next year an d see some of our customers continue to grow, that \nrevenue will be faster rate than we've seen in prior years.  \n \n And given the mix that that represents in the segments driving faster top line again, at a lower margin rate on the \nbottom line from that partic ular business, 3PL business.  So the underlying technology businesses are continuing \nto grow in a consistent manner, and we're really pleased with the growth that we're seeing there.  But what you're \nseeing is a mix impact in FY 2025 from the 3PL business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley. ", "original_text": "But what you're \nseeing is a mix impact in FY 2025 from the 3PL business.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5fb8371ab6f895d394ff4bcbdaea2e37603103828615feac885bfb2e5bd10f0a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7e22737-4279-4215-b456-928a12f43139", "node_type": "1", "metadata": {"window": "As we've talked about before, the 3PL business generally represents a \nlittle more than half of the revenue in the segment, but less than 10% of the adjusted operating profit.  And so as \nwe expect to win some additional business next year an d see some of our customers continue to grow, that \nrevenue will be faster rate than we've seen in prior years.  \n \n And given the mix that that represents in the segments driving faster top line again, at a lower margin rate on the \nbottom line from that partic ular business, 3PL business.  So the underlying technology businesses are continuing \nto grow in a consistent manner, and we're really pleased with the growth that we're seeing there.  But what you're \nseeing is a mix impact in FY 2025 from the 3PL business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "So the underlying technology businesses are continuing \nto grow in a consistent manner, and we're really pleased with the growth that we're seeing there. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "9a262cabc0582d4d24de7720985f46c232763a6465bc8f05f6b6b00f8bbf181c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20d23907-fb46-4c64-92d8-181f701c40cf", "node_type": "1", "metadata": {"window": "And given the mix that that represents in the segments driving faster top line again, at a lower margin rate on the \nbottom line from that partic ular business, 3PL business.  So the underlying technology businesses are continuing \nto grow in a consistent manner, and we're really pleased with the growth that we're seeing there.  But what you're \nseeing is a mix impact in FY 2025 from the 3PL business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  "}, "hash": "d05108aaad865df605024884cdea2f653352f33d2ff11fd262f7c9a01874bb67", "class_name": "RelatedNodeInfo"}}, "text": "But what you're \nseeing is a mix impact in FY 2025 from the 3PL business.  \n ", "start_char_idx": 2005, "end_char_idx": 2082, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20d23907-fb46-4c64-92d8-181f701c40cf": {"__data__": {"id_": "20d23907-fb46-4c64-92d8-181f701c40cf", "embedding": null, "metadata": {"window": "And given the mix that that represents in the segments driving faster top line again, at a lower margin rate on the \nbottom line from that partic ular business, 3PL business.  So the underlying technology businesses are continuing \nto grow in a consistent manner, and we're really pleased with the growth that we're seeing there.  But what you're \nseeing is a mix impact in FY 2025 from the 3PL business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5fb8371ab6f895d394ff4bcbdaea2e37603103828615feac885bfb2e5bd10f0a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af9726ed-fd53-4543-97d5-d4d837ce1427", "node_type": "1", "metadata": {"window": "And so as \nwe expect to win some additional business next year an d see some of our customers continue to grow, that \nrevenue will be faster rate than we've seen in prior years.  \n \n And given the mix that that represents in the segments driving faster top line again, at a lower margin rate on the \nbottom line from that partic ular business, 3PL business.  So the underlying technology businesses are continuing \nto grow in a consistent manner, and we're really pleased with the growth that we're seeing there.  But what you're \nseeing is a mix impact in FY 2025 from the 3PL business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley. ", "original_text": "But what you're \nseeing is a mix impact in FY 2025 from the 3PL business.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5591300935400e2ddfdda282219b926bd626da6325edc6446d856f4f5356c388", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "084f174b-8c6d-4f35-a085-deec06b46285", "node_type": "1", "metadata": {"window": "So the underlying technology businesses are continuing \nto grow in a consistent manner, and we're really pleased with the growth that we're seeing there.  But what you're \nseeing is a mix impact in FY 2025 from the 3PL business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "original_text": "A \nNext question, please.  \n "}, "hash": "fcc1cb5d6876393b49739da15aced32c48226665962ba0aba9895100b6cd9367", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "start_char_idx": 2082, "end_char_idx": 2427, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "084f174b-8c6d-4f35-a085-deec06b46285": {"__data__": {"id_": "084f174b-8c6d-4f35-a085-deec06b46285", "embedding": null, "metadata": {"window": "So the underlying technology businesses are continuing \nto grow in a consistent manner, and we're really pleased with the growth that we're seeing there.  But what you're \nseeing is a mix impact in FY 2025 from the 3PL business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "original_text": "A \nNext question, please.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5fb8371ab6f895d394ff4bcbdaea2e37603103828615feac885bfb2e5bd10f0a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20d23907-fb46-4c64-92d8-181f701c40cf", "node_type": "1", "metadata": {"window": "And given the mix that that represents in the segments driving faster top line again, at a lower margin rate on the \nbottom line from that partic ular business, 3PL business.  So the underlying technology businesses are continuing \nto grow in a consistent manner, and we're really pleased with the growth that we're seeing there.  But what you're \nseeing is a mix impact in FY 2025 from the 3PL business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ca175e9e69f030bb5721e34b389afccf8c41f4e67ae6271ee472648762f66ab2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3bda7636-9cd0-4197-ad25-e95e27a55c80", "node_type": "1", "metadata": {"window": "But what you're \nseeing is a mix impact in FY 2025 from the 3PL business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat, thanks. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley. "}, "hash": "eb85491e2161e2bc4276d84fef4cbe5712e2a840ccfa4e940069c90e3c048154", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please.  \n ", "start_char_idx": 2427, "end_char_idx": 2456, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3bda7636-9cd0-4197-ad25-e95e27a55c80": {"__data__": {"id_": "3bda7636-9cd0-4197-ad25-e95e27a55c80", "embedding": null, "metadata": {"window": "But what you're \nseeing is a mix impact in FY 2025 from the 3PL business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat, thanks. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5fb8371ab6f895d394ff4bcbdaea2e37603103828615feac885bfb2e5bd10f0a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "084f174b-8c6d-4f35-a085-deec06b46285", "node_type": "1", "metadata": {"window": "So the underlying technology businesses are continuing \nto grow in a consistent manner, and we're really pleased with the growth that we're seeing there.  But what you're \nseeing is a mix impact in FY 2025 from the 3PL business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "original_text": "A \nNext question, please.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "1b1b83104bb5a894b16a065578d788e5268f2161e84fb96669c89eaff962a2a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0df8270c-b18e-4852-a670-518ae6941765", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat, thanks.  I wanted to get a little bit of color on what you're seeing and what's embedded in your guidance in \nterms of the pricing environment on the US pharma business and what assumptions you're making in terms of \ngeneric pricing trends and environment that you're s eeing as well as kind of on the branded side. ", "original_text": "Please go ahead.  \n "}, "hash": "a192dc865387bebe71bbf219e6a4e5f11bbbcdcd804ff23be2741512dc1d971b", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley. ", "start_char_idx": 2456, "end_char_idx": 2791, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0df8270c-b18e-4852-a670-518ae6941765": {"__data__": {"id_": "0df8270c-b18e-4852-a670-518ae6941765", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat, thanks.  I wanted to get a little bit of color on what you're seeing and what's embedded in your guidance in \nterms of the pricing environment on the US pharma business and what assumptions you're making in terms of \ngeneric pricing trends and environment that you're s eeing as well as kind of on the branded side. ", "original_text": "Please go ahead.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5fb8371ab6f895d394ff4bcbdaea2e37603103828615feac885bfb2e5bd10f0a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3bda7636-9cd0-4197-ad25-e95e27a55c80", "node_type": "1", "metadata": {"window": "But what you're \nseeing is a mix impact in FY 2025 from the 3PL business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat, thanks. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a99b4037325769d46f4fc5ccc3595dba44210557bdcd59e3135aa1cc9b1d25d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef404db4-664a-43e7-96ad-694055c63211", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat, thanks.  I wanted to get a little bit of color on what you're seeing and what's embedded in your guidance in \nterms of the pricing environment on the US pharma business and what assumptions you're making in terms of \ngeneric pricing trends and environment that you're s eeing as well as kind of on the branded side.  I know that's \nless of a swing factor for you, but how is that playing out relative to your expectations here?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co. "}, "hash": "d65f9c9715f7a02ee04d07e301eb2ec744a852467313d2a624db355218b45a52", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 2791, "end_char_idx": 2811, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef404db4-664a-43e7-96ad-694055c63211": {"__data__": {"id_": "ef404db4-664a-43e7-96ad-694055c63211", "embedding": null, "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat, thanks.  I wanted to get a little bit of color on what you're seeing and what's embedded in your guidance in \nterms of the pricing environment on the US pharma business and what assumptions you're making in terms of \ngeneric pricing trends and environment that you're s eeing as well as kind of on the branded side.  I know that's \nless of a swing factor for you, but how is that playing out relative to your expectations here?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5fb8371ab6f895d394ff4bcbdaea2e37603103828615feac885bfb2e5bd10f0a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0df8270c-b18e-4852-a670-518ae6941765", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat, thanks.  I wanted to get a little bit of color on what you're seeing and what's embedded in your guidance in \nterms of the pricing environment on the US pharma business and what assumptions you're making in terms of \ngeneric pricing trends and environment that you're s eeing as well as kind of on the branded side. ", "original_text": "Please go ahead.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "15668199466a0505b5f4cae6c3b7110d4be40c997393d2c3e5638ecbdaa4baf1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa4fc28e-c233-4b95-afd0-f4d4718563fb", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat, thanks.  I wanted to get a little bit of color on what you're seeing and what's embedded in your guidance in \nterms of the pricing environment on the US pharma business and what assumptions you're making in terms of \ngeneric pricing trends and environment that you're s eeing as well as kind of on the branded side.  I know that's \nless of a swing factor for you, but how is that playing out relative to your expectations here?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "LLC  Q \nGreat, thanks. "}, "hash": "79e285966689aadc03ab0cd89398bf8fe15393d9c7ffe98976e592f4ab21f956", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "start_char_idx": 2811, "end_char_idx": 3134, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa4fc28e-c233-4b95-afd0-f4d4718563fb": {"__data__": {"id_": "fa4fc28e-c233-4b95-afd0-f4d4718563fb", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat, thanks.  I wanted to get a little bit of color on what you're seeing and what's embedded in your guidance in \nterms of the pricing environment on the US pharma business and what assumptions you're making in terms of \ngeneric pricing trends and environment that you're s eeing as well as kind of on the branded side.  I know that's \nless of a swing factor for you, but how is that playing out relative to your expectations here?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "LLC  Q \nGreat, thanks. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5fb8371ab6f895d394ff4bcbdaea2e37603103828615feac885bfb2e5bd10f0a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef404db4-664a-43e7-96ad-694055c63211", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat, thanks.  I wanted to get a little bit of color on what you're seeing and what's embedded in your guidance in \nterms of the pricing environment on the US pharma business and what assumptions you're making in terms of \ngeneric pricing trends and environment that you're s eeing as well as kind of on the branded side.  I know that's \nless of a swing factor for you, but how is that playing out relative to your expectations here?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5428ba0d536928f7a019ca0418ea7e9325151270dde32db78b10dee89303293c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4618abf-a0e4-4bbb-ac88-d512157d8193", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat, thanks.  I wanted to get a little bit of color on what you're seeing and what's embedded in your guidance in \nterms of the pricing environment on the US pharma business and what assumptions you're making in terms of \ngeneric pricing trends and environment that you're s eeing as well as kind of on the branded side.  I know that's \nless of a swing factor for you, but how is that playing out relative to your expectations here?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, happ y to answer that question. ", "original_text": "I wanted to get a little bit of color on what you're seeing and what's embedded in your guidance in \nterms of the pricing environment on the US pharma business and what assumptions you're making in terms of \ngeneric pricing trends and environment that you're s eeing as well as kind of on the branded side. "}, "hash": "111d4d6f2ab2d3aa08073ab482b373513e2369b09d8065f5d941484e246ef872", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nGreat, thanks. ", "start_char_idx": 3134, "end_char_idx": 3157, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4618abf-a0e4-4bbb-ac88-d512157d8193": {"__data__": {"id_": "f4618abf-a0e4-4bbb-ac88-d512157d8193", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat, thanks.  I wanted to get a little bit of color on what you're seeing and what's embedded in your guidance in \nterms of the pricing environment on the US pharma business and what assumptions you're making in terms of \ngeneric pricing trends and environment that you're s eeing as well as kind of on the branded side.  I know that's \nless of a swing factor for you, but how is that playing out relative to your expectations here?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, happ y to answer that question. ", "original_text": "I wanted to get a little bit of color on what you're seeing and what's embedded in your guidance in \nterms of the pricing environment on the US pharma business and what assumptions you're making in terms of \ngeneric pricing trends and environment that you're s eeing as well as kind of on the branded side. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5fb8371ab6f895d394ff4bcbdaea2e37603103828615feac885bfb2e5bd10f0a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa4fc28e-c233-4b95-afd0-f4d4718563fb", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat, thanks.  I wanted to get a little bit of color on what you're seeing and what's embedded in your guidance in \nterms of the pricing environment on the US pharma business and what assumptions you're making in terms of \ngeneric pricing trends and environment that you're s eeing as well as kind of on the branded side.  I know that's \nless of a swing factor for you, but how is that playing out relative to your expectations here?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "LLC  Q \nGreat, thanks. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "683d575d3e106e0b01e6bb098174abd52e78d6d4eeb1a38f57300b0fc23a4016", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2354d82d-9c1f-4e46-b8e3-cdeded942e08", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat, thanks.  I wanted to get a little bit of color on what you're seeing and what's embedded in your guidance in \nterms of the pricing environment on the US pharma business and what assumptions you're making in terms of \ngeneric pricing trends and environment that you're s eeing as well as kind of on the branded side.  I know that's \nless of a swing factor for you, but how is that playing out relative to your expectations here?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, happ y to answer that question.  As we think about the pricing environment for branded products, it is going \nto be \u2013 our anticipation is it would be very consistent with what we've seen in the past several years, so stable \nand competitive branded price environme nt. ", "original_text": "I know that's \nless of a swing factor for you, but how is that playing out relative to your expectations here?  \n "}, "hash": "548fe9720ae343963da5f9ed9cb50de09cb8b7f2b82049ef9db2c155b675a3a7", "class_name": "RelatedNodeInfo"}}, "text": "I wanted to get a little bit of color on what you're seeing and what's embedded in your guidance in \nterms of the pricing environment on the US pharma business and what assumptions you're making in terms of \ngeneric pricing trends and environment that you're s eeing as well as kind of on the branded side. ", "start_char_idx": 3157, "end_char_idx": 3464, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2354d82d-9c1f-4e46-b8e3-cdeded942e08": {"__data__": {"id_": "2354d82d-9c1f-4e46-b8e3-cdeded942e08", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat, thanks.  I wanted to get a little bit of color on what you're seeing and what's embedded in your guidance in \nterms of the pricing environment on the US pharma business and what assumptions you're making in terms of \ngeneric pricing trends and environment that you're s eeing as well as kind of on the branded side.  I know that's \nless of a swing factor for you, but how is that playing out relative to your expectations here?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, happ y to answer that question.  As we think about the pricing environment for branded products, it is going \nto be \u2013 our anticipation is it would be very consistent with what we've seen in the past several years, so stable \nand competitive branded price environme nt. ", "original_text": "I know that's \nless of a swing factor for you, but how is that playing out relative to your expectations here?  \n ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5fb8371ab6f895d394ff4bcbdaea2e37603103828615feac885bfb2e5bd10f0a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4618abf-a0e4-4bbb-ac88-d512157d8193", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat, thanks.  I wanted to get a little bit of color on what you're seeing and what's embedded in your guidance in \nterms of the pricing environment on the US pharma business and what assumptions you're making in terms of \ngeneric pricing trends and environment that you're s eeing as well as kind of on the branded side.  I know that's \nless of a swing factor for you, but how is that playing out relative to your expectations here?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, happ y to answer that question. ", "original_text": "I wanted to get a little bit of color on what you're seeing and what's embedded in your guidance in \nterms of the pricing environment on the US pharma business and what assumptions you're making in terms of \ngeneric pricing trends and environment that you're s eeing as well as kind of on the branded side. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "343860c1000388f6a68c767db817f65ae7a831474a2454951ef9b069a81f8a09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "869d5d4b-7e2a-4242-9951-f32a6fd943c9", "node_type": "1", "metadata": {"window": "LLC  Q \nGreat, thanks.  I wanted to get a little bit of color on what you're seeing and what's embedded in your guidance in \nterms of the pricing environment on the US pharma business and what assumptions you're making in terms of \ngeneric pricing trends and environment that you're s eeing as well as kind of on the branded side.  I know that's \nless of a swing factor for you, but how is that playing out relative to your expectations here?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, happ y to answer that question.  As we think about the pricing environment for branded products, it is going \nto be \u2013 our anticipation is it would be very consistent with what we've seen in the past several years, so stable \nand competitive branded price environme nt.  And in the generic space, again, we look to drive value for our \ncustomers through our sourcing operations and looking to drive the lowest cost at the highest availability supply. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "9f1353d521f949333d9891b8c10b2bfb0a8c4391f5d8bb0b87cbdebbebf309f4", "class_name": "RelatedNodeInfo"}}, "text": "I know that's \nless of a swing factor for you, but how is that playing out relative to your expectations here?  \n ", "start_char_idx": 3464, "end_char_idx": 3578, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "869d5d4b-7e2a-4242-9951-f32a6fd943c9": {"__data__": {"id_": "869d5d4b-7e2a-4242-9951-f32a6fd943c9", "embedding": null, "metadata": {"window": "LLC  Q \nGreat, thanks.  I wanted to get a little bit of color on what you're seeing and what's embedded in your guidance in \nterms of the pricing environment on the US pharma business and what assumptions you're making in terms of \ngeneric pricing trends and environment that you're s eeing as well as kind of on the branded side.  I know that's \nless of a swing factor for you, but how is that playing out relative to your expectations here?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, happ y to answer that question.  As we think about the pricing environment for branded products, it is going \nto be \u2013 our anticipation is it would be very consistent with what we've seen in the past several years, so stable \nand competitive branded price environme nt.  And in the generic space, again, we look to drive value for our \ncustomers through our sourcing operations and looking to drive the lowest cost at the highest availability supply. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5fb8371ab6f895d394ff4bcbdaea2e37603103828615feac885bfb2e5bd10f0a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2354d82d-9c1f-4e46-b8e3-cdeded942e08", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat, thanks.  I wanted to get a little bit of color on what you're seeing and what's embedded in your guidance in \nterms of the pricing environment on the US pharma business and what assumptions you're making in terms of \ngeneric pricing trends and environment that you're s eeing as well as kind of on the branded side.  I know that's \nless of a swing factor for you, but how is that playing out relative to your expectations here?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, happ y to answer that question.  As we think about the pricing environment for branded products, it is going \nto be \u2013 our anticipation is it would be very consistent with what we've seen in the past several years, so stable \nand competitive branded price environme nt. ", "original_text": "I know that's \nless of a swing factor for you, but how is that playing out relative to your expectations here?  \n ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5ef07814457ff7e4eb64cfd98112dccc328b0b4cca64052a963708566de24e8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48d3232f-ecce-4316-946d-e18f62fb201a", "node_type": "1", "metadata": {"window": "I wanted to get a little bit of color on what you're seeing and what's embedded in your guidance in \nterms of the pricing environment on the US pharma business and what assumptions you're making in terms of \ngeneric pricing trends and environment that you're s eeing as well as kind of on the branded side.  I know that's \nless of a swing factor for you, but how is that playing out relative to your expectations here?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, happ y to answer that question.  As we think about the pricing environment for branded products, it is going \nto be \u2013 our anticipation is it would be very consistent with what we've seen in the past several years, so stable \nand competitive branded price environme nt.  And in the generic space, again, we look to drive value for our \ncustomers through our sourcing operations and looking to drive the lowest cost at the highest availability supply. \n And we believe that in our outlook for FY 2025, we expect to see a compet itive and stable environment in the \ngeneric space as well.  \n \n", "original_text": "A \nSure, happ y to answer that question. "}, "hash": "556d16105f248071527312786a34763bc5cab07f71e88a5185aea0c6a4627d66", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 805, "end_char_idx": 1165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48d3232f-ecce-4316-946d-e18f62fb201a": {"__data__": {"id_": "48d3232f-ecce-4316-946d-e18f62fb201a", "embedding": null, "metadata": {"window": "I wanted to get a little bit of color on what you're seeing and what's embedded in your guidance in \nterms of the pricing environment on the US pharma business and what assumptions you're making in terms of \ngeneric pricing trends and environment that you're s eeing as well as kind of on the branded side.  I know that's \nless of a swing factor for you, but how is that playing out relative to your expectations here?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, happ y to answer that question.  As we think about the pricing environment for branded products, it is going \nto be \u2013 our anticipation is it would be very consistent with what we've seen in the past several years, so stable \nand competitive branded price environme nt.  And in the generic space, again, we look to drive value for our \ncustomers through our sourcing operations and looking to drive the lowest cost at the highest availability supply. \n And we believe that in our outlook for FY 2025, we expect to see a compet itive and stable environment in the \ngeneric space as well.  \n \n", "original_text": "A \nSure, happ y to answer that question. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5fb8371ab6f895d394ff4bcbdaea2e37603103828615feac885bfb2e5bd10f0a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "869d5d4b-7e2a-4242-9951-f32a6fd943c9", "node_type": "1", "metadata": {"window": "LLC  Q \nGreat, thanks.  I wanted to get a little bit of color on what you're seeing and what's embedded in your guidance in \nterms of the pricing environment on the US pharma business and what assumptions you're making in terms of \ngeneric pricing trends and environment that you're s eeing as well as kind of on the branded side.  I know that's \nless of a swing factor for you, but how is that playing out relative to your expectations here?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, happ y to answer that question.  As we think about the pricing environment for branded products, it is going \nto be \u2013 our anticipation is it would be very consistent with what we've seen in the past several years, so stable \nand competitive branded price environme nt.  And in the generic space, again, we look to drive value for our \ncustomers through our sourcing operations and looking to drive the lowest cost at the highest availability supply. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "eaf9b472ba5732440e10857f6a6b7985178e6e09e5b9b40427ca82e3ddabd84c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7c74aa0-261f-41fb-a626-8eb823a119fc", "node_type": "1", "metadata": {"window": "I know that's \nless of a swing factor for you, but how is that playing out relative to your expectations here?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, happ y to answer that question.  As we think about the pricing environment for branded products, it is going \nto be \u2013 our anticipation is it would be very consistent with what we've seen in the past several years, so stable \nand competitive branded price environme nt.  And in the generic space, again, we look to drive value for our \ncustomers through our sourcing operations and looking to drive the lowest cost at the highest availability supply. \n And we believe that in our outlook for FY 2025, we expect to see a compet itive and stable environment in the \ngeneric space as well.  \n \n So we don't see a lot of changes in the environment for both branded and generics pricing in our outlook versus \nFY 2024. ", "original_text": "As we think about the pricing environment for branded products, it is going \nto be \u2013 our anticipation is it would be very consistent with what we've seen in the past several years, so stable \nand competitive branded price environme nt. "}, "hash": "92524b48d692a001a653bdcf182dc8f5682dfa1db4803bd42facd30401ce8aa3", "class_name": "RelatedNodeInfo"}}, "text": "A \nSure, happ y to answer that question. ", "start_char_idx": 3938, "end_char_idx": 3979, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7c74aa0-261f-41fb-a626-8eb823a119fc": {"__data__": {"id_": "d7c74aa0-261f-41fb-a626-8eb823a119fc", "embedding": null, "metadata": {"window": "I know that's \nless of a swing factor for you, but how is that playing out relative to your expectations here?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, happ y to answer that question.  As we think about the pricing environment for branded products, it is going \nto be \u2013 our anticipation is it would be very consistent with what we've seen in the past several years, so stable \nand competitive branded price environme nt.  And in the generic space, again, we look to drive value for our \ncustomers through our sourcing operations and looking to drive the lowest cost at the highest availability supply. \n And we believe that in our outlook for FY 2025, we expect to see a compet itive and stable environment in the \ngeneric space as well.  \n \n So we don't see a lot of changes in the environment for both branded and generics pricing in our outlook versus \nFY 2024. ", "original_text": "As we think about the pricing environment for branded products, it is going \nto be \u2013 our anticipation is it would be very consistent with what we've seen in the past several years, so stable \nand competitive branded price environme nt. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5fb8371ab6f895d394ff4bcbdaea2e37603103828615feac885bfb2e5bd10f0a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48d3232f-ecce-4316-946d-e18f62fb201a", "node_type": "1", "metadata": {"window": "I wanted to get a little bit of color on what you're seeing and what's embedded in your guidance in \nterms of the pricing environment on the US pharma business and what assumptions you're making in terms of \ngeneric pricing trends and environment that you're s eeing as well as kind of on the branded side.  I know that's \nless of a swing factor for you, but how is that playing out relative to your expectations here?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, happ y to answer that question.  As we think about the pricing environment for branded products, it is going \nto be \u2013 our anticipation is it would be very consistent with what we've seen in the past several years, so stable \nand competitive branded price environme nt.  And in the generic space, again, we look to drive value for our \ncustomers through our sourcing operations and looking to drive the lowest cost at the highest availability supply. \n And we believe that in our outlook for FY 2025, we expect to see a compet itive and stable environment in the \ngeneric space as well.  \n \n", "original_text": "A \nSure, happ y to answer that question. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "9e0b71b4b958760f628fb39fd4b7d413c96e73d816b56ff86c3d256d3e3ae518", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c0570c3-d9a4-46a8-8e79-597ff9963c05", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, happ y to answer that question.  As we think about the pricing environment for branded products, it is going \nto be \u2013 our anticipation is it would be very consistent with what we've seen in the past several years, so stable \nand competitive branded price environme nt.  And in the generic space, again, we look to drive value for our \ncustomers through our sourcing operations and looking to drive the lowest cost at the highest availability supply. \n And we believe that in our outlook for FY 2025, we expect to see a compet itive and stable environment in the \ngeneric space as well.  \n \n So we don't see a lot of changes in the environment for both branded and generics pricing in our outlook versus \nFY 2024.  And we anticipate that we can continue to drive good value in the generic s pace for our customers.  \n ", "original_text": "And in the generic space, again, we look to drive value for our \ncustomers through our sourcing operations and looking to drive the lowest cost at the highest availability supply. \n"}, "hash": "5177dd2263f6dc3cb4fbdc86ad9b71981a31e926a43c91dbdb86727d2164196a", "class_name": "RelatedNodeInfo"}}, "text": "As we think about the pricing environment for branded products, it is going \nto be \u2013 our anticipation is it would be very consistent with what we've seen in the past several years, so stable \nand competitive branded price environme nt. ", "start_char_idx": 3979, "end_char_idx": 4215, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c0570c3-d9a4-46a8-8e79-597ff9963c05": {"__data__": {"id_": "2c0570c3-d9a4-46a8-8e79-597ff9963c05", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, happ y to answer that question.  As we think about the pricing environment for branded products, it is going \nto be \u2013 our anticipation is it would be very consistent with what we've seen in the past several years, so stable \nand competitive branded price environme nt.  And in the generic space, again, we look to drive value for our \ncustomers through our sourcing operations and looking to drive the lowest cost at the highest availability supply. \n And we believe that in our outlook for FY 2025, we expect to see a compet itive and stable environment in the \ngeneric space as well.  \n \n So we don't see a lot of changes in the environment for both branded and generics pricing in our outlook versus \nFY 2024.  And we anticipate that we can continue to drive good value in the generic s pace for our customers.  \n ", "original_text": "And in the generic space, again, we look to drive value for our \ncustomers through our sourcing operations and looking to drive the lowest cost at the highest availability supply. \n", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5fb8371ab6f895d394ff4bcbdaea2e37603103828615feac885bfb2e5bd10f0a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7c74aa0-261f-41fb-a626-8eb823a119fc", "node_type": "1", "metadata": {"window": "I know that's \nless of a swing factor for you, but how is that playing out relative to your expectations here?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, happ y to answer that question.  As we think about the pricing environment for branded products, it is going \nto be \u2013 our anticipation is it would be very consistent with what we've seen in the past several years, so stable \nand competitive branded price environme nt.  And in the generic space, again, we look to drive value for our \ncustomers through our sourcing operations and looking to drive the lowest cost at the highest availability supply. \n And we believe that in our outlook for FY 2025, we expect to see a compet itive and stable environment in the \ngeneric space as well.  \n \n So we don't see a lot of changes in the environment for both branded and generics pricing in our outlook versus \nFY 2024. ", "original_text": "As we think about the pricing environment for branded products, it is going \nto be \u2013 our anticipation is it would be very consistent with what we've seen in the past several years, so stable \nand competitive branded price environme nt. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "997986a3dd32a596b67c57994d52af364aa093ea68e4911059e02c1ab8dd1696", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "076be851-43d4-409f-b473-1244a27cb589", "node_type": "1", "metadata": {"window": "A \nSure, happ y to answer that question.  As we think about the pricing environment for branded products, it is going \nto be \u2013 our anticipation is it would be very consistent with what we've seen in the past several years, so stable \nand competitive branded price environme nt.  And in the generic space, again, we look to drive value for our \ncustomers through our sourcing operations and looking to drive the lowest cost at the highest availability supply. \n And we believe that in our outlook for FY 2025, we expect to see a compet itive and stable environment in the \ngeneric space as well.  \n \n So we don't see a lot of changes in the environment for both branded and generics pricing in our outlook versus \nFY 2024.  And we anticipate that we can continue to drive good value in the generic s pace for our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And we believe that in our outlook for FY 2025, we expect to see a compet itive and stable environment in the \ngeneric space as well.  \n \n"}, "hash": "80e863411d14fc3131e40936fb5ee27be55677ae6108e825a7a3874c94484557", "class_name": "RelatedNodeInfo"}}, "text": "And in the generic space, again, we look to drive value for our \ncustomers through our sourcing operations and looking to drive the lowest cost at the highest availability supply. \n", "start_char_idx": 4215, "end_char_idx": 4396, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "076be851-43d4-409f-b473-1244a27cb589": {"__data__": {"id_": "076be851-43d4-409f-b473-1244a27cb589", "embedding": null, "metadata": {"window": "A \nSure, happ y to answer that question.  As we think about the pricing environment for branded products, it is going \nto be \u2013 our anticipation is it would be very consistent with what we've seen in the past several years, so stable \nand competitive branded price environme nt.  And in the generic space, again, we look to drive value for our \ncustomers through our sourcing operations and looking to drive the lowest cost at the highest availability supply. \n And we believe that in our outlook for FY 2025, we expect to see a compet itive and stable environment in the \ngeneric space as well.  \n \n So we don't see a lot of changes in the environment for both branded and generics pricing in our outlook versus \nFY 2024.  And we anticipate that we can continue to drive good value in the generic s pace for our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And we believe that in our outlook for FY 2025, we expect to see a compet itive and stable environment in the \ngeneric space as well.  \n \n", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5fb8371ab6f895d394ff4bcbdaea2e37603103828615feac885bfb2e5bd10f0a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c0570c3-d9a4-46a8-8e79-597ff9963c05", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, happ y to answer that question.  As we think about the pricing environment for branded products, it is going \nto be \u2013 our anticipation is it would be very consistent with what we've seen in the past several years, so stable \nand competitive branded price environme nt.  And in the generic space, again, we look to drive value for our \ncustomers through our sourcing operations and looking to drive the lowest cost at the highest availability supply. \n And we believe that in our outlook for FY 2025, we expect to see a compet itive and stable environment in the \ngeneric space as well.  \n \n So we don't see a lot of changes in the environment for both branded and generics pricing in our outlook versus \nFY 2024.  And we anticipate that we can continue to drive good value in the generic s pace for our customers.  \n ", "original_text": "And in the generic space, again, we look to drive value for our \ncustomers through our sourcing operations and looking to drive the lowest cost at the highest availability supply. \n", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "021efc00ac3e7922b6c2c27b70abfe55b1f7cf0f4689ca199e2bce0c05efb2aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "352bea7a-7b68-49a9-97a2-a1be51e41432", "node_type": "1", "metadata": {"window": "As we think about the pricing environment for branded products, it is going \nto be \u2013 our anticipation is it would be very consistent with what we've seen in the past several years, so stable \nand competitive branded price environme nt.  And in the generic space, again, we look to drive value for our \ncustomers through our sourcing operations and looking to drive the lowest cost at the highest availability supply. \n And we believe that in our outlook for FY 2025, we expect to see a compet itive and stable environment in the \ngeneric space as well.  \n \n So we don't see a lot of changes in the environment for both branded and generics pricing in our outlook versus \nFY 2024.  And we anticipate that we can continue to drive good value in the generic s pace for our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "So we don't see a lot of changes in the environment for both branded and generics pricing in our outlook versus \nFY 2024. "}, "hash": "368f835b3091f0bec105639ed70c85152d68f4af91cd0af7590e658b894aba6f", "class_name": "RelatedNodeInfo"}}, "text": "And we believe that in our outlook for FY 2025, we expect to see a compet itive and stable environment in the \ngeneric space as well.  \n \n", "start_char_idx": 4396, "end_char_idx": 4534, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "352bea7a-7b68-49a9-97a2-a1be51e41432": {"__data__": {"id_": "352bea7a-7b68-49a9-97a2-a1be51e41432", "embedding": null, "metadata": {"window": "As we think about the pricing environment for branded products, it is going \nto be \u2013 our anticipation is it would be very consistent with what we've seen in the past several years, so stable \nand competitive branded price environme nt.  And in the generic space, again, we look to drive value for our \ncustomers through our sourcing operations and looking to drive the lowest cost at the highest availability supply. \n And we believe that in our outlook for FY 2025, we expect to see a compet itive and stable environment in the \ngeneric space as well.  \n \n So we don't see a lot of changes in the environment for both branded and generics pricing in our outlook versus \nFY 2024.  And we anticipate that we can continue to drive good value in the generic s pace for our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "So we don't see a lot of changes in the environment for both branded and generics pricing in our outlook versus \nFY 2024. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5fb8371ab6f895d394ff4bcbdaea2e37603103828615feac885bfb2e5bd10f0a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "076be851-43d4-409f-b473-1244a27cb589", "node_type": "1", "metadata": {"window": "A \nSure, happ y to answer that question.  As we think about the pricing environment for branded products, it is going \nto be \u2013 our anticipation is it would be very consistent with what we've seen in the past several years, so stable \nand competitive branded price environme nt.  And in the generic space, again, we look to drive value for our \ncustomers through our sourcing operations and looking to drive the lowest cost at the highest availability supply. \n And we believe that in our outlook for FY 2025, we expect to see a compet itive and stable environment in the \ngeneric space as well.  \n \n So we don't see a lot of changes in the environment for both branded and generics pricing in our outlook versus \nFY 2024.  And we anticipate that we can continue to drive good value in the generic s pace for our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And we believe that in our outlook for FY 2025, we expect to see a compet itive and stable environment in the \ngeneric space as well.  \n \n", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "39a4e1a9ddd587d5cc9d1c3173f34b71ffda847e00b4db565dce3f12db010f97", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "992f672d-23d1-4e7c-8097-d262e5ff9519", "node_type": "1", "metadata": {"window": "And in the generic space, again, we look to drive value for our \ncustomers through our sourcing operations and looking to drive the lowest cost at the highest availability supply. \n And we believe that in our outlook for FY 2025, we expect to see a compet itive and stable environment in the \ngeneric space as well.  \n \n So we don't see a lot of changes in the environment for both branded and generics pricing in our outlook versus \nFY 2024.  And we anticipate that we can continue to drive good value in the generic s pace for our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And we anticipate that we can continue to drive good value in the generic s pace for our customers.  \n "}, "hash": "2ae02ad6ee9a8e69cb071837f239b9d78cd9f1b12455217fe2de91188ac5a91f", "class_name": "RelatedNodeInfo"}}, "text": "So we don't see a lot of changes in the environment for both branded and generics pricing in our outlook versus \nFY 2024. ", "start_char_idx": 4534, "end_char_idx": 4656, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "992f672d-23d1-4e7c-8097-d262e5ff9519": {"__data__": {"id_": "992f672d-23d1-4e7c-8097-d262e5ff9519", "embedding": null, "metadata": {"window": "And in the generic space, again, we look to drive value for our \ncustomers through our sourcing operations and looking to drive the lowest cost at the highest availability supply. \n And we believe that in our outlook for FY 2025, we expect to see a compet itive and stable environment in the \ngeneric space as well.  \n \n So we don't see a lot of changes in the environment for both branded and generics pricing in our outlook versus \nFY 2024.  And we anticipate that we can continue to drive good value in the generic s pace for our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And we anticipate that we can continue to drive good value in the generic s pace for our customers.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5fb8371ab6f895d394ff4bcbdaea2e37603103828615feac885bfb2e5bd10f0a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "352bea7a-7b68-49a9-97a2-a1be51e41432", "node_type": "1", "metadata": {"window": "As we think about the pricing environment for branded products, it is going \nto be \u2013 our anticipation is it would be very consistent with what we've seen in the past several years, so stable \nand competitive branded price environme nt.  And in the generic space, again, we look to drive value for our \ncustomers through our sourcing operations and looking to drive the lowest cost at the highest availability supply. \n And we believe that in our outlook for FY 2025, we expect to see a compet itive and stable environment in the \ngeneric space as well.  \n \n So we don't see a lot of changes in the environment for both branded and generics pricing in our outlook versus \nFY 2024.  And we anticipate that we can continue to drive good value in the generic s pace for our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "So we don't see a lot of changes in the environment for both branded and generics pricing in our outlook versus \nFY 2024. ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "cad251679b6474650426b9a81cb5c33f2607fc01a9b026bdafcb38d9759ece2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "534e5f4a-dff4-4ade-beff-bc5bf1a3409e", "node_type": "1", "metadata": {"window": "And we believe that in our outlook for FY 2025, we expect to see a compet itive and stable environment in the \ngeneric space as well.  \n \n So we don't see a lot of changes in the environment for both branded and generics pricing in our outlook versus \nFY 2024.  And we anticipate that we can continue to drive good value in the generic s pace for our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  "}, "hash": "b1d607cbdb7d3392b718f8d41352650ceed3008b6c3e16cd605841c6895b03e3", "class_name": "RelatedNodeInfo"}}, "text": "And we anticipate that we can continue to drive good value in the generic s pace for our customers.  \n ", "start_char_idx": 4656, "end_char_idx": 4759, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "534e5f4a-dff4-4ade-beff-bc5bf1a3409e": {"__data__": {"id_": "534e5f4a-dff4-4ade-beff-bc5bf1a3409e", "embedding": null, "metadata": {"window": "And we believe that in our outlook for FY 2025, we expect to see a compet itive and stable environment in the \ngeneric space as well.  \n \n So we don't see a lot of changes in the environment for both branded and generics pricing in our outlook versus \nFY 2024.  And we anticipate that we can continue to drive good value in the generic s pace for our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "5fb8371ab6f895d394ff4bcbdaea2e37603103828615feac885bfb2e5bd10f0a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "992f672d-23d1-4e7c-8097-d262e5ff9519", "node_type": "1", "metadata": {"window": "And in the generic space, again, we look to drive value for our \ncustomers through our sourcing operations and looking to drive the lowest cost at the highest availability supply. \n And we believe that in our outlook for FY 2025, we expect to see a compet itive and stable environment in the \ngeneric space as well.  \n \n So we don't see a lot of changes in the environment for both branded and generics pricing in our outlook versus \nFY 2024.  And we anticipate that we can continue to drive good value in the generic s pace for our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And we anticipate that we can continue to drive good value in the generic s pace for our customers.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "90faab448a5962ef74bb192c56288a1c6eb7cb40cb619e054a8fa2e12a736aa0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35fea3da-78e4-425e-9a3a-ecaedfa1aaa0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nI think we have time for probably one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "original_text": "McKesson Corp.  "}, "hash": "aad23d2de0d68d944018ec11d69b0168f71938720813ca79f6fdcf5716bdd938", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "start_char_idx": 805, "end_char_idx": 1076, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35fea3da-78e4-425e-9a3a-ecaedfa1aaa0": {"__data__": {"id_": "35fea3da-78e4-425e-9a3a-ecaedfa1aaa0", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nI think we have time for probably one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f00a882ac27d4543b15dbda7ec68423d1eb2a4d27a9aeee1c12629c0aef013a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "534e5f4a-dff4-4ade-beff-bc5bf1a3409e", "node_type": "1", "metadata": {"window": "And we believe that in our outlook for FY 2025, we expect to see a compet itive and stable environment in the \ngeneric space as well.  \n \n So we don't see a lot of changes in the environment for both branded and generics pricing in our outlook versus \nFY 2024.  And we anticipate that we can continue to drive good value in the generic s pace for our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "95d8af646b3b68150d500ea3b5c93a8664047d2ffc40aa08066d9825424f516a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b680483-a32b-4ed7-8f18-46f1d4aeb952", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nI think we have time for probably one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Stephen Baxter with Wells Fargo. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  "}, "hash": "4c72e42fa51c814d73ce92b4cb6c414fa33cdbb22eb95ebe8716a95c4232bedd", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b680483-a32b-4ed7-8f18-46f1d4aeb952": {"__data__": {"id_": "0b680483-a32b-4ed7-8f18-46f1d4aeb952", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nI think we have time for probably one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Stephen Baxter with Wells Fargo. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f00a882ac27d4543b15dbda7ec68423d1eb2a4d27a9aeee1c12629c0aef013a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35fea3da-78e4-425e-9a3a-ecaedfa1aaa0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nI think we have time for probably one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a5f7d81790d2876968bb7894c0ebab6aef562a8a44711053a05871865ad111b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8b193f8-e584-4ea5-a009-e5b25fcf5eb8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nI think we have time for probably one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Stephen Baxter with Wells Fargo.  Please go ahead.  \n ", "original_text": "A \nI think we have time for probably one more question.  \n "}, "hash": "ac508ce08349056f1f53e793fc9939d58969c821f337112eed45a60c35389458", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 254, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8b193f8-e584-4ea5-a009-e5b25fcf5eb8": {"__data__": {"id_": "a8b193f8-e584-4ea5-a009-e5b25fcf5eb8", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nI think we have time for probably one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Stephen Baxter with Wells Fargo.  Please go ahead.  \n ", "original_text": "A \nI think we have time for probably one more question.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f00a882ac27d4543b15dbda7ec68423d1eb2a4d27a9aeee1c12629c0aef013a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b680483-a32b-4ed7-8f18-46f1d4aeb952", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nI think we have time for probably one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Stephen Baxter with Wells Fargo. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "2bb82ece9ee0d7b5e8ad82502f4c58683e9f9a33717cd3a9543dfff9cf61c2f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45ac1bd1-c80f-480d-b951-f1dbcfb244f8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nI think we have time for probably one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Stephen Baxter with Wells Fargo.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  Q \nHey, thanks for the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. "}, "hash": "027efaebd4bfd61911470deaae59e1bf43536f7c4783c695b2b9a6d58724821e", "class_name": "RelatedNodeInfo"}}, "text": "A \nI think we have time for probably one more question.  \n ", "start_char_idx": 254, "end_char_idx": 313, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45ac1bd1-c80f-480d-b951-f1dbcfb244f8": {"__data__": {"id_": "45ac1bd1-c80f-480d-b951-f1dbcfb244f8", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nI think we have time for probably one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Stephen Baxter with Wells Fargo.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  Q \nHey, thanks for the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f00a882ac27d4543b15dbda7ec68423d1eb2a4d27a9aeee1c12629c0aef013a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8b193f8-e584-4ea5-a009-e5b25fcf5eb8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nI think we have time for probably one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Stephen Baxter with Wells Fargo.  Please go ahead.  \n ", "original_text": "A \nI think we have time for probably one more question.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ab627a64318cdf6f6931cf2fa6f4eafb172957bd46ad5f5a6fe4e9d3272ae813", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72b5717b-5110-4204-9fea-4f1015d8e7af", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nI think we have time for probably one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Stephen Baxter with Wells Fargo.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  Q \nHey, thanks for the question.  Much of the guidance, I wanted to ask one on the quarter. ", "original_text": "That question will come from Stephen Baxter with Wells Fargo. "}, "hash": "722b4b0a44b542837ead451cdb3bcfed7160c19bc4289d356aa43cc9a1aa0ff9", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "start_char_idx": 313, "end_char_idx": 609, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72b5717b-5110-4204-9fea-4f1015d8e7af": {"__data__": {"id_": "72b5717b-5110-4204-9fea-4f1015d8e7af", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nI think we have time for probably one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Stephen Baxter with Wells Fargo.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  Q \nHey, thanks for the question.  Much of the guidance, I wanted to ask one on the quarter. ", "original_text": "That question will come from Stephen Baxter with Wells Fargo. ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f00a882ac27d4543b15dbda7ec68423d1eb2a4d27a9aeee1c12629c0aef013a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45ac1bd1-c80f-480d-b951-f1dbcfb244f8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nI think we have time for probably one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Stephen Baxter with Wells Fargo.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  Q \nHey, thanks for the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3f578a2b938a003905a6603308421b35cae334da58d93a10a7de3dd5ec3dee10", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4d2d077-ab69-4dae-861e-ca4d6fd07dfa", "node_type": "1", "metadata": {"window": "A \nI think we have time for probably one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Stephen Baxter with Wells Fargo.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  Q \nHey, thanks for the question.  Much of the guidance, I wanted to ask one on the quarter.  Just on the pharma \nrevenue growth rate, was wondering if you could help us think about any impact you might have seen from insulin \nlist price changes in the quarter. ", "original_text": "Please go ahead.  \n "}, "hash": "0c71b8bb50608a549fe06bef3c74a40a4dce0e6c260eb9a9b8f107d8f45d88b4", "class_name": "RelatedNodeInfo"}}, "text": "That question will come from Stephen Baxter with Wells Fargo. ", "start_char_idx": 609, "end_char_idx": 671, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4d2d077-ab69-4dae-861e-ca4d6fd07dfa": {"__data__": {"id_": "f4d2d077-ab69-4dae-861e-ca4d6fd07dfa", "embedding": null, "metadata": {"window": "A \nI think we have time for probably one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Stephen Baxter with Wells Fargo.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  Q \nHey, thanks for the question.  Much of the guidance, I wanted to ask one on the quarter.  Just on the pharma \nrevenue growth rate, was wondering if you could help us think about any impact you might have seen from insulin \nlist price changes in the quarter. ", "original_text": "Please go ahead.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f00a882ac27d4543b15dbda7ec68423d1eb2a4d27a9aeee1c12629c0aef013a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72b5717b-5110-4204-9fea-4f1015d8e7af", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nI think we have time for probably one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Stephen Baxter with Wells Fargo.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  Q \nHey, thanks for the question.  Much of the guidance, I wanted to ask one on the quarter. ", "original_text": "That question will come from Stephen Baxter with Wells Fargo. ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "007263c72bed57a5051508b2951f45ea011808bf04992f6ca25b99f0a2c4dce9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0593d9b9-4967-44f9-a019-6006ca2d8174", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Stephen Baxter with Wells Fargo.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  Q \nHey, thanks for the question.  Much of the guidance, I wanted to ask one on the quarter.  Just on the pharma \nrevenue growth rate, was wondering if you could help us think about any impact you might have seen from insulin \nlist price changes in the quarter.  It sounds like that was probably a headwind to your revenue growth rate? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  Q \nHey, thanks for the question. "}, "hash": "c5f6013b2a1bee4dabf8ae4f9cee9235417a1c7626e4cdde96ba51b2e62d08a0", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 671, "end_char_idx": 691, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0593d9b9-4967-44f9-a019-6006ca2d8174": {"__data__": {"id_": "0593d9b9-4967-44f9-a019-6006ca2d8174", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Stephen Baxter with Wells Fargo.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  Q \nHey, thanks for the question.  Much of the guidance, I wanted to ask one on the quarter.  Just on the pharma \nrevenue growth rate, was wondering if you could help us think about any impact you might have seen from insulin \nlist price changes in the quarter.  It sounds like that was probably a headwind to your revenue growth rate? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  Q \nHey, thanks for the question. ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f00a882ac27d4543b15dbda7ec68423d1eb2a4d27a9aeee1c12629c0aef013a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4d2d077-ab69-4dae-861e-ca4d6fd07dfa", "node_type": "1", "metadata": {"window": "A \nI think we have time for probably one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Stephen Baxter with Wells Fargo.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  Q \nHey, thanks for the question.  Much of the guidance, I wanted to ask one on the quarter.  Just on the pharma \nrevenue growth rate, was wondering if you could help us think about any impact you might have seen from insulin \nlist price changes in the quarter. ", "original_text": "Please go ahead.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "fac087faf2fa46cb8db8927bc4743f510b9ad8309b0fbecab3abdf603a222b11", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e7c4ec4-6cc8-4af1-8326-cc02db2107ea", "node_type": "1", "metadata": {"window": "That question will come from Stephen Baxter with Wells Fargo.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  Q \nHey, thanks for the question.  Much of the guidance, I wanted to ask one on the quarter.  Just on the pharma \nrevenue growth rate, was wondering if you could help us think about any impact you might have seen from insulin \nlist price changes in the quarter.  It sounds like that was probably a headwind to your revenue growth rate?  And \nany contribution from commercial COVID vaccines in the quarter that we should be mindful of? ", "original_text": "Much of the guidance, I wanted to ask one on the quarter. "}, "hash": "addaedb0630075ea472d1482091626e0940068b90e451adf46d9b60b826e5856", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  Q \nHey, thanks for the question. ", "start_char_idx": 691, "end_char_idx": 1050, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e7c4ec4-6cc8-4af1-8326-cc02db2107ea": {"__data__": {"id_": "1e7c4ec4-6cc8-4af1-8326-cc02db2107ea", "embedding": null, "metadata": {"window": "That question will come from Stephen Baxter with Wells Fargo.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  Q \nHey, thanks for the question.  Much of the guidance, I wanted to ask one on the quarter.  Just on the pharma \nrevenue growth rate, was wondering if you could help us think about any impact you might have seen from insulin \nlist price changes in the quarter.  It sounds like that was probably a headwind to your revenue growth rate?  And \nany contribution from commercial COVID vaccines in the quarter that we should be mindful of? ", "original_text": "Much of the guidance, I wanted to ask one on the quarter. ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f00a882ac27d4543b15dbda7ec68423d1eb2a4d27a9aeee1c12629c0aef013a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0593d9b9-4967-44f9-a019-6006ca2d8174", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Stephen Baxter with Wells Fargo.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  Q \nHey, thanks for the question.  Much of the guidance, I wanted to ask one on the quarter.  Just on the pharma \nrevenue growth rate, was wondering if you could help us think about any impact you might have seen from insulin \nlist price changes in the quarter.  It sounds like that was probably a headwind to your revenue growth rate? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  Q \nHey, thanks for the question. ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "7f9026c639da52e258f12ac33f845843132622aee865892687859d291d1f1c88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc5f0957-08a4-4a78-ad41-3e18d8fae635", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  Q \nHey, thanks for the question.  Much of the guidance, I wanted to ask one on the quarter.  Just on the pharma \nrevenue growth rate, was wondering if you could help us think about any impact you might have seen from insulin \nlist price changes in the quarter.  It sounds like that was probably a headwind to your revenue growth rate?  And \nany contribution from commercial COVID vaccines in the quarter that we should be mindful of?  Thanks.  \n ", "original_text": "Just on the pharma \nrevenue growth rate, was wondering if you could help us think about any impact you might have seen from insulin \nlist price changes in the quarter. "}, "hash": "b061dfd5a0a7bb414519298b645c724869eada9e1541b926ffa311277df1e2c3", "class_name": "RelatedNodeInfo"}}, "text": "Much of the guidance, I wanted to ask one on the quarter. ", "start_char_idx": 1050, "end_char_idx": 1108, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc5f0957-08a4-4a78-ad41-3e18d8fae635": {"__data__": {"id_": "dc5f0957-08a4-4a78-ad41-3e18d8fae635", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  Q \nHey, thanks for the question.  Much of the guidance, I wanted to ask one on the quarter.  Just on the pharma \nrevenue growth rate, was wondering if you could help us think about any impact you might have seen from insulin \nlist price changes in the quarter.  It sounds like that was probably a headwind to your revenue growth rate?  And \nany contribution from commercial COVID vaccines in the quarter that we should be mindful of?  Thanks.  \n ", "original_text": "Just on the pharma \nrevenue growth rate, was wondering if you could help us think about any impact you might have seen from insulin \nlist price changes in the quarter. ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f00a882ac27d4543b15dbda7ec68423d1eb2a4d27a9aeee1c12629c0aef013a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e7c4ec4-6cc8-4af1-8326-cc02db2107ea", "node_type": "1", "metadata": {"window": "That question will come from Stephen Baxter with Wells Fargo.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  Q \nHey, thanks for the question.  Much of the guidance, I wanted to ask one on the quarter.  Just on the pharma \nrevenue growth rate, was wondering if you could help us think about any impact you might have seen from insulin \nlist price changes in the quarter.  It sounds like that was probably a headwind to your revenue growth rate?  And \nany contribution from commercial COVID vaccines in the quarter that we should be mindful of? ", "original_text": "Much of the guidance, I wanted to ask one on the quarter. ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "90f0604d9696452aac0de58b10f8a2e8a1b178f6c86dd1dfcfb0a9110bcae5c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1484556-0c61-4d2f-a10b-fa0f24848a62", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  Q \nHey, thanks for the question.  Much of the guidance, I wanted to ask one on the quarter.  Just on the pharma \nrevenue growth rate, was wondering if you could help us think about any impact you might have seen from insulin \nlist price changes in the quarter.  It sounds like that was probably a headwind to your revenue growth rate?  And \nany contribution from commercial COVID vaccines in the quarter that we should be mindful of?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief  Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "It sounds like that was probably a headwind to your revenue growth rate? "}, "hash": "c1720e90f07305f169fbb5219c7e86ac53ac4cb81c66df27e7deaebc7d132536", "class_name": "RelatedNodeInfo"}}, "text": "Just on the pharma \nrevenue growth rate, was wondering if you could help us think about any impact you might have seen from insulin \nlist price changes in the quarter. ", "start_char_idx": 1108, "end_char_idx": 1276, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1484556-0c61-4d2f-a10b-fa0f24848a62": {"__data__": {"id_": "d1484556-0c61-4d2f-a10b-fa0f24848a62", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  Q \nHey, thanks for the question.  Much of the guidance, I wanted to ask one on the quarter.  Just on the pharma \nrevenue growth rate, was wondering if you could help us think about any impact you might have seen from insulin \nlist price changes in the quarter.  It sounds like that was probably a headwind to your revenue growth rate?  And \nany contribution from commercial COVID vaccines in the quarter that we should be mindful of?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief  Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "It sounds like that was probably a headwind to your revenue growth rate? ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f00a882ac27d4543b15dbda7ec68423d1eb2a4d27a9aeee1c12629c0aef013a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc5f0957-08a4-4a78-ad41-3e18d8fae635", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  Q \nHey, thanks for the question.  Much of the guidance, I wanted to ask one on the quarter.  Just on the pharma \nrevenue growth rate, was wondering if you could help us think about any impact you might have seen from insulin \nlist price changes in the quarter.  It sounds like that was probably a headwind to your revenue growth rate?  And \nany contribution from commercial COVID vaccines in the quarter that we should be mindful of?  Thanks.  \n ", "original_text": "Just on the pharma \nrevenue growth rate, was wondering if you could help us think about any impact you might have seen from insulin \nlist price changes in the quarter. ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "bbd587806ac1bf439c07407be1e892e997ff8859823e0e7837ad40c2d73504fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a20a6a1-bb5e-444e-b7dd-7abf17ddb69a", "node_type": "1", "metadata": {"window": "Much of the guidance, I wanted to ask one on the quarter.  Just on the pharma \nrevenue growth rate, was wondering if you could help us think about any impact you might have seen from insulin \nlist price changes in the quarter.  It sounds like that was probably a headwind to your revenue growth rate?  And \nany contribution from commercial COVID vaccines in the quarter that we should be mindful of?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief  Financial Officer & Executive Vice President, McKesson Corp.   A \nYes, nothing really specific to call out there, Stephen. ", "original_text": "And \nany contribution from commercial COVID vaccines in the quarter that we should be mindful of? "}, "hash": "09822946a30c1ce5213c94ed22db737a182fbd56ae93c3136083f577338ce873", "class_name": "RelatedNodeInfo"}}, "text": "It sounds like that was probably a headwind to your revenue growth rate? ", "start_char_idx": 1276, "end_char_idx": 1349, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a20a6a1-bb5e-444e-b7dd-7abf17ddb69a": {"__data__": {"id_": "6a20a6a1-bb5e-444e-b7dd-7abf17ddb69a", "embedding": null, "metadata": {"window": "Much of the guidance, I wanted to ask one on the quarter.  Just on the pharma \nrevenue growth rate, was wondering if you could help us think about any impact you might have seen from insulin \nlist price changes in the quarter.  It sounds like that was probably a headwind to your revenue growth rate?  And \nany contribution from commercial COVID vaccines in the quarter that we should be mindful of?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief  Financial Officer & Executive Vice President, McKesson Corp.   A \nYes, nothing really specific to call out there, Stephen. ", "original_text": "And \nany contribution from commercial COVID vaccines in the quarter that we should be mindful of? ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f00a882ac27d4543b15dbda7ec68423d1eb2a4d27a9aeee1c12629c0aef013a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1484556-0c61-4d2f-a10b-fa0f24848a62", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wells Fargo Securities LLC  Q \nHey, thanks for the question.  Much of the guidance, I wanted to ask one on the quarter.  Just on the pharma \nrevenue growth rate, was wondering if you could help us think about any impact you might have seen from insulin \nlist price changes in the quarter.  It sounds like that was probably a headwind to your revenue growth rate?  And \nany contribution from commercial COVID vaccines in the quarter that we should be mindful of?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief  Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "It sounds like that was probably a headwind to your revenue growth rate? ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "efc926d247a7da9ad50e3a3ea00637bf6b1113824560d46c81afbd2d852d51ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b471fcb-0973-44c2-9846-e4c353536cd9", "node_type": "1", "metadata": {"window": "Just on the pharma \nrevenue growth rate, was wondering if you could help us think about any impact you might have seen from insulin \nlist price changes in the quarter.  It sounds like that was probably a headwind to your revenue growth rate?  And \nany contribution from commercial COVID vaccines in the quarter that we should be mindful of?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief  Financial Officer & Executive Vice President, McKesson Corp.   A \nYes, nothing really specific to call out there, Stephen.  And as it relates to COVID vaccines, as I mentioned, we are \nlapping the COVID programs that we had last year and from a commercial vaccine perspective, lower contribution \nthat we saw in the third quarter, really a non -material amount of contribution to our fourth quarter results.  \n ", "original_text": "Thanks.  \n "}, "hash": "e964d3f51e8d8e0e9091a6a031313075147724eda60cad25634e3c6b7c2e120b", "class_name": "RelatedNodeInfo"}}, "text": "And \nany contribution from commercial COVID vaccines in the quarter that we should be mindful of? ", "start_char_idx": 1349, "end_char_idx": 1447, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b471fcb-0973-44c2-9846-e4c353536cd9": {"__data__": {"id_": "7b471fcb-0973-44c2-9846-e4c353536cd9", "embedding": null, "metadata": {"window": "Just on the pharma \nrevenue growth rate, was wondering if you could help us think about any impact you might have seen from insulin \nlist price changes in the quarter.  It sounds like that was probably a headwind to your revenue growth rate?  And \nany contribution from commercial COVID vaccines in the quarter that we should be mindful of?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief  Financial Officer & Executive Vice President, McKesson Corp.   A \nYes, nothing really specific to call out there, Stephen.  And as it relates to COVID vaccines, as I mentioned, we are \nlapping the COVID programs that we had last year and from a commercial vaccine perspective, lower contribution \nthat we saw in the third quarter, really a non -material amount of contribution to our fourth quarter results.  \n ", "original_text": "Thanks.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f00a882ac27d4543b15dbda7ec68423d1eb2a4d27a9aeee1c12629c0aef013a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a20a6a1-bb5e-444e-b7dd-7abf17ddb69a", "node_type": "1", "metadata": {"window": "Much of the guidance, I wanted to ask one on the quarter.  Just on the pharma \nrevenue growth rate, was wondering if you could help us think about any impact you might have seen from insulin \nlist price changes in the quarter.  It sounds like that was probably a headwind to your revenue growth rate?  And \nany contribution from commercial COVID vaccines in the quarter that we should be mindful of?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief  Financial Officer & Executive Vice President, McKesson Corp.   A \nYes, nothing really specific to call out there, Stephen. ", "original_text": "And \nany contribution from commercial COVID vaccines in the quarter that we should be mindful of? ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "129153f466e3bbb22c24900e011c0a21416a2f28fe77c79338030b6e7fe26d61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "376bdbf3-4505-4949-a2ca-7160ed2541fd", "node_type": "1", "metadata": {"window": "It sounds like that was probably a headwind to your revenue growth rate?  And \nany contribution from commercial COVID vaccines in the quarter that we should be mindful of?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief  Financial Officer & Executive Vice President, McKesson Corp.   A \nYes, nothing really specific to call out there, Stephen.  And as it relates to COVID vaccines, as I mentioned, we are \nlapping the COVID programs that we had last year and from a commercial vaccine perspective, lower contribution \nthat we saw in the third quarter, really a non -material amount of contribution to our fourth quarter results.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief  Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "a46f26c8781bf803b8a10c06fc20c752d32cd17be18845f2b33650bb9c802eb0", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 1447, "end_char_idx": 1458, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "376bdbf3-4505-4949-a2ca-7160ed2541fd": {"__data__": {"id_": "376bdbf3-4505-4949-a2ca-7160ed2541fd", "embedding": null, "metadata": {"window": "It sounds like that was probably a headwind to your revenue growth rate?  And \nany contribution from commercial COVID vaccines in the quarter that we should be mindful of?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief  Financial Officer & Executive Vice President, McKesson Corp.   A \nYes, nothing really specific to call out there, Stephen.  And as it relates to COVID vaccines, as I mentioned, we are \nlapping the COVID programs that we had last year and from a commercial vaccine perspective, lower contribution \nthat we saw in the third quarter, really a non -material amount of contribution to our fourth quarter results.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief  Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f00a882ac27d4543b15dbda7ec68423d1eb2a4d27a9aeee1c12629c0aef013a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b471fcb-0973-44c2-9846-e4c353536cd9", "node_type": "1", "metadata": {"window": "Just on the pharma \nrevenue growth rate, was wondering if you could help us think about any impact you might have seen from insulin \nlist price changes in the quarter.  It sounds like that was probably a headwind to your revenue growth rate?  And \nany contribution from commercial COVID vaccines in the quarter that we should be mindful of?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief  Financial Officer & Executive Vice President, McKesson Corp.   A \nYes, nothing really specific to call out there, Stephen.  And as it relates to COVID vaccines, as I mentioned, we are \nlapping the COVID programs that we had last year and from a commercial vaccine perspective, lower contribution \nthat we saw in the third quarter, really a non -material amount of contribution to our fourth quarter results.  \n ", "original_text": "Thanks.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "42b226cc7f3fdca86c29ff2c65a69973875f0aaa897b10243f0098cedca38a3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b3b845cb-2e2c-42f1-8d84-306c5fbb38e5", "node_type": "1", "metadata": {"window": "And \nany contribution from commercial COVID vaccines in the quarter that we should be mindful of?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief  Financial Officer & Executive Vice President, McKesson Corp.   A \nYes, nothing really specific to call out there, Stephen.  And as it relates to COVID vaccines, as I mentioned, we are \nlapping the COVID programs that we had last year and from a commercial vaccine perspective, lower contribution \nthat we saw in the third quarter, really a non -material amount of contribution to our fourth quarter results.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thanks again, everyone, for joining our call this evening. ", "original_text": "A \nYes, nothing really specific to call out there, Stephen. "}, "hash": "f9c65d4fcfc8f87aa7797f186cbfd8d31067ae41d06c066ed5c51ee023381523", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief  Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 1458, "end_char_idx": 1819, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b3b845cb-2e2c-42f1-8d84-306c5fbb38e5": {"__data__": {"id_": "b3b845cb-2e2c-42f1-8d84-306c5fbb38e5", "embedding": null, "metadata": {"window": "And \nany contribution from commercial COVID vaccines in the quarter that we should be mindful of?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief  Financial Officer & Executive Vice President, McKesson Corp.   A \nYes, nothing really specific to call out there, Stephen.  And as it relates to COVID vaccines, as I mentioned, we are \nlapping the COVID programs that we had last year and from a commercial vaccine perspective, lower contribution \nthat we saw in the third quarter, really a non -material amount of contribution to our fourth quarter results.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thanks again, everyone, for joining our call this evening. ", "original_text": "A \nYes, nothing really specific to call out there, Stephen. ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f00a882ac27d4543b15dbda7ec68423d1eb2a4d27a9aeee1c12629c0aef013a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "376bdbf3-4505-4949-a2ca-7160ed2541fd", "node_type": "1", "metadata": {"window": "It sounds like that was probably a headwind to your revenue growth rate?  And \nany contribution from commercial COVID vaccines in the quarter that we should be mindful of?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief  Financial Officer & Executive Vice President, McKesson Corp.   A \nYes, nothing really specific to call out there, Stephen.  And as it relates to COVID vaccines, as I mentioned, we are \nlapping the COVID programs that we had last year and from a commercial vaccine perspective, lower contribution \nthat we saw in the third quarter, really a non -material amount of contribution to our fourth quarter results.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief  Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ad5d5b5b5ecb0c32020ec99be08f9b00de89abd178fb72e1d9d8af6044afa9d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a3c2696-cf44-4b56-9ab4-db5a3618b61d", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief  Financial Officer & Executive Vice President, McKesson Corp.   A \nYes, nothing really specific to call out there, Stephen.  And as it relates to COVID vaccines, as I mentioned, we are \nlapping the COVID programs that we had last year and from a commercial vaccine perspective, lower contribution \nthat we saw in the third quarter, really a non -material amount of contribution to our fourth quarter results.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thanks again, everyone, for joining our call this evening.  We appreciate your ongoing interest and support of \nMcKesson. ", "original_text": "And as it relates to COVID vaccines, as I mentioned, we are \nlapping the COVID programs that we had last year and from a commercial vaccine perspective, lower contribution \nthat we saw in the third quarter, really a non -material amount of contribution to our fourth quarter results.  \n "}, "hash": "451a51e76b1cadbaf6c71c0ffbb3f4c57fad86b93aeb8631ddd39814c941a2d0", "class_name": "RelatedNodeInfo"}}, "text": "A \nYes, nothing really specific to call out there, Stephen. ", "start_char_idx": 1819, "end_char_idx": 1879, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a3c2696-cf44-4b56-9ab4-db5a3618b61d": {"__data__": {"id_": "1a3c2696-cf44-4b56-9ab4-db5a3618b61d", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief  Financial Officer & Executive Vice President, McKesson Corp.   A \nYes, nothing really specific to call out there, Stephen.  And as it relates to COVID vaccines, as I mentioned, we are \nlapping the COVID programs that we had last year and from a commercial vaccine perspective, lower contribution \nthat we saw in the third quarter, really a non -material amount of contribution to our fourth quarter results.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thanks again, everyone, for joining our call this evening.  We appreciate your ongoing interest and support of \nMcKesson. ", "original_text": "And as it relates to COVID vaccines, as I mentioned, we are \nlapping the COVID programs that we had last year and from a commercial vaccine perspective, lower contribution \nthat we saw in the third quarter, really a non -material amount of contribution to our fourth quarter results.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f00a882ac27d4543b15dbda7ec68423d1eb2a4d27a9aeee1c12629c0aef013a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b3b845cb-2e2c-42f1-8d84-306c5fbb38e5", "node_type": "1", "metadata": {"window": "And \nany contribution from commercial COVID vaccines in the quarter that we should be mindful of?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief  Financial Officer & Executive Vice President, McKesson Corp.   A \nYes, nothing really specific to call out there, Stephen.  And as it relates to COVID vaccines, as I mentioned, we are \nlapping the COVID programs that we had last year and from a commercial vaccine perspective, lower contribution \nthat we saw in the third quarter, really a non -material amount of contribution to our fourth quarter results.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thanks again, everyone, for joining our call this evening. ", "original_text": "A \nYes, nothing really specific to call out there, Stephen. ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "13f8fb11b99b41c0bd9327b99468f4efec85adde45580e400cb1ff4419562180", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea5e01c1-933a-44c7-bbd2-59643aea09ff", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief  Financial Officer & Executive Vice President, McKesson Corp.   A \nYes, nothing really specific to call out there, Stephen.  And as it relates to COVID vaccines, as I mentioned, we are \nlapping the COVID programs that we had last year and from a commercial vaccine perspective, lower contribution \nthat we saw in the third quarter, really a non -material amount of contribution to our fourth quarter results.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thanks again, everyone, for joining our call this evening.  We appreciate your ongoing interest and support of \nMcKesson.  I want to thank you, operator, for facilitating the call.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n"}, "hash": "3fe97dd5c99018bdedfa2858bab1493662a1b43948b9d273d87474133e6726bc", "class_name": "RelatedNodeInfo"}}, "text": "And as it relates to COVID vaccines, as I mentioned, we are \nlapping the COVID programs that we had last year and from a commercial vaccine perspective, lower contribution \nthat we saw in the third quarter, really a non -material amount of contribution to our fourth quarter results.  \n ", "start_char_idx": 1879, "end_char_idx": 2166, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea5e01c1-933a-44c7-bbd2-59643aea09ff": {"__data__": {"id_": "ea5e01c1-933a-44c7-bbd2-59643aea09ff", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief  Financial Officer & Executive Vice President, McKesson Corp.   A \nYes, nothing really specific to call out there, Stephen.  And as it relates to COVID vaccines, as I mentioned, we are \nlapping the COVID programs that we had last year and from a commercial vaccine perspective, lower contribution \nthat we saw in the third quarter, really a non -material amount of contribution to our fourth quarter results.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thanks again, everyone, for joining our call this evening.  We appreciate your ongoing interest and support of \nMcKesson.  I want to thank you, operator, for facilitating the call.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f00a882ac27d4543b15dbda7ec68423d1eb2a4d27a9aeee1c12629c0aef013a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a3c2696-cf44-4b56-9ab4-db5a3618b61d", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief  Financial Officer & Executive Vice President, McKesson Corp.   A \nYes, nothing really specific to call out there, Stephen.  And as it relates to COVID vaccines, as I mentioned, we are \nlapping the COVID programs that we had last year and from a commercial vaccine perspective, lower contribution \nthat we saw in the third quarter, really a non -material amount of contribution to our fourth quarter results.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thanks again, everyone, for joining our call this evening.  We appreciate your ongoing interest and support of \nMcKesson. ", "original_text": "And as it relates to COVID vaccines, as I mentioned, we are \nlapping the COVID programs that we had last year and from a commercial vaccine perspective, lower contribution \nthat we saw in the third quarter, really a non -material amount of contribution to our fourth quarter results.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "43e5fb4b39361db042ae94b0b0f2482490d508d306d633a6818694eb56d020f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa349d7d-5f9f-40e2-8092-8992d6b64e7c", "node_type": "1", "metadata": {"window": "A \nYes, nothing really specific to call out there, Stephen.  And as it relates to COVID vaccines, as I mentioned, we are \nlapping the COVID programs that we had last year and from a commercial vaccine perspective, lower contribution \nthat we saw in the third quarter, really a non -material amount of contribution to our fourth quarter results.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thanks again, everyone, for joining our call this evening.  We appreciate your ongoing interest and support of \nMcKesson.  I want to thank you, operator, for facilitating the call.  \n \n McKesson reported solid performance in fiscal 2024. ", "original_text": "Well, thanks again, everyone, for joining our call this evening. "}, "hash": "e98991f4f03b7da969fa7785698f5120e857cfe46b784862b2b95d5dd28a6669", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "start_char_idx": 2166, "end_char_idx": 2511, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa349d7d-5f9f-40e2-8092-8992d6b64e7c": {"__data__": {"id_": "fa349d7d-5f9f-40e2-8092-8992d6b64e7c", "embedding": null, "metadata": {"window": "A \nYes, nothing really specific to call out there, Stephen.  And as it relates to COVID vaccines, as I mentioned, we are \nlapping the COVID programs that we had last year and from a commercial vaccine perspective, lower contribution \nthat we saw in the third quarter, really a non -material amount of contribution to our fourth quarter results.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thanks again, everyone, for joining our call this evening.  We appreciate your ongoing interest and support of \nMcKesson.  I want to thank you, operator, for facilitating the call.  \n \n McKesson reported solid performance in fiscal 2024. ", "original_text": "Well, thanks again, everyone, for joining our call this evening. ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f00a882ac27d4543b15dbda7ec68423d1eb2a4d27a9aeee1c12629c0aef013a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea5e01c1-933a-44c7-bbd2-59643aea09ff", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief  Financial Officer & Executive Vice President, McKesson Corp.   A \nYes, nothing really specific to call out there, Stephen.  And as it relates to COVID vaccines, as I mentioned, we are \nlapping the COVID programs that we had last year and from a commercial vaccine perspective, lower contribution \nthat we saw in the third quarter, really a non -material amount of contribution to our fourth quarter results.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thanks again, everyone, for joining our call this evening.  We appreciate your ongoing interest and support of \nMcKesson.  I want to thank you, operator, for facilitating the call.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c85a4c79f86e05831c7059907028f6d205751df8f02a1bfbc17af4a32c610c54", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f2a245f-3f5b-4b34-936b-098f204a14ec", "node_type": "1", "metadata": {"window": "And as it relates to COVID vaccines, as I mentioned, we are \nlapping the COVID programs that we had last year and from a commercial vaccine perspective, lower contribution \nthat we saw in the third quarter, really a non -material amount of contribution to our fourth quarter results.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thanks again, everyone, for joining our call this evening.  We appreciate your ongoing interest and support of \nMcKesson.  I want to thank you, operator, for facilitating the call.  \n \n McKesson reported solid performance in fiscal 2024.  I'm really pleased with the momentum across the segme nts \nand the continued commitment to our company's priorities.  \n \n", "original_text": "We appreciate your ongoing interest and support of \nMcKesson. "}, "hash": "e22f5bae4081678a6dbb9684f232ac7ca3a5f4bbdbdb8277c9c3fc54b9e1016f", "class_name": "RelatedNodeInfo"}}, "text": "Well, thanks again, everyone, for joining our call this evening. ", "start_char_idx": 2511, "end_char_idx": 2576, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f2a245f-3f5b-4b34-936b-098f204a14ec": {"__data__": {"id_": "0f2a245f-3f5b-4b34-936b-098f204a14ec", "embedding": null, "metadata": {"window": "And as it relates to COVID vaccines, as I mentioned, we are \nlapping the COVID programs that we had last year and from a commercial vaccine perspective, lower contribution \nthat we saw in the third quarter, really a non -material amount of contribution to our fourth quarter results.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thanks again, everyone, for joining our call this evening.  We appreciate your ongoing interest and support of \nMcKesson.  I want to thank you, operator, for facilitating the call.  \n \n McKesson reported solid performance in fiscal 2024.  I'm really pleased with the momentum across the segme nts \nand the continued commitment to our company's priorities.  \n \n", "original_text": "We appreciate your ongoing interest and support of \nMcKesson. ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f00a882ac27d4543b15dbda7ec68423d1eb2a4d27a9aeee1c12629c0aef013a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa349d7d-5f9f-40e2-8092-8992d6b64e7c", "node_type": "1", "metadata": {"window": "A \nYes, nothing really specific to call out there, Stephen.  And as it relates to COVID vaccines, as I mentioned, we are \nlapping the COVID programs that we had last year and from a commercial vaccine perspective, lower contribution \nthat we saw in the third quarter, really a non -material amount of contribution to our fourth quarter results.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thanks again, everyone, for joining our call this evening.  We appreciate your ongoing interest and support of \nMcKesson.  I want to thank you, operator, for facilitating the call.  \n \n McKesson reported solid performance in fiscal 2024. ", "original_text": "Well, thanks again, everyone, for joining our call this evening. ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "6e4c8fb411351516b9bf69578677abb1643afad29d32ac6b373b00b2d4eab98c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c64a29ae-396c-4d03-aae9-21f83dedb480", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thanks again, everyone, for joining our call this evening.  We appreciate your ongoing interest and support of \nMcKesson.  I want to thank you, operator, for facilitating the call.  \n \n McKesson reported solid performance in fiscal 2024.  I'm really pleased with the momentum across the segme nts \nand the continued commitment to our company's priorities.  \n \n Looking ahead to 2025, I remain confident in our ability to consistently execute against our strategies, which will \nsupport and sustain growth in the long term. ", "original_text": "I want to thank you, operator, for facilitating the call.  \n \n"}, "hash": "594d087ff13e87495600ad5092aa11187e96ef5e0c00beb1750c967c16e44789", "class_name": "RelatedNodeInfo"}}, "text": "We appreciate your ongoing interest and support of \nMcKesson. ", "start_char_idx": 2576, "end_char_idx": 2638, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c64a29ae-396c-4d03-aae9-21f83dedb480": {"__data__": {"id_": "c64a29ae-396c-4d03-aae9-21f83dedb480", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thanks again, everyone, for joining our call this evening.  We appreciate your ongoing interest and support of \nMcKesson.  I want to thank you, operator, for facilitating the call.  \n \n McKesson reported solid performance in fiscal 2024.  I'm really pleased with the momentum across the segme nts \nand the continued commitment to our company's priorities.  \n \n Looking ahead to 2025, I remain confident in our ability to consistently execute against our strategies, which will \nsupport and sustain growth in the long term. ", "original_text": "I want to thank you, operator, for facilitating the call.  \n \n", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f00a882ac27d4543b15dbda7ec68423d1eb2a4d27a9aeee1c12629c0aef013a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f2a245f-3f5b-4b34-936b-098f204a14ec", "node_type": "1", "metadata": {"window": "And as it relates to COVID vaccines, as I mentioned, we are \nlapping the COVID programs that we had last year and from a commercial vaccine perspective, lower contribution \nthat we saw in the third quarter, really a non -material amount of contribution to our fourth quarter results.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thanks again, everyone, for joining our call this evening.  We appreciate your ongoing interest and support of \nMcKesson.  I want to thank you, operator, for facilitating the call.  \n \n McKesson reported solid performance in fiscal 2024.  I'm really pleased with the momentum across the segme nts \nand the continued commitment to our company's priorities.  \n \n", "original_text": "We appreciate your ongoing interest and support of \nMcKesson. ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "9a8fde796868f9a0ec2c6c86499a968b87066ff14d62fcd219c7165fa8e9b856", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "008038b6-81ae-49cc-b61d-83598f547e8f", "node_type": "1", "metadata": {"window": "Well, thanks again, everyone, for joining our call this evening.  We appreciate your ongoing interest and support of \nMcKesson.  I want to thank you, operator, for facilitating the call.  \n \n McKesson reported solid performance in fiscal 2024.  I'm really pleased with the momentum across the segme nts \nand the continued commitment to our company's priorities.  \n \n Looking ahead to 2025, I remain confident in our ability to consistently execute against our strategies, which will \nsupport and sustain growth in the long term.  We're excited about the opportun ity to grow with our customers, to \ndrive innovation through our differentiated portfolio of services and solutions. ", "original_text": "McKesson reported solid performance in fiscal 2024. "}, "hash": "02e8f73e2d33f695fa23982d52e85f81e4ccb209f681d6736214c92ee42929c2", "class_name": "RelatedNodeInfo"}}, "text": "I want to thank you, operator, for facilitating the call.  \n \n", "start_char_idx": 2638, "end_char_idx": 2700, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "008038b6-81ae-49cc-b61d-83598f547e8f": {"__data__": {"id_": "008038b6-81ae-49cc-b61d-83598f547e8f", "embedding": null, "metadata": {"window": "Well, thanks again, everyone, for joining our call this evening.  We appreciate your ongoing interest and support of \nMcKesson.  I want to thank you, operator, for facilitating the call.  \n \n McKesson reported solid performance in fiscal 2024.  I'm really pleased with the momentum across the segme nts \nand the continued commitment to our company's priorities.  \n \n Looking ahead to 2025, I remain confident in our ability to consistently execute against our strategies, which will \nsupport and sustain growth in the long term.  We're excited about the opportun ity to grow with our customers, to \ndrive innovation through our differentiated portfolio of services and solutions. ", "original_text": "McKesson reported solid performance in fiscal 2024. ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f00a882ac27d4543b15dbda7ec68423d1eb2a4d27a9aeee1c12629c0aef013a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c64a29ae-396c-4d03-aae9-21f83dedb480", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thanks again, everyone, for joining our call this evening.  We appreciate your ongoing interest and support of \nMcKesson.  I want to thank you, operator, for facilitating the call.  \n \n McKesson reported solid performance in fiscal 2024.  I'm really pleased with the momentum across the segme nts \nand the continued commitment to our company's priorities.  \n \n Looking ahead to 2025, I remain confident in our ability to consistently execute against our strategies, which will \nsupport and sustain growth in the long term. ", "original_text": "I want to thank you, operator, for facilitating the call.  \n \n", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ef99b52e01c5fa51e572290bd5ff0fbf0722ea4e6bb33edea69249cb99226b0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55c24782-a039-43e4-af13-5f589bd35e32", "node_type": "1", "metadata": {"window": "We appreciate your ongoing interest and support of \nMcKesson.  I want to thank you, operator, for facilitating the call.  \n \n McKesson reported solid performance in fiscal 2024.  I'm really pleased with the momentum across the segme nts \nand the continued commitment to our company's priorities.  \n \n Looking ahead to 2025, I remain confident in our ability to consistently execute against our strategies, which will \nsupport and sustain growth in the long term.  We're excited about the opportun ity to grow with our customers, to \ndrive innovation through our differentiated portfolio of services and solutions.  But most importantly, it's in service \nof our mission to advance \u2013 improve healthcare in every setting  \n \nSo I appreciate everyone's time. ", "original_text": "I'm really pleased with the momentum across the segme nts \nand the continued commitment to our company's priorities.  \n \n"}, "hash": "e9a21b77af4dba74623133290db571dfe0c21b4f1b2b3bc27cb716d8cd10ff71", "class_name": "RelatedNodeInfo"}}, "text": "McKesson reported solid performance in fiscal 2024. ", "start_char_idx": 2700, "end_char_idx": 2752, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55c24782-a039-43e4-af13-5f589bd35e32": {"__data__": {"id_": "55c24782-a039-43e4-af13-5f589bd35e32", "embedding": null, "metadata": {"window": "We appreciate your ongoing interest and support of \nMcKesson.  I want to thank you, operator, for facilitating the call.  \n \n McKesson reported solid performance in fiscal 2024.  I'm really pleased with the momentum across the segme nts \nand the continued commitment to our company's priorities.  \n \n Looking ahead to 2025, I remain confident in our ability to consistently execute against our strategies, which will \nsupport and sustain growth in the long term.  We're excited about the opportun ity to grow with our customers, to \ndrive innovation through our differentiated portfolio of services and solutions.  But most importantly, it's in service \nof our mission to advance \u2013 improve healthcare in every setting  \n \nSo I appreciate everyone's time. ", "original_text": "I'm really pleased with the momentum across the segme nts \nand the continued commitment to our company's priorities.  \n \n", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f00a882ac27d4543b15dbda7ec68423d1eb2a4d27a9aeee1c12629c0aef013a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "008038b6-81ae-49cc-b61d-83598f547e8f", "node_type": "1", "metadata": {"window": "Well, thanks again, everyone, for joining our call this evening.  We appreciate your ongoing interest and support of \nMcKesson.  I want to thank you, operator, for facilitating the call.  \n \n McKesson reported solid performance in fiscal 2024.  I'm really pleased with the momentum across the segme nts \nand the continued commitment to our company's priorities.  \n \n Looking ahead to 2025, I remain confident in our ability to consistently execute against our strategies, which will \nsupport and sustain growth in the long term.  We're excited about the opportun ity to grow with our customers, to \ndrive innovation through our differentiated portfolio of services and solutions. ", "original_text": "McKesson reported solid performance in fiscal 2024. ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "2feb6f5729c10f0ca03b5a361bfa98d4f98dc5df5963153aaaa3c56add294200", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "396d004d-c81d-4799-b409-099ad3c8a5b0", "node_type": "1", "metadata": {"window": "I want to thank you, operator, for facilitating the call.  \n \n McKesson reported solid performance in fiscal 2024.  I'm really pleased with the momentum across the segme nts \nand the continued commitment to our company's priorities.  \n \n Looking ahead to 2025, I remain confident in our ability to consistently execute against our strategies, which will \nsupport and sustain growth in the long term.  We're excited about the opportun ity to grow with our customers, to \ndrive innovation through our differentiated portfolio of services and solutions.  But most importantly, it's in service \nof our mission to advance \u2013 improve healthcare in every setting  \n \nSo I appreciate everyone's time.  I hope you have a terrific evening.  \n ", "original_text": "Looking ahead to 2025, I remain confident in our ability to consistently execute against our strategies, which will \nsupport and sustain growth in the long term. "}, "hash": "ad2e0202db43b5264311584482c7af32db236be99faafea5bffacd1d904db7f4", "class_name": "RelatedNodeInfo"}}, "text": "I'm really pleased with the momentum across the segme nts \nand the continued commitment to our company's priorities.  \n \n", "start_char_idx": 2752, "end_char_idx": 2873, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "396d004d-c81d-4799-b409-099ad3c8a5b0": {"__data__": {"id_": "396d004d-c81d-4799-b409-099ad3c8a5b0", "embedding": null, "metadata": {"window": "I want to thank you, operator, for facilitating the call.  \n \n McKesson reported solid performance in fiscal 2024.  I'm really pleased with the momentum across the segme nts \nand the continued commitment to our company's priorities.  \n \n Looking ahead to 2025, I remain confident in our ability to consistently execute against our strategies, which will \nsupport and sustain growth in the long term.  We're excited about the opportun ity to grow with our customers, to \ndrive innovation through our differentiated portfolio of services and solutions.  But most importantly, it's in service \nof our mission to advance \u2013 improve healthcare in every setting  \n \nSo I appreciate everyone's time.  I hope you have a terrific evening.  \n ", "original_text": "Looking ahead to 2025, I remain confident in our ability to consistently execute against our strategies, which will \nsupport and sustain growth in the long term. ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f00a882ac27d4543b15dbda7ec68423d1eb2a4d27a9aeee1c12629c0aef013a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55c24782-a039-43e4-af13-5f589bd35e32", "node_type": "1", "metadata": {"window": "We appreciate your ongoing interest and support of \nMcKesson.  I want to thank you, operator, for facilitating the call.  \n \n McKesson reported solid performance in fiscal 2024.  I'm really pleased with the momentum across the segme nts \nand the continued commitment to our company's priorities.  \n \n Looking ahead to 2025, I remain confident in our ability to consistently execute against our strategies, which will \nsupport and sustain growth in the long term.  We're excited about the opportun ity to grow with our customers, to \ndrive innovation through our differentiated portfolio of services and solutions.  But most importantly, it's in service \nof our mission to advance \u2013 improve healthcare in every setting  \n \nSo I appreciate everyone's time. ", "original_text": "I'm really pleased with the momentum across the segme nts \nand the continued commitment to our company's priorities.  \n \n", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f12c16a93957c644266dbf22297afdbe095d7b49f0fce1dbcd7e0c5fe376b49e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9468d174-6f5c-47aa-8de0-219e9a4d340c", "node_type": "1", "metadata": {"window": "McKesson reported solid performance in fiscal 2024.  I'm really pleased with the momentum across the segme nts \nand the continued commitment to our company's priorities.  \n \n Looking ahead to 2025, I remain confident in our ability to consistently execute against our strategies, which will \nsupport and sustain growth in the long term.  We're excited about the opportun ity to grow with our customers, to \ndrive innovation through our differentiated portfolio of services and solutions.  But most importantly, it's in service \nof our mission to advance \u2013 improve healthcare in every setting  \n \nSo I appreciate everyone's time.  I hope you have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "original_text": "We're excited about the opportun ity to grow with our customers, to \ndrive innovation through our differentiated portfolio of services and solutions. "}, "hash": "0cb36c8af84f0959f202c9cc56a262402783a808d7f0f58df554956ea99e558b", "class_name": "RelatedNodeInfo"}}, "text": "Looking ahead to 2025, I remain confident in our ability to consistently execute against our strategies, which will \nsupport and sustain growth in the long term. ", "start_char_idx": 2873, "end_char_idx": 3035, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9468d174-6f5c-47aa-8de0-219e9a4d340c": {"__data__": {"id_": "9468d174-6f5c-47aa-8de0-219e9a4d340c", "embedding": null, "metadata": {"window": "McKesson reported solid performance in fiscal 2024.  I'm really pleased with the momentum across the segme nts \nand the continued commitment to our company's priorities.  \n \n Looking ahead to 2025, I remain confident in our ability to consistently execute against our strategies, which will \nsupport and sustain growth in the long term.  We're excited about the opportun ity to grow with our customers, to \ndrive innovation through our differentiated portfolio of services and solutions.  But most importantly, it's in service \nof our mission to advance \u2013 improve healthcare in every setting  \n \nSo I appreciate everyone's time.  I hope you have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "original_text": "We're excited about the opportun ity to grow with our customers, to \ndrive innovation through our differentiated portfolio of services and solutions. ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f00a882ac27d4543b15dbda7ec68423d1eb2a4d27a9aeee1c12629c0aef013a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "396d004d-c81d-4799-b409-099ad3c8a5b0", "node_type": "1", "metadata": {"window": "I want to thank you, operator, for facilitating the call.  \n \n McKesson reported solid performance in fiscal 2024.  I'm really pleased with the momentum across the segme nts \nand the continued commitment to our company's priorities.  \n \n Looking ahead to 2025, I remain confident in our ability to consistently execute against our strategies, which will \nsupport and sustain growth in the long term.  We're excited about the opportun ity to grow with our customers, to \ndrive innovation through our differentiated portfolio of services and solutions.  But most importantly, it's in service \nof our mission to advance \u2013 improve healthcare in every setting  \n \nSo I appreciate everyone's time.  I hope you have a terrific evening.  \n ", "original_text": "Looking ahead to 2025, I remain confident in our ability to consistently execute against our strategies, which will \nsupport and sustain growth in the long term. ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "bbf6effba1e33ffd0e035b78794bc151a1c68ac83479a02cce57c6e69295b03a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a7ad7be-b266-40e7-bf4a-14d48178da56", "node_type": "1", "metadata": {"window": "I'm really pleased with the momentum across the segme nts \nand the continued commitment to our company's priorities.  \n \n Looking ahead to 2025, I remain confident in our ability to consistently execute against our strategies, which will \nsupport and sustain growth in the long term.  We're excited about the opportun ity to grow with our customers, to \ndrive innovation through our differentiated portfolio of services and solutions.  But most importantly, it's in service \nof our mission to advance \u2013 improve healthcare in every setting  \n \nSo I appreciate everyone's time.  I hope you have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n ", "original_text": "But most importantly, it's in service \nof our mission to advance \u2013 improve healthcare in every setting  \n \nSo I appreciate everyone's time. "}, "hash": "acd7eedda8f547e3c6d012b55bfb8a1d7610ead20adb083f470f891cc059f96e", "class_name": "RelatedNodeInfo"}}, "text": "We're excited about the opportun ity to grow with our customers, to \ndrive innovation through our differentiated portfolio of services and solutions. ", "start_char_idx": 3035, "end_char_idx": 3185, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a7ad7be-b266-40e7-bf4a-14d48178da56": {"__data__": {"id_": "4a7ad7be-b266-40e7-bf4a-14d48178da56", "embedding": null, "metadata": {"window": "I'm really pleased with the momentum across the segme nts \nand the continued commitment to our company's priorities.  \n \n Looking ahead to 2025, I remain confident in our ability to consistently execute against our strategies, which will \nsupport and sustain growth in the long term.  We're excited about the opportun ity to grow with our customers, to \ndrive innovation through our differentiated portfolio of services and solutions.  But most importantly, it's in service \nof our mission to advance \u2013 improve healthcare in every setting  \n \nSo I appreciate everyone's time.  I hope you have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n ", "original_text": "But most importantly, it's in service \nof our mission to advance \u2013 improve healthcare in every setting  \n \nSo I appreciate everyone's time. ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f00a882ac27d4543b15dbda7ec68423d1eb2a4d27a9aeee1c12629c0aef013a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9468d174-6f5c-47aa-8de0-219e9a4d340c", "node_type": "1", "metadata": {"window": "McKesson reported solid performance in fiscal 2024.  I'm really pleased with the momentum across the segme nts \nand the continued commitment to our company's priorities.  \n \n Looking ahead to 2025, I remain confident in our ability to consistently execute against our strategies, which will \nsupport and sustain growth in the long term.  We're excited about the opportun ity to grow with our customers, to \ndrive innovation through our differentiated portfolio of services and solutions.  But most importantly, it's in service \nof our mission to advance \u2013 improve healthcare in every setting  \n \nSo I appreciate everyone's time.  I hope you have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "original_text": "We're excited about the opportun ity to grow with our customers, to \ndrive innovation through our differentiated portfolio of services and solutions. ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "8b4af5448366b49c72b36cb7a8c6c44e2762297e4dfda0fad61c944677df47b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e543d5e-8f63-47ef-b161-d119134b322e", "node_type": "1", "metadata": {"window": "Looking ahead to 2025, I remain confident in our ability to consistently execute against our strategies, which will \nsupport and sustain growth in the long term.  We're excited about the opportun ity to grow with our customers, to \ndrive innovation through our differentiated portfolio of services and solutions.  But most importantly, it's in service \nof our mission to advance \u2013 improve healthcare in every setting  \n \nSo I appreciate everyone's time.  I hope you have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n ", "original_text": "I hope you have a terrific evening.  \n "}, "hash": "aaa6e78b57d0536a8ce4339845ecc9ac552b966809d8607e10dc9cec03cce994", "class_name": "RelatedNodeInfo"}}, "text": "But most importantly, it's in service \nof our mission to advance \u2013 improve healthcare in every setting  \n \nSo I appreciate everyone's time. ", "start_char_idx": 3185, "end_char_idx": 3325, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e543d5e-8f63-47ef-b161-d119134b322e": {"__data__": {"id_": "6e543d5e-8f63-47ef-b161-d119134b322e", "embedding": null, "metadata": {"window": "Looking ahead to 2025, I remain confident in our ability to consistently execute against our strategies, which will \nsupport and sustain growth in the long term.  We're excited about the opportun ity to grow with our customers, to \ndrive innovation through our differentiated portfolio of services and solutions.  But most importantly, it's in service \nof our mission to advance \u2013 improve healthcare in every setting  \n \nSo I appreciate everyone's time.  I hope you have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n ", "original_text": "I hope you have a terrific evening.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f00a882ac27d4543b15dbda7ec68423d1eb2a4d27a9aeee1c12629c0aef013a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a7ad7be-b266-40e7-bf4a-14d48178da56", "node_type": "1", "metadata": {"window": "I'm really pleased with the momentum across the segme nts \nand the continued commitment to our company's priorities.  \n \n Looking ahead to 2025, I remain confident in our ability to consistently execute against our strategies, which will \nsupport and sustain growth in the long term.  We're excited about the opportun ity to grow with our customers, to \ndrive innovation through our differentiated portfolio of services and solutions.  But most importantly, it's in service \nof our mission to advance \u2013 improve healthcare in every setting  \n \nSo I appreciate everyone's time.  I hope you have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n ", "original_text": "But most importantly, it's in service \nof our mission to advance \u2013 improve healthcare in every setting  \n \nSo I appreciate everyone's time. ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "7b9aac8ba1173c9f0fdd1ead7bf2790881e5bc74a9e9b88de5ad7e1cd9649daf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7462ea1-c066-4c4f-8e84-2ecf025a48f8", "node_type": "1", "metadata": {"window": "We're excited about the opportun ity to grow with our customers, to \ndrive innovation through our differentiated portfolio of services and solutions.  But most importantly, it's in service \nof our mission to advance \u2013 improve healthcare in every setting  \n \nSo I appreciate everyone's time.  I hope you have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. "}, "hash": "47532197334ff914cc30a7068a639300667dfc6e247f123d9a7ae0be2c26cf37", "class_name": "RelatedNodeInfo"}}, "text": "I hope you have a terrific evening.  \n ", "start_char_idx": 3325, "end_char_idx": 3364, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7462ea1-c066-4c4f-8e84-2ecf025a48f8": {"__data__": {"id_": "d7462ea1-c066-4c4f-8e84-2ecf025a48f8", "embedding": null, "metadata": {"window": "We're excited about the opportun ity to grow with our customers, to \ndrive innovation through our differentiated portfolio of services and solutions.  But most importantly, it's in service \nof our mission to advance \u2013 improve healthcare in every setting  \n \nSo I appreciate everyone's time.  I hope you have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f00a882ac27d4543b15dbda7ec68423d1eb2a4d27a9aeee1c12629c0aef013a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e543d5e-8f63-47ef-b161-d119134b322e", "node_type": "1", "metadata": {"window": "Looking ahead to 2025, I remain confident in our ability to consistently execute against our strategies, which will \nsupport and sustain growth in the long term.  We're excited about the opportun ity to grow with our customers, to \ndrive innovation through our differentiated portfolio of services and solutions.  But most importantly, it's in service \nof our mission to advance \u2013 improve healthcare in every setting  \n \nSo I appreciate everyone's time.  I hope you have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n ", "original_text": "I hope you have a terrific evening.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "4dea70016151f20712139b047bed7396b42e50477d4e2a9179ba08001e4c37d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b8e2a0f-fb00-495c-9d80-c8b6a67bc28c", "node_type": "1", "metadata": {"window": "But most importantly, it's in service \nof our mission to advance \u2013 improve healthcare in every setting  \n \nSo I appreciate everyone's time.  I hope you have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n ", "original_text": "You may now disconnect, and have a great day.  \n \n \n \n \n \n "}, "hash": "02dcbb3b637cbd196545d8a904a4ec4683d100c63f73a68ecfab4ed5e02d12cb", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "start_char_idx": 3364, "end_char_idx": 3696, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b8e2a0f-fb00-495c-9d80-c8b6a67bc28c": {"__data__": {"id_": "5b8e2a0f-fb00-495c-9d80-c8b6a67bc28c", "embedding": null, "metadata": {"window": "But most importantly, it's in service \nof our mission to advance \u2013 improve healthcare in every setting  \n \nSo I appreciate everyone's time.  I hope you have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n ", "original_text": "You may now disconnect, and have a great day.  \n \n \n \n \n \n ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "f00a882ac27d4543b15dbda7ec68423d1eb2a4d27a9aeee1c12629c0aef013a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7462ea1-c066-4c4f-8e84-2ecf025a48f8", "node_type": "1", "metadata": {"window": "We're excited about the opportun ity to grow with our customers, to \ndrive innovation through our differentiated portfolio of services and solutions.  But most importantly, it's in service \nof our mission to advance \u2013 improve healthcare in every setting  \n \nSo I appreciate everyone's time.  I hope you have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "9c1c1348bbb8dd0d2193faed0def61b1443fe9eaca15eaf09699df802879ad9a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "021ad1da-3768-4489-9bdc-3022d80ea075", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed b y us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all r isks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "McKesson Corp.  "}, "hash": "e43b61b20327183893227ece4ab46dc4f6f1d52982b645e554999bc339818198", "class_name": "RelatedNodeInfo"}}, "text": "You may now disconnect, and have a great day.  \n \n \n \n \n \n ", "start_char_idx": 3696, "end_char_idx": 3755, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "021ad1da-3768-4489-9bdc-3022d80ea075": {"__data__": {"id_": "021ad1da-3768-4489-9bdc-3022d80ea075", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed b y us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all r isks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d29b7765-5e1e-409d-b74c-8578a080001b", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a9c4b9ff6c1913dd88bf1c48774cec25cc1977ec93228291500f378cc6bf0ea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b8e2a0f-fb00-495c-9d80-c8b6a67bc28c", "node_type": "1", "metadata": {"window": "But most importantly, it's in service \nof our mission to advance \u2013 improve healthcare in every setting  \n \nSo I appreciate everyone's time.  I hope you have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n ", "original_text": "You may now disconnect, and have a great day.  \n \n \n \n \n \n ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "83d966b0440b7e077939ba104ed8ac9bc594c2229760e0153e7f5eac28620bdb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3fc85ad-2a27-4d7c-8bf3-adf86131db15", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed b y us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all r isks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  I t should not be construed as advice designed to meet the particular investment needs of any investor. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed b y us and does not purport to be a complete or error -free statement or summary of the available data. \n"}, "hash": "2ad31566f153ec22a0f2d0716f4e2fd9eed7424b56935e6971d44990c2820218", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3fc85ad-2a27-4d7c-8bf3-adf86131db15": {"__data__": {"id_": "f3fc85ad-2a27-4d7c-8bf3-adf86131db15", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed b y us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all r isks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  I t should not be construed as advice designed to meet the particular investment needs of any investor. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed b y us and does not purport to be a complete or error -free statement or summary of the available data. \n", "page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d29b7765-5e1e-409d-b74c-8578a080001b", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a9c4b9ff6c1913dd88bf1c48774cec25cc1977ec93228291500f378cc6bf0ea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "021ad1da-3768-4489-9bdc-3022d80ea075", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed b y us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all r isks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "75bb58b207af4dda1bd47868d8931a25eabc8586e14b3a79c6a20993ac129b8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc7cfad6-437b-4d79-883a-38f835c3c360", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed b y us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all r isks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  I t should not be construed as advice designed to meet the particular investment needs of any investor.  This report is publishe d solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitati on of an offer to buy any security in any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. "}, "hash": "a5a8dd4e09cb2c1e60efc684669ab8eb9bd9458a96ae17122f233c8fbdb34dc5", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed b y us and does not purport to be a complete or error -free statement or summary of the available data. \n", "start_char_idx": 16, "end_char_idx": 400, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc7cfad6-437b-4d79-883a-38f835c3c360": {"__data__": {"id_": "cc7cfad6-437b-4d79-883a-38f835c3c360", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed b y us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all r isks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  I t should not be construed as advice designed to meet the particular investment needs of any investor.  This report is publishe d solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitati on of an offer to buy any security in any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d29b7765-5e1e-409d-b74c-8578a080001b", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a9c4b9ff6c1913dd88bf1c48774cec25cc1977ec93228291500f378cc6bf0ea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3fc85ad-2a27-4d7c-8bf3-adf86131db15", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed b y us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all r isks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  I t should not be construed as advice designed to meet the particular investment needs of any investor. ", "original_text": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed b y us and does not purport to be a complete or error -free statement or summary of the available data. \n", "page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "91095825888ef2be25b24abd088ebc33f2748bed9c646527cda23796cba37d2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1ecef94-5c54-4598-9b15-c245e2c851b2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed b y us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all r isks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  I t should not be construed as advice designed to meet the particular investment needs of any investor.  This report is publishe d solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitati on of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice. ", "original_text": "You  must evaluate, and bear all r isks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. "}, "hash": "8ece3ee28ab7ef2418b566a4f4b3e5839c9b4aaa758e443fbcddde77be6b62ec", "class_name": "RelatedNodeInfo"}}, "text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "start_char_idx": 400, "end_char_idx": 522, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1ecef94-5c54-4598-9b15-c245e2c851b2": {"__data__": {"id_": "a1ecef94-5c54-4598-9b15-c245e2c851b2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed b y us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all r isks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  I t should not be construed as advice designed to meet the particular investment needs of any investor.  This report is publishe d solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitati on of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice. ", "original_text": "You  must evaluate, and bear all r isks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d29b7765-5e1e-409d-b74c-8578a080001b", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a9c4b9ff6c1913dd88bf1c48774cec25cc1977ec93228291500f378cc6bf0ea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc7cfad6-437b-4d79-883a-38f835c3c360", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed b y us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all r isks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  I t should not be construed as advice designed to meet the particular investment needs of any investor.  This report is publishe d solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitati on of an offer to buy any security in any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a7c429e3011be9c905c2c507e8b75d1bc15a944ad310de66554d2ed09ca0e5d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bcf09b05-7d3d-4643-92f3-fc234fcbe577", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed b y us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all r isks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  I t should not be construed as advice designed to meet the particular investment needs of any investor.  This report is publishe d solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitati on of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represe nt the opinions or beliefs of FactSet \nCallStreet, LLC. ", "original_text": "I t should not be construed as advice designed to meet the particular investment needs of any investor. "}, "hash": "15c4b73b388a14750677afad119bd6aa5fc09b3b8b486fa585a709e8f3847286", "class_name": "RelatedNodeInfo"}}, "text": "You  must evaluate, and bear all r isks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "start_char_idx": 522, "end_char_idx": 815, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bcf09b05-7d3d-4643-92f3-fc234fcbe577": {"__data__": {"id_": "bcf09b05-7d3d-4643-92f3-fc234fcbe577", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed b y us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all r isks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  I t should not be construed as advice designed to meet the particular investment needs of any investor.  This report is publishe d solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitati on of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represe nt the opinions or beliefs of FactSet \nCallStreet, LLC. ", "original_text": "I t should not be construed as advice designed to meet the particular investment needs of any investor. ", "page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d29b7765-5e1e-409d-b74c-8578a080001b", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a9c4b9ff6c1913dd88bf1c48774cec25cc1977ec93228291500f378cc6bf0ea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1ecef94-5c54-4598-9b15-c245e2c851b2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed b y us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all r isks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  I t should not be construed as advice designed to meet the particular investment needs of any investor.  This report is publishe d solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitati on of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice. ", "original_text": "You  must evaluate, and bear all r isks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a0c1ab04729be5a950c63c315e2a6a4c8350acecb40a1fc6769e2c88a3af5c15", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed185abc-3fdd-4768-ba76-bfc5aeca199a", "node_type": "1", "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all r isks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  I t should not be construed as advice designed to meet the particular investment needs of any investor.  This report is publishe d solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitati on of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represe nt the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "original_text": "This report is publishe d solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitati on of an offer to buy any security in any state where such an offer or solicitation would be illegal. "}, "hash": "81652d049c150cfbbb73a9b8e68743b05b03365066a7b731420d94ecabdf62b6", "class_name": "RelatedNodeInfo"}}, "text": "I t should not be construed as advice designed to meet the particular investment needs of any investor. ", "start_char_idx": 815, "end_char_idx": 919, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed185abc-3fdd-4768-ba76-bfc5aeca199a": {"__data__": {"id_": "ed185abc-3fdd-4768-ba76-bfc5aeca199a", "embedding": null, "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all r isks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  I t should not be construed as advice designed to meet the particular investment needs of any investor.  This report is publishe d solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitati on of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represe nt the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "original_text": "This report is publishe d solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitati on of an offer to buy any security in any state where such an offer or solicitation would be illegal. ", "page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d29b7765-5e1e-409d-b74c-8578a080001b", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a9c4b9ff6c1913dd88bf1c48774cec25cc1977ec93228291500f378cc6bf0ea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bcf09b05-7d3d-4643-92f3-fc234fcbe577", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed b y us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all r isks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  I t should not be construed as advice designed to meet the particular investment needs of any investor.  This report is publishe d solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitati on of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represe nt the opinions or beliefs of FactSet \nCallStreet, LLC. ", "original_text": "I t should not be construed as advice designed to meet the particular investment needs of any investor. ", "page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "3686d22b10a07d21febcb7df06d53e4169410a550a2040c7ca819e8a3a09cf13", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c3a1fe21-9341-4cd9-9760-a7fbea490e4b", "node_type": "1", "metadata": {"window": "You  must evaluate, and bear all r isks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  I t should not be construed as advice designed to meet the particular investment needs of any investor.  This report is publishe d solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitati on of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represe nt the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIM ITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date is subject to change without notice. "}, "hash": "4b68a8619b40698c575731920b5c85241b78c7511f72884d4636d5556dba62e2", "class_name": "RelatedNodeInfo"}}, "text": "This report is publishe d solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitati on of an offer to buy any security in any state where such an offer or solicitation would be illegal. ", "start_char_idx": 919, "end_char_idx": 1178, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c3a1fe21-9341-4cd9-9760-a7fbea490e4b": {"__data__": {"id_": "c3a1fe21-9341-4cd9-9760-a7fbea490e4b", "embedding": null, "metadata": {"window": "You  must evaluate, and bear all r isks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  I t should not be construed as advice designed to meet the particular investment needs of any investor.  This report is publishe d solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitati on of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represe nt the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIM ITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date is subject to change without notice. ", "page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d29b7765-5e1e-409d-b74c-8578a080001b", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a9c4b9ff6c1913dd88bf1c48774cec25cc1977ec93228291500f378cc6bf0ea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed185abc-3fdd-4768-ba76-bfc5aeca199a", "node_type": "1", "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all r isks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  I t should not be construed as advice designed to meet the particular investment needs of any investor.  This report is publishe d solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitati on of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represe nt the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "original_text": "This report is publishe d solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitati on of an offer to buy any security in any state where such an offer or solicitation would be illegal. ", "page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "8d49c32024e10bf81fcc2744a88ffde82b0bda5066e22a7677a66883cfe6d8ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3613dd4f-fe91-4bf6-8b39-7091dbbf8e38", "node_type": "1", "metadata": {"window": "I t should not be construed as advice designed to meet the particular investment needs of any investor.  This report is publishe d solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitati on of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represe nt the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIM ITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PART NERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREA CHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SU CH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY  OTHER SUBJECT MATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this i nformation do not represe nt the opinions or beliefs of FactSet \nCallStreet, LLC. "}, "hash": "9e9f629dc841f65b9a7bef5bfd8624d3d0ef6ecddfba0184be4ec910c4dfbd3f", "class_name": "RelatedNodeInfo"}}, "text": "Any \ninformation expressed herein on this date is subject to change without notice. ", "start_char_idx": 1178, "end_char_idx": 1262, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3613dd4f-fe91-4bf6-8b39-7091dbbf8e38": {"__data__": {"id_": "3613dd4f-fe91-4bf6-8b39-7091dbbf8e38", "embedding": null, "metadata": {"window": "I t should not be construed as advice designed to meet the particular investment needs of any investor.  This report is publishe d solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitati on of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represe nt the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIM ITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PART NERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREA CHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SU CH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY  OTHER SUBJECT MATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this i nformation do not represe nt the opinions or beliefs of FactSet \nCallStreet, LLC. ", "page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d29b7765-5e1e-409d-b74c-8578a080001b", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a9c4b9ff6c1913dd88bf1c48774cec25cc1977ec93228291500f378cc6bf0ea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c3a1fe21-9341-4cd9-9760-a7fbea490e4b", "node_type": "1", "metadata": {"window": "You  must evaluate, and bear all r isks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  I t should not be construed as advice designed to meet the particular investment needs of any investor.  This report is publishe d solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitati on of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represe nt the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIM ITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date is subject to change without notice. ", "page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "267b1057cbd47dc6375d3646a72b590daa671cd9807517a9fc01b3e7ec971203", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91db2156-cc36-4e72-b7bf-fa26e6b7642c", "node_type": "1", "metadata": {"window": "This report is publishe d solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitati on of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represe nt the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIM ITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PART NERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREA CHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SU CH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY  OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n"}, "hash": "7426d83ccf79a4a2ed4f0a1bab3b79eff285c7c492ea4fb1a65437cca714c7bc", "class_name": "RelatedNodeInfo"}}, "text": "Any opinions or assertions contained in this i nformation do not represe nt the opinions or beliefs of FactSet \nCallStreet, LLC. ", "start_char_idx": 1262, "end_char_idx": 1391, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91db2156-cc36-4e72-b7bf-fa26e6b7642c": {"__data__": {"id_": "91db2156-cc36-4e72-b7bf-fa26e6b7642c", "embedding": null, "metadata": {"window": "This report is publishe d solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitati on of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represe nt the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIM ITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PART NERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREA CHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SU CH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY  OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d29b7765-5e1e-409d-b74c-8578a080001b", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a9c4b9ff6c1913dd88bf1c48774cec25cc1977ec93228291500f378cc6bf0ea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3613dd4f-fe91-4bf6-8b39-7091dbbf8e38", "node_type": "1", "metadata": {"window": "I t should not be construed as advice designed to meet the particular investment needs of any investor.  This report is publishe d solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitati on of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represe nt the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIM ITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PART NERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREA CHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SU CH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY  OTHER SUBJECT MATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this i nformation do not represe nt the opinions or beliefs of FactSet \nCallStreet, LLC. ", "page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "6cd0163df32c35567c5bed928e24af88418c382d68fe6d75209b77aeb4816995", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d262e81-1477-446b-8dde-96182112817e", "node_type": "1", "metadata": {"window": "Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represe nt the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIM ITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PART NERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREA CHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SU CH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY  OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are tr ademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIM ITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. "}, "hash": "95e1d0cbc54848454e5b77f6aa7af68253339fc0d385382ed73dfc2429a05bf4", "class_name": "RelatedNodeInfo"}}, "text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "start_char_idx": 1391, "end_char_idx": 1554, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d262e81-1477-446b-8dde-96182112817e": {"__data__": {"id_": "7d262e81-1477-446b-8dde-96182112817e", "embedding": null, "metadata": {"window": "Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represe nt the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIM ITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PART NERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREA CHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SU CH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY  OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are tr ademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIM ITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d29b7765-5e1e-409d-b74c-8578a080001b", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a9c4b9ff6c1913dd88bf1c48774cec25cc1977ec93228291500f378cc6bf0ea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91db2156-cc36-4e72-b7bf-fa26e6b7642c", "node_type": "1", "metadata": {"window": "This report is publishe d solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitati on of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represe nt the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIM ITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PART NERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREA CHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SU CH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY  OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c84ed01238b68bd97d2b5273a21363122ce401c19735dc611de706f18f764855", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb4801ee-d4c3-4ca7-8bb7-35799f061e29", "node_type": "1", "metadata": {"window": "Any opinions or assertions contained in this i nformation do not represe nt the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIM ITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PART NERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREA CHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SU CH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY  OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are tr ademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PART NERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREA CHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SU CH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY  OTHER SUBJECT MATTER HEREOF.  \n \n"}, "hash": "1b75157c856936f4ed4537f100e53f3c0b55a2cb5b7a445f9cd088b4166b431f", "class_name": "RelatedNodeInfo"}}, "text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIM ITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "start_char_idx": 1554, "end_char_idx": 1988, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb4801ee-d4c3-4ca7-8bb7-35799f061e29": {"__data__": {"id_": "fb4801ee-d4c3-4ca7-8bb7-35799f061e29", "embedding": null, "metadata": {"window": "Any opinions or assertions contained in this i nformation do not represe nt the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIM ITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PART NERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREA CHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SU CH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY  OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are tr ademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PART NERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREA CHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SU CH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY  OTHER SUBJECT MATTER HEREOF.  \n \n", "page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d29b7765-5e1e-409d-b74c-8578a080001b", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a9c4b9ff6c1913dd88bf1c48774cec25cc1977ec93228291500f378cc6bf0ea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d262e81-1477-446b-8dde-96182112817e", "node_type": "1", "metadata": {"window": "Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represe nt the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIM ITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PART NERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREA CHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SU CH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY  OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are tr ademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIM ITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "ef61edc54047d4b5fa61325c90cab9436560d7c7013851f690db265f7566c95f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6bf63b4-3a84-470f-afa0-407308d91b05", "node_type": "1", "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIM ITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PART NERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREA CHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SU CH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY  OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are tr ademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. "}, "hash": "4489a1074892fa96aa9ead6a016b3d8a1c3586e7572583de99ad41a2dcd91217", "class_name": "RelatedNodeInfo"}}, "text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PART NERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREA CHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SU CH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY  OTHER SUBJECT MATTER HEREOF.  \n \n", "start_char_idx": 1988, "end_char_idx": 2668, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6bf63b4-3a84-470f-afa0-407308d91b05": {"__data__": {"id_": "f6bf63b4-3a84-470f-afa0-407308d91b05", "embedding": null, "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIM ITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PART NERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREA CHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SU CH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY  OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are tr ademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d29b7765-5e1e-409d-b74c-8578a080001b", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a9c4b9ff6c1913dd88bf1c48774cec25cc1977ec93228291500f378cc6bf0ea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb4801ee-d4c3-4ca7-8bb7-35799f061e29", "node_type": "1", "metadata": {"window": "Any opinions or assertions contained in this i nformation do not represe nt the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIM ITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PART NERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREA CHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SU CH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY  OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are tr ademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PART NERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREA CHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SU CH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY  OTHER SUBJECT MATTER HEREOF.  \n \n", "page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "9521f79a2bc22cd6a07ce275b165a697b6a738f29f5c7c883bb23c8521d8f970", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31e41d11-622e-4600-b250-a94f6366bbaa", "node_type": "1", "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIM ITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PART NERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREA CHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SU CH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY  OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are tr ademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are tr ademarks of their respective companies. "}, "hash": "2acf54eb7d32aac519ba6a6d4b3cb2f1664b4aaa1517d42afce9a00889e962c5", "class_name": "RelatedNodeInfo"}}, "text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "start_char_idx": 2668, "end_char_idx": 2857, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31e41d11-622e-4600-b250-a94f6366bbaa": {"__data__": {"id_": "31e41d11-622e-4600-b250-a94f6366bbaa", "embedding": null, "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIM ITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PART NERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREA CHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SU CH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY  OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are tr ademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are tr ademarks of their respective companies. ", "page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d29b7765-5e1e-409d-b74c-8578a080001b", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a9c4b9ff6c1913dd88bf1c48774cec25cc1977ec93228291500f378cc6bf0ea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6bf63b4-3a84-470f-afa0-407308d91b05", "node_type": "1", "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIM ITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PART NERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREA CHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SU CH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY  OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are tr ademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "b44fa637dfc0eee8d346a320f6edfe38d9bc4d090500cc0851b2042c00a71971", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5865583-c798-4e00-8e03-8fc2fb9178b9", "node_type": "1", "metadata": {"window": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PART NERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREA CHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SU CH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY  OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are tr ademarks of their respective companies.  All rights reserved.  ", "original_text": "All rights reserved.  "}, "hash": "174081712183b773e20f7fb61bc77597c95bd6c6cfc509ac2890773d7f741e40", "class_name": "RelatedNodeInfo"}}, "text": "All \nother trademarks mentioned are tr ademarks of their respective companies. ", "start_char_idx": 2857, "end_char_idx": 2936, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5865583-c798-4e00-8e03-8fc2fb9178b9": {"__data__": {"id_": "e5865583-c798-4e00-8e03-8fc2fb9178b9", "embedding": null, "metadata": {"window": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PART NERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREA CHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SU CH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY  OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are tr ademarks of their respective companies.  All rights reserved.  ", "original_text": "All rights reserved.  ", "page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d29b7765-5e1e-409d-b74c-8578a080001b", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "a9c4b9ff6c1913dd88bf1c48774cec25cc1977ec93228291500f378cc6bf0ea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31e41d11-622e-4600-b250-a94f6366bbaa", "node_type": "1", "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIM ITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PART NERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREA CHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SU CH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY  OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are tr ademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are tr ademarks of their respective companies. ", "page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}, "hash": "c5b39f9eb352a7793f3ff45367bc0663d716e7dd3ab0f80ceed61771aea667cc", "class_name": "RelatedNodeInfo"}}, "text": "All rights reserved.  ", "start_char_idx": 2936, "end_char_idx": 2958, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"8ac40fc7-e5ac-411f-8bcc-384ec7db88a0": {"doc_hash": "850856187dd65e00e04fad65aff186f39077f1da0c9705bd6ce41b56771d1e6d", "ref_doc_id": "55848cdd-003c-4ab4-b1df-376659bdd34c"}, "ff05beac-fb15-422d-99fe-e0eb2ab3244c": {"doc_hash": "2a948111001e037fef56503c7a54e81d0e65eae5bb39f0c4349a07360243c91f", "ref_doc_id": "55848cdd-003c-4ab4-b1df-376659bdd34c"}, "e29a353b-2a1b-4319-95e4-787dccc2683f": {"doc_hash": "e346b18d6fd417d428e699c0dc95bd828fe76ed22dabaed941e1474f847b2c4f", "ref_doc_id": "6b5d4127-351d-4c2c-ad83-61d686441325"}, "f30a7767-cc81-49a9-837d-328a55032937": {"doc_hash": "3f08aa4f955a91af4e55a83a67977e1a613c7349d3e3856b386a69ca2d9196a6", "ref_doc_id": "6b5d4127-351d-4c2c-ad83-61d686441325"}, "de984c38-4c8e-4d31-a34c-6b16fce63e37": {"doc_hash": "c0bd268e08ab5b0ab7d20179629cd5988ac63430683b5f00686fe66bcbfef8cb", "ref_doc_id": "6b5d4127-351d-4c2c-ad83-61d686441325"}, "ee94e062-8f38-4681-b95e-291331278a0d": {"doc_hash": "f7b17d0be286ba26710c6a98e801b5a7b3db41672b85452aadb087bfee4409a6", "ref_doc_id": "6b5d4127-351d-4c2c-ad83-61d686441325"}, "b26c2c2e-22d2-4989-b921-ae614e541ed5": {"doc_hash": "4e4a5ff08f9479325a660b5f122d084a9eacfef3dbbb29436052430445da9897", "ref_doc_id": "6b5d4127-351d-4c2c-ad83-61d686441325"}, "0087b70c-f693-4502-bd3b-1478adab45f0": {"doc_hash": "0e5127a90f6bbc386cf442e189d6ef825a2ead3ce1afba63d240f45a8679b215", "ref_doc_id": "6b5d4127-351d-4c2c-ad83-61d686441325"}, "1544a74c-3b5a-4abb-8665-984f7b33654e": {"doc_hash": "00ede2f843b0ad3e1fa806e812345792170c9dee3767303d3e7fb007e4d50fe5", "ref_doc_id": "6b5d4127-351d-4c2c-ad83-61d686441325"}, "36ff605a-6c7a-4f45-94e2-09f56987a36e": {"doc_hash": "bd449311edab646a8060f531e6318c2e03c641c34d1f765bbceec320e8c02d58", "ref_doc_id": "6b5d4127-351d-4c2c-ad83-61d686441325"}, "f1f499d1-5560-411e-87b1-7da7f6445af4": {"doc_hash": "e003a65209f5e715d9a62fb8adb6bfd04ab794255e646ad992d37b1122470856", "ref_doc_id": "81722f07-6765-4bf6-940a-500c9ac23a6e"}, "8e5f357d-70eb-41ef-8258-af91943248f0": {"doc_hash": "2e370cbd45830eca578900c4b707409bcceb244b75af4de0717b350e44d203dc", "ref_doc_id": "81722f07-6765-4bf6-940a-500c9ac23a6e"}, "41e010d6-2397-4ccb-866f-ca40463df7a8": {"doc_hash": "153c09cfb2ee4ab421f3a5964b7827d67f459067c5d68cab609d00fd4f1c3f08", "ref_doc_id": "81722f07-6765-4bf6-940a-500c9ac23a6e"}, "65520944-fe11-4371-8335-73117a437ad3": {"doc_hash": "e410a0589190b863ae1022a4335548ee0ff532c2ba621ad8203dccdb7bbe96e1", "ref_doc_id": "81722f07-6765-4bf6-940a-500c9ac23a6e"}, "114dd88b-cc59-416e-b2c1-1522266c79dd": {"doc_hash": "e93dad97dda954636ecf674f2dcec23b8dbf0296df0a48dfcb25c65253d9f591", "ref_doc_id": "81722f07-6765-4bf6-940a-500c9ac23a6e"}, "400152eb-be86-4d8f-9219-c29ee796786a": {"doc_hash": "1b6f568e00f747e568f905de1928ddc0a49d0650cee69938e8c69656cb076278", "ref_doc_id": "81722f07-6765-4bf6-940a-500c9ac23a6e"}, "3f3ec541-6387-4e90-8561-9e06ea491b03": {"doc_hash": "f2ec0e685e21ca6f7c70d5d44892d915925e52077407cb14a1ae07e30d1153d7", "ref_doc_id": "81722f07-6765-4bf6-940a-500c9ac23a6e"}, "ff1b7a4a-3ef4-4539-ba2b-9490310efce3": {"doc_hash": "3bfd7cf935a1fa75fd03636cfd663bac1f53163e990e47f3f80f09c25c3b99d6", "ref_doc_id": "81722f07-6765-4bf6-940a-500c9ac23a6e"}, "847f5d51-e7e9-4e1a-8887-4e689f9921d8": {"doc_hash": "5d80158aa182bfafce26e9cf205df98ec79145b1670bd13c884e4f742bb09549", "ref_doc_id": "81722f07-6765-4bf6-940a-500c9ac23a6e"}, "3e560d79-dd58-4b3d-a869-70295d5c151e": {"doc_hash": "94612ad2518198db20542bf815d8cab775e6af18feb4152664864190a91a90a6", "ref_doc_id": "81722f07-6765-4bf6-940a-500c9ac23a6e"}, "84b84bca-2089-4868-b727-6e6bac65609f": {"doc_hash": "e08c4bdbd59201a7bbba3e14b79e334059256d00338394db92aa683e5ac9cb5d", "ref_doc_id": "81722f07-6765-4bf6-940a-500c9ac23a6e"}, "3a638280-07eb-4328-82db-a2a79b041f43": {"doc_hash": "7ed4ccb6fbe0cccd5651e59553c837191cfa743f1f78a5f1f88f11448632a1cd", "ref_doc_id": "81722f07-6765-4bf6-940a-500c9ac23a6e"}, "17fd159e-c8cc-4503-a560-bd88e74814d4": {"doc_hash": "e202b8cb62e9384b477f487ad5798bb993c697f729c7234dcc2bb741ff493c8d", "ref_doc_id": "81722f07-6765-4bf6-940a-500c9ac23a6e"}, "358dd6ec-fecb-4ee6-a491-e829d7441b79": {"doc_hash": "81d7f54ae9cd5cfedf667251c4d6177094bf0476ac4b81597cebde69530d0648", "ref_doc_id": "81722f07-6765-4bf6-940a-500c9ac23a6e"}, "c4a2eb5d-ea15-471a-ae4e-644305267a1b": {"doc_hash": "73390fb1c6dc3b47b87dc4a7145f6d72e71c8e3b750f334cc793fb8a84fc1590", "ref_doc_id": "81722f07-6765-4bf6-940a-500c9ac23a6e"}, "82674211-3c89-47ee-b4dc-34c08c748ae9": {"doc_hash": "03771fa1364c78e2dbf3227f1641463a5abc9ba8a74c114abe1d737747a8d013", "ref_doc_id": "81722f07-6765-4bf6-940a-500c9ac23a6e"}, "c5c3283b-81a6-459b-b94c-03188fb1f5b8": {"doc_hash": "3d1865e9cf73dce2d5d910715dfb061e2ce30597fdd086b21c80143bee2459f1", "ref_doc_id": "81722f07-6765-4bf6-940a-500c9ac23a6e"}, "c9f64c39-9358-486e-b2db-845a40ecdcba": {"doc_hash": "c63c9cc8bddb6938637d27d38add66c04482f9e675e2a6fac90a5a0d058e8278", "ref_doc_id": "81722f07-6765-4bf6-940a-500c9ac23a6e"}, "8ea9dbdd-9591-43fd-8025-457cca8b6b73": {"doc_hash": "b3960221a59a999f45eea487ede8a40c47570345b9ae72efb357f5bdf9f2c200", "ref_doc_id": "81722f07-6765-4bf6-940a-500c9ac23a6e"}, "911bb5f5-525a-471a-9e29-da5714a131cb": {"doc_hash": "f1ac37e7afc699fb61b7227bf8d6b22e482ba63902ea0165d86a93722eface6b", "ref_doc_id": "81722f07-6765-4bf6-940a-500c9ac23a6e"}, "0b0398bd-b3a7-409c-9c24-1356f3f9c48c": {"doc_hash": "5e500bb3c408d32fe37bbd0b317d2f8e8fcceed2d88229d56ed8e5337ff18920", "ref_doc_id": "81722f07-6765-4bf6-940a-500c9ac23a6e"}, "7f95d24c-b104-4076-8dba-f4b315cbde5a": {"doc_hash": "f91ac134dfb5f6443541bbca07a195b9f1950b0675388931dcdee9c680528659", "ref_doc_id": "81722f07-6765-4bf6-940a-500c9ac23a6e"}, "e73320f9-7388-4d11-8cd2-f6b176def608": {"doc_hash": "5c9a2dd168cfd70338b82664b4b3e9ae575bb7db822af776f4883e5f8be5bf63", "ref_doc_id": "81722f07-6765-4bf6-940a-500c9ac23a6e"}, "fb83b04a-775e-4d46-81f5-408f41092e75": {"doc_hash": "31fc515d8ea34c9b19b568ac084eac9cf77cb674e0248c17b65d6797a55bf9e3", "ref_doc_id": "81722f07-6765-4bf6-940a-500c9ac23a6e"}, "90b60628-780f-4a16-8ee3-c5ad9c47b691": {"doc_hash": "7cef4530d4be17da64ac2f3497a51ee24c5984324a7910d533406e4c4f07462c", "ref_doc_id": "81722f07-6765-4bf6-940a-500c9ac23a6e"}, "b16761de-a178-4252-8846-526b974a5d34": {"doc_hash": "60e9cf0e7f6c5e971eed397e684b5cfcf7c0e2f50663e48c8c428bf9d0fa49de", "ref_doc_id": "81722f07-6765-4bf6-940a-500c9ac23a6e"}, "49dd4c39-6e1e-41a1-8817-ac5fb727941e": {"doc_hash": "3509b5c5b273058a44a1753f43298bd761181fc8a7ccb3f0a5dc2a201299a4cd", "ref_doc_id": "503d358d-7b15-4003-8931-8eb136775d00"}, "c1bb7daf-5f15-46e1-a941-d58eb7d958fc": {"doc_hash": "a8556e1baa46d80777d6c1877d26ef120c3e77af94abede61131ebf92943a10b", "ref_doc_id": "503d358d-7b15-4003-8931-8eb136775d00"}, "3e06340e-9eeb-422d-9fbd-80599851967d": {"doc_hash": "aa1d81abc1c92a3c9fe0d28e3475597546b15771f173f8e959b565244081175f", "ref_doc_id": "503d358d-7b15-4003-8931-8eb136775d00"}, "1b9d393a-3654-4739-b091-9e9e99c314a7": {"doc_hash": "0671042970719529625908ce9f538701fbe90b40556b0f688403810d2e78f59f", "ref_doc_id": "503d358d-7b15-4003-8931-8eb136775d00"}, "1184817b-9066-4074-93aa-d17f6acd4ca7": {"doc_hash": "c02d4b981ff42ebda8a58f765a1e30191b437cf676fc93485cf20a4f6cf3fe05", "ref_doc_id": "503d358d-7b15-4003-8931-8eb136775d00"}, "66aaadc4-e258-4e1f-86fb-a2660cd47fec": {"doc_hash": "48e7dc6c6ce4d7d78f7bcac45e22ec15bdae86d89ba0b49401058a191bf61bd2", "ref_doc_id": "503d358d-7b15-4003-8931-8eb136775d00"}, "e586b312-7f70-4d10-bd1a-6246a85c7a94": {"doc_hash": "6142ef34f3a8e5614cdbfa129a6d7d779d2edb57e755642df9ab5de4956ba58d", "ref_doc_id": "503d358d-7b15-4003-8931-8eb136775d00"}, "2f160a86-0932-4ccf-a449-a096bfde2db7": {"doc_hash": "2bb1a18e221085f56b991054821e4842a847a9959b1e2c60908fc3f26cccefba", "ref_doc_id": "503d358d-7b15-4003-8931-8eb136775d00"}, "69aae43d-dd34-481c-9b37-77831a5d3b03": {"doc_hash": "6ff80c8a6406c59d615d20c0c446082b2502dfb60014007a4c3c3198dd6752e8", "ref_doc_id": "503d358d-7b15-4003-8931-8eb136775d00"}, "04ee86d4-c4ba-4a33-b27a-f72e60b834d8": {"doc_hash": "6b87f806eacc7c19480969004ba5997ad440f2cf256b0d88a2f14bf6f5516822", "ref_doc_id": "503d358d-7b15-4003-8931-8eb136775d00"}, "f1b21d7c-09c9-4cb7-8e57-cc6032d5d5f5": {"doc_hash": "10207345ab7e7938fbcbb7111698da8e3fbc47f8c94b6bba4294a58b4a6517ca", "ref_doc_id": "503d358d-7b15-4003-8931-8eb136775d00"}, "59608038-bc94-4f58-aac6-4e99e30048f4": {"doc_hash": "cc23158b08d3f709383d7c869210c72c0bb696ec4cc3100b411ff6901eb67a88", "ref_doc_id": "503d358d-7b15-4003-8931-8eb136775d00"}, "715a73d7-5165-4fd8-97b9-8dccfae137d6": {"doc_hash": "447994def7630f758247501b0014b3a3671f252bdd7ca114b8f159db8e5f5620", "ref_doc_id": "503d358d-7b15-4003-8931-8eb136775d00"}, "bce1fa01-88ce-417d-ae64-763903514008": {"doc_hash": "79621631cb0437ae7ea33531530d8f663c2e8861834c84990878104d3a485616", "ref_doc_id": "503d358d-7b15-4003-8931-8eb136775d00"}, "cd1943b9-4636-4b58-9243-d0faa51e4b8e": {"doc_hash": "8c50b03dcd0b29c8742fe76e318f3a08afc7444bc737479aebf17aafeed55dc7", "ref_doc_id": "503d358d-7b15-4003-8931-8eb136775d00"}, "28005547-bda4-404a-ba43-03a2b14e5ac4": {"doc_hash": "73e2d86cd78f5597d9019a916c8aba77dfd7c76bd7f7e822b86546a420d8ea2b", "ref_doc_id": "503d358d-7b15-4003-8931-8eb136775d00"}, "47f08763-68c6-4139-958b-0bb8761985da": {"doc_hash": "015582357aac6dfaf9b68f72771dc9d6d46078e5b82634b692051528b6cffe4b", "ref_doc_id": "503d358d-7b15-4003-8931-8eb136775d00"}, "bb6bead6-54ad-4589-a625-4c441c3f7f22": {"doc_hash": "30086cc59eb2082eeb89792cb9f8faa4d04ebe850ff930f320ac12598905d804", "ref_doc_id": "503d358d-7b15-4003-8931-8eb136775d00"}, "398deb55-1fa8-4e5b-bb42-2b32e8108058": {"doc_hash": "659e61cead69c2e3efa2788d4d86773f764a22123920d170697d237a82837e24", "ref_doc_id": "503d358d-7b15-4003-8931-8eb136775d00"}, "63737ea7-8485-4901-8546-df272bb8ff1a": {"doc_hash": "b9f01bd1199d8518e5cbcfe73c03e7ed474897bc084dd2e62245ecc20cf008cb", "ref_doc_id": "503d358d-7b15-4003-8931-8eb136775d00"}, "4479e483-c95b-45db-9645-9c3f24ac4ee4": {"doc_hash": "d51acb04233dc42db2a169b3ffb9d75817a7d5e5803fbae4d41651672cd425d1", "ref_doc_id": "503d358d-7b15-4003-8931-8eb136775d00"}, "22bf9e01-60d2-4c4c-b0c5-a51fc89c0fa5": {"doc_hash": "8176403de30807074bea3f8731b6741a4ec3162feb6fa5e398ddce2f4f8ef5d1", "ref_doc_id": "503d358d-7b15-4003-8931-8eb136775d00"}, "30b9c8a0-1936-4b34-8868-7710a84f7e6c": {"doc_hash": "4cf3f7da85418c0cacb67a3319bba2bc407942a45a26b1fb3cadb65ca6c94da6", "ref_doc_id": "503d358d-7b15-4003-8931-8eb136775d00"}, "6752e97b-3955-4822-a0c0-7b49bdf6140e": {"doc_hash": "b5be19a07dc1072c61b31c2074dba71a7b9ea05ec001dfa8db08bef02cf5c885", "ref_doc_id": "503d358d-7b15-4003-8931-8eb136775d00"}, "16965107-e56b-4cb2-ad31-3a69904e5f13": {"doc_hash": "fe14b5ff9847ae6d9fff204b81ba307f0265798b5daf641995b4ffe1e10f2550", "ref_doc_id": "503d358d-7b15-4003-8931-8eb136775d00"}, "03c906eb-8e63-41fa-958c-2a8e21df420a": {"doc_hash": "27ca0d1027ef352084308805141e971bd791ea4e7876c8f3f1cc23a61d9aaf98", "ref_doc_id": "503d358d-7b15-4003-8931-8eb136775d00"}, "1fe5fce4-3521-4766-84dc-ba60369c8962": {"doc_hash": "c7ffe4be4f7d9d69b1a1a74b53159e120da0ec7b25fcea7c5903264da2477059", "ref_doc_id": "503d358d-7b15-4003-8931-8eb136775d00"}, "7b135ab0-7f06-475a-88b4-fb83f35d2d4f": {"doc_hash": "67275783f3078dbf745b17c702f59a79211c4a00e7587a816dfa1b6385b62195", "ref_doc_id": "503d358d-7b15-4003-8931-8eb136775d00"}, "8ff67d7e-9ce5-4120-95d5-e6593656080d": {"doc_hash": "d7baeccbfcfb057d83dcc8c10c01fc69ca05a3a94a4c0c104bf6fbc8462d4cad", "ref_doc_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d"}, "5143b55d-10db-44ab-ac47-f3a30a673bd6": {"doc_hash": "673a3b90c5bc10f418a905664092018e11fc56957687ba0ea906d1dc01a8ed8e", "ref_doc_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d"}, "5339c02b-7b09-48df-9f37-e60302c5b277": {"doc_hash": "1693cd10bee900edffa7c86a517b1b6b710832ce9e761c8caa157a98cc0bf25d", "ref_doc_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d"}, "cff9e3a0-208b-4eb2-b117-f483be089945": {"doc_hash": "9bd4d05ccd2e74177a062cfba1a0625da6877944bc7d6ed265e814b5e4c5fa0a", "ref_doc_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d"}, "dbdf2d43-4daa-4b5c-8c69-f520cdd10a1d": {"doc_hash": "4cb684aa77f9cee4551920fde1f761e41aa84d04a9d3f6bd3b2481b83eb0ce75", "ref_doc_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d"}, "4dc00ae4-9a6e-48e4-9970-d8062e5559fe": {"doc_hash": "9ab9f6f3fc517d6f79be47065de148d0f6f1ea402041f4e2a5f4ce3d183177c4", "ref_doc_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d"}, "90c9dafc-38d7-444a-b4c9-a459f006f8b8": {"doc_hash": "786a127bab4478b581bdb99bb93abb839cfc3735e026d453280c765158518ab0", "ref_doc_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d"}, "09285cbd-d231-46c6-997a-ceece6efb841": {"doc_hash": "fb75f7394b663e2e11ffb12fe240d754fd2084b82546b7a2c2c0f70fa243b053", "ref_doc_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d"}, "82530308-be1a-4fe7-89bb-ed44f04fce01": {"doc_hash": "d5af5c463370be7331653e8a8f03b4d78b482bb45fb2a2d2235f528f4e4d2320", "ref_doc_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d"}, "de25fd6e-fc1b-407f-acae-f17bf2140c4e": {"doc_hash": "af37108df3bbb67ef8475070ba34416cc5f0832c0430ed3e44e79d9edce3b055", "ref_doc_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d"}, "dbb49de7-1b3d-4360-8bd2-1d25376dd937": {"doc_hash": "3812f57aa5c34786025a2d3bdce5147e210373bab7ac9b39c2357f6650025d74", "ref_doc_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d"}, "8d377790-53a1-439e-8914-85a1f707e5e0": {"doc_hash": "ee01ca4332c185b00b98cf7773be0bb923fa4154aef4c2156930e0708cf677dc", "ref_doc_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d"}, "abe49091-9fdf-40c5-9a1d-4c3bee95edf7": {"doc_hash": "3597474253b415ba586a28274e40e00046bd0c22435519c413e0a934d1ab7423", "ref_doc_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d"}, "5f0cf240-0ed4-4d56-8c8d-df0e82c93a17": {"doc_hash": "392b3bb808dd6237a0c5c94ecbbd742a80347f2fe6e8efbcf492077583e9510a", "ref_doc_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d"}, "6af05515-99d6-43bf-8697-5d5e5dbc4a41": {"doc_hash": "a960d281e5c9f21f475f1c24063abe33679644487738b8dbf87ce3d274eb8389", "ref_doc_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d"}, "9c9ae138-8bd7-43b7-b0f8-310fb0977303": {"doc_hash": "86d47204d7db43ba5ddb7d7e53914e1f89f926e7321afdb199814cd2e6a3de2c", "ref_doc_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d"}, "87029daa-966a-46ef-91b5-2aca16fc19fd": {"doc_hash": "20069d00e2fc6177f7e44a5b860257a3e48b534735aa27dc6f521ad5eb8ac2d9", "ref_doc_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d"}, "361678fa-a06c-4cdd-89b3-904b763b5e27": {"doc_hash": "8c7b8618a717cdb4eb6cd33279fc0bfb78ab5c9a7ef170a54ac6e35776cf974b", "ref_doc_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d"}, "ab0407de-c66d-4b19-8b63-7e801925c092": {"doc_hash": "26c3cd223fa2b2d64bd35000e9875c20a1082ebce0549e5ca0769318ad306e0c", "ref_doc_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d"}, "595d3959-07a1-42fd-83b9-13df68bbb9d8": {"doc_hash": "1fb30a87d4415fbf4dd5b86c2adb1e820c5e445a6dd8b5db8c26f85db450d27d", "ref_doc_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d"}, "fcc772bb-84ec-4b50-b508-ac6f6bbec005": {"doc_hash": "0b130d9eda52ef4ede4896f28add769012e9821c2de3155618b4b6a77b84776a", "ref_doc_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d"}, "c8a8d3c9-9b21-467d-9476-c1e4f22d8d2e": {"doc_hash": "95746423e77185ee21b24ad47afce851d685c5747231c8efd3df0253cd1eaafe", "ref_doc_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d"}, "b40388ad-29f9-46cf-84b7-a5a51c7168b3": {"doc_hash": "6fd9618ea78f113e117310ca3808ed932bc54ea3a995970a0df196f5deddfd95", "ref_doc_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d"}, "36bc7910-7a82-425b-b974-4bd5bc15f7ac": {"doc_hash": "e4c4f50357bf6edc7b7e0dffed7a514bdf0b489a7250e3cfdd95966aaec3125c", "ref_doc_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d"}, "6efd9bbe-adbd-4103-bf23-479418c84465": {"doc_hash": "a73c216091c81e72c293fa320b354eddb53e379286f1e63e7ae8d3f8c077edf6", "ref_doc_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d"}, "824b8022-6178-4691-9bbc-cdb975d09131": {"doc_hash": "5b57395c5bcb786a6c2fc05965bdfd3e420fa3e9275b90c5de15e8454745dc9d", "ref_doc_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d"}, "332fff5d-26ea-4f4e-981a-b7b47b619a3b": {"doc_hash": "214586d9f26c3d9355494bfde88c779af884106b5bd990a3c7bba012f153255b", "ref_doc_id": "5022ec88-98bf-4e78-bf96-c8f06599b68d"}, "74ede774-3dbd-4c92-92fe-9ffe15c7aed3": {"doc_hash": "018bbadeca2f32d4a7820f23dc653c1d069ad55731d903ecca6505c60c738ad5", "ref_doc_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101"}, "380bd4e2-2f70-47fd-8d9e-5e85f9a43d96": {"doc_hash": "fcd1118f5e8fb28e2c9a7a49746e99071623fa72f7de554b6d30e988bf62cb0e", "ref_doc_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101"}, "339537f8-5f06-4c07-900c-97c2efd870ca": {"doc_hash": "02e4d4d4d9b5886b0363d5b4de106444c9d2863bfd1f3d3e639f818c8b7790bd", "ref_doc_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101"}, "cc322728-c0fb-487d-a2f4-e88b7e9b145f": {"doc_hash": "afb7cf38445bd5c1c533858467995414f301c379756d17a00cbe4d0b1d4de7d0", "ref_doc_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101"}, "bb887d2c-67c4-4eb6-b56b-c17265e67a14": {"doc_hash": "a0c03131821dfa793ab7230988cd0e474cd819111942700645b59277df1abc26", "ref_doc_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101"}, "905b0661-4a25-4ed2-bb7c-2efd98894e46": {"doc_hash": "0bbb2b6a7a9114d832306b4ab2663101c13d5136293ee04add5cc68ac14313a2", "ref_doc_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101"}, "8bb5cf1e-87cd-45f9-9083-68d7864a9ed0": {"doc_hash": "5d1da5792d45f6ed97f375757895046257b7094ff2a98383502d048827e6bf8c", "ref_doc_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101"}, "974d5f55-766b-454c-8ff5-408f6796719e": {"doc_hash": "0940f4a09bb31df975853e4714fccabae31592d7bca025fcc234657a0c7298d5", "ref_doc_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101"}, "365c27f4-81ca-4d09-9536-e2f8622d150d": {"doc_hash": "75abd24b2a2cd7c888fcd8abb95528c3c5209bec0826c693be3621bd7f39674a", "ref_doc_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101"}, "a577b514-f183-4755-8e36-5548f8c60c8b": {"doc_hash": "25891221bbf18eb6935cc7808a311e1f47aab18e2692989ccb2bc264a4fd0f3b", "ref_doc_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101"}, "e46ca8cb-af20-455d-9644-49aa158daebf": {"doc_hash": "c57b1dce02bcb8cecc97c13eac4c9db7cf5bf5bfdfff0967bf676f80c1101cbe", "ref_doc_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101"}, "35fabb68-7891-448c-945a-c7b7ba526a83": {"doc_hash": "4afecd587f2b8ce9090f112d700587b87a68656918a1434361b6ad8eab9e0d3f", "ref_doc_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101"}, "2f13d2ef-f8df-4b35-bd3f-7bb58263d129": {"doc_hash": "e893a4f9b4ad2d6a0055902ee743bc47bd0565ff23b3f9f4c53dc91f44c6dafd", "ref_doc_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101"}, "e752af75-f600-4087-ade6-e1c60c191496": {"doc_hash": "73f88decdf841523fc163362d90301b3558f47cc83c88a783926afae7598e446", "ref_doc_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101"}, "3b252176-21d4-4718-adb5-e5932cb216a6": {"doc_hash": "872dec0cd85e0bed780490557a052b7bb2f6d0821df7ffaf546574392cca6c68", "ref_doc_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101"}, "c75275ae-3c29-4f48-a04e-3be8632301ba": {"doc_hash": "45a63768d09e3e7eae778ec52307e7adfa2a92b100fab5f963fe3e86587004e0", "ref_doc_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101"}, "7d1778ab-2d9c-44e4-a861-6318f6ff1980": {"doc_hash": "661e4dae96b3683532b0d1c6973d7cfc8d2d0e74232e85bc2242553474a315cf", "ref_doc_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101"}, "bb1ffe2e-b91d-4dca-87b8-1a4b80a2f4c0": {"doc_hash": "d3357dd85aa1d12063bce91f4eac8443ca4affcd3e7a7368e249749f154c0e5a", "ref_doc_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101"}, "344df026-a303-4f37-a2fa-88f68b706d1e": {"doc_hash": "9375def146a65f6e30abbb110b5cc660c63592b292b5b3e906977a392139aeda", "ref_doc_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101"}, "0c4d9547-a9d4-4b2d-96d5-e9868c9eec46": {"doc_hash": "2a1b791246e6988c3768fe8f9d83080c0f60983170539953104c4de3dbedbd5b", "ref_doc_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101"}, "6e66ad0d-3d88-44d5-b2ee-e527d723a23d": {"doc_hash": "57dfd1099b8a031facd1ac152108d850f7b909fcfa86de7494380d5aa712a39c", "ref_doc_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101"}, "6c2d1388-9671-4bf5-ac05-d951b0e0d111": {"doc_hash": "69b4df9a72ab1869abac611ad90febfb548fa4e1cda5365203ce0aac2f2f2818", "ref_doc_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101"}, "f0b8d31d-449d-4f87-be4b-6eabfdf2b834": {"doc_hash": "2e235cf396cca6eb11416957a987e5bcfca88b553107f86cf33657ea32c4ae51", "ref_doc_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101"}, "60262635-2b33-452c-ba58-738437a6b69a": {"doc_hash": "25d5e8929c2bcd9cde7286749c474a949566c13d20d4f96ffeaba3c18c298a10", "ref_doc_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101"}, "9b8bf4ae-942d-4c4f-a4c9-522b623b8e98": {"doc_hash": "e0f6955cd3f49cb365068e1042c960f77219065dec8fc435b0c6251d8fa8aad3", "ref_doc_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101"}, "d6cd5179-011e-441b-8994-5223357d95f5": {"doc_hash": "cef7fcc358e14be0035811225fe1ad791e5b896deaca223ef6e64012aa41d288", "ref_doc_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101"}, "09b91605-ac46-4ff9-a534-743363b67940": {"doc_hash": "793db92867fe249514f4f3e3c1cfb2f23ceeff21c879776745e3bad60dae6dd3", "ref_doc_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101"}, "e1d8d47e-728a-4728-99ab-385abaedcf7c": {"doc_hash": "7d489b1b83108c9394ccc27c8ee357b046bfe473e4b4ce06cdbb1530cf5b8bda", "ref_doc_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101"}, "eb6beb49-5567-4fa8-a3ec-ea61b4d7fdd4": {"doc_hash": "05b9b2679244f08000a10455d2ddd9a1f4b44d8625be5415dff315417c5fd1aa", "ref_doc_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101"}, "421a3275-fed2-4637-8985-5f91dc93c4a8": {"doc_hash": "41224fb8660db350fc8150bd97908c77dbb6218059ba0f4c798bbfbfa02c9fd9", "ref_doc_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101"}, "c87be482-b8e0-4df1-b59b-84c7c7fee107": {"doc_hash": "6f85beeb00b44907bf99041840ee0d18ae037a19eb88d80ae8fed05f553a09f2", "ref_doc_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101"}, "be2e2175-c71c-404c-9e5f-d9377877646d": {"doc_hash": "730c3e4379d1fbd16f8c69a27b355a0448924b012679e1b2b899a3986cf4b159", "ref_doc_id": "501ddb3b-c6b0-49c4-9bbf-4e77619fa101"}, "b43a3cfa-4587-40ad-89e6-6e27c7b4e777": {"doc_hash": "5592001e8d936a6501e859f34daa0f288ad1cd57d43484f978c6fae05d56b51e", "ref_doc_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3"}, "5a6019e2-a159-4f4f-8ec2-53736662c676": {"doc_hash": "ac090409539ebc91a5d5d38785b4906e16638f5644ab4b2609b2303293538c4f", "ref_doc_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3"}, "f6e1c877-d22f-4eb3-9238-892d3c428be3": {"doc_hash": "34136e6707ddb947e1006b9f55fb84145ae137ae1a50209c88fa3fe871a1393e", "ref_doc_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3"}, "d0beddf3-650b-4b62-8ec2-1895f2e8c4aa": {"doc_hash": "eac9fa31a26d4acda08d1844a297ec7631dabade2edbe9ac42471b89954444e3", "ref_doc_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3"}, "143207ad-1c0a-4709-a6b2-5ecfcaed702e": {"doc_hash": "9ca50f956e0a331b494a6bdeca9827b81be9e6e9a8f0c8821a81a5dcc8e844b7", "ref_doc_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3"}, "49fc402e-1b88-4b02-a411-39322df34800": {"doc_hash": "8cd7973b42f9f1c6c2ed87921949451ec5026fb2288696e667ef019b5bc9e590", "ref_doc_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3"}, "08751485-bd05-47ea-9e71-bf5dfa8d2591": {"doc_hash": "d720e38a1aa0a103a34b0d7e3bfd7b8620ab9d7468d59ea2106d2a66e9a44346", "ref_doc_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3"}, "a4b9d2e9-eb58-4dbb-b59e-e9fec18c1b22": {"doc_hash": "8b4ef561f3f51b91cd1abef8078cc135cb0138ca5e90db37eacd988e3664fa68", "ref_doc_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3"}, "69a19da3-7319-4658-9057-0887341b178a": {"doc_hash": "a49c79da5a82c2c8a18da12e6fe49f2a586cc37882770e9454aaab50dc66c270", "ref_doc_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3"}, "afc07965-63a2-474d-9ed8-469a36b01856": {"doc_hash": "8be15023e8bf70e0040491c6219d66f3f1cb4a721ba60c30ec938685bf73d04e", "ref_doc_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3"}, "de33f76c-e38e-47ce-bafa-0d28b8c12f3f": {"doc_hash": "c9e40f49ac9b41cff427d8e37924722247e36e979faf45c32dde57c94c7cfdf5", "ref_doc_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3"}, "28379bbe-1016-4646-8269-88589887374a": {"doc_hash": "b192e9a0f5b48ff83bc6d89e57c84b7ca87415be7412a8624d4e350fc2aae497", "ref_doc_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3"}, "bf615f13-7b72-4cd5-b5e2-d8225d8e8718": {"doc_hash": "f2a8a6e30de1f925a86cbddd1865b71521036564aee1a662057d28db6084975f", "ref_doc_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3"}, "ab685eb2-112b-4216-bf84-cfa2783b9b6c": {"doc_hash": "f801e32ab7562f32028df2ebaa7abc8557a2b3fcdfc0ab9339733556d86df352", "ref_doc_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3"}, "1e1aa21d-b7e9-4a6e-8a14-0daf93818fce": {"doc_hash": "9c15dd580067371ab459bf23f2f62397927f5d1e72f4757ebc594ce14fec55e5", "ref_doc_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3"}, "a06cb467-ef04-4c0f-88da-7ca4f4426cab": {"doc_hash": "f8e9e4dfa20bb7197602599b0d76cff03741bda9b1dd4798cc4191a91794789c", "ref_doc_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3"}, "6b13e28a-8c2f-4b0b-ba42-3d3fec236d85": {"doc_hash": "bd56500f971a9f8e98ee9f1ee5f7f714abec16650f1db89b22976117db1a660f", "ref_doc_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3"}, "b7782c9e-5af3-4fd3-ac45-311c046c4f68": {"doc_hash": "c2fccddf9086ad7596d7fceb0066901276698fe4e2959ab6034a06a9aab09a51", "ref_doc_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3"}, "0842ba64-f75e-4112-a5e2-0b56ac0b2261": {"doc_hash": "31ca3c29a840e58c4839b6c4c8b81270ed144c032b2a9f876ceb8676406dfb4b", "ref_doc_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3"}, "f47e8d8b-d2b7-4951-98e9-9e785b20aff5": {"doc_hash": "b603c08024a33dfd19f1a6d0a81a0923bd79670253ae60c478fa97480ef40e8d", "ref_doc_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3"}, "896f0cc5-23e9-466b-80c4-d14900911c43": {"doc_hash": "482af49dd591e09b92d69e0f7f4a174492ba3700b1f24c6fc2da442bb9996c9f", "ref_doc_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3"}, "4f3a7c40-62cb-42c3-bfe1-6d37a51c5b47": {"doc_hash": "0c001b81dc3897fb39c072d59404cf564b5e45c5522d023a394df8bee01b46f8", "ref_doc_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3"}, "7e6939a9-ad83-4987-a232-0437c58d146e": {"doc_hash": "7adc813fd41fa7e7bb653940558cbbdc527cca8af33109eac5832bd8308a2eef", "ref_doc_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3"}, "6614de2f-e6ef-4b89-9fa1-985b64d3c424": {"doc_hash": "d776acf574489397db74898aa4f9e1c3032e3e72b74cc5561f18e82bbff64272", "ref_doc_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3"}, "b9ae0397-0f32-43ef-9ad9-b4abf334528e": {"doc_hash": "b5e78a0ff1da226f64e8afa9352f99b18437e3cf46d1ffba5189d8e53d795ba6", "ref_doc_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3"}, "485f756e-de49-4a78-add2-bf1cbcf9a3e5": {"doc_hash": "2a747832389141df8c674458ed232a830151e1a95403070f4df7fb47d4da41af", "ref_doc_id": "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3"}, "4c44a06c-8ee9-48f3-a4a6-9d41e51c5c1e": {"doc_hash": "d5c4bde25ba6a3a6a2f2fd58b3bc0f59118da0f46f0c419e885c55f9e84dc847", "ref_doc_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561"}, "7b0829ee-212d-4106-9a36-ec850f0c07b4": {"doc_hash": "892b3d3b6b4d1f9e08701176393e83a03c54277462e537e367f787bcc03b39de", "ref_doc_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561"}, "e88e08a7-f3e4-4683-86ff-9c5b37640e87": {"doc_hash": "a8a41c50aefd6e1e58c469984fb3066e6b8d2f87dc3a319230d7dd20a2c49c34", "ref_doc_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561"}, "b858aeba-1b89-4c13-ba7c-dd5ec51a4600": {"doc_hash": "521557ba4183b52127d7005dad1a8f4d645a261d8502d1999bead66e52ef17d3", "ref_doc_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561"}, "b1cf367d-ef1c-4eac-b95d-46bd1ea3e834": {"doc_hash": "0c42160ce3db45525527ccf66c461c1cc3e9e171f5cda0005929081889a5003d", "ref_doc_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561"}, "e1d5490c-a5eb-460f-a8c2-eaaf4b6700a4": {"doc_hash": "023c7a81cfbcd3870eda577dd8694bce24fa47eea10afdd63fd61a03d75aa190", "ref_doc_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561"}, "17585a7f-75c6-4ae7-844a-ec10eeca85dd": {"doc_hash": "63f3fd5b0fdcec1cdc01c56c54de15885b8bd4cee978d094764b5ed33a8fadb7", "ref_doc_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561"}, "857f6cc1-d0f0-43c8-87f7-2318785ea4eb": {"doc_hash": "ff5ecc216456ff77876c9f6ad0d58f9bbe34a06ff3827c1306ddb51515670820", "ref_doc_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561"}, "bbcef71c-8f56-453d-8ff0-73d1641ac3de": {"doc_hash": "39aad9b4ee1f49a06d18e16823fad190069f48bbdbe2a2d8fd77b175cb5e8c21", "ref_doc_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561"}, "6cc1b1fc-0f90-4c31-b421-f4a7148e3e23": {"doc_hash": "e5e86de07b726df03fdb16941281297f4f984b44a7014bbc918e16d01e4157aa", "ref_doc_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561"}, "d89ee0b9-8e9d-4877-a6a2-feb6b1631af6": {"doc_hash": "46f2fe3c723ca7221e4583375c52b267996ef59b9a10192d5e401e820d740f05", "ref_doc_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561"}, "895b8ae8-2abe-4699-b487-a8f063c8b4b2": {"doc_hash": "e579354313299702ba45d5badcf0081ef1642b18bed0948d5ed48ceb1ebf3255", "ref_doc_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561"}, "6d3e953c-149a-4a06-b62a-3d86acf171ea": {"doc_hash": "6cbaa7d6900e3bfaccc72dd6d822fc15da6685dc874416c5bb6127299968f6b7", "ref_doc_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561"}, "352868c6-5d36-4875-ba9f-843a8c66a993": {"doc_hash": "55a4876195ed6743966f63beae5117942b9e2b690a340b7fba6b4ce6fb73821c", "ref_doc_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561"}, "db65b094-fe05-4670-bf1a-a1ef2840e779": {"doc_hash": "cc7d8433449366ce2e22879674781892e037282fc14b6016c69ccce4c6f76adb", "ref_doc_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561"}, "9f16bc65-6d77-4525-9f9e-6fb795d4ec3c": {"doc_hash": "98f7bebb626db1be70b7f02b2034e20772401c988d4f48130969c2a7f52ece55", "ref_doc_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561"}, "f2a0c458-2532-4872-821b-9d5648c44201": {"doc_hash": "a5858cb84d6a2eaa6977a1804b0e9bde6eb9dcc677ec884900e108e5953cb31e", "ref_doc_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561"}, "82194558-082c-49b6-98d6-5d7e8a1ce63e": {"doc_hash": "735eaeddedf76c43414d35aa36d960a9ec61bfceec6d790cac8d24f4371b72b8", "ref_doc_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561"}, "703f7ca5-e788-4f94-9455-416b5bd7cdfa": {"doc_hash": "9094638f4b5a8ebc77a3ef546b3b8b8e56642353312d8574e362a2ee94721714", "ref_doc_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561"}, "e08df7c5-fad0-48b0-b005-b8829fd29a5f": {"doc_hash": "963f1fbe6bd3138ab3073268d46ce4ce17a99d5980f42ee7e5145a39d96d1f0f", "ref_doc_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561"}, "14b9fe16-c167-4a85-a755-db6980133991": {"doc_hash": "bec38fef7452c3b1fd812f1c44fc1b3d3eea942ee5bd24f0e0e6dad7727578ea", "ref_doc_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561"}, "4f181601-711c-4e2c-8f12-024f78c29635": {"doc_hash": "d2e87479e69be76083b0bd17822085f5e5e54ea355a1a2581c29c56bfbe6f522", "ref_doc_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561"}, "f09a82d5-eec1-4538-a576-47f5d39790b7": {"doc_hash": "7f2c55b011b4f88216cf258805e4355ec9e82befb55961e73c75dbc16b61352a", "ref_doc_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561"}, "6e92a396-0532-4271-9d35-d881805e2691": {"doc_hash": "2ec35a7d5201b6ebb4f1c77e9e24129bf7c93227a5240ad72c99ecb19c58d75a", "ref_doc_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561"}, "94e7c04a-b5ee-4daa-8a95-ef6d9ac4fb79": {"doc_hash": "f4faab6e2b36df224984007db49bf1ecc67e655b925e5ec69d0a8167bca5e02c", "ref_doc_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561"}, "710b52ee-572b-4752-81ab-69455b2cb0f5": {"doc_hash": "fe0e1bbee8336126e61042b6823d4b51c454fb0ec96c77fba90a0b5cd5985be3", "ref_doc_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561"}, "27ad667c-f83f-4383-bc69-e8e4d06a9c54": {"doc_hash": "1658d6bfd71875f00488000e7ef19416382dda4549d6deef7b588823bfc0a967", "ref_doc_id": "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561"}, "2486b7d7-8c18-470f-a9e7-b12111c60908": {"doc_hash": "e1e0932907a4874902daf2c086b761a6af222c0c7fd1785d2f40ae1cb8a1ae4d", "ref_doc_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4"}, "4b64dded-0068-4e47-90b9-47ef5b0016f1": {"doc_hash": "cbcf485c5643c6b7009d16aed55fa4418a373136d6e4a3171186b6411447eac9", "ref_doc_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4"}, "a3411858-78ce-4726-9f7d-6e0043965945": {"doc_hash": "4e1532e4460c0685a3c041189a98eaa0ef4f5cd74ac746dfd426c9e0fd63eef0", "ref_doc_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4"}, "42d0222c-80bf-4af0-a259-ed68ec56ae54": {"doc_hash": "d88201e0b9e3af0fc91b456d6fc20b5d12e613561caf041cb5ef62429991f898", "ref_doc_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4"}, "43947561-9b21-417b-8fad-7862167acf99": {"doc_hash": "76c4e4c02a0a207426c9029bcf7dae3ba4377f99904c445316a85f2f5d32c965", "ref_doc_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4"}, "b4526a51-c4b0-422e-a410-08f551995553": {"doc_hash": "771b05b474b893b537976994b6f39870e878cd9625dde142a37a0ed74ff4b043", "ref_doc_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4"}, "fae03bb5-1ac7-4d8a-a1d3-43d18f722da2": {"doc_hash": "e4392a9ffe984d1c12d9ecdcdaecdf90ce665532a0539a3f89a5d0275b1324fc", "ref_doc_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4"}, "82aa04a4-76f1-47da-a4fc-c472816598b6": {"doc_hash": "3cdab9d6691ca5226ef270ab66c90b951346b434c01c111b642e96fbb9b9663f", "ref_doc_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4"}, "13b718db-6114-4638-aded-5b1a632401cf": {"doc_hash": "225acac3a4ed070714e86c2c6fa0379852f7f97f4dd2b0b17f637f5bfb0037d7", "ref_doc_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4"}, "ce90eec4-e7d6-4dd1-92d6-b7ff81446a51": {"doc_hash": "18ca51993ddd7dbdc65f548d398f253ff2f77e41dfcd086c18c1a3b732523e2c", "ref_doc_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4"}, "467c9dea-820b-41d0-8ccc-fbb1190191cf": {"doc_hash": "c5c2b998593c546794cd514ac93cadf524d59817bbe0f65d5256c2f5a0b56173", "ref_doc_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4"}, "e631ffd2-93fd-46cc-95b9-0ead9241bb07": {"doc_hash": "9d2652c80752a591e57f9e5e9d991839be0c2e39c36ef3521adb17f5978f7204", "ref_doc_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4"}, "8f2846a6-80f0-4fdf-bb02-9d4e2132f879": {"doc_hash": "cbcd0c922bd8de76f4d2b50d263e11d09174b84232cbf25597907a453b81f2dc", "ref_doc_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4"}, "f9ac5b92-6be7-49b3-a381-d2cb73e6d5ac": {"doc_hash": "188f31c7deab4ce42130358e7bdbc9e603a90eac341543d2d27dbf078e845f5d", "ref_doc_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4"}, "078c99b7-9a83-4be9-acbd-be31c9860397": {"doc_hash": "8b5cc058ada29c7d669f34fd232eff8af1ba337242c3494d4ced1666e82f4e8d", "ref_doc_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4"}, "71ac2222-3677-4d07-af67-0e90a82a61bc": {"doc_hash": "e358f8d7303a685e8b4d06a096865f4c9315c0281ae516a89a4f8be26167f67e", "ref_doc_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4"}, "09443bee-e8c3-453f-9b3d-81334763cb17": {"doc_hash": "8901a8e4ceb7416a34309198b3e379f1f9d8c76727a2ab81ae0f78ef188e97b4", "ref_doc_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4"}, "8d71ecd9-d023-441d-9623-bf81fcc4b1b1": {"doc_hash": "3f13e1084aa6d6260be45ac634e8caa4dad6ab796b0416c3cab8ecf0a49cd23e", "ref_doc_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4"}, "a44973ce-ecf3-4ccf-a631-49bb4b3ae240": {"doc_hash": "9ff927d63d25772d5ea6825e97ff0b5e80b642763c3965b7256a09d9a7dd0c21", "ref_doc_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4"}, "0abd5464-9b4c-4ad9-bf36-10bafc28e2a7": {"doc_hash": "25e6fe296f86c89a28d78819ab11807ce56420453498ff546a8d263717a5b01e", "ref_doc_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4"}, "f566e053-56b9-417c-bc4a-aa1bfcc5c689": {"doc_hash": "34c216ec8126f5cf391a8e2efc75e60bbd3c813673ed6eac97bed1eb1e8fe556", "ref_doc_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4"}, "454195e0-9e7e-4c0e-987d-69a03361eff9": {"doc_hash": "fb91f633687b1a91521a6b712ce87ce08acfb03fd356fd08870542dbec1f81c2", "ref_doc_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4"}, "13cd2a0a-93e6-4955-8a9d-a16927c86c22": {"doc_hash": "bde15d860f189fd5dea85143622632bf31cf1c57f90cb4b6b6746d10273f47e3", "ref_doc_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4"}, "6de37fbe-b35c-441d-be75-505eec1716a5": {"doc_hash": "29e08a87e7de16e0c425393026197f419407c6f27bed42c6722a5fa2c832d2e2", "ref_doc_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4"}, "a8400fec-4032-4c3e-8b9b-2f8933e525ee": {"doc_hash": "fd1045e14aa9a6ab84b7cde38e56d69aa3b0111933f68ca06efb7357ca821bb6", "ref_doc_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4"}, "b6e886e4-567d-4fc2-b593-7a4aebae0355": {"doc_hash": "5e653c07dcbed4e03a6c382e26b9d8d39378d4d3539c0aa04caf6d0d3f976529", "ref_doc_id": "537a8a58-2171-4c25-8417-36f4e9bf2cd4"}, "d440c117-e651-4bb9-b8da-1997cfc03768": {"doc_hash": "202f2b74c5007c7099c24207b522c2fe2aa3956e6ce4981a931336e5368688b3", "ref_doc_id": "0b4739fd-a210-4020-aa76-6a4d4c165542"}, "d94be135-37cf-4d75-83cf-c3a278d83644": {"doc_hash": "61df6e2e02c6f0b5c5b52aa50d29347ed9f8563c6cd90d071135aa9f27bb7682", "ref_doc_id": "0b4739fd-a210-4020-aa76-6a4d4c165542"}, "cac09502-6524-4c8c-b0b2-2730ea674f2a": {"doc_hash": "755f3ccfb328781520bf42539da13a8f9e44b1813dacfb99e3f487deb0cbd082", "ref_doc_id": "0b4739fd-a210-4020-aa76-6a4d4c165542"}, "09160517-6042-47b0-b639-2cddb956a2c3": {"doc_hash": "ba35616fdb3de6e02a7debc3e6976913718cd5d54b98070e376bb4b460d7fc9d", "ref_doc_id": "0b4739fd-a210-4020-aa76-6a4d4c165542"}, "b28ff09e-9953-483e-b900-a576d011c081": {"doc_hash": "2fb546bc496635011c95392b1fb6143e0535d23a35de74afecd85cbc082fbc2b", "ref_doc_id": "0b4739fd-a210-4020-aa76-6a4d4c165542"}, "5be6ff53-d4cb-4116-8d00-b57356d2e800": {"doc_hash": "d9d8a39ca7f47c92a505fe9d6c1aa6a63fc7103d119618394db6dc85f25fc364", "ref_doc_id": "0b4739fd-a210-4020-aa76-6a4d4c165542"}, "578b3af0-3642-4a8e-b8a6-b8347f4dc39e": {"doc_hash": "ca663e7f6392aac83381eef751ddad9dbfd88e0f0e39cc2e57832a2abe2e6824", "ref_doc_id": "0b4739fd-a210-4020-aa76-6a4d4c165542"}, "490468b6-7405-4fb5-ade5-8a2e568c6652": {"doc_hash": "21e4f93bd7aae49a5cd935babcd62e197a14619237e0f3cbc1f6eec94b44860a", "ref_doc_id": "0b4739fd-a210-4020-aa76-6a4d4c165542"}, "1bb80b24-e18c-4e5e-aefc-7c22901a888b": {"doc_hash": "261a704f6a771f76b25ea563c7c50b29cc252ea6e53d2b64ed87343feadfc7be", "ref_doc_id": "0b4739fd-a210-4020-aa76-6a4d4c165542"}, "fb17da20-897a-46e8-9c2a-5e70e2df4f0e": {"doc_hash": "8dce91c8a3ea827cfbb3aa56f3542420816a8d145facc09d6c262d16e4f0729a", "ref_doc_id": "0b4739fd-a210-4020-aa76-6a4d4c165542"}, "1c067191-e598-47a8-b656-ff26c1febee3": {"doc_hash": "a5c439f047d646e5f5e5f326868751ec83152f885967d590e8290d4cc3971636", "ref_doc_id": "0b4739fd-a210-4020-aa76-6a4d4c165542"}, "c28fc01a-a6b7-41ac-88af-e7a6bdf75d2b": {"doc_hash": "e189b0ef08839911af95e00743671c5ca7c7cb14240086e5f07aa0b2129a598e", "ref_doc_id": "0b4739fd-a210-4020-aa76-6a4d4c165542"}, "ffa44fd8-68da-4afc-8905-ee84eb175bc7": {"doc_hash": "c94d4e70d93b0a24f7c6919560f999a0c81831e5797da8cbe0615e45d447bff5", "ref_doc_id": "0b4739fd-a210-4020-aa76-6a4d4c165542"}, "2a1d8b1c-89a3-4da3-be8e-fa18ad34e1f7": {"doc_hash": "3a7230085a6f4588a26e10ebf1d6f41636a1eb92c5afe5181435aa74f9673107", "ref_doc_id": "0b4739fd-a210-4020-aa76-6a4d4c165542"}, "dea283fd-d725-401e-9b6b-4a4473add89e": {"doc_hash": "8b5d1e74d28b46e46d132a0e28dbccec2e4a075824f45e91f649cebf2cc9d581", "ref_doc_id": "0b4739fd-a210-4020-aa76-6a4d4c165542"}, "bae7a823-d919-4fff-af03-bbaa85b55eea": {"doc_hash": "fdb945ca191c4eee5739771e84d6bd03150f93f0c66bb4c8ed3b146682f31963", "ref_doc_id": "0b4739fd-a210-4020-aa76-6a4d4c165542"}, "03c30d01-39b6-499d-9877-a02af067d8a0": {"doc_hash": "f57a4a64eba3154963b5c16f9c0010d0fb402ea703e64a2e081c05bb125b9b7f", "ref_doc_id": "0b4739fd-a210-4020-aa76-6a4d4c165542"}, "ad45e2f2-ce2f-484b-92af-2cc7dc381961": {"doc_hash": "11664ae33fe87c74b53d020aa0345cde0043667fa64eb7925535da5f851f555c", "ref_doc_id": "0b4739fd-a210-4020-aa76-6a4d4c165542"}, "bc18613b-55a1-4d73-88d7-37c1faae23d7": {"doc_hash": "1b4b1a4b602c3dd0fa554e59014cb766f6b64d58f6d95150cf9c259e748db57c", "ref_doc_id": "0b4739fd-a210-4020-aa76-6a4d4c165542"}, "17277776-8340-42a5-93a1-e3c8d303e8ff": {"doc_hash": "be9508a62fda24304f9739c7773216f4968c2fd147852790cbe4191d0532cacd", "ref_doc_id": "0b4739fd-a210-4020-aa76-6a4d4c165542"}, "df378f16-01c5-46a1-8100-e6f100f4a2a9": {"doc_hash": "4d7980cc4dbf6d5f3f01790c4c96a296a80711b1f14345ade038997dd28b3c06", "ref_doc_id": "0b4739fd-a210-4020-aa76-6a4d4c165542"}, "35f6c835-e1de-495e-b08e-70f0b0f0fb9f": {"doc_hash": "d01c8a2de033727a215e31189d034009c2592f982dbf36cf14a7bba0cfb90392", "ref_doc_id": "0b4739fd-a210-4020-aa76-6a4d4c165542"}, "252b97b9-d573-46c8-889a-4d2abaa1f822": {"doc_hash": "d671387bf283dced8105ebfb279f60a1c50b3cb9eef048d89b084cf6baae3c96", "ref_doc_id": "0b4739fd-a210-4020-aa76-6a4d4c165542"}, "d4af490a-fe7f-448c-aae1-06f482452e05": {"doc_hash": "f29ec8cf42a98d78c465da9efd91ec9663a44fdef68191152cdf2cd165ce838c", "ref_doc_id": "0b4739fd-a210-4020-aa76-6a4d4c165542"}, "59331b4f-93ab-4a88-a594-ba5080e05e77": {"doc_hash": "55ab812eae9cf48223e3855fb55c1fffbc8147bc92a948b41445f4ddb9d23685", "ref_doc_id": "0b4739fd-a210-4020-aa76-6a4d4c165542"}, "ca9d6e59-6d9f-47cc-ba35-442130f2d4db": {"doc_hash": "aff669773a1e42f817a6557c759cc708e750f10533afcd5cc0282ccbf7b1153e", "ref_doc_id": "0b4739fd-a210-4020-aa76-6a4d4c165542"}, "42de0b0f-cf97-4afc-8b99-d4eb4948704b": {"doc_hash": "a6ae989af258d2254271f630798fa4057f417b8769850b2e32592a2564f6984d", "ref_doc_id": "bd6eacc3-18ee-4daa-936d-290440082d8d"}, "f52ffaee-7b46-477d-a1a3-0883c78fe76b": {"doc_hash": "0dfc3975923f3dcb2e16cedfdffb43621ceeaff8e32134820f3a53d90a0f81d5", "ref_doc_id": "bd6eacc3-18ee-4daa-936d-290440082d8d"}, "41e30d40-fc09-4f75-81d7-f8f5f9824ff3": {"doc_hash": "22b78c4f9885f319f0e4e0755c873580c58de1bb23817bd11d21b7bd9b033ea7", "ref_doc_id": "bd6eacc3-18ee-4daa-936d-290440082d8d"}, "93f70569-5c39-440b-88e5-01fa382a56e2": {"doc_hash": "268dde941d47a1a32f558dd182e8e3d569d10a2f5f9da87cd45b616361cbad89", "ref_doc_id": "bd6eacc3-18ee-4daa-936d-290440082d8d"}, "e9409955-f515-423e-b4d6-f8c7802ec090": {"doc_hash": "97b60f080cb2c71568bcccc02f5055b99afae55578e5e07e471228e76c16b5b2", "ref_doc_id": "bd6eacc3-18ee-4daa-936d-290440082d8d"}, "fbd36146-593d-4b56-af1f-e3b788b0da1f": {"doc_hash": "090348e8445d2c57f50f430580f9e7e90a8dfd99643ba8205c0d8d2e7463601e", "ref_doc_id": "bd6eacc3-18ee-4daa-936d-290440082d8d"}, "4d8be690-28e0-40bc-a2c5-826e545d2674": {"doc_hash": "375d1885cbba6a6d350f26d5c3ad5335f78825e6b3e65991c9312de3bbce2994", "ref_doc_id": "bd6eacc3-18ee-4daa-936d-290440082d8d"}, "6c4ee0ba-92b9-41dd-bf1c-b1d733f81381": {"doc_hash": "4a70d6e03af2a93739d6e9999232afe1ced8dfdeae95097f6caaaddd2d86ce4a", "ref_doc_id": "bd6eacc3-18ee-4daa-936d-290440082d8d"}, "89f02fa5-8f79-4ed0-b147-1cffed7f34f8": {"doc_hash": "9d530913ec991b1f2484160583b369a3ebfbaa847e7b50a83019fc2d5dd92470", "ref_doc_id": "bd6eacc3-18ee-4daa-936d-290440082d8d"}, "f81f85e0-103e-4364-9c38-f2507c42fea9": {"doc_hash": "a4c1f5548c13b2281b85f254dd6240b47c1759c5ee88e86a7b5a0e4b0a6e48c2", "ref_doc_id": "bd6eacc3-18ee-4daa-936d-290440082d8d"}, "75970add-9264-4031-8c95-ed60aa8ae899": {"doc_hash": "11ad682335e5947b7431f0babf663ae362f1ffd457de7062fd416b34a6588c07", "ref_doc_id": "bd6eacc3-18ee-4daa-936d-290440082d8d"}, "57ba9e51-0e4f-4872-9a0a-c5de3a66676f": {"doc_hash": "baee538674e4f05fc8191ff493c47c35db201547b04d0737da481f9236be0567", "ref_doc_id": "bd6eacc3-18ee-4daa-936d-290440082d8d"}, "94cc51a9-ba7e-440d-90a0-eb43a51b5bcb": {"doc_hash": "325f082dd81c3cae7882eda24aa23cb333b459551ba498652b6a14b31d32684f", "ref_doc_id": "bd6eacc3-18ee-4daa-936d-290440082d8d"}, "6e52838c-c35e-48c5-8ce1-12d39a751bc4": {"doc_hash": "f820e9e7198fafd39cc596e54e8cdfbc8fbc3dcdb7b2a7a88efe3364ce144f07", "ref_doc_id": "bd6eacc3-18ee-4daa-936d-290440082d8d"}, "18886824-e815-40cc-8067-8de1cadca36a": {"doc_hash": "a727230de99eb503d2e72467bb927137b670c167f6a672f48b271541988bd335", "ref_doc_id": "bd6eacc3-18ee-4daa-936d-290440082d8d"}, "efca4bd1-bbff-40bc-a75b-b26d46ec023b": {"doc_hash": "311daa8e98130b8a77d5c3e25da5b8534a66a64709eb7db4f30658d8430c17c7", "ref_doc_id": "bd6eacc3-18ee-4daa-936d-290440082d8d"}, "866c13e6-cff3-4b79-875d-b9e3c5b50a6b": {"doc_hash": "f459bdd77ede79779a829f6ca72cdb4e77493e08faaaf869c37b05d509be2caa", "ref_doc_id": "bd6eacc3-18ee-4daa-936d-290440082d8d"}, "18a1cb3b-8011-464b-a98c-256ee2927578": {"doc_hash": "c037e03a4abfa89a08fc0447b7a8b4953478d45a8196ea5ca0ef394a04d8e3cf", "ref_doc_id": "bd6eacc3-18ee-4daa-936d-290440082d8d"}, "e2e65a66-db25-428b-ac66-2cb8b0f938d1": {"doc_hash": "e75aecc2dc49379a8f7fbbe8eb9d7d1d890d0b10949710fe91d89720ef92bca9", "ref_doc_id": "bd6eacc3-18ee-4daa-936d-290440082d8d"}, "69353733-eb16-438e-8302-7535f4a4ea16": {"doc_hash": "7ebe82266a35fb7b5bfa024106cccc44bb3902906b352b3042e91dceb13f4627", "ref_doc_id": "bd6eacc3-18ee-4daa-936d-290440082d8d"}, "2c59410e-8ac3-4b97-91b8-c3a0c6c5af0c": {"doc_hash": "47d0777ab7f117fc7d648eab94d670edde44e97b65bc19a4081324fac3e3d7fa", "ref_doc_id": "bd6eacc3-18ee-4daa-936d-290440082d8d"}, "7c01ffc8-294c-4c6d-b7e4-b5532d61381b": {"doc_hash": "b7e22d845d4378587a4f15b1b562eda8d963bb6c566de1cb0597dfe5d3dfc52b", "ref_doc_id": "bd6eacc3-18ee-4daa-936d-290440082d8d"}, "7d0cba2c-a85f-482e-8e66-91c8f2aa06f3": {"doc_hash": "21561f54331ad45b52c4b902a1d5511f2e27254329a646bfa7d347cc7172a414", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "0a3de324-84b0-4de3-8116-fcd551574684": {"doc_hash": "77f920f4e2f92d57a620eeb6e4dd9f3e984e2d19c173bb236e9d486373b6cc86", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "c0d93f61-4f23-466f-aa1e-497b404f6afb": {"doc_hash": "602214dab6077ea8a82720dfbfae6c6b1c7fefcff5c1564873c3c91ae3251547", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "08e8d609-ba88-4e88-90a8-c3f9455fbe1c": {"doc_hash": "4d3e4927a6baa2e5e910d9ab4dcec533d9218b12b9ff22b54fbf51851c5069f1", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "8d3ca547-754d-4941-870e-ddf9e91f6d47": {"doc_hash": "eb9d2e50e022e7cdf640f071ff53081208df5f7375eb78e6ae5bb37262884f66", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "cb18493a-0d58-4189-8d9a-5c635a719b9f": {"doc_hash": "f00eaa66682bde9f74d1e23355bf1d73c9afa0ea1714e8d4d977e453c3d68fa1", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "e993a1c7-1f1b-4e42-ad2b-acbeff25c359": {"doc_hash": "587dd88712fc379e347a928f76527015402f0e3f3e06521ccf391f32c17acf81", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "d9b2ed59-1aa8-4ee0-8d45-0dd107d8717d": {"doc_hash": "8c42553e1689247e60850b3d1db22303d306a788e74418fbf8fb0295798db000", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "294cdb5b-a4a8-4a2f-9e7f-dbd689c450e2": {"doc_hash": "64d6d69b380ec7a8adc44f3c57273a6855d2d515eb1647d76c2e6262256bacb6", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "51abc90c-0dd4-4192-a258-5e5b37009c6d": {"doc_hash": "6a0cf614a68b0a3458d7d968687abe7aac98bf623ae35dcccc1630a24559750d", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "f6222e6a-42e6-4981-b3ec-b097d7cfa9ff": {"doc_hash": "7f7b8d411c3e744cfbb218acf10e8f8d7b55c74d45eb3bcccbd5e73f7b38e26f", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "1234c52e-5a57-48ce-a9e5-5640bff9f9e9": {"doc_hash": "869cb8e38cd66a00f5d2c373ce1db23ad5cdfdebb04df03698cf6d86449d3e77", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "3c0e0a0c-13dd-4304-b1ff-0d3e335f0ed4": {"doc_hash": "f43b41e3d4f0e2691b22a90d8450672a8537b6014caebedf7c5234623ce3395b", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "250b8ed7-74ae-4cb9-bd01-6133ae1494d8": {"doc_hash": "042294fc15d6810f5b8bb840ad36305f855f39dda231cc4c43388068be650a83", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "ca26a64e-19bf-4bb4-9b24-921604de3de3": {"doc_hash": "167d9fefe06eed5b949d70ef85544be389037782d5b31c2765c161f7433589e8", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "c98109cc-d651-4c5f-bb2d-d648731d3d70": {"doc_hash": "ca6c5349e5dc72cf3fef71459bf43ba8209a362ee56cbd9fdbd4b4d0648745d0", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "bec0e24f-87a8-4394-aec1-bd24f3bfedf2": {"doc_hash": "8f6a0291903e75ade9b811855a9c9a3490d95c5f813799ba115cadfe0187c9c5", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "076520a3-3725-49af-814c-6bd2fcee8d4d": {"doc_hash": "80fd7e1fb67275cba76918ca3fc665014b502dced49d88d2eb3537c88d8abdc2", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "eb98ff75-8bbe-4cf1-ab75-b270b39415fb": {"doc_hash": "a74d5b0875d63a1300a37bfdd014db30a4dddaa009319cde5eec95e2906ca8ac", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "3ffad55a-c889-4952-9bc4-d777df738b7a": {"doc_hash": "9170d13ebb000ad1feed90cb6c600a16606fa9be1dcc935a5b0baed9db396626", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "fb10868f-579d-422b-b549-33e3dfbc575a": {"doc_hash": "a16a29b6882b0e7d62212ae3a208097787fa80125b7eab7b349988c7072345fa", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "583a7b99-ed16-4acc-a252-aa5af3aadaa1": {"doc_hash": "040babaddbc6d7172fbdbee18a0a7badcbb76361715be1c628aca2fc9f4a73e7", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "27df0b27-aacc-480b-8c25-0f763e954650": {"doc_hash": "dc49f0e56813ff19f02e31fcdc860c5e94f31e872bb29ecaede63c0f6f62d051", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "23d871fe-c1de-4d00-bca8-6564815ff92a": {"doc_hash": "cc3051327b464f33c5aca4750cee82b4699d16a1311ded4a4f10ed5b85eb1d92", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "cd753cc4-6c9f-4980-b74c-eae6a2f696cc": {"doc_hash": "a0073ec01cd16294174d82d37fb2e71aa4b40a963b353304443d589d67baca6c", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "800d2f17-b9bd-45d2-a66f-6ffaa2ab7e0e": {"doc_hash": "6986c7d4110b84946a95b3428f945991f71a2f8d93866e4b9fe7d3d887e58b9e", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "262260fd-adb5-46f0-a15e-54f5072c7667": {"doc_hash": "0b475604ee60c51cf092dcd1eccbf4c1b81703ca53e62e458cc6127ca3eb1412", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "6d85c177-4077-4af6-9da7-58d9a8301e0e": {"doc_hash": "7bff669d407919e2c14ae6d324248ed4fabe8863e13a0fa79f5d01f53ab7d710", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "45c45a1e-0f06-4a0f-9382-91ef808dbc04": {"doc_hash": "fc9da1fbc72c9c5fa63a3cd1acc84c5129e44fcb20b7face47db0a32c8851950", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "7b1e1e46-93f2-4a4d-873a-a65aeee58c19": {"doc_hash": "e9bdea7497953f433b551d98c2d628ea3e867d7e2aaa29bc5e09ef3be9326f63", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "98897dcc-eb46-42b3-9264-b8c90087f0fe": {"doc_hash": "2e5572247d4c369a72ae82371ffb721c3ca5451f11bba9fc99405797bfbd804f", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "3fd04acf-7a95-4976-b999-a6deb07ff29b": {"doc_hash": "a9d0c894e47b62a534a3b7d5c27c13bc89357cb6c73e736f4df19d871d04ddaa", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "4bd6292e-da66-40b2-bffd-0e7e8031325f": {"doc_hash": "2cd5acb28f313dbb99fd67e52531eba7e8bdddb2b3f8bc27870cccf5eeb726fa", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "399a0073-b49e-44c8-88e0-6ea141907c51": {"doc_hash": "6fbd8364b1354fe50e77ef6e6490fb0ab30b6568611c4187ef2af3ed0842b707", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "156755df-165e-4907-a125-0ad230d5ee01": {"doc_hash": "cd4029d5fa7c0e2c47ffad8e44d56ace6460c96fe8a27fb10beb5994ac6c4434", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "72c7b5a3-2c99-421a-ac6e-40d7227724f7": {"doc_hash": "cf079cf7890a04daedca0dee38958a0fa90af024fa71ee690325313f1ddaf1e4", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "d651ef9a-9cd9-457d-95c6-fa16086344a9": {"doc_hash": "54da1555707f87cd73ad7004ea517d57a36b661f6a017ce7fb7e834a68b5dd62", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "d96892a1-e59b-4d74-bb05-90f921c095eb": {"doc_hash": "17ad05d39b72568a8cf8a8f8e821fd694220df50a99ab121ba8481904b89a522", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "e2a64860-36c3-474f-b8ad-ed8d2939105b": {"doc_hash": "3a3bf2d7f4e042089be85092adfcd517a7d798880470923bd32090a849bca3c1", "ref_doc_id": "52c2f2de-784b-4a2c-b4c0-e71ce680eb73"}, "8a95a5ac-540a-4f92-9059-6cecb4796aa7": {"doc_hash": "0ebf633413c8296c8598efa880dc82de74b13abdd256a445b865df1d51ca732a", "ref_doc_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231"}, "1b4c5952-4155-4365-9def-21fbe067eee8": {"doc_hash": "cd846b3114831ee615c16c3418a4cd9e76063d9586f3ea20b996698f4b0573dd", "ref_doc_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231"}, "d982ddfa-cd29-4863-bee2-bc3cbd2b8ef1": {"doc_hash": "b52b7bdec67b21b0b5b220c1b3c088cec618678076df7470b6612226d87372bb", "ref_doc_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231"}, "7bc891e7-56ea-452d-b256-047978d3c099": {"doc_hash": "442b34686100b46eb0a60ad1b208aae8f296fe0f7a59b28c3f8f7181345aaa9e", "ref_doc_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231"}, "1860fd08-e980-41a9-ad08-2a9f7c33c68f": {"doc_hash": "e691c78ad3735e2d8bf23dd158336f71f8d91344c38116a19b257cf4219f1bc6", "ref_doc_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231"}, "54d581e7-e554-45c1-9c7c-998716e4ae5e": {"doc_hash": "838eff89411c6448a8ea5cc67c6425f74edea29d50e2dcc48c35b4ba8e678bea", "ref_doc_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231"}, "d5e58d7b-d435-4093-9e03-262157e76e7c": {"doc_hash": "6a0c88d2c527b7b50e71827ea774a4639d61f1491a404fc9307d6480ed071864", "ref_doc_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231"}, "e2561468-4c4b-4a8b-b781-ebd35c734bb5": {"doc_hash": "5ef40ee5bc660de6c7bd9794de48ae6334fed30172d2c0808967bbc2f3bcd39d", "ref_doc_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231"}, "61c0cb39-4565-4341-aecf-e34694726350": {"doc_hash": "3d6a606e8b612c4723982e95b3f2722eb517c0291f42e04268b7d2607ab2c1b3", "ref_doc_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231"}, "29508c18-fc28-424a-b39b-286f8e483938": {"doc_hash": "257aae61361e99386d77c7fec427ec7968c026ea3c78591ca687f112aba5a0fc", "ref_doc_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231"}, "b75cd9f5-b2f1-45aa-8232-a7f62f357ba9": {"doc_hash": "1bb428d100120c46f19e523f391254b3b4a635763464e18297072eb5fdae3dad", "ref_doc_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231"}, "fae67ec7-0924-4510-91c5-f4108fc2e5b3": {"doc_hash": "932be1e0e17149cabfab2fe5db350f09cf7f74e6d8d47a6b6ffecdb7a9b13764", "ref_doc_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231"}, "34e978c5-8b27-4d0d-ad5a-dcb2e7922a61": {"doc_hash": "861d77c8d19d8f3cc313714c74ef5ef49cc24e19b6f56aa887bd6b6ce0b1f75d", "ref_doc_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231"}, "a686d9e4-a369-4c7d-96ea-9f7e71c492e1": {"doc_hash": "25b847f04000a6cecb10f4897aa08bd1383ab7ec131f4c06bb85e82891c88761", "ref_doc_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231"}, "5bbd12d1-7e6b-400f-a3d0-17b3214e7699": {"doc_hash": "f9484eaca03fae2f78e2f87785efa5ae4e448d34a59ac28094bc06e65d23430a", "ref_doc_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231"}, "db3731f1-fd57-4720-81b8-e405cdfbf6d4": {"doc_hash": "fcf67770f675ac25a697c420f5830b9e785527bceb7c627b75bbdeccb798d44b", "ref_doc_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231"}, "5717f748-6c63-407d-8980-3e33fe971360": {"doc_hash": "ae894182294bccc86e0f370641dfd6bb50da99d066fc2ccb66af999dce61d9db", "ref_doc_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231"}, "7fc313df-3e32-45af-98a2-776583b1ad4d": {"doc_hash": "ffd446b58e7b6900f9eb44d9f99d020c26b4c14fa2cd8d3060603a970853c53e", "ref_doc_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231"}, "1ad03831-a761-49ee-a46c-0d95853c64f8": {"doc_hash": "c33fdb2f227f9dcf73e5042dac8cf8bea00feba3a4ad8022366e282fbd904ba2", "ref_doc_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231"}, "eb518ca1-279b-42ca-ac21-6b81e9449762": {"doc_hash": "c3ddbd3c7fa890fdb73db035817ee458d5b23794eb7df91a30f87e762543de19", "ref_doc_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231"}, "b16b8379-ef02-4fe5-b884-5c96b9499773": {"doc_hash": "f10132f9b6db8d33b3b47028ca6a93956786a285c102a42602aa9172df900b13", "ref_doc_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231"}, "7c49d8c7-cd6f-488a-b02e-800e41c6bbf0": {"doc_hash": "ac35a804c1b3d3997828e60668cbda5595b90e5da37d531eebd3d52cec30cc28", "ref_doc_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231"}, "8c080594-1cfa-4397-a842-73e96476bd0c": {"doc_hash": "b2a9d5f173103fd82b2b4656b53c7f681d664bb15aeaea7149b0a3b81ec3eecd", "ref_doc_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231"}, "a64fa916-2585-411f-b2a3-7c28e0d9a24b": {"doc_hash": "9976cd29155ce7b92e8f8e0173a7e089cbda5635a08c142cb9e1e5710b2d32fc", "ref_doc_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231"}, "88b84626-4943-4a37-bbcc-072575c60934": {"doc_hash": "b92a83481d2e550a231692f78b224c50f1f1015caa68da005978e8ec39daead2", "ref_doc_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231"}, "f82035a4-6c8b-4624-ac5b-6e8ec8f9db16": {"doc_hash": "f397b0dcd64a50379e7b6d70473df01f345701aa908db07c54eb0fae5ca71065", "ref_doc_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231"}, "ce48bb2f-fe86-4525-94d4-7c210c572930": {"doc_hash": "5b7823ae17e43370bb18e012e42ebd27c40d85fc61473aef70ab073ae60225ee", "ref_doc_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231"}, "b9452c8e-12c9-49b7-90a6-8bae8bd37fee": {"doc_hash": "46c549e616af3c5709a9ea431a9d131f577909bedd9f360a941cc3d0fb1606a6", "ref_doc_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231"}, "44f14888-86b2-45b9-9946-cd46ab275f6e": {"doc_hash": "4685e986f88b85e74fa7315f9f965ddd02e57a141f1d6674d623ad43fcc901ea", "ref_doc_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231"}, "8a6e5fdf-a827-42cb-a804-29901157840f": {"doc_hash": "abddc74e1169de256b74f6ffc7764760b41cb1c28ecc81c55ba3e1830ba2a51c", "ref_doc_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231"}, "41c63d24-4842-4fe2-b9ee-d20cd70c4a86": {"doc_hash": "cc20f443c7fe23cf41dcd0f75e04bf3a3829cff07a6c155e6ea62b99a0043981", "ref_doc_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231"}, "2df21050-6f9c-4ceb-8a07-d19dc6cc3931": {"doc_hash": "5fbee5d81089551a1ff99966bcf633d76b4519c523976138acd6266a3594e544", "ref_doc_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231"}, "53afae79-7be3-4299-9eac-f8869771a81f": {"doc_hash": "80f38aa43e1f6f6e6780ad18ce144d38d2460993656d7fc76c3472cd60db6e0f", "ref_doc_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231"}, "ddc448ba-7e6f-4478-b6c6-476a13941e57": {"doc_hash": "1d40d743e5f13c4a4bfeff8d47af890c478b80ed6130e1d9ceb7a3b20f0b0ab5", "ref_doc_id": "e49bb75a-5fcc-4a72-9208-c8db0df48231"}, "14823974-546b-465d-893b-39cee0308cd5": {"doc_hash": "0c175dfe0e049b890cceed999c5c3705af7369b551be68ed52f99d110fca3f69", "ref_doc_id": "05741e79-c295-4ca9-8e03-5359351afb04"}, "b130c306-1fee-4efb-a71a-8d27b6ced077": {"doc_hash": "eb0eea34d445f997476585ad5499ebeeb11128d321167f25d2df0ba1908bdb4d", "ref_doc_id": "05741e79-c295-4ca9-8e03-5359351afb04"}, "b8910f53-7681-4a1e-b7d2-d17d84e191f2": {"doc_hash": "1e87313a316825c320fdc64ddbfcb912512c9bf8b416f7d005259fe4a35bb055", "ref_doc_id": "05741e79-c295-4ca9-8e03-5359351afb04"}, "14294311-682e-4b3a-9a9f-9a4aea6f6f23": {"doc_hash": "c8dff30ea930feb0bcbc9da89358d6a06ec3426544e256df8f4fad5aaa64aaa0", "ref_doc_id": "05741e79-c295-4ca9-8e03-5359351afb04"}, "809485e5-d879-4fe0-8c13-f0049bcec8fa": {"doc_hash": "c28e3b5d3aea610e806d8aedfbb78604ca04645ebd1890b48a5a69865b8267de", "ref_doc_id": "05741e79-c295-4ca9-8e03-5359351afb04"}, "0021cb65-01a2-4abb-a5f5-fb469b20d1a9": {"doc_hash": "160275401a6f47443f679721b8a63dee304f398146ce75f29f4b8b1c2256fba8", "ref_doc_id": "05741e79-c295-4ca9-8e03-5359351afb04"}, "2ee064aa-c3ed-4ad0-94da-5b19b7cef415": {"doc_hash": "48671e67e05934a6c5ca220696baec8d7771125d4aa390aae1d8592d2c1eedec", "ref_doc_id": "05741e79-c295-4ca9-8e03-5359351afb04"}, "a6aaedec-4e4c-4429-af85-24294b915901": {"doc_hash": "834ddd96c055c54a3c89360cb0141233c8efc0f4610eee191f19b0caacea031f", "ref_doc_id": "05741e79-c295-4ca9-8e03-5359351afb04"}, "782bd23d-99f9-4d64-a441-4e2e547bf1ec": {"doc_hash": "d4b6f3d9806ea482bd98d21717a2adaae3655974ff9a1a0f94e613ad4e3b1a29", "ref_doc_id": "05741e79-c295-4ca9-8e03-5359351afb04"}, "9fa34d35-bf99-490a-aa0a-08ab6a718f6d": {"doc_hash": "8ae6793b72f7c5a62819cb7a8d518c9136062954908a62194a130db095f97ff2", "ref_doc_id": "05741e79-c295-4ca9-8e03-5359351afb04"}, "aead0c3b-07f0-496f-bc54-176dd707240f": {"doc_hash": "948a58dd170ef9eb8931812b6c7655e2e00466cf7e7fcff176a540c458f0f185", "ref_doc_id": "05741e79-c295-4ca9-8e03-5359351afb04"}, "1a0d84f8-f7bc-40b4-bdd9-aeecb1bc270d": {"doc_hash": "f3dad85b70faf4879c07b16dbb1d38c2100e45a358ab298e9e54419a5b0a403b", "ref_doc_id": "05741e79-c295-4ca9-8e03-5359351afb04"}, "7d9a8cf6-ba1f-45f4-9758-5a68858c6a90": {"doc_hash": "11170aeba5ff8c9a1b1119634eb75a2ea7f115705a40109c3f97810aa99ae7a1", "ref_doc_id": "05741e79-c295-4ca9-8e03-5359351afb04"}, "c2f528c9-b8da-4746-b5a9-c458efe30db5": {"doc_hash": "a98c276d37d12f5901299b136394514f64dbce731596cd225dad28492b1ddf2e", "ref_doc_id": "05741e79-c295-4ca9-8e03-5359351afb04"}, "2f5610d1-16f6-4269-a272-cc20c6dc772b": {"doc_hash": "1a330c142154b81567ed997ae54a9d9fe8808177a4bdad3f8b7608781905a544", "ref_doc_id": "05741e79-c295-4ca9-8e03-5359351afb04"}, "6523ab68-79d3-441b-a378-483b6d822222": {"doc_hash": "663ee47e48d57aa24018cd16494105254a66e7b166ec3fbabcfa8dbd254d4abd", "ref_doc_id": "05741e79-c295-4ca9-8e03-5359351afb04"}, "bf22e1e4-5564-4745-a679-5bbb9fbd6ace": {"doc_hash": "725687c55b3cf123d44c9b562580b004522b1e700d3e78ac73f94d95ee6d92ce", "ref_doc_id": "05741e79-c295-4ca9-8e03-5359351afb04"}, "647f33a3-3b52-4cb3-979d-a19e3bd71ed8": {"doc_hash": "8ac3cee1455b1e499ce4ec04bfe425032c1a4eccb4ac5bf5534307b2199361a9", "ref_doc_id": "05741e79-c295-4ca9-8e03-5359351afb04"}, "0141545c-e756-4c1c-aafc-61b46a10029e": {"doc_hash": "94207fddacd01796efbba5a0faa78b5df6bcc89b078a43626996e7be51dbab0d", "ref_doc_id": "05741e79-c295-4ca9-8e03-5359351afb04"}, "ea21a2bc-d08c-45fc-861e-d0eb8dea3c1b": {"doc_hash": "d503d8b41e01b996a87e258e1e93e8fb9501c7ec812e1a75bb34ad85d8d70df4", "ref_doc_id": "05741e79-c295-4ca9-8e03-5359351afb04"}, "f0c4b3ff-29d4-4525-879d-6818847ba48e": {"doc_hash": "f977f1d22d1440d4b3ff9632c3efdadea30859c6e5bec58f6cae44dcf0c1e207", "ref_doc_id": "05741e79-c295-4ca9-8e03-5359351afb04"}, "35d4d5ab-629f-4b7e-8c34-cf53c0eb51c2": {"doc_hash": "e1471006d7cfefe10dd8d37676234b0e2500c544837037c572ba583db96615d5", "ref_doc_id": "05741e79-c295-4ca9-8e03-5359351afb04"}, "48f031c8-2359-40b9-9c53-bf57cc994cdd": {"doc_hash": "a2d6b4f8977c420dc77003c191b26f03dbc2b83dd4e98ad436d78bbba63347cf", "ref_doc_id": "05741e79-c295-4ca9-8e03-5359351afb04"}, "5c6b9043-a55d-404f-bc8d-581c7ef2ff6a": {"doc_hash": "dd562aec61aa8287477bb80b50a7b38576c873eda7f4d849c8d0f03b57b149b9", "ref_doc_id": "05741e79-c295-4ca9-8e03-5359351afb04"}, "d0ecf790-ec74-4a77-915c-7c92fa8ce40a": {"doc_hash": "bbcd679d790ce9f7dad7b39f85738b44222f46b8adb8aec8809c0bbf73401f48", "ref_doc_id": "05741e79-c295-4ca9-8e03-5359351afb04"}, "28fd606d-5cc3-4ea7-8ea7-ccfeab28d896": {"doc_hash": "e30d79f1610facfaa5ef1cbf8a3f95d7dd695a3d62aefa5b758d8e753a0b481e", "ref_doc_id": "05741e79-c295-4ca9-8e03-5359351afb04"}, "e4a75192-81d2-49de-bc80-5ae83be20556": {"doc_hash": "25b6b424bf1c13c8de3bf71d0745acf419c04a07565489be4fcd863c8a7d5739", "ref_doc_id": "05741e79-c295-4ca9-8e03-5359351afb04"}, "c54ebc60-9f18-483e-9006-cd6cc07f51a1": {"doc_hash": "c474127f1f1a74e83cf1ee47c5135c016c8e684ab95b82f32d05e57bdc02dd95", "ref_doc_id": "05741e79-c295-4ca9-8e03-5359351afb04"}, "6ffa91fb-fd7c-46f0-8aa5-132bd2153ae6": {"doc_hash": "897f23262509597dc617572e376a69369041d5d07c3f777ee9b4eb0ea649633a", "ref_doc_id": "05741e79-c295-4ca9-8e03-5359351afb04"}, "842531df-9ff8-48c1-98e5-5693d772c333": {"doc_hash": "2f368a3565eda53f0a506cc6aac1e5003c95505e80dfc981303d8621c2ec07ce", "ref_doc_id": "05741e79-c295-4ca9-8e03-5359351afb04"}, "1bdee844-68d0-454f-93b2-1d8003f9c525": {"doc_hash": "13f9e38f12c36f10a318ed3bc3bda6a4e5b6c093cfed6381c35f1b2ef19a295d", "ref_doc_id": "05741e79-c295-4ca9-8e03-5359351afb04"}, "0311cb09-d9c9-41b8-b9f1-ed7bb158eabe": {"doc_hash": "55208a77b644f833978dffbd79b7fd676b0d8b85e69b6f89c6b79b18a6c4643b", "ref_doc_id": "05741e79-c295-4ca9-8e03-5359351afb04"}, "dd12198b-eec0-44a5-8b4a-e89ce348451d": {"doc_hash": "562dbc88fe2a2640849ae3aa389ea15e98c2c72569aec77c327aa4b8d51ed6b8", "ref_doc_id": "05741e79-c295-4ca9-8e03-5359351afb04"}, "8d662d5f-152d-4808-952e-507da404da9b": {"doc_hash": "e7c68501dd327cf5db3ee3720235aa16ad6316071381b324b991eb04944ac6ca", "ref_doc_id": "05741e79-c295-4ca9-8e03-5359351afb04"}, "54b47dde-58d5-4cea-a851-b091c3143772": {"doc_hash": "ec5b6fd2293fd6aa5d5d6afba650f4886bbd28ee38a35ee854ea8c0d5a3b1521", "ref_doc_id": "05741e79-c295-4ca9-8e03-5359351afb04"}, "edd5a3b3-e9e3-42e1-86aa-dabf0421ae20": {"doc_hash": "791319d8c6176d93a1c75d43d5e91fd38d71ad4ceac3fbfdad90abcd9d295a3c", "ref_doc_id": "05741e79-c295-4ca9-8e03-5359351afb04"}, "ea0a92b2-cd45-4c25-bb66-6ab6c4ba517b": {"doc_hash": "1941e9a165a538c16c0c0d967ad290fda195a0ae13827beca2cc606124471640", "ref_doc_id": "98047684-7eaf-431b-abdc-d76ed6294538"}, "5c93743f-e700-45d0-bbf9-5f76e9ee4c77": {"doc_hash": "c9bc17fd5376791ce864cc71331f5a2acf634c8e50bc3f442d4ccff1040a1d2a", "ref_doc_id": "98047684-7eaf-431b-abdc-d76ed6294538"}, "0ae4e56b-c7df-4227-b02f-5d1dcf31c018": {"doc_hash": "eff559e00157b5d18527ddb78ec7c7d298c1ddaec4fdefeb86a5ad90b197c5b2", "ref_doc_id": "98047684-7eaf-431b-abdc-d76ed6294538"}, "07867a1c-7e21-4924-b332-b4477a577b95": {"doc_hash": "20ee7d6fb62c5d6d638f19c933bfb6563f9b93000570813e7b9a565ce50fa1d0", "ref_doc_id": "98047684-7eaf-431b-abdc-d76ed6294538"}, "1ee4048e-9f98-457e-93bf-b5bfa12a1352": {"doc_hash": "30447b44a5739b639edea9aa1c3f1300c89ddee7fe24bbf639b99647f4d9da0f", "ref_doc_id": "98047684-7eaf-431b-abdc-d76ed6294538"}, "f7da0328-088f-4837-a632-5d81205a6d6d": {"doc_hash": "49584b97963a7d2cb3b729918d00a017c17af44b8ca01d740846e4c1b834e122", "ref_doc_id": "98047684-7eaf-431b-abdc-d76ed6294538"}, "59344675-7454-457d-a7ad-9af4f73608f2": {"doc_hash": "c28eae12c923c8c9b5742286d20c0b89957c54a43ba8120a500488d04270b1dc", "ref_doc_id": "98047684-7eaf-431b-abdc-d76ed6294538"}, "6633efc3-52fc-46c0-9255-aeebde3efdec": {"doc_hash": "bf536f55d26424945fbcf32beef2f23a2de08693a386b40e47c4dc6ad17dfd45", "ref_doc_id": "98047684-7eaf-431b-abdc-d76ed6294538"}, "6031ce14-4f84-4e56-b3ff-ed58e447abf9": {"doc_hash": "d950f9e4b675c767ebf7c9f4774e94c2c6469de8fc3979fb794714f330cb7296", "ref_doc_id": "98047684-7eaf-431b-abdc-d76ed6294538"}, "bca3e4b4-649f-4389-9f83-7f45e0991803": {"doc_hash": "79d3c715fd032dffc157c922e5a51ea2d29e95612edf8644a70b44cda1fab63a", "ref_doc_id": "98047684-7eaf-431b-abdc-d76ed6294538"}, "74e3a48d-51cd-4f80-9668-c7bd2b189dd5": {"doc_hash": "b6f242555f73323f007b9f4b1c9cfef3d0186c1b2fdb381ea80209d415ed01dd", "ref_doc_id": "98047684-7eaf-431b-abdc-d76ed6294538"}, "5a68360c-9cf6-44ae-9b6e-1cdad2f93d5f": {"doc_hash": "edd5537f02e79e14454a4c55ed3bef4e9c5865119738bea79d077761bac05f85", "ref_doc_id": "98047684-7eaf-431b-abdc-d76ed6294538"}, "a30d2ca5-2f1a-4931-a96a-f6d8f063ebe2": {"doc_hash": "f78145dd446b91c735f576e984ba688ce3157286c22f56ab7aefd5e101055ae4", "ref_doc_id": "98047684-7eaf-431b-abdc-d76ed6294538"}, "e1224e2c-c3de-4888-858e-ac6f7848b242": {"doc_hash": "729e2daae11bfd482c52c8e1c0c27675e11ba9100e78743d448f1e7d3dd660b0", "ref_doc_id": "98047684-7eaf-431b-abdc-d76ed6294538"}, "a5bf65d9-e9bc-4917-aaac-50dac40f7af5": {"doc_hash": "198c520fac4ec4b6f18c52de09b01395348d2161a0fc89cba4de79a37f90e1e8", "ref_doc_id": "98047684-7eaf-431b-abdc-d76ed6294538"}, "9efd44d8-d25e-4e7d-b895-b28b7275fd81": {"doc_hash": "959d7df4fd0a657bb286e1ae8060bc89c946d1d264350b87015e360886138b41", "ref_doc_id": "98047684-7eaf-431b-abdc-d76ed6294538"}, "0b50205b-447f-4882-8899-c69ab5e4df78": {"doc_hash": "96ab4a05e790d517089a4fad02e9b6d4e19d27a88ec69b42346aff26953ec582", "ref_doc_id": "98047684-7eaf-431b-abdc-d76ed6294538"}, "3fb9816b-ac1b-4f78-894a-9dd9dd35b07c": {"doc_hash": "a9db0d3d2254b0477a4eb206fbcc3781e23658c7f9bdb3946c784033a2163051", "ref_doc_id": "98047684-7eaf-431b-abdc-d76ed6294538"}, "3189d73e-fb7c-48f3-a2bd-2d5ea43100c3": {"doc_hash": "fde50bdb690809ec350a4683537dae38adb80035d81e1cd5686003c3e90e3dd1", "ref_doc_id": "98047684-7eaf-431b-abdc-d76ed6294538"}, "11e6535f-9c7d-4bd7-b6e1-b2fe42b237a3": {"doc_hash": "dbb0657588cdc4f26027af011a24ee62825523c48c928d622f326424b23613be", "ref_doc_id": "98047684-7eaf-431b-abdc-d76ed6294538"}, "3fd468c5-c500-433c-a7e8-f14e083e8bad": {"doc_hash": "730f8f365f5867cf947340a285d6636cd8bbf2c2aca48bea258892145e01cd68", "ref_doc_id": "98047684-7eaf-431b-abdc-d76ed6294538"}, "3ed0612e-5c0f-4df6-a817-8242dbc881a7": {"doc_hash": "0139282c5bf3f60712f55609e523d6e8931e79f22adc54600c979d2d04aa33eb", "ref_doc_id": "98047684-7eaf-431b-abdc-d76ed6294538"}, "1049d467-2585-4876-b6b7-c4e8fe1d6858": {"doc_hash": "2a6cc24fde661c074a787f413aca009a31981c93bd52555b107919a3b8773919", "ref_doc_id": "98047684-7eaf-431b-abdc-d76ed6294538"}, "c449142b-e8a4-4ec8-96c8-5693e9dd7aeb": {"doc_hash": "c675a16aff42e2b13df4be8669a1878bbfd09ede8a9ff16e7fc7585742c688cf", "ref_doc_id": "98047684-7eaf-431b-abdc-d76ed6294538"}, "f086e2a9-2a55-431d-b39c-3fbb687e5e10": {"doc_hash": "dc69e187a2ea660d96fc848a4d9ce80846bb0cc35dbb1a81ebf084b6d48cc50e", "ref_doc_id": "98047684-7eaf-431b-abdc-d76ed6294538"}, "291424e6-0cac-4618-a5df-bff01e25ef86": {"doc_hash": "d821e11d71142e358ab60f91a2f0c06b311fb8b7902b92c9e43007b128f4dc3f", "ref_doc_id": "98047684-7eaf-431b-abdc-d76ed6294538"}, "79a77e6e-4f4d-4a22-a8a6-e30f0092bf14": {"doc_hash": "20811a62c1a890246fbe75119a73282041a0b03da584cd778d2d72e14a0d4b81", "ref_doc_id": "98047684-7eaf-431b-abdc-d76ed6294538"}, "a3dea05e-8db8-4c1d-8022-d74f856e8604": {"doc_hash": "5bd3a58d9280608b6c46332b04cc3b51c61674fcdc739e8caa5f510da0113b83", "ref_doc_id": "98047684-7eaf-431b-abdc-d76ed6294538"}, "0e78c846-8e3d-490c-85fe-1265fac09a4f": {"doc_hash": "4e8d3a27ccb1af58633a43c4d747a44af1a427a67fa3e59b2f440d75f8700b6a", "ref_doc_id": "98047684-7eaf-431b-abdc-d76ed6294538"}, "d874a44a-8c0f-4cd6-aba1-886a05a7ca00": {"doc_hash": "4ecbce11133f495f4a19529a3bbcb0292ebb21426d3edd4f0cc01e8610d89d02", "ref_doc_id": "98047684-7eaf-431b-abdc-d76ed6294538"}, "b31fa255-8aad-45a2-b60e-b97b0f34f85b": {"doc_hash": "0f96d15d8cc4de1ea497c7975cc5eba32f5633e04038515c300aeddd284acbd9", "ref_doc_id": "98047684-7eaf-431b-abdc-d76ed6294538"}, "5930a1be-db59-4b83-a67d-04099ebc6032": {"doc_hash": "0251ad83a2feab83fd8ac7d1604d1c30d42962e8e3bea5b037f1bf71eb970d86", "ref_doc_id": "98047684-7eaf-431b-abdc-d76ed6294538"}, "7e7a0f7d-7c9f-4763-8c78-ecc792e369a1": {"doc_hash": "d1d1896198cec78a90af3d952f1a5e28580e98ec2dce8c53c40609a2b2962d48", "ref_doc_id": "98047684-7eaf-431b-abdc-d76ed6294538"}, "a729acfa-e2ae-42b3-a6b7-200d118ff5e1": {"doc_hash": "837cb48c3ab59e550ec481e254f491d8b14293c4bf5fb068ec506dd67b509bef", "ref_doc_id": "98047684-7eaf-431b-abdc-d76ed6294538"}, "995a0bfb-dea4-4148-a06c-6109c5973123": {"doc_hash": "8966330d2264a5d6b8b5fc98ce46f44ef0ef3a022a0d0329692eba9f4d56615c", "ref_doc_id": "98047684-7eaf-431b-abdc-d76ed6294538"}, "be4d602b-c449-4e6d-9fd8-0e34161270d9": {"doc_hash": "dcafafb58a4f8b4f3f1767073779baffd52e6c437beb9167fd3bef87455020ac", "ref_doc_id": "c43cfbd4-7d3d-4708-b910-e363c305368e"}, "196fddef-c9f2-4745-baff-9c02ba34a61f": {"doc_hash": "36b0cce1cc4e671b1ee52e058d96194cdfd35e93003778c91d68e72d8d136708", "ref_doc_id": "c43cfbd4-7d3d-4708-b910-e363c305368e"}, "1cebcfde-aaad-4204-bc65-ffa989c104e5": {"doc_hash": "6d3f7e1b8049c982bade929a3f39e3a8895e5117cc8fc6d898ccac6340eb5ca8", "ref_doc_id": "c43cfbd4-7d3d-4708-b910-e363c305368e"}, "59e48306-3c22-420e-85c1-64f8977c99d8": {"doc_hash": "2c12d14a6b49693c03ae2d1000c54ebec13a45f8ae5b76fc1baaf106316eb8d1", "ref_doc_id": "c43cfbd4-7d3d-4708-b910-e363c305368e"}, "5e762317-a3dd-4964-b0f3-6e74ba73ef5a": {"doc_hash": "f7d913befe69dab1ff4ee51fb6ca8d848ddfc9b95146411cc03a726a8cc7e193", "ref_doc_id": "c43cfbd4-7d3d-4708-b910-e363c305368e"}, "2c17526c-e866-4019-9bb3-3ef9af9b0081": {"doc_hash": "12b6cca7e3a81e5b198043f519e274b36a96a24a961d0c3d3bd2418fbfe7e698", "ref_doc_id": "c43cfbd4-7d3d-4708-b910-e363c305368e"}, "c940a4b6-c4d9-4082-bd19-a4ba21685329": {"doc_hash": "6dbd3e8ababde6071e476988bee562c107c5bc1ed1f4985070bc13aa661f0383", "ref_doc_id": "c43cfbd4-7d3d-4708-b910-e363c305368e"}, "2ba52f94-68c3-4062-8193-4e037cd02b4d": {"doc_hash": "9f9b458fd8cfdd5823d532a301f9052d1bbcc33b8f9dfd6055b26a75a7b71a97", "ref_doc_id": "c43cfbd4-7d3d-4708-b910-e363c305368e"}, "5e16c010-b99d-4168-b497-2647a106bf49": {"doc_hash": "f9954aa284bed3768778b2dff327751d30d1158839ba7cc105603daf9ff37a56", "ref_doc_id": "c43cfbd4-7d3d-4708-b910-e363c305368e"}, "2ef8c035-5d03-4dc7-9ebf-b9c012e1bec6": {"doc_hash": "7d9e5239b0c84388a0f19c79dbfce7932c7fc01ef15a2c9f21efcd9c77aeffe0", "ref_doc_id": "c43cfbd4-7d3d-4708-b910-e363c305368e"}, "64ebce46-02eb-47ab-84b3-14a6f249128c": {"doc_hash": "a98b0592275a9cd232b46a29ef5f7079de933aa047f266f51928e8e93f714cd0", "ref_doc_id": "c43cfbd4-7d3d-4708-b910-e363c305368e"}, "cf6d0c8c-be48-401e-9a96-110889d8e6af": {"doc_hash": "7d1ce5926086b28214e8320ca413beee2bddb94225fc05d0bcb4e5625feb9107", "ref_doc_id": "c43cfbd4-7d3d-4708-b910-e363c305368e"}, "25d3136a-ee0b-4376-9aac-3abfed9c79c5": {"doc_hash": "fd6602b4d53f21a14f68f91c911a3d5ebb428e38ab799317fecf51b952f1e463", "ref_doc_id": "c43cfbd4-7d3d-4708-b910-e363c305368e"}, "5ebfd5c6-0946-456b-ad7c-f24e16790b2c": {"doc_hash": "d912709b9cfb33703f75bf8347230d18e0cd6abd9063f0f133709934b65102ce", "ref_doc_id": "c43cfbd4-7d3d-4708-b910-e363c305368e"}, "ac6a3550-1ad8-40c5-93b1-7c048f6bc73e": {"doc_hash": "1e5052493091b76beb00f9f05b1d4febbfd2563aa51d0b2c8df35a6344155c4b", "ref_doc_id": "c43cfbd4-7d3d-4708-b910-e363c305368e"}, "232f9546-3b37-4090-beae-65177e256295": {"doc_hash": "c2351870817798610df1d319bdfd6238190f30d2e757369ccc3dc3429aeec933", "ref_doc_id": "c43cfbd4-7d3d-4708-b910-e363c305368e"}, "481d7454-285a-4c45-9cfc-7dc20809f40d": {"doc_hash": "c759c544ec3db35128171b7536d7956ed468149fe303e06ef4966f813780be84", "ref_doc_id": "c43cfbd4-7d3d-4708-b910-e363c305368e"}, "02e5cb42-1bba-4ec0-871c-b3f2be726426": {"doc_hash": "c913e0b89d394196448e5aa16331082286d4e462fe1ee434e85c5cdfc3df17ff", "ref_doc_id": "c43cfbd4-7d3d-4708-b910-e363c305368e"}, "3d642ae8-54d0-4125-bfe6-060179aefe50": {"doc_hash": "f3993f5cb926b1a497def856ebea8adc8277f3c7576e48d5df1c33b5ce3299ae", "ref_doc_id": "c43cfbd4-7d3d-4708-b910-e363c305368e"}, "8e99a060-1bd9-44cc-b967-5e9d68861c86": {"doc_hash": "51a1fce5c8f8b7f558807547efe670ad177480a5064cbadd03585811fc4077fa", "ref_doc_id": "c43cfbd4-7d3d-4708-b910-e363c305368e"}, "14597d71-cdd3-4755-a5c4-e11628aba269": {"doc_hash": "dd4609402fd9d28cf6b486ca799a3808bf2c4166088ef96a0f473ae0cca620d6", "ref_doc_id": "c43cfbd4-7d3d-4708-b910-e363c305368e"}, "142b2123-f432-477a-b824-f41243a836d6": {"doc_hash": "9833d0851b643b7ef86ee16653c537e020da4e261af4a9188a3bad529286aa5f", "ref_doc_id": "c43cfbd4-7d3d-4708-b910-e363c305368e"}, "d5ce631a-9fb9-4772-a0ba-b72b15ac87d3": {"doc_hash": "a37972f9613a864f50222b5cf35df02cd1f4292c460c2c36bba25c696e8a98d2", "ref_doc_id": "c43cfbd4-7d3d-4708-b910-e363c305368e"}, "90ef63a4-b34a-4a30-9251-51d658f3e11b": {"doc_hash": "357c19d69dda019039dd114f70078398ae0916835899477d2e663320b83307af", "ref_doc_id": "c43cfbd4-7d3d-4708-b910-e363c305368e"}, "05487628-7938-4a9a-9110-7bcfe40d2bf8": {"doc_hash": "9a89392a7f2e0e7a26a961806442e7bb30a5d1db847a285789e2bec12f076d01", "ref_doc_id": "c43cfbd4-7d3d-4708-b910-e363c305368e"}, "ddea0275-67cd-4e35-88e2-a4e573475e4f": {"doc_hash": "2c8341e41b4fc63b4fadc391844a186e1c1ebc93f8d40b6af4869b6f023cbcd3", "ref_doc_id": "c43cfbd4-7d3d-4708-b910-e363c305368e"}, "8cea02c8-85e8-417a-b058-229f774e5525": {"doc_hash": "a1f294a626eec89177e4fc86154a17f37ec99fb40c465357e6a859436e6f896a", "ref_doc_id": "c43cfbd4-7d3d-4708-b910-e363c305368e"}, "68340171-4f6b-4cb4-9767-fe695bbfe8cb": {"doc_hash": "16e50ccf3d5901a94c3e77c0b9bbe430acfca09d2cd8ea234754121fcd78e47b", "ref_doc_id": "c43cfbd4-7d3d-4708-b910-e363c305368e"}, "dfa8fc22-de74-45ae-95c4-971a627d9379": {"doc_hash": "e141dd1e64d02bcae926aa1284b3f7963f880218ee476a8f13a3eabbde35c1b5", "ref_doc_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c"}, "60ad3e2e-ea2e-49ae-a457-d059404225b1": {"doc_hash": "d60d9ddd3dd14689298bf9ca25b460fecf1df499e303a04b0d5f0ae7f1d943f8", "ref_doc_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c"}, "4cb61342-3415-4048-91ef-21794a2cf8f3": {"doc_hash": "20707f5edc90a98ed577171fb213633702ce138496b71fe245dee68aca169042", "ref_doc_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c"}, "e21bb1bc-0138-4b73-992c-658fcc0ab533": {"doc_hash": "df25e5e0fffab4593c63fed138bd3b0d7e57acf7efe288dd21198862b73016c5", "ref_doc_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c"}, "d7d99f01-e9a1-49a5-a938-934293b38e61": {"doc_hash": "c24f0cd1ec597cad67dbbc4bb0f5031fa19bedfe41a97022c2da8f08730e99a6", "ref_doc_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c"}, "2f72314f-f9f3-42c3-9a06-bdcfaa77f007": {"doc_hash": "4007b149a0709debc9f793260ced1bd4c607aa25ee079d4c4ce82a8a92050c9a", "ref_doc_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c"}, "8ea13848-c32c-4a65-a332-e97d3f699b6a": {"doc_hash": "4d7d05d174d10994d9fc8c2b852dc663facd2baad33a416f2c44087aebe9eadd", "ref_doc_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c"}, "37307ed3-4a12-420b-911a-3eb6161ced48": {"doc_hash": "637c506ef5ad988e1e3a38aecd8a77d93b941644335bda322423910ad22cd3eb", "ref_doc_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c"}, "d4008944-10ef-48ed-8a8d-0ffbd527ed7e": {"doc_hash": "2292d344f0ab8414380537f86ac9e92cb875249d6304cea771d8496db44d80e1", "ref_doc_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c"}, "20a08aaf-48b1-4728-993e-8c4c2452f006": {"doc_hash": "03ad7ad41195304dc43b12cc9eb25b8bbce4d6c22f5a61d4db958ace9b6c9c8d", "ref_doc_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c"}, "bee94bd7-c020-4380-aede-6cc895169753": {"doc_hash": "9ec23db8b77719457601d06907f86d7a72030deda172c58edba9e268d100b00a", "ref_doc_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c"}, "727dce1b-ca5d-40cc-a293-847d683a992c": {"doc_hash": "79db8bb2065057f21336f0df713d1093372b30c3154c885c20552c18e46ce4ab", "ref_doc_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c"}, "a47b62f5-6248-4e0d-a7ec-11064462b3a1": {"doc_hash": "5cba586e4d3ec510d38641b31bb136710bd633302d91465eb2af2ce49600f124", "ref_doc_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c"}, "865dfbb0-93ec-44e6-8b15-4fdd3e720e4d": {"doc_hash": "887b36cb392d883198f836d0dc19cd684e3f7c54d0666f42161b16c58d5aa7b9", "ref_doc_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c"}, "8c22d2d2-db5c-4c3d-9abf-18cb7f125201": {"doc_hash": "b309146f4fa5884e7076cc5819895a45acbccfc6542549900bac8de121a34b24", "ref_doc_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c"}, "27c2cedc-eda7-4627-a3cb-c476a748eee1": {"doc_hash": "cfbe24d8f0b175efa329a226890ccb1a9a9a241af93cc627e2568d01f2807dd8", "ref_doc_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c"}, "e30f53f4-6bef-4128-84b0-6296b3132047": {"doc_hash": "4568874ba6484b4cb5f30809cc834cad1f7f831887926255c3fe00ac6120eb23", "ref_doc_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c"}, "66f7e7c1-54a4-4bf7-9a76-ecc26ba9ee63": {"doc_hash": "45202dd7e2ddee29ceb72b26b51629b55b2905e33da025e32bad1f5f4806081f", "ref_doc_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c"}, "2020b708-72f9-471a-845d-7df7dceed5c3": {"doc_hash": "2659d0c67c72b9b23c83db5a3a7e0f63fc2bd4ec5476f0027ac3fb2ed1e36446", "ref_doc_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c"}, "667431cf-fcde-471f-9b77-009b1d3479f4": {"doc_hash": "1eb0e9d1c5f5d1b32ba0f2263abe909e1e85c1fd79f3468d99fbf8b09a73683e", "ref_doc_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c"}, "0010a6d9-b9de-4042-9f4a-dbc03f36ff9c": {"doc_hash": "d1feb8900d3cf0fcf7ffe67c559dff04a4c510332921bd043276fc00e7fb76c0", "ref_doc_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c"}, "828b9072-4682-49cf-b9f5-de40661705e2": {"doc_hash": "5fadc04f193b3e0cd6c530a5662313cd9ef39ec73552e8d38c8405dcd28b59e4", "ref_doc_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c"}, "c51a94da-67cb-4999-a40b-50e769dcebe8": {"doc_hash": "a12f3df1bbe4a9b2e15d529be3db01fc442c66e7c98a8a96de1cf3e43d827136", "ref_doc_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c"}, "4212dde1-58ad-4a3b-8ba6-956dba97efab": {"doc_hash": "95e63b8f6e04dd55417f7f151422694ea157941a579a7304818ed877e3052b71", "ref_doc_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c"}, "14248ca7-04b2-46cb-bf0e-b7a2de5918dd": {"doc_hash": "71ea7974a204fcdb88e4c2e23058654a730fe67746dbcccd5d8b81a4e4c17421", "ref_doc_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c"}, "a199ca5f-aa55-45cb-bc02-823c56724aab": {"doc_hash": "35cc172d56bd3e48b5b6782d68f1471c673e3c42f01f0327559782e568cc20e1", "ref_doc_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c"}, "790d479a-aecf-4342-a23b-481624024b29": {"doc_hash": "f2f5cf7482d79177434a3494c1915aa4e149bde7b3914688a6694b029d63afce", "ref_doc_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c"}, "572cfe70-78cc-4632-80fc-208c6f911530": {"doc_hash": "097136386903284bf974db68440ed86f97ca05148ea305e1ac5162e33e370d79", "ref_doc_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c"}, "1c1c8df6-94bf-4334-ae09-40069f20d656": {"doc_hash": "5c7d11323cc23cd52f858250461422d8742879d48bfe18e32f26962670601923", "ref_doc_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c"}, "ad22aaea-306a-4ad4-ab03-4dffdac571ea": {"doc_hash": "16bbb0783ef78312ecb2d0c7c27b1fefbea214ef3c5afa4b9bcd38bf1d23cb7d", "ref_doc_id": "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c"}, "24cfb745-772d-4936-8891-107c83def0ce": {"doc_hash": "c32b6f73cfdf1862d88f59fc5b76a85f090253af5ccfcb0492bfc3cc0d4711ff", "ref_doc_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8"}, "da5c07c8-b49c-4fe9-be3a-877e539d76c8": {"doc_hash": "57934f49e0a37858fcef403c8c22b666043905fe5845e8628a61add9bba33248", "ref_doc_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8"}, "3db19a3c-bb30-462b-bca8-f5559373c375": {"doc_hash": "b095f70b840a1180e641febf5616669f0a85e2789117e63f97217dbf34a77b23", "ref_doc_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8"}, "93c6db2b-ce4d-45dd-af32-7323b96540eb": {"doc_hash": "e67057666bc58f1837cab6fc756725de8f05a6e83ea55e919dd3a79ba13936d5", "ref_doc_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8"}, "522dffa0-d330-4982-9283-aa8a0af7dbeb": {"doc_hash": "5e999708c9347577c9106634a5348786429443ae3373f2d290cec3eb797c5f88", "ref_doc_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8"}, "59864f47-4310-4c90-a9fe-ecb8b64737d5": {"doc_hash": "6f7bc977514ff9b7322f4582c6ea3e444850c07850ea5dc17cb7d9af224c9188", "ref_doc_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8"}, "8f30ac62-9943-431d-902b-609e8004a33d": {"doc_hash": "903172eec38b0315efcc9aafd5cfb93a3b05a6a6c02d2673212e9801b6404bdc", "ref_doc_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8"}, "a9e9cb97-8f1c-4d56-bf26-73d4994ae4ed": {"doc_hash": "dae489800ff764ddc11ed2e18a5650be96df7ece46ac9949cafea03380e81c7b", "ref_doc_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8"}, "5dc3c628-a538-4152-9e48-4d654878fc99": {"doc_hash": "2fcf95bea0951dec40b75791cd93a1b3eaaab7a68cd28d8784bad7d78ac27950", "ref_doc_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8"}, "e5cf0d87-8087-4917-81f3-a9082a39076a": {"doc_hash": "e7ea1eeb63c875114de4f0a85e020eb6969d6901fa939a86bff47eb7264eb471", "ref_doc_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8"}, "0492be5b-b309-4e40-b373-0736cd36a0a3": {"doc_hash": "2b0610869eeb61e28881432dd023b8dbfb5968838bc8d37c13875bab9ed1b8a7", "ref_doc_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8"}, "d69a87ce-2373-44bb-a58e-d32f1f900774": {"doc_hash": "660372ce08082e3dbb72e34524d9a3fde3015fc8fadf18b264a54a24e9652464", "ref_doc_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8"}, "f418f31f-f6f4-4d7b-9ffc-7b1c4265017f": {"doc_hash": "eb9d060aefc8b9759b2960177e8bd301e1a4e43ff5b9f4685252a949d16473ba", "ref_doc_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8"}, "6d419631-835e-4ad5-abf4-8f3f9a244380": {"doc_hash": "55c94582f9d98203c49f3535b74fc9fc1a425ea1d5df26c4b90febed175be290", "ref_doc_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8"}, "ff54db1d-4027-4187-a82a-b09776d1b602": {"doc_hash": "9004727fdd8398da07fc20bdb5bc0639aeec1f4f9dd61b7bad70b949c615a0bf", "ref_doc_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8"}, "2bd4993c-715a-4bab-a8dc-d810ddb5af6e": {"doc_hash": "afca8c530bd4ab19bb98d3d29cb3f05526e48fac7198b03007721bb6f737ea77", "ref_doc_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8"}, "fa515cc8-7177-424a-99f0-9cd6fc471f7c": {"doc_hash": "aae88f9c446e68de832b873e8204c3aa37def4cfb53da2472aacbc3d890deeb0", "ref_doc_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8"}, "e0075170-f557-4759-b796-7f96bcadf986": {"doc_hash": "054ea69d76cdb3a9c185c74e6a457a443afd067cfc30b6064df25470cda5141a", "ref_doc_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8"}, "c7e22737-4279-4215-b456-928a12f43139": {"doc_hash": "9a262cabc0582d4d24de7720985f46c232763a6465bc8f05f6b6b00f8bbf181c", "ref_doc_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8"}, "af9726ed-fd53-4543-97d5-d4d837ce1427": {"doc_hash": "5591300935400e2ddfdda282219b926bd626da6325edc6446d856f4f5356c388", "ref_doc_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8"}, "20d23907-fb46-4c64-92d8-181f701c40cf": {"doc_hash": "ca175e9e69f030bb5721e34b389afccf8c41f4e67ae6271ee472648762f66ab2", "ref_doc_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8"}, "084f174b-8c6d-4f35-a085-deec06b46285": {"doc_hash": "1b1b83104bb5a894b16a065578d788e5268f2161e84fb96669c89eaff962a2a8", "ref_doc_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8"}, "3bda7636-9cd0-4197-ad25-e95e27a55c80": {"doc_hash": "a99b4037325769d46f4fc5ccc3595dba44210557bdcd59e3135aa1cc9b1d25d2", "ref_doc_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8"}, "0df8270c-b18e-4852-a670-518ae6941765": {"doc_hash": "15668199466a0505b5f4cae6c3b7110d4be40c997393d2c3e5638ecbdaa4baf1", "ref_doc_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8"}, "ef404db4-664a-43e7-96ad-694055c63211": {"doc_hash": "5428ba0d536928f7a019ca0418ea7e9325151270dde32db78b10dee89303293c", "ref_doc_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8"}, "fa4fc28e-c233-4b95-afd0-f4d4718563fb": {"doc_hash": "683d575d3e106e0b01e6bb098174abd52e78d6d4eeb1a38f57300b0fc23a4016", "ref_doc_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8"}, "f4618abf-a0e4-4bbb-ac88-d512157d8193": {"doc_hash": "343860c1000388f6a68c767db817f65ae7a831474a2454951ef9b069a81f8a09", "ref_doc_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8"}, "2354d82d-9c1f-4e46-b8e3-cdeded942e08": {"doc_hash": "5ef07814457ff7e4eb64cfd98112dccc328b0b4cca64052a963708566de24e8a", "ref_doc_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8"}, "869d5d4b-7e2a-4242-9951-f32a6fd943c9": {"doc_hash": "eaf9b472ba5732440e10857f6a6b7985178e6e09e5b9b40427ca82e3ddabd84c", "ref_doc_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8"}, "48d3232f-ecce-4316-946d-e18f62fb201a": {"doc_hash": "9e0b71b4b958760f628fb39fd4b7d413c96e73d816b56ff86c3d256d3e3ae518", "ref_doc_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8"}, "d7c74aa0-261f-41fb-a626-8eb823a119fc": {"doc_hash": "997986a3dd32a596b67c57994d52af364aa093ea68e4911059e02c1ab8dd1696", "ref_doc_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8"}, "2c0570c3-d9a4-46a8-8e79-597ff9963c05": {"doc_hash": "021efc00ac3e7922b6c2c27b70abfe55b1f7cf0f4689ca199e2bce0c05efb2aa", "ref_doc_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8"}, "076be851-43d4-409f-b473-1244a27cb589": {"doc_hash": "39a4e1a9ddd587d5cc9d1c3173f34b71ffda847e00b4db565dce3f12db010f97", "ref_doc_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8"}, "352bea7a-7b68-49a9-97a2-a1be51e41432": {"doc_hash": "cad251679b6474650426b9a81cb5c33f2607fc01a9b026bdafcb38d9759ece2b", "ref_doc_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8"}, "992f672d-23d1-4e7c-8097-d262e5ff9519": {"doc_hash": "90faab448a5962ef74bb192c56288a1c6eb7cb40cb619e054a8fa2e12a736aa0", "ref_doc_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8"}, "534e5f4a-dff4-4ade-beff-bc5bf1a3409e": {"doc_hash": "95d8af646b3b68150d500ea3b5c93a8664047d2ffc40aa08066d9825424f516a", "ref_doc_id": "f9192739-5ba9-4d99-a701-bfd6fcac29e8"}, "35fea3da-78e4-425e-9a3a-ecaedfa1aaa0": {"doc_hash": "a5f7d81790d2876968bb7894c0ebab6aef562a8a44711053a05871865ad111b9", "ref_doc_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71"}, "0b680483-a32b-4ed7-8f18-46f1d4aeb952": {"doc_hash": "2bb82ece9ee0d7b5e8ad82502f4c58683e9f9a33717cd3a9543dfff9cf61c2f9", "ref_doc_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71"}, "a8b193f8-e584-4ea5-a009-e5b25fcf5eb8": {"doc_hash": "ab627a64318cdf6f6931cf2fa6f4eafb172957bd46ad5f5a6fe4e9d3272ae813", "ref_doc_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71"}, "45ac1bd1-c80f-480d-b951-f1dbcfb244f8": {"doc_hash": "3f578a2b938a003905a6603308421b35cae334da58d93a10a7de3dd5ec3dee10", "ref_doc_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71"}, "72b5717b-5110-4204-9fea-4f1015d8e7af": {"doc_hash": "007263c72bed57a5051508b2951f45ea011808bf04992f6ca25b99f0a2c4dce9", "ref_doc_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71"}, "f4d2d077-ab69-4dae-861e-ca4d6fd07dfa": {"doc_hash": "fac087faf2fa46cb8db8927bc4743f510b9ad8309b0fbecab3abdf603a222b11", "ref_doc_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71"}, "0593d9b9-4967-44f9-a019-6006ca2d8174": {"doc_hash": "7f9026c639da52e258f12ac33f845843132622aee865892687859d291d1f1c88", "ref_doc_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71"}, "1e7c4ec4-6cc8-4af1-8326-cc02db2107ea": {"doc_hash": "90f0604d9696452aac0de58b10f8a2e8a1b178f6c86dd1dfcfb0a9110bcae5c8", "ref_doc_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71"}, "dc5f0957-08a4-4a78-ad41-3e18d8fae635": {"doc_hash": "bbd587806ac1bf439c07407be1e892e997ff8859823e0e7837ad40c2d73504fd", "ref_doc_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71"}, "d1484556-0c61-4d2f-a10b-fa0f24848a62": {"doc_hash": "efc926d247a7da9ad50e3a3ea00637bf6b1113824560d46c81afbd2d852d51ad", "ref_doc_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71"}, "6a20a6a1-bb5e-444e-b7dd-7abf17ddb69a": {"doc_hash": "129153f466e3bbb22c24900e011c0a21416a2f28fe77c79338030b6e7fe26d61", "ref_doc_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71"}, "7b471fcb-0973-44c2-9846-e4c353536cd9": {"doc_hash": "42b226cc7f3fdca86c29ff2c65a69973875f0aaa897b10243f0098cedca38a3b", "ref_doc_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71"}, "376bdbf3-4505-4949-a2ca-7160ed2541fd": {"doc_hash": "ad5d5b5b5ecb0c32020ec99be08f9b00de89abd178fb72e1d9d8af6044afa9d3", "ref_doc_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71"}, "b3b845cb-2e2c-42f1-8d84-306c5fbb38e5": {"doc_hash": "13f8fb11b99b41c0bd9327b99468f4efec85adde45580e400cb1ff4419562180", "ref_doc_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71"}, "1a3c2696-cf44-4b56-9ab4-db5a3618b61d": {"doc_hash": "43e5fb4b39361db042ae94b0b0f2482490d508d306d633a6818694eb56d020f0", "ref_doc_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71"}, "ea5e01c1-933a-44c7-bbd2-59643aea09ff": {"doc_hash": "c85a4c79f86e05831c7059907028f6d205751df8f02a1bfbc17af4a32c610c54", "ref_doc_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71"}, "fa349d7d-5f9f-40e2-8092-8992d6b64e7c": {"doc_hash": "6e4c8fb411351516b9bf69578677abb1643afad29d32ac6b373b00b2d4eab98c", "ref_doc_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71"}, "0f2a245f-3f5b-4b34-936b-098f204a14ec": {"doc_hash": "9a8fde796868f9a0ec2c6c86499a968b87066ff14d62fcd219c7165fa8e9b856", "ref_doc_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71"}, "c64a29ae-396c-4d03-aae9-21f83dedb480": {"doc_hash": "ef99b52e01c5fa51e572290bd5ff0fbf0722ea4e6bb33edea69249cb99226b0a", "ref_doc_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71"}, "008038b6-81ae-49cc-b61d-83598f547e8f": {"doc_hash": "2feb6f5729c10f0ca03b5a361bfa98d4f98dc5df5963153aaaa3c56add294200", "ref_doc_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71"}, "55c24782-a039-43e4-af13-5f589bd35e32": {"doc_hash": "f12c16a93957c644266dbf22297afdbe095d7b49f0fce1dbcd7e0c5fe376b49e", "ref_doc_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71"}, "396d004d-c81d-4799-b409-099ad3c8a5b0": {"doc_hash": "bbf6effba1e33ffd0e035b78794bc151a1c68ac83479a02cce57c6e69295b03a", "ref_doc_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71"}, "9468d174-6f5c-47aa-8de0-219e9a4d340c": {"doc_hash": "8b4af5448366b49c72b36cb7a8c6c44e2762297e4dfda0fad61c944677df47b1", "ref_doc_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71"}, "4a7ad7be-b266-40e7-bf4a-14d48178da56": {"doc_hash": "7b9aac8ba1173c9f0fdd1ead7bf2790881e5bc74a9e9b88de5ad7e1cd9649daf", "ref_doc_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71"}, "6e543d5e-8f63-47ef-b161-d119134b322e": {"doc_hash": "4dea70016151f20712139b047bed7396b42e50477d4e2a9179ba08001e4c37d5", "ref_doc_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71"}, "d7462ea1-c066-4c4f-8e84-2ecf025a48f8": {"doc_hash": "9c1c1348bbb8dd0d2193faed0def61b1443fe9eaca15eaf09699df802879ad9a", "ref_doc_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71"}, "5b8e2a0f-fb00-495c-9d80-c8b6a67bc28c": {"doc_hash": "83d966b0440b7e077939ba104ed8ac9bc594c2229760e0153e7f5eac28620bdb", "ref_doc_id": "4901b80c-19ab-4b4a-bb47-383eb2913a71"}, "021ad1da-3768-4489-9bdc-3022d80ea075": {"doc_hash": "75bb58b207af4dda1bd47868d8931a25eabc8586e14b3a79c6a20993ac129b8a", "ref_doc_id": "d29b7765-5e1e-409d-b74c-8578a080001b"}, "f3fc85ad-2a27-4d7c-8bf3-adf86131db15": {"doc_hash": "91095825888ef2be25b24abd088ebc33f2748bed9c646527cda23796cba37d2e", "ref_doc_id": "d29b7765-5e1e-409d-b74c-8578a080001b"}, "cc7cfad6-437b-4d79-883a-38f835c3c360": {"doc_hash": "a7c429e3011be9c905c2c507e8b75d1bc15a944ad310de66554d2ed09ca0e5d2", "ref_doc_id": "d29b7765-5e1e-409d-b74c-8578a080001b"}, "a1ecef94-5c54-4598-9b15-c245e2c851b2": {"doc_hash": "a0c1ab04729be5a950c63c315e2a6a4c8350acecb40a1fc6769e2c88a3af5c15", "ref_doc_id": "d29b7765-5e1e-409d-b74c-8578a080001b"}, "bcf09b05-7d3d-4643-92f3-fc234fcbe577": {"doc_hash": "3686d22b10a07d21febcb7df06d53e4169410a550a2040c7ca819e8a3a09cf13", "ref_doc_id": "d29b7765-5e1e-409d-b74c-8578a080001b"}, "ed185abc-3fdd-4768-ba76-bfc5aeca199a": {"doc_hash": "8d49c32024e10bf81fcc2744a88ffde82b0bda5066e22a7677a66883cfe6d8ae", "ref_doc_id": "d29b7765-5e1e-409d-b74c-8578a080001b"}, "c3a1fe21-9341-4cd9-9760-a7fbea490e4b": {"doc_hash": "267b1057cbd47dc6375d3646a72b590daa671cd9807517a9fc01b3e7ec971203", "ref_doc_id": "d29b7765-5e1e-409d-b74c-8578a080001b"}, "3613dd4f-fe91-4bf6-8b39-7091dbbf8e38": {"doc_hash": "6cd0163df32c35567c5bed928e24af88418c382d68fe6d75209b77aeb4816995", "ref_doc_id": "d29b7765-5e1e-409d-b74c-8578a080001b"}, "91db2156-cc36-4e72-b7bf-fa26e6b7642c": {"doc_hash": "c84ed01238b68bd97d2b5273a21363122ce401c19735dc611de706f18f764855", "ref_doc_id": "d29b7765-5e1e-409d-b74c-8578a080001b"}, "7d262e81-1477-446b-8dde-96182112817e": {"doc_hash": "ef61edc54047d4b5fa61325c90cab9436560d7c7013851f690db265f7566c95f", "ref_doc_id": "d29b7765-5e1e-409d-b74c-8578a080001b"}, "fb4801ee-d4c3-4ca7-8bb7-35799f061e29": {"doc_hash": "9521f79a2bc22cd6a07ce275b165a697b6a738f29f5c7c883bb23c8521d8f970", "ref_doc_id": "d29b7765-5e1e-409d-b74c-8578a080001b"}, "f6bf63b4-3a84-470f-afa0-407308d91b05": {"doc_hash": "b44fa637dfc0eee8d346a320f6edfe38d9bc4d090500cc0851b2042c00a71971", "ref_doc_id": "d29b7765-5e1e-409d-b74c-8578a080001b"}, "31e41d11-622e-4600-b250-a94f6366bbaa": {"doc_hash": "c5b39f9eb352a7793f3ff45367bc0663d716e7dd3ab0f80ceed61771aea667cc", "ref_doc_id": "d29b7765-5e1e-409d-b74c-8578a080001b"}, "e5865583-c798-4e00-8e03-8fc2fb9178b9": {"doc_hash": "246bb1197caa7708b4c4442751c1e0de39dcea078ab2e22bd99a18f1a9c769b7", "ref_doc_id": "d29b7765-5e1e-409d-b74c-8578a080001b"}}, "docstore/ref_doc_info": {"55848cdd-003c-4ab4-b1df-376659bdd34c": {"node_ids": ["8ac40fc7-e5ac-411f-8bcc-384ec7db88a0", "ff05beac-fb15-422d-99fe-e0eb2ab3244c"], "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n07-May -2024  \nMcKesson Corp.   (MCK ) \nQ4 2024 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n07-May -2024  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}}, "6b5d4127-351d-4c2c-ad83-61d686441325": {"node_ids": ["e29a353b-2a1b-4319-95e4-787dccc2683f", "f30a7767-cc81-49a9-837d-328a55032937", "de984c38-4c8e-4d31-a34c-6b16fce63e37", "ee94e062-8f38-4681-b95e-291331278a0d", "b26c2c2e-22d2-4989-b921-ae614e541ed5", "0087b70c-f693-4502-bd3b-1478adab45f0", "1544a74c-3b5a-4abb-8665-984f7b33654e", "36ff605a-6c7a-4f45-94e2-09f56987a36e"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}}, "81722f07-6765-4bf6-940a-500c9ac23a6e": {"node_ids": ["f1f499d1-5560-411e-87b1-7da7f6445af4", "8e5f357d-70eb-41ef-8258-af91943248f0", "41e010d6-2397-4ccb-866f-ca40463df7a8", "65520944-fe11-4371-8335-73117a437ad3", "114dd88b-cc59-416e-b2c1-1522266c79dd", "400152eb-be86-4d8f-9219-c29ee796786a", "3f3ec541-6387-4e90-8561-9e06ea491b03", "ff1b7a4a-3ef4-4539-ba2b-9490310efce3", "847f5d51-e7e9-4e1a-8887-4e689f9921d8", "3e560d79-dd58-4b3d-a869-70295d5c151e", "84b84bca-2089-4868-b727-6e6bac65609f", "3a638280-07eb-4328-82db-a2a79b041f43", "17fd159e-c8cc-4503-a560-bd88e74814d4", "358dd6ec-fecb-4ee6-a491-e829d7441b79", "c4a2eb5d-ea15-471a-ae4e-644305267a1b", "82674211-3c89-47ee-b4dc-34c08c748ae9", "c5c3283b-81a6-459b-b94c-03188fb1f5b8", "c9f64c39-9358-486e-b2db-845a40ecdcba", "8ea9dbdd-9591-43fd-8025-457cca8b6b73", "911bb5f5-525a-471a-9e29-da5714a131cb", "0b0398bd-b3a7-409c-9c24-1356f3f9c48c", "7f95d24c-b104-4076-8dba-f4b315cbde5a", "e73320f9-7388-4d11-8cd2-f6b176def608", "fb83b04a-775e-4d46-81f5-408f41092e75", "90b60628-780f-4a16-8ee3-c5ad9c47b691", "b16761de-a178-4252-8846-526b974a5d34"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's fourth quarter fiscal 2024 earnings conference call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}}, "503d358d-7b15-4003-8931-8eb136775d00": {"node_ids": ["49dd4c39-6e1e-41a1-8817-ac5fb727941e", "c1bb7daf-5f15-46e1-a941-d58eb7d958fc", "3e06340e-9eeb-422d-9fbd-80599851967d", "1b9d393a-3654-4739-b091-9e9e99c314a7", "1184817b-9066-4074-93aa-d17f6acd4ca7", "66aaadc4-e258-4e1f-86fb-a2660cd47fec", "e586b312-7f70-4d10-bd1a-6246a85c7a94", "2f160a86-0932-4ccf-a449-a096bfde2db7", "69aae43d-dd34-481c-9b37-77831a5d3b03", "04ee86d4-c4ba-4a33-b27a-f72e60b834d8", "f1b21d7c-09c9-4cb7-8e57-cc6032d5d5f5", "59608038-bc94-4f58-aac6-4e99e30048f4", "715a73d7-5165-4fd8-97b9-8dccfae137d6", "bce1fa01-88ce-417d-ae64-763903514008", "cd1943b9-4636-4b58-9243-d0faa51e4b8e", "28005547-bda4-404a-ba43-03a2b14e5ac4", "47f08763-68c6-4139-958b-0bb8761985da", "bb6bead6-54ad-4589-a625-4c441c3f7f22", "398deb55-1fa8-4e5b-bb42-2b32e8108058", "63737ea7-8485-4901-8546-df272bb8ff1a", "4479e483-c95b-45db-9645-9c3f24ac4ee4", "22bf9e01-60d2-4c4c-b0c5-a51fc89c0fa5", "30b9c8a0-1936-4b34-8868-7710a84f7e6c", "6752e97b-3955-4822-a0c0-7b49bdf6140e", "16965107-e56b-4cb2-ad31-3a69904e5f13", "03c906eb-8e63-41fa-958c-2a8e21df420a", "1fe5fce4-3521-4766-84dc-ba60369c8962", "7b135ab0-7f06-475a-88b4-fb83f35d2d4f"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwill take away from both of us today is  our confidence in the strength of the underlying businesses, our \ncommitment to continue carrying out the strategy, and the momentum into the next year.  \n \n The first company priority I want to touch on is our focus on people and culture.  Over the past few ye ars, we've \nmade continued progress in transforming McKesson into a diversified healthcare services company. ", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}}, "5022ec88-98bf-4e78-bf96-c8f06599b68d": {"node_ids": ["8ff67d7e-9ce5-4120-95d5-e6593656080d", "5143b55d-10db-44ab-ac47-f3a30a673bd6", "5339c02b-7b09-48df-9f37-e60302c5b277", "cff9e3a0-208b-4eb2-b117-f483be089945", "dbdf2d43-4daa-4b5c-8c69-f520cdd10a1d", "4dc00ae4-9a6e-48e4-9970-d8062e5559fe", "90c9dafc-38d7-444a-b4c9-a459f006f8b8", "09285cbd-d231-46c6-997a-ceece6efb841", "82530308-be1a-4fe7-89bb-ed44f04fce01", "de25fd6e-fc1b-407f-acae-f17bf2140c4e", "dbb49de7-1b3d-4360-8bd2-1d25376dd937", "8d377790-53a1-439e-8914-85a1f707e5e0", "abe49091-9fdf-40c5-9a1d-4c3bee95edf7", "5f0cf240-0ed4-4d56-8c8d-df0e82c93a17", "6af05515-99d6-43bf-8697-5d5e5dbc4a41", "9c9ae138-8bd7-43b7-b0f8-310fb0977303", "87029daa-966a-46ef-91b5-2aca16fc19fd", "361678fa-a06c-4cdd-89b3-904b763b5e27", "ab0407de-c66d-4b19-8b63-7e801925c092", "595d3959-07a1-42fd-83b9-13df68bbb9d8", "fcc772bb-84ec-4b50-b508-ac6f6bbec005", "c8a8d3c9-9b21-467d-9476-c1e4f22d8d2e", "b40388ad-29f9-46cf-84b7-a5a51c7168b3", "36bc7910-7a82-425b-b974-4bd5bc15f7ac", "6efd9bbe-adbd-4103-bf23-479418c84465", "824b8022-6178-4691-9bbc-cdb975d09131", "332fff5d-26ea-4f4e-981a-b7b47b619a3b"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n$8.8 billion on brand and specialty medications.  We helped to prevent approxi mately 10.7 million prescriptions \nfrom being abandoned due to affordability challenges, and we helped patients access their medicine more than \n94 million times.  \n \n The biopharma services platform was built through years of strategic investments. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}}, "501ddb3b-c6b0-49c4-9bbf-4e77619fa101": {"node_ids": ["74ede774-3dbd-4c92-92fe-9ffe15c7aed3", "380bd4e2-2f70-47fd-8d9e-5e85f9a43d96", "339537f8-5f06-4c07-900c-97c2efd870ca", "cc322728-c0fb-487d-a2f4-e88b7e9b145f", "bb887d2c-67c4-4eb6-b56b-c17265e67a14", "905b0661-4a25-4ed2-bb7c-2efd98894e46", "8bb5cf1e-87cd-45f9-9083-68d7864a9ed0", "974d5f55-766b-454c-8ff5-408f6796719e", "365c27f4-81ca-4d09-9536-e2f8622d150d", "a577b514-f183-4755-8e36-5548f8c60c8b", "e46ca8cb-af20-455d-9644-49aa158daebf", "35fabb68-7891-448c-945a-c7b7ba526a83", "2f13d2ef-f8df-4b35-bd3f-7bb58263d129", "e752af75-f600-4087-ade6-e1c60c191496", "3b252176-21d4-4718-adb5-e5932cb216a6", "c75275ae-3c29-4f48-a04e-3be8632301ba", "7d1778ab-2d9c-44e4-a861-6318f6ff1980", "bb1ffe2e-b91d-4dca-87b8-1a4b80a2f4c0", "344df026-a303-4f37-a2fa-88f68b706d1e", "0c4d9547-a9d4-4b2d-96d5-e9868c9eec46", "6e66ad0d-3d88-44d5-b2ee-e527d723a23d", "6c2d1388-9671-4bf5-ac05-d951b0e0d111", "f0b8d31d-449d-4f87-be4b-6eabfdf2b834", "60262635-2b33-452c-ba58-738437a6b69a", "9b8bf4ae-942d-4c4f-a4c9-522b623b8e98", "d6cd5179-011e-441b-8994-5223357d95f5", "09b91605-ac46-4ff9-a534-743363b67940", "e1d8d47e-728a-4728-99ab-385abaedcf7c", "eb6beb49-5567-4fa8-a3ec-ea61b4d7fdd4", "421a3275-fed2-4637-8985-5f91dc93c4a8", "c87be482-b8e0-4df1-b59b-84c7c7fee107", "be2e2175-c71c-404c-9e5f-d9377877646d"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nhealthcare in many of these communities.  With this project, we look t o identify and address pharmacy deserts \nwhere residents face significant challenges in accessing essential pharmacy services.  \n \n We chose Avondale, Ohio as our pilot activation site. ", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}}, "b3bb0e0f-eb16-4b60-8ed0-eaa3bcf0b1e3": {"node_ids": ["b43a3cfa-4587-40ad-89e6-6e27c7b4e777", "5a6019e2-a159-4f4f-8ec2-53736662c676", "f6e1c877-d22f-4eb3-9238-892d3c428be3", "d0beddf3-650b-4b62-8ec2-1895f2e8c4aa", "143207ad-1c0a-4709-a6b2-5ecfcaed702e", "49fc402e-1b88-4b02-a411-39322df34800", "08751485-bd05-47ea-9e71-bf5dfa8d2591", "a4b9d2e9-eb58-4dbb-b59e-e9fec18c1b22", "69a19da3-7319-4658-9057-0887341b178a", "afc07965-63a2-474d-9ed8-469a36b01856", "de33f76c-e38e-47ce-bafa-0d28b8c12f3f", "28379bbe-1016-4646-8269-88589887374a", "bf615f13-7b72-4cd5-b5e2-d8225d8e8718", "ab685eb2-112b-4216-bf84-cfa2783b9b6c", "1e1aa21d-b7e9-4a6e-8a14-0daf93818fce", "a06cb467-ef04-4c0f-88da-7ca4f4426cab", "6b13e28a-8c2f-4b0b-ba42-3d3fec236d85", "b7782c9e-5af3-4fd3-ac45-311c046c4f68", "0842ba64-f75e-4112-a5e2-0b56ac0b2261", "f47e8d8b-d2b7-4951-98e9-9e785b20aff5", "896f0cc5-23e9-466b-80c4-d14900911c43", "4f3a7c40-62cb-42c3-bfe1-6d37a51c5b47", "7e6939a9-ad83-4987-a232-0437c58d146e", "6614de2f-e6ef-4b89-9fa1-985b64d3c424", "b9ae0397-0f32-43ef-9ad9-b4abf334528e", "485f756e-de49-4a78-add2-bf1cbcf9a3e5"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me start with a review of the fiscal fourth quarter.  Revenues increased 11% to $76.4 billion, led by gr owth in \nthe US Pharmaceutical segment, resulting from increased prescription volumes, including higher volumes from \nspecialty products, retail national account customers, and GLP -1 medications.  Gross profit was $3.3 billion, an \nincrease of 7%, primarily a result of specialty distribution growth within the US Pharmaceutical segment, including \nour leading plasma and biologics business.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}}, "e28ad7fc-7e51-4e7c-8e0a-f29d95bd1561": {"node_ids": ["4c44a06c-8ee9-48f3-a4a6-9d41e51c5c1e", "7b0829ee-212d-4106-9a36-ec850f0c07b4", "e88e08a7-f3e4-4683-86ff-9c5b37640e87", "b858aeba-1b89-4c13-ba7c-dd5ec51a4600", "b1cf367d-ef1c-4eac-b95d-46bd1ea3e834", "e1d5490c-a5eb-460f-a8c2-eaaf4b6700a4", "17585a7f-75c6-4ae7-844a-ec10eeca85dd", "857f6cc1-d0f0-43c8-87f7-2318785ea4eb", "bbcef71c-8f56-453d-8ff0-73d1641ac3de", "6cc1b1fc-0f90-4c31-b421-f4a7148e3e23", "d89ee0b9-8e9d-4877-a6a2-feb6b1631af6", "895b8ae8-2abe-4699-b487-a8f063c8b4b2", "6d3e953c-149a-4a06-b62a-3d86acf171ea", "352868c6-5d36-4875-ba9f-843a8c66a993", "db65b094-fe05-4670-bf1a-a1ef2840e779", "9f16bc65-6d77-4525-9f9e-6fb795d4ec3c", "f2a0c458-2532-4872-821b-9d5648c44201", "82194558-082c-49b6-98d6-5d7e8a1ce63e", "703f7ca5-e788-4f94-9455-416b5bd7cdfa", "e08df7c5-fad0-48b0-b005-b8829fd29a5f", "14b9fe16-c167-4a85-a755-db6980133991", "4f181601-711c-4e2c-8f12-024f78c29635", "f09a82d5-eec1-4538-a576-47f5d39790b7", "6e92a396-0532-4271-9d35-d881805e2691", "94e7c04a-b5ee-4daa-8a95-ef6d9ac4fb79", "710b52ee-572b-4752-81ab-69455b2cb0f5", "27ad667c-f83f-4383-bc69-e8e4d06a9c54"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nWithin this segment, CoverMyMeds continues to deliver value for our partners by increasing connectivity between \npharmacies, providers, payers, and biopharma manufacturers through next -generation access, affordabil ity, and \nadherence solutions that are automated and integrated into provider workflows.  \n \n Results in the fourth quarter reflect organic growth across our access solutions, including prior authorization \nservices, as we extended existing partnerships with bio pharma manufacturers.  In addition to the strength of our \naccess solutions, year -over-year performance was also supported by higher volumes across our affordability \nsolutions.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}}, "537a8a58-2171-4c25-8417-36f4e9bf2cd4": {"node_ids": ["2486b7d7-8c18-470f-a9e7-b12111c60908", "4b64dded-0068-4e47-90b9-47ef5b0016f1", "a3411858-78ce-4726-9f7d-6e0043965945", "42d0222c-80bf-4af0-a259-ed68ec56ae54", "43947561-9b21-417b-8fad-7862167acf99", "b4526a51-c4b0-422e-a410-08f551995553", "fae03bb5-1ac7-4d8a-a1d3-43d18f722da2", "82aa04a4-76f1-47da-a4fc-c472816598b6", "13b718db-6114-4638-aded-5b1a632401cf", "ce90eec4-e7d6-4dd1-92d6-b7ff81446a51", "467c9dea-820b-41d0-8ccc-fbb1190191cf", "e631ffd2-93fd-46cc-95b9-0ead9241bb07", "8f2846a6-80f0-4fdf-bb02-9d4e2132f879", "f9ac5b92-6be7-49b3-a381-d2cb73e6d5ac", "078c99b7-9a83-4be9-acbd-be31c9860397", "71ac2222-3677-4d07-af67-0e90a82a61bc", "09443bee-e8c3-453f-9b3d-81334763cb17", "8d71ecd9-d023-441d-9623-bf81fcc4b1b1", "a44973ce-ecf3-4ccf-a631-49bb4b3ae240", "0abd5464-9b4c-4ad9-bf36-10bafc28e2a7", "f566e053-56b9-417c-bc4a-aa1bfcc5c689", "454195e0-9e7e-4c0e-987d-69a03361eff9", "13cd2a0a-93e6-4955-8a9d-a16927c86c22", "6de37fbe-b35c-441d-be75-505eec1716a5", "a8400fec-4032-4c3e-8b9b-2f8933e525ee", "b6e886e4-567d-4fc2-b593-7a4aebae0355"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nSince the beginning of fiscal 2019, we have returned $16.2 billion of cash to shareholders through share \nrepurchases and dividends.  Of this amount, approxima tely $14.5 billion has been returned through share \nrepurchases, reducing our total average shares outstanding by nearly 36%.  \n \n The strength of our balance sheet and strong credit metrics, supported by our strong operating performance and \ndisciplined and balanced financial policy, was recognized in the quarter by the recent Moody's credit rating \nupgrade to A3 from Baa1. ", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}}, "0b4739fd-a210-4020-aa76-6a4d4c165542": {"node_ids": ["d440c117-e651-4bb9-b8da-1997cfc03768", "d94be135-37cf-4d75-83cf-c3a278d83644", "cac09502-6524-4c8c-b0b2-2730ea674f2a", "09160517-6042-47b0-b639-2cddb956a2c3", "b28ff09e-9953-483e-b900-a576d011c081", "5be6ff53-d4cb-4116-8d00-b57356d2e800", "578b3af0-3642-4a8e-b8a6-b8347f4dc39e", "490468b6-7405-4fb5-ade5-8a2e568c6652", "1bb80b24-e18c-4e5e-aefc-7c22901a888b", "fb17da20-897a-46e8-9c2a-5e70e2df4f0e", "1c067191-e598-47a8-b656-ff26c1febee3", "c28fc01a-a6b7-41ac-88af-e7a6bdf75d2b", "ffa44fd8-68da-4afc-8905-ee84eb175bc7", "2a1d8b1c-89a3-4da3-be8e-fa18ad34e1f7", "dea283fd-d725-401e-9b6b-4a4473add89e", "bae7a823-d919-4fff-af03-bbaa85b55eea", "03c30d01-39b6-499d-9877-a02af067d8a0", "ad45e2f2-ce2f-484b-92af-2cc7dc381961", "bc18613b-55a1-4d73-88d7-37c1faae23d7", "17277776-8340-42a5-93a1-e3c8d303e8ff", "df378f16-01c5-46a1-8100-e6f100f4a2a9", "35f6c835-e1de-495e-b08e-70f0b0f0fb9f", "252b97b9-d573-46c8-889a-4d2abaa1f822", "d4af490a-fe7f-448c-aae1-06f482452e05", "59331b4f-93ab-4a88-a594-ba5080e05e77", "ca9d6e59-6d9f-47cc-ba35-442130f2d4db"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWithin the primary care market, we anticipate continued growth in Lab Sol utions and Specialty Pharmaceuticals. \n Our scale, sourcing, and distribution footprint has propelled expansion and growth of our private label portfolio, \nproviding superior value for our customers while maintaining sound economics for McKesson.  \n \n In fiscal 2 025, we're making investments in this segment to support the recent acquisition of Compile, a \nhealthcare data platform that captures and aggregates data to provide insights and analytics for biopharma. ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}}, "bd6eacc3-18ee-4daa-936d-290440082d8d": {"node_ids": ["42de0b0f-cf97-4afc-8b99-d4eb4948704b", "f52ffaee-7b46-477d-a1a3-0883c78fe76b", "41e30d40-fc09-4f75-81d7-f8f5f9824ff3", "93f70569-5c39-440b-88e5-01fa382a56e2", "e9409955-f515-423e-b4d6-f8c7802ec090", "fbd36146-593d-4b56-af1f-e3b788b0da1f", "4d8be690-28e0-40bc-a2c5-826e545d2674", "6c4ee0ba-92b9-41dd-bf1c-b1d733f81381", "89f02fa5-8f79-4ed0-b147-1cffed7f34f8", "f81f85e0-103e-4364-9c38-f2507c42fea9", "75970add-9264-4031-8c95-ed60aa8ae899", "57ba9e51-0e4f-4872-9a0a-c5de3a66676f", "94cc51a9-ba7e-440d-90a0-eb43a51b5bcb", "6e52838c-c35e-48c5-8ce1-12d39a751bc4", "18886824-e815-40cc-8067-8de1cadca36a", "efca4bd1-bbff-40bc-a75b-b26d46ec023b", "866c13e6-cff3-4b79-875d-b9e3c5b50a6b", "18a1cb3b-8011-464b-a98c-256ee2927578", "e2e65a66-db25-428b-ac66-2cb8b0f938d1", "69353733-eb16-438e-8302-7535f4a4ea16", "2c59410e-8ac3-4b97-91b8-c3a0c6c5af0c", "7c01ffc8-294c-4c6d-b7e4-b5532d61381b"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nexample of many where we're using AI to power insights and deliver clinical and financial value to our \nstakeholders.  \n \n We've been pleased with our progress to date as we work to develop and implement various AI technologies, and \nwe remain committed to increased inv estment to further extend our leadership positions and deliver value to our \npartners and stakeholders.  \n \n Now moving below the line, we anticipate interest expense to be approximately $220 million to $240 million, and \nincome attributable to non -controlling i nterests to be in the range of $140 million to $160 million. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}}, "52c2f2de-784b-4a2c-b4c0-e71ce680eb73": {"node_ids": ["7d0cba2c-a85f-482e-8e66-91c8f2aa06f3", "0a3de324-84b0-4de3-8116-fcd551574684", "c0d93f61-4f23-466f-aa1e-497b404f6afb", "08e8d609-ba88-4e88-90a8-c3f9455fbe1c", "8d3ca547-754d-4941-870e-ddf9e91f6d47", "cb18493a-0d58-4189-8d9a-5c635a719b9f", "e993a1c7-1f1b-4e42-ad2b-acbeff25c359", "d9b2ed59-1aa8-4ee0-8d45-0dd107d8717d", "294cdb5b-a4a8-4a2f-9e7f-dbd689c450e2", "51abc90c-0dd4-4192-a258-5e5b37009c6d", "f6222e6a-42e6-4981-b3ec-b097d7cfa9ff", "1234c52e-5a57-48ce-a9e5-5640bff9f9e9", "3c0e0a0c-13dd-4304-b1ff-0d3e335f0ed4", "250b8ed7-74ae-4cb9-bd01-6133ae1494d8", "ca26a64e-19bf-4bb4-9b24-921604de3de3", "c98109cc-d651-4c5f-bb2d-d648731d3d70", "bec0e24f-87a8-4394-aec1-bd24f3bfedf2", "076520a3-3725-49af-814c-6bd2fcee8d4d", "eb98ff75-8bbe-4cf1-ab75-b270b39415fb", "3ffad55a-c889-4952-9bc4-d777df738b7a", "fb10868f-579d-422b-b549-33e3dfbc575a", "583a7b99-ed16-4acc-a252-aa5af3aadaa1", "27df0b27-aacc-480b-8c25-0f763e954650", "23d871fe-c1de-4d00-bca8-6564815ff92a", "cd753cc4-6c9f-4980-b74c-eae6a2f696cc", "800d2f17-b9bd-45d2-a66f-6ffaa2ab7e0e", "262260fd-adb5-46f0-a15e-54f5072c7667", "6d85c177-4077-4af6-9da7-58d9a8301e0e", "45c45a1e-0f06-4a0f-9382-91ef808dbc04", "7b1e1e46-93f2-4a4d-873a-a65aeee58c19", "98897dcc-eb46-42b3-9264-b8c90087f0fe", "3fd04acf-7a95-4976-b999-a6deb07ff29b", "4bd6292e-da66-40b2-bffd-0e7e8031325f", "399a0073-b49e-44c8-88e0-6ea141907c51", "156755df-165e-4907-a125-0ad230d5ee01", "72c7b5a3-2c99-421a-ac6e-40d7227724f7", "d651ef9a-9cd9-457d-95c6-fa16086344a9", "d96892a1-e59b-4d74-bb05-90f921c095eb", "e2a64860-36c3-474f-b8ad-ed8d2939105b"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Kevin Caliendo with UBS. \n Please go ahead.  \n ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}}, "e49bb75a-5fcc-4a72-9208-c8db0df48231": {"node_ids": ["8a95a5ac-540a-4f92-9059-6cecb4796aa7", "1b4c5952-4155-4365-9def-21fbe067eee8", "d982ddfa-cd29-4863-bee2-bc3cbd2b8ef1", "7bc891e7-56ea-452d-b256-047978d3c099", "1860fd08-e980-41a9-ad08-2a9f7c33c68f", "54d581e7-e554-45c1-9c7c-998716e4ae5e", "d5e58d7b-d435-4093-9e03-262157e76e7c", "e2561468-4c4b-4a8b-b781-ebd35c734bb5", "61c0cb39-4565-4341-aecf-e34694726350", "29508c18-fc28-424a-b39b-286f8e483938", "b75cd9f5-b2f1-45aa-8232-a7f62f357ba9", "fae67ec7-0924-4510-91c5-f4108fc2e5b3", "34e978c5-8b27-4d0d-ad5a-dcb2e7922a61", "a686d9e4-a369-4c7d-96ea-9f7e71c492e1", "5bbd12d1-7e6b-400f-a3d0-17b3214e7699", "db3731f1-fd57-4720-81b8-e405cdfbf6d4", "5717f748-6c63-407d-8980-3e33fe971360", "7fc313df-3e32-45af-98a2-776583b1ad4d", "1ad03831-a761-49ee-a46c-0d95853c64f8", "eb518ca1-279b-42ca-ac21-6b81e9449762", "b16b8379-ef02-4fe5-b884-5c96b9499773", "7c49d8c7-cd6f-488a-b02e-800e41c6bbf0", "8c080594-1cfa-4397-a842-73e96476bd0c", "a64fa916-2585-411f-b2a3-7c28e0d9a24b", "88b84626-4943-4a37-bbcc-072575c60934", "f82035a4-6c8b-4624-ac5b-6e8ec8f9db16", "ce48bb2f-fe86-4525-94d4-7c210c572930", "b9452c8e-12c9-49b7-90a6-8bae8bd37fee", "44f14888-86b2-45b9-9946-cd46ab275f6e", "8a6e5fdf-a827-42cb-a804-29901157840f", "41c63d24-4842-4fe2-b9ee-d20cd70c4a86", "2df21050-6f9c-4ceb-8a07-d19dc6cc3931", "53afae79-7be3-4299-9eac-f8869771a81f", "ddc448ba-7e6f-4478-b6c6-476a13941e57"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nbusiness.  Our 3PL business, as we talked about in the past, is slightly more than half of the revenue.  And as I \nmentioned in my comments, the 3PL performance was lower than the prior year for various customer and contract \nconsiderations.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}}, "05741e79-c295-4ca9-8e03-5359351afb04": {"node_ids": ["14823974-546b-465d-893b-39cee0308cd5", "b130c306-1fee-4efb-a71a-8d27b6ced077", "b8910f53-7681-4a1e-b7d2-d17d84e191f2", "14294311-682e-4b3a-9a9f-9a4aea6f6f23", "809485e5-d879-4fe0-8c13-f0049bcec8fa", "0021cb65-01a2-4abb-a5f5-fb469b20d1a9", "2ee064aa-c3ed-4ad0-94da-5b19b7cef415", "a6aaedec-4e4c-4429-af85-24294b915901", "782bd23d-99f9-4d64-a441-4e2e547bf1ec", "9fa34d35-bf99-490a-aa0a-08ab6a718f6d", "aead0c3b-07f0-496f-bc54-176dd707240f", "1a0d84f8-f7bc-40b4-bdd9-aeecb1bc270d", "7d9a8cf6-ba1f-45f4-9758-5a68858c6a90", "c2f528c9-b8da-4746-b5a9-c458efe30db5", "2f5610d1-16f6-4269-a272-cc20c6dc772b", "6523ab68-79d3-441b-a378-483b6d822222", "bf22e1e4-5564-4745-a679-5bbb9fbd6ace", "647f33a3-3b52-4cb3-979d-a19e3bd71ed8", "0141545c-e756-4c1c-aafc-61b46a10029e", "ea21a2bc-d08c-45fc-861e-d0eb8dea3c1b", "f0c4b3ff-29d4-4525-879d-6818847ba48e", "35d4d5ab-629f-4b7e-8c34-cf53c0eb51c2", "48f031c8-2359-40b9-9c53-bf57cc994cdd", "5c6b9043-a55d-404f-bc8d-581c7ef2ff6a", "d0ecf790-ec74-4a77-915c-7c92fa8ce40a", "28fd606d-5cc3-4ea7-8ea7-ccfeab28d896", "e4a75192-81d2-49de-bc80-5ae83be20556", "c54ebc60-9f18-483e-9006-cd6cc07f51a1", "6ffa91fb-fd7c-46f0-8aa5-132bd2153ae6", "842531df-9ff8-48c1-98e5-5693d772c333", "1bdee844-68d0-454f-93b2-1d8003f9c525", "0311cb09-d9c9-41b8-b9f1-ed7bb158eabe", "dd12198b-eec0-44a5-8b4a-e89ce348451d", "8d662d5f-152d-4808-952e-507da404da9b", "54b47dde-58d5-4cea-a851-b091c3143772", "edd5a3b3-e9e3-42e1-86aa-dabf0421ae20"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nI do think it's a reflection on the investments that we've made over the past several years and the efficiency of our \ncore operations, our commitment to continuing to make those investments, not just in efficiency, but in innovations \nand thinking about how we use our tools to solve different problems.  This is very much  today a distribution \nagreement.  We'll be servicing Optum home delivery to Optum infusion, OptumCare, the specialty pharmacy. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}}, "98047684-7eaf-431b-abdc-d76ed6294538": {"node_ids": ["ea0a92b2-cd45-4c25-bb66-6ab6c4ba517b", "5c93743f-e700-45d0-bbf9-5f76e9ee4c77", "0ae4e56b-c7df-4227-b02f-5d1dcf31c018", "07867a1c-7e21-4924-b332-b4477a577b95", "1ee4048e-9f98-457e-93bf-b5bfa12a1352", "f7da0328-088f-4837-a632-5d81205a6d6d", "59344675-7454-457d-a7ad-9af4f73608f2", "6633efc3-52fc-46c0-9255-aeebde3efdec", "6031ce14-4f84-4e56-b3ff-ed58e447abf9", "bca3e4b4-649f-4389-9f83-7f45e0991803", "74e3a48d-51cd-4f80-9668-c7bd2b189dd5", "5a68360c-9cf6-44ae-9b6e-1cdad2f93d5f", "a30d2ca5-2f1a-4931-a96a-f6d8f063ebe2", "e1224e2c-c3de-4888-858e-ac6f7848b242", "a5bf65d9-e9bc-4917-aaac-50dac40f7af5", "9efd44d8-d25e-4e7d-b895-b28b7275fd81", "0b50205b-447f-4882-8899-c69ab5e4df78", "3fb9816b-ac1b-4f78-894a-9dd9dd35b07c", "3189d73e-fb7c-48f3-a2bd-2d5ea43100c3", "11e6535f-9c7d-4bd7-b6e1-b2fe42b237a3", "3fd468c5-c500-433c-a7e8-f14e083e8bad", "3ed0612e-5c0f-4df6-a817-8242dbc881a7", "1049d467-2585-4876-b6b7-c4e8fe1d6858", "c449142b-e8a4-4ec8-96c8-5693e9dd7aeb", "f086e2a9-2a55-431d-b39c-3fbb687e5e10", "291424e6-0cac-4618-a5df-bff01e25ef86", "79a77e6e-4f4d-4a22-a8a6-e30f0092bf14", "a3dea05e-8db8-4c1d-8022-d74f856e8604", "0e78c846-8e3d-490c-85fe-1265fac09a4f", "d874a44a-8c0f-4cd6-aba1-886a05a7ca00", "b31fa255-8aad-45a2-b60e-b97b0f34f85b", "5930a1be-db59-4b83-a67d-04099ebc6032", "7e7a0f7d-7c9f-4763-8c78-ecc792e369a1", "a729acfa-e2ae-42b3-a6b7-200d118ff5e1", "995a0bfb-dea4-4148-a06c-6109c5973123"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ngeneral and the leading player in the community oncology space, we're very familiar with a lot of, I would call, \nemerging tools, technologies, and companies out there.  And anywhere that we can find an asset that's aligned to \nour strategy in community oncology that we think is additive to either the footprint that we ha ve in US oncology or \nour leading EMR or our adds capability to our data insight business or accelerates clinical trials would be very \nmuch a sweet spot for us.  \n \n Britt actually referenced in his comments some internal stuff we're doing around AI. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}}, "c43cfbd4-7d3d-4708-b910-e363c305368e": {"node_ids": ["be4d602b-c449-4e6d-9fd8-0e34161270d9", "196fddef-c9f2-4745-baff-9c02ba34a61f", "1cebcfde-aaad-4204-bc65-ffa989c104e5", "59e48306-3c22-420e-85c1-64f8977c99d8", "5e762317-a3dd-4964-b0f3-6e74ba73ef5a", "2c17526c-e866-4019-9bb3-3ef9af9b0081", "c940a4b6-c4d9-4082-bd19-a4ba21685329", "2ba52f94-68c3-4062-8193-4e037cd02b4d", "5e16c010-b99d-4168-b497-2647a106bf49", "2ef8c035-5d03-4dc7-9ebf-b9c012e1bec6", "64ebce46-02eb-47ab-84b3-14a6f249128c", "cf6d0c8c-be48-401e-9a96-110889d8e6af", "25d3136a-ee0b-4376-9aac-3abfed9c79c5", "5ebfd5c6-0946-456b-ad7c-f24e16790b2c", "ac6a3550-1ad8-40c5-93b1-7c048f6bc73e", "232f9546-3b37-4090-beae-65177e256295", "481d7454-285a-4c45-9cfc-7dc20809f40d", "02e5cb42-1bba-4ec0-871c-b3f2be726426", "3d642ae8-54d0-4125-bfe6-060179aefe50", "8e99a060-1bd9-44cc-b967-5e9d68861c86", "14597d71-cdd3-4755-a5c4-e11628aba269", "142b2123-f432-477a-b824-f41243a836d6", "d5ce631a-9fb9-4772-a0ba-b72b15ac87d3", "90ef63a4-b34a-4a30-9251-51d658f3e11b", "05487628-7938-4a9a-9110-7bcfe40d2bf8", "ddea0275-67cd-4e35-88e2-a4e573475e4f", "8cea02c8-85e8-417a-b058-229f774e5525", "68340171-4f6b-4cb4-9767-fe695bbfe8cb"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, a question related to competitive intensity, and specifically contract movement we've seen.  I think with \nOptum, there was a real concern that the con tract could even be outsourced or element of specialty could be \noutsourced.  And yet here it comes to you, and we've also seen CVS outsourcing scale to you.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}}, "4dd5eda0-3490-4f42-8345-b5edc3eb3f6c": {"node_ids": ["dfa8fc22-de74-45ae-95c4-971a627d9379", "60ad3e2e-ea2e-49ae-a457-d059404225b1", "4cb61342-3415-4048-91ef-21794a2cf8f3", "e21bb1bc-0138-4b73-992c-658fcc0ab533", "d7d99f01-e9a1-49a5-a938-934293b38e61", "2f72314f-f9f3-42c3-9a06-bdcfaa77f007", "8ea13848-c32c-4a65-a332-e97d3f699b6a", "37307ed3-4a12-420b-911a-3eb6161ced48", "d4008944-10ef-48ed-8a8d-0ffbd527ed7e", "20a08aaf-48b1-4728-993e-8c4c2452f006", "bee94bd7-c020-4380-aede-6cc895169753", "727dce1b-ca5d-40cc-a293-847d683a992c", "a47b62f5-6248-4e0d-a7ec-11064462b3a1", "865dfbb0-93ec-44e6-8b15-4fdd3e720e4d", "8c22d2d2-db5c-4c3d-9abf-18cb7f125201", "27c2cedc-eda7-4627-a3cb-c476a748eee1", "e30f53f4-6bef-4128-84b0-6296b3132047", "66f7e7c1-54a4-4bf7-9a76-ecc26ba9ee63", "2020b708-72f9-471a-845d-7df7dceed5c3", "667431cf-fcde-471f-9b77-009b1d3479f4", "0010a6d9-b9de-4042-9f4a-dbc03f36ff9c", "828b9072-4682-49cf-b9f5-de40661705e2", "c51a94da-67cb-4999-a40b-50e769dcebe8", "4212dde1-58ad-4a3b-8ba6-956dba97efab", "14248ca7-04b2-46cb-bf0e-b7a2de5918dd", "a199ca5f-aa55-45cb-bc02-823c56724aab", "790d479a-aecf-4342-a23b-481624024b29", "572cfe70-78cc-4632-80fc-208c6f911530", "1c1c8df6-94bf-4334-ae09-40069f20d656", "ad22aaea-306a-4ad4-ab03-4dffdac571ea"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Of ficer & Director, McKesson Corp.   A \nYes.  So I'll start, and if Britt wants to add anything he can. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}}, "f9192739-5ba9-4d99-a701-bfd6fcac29e8": {"node_ids": ["24cfb745-772d-4936-8891-107c83def0ce", "da5c07c8-b49c-4fe9-be3a-877e539d76c8", "3db19a3c-bb30-462b-bca8-f5559373c375", "93c6db2b-ce4d-45dd-af32-7323b96540eb", "522dffa0-d330-4982-9283-aa8a0af7dbeb", "59864f47-4310-4c90-a9fe-ecb8b64737d5", "8f30ac62-9943-431d-902b-609e8004a33d", "a9e9cb97-8f1c-4d56-bf26-73d4994ae4ed", "5dc3c628-a538-4152-9e48-4d654878fc99", "e5cf0d87-8087-4917-81f3-a9082a39076a", "0492be5b-b309-4e40-b373-0736cd36a0a3", "d69a87ce-2373-44bb-a58e-d32f1f900774", "f418f31f-f6f4-4d7b-9ffc-7b1c4265017f", "6d419631-835e-4ad5-abf4-8f3f9a244380", "ff54db1d-4027-4187-a82a-b09776d1b602", "2bd4993c-715a-4bab-a8dc-d810ddb5af6e", "fa515cc8-7177-424a-99f0-9cd6fc471f7c", "e0075170-f557-4759-b796-7f96bcadf986", "c7e22737-4279-4215-b456-928a12f43139", "af9726ed-fd53-4543-97d5-d4d837ce1427", "20d23907-fb46-4c64-92d8-181f701c40cf", "084f174b-8c6d-4f35-a085-deec06b46285", "3bda7636-9cd0-4197-ad25-e95e27a55c80", "0df8270c-b18e-4852-a670-518ae6941765", "ef404db4-664a-43e7-96ad-694055c63211", "fa4fc28e-c233-4b95-afd0-f4d4718563fb", "f4618abf-a0e4-4bbb-ac88-d512157d8193", "2354d82d-9c1f-4e46-b8e3-cdeded942e08", "869d5d4b-7e2a-4242-9951-f32a6fd943c9", "48d3232f-ecce-4316-946d-e18f62fb201a", "d7c74aa0-261f-41fb-a626-8eb823a119fc", "2c0570c3-d9a4-46a8-8e79-597ff9963c05", "076be851-43d4-409f-b473-1244a27cb589", "352bea7a-7b68-49a9-97a2-a1be51e41432", "992f672d-23d1-4e7c-8097-d262e5ff9519", "534e5f4a-dff4-4ade-beff-bc5bf1a3409e"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nHey, guys.  Thanks for taking my question.  I want to go back to the question that Charles asked on RxTS. ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}}, "4901b80c-19ab-4b4a-bb47-383eb2913a71": {"node_ids": ["35fea3da-78e4-425e-9a3a-ecaedfa1aaa0", "0b680483-a32b-4ed7-8f18-46f1d4aeb952", "a8b193f8-e584-4ea5-a009-e5b25fcf5eb8", "45ac1bd1-c80f-480d-b951-f1dbcfb244f8", "72b5717b-5110-4204-9fea-4f1015d8e7af", "f4d2d077-ab69-4dae-861e-ca4d6fd07dfa", "0593d9b9-4967-44f9-a019-6006ca2d8174", "1e7c4ec4-6cc8-4af1-8326-cc02db2107ea", "dc5f0957-08a4-4a78-ad41-3e18d8fae635", "d1484556-0c61-4d2f-a10b-fa0f24848a62", "6a20a6a1-bb5e-444e-b7dd-7abf17ddb69a", "7b471fcb-0973-44c2-9846-e4c353536cd9", "376bdbf3-4505-4949-a2ca-7160ed2541fd", "b3b845cb-2e2c-42f1-8d84-306c5fbb38e5", "1a3c2696-cf44-4b56-9ab4-db5a3618b61d", "ea5e01c1-933a-44c7-bbd2-59643aea09ff", "fa349d7d-5f9f-40e2-8092-8992d6b64e7c", "0f2a245f-3f5b-4b34-936b-098f204a14ec", "c64a29ae-396c-4d03-aae9-21f83dedb480", "008038b6-81ae-49cc-b61d-83598f547e8f", "55c24782-a039-43e4-af13-5f589bd35e32", "396d004d-c81d-4799-b409-099ad3c8a5b0", "9468d174-6f5c-47aa-8de0-219e9a4d340c", "4a7ad7be-b266-40e7-bf4a-14d48178da56", "6e543d5e-8f63-47ef-b161-d119134b322e", "d7462ea1-c066-4c4f-8e84-2ecf025a48f8", "5b8e2a0f-fb00-495c-9d80-c8b6a67bc28c"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nI think we have time for probably one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}}, "d29b7765-5e1e-409d-b74c-8578a080001b": {"node_ids": ["021ad1da-3768-4489-9bdc-3022d80ea075", "f3fc85ad-2a27-4d7c-8bf3-adf86131db15", "cc7cfad6-437b-4d79-883a-38f835c3c360", "a1ecef94-5c54-4598-9b15-c245e2c851b2", "bcf09b05-7d3d-4643-92f3-fc234fcbe577", "ed185abc-3fdd-4768-ba76-bfc5aeca199a", "c3a1fe21-9341-4cd9-9760-a7fbea490e4b", "3613dd4f-fe91-4bf6-8b39-7091dbbf8e38", "91db2156-cc36-4e72-b7bf-fa26e6b7642c", "7d262e81-1477-446b-8dde-96182112817e", "fb4801ee-d4c3-4ca7-8bb7-35799f061e29", "f6bf63b4-3a84-470f-afa0-407308d91b05", "31e41d11-622e-4600-b250-a94f6366bbaa", "e5865583-c798-4e00-8e03-8fc2fb9178b9"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2024 Earnings Call  Corrected Transcript  \n07-May-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed b y us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all r isks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 307642, "creation_date": "2024-07-11", "last_modified_date": "2024-07-11"}}}}